<SEC-DOCUMENT>0001570562-25-000020.txt : 20250304
<SEC-HEADER>0001570562-25-000020.hdr.sgml : 20250304
<ACCEPTANCE-DATETIME>20250304164000
ACCESSION NUMBER:		0001570562-25-000020
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		94
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250304
DATE AS OF CHANGE:		20250304

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Evolus, Inc.
		CENTRAL INDEX KEY:			0001570562
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				461385614
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38381
		FILM NUMBER:		25705421

	BUSINESS ADDRESS:	
		STREET 1:		520 NEWPORT CENTER DRIVE
		STREET 2:		SUITE 1200
		CITY:			NEWPORT BEACH
		STATE:			CA
		ZIP:			92660
		BUSINESS PHONE:		(949) 284-4555

	MAIL ADDRESS:	
		STREET 1:		520 NEWPORT CENTER DRIVE
		STREET 2:		SUITE 1200
		CITY:			NEWPORT BEACH
		STATE:			CA
		ZIP:			92660
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>eols-20241231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:919f993d-eaea-4622-b01f-fde76d4f5f0d,g:96b2bf92-d476-42b7-9d6e-4ee6308f0735,d:d181047532df422ab5a549dd869deccb-->
<html xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:srt="http://fasb.org/srt/2024" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:eols="http://www.evolus.com/20241231" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>eols-20241231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-32">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-33">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-34">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-35">0001570562</ix:nonNumeric><ix:nonNumeric contextRef="c-12" name="us-gaap:TypeOfCostGoodOrServiceExtensibleList" id="f-141">http://fasb.org/us-gaap/2024#ProductMember</ix:nonNumeric><ix:nonNumeric contextRef="c-13" name="us-gaap:TypeOfCostGoodOrServiceExtensibleList" id="f-142">http://fasb.org/us-gaap/2024#ProductMember</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:TypeOfCostGoodOrServiceExtensibleList" id="f-143">http://fasb.org/us-gaap/2024#ProductMember</ix:nonNumeric><ix:nonNumeric contextRef="c-49" name="eols:AccountsReceivableCreditCardTransactionConvertedToCashPeriod" id="f-398">P2D</ix:nonNumeric><ix:nonNumeric contextRef="c-51" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="f-403">P3Y</ix:nonNumeric><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="0" name="us-gaap:NumberOfReportableSegments" scale="0" id="f-508">1</ix:nonFraction><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="0" name="us-gaap:NumberOfOperatingSegments" scale="0" id="f-509">1</ix:nonFraction><ix:nonNumeric contextRef="c-85" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="f-510">fourteen years, two months</ix:nonNumeric><ix:nonNumeric contextRef="c-116" name="us-gaap:DebtInstrumentTerm" id="f-623">P6Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-121" decimals="4" name="eols:DebtInstrumentPeriodicPaymentOutstandingPrincipalAmountDuePercentage" scale="0" id="f-651">0.0833</ix:nonFraction><ix:nonNumeric contextRef="c-152" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="f-739">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="c-159" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="f-786">P1Y</ix:nonNumeric><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-1056">one</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="eols-20241231.xsd"/></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="product"><xbrli:measure>eols:product</xbrli:measure></xbrli:unit><xbrli:unit id="reporting_unit"><xbrli:measure>eols:reporting_unit</xbrli:measure></xbrli:unit><xbrli:unit id="productcandidate"><xbrli:measure>eols:productCandidate</xbrli:measure></xbrli:unit><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="country"><xbrli:measure>eols:country</xbrli:measure></xbrli:unit><xbrli:unit id="milestonepayment"><xbrli:measure>eols:milestonePayment</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>eols:segment</xbrli:measure></xbrli:unit><xbrli:unit id="tranche"><xbrli:measure>eols:tranche</xbrli:measure></xbrli:unit><xbrli:unit id="installment"><xbrli:measure>eols:installment</xbrli:measure></xbrli:unit><xbrli:unit id="payment"><xbrli:measure>eols:payment</xbrli:measure></xbrli:unit><xbrli:unit id="complaint"><xbrli:measure>eols:complaint</xbrli:measure></xbrli:unit><xbrli:unit id="officer"><xbrli:measure>eols:officer</xbrli:measure></xbrli:unit><xbrli:unit id="plaintiff"><xbrli:measure>eols:plaintiff</xbrli:measure></xbrli:unit><xbrli:unit id="trading_day"><xbrli:measure>eols:trading_day</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseEuropeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseU.S.AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:FollowOnOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:FollowOnOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseU.S.AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseU.S.AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-09</xbrli:startDate><xbrli:endDate>2023-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseU.S.AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseU.S.AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseEuropeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseU.S.AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-20</xbrli:startDate><xbrli:endDate>2023-12-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseEuropeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-20</xbrli:startDate><xbrli:endDate>2023-12-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eols:DistributionRightsEvolysseNasolabialFoldProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseEuropeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eols:DistributionRightsEvolysseNasolabialFoldProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseEuropeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseEuropeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-20</xbrli:startDate><xbrli:endDate>2023-12-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eols:DistributionRightsEvolysseNasolabialFoldProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseEuropeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseEuropeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseEuropeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseEuropeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="eols:MilestoneAxis">eols:FirstMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseEuropeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="eols:MilestoneAxis">eols:SecondMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseEuropeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:SCHAEONLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-14</xbrli:startDate><xbrli:endDate>2017-12-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eols:PerformanceRestrictedStockUnitsPRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eols:DistributionRightsEvolysseProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseEuropeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eols:ContingentRoyaltyObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eols:ContingentRoyaltyObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eols:DistributionRightsEvolysseNasolabialFoldProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseEuropeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eols:MarketingFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eols:MarketingFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-05</xbrli:startDate><xbrli:endDate>2022-12-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-05</xbrli:startDate><xbrli:endDate>2022-12-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-09</xbrli:startDate><xbrli:endDate>2023-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="eols:DebtInstrumentPrepaymentTermsAxis">eols:TermOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-31</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="eols:DebtInstrumentPrepaymentTermsAxis">eols:TermTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-15</xbrli:startDate><xbrli:endDate>2023-12-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-09</xbrli:startDate><xbrli:endDate>2023-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">eols:LondonInterbankOfferedRateLIBOR1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-05</xbrli:startDate><xbrli:endDate>2022-12-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">eols:SecuredFinancingOfferedRateSOFRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">eols:SecuredFinancingOfferedRateSOFRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-09</xbrli:startDate><xbrli:endDate>2023-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="eols:DebtInstrumentPrepaymentTermsAxis">eols:TermOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="eols:DebtInstrumentPrepaymentTermsAxis">eols:TermTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="eols:DebtInstrumentPrepaymentTermsAxis">eols:TermThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-07-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-10-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-16</xbrli:startDate><xbrli:endDate>2020-10-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-17</xbrli:startDate><xbrli:endDate>2021-11-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-27</xbrli:startDate><xbrli:endDate>2020-12-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eols:A2024EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eols:A2024EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-06</xbrli:startDate><xbrli:endDate>2024-06-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eols:A2024EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-08</xbrli:startDate><xbrli:endDate>2023-03-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-21</xbrli:startDate><xbrli:endDate>2017-11-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eols:A2023InducementIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eols:A2023InducementIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eols:PerformanceRestrictedStockUnitsPRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eols:PerformanceRestrictedStockUnitsPRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eols:PerformanceRestrictedStockUnitsPRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eols:PerformanceRestrictedStockUnitsPRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eols:PerformanceRestrictedStockUnitsPRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eols:CEOPerformanceRestrictedShareUnitsCPRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eols:TwoThousandAndSeventeenOmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-08</xbrli:startDate><xbrli:endDate>2023-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eols:TwoThousandAndSeventeenOmnibusIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eols:CEOPerformanceRestrictedShareUnitsCPRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-08</xbrli:startDate><xbrli:endDate>2023-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eols:TwoThousandAndSeventeenOmnibusIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eols:CEOPerformanceRestrictedShareUnitsCPRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-08</xbrli:startDate><xbrli:endDate>2023-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-18</xbrli:startDate><xbrli:endDate>2021-02-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-18</xbrli:startDate><xbrli:endDate>2021-02-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-18</xbrli:startDate><xbrli:endDate>2021-02-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">eols:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">eols:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">eols:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="id181047532df422ab5a549dd869deccb_1"></div><div style="min-height:9pt;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:15pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">For the fiscal year ended&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">December 31</ix:nonNumeric>, 2024</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">or</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION&#160;13 O</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">R 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to      </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">                  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Commission File Number:&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-38381</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">EVOLUS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">46-1385614</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(State or other jurisdiction of <br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(I.R.S. Employer<br/>Identification Number)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">520 Newport Center Dr., Suite 1200</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Newport Beach</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-12">California</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">92660</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">949</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">284-4555</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_____________________________</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, $0.00001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">EOLS</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Securities registered pursuant to Section&#160;12(g) of the Act:</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">None</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-19">Yes</ix:nonNumeric>&#160;&#9746; No&#160;&#160;&#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-20">No</ix:nonNumeric>&#160;&#160;&#9746;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric>&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be&#160;submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;No&#160;&#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.834%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.179%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.664%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-23">Accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9746;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-24">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-25">&#9744;</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. Yes <ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-26">&#9746;</ix:nonNumeric>    No  &#9744; </span></div><div><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. <ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-27">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to &#167;&#8201;240.10D-1(b). &#9744;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#9744;&#160;&#160;&#160;&#160;No&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-28">&#9746;</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The aggregate market value of the registrant&#8217;s common stock held by non-affiliates of the registrant as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter was approximately$<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="f-29">671.4</ix:nonFraction>&#160;million, based on the closing price of the registrant&#8217;s common stock on the Nasdaq Global Market of $10.85&#160;per share for such date.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">As of February&#160;28, 2025, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-30">63,586,753</ix:nonFraction> shares of the registrant&#8217;s sole class of common stock were outstanding.</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-31" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Portions of the registrant's definitive proxy statement (the &#8220;Proxy Statement&#8221;) for its 2024 Annual Meeting of Stockholders are incorporated by reference into Part III, Items 10, 11, 12, 13 and 14 of this Annual Report on Form 10-K. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant's fiscal year ended December 31, 2024.</span></ix:nonNumeric><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div></div></div><div id="id181047532df422ab5a549dd869deccb_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:78.810%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.020%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EVOLUS, INC.</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_16">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_19">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_19">16</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1B</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_22">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1C</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_25">Cybersecurity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_22">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_28">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_28">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_31">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_31">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_34">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_34">45</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_40">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_40">46</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_43">[Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_43">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_46">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_46">49</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_64">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_64">60</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_67">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_67">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_133">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_133">97</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_136">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_136">98</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9B</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_139">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_139">100</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9C</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_142">Disclosure Regarding Foreign Jurisdictions that Prevent Inspection</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_142">100</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART III</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 10</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_148">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_148">100</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 11</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_151">Executive Compensation </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_151">100</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 12</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_154">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_154">100</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 13</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_157">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_157">100</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 14</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_160">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_160">100</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART IV</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 15</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_166">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_166">101</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 16</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_169">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_169">104</a></span></div></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#3216ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#3216ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_172">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="margin-bottom:10pt;margin-top:6pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div></div></div><div id="id181047532df422ab5a549dd869deccb_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Special Note Regarding Forward-Looking Statements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K, or Annual Report, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that involve risks and uncertainties, including statements regarding future events, our business, financial condition, results of operations and prospects, our plans and expectations regarding regulatory approval, our industry and the regulatory environment in which we operate. Any statements contained herein that are not statements of historical or current facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of those terms, or other comparable terms intended to identify statements about the future. These statements include, among other things, statements relating to our expectations regarding our business, operations and market conditions, including our expectations regarding the market size and opportunity of our products.  The forward-looking statements included herein are based on our current expectations, assumptions, estimates and projections, which we believe to be reasonable, and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements. These risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond our control, include, but are not limited to, those made below under &#8220;Summary of Risk Factors&#8221; and in Item 1A Risk Factors in this Annual Report.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should carefully consider these risks, as well as the additional risks described in other documents we file with the U.S. Securities and Exchange Commission, or SEC, in the future, including subsequent Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, which may from time to time amend, supplement or supersede the risks and uncertainties we disclose. We also operate in a very competitive and rapidly changing environment. New risks emerge from time to time and it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In light of the significant risks and uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that such results will be achieved, and readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. Except as required by law, we undertake no obligation to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. You should read this Annual Report on Form 10-K and the other documents we file with the SEC with the understanding that our actual future results, levels of activity, performance and achievements may be materially different from what we expect. We qualify all of our forward-looking statements by the cautionary statements referenced above.</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Risk Factors</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An investment in our securities involves various risks and you are urged to carefully consider the risks discussed under Item 1A &#8220;Risk Factors,&#8221; in this Annual Report on Form 10-K prior to making an investment in our securities. If any of the risks below or in Item 1A &#8220;Risk Factors&#8221; occurs, our business could be materially and adversely affected. As more fully described in Item 1A &#8220;Risk Factors&#8221;, the principal risks and uncertainties that may affect our business, financial condition and results of operations include, but are not limited to, the following:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant losses since our inception.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">faces, and any of our future product candidates will face, significant competition and our failure to effectively compete may prevent us from maintaining our market share and expansion.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our products may fail to achieve the broad degree of aesthetic practitioner adoption and use or consumer demand necessary for continued commercial success.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are dependent on Symatese Aesthetics, S.A.S., or Symatese, to achieve regulatory approval for the Evolysse&#8482; hyaluronic acid gels product line in the United States and Europe.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to obtain approval or obtain approval on our estimated time frame for the Evolysse&#8482; product line would negatively affect our ability to sell these products.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may require additional financing to fund our future operations or execute corporate development activities, and a failure to obtain additional capital when so needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our operations.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we or our counterparties do not comply with the terms of our settlement agreements with Medytox, Inc., or Medytox, we may face litigation or lose our ability to market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which would materially and adversely affect our ability to carry out our business and our financial condition and ability to continue as a going concern.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The terms of the Medytox Settlement Agreements will continue to reduce our profitability.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on our licensing agreements with Daewoong Pharmaceutical Co. Ltd, or Daewoong, and Symatese and any termination or loss of significant rights, including exclusivity, under these agreements would materially and adversely affect our business. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our failure to successfully in-license, acquire, develop and market additional product candidates or approved products would impair our ability to grow our business.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to market our products is limited to their approved indications, and if we want to expand the indications for which we market our products, we will need to obtain additional regulatory approvals, which will be expensive and may not be granted.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third party claims of intellectual property infringement may prevent or delay our commercialization efforts and interrupt our supply of products.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we or any of our current or future licensors, including Daewoong and Symatese, are unable to maintain, obtain or protect intellectual property rights related to our products or any of our future product candidates, we may not be able to compete effectively in our market.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may need to increase the size of our organization, including our sales and marketing capabilities in order to further market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and we may experience difficulties in managing this growth.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on our digital technology and applications and our business and operations would suffer in the event of information system failures or a cybersecurity incident.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to extensive government regulation, and we may face delays in or not obtain regulatory approval of our product candidates and our compliance with ongoing regulatory requirements may result in significant additional expense, limit or delay regulatory approval or subject us to penalties if we fail to comply.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context indicates otherwise, as used in this Annual Report on Form 10-K, the terms &#8220;Evolus,&#8221; &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Evolus, Inc., a Delaware corporation, and our subsidiaries taken as a whole, unless otherwise noted. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EVOLUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Evolux</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Evolysse&#8482; are trademarks of ours that are used in this Annual Report on Form 10-K. Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the trade name in the United States for our approved product with non-proprietary name, prabotulinumtoxinA-xvfs. This product has different trade names outside of the United States, including Nuceiva</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Canada, Europe and Australia, but is referred to throughout this Annual Report on Form 10-K as Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our hyaluronic acid gel products have different trade names outside of the United States, including Estyme</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Europe, but are referred to throughout this Annual Report on Form 10-K as Evolysse&#8482;. This Annual Report on Form 10-K also includes trademarks, trade names and service marks that are the property of other organizations, such as BOTOX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and BOTOX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cosmetic, which we refer to throughout this Annual Report on Form 10-K as BOTOX. Solely for convenience, trademarks and trade names referred to in this Annual Report on Form 10-K may appear without the &#174; and &#8482; symbols, but those references are not intended to indicate that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert its rights, to these trademarks and trade names. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Website References</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this Annual Report on Form 10-K, we make references to our website at www.evolus.com. References to our website through this Form 10-K are provided for convenience only and the content on our website does not constitute a part of, and shall not be deemed incorporated by reference into, this Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="id181047532df422ab5a549dd869deccb_13"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part I</span></div><div id="id181047532df422ab5a549dd869deccb_16"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. &#160;&#160;&#160;&#160;Business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a global performance beauty company with a customer-centric approach to delivering breakthrough products. Our primary market is the cash-pay aesthetic market, which consists of medical products that consumers pay for directly out of pocket. Our customers are aesthetic practitioners who are properly licensed to deliver our products. By avoiding the regulatory burdens that accompany reimbursed products and pursuing an aesthetic-only non-reimbursed product strategy, we believe that we create flexibility to deliver a unique value proposition to our customers. We utilize this flexibility to drive customer adoption efforts through programs such as our consumer loyalty program, co-branded marketing programs, promotional events and pricing strategies.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Products and Product Candidates</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our currently commercially available product and our product candidates represent two of the largest product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels, respectively.</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is our commercially available proprietary 900 kilodalton, or kDa, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as &#8220;frown lines,&#8221; in adults. Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). We believe aesthetic practitioners generally prefer the performance characteristics of the complete 900 kDa neurotoxin complex and are accustomed to injecting this formulation.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is bolstered by the results from our TRANSPARENCY global clinical program which included more than 2,100 patients and provides robust data to physicians evaluating the purchase of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We believe the comprehensive TRANSPARENCY clinical data set, including a head-to-head Phase III study comparing Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and BOTOX, provides physicians with confidence in recommending Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to their patients.</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is currently available in the United States, Canada and certain European markets and we plan to make the product available in Australia and additional European markets.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolysse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a collection of injectable hyaluronic acid gels which utilize first-generation cold technology. The line includes a variety of products including mid face, nasolabial folds, lips and eyes in the United States and Europe. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2024, regulatory approval was received in the European Union for four products in the Evolysse&#8482; line: Evolysse&#8482; Form, Evolysse&#8482; Smooth, Evolysse&#8482; Sculpt and Evolysse&#8482; Lips. In February 2025, we received approval from the U.S. Food and Drug Administration, or FDA, for Evolysse&#8482; Form and Evolysse&#8482; Smooth injectable hyaluronic acid gels for wrinkles and folds, such as nasolabial folds. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate launching Evolysse&#8482; Form and Evolysse&#8482; Smooth in the United States in the second quarter of 2025. We also anticipate launching all four approved Evolysse&#8482; products in Europe in the second half of 2025. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are seeking premarket approval, or PMA, with the FDA for Evolysse&#8482; Sculpt and Evolysse&#8482; Lips and, if approved, we</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expect to launch those products in the United States in 2026 and 2027, respectively.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following chart details certain important features of our primary product lines:</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;padding-right:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.833%"><tr><td style="width:1.0%"/><td style="width:10.080%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.167%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.136%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.620%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.398%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product Line</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Status</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Treatment</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Approvals</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Market Size in 2028</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Injectable botulinum toxin type A</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Temporary improvement in the appearance of frown lines in adults</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States - 2019</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada - 2018</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">European Union/United Kingdom/European Economic Area - 2019</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia - 2023</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland - 2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States* - $4.3 billion</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe** - $1.0 billion</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evolysse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Launching in 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portfolio of injectable hyaluronic acids</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Improvement of moderate to severe nasolabial folds facial wrinkles, mid face volume, lip fullness and infraorbital hollow correction</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">European Union - 2024 (4 products)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States - 2025 (2 products)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States* - $1.8 billion</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe** - $1.0 billion</span></div></td></tr></table></div><div style="padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Source: Medical Insight&#8217;s The Global Aesthetic Market Study</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">** Source: Clarivate Aesthetic Injectables Market Insights</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Medical Aesthetics Market Opportunity </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to Medical Insights, in 2024, total sales of professional medical aesthetic products were estimated to be $17.1 billion globally. Through 2028, the total sales of professional medical aesthetic products is expected to expand by 7.0% per year to $21.9 billion. Within this market, the facial injectables market, consisting of neurotoxins and hyaluronic acid gels, is estimated to be $10.9 billion in 2024 and is expected to grow to $14.5 billion in 2028.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the medical aesthetics market and the facial injectables market are poised for consistent growth driven by a number of factors, including:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased use by millennials and younger demographics who are increasingly seeking medical aesthetic treatments and utilizing neurotoxins as an entry point for aesthetic procedures due to their minimally invasive nature;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an aging population together with an increasing life expectancy, which is resulting in more consumers with a desire for improved appearance and well-being over a longer period of time; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">rising disposable income, with the United States Bureau of Economic Analysis reporting that real disposable income in the United States increased approximately 29% from December 2014 to December 2024;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">growing awareness, including through social media, utilization and acceptance of elective or minimally invasive aesthetic procedures;&#160;and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued innovation and improved accessibility to these treatments due to an increase in the number of aesthetic practitioners who perform these procedures.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within the multiple age groups that utilize our products, we strategically focus our marketing efforts on the millennial segment which is the largest cohort in the United States population. Millennials are defined as individuals born between 1981 and 1996. We believe millennials view aesthetic treatments as integral to personal health and self-care, heavily influenced by social media and the internet.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategic Differentiation</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key components of our strategy are to:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Focus on the largest segments of the medical aesthetic market.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aesthetic neurotoxins and hyaluronic acid gels are the largest and two of the fastest growing segments in the rapidly expanding global aesthetics market. With their high regulatory barriers to entry, these economically resilient product segments are poised for continued growth and adoption.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pursue an aesthetic-only strategy to enhance marketing and pricing flexibility along with improving transparency for our customers. With a reduced regulatory burden compared to third-party payor reimbursed therapeutic products, there are a number of benefits that market participants in reimbursed markets are unable to achieve. Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is currently the only U.S. commercialized neurotoxin without a therapeutic indication.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Launch directly or partner outside of the United States to reach and serve aesthetic practitioners and consumers in those territories. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Leverage our differentiated digital platform to efficiently open new customer accounts, personalize the purchasing process and efficiently deploy marketing programs at scale, including co-branded media. We have built and continue to improve our platform with the goal of limiting friction and enhancing the overall experience for aesthetic practitioners and ultimately consumers. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Establish a leading medical aesthetics company with a diversified product offering by in-licensing technology, developing partnerships and potentially acquiring products.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory Development</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolysse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hyaluronic Acid Gels Pipeline</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The graphic below provides a summary of the current status of development of the Evolysse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> collection of hyaluronic acid gels in the United States and European Union and anticipated key milestones. In the United States we obtained FDA approval of Evolysse&#8482; Form and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolysse&#8482; Smooth in February 2025 and we are seeking a PMA approval for Evolysse&#8482; Sculpt and Evolysse&#8482; Lips. In the European Union we obtained a CE mark for the Evolysse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> collection of hyaluronic acid gels in December 2024.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><img src="eols-20241231_g1.jpg" alt="Capture.jpg" style="height:309px;margin-bottom:5pt;vertical-align:text-bottom;width:672px"/></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Daewoong Pharmaceuticals Co. Ltd., or Daewoong, manufactures and supplies Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to us. Daewoong has over 70 years of experience manufacturing pharmaceutical products and is one of the largest pharmaceutical companies in South Korea. Daewoong constructed a facility in South Korea where Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is produced. We believe this facility will be sufficient to meet demand for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the foreseeable future. The Daewoong facility has been cleared by regulators in each jurisdiction in which Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is approved and is subject to continuous inspections from these regulators.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolysse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Symatese Aesthetics S.A.S., or Symatese, manufactures and supplies Evolysse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for us. Symatese has 25 years of experience in manufacturing biomaterials and over a decade of experience manufacturing hyaluronic-acid based gels which have been approved in the United States, Europe and elsewhere. Symatese maintains a manufacturing facility outside Lyon, France for the production of Evolysse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We believe this facility will be sufficient to meet the foreseeable demand for Evolysse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In connection with regulatory approvals for the United States and Europe, the Symatese facility will be inspected by regulators in those countries.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Daewoong License and Supply Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2013, we entered into a License and Supply Agreement with Daewoong, the Daewoong Agreement, which has been amended from time to time, pursuant to which Daewoong agreed to manufacture and supply Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and grant us an exclusive license to import, distribute, promote, market, develop, offer for sale and otherwise commercialize and exploit Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for aesthetic indications in the United States, EU, United Kingdom, members of the European Economic Area, Switzerland, Canada, Australia, New Zealand, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. Under the Daewoong Agreement, we are required to make certain minimum annual purchases in order to maintain the exclusivity of the license. If we fail to meet these purchase requirements, Daewoong may, at its option, convert the exclusive license for such covered territory to a non-exclusive license. These minimum purchase obligations are contingent upon the occurrence of future events, including receipt of governmental approvals and our future market share in various jurisdictions. Under the Daewoong Agreement, Daewoong is responsible for all costs related to the manufacturing of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including costs related to the operation and upkeep of its manufacturing facility, and we are responsible for all costs related to obtaining regulatory approval, including clinical expenses, and commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial term of the Daewoong Agreement expired September 30, 2023, and automatically renewed for an additional three-year term. The Daewoong Agreement automatically renews for unlimited additional three-year terms if we meet certain performance requirements. We expect to meet these performance requirements. The Daewoong Agreement will terminate (A) upon written notice by either us or Daewoong upon a continuing default that remains uncured within 90 days (or 30 days for a payment default) by the other party, or (B) without notice upon the bankruptcy or insolvency of our company.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Daewoong Agreement, we are the sole owner of any marketing authorization and clinical trial results we pursue in a covered territory. However, if we do not renew the Daewoong Agreement or upon termination of the Daewoong Agreement due to a breach by us, we are obligated to transfer our rights to Daewoong.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Symatese License, Supply and Distribution Agreements</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 9, 2023, we entered into a License, Supply and Distribution Agreement, or the Symatese U.S. Agreement, with Symatese, pursuant to which Symatese granted us an exclusive right to commercialize and distribute its five Evolysse&#8482; hyaluronic acid gels product candidates, including the products referred to as: (i) Form; (ii) Smooth; (iii) Sculpt; (iv) Lips; and (v) Eye in the United States for use in the aesthetics and dermatological field of use. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 20, 2023, we entered into a License, Supply and Distribution Agreement, or the Symatese Europe Agreement, pursuant to which Symatese granted to us an exclusive right to commercialize and distribute four hyaluronic acid gel product candidates, which are referred to as: (i) Form; (ii) Smooth; (iii) Sculpt and (iv) Lips  in 50 countries in Europe for use in the aesthetics and dermatological fields. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under both agreements, which we refer to collectively as the Symatese agreements, we also have the right of first negotiation to obtain a license from Symatese to commercialize and distribute any new products developed using the same technology as the Evolysse&#8482; collection of hyaluronic acid gels.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both Symatese agreements require us to make certain minimum purchases in order to maintain the exclusivity of our licenses. Both agreements have a 15-year term from the first product that is approved under the agreement and contain unlimited automatic renewal terms of 5-years thereafter. The agreements can be terminated based upon a material breach that remains uncured or failure to meet the minimum purchase requirements. Under the agreements, Symatese is responsible for all costs related to the manufacturing of Evolysse&#8482; including costs related to the operation and upkeep of its manufacturing facility, and we are responsible for certain costs related to the registration of the Lips and Eye Products with the FDA and all costs related to commercialization of Evolysse&#8482;. Under both agreements, Symatese will be responsible for and the sole owner of any marketing authorization and clinical trial results for the hyaluronic acid gel products.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of Settlement Agreements</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we settled certain litigation claims related to a complaint against us filed by Allergan, Inc. and Allergan Limited, collectively Allergan, and Medytox, Inc. in the U.S. International Trade Commission related to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and certain related matters by entering into a Settlement and License Agreement with Medytox and Allergan, which we refer to as the U.S. Settlement Agreement, and another Settlement and License Agreement with Medytox, which we refer to as the ROW Settlement Agreement. We refer to the U.S. Settlement Agreement and the ROW Settlement Agreement collectively as the Medytox Settlement Agreements.</span></div><div style="margin-bottom:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2022, we made our second cash payment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$15.0 million, and in the first quarter of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023, we completed our final cash payment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our remaining obligation is to pay Medytox a mid-single digit royalty percentage on net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States and all territories we have licensed outside the United States through September 16, 2032. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aesthetic Neurotoxins</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are only six approved injectable botulinum toxin type A neurotoxins in the United States for aesthetic indications, including Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. There are also other injectable botulinum toxin type A products being developed for the U.S. market. We believe the primary competing products in this market include BOTOX, Dysport, Xeomin, Daxxify and Letybo:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">BOTOX, marketed by AbbVie, received FDA approval in 2002 for glabellar lines.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Dysport, marketed by Galderma S.A., or Galderma, received FDA approval in 2009 for glabellar lines.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Xeomin, marketed by Merz Pharma GmbH &amp; Co., or Merz, received FDA approval in 2011 for glabellar lines.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Daxxify, marketed by Revance Therapeutics, Inc., or Revance, received FDA approval in late 2022 for glabellar lines.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Letybo, marketed by Hugel, Inc., or Hugel, received FDA approval in February 2024 for glabellar lines.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, Medytox, Inc. and Galderma S.A. have each submitted a Biologics License Application, or BLA, to the FDA for injectable botulinum toxin type A neurotoxins. If any one of these BLAs is approved, we expect the competition in the U.S. injectable botulinum toxin market to further increase. Most of our primary competitors are also approved to sell injectable botulinum toxin type A neurotoxins in Europe and other markets that we may enter.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dermal Filler Market</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Evolysse&#8482; collection of injectable hyaluronic acid gels competes in the Dermal Filler market in the United States. The major competitive products in the United States are:</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hyaluronic Acid Based Dermal Fillers</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Juv&#233;derm line of fillers, marketed by AbbVie. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Restylane line of fillers, marketed by Galderma. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Belotero line of fillers, marketed by Merz. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">RHA line of fillers, manufactured by Teoxane S.A. and marketed by Revance.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Revanesse line of fillers, marketed by Prollenium Medical Technologies, Inc.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Hyaluronic Acid Dermal Fillers</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Sculptra Aesthetic, marketed by Galderma.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">RADIESSE line of fillers, marketed by Merz.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of companies are currently developing hyaluronic acid gels for the United States market. Outside of the United States there are an even greater number of competitors with hyaluronic acid gel products available.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Medical Aesthetics Products</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the companies commercializing and developing neurotoxins and dermal fillers, there are other products and treatments that may indirectly compete with our products and product candidates, including but not limited to laser treatments, brow lifts, chemical peels, medical grade and mass-market skin care products, fat injections and removal and cold therapy. We compete with various companies that have products in these medical aesthetic categories. Among these companies are AbbVie, Sanofi, Revance, Sun Pharma, Bausch Health Companies, Mentor Worldwide LLC, a division of Johnson &amp; Johnson, Merz, Galderma, and Skinceuticals, a division of L&#8217;Oreal SA.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Seasonality</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not observed significant seasonality in our net revenues in recent years. However, we are aware that sales of aesthetic neurotoxins and dermal fillers are historically subject to the impact of traditional seasonality in the medical aesthetic market, which generally experiences higher revenue in the second and fourth calendar quarters as compared to the first and third calendar quarters. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation in the United States</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a highly regulated industry that is subject to significant federal, state, local and foreign regulation. Our business has been, and will continue to be, subject to a variety of laws including the Federal Food Drug and Cosmetic Act, or FFDCA, and the Public Health Service Act, or the PHS Act, among others. Biologics, such as our neurotoxin product, and medical devices, including our hyaluronic acid gel product candidates, are subject to regulation under the FFDCA and PHS Act.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, biopharmaceutical products and medical devices are subject to extensive regulation by the FDA. The FFDCA, PHS Act, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, regulatory approval, license or clearance, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of these products. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as the FDA&#8217;s refusal to approve pending license or marketing applications, warning letters and other enforcement actions, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FDA Marketing Approval of Biologics</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process required by the FDA before a biological product may be marketed in the United States generally involves the following:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completion of nonclinical laboratory tests and animal studies according to good laboratory practices, or GLPs, and applicable requirements for the humane use of laboratory animals or other applicable regulations;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submission to the FDA of an investigative new drug application, or IND, which must become effective before human clinical trials may begin;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed biological product for its intended use, according to the FDA&#8217;s regulations, commonly referred to as good clinical practices, or GCPs, and any additional requirements including those for the protection of human research subjects and their health and other personal information;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submission to the FDA of a BLA for marketing approval that includes substantive evidence of safety;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">purity and potency from results of nonclinical testing and clinical trials;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological product is produced to assess compliance with cGMP, to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s identity, strength, quality and purity and, if applicable, the FDA&#8217;s current good tissue practices for the use of human cellular and tissue products;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential FDA audits of the nonclinical study and clinical trial sites that generated the data in support of the BLA; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA review and approval of the BLA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-Approval Requirements for Biologics in the United States</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a BLA is approved, a product is subject to certain post-approval requirements. For instance, the FDA closely regulates the post-approval marketing and promotion of biologics, including standards and regulations, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the internet. Biologics may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Adverse event reporting and submission of periodic reports is required following the FDA approval of a BLA. The FDA also may require post-marketing testing, known as Phase IV testing, Risk Evaluation and Mitigation Strategies, or REMS, and surveillance to monitor the effects of an approved product or place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control as well as product manufacturing, packaging and labeling procedures must continue to conform to cGMP after approval. Manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA during which the agency inspects manufacturing facilities to assess compliance with applicable regulations such as cGMP and the Quality System Regulation. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMP. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Medical Device Regulation</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA regulates the sale and distribution in interstate commerce of medical devices under FFDCA. Devices must undergo premarket review by the FDA prior to commercialization unless the device is of a type exempted from such review by statute, regulation, or pursuant to the FDA&#8217;s exercise of enforcement discretion. Pursuant to the FFDCA, medical devices are subject to varying degrees of regulatory control and are classified in one of three classes depending on the controls the FDA determines necessary to reasonably ensure their safety and effectiveness.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class I devices are those for which reasonable assurance of safety and effectiveness can be provided by adherence to the FDA&#8217;s general controls for medical devices, which include applicable portions of the FDA&#8217;s Quality System Regulation, or QSR, facility registration and product listing, reporting of adverse medical events and appropriate, truthful and non-misleading labeling, advertising and promotional materials. Many Class I devices are exempt from premarket regulation; however, some Class I devices require premarket clearance by the FDA through the 510(k) premarket notification process described below.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class II devices are subject to the FDA&#8217;s general controls, and any other special controls, such as performance standards, post-market surveillance, and the FDA guidelines, deemed necessary by the FDA to provide reasonable assurance of the devices&#8217; safety and effectiveness. Premarket review and clearance by the FDA for Class II devices are accomplished through the 510(k) premarket notification procedure, although some Class II devices are exempt from the 510(k) requirements. Premarket notifications are subject to user fees, unless a specific exemption applies. To obtain 510(k) clearance, a manufacturer must submit a premarket notification demonstrating that the proposed device is &#8220;substantially equivalent&#8221; to a predicate device, which is a previously cleared 510(k) device or a pre-amendment device that was in commercial distribution before May 28, 1976, for which the FDA has not yet called for the submission of a PMA application. In determining substantial equivalence, the FDA assesses whether the proposed device has the same intended use as the predicate device, and the same technological characteristics as the predicate device or different technological characteristics but the information submitted in the premarket notification demonstrates the device is as safe and effective as a legally marketed device and does not raise different questions of safety and effectiveness than the predicate device. The FDA may request additional information, including clinical data. Under the FFDCA, a manufacturer submits a premarket notification 90 days before introducing a device into interstate commerce, but the FDA&#8217;s review of the premarket notification can take significantly longer. If the FDA determines that the device is substantially equivalent to the predicate device(s), the subject device may be marketed. However, if the FDA makes a not substantially equivalent determination, then the device would be regulated as a Class III device, discussed below. If a manufacturer obtains a 510(k) clearance for its device and then makes a modification that could significantly affect the device&#8217;s safety or effectiveness, a new premarket notification must be submitted to the FDA.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class III devices are deemed by the FDA to pose the greatest risk, such as those for which reasonable assurance of the device&#8217;s safety and effectiveness cannot be assured solely by the general controls and special controls described above and that are life-sustaining or life-supporting. Some pre-amendment Class III devices for which the FDA has not yet required a PMA require the FDA&#8217;s clearance of a premarket notification in order to be marketed.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, most Class III devices are required to undergo the PMA process in which the manufacturer must demonstrate reasonable assurance of the safety and effectiveness of the device to the FDA&#8217;s satisfaction. A PMA application must provide valid scientific evidence, typically extensive preclinical and clinical trial data and information about the device and its components regarding, among other things, device design, manufacturing and labeling. PMA applications (and supplemental PMA applications) are subject to significantly higher user fees than are 510(k) premarket notifications. Some PMA applications are exempt from a user fee, for example a small business&#8217;s first PMA.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a PMA application is submitted and found to be sufficiently complete, the FDA begins an in-depth review of the submitted information. During this review period, the FDA may request additional information or clarification of information already provided. The FDA also may convene an advisory panel of outside experts to review and evaluate the application and provide recommendations to the FDA as to the approvability of the device. In addition, the FDA generally will conduct a pre-approval inspection of the manufacturing facility to ensure compliance with the QSR. The FDA can delay, limit or deny approval of a PMA application for many reasons.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA&#8217;s evaluations of both the PMA application and the manufacturing facilities are favorable, the FDA will either issue an approval letter authorizing commercial marketing or an approvable letter that usually contains a number of conditions that must be met in order to secure final approval. If the FDA&#8217;s evaluations are not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. The agency may determine that additional clinical trials are necessary, in which case the PMA approval may be delayed while the trials are conducted and the data acquired are submitted in an amendment to the PMA. Even with additional trials, the FDA may not approve the PMA application. The PMA process, including the gathering of clinical and nonclinical data and the submission to and review by the FDA, can take several years, and the process can be expensive and uncertain.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the FDA approves a PMA, the agency can impose post approval conditions that it believes necessary to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution. After approval of a PMA, a new PMA or PMA supplement may be required for a modification to the device, its labeling or its manufacturing process.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A clinical trial may be required in support of a 510(k) submission and generally is required for a PMA application. These trials generally require an Investigational Device Exemption, or IDE, approved by the FDA for a specified number of patients, unless the product is exempt from IDE requirements or deemed a non-significant risk device eligible for more abbreviated IDE requirements. The IDE application must be supported by appropriate data, such as animal and laboratory testing results, showing that it is safe to test the device in humans and that the testing protocol is scientifically sound. Clinical trials may begin 30 days after the submission of the IDE application unless the FDA disapproves the IDE or places the trial on clinical hold. Additionally, clinical trials may not begin until their protocol and informed consent receive approval from the appropriate institutional review boards, or IRBs, at the clinical trial sites. All clinical trials must be conducted in accordance with the FDA&#8217;s IDE regulations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if regulatory approval or clearance of a device is granted, the FDA may impose limitations on the uses and indications for which the device may be labeled and promoted, and the device remains subject to significant regulatory requirements. Medical devices may be marketed only for the uses and indications for which they are cleared or approved. Device manufacturers must register their facilities and list their devices with the FDA. A device manufacturer&#8217;s manufacturing processes and those of some of its suppliers are required to comply with the applicable portions of the QSR, which covers quality management, design, production and process controls, quality assurance, labeling, packaging, shipping, and complaint handling. Device manufacturers must submit to the FDA medical device reports for deaths, serious injuries, and certain malfunctions and report certain field corrections and product recalls or removals. Some manufacturers also may be subject to post-market surveillance regulations. Facility records and manufacturing processes are subject to periodic unscheduled inspections by the FDA.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may include any of the following sanctions: public warning letters, fines, injunctions, civil or criminal penalties, recall or seizure of products, operating restrictions, partial suspension or total shutdown of production, delays in or denial of 510(k) clearance or PMA applications for new products, challenges to existing 510(k) clearances or PMA applications, and a recommendation by </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the FDA to disallow a device manufacturer from entering into government contracts. The FDA also has the authority to request repair, replacement or refund of the cost of any device manufactured or distributed. In the event that a supplier fails to maintain compliance with a device manufacturer&#8217;s quality requirements, the manufacturer may have to qualify a new supplier and could experience manufacturing delays as a result.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Regulation of the Healthcare Industry</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we do not currently have plans for our products to be covered by insurance or government reimbursement programs, if we were to offer reimbursable products, we could be subject to federal laws and regulations covering reimbursable products, such as the Anti-Kickback Statute, Stark Law and Physician Payment Sunshine Act. These laws that may affect our ability to operate include, but are not limited to:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Anti-Kickback Statute, which prohibit persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce either the referral of an individual, or furnishing or arranging for a good or service, for which payment may be made under a federal healthcare program;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Federal False Claims Act which imposes civil and criminal liability on individuals and entities who submit, or cause to be submitted, false or fraudulent claims for payment to the government;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Federal Civil Monetary Penalties Law, which prohibits, among other things, offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary&#8217;s decision to order or receive items or services reimbursable by the government from a particular provider or supplier;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Foreign Corrupt Practices Act (&#8220;FCPA&#8221;), which prohibits certain payments made to foreign government officials;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services relating to healthcare matters; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Federal Physician Payments Sunshine Act, and its implementing regulations, which require that certain manufacturers of drugs, medical devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program (with certain exceptions) to report to the Centers for Medicare &amp; Medicaid Services, or CMS, information related to certain payments or other transfers of value made or distributed to physicians, which is defined broadly to include other healthcare providers, teaching hospitals, and ownership and investment interests held by physicians and their immediate family members; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">State and foreign law equivalents of the foregoing and state laws regarding pharmaceutical company marketing compliance, reporting and disclosure obligations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our operations are found to be in violation of any of these laws, regulations, rules or policies or any other law or governmental regulation, or if interpretations of the foregoing change, we may be subject to civil and criminal penalties, damages, fines and the curtailment or restructuring of our operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation in Europe</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EU Regulation of Biologics</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Economic Area, or EEA (which is composed of the 27 Member States of the EU plus Norway, Iceland and Liechtenstein), medicinal products can only be commercialized after obtaining a Marketing Authorization, or MA.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are two types of MAs:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Community MA, which is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMA. and which is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, and medicinal products indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the Centralized Procedure. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we are a biotechnology medicinal products company, we are eligible for a Community MA under the Centralized Procedure.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the above described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EU Regulation of Medical Devices</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Union, medical devices must be CE marked in order to be marketed. CE marking a device involves working with a Notified Body (or in some cases, for the lowest risk class devices, the manufacturer can self-certify) to demonstrate that the device meets all applicable requirements of the EU medical devices legislation and that the Quality Management System is compliant. The EU&#8217;s Medical Device Directive, or MDD, has been replaced by the EU Medical Device Regulation, or EU MDR, enacted in 2017, and which became effective on May 26, 2021. EU MDR requirements will phase in on a product-by-product basis as certifications issued under the MDD lapse and will require all products to undergo review and approval under these new regulations. The timing for this transition has been extended from no later than May 26, 2024 to December 2027 or December 2028, depending on device classification, provided certain conditions are met with regard to the new regulation, one of which being that all submissions are filed by May 26, 2024. The EU MDR will generally require increased levels of clinical data as compared to MDD requirements, and all product technical data must comply to the latest standards regardless of when the product was initially developed.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UK Regulation of Biologics and Medical Devices</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The UK formally left the EU on January 31, 2020. The EU and the UK have concluded a trade and cooperation agreement, or TCA, which was provisionally applicable since January 1, 2021 and has been formally applicable since May 1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of GMP, inspections of manufacturing facilities for medicinal products and GMP documents issued, but does not foresee wholesale mutual recognition of UK and EU pharmaceutical regulations. At present, Great Britain has implemented EU legislation on the marketing, promotion and sale of medicinal products through the Human Medicines Regulations 2012 (as amended) (under the Northern Ireland Protocol, the EU regulatory framework will continue to apply in Northern Ireland). The regulatory regime in Great Britain therefore currently aligns with EU regulations in many ways, however it is possible that these regimes will diverge more significantly in the future now that Great Britain&#8217;s regulatory system is independent from the EU.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In respect of medical devices, since the end of the Brexit transitional period on January 1, 2021, new regulations require medical devices to be registered with the Medicines and Healthcare products Regulatory Agency, or MHRA (the UK medicines and medical devices regulator) before being placed on the Great Britain market. The MHRA will only register devices where the manufacturer or their United Kingdom Responsible Person has a registered place of business in the United Kingdom. As of July 1, 2023, in Great Britain, all medical devices will require a UKCA (UK Conformity Assessed) mark. UCKA marking will, however, not be recognized in the EU. The rules for placing medical devices on the market in Northern Ireland, which is part of the United Kingdom, differ from those in the rest of the United Kingdom.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulation Outside of the United States and Europe</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the United States and EU, we may be subject to a variety of regulations in other jurisdictions governing manufacturing, clinical trials, commercial sales and distribution of our future products. Whether or not we obtain FDA approval or MA approval for a product candidate, we must obtain approval of the product by the comparable regulatory authorities of foreign countries before commencing clinical trials or marketing in those countries. The approval process varies from country to country, and the time may be longer or shorter than that required for FDA approval or MA approval. The </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Data Privacy and Security Laws and Regulations</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to data privacy and security regulation by the federal government, states and non-U.S. jurisdictions in which we conduct our business. For example, HIPAA, as amended by the Health Information Technology and Clinical Health Act, or HITECH, and its implementing regulations, imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s privacy and security standards directly applicable to &#8220;business associates,&#8221; those independent contractors or agents of covered entities that create, receive, maintain, transmit or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, state and non-U.S. laws, including the General Data Protection Regulation adopted by the EU, govern the privacy and security of health and other personal information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous other laws and legislative and regulatory initiatives at the federal and state levels addressing privacy and security concerns. We also remain subject to federal or state privacy-related laws that are more restrictive than the privacy regulations issued under HIPAA. These laws vary and could impose additional penalties. For example, the Federal Trade Commission uses its consumer protection authority to initiate enforcement actions in response to alleged privacy and data security violations. Further, certain states have proposed or enacted legislation that will create new data privacy and security obligations for certain entities, such as the California Consumer Privacy Act, or CCPA, which came into effect January 1, 2020 and was recently amended and expanded by the California Privacy Rights Act, or the CRPA, passed on November 3, 2020. The CCPA and CPRA, among other things, create new data privacy obligations for covered companies and provides new privacy rights to California residents, including the right to opt out of certain disclosures of their information. The CCPA also created a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach. It remains unclear what, if any, additional modifications will be made to the CPRA by the California legislature or how it will be interpreted. Therefore, the effects of the CCPA and CPRA are significant and will likely require us to modify our data processing practices and may cause us to incur substantial costs and expenses to comply, particularly given our base of operations in California.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Regulation</span></div><div style="margin-bottom:10pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to numerous foreign, federal, state, and local environmental, health and safety laws and regulations relating to, among other matters, safe working conditions, manufacturing practices, fire hazard control, product stewardship and end-of-life handling or disposition of products, and environmental protection, including those governing the generation, storage, handling, use, transportation and disposal of hazardous or potentially hazardous substances and biological materials. We believe that we have been and remain in substantial compliance with all applicable environmental laws and regulations and that we currently have no liabilities under such environmental requirements that could reasonably be expected to materially harm our business, results of operations or financial condition.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Resources</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we had 332 employees, all of whom were full-time in the United States, Canada and Europe, and 57% of our full-time employees were women. None of our employees are represented by labor unions or covered by collective bargaining agreements, and we have never experienced any work stoppage. We believe we have good relations with our employees.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Attracting and Developing Talent</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our employees are our greatest asset, and our future success largely depends upon our continued ability to attract and retain high caliber talent. Talent management is critical to our ability to execute our long-term growth strategy. To facilitate talent attraction and retention, we strive to make our company a rewarding workplace. We provide opportunities for our employees to grow and develop in their careers, through professional development, leadership coaching, formal and informal training opportunities, and an annual performance review process to encourage ongoing growth and development. These opportunities are supported by strong total rewards packages, and by programs that build connections among our employees. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation and Benefits</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to a Total Rewards strategy that complements our mission, culture, and business objectives. Our goal is to provide competitive compensation and benefit programs that drive a high level of employee satisfaction and allow us to attract and retain the best and brightest talent. We want employees to feel at their best and be at their best so they can make a profound impact on our culture, community and business results. Compensation and benefits are two of the main pillars of our total rewards package. We provide total cash compensation (base pay and bonus/commission) that is highly competitive in the labor markets in which we compete for talent. We also ensure that pay is internally equitable by differentiating rewards based on employee performance and impact to the company. This empowers employees to take ownership over their career and development trajectory. Long-term incentives in the form of equity (Stock Options and RSUs) provide a sense of ownership in the company&#8217;s long-term success and help retain talent that can make a difference. We also provide a robust and highly competitive benefits package to ensure employees&#8217; personal and family needs are met whether it&#8217;s health (medical/dental/vision), wealth and retirement (401k with competitive employer match), or well-being (flexible PTO, paid leave, wellness coaching). We want employees to know that we are investing in their success so they can bring the best version of themselves each day.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health, Safety and Wellness</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to the health, safety and wellness of our employees. We provide our employees with access to a variety of health and wellness programs, including programs that support physical and mental health and well-being by providing tools, resources, and coaching to help them improve or maintain a healthy lifestyle. We maintain a healthy workplace by encouraging employees to work remotely if feeling ill and offering a hybrid work schedule.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inclusion and Belonging</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We promote an inclusive culture that values equity, opportunity, and respect. In 2019, we formed an employee-led Culture &amp; Belonging Council. This council has a vision to create and foster a culture that reflects diversity and inclusion so that each of our employees has a sense of belonging as their authentic, unique selves. In support of our inclusive culture, we provide a variety of diversity, equity, and inclusion trainings, including unconscious bias training for employees and managers to strengthen employee awareness and strive to recruit a diverse talent pool across all levels of the organization. We are an equal opportunity employer and believe that diverse and differentiated views contribute to making us a better organization. It is our conscious effort to support and promote equal opportunity for all our employees within the workplace.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our company has been built on the belief and commitment of evolving together. This applies not only to our employees and customers, but also to the communities in which we operate. We offer paid volunteer time off to our employees and encourage our team of employees to become involved in their communities, lending their voluntary support to programs that positively impact the quality of life within these communities.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive offices are located at&#160;520 Newport Center Drive, Suite 1200, Newport Beach, California 92660,&#160;and our telephone number is (949) 284-4555. Our website address is www.evolus.com. We do not incorporate the information on or accessible through our website into this Annual Report on Form 10-K, and you should not consider any information on, or that can be accessed through, our website a part of this Annual Report on Form 10-K or any other filing we make with the SEC.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make available, free of charge, on our website at www.evolus.com our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and any amendments to such reports, as soon as reasonably practicable after such reports are electronically filed with, or furnished to, the SEC. All such reports are also available free of charge via EDGAR through the SEC website at www.sec.gov.&#160;We do not incorporate the information on or accessible through these websites into this Annual Report on Form 10-K, and you should not consider any information on, or that can be accessed through, these websites a part of this Annual Report on Form 10-K or any other filing we make with the SEC.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="id181047532df422ab5a549dd869deccb_19"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">An investment in our company involves a high degree of risk. You should carefully consider the risks and uncertainties described below, together with all the other information in this Annual Report on Form 10-K, including Item 7&#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and the consolidated financial statements and the notes thereto included in Item 8 &#8220;Consolidated Financial Statements and Supplementary Data.&#8221; If any of the following risks actually occurs, our business, reputation, financial condition, results of operations, revenue, and future prospects could be seriously harmed. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that adversely affect our business. Unless otherwise indicated, references to our business being seriously harmed in these risk factors will include harm to our business, reputation, financial condition, results of operations, revenue and future prospects. In that event, the market price of our common stock could decline, and you could lose part or all of your investment.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and Strategy</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses since our inception. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a global performance beauty company with a history of significant losses. To date, we have invested substantially all of our efforts and financial resources in the clinical development, regulatory approval, and commercial launch of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Evolysse&#8482;. We began generating revenue in May 2019 and have incurred losses in each year since our inception in 2012.  Consequently, any predictions about our future success, performance or viability may not be as accurate as they could be if we had a longer operating history of profitability. We recorded net losses of $50.4 million and $61.7 million for the years ended December&#160;31, 2024 and 2023, respectively. We had an accumulated deficit as of December&#160;31, 2024 of $609.4 million. Our ability to achieve profitability is dependent on our ability to successfully market and sell our commercial products. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our prior losses, combined with expected future losses, may adversely affect the market price of our common stock and, if needed, our ability to raise capital to continue operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products face significant competition and our failure to effectively compete may prevent us from achieving significant market penetration and expansion. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Both Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and Evolysse&#8482; compete within the medical aesthetics market. The medical aesthetic market is highly competitive and dynamic and is characterized by rapid and substantial technological development and product innovations. Our products face, and we anticipate that our future products will face, significant competition from other facial aesthetic products, such as other injectable toxins and dermal fillers. Our products may also compete with unapproved and off-label treatments. Many of our potential competitors, including AbbVie, who first launched BOTOX for cosmetic uses in 2002 and has since maintained the highest market share position in the aesthetic neurotoxin market with its BOTOX product, are large, experienced companies that enjoy significant competitive advantages, such as substantially greater financial resources enabling them to, among other things, market and discount aggressively. Within the dermal filler market we will also face large, experienced competitors such as AbbVie and Galderma. Competitors may also have greater brand recognition for their products, larger sales forces and larger aesthetic product portfolios allowing the companies to bundle products to provide customers more choices and to further discount their products. Additionally, our competitors have greater existing market share in the medical aesthetic market and long-standing customer loyalty programs and sales contracts with large customers which creates established business and financial relationships with customers, aesthetic societies and universities.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These competitors may also try to compete with our aesthetic products on price both directly, through rebates and promotional programs to high volume customers and coupons to consumers, and indirectly, through attractive product bundling with complimentary products, such as hyaluronic acid gels that offer convenience and an effectively lower price compared to the total price of purchasing each product separately. These companies may also seek to compete based on their longer operating history. Larger companies may be better capitalized than us and, accordingly, are able to offer greater customer loyalty benefits to encourage repeat use of their products and finance a sustained global advertising campaign to compete with our commercialization efforts at launch. A number of our larger competitors also have access to a significant number of studies and publications that they could use to compete with us.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the long term, we expect to expand our focus to the broader cash-pay healthcare market. Competitors and other parties may seek to impact regulatory approval of our future product applications through the filing of citizen petitions or other similar documents, which could require costly and time-consuming responses to the regulatory agencies. Larger competitors could seek to prevent or delay our commercialization efforts via costly litigation which can be lengthy and expensive and serve to distract our management team&#8217;s attention. We could face competition from other sources as well, including academic </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">institutions, governmental agencies and public and private research institutions. In addition, we are aware of other companies also developing and/or marketing products in one or more of our target markets, including competing injectable botulinum toxin type A formulations that are currently in Phase III clinical development in North America for the treatment of glabellar lines. For example, Revance Therapeutics, Inc. obtained approval for an injectable botulinum toxin type A neurotoxin on September 8, 2022, called &#8220;Daxxify&#8221; and Hugel, Inc. obtained approval for its injectable botulinum toxin type A neurotoxin on February 29, 2024. Additionally, both Galderma S.A. and Medytox, Inc. have submitted a BLA to the FDA for an injectable botulinum toxin type A neurotoxin. With the approval of Revance Therapeutic&#8217;s and Hugel&#8217;s BLAs and the potential approval of additional BLAs, we expect the competition in the U.S. injectable botulinum toxin market to further increase. We would face similar risks with respect to any future product candidates that we may seek to develop or commercialize in the broader cash-pay healthcare market. Successful competitors in that market have the ability to effectively discover, obtain patents, develop, test and obtain regulatory approvals for products, as well as the ability to effectively commercialize, market and promote approved products, including communicating the effectiveness, safety and value of products to actual and prospective customers and medical staff.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy of competing in the aesthetic neurotoxin market is dependent on the marketing and pricing flexibility that we believe is afforded to a company with a portfolio limited to cash-pay healthcare, comprised of products and procedures that are not reimbursed by third-party payors. In the event that regulations applicable to reimbursed products are changed to apply to cash-pay healthcare products, we would no longer have this flexibility and we may not be able to compete as effectively with our competitors which may have a material effect on our business, financial condition and results of operations. Additionally, as a result of the royalty payments that we are required to pay under the Medytox Settlement Agreements, we may not be able to discount Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the extent that we previously provided discounts to customers without impacting our gross profit margins. If we increase prices for any customers, their volume of purchases may decrease which would have a material and adverse effect on our business and results of operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, competitors may develop new technologies within the medical aesthetic market that may be superior in safety and efficacy to our products or offer alternatives to the use of toxins or hyaluronic acid gels, including surgical and radio frequency techniques. To compete successfully in the medical aesthetic market, we will have to demonstrate that our products are at least as safe and effective as current products sold by our competitors. Our products also compete with other medical aesthetic products or non-urgent aesthetic services. For example, consumers have recently prioritized spending on weight loss drugs or other beauty products which may impact the amount of discretionary income they have to spend on our products.  Competition in the medical aesthetic market could result in price-cutting and reduced profit margins, any of which would harm our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to less stringent regulatory requirements, there are many more aesthetic products and procedures available for use in international markets than are approved for use in the United States. There are also fewer limitations on the claims that our competitors in international markets can make about the effectiveness of their products and the manner in which they can market them. As a result, we expect to face more competition in these markets than in the United States.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial opportunity could also be reduced or eliminated if our competitors develop and commercialize products that are safer, are more effective, have fewer or less severe side effects, are more convenient or are less expensive than Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any other product that we may develop. Our competitors also may obtain FDA or other regulatory approval for these products more rapidly than we may obtain approval for our products, which could result in our competitors establishing a strong market position before we are able to enter the market, which may create additional barriers to successfully commercializing Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and any future product candidates and attracting practitioner and consumer demand.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products may fail to achieve the broad degree of aesthetic practitioner adoption and use or consumer demand necessary for continued commercial success. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or the Evolysse&#8482; collection of hyaluronic acid gels may fail to gain sufficient market acceptance by aesthetic practitioners, consumers and others in the medical aesthetics community to continue to grow our net revenues. The continued commercial success of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and any future product candidates, including a proposed higher strength dose of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the Evolysse&#8482; collection of hyaluronic acid gels, will depend significantly on the broad adoption and use of the resulting product by aesthetic practitioners for approved indications, including, in the case of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the treatment of glabellar lines and other aesthetic indications that we may seek to pursue. We are aware that other companies are seeking to develop alternative products and treatments, any of which could impact the demand for our products.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree and rate of practitioner adoption of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Evolysse&#8482;, and any product candidates depend on a number of factors, including the cost, profitability to our customers, consumer demand, characteristics and effectiveness of the product. Our success will also depend our ability to create compelling marketing programs, training of our customers and ability to </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">overcome any biases aesthetic practitioners or consumers may have toward the use, safety and efficacy of existing products over our products. Moreover, our competitors may utilize negative selling efforts or offer more compelling marketing or discounting programs than we are able to offer, including by bundling multiple aesthetic products to provide a more comprehensive offering than our current approved product offering allows.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in its clinical trials, Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was clinically tested and compared to BOTOX, both of which contain a 900 kDa complex. We believe that aesthetic practitioners&#8217; familiarity with the 900 kDa complex&#8217;s handling, preparation and dosing will more easily facilitate incorporation of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> into their practices. However, the ease of integration of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> into an aesthetic practitioner&#8217;s practice may not be as seamless as we anticipate.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to consumer demand, the treatment with our products is an elective procedure, the cost of which must be borne by the consumer, and we do not expect costs related to the treatment to be reimbursable through any third-party payor, such as Medicaid, Medicare or commercial insurance. The decision by a consumer to undergo treatment with our products for aesthetic indications may be influenced by a number of factors, including the cost, efficacy, safety, perception, marketing programs for, and aesthetic practitioner recommendations of our products versus competitive products or procedures. Moreover, consumer demand may fluctuate over time as a result of consumer sentiment about the benefits and risks of aesthetic procedures generally and our products in particular, changes in demographics and social trends, rising inflation and general consumer confidence and consumer discretionary spending, which may be impacted by economic and political conditions.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Evolysse&#8482;, or any product candidates fails to achieve the broad degree of aesthetic practitioner adoption necessary for commercial success or the requisite consumer demand, our operating results and financial condition will be adversely affected, which may delay, prevent or limit our ability to generate revenue and continue our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are reliant on Symatese to achieve and maintain regulatory approval for the Evolysse&#8482; product line in the United States and Europe. Failure to obtain approval, maintain approval, or obtain approval on our estimated time frame for the Evolysse&#8482; product line would negatively affect our ability to sell these products.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and European regulatory processes for medical devices such as Evolysse&#8482; are complex, time-consuming and subject to numerous inherent risks.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before future products within the Evolysse&#8482; collection can be marketed in the United States, Symatese must obtain regulator approval for the hyaluronic acid gels. Regulators must determine that a proposed device is safe and effective for its intended use based, in part, on extensive data, including, but not limited to, technical, pre-clinical, clinical trial, manufacturing and labeling data. In addition, modifications to products that are approved by regulatory agencies generally require approval.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are substantially dependent on our relationship with Symatese for the regulatory approval process of the Evolysse&#8482; hyaluronic acid gel product candidates. While we have agreed to share certain costs associated with the regulatory approval process to provide our experience to Symatese, Symatese is ultimately responsible for obtaining regulatory approval of the Evolysse&#8482; product line. If Symatese encounters difficulties or delays in obtaining regulatory approvals for these products, our ability to commercialize and generate revenue from these products could be materially and adversely affected. As a result, our reliance on Symatese for the regulatory approval process exposes us to risks associated with Symatese&#8217;s ability to successfully navigate the complex regulatory landscape. If we are unable to manage these risks effectively, it could have a material adverse effect on our business, financial condition, and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if Symatese fails to maintain compliance with applicable regulatory requirements or if regulatory authorities impose new requirements, the approval process could be delayed or approvals could be denied. This may result in additional costs, reduced revenue projections, and potential harm to our business, reputation and market position.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may require additional financing to fund our future operations or execute corporate development activities, and a failure to obtain additional capital when so needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have utilized substantial amounts of cash since our inception in order to conduct clinical development to support regulatory approval and launch of our products in multiple markets. We expect that we will continue to expend substantial resources for the foreseeable future in order to continue to market and sell our products and for the continued clinical development of Evolysse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and any additional product candidates we may choose to pursue. While we believe that we currently have adequate capital resources, which consist of cash and cash equivalents and cash generated from operations, to operate our business until our business generates profits and positive cash flow, this belief is based upon certain financial assumptions including net revenue, gross margin, working capital and expense assumptions. If these assumptions are </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incorrect, or if we experience other risks or uncertainties set forth in this Annual Report on Form 10-K, we may require additional capital to operate our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to expend resources furthering the development and continuation of our marketing programs and commercialization infrastructure in connection with commercializing our products within and outside of the United States. We have also agreed to reimburse Symatese for certain clinical trial expenses related to the Evolysse&#8482; Lip and Eye products in the United States and for certain regulatory filing fees in Europe. In the long term, our expenditures will include costs associated with the commercialization of our products, research and development, approval and commercialization of products and any of our future product candidates, including continued development of the Evolysse&#8482; collection of hyaluronic acid gels, such as research and development, conducting preclinical studies and clinical trials and manufacturing and supplying as well as marketing and selling any products approved for sale. Because the commercialization expenditures needed to meet our sales objectives are highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully market and sell our products. We may in the future, also, acquire other companies or products which may be costly and which may require additional capital to operate. In addition, other unanticipated costs may arise. Accordingly, our actual cash needs may exceed our expectations.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we were to raise additional capital through marketing and distribution arrangements, or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. If we raise additional capital through public or private equity offerings or offerings of securities convertible into our equity, the ownership interest of our existing stockholders will be diluted and the terms of any such securities may have a preference over our common stock. Debt financing, receivables financing and royalty financing may also be coupled with an equity component, such as warrants to purchase our capital stock, which could also result in dilution of our existing stockholders&#8217; ownership, and such dilution may be material. Additionally, if we raise additional capital through debt financing, we will have increased fixed or variable payment obligations and may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt or making capital expenditures to meet specified financial ratios, and other operational restrictions, any of which could restrict our ability to market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any future product candidates or operate as a business and may result in liens being placed on our assets. If we were to default on any of our indebtedness, we could lose such assets.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the global economy, including the financial and credit markets, has recently experienced significant volatility and disruptions, including severely diminished liquidity and credit availability and rising interest rates. In the event we are unable to raise sufficient capital to fund our commercialization efforts to achieve specified minimum sales targets under the Daewoong Agreement, Symatese U.S. Agreement and the Symatese Europe Agreement, we will lose exclusivity of the license that we have been granted under those respective agreements. In addition, if we are unable to raise additional capital when required or on acceptable terms, we will be required to take actions to address our liquidity needs which may include the following: significantly reduce operating expenses and delay, reduce the scope of or discontinue some of our development programs, commercialization efforts or other aspects of our business plan, out-license intellectual property rights to our product candidates and sell unsecured assets, or a combination of the above. As a result, our ability to achieve profitability or to respond to competitive pressures would be significantly limited and may have a material adverse effect on our business, results of operations, financial condition and/or our ability to fund our scheduled obligations on a timely basis or at all.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our counterparties do not comply with the terms of our settlement agreement with Medytox, we may face litigation or lose our ability to market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">which would materially and adversely affect our ability to carry out our business and our financial condition and ability to continue as a going concern. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 18, 2021, we entered into the Medytox Settlement Agreements, under which we obtained (i) a license to commercialize, manufacture and to have manufactured for us certain products identified in the Medytox Settlement Agreements, including Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States and other territories where we license Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (ii) the dismissal of outstanding litigation and related remedies, which we refer to together with any claims (including claims brought in Korean courts) with a common nexus of fact as the Medytox Actions, and (iii) releases of claims against us for the Medytox Actions. Under the agreement, we remain obligated to pay to Medytox a mid-single digit royalty percentage on net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States and all territories we have licensed outside the United States until September 16, 2032. In addition, under the Medytox Settlement Agreements we made certain representations and warranties and agreed to certain customary positive and negative covenants.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event we fail to comply with the terms of the Medytox Settlement Agreements, subject to applicable cure periods, Medytox would have the ability to terminate the Medytox Settlement Agreements and thereby cancel the licenses granted to </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">us and re-institute litigation against us. Any litigation may result in remedies against our products, resulting in either an injunction prohibiting our sales, or with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, any of which would materially and adversely affect our ability to generate revenue from Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to carry out our business, and to continue as a going concern.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if Medytox fails to comply with the terms of the Medytox Settlement Agreements and comply with the covenants and agreements under the Medytox Settlement Agreements, it could materially and adversely affect our ability to generate revenue from Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to carry out our business, and to continue as a going concern. For example, as required by the Medytox Settlement Agreements, in February 2021 Medytox filed a document with the Korean court that its litigation with Daewoong would not affect our right to have Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> manufactured by Daewoong or exported to us. If Medytox were to breach the Medytox Settlement Agreements and rescind this filing and the Korean court issued a ruling against Daewoong, our supply of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> could be hindered. We would also be required to engage in costly and time-consuming litigation in order to enforce our rights under the Medytox Settlement Agreements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The terms of the Medytox Settlement Agreements will reduce our profitability until the royalty obligations expire, and may affect the extent of any discounts we may offer to our customers.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the royalty payments that we are required to pay under the Medytox Settlement Agreements, our profitability has and will be adversely impacted for the period that we are required to pay royalties. We may be able to offset a portion of the loss of profitability by decreasing any discount to customers on Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as compared to discounts we provided to customers prior to the Medytox Settlement Agreements. If we reduce discounts for any customers, their volume of purchases may decrease which would have a material and adverse effect on our business and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we do not expect our products to be reimbursed by any government or third-party payor, our products will continue to be paid for directly by the consumer. Demand for our products is accordingly tied to the discretionary spending levels of our targeted consumer population. A severe or prolonged economic downturn, instability or crises affecting banks or other financial institutions, or inflation in consumer prices, as we are currently experiencing, could result in a variety of risks to our business, including a decline in the discretionary spending of our target consumer population, which could lead to a weakened demand for our products, or any future product candidates. A severe or prolonged economic downturn may also affect our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy, instability or crises affecting banks or other financial institutions, or political disruption or geopolitical conflicts, including the military conflict between Russia and Ukraine and the ongoing conflict in the Middle East, could also strain our suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our products. Additionally, changes in trade policies, including increased or proposed tariffs in the United States or retaliatory tariffs in response to such tariffs would cause in increase in our cost of goods related to our products.  Inflation in the markets we serve could similarly impact our revenues, as consumer spending power could decline. Any of the foregoing could harm our business. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our business strategy was developed based on a number of important assumptions about the cash-pay healthcare market. For example, we believe that the number of cash-pay healthcare procedures will increase in the future. However, these trends are uncertain and limited sources exist to obtain reliable market data. Therefore, sales of our products or any of our future product candidates could differ materially from our projections if our assumptions are incorrect.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse developments affecting the financial services industry, including events or concerns involving liquidity, defaults or non-performance by financial institutions, could adversely affect our business, financial condition or results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The funds in our operating accounts are held in banks or other financial institutions. Our cash held in non-interest bearing and interest-bearing accounts exceeds applicable Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance limits. Bank failures, events involving limited liquidity, defaults, non-performance or other adverse developments occur with respect to the banks or other financial institutions that hold our funds, or that affect financial institutions or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks may lead to widespread demands for customer withdrawals and liquidity constraints that may result in market-wide liquidity problems, which could adversely impact our liquidity. For example, on March 10, 2023, the FDIC announced that Silicon Valley Bank had been closed by the California Department of Financial Protection and Innovation. On March 26, 2023, the assets, deposits and loans of Silicon Valley Bank were acquired by First-Citizens Bank &amp; Trust Company. Although we did not have any funds in Silicon Valley Bank or other institutions that have been closed, we cannot guarantee that the banks or other financial institutions that hold our funds will not experience similar issues.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on terms favorable to us, or at all, and could have material adverse impacts on our liquidity, our business, financial condition or results of operations, and our prospects. Our business may be adversely impacted by these developments in ways that we cannot predict at this time, there may be additional risks that we have not yet identified, and we cannot guarantee that we will be able to avoid negative consequences.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to market our products is limited to their indicated uses, and if we want to expand the indications for which we market our products, we will need to obtain additional regulatory approvals, which will be expensive and may not be granted. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of our approved products have specific approved indications for use.  The terms of the approvals for each of our products restrict our ability to market or advertise those products for other indications, which could limit aesthetic practitioner and consumer adoption. Under the FFDCA, we may generally only market products for approved indications. Many of our competitors have received approval of multiple aesthetic and therapeutic indications for their neurotoxin and dermal filler products and may be able to market such products for use in a way we cannot. For example, we are aware that one of our competitors, AbbVie, has obtained and plans to obtain additional indications for its neurotoxin and dermal filler products within medical aesthetics and, therefore, is able to market its product across a greater number of indications than Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Evolysse&#8482;. If we are unable to obtain approval for indications in addition to our approved indications, our marketing efforts for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Evolysse&#8482; will be severely limited. As a result, we may not generate aesthetic practitioner and consumer demand or approval our products.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on our digital technology and applications and our business and operations could suffer in the event of information system failures or a cybersecurity incident.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are reliant on our digital technology, including our Evolus Practice App, which allows customers to open a new account, order products, pay invoices and engage with our customer experience team and medical affairs representatives. In the event that our digital technology is unable to function in the manner it was designed or at all, we would experience difficulty processing customer orders and requests in a timely manner or at all which would have a material adverse effect on our business, results of operations and financial condition. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information systems underlying our digital technology may not be adequately designed or may not operate with the reliability and redundancy necessary to avoid performance delays or outages that could be harmful to our business. If our digital technology is unavailable when customers attempt to access them, or if they do not load as quickly as expected, users may not use our technology as often in the future, or at all, and our ability to sell our products through a more limited sales force may be disrupted and we may not realize the efficiencies of leveraging our digital technology, any of which could adversely affect our business and financial performance. As the number of users of our digital technology continues to grow we will need an increasing amount of technical infrastructure, including network capacity and computing power, to continue to satisfy our needs. It is possible that we may fail to continue to effectively scale and grow our technical infrastructure to accommodate these increased demands, which may adversely affect our customers&#8217; experience with our digital technology which may decrease our revenue and harm our results of operations. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures, our internal computer systems, including our information systems, and those of third parties on which we rely, are vulnerable to disruption or damage from computer viruses, malware, natural disasters, terrorism, war, telecommunication and electrical failures, cybersecurity incidents, insider threats, persons who access our information systems in an unauthorized manner, or inadvertent misconfiguration of our systems. The risk of a security incident or system disruption, particularly through cybersecurity incidents, including by computer hackers, foreign governments and cybercriminals, has generally increased as the number, intensity and sophistication of attempted attacks, including through the use of emerging technologies, such as artificial intelligence, and intrusions from around the world have increased. While none of the cybersecurity incidents that we have experienced to date have had a material adverse impact on our business, financial condition or operations, future interruptions in our operations caused by such an event could result in a material disruption of our current or future product development programs. The costs to us to mitigate network security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant, and while we have implemented security measures to protect our data security and information systems, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service, government files or penalties and other harm to our business and our competitive position. Interruptions in our operations caused by such an event could also result in a material disruption in our relationship with our customers. For example, if our </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolus Practice App were rendered inoperable, we would have to process orders by telephone or otherwise which may result in slower processing times and harm to our reputation.  Our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cybersecurity incidents and other related security incidents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with confidentiality and data privacy obligations could have a material adverse effect on our business. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our normal operations, we collect, process, transmit and, where appropriate, retain certain sensitive and confidential employee and customer information, including credit card information. As a result, we are subject to  various international, federal and state privacy and security laws, including the General Data Protection Regulation, or GDPR, the HIPPA, as amended by HITECH, and its implementing rules and regulations, as well as regulations promulgated by the Federal Trade Commission and state breach notification laws. Additionally, the regulatory environment governing information, security and privacy laws is increasingly demanding and continues to evolve and a number of states have adopted laws and regulations that may affect our privacy and data security practices regarding the use, disclosure and protection of personally identifiable information, or PII. For example, the California Consumer Privacy Act, among other things, has created new individual privacy rights and imposes increased obligations on companies handling PII. We also rely on third parties to host or otherwise process some of the data we collect, process and store. In some instances, these third parties have experienced failures to protect data privacy.  If we or these third parties experience a security incident that affects our information systems or results in the unauthorized access to financial information, PII, customer information or data, including credit card transaction data or other sensitive information, our reputation could be materially damaged. Our failure, or the failure of third parties, to protect PII or other sensitive information or our failure to comply with such data privacy and security laws, could expose us to litigation and potential liability, which could materially adversely affect our business, results of operations and financial condition</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> or any other product candidate for which we seek approval as a biologic may face competition sooner than anticipated.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the enactment of the Biologics Price Competition and Innovation Act of 2009, or the BPCI Act, as part of the Patient Protection and Affordable Care Act, an abbreviated pathway for the approval of biosimilar or interchangeable biological products was created. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics. Under the BPCI Act, an application for a biosimilar product cannot be approved by the FDA until twelve years after the original branded product was approved under a BLA. The FDA has licensed multiple biosimilar products under the BCPI Act.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> should qualify for the twelve-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider any of our product candidates to be a reference product for competing products, potentially creating the opportunity for competition sooner than anticipated. Moreover, the extent to which a biosimilar product, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear and will depend on a number of marketplace and regulatory factors that are still developing.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are found to have improperly promoted off-label uses, or if customers misuse our products or use our products off-label, we may become subject to prohibitions on the sale or marketing of our products, significant fines, penalties, sanctions, or product liability claims, and our image and reputation within the industry and marketplace could be harmed. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other regulatory agencies strictly regulate the marketing and promotional claims that are made about regulated products, such as Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Evolysse&#8482;.  In particular, a product may not be promoted for uses or indications that are not approved by the FDA or other similar regulatory authorities as reflected in the product&#8217;s approved labeling. Customers could use our products on their patients in a manner that is inconsistent with the approved label, potentially including for the treatment of other aesthetic or therapeutic indications. Additionally, we maintain relationships with social media and celebrity influencers as part of our marketing strategy. Our use of social media and influencers for promotion and marketing of our products may increase the risk that such materials could contain problematic product or marketing claims in violation of applicable FDA regulations. For example, in recent years, the FDA has issued multiple untitled letters related to false or misleading promotion by influencers and/or using social media. Although we contract with and monitor our influencers&#8217; posts on social media, they may fail to comply with our content-related requirements.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are found to have promoted such off-label uses, we may receive warning letters from and be subject to other enforcement actions by the FDA, the EMA, and other regulatory agencies, and become subject to significant liability, which would materially harm our business. The federal government has levied large civil and criminal fines against companies for </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alleged improper promotion and has enjoined several companies from engaging in off-label promotion. If we become the target of such an investigation or prosecution based on our marketing and promotional practices, we could face similar sanctions, which would materially harm our business. In addition, management&#8217;s attention could be diverted from our business operations, significant legal expenses could be incurred, and our reputation could be damaged. The FDA has also required that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed in order to resolve FDA enforcement actions. If we are deemed by the FDA to have engaged in the promotion of our products for off-label use, we could be subject to the FDA prohibitions or other restrictions on the sale or marketing of our products and other operations or significant fines and penalties, and the imposition of these sanctions could also affect our reputation and position within the industry. In addition, regulatory authorities outside the United States may impose similar fines, penalties or sanctions.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers may also misuse Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Evolysse&#8482;, or any future product we offer or use improper techniques, potentially leading to adverse results, side effects or injury, which may lead to product liability claims. If Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Evolysse&#8482;, or any future product we offer are misused or used with improper techniques or are determined to cause or contribute to consumer harm, we may become subject to costly litigation by our customers or their patients. Product liability claims could divert management&#8217;s attention from our core business, be expensive to defend, result in sizable damage awards against us that may not be covered by insurance and subject us to negative publicity resulting in reduced sales of our products. Furthermore, the use of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Evolysse&#8482;, or any future product we offer for indications other than those cleared by the FDA may not effectively treat such conditions, which could harm our reputation in the marketplace among customers and consumers. Any of these events could harm our business and results of operations and cause our stock price to decline. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products may cause serious or undesirable side effects or possess other unexpected properties that could delay or prevent their regulatory approval, limit the commercial profile of approved labeling, result in post-approval regulatory action or in product liability lawsuits.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unforeseen side effects from Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Evolysse&#8482;, or any product we may offer in the future could arise either during clinical development or after marketing such product. Undesirable side effects caused by product candidates could cause us or regulatory authorities to interrupt, modify, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, the EMA or similar regulatory authorities. Results of clinical trials could reveal a high and unacceptable severity and prevalence of side effects. In such an event, trials could be suspended or terminated and the FDA, the EMA or similar regulatory authorities could order us to cease further development of or deny approval of product candidates for any or all targeted indications. The drug or device-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in product liability claims. Any of these occurrences may harm our business, financial condition, operating results and prospects.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if we or others identify undesirable side effects, or other previously unknown problems, caused by Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or any of our future product candidates, after obtaining regulatory approval in the United States or other jurisdictions, a number of potentially negative consequences could result, including regulatory authorities withdrawing approval or limiting the marketing of our products, requiring a recall of the product, requiring additional warnings on our product labeling or medication guides or instituting REMS. In order to mitigate these risks, regulatory authorities may require additional costly clinical trials or costly post-marketing testing and surveillance to monitor the safety or efficacy of the product. As a result of any of these actions our sales of the product may decrease significantly, we may be required to expend material amounts to comply with any requirements of the regulatory authorities, we could be sued in a product liability lawsuit and held liable for harm caused to patients, and our brand and reputation may suffer.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability as a result of the commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Evolysse&#8482;, and any of our future product candidates. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted against us under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our products. Even a successful defense would require significant financial and management resources and result in decreased demand for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Evolysse&#8482;, or any future product candidates or products we may develop, termination of clinical trial sites or entire trial programs, injury to our reputation and significant negative media attention, withdrawal of clinical trial participants or cancellation of clinical trials and significant costs and diversion management&#8217;s time to defend the related litigation.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">protect against potential product liability claims could prevent or inhibit the commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Evolysse&#8482;, or any future products that we develop. We currently carry product liability insurance covering our clinical trials. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the above events could prevent us from achieving or maintaining market acceptance of the affected product, negatively impact our revenues and could substantially increase the costs of commercializing our products. The demand for our products could also be negatively impacted by any adverse effects of a competitor&#8217;s product or treatment.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to successfully in-license, acquire, develop and market additional product candidates or approved products would impair our ability to grow our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although most of our effort is focused on the commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Evolysse&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a key element of our long-term strategy is to in-license, acquire, develop, market and commercialize a portfolio of products to serve the cash-pay aesthetic market. Our competitors are currently able to bundle multiple aesthetic products to provide a more comprehensive offering than we can. Because our internal research and development capabilities are limited, we may be dependent upon pharmaceutical and other companies, academic scientists and other researchers to sell or license products or technology to us. The success of this strategy depends partly upon our ability to identify and select promising aesthetic product candidates and products, negotiate licensing or acquisition agreements with their current owners and finance these arrangements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of proposing, negotiating and implementing a license or acquisition of a product candidate or approved product is lengthy and complex. Other companies, including some with substantially greater financial, marketing, sales and other resources, may compete with us for the license or acquisition of product candidates and approved products. We have limited resources to identify and execute the acquisition or in-licensing of third-party products, businesses and technologies and integrate them into our current infrastructure. Moreover, we may devote resources to potential acquisitions or licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts. We may not be able to acquire the rights to additional product candidates on terms that we find acceptable, or at all.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, any product candidates that we acquire may require additional development efforts prior to commercial sale, including preclinical or clinical testing and approval by the FDA, the EMA and other similar regulatory authorities. All product candidates are prone to risks of failure during product development, including the possibility that a product candidate will not be shown to be sufficiently safe and effective for approval by regulatory authorities. In addition, any approved products that we acquire may not be manufactured or sold profitably or achieve market acceptance.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to increase the size of our organization, including our sales and marketing capabilities, in order to further market and sell our products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">and we may experience difficulties in managing this growth.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we had 332 employees, all of whom were full-time employees. Our management and personnel, systems and facilities currently in place may not be adequate to support future growth. Our need to effectively execute our growth strategy requires that we identify, recruit, retain, incentivize and integrate any additional employees to effectively manage any future clinical trials, manage our internal development efforts effectively while carrying out our contractual obligations to third parties, and continue to improve our operational, financial and management controls, reporting systems and procedures.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face risks in building and managing a sales organization whether internally or by utilizing third parties, including our ability to retain and incentivize qualified individuals, provide adequate training to sales and marketing personnel, generate sufficient sales leads, effectively manage a geographically dispersed sales and marketing team, adequately provide complementary products to be offered by sales personnel, which may otherwise put us at a competitive disadvantage relative to companies with more extensive product lines, and handle any unforeseen costs and expenses. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to our limited financial resources and our limited experience in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">physical expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our development and strategic objectives or disrupt our operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our international operations will expose us to risks, and failure to manage these risks may adversely affect our operating results and financial condition.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have operations in the United States, Canada, Europe and Australia. International operations are subject to a number of inherent risks, and our future results could be adversely affected by a number of factors, including differences in demand for our products due to local requirements or preferences, the difficulty of hiring and managing employees with cultural and geographic differences and the costs of complying with differing regulatory requirements. Additionally, we may experience difficulties and increased costs due to differences in laws related to enforcing contracts, protecting intellectual property, taxes, tariffs and export regulations. The current conflict between Ukraine and Russia may also impact European economies and consumer discretionary spending negatively, and the conflict in the Middle East may have similar regional impacts. We do not have significant international operations in Russia, Ukraine, Israel, Palestine or the surrounding regions that have been impacted by the conflicts directly.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our international operations will also subject us to risks related to multiple, conflicting and changing laws and regulations such as privacy regulations, including the GDPR, tax laws, export and import restrictions, employment laws, immigration laws, labor laws, regulatory requirements and other governmental approvals, permits and licenses. Additionally, we will face heightened risk of unfair or corrupt business practices in certain geographies and of improper or fraudulent sales arrangements that may impact financial results and result in restatements of, or irregularities in, financial statements. These and other factors could harm our ability to gain future revenue and, consequently, materially impact our business, operating results and financial condition.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fluctuations in currency exchange rates may negatively affect our financial condition and results of operation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange rate fluctuations may affect the costs that we incur in our operations. The main currencies to which we are exposed to such fluctuations are the British pound and the EU euro. The exchange rates between these currencies and the U.S. dollar in recent years have fluctuated significantly and may continue to do so in the future. A depreciation of these currencies against the U.S. dollar will decrease the U.S. dollar equivalent of the amounts derived from foreign operations reported in our consolidated financial statements, and an appreciation of these currencies will result in a corresponding increase in such amounts. The cost of certain items, such as raw materials, manufacturing, employee salaries and transportation and freight, required by our operations may be affected by changes in the value of the relevant currencies. To the extent that we are required to pay for goods or services in foreign currencies, such as under our Symatese U.S. Agreement and Symatese Europe Agreement, which has payments denominated in Euros, the appreciation of such currencies against the U.S. dollar will tend to negatively affect our business. There can be no assurance that foreign currency fluctuations will not have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to attract and keep senior management and key personnel, we may be unable to market and sell our products successfully, or any future products we develop. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in part on our continued ability to attract, retain and motivate highly qualified management. We believe that our future success is highly dependent upon the contributions of our senior management, particularly David Moatazedi, our President, Chief Executive Officer and member of our Board of Directors, Sandra Beaver, our Chief Financial Officer, Rui Avelar, our Chief Medical Officer and Head of Research and Development, and Tomoko Yamagishi-Dressler, our Chief Marketing Officer, as well as other members of our senior management team. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, completion of our planned clinical trials or the commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Evolysse&#8482;, or any future products we develop. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we could experience difficulties attracting and retaining qualified employees in the future. For example, competition for qualified personnel in the pharmaceuticals and medical aesthetic field is intense due to the limited number of individuals who possess the skills and experience required by our industry. We may not be able to attract and retain quality personnel on acceptable terms, or at all. In addition, to the extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information or that their former employers own their research output. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our strategy of focusing exclusively on the cash-pay healthcare market may limit our ability to increase sales or achieve profitability.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy is to focus exclusively on the cash-pay healthcare market. This focus may limit our ability to increase sales or achieve profitability. For example, to maintain our business model, we have chosen not to offer products or services available in the broader healthcare market that are reimbursed by third-party payors such as Medicare, Medicaid or commercial insurance. This eliminates our ability to offer a substantial number of products and indications for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Evolysse&#8482;.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, under the Daewoong Agreement our rights to market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are limited to cosmetic indications and under the Symatese U.S. Agreement and Symatese Europe Agreement our rights are limited to aesthetic and dermatologic uses. Daewoong has subsequently licensed the rights to the therapeutic indications for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to a third party. As a result, we do not have the ability to expand the permitted uses of our products for therapeutic indications.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the only U.S. neurotoxin without a therapeutic indication, although other companies may seek to develop a similar product in the future. We believe pursuing an aesthetic-only non-reimbursed product strategy allows for meaningful strategic advantages in the United States, including pricing and marketing flexibility. However, customers may choose to not pass any cost benefits received by them due to such pricing flexibility to their patients. In addition, companies offering aesthetic products competitive to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, whether they pursue an aesthetic-only non-reimbursed product strategy or not, may nonetheless try to compete with Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on price both directly through rebates, promotional programs and coupons and indirectly through attractive product bundling and customer loyalty programs. Our business, financial results and future prospects will be materially harmed if we cannot generate sufficient consumer demand for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business involves the use of hazardous materials, and we and our third-party manufacturer and supplier must comply with environmental laws and regulations, which can be expensive and restrict how we do business. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development and manufacturing activities in the future may, and our licensors&#8217; manufacturing and supplying activities presently do, involve the controlled storage, use and disposal of hazardous materials, including botulinum toxin type A, a key component of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and other hazardous compounds. We and our licensors are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at our licensors&#8217; facilities pending their use and disposal. We and our licensors cannot eliminate the risk of contamination, which could cause an interruption of any of our licensors&#8217; manufacturing processes, our commercialization efforts, business operations and environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, manufacture, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by our licensors for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, this may not eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources, and state or federal or other applicable authorities may curtail our use of certain materials and interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may use third-party collaborators to help us develop, validate or commercialize any new products, and our ability to commercialize such products could be impaired or delayed if these collaborations are unsuccessful. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may license or selectively pursue strategic collaborations for the development, validation and commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Evolysse&#8482;, and any future product candidates. In any third-party collaboration, we would be dependent upon the success of the collaborators in performing their responsibilities and their continued cooperation. Our collaborators may not cooperate with us or perform their obligations under our agreements with them. Our collaborators may choose to pursue alternative technologies in preference to those being developed in collaboration with us. The development, validation and commercialization of our product candidates will be delayed if collaborators fail to conduct their responsibilities in a timely manner or in accordance with applicable regulatory requirements or if they breach or terminate their collaboration agreements with us. Disputes with our collaborators could also impair our reputation or result in development delays, decreased revenues and litigation expenses.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to consumers, the potential of competing products, the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. Collaborations are complex and time-consuming to negotiate and document. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of such product</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates or bring them to market and generate revenue.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred substantial losses during our history and we may never achieve profitability. We have generated taxable losses and unused losses will carry forward to offset future taxable income, if any, until such unused losses expire. Under Section 382 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards, or NOLs, and other pre-change tax attributes, such as research tax credits, and Section 163(j) interest expense carryforwards, to offset its post-change income may be limited. As of December&#160;31, 2024, we had $315.2 million of federal NOLs, $38.9 million of foreign NOLs, and $232.0 million of state NOLs available to offset our future taxable income, if any. Additionally, we had federal and California research and development credit carryforwards of $2.9 million each, as well as $34.7 million in federal Section 163(j) interest expense carryforwards as of December&#160;31, 2024. These tax attributes, such as NOLs, and research and development tax credit carryforwards are set to expire at various dates beginning in 2034. We may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, which could restrict our ability to utilize our pre-change NOLs , research and development credit, and Section 163(j) interest expense carryforwards for offsetting U.S. federal taxable income, potentially leading to increased future tax liability. In addition, there may be periods during which the use of tax attributes is suspended or otherwise limited, which could accelerate or permanently increase taxes owed. </span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Increases in interest rates would increase the cost of servicing our debt and could reduce our profitability and limit our cash available to fund our growth strategy.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmakon Term Loans (as defined below) have, and any additional debt we subsequently incur may have, a variable rate of interest. Higher interest rates could increase debt service requirements on our current variable rate indebtedness (even though the amount borrowed remains the same) and on any debt we subsequently incur, and could reduce funds available for operations, future business opportunities or other purposes and materially and adversely affect our profitability, cash flows and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 9, 2023, we and Pharmakon entered into the Third Amendment to the Loan Agreement. Among other changes, the Third Amendment implements the transition from a London Interbank Offered Rate (&#8220;LIBOR&#8221;) based interest rate to a Secured Overnight Financing Rate (&#8220;SOFR&#8221;) based interest rate. SOFR is calculated differently from LIBOR and since the initial publication of SOFR, daily changes in the rate have, on occasion, been more volatile than daily changes in comparable benchmark or market rates. It is possible that SOFR over time may bear little or no relation to the historical actual or historical indicative data. It is possible that the volatility of and uncertainty around SOFR as a LIBOR replacement rate and the applicable credit adjustment would result in higher borrowing costs for us, and could adversely affect our liquidity, financial condition, and earnings. The consequences of these developments with respect to LIBOR cannot be entirely predicted and span multiple future periods but could result in an increase in the cost of our variable rate debt which may negatively impact our financial results.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Relationship with Our Licensors</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on the Daewoong Agreement, the Symatese U.S. Agreement and the Symatese Europe Agreement and any termination or loss of significant rights, including exclusivity, under these agreements would materially and adversely affect our business. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to exclusively commercialize Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Evolysse&#8482; are completely dependent on the Daewoong Agreement, </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the Symatese U.S. Agreement and Symatese Europe Agreement, respectively. Under each agreement we have numerous obligations, including minimum product purchases, milestone payments and commercialization and development obligations. If we breach any material obligation, our partners may terminate or decrease our rights under the agreements. If we were to lose rights under the Daewoong Agreement, or either of the Symatese agreements, we would experience an immediate reduction in our revenues and future business opportunities. We believe it would be difficult to find an alternative supplier of these products. In addition, to the extent the alternative supplier has not secured regulatory approvals in a jurisdiction, we would have to expend significant resources to obtain regulatory approvals that may never be obtained or require several years to obtain, which could significantly delay commercialization. We may be unable to raise additional capital to fund our operations during this extended time on terms acceptable to us or at all. Additionally, if we experience delays as a result of a dispute with either of our partners the demand for our products could be materially and adversely affected.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently rely solely on Daewoong to manufacture Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">, and on Symatese to manufacture Evolysse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> and as such, any production or other problems with either licensor could adversely affect us.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend solely upon Daewoong for the manufacturing of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and on Symatese to manufacture Evolysse&#8482;. Although alternative sources of supply may exist, the number of third-party suppliers with the necessary manufacturing and regulatory expertise and facilities is limited, and it could be expensive and take a significant amount of time to arrange for and qualify alternative suppliers, which could have a material adverse effect on our business. Suppliers of any new product candidate would be required to qualify under applicable regulatory requirements and would need to have sufficient rights under applicable intellectual property laws to the method of manufacturing the product candidate. Obtaining the necessary FDA approvals or other qualifications under applicable regulatory requirements and ensuring non-infringement of third-party intellectual property rights could result in a significant interruption of supply and could require the new manufacturer to bear significant additional costs which may be passed on to us.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our reliance on Daewoong and Symatese entails additional risks, including reliance on our partners for regulatory compliance and quality assurance, the possible breach of either the Daewoong Agreement by Daewoong or the Symatese U.S. Agreement and Symatese Europe Agreement by Symatese, and the possible termination or nonrenewal of either agreement at a time that is costly or inconvenient for us. Our failure, or the failure of our partners, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products. Our dependence on our partners also subjects us to all of the risks related to our partner&#8217;s business, which are all generally beyond our control. Our partners&#8217; ability to perform their obligations under their respective agreements is dependent on their operational and financial health, which could be negatively impacted by several factors, including changes in the economic, political and legislative conditions in their home countries and the broader region in general and the ability of our partners to continue to successfully attract customers and compete in its market. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we are dependent on our licensors for day-to-day compliance with cGMP for production of our products. Facilities used by our licensors to produce the drug substance, devices and materials or finished products for commercial sale must pass inspection and be approved by the FDA and other relevant regulatory authorities. If the safety of our products is compromised due to a failure to adhere to applicable laws or for other reasons, we may not be able to successfully commercialize our product and we may be held liable for injuries sustained as a result. In addition, the manufacturing facilities of certain of our suppliers are located outside of the United States. This may give rise to difficulties in importing our product into the United States or other countries as a result of, among other things, regulatory agency approval requirements, taxes, tariffs, local import requirements such as import duties or inspections, incomplete or inaccurate import documentation or defective packaging. Any of these factors could adversely impact our ability to effectively market and sell our products.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any failure or refusal by our licensors or any other third party to supply our products that we may develop could delay, prevent or impair our clinical development or commercialization efforts.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, our licensors developed the manufacturing process for our products in facilities outside the United States. If these facilities were to be damaged, destroyed or otherwise unable to operate or comply with regulatory requirements, whether due to earthquakes, fire, floods, hurricanes, storms, tornadoes, other natural disasters, public health emergencies, employee malfeasance, terrorist acts, power outages or otherwise, or if operations at the facility is disrupted for any other reason, such an event could jeopardize our licensors&#8217; ability to manufacture our products as promptly as we or our customers expect or possibly at all. If our licensors are unable to manufacture our products within a timeframe that meets our and our customers&#8217; expectations, our business, prospects, financial results and reputation could be materially harmed. Any disaster recovery and business continuity plans that we and our licensors may have in place or put in place may not be adequate in the event of a </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">serious disaster or similar event. We may incur substantial expenses as a result of our or our licensors&#8217; lack of disaster recovery and business continuity plans, or the adequacy thereof, which could have a material adverse effect on our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We forecast the demand for commercial quantities of our products, and if our forecasts are inaccurate, we may experience delays in shipments, increased inventory costs or inventory levels, and reduced cash flow.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We purchase our products from our licensors, Daewoong and Symatese. Pursuant to our agreements with our licensors, we are obligated to submit forecasts of anticipated product orders and may, from time to time, submit purchase orders on the basis of these forecasting requirements. For a variety of reasons we may not be able to accurately predict future demand. In addition, we expect our licensors to manufacture our products for other markets in which we do not have exclusive rights. If our business significantly expands, our demand for commercial products would increase and our licensors may be unable to meet our increased demand. In addition, our products have fixed future expiration dates. If we overestimate demand for our products, we will have excess inventory, which may have to be disposed of if such inventory exceeds approved expiration dates, which would result in lost revenues and increase our expenses. If we underestimate requirements for our products, we may have inadequate inventory, which could interrupt, delay or prevent delivery of our products to our customers. Any of these occurrences would negatively affect our financial performance.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-party claims of intellectual property infringement may prevent or delay our commercialization efforts and interrupt our supply of products.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our avoiding infringement of the proprietary rights of third parties. Competitors in the field of dermatology, medical aesthetic and neurotoxins have developed large portfolios of patents and patent applications in fields relating to our business. In particular, there are patents held by third parties that relate to the treatment with neurotoxin-based products for the indication we are currently marketing. There may also be patent applications that have been filed but not published that, when issued as patents, could be asserted against us. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the technology, medical device and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions and inter-party reexamination proceedings before the U.S. Patent and Trademark Office, or USPTO. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As the technology, medical device and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may assert that we or any of our current or future licensors, including Daewoong or Symatese, are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, methods of manufacture or methods for treatment related to the use or manufacture of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any future product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our products or any future product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of our products or any future product candidates, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtain a license under the applicable patents or until such patents expire. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our methods of use, the holders of any such patent may be able to block our ability to develop and commercialize the applicable product candidate unless we obtain a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to claims of patent infringement, third parties may bring claims against us asserting misappropriation of proprietary technology or other information in the development, manufacture and commercialization of our products or any of our future product candidates. Defense of such a claim would require dedicated time and resources, which time and resources could otherwise be used by us toward the maintenance of our own intellectual property and the development and commercialization of our products and any of our future product candidates or by any of our current or future licensors for operational upkeep and manufacturing of our products. For example, prior to entering into the Medytox Settlement Agreements, we were a defendant in a lawsuit brought by Medytox in the Superior Court of the State of California, or the Medytox Litigation, and a respondent in an action filed by Allergan and Medytox in the ITC Action, each alleging, among other things, that Daewoong stole Medytox&#8217;s botulinum toxin bacterial strain, or the BTX strain, that Daewoong misappropriated certain trade secrets of Medytox, including the process used to manufacture Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (which Medytox claims is similar to its biopharmaceutical drug, Meditoxin) using the BTX strain, and that Daewoong thereby interfered with </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medytox&#8217;s plan to license Meditoxin to us, or the Medytox Litigation. Both the Medytox Litigation and ITC Action diverted the attention of our senior management and were costly, in terms of legal costs and the ultimate payments and royalties to be paid under the Medytox Settlement Agreements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we are aware that multiple entrants into the hyaluronic acid gel market have faced litigation related to allegations of intellectual property infringement and have either expended large amounts of money to defend these claims, attempted to invalidate a third-party&#8217;s intellectual property as a defense, or have entered into settlement and license agreements in order to commercialize their hyaluronic acid gel products. As the importer of record and commercial distributor of Evolysse&#8482;, we may be required to defend these cases, which may result in increased legal costs and royalty costs.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us or any of our current or future licensors may request and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement, we or any of our current or future licensors may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties which may not be commercially or more available, pay royalties or redesign our infringing products or manufacturing processes, which may be impossible or require substantial time and monetary expenditure. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research, manufacture clinical trial supplies or allow commercialization of our products or any future product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our product candidates, which could harm our business significantly. Similarly, third-party patents could exist that might be enforced against our products, resulting in either an injunction prohibiting our sales, or with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or any of our current or future licensors, including Daewoong and Symatese, are unable to maintain, obtain or protect intellectual property rights related to our products, we may not be able to compete effectively in our market.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our current licensors, Daewoong and Symatese, currently rely upon a combination of trademarks, trade secret protection, confidentiality agreements and proprietary know-how. Botulinum toxin cannot be patented, as it is produced by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clostridium</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">botulinum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a gram-positive, rod-shaped, anaerobic, spore-forming, motile bacterium with the ability to produce the neurotoxin botulinum. Only the manufacturing process for botulinum toxin can be patented, for which Daewoong has obtained a U.S. patent. Our trade secrets and other confidential proprietary information and those of our licensors could be disclosed or competitors could otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we or any of our current or future licensors may encounter significant problems in protecting and defending our or their intellectual property both in the United States and internationally. If we or any of our current or future licensors are unable to prevent material disclosure of the non-patented intellectual property related to our products to third parties, we may not be able to establish or maintain a competitive advantage in our market, which could adversely affect our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the protection afforded by trademarks, confidentiality agreements and proprietary know-how, we may in the future rely upon in-licensed patents for any future product offerings. The strength of patents we may in-license in the technology and healthcare fields involves complex legal and scientific questions and can be uncertain. The patent applications that we may in-license may fail to result in issued patents with claims that cover any of our future product candidates in the United States or in other foreign countries, and the issued patents that we may in-license may be declared invalid or unenforceable. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are reliant on the ability of our licensors, to maintain their intellectual property and protect their intellectual property against misappropriation, infringement or other violation. We may not have primary control over our future licensors&#8217; patent prosecution activities. Furthermore, we may not be allowed to comment on prosecution strategies, and patent applications may be abandoned by the patent owner without our knowledge or consent. With respect to patents that are issued to our licensors, or patents that may be issued on patent applications, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed or invalidated. As a licensee, we are reliant on Daewoong, Symatese, and our future licensors to defend any third-party claims. Our licensors may not defend or prosecute such actions as vigorously or in the manner that we would have if entitled to do so, and we will be subject to any judgment or settlement resulting from such actions. Also, a third-party may challenge the validity of our in-licensing transactions. Furthermore, even </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">if they are unchallenged, any of our future in-licensed patents and patent applications may not adequately protect the licensors or our intellectual property or prevent others from designing around their or our claims.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits to protect or enforce our intellectual property or the patents and other intellectual property of our licensors, which could be expensive and time-consuming. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our intellectual property, including any future patents we may acquire, or the patents and other intellectual property of our licensors, including Daewoong or Symatese. As a result, we or any of our current or future licensors may be required to file infringement claims to stop third-party infringement or unauthorized use. This can be expensive, particularly for a company of our size, and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or any of our current or future licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patent claims do not cover its technology or that the factors necessary to grant an injunction against an infringer are not satisfied. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An adverse determination of any litigation or other proceedings could put one or more of such patents at risk of being invalidated or interpreted narrowly. Interference, derivation or other proceedings brought at the USPTO may be necessary to determine the priority or patentability of inventions with respect to any of our future patent applications or those of our licensors or collaborators. Litigation or USPTO proceedings brought by us or any of our current or future licensors may fail or may be invoked against us or our licensors by third parties. Even if we are successful, domestic or foreign litigation or USPTO or foreign patent office proceedings may result in substantial costs and distraction to our management or the management of any of our current or future licensors, including Daewoong or Symatese. We may not be able, alone or with any of our current or future licensors or collaborators, to prevent misappropriation of our proprietary rights, particularly in countries where the laws may not protect such rights as fully as in the United States. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other proceedings, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or proceedings. In addition, during the course of this kind of litigation or proceedings, there could be public announcements of the results of hearings, motions or other interim proceedings or developments or public access to related documents. If investors perceive these results to be negative, the market price for our common stock could be significantly harmed. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of our competitors are larger than we are and have substantially greater resources. They are, therefore, likely to be able to sustain the costs of complex patent litigation longer than we could. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating our intellectual property. In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to continue our clinical trials, continue our internal research programs, or in-license needed technology or other product candidates. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States and in some cases may even force us to grant a compulsory license to competitors or other third parties. Consequently, we may not be able to prevent third parties from using our inventions in all countries outside the United States or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in domestic and foreign intellectual property laws. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patents for our product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to protect our trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, collaborators, consultants, advisors and other third parties. We expect to enter into confidentiality and invention assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts within and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We employ individuals who were previously employed at other pharmaceutical or medical aesthetic companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#8217; former employers or other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against these claims. We may not be successful in defending these claims, and even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees. Any litigation or the threat thereof may adversely affect our ability to hire employees. A loss of key personnel or their work product could diminish or prevent our ability to commercialize product candidates, which could have an adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A third party may hold intellectual property, including patent rights that are important or necessary to the development of Evolysse&#8482; or our future product candidates including certain formulations and methods of production of these products. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our product candidates, in which case we would be required to obtain a license from these third parties on commercially reasonable terms, or our business could be harmed, possibly materially.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition by potential partners or customers in our markets of interest. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may assert that we are using trademarks or trade names that are confusingly similar to their marks. If any third party were able to establish that our trademarks or trade names were infringing their marks, that third party may be able to block our ability to use the infringing trademark or trade name. In addition, if a third party were to bring such a claim, we would be required to dedicate time and resources to fight the claim, which time and resources could otherwise be used toward the maintenance of our own intellectual property.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us may request and obtain injunctive or other equitable relief, which could prevent our ability to use the subject trademarks or trade names. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement. We may be required to re-brand one or more of our products, product candidates, or services offered under the infringing trademark or trade name, which may require substantial time and monetary expenditure. Third parties could claim senior rights in marks which might be enforced against our use of trademarks or trade names, resulting in either an injunction prohibiting our sales under those trademarks or trade names.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and products are subject to extensive government regulation. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to extensive, complex, costly and evolving regulation by federal and state governmental authorities in the United States, the EU, Canada, Australia and other countries, principally by the FDA, the U.S. Drug Enforcement Administration, the Centers for Disease Control and Prevention, the EMA and other similar regulatory authorities. Our partners Daewoong and Symatese are also subject to extensive regulation by the FDA and their own country&#8217;s regulatory authorities as well as other regulatory authorities. Our failure to comply with all applicable regulatory requirements, or our partner&#8217;s failure to comply with applicable regulatory requirements, including those promulgated under the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act, and the Controlled Substances Act, may subject us to operating restrictions and criminal prosecution, monetary penalties and other enforcement or administrative actions, including, sanctions, warnings, product seizures, recalls, fines, injunctions, suspension, revocation of approvals, or exclusion from future participation in the Medicare and Medicaid programs. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following regulatory approval, we, and our direct and indirect suppliers, including Daewoong and Symatese, remain subject to the periodic inspection of our plants and facilities, review of production processes, and testing of our products to confirm that we are in compliance with all applicable regulations. Adverse findings during regulatory inspections may result in requirements that we implement REMS programs, requirements that we complete government mandated clinical trials, and government enforcement actions including those relating to labeling, advertising, marketing and promotion, as well as regulations governing manufacturing controls. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenue will be materially impaired.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not obtain regulatory approval for the commercialization of any future product candidates. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research, testing, manufacturing, labeling, approval, selling, import, export, marketing and distribution of drug and biologic products, such as our neurotoxin product, and medical devices, such as our hyaluronic acid gel product candidates, are subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries, with regulations differing from country to country. If we, our products or the manufacturing facilities for our products fail to comply with applicable regulatory requirements, a regulatory agency may:</span></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose restrictions on the marketing or manufacturing of the product, suspend or withdraw product approvals or revoke necessary licenses;</span></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issue warning letters, show cause notices or untitled letters describing alleged violations, which may be publicly available;</span></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">mandate modifications to promotional materials or require us to provide corrective information to aesthetic practitioners;</span></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require us to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for specific actions and penalties for noncompliance;</span></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commence criminal investigations and prosecutions;</span></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose injunctions;</span></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose other civil or criminal penalties;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend any ongoing clinical trials;</span></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay or refuse to approve pending applications or supplements to approved applications filed by us;</span></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refuse to permit drugs or active ingredients to be imported or exported;</span></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend or impose restrictions on operations, including costly new manufacturing requirements; or </span></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seize or detain products or require us to initiate a product recall.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the foregoing could materially harm our business and reputation. Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we or our collaborators must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA, the EMA or other similar foreign regulatory authorities, that such product candidates are safe and effective for their intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we and our collaborators believe the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA, the EMA and other similar regulatory authorities. Administering product candidates to humans may produce undesirable side effects, which could interrupt, delay or halt clinical trials and result in the FDA, the EMA or other similar regulatory authorities delaying or denying approval of a product candidate for any or all targeted indications. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory approval of a BLA or BLA supplement, PMA, marketing authorization application, or MAA, or other product approval is not guaranteed, and the approval process is expensive and may take several years. The FDA, the EMA and other regulatory authorities have substantial discretion in the approval process. Despite the time and expense expended, failure can occur at any stage, and we could encounter problems that cause us to abandon, modify or repeat clinical trials, or perform additional preclinical studies and clinical trials. The number of preclinical studies and clinical trials that will be required for the FDA, the EMA or other regulatory approval varies depending on the product candidate, the disease or condition that the product candidate is designed to address and the regulations applicable to any particular product candidate. The FDA, the EMA and other regulatory authorities can delay, limit or deny approval of a product candidate for many reasons, including the following:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a product candidate may not be deemed safe, effective, pure or potent;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the data from preclinical studies and clinical trials may not be deemed sufficient;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or other regulatory authorities might not approve our third-party manufacturers&#8217; processes or facilities; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">deficiencies in the formulation, quality control, labeling, or specifications of a product candidate or in response to citizen petitions or similar documents filed in connection with the product candidate;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general requirements intended to address risks associated with a class of drugs, such as a new REMS requirement for neurotoxins, hyaluronic acid gels or other aesthetic products;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the enactment of new laws or promulgation of new regulations that change the approval requirements; or</span></div><div style="margin-bottom:10pt;padding-left:36pt;padding-right:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or other regulatory authorities may change their approval policies or adopt new regulations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any future product candidates fail to demonstrate safety and efficacy in clinical trials or do not gain approval, our business and results of operations will be materially and adversely harmed. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, limit or delay regulatory approval and subject us to penalties if we fail to comply with applicable regulatory requirements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Evolysse&#8482; and any other regulated products we may offer are subject to continual regulatory review by the FDA, the EMA and other similar regulatory authorities.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any regulatory approvals that we or our collaborators receive for any future product candidates may also be subject to limitations on the approved indications for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase IV clinical trials, and surveillance to monitor the safety and efficacy of the product. In addition, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for our products and any other future product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP requirements and compliance with good clinical practice, or GCP, requirements, for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any future product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things: restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls; fines, warning letters or holds on clinical trials; refusal by the FDA, the EMA or other similar regulatory authorities to approve pending applications or supplements to approved applications filed by us or our strategic collaborators or suspension or revocation of product license approvals; product seizure or detention or refusal to permit the import or export of products; and injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ongoing regulatory requirements may also change from time to time, potentially harming or making costlier our commercialization efforts. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to obtain regulatory approvals in foreign jurisdictions for our products or any future product candidates, we will be unable to market our products outside of the United States. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the United States, we are and will be subject to a variety of foreign regulations governing manufacturing, clinical trials, commercial sales and distribution of our future products. Whether or not we obtain FDA approval for a product candidate, we must obtain approval of the product by the comparable regulatory authorities of foreign countries before commencing clinical trials or marketing in those countries. The approval procedures vary among countries and can involve additional clinical testing, and the time required to obtain approval may differ from that required to obtain FDA approval. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one or more foreign regulatory authorities does not ensure approval by regulatory authorities in other foreign countries or by the FDA. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval. We may not be able to file for regulatory approvals or to do so on a timely basis, and even if we do file, we may not receive necessary approvals to commercialize our products in markets outside of the United States. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products or any future products may cause or contribute to adverse medical events that we are required to report to regulatory agencies and if we fail to do so, we could be subject to sanctions that would materially harm our business. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some participants in our clinical trials have reported adverse events after being treated with our products. If we are successful in commercializing our products or any other product candidate the FDA and other regulatory agency regulations require that we report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events that we become aware of within the prescribed timeframe. We may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our products. If we fail to comply with our reporting obligations, the FDA, the EMA or other similar regulatory authorities could take action including criminal prosecution, the imposition of civil monetary penalties, seizure of our products, or delay in approval or clearance of future products. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may in the future be subject to various U.S. federal and state laws pertaining to health care fraud and abuse, including anti-kickback, self-referral, false claims and fraud laws, and any violations by us of such laws could result in fines or other penalties. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we do not expect that our products will subject us to the various U.S. federal and most state laws intended to prevent health care fraud and abuse, we may in the future become subject to such laws. The Anti-Kickback Statute prohibits the offer, receipt, or payment of remuneration in exchange for or to induce the referral of patients or the use of products or services that </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">would be paid for in whole or part by Medicare, Medicaid or other federal health care programs. Remuneration has been broadly defined to include anything of value, including cash, improper discounts, and free or reduced price items and services. Many states have similar laws that apply to their state health care programs as well as private payors. Violations of anti-kickback and other applicable laws can result in exclusion from federal health care programs and substantial civil and criminal penalties. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal False Claims Act, or FCA, imposes liability on persons who, among other things, present or cause to be presented false or fraudulent claims for payment by a federal health care program. The FCA has been used to prosecute persons submitting claims for payment that are inaccurate or fraudulent, that are for services not provided as claimed, or for services that are not medically necessary. The FCA includes a whistleblower provision that allows individuals to bring actions on behalf of the federal government and share a portion of the recovery of successful claims. Some state law equivalents of the above federal laws, such as the Anti-Kickback Statute and FCA, apply to items or services regardless of whether the good or service was reimbursed by a government program, so called all-payor laws. These all-payor laws could apply to our sales and marketing activities even if the Anti-Kickback Statute and FCA laws are inapplicable.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our marketing or other arrangements were determined to violate anti-kickback or related laws, including the FCA or an all-payor law, then we could be subject to penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, the exclusion from participation in federal and state healthcare programs, individual imprisonment or the curtailment or restructuring of our operations, any of which could materially and adversely affect our ability to operate our business and our financial results. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State and federal authorities have aggressively targeted pharmaceutical companies for alleged violations of these anti-fraud statutes, based on improper research or consulting contracts with doctors, certain marketing arrangements with pharmacies and other healthcare providers that rely on volume-based pricing, off-label marketing schemes, and other improper promotional practices. Companies targeted in such prosecutions have paid substantial fines, have been ordered to implement extensive corrective action plans, and have in many cases become subject to consent decrees severely restricting the manner in which they conduct their business, among other consequences. Additionally, federal and state regulators have brought criminal actions against individual employees responsible for alleged violations. If we become the target of such an investigation or prosecution based on our contractual relationships with providers or institutions, or our marketing and promotional practices, we could face similar sanctions, which would materially harm our business. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, the FCPA and similar worldwide anti-bribery laws generally prohibit companies and their intermediaries from making improper payments to non-U.S. officials for the purpose of obtaining or retaining business. Our internal control policies and procedures may not protect us from reckless or negligent acts committed by our employees, future distributors, partners, collaborators or agents. Violations of these laws, or allegations of such violations, could result in fines, penalties or prosecution and have a negative impact on our business, results of operations and reputation.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legislative or regulatory healthcare reforms in the United States and other countries may make it more difficult and costly for us to obtain regulatory clearance or approval of any future product candidates and to produce, market, and distribute our products after clearance or approval is obtained. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, legislation is drafted and introduced in the U.S. Congress or other countries that could significantly change the statutory provisions governing the regulatory clearance or approval, manufacture, and marketing of regulated products or the reimbursement thereof. In addition, regulations and guidance are often revised or reinterpreted by the FDA and other regulatory authorities in ways that may significantly affect our business and our products. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of any future product candidates. Such changes could, among other things, require changes to manufacturing or marketing methods, changes to product labeling or promotional materials, recall, replacement, or discontinuance of one or more of our products; and additional recordkeeping. Additionally, the ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, the ability to hire and retain key personnel, the ability to accept the payment of user fees, statutory, regulatory and policy changes and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these would likely entail substantial time and cost and could materially harm our business and our financial results. In addition, delays in receipt of or failure to receive regulatory clearances or approvals for any future products would harm our business, financial condition and results of operations.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in its June 2024 decision in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loper Bright Enterprises v. Raimondo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or Loper, the U.S. Supreme Court overturned the longstanding Chevron doctrine, under which courts were required to give deference to regulatory agencies&#8217; reasonable interpretations of ambiguous federal statutes. The Loper decision could result in additional legal challenges to regulations and guidance issued by federal agencies applicable to our current or future operations, including those issued by the FDA and CMS. Further, the Loper decision may result in increased regulatory uncertainty, inconsistent judicial interpretations and other impacts to the agency rulemaking process. We cannot predict which additional measures may be adopted or the impact of current and additional measures on the marketing, pricing and demand for our products, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities class action and derivative lawsuits have been filed against us and certain of our officers and directors, which could result in substantial costs and could divert management attention.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As disclosed in Part I, Item 3 &#8220;Legal Proceedings,&#8221; we and certain of our officers were previously named as defendants in a securities class action lawsuit and we are a nominal defendant in derivative lawsuits filed against certain of our officers and directors. We maintain director and officer&#8217;s insurance coverage and continue to engage in vigorous defense of such litigation. If we are not successful in our defense of such litigation, we could be forced to make significant payments to or other settlements with our stockholders and their lawyers outside of our insurance coverage, and such payments or settlement arrangements could have a material adverse effect on our business, operating results or financial condition. We may also be the target of this type of litigation in the future, as companies that have experienced volatility in the market price of their stock have been subject to securities act litigation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the claims asserted in these lawsuits are not successful, the litigation could result in substantial costs and significant adverse impact on our reputation and divert management&#8217;s attention and resources, which could have a material adverse effect on our business, operating results or financial condition.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The trading price of our common stock has been volatile, and purchasers of our common stock could incur substantial losses. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price is volatile. For example, the closing price of our common stock during the year ended December 31, 2024 has ranged from a low of $9.99 to a high of $17.49. The stock market in general and the market for earlier stage pharmaceutical and medical aesthetic companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price for our common stock may be influenced by many factors, some of which are beyond our control, including: </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in financial estimates or guidance, including our ability to meet our future revenue and operating profit or loss estimates or guidance;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the public&#8217;s reaction to our earnings releases, other public announcements and filings with the SEC or those of companies that are perceived to be similar to us;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in our financial results or those of companies that are perceived to be similar to us;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any termination or loss of rights under the Daewoong Agreement, the Symatese U.S. Agreement or the Symatese Europe Agreement;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse developments in the regulatory approval process for Evolysse&#8482;;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or other U.S. or foreign regulatory or legal actions or changes affecting us or our industry;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse developments concerning our manufacturer or any future strategic partnerships;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse developments affecting our compliance with the Medytox Settlement Agreements;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse developments concerning litigation pending against us;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">introductions and announcements of new technologies and products by us, any commercialization partners or our competitors, and the timing of these introductions and announcements;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">success or failure of competitive products or medical aesthetic products generally;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of results of clinical trials or regulatory approval or disapproval of product candidates;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unanticipated safety concerns related to the use of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or any of our future products;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us or our competitors of significant acquisitions, licenses, strategic partnerships, new product approvals and introductions, joint ventures or capital commitments;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">overall financial market conditions for the pharmaceutical and biopharmaceutical sectors and issuance of securities analysts&#8217; reports or recommendations;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">rumors and market speculation involving us or other companies in our industry;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">short selling of our common stock or the publication of opinions regarding our business prospects in a manner that is designed to create negative market momentum;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of substantial amounts of our stock by significant stockholders or our insiders, or the expectation that such sales might occur;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">news reports relating to trends, concerns and other issues in medical aesthetics market or the pharmaceutical or biopharmaceutical industry;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operating and stock performance of other companies that investors deem comparable to us and overall performance of the equity markets;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel, including our Chief Executive Officer, Chief Financial Officer, Chief Medical Officer and Chief Marketing Officer;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">intellectual property, product liability or other litigation against us, our manufacturer or other parties on which we rely or litigation against our general industry;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in our capital structure, such as future issuances of securities and the incurrence of additional debt;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting standards, policies, guidelines, interpretations or principles; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic conditions in the markets in which we operate and ongoing geopolitical conflicts; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other factors described in this &#8220;Risk Factors&#8221; section.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock market in general, and the market for pharmaceutical, biotechnology and medical aesthetics companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors may affect the market price of our common stock, regardless of our actual operating performance. In the past, following periods of volatility in the overall market and the market prices of a particular company&#8217;s securities, securities class action litigation has often been instituted against that company. We may become the target of this type of litigation in the future. Securities litigation, if instituted against us, could result in substantial costs and divert our management&#8217;s attention and resources from our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales of our common stock by us or the perception that such sales may occur, could depress the market price of our common stock.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales by us of a substantial number of shares of our common stock in the public market, or the perception that these sales might occur, could significantly reduce the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have filed a registration statement with the SEC covering shares of our common stock available for future issuance under our&#160;2017 Omnibus Incentive Plan and 2023 Inducement Incentive Plan and may file future registration statements covering shares of our common stock for future issuance under any future plans. Upon effectiveness of such registration statements, any shares subsequently issued under such plans will be eligible for sale in the public market, except to the extent that they are restricted by the contractual arrangements discussed above and subject to compliance with Rule 144 in the case of our </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">affiliates. We have also filed a registration statement on Form S-3 covering the offering and sale from time to time of shares of our common stock and certain other securities, which we used to complete our March 2024 follow-on offering as well as to register the sale of shares of our common stock pursuant to our ATM Program. Sales of a large number of the shares issued under these plans in the public market, or a perception that such sales could occur, could significantly reduce the market price of our common stock. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our certificate of incorporation and bylaws, as well as Delaware law, could discourage a takeover.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation, bylaws and Delaware law contain provisions that might enable our management to resist a takeover and might make it more difficult for an investor to acquire a substantial block of our common stock. These include the following provisions:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">permit our Board of Directors to issue shares of preferred stock, with any rights, preferences and privileges as they may designate, without stockholder approval, which could be used to dilute the ownership of a hostile bidder significantly;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that the authorized number of directors may be changed only by resolution of our Board of Directors and that a director may only be removed for cause by the affirmative vote of the holders of at least 66 2/3% of our voting stock;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">divide our Board of Directors into three classes, with each class serving staggered three-year terms, which may delay the ability of stockholders to change the membership of a majority of our Board of Directors;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner and also specify requirements as to the form and content of a stockholder&#8217;s notice, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of our company;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prohibit cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that special meetings of our stockholders may be called only by the chairman of the Board of Directors, our Chief Executive Officer or by our Board of Directors pursuant to a resolution adopted by a majority of the total number of authorized directors, which may delay the ability of our stockholders to force consideration by our company of a take-over proposal or to take certain corporate actions, including the removal of directors.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our Board of Directors, which is responsible for appointing the members of our management. In addition, we are subject to Section 203 of the General Corporation Law of the State of Delaware, or the DGCL, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with an interested stockholder who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. This provision could have the effect of delaying or preventing a change-of-control, whether or not it is desired by or beneficial to our stockholders. Further, other provisions of Delaware law may also discourage, delay or prevent someone from acquiring us or merging with us.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our certificate of incorporation designates the Court of Chancery of the State of Delaware as the&#160;sole and exclusive forum&#160;for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation provides that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the&#160;sole and exclusive forum&#160;for all &#8220;internal corporate claims.&#8221; &#8220;Internal corporate claims&#8221; are claims that are based upon a violation of a duty by a current or former director, officer or stockholder in such capacity, or as to which Title 8 of the DGCL confers jurisdiction upon the Court of Chancery of the State of Delaware, or the Court of Chancery, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants and the claim not being one which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, or for which the Court of Chancery does not have subject matter jurisdiction. For example, this choice of forum provision would not apply to claims brought pursuant to the Exchange Act or the Securities Act of 1933, as amended, or any other claim for which the federal courts have exclusive jurisdiction. Any person purchasing or otherwise acquiring any interest in any shares of our capital stock shall be deemed to have notice of and to have consented to this provision of our certificate of incorporation. The choice of forum provision in our certificate of incorporation will not relieve us of our duties to comply with the federal securities laws and the rules and regulations thereunder, and our stockholders will not be deemed to have waived our compliance with these laws, rules and regulations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This choice of forum provision may limit our stockholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers, employees or agents, which may discourage such lawsuits against us and our directors, officers, employees and agents even though an action, if successful, might benefit our stockholders. Stockholders who do bring a claim in the Court of Chancery could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near Delaware. The Court of Chancery may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders. Alternatively, if a court were to find this provision of our certificate of incorporation inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation and bylaws provide that we can indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. Separate indemnity agreements have been issued with each director and executive officer.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as permitted by Section 145 of the DGCL, our bylaws and our indemnification agreements that we have entered into with our directors and officers, among other things provide that:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have indemnified our directors and officers for serving us in those capacities, or for serving as a director, officer, employee or agent of other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that we may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to our best interest and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will be required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The rights conferred in our bylaws will not be exclusive. We may not retroactively amend our bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be negatively affected as a result of actions of activist stockholders, and such activism could impact the trading value of our securities.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders may, from time to time, engage in proxy solicitations or advance stockholder proposals, or otherwise attempt to effect changes and assert influence on our Board of Directors and management. Activist campaigns that contest or conflict with our strategic direction or seek changes in the composition of our Board of Directors could have an adverse effect on our operating results and financial condition. A proxy contest would require us to incur significant legal and advisory fees, proxy solicitation expenses and administrative and associated costs and require significant time and attention by our Board of Directors and management, diverting their attention from the pursuit of our business strategy. Any perceived uncertainties as to our future direction and control, our ability to execute on our strategy, or changes to the composition of our Board of Directors or senior management team arising from a proxy contest could lead to the perception of a change in the direction of our business or instability which may result in the loss of potential business opportunities, make it more difficult to pursue our strategic initiatives, or limit our ability to attract and retain qualified personnel and business partners, any of which could adversely affect our business and operating results. If individuals are ultimately elected to our Board of Directors with a specific agenda, it may adversely affect our ability to effectively implement our business strategy and create additional value for our stockholders. We may choose to initiate, or may become subject to, litigation as a result of the proxy contest or matters arising from the proxy contest, which would serve as a further distraction to our Board of Directors and management and would require us to incur significant additional costs. In addition, actions such as those described above could cause significant fluctuations in our stock price based upon temporary or speculative market perceptions or other factors that do not necessarily reflect the underlying fundamentals and prospects of our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts publish unfavorable research about our business or decrease the frequency or cease to provide coverage of our company, our stock price and trading volume could decline.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock depends in part on the research and reports that equity research analysts publish about us and our business. If one or more of the equity research analysts who cover us downgrades our common stock or issues other unfavorable commentary or research the price of our common stock may decline. If one or more equity research analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our common stock could decrease, which in turn could cause the trading price or trading volume of our common stock to decline.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have not paid dividends in the past and do not expect to pay dividends in the future, and any return on investment may be limited to the value of our stock.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never paid cash dividends on our common stock and do not anticipate paying cash dividends on our common stock in the foreseeable future, and the payment of dividends is also restricted under our credit facility. The payment of dividends on our common stock will depend on our earnings, financial condition and other business and economic factors affecting us at such time as our Board of Directors may consider relevant. If we do not pay dividends, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The requirements of being a public company may strain our resources, divert management&#8217;s attention and affect our ability to attract and retain executive management and qualified Board members.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the Nasdaq Marketplace Rules and other applicable securities rules and regulations. Complying with these rules and regulations will increase our legal and financial compliance costs, make some activities more difficult, time-consuming or costly and increase demand on our systems and resources, particularly after we are no longer an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. The Exchange Act requires, among other things, that we file annual, quarterly and current reports with respect to our business and operating results. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. In order to maintain and, if required, improve our disclosure controls and procedures and internal control over financial reporting to meet this standard, significant resources and management oversight may be required. As a result, management&#8217;s attention may be diverted from other business concerns, which could adversely affect our business and operating results. We may need to hire more employees in the future or engage outside consultants to assist us in complying with these requirements, which will increase our costs and expenses.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased selling, general and administrative expenses and a diversion of our management&#8217;s time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and our business may be adversely affected.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><div id="id181047532df422ab5a549dd869deccb_22"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="id181047532df422ab5a549dd869deccb_25"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1C. Cybersecurity.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Management and Strategy</span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="f-36" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true" id="f-37">Our cybersecurity risk management process is designed to identify and manage internal and external cybersecurity threats and vulnerabilities to and within our business and operations.</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="f-38" escape="true">Our cybersecurity program is integrated into our overall risk management systems, business continuity and crisis management programs, third-party risk management program, insurance risk management program, and employee compliance programs. Our cybersecurity program includes systems and processes such as, but not limited to, maintenance and monitoring of information security policies, implementation and maintenance of infrastructure security systems, programs and policies designed to promote employee awareness of cyber policies and practices (including implementing an annual process for employees to complete security awareness training in addition to new employee cybersecurity awareness training), information systems configuration management, use of third-party risk management systems, process to promote identity and information asset protection and cybersecurity threat operations with continuous monitoring. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true" id="f-39">This program also includes processes to oversee and identify material risks from cybersecurity threats associated with our use of third-party service providers.</ix:nonNumeric></ix:nonNumeric></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true" id="f-40">We have developed an incident response plan designed to coordinate the activities that we and our third-party security service providers take to prepare to respond and recover from cybersecurity incidents, which include processes to triage, assess severity, investigate, escalate, contain, and remediate an incident, as well as to comply with potentially applicable legal obligations and mitigate any reputational damage.</ix:nonNumeric> Additionally, as part of our overall risk management program, we maintain a global insurance portfolio with cybersecurity coverage.</span></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false" id="f-41">To date, we do not believe that our business, including our business strategy,, results of operations, or financial condition have been materially affected, or are reasonably likely to be materially affected, as a result of identified cybersecurity threats or incidents, including as a result of any previous cybersecurity incidents that we are aware of. However, we cannot provide assurance that we will not be materially affected in the future by such risks or any future cybersecurity incidents.</ix:nonNumeric> For more information on our cybersecurity-related risks, please refer to the risk factor titled &#8220;We rely on our digital technology and applications and our business and operations could suffer in the event of information system failures or a cybersecurity incident&#8221; in Part I, Item 1A of this Report.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governance </span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="f-43" continuedAt="f-43-1" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="f-42" escape="true">Our cybersecurity team is led by the <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true" id="f-44">SVP of IT and Operations</ix:nonNumeric>, who reports to our Chief Financial Officer.</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="f-45" escape="true">Our SVP of IT and Operations and the cybersecurity team have over 25 years of experience managing and securing technology infrastructure.</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="f-46" escape="true">The cybersecurity team has responsibility for the planning and execution of our processes to manage cybersecurity and other information technology risks. The cybersecurity team also institutes and maintains controls for our systems, applications, and databases. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-48" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="f-47" escape="true">Our management, with involvement and input from our Board of Directors, performs annual enterprise-wide cybersecurity assessments to identify and manage key existing and emerging risks for our company.</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-49" escape="true"><ix:continuation id="f-43-1"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true" id="f-50">The Board of Directors</ix:nonNumeric> receives periodic updates on our cybersecurity risks from our SVP of IT and Operations, which include risk assessments, areas of emerging risks, incidents and industry trends, and other areas of importance. These reports include updates on our progress preparing for, preventing, detecting, responding to and recovering from material cyber incidents, if any. In addition, as needed, management updates the Board of Directors regarding any material cybersecurity incidents.</ix:continuation></ix:nonNumeric> </span></div><div id="id181047532df422ab5a549dd869deccb_28"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;Properties.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters is located at 520 Newport Center Drive, Suite 1200, Newport Beach, CA 92660, in a facility that we lease, encompassing approximately 17,758 square feet of space. On July 27, 2023, we entered into an amendment to the existing lease agreement for our corporate headquarters for additional office space of approximately 8,333 square feet of space.  On October 16, 2024, we entered into the Second Amendment to the Lease Agreement (the &#8220;Second Lease Amendment&#8221;) to lease additional office space for our corporate headquarters. The lease term for the Second Lease Amendment is expected to commence in the second half of 2025. The lease agreement expires on January 31, 2030. With the additional office space, we believe our facilities are sufficient for our current needs. When our lease expires, we may exercise </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our renewal option or look for additional or alternate space for our operations, and we believe that suitable additional or alternative space will be available in the future on commercially reasonable terms.</span></div><div id="id181047532df422ab5a549dd869deccb_31"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. &#160;&#160;&#160;&#160;Legal Proceedings.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Class Action Lawsuit</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 16 and 28, 2020, two putative securities class action complaints were filed in the U.S. District Court for the Southern District of New York by Evolus shareholders Armin Malakouti and Clinton Cox, respectively, naming us and certain of our officers as defendants. The complaints assert violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and Rule 10b-5 promulgated thereunder, claiming that the defendants made false and materially misleading statements and failed to disclose material adverse facts related to our acquisition of the right to sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the complaint against us filed by Allergan and Medytox in the U.S. International Trade Commission related to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;ITC Action&#8221;), and risks related to the ITC Action. The complaints assert a putative class period of February 1, 2019 to July 6, 2020. The court consolidated the actions on November 13, 2020, under the caption In re Evolus Inc. Securities Litigation, No. 1:20-cv-08647 (PGG), which we refer to as the Securities Class Action. On September 17, 2021, the court appointed a lead plaintiff and lead counsel. On November 17, 2021, the lead plaintiff filed an amended class action complaint against us, three of our officers, and Alphaeon Corporation, our former majority shareholder. On January 18, 2022, we and the officer defendants served a motion to dismiss the amended complaint. On February 10, 2022, Alphaeon Corporation served its motion to dismiss the amended complaint. Both motions were fully briefed on June 16, 2022. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 26, 2024, the court granted our motion to dismiss the amended complaint and on October 18, 2024, the court entered final judgment in favor of us, which the Plaintiffs did not appeal.  Accordingly, the Securities Class Action is now concluded.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder Derivative Lawsuit</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2020 and December 2, 2020, two putative Evolus shareholders filed substantially similar shareholder derivative actions in the U.S. District Court for the Southern District of New York against certain of our officers and directors as defendants. The complaints alleged substantially similar facts as those in the Securities Class Action and assert claims for, among other things, breach of fiduciary duty, waste of corporate assets, unjust enrichment, and violations of Section 14(a) of the Exchange Act and for contribution under Sections 10(b) and 21(D) of the Exchange Act. On December 29, 2020, the plaintiffs filed a joint stipulation to consolidate their actions and on February 5, 2021, the court consolidated the action under the caption In re Evolus, Inc. Derivative Litigation, No. 1:20-cv-09986-PPG, which we refer to as the Derivative Complaint, and adjourned defendants&#8217; time to move, answer or otherwise respond to the complaints. On September 20, 2021, the court so-ordered the parties&#8217; stipulated stay of the consolidated derivative suit pending the court&#8217;s decision on the defendants&#8217; motion to dismiss the Securities Class Action.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that additional suits will be filed, or additional allegations will be made by stockholders, with respect to these same or similar or other matters and also naming us and/or our officers and directors as defendants. We believe that the complaints are without merit and intends to vigorously defend against it. However, the outcome of the legal proceeding is uncertain at this point. Based on information available to us at present, management cannot reasonably estimate a range of loss with respect to this matter.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Books and Records Demand</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 5, 2021, we received a letter from a putative stockholder demanding inspection of specified categories of our books and records under Section 220 of the Delaware General Corporations Law. We were subsequently informed that the stockholder sold his shares of our common stock. On October 13, 2021, we received a substantially similar demand to inspect specified categories of our books and records under Section 220 of the Delaware General Corporations Law from another putative stockholder. The subject of the demand is substantially similar to the allegations in the Securities Class Action and Derivative Complaint described above. We responded to the demand in December 2021. The outcome of this matter is uncertain at this point. Based on information available to us at present, management cannot reasonably estimate a range of loss with respect to this matter.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Legal Matters</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the legal proceedings set forth above, from time to time, we may be subject to other legal proceedings and claims in the ordinary course of business.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><div id="id181047532df422ab5a549dd869deccb_34"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.&#160;&#160;&#160;&#160;Mine Safety Disclosures.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><div id="id181047532df422ab5a549dd869deccb_37"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II</span></div><div id="id181047532df422ab5a549dd869deccb_40"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. &#160;&#160;&#160;&#160;Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock has been listed and traded on the Nasdaq Stock Market under the symbol &#8220;EOLS&#8221; since February 12, 2018. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders of Record</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;February&#160;28, 2025, we had approximately 24&#160;holders of record of our common stock. This number does not include beneficial owners whose shares were held in street name. The actual number of holders of our common stock is greater than this number of record holders and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers or held by other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any cash dividends on our capital stock and we do not currently intend to pay any cash dividends on our capital stock for the foreseeable future. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. Any future determination related to our dividend policy will be made at the discretion of our Board of Directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, tax considerations, legal or contractual restrictions, business prospects, the requirements of current or then-existing debt instruments, general economic conditions and other factors our Board of Directors may deem relevant. The payment of dividends is also restricted under our credit facility.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This performance graph shall not be deemed &#8220;soliciting material&#8221; or &#8220;filed&#8221; with the SEC for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities under that Section, and shall not be deemed incorporated by reference into any of our filings under the Securities Act or Exchange Act, except as shall be expressly set forth by specific reference in such filing.</span></div><div style="margin-bottom:9pt;text-align:center"><img src="eols-20241231_g2.jpg" alt="2055" style="height:374px;margin-bottom:5pt;vertical-align:text-bottom;width:613px"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This graph shows a comparison of the cumulative total return on our common stock, The Nasdaq Composite Index, and The Nasdaq Biotechnology Index for the five years ended December&#160;31, 2024. The graph assumes that $100 was invested at the market close on the last trading day for the year ended December 31, 2019 in each investment and assumes the reinvestment of any dividends. The stock price performance on the graph is not necessarily indicative of future stock price performance.</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:15.144%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.169%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Company/Index</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolus</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.71&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.71&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nasdaq Composite Index</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nasdaq Biotechnology Index</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><div id="id181047532df422ab5a549dd869deccb_43"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.&#160;&#160;&#160;&#160;[Reserved].</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="id181047532df422ab5a549dd869deccb_46"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion contains management&#8217;s discussion and analysis of our financial condition and consolidated results of operations and should be read together with the consolidated financial statements and the notes thereto included in Item 8 &#8220;Consolidated Financial Statements and Supplementary Data&#8221; and included elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements that reflect our plans, estimates and beliefs and involve numerous risks and uncertainties, including but not limited to those described in the Item 1A &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K. Actual results may differ materially from those contained in any forward-looking statements. You should carefully read &#8220;Special Note Regarding Forward-Looking Statements&#8221; and Item 1A &#8220;Risk Factors.&#8221;</span></div><div id="id181047532df422ab5a549dd869deccb_49"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a global performance beauty company with a customer-centric approach to delivering breakthrough products in the cash-pay aesthetic market. Our first product, Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (prabotulinumtoxinA-xvfs), is currently sold in the United States, Canada, certain European countries and Australia. We have commercial launch plans in additional countries which we expect to implement in the next few years. We are also actively pursuing the commercialization and further regulatory approvals of Evolysse&#8482;, a collection of injectable hyaluronic acid gels that includes mid face, nasolabial folds, lips and eyes. In October 2024, regulatory approval was received in the European Union for four products in the Evolysse&#8482; line: Evolysse&#8482; Form, Evolysse&#8482; Smooth, Evolysse&#8482; Sculpt and Evolysse&#8482; Lips. In February 2025, we received approval from the U.S. Food and Drug Administration, or the FDA, for Evolysse&#8482; Form and Evolysse&#8482; Smooth injectable hyaluronic acid gels for wrinkles and folds, such as nasolabial folds. We anticipate launching Evolysse&#8482; Form and Evolysse&#8482; Smooth in the United States in the second quarter of 2025.  We also anticipate launching all four approved Evolysse&#8482; products in Europe in the second half of 2025.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary market is the cash-pay aesthetic market, which consists of medical products that consumers pay for directly out of pocket. Our customers are aesthetic practitioners who are properly licensed to deliver our products. By avoiding the regulatory burdens that accompany reimbursed products and pursuing an aesthetic-only non-reimbursed product strategy, we create flexibility to deliver a unique value proposition to our customers. We utilize this flexibility to drive customer adoption through programs such as our consumer loyalty program, co-branded marketing programs, promotional events and pricing strategies.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Trends and Uncertainties</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global economy, including the financial and credit markets, has recently experienced volatility and disruptions, increases in inflation rates, rising interest rates, new and threatened tariffs, severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, and uncertainty about economic stability. We expect elevated levels of cost inflation to continue, potentially impacting consumer discretionary spending for aesthetic medical procedures. Markets experiencing uncertainty could have substantial high rates of inflation. We cannot reasonably estimate the financial impact of increased inflation on our financial condition, results of operations or cash flows in the future.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><div id="id181047532df422ab5a549dd869deccb_52"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Years Ended December 31, 2024 and 2023</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the periods indicated:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.757%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation of contingent royalty obligation payable to Evolus Founders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-operating expense, net </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes:</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss, net of tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50.9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our gross profit margin for the periods indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.757%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9.75pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Gross profit margin</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Revenues</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently operate in one reportable segment, and all of our net revenues are derived from sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Net revenues consist of revenues, net of adjustments primarily for customer rebates, rewards related to the consumer loyalty program and co-branded marketing programs. Revenues are recognized when the control of the promised goods is transferred to the customer in an amount that reflects the consideration allocated to the related performance obligations and to which we expect to be entitled in exchange for those products or services. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales increased by $64.2 million, or 32%, to $266.3 million for the year ended December 31, 2024 from $202.1 million for the year ended December 31, 2023, primarily due to higher sales volumes. Net revenues during the year ended December 31, 2024 and 2023 consisted of $2.0 million and $2.4 million of service revenue, respectively, from the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through a distribution partner in Canada. We anticipate our continued sales growth will depend on our ability to grow our customer base and increase purchases by our current customers in the competitive aesthetic market as well as the success of the commercial launch of Evolysse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Form and Evolysse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smooth products in the United States and the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolysse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hyaluronic acid gel product collection in Europe, and on regulatory approval for the Evolysse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sculpt, and Lips products in the United States.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold</span></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> goods sold, primarily&#160;consisted of the cost of inventory purchased from Daewoong and amortization of intangible asset distribution right. In addition, cost of goods sold includes certain royalties on the sale of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jeuveau</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> payable to Medytox related to the Medytox Settlement Agreements.  Our royalty obligations to Medytox are a mid-single digit percentage of net revenue through the expiration of our Medytox royalty obligation in September 2032.</span></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold, increased </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$19.5 million, or 30%,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$84.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;for&#160;the&#160;year ended December 31, 2024 from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$64.5 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December 31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> primarily due to higher sales volume. We anticipate that our cost of goods sold will fluctuate in line with changes in revenues until the expiration of our Medytox royalty obligation in September 2032.</span></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gross Profit Margin</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our gross profit margin was 68% and 68% for the years ended December 31, 2024 and 2023, respectively. We also anticipate our gross profit margin will fluctuate as we implement various marketing p</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rograms that may affect the average selling price for Jeuveau</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and as we expand internationally.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses&#160;increased by&#160;$33.1 million, or 20%,&#160;to&#160;$198.0 million&#160;for the&#160;year ended December 31, 2024&#160;from&#160;$164.9 million&#160;for the&#160;year ended December 31, 2023, primarily resulting from increasing personnel costs and related to our commercial activities. Selling, general and administrative expenses may fluctuate in the future primarily due to potential changes in marketing strategies and international launches.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses&#160;increased by&#160;$2.6 million, or 39%,&#160;to&#160;$9.2 million&#160;for the&#160;year ended December 31, 2024&#160;from&#160;$6.6 million&#160;for the&#160;year ended December 31, 2023. The increase was primarily attributable to increasing our clinical operations and research and development expenses related to Evolysse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We expect our research and development expenses to continue to increase if and when we develop further product candidates and as we pursue regulatory approvals in other jurisdictions.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-process Research and Development</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the twelve months ended December 31, 2023, we recorded $8.9 million of in-process research and development expense in connection with the Symatese agreements. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the Notes to the Consolidated Financial Statements in Part II, Item 8 of this Annual Report on Form 10-K for additional information.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revaluation of Contingent Royalty Obligation Payable to Evolus Founders</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the fair value of the contingent royalty obligation payable to the founders of Evolus, or Evolus Founders, is recorded in operating expenses in each reporting period. During the&#160;years ended December 31, 2024&#160;and 2023, the revaluation charges of&#160;$7.2 million&#160;and&#160;$4.3 million, respectively, were primarily driven by changes in management assumptions relating to revenue forecasts, the discount rate used and the timing of cash flows. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Depreciation and Amortization</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization&#160;increased by $0.1 million, or 5%,&#160;to&#160;$2.3 million&#160;for the&#160;year ended December 31, 2024&#160;from $2.2 million for the&#160;year ended December 31, 2023, primarily due to an increase in amortization of internal-use software and leasehold improvements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Operating Expense, Net</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-operating expense, net, increased by&#160;$3.0 million, or 24%,&#160;to&#160;$15.3 million&#160;for the&#160;year ended December 31, 2024&#160;from $12.3 million&#160;for the&#160;year ended December 31, 2023, primarily due to interest expense on the Pharmakon Term Loans which </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increased due to higher average outstanding borrowings during the&#160;year ended December 31, 2024. Interest on the Pharmakon Term Loans is based on a variable interest rate, which we expect will continue to fluctuate with the market.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes Expense</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was minimal income tax expense&#160;for the&#160;years ended December 31, 2024&#160;and 2023.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Years Ended December 31, 2023 and 2022</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the periods indicated:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.757%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation of contingent royalty obligation payable to Evolus Founders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-operating expense, net </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes:</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61.5)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss, net of tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our gross profit margin for the periods indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.757%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt 0 5.5pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Gross profit margin</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Revenues</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently operate in one reportable segment, and all of our net revenues are derived from sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Net revenues consist of revenues, net of adjustments primarily for customer rebates, rewards related to the consumer loyalty program and co-branded marketing programs. Revenues are recognized when the control of the promised goods is transferred to the customer in an amount that reflects the consideration allocated to the related performance obligations and to which we expect to be entitled in exchange for those products or services. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales increased by $53.5 million, or 36%, to $202.1 million for the year ended December 31, 2023 from $148.6 million for the year ended December 31, 2022, primarily due to higher sales volumes. Net revenues during the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years ended December 31, 2023 and 2022 consisted of $2.4 million and $2.0 million of service revenue, respectively, from the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through a distribution partner in Canada. We anticipate our continued sales growth will depend on our ability to grow our customer base and increase purchases by our current customers in the competitive aesthetic market as well as on regulatory approval for the Evolysse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hyaluronic acid gel product line in the United States and Europe by Symatese.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold</span></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> goods sold, primarily&#160;consisted of the cost of inventory purchased from Daewoong and amortization of intangible asset distribution right. In addition, during the period from December 2020 to September 2022, cost of goods sold also included certain royalties on the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> payable to Medytox and Allergan pursuant to the Medytox Settlement Agreements, partially offset by reimbursement receivable from Daewoong pursuant to the Daewoong Arrangement with respect to such royalties. Our royalty obligations to Allergan concluded on September 16, 2022, and beginning on September 17, 2022, our royalty obligations to Medytox were reduced to a mid-single digit percentage of net revenue through the expiration of our Medytox royalty obligation in September 2032.</span></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold, increased by </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5.7 million, or 10%,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$64.5 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;for&#160;the&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December 31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$58.8 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December 31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> primarily due to higher sales volume, offset by reduced royalty obligations to Medytox. We anticipate that our cost of goods sold will fluctuate in line with changes in revenues until the expiration of our Medytox royalty obligation in September 2032.</span></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gross Profit Margin</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our gross profit margin was 68% and 60% for the years ended December 31, 2023 and 2022, respectively. Our gross profit margin was impacted negatively and materially through September 2022, by our payments under the Medytox Settlement Agreements. Our gross profit margin has been and will continue to be negatively impacted to a lesser extent from September 2022 to September 2032 as we pay royalty obligations to Medytox at a mid-single digit percentage of net revenue. We also anticipate our gross profit margin will fluctuate as we implement various marketing p</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rograms that may affect the average selling price for Jeuveau</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and as we expand internationally.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses&#160;increased by&#160;$23.1 million, or 16%,&#160;to&#160;$164.9 million&#160;for the&#160;year ended December 31, 2023&#160;from&#160;$141.8 million&#160;for the&#160;year ended December 31, 2022, primarily resulting from increasing personnel costs and related to our commercial activities. Selling, general and administrative expenses may fluctuate in the future primarily due to potential changes in marketing strategies and international launches.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses&#160;increased by&#160;$1.9 million, or 40%,&#160;to&#160;$6.6 million&#160;for the&#160;year ended December 31, 2023&#160;from&#160;$4.7 million&#160;for the&#160;year ended December 31, 2022. The increase was primarily attributable to increasing our clinical operations and research and development expenses related to Evolysse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We expect our research and development expenses to continue to increase if and when we develop further product candidates and as we pursue regulatory approvals in other jurisdictions.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-process Research and Development</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-process research and development increased by $6.9 million, or 345%, to $8.9 million for the&#160;year ended December 31, 2023&#160;from $2.0 million&#160;for the&#160;year ended December 31, 2022. In 2022, we recorded an upfront payment of $2.0 million in connection with the License and Research Collaboration Agreement (the &#8220;Collaboration Agreement&#8221;) we entered into with a 3D printing company with biomaterial capabilities. In 2023, we recorded the upfront payment of $4.4 million and the issuance of shares of $4.4 million in connection with the Symatese U.S. Agreement and Symatese Europe Agreement, respectively. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Summary of Significant Accounting Policies </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the Notes to the Consolidated Financial Statements in Part II, Item 8 of this Annual Report on Form 10-K for additional information.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revaluation of Contingent Royalty Obligation Payable to Evolus Founders</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the fair value of the contingent royalty obligation payable to Evolus Founders is recorded in operating expenses in each reporting period. During the&#160;years ended December 31, 2023&#160;and 2022, the revaluation charges of&#160;$4.3 million&#160;and&#160;$5.8 million, respectively, were primarily driven by changes in management assumptions relating to revenue forecasts, the discount rate used and the timing of cash flows. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Depreciation and Amortization</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization&#160;increased by $1.4 million, or 175%,&#160;to&#160;$2.2 million&#160;for the&#160;year ended December 31, 2023&#160;from $0.8 million for the&#160;year ended December 31, 2022, primarily due to an increase in amortization of internal-use software and leasehold improvements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Operating Expense, Net</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-operating expense, net, increased by&#160;$3.3 million, or 37%,&#160;to&#160;$12.3 million&#160;for the&#160;year ended December 31, 2023&#160;from $9.0 million&#160;for the&#160;year ended December 31, 2022, primarily due the advancement of the $50.0 million second tranche of the Pharmakon Term Loans in 2023. Interest on the Pharmakon Term Loans is based on a variable interest rate, which we expect will continue to fluctuate with the market.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes Expense</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was minimal income tax expense&#160;for the&#160;years ended December 31, 2023&#160;and 2022.</span></div><div id="id181047532df422ab5a549dd869deccb_55"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we had cash and cash equivalents of $87.0 million, positive working capital of $88.4 million and stockholders&#8217; equity of $5.5 million.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We began selling Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in May 2019 and have a relatively limited history of generating revenues. Since inception, we have incurred recurring net operating losses and have an accumulated deficit of $609.4 million as of December&#160;31, 2024 as a result of ongoing efforts to develop and commercialize Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including providing selling, general and administrative support for our operations. We had net loss of $50.4 million and $61.7 million in the years ended December 31, 2024 and 2023, respectively. We had a loss from operations of $34.4 million and $49.2 million in the years ended December 31, 2024 and 2023, respectively. We used net cash of $18.0 million and $34.0 million in operating activities for the years ended December 31, 2024 and 2023, respectively. We expect to continue to incur significant expenses for the foreseeable future as we increase marketing efforts for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S., Europe, and Australia, pursue regulatory approvals in other jurisdictions and ready for commercial launch of the Evolysse&#8482; Form, Smooth, Sculpt and Eye hyaluronic acid gel product line.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impact of Inflation</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The markets in which we operate are currently experiencing increased inflation. While we do not believe that inflation has had a material impact on our business, revenues or operating results during the periods presented, a prolonged inflationary environment could impact consumer discretionary spending for aesthetic medical procedures, increase our cash required for operations and impact our liquidity position.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Follow-On Offering</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, we completed a follow-on offering and issued 3,554,000 shares of our common stock, at a price to the public of $14.07 per share. We received net proceeds of $46.8 million from the offering, after deducting underwriting discounts and commissions and other offering expenses. In addition, we granted the underwriters an option, exercisable for 30 days, to purchase up to 533,100 additional shares of common stock (the &#8220;option shares&#8221;) at the purchase price, which the underwriters exercised in April 2024 with respect to 318,100 of the allotted option shares. The net proceeds to us from the sale of the option shares, after deducting the underwriters&#8217; discounts and commissions, was $4.2 million.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;At-the-market&#8221; Offerings of Common Stock</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 8, 2023, we entered into an &#8220;at-the-market&#8221; sales agreement (the &#8220;ATM Sales Agreement&#8221;) and filed a shelf registration statement on Form S-3 and corresponding prospectus with the SEC to permit sales under the ATM Sales Agreement, which registration statement became effective on June 8, 2023. We have not sold any shares under the ATM Sales Agreement. See Note 10. Stockholders&#8217; Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Pharmakon Term Loans</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2021, we entered into a loan agreement with Pharmakon. Pursuant to the terms of the agreement, Pharmakon agreed to make term loans to us in two tranches. The first tranche of $75.0&#160;million was funded on December 29, </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021. We received net proceeds of approximately $68.7&#160;million from Pharmakon, after issuance costs and debt discounts. On December 5, 2022, we entered into a Second Amendment to the loan agreement to extend our option to draw down the second tranche of $50.0&#160;million until December 31, 2023. On May 9, 2023, we entered into a Third Amendment to the loan agreement, which provided for the advancement of the second tranche of $50.0 million in two installments: (i) $25.0 million advanced on May 31, 2023 and (ii) $25.0 million advanced on December 15, 2023, which amounts were advanced on such dates subject to the terms and conditions of the Pharmakon Term Loans. We are required to pay interest only under the loan agreement until March 2026, after which we make seven equal quarterly payments, each in an amount equal to 1/12th of the outstanding principal amount of the loan. We pay the remaining principal of the loan on the maturity date. The Pharmakon Term Loans will mature on the sixth year anniversary of the closing date of the first tranche. The term loan bears an annual interest rate equal to the 3-month secured overnight financing rate (&#8220;SOFR&#8221;) (subject to a SOFR rate floor of 1.0%) plus 8.5% per annum. The proceeds of the Pharmakon Term Loans are used to fund our general corporate and working capital requirements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Royalties to Evolus Founders</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to make quarterly royalty payments of a low single digit percentage of net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the Evolus Founders. These obligations terminate at the end of the second quarter of 2029. The fair value of the obligations is valued quarterly and is referred to in our consolidated financial statements as the contingent royalty obligation.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, we recorded an aggregate balance of $44.8 million and $45.0 million, respectively, on our consolidated balance sheet for the future royalty payment obligation to Evolus Founders.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Settlement</span></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 18, 2021, upon entering into the Medytox Settlement Agreements, we agreed to pay to Allergan and Medytox $35.0&#160;million in multiple payments over two years, of which we paid the first payment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$15.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the third quarter of 2021, the second payment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$15.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the first quarter of 2022, and the final pay</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ment of $5.0 million in the first quarter of 2023. We also issued 6,762,652 shares of common stock to Medytox. In addition, during the period from December 16, 2020 through September 16, 2022, we agreed to pay to Allergan and Medytox royalties on the sal</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e of Jeuveau</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, based on a certain dollar amount per vial sold in the United States, and a low-double digit royalty on net sales of Jeuveau</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sold in other Evolus territories. During the period from September 17, 2022 to September 16, 2032, we agreed to pay to Medytox a mid-single digit royalty percentage on all net sales of Jeuveau</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The royalty payments are made quarterly.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Daewoong Agreement</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Daewoong Agreement includes certain minimum annual purchases we are required to make in order to maintain the exclusivity of the license. We may, however, meet these minimum purchase obligations by achieving certain market share in our licensed territories. These potential minimum purchase obligations are contingent upon the occurrence of future events, including receipt of governmental approvals and our future market share in various jurisdictions.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Symatese U.S. Agreement</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Symatese U.S. Agreement includes certain milestone payments, development cost-sharing arrangements, and minimum annual purchases we are required to make in order to maintain the exclusivity of the license. We may, however, meet these minimum purchase obligations by achieving certain market share in our licensed territory. These potential minimum purchase obligations are contingent upon the occurrence of future events, including receipt of governmental approvals and our future market share.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Symatese Europe Agreement</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Symatese Europe Agreement includes certain milestone payments and minimum annual purchases we are required to make in order to maintain the exclusivity of the license. We may, however, meet these minimum purchase obligations by achieving certain market share in our licensed territory. These potential minimum purchase obligations are contingent upon the occurrence of future events, including receipt of governmental approvals and our future market share.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Leases</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters in Newport Beach, California is under a non-cancelable operating lease, which expires on January 31, 2030 with an option to extend the term for an additional 60 months. Lease payments increase based on an annual rent </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">escalation clause that occurs on each February 1 anniversary. On October 16, 2024, the Company entered into the Second Amendment to the Lease Agreement (the &#8220;Second Lease Amendment&#8221;) to lease additional office space for its corporate headquarters and the lease is expected to commence on or around the second half of 2025.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Current and Future Capital Requirements</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our current capital resources, which consist of cash and cash equivalents, future cash generated from operations and sales under the ATM Sales Agreement will be sufficient to satisfy our cash requirements for at least the next twelve months for working capital to support our daily operations and meet commitments under our contractual obligations with third parties, although we may wish to access the debt and equity markets or other sources of financing to satisfy our long-term cash requirements as further discussed below.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have based our projections of capital requirements on assumptions that may prove to be incorrect and we may use all our available capital resources, which consist of cash and cash equivalents and cash generated from operations, sooner than we expect. Our cash requirements depend on numerous factors, including but not limited to, the impact of any potential disruptions to our supply chain, inflation or other economic conditions, uncertainty regarding the stability of certain financial institutions, and other long-term commitments and contingencies. Because of the numerous risks and uncertainties associated with research, development and commercialization of our products, we are unable to estimate the exact amount of our operating capital requirements, including our requirements beyond the next twelve months. In such case, we may be required to raise additional capital to fund future operations through the incurrence of debt, the entry into licensing or collaboration agreements with partners, sale of equity securities, grants or other sources of financing. However, there can be no assurance such financing or other alternatives will be available to us on acceptable terms, or at all. The global economy, including the financial and credit markets, has recently experienced significant volatility and disruptions, including severely diminished liquidity and credit availability and rising interest rates. These conditions may adversely impact our ability to raise additional capital on acceptable terms, or at all.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future funding requirements will depend on many factors, including, but not limited to:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate of revenue growth for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Evolysse&#8482; in the markets in which they are launched;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of regulatory approval for the additional Evolysse&#8482; products in the United States and Europe by Symatese and our ability to successfully commercialize these products;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">development costs and milestone payments related to the Evolysse&#8482; products;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to forecast demand for our products, scale our supply to meet that demand and manage working capital effectively;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">corporate development activities including the purchase, license, or other acquisition of products and services to add to our product or service offerings;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number, characteristics, and development stage of any future product candidates we may develop or acquire;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and costs of any ongoing or future clinical programs we may conduct;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing our product or any future product candidates and any products we successfully commercialize, including costs associated with our supply chain;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and amounts of the royalty and other payments payable in connection with the Medytox Settlement Agreements;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the amounts of the royalty payable to the Evolus Founders;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of commercialization activities for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Evolysse&#8482; hyaluronic acid gel product line or any future product candidates that are approved or cleared for sale, including marketing, sales and distribution costs;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of maintaining a sales force, the productivity of that sales force, the market acceptance of our products and the actions and product introductions of our competitors;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of any such agreements that we may enter into; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any product liability or other lawsuits related to our products; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of any current litigation, including our ongoing securities class action lawsuit and shareholder derivative lawsuit;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expenses needed to attract and retain skilled personnel; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with being a public company; </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing intellectual property and any other future intellectual litigation we may be involved in; and </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt and amount of sales of any future approved or cleared products, if any.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.269%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.758%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.644%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #231f20;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #231f20;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #231f20;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #231f20;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #231f20;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #231f20;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #231f20;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt;padding-left:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities </span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:4.5pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;padding-right:4.5pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in cash and cash equivalents</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92.3)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of period</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Activities </span></div><div style="margin-bottom:9pt;padding-right:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2024, operating activities used $18.0 million of cash, which primarily resulted from our net loss of $50.4 million. Net operating assets and liabilities changed by $6.6 million, primarily driven by timing of collections from customers, payments to vendors, and the timing of inventory purchases from our supplier. Operating activities also includes adjustments for certain non-cash charges including $22.3 million of stock-based compensation expense, $2.4 million of provision of allowance for doubtful accounts, $1.1 million of amortization of debt discount and issuance costs, $5.3 million of depreciation and amortization, and $7.2 million in revaluation of our contingent royalty obligation.</span></div><div style="margin-bottom:9pt;padding-right:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2023, operating activities used $34.0 million of cash, which primarily resulted from our net loss of $61.7 million. Net operating assets and liabilities changed by $5.9 million, primarily driven by timing of receipts from customers and payments to vendors and the second cash litigation settlement payment of $5.0 million to Medytox and Allergan. Operating activities also includes adjustments for certain non-cash charges including $16.5 million of stock-based compensation expense, $4.3 million in revaluation of our contingent royalty obligation, $1.4 million of provision of allowance for doubtful accounts, $1.1 million of amortization of debt discount and issuance costs and $5.1 million of depreciation and amortization and $4.4 million of in-process research and development expense.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;padding-right:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2022, operating activities used $84.9 million of cash, which primarily resulted from our net loss of $74.4 million. Net operating assets and liabilities changed by $34.3 million, primarily driven by timing of receipts from customers and payments to vendors and second cash litigation settlement payment of $15.0 million to Medytox and Allergan. Operating activities also includes adjustments for certain non-cash charges including $10.8 million of stock-based compensation expense, $5.8 million in revaluation of our contingent royalty obligation, $1.6 million of provision of allowance for doubtful accounts, $1.1 million of amortization of debt discount and issuance costs and $3.7 million of depreciation and amortization.</span></div><div style="margin-bottom:9pt;padding-right:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investing Activities </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities was $4.8 million for the&#160;year ended December 31, 2024, compared to $1.6 million for the year ended December 31, 2023. For the year ended December 31, 2024, cash used in investing activities driven by the purchase of property, plant, and equipment and additions to capitalized software.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities was $1.6 million for the year ended December 31, 2023, compared to $2.9 million for the year ended December 31, 2022. For the year ended December 31, 2023, cash used in investing activities driven by the purchase of property, plant, and equipment and additions to capitalized software.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financing Activities</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities was $47.4 million for the year ended December 31, 2024, compared to $44.6 million of cash provided by financing activities for the year ended December 31, 2023. For the year ended December 31, 2024, cash provided by financing activities primarily resulted from $51.2 million net proceeds from the follow-up equity offering, net of discounts.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities was $44.6 million for the year ended December 31, 2023, compared to $4.1 million of cash used in financing activities for the year ended December 31, 2022. For the year ended December 31, 2023, cash provided by financing activities primarily resulted from $50.0 million net proceeds from drawing on the second tranche of the Pharmakon Term Loans as described above.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indebtedness</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;Liquidity and Capital Resources&#8212;The Pharmakon Term Loans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for a description of our Pharmakon Term Loans.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Material Cash Requirements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our material cash requirements from known contractual and other obligations, including commitments for capital expenditures, primarily consist of (i) principal and interest payments related to our Pharmakon Term Loans (future interest payments on our outstanding Pharmakon Term Loans total approximately $40.6&#160;million, with $16.8&#160;million due within twelve months), (ii) quarterly royalty payments to the Evolus Founders of a low single digit percentage of net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (these obligations terminate in the quarter after the 10-year anniversary of the first commercial sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States), (iii) quarterly royalty payments to Medytox of a low-double digit royalty on net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sold in the United States and other Evolus territories (during the period from September 17, 2022 to September 16, 2032), (iv) minimum purchase obligations under the Daewoong Agreement, (v) &#8364;12.1 milestone payments under the Symatese U.S. Agreement consisting of &#8364;1.6 million in June 2025, &#8364;4.1 million in June 2026, &#8364;3.2 million in June 2027, and &#8364;3.2 million in June 2028, in each case subject to three of the hyaluronic acid gel products gaining approval prior to that date, (vi) &#8364;3.1 million of milestone payments under the Symatese Europe Agreement consisting of: &#8364;1.2 million on the second anniversary of certain regulatory approvals and &#8364;1.9 million on the earlier of the third anniversary of certain regulatory approvals or following a year in which we achieves &#8364;25 million in revenue in Europe for the hyaluronic acid gel products, and (vii) obligations under operating leases related to our office space which are described in more detail in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">  Note 8. Operating Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the Notes to Consolidated Financial Statements in Part II, Item 8. of this Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div id="id181047532df422ab5a549dd869deccb_58"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management&#8217;s discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and related disclosure of contingent assets and liabilities, revenue and expenses at the date of the consolidated financial statements as well as the expenses incurred during the reporting period. Generally, we base our estimates on historical </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">experience and on various other assumptions in accordance with GAAP that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions and such differences could be material to the financial position and results of operations. On an ongoing basis, we evaluate our estimates and assumptions in light of changes in circumstances, facts and experience. </span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our significant accounting policies are more fully described in the Notes to Consolidated Financial Statements in Part II, Item 8 of this Annual Report on Form 10-K, we believe the following accounting policies to be most critical for fully understanding and evaluating our financial condition and results of operations, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration to which we expect to be entitled in exchange for the goods or services. In order to achieve that core principle, a five-step approach is applied: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue allocated to each performance obligation when (or as) we satisfy the performance obligations. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account for revenue recognition.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate product revenue from the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States, Europe, and Australia and service revenue from the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through a distribution partner in Canada. For product revenue, we&#160;recognize revenue when control of&#160;Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;is transferred to a customer upon receipt. For service revenue, we are determined to be the agent in the distribution of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in Canada and record the sale as service revenue on a net basis.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues are recorded net of sales-related adjustments, wherever applicable. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consumer loyalty program allows participating customers to earn rewards for qualifying treatments to their patients (i.e. consumers) using Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and redeem the rewards for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the future at no additional cost. The loyalty program represents a customer option that provides a material right and, accordingly, is a performance obligation. At the time Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product is sold to customers, the invoice price is allocated between the product sold and the estimated material right reward, or Reward, that the customer might redeem in the future. The standalone selling price of the Reward is measured based on estimated average selling price of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at the time of redemption and the expected redemption rate by customers based on historical sales data. We do not believe there is a reasonable likelihood that there will be a material change in the future estimates or assumptions we use to establish the liability for the Reward. However, if the actual customer and consumer participation rates and number of qualifying treatments in any future periods materially differ from the estimates, we may be exposed to adjustments that could be material. The portion of invoice price allocated to the Reward is initially recorded as deferred revenue, and when customers redeem the Reward and the related product is delivered, the deferred revenue is reversed and included in net revenues.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Royalty Obligation to the Evolus Founders</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the fair value of the contingent royalty obligation payable to the Evolus Founders based on significant unobservable inputs using a discounted cash flows method. Changes in the fair value of this contingent royalty obligation are determined each period end and recorded in operating expenses in the consolidated statements of operations and comprehensive loss and in the current and non-current liabilities in the consolidated balance sheets. The significant unobservable input assumptions that can significantly change the fair value includes (i) projected net revenues during the payment period, (ii) the discount rate and (iii) the timing of payments. Significant increases (decreases) in the discount rate would result in a significantly lower (higher) fair value measurement, which could materially impact the fair value reported on the consolidated balance sheet.</span></div><div id="id181047532df422ab5a549dd869deccb_61"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued and Adopted Accounting Pronouncements</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We describe the recently issued accounting pronouncements that apply to us in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Summary of Significant Accounting Policies&#8212;Recent Accounting Pronouncements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in Part II, Item 8 of this Annual Report on Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><div id="id181047532df422ab5a549dd869deccb_64"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A.  Quantitative and Qualitative Disclosure About Market Risk.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of fluctuations in interest rates and foreign currency exchange rates.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate and Market Risk</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks in the ordinary course of our business. Our cash and cash equivalents include cash in readily available checking and money market accounts. These securities are not dependent on interest rate fluctuations that could cause the principal amount of these assets to fluctuate and thus do not pose any interest rate risk to us. While we believe our cash and cash equivalents do not contain excessive risk, we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in market value.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to risks related to fluctuations in interest rates on our outstanding variable rate for the Pharmakon Term Loans. As of December&#160;31, 2024, we had $121.5 million outstanding on the term loan. We estimate that a 1% increase or decrease in underlying interest rates as of December&#160;31, 2024 would not have a material impact on annual interest expense.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Exchange</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are primarily conducted in the U.S. dollar. Exchange rate fluctuations may affect the costs that we incur in our operations. We conduct operations in foreign countries and are mainly exposed to fluctuations in the British pound and the EU euro. Transactional exposure arises when transactions occur in currencies other than the U.S. dollar. Transactions denominated in foreign currencies are recorded at the exchange rate prevailing at the date of the transaction with the resulting liabilities being translated into the U.S. dollar at exchange rates prevailing at the balance sheet date. The resulting gains and losses, which were insignificant for the years ended December 31, 2024, 2023, and 2022, are included in other expenses in the consolidated statement of operations and comprehensive loss.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><div id="id181047532df422ab5a549dd869deccb_67"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.&#160; &#160;&#160;&#160;&#160;Consolidated Financial Statements and Supplementary Data.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:10pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index to Consolidated Financial Statements</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:88.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.424%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_73">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (PCAOB ID: <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-51">42</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_73">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_67">Consolidated Financial Statements:</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_76">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_76">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_82">Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_82">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_85">Consolidated Statements of Stockholders&#8217; Equity (Deficit)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_85">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_88">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_88">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_91">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_91">69</a></span></div></td></tr></table></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><div id="id181047532df422ab5a549dd869deccb_73"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Evolus, Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Evolus, Inc. (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, stockholders' equity (deficit) and cash flows for each of the three years in the period ended December 31, 2024, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated March 4, 2025 expressed an unqualified opinion thereon.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the account or disclosure to which it relates.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:78.067%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation of fair value of contingent royalty obligation</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As discussed in Note 2 of the consolidated financial statements, the Company records payment obligations to its founders which consists of quarterly royalty payments of a low single digit percentage of net sales of Jeuveau&#174;. The obligations terminate in the second quarter of 2029, which is the 10-year anniversary of the first commercial sale of Jeuveau&#174; in the United States. The Company determines the fair value of the contingent royalty obligation at each reporting period end based on significant unobservable inputs using a discounted cash flows method.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Auditing the Company&#8217;s contingent royalty obligation was challenging due to the effort required to evaluate the appropriateness of the significant unobservable inputs used in the fair value calculation, specifically the US projected net revenues of Jeuveau&#174; during the payment period.</span></div><div><span><br/></span></div><div><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We obtained an understanding, evaluated the design, and tested the operating effectiveness of internal controls over the Company&#8217;s contingent royalty obligation process. For example, we tested controls over management&#8217;s development of the above-described assumption used in the contingent royalty obligation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">To test the estimated fair value of the contingent royalty obligation, we performed audit procedures that included, among others, assessing the terms of the arrangement, evaluating the methodology used, and testing the US projected net revenues of Jeuveau&#174; used by the Company in its analysis. We also compared the US projected net revenues to current industry, market and economic trends and performed sensitivity analyses of other assumptions to evaluate the changes in the contingent royalty obligation that would result from changes in the assumptions. We also assessed the historical accuracy of management&#8217;s forecasts of US net revenues used in developing the estimate to assist in evaluating the reliability of the US projected net revenues of Jeuveau&#174; utilized in the estimate.</span></div><div><span><br/></span></div><div><span><br/></span></div></td></tr></table></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"/><td style="width:22.103%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:75.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-52">Ernst &amp; Young LLP</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2017.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-53">Irvine, California</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;4, 2025 </span></div><div style="margin-bottom:9pt"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="id181047532df422ab5a549dd869deccb_76"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except par value and share data)</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.107%"><tr><td style="width:1.0%"/><td style="width:70.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.863%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.866%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-54">86,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-55">62,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-56">47,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-57">30,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-58">12,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-59">10,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">3,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">5,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">1,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">2,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-64">151,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-65">112,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-66">3,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-67">2,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-68">7,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-69">5,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-70">48,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-71">47,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-72">21,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-73">21,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-74">858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-75">409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-76">232,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-77">188,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-78">9,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-79">4,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-80">40,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-81">33,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-82">1,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-83">1,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent royalty obligation payable to Evolus Founders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="eols:ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" format="ixt:num-dot-decimal" scale="3" id="f-84">11,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="eols:ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" format="ixt:num-dot-decimal" scale="3" id="f-85">8,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-86">62,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-87">48,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-88">6,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-89">4,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent royalty obligation payable to Evolus Founders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractualObligation" format="ixt:num-dot-decimal" scale="3" id="f-90">33,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractualObligation" format="ixt:num-dot-decimal" scale="3" id="f-91">36,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term loan, net of discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:SecuredLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-92">121,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:SecuredLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-93">120,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent milestone payment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="eols:LicenseSupplyAndDistributionAgreementContingentMilestoneLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-94">2,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="eols:LicenseSupplyAndDistributionAgreementContingentMilestoneLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="f-96">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="f-97">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-98">227,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-99">209,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 9)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-100"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-101"></ix:nonFraction></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stockholders&#8217; equity (deficit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred Stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-102"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-103">0.00001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-104"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-105">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-106"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-107"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-108"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-109">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2024 and 2023, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-110">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-111">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common Stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-112"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-113">0.00001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-114"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-115">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized; </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-116"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-117">63,497,548</ix:nonFraction></ix:nonFraction> and</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-118"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-119">57,820,621</ix:nonFraction></ix:nonFraction></span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> shares issued and outstanding at December&#160;31, 2024 and 2023, re</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">spectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-120">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-121">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-122">615,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-123">538,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-124">905</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-125">427</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-126">609,399</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-127">558,979</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total stockholders&#8217; equity (deficit)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-128">5,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-129">20,689</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 41.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities and stockholders&#8217; equity (deficit)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-130">232,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-131">188,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="id181047532df422ab5a549dd869deccb_82"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.738%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.901%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-132">264,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-133">199,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-134">146,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-135">1,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-136">2,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-137">2,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-138">266,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-139">202,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-140">148,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-141"><span style="-sec-ix-hidden:f-142"><span style="-sec-ix-hidden:f-143">Cost of goods sold</span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-144">83,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-145">64,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-146">58,842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-147">182,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-148">137,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-149">89,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-150">198,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-151">164,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-152">141,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-153">9,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-154">6,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-155">4,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="eols:ResearchAndDevelopmentInProcess1" format="ixt:fixed-zero" scale="3" id="f-156">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="eols:ResearchAndDevelopmentInProcess1" format="ixt:num-dot-decimal" scale="3" id="f-157">8,869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="eols:ResearchAndDevelopmentInProcess1" format="ixt:num-dot-decimal" scale="3" id="f-158">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation of contingent royalty obligation payable to Evolus Founders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="f-159">7,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="f-160">4,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="f-161">5,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-162">2,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-163">2,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization" scale="3" id="f-164">767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-165">216,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-166">186,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-167">155,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-168">34,411</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-169">49,233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-170">65,330</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="3" id="f-171">3,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="f-172">860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="f-173">119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-174">18,735</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-175">13,832</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-176">9,097</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-177">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-178">696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-179">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes:</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-180">49,756</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-181">61,509</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-182">74,317</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-183">664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-184">176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-185">95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-186">50,420</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-187">61,685</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-188">74,412</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-189">478</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-190">90</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-191">337</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-192">50,898</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-193">61,775</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-194">74,749</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-195"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-196">0.81</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-197"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-198">1.08</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-199"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-200">1.33</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding used to compute basic and diluted net loss per share</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-201"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-202">62,016,853</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-203"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-204">56,918,721</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-205"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-206">56,065,297</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="id181047532df422ab5a549dd869deccb_85"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity (Deficit)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share data)</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.643%"><tr><td style="width:1.0%"/><td style="width:51.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.085%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.528%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.726%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.480%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.494%"/><td style="width:0.1%"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid In Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other Comprehensive Loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-207">55,576,988</ix:nonFraction></span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-208">1</ix:nonFraction></span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-209">504,757</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-210">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-211">422,882</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-212">81,876</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in connection with the incentive equity plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="eols:StockIssuedDuringPeriodSharesIncentiveEquityPlan" format="ixt:num-dot-decimal" scale="0" id="f-213">683,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="eols:StockIssuedDuringPeriodValueIncentiveEquityPlan" scale="3" id="f-214">539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="eols:StockIssuedDuringPeriodValueIncentiveEquityPlan" scale="3" id="f-215">539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-216">10,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-217">10,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-218">74,412</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-219">74,412</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-220">337</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-221">337</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-222">56,260,570</ix:nonFraction></span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-223">1</ix:nonFraction></span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-224">516,129</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-225">337</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-226">497,294</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-227">18,499</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in connection with the incentive equity plan</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="eols:StockIssuedDuringPeriodSharesIncentiveEquityPlan" format="ixt:num-dot-decimal" scale="0" id="f-228">950,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="eols:StockIssuedDuringPeriodValueIncentiveEquityPlan" scale="3" id="f-229">224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="eols:StockIssuedDuringPeriodValueIncentiveEquityPlan" scale="3" id="f-230">224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in connection with Symatese Europe Agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="eols:StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement" format="ixt:num-dot-decimal" scale="0" id="f-231">610,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="eols:StockIssuedDuringPeriodValueIssuedForLicenseSupplyAndDistributionAgreement" format="ixt:num-dot-decimal" scale="3" id="f-232">5,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="eols:StockIssuedDuringPeriodValueIssuedForLicenseSupplyAndDistributionAgreement" format="ixt:num-dot-decimal" scale="3" id="f-233">5,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-234">16,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-235">16,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-236">61,685</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-237">61,685</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-238">90</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-239">90</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-240">57,820,621</ix:nonFraction></span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-241">1</ix:nonFraction></span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-242">538,716</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-243">427</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-244">558,979</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-245">20,689</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in connection with the incentive equity plan</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-35" decimals="INF" name="eols:StockIssuedDuringPeriodSharesIncentiveEquityPlan" format="ixt:num-dot-decimal" scale="0" id="f-246">1,804,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="eols:StockIssuedDuringPeriodValueIncentiveEquityPlan" format="ixt:num-dot-decimal" scale="3" id="f-247">3,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="eols:StockIssuedDuringPeriodValueIncentiveEquityPlan" format="ixt:num-dot-decimal" scale="3" id="f-248">3,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon follow-on offering, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-35" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-249">3,872,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-250">50,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-251">50,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-252">22,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-253">22,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-254">50,420</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-255">50,420</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-256">478</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-257">478</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-258">63,497,548</ix:nonFraction></span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-259">1</ix:nonFraction></span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-260">615,825</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-261">905</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-262">609,399</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-263">5,522</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="id181047532df422ab5a549dd869deccb_88"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows </span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.727%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.489%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.727%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.351%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.731%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-264">50,420</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-265">61,685</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-266">74,412</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-267">5,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-268">5,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-269">3,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-270">22,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-271">16,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-272">10,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for bad debts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="f-273">2,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="f-274">1,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="f-275">1,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="f-276">723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="f-277">734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="f-278">775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-279">1,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-280">1,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-281">1,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="f-282">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="f-283">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="f-284">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revaluation of contingent royalty obligation to Evolus Founders</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-285">7,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-286">4,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-287">5,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash in-process research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="eols:NonCashInResearchAndDevelopmentInProcessExpenses" format="ixt:fixed-zero" scale="3" id="f-288">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="eols:NonCashInResearchAndDevelopmentInProcessExpenses" format="ixt:num-dot-decimal" scale="3" id="f-289">4,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="eols:NonCashInResearchAndDevelopmentInProcessExpenses" format="ixt:fixed-zero" scale="3" id="f-290">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-291">3,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-292">4,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-293">10,688</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-294">19,602</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-295">9,521</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-296">9,389</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="f-297">2,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="f-298">1,798</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="f-299">1,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" id="f-300">706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" scale="3" id="f-301">864</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-302">4,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-303">391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-304">1,017</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-305">968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-306">7,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-307">9,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-308">5,199</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued litigation settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsForLegalSettlements" format="ixt:fixed-zero" scale="3" id="f-309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="3" id="f-310">5,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="3" id="f-311">15,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="eols:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="f-312">716</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="eols:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="f-313">907</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="eols:IncreaseDecreaseInOperatingLeaseLiabilities" scale="3" id="f-314">977</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 39.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-315">17,999</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-316">34,008</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-317">84,912</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-318">1,472</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-319">473</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-320">1,618</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions to capitalized software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsForSoftware" format="ixt:num-dot-decimal" scale="3" id="f-321">3,351</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PaymentsForSoftware" format="ixt:num-dot-decimal" scale="3" id="f-322">1,154</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsForSoftware" format="ixt:num-dot-decimal" scale="3" id="f-323">1,321</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 39.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-324">4,823</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-325">1,627</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-326">2,939</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment of contingent royalty obligation to Evolus Founders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="eols:PaymentsOfContingentRoyaltyObligation" format="ixt:num-dot-decimal" scale="3" id="f-327">7,441</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="eols:PaymentsOfContingentRoyaltyObligation" format="ixt:num-dot-decimal" scale="3" id="f-328">5,537</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="eols:PaymentsOfContingentRoyaltyObligation" format="ixt:num-dot-decimal" scale="3" id="f-329">4,185</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of long-term debt, net of discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-330">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-331">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-332">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments for debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-333">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="f-334">46</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="f-335">500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from follow-on offering, net of underwriting fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-336">51,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-337">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-338">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments for offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="f-339">248</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-340">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-341">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-342">4,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-343">231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-344">539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax withholding paid on behalf of employees for net share settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-345">990</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="f-346">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="f-347">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 39.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-348">47,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-349">44,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-350">4,146</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rates on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-351">478</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-352">90</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-353">337</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-354">24,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-355">8,916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-356">92,334</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-357">62,838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-358">53,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-359">146,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of period</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-360">86,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-361">62,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-362">53,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:3.7pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows (Continued)</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-top:3.7pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span><br/></span></div><div style="margin-top:8.7pt;padding-right:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"/><td style="width:64.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.877%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.877%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.401%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-363">17,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-364">12,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-365">7,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="f-366">235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="f-367">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="f-368">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-cash investing and financing information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use assets obtained in exchange for operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-369">3,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-370">4,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-371">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in connection with Symatese Europe Agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="f-372">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="3" id="f-373">1,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="f-374">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:3.7pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span><br/></span></div><div style="margin-top:3.7pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="id181047532df422ab5a549dd869deccb_91"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><div><span><br/></span></div><div id="id181047532df422ab5a549dd869deccb_94"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-375" continuedAt="f-375-1" escape="true">Description of Business </ix:nonNumeric></span></div><ix:continuation id="f-375-1" continuedAt="f-375-2"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolus, Inc., (&#8220;Evolus&#8221; or the &#8220;Company&#8221;) is a global performance beauty company focused on delivering products in the cash-pay aesthetic market. The Company received the approval of its first product Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (prabotulinumtoxinA-xvfs) from the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) in February 2019. The product was also approved by Health Canada in August 2018, the European Commission (&#8220;EC&#8221;) in September 2019, the Australian Therapeutics Good Administration (&#8220;TGA&#8221;) in January 2023, and Swissmedic in November 2023. Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a proprietary 900 kDa purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as &#8220;frown lines,&#8221; in adults. The Company commercially launched Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States in May 2019, in Canada through a distribution partner in October 2019, and began its launch in Europe in September 2022. In 2023, the Company entered into an agreement to be the exclusive distributor of Evolysse&#8482;, a collection of hyaluronic acid gels currently in late-stage development in the U.S. and Europe. Regulatory approval has been received for the <ix:nonFraction unitRef="product" contextRef="c-43" decimals="INF" name="eols:LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts" format="ixt-sec:numwordsen" scale="0" id="f-376">four</ix:nonFraction> Evolysse&#8482; hyaluronic acid gel products in Europe under the brand name Estyme</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company anticipates launching all <ix:nonFraction unitRef="product" contextRef="c-43" decimals="INF" name="eols:LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts" format="ixt-sec:numwordsen" scale="0" id="f-377">four</ix:nonFraction> approved Evolysse&#8482; products in Europe in the second half of 2025. In February 2025, the Company received approval from the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) for Evolysse&#8482; Form and Evolysse&#8482; Smooth injectable hyaluronic acid gels for wrinkles and folds, such as nasolabial folds. The Company anticipates launching Evolysse&#8482; Form and Evolysse&#8482; Smooth in the United States in the second quarter of 2025. The Company anticipates <ix:nonFraction unitRef="product" contextRef="c-44" decimals="0" name="eols:LicenseSupplyAndDistributionAgreementExpectedRegulatoryApprovalNumberOfProducts" format="ixt-sec:numwordsen" scale="0" id="f-378">two</ix:nonFraction> additional Evolysse&#8482; products to be approved and launched in the United States in 2026 and 2027. The Company currently generates all of its net revenues from Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company is headquartered in Newport Beach, California.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Financial Condition</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared on a basis that assumes that the Company will continue as a going concern. This basis of accounting contemplates the recovery of the Company&#8217;s assets and the satisfaction of the Company&#8217;s liabilities and commitments in the normal course of business and does not include any adjustments to reflect the possible future effects of the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, the Company has incurred recurring net operating losses and negative cash flows from operating activities; however, management anticipates achieving operating income and positive cash flows based on current projections for at least the next twelve months. The Company recorded loss from operations of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-379">34,411</ix:nonFraction> and a total net loss of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-380">50,420</ix:nonFraction> for the twelve months ended December 31, 2024. The Company used cash of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-381">17,999</ix:nonFraction> from operations during the twelve months ended December 31, 2024. As of December&#160;31, 2024, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-382">86,952</ix:nonFraction> in cash and cash equivalents and an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-383">609,399</ix:nonFraction>. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, the Company completed a follow-on offering and issued <ix:nonFraction unitRef="shares" contextRef="c-45" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-384">3,554,000</ix:nonFraction> shares of its common stock, at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-46" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-385">14.07</ix:nonFraction> per share. The Company received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="f-386">46,794</ix:nonFraction> from the offering, after deducting underwriting discounts and commissions and other offering expenses. In addition, the Company granted the underwriters an option, exercisable for <ix:nonNumeric contextRef="c-47" name="eols:SaleOfStockGrantedOptionsExercisablePeriod" format="ixt-sec:durday" id="f-387">30</ix:nonNumeric> days, to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-47" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-388">533,100</ix:nonFraction> additional shares of common stock (the &#8220;option shares&#8221;) at the purchase price. In April 2024, the underwriters exercised their option to purchase <ix:nonFraction unitRef="shares" contextRef="c-48" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-389">318,100</ix:nonFraction> of the allotted option shares. The net proceeds to the Company from the sale of the option shares, after deducting the underwriters&#8217; discounts and commissions, was $<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="f-390">4,169</ix:nonFraction>.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 8, 2023, the Company entered into an &#8220;at-the-market&#8221; sales agreement (the &#8220;ATM Sales Agreement&#8221;) and filed a shelf registration statement on Form S-3 and corresponding prospectus with the Securities and Exchange Commission (&#8220;SEC&#8221;) to permit sales under the ATM Sales Agreement, which registration statement became effective on June 8, 2023. The Company has not sold any shares under the ATM Sales Agreement. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stockholders&#8217; Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-375-2"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that its current capital resources, which consist of cash and cash equivalents, will be sufficient to fund its operations through at least the next twelve months from the date the accompanying consolidated financial statements are issued based on its expected cash needs. The Company may need to raise additional capital to fund future operations or execute corporate development activities through entering into licensing or collaboration agreements with partners, grants or other sources of financing. Sufficient funds may not be available to the Company at all or on attractive terms when needed from equity or debt financings. If the Company is unable to obtain additional funding from these or other sources when needed, or to the extent needed, it may be necessary to reduce its scope of operations to reduce the current rate of spending through actions such as reductions in staff and delaying, scaling back, or suspending certain research and development, sales and marketing programs and other operational goals.</span></div></ix:continuation><div id="id181047532df422ab5a549dd869deccb_97"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-391" continuedAt="f-391-1" escape="true">Basis of Presentation and Summary of Significant Accounting Policies </ix:nonNumeric></span></div><ix:continuation id="f-391-1" continuedAt="f-391-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-392" continuedAt="f-392-1" escape="true"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-392-1">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-393" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s consolidated financial statements include the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries and have been prepared in conformity with GAAP. All intercompany transactions have been eliminated.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-394" escape="true"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is required to make certain estimates and assumptions in order to prepare consolidated financial statements in conformity with GAAP. Such estimates and assumptions affect the reported consolidated financial statements. These estimates include, but are not limited to net revenues, allowance for doubtful accounts, fair value measurements and stock-based compensation, among others. Management bases estimates on historical experience and on assumptions that management believes are reasonable. The Company&#8217;s actual results could differ materially from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-395" continuedAt="f-395-1" escape="true"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to an agreement (the &#8220;Daewoong Agreement&#8221;) with Daewoong Pharmaceutical Co. Ltd. (&#8220;Daewoong&#8221;), pursuant to which the Company received an exclusive distribution license to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from Daewoong for aesthetic indications in the United States, European Union, United Kingdom, members of the European Economic Area, Switzerland, Canada, Australia, New Zealand, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;is manufactured by Daewoong in a facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in a territory covered by the Daewoong Agreement. The Company relies on Daewoong, its exclusive and sole supplier, to manufacture Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company&#8217;s commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9. Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company commercially launched Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;starting in the United States in May 2019 and in Canada through its distribution partner in October 2019. The Company also began commercially launching Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Europe in 2022 and Australia in 2024 and, as such, has a limited history of sales in those markets. If any previously granted approval to market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is retracted or the Company is denied approval or approval is delayed by regulators in any other jurisdictions, it may have a material adverse impact on the Company&#8217;s business and its consolidated financial statements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to risks common to companies in the pharmaceutical industry including, but not limited to, dependency on the commercial success of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Evolysse&#8482; the Company&#8217;s approved products, significant competition within the medical aesthetics industry, its ability to maintain regulatory approval of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, third party litigation and challenges to its intellectual property, uncertainty of broad adoption of its product by aesthetic practitioners and patients, its ability to in-license, acquire or develop additional product candidates and to obtain the necessary approvals for those product candidates, and the need to scale manufacturing capabilities over time.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-391-2" continuedAt="f-391-3"><ix:continuation id="f-395-1" continuedAt="f-395-2"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any disruption and volatility in the global capital markets, including caused by other events, such as public health crises, increased inflation and rising interest rates, increased tariffs, and geopolitical conflicts, including the military conflict between Russia and Ukraine and the ongoing conflict in the Middle East, may increase the Company&#8217;s cost of capital and adversely affect its ability to access financing when and on terms that the Company desires. Any of these events could have a material adverse effect on the Company&#8217;s business, financial condition, results of operations and cash flows.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-396" escape="true"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that it operates in a single operating and reportable segment. The Company&#8217;s chief operating decision maker is its Chief Executive Officer who manages operations and reviews the financial information as a single operating segment for the purposes of allocating resources and evaluating its financial performance.</span></div></ix:nonNumeric><ix:continuation id="f-395-2"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and accounts receivable. Substantially all of the Company&#8217;s cash is held by financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. To date, the Company has not experienced any losses associated with this credit risk and continues to believe that this exposure is not significant. The Company invests, or plans to soon invest, its excess cash, in line with its investment policy, primarily in money market funds and debt instruments of U.S. government agencies. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts receivable is derived from customers located principally in the United States and Europe. Concentrations of credit risk with respect to trade receivables are limited due to the Company&#8217;s credit evaluation process. The Company does not typically require collateral from its customers. The Company continuously monitors customer payments and maintains an allowance for credit losses based on its assessment of various factors including historical experience, age of the receivable balances, and other current economic conditions or other factors that may affect customers&#8217; ability to pay.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-397" escape="true"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash and highly liquid investments with remaining maturities at purchase of three months or less that can be liquidated without prior notice or penalty. Cash and cash equivalents may include deposits, money market funds and debt securities. Amounts receivable from credit card issuers are typically converted to cash within <span style="-sec-ix-hidden:f-398">two</span> to <ix:nonNumeric contextRef="c-50" name="eols:AccountsReceivableCreditCardTransactionConvertedToCashPeriod" format="ixt-sec:durwordsen" id="f-399">four days</ix:nonNumeric> of the original sales transaction and are considered to be cash equivalents.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryPolicyTextBlock" id="f-400" escape="true"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories and cost of goods sold</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of finished goods held for sale and distribution. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost is determined using the first-in, first-out method. Inventory is measured at the lower of cost and net realizable value based on a number of factors including, but not limited to, damage, expiration, or changes in price level.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2024, cost of goods sold, consisted of the inventory cost, amortization of distribution right intangible assets related to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and certain royalties on the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> payable to Medytox and Allergan pursuant to the Medytox Settlement Agreements (as such term is defined in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11. Medytox Settlement Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The prior years Consolidated Statements of Operations and Comprehensive Loss has been adjusted to conform to this presentation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-401" continuedAt="f-401-1" escape="true"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in an orderly transaction between market participants in a principal market on the measurement date.</span></div><div style="margin-bottom:9pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy defines a three-tiered valuation hierarchy for disclosure of fair value measurement is classified and disclosed by the Company in one of the three categories as follows:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1&#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-391-3" continuedAt="f-391-4"><ix:continuation id="f-401-1"><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2&#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets; quoted prices in markets that are not active; or other inputs that are observable, either directly or indirectly, or can be corroborated by observable market data for substantially the full term of the asset or liability; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3&#8212;Prices or valuation techniques that require inputs that are unobservable that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-402" continuedAt="f-402-1" escape="true"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-402-1">Property and equipment are stated at cost. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of approximately <span style="-sec-ix-hidden:f-403">three</span> to <ix:nonNumeric contextRef="c-52" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-404">five years</ix:nonNumeric>. Leasehold improvements are amortized over the shorter of the estimated useful lives of the improvements or the term of the related lease.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="f-405" continuedAt="f-405-1" escape="true"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-405-1">Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. The Company assesses goodwill for impairment annually and whenever events or changes in circumstances indicate that the carrying amount of goodwill may not be recoverable. The Company performs an annual qualitative assessment of its goodwill in the fourth quarter of each calendar year to determine if any events or circumstances exist, such as an adverse change in business climate or a decline in the overall industry demand, that would indicate that it would more likely than not reduce the fair value of a reporting unit below its carrying amount, including goodwill. If events or circumstances do not indicate that the fair value of a reporting unit is below its carrying amount, then goodwill is not considered to be impaired and no further testing is required. For the purpose of impairment testing, the Company has determined that it has <ix:nonFraction unitRef="reporting_unit" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="f-406">one</ix:nonFraction> reporting unit.</ix:continuation> There was <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-407"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-408">no</ix:nonFraction></ix:nonFraction> impairment of goodwill for any of the periods presented.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InProcessResearchAndDevelopmentPolicy" id="f-409" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-process Research and Development</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets acquired that are used for research and development, do not yet have regulatory approval for commercialization, and have no future alternative use are expensed as in-process research and development.</span></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company entered into a License and Research Collaboration Agreement (the &#8220;Collaboration Agreement&#8221;) with a 3D printing company with biomaterial capabilities (the &#8220;Licensor&#8221;). Under the terms of the Collaboration Agreement, the Company was granted a license to the Licensor&#8217;s technology to develop and commercialize any aesthetic product or non-therapeutic product that is created through the use or practice of the Licensor&#8217;s patents. The Company paid $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="eols:ResearchAndDevelopmentInProcess1" format="ixt:num-dot-decimal" scale="3" id="f-410">2,000</ix:nonFraction> upon the signing of the Collaboration Agreement and has research funding, ongoing milestone and royalty payment obligations depending on the development plans, the success of such development and approval and commercialization of products. The upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="eols:ResearchAndDevelopmentInProcess1" format="ixt:num-dot-decimal" scale="3" id="f-411">2,000</ix:nonFraction> was recorded as in-process research and development expense.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Symatese U.S. Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 9, 2023, the Company and Symatese Aesthetics S.A.S (&#8220;Symatese&#8221;), entered into a License, Supply and Distribution Agreement (the &#8220;Symatese U.S. Agreement&#8221;), pursuant to which Symatese granted to the Company an exclusive right to commercialize and distribute its <ix:nonFraction unitRef="productcandidate" contextRef="c-53" decimals="0" name="eols:LicenseSupplyAndDistributionAgreementRightToCommercializeAndDistributeNumberOfProductCandidates" format="ixt-sec:numwordsen" scale="0" id="f-412">five</ix:nonFraction> hyaluronic acid gel product candidates, including the products referred to as: (i) Form; (ii) Smooth; (iii) Sculpt; (iv) Lips; and (v) Eye (collectively, the &#8220;Products&#8221;) in the United States for use in the aesthetics and dermatological field of use. The Company also has the right of first negotiation to obtain a license from Symatese to commercialize and distribute any new products developed using the same technology as the Evolysse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> collection of hyaluronic acid gels.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the rights granted under the Symatese U.S. Agreement, the Company is required to make up to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-54" decimals="-3" name="eols:LicenseSupplyAndDistributionAgreementMinimumMilestonePayment" format="ixt:num-dot-decimal" scale="3" id="f-413">16,200</ix:nonFraction> in milestone payments to Symatese, including an initial payment of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-54" decimals="-3" name="eols:LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement" format="ixt:num-dot-decimal" scale="3" id="f-414">4,100</ix:nonFraction> within <ix:nonNumeric contextRef="c-54" name="eols:LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod" format="ixt-sec:durday" id="f-415">30</ix:nonNumeric> days of execution of the Symatese U.S. Agreement, and additional annual payments of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-53" decimals="-3" name="eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne" format="ixt:num-dot-decimal" scale="3" id="f-416">1,600</ix:nonFraction> in June 2025, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-53" decimals="-3" name="eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-417">4,100</ix:nonFraction> in June 2026, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-53" decimals="-3" name="eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree" format="ixt:num-dot-decimal" scale="3" id="f-418">3,200</ix:nonFraction> in June 2027, and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-53" decimals="-3" name="eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour" format="ixt:num-dot-decimal" scale="3" id="f-419">3,200</ix:nonFraction> in </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-391-4" continuedAt="f-391-5"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 2028, in each case subject to <ix:nonFraction unitRef="product" contextRef="c-53" decimals="0" name="eols:LicenseSupplyAndDistributionAgreementAnnualPaymentTriggeredRegulatoryApprovalNumberOfProducts" format="ixt-sec:numwordsen" scale="0" id="f-420">three</ix:nonFraction> of the Products gaining approval prior to that date. In June 2023, the Company paid $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="eols:LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-421">4,441</ix:nonFraction> as an upfront payment upon the signing of the Symatese U.S. Agreement and has developmental costs, ongoing milestone and royalty payment obligations. The Symatese U.S. Agreement is also subject to minimum purchase requirements and failure to meet such requirements may result in a reduction or termination of the Company&#8217;s exclusive rights, subject to certain exceptions. Additionally, the Company agreed to a specified cost-sharing agreement with Symatese related to the registration of the Lips and Eye Products with the FDA.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial term of the Symatese U.S. Agreement is fifteen (<ix:nonNumeric contextRef="c-54" name="eols:LicenseSupplyAndDistributionAgreementInitialTerm" format="ixt-sec:duryear" id="f-422">15</ix:nonNumeric>) years from the first FDA approval of a Product, with automatic renewals for successive five (<ix:nonNumeric contextRef="c-54" name="eols:LicenseSupplyAndDistributionAgreementRenewalTerm" format="ixt-sec:duryear" id="f-423">5</ix:nonNumeric>)-year terms subject to the terms of the Symatese U.S. Agreement. The upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="eols:LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-424">4,441</ix:nonFraction> was recorded as in-process research and development expense in the twelve months ended December&#160;31, 2023.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Symatese Europe Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 20, 2023, the Company entered into a License, Supply and Distribution Agreement (the &#8220;Symatese Europe Agreement&#8221;), pursuant to which Symatese granted to us an exclusive right to commercialize and distribute <ix:nonFraction unitRef="productcandidate" contextRef="c-57" decimals="INF" name="eols:LicenseSupplyAndDistributionAgreementNumberOfProductCandidates" format="ixt-sec:numwordsen" scale="0" id="f-425">four</ix:nonFraction> hyaluronic acid gel product candidates, which are referred to as: (i) Form; (ii) Smooth; (iii) Sculpt and (iv) Lips in <ix:nonFraction unitRef="country" contextRef="c-57" decimals="INF" name="eols:LicenseSupplyAndDistributionAgreementNumberOfCountriesUseAestheticsAndDermatologicalFields" scale="0" id="f-426">50</ix:nonFraction> countries in Europe for use in the aesthetics and dermatological fields. The initial agreement is for a term of fifteen (<ix:nonNumeric contextRef="c-58" name="eols:LicenseSupplyAndDistributionAgreementInitialTerm" format="ixt-sec:duryear" id="f-427">15</ix:nonNumeric>) years, with automatic year renewal provisions.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In exchange for the rights granted under the Symatese Europe Agreement, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-59" decimals="INF" name="eols:StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement" format="ixt:num-dot-decimal" scale="0" id="f-428">610,000</ix:nonFraction> shares of common stock and is required to pay <ix:nonFraction unitRef="milestonepayment" contextRef="c-57" decimals="INF" name="eols:LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment" format="ixt-sec:numwordsen" scale="0" id="f-429">two</ix:nonFraction> milestone payments: (i) &#8364;<ix:nonFraction unitRef="eur" contextRef="c-57" decimals="-3" name="eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-430">1,200</ix:nonFraction> on the second anniversary of certain regulatory approvals, and (ii) &#8364;<ix:nonFraction unitRef="eur" contextRef="c-57" decimals="-3" name="eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree" format="ixt:num-dot-decimal" scale="3" id="f-431">1,900</ix:nonFraction> on the earlier of the third anniversary of certain regulatory approvals or following a year in which the Company achieves &#8364;<ix:nonFraction unitRef="eur" contextRef="c-57" decimals="-3" name="eols:LicenseSupplyAndDistributionAgreementAnnualRevenue" format="ixt:num-dot-decimal" scale="3" id="f-432">25,000</ix:nonFraction> in revenue in Europe; provided that the payment shall occur no later than December 2029. The Symatese Europe Agreement is also subject to minimum purchase requirements and failure to meet such requirements may result in a reduction or termination of the Company&#8217;s exclusive rights, subject to certain exceptions. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon signing of the Symatese Europe Agreement and issuance of <ix:nonFraction unitRef="shares" contextRef="c-59" decimals="INF" name="eols:StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement" format="ixt:num-dot-decimal" scale="0" id="f-433">610,000</ix:nonFraction> shares, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="eols:NonCashInResearchAndDevelopmentInProcessExpenses" format="ixt:num-dot-decimal" scale="3" id="f-434">4,429</ix:nonFraction> in in-process research and development expense and $<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="3" id="f-435">1,476</ix:nonFraction> in intangible assets in the twelve months ended December&#160;31, 2023 for the stock issuance of <ix:nonFraction unitRef="shares" contextRef="c-59" decimals="INF" name="eols:StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement" format="ixt:num-dot-decimal" scale="0" id="f-436">610,000</ix:nonFraction> shares. The intangible assets of $<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="3" id="f-437">1,476</ix:nonFraction> represents the value of the nasolabial fold product in Europe which was already approved at the time of signing the Symatese Europe Agreement and is amortized over its estimated useful life of <ix:nonNumeric contextRef="c-61" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-438">15</ix:nonNumeric> years. The remaining value recorded in in-process research and development expense relates to the distribution rights for the <ix:nonFraction unitRef="product" contextRef="c-62" decimals="0" name="eols:LicenseSupplyAndDistributionAgreementPendingRegulatoryApprovalNumberOfProducts" format="ixt-sec:numwordsen" scale="0" id="f-439">three</ix:nonFraction> remaining products that did not yet have regulatory approval as of the execution date.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="f-440" continuedAt="f-440-1" escape="true"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The distribution right intangible asset related to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is amortized over the period the asset is expected to contribute to the future cash flows of the Company. The Company determined the pattern of this intangible asset&#8217;s future cash flows could not be readily determined with a high level of precision. As a result, the distribution right intangible asset is being amortized on a straight-line basis over the estimated useful life of&#160;<ix:nonNumeric contextRef="c-63" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-441">20</ix:nonNumeric> years.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of the Symatese Europe Agreement represents the license and distribution right to Evolysse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Europe. The definite-lived distribution right intangible asset related to the Evolysse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> nasolabial fold product approved in Europe is amortized on a straight-line basis over the estimated useful life of <ix:nonNumeric contextRef="c-64" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-442">15</ix:nonNumeric> years.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Symatese Europe Agreement, the Company is required to pay <ix:nonFraction unitRef="milestonepayment" contextRef="c-57" decimals="INF" name="eols:LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment" format="ixt-sec:numwordsen" scale="0" id="f-443">two</ix:nonFraction> milestone payments: (i) &#8364;<ix:nonFraction unitRef="eur" contextRef="c-57" decimals="-3" name="eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-444">1,200</ix:nonFraction> on the second anniversary of certain regulatory approvals, and (ii) &#8364;<ix:nonFraction unitRef="eur" contextRef="c-57" decimals="-3" name="eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree" format="ixt:num-dot-decimal" scale="3" id="f-445">1,900</ix:nonFraction> on the earlier of the third anniversary of certain regulatory approvals or following a year in which the Company achieves &#8364;<ix:nonFraction unitRef="eur" contextRef="c-65" decimals="-3" name="eols:LicenseSupplyAndDistributionAgreementAnnualRevenue" format="ixt:num-dot-decimal" scale="3" id="f-446">25,000</ix:nonFraction> in revenue in Europe, provided that the payment shall occur no later than December 2029.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2024, the Company received European Union Medical Device Regulation (&#8220;MDR&#8221;) approval for the remaining <ix:nonFraction unitRef="product" contextRef="c-66" decimals="INF" name="eols:LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts" format="ixt-sec:numwordsen" scale="0" id="f-447">three</ix:nonFraction> hyaluronic acid gel products. As a result, the <ix:nonFraction unitRef="milestonepayment" contextRef="c-67" decimals="INF" name="eols:LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment" format="ixt-sec:numwordsen" scale="0" id="f-448">two</ix:nonFraction> milestone payments have been triggered. The first milestone payment is payable in October 2026, the <ix:nonNumeric contextRef="c-66" name="eols:LicenseSupplyAndDistributionAgreementMilestonePaymentPayablePeriod" format="ixt-sec:durwordsen" id="f-449">two-year</ix:nonNumeric> anniversary of the approval. For the second milestone payment, the Company determined that it is probable the payment will be made no later than December 2029. As such, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="eols:LicenseSupplyAndDistributionAgreementLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-450">1,035</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="eols:LicenseSupplyAndDistributionAgreementLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-451">1,200</ix:nonFraction> in long-term liabilities for the first and second milestone payments, and $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="eols:LicenseSupplyAndDistributionAgreementIntangibleAsset" format="ixt:num-dot-decimal" scale="3" id="f-452">1,035</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="eols:LicenseSupplyAndDistributionAgreementIntangibleAsset" format="ixt:num-dot-decimal" scale="3" id="f-453">1,200</ix:nonFraction> in intangible assets for the first and second milestone payments as of December&#160;31, 2024. These amounts reflect the </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-391-5" continuedAt="f-391-6"><ix:continuation id="f-440-1" continuedAt="f-440-2"><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">application of a discount to account for the time value of money, which adjusts the present value of the liabilities and intangible assets based on the timing of future payments. The definite-lived distribution right intangible asset related to the Evolysse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products approved in Europe is amortized on a straight-line basis over the remaining estimated useful life of 14 years and 2 months. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain internal-use software costs associated with the development of its mobile and web-based customer platforms. These costs include personnel expenses and external costs that are directly associated with the software projects. These costs are included as intangible assets in the accompanying consolidated balance sheets. The capitalized internal-use software costs are amortized on a straight-line basis over the estimated useful life of&#160;<ix:nonNumeric contextRef="c-70" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="f-454">two years</ix:nonNumeric>&#160;upon being placed in service.</span></div></ix:continuation><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-440-2">The Company reviews long-term and identifiable definite-lived intangible assets or asset groups for impairment when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset or an asset group, further impairment analysis is performed. An impairment loss is measured as the amount by which the carrying amount of the asset or asset groups exceeds the fair value for assets to be held and used or fair value less cost to sell for assets to be disposed of. The Company also reviews the useful lives of its assets periodically to determine whether events and circumstances warrant a revision to the remaining useful life. Changes in the useful life are adjusted prospectively by revising the remaining period over which the asset is amortized.</ix:continuation> There was <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="f-455"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="f-456">no</ix:nonFraction></ix:nonFraction> material impairment of long-lived assets for any periods presented.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-457" escape="true"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, upon lease commencement, the Company records a lease liability which represents the Company&#8217;s obligation to make lease payments arising from the lease, and a corresponding right-of-use (&#8220;ROU&#8221;) asset which represents the Company&#8217;s right to use an underlying asset during the lease term. Operating lease assets and liabilities are included in ROU assets, current portion of operating lease liabilities and noncurrent operating lease liabilities in the accompanying consolidated balance sheets.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease ROU assets and lease liabilities are initially recognized based on the present value of the future minimum lease payments over the lease term at commencement date calculated using the Company&#8217;s incremental borrowing rate applicable to the underlying asset unless the implicit rate is readily determinable. The incremental borrowing rate, the ROU asset and the lease liability are reevaluated upon a lease modification. Operating lease ROU assets also include any lease payments made at or before lease commencement and exclude any lease incentives received, if any. The Company determines the lease term as the noncancellable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. The Company&#8217;s leases do not contain any residual value guarantees. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets. For operating leases, the Company recognized rent expense on a straight-line basis over the lease term. There were no significant finance leases as of&#160;December&#160;31, 2024.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-391-6" continuedAt="f-391-7"><ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="f-458" escape="true"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Royalty Obligation Payable to Evolus Founders</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was acquired by Strathspey Crown Holdings Group, LLC (&#8220;SCH&#8221;) in 2013 and subsequently by its subsidiary, Alphaeon Corporation (&#8220;Alphaeon&#8221;), by means of a stock purchase agreement (&#8220;Stock Purchase Agreement&#8221;) pursuant to which Alphaeon assumed certain payment obligations related to the acquisition. On December 14, 2017, the Stock Purchase Agreement was amended (&#8220;Amended Stock Purchase Agreement&#8221;), and, as a result, effective upon the closing of the Company&#8217;s initial public offering in February 2018, the Company assumed all of Alphaeon&#8217;s payment obligations under the Amended Stock Purchase Agreement.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment obligations to the Evolus Founders consist of quarterly royalty payments of a low single digit percentage of net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The obligations terminate in the second quarter of 2029, which is the&#160;<ix:nonNumeric contextRef="c-71" name="eols:RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale" format="ixt-sec:durwordsen" id="f-459">10-year</ix:nonNumeric> anniversary of the first commercial sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;in the United States. Under the Amended Stock Purchase Agreement, the Company recorded the fair value of all revised payment obligations owed to the Evolus Founders. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value of the contingent royalty obligation payable at each reporting period end based on Level 3 inputs using a discounted cash flows method. Changes in the fair value of the contingent royalty obligation payable are determined at each reporting period end and recorded in operating expenses in the accompanying consolidated statements of operations and comprehensive loss and as a liability in the accompanying consolidated balance sheets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtPolicyTextBlock" id="f-460" escape="true"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Term Debt</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt represents the debt balance with Pharmakon (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7. Term Loans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), net of discount and issuance costs. Debt issuance costs represent legal, lender and consulting costs or fees associated with debt financing. Debt&#160;discounts and issuance costs are amortized into interest expense over the term of the debt.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-461" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements of foreign subsidiaries are measured using the local currency as the functional currency. Assets and liabilities are translated into U.S. dollars at current exchange rates as of balance sheet date, and income and expense items are translated into U.S. dollars using the average rates of exchange prevailing during the period. Gains and losses arising from translation are recorded in other comprehensive loss as a separate component of stockholders&#8217; equity. Foreign currency gains or losses on transactions denominated in a currency other than the Company&#8217;s functional currency are recorded in other expenses, net in the accompanying consolidated statements of operations and comprehensive loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-462" continuedAt="f-462-1" escape="true"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when control of the promised goods or services is transferred to its customers, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for the goods or services. In order to achieve that core principle, a five-step approach is applied: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue allocated to each performance obligation when the Company satisfies the performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account for revenue recognition.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates product revenue from the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States, Europe, and Australia, and service revenue from the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through a distribution partner in Canada.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For product revenue, the Company recognizes revenue when control of the promised goods under a contract is transferred to a customer, in an amount that reflects the consideration the Company expects to receive in exchange for those goods as specified in the customer contract. The transfer of control occurs upon receipt of the goods by the customer since that is when the customer has obtained control of the goods&#8217; economic benefits. The Company does not provide any service-type warranties and does not accept product returns except under limited circumstances such as damages in transit or ineffective product. The Company also excludes any amounts related to taxes assessed by governmental authorities from revenue measurement. Shipping and handling costs associated with outbound product freight are accounted for as fulfillment costs </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-462-1" continuedAt="f-462-2"><ix:continuation id="f-391-7" continuedAt="f-391-8"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and are included in selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For service revenue, the Company evaluated the arrangement with the distribution partner in Canada and determined that it acts as an agent in the distribution of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in Canada as it does not control the product before control is transferred to a customer. The indicators of which party exercises control include primary responsibility over performance obligations, inventory risk before the good or service is transferred and discretion in establishing the price. Accordingly, the Company records the sale as service revenue on a net basis. Revenue from services is recognized in the period the service is performed for the amount of consideration expected to be received.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s disaggregation of revenue is consistent with its operating segment as disclosed above.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gross-to-Net Revenue Adjustments</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides customers with discounts, such as trade and volume discounts and prompt pay discounts, that are directly reflected in the invoice price. Revenues are recorded net of sales-related adjustments, wherever applicable, primarily for the volume based rebates, consumer loyalty programs and co-branded marketing programs. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Volume-Based Rebates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Volume-based rebates are contractually offered to certain customers. The rebates payable to each customer are determined based on the contract and quarterly purchase volumes. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Consumer Loyalty Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company&#8217;s consumer loyalty program allows participating customers to earn rewards for qualifying treatments to their patients (i.e. consumers) using Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and redeem the rewards for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the future at no additional cost. The loyalty program represents a customer option that provides a material right and, accordingly, is a performance obligation. At the time Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product is sold to customers, the invoice price is allocated between the product sold and the estimated material right reward (&#8220;Reward&#8221;) that the customer might redeem in the future. The standalone selling price of the Reward is measured based on estimated average selling price of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at the time of redemption and the expected redemption rate by customers based on historical sales data. The portion of invoice price allocated to the Reward is initially recorded as deferred revenue. Subsequently, when customers redeem the Reward and the related product is delivered, the deferred revenue is recognized in net revenues at that time. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Co-Branded Marketing Programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company offers eligible customers with a certain level of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> purchases to receive advertising co-branded with the Company. The co-branded advertising represents a performance obligation. At the time Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product is sold to customers, the invoice price is allocated between the product sold and the advertisement. The standalone selling price of the advertisement is measured based on the estimated market value of similar advertisement adjusted for the customer&#8217;s portion of the advertisement. The portion of invoice price allocated to the advertisement is initially recorded as deferred revenue. Subsequently, when the advertisement airs, the deferred revenue is recognized in net revenues at that time.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Balances</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A contract with a customer states the terms of the sale, including the description, quantity and price of each product purchased. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration becomes unconditional. The Company does not have any significant financing components in customer contracts given the expected time between transfer of the promised products and the payment of the associated consideration is less than one year. As of&#160;December&#160;31, 2024 and 2023, all amounts included in accounts receivable, net on the accompanying consolidated balance sheets are related to contracts with customers.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any contract assets nor unbilled receivables as of&#160;December&#160;31, 2024 or 2023. Sales commissions are included in selling, general and administrative expenses when incurred.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities reflect estimated amounts that the Company is obligated to pay to customers or patients primarily under the rebate and deferred revenue associated with Rewards under the consumer loyalty program and co-branded marketing </span></div></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-391-8" continuedAt="f-391-9"><ix:continuation id="f-462-2"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">programs. The Company&#8217;s contract liabilities are included in accounts payable and accrued expenses in the accompanying consolidated balance sheets.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, 2023, and 2022, the accrued revenue contract liabilities, primarily related to volume-based rebates, consumer loyalty program and co-branded marketing programs, were $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-463">14,454</ix:nonFraction>,  $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-464">11,033</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-465">9,011</ix:nonFraction>,respectively, which were recorded in accrued expenses in the accompanying consolidated balance sheets. For the years ended December 31, 2024, 2023, and 2022 provisions for rebate, consumer loyalty programs and co-branded marketing programs were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="eols:RebatesAndCouponsCreditsAndPayments" format="ixt:num-dot-decimal" scale="3" id="f-466">40,783</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="eols:RebatesAndCouponsCreditsAndPayments" format="ixt:num-dot-decimal" scale="3" id="f-467">32,511</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="eols:RebatesAndCouponsCreditsAndPayments" format="ixt:num-dot-decimal" scale="3" id="f-468">22,759</ix:nonFraction>,respectively, which were offset by related payments, redemptions and adjustments of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="eols:PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability" format="ixt:num-dot-decimal" scale="3" id="f-469">37,362</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="eols:PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability" format="ixt:num-dot-decimal" scale="3" id="f-470">30,489</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="eols:PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability" format="ixt:num-dot-decimal" scale="3" id="f-471">21,682</ix:nonFraction>, respectively, which were recorded as adjustments to gross revenues in the accompanying consolidated statement of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the&#160;years ended December 31, 2024, 2023, and 2022, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="f-472">10,220</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="f-473">7,868</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="f-474">7,566</ix:nonFraction>, respectively, of revenue related to amounts included in contract liabilities at the beginning of the period and did not recognize any revenue related to changes in transaction prices regarding its contracts with customers from previous periods.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collectability</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded at the invoiced amount and do not bear interest. At the time of contract inception or new customer account set-up, the Company performs a collectability assessment of the customer&#8217;s creditworthiness. The Company assesses the probability that the Company will collect the entitled consideration in exchange for the goods sold, by considering the customer&#8217;s ability and intention to pay when consideration is due. The Company&#8217;s expected loss allowance methodology for accounts receivable is developed using historical collection experience, current and future economic and market conditions and periodic evaluation of customers&#8217; receivables balances using relevant available information, from internal and external sources, relating to past events, current conditions and forecasts. Historical credit loss experience provides the basis for estimation of expected credit losses and are adjusted as necessary using the relevant information available. The Company writes off accounts receivable balances when it is determined that there is no possibility of collection. As of December 31, 2024, 2023, and 2022, allowance for credit losses was $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-475">2,714</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-476">1,490</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-477">2,050</ix:nonFraction>, respectively. For the years ended December 31, 2024, 2023, and 2022, provision for bad debts was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="f-478">2,449</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="f-479">1,440</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="f-480">1,598</ix:nonFraction>, respectively, and the write-off amount was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="eols:AccountsReceivableAllowanceForCreditLossWriteOffRecovery" format="ixt:num-dot-decimal" scale="3" id="f-481">1,225</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="eols:AccountsReceivableAllowanceForCreditLossWriteOffRecovery" format="ixt:num-dot-decimal" scale="3" id="f-482">2,000</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="eols:AccountsReceivableAllowanceForCreditLossWriteOffRecovery" format="ixt:num-dot-decimal" scale="3" id="f-483">1,933</ix:nonFraction>, respectively.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Practical Expedients</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses sales commissions when incurred as the amortization period is one year or less. These costs are recorded within selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss. The Company does not adjust the amount of promised consideration for the effects of the time value of money for contracts in which the anticipated period between when the Company transfers the goods or services to the customer and when the customer pays within one year.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-484" escape="true"><div style="margin-bottom:10pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses include personnel-related costs, costs associated with pre-clinical and clinical development activities, costs associated with and costs for prototype products that are manufactured prior to market approval for that prototype product, internal and external costs associated with the Company&#8217;s regulatory compliance and quality assurance functions, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs, including allocated facility related expenses.</span></div></ix:nonNumeric><div style="margin-bottom:10pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation Settlement</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, upon entering into certain agreements to settle intellectual property disputes relating to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company agreed to pay to Allergan and Medytox </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-485">35,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in multiple payments over <ix:nonNumeric contextRef="c-73" name="eols:LossContingencySettlementAgreementPaymentTerms" format="ixt-sec:durwordsen" id="f-486">two years</ix:nonNumeric>, of which $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="3" id="f-487">15,000</ix:nonFraction> was paid in the third quarter of 2021, $<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="3" id="f-488">15,000</ix:nonFraction> was paid in the first quarter of 2022, and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="3" id="f-489">5,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was paid in the first quarter of 2023, and issued <ix:nonFraction unitRef="shares" contextRef="c-77" decimals="INF" name="eols:StockIssuedDuringPeriodSharesLitigationSettlement" format="ixt:num-dot-decimal" scale="0" id="f-490">6,762,652</ix:nonFraction> shares of its common stock to Medytox. As of December&#160;31, 2024 and 2023, there were <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LitigationReserveCurrent" format="ixt:fixed-zero" scale="0" id="f-491"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LitigationReserveCurrent" format="ixt:fixed-zero" scale="0" id="f-492">no</ix:nonFraction></ix:nonFraction> liabilities recorded in the accompanying consolidated balance sheets related to the litigation settlement with Allergan and Medytox.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-391-9" continuedAt="f-391-10"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, for the period from December 16, 2020 through September 16, 2022 (the &#8220;Restricted Period&#8221;), the Company agreed to pay to Allergan and Medytox a royalty on the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, based on a certain dollar amount per vial sold in the United States and a low-double digit royalty on net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sold in other Evolus territories. Royalties for sales during the Restricted Period ended in the third quarter of 2022. For the period from December 16, 2020 to September 16, 2022, Daewoong agreed to reimburse the Company certain amounts with respect to the royalties payable to Medytox and Allergan. This reimbursement was received quarterly and recorded as an offset to the related royalties to Medytox and Allergan in the cost of goods sold on the accompanying consolidated statements of operations and comprehensive loss. For the period from September 17, 2022 to September 16, 2032, the Company agreed to pay Medytox a mid-single digit royalty percentage on all net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The royalty payments are made quarterly and recorded as cost of goods sold on the accompanying consolidated statements of operations and comprehensive loss in the periods the royalties are incurred.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11. Medytox Settlement Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the details of all litigation settlement agreements.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-493" escape="true"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes stock-based compensation expense for employees, consultants and members of the Board of Directors based on the fair value at the date of grant.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option pricing model to value stock option grants. The Black-Scholes option pricing model requires the input of subjective assumptions, including the expected volatility of the Company&#8217;s common stock, expected risk-free interest rate, and the option&#8217;s expected life. The fair value of the Company&#8217;s restricted stock units (&#8220;RSUs&#8221;) is based on the fair value on the grant date of the Company&#8217;s common stock. The Company also evaluates the impact of modifications made to the original terms of equity awards when they occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a Monte Carlo simulation model to determine the fair value of performance units with market conditions at the grant date. The Monte Carlo simulation model involves the generation of a large number of possible stock price outcomes for the Company&#8217;s stock which is assumed to follow a Geometric Brownian Motion. The use of the Monte Carlo simulation model requires the input of a number of assumptions including expected volatility of the Company&#8217;s stock price, which is based on the historical volatility of its stock; risk-free interest rate, which is based on the treasury zero-coupon yield commensurate with the term of the performance unit as of the grant date; and expected dividends as applicable, which is <ix:nonFraction unitRef="number" contextRef="c-78" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-494">zero</ix:nonFraction>, as the Company has never paid any cash dividends.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options and RSUs with service conditions that are expected to vest is amortized on a straight-line basis over the requisite service period. Stock-based compensation for RSUs with performance or market conditions is recorded over the requisite service period using the accelerated attribution method. Stock-based compensation expense is recognized net of actual forfeitures when they occur, as an increase to additional paid-in capital in the consolidated balance sheets and in the selling, general and administrative or research and development expenses in the consolidated statements of operations and comprehensive loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="f-495" continuedAt="f-495-1" escape="true"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Costs</span></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-495-1">Advertising costs are expensed as incurred and primarily include costs related to social media ads and co-branded marketing programs. Advertising costs are included in selling, general and administrative expenses.</ix:continuation> For the years ended December 31, 2024, 2023, and 2022, the Company incurred advertising costs of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="3" id="f-496">8,698</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="3" id="f-497">7,490</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="3" id="f-498">11,642</ix:nonFraction>, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-499" continuedAt="f-499-1" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:9pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined on the basis of differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. </span></div><div style="margin-bottom:9pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is recorded against deferred tax assets to reduce the net carrying value when it is more likely than not that some portion or all of a deferred tax asset will not be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, and ongoing prudent and feasible tax planning strategies in assessing the amount of the valuation </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-391-10" continuedAt="f-391-11"><ix:continuation id="f-499-1"><div style="margin-bottom:9pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allowance. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. Accordingly, the Company establishes reserves for uncertain tax positions. The Company has not recognized interest or penalties in its consolidated statement of operations and comprehensive loss.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to file federal and state income tax returns in the United States and various other state jurisdictions. The preparation of these income tax returns requires the Company to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company. An amount is accrued for the estimate of additional tax liability, including interest and penalties, for any uncertain tax positions taken or expected to be taken in an income tax return. The Company reviews and updates the accrual for uncertain tax positions as more definitive information becomes available. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of the Company&#8217;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than&#160;50%&#160;likely of being realized upon settlement. While the Company believes it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcomes of examinations by tax authorities in determining the adequacy of its provision for income taxes. The Company continually assesses the likelihood and amount of potential revisions and adjusts the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company monitors changes to the tax laws in the states it conducts business and files corporate income tax returns. The Company does not expect changes to state tax laws through December&#160;31, 2024 to materially impact its consolidated financial statements.</span></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-500" continuedAt="f-500-1" escape="true"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-500-1">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period including contingently issuable shares. Diluted earnings per share is based on the treasury stock method and includes the effect from potential issuance of ordinary shares, such as shares issuable pursuant to the exercise of stock options and the vesting of restricted stock units. Because the impact of the options and non-vested RSUs are anti-dilutive during periods of net loss, there was no difference between the weighted-average number of shares used to calculate basic and diluted net loss per common share for the periods presented. Excluded from the dilutive net loss per share computation for the twelve months ended</ix:continuation> December&#160;31, 2024, 2023, and 2022, were stock options of <ix:nonFraction unitRef="shares" contextRef="c-79" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-501">6,151,069</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="c-80" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-502">5,753,466</ix:nonFraction>, and <ix:nonFraction unitRef="shares" contextRef="c-81" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-503">4,769,521</ix:nonFraction>, respectively, and non-vested RSUs of <ix:nonFraction unitRef="shares" contextRef="c-82" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-504">3,476,314</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="c-83" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-505">3,281,045</ix:nonFraction>, and <ix:nonFraction unitRef="shares" contextRef="c-84" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-506">2,663,320</ix:nonFraction>, respectively. Although these securities were anti-dilutive for these periods, they could be dilutive in future periods.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-507" continuedAt="f-507-1" escape="true"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Pronouncements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting - Improving Reportable Segment Disclosures (Topic 280)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The standard requires disclosures to include significant segment expenses that are regularly provided to the chief operating decision maker (&#8220;CODM&#8221;), a description of other segment items by reportable segment, and any additional measures of a segment's profit or loss used by the CODM when deciding how to allocate resources. The ASU also requires all annual disclosures currently required by Topic 280 to be included in interim periods. ASU 2023-07 is effective for annual reporting periods beginning after December </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-507-1"><ix:continuation id="f-391-11"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15, 2023 and interim reporting periods after December 15, 2024. The Company adopted this guidance on December&#160;31, 2024 and updated its disclosures to conform to this new segment disclosure requirement.</span></div><div style="margin-bottom:9pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements&#160;Issued But Not&#160;Adopted&#160;</span></div><div style="margin-bottom:9pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This update requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income taxes paid. ASU No. 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.</span></div><div style="margin-bottom:9pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU No. 2024-03 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires disaggregated disclosure of certain costs and expenses on an interim and annual basis. ASU No. 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The disclosure updates are required to be applied prospectively with the option for retrospective application. The Company is currently evaluating the impact of adopting ASU No. 2024-03.</span></div><div style="margin-bottom:9pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by management to, have a material impact on the Company&#8217;s present or future financial position, results of operations or cash flows.</span></div></ix:continuation></ix:continuation><div id="id181047532df422ab5a549dd869deccb_100"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-511" continuedAt="f-511-1" escape="true">Fair Value Measurements </ix:nonNumeric></span></div><ix:continuation id="f-511-1" continuedAt="f-511-2"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-512" escape="true"><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. The fair value of these instruments was as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:52.873%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent royalty obligation payable to Evolus Founders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-513">44,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-514">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-515">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-516">44,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"/><td style="width:52.873%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.848%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent royalty obligation payable to Evolus Founders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-517">45,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-518">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-519">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-520">45,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not transfer any assets or liabilities measured at fair value on a recurring basis between levels during the&#160;year ended December 31, 2024.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value of the contingent royalty obligation payable to Evolus Founders based on Level 3 inputs using a discounted cash flows method. The significant unobservable input assumptions that can significantly change the fair value include (i) projected amount and timing of U.S. net revenues of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the payment period, which terminates at the end of the second quarter of 2029, (ii) the discount rate, and (iii) the timing of payments. During the years ended December 31, 2024 and 2023, the Company utilized discount rates between <ix:nonFraction unitRef="number" contextRef="c-94" decimals="INF" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="-2" id="f-521">14</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-95" decimals="INF" name="us-gaap:AlternativeInvestmentMeasurementInput" scale="-2" id="f-522">15</ix:nonFraction>%, reflecting changes in the Company&#8217;s risk profile. Net revenue projections are also updated to reflect changes in the timing of expected sales. Significant increases (decreases) in the discount rate and to the projected net revenues would result in a significantly lower (higher) fair value measurement, which could materially impact their fair value reported on the consolidated balance sheet.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-511-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-523" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a reconciliation of the beginning and ending fair value measurements of the contingent royalty obligation payable:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-524">45,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-525">46,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-526">44,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="3" id="f-527">7,441</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="3" id="f-528">5,537</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="3" id="f-529">4,185</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value recorded in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="f-530">7,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="f-531">4,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="f-532">5,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-533">44,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-534">45,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-535">46,310</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Financial Assets and Liabilities</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist primarily of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses, lease liabilities, and long-term debt. The carrying amount of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of long-term debt and operating lease liabilities using the discounted cash flow analysis based on the interest rates for similar rated debt securities (Level 2). As of December 31, 2024 and 2023, the fair value of long-term debt was $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-536">132,078</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-537">140,241</ix:nonFraction>, respectively. The fair value of operating lease liabilities&#160;as of December&#160;31, 2024 and 2023 approximated their carrying value.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="id181047532df422ab5a549dd869deccb_103"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="f-538" continuedAt="f-538-1" escape="true">Goodwill and Intangible Assets </ix:nonNumeric></span></div><ix:continuation id="f-538-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="f-539" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below shows the weighted-average life, original cost, accumulated amortization and net book value by major intangible asset classification:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.824%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Original Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Book Value</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution rights</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-540">62,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-541">17,580</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-542">45,207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-543">13,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-544">9,770</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-545">3,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-546">76,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-547">27,350</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-548">48,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Indefinite-lived intangible asset</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-549">21,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-550">21,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total as of December&#160;31, 2024</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="eols:IntangibleAssetsGrossIncludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-551">97,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-552">27,350</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-553">69,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.824%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Original Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Book Value</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution right</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-554">60,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-555">14,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-556">46,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-557">9,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-558">8,746</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-559">1,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-560">70,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-561">23,246</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-562">47,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Indefinite-lived intangible asset</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-563">21,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-564">21,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total as of December&#160;31, 2023</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="eols:IntangibleAssetsGrossIncludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-565">91,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-566">23,246</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-567">68,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="f-568" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table outlines the estimated future amortization expense related to intangible assets held as of&#160;December&#160;31, 2024 that are subject to amortization:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.142%"><tr><td style="width:1.0%"/><td style="width:55.931%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.869%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-569">4,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-570">4,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="f-571">3,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="f-572">3,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="3" id="f-573">3,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-574">29,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-575">48,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distribution rights represent the license and associated distribution rights to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Evolysse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For the years ended December 31, 2024 and 2023, the Company capitalized $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="3" id="f-576">2,235</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="3" id="f-577">1,476</ix:nonFraction> related to the license and distribution right to Evolysse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> nasolabial fold product in Europe, which is amortized on a straight-line basis over the estimated useful life of <ix:nonNumeric contextRef="c-64" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-578">15</ix:nonNumeric> years.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2024 and 2023, the Company capitalized $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalizedComputerSoftwareAdditions" format="ixt:num-dot-decimal" scale="3" id="f-579">3,513</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CapitalizedComputerSoftwareAdditions" format="ixt:num-dot-decimal" scale="3" id="f-580">1,168</ix:nonFraction>, respectively, related to costs of computer software developed for internal use. The software is amortized over a <ix:nonNumeric contextRef="c-98" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:durwordsen" id="f-581">two-year</ix:nonNumeric> period using the straight-line method. For the years ended December 31, 2024, 2023, and 2022, total intangible assets amortization expense of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-582">4,104</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-583">4,072</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-584">3,350</ix:nonFraction>, respectively, was recorded within depreciation and amortization on the accompanying consolidated statements of operations and comprehensive loss.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><div id="id181047532df422ab5a549dd869deccb_106"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="f-585" continuedAt="f-585-1" escape="true">Accrued Expenses </ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="f-586" escape="true"><ix:continuation id="f-585-1"><div style="margin-bottom:9pt;padding-right:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.693%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalties under the Medytox Settlement Agreements</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-587">4,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-588">3,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and related benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-589">14,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-590">13,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued revenue contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-591">14,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-592">11,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-593">7,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-594">5,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-595">40,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-596">33,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="id181047532df422ab5a549dd869deccb_1584"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6. <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-597" continuedAt="f-597-1" escape="true">Property, Plant and Equipment</ix:nonNumeric></span></div><ix:continuation id="f-597-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-598" escape="true"><div style="margin-bottom:9pt;padding-right:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment consisted of the following:</span></div><div style="margin-bottom:9pt;padding-right:15.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.693%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-599">452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-600">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-601">702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-602">345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold Improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-603">3,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-604">2,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-605">317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-606">149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing Fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-607">1,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-608">1,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant, and equipment</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-609">6,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-610">4,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-611">3,523</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-612">2,400</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-613">3,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-614">2,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;padding-right:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2024, 2023, and 2022, depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-615">1,194</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-616">1,001</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-617">373</ix:nonFraction>, respectively.</span></div></ix:continuation><div id="id181047532df422ab5a549dd869deccb_109"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-618" continuedAt="f-618-1" escape="true">Term Loans</ix:nonNumeric></span></div><ix:continuation id="f-618-1" continuedAt="f-618-2"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmakon Term Loans</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2021, the Company entered into a loan agreement with Pharmakon. Pursuant to the terms of the agreement, Pharmakon agreed to make term loans to the Company in <ix:nonFraction unitRef="tranche" contextRef="c-112" decimals="INF" name="eols:DebtInstrumentNumberOfTranches" format="ixt-sec:numwordsen" scale="0" id="f-619">two</ix:nonFraction> tranches (the &#8220;Pharmakon Term Loans&#8221;). The first tranche of $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-620">75,000</ix:nonFraction> was funded on December 29, 2021. On December 5, 2022, the Company entered into a Second Amendment to the loan agreement to extend the Company&#8217;s option to draw down the second tranche of $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-621">50,000</ix:nonFraction> until December 31, 2023, and paid an amendment fee of $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="f-622">500</ix:nonFraction> to Pharmakon. The Pharmakon Term Loans will mature on the <span style="-sec-ix-hidden:f-623">sixth year</span> anniversary of the closing date of the first tranche (the &#8220;Maturity Date&#8221;). </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 9, 2023, the Company entered into the Third Amendment to the loan agreement. Under the Third Amendment, Pharmakon agreed to advance the second tranche of $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-624">50,000</ix:nonFraction> to the Company in <ix:nonFraction unitRef="installment" contextRef="c-118" decimals="INF" name="eols:DebtInstrumentNumberOfInstallments" format="ixt-sec:numwordsen" scale="0" id="f-625">two</ix:nonFraction> installments: (i) $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-626">25,000</ix:nonFraction> advanced on May 31, 2023 and (ii) $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-627">25,000</ix:nonFraction> advanced on December 15, 2023. The Third Amendment amended the principal payment terms to <ix:nonFraction unitRef="payment" contextRef="c-121" decimals="INF" name="eols:DebtInstrumentPeriodicPaymentNumberOfPrincipalPayments" format="ixt-sec:numwordsen" scale="0" id="f-628">seven</ix:nonFraction> quarterly payments, each in an amount equal to 1/12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the outstanding principal amount of the Pharmakon Term Loans following the <ix:nonNumeric contextRef="c-121" name="eols:DebtInstrumentPeriodicPaymentInitialPrincipalPaymentDuePeriod" format="ixt-sec:durmonth" id="f-629">51</ix:nonNumeric>st-month anniversary of the closing date of the first tranche and the remaining principal balance of the Pharmakon Term Loans on the Maturity Date. The Third Amendment replaced the interest rates based on LIBOR with </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-618-2"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interest rates based on the Secured Overnight Financing Rate (&#8220;SOFR&#8221;) throughout the remaining term of the Pharmakon Term Loans.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Initially, the Pharmakon Term Loans accrued interest at a per annum rate equal to the 3-month U.S. Dollar LIBOR rate (subject to a LIBOR rate floor of <ix:nonFraction unitRef="number" contextRef="c-122" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-630">1.0</ix:nonFraction>%) plus <ix:nonFraction unitRef="number" contextRef="c-123" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-631">8.5</ix:nonFraction>% per annum. Beginning May 2023, the Pharmakon Term Loans accrue interest at a per annum rate equal to the 3-month SOFR rate (subject to a SOFR rate floor of <ix:nonFraction unitRef="number" contextRef="c-124" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-632">1.0</ix:nonFraction>%) plus <ix:nonFraction unitRef="number" contextRef="c-125" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-633">8.5</ix:nonFraction>% per annum.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may elect to prepay all amounts, not less than $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="eols:DebtInstrumentPrepaymentAmountThreshold" format="ixt:num-dot-decimal" scale="3" id="f-634">20,000</ix:nonFraction>, owed prior to the Maturity Date. Prepayments of the first tranche prior to the second anniversary of the closing date of the first tranche and prepayments of the second tranche prior to the second anniversary of the date on which the second tranche is drawn by the Company will be accompanied by a make whole amount equal to the sum of all interest that would have accrued through such second anniversary. Prepayments of the Pharmakon Term Loans will also be accompanied by a prepayment premium equal to the principal amount so prepaid multiplied by <ix:nonFraction unitRef="number" contextRef="c-127" decimals="INF" name="eols:DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount" scale="-2" id="f-635">3.0</ix:nonFraction>% if made prior to the third anniversary of the closing date of the first tranche, <ix:nonFraction unitRef="number" contextRef="c-128" decimals="INF" name="eols:DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount" scale="-2" id="f-636">2.0</ix:nonFraction>% if made on or after the third anniversary of the closing date of the first tranche but prior to the fourth anniversary of the closing date of the first tranche, and <ix:nonFraction unitRef="number" contextRef="c-129" decimals="INF" name="eols:DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount" scale="-2" id="f-637">1.0</ix:nonFraction>% if made on or after the fourth anniversary of the closing date of the first tranche but prior to the Maturity Date. If the Pharmakon Term Loans are accelerated following the occurrence of an event of default, including a material adverse change, the Company is required to immediately pay Pharmakon an amount equal to the sum of all outstanding principal, unpaid interest, and applicable make whole and prepayment premiums.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmakon Term Loans are secured by substantially all of the Company&#8217;s assets. The Pharmakon Term Loans contain customary affirmative and restrictive covenants and representations and warranties. The affirmative covenants include, among others, certain information delivery requirements, obligations to maintain certain insurance, and certain notice requirements. The restrictive covenants include, among others, incurring certain additional indebtedness, consummating certain change in control transactions, or incurring any non- permitted lien or other encumbrance on the Company&#8217;s assets, without Pharmakon&#8217;s prior written consent. The Pharmakon Term Loans do not contain covenants requiring the Company to maintain a minimum cash threshold or minimum revenues or earnings. As of December&#160;31, 2024, the Company was in compliance with its debt covenants.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing date of the first tranche, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-638">3,042</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="3" id="f-639">3,263</ix:nonFraction> in debt discounts and issuance costs related to the Pharmakon Term Loans, respectively. Debt discounts and issuance costs related to the entire Pharmakon Term Loans have been allocated pro rata between the funded and unfunded portions. Debt discounts and issuance costs allocated to the first tranche of $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-640">75,000</ix:nonFraction> have been presented as a deduction to the debt balance and amortized into interest expense using the effective interest method. Debt discounts and issuance costs associated with the unfunded second tranche are deferred as assets until the tranche is drawn and are amortized into interest expense using the straight-line method over the term of the debt. Upon the first draw of the second tranche in May 2023, debt discounts and issuance costs associated with the second tranche were reclassified from assets to debt as a deduction to the debt balance.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the borrowings outstanding under the Pharmakon Term Loans were classified as long-term debt in the accompanying consolidated balance sheets. The overall effective interest rate was approximately <ix:nonFraction unitRef="number" contextRef="c-130" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-641">14.52</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-131" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-642">13.21</ix:nonFraction>% for the first and second tranche, respectively, as of December&#160;31, 2024.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="f-643" escape="true"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the principal amounts of long-term debt maturities for each of the next five fiscal years are as follows:</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.476%"><tr><td style="width:1.0%"/><td style="width:68.218%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.582%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:fixed-zero" scale="3" id="f-644">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-645">41,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="f-646">83,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:fixed-zero" scale="3" id="f-647">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total principal payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-648">125,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discounts and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-649">3,494</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term debt, net of discounts and issuance costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-650">121,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><div id="id181047532df422ab5a549dd869deccb_115"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-652" continuedAt="f-652-1" escape="true">Operating Leases</ix:nonNumeric></span></div><ix:continuation id="f-652-1" continuedAt="f-652-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 15, 2019, the Company entered into a <ix:nonNumeric contextRef="c-132" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="f-653">five-year</ix:nonNumeric> non-cancelable operating lease (the &#8220;Lease Agreement&#8221;), which was set to expire January 31, 2025, for its corporate headquarters in Newport Beach, California. Lease payments increase each year on February 1 based on an annual rent escalation clause. The Company has an option to extend the term of the lease for an additional <ix:nonNumeric contextRef="c-4" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durmonth" id="f-654">60</ix:nonNumeric> months, which was not recognized as part of its ROU assets and lease liabilities.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 27, 2023, the Company entered into the First Amendment to the Lease Agreement (the &#8220;First Lease Amendment&#8221;) for its corporate headquarters. The First Lease Amendment includes a lease extension to January 31, 2030 with a <ix:nonNumeric contextRef="c-133" name="eols:LesseeOperatingLeaseAbatementPeriod" format="ixt-sec:durwordsen" id="f-655">three-month</ix:nonNumeric> rent abatement period and additional office space. On July 27, 2023, the effective date of the First Lease Amendment, the Company recognized additional ROU assets and lease liabilities in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-656"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-657">4,550</ix:nonFraction></ix:nonFraction>. On August 1, 2024, the lease commencement date for the additional office space, the Company recognized additional ROU assets and lease liabilities in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-658"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-659">3,002</ix:nonFraction></ix:nonFraction>.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 16, 2024, the Company entered into the Second Amendment to the Lease Agreement (the &#8220;Second Lease Amendment&#8221;) to lease additional office space for its corporate headquarters. The lease is expected to commence on or around the second half of 2025 and is set to expire January 31, 2030. Fixed cash payments under this amendment are estimated to be $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" format="ixt:num-dot-decimal" scale="3" id="f-660">1,876</ix:nonFraction> over the term of the lease. The Company expects to account for this lease an operating lease.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s lease agreement does not contain any residual value guarantees or material restrictive covenants. The payments associated with the renewal will only be included in the measurement of the lease liability and ROU assets if the exercise of the renewal option is determined to be reasonably certain. The Company considers the timing of the renewal period and other economic factors such as the financial implications of a decision to extend or not to extend a lease&#160;in&#160;determining&#160;if the renewal option is reasonably certain to be exercised.</span></div><div style="margin-bottom:9pt"><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-661" continuedAt="f-661-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease expense are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-662">1,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-663">1,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-664">1,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable operating lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="f-665">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="f-666">183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="f-667">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-668">1,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-669">1,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-670">1,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><ix:continuation id="f-661-1"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average remaining lease term and discount rate are as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-671">5.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-5" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-672">6.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-26" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-673">2.1</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-674">9.7</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-675">11.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-26" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-676">9.4</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-677">1,433</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-678">1,320</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-679">1,265</ix:nonFraction></span></td></tr></table></div></ix:continuation><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease&#160;expenses were included in the selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-680" escape="true"><ix:continuation id="f-652-2"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the future minimum payments under the operating lease agreements with non-cancelable terms as of December&#160;31, 2024:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.327%"><tr><td style="width:1.0%"/><td style="width:76.348%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.452%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-681">1,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-682">2,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-683">2,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-684">2,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="f-685">2,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="f-686">198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-687">10,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-688">2,453</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-689">8,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="id181047532df422ab5a549dd869deccb_118"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-690" continuedAt="f-690-1" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><ix:continuation id="f-690-1" continuedAt="f-690-2"><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Daewoong Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Daewoong Agreement includes certain minimum annual purchases that the Company is required to make in order to maintain the exclusivity of the license. The Company may, however, meet these minimum purchase obligations by achieving certain market share in the licensed territories. These potential minimum purchase obligations are contingent upon the occurrence of future events, including receipt of governmental approvals and the Company&#8217;s future market share in various jurisdictions.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total inventory payments to Daewoong were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="eols:PaymentsForInventory" format="ixt:num-dot-decimal" scale="3" id="f-691">62,233</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="eols:PaymentsForInventory" format="ixt:num-dot-decimal" scale="3" id="f-692">50,770</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="eols:PaymentsForInventory" format="ixt:num-dot-decimal" scale="3" id="f-693">50,685</ix:nonFraction> for the years ended December 31, 2024, 2023, and 2022, respectively.</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Symatese U.S. Agreement and Symatese Europe Agreement</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Symatese U.S. Agreement and the Symatese Europe Agreement include certain minimum purchase requirements, and failure to meet such requirements may result in a reduction or termination of the Company&#8217;s exclusive rights, subject to certain exceptions. These potential minimum purchase obligations are contingent upon the occurrence of future events, including receipt of governmental approvals and the Company&#8217;s future market share in various jurisdictions.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Symatese U.S. Agreement, the Company is required to make up to &#8364;<ix:nonFraction unitRef="eur" contextRef="c-54" decimals="-3" name="eols:LicenseSupplyAndDistributionAgreementMinimumMilestonePayment" format="ixt:num-dot-decimal" scale="3" id="f-694">16,200</ix:nonFraction> in milestone payments to Symatese, including an initial payment of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-54" decimals="-3" name="eols:LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement" format="ixt:num-dot-decimal" scale="3" id="f-695">4,100</ix:nonFraction> within <ix:nonNumeric contextRef="c-54" name="eols:LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod" format="ixt-sec:durday" id="f-696">30</ix:nonNumeric> days of execution of the Symatese U.S. Agreement, and additional annual payments of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-53" decimals="-3" name="eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne" format="ixt:num-dot-decimal" scale="3" id="f-697">1,600</ix:nonFraction> in June 2025, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-53" decimals="-3" name="eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-698">4,100</ix:nonFraction> in June 2026, &#8364;<ix:nonFraction unitRef="eur" contextRef="c-53" decimals="-3" name="eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree" format="ixt:num-dot-decimal" scale="3" id="f-699">3,200</ix:nonFraction> in June 2027, and &#8364;<ix:nonFraction unitRef="eur" contextRef="c-53" decimals="-3" name="eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour" format="ixt:num-dot-decimal" scale="3" id="f-700">3,200</ix:nonFraction> in June 2028, in each case subject to <ix:nonFraction unitRef="product" contextRef="c-53" decimals="INF" name="eols:LicenseSupplyAndDistributionAgreementAnnualPaymentTriggeredRegulatoryApprovalNumberOfProducts" format="ixt-sec:numwordsen" scale="0" id="f-701">three</ix:nonFraction> of the Products gaining approval prior to that date. In June 2023, the Company paid $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="eols:LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-702">4,441</ix:nonFraction> as an upfront payment upon the signing of the Symatese U.S. Agreement and has developmental costs, ongoing milestone and royalty payment obligations.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Symatese Europe Agreement, the Company is required to pay <ix:nonFraction unitRef="milestonepayment" contextRef="c-57" decimals="INF" name="eols:LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment" format="ixt-sec:numwordsen" scale="0" id="f-703">two</ix:nonFraction> milestone payments: (i) &#8364;<ix:nonFraction unitRef="eur" contextRef="c-57" decimals="-3" name="eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-704">1,200</ix:nonFraction> on the second anniversary of certain regulatory approvals, and (ii) &#8364;<ix:nonFraction unitRef="eur" contextRef="c-57" decimals="-3" name="eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree" format="ixt:num-dot-decimal" scale="3" id="f-705">1,900</ix:nonFraction> on the earlier of the third anniversary of certain regulatory approvals or following a year in which the Company achieves &#8364;<ix:nonFraction unitRef="eur" contextRef="c-65" decimals="-3" name="eols:LicenseSupplyAndDistributionAgreementAnnualRevenue" format="ixt:num-dot-decimal" scale="3" id="f-706">25,000</ix:nonFraction> in revenue in Europe, provided that the payment shall occur no later than December 2029.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2024, the Company received European Union Medical Device Regulation (&#8220;MDR&#8221;) approval for the remaining <ix:nonFraction unitRef="product" contextRef="c-66" decimals="INF" name="eols:LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts" format="ixt-sec:numwordsen" scale="0" id="f-707">three</ix:nonFraction> hyaluronic acid gel products. As a result, the <ix:nonFraction unitRef="milestonepayment" contextRef="c-67" decimals="INF" name="eols:LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment" format="ixt-sec:numwordsen" scale="0" id="f-708">two</ix:nonFraction> milestone payments have been triggered. The first milestone </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-690-2" continuedAt="f-690-3"><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payment is payable on the <ix:nonNumeric contextRef="c-66" name="eols:LicenseSupplyAndDistributionAgreementMilestonePaymentPayablePeriod" format="ixt-sec:durwordsen" id="f-709">two-year</ix:nonNumeric> anniversary of the approval. For the second milestone payment, the Company determined that it is probable the payment will be made no later than December 2029.</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Class Action Lawsuit</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 16 and 28, 2020, <ix:nonFraction unitRef="complaint" contextRef="c-136" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="f-710">two</ix:nonFraction> putative securities class action complaints were filed in the U.S. District Court for the Southern District of New York by Evolus shareholders Armin Malakouti and Clinton Cox, respectively, naming the Company and certain of its officers as defendants. The complaints assert violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, claiming that the defendants made false and materially misleading statements and failed to disclose material adverse facts related to the Company&#8217;s acquisition of the right to sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the complaint against the Company filed by Allergan and Medytox in the U.S. International Trade Commission related to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;ITC Action&#8221;), and risks related to the ITC Action. The complaints assert a putative class period of February 1, 2019 to July 6, 2020. The court consolidated the actions on November 13, 2020, under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Evolus Inc. Securities Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 1:20-cv-08647 (PGG). On September 17, 2021, the court appointed a lead plaintiff and lead counsel. On November 17, 2021, the lead plaintiff filed an amended class action complaint against the Company, <ix:nonFraction unitRef="officer" contextRef="c-137" decimals="INF" name="eols:LossContingencyNumberDefendantsOfficers" format="ixt-sec:numwordsen" scale="0" id="f-711">three</ix:nonFraction> of its officers, and Alphaeon Corporation, the Company&#8217;s former majority shareholder. On January 18, 2022, the Company and the officer defendants served their motion to dismiss the amended complaint. On February 10, 2022, Alphaeon Corporation served its motion to dismiss the amended complaint. Both motions were fully briefed on June 16, 2022.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 26, 2024, the court granted the Company&#8217;s motion to dismiss the amended complaint and on October 18, 2024, the court entered final judgment in favor of the defendants.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shareholder Derivative Lawsuit</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2020 and December 2, 2020, <ix:nonFraction unitRef="plaintiff" contextRef="c-138" decimals="INF" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt-sec:numwordsen" scale="0" id="f-712">two</ix:nonFraction> putative Evolus shareholders filed substantially similar shareholder derivative actions in the U.S. District Court for the Southern District of New York against certain of the Company&#8217;s officers and directors as defendants. The complaints alleged substantially similar facts as those in the Securities Class Action and assert claims for, among other things, breach of fiduciary duty, waste of corporate assets, unjust enrichment, and violations of Section 14(a) of the Exchange Act and for contribution under Sections 10(b) and 21(D) of the Exchange Act. On December 29, 2020, the plaintiffs filed a joint stipulation to consolidate their actions and on February 5, 2021, the court consolidated the action under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Evolus, Inc. Derivative Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 1:20-cv-09986-PPG, and adjourned defendants&#8217; time to move, answer or otherwise respond to the complaints. On September 20, 2021, the court so-ordered the parties&#8217; stipulated stay of the consolidated derivative suit pending the court&#8217;s decision on the defendants&#8217; motion to dismiss the Securities Class Action.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that additional suits will be filed, or additional allegations will be made by stockholders, with respect to these same or similar or other matters and also naming the Company and/or its officers and directors as defendants. The Company believes that the complaints are without merit and intends to vigorously defend against it. However, the outcome of the legal proceeding is uncertain at this point. Based on information available to the Company at present, management cannot reasonably estimate a range of loss with respect to this matter.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Books and Records Demand</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 5, 2021, the Company received a letter from a putative stockholder demanding inspection of specified categories of the Company&#8217;s books and records under Section 220 of the Delaware General Corporations Law. The Company was subsequently informed that the stockholder sold his shares of the Company&#8217;s common stock. On October 13, 2021, the Company received a substantially similar demand to inspect specified categories of the Company&#8217;s books and records under Section 220 of the Delaware General Corporations Law from another putative stockholder. The subject of the demand is substantially similar to the allegations in the putative securities class action and derivative complaints described above. The Company responded to the demand in December 2021. The outcome of this matter is uncertain at this point. Based on information available to the Company at present, management cannot reasonably estimate a range of loss with respect to this matter.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Legal Matters</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-690-3" continuedAt="f-690-4"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is, from time to time, involved in various litigation matters or regulatory encounters arising in the ordinary course of business that could result in unasserted or asserted claims or litigation. These other matters may raise difficult and complex legal issues and are subject to many uncertainties, including, but not limited to, the facts and circumstances of each particular case or claim, the jurisdiction in which each suit or regulatory encounter is brought, and differences in applicable laws and regulations. Except as set forth above, the Company does not believe that these other matters would have a material adverse effect on its accompanying financial position, results of operations or cash flows. However, the resolution of one or more of the other matters in any reporting period could have a material adverse impact on the Company&#8217;s financial results for that period.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company&#8217;s exposure under these agreements is unknown because they involve claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. <ix:nonFraction unitRef="usd" contextRef="c-4" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="0" id="f-713">No</ix:nonFraction> amounts were accrued as of December&#160;31, 2024.</span></div></ix:continuation><div><span><br/></span></div><div id="id181047532df422ab5a549dd869deccb_121"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-714" continuedAt="f-714-1" escape="true">Stockholders&#8217; Equity </ix:nonNumeric></span></div><ix:continuation id="f-714-1" continuedAt="f-714-2"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-715">10,000,000</ix:nonFraction> authorized shares of preferred stock with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-716">0.00001</ix:nonFraction> per share. As of December&#160;31, 2024, <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-717"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-718">no</ix:nonFraction></ix:nonFraction> shares of its preferred stock were issued and outstanding.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-719">100,000,000</ix:nonFraction> authorized shares of common stock with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-720">0.00001</ix:nonFraction> per share. As of December&#160;31, 2024, <ix:nonFraction unitRef="shares" contextRef="c-39" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-721">63,497,548</ix:nonFraction> shares of its common stock were issued and outstanding.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, the Company completed a follow-on offering and issued <ix:nonFraction unitRef="shares" contextRef="c-45" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-722">3,554,000</ix:nonFraction> shares of its common stock, at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-46" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-723">14.07</ix:nonFraction> per share. Refer to Note 1. Description of Business for additional details regarding the follow-on offering.</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2024 Employee Stock Purchase Plan (&#8220;ESPP&#8221;)</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2024, the Company approved the adoption of the 2024 Employee Stock Purchase Plan. The 2024 ESPP provides an opportunity to purchase shares of the Company&#8217;s common stock at a favorable price and upon favorable terms in consideration of the participating employees&#8217; continued services. Eligible employees will be entitled to purchase, by means of payroll deductions, limited amounts of the Company&#8217;s common stock at a discount during periodic offering periods. There were <ix:nonFraction unitRef="shares" contextRef="c-139" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-724">579,648</ix:nonFraction> shares initially reserved for issuance under the 2024 ESPP, which shall automatically increase on March 5 of each calendar year, by an amount equal to the lesser of (i) <ix:nonFraction unitRef="number" contextRef="c-140" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="f-725">1.0</ix:nonFraction>% of the total number of shares of common stock issued and outstanding on March 4 of the year in which such increase is to occur, (ii) <ix:nonFraction unitRef="shares" contextRef="c-139" decimals="INF" name="eols:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalShareIncreaseAvailableForIssuance" format="ixt:num-dot-decimal" scale="0" id="f-726">579,648</ix:nonFraction> shares of common stock, or (iii) such number of shares of common stock as may be established by the Board of Directors. There were <ix:nonFraction unitRef="shares" contextRef="c-141" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt-sec:numwordsen" id="f-727">no</ix:nonFraction> shares issued under the 2024 ESPP during the twelve months ended December 31, 2024.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8220;At-the-market&#8221; Offerings of Common Stock</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 8, 2023, the Company entered into the ATM Sales Agreement with Leerink Partners LLC (formerly known as SVB Securities LLC) (the &#8220;Sales Agent&#8221;) pursuant to which shares of the Company&#8217;s common stock can be sold from time to time for aggregate gross proceeds of up to $<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="eols:SaleOfStockMaximumConsiderationReceivable" format="ixt:num-dot-decimal" scale="3" id="f-728">50,000</ix:nonFraction> (the &#8220;ATM Program&#8221;). Under the ATM Sales Agreement, the Sales Agent is entitled to compensation, at a commission rate equal to <ix:nonFraction unitRef="number" contextRef="c-143" decimals="3" name="eols:SaleOfStockCommissionPaymentUponGrossProceedsPercentage" scale="-2" id="f-729">3.0</ix:nonFraction>% of the gross proceeds from sales of the Company&#8217;s common shares under the ATM Program. The Company has <ix:nonFraction unitRef="shares" contextRef="c-144" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="f-730">not</ix:nonFraction> sold any shares under the ATM Sales Agreement.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Omnibus Incentive Plan and Stock-based Compensation Allocation</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 2017 Omnibus Incentive Plan (the &#8220;Plan&#8221;) provides for the grant of incentive options to employees of the Company, and for the grant of non-statutory options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of stock compensation to the Company&#8217;s officers, directors, consultants </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-714-2" continuedAt="f-714-3"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and employees of the Company. The maximum number of shares of common stock that may be issued under the Plan is <ix:nonFraction unitRef="shares" contextRef="c-145" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-731">4,361,291</ix:nonFraction> shares, plus an annual increase on November 21 of each year equal to <ix:nonFraction unitRef="number" contextRef="c-146" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="f-732">4.0</ix:nonFraction>% of the total issued and outstanding shares of the Company&#8217;s common stock as of such anniversary (or such lesser number of shares as may be determined by the Company&#8217;s Board of Directors). On November 21, 2024, 2023, and 2022, an additional <ix:nonFraction unitRef="shares" contextRef="c-147" decimals="INF" name="eols:CommonStockAdditionalCapitalSharesReservedforFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-733">2,535,476</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="c-148" decimals="INF" name="eols:CommonStockAdditionalCapitalSharesReservedforFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-734">2,287,649</ix:nonFraction>, and <ix:nonFraction unitRef="shares" contextRef="c-149" decimals="INF" name="eols:CommonStockAdditionalCapitalSharesReservedforFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-735">2,249,863</ix:nonFraction>, shares, respectively, were reserved under the evergreen provision of the Plan. As of December&#160;31, 2024, the Company had an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-736">3,605,334</ix:nonFraction> shares of its common stock available for future issuance under the Plan.</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2023 Inducement Incentive Plan</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, the Company&#8217;s Board of Directors adopted the Company&#8217;s 2023 Inducement Incentive Plan (the &#8220;Inducement Plan&#8221;) in accordance with Nasdaq Listing Rule 5635(c)(4). The Company&#8217;s Inducement Plan provides for the grant of equity awards to selected individuals in connection with their commencing employment with the Company as an inducement material to their accepting such employment. The Board of Directors reserved <ix:nonFraction unitRef="shares" contextRef="c-150" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-737">1,000,000</ix:nonFraction> shares of common stock for issuance under the Inducement Plan. As of December&#160;31, 2024, the Company had an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-151" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-738">105,788</ix:nonFraction> shares of its common stock available for future issuance under the Inducement Plan. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inducement Grants</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company has granted equity awards to its newly hired employees, including executives, in accordance with Nasdaq Listing Rule 5635(c)(4) and outside of the Company&#8217;s Plan and Inducement Plan. Such grants were made pursuant to a stand-alone nonstatutory stock option agreement and a stand-alone RSU agreement, which were approved by the Compensation Committee of the Board of Directors. Any shares underlying the inducement grants are not, upon forfeiture, cancellation or expiration, returned to a pool of shares reserved for future issuance. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options to purchase the Company&#8217;s stock are granted at exercise prices based on the Company&#8217;s common stock price on the date of grant. The option grants generally vest over a <span style="-sec-ix-hidden:f-739">one</span>-to <ix:nonNumeric contextRef="c-153" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-740">four-year</ix:nonNumeric> period. The options have a contractual term of <ix:nonNumeric contextRef="c-154" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-741">ten years</ix:nonNumeric>. The fair value of options is estimated using the Black&#8209;Scholes option pricing model, which has various inputs, including the grant date common share price, exercise price, risk&#8209;free interest rate, volatility, expected life and dividend yield. The change of any of these inputs could significantly impact the determination of the fair value of the Company&#8217;s options as well as significantly impact its results of operations. The Company records stock-based compensation expense net of actual forfeitures when they occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant assumptions used in the Black-Scholes option-pricing are as follows:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Volatility.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The expected volatility of common stock is estimated based on the historical volatility of the Company&#8217;s common stock over the most recent period commensurate with the estimated expected term of the stock options.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Term.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The expected term represents the period of time in which the options granted are expected to be outstanding. The Company estimates the expected term of options with consideration of vesting date, contractual term, and historical experience. The expected term of &#8220;plain vanilla&#8221; options is estimated based on the midpoint between the vesting date and the end of the contractual term under the simplified method permitted by the SEC implementation guidance. The weighted&#8209;average expected term of the Company&#8217;s options is approximately <ix:nonNumeric contextRef="c-154" name="eols:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm" format="ixt-sec:durwordsen" id="f-742">six years</ix:nonNumeric>.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Risk&#8209;Free Rate.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The risk&#8209;free interest rate is selected based upon the implied yields in effect at the time of the option grant on U.S. Treasury zero&#8209;coupon issues with a term approximately equal to the expected life of the option being valued.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Dividends.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Company does not anticipate paying cash dividends in the foreseeable future. Consequently, the Company uses an expected dividend yield rate of <ix:nonFraction unitRef="number" contextRef="c-154" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-743">zero</ix:nonFraction>.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-714-3" continuedAt="f-714-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-744" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used in determining the fair value of stock options granted were as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:38.095%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.721%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.721%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt 0 5.5pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-154" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-745">83.7</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-155" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-746">83.6</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-156" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-747">78.9</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-154" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-748">4.1</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-155" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-749">3.7</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-156" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-750">2.1</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-154" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-751">6.21</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-155" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-752">6.21</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-156" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-753">6.19</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-154" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-754">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-155" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-755">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-156" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-756">&#8212;</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-757" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity for the year ended December 31, 2024, 2023, and 2022 is presented below:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:41.224%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.764%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contractual</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intrinsic</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Terms (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-157" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-758">5,753,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-157" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-759">9.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-155" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-760">6.69</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-761">11,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-154" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-762">1,127,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-154" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-763">13.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-154" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-764">537,293</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-154" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-765">7.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-154" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-766">192,937</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-154" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-767">10.56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-158" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-768">6,151,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-158" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-769">10.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-154" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-770">6.16</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-771">10,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-158" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-772">6,151,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-158" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-773">10.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-154" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-774">6.16</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-775">10,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-158" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-776">3,619,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-158" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-777">9.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-154" name="eols:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable" format="ixt-sec:duryear" id="f-778">4.64</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="f-779">7,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share of stock options granted during the years ended December&#160;31, 2024, 2023, and 2022 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-154" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-780">9.71</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-155" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-781">7.73</ix:nonFraction>, and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-156" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-782">4.76</ix:nonFraction>, respectively. The total intrinsic value of stock options that vested during the years ended December&#160;31, 2024, 2023, and 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="eols:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="3" id="f-783">3,171</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="eols:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueVested" scale="3" id="f-784">136</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="eols:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueVested" scale="3" id="f-785">55</ix:nonFraction>, respectively. The aggregate intrinsic value of outstanding and exercisable options represents the excess of the fair market value of the Company&#8217;s common stock over the exercise price of underlying options as of&#160;December&#160;31, 2024, 2023, and 2022.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSU grants generally vest over a <span style="-sec-ix-hidden:f-786">one</span>- to <ix:nonNumeric contextRef="c-160" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-787">four-year</ix:nonNumeric> period. The fair value of RSU grants is determined at the grant date based on the common share price. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="f-788" continuedAt="f-788-1" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU activity for the year ended December 31, 2024, 2023, and 2022, is presented below:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:58.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.721%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-161" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-789">3,281,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-161" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-790">8.88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-162" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-791">1,571,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-162" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-792">13.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-162" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-793">1,131,101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-162" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-794">8.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-162" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-795">342,357</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-162" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-796">9.73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-163" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-797">3,378,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-163" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-798">10.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-714-4" continuedAt="f-714-5"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of restricted stock units that vested during the years ended December&#160;31, 2024, 2023, and 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="3" id="f-799">15,740</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="3" id="f-800">7,593</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="3" id="f-801">6,008</ix:nonFraction>, respectively.</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Restricted Stock Units</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the Company&#8217;s Board of Directors granted <ix:nonFraction unitRef="shares" contextRef="c-166" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-802">292,349</ix:nonFraction> shares of performance restricted stock units (&#8220;PRSUs&#8221;) to certain executive officers under the Plan. The PRSU awards function in the same manner as restricted stock units except that vesting terms are based on achievement of certain pre-established performance measures. </span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2024, the Company&#8217;s Board of Directors granted <ix:nonFraction unitRef="shares" contextRef="c-167" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-803">219,485</ix:nonFraction> shares of PRSUs to certain executive officers under the Plan. The PRSU awards are measured on a cumulative <ix:nonNumeric contextRef="c-167" name="eols:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod" format="ixt-sec:durwordsen" id="f-804">two-year</ix:nonNumeric> period ending in 2025. The performance measure milestones have not been met, and all were outstanding as of December&#160;31, 2024. As of December&#160;31, 2024, the achievement of the performance measure milestones was considered probable.</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2024, the Company&#8217;s Board of Directors granted <ix:nonFraction unitRef="shares" contextRef="c-168" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-805">79,052</ix:nonFraction> shares of PRSUs to an executive officer under the Plan. The PRSU awards are measured on regulatory approval ending in 2027. The performance measure milestones have not been met and all were outstanding as of December&#160;31, 2024. As of December&#160;31, 2024, one of the three achievement of the performance measure milestones was considered probable. </span></div><ix:continuation id="f-788-1"><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of PRSU activity for the year ended December 31, 2024 and 2023, is presented below:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:58.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.721%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Performance</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-169" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-806">233,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-169" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-807">10.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-78" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-808">298,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-78" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-809">12.73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-78" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-810">136,433</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-78" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-811">10.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-78" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="0" id="f-812">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-78" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-813">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-170" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-814">395,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-170" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-815">12.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CEO Performance Award</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For RSUs granted to employees that vest based on market conditions, such as the trading price of the Company&#8217;s common stock exceeding certain price targets, the Company uses a Monte Carlo Simulation in estimating the fair value at grant date and recognizes compensation cost over the requisite service period. On May 8, 2023, the Company granted the Company&#8217;s Chief Executive Officer (&#8220;CEO&#8221;) an award of <ix:nonFraction unitRef="shares" contextRef="c-171" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-816">560,000</ix:nonFraction> PRSUs under the Plan.</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock units subject to the award are subject to both performance- and time-based vesting requirements. <ix:nonFraction unitRef="number" contextRef="c-172" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-817">40</ix:nonFraction>% of the stock units subject to the award are eligible to vest if the average of the closing prices for a share of the Company&#8217;s common stock over a period of <ix:nonFraction unitRef="trading_day" contextRef="c-172" decimals="INF" name="eols:ShareBasedPaymentArrangementNumberOfConsecutiveDays" scale="0" id="f-818">20</ix:nonFraction> consecutive trading days is $<ix:nonFraction unitRef="usdPerShare" contextRef="c-172" decimals="INF" name="eols:ShareBasedCompensationConsecutiveTradingDaysPerShareTarget" scale="0" id="f-819">30</ix:nonFraction> or more and an additional <ix:nonFraction unitRef="number" contextRef="c-173" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-820">60</ix:nonFraction>% of the stock units subject to the award are eligible to vest if the average of the closing prices for a share of the Company&#8217;s common stock over a period of <ix:nonFraction unitRef="trading_day" contextRef="c-173" decimals="INF" name="eols:ShareBasedPaymentArrangementNumberOfConsecutiveDays" scale="0" id="f-821">20</ix:nonFraction> consecutive trading days is $<ix:nonFraction unitRef="usdPerShare" contextRef="c-173" decimals="INF" name="eols:ShareBasedCompensationConsecutiveTradingDaysPerShareTarget" scale="0" id="f-822">50</ix:nonFraction> or more, in each case within <ix:nonNumeric contextRef="c-171" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:durwordsen" id="f-823">five years</ix:nonNumeric> after the grant of the award and while the CEO is employed by the Company (or, in certain circumstances, within <ix:nonNumeric contextRef="c-171" name="eols:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsAfterTermination" format="ixt-sec:durday" id="f-824">20</ix:nonNumeric> days following a termination of his employment). Any stock units that become eligible to vest based on stock price will vest, subject to the CEO&#8217;s continued service, over the <ix:nonNumeric contextRef="c-171" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-825">four-year</ix:nonNumeric> period after the grant date.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used a Monte Carlo simulation to determine that the grant date fair value of the awards was $<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-826">3,774</ix:nonFraction>. Compensation expense is recorded if the service condition is met regardless of whether the market condition is satisfied.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-714-5"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-827" escape="true"><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock-based compensation expense:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.875%"><tr><td style="width:1.0%"/><td style="width:36.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.330%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.330%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.331%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-828">21,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-829">15,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-830">10,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-831">1,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-832">894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-833">268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-834">22,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-835">16,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-836">10,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the amounts recorded in selling, general and administrative and research and development, the Company capitalized $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="3" id="f-837">66</ix:nonFraction> of stock-based compensation expense as part of capitalized software during the year ended December 31, 2024. As of December&#160;31, 2024, unrecognized compensation cost totaled $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="3" id="f-838">47,092</ix:nonFraction> and will be recognized over a weighted-average period of <ix:nonNumeric contextRef="c-1" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-839">2.2</ix:nonNumeric> years.</span></div></ix:continuation><div id="id181047532df422ab5a549dd869deccb_124"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11.<ix:continuation id="f-690-4" continuedAt="f-690-5"> Medytox Settlement Agreements</ix:continuation></span></div><ix:continuation id="f-690-5" continuedAt="f-690-6"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">U.S. Settlement Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 18, 2021, the Company, Allergan and Medytox entered into a Settlement and License Agreement (the &#8220;U.S. Settlement Agreement&#8221;), pursuant to which, among other things: (i) Allergan and Medytox agreed to file a petition requesting the remedial orders related to the ITC Action be rescinded with respect to the Company; (ii) Medytox agreed to dismiss substantially similar litigation in California against the Company; (iii) the Company, on the one hand, and Medytox and Allergan, on the other hand, agreed to mutually release certain claims they may have against one another and their respective affiliates; (iv) Allergan and Medytox granted to the Company and its agents a license to manufacture and commercialize certain products identified in the U.S. Settlement Agreement, including Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;Licensed Products&#8221;), in the United States during the <ix:nonNumeric contextRef="c-180" name="eols:LossContingencySettlementAgreementManufacturingLicensePeriod" format="ixt-sec:durmonth" id="f-840">21</ix:nonNumeric> month period that, pursuant to the ITC Action, the Company was restricted from, among other things, selling, marketing, or promoting such imported Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States (the &#8220;Restricted Period&#8221;); (v) the Company agreed to pay to Allergan and Medytox $<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-3" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-841">35,000</ix:nonFraction> in multiple payments over <ix:nonNumeric contextRef="c-182" name="eols:LossContingencySettlementAgreementPaymentTerms" format="ixt-sec:durwordsen" id="f-842">two years</ix:nonNumeric>, of which the Company paid the first cash payment of $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="3" id="f-843">15,000</ix:nonFraction> in the third quarter of 2021, the second cash payment of $<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="3" id="f-844">15,000</ix:nonFraction> in the first quarter of 2022, and the final cash payment of $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="3" id="f-845">5,000</ix:nonFraction> in the first quarter of 2023; and (vi) during the Restricted Period, the Company agreed to pay to Allergan and Medytox certain confidential royalties on the sale of Licensed Products, calculated on dollar amount per vial sold of Licensed Products by or on behalf of the Company in the United States. Royalties for sales during the Restricted Period ended on September 16, 2022.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ROW Settlement Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 18, 2021, the Company and Medytox entered into a Settlement and License Agreement (the &#8220;ROW Settlement Agreement&#8221; and, together with the U.S. Settlement Agreement, the &#8220;Medytox/Allergan Settlement Agreements&#8221;), pursuant to which, among other things: (i) the Company and Medytox agreed to mutually release certain claims they may have against one another and their respective affiliates; (ii) Medytox granted to the Company and its agents a license to manufacture and commercialize the Licensed Products, in Canada, the European Union, Switzerland, member countries and cooperating countries of the European Economic Area, certain members of the Commonwealth of Independent States, South Africa, Australia and Japan (the &#8220;ROW Territories&#8221;) during the Restricted Period; (iii) Medytox granted to the Company and its agents a fully paid up license to manufacture and commercialize the Licensed Products in the ROW Territories and the United States from the end of the Restricted Period (the &#8220;Medytox License Period&#8221;); (iv) the Company and Medytox agreed to enter into the Share Issuance Agreement (as defined below) pursuant to which the Company issued <ix:nonFraction unitRef="shares" contextRef="c-183" decimals="INF" name="eols:StockIssuedDuringPeriodSharesLitigationSettlement" format="ixt:num-dot-decimal" scale="0" id="f-846">6,762,652</ix:nonFraction> shares (the &#8220;Settlement Shares&#8221;) of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-181" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-847">0.00001</ix:nonFraction> per share, to Medytox; (v) the Company and Medytox agreed to enter into the Registration Rights Agreement (as defined below), pursuant to which the Company granted certain registration rights to Medytox with respect to the Settlement Shares; (vi) during the Restricted Period that ended September 16, 2022, the Company agreed to pay Medytox a confidential low-double digit royalty on net sales of the Licensed Products sold by or on behalf of the Company in the ROW Territories; and (vii) during the Medytox License Period from September 17, 2022 to September 16, 2032, the Company agreed to pay Medytox a mid-single digit royalty percentage on net sales of the Licensed Products sold by or on behalf of the Company in the United States and the ROW Territories.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Share Issuance Agreement</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-690-6" continuedAt="f-690-7"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the ROW Settlement Agreement, the Company and Medytox entered into a Share Issuance Agreement effective February 18, 2021 (the &#8220;Share Issuance Agreement&#8221;). Pursuant to the Share Issuance Agreement and subject to the terms and conditions set forth therein, among other things, the Company issued to Medytox the Settlement Shares to enter into the ROW Settlement Agreement and in consideration for Medytox&#8217;s representations, warranties, and other agreements set forth in the Share Issuance Agreement. The Settlement Shares are subject to contractual restrictions on transfer that, subject to certain limited exceptions such as transfers to affiliates, prevented Medytox from transferring any shares of common stock prior to February 16, 2022 or more than <ix:nonFraction unitRef="number" contextRef="c-184" decimals="2" name="eols:ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodOne" scale="-2" id="f-848">25</ix:nonFraction>% of the shares it held prior to September 16, 2023 and, thereafter, prohibit Medytox from transferring more than <ix:nonFraction unitRef="number" contextRef="c-184" decimals="2" name="eols:ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodTwo" scale="-2" id="f-849">50</ix:nonFraction>% of the shares it holds prior to September 16, 2024 and more than <ix:nonFraction unitRef="number" contextRef="c-184" decimals="2" name="eols:ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodThree" scale="-2" id="f-850">75</ix:nonFraction>% of the shares it holds prior to September 16, 2025, with such contractual restrictions terminating on September 16, 2025.</span></div></ix:continuation><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-690-7">As of December&#160;31, 2024 and 2023, the Company accrued $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-851">4,743</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-852">3,657</ix:nonFraction> for royalties under the Medytox Settlement Agreements.</ix:continuation> </span></div><div id="id181047532df422ab5a549dd869deccb_127"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12. <ix:nonNumeric contextRef="c-1" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="f-853" continuedAt="f-853-1" escape="true">Employee Benefit Plan</ix:nonNumeric></span></div><ix:continuation id="f-853-1"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a defined contribution&#160;401(k) plan covering substantially all employees. Matching contributions totaled $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="3" id="f-854">2,023</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="3" id="f-855">1,582</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" scale="3" id="f-856">773</ix:nonFraction>&#160;for the years ended December 31, 2024, 2023, and 2022, respectively.</span></div></ix:continuation><div id="id181047532df422ab5a549dd869deccb_130"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13.&#160;&#160;&#160;&#160; <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-857" continuedAt="f-857-1" escape="true">Income Taxes </ix:nonNumeric></span></div><ix:continuation id="f-857-1" continuedAt="f-857-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="f-858" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s loss before income taxes was generated from its U.S. operations and foreign operations as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.096%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.096%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.098%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-859">33,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-860">51,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-861">66,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-862">16,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-863">10,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-864">8,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-865">49,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-866">61,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-867">74,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-868" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the expense (benefit) for income taxes:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.694%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provision:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-869">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-870">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-871">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-872">279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-873">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-874">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-875">406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-876">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-877">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current provision</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-878">685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-879">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-880">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred provision (benefit):</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="f-881">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="f-882">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="f-883">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="f-884">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="f-885">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="f-886">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-887">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-888">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-889">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred (benefit) provision</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="f-890">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="f-891">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="f-892">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-893">664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-894">176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-895">95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company has federal net operating loss (&#8220;NOL&#8221;) carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-896">315,179</ix:nonFraction>, of which $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="3" id="f-897">68,301</ix:nonFraction> will begin to expire in 2034. The federal NOLs generated in 2018 and in the subsequent years in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" format="ixt:num-dot-decimal" scale="3" id="f-898">246,877</ix:nonFraction> have an indefinite carryforward period. As of December&#160;31, 2024,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company has state NOL carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-899">231,980</ix:nonFraction>, which will begin to expire in 2024. As of December&#160;31, 2024, the Company has foreign NOL carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-900">38,922</ix:nonFraction>, which can be carried forward indefinitely. As of December&#160;31, 2024, the Company has federal research and development </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-857-2" continuedAt="f-857-3"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;R&amp;D&#8221;) credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="3" id="f-901">2,929</ix:nonFraction>, which will begin to expire in 2034. The Company also has California R&amp;D credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="3" id="f-902">2,918</ix:nonFraction>, which has an indefinite carryforward period. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, if a company experiences a greater than 50 percentage point aggregate change in ownership of certain significant stockholders over a three-year period, utilization of its pre-change NOL carryforwards and R&amp;D credit carryforwards, and interest expense under section 163(j), is subject to an annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and similar state laws. The annual limitation may result in the expiration of the Company&#8217;s tax attribute carryforwards before utilization and may be material. The Company has completed a study to evaluate whether an ownership change, as defined by Section 382 of the Internal Revenue Code, occurred from the Company's formation through December 31, 2023. Based on the findings of this study, the Company has determined that several ownership changes have occurred. Consequently, the Company&#8217;s tax attribute carryforwards allocable to the periods preceding the ownership change are subject to limitation under Section 382. However, it is important to note that the Company&#8217;s tax attribute carryforwards, which include net operating losses (NOLs), research and development (R&amp;D) credits, and interest expense under Section 163(j), are not anticipated to expire unused, solely due to the limitations under Section 382. The Company started but has not completed a study to determine whether its tax attribute carryforwards generated through December 31, 2024, are likely to be limited by Section 382 and 383. The Company&#8217;s net deferred income tax assets have been offset by a valuation allowance. Therefore, any resulting reduction to the Company&#8217;s tax attribute carryforwards once the analysis is completed will be offset by a corresponding reduction of the valuation allowance and there would be no impact on the Company&#8217;s consolidated balance sheet, statement of operations, or cash flows.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-903" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of deferred tax assets and liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.334%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.694%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-904">86,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-905">83,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-906">80,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-907">7,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-908">5,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-909">5,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-910">2,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-911">2,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-912">2,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" format="ixt:num-dot-decimal" scale="3" id="f-913">6,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" format="ixt:num-dot-decimal" scale="3" id="f-914">5,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" format="ixt:num-dot-decimal" scale="3" id="f-915">4,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="eols:DeferredTaxAssetsOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-916">2,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="eols:DeferredTaxAssetsOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-917">1,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="eols:DeferredTaxAssetsOperatingLeaseLiabilities" scale="3" id="f-918">646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" format="ixt:num-dot-decimal" scale="3" id="f-919">16,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" format="ixt:num-dot-decimal" scale="3" id="f-920">17,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" format="ixt:num-dot-decimal" scale="3" id="f-921">19,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;E capitalization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="eols:DeferredTaxAssetsResearchAndExperimentationCapitalization" format="ixt:num-dot-decimal" scale="3" id="f-922">4,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="eols:DeferredTaxAssetsResearchAndExperimentationCapitalization" format="ixt:num-dot-decimal" scale="3" id="f-923">3,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="eols:DeferredTaxAssetsResearchAndExperimentationCapitalization" format="ixt:num-dot-decimal" scale="3" id="f-924">1,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed asset depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="eols:DeferredTaxAssetsFixedAssetDepreciation" scale="3" id="f-925">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="eols:DeferredTaxAssetsFixedAssetDepreciation" scale="3" id="f-926">183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="eols:DeferredTaxAssetsFixedAssetDepreciation" format="ixt:fixed-zero" scale="3" id="f-927">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-928">8,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-929">5,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-930">2,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-931">124,895</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-932">116,073</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-933">103,695</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-934">9,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-935">9,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-936">12,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-937">7,343</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-938">7,730</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-939">11,525</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-940">1,825</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-941">1,460</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="f-942">495</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed asset depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-943">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-944">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="f-945">345</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-946">9,168</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-947">9,190</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-948">12,365</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilities" scale="3" id="f-949">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilities" scale="3" id="f-950">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:DeferredTaxLiabilities" scale="3" id="f-951">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-857-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-952" escape="true"><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the difference between the provision (benefit) for income taxes and income taxes at the statutory U.S. federal income tax rate is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.334%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.694%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax at statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-953">10,413</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-954">12,917</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-955">15,607</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="f-956">753</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-957">1,981</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-958">2,673</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation of contingent royalty obligation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="eols:EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation" format="ixt:num-dot-decimal" scale="3" id="f-959">1,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="eols:EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation" format="ixt:num-dot-decimal" scale="3" id="f-960">1,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="eols:EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation" format="ixt:num-dot-decimal" scale="3" id="f-961">1,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Meals and entertainment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" scale="3" id="f-962">713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" scale="3" id="f-963">385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" scale="3" id="f-964">358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in state tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" id="f-965">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" id="f-966">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" id="f-967">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers' compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="eols:EffectiveIncomeTaxRateReconciliationOfficersCompensation" format="ixt:num-dot-decimal" scale="3" id="f-968">1,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="eols:EffectiveIncomeTaxRateReconciliationOfficersCompensation" scale="3" id="f-969">793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="eols:EffectiveIncomeTaxRateReconciliationOfficersCompensation" format="ixt:num-dot-decimal" scale="3" id="f-970">1,529</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Rate Differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="f-971">443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="f-972">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="f-973">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-974">1,377</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="f-975">449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="f-976">299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxContingenciesOther" scale="3" id="f-977">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationTaxContingenciesOther" scale="3" id="f-978">449</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationTaxContingenciesOther" scale="3" id="f-979">391</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-980">8,822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-981">12,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-982">18,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-983">664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-984">176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-985">95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="f-986" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.401%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.401%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-987">2,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-988">2,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-989">2,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-990">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-991">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-992">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to current year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-993">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-994">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-995">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-996">2,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-997">2,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-998">2,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has considered the amounts and probabilities of the outcomes that can be realized upon ultimate settlement with the tax authorities and determined unrecognized tax benefits primarily related to credits should be established as noted in the summary rollforward above. The Company&#8217;s effective income tax rate would not be impacted if the unrecognized tax benefits are recognized. Additional amounts in the summary rollforward could impact the Company&#8217;s effective tax rate if it did not maintain a full valuation allowance on its net deferred tax assets. The Company does not expect its unrecognized tax benefits to change significantly over the next 12&#160;months.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy is to recognize interest expense and penalties related to income tax matters as a component of income tax expense. There were <ix:nonFraction unitRef="usd" contextRef="c-26" decimals="INF" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="f-999"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="INF" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="f-1000"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="INF" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="f-1001">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> accrued interest and penalties associated with uncertain tax positions as of December&#160;31, 2024, 2023, and 2022. The Company&#8217;s tax returns for all years since inception are open for audit. The Internal Revenue Service (&#8220;IRS&#8221;) commenced an examination of our U.S. income tax returns for the tax year ended December&#160;31, 2022, in the third quarter of 2024. The exam is still in progress. As of December&#160;31, 2024, the IRS has not proposed any adjustments to our tax positions.</span></div></ix:continuation><div style="margin-bottom:9pt;padding-right:9pt"><span><br/></span></div><div id="id181047532df422ab5a549dd869deccb_549755815376"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 14. <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-1002" continuedAt="f-1002-1" escape="true">Segment Reporting</ix:nonNumeric></span></div><ix:continuation id="f-1002-1" continuedAt="f-1002-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducts business as a single operating segment, which is the business of performance beauty focused on delivering products in the cash-pay aesthetic market. The Company&#8217;s chief executive officer, who is the chief operating decision maker (&#8220;CODM&#8221;), reviews financial information on a consolidated basis for allocating and evaluating financial performance. The single operating segment is further based upon the Company&#8217;s organizational and management structure and other factors.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key measure of segment profit and loss that the CODM uses to allocate resources and assess performance is the Company&#8217;s net loss, which is utilized to evaluate the achievement of the Company&#8217;s business operations. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-1003" continuedAt="f-1003-1" escape="true">The table below </ix:nonNumeric></span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolus, Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div></div><ix:continuation id="f-1002-2"><ix:continuation id="f-1003-1"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shows the Company&#8217;s reconciliation of revenue and significant segment items to net loss, regularly provided to and reviewed by the CODM, as computed under U.S. GAAP:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.042%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt 0 5.5pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1004">266,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1005">202,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1006">148,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product cost of goods sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-1007">81,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-1008">61,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-1009">55,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of distribution right</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1010">2,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1011">2,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1012">2,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1013">176,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1014">149,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1015">131,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-1016">8,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-1017">5,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-1018">4,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In process research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="eols:ResearchAndDevelopmentInProcess1" format="ixt:fixed-zero" scale="3" id="f-1019">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="eols:ResearchAndDevelopmentInProcess1" format="ixt:num-dot-decimal" scale="3" id="f-1020">8,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="eols:ResearchAndDevelopmentInProcess1" format="ixt:num-dot-decimal" scale="3" id="f-1021">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation of contingent royalty obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="f-1022">7,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="f-1023">4,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="f-1024">5,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1025">22,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1026">16,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1027">10,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1028">2,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1029">2,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-1030">767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="3" id="f-1031">3,263</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="f-1032">860</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="f-1033">119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-1034">18,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-1035">13,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-1036">9,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-1037">127</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-1038">696</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-1039">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-1040">664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-1041">176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-1042">95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1043">50,420</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1044">61,685</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1045">74,412</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:continuation><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets provided to the CODM are consistent with those reported on the Balance Sheets with particular emphasis on the Company&#8217;s available liquidity, including its cash and cash equivalents, and financial instruments owned, reduced by current liabilities. All long-lived assets are maintained in the United States of America.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="f-1046" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The product and service revenue attributed to foreign countries from which the Company derives product and service revenue is as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.042%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue by country, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1047">253,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1048">195,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1049">146,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1050">13,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1051">6,661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1052">2,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue by country, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1053">266,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1054">202,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1055">148,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="id181047532df422ab5a549dd869deccb_549755815446"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 15.  <ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-1057" continuedAt="f-1057-1" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="f-1057-1"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 13, 2025, the Company received FDA approval for Evolysse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Form and Evolysse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Smooth injectable hyaluronic acid gels for the treatment and improvement of moderate to severe nasolabial folds facial wrinkles.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><div id="id181047532df422ab5a549dd869deccb_133"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. &#160;&#160;&#160;&#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><div id="id181047532df422ab5a549dd869deccb_136"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. Controls and Procedures.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer, our principal executive and principal financial officers, respectively, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act of 1934, as amended, as of the end of the period covered by this Annual Report on Form 10-K. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of December&#160;31, 2024, our disclosure controls and procedures were effective (a)&#160;to ensure that information that we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and (b)&#160;to include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Exchange Act. Under the supervision and with the participation of senior management, including our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of our internal control over financial reporting based on the framework in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based on the evaluation under that framework and applicable SEC rules, our management concluded that our internal control over financial reporting was effective as of December&#160;31, 2024.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s independent registered public accounting firm, Ernst&#160;&amp; Young LLP, has issued an attestation report on the effectiveness of our internal control over financial reporting as of December&#160;31, 2024, which is included in this Item 9A under the caption "Report of Independent Registered Public Accounting Firm."</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended December&#160;31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inherent Limitations of Internal Controls</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well&#160;designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management overriding of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Evolus, Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Evolus, Inc.&#8217;s internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Evolus, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on the COSO criteria.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity (deficit) and cash flows for each of the three years in the period ended December 31, 2024, and the related notes and our report dated March 4, 2025 expressed an unqualified opinion thereon.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Irvine, California</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;4, 2025</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div id="id181047532df422ab5a549dd869deccb_139"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B.  Other Information.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insider Trading Arrangements</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-199" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1058"><ix:nonNumeric contextRef="c-199" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1059"><ix:nonNumeric contextRef="c-199" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1060"><ix:nonNumeric contextRef="c-199" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1061">None.</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></div><div id="id181047532df422ab5a549dd869deccb_142"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C.  Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:10pt"><span><br/></span></div><div id="id181047532df422ab5a549dd869deccb_145"></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part III</span></div><div id="id181047532df422ab5a549dd869deccb_148"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10.  Directors, Executive Officers and Corporate Governance.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as disclosed below with respect to our Code of Conduct, the information required by this item is incorporated herein by reference to information contained in the Proxy Statement for our 2025 Annual Meeting of Stockholders.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a Code of Conduct applicable to all directors, officers and employees of the Company. We have posted the Code of Business Conduct on our website at www.evolus.com. We will post any amendments to the Code of Conduct on our website. In accordance with the requirements of the SEC and Nasdaq, we will also post waivers applicable to any of our officers or directors from provisions of the Code of Conduct on our website.</span></div><div id="id181047532df422ab5a549dd869deccb_151"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11.  Executive Compensation.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated herein by reference to information contained in the Proxy Statement for our 2025 Annual Meeting of Stockholders.</span></div><div id="id181047532df422ab5a549dd869deccb_154"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated herein by reference to information contained in the Proxy Statement for our 2025 Annual Meeting of Stockholders.</span></div><div id="id181047532df422ab5a549dd869deccb_157"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13.  Certain Relationships and Related Transactions, and Director Independence.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated herein by reference to information contained in the Proxy Statement for our 2025 Annual Meeting of Stockholders.</span></div><div id="id181047532df422ab5a549dd869deccb_160"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14.  Principal Accounting Fees and Services.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated herein by reference to information contained in the Proxy Statement for our 2025 Annual Meeting of Stockholders.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><div id="id181047532df422ab5a549dd869deccb_163"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part IV</span></div><div id="id181047532df422ab5a549dd869deccb_166"></div><div style="-sec-extract:summary;margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15.  Exhibits, Financial Statement Schedules. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The following documents are filed as part of this Annual Report on Form 10-K:</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1) Financial Statements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> See Item 8 &#8220;Consolidated Financial Statements and Supplementary Data&#8221; elsewhere in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2) Financial Statement Schedules. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. Financial statement schedules have been omitted because they are not applicable or the information called for is shown either in the consolidated financial statements or in the notes thereto.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3) Exhibits.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The following exhibits are filed (or incorporated by reference herein) as part of this Annual Report on Form&#160;10-K:</span></div><div style="margin-bottom:10pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:45.408%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.992%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.746%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.883%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.228%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">File No.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filing Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filed Herewith<br/>(x)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000162828018001474/exhibit318-k21218.htm">Amended and Restated Certificate of Incorporation.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/12/18</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000157056223000079/evolus0certificateofamendm.htm">Certificate of Amendment to Amended and Restated Certificate of Incorporation, dated June 12, 2023</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/14/23</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000162828018001474/exhibit328-k21218.htm">Amended and Restated Bylaws.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/12/18</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000162828018000572/exhibit41s-1a1.htm">Specimen certificate evidencing shares of common stock of the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-222478</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/25/18</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000157056224000041/exhibit4312312310k.htm">Description of Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/7/24</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#8225;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000157056224000041/ex-101evolus.htm">Stock Purchase Agreement, dated as of September 30, 2014, by and between Strathspey Crown Holdings, LLC and ALPHAEON Corporation.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/7/24</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#8225;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000157056224000041/ex-102evolusinc.htm">Amendment to Stock Purchase Agreement, dated as of September 30, 2014, by and between Strathspey Crown Holdings, LLC and ALPHAEON Corporation.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/7/24</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#8225;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000157056223000038/exhibit103.htm">License and Supply Agreement, dated as of September 30, 2013, by and between Daewoong Pharmaceutical Co., Ltd. and the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/23</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#8225;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000157056224000041/ex-104evolusinc.htm">First Amendment to License and Supply Agreement, dated as of February 26, 2014, by and between Daewoong Pharmaceutical Co., Ltd. and the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/7/24</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#8225;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000157056224000041/ex-105evolusinc.htm">Second Amendment to License and Supply Agreement, dated as of July 15, 2014, by and between Daewoong Pharmaceutical Co., Ltd. and the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/7/24</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit106s-1.htm">2017 Omnibus Incentive Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-222478</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/9/18</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit107s-1.htm">Form of Option Award Agreement under 2017 Omnibus Incentive Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-222478</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/9/18</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit108s-1.htm">Form of Dueling Option Award Agreement under 2017 Omnibus Incentive Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-222478</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/9/18</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit109s-1.htm">Form of Restricted Shares Award Agreement under 2017 Omnibus Incentive Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-222478</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/9/18</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1010s-1.htm">Form of RSU Award Agreement under 2017 Omnibus Incentive Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-222478</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/9/18</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11+ </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000157056220000061/exhibit101112311910k.htm">Form of RSU Award Agreement under 2017 Omnibus Incentive Plan (Updated 2020)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/25/20</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000157056222000074/evolus-formofstandxalone_o.htm">Form of Inducement Stock Option Award Agreement</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-263325</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/4/22</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000157056222000074/evolus-formofstandxalone_r.htm">Form of Inducement Restricted Stock Unit Award Agreement</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-263325</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/4/22</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary;margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:45.408%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.992%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.746%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.883%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.228%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000157056223000038/exhibit1014.htm">Form of Performance Restricted Stock Unit Agreement</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/23</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000157056223000109/a2023inducementincentivepl.htm">2023 Inducement Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-274906</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/6/23</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000162828018000572/exhibit1011s-1a.htm">Form of Indemnification Agreement by and between the Registrant and its directors and officers.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1/A</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-222478</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/25/18</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17&#8225;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1017.htm">Second Amendment to Stock Purchase Agreement, dated as of December 14, 2017, by and among SCH-AEON, LLC (f/k/a Strathspey Crown Holdings, LLC), ALPHAEON Corporation, the Registrant and J. Christopher Marmo, as Contributors&#8217; Representative, and acknowledged by the parties listed as Contributors on the signature pages thereto.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000157056218000078/exhibit1029s-1.htm">Employment Agreement, dated as of May 6, 2018, by and between David Moatazedi and the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-226186</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/16/18</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000157056222000119/dmoatazediemploymentagreem.htm">Amendment to Employment Agreement, dated August 1, 2022, by and between Evolus, Inc. and David Moatazedi</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/2/22</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000157056222000119/ravelararemploymentagreeme.htm">Amended and Restated Employment Agreement, dated August 1, 2022, by and between Evolus, Inc. and Rui Avelar, M.D.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/2/22</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000157056222000143/sandrabeaveremploymentagre.htm">Employment Agreement, dated September 5, 2022, by and between Sandra Beaver and the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/8/22</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000157056219000085/ticlease.htm">Lease, dated as of May 15, 2019, between the Registrant and 520 Newport Center Drive LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/21/19</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.23&#8225;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000157056221000141/a3312110qex103.htm">Settlement and License Agreement, dated February 18, 2021, by and between Evolus, Inc. and Medytox, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/12/21</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000157056221000141/a3312110qex104.htm">Share Issuance Agreement, dated February 18, 2021, by and between Evolus Inc. and Medytox, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/12/21</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.25&#8225;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000157056221000141/a3312110qex105.htm">Confidential Settlement and Release Agreement, dated March 23, 2021, by and between Evolus, Inc. and Daewoong Pharmaceutical Co. Ltd.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/12/21</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.26&#8225;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000157056221000141/a3312110qex107.htm">Third Amendment to Supply Agreement, dated March 23, 2021, by and between Evolus, Inc. and Daewoong Pharmaceutical Co. Ltd.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/12/21</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27&#8225;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000157056221000177/ex101121421.htm">Loan Agreement, dated as of December 14, 2021, by and among Evolus, Inc. (as Borrower and a Credit Party), BioPharma Credit PLC (as Collateral Agent), BPCR Limited Partnership (as a Lender), and BioPharma Credit Investments V (Master) LP (as a Lender).</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/14/21</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000157056222000119/a6302210qex102.htm">First Amendment to Loan Agreement, dated April 5, 2022, by and among Evolus, Inc. (as Borrower and a Credit Party), BioPharma Credit PLC (as Collateral Agent), BPCR Limited Partnership (as a Lender), and BioPharma Credit Investments V (Master) LP (as a Lender).</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/2/22</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000157056222000146/a128228kex101.htm">Second Amendment to Loan Agreement, dated as of December 5, 2022, by and among Evolus, Inc. (as Borrower and a Credit Party), BioPharma Credit PLC (as Collateral Agent), BPCR Limited Partnership (as a Lender), and BioPharma Credit Investments V (Master) LP (as a Lender).</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/8/22</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30&#8225;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000157056222000149/a1212228kex101.htm">Fourth Amendment to Supply Agreement, dated December 12, 2022, by and between Evolus, Inc. and Daewoong Pharmaceutical Co. Ltd.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/13/22</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31&#8225;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000157056223000088/exhibit101q22023.htm">Fifth Amendment to Supply Agreement, dated as of April 20, 2023, by and between Daewoong Pharmaceutical Co. Ltd. and Evolus, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/2/23</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32&#8225;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000157056223000088/exhibit102q22023.htm">License, Supply, and Distribution Agreement, dated as of May 9, 2023 by and between Symatese S.A.S. and the Registrant</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/2/23</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary;margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:45.408%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.992%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.746%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.883%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.228%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.33</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000157056223000088/exhibit103q22023.htm">Third Amendment to Loan Agreement, dated as of May 9, 2023, by and among Evolus, Inc. (as Borrower and a Credit Party), BioPharma Credit PLC (as Collateral Agent), BPCR Limited Partnership (as a Lender), and BioPharma Credit Investments V (Master) LP (as a Lender).</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/2/23</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.34+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000157056223000115/a93023ex102-tomokoemployme.htm">Employment Agreement, dated August 21, 2023, by and between Tomoko Yamagishi-Dressler and the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/7/23</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.35&#8225;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000157056224000041/ex1035.htm">License, Supply, and Distribution Agreement (Europe), dated as of December 20, 2024, by and between Evolus Pharma B.V. and Symatese Aesthetics S.A.S</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.35</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/7/24</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.36</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000157056224000041/ex1036.htm">First Amendment to Lease, dated as of July 27, 2023, by and between the Registrant and 520 Newport Center Drive LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.36</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/7/24</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.37&#8225;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1570562/000157056224000080/eols-20240331.htm">Sixth Amendment to Supply Agreement, dated as of February 22, 2024, by and between Daewoong Pharmaceutical Co. Ltd. and Evolus, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/7/24</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.38</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1038.htm">S</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1038.htm">econd Amendment to Lease, dated as of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1038.htm">October 16, 2024</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1038.htm">, by and between t</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1038.htm">h</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1038.htm">e</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1038.htm"> Registrant and 520 Newport Center Drive LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000157056224000098/eols2024espp.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000157056224000098/eols2024espp.htm">024 Employee Stock Purchase Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/11/24</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex19.htm"><ix:nonNumeric contextRef="c-1" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true" id="f-1062">Insider Trading Policy</ix:nonNumeric></a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit21112312410k.htm">List of Subsidiaries.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit23112312410k.htm">Consent of independent registered public accounting firm.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_172">Power of Attorney (included on signature page).</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit31112312410k.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit31212312410k.htm">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit32112312410k.htm">Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1570562/000157056224000041/ex97recoupmentpolicy.htm">Policy Regarding the Recoupment of Certain Compensation Payments</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-38381</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/7/24</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.311%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.389%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicates management contract or compensatory plan.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8225;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portions of this exhibit have been omitted pursuant to Item 601(b)(10) of Regulation S-K.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The information in Exhibit 32.1 shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act (including this Annual Report on Form 10-K), unless the Registrant specifically incorporates the foregoing information into those documents by reference.</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><div id="id181047532df422ab5a549dd869deccb_169"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. Form 10-K Summary.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><div id="id181047532df422ab5a549dd869deccb_172"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on March&#160;4, 2025.</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.005%"><tr><td style="width:1.0%"/><td style="width:8.934%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.866%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EVOLUS, INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ David Moatazedi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">David Moatazedi</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</span></td></tr></table></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The undersigned directors and officers of Evolus, Inc. constitute and appoint David Moatazedi and Sandra Beaver, and each of them, as their true and lawful attorneys and agents with power of substitution, to do any and all acts and things in our name and behalf in our capacities as directors and officers and to execute any and all instruments for us and in our names in the capacities indicated below, which said attorneys and agents may deem necessary or advisable to enable said corporation to comply with the Securities Exchange Act of 1934, as amended, and any rules, regulations and requirements of the Securities and Exchange Commission, in connection with this Annual Report on Form&#160;10-K, including specifically but without limitation, power and authority to sign for us or any of us in our names in the capacities indicated below, any and all amendments hereto; and we do hereby ratify and confirm all that said attorneys and agents shall do or cause to be done by virtue hereof.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:28.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.037%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.318%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Signature</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ David Moatazedi</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member of the Board of Directors</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 4, 2025</span></td></tr><tr style="height:21pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">David Moatazedi</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Sandra Beaver</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer<br/>(Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 4, 2025</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sandra Beaver</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Vikram Malik</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 4, 2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vikram Malik</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Simone Blank</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 4, 2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Simone Blank</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David Gill</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 4, 2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Gill</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Karah Parschauer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 4, 2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Karah Parschauer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Brady Stewart</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 4, 2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brady Stewart</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#id181047532df422ab5a549dd869deccb_7">Table of Contents</a></span></div></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:28.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.037%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.318%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Signature</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Albert G. White III</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 4, 2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Albert G. White III</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>2
<FILENAME>exhibit1017.htm
<DESCRIPTION>EX-10.17
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i258a7927b61f440783ac5b1c8fda6017_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH &#8220;&#91;***&#93;&#8221;.</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Second Amendment to Stock Purchase Agreement</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Second Amendment to Stock Purchase Agreement  (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is made and entered into as of December 14, 2017 among SCH-AEON, LLC (f&#47;k&#47;a STRATHSPEY CROWN HOLDINGS,  LLC), a Delaware limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Seller</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), ALPHAEON CORPORATION, a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Purchaser</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), Evolus, Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Evolus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and J Christopher Marmo, in his capacity as Contributors&#8217; Representative (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contributors&#8217; Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), with the acknowledgment and consent of the parties listed as &#8220;Contributors&#8221; on the signature pages hereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contributors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RECITALS</font></div><div style="margin-bottom:12pt;padding-right:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:119%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%;padding-left:24.34pt">WHEREAS, pursuant to the Contribution Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:119%">Contribution Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">&#8221;) by and among Seller, the Contributors, and the Contributors&#8217; Representative, the Contributors contributed to Seller 10,000,000 shares of common stock and 1,250,000 shares of series A preferred stock of Evolus, representing one hundred percent (100%) of the outstanding capital stock of Evolus, of which (i) 125,000 shares of the series A preferred stock of Evolus and 1,000,000 shares of common stock of Evolus (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:119%">Class D Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">&#8221;) were contributed in exchange for Class D Units of Seller (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:119%">Class D Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">&#8221;) and (ii) the remaining shares were contributed in exchange for Class AA Units of Seller.</font></div><div style="margin-bottom:12pt;padding-right:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:119%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%;padding-left:25pt">WHEREAS, pursuant to the Contribution Agreement, the Contributors were given the right to require that Seller sell all of the Class D Shares to Alphaeon, and the Contributors subsequently exercised such right.</font></div><div style="margin-bottom:12pt;padding-right:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:119%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%;padding-left:24.34pt">WHEREAS, Seller and Purchaser entered into that certain Stock Purchase Agreement, dated as of September 30, 2014, as amended by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:119%">that certain Amendment to Stock Purchase Agreement (undated)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%"> (so amended, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:119%">Original Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">&#8221;), of which the Contributors are express third party beneficiaries, pursuant to which and subject to the terms and conditions of which, Seller sold to Purchaser, and Purchaser purchased from Seller, all of the Class D Shares of Evolus, in exchange for the consideration including the payments specified in Sections 2(a) and 2(b) thereof (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:119%">Contingent Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">&#8221;)&#59;</font></div><div style="margin-bottom:12pt;padding-right:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:119%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%;padding-left:24.34pt">WHEREAS, pursuant to the terms of that certain Second Amended and Restated Limited Liability Company Agreement of Seller, dated August 15, 2013, as amended by that certain Amendment No. 1 dated October 3, 2013, the Contributors, through their ownership of the Class D Units, are entitled, subject to certain conditions, to the distribution of all cash received by Seller directly attributable to the Class D Shares, including dividends on the Class D Shares, sales of the Class D Shares and redemptions of the Class D Shares and, accordingly, are entitled, subject to such conditions, to the distribution of all proceeds that may be received by Seller on account of its sale of the Class D Shares pursuant to the Original Agreement, including the Contingent Payments&#59;</font></div><div style="margin-bottom:12pt;padding-right:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:119%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%;padding-left:25pt">WHEREAS, the Original Agreement may be amended by written instrument signed by Purchaser, Seller and Contributors&#8217; Representative on behalf of the Contributors&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-right:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:119%">F.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%;padding-left:25.67pt">WHEREAS, as of the date hereof, Evolus is a wholly-owned subsidiary of Purchaser&#59;</font></div><div style="margin-bottom:12pt;padding-right:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:119%">G.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%;padding-left:23.67pt">WHEREAS, Evolus is currently contemplating corporate transactions including the offering of its equity&#59;</font></div><div style="margin-bottom:12pt;padding-right:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:119%">H.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%;padding-left:23.67pt">WHEREAS, the parties agree that Evolus has received and will receive substantial tangible and intangible benefits, including the increased ability to conduct such corporate transactions, by entering into this Amendment&#59; </font></div><div style="margin-bottom:12pt;padding-right:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:119%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%;padding-left:28.34pt">WHEREAS, Contributors&#8217; Representative is the representative of the Contributors under the Contribution Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-right:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:119%">J.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%;padding-left:27pt">WHEREAS, Seller and Purchaser now desire to amend certain portions of the Original Agreement, including the terms of the Contingent Payments (the Original Agreement, as amended by this Amendment, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:119%">Amended Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">&#8221;), and Evolus and the Contributors&#8217; Representative, with the consent of the Contributors, agree to enter into this Amendment, on the terms and subject to the conditions set forth herein&#59;</font></div><div style="margin-bottom:12pt;padding-right:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:119%">K.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%;padding-left:23.67pt">WHEREAS, the Contributors and the Seller desire that the Contributors surrender their respective Class D Units to Seller in consideration of the Contributors&#8217; Representative becoming the direct beneficiary, on the Contributors&#8217; behalf, of the Contingent Obligations and related rights under the Amended Agreement&#59; and</font></div><div style="margin-bottom:12pt;padding-right:5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:119%">L.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%;padding-left:25pt">WHEREAS, as a condition to the willingness of the Contributors to consent this Amendment, Evolus, the Contributors and the Contributors&#8217; Representative are entering into a Tax Indemnity Agreement of even date herewith (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:119%">Tax Indemnity Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">&#8221;).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOW, THEREFORE, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">in consideration of the foregoing, and for other good  and  valuable consideration, the receipt and sufficiency of which is hereby acknowledged by all signatories hereto, it is agreed  as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AGREEMENT</font></div><div style="margin-bottom:12pt;padding-right:14.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%;padding-left:27pt;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:119%">. Capitalized terms used but not defined in this Amendment shall have the meaning set forth in the Original Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Amendment of Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Section 1 of the Original Agreement is hereby amended to add the following defined terms&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220; &#8216;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8217; means&#58; (a) the sale of all or substantially all the assets of the Purchaser (at any time prior to the assignment of its obligations to Evolus pursuant to Section 7 of this Agreement) or Evolus&#59; (b) the exclusive license in whole of the Product or the business related to the Product to a third party (other than the sub-license (or similar arrangement) of any rights under the Daewoong Agreement to a third party for a given territory(ies) or indication(s) shall not constitute an exclusive license of the Product so long as, under such arrangement, Purchaser or Evolus (as the case may be) shall </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">continue to make sales to such third party)&#59; (c) any merger, consolidation or acquisition of Purchaser (at any time prior to the assignment of its obligations to Evolus pursuant to Section 7 of this Agreement) or Evolus with, by or into another corporation, entity or person (except a merger or consolidation in which the holders of capital stock of such entity immediately prior to such merger or consolidation continue to hold at least fifty percent (50%) of the voting power of the capital stock of such entity or the surviving or acquiring entity&#59; or (d) any change in the ownership of more than fifty percent (50%) of the voting capital stock of Purchaser (at any time prior to the assignment of its obligations to Evolus pursuant to Section 7 of this Agreement) or Evolus in one or more related transactions&#59; provided, however that a Change of Control shall expressly not include any public offering of Evolus&#8217; capital stock.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220; &#8216;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Class D Pro Rata Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8217; means, with respect to each Contributor, (i) the number of Class D Units of Seller owned by such Contributor immediately prior to the Second Amendment Effective Date, divided by (ii) the aggregate number of Class D Units of Seller owned by all Contributors immediately prior to the Second Amendment Effective Date.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220; &#8216;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Second Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8217; means that certain Second Amendment to this Agreement, dated as of the Second Amendment Effective Date, among Seller, Purchaser, Evolus and Contributors&#8217; Representative.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220; &#8216;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Second Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8217; means December 14, 2017.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt;text-decoration:underline">Amendment of Section 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:78.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:21.23pt">Sections 2(b) and 2(c) of the Original Agreement are hereby amended and restated in their entirety to read as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;(b)&#160;&#160;&#160;&#160;In consideration for the Class D Shares, Purchaser shall do the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(i)&#160;&#160;&#160;&#160;on the Second Amendment Effective Date, issue to Contributors&#8217; Representative, for the benefit of the Contributors, a promissory note in the principal amount of twenty million ($20,000,0000) in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> to the Second Amendment (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Promissory Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(ii)&#160;&#160;&#160;&#160;make the following payments to Contributors&#8217; Representative, for the benefit of the Contributors&#58; (A) a payment in an aggregate amount equal to Nine Million Two-Hundred Twelve Thousand Five Hundred United States Dollars ($9,212,500) upon U.S. Approval (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; (B) quarterly payments in an aggregate amount equal to &#91;***&#93; of the Net Sales of the Product in the United States and its territories and possessions for each quarter (or portion thereof) following the U.S. Approval&#59; and (C) quarterly payments in an aggregate amount equal  to &#91;***&#93;  of the Net Sales  of the  Product  in any region, territory or jurisdiction  other than the United  States and its territories and  possessions for  each quarter  (or  portion  thereof)  for  any  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">indication in such  non-United  States  region,  territory  or jurisdiction for which Purchaser or any of its Affiliates has the right to market or sell the Product.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The obligation to make the payments set forth in Clauses 2(b)(ii)(B) and 2(b)(ii)(C) shall terminate with respect to any quarter commencing after the 10-year anniversary of the first commercial sale of the Product in the United States after the receipt of U.S. Approval.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:78.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.55pt">Section 2 of the Original Agreement is hereby amended to add the following clauses (d) and (e) thereto&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;(d) &#160;&#160;&#160;&#160;Except as may otherwise be agreed among the Contributors and Contributors&#8217; Representative, any payments received by Contributors&#8217; Representative in respect of the Promissory Note or pursuant to Section (2)(b)(ii) of this Agreement shall be distributed by Contributors&#8217; Representative to the Contributors in accordance with their respective Class D Pro Rata Shares.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;Notwithstanding any provision of any agreement to the contrary, Purchaser agrees that it shall be solely responsible for any obligations to make payments to &#91;***&#93; upon U.S. Approval or on account of the payment of the Milestone Payment (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Employee Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  Without limiting the foregoing, Purchaser shall indemnify, defend and hold harmless Contributors&#8217; Representative, each Contributor and Seller from and against any and all losses, claims, liabilities, demands, charges, costs, awards, penalties, fines and expenses (including reasonable fees and disbursements of legal counsel) arising from or relating to any Employee Milestone Payments or any allegation that Employee Milestone Payments may be due or payable.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:26.7pt;text-decoration:underline">Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All payments to be made under Section 2 hereof shall be made by wire transfer to an account designated by the Contributor Representative.  Contributor Representative shall be responsible for the allocation of all such funds pursuant to the Contributors. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:26.7pt;text-decoration:underline">Continuation and Powers of Contributors&#8217; Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Contributors&#8217; Representative represents and warrants that he still has the powers set forth in Article VIII of the Contribution Agreement.  In the event that Purchaser or Evolus shall make a payment under Section 2 to Contributors&#8217; Representative, Contributors&#8217; Representative shall indemnify, defend and hold harmless Evolus, Seller and Purchaser from any allegation or claim related to failure to properly allocate such payment to a Contributor.  Without limiting any other provision of the Amended Agreement, Seller, Purchaser, Evolus hereby acknowledge and agree that (a) Contributors are express third party beneficiaries of Sellers&#8217; rights and Purchaser&#8217;s obligations under the Amended Agreement, (b) Contributors&#8217; Representative shall have the power to enforce any and all such rights and obligations on behalf of Contributors as if Contributors&#8217; Representative were an original party thereto and (c) Seller shall have no right to amend, waive, settle or otherwise compromise any such rights or obligations without the express written consent of Contributors&#8217; Representative. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:26.7pt;text-decoration:underline">Termination of Development Budget Default and Non-Competition Clause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Immediately upon execution of this Agreement, each of Evolus, Seller and Purchaser agree that (a) the terms of Sections 2.2(g) and (h) and Sections 6.6(a)(i) and (iii) of the Contribution Agreement are hereby terminated and shall be of no further force and effect and (b) any communications among any of the Contributors shall not be deemed to contravene Section 6.6(a)(ii) of the Contribution Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:26.7pt;text-decoration:underline">Additional Amendments to Original Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">The Original Agreement is hereby amended to add the following new Section 7 thereto&#58;</font></div><div style="margin-bottom:12pt;padding-left:36.3pt;text-align:justify;text-indent:35.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Assignment of Obligations to Evolus upon Public Offering</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Evolus is hereby joined as a party to this Agreement and agrees to be bound by this Agreement as if an original party hereto.  Concurrent with and contingent upon the closing of a public offering of the capital stock of Evolus pursuant to a registration statement under the Securities Act of 1933, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Triggering Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; without any further action on the parts of the parties hereto or the Contributors, Purchaser shall immediately and automatically be deemed to have assigned to Evolus, and Evolus shall immediately and automatically be deemed to have accepted and directly assume and undertake, all obligations of Purchaser set forth in this Agreement (including, but not limited to the payment obligations set forth in Section 2 hereof), and as a result Evolus shall concurrently and immediately become the &#8220;Borrower&#8221; under the Promissory Note&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the foregoing shall not relieve Purchaser of any breach of this Agreement or default under the Promissory Note that may have occurred prior to such assignment.  From and after the Triggering Event, Purchaser shall have no further obligations under this Agreement or the Promissory Note and the Contributors&#8217; Representative and the Contributors shall look solely to Evolus to fulfill the obligations set forth in this Agreement and the Promissory Note, except that the foregoing shall not relieve Purchaser or any breach of this Agreement or default under the Promissory Note that may have occurred prior to such assignment.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27pt">The Original Agreement is hereby amended to add the following new Section 8 thereto&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Binding Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement shall be binding on any successor or permitted assign of this Agreement.  Except in accordance with Section 7 hereof, neither Purchaser nor Evolus shall be permitted to directly or indirectly assign, transfer or delegate this Agreement or any of its obligations hereunder by transfer or assets or liabilities, Change of Control or otherwise&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that Purchaser or Evolus shall be permitted to effect a Change of Control provided that, as a condition to such Change of Control, the acquiring Person expressly agrees to assume all obligations of Purchaser or Evolus (as the case may be) hereunder in a writing in form and substance reasonably satisfactory to Contributors&#8217; Representative.&#8221;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:27.68pt">The Original Agreement is hereby amended to add the following new Section 9 thereto&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Each party agrees to take such further actions, and execute and deliver such additional documents, as may be reasonably requested by any other party to effectuate the intent and purposes of this Agreement.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:26.7pt;text-decoration:underline">Consideration to Alphaeon and Evolus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The parties acknowledge and agree that the economic concessions of the Contributors reflected herein, together with the other consideration being provided by the Contributors, are fair and provide reasonably equivalent value to Alphaeon in exchange for the benefits being provided to the Contributors hereunder.  In exchange for the agreement by Evolus to enter into this Amendment and to undertake, concurrent and contingent upon the Triggering Event, all obligations of Purchaser set forth in the Amended Agreement and pursuant to the Promissory Note (as defined therein) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), Purchaser shall, on a dollar for dollar basis, setoff and reduce the amount of intercompany loans owing by Evolus to the Purchaser (taking into account the fair value of all the Obligations), and the analysis of the provisions of this Amendment for purposes of Fraudulent Transfer Laws shall give effect to any discharge of intercompany debt as a result of the assumption by Evolus of the Obligations.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fraudulent Transfer Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean applicable law relating to fraudulent conveyance or fraudulent transfer (including the Uniform Fraudulent Conveyance Act, the Uniform Fraudulent Transfer Act and Section 548 of Title 11 of the United States Code or any applicable provisions of comparable law).  Purchaser and Evolus shall have the fair value of the Obligations valued by a third-party accounting firm for purposes of the foregoing offset. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:26.7pt;text-decoration:underline">Tax Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The parties intend that for U.S. federal income tax purposes the Contributors shall be treated as receiving a distribution from Seller of the right to receive payments from Purchaser under the Amended Agreement in a transaction in which no gain or loss is recognized, such that the Contributors may continue reporting of the consideration payable under the Amended Agreement under the installment sale method of Internal Revenue Code section 453 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Installment Sale Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to the same extent that Installment Sale Reporting was available to Seller prior to the execution of this Amendment.  In connection with the foregoing, upon the Second Amendment Effective Date, (a) each Contributor hereby contributes, transfers and assigns to Seller all of its right, title and interest in and to such Contributor&#8217;s Class D Units and (b) Seller accepts the contribution, transfer and assignment of such Class D Units, which Class D Units shall henceforth be deemed cancelled, and hereby irrevocably waives any claim that it may otherwise have to any of the proceeds of the Contingent Payments.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.7pt;text-decoration:underline">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Regardless of whether this Amendment is executed, Purchaser will reimburse Contributors&#8217; Representative for its out of pocket legal fees and related disbursements incurred in connection with this Amendment, against reasonable evidence thereof, and subject to a maximum aggregate cap of $41,500.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.7pt;text-decoration:underline">Continuing Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Amendment shall be deemed to form an integral part of the Original Agreement and construed in connection with and as part of the Original Agreement, and all terms, conditions, covenants and agreements set forth in the Original Agreement and each </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">other instrument or agreement referred to therein, as applicable, except as explicitly set forth herein, are hereby ratified and confirmed and shall remain in full force and effect, unmodified in any way.  In the event of any inconsistency or conflict between the provisions of the Original Agreement and this Amendment, the provisions of this Amendment will prevail and govern.  All references to the &#8220;Agreement&#8221; in the Original Agreement shall hereinafter refer to the Agreement as amended and supplemented by this Amendment.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:20.7pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Amendment may be executed in two (2) or more counterparts (any of which may be delivered by electronic transmission), each of which will be deemed an original, but all of which together will constitute one and the same instrument.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;Remainder of Page Left Intentionally Blank&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">the undersigned have executed this Amendment as of the date first set forth above.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SELLER&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SCH-AEON, LLC</font></div><div style="margin-bottom:12pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;  _</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47;Robert Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">__________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;  Robert Grant</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;  Manager</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PURCHASER&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ALPHAEON CORPORATION</font></div><div style="margin-bottom:12pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;  __</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47;Murthy Simhambhatla</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">____________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;  Murthy Simhambhatla</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;  CEO</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EVOLUS&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Evolus, Inc.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;  __</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47;Murthy Simhambhatla</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">______________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;  Murthy Simhambhatla</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;  CEO</font></div><div style="margin-bottom:12pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.410%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CONTRIBUTORS&#8217; REPRESENTATIVE&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47;J. Christopher Marmo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">_________________</font></div><div style="margin-bottom:12pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">J. Christopher Marmo,<br>as the Contributors&#8217; Representative</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Acknowledged and Agreed by the Contributors&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.410%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">_&#47;s&#47;J. Christopher Marmo___________________</font></div><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">J. Christopher Marmo</font></div></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.410%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">_&#47;s&#47;Scott Cannizzaro_____________________</font></div><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Scott Cannizzaro</font></div></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.410%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">_</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47;John Gross</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">____________________________</font></div><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">John Gross</font></div></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.410%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Gordon and Dona Crawford Trust UTD 8&#47;23&#47;77</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;__ </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Gordon Crawford</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">________________</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Trustee</font></div></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit A</font></div><div style="margin-bottom:12pt;padding-right:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This exhibit has been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Registrant undertakes to provide such information to the Securities and Exchange Commission upon request.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.38
<SEQUENCE>3
<FILENAME>ex1038.htm
<DESCRIPTION>EX-10.38
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i6cc9fc3964ca4126a5d7032fdb942c37_1"></div><div style="min-height:66.96pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:111.82pt;padding-right:111.82pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SECOND AMENDMENT TO LEASE</font></div><div><font><br></font></div><div style="padding-left:41pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">I.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.46pt">PARTIES AND DATE.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Second Amendment to Lease (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amendment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) dated October 16, 2024, by and between </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">520 NEWPORT CENTER DRIVE LLC</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a Delaware limited liability company (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Landlord</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EVOLUS, INC.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tenant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div><font><br></font></div><div style="padding-left:41pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">II.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:27.69pt">RECITALS.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:6.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Landlord and Tenant entered into a lease dated May 15, 2019, which lease was amended by First Amendment to Lease dated July 27, 2023 (collectively, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) for space consisting of approximately 25,963 rentable square feet known as Suites 1200 and 1400 in the building (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Building</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) located at 520 Newport Center Drive, Newport Beach, California (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Premises</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="padding-left:5pt;padding-right:6.75pt;text-align:justify;text-indent:35.95pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6.55pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Landlord and Tenant each desire to modify the Lease to add approximately 4,753 rentable square feet of space known as Suite 1420 on the fourteenth floor of the Building (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expansion Space</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), adjust the Basic Rent, and make such other modifications as are set forth in &#8220;III. MODIFICATIONS&#8221; next below.</font></div><div style="padding-left:5pt;padding-right:6.55pt;text-align:justify;text-indent:35.95pt"><font><br></font></div><div style="padding-left:41pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">III.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.92pt">MODIFICATIONS.</font></div><div><font><br></font></div><div style="padding-left:77pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt;text-decoration:underline">Basic Lease Provisions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Basic Lease Provisions are hereby amended as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:113pt;padding-right:6.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Effective as of the Commencement Date for the Expansion Space, Item 2 will be amended by adding &#8220;and Suite No. 1420&#8221; to the Premises.</font></div><div style="padding-left:113pt;padding-right:6.85pt"><font><br></font></div><div style="padding-left:113pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Item 4 is hereby amended by adding the following&#58;</font></div><div style="padding-left:113pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Estimated Commencement Date for the Expansion Space</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; June 1, 2025&#8221;</font></div><div><font><br></font></div><div style="padding-left:113pt;padding-right:6.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Effective as of the Commencement Date for the Expansion Space, Item 6 will be amended by adding the following for the Expansion Space&#58;</font></div><div style="padding-left:113pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basic Rent for Suite 1420 </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i.e., 4,753 rentable square feet)&#58;</font></div><div><font><br></font></div><div style="padding-left:114.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.431%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.84pt;padding-right:15.84pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Months of Term or Period for Suite 1420</font></div></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.97pt;padding-right:4.97pt;text-align:center;text-indent:-0.1pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Monthly Rate Per Rentable Square Foot of Suite 1420</font></div></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:32.57pt;padding-right:-2.63pt;text-indent:-29.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Monthly Basic Rent for Suite 1420</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.57pt;padding-right:0.57pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencement Date</font></div><div style="padding-left:0.52pt;padding-right:0.52pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the Expansion Space to 1&#47;31&#47;26</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.63pt"><font><br></font></div><div style="padding-right:-2.63pt"><font><br></font></div><div style="padding-left:0.59pt;padding-right:0.59pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$6.65</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:-2.63pt"><font><br></font></div><div style="padding-right:-2.63pt"><font><br></font></div><div style="padding-left:0.62pt;padding-right:0.62pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$31,607.45</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.52pt;padding-right:0.52pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#47;1&#47;26 to 1&#47;31&#47;27</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.59pt;padding-right:0.59pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$6.88</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.62pt;padding-right:0.62pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$32,700.64</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.52pt;padding-right:0.52pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#47;1&#47;27 to 1&#47;31&#47;28</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.59pt;padding-right:0.59pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$7.12</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.62pt;padding-right:0.62pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$33,841.36</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.52pt;padding-right:0.52pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#47;1&#47;28 to 1&#47;31&#47;29</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.59pt;padding-right:0.59pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$7.37</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.62pt;padding-right:0.62pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$35,029.61</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.52pt;padding-right:0.52pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2&#47;1&#47;29 to 1&#47;31&#47;30</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.59pt;padding-right:0.59pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$7.63</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.62pt;padding-right:0.62pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$36,265.39</font></div></td></tr></table></div><div style="padding-left:113pt;padding-right:6.8pt;text-align:justify"><font><br></font></div><div style="padding-left:113pt;padding-right:6.8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the above schedule of Basic Rent for Suite 1420 to the contrary, as long as Tenant is not in Default (as defined in Section 14.1 of the Lease) under the Lease, Tenant will be entitled to an abatement of one (1) full calendar month of Basic Rent for Suite 1420 in the amount of $31,607.45 (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Abated Basic Rent for Suite 1420</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) for the first full calendar month following the Commencement Date for Suite 1420 (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Abatement Period for Suite 1420</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). In the event Tenant is in Default at any time during the Term, which Default results in the termination of the Lease or in Tenant&#8217;s right to possession of the Premises, the unamortized portion of the Abated Basic Rent for Suite 1420 (amortized on a straight-line basis over the period commencing on the Commencement Date for Suite 1420 and ending January 31, 2030) will immediately become due and payable. The payment by Tenant of the Abated Basic Rent for Suite 1420 in the event of a Default will not limit or affect any of Landlord's other rights, pursuant to the Lease or at law or in equity. Only Basic Rent for Suite 1420 will be abated during the Abatement Period for Suite 1420 and all other rent and other costs and charges specified in the Lease will remain as due and payable pursuant to the provisions of the Lease.&#8221;</font></div><div><font><br></font></div><div style="padding-left:113pt;padding-right:6.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Effective as of the Commencement Date for the Expansion Space, Item 7 will be amended by adding the following for Suite 1420&#58;</font></div><div style="padding-left:113pt;padding-right:6.85pt"><font><br></font></div><div style="padding-left:113pt;padding-right:6.9pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property Tax Base for Suite 1420</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; The Property Taxes per rentable square foot of Suite 1420 incurred by Landlord and attributable to the twelve-month period ending June 30, 2026 (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Base Year</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for Suite 1420).</font></div><div style="padding-left:113pt;padding-right:6.9pt;text-align:justify"><font><br></font></div><div style="padding-left:113pt;padding-right:6.85pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Project Cost Base for Suite 1420</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; The Project Costs per rentable square foot of Suite 1420 incurred by Landlord and attributable to the Base Year for Suite 1420.&#8221;</font></div><div><font><br></font></div><div style="height:51.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:5.309%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-top:0.75pt"><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:113pt;padding-right:6.85pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Effective as of the Commencement Date for the Expansion Space, Item 8 will be deleted in its entirety and the following substituted in lieu thereof&#58;</font></div><div style="padding-left:113pt;padding-right:6.85pt"><font><br></font></div><div style="padding-left:149.05pt;padding-right:6.9pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;8. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Floor Area of Premises</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; approximately 30,716 rentable square feet, comprised of approximately 17,630 rentable square feet in Suite 1200, approximately 8,333 rentable square feet in Suite 1400, and approximately 4,753 rentable square feet in Suite 1420</font></div><div style="padding-left:149.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Floor Area of Building</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; approximately 326,121 rentable square feet&#8221;</font></div><div><font><br></font></div><div style="padding-left:113pt;padding-right:7.35pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Item 9 is hereby deleted in its entirety and the following substituted in lieu thereof&#58; </font></div><div style="padding-left:113pt;padding-right:7.35pt"><font><br></font></div><div style="padding-left:113pt;padding-right:7.35pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Security Deposit</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; $320,891.93&#8221;</font></div><div style="padding-left:113pt;padding-right:6.75pt"><font><br></font></div><div style="padding-left:113pt;padding-right:6.75pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Effective as of the Commencement Date for the Expansion Space, Item 11 will be deleted in its entirety and the following substituted in lieu thereof&#58;</font></div><div style="padding-left:113pt;padding-right:6.75pt"><font><br></font></div><div style="padding-left:149.05pt;padding-right:7.15pt;text-align:justify;text-indent:-36.05pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;11.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Parking</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; 104 parking passes in accordance with the provisions set forth in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit F </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to this Lease.&#8221;</font></div><div style="padding-left:149.05pt;padding-right:7.15pt;text-align:justify;text-indent:-36.05pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6.7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.62pt;text-decoration:underline">Commencement Date for the Expansion Space</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As used herein, the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commencement Date for the Expansion Space</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; will occur on the earlier of (a) the date the Expansion Space is deemed ready for occupancy as set forth below, or (b) the date Tenant commences its business activities within the Expansion Space. Promptly following request by Landlord, the parties will memorialize on a form provided by Landlord (the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Expansion Space Commencement Memorandum</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) the actual Commencement Date for the Expansion Space&#59; if Tenant fails to execute and return the Expansion Space Commencement Memorandum to Landlord within 5 business days (or provide specific written objections thereto within that period), then Landlord&#8217;s determination of the Commencement Date for the Expansion Space as set forth in the Expansion Space Commencement Memorandum will be conclusive. The Expansion Space will be deemed &#8220;ready for occupancy&#8221; if and when Landlord, to the extent applicable, has substantially completed all the work required to be completed by Landlord pursuant to the Work Letter for the Expansion Space attached to this Amendment but for minor punch list matters, and has obtained the requisite governmental approvals for Tenant&#8217;s occupancy in connection with such work.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:6.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.06pt;text-decoration:underline">Delay in Possession</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If Landlord, for any reason whatsoever, cannot deliver possession of the Expansion Space to Tenant on or before the Estimated Commencement Date for the Expansion Space set forth in Section III.A.2 above, this Amendment will not be void or voidable nor will Landlord be liable to Tenant for any resulting loss or damage. However, Tenant will not be liable for any rent for the Expansion Space until the Commencement Date for the Expansion Space occurs as provided in Section III.B above, except that if Landlord&#8217;s failure to substantially complete all work required of Landlord pursuant to Section III.B above is attributable to any action or inaction by Tenant (including without limitation any Tenant Delay described in the Work Letter the Expansion Space, if any, attached to this Amendment), then the Expansion Space will be deemed ready for occupancy, and Landlord will be entitled to full performance by Tenant (including the payment of rent), as of the date Landlord would have been able to substantially complete such work and deliver the Expansion Space to Tenant but for Tenant&#8217;s delay(s).</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">D.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.06pt;text-decoration:underline">Contingency</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Commencement Date for the Expansion Space is contingent upon the mutual execution and delivery of a lease surrender and termination agreement between Landlord and Daniel Alain, Inc., the current tenant in possession of the Expansion Space.</font></div><div style="padding-right:7pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">E.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.62pt;text-decoration:underline">Security Deposit for the Expansion Space</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Concurrently with Tenant&#8217;s delivery of this Amendment, Tenant will deliver the sum of $39,891.93 (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Security Deposit Shortfall</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) to Landlord, which sum will be added to the Security Deposit presently being held by Landlord in accordance with Section 4.3 of the Lease.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:6.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.18pt;text-decoration:underline">Operating Expenses for the Expansion Space</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Notwithstanding any contrary provision in the Lease, Tenant will not be obligated to pay Landlord for Operating Expenses accruing in connection with the Expansion Space during the 12-month period commencing as of the Commencement Date for the Expansion Space.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:6.9pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.51pt;text-decoration:underline">Right to Extend</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Effective as of the Commencement Date for the Expansion Space, the Premises in Section 3 of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit G </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the Lease, &#8220;Right to Extend&#8221;, will include the Expansion Space.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:6.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.06pt;text-decoration:underline">Signage</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Landlord, at its sole cost and expense, will affix and maintain a sign (restricted solely to Tenant&#8217;s name as set forth herein) adjacent to the entry door of the Expansion Space, and will add an identification strip in the lobby directory of the Building. Any subsequent changes to that initial signage will be made at Tenant&#8217;s expense in accordance with Section 5.2 of the Lease.</font></div><div style="padding-right:6.75pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.51pt;text-decoration:underline">Floor Plan of Premises</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Effective as of the Commencement Date for the Expansion Space, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit A </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">attached to the Lease will be deleted and </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Replacement Exhibit A </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">attached to this Amendment will be substituted in lieu thereof.</font></div><div style="padding-right:6.85pt"><font><br></font></div><div style="height:51.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:5.309%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-top:0.75pt"><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:5pt;padding-right:6.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">J.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.28pt;text-decoration:underline">Parking</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Notwithstanding any contrary provision in the Lease, effective as of the Commencement Date for the Expansion Space, Tenant purchase, at the rates set forth in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit F </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the Lease, as amended, up to 15 additional Parking Passes (which for the avoidance of doubt, are in addition to the 89 Parking Passes allocated to the existing Premises) for unreserved parking spaces in connection with its leasing of the Expansion Space (as reflected in Section III.A.7 of this Amendment). Tenant acknowledges that up to 50% of the additional Parking Passes may be located in the parking structure located at 555 San Nicolas. Tenant may, subject to availability as determined by Landlord, convert up to 2 of the additional Parking Passes to Converted Stalls at the rates set forth in </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit F </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the Lease, as amended, by providing written notice of such election to Landlord at any time following the date of this Amendment.</font></div><div style="padding-left:5pt;padding-right:6.8pt;text-align:justify"><font><br></font></div><div style="padding-left:5pt;padding-right:6.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">K.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.62pt;text-decoration:underline">Tenant Improvements</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Landlord will complete the Tenant Improvements for the Expansion Space in accordance with the provisions of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit X</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Work Letter for the Expansion Space, attached hereto.</font></div><div style="padding-right:6.75pt"><font><br></font></div><div style="padding-left:77pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">L.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt;text-decoration:underline">Tenant&#8217;s Insurance</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The following will be added to the end of </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit D </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the Lease&#58;</font></div><div><font><br></font></div><div style="padding-left:77pt;padding-right:79.15pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.07pt">If Tenant hires any vendor or contractor to complete work on the Premises&#59; Tenant will cause such vendor or contractor to comply with the following insurance requirements&#58;</font></div><div><font><br></font></div><div style="padding-left:90.55pt;padding-right:79.05pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.42pt">Commercial general liability insurance with coverage limits of not less than $1,000,000 combined single limit for bodily injury, personal injury, death and property damage liability per occurrence or the current limit carried by vendor or contractor, whichever is greater,</font></div><div><font><br></font></div><div style="padding-left:90.55pt;padding-right:78.8pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.42pt">Worker's compensation coverage as required by law, including employer's liability coverage with a limit of not less than</font></div><div style="padding-left:90.55pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1,000,000 each employee, each accident and each disease.</font></div><div><font><br></font></div><div style="padding-left:90.55pt;padding-right:78.85pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.86pt">Vendor or Contractor and its insurer(s) providing the insurance coverages described in this Section 4 Parts A, and B above, will waive any and all rights of recovery against Landlord and all entities controlling, controlled by, or under common control with Landlord, together with their respective owners, shareholders, partners, members, divisions, officers, directors, employees, representatives and agents, and all of their respective successors.</font></div><div><font><br></font></div><div style="padding-left:90.55pt;padding-right:78.8pt;text-align:justify;text-indent:21.6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">D.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.86pt">The commercial general liability insurance policy required in Section 4 Part A, will name Landlord and all entities controlling, controlled by, or under common control with Landlord, together with their respective owners, shareholders, partners, members, divisions, officers, directors, employees, representatives and agents, and all of their respective successors as additional insured for both operations and product completed operations coverage. Such coverage will be primary and non-contributory to any insurance or self-insurance carried by Landlord and all entities controlling, controlled by, or under common control with Landlord.</font></div><div style="padding-right:78.8pt"><font><br></font></div><div style="padding-left:41pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IV.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.8pt">GENERAL.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:7.2pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.62pt;text-decoration:underline">Effect of Amendments.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Lease will remain in full force and effect except to the extent that it is modified by this Amendment.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.62pt;text-decoration:underline">Entire Agreement.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This Amendment embodies the entire understanding between Landlord and Tenant with respect to the modifications set forth in &#8220;III. MODIFICATIONS&#8221; above and can be changed only by a writing signed by Landlord and Tenant.</font></div><div style="padding-right:7pt"><font><br></font></div><div style="padding-left:5pt;padding-right:6.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.06pt;text-decoration:underline">Counterparts&#59; Digital Signatures</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Amendment may be executed in one or more counterparts, each of which will constitute an original and all of which will be one and the same agreement. The parties expressly agree that one or each of the parties may execute and deliver this Amendment electronically using a certificate-based electronic signature and delivery software service approved and initiated by Landlord that provides an audit trail and method for authenticating signers (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Approved Service</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The Approved Service will have the same legal effect as a handwritten signature and will be admissible evidence of the parties' mutual intent to be legally bound by this Amendment. The parties declare that they have received all of the information required to be fully aware of the certificate-based electronic signature software process and each party hereby waives any claim which it may have against the enforceability of this Amendment based on the use of the Approved Service.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:6.95pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">D.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.06pt;text-decoration:underline">Defined Terms.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> All words commencing with initial capital letters in this Amendment and defined in the Lease will have the same meaning in this Amendment as in the Lease, unless they are otherwise defined in this Amendment.</font></div><div style="padding-right:6.95pt"><font><br></font></div><div style="height:51.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:5.309%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-top:0.75pt"><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:5pt;padding-right:7pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">E.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:21.62pt;text-decoration:underline">Authority.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If Tenant is a corporation, limited liability company or partnership, or is comprised of any of them, each individual executing this Amendment for the corporation, limited liability company or partnership represents that he or she is duly authorized to execute and deliver this Amendment on behalf of such entity and that this Amendment is binding upon such entity in accordance with its terms.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:6.75pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:22.18pt;text-decoration:underline">California Certified Access Specialist Inspection</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Pursuant to California Civil Code &#167; 1938, Landlord hereby states that the Premises have not undergone inspection by a Certified Access Specialist (CASp) (defined in California Civil Code &#167; 55.52(a)(3)). Pursuant to Section 1938 of the California Civil Code, Landlord hereby provides the following notification to Tenant&#58; &#8220;A Certified Access Specialist (CASp) can inspect the subject premises and determine whether the subject premises comply with all of the applicable construction-related accessibility standards under state law. Although state law does not require a CASp inspection of the subject premises, the commercial property owner or lessor may not prohibit the lessee or tenant from obtaining a CASp inspection of the subject premises for the occupancy or potential occupancy of the lessee or tenant, if requested by the lessee or tenant. The parties shall mutually agree on the arrangements for the time and manner of the CASp inspection, the payment of the fee for the CASp inspection, and the cost of making any repairs necessary to correct violations of construction related accessibility standards within the premises.&#8221;</font></div><div style="padding-left:40.95pt;padding-right:6.75pt;text-align:justify"><font><br></font></div><div style="padding-left:5pt;padding-right:6.85pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.51pt;text-decoration:underline">Attorneys&#8217; Fees</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The provisions of the Lease respecting payment of attorneys&#8217; fees will also apply to this Amendment.</font></div><div><font><br></font></div><div style="padding-left:5.05pt;padding-right:7.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.96pt;text-decoration:underline">Nondisclosure of Lease Terms</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Tenant acknowledges that the content of this Amendment and any related documents are confidential information. Except to the extent disclosure is required by law, Tenant will keep such confidential information strictly confidential and will not disclose such confidential information to any person or entity other than Tenant&#8217;s financial, legal and space-planning consultants, provided, however, that Tenant may disclose the terms to prospective subtenants or assignees under the Lease, as long as such parties agree to keep such information confidential, or pursuant to legal requirement.</font></div><div><font><br></font></div><div style="padding-left:5pt;padding-right:6.8pt;text-align:justify;text-indent:35.95pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.51pt;text-decoration:underline">Brokers.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Article 18 of the Lease is amended to provide that the parties recognize the following parties as the brokers who negotiated this Amendment, and agree that Landlord will be responsible for payment of brokerage commissions to such brokers pursuant to its separate agreements with such brokers&#58; Irvine Management Company (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Landlord&#8217;s Broker</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is the agent of Landlord exclusively and Savills (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tenant&#8217;s Broker</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is the agent of Tenant exclusively. By the execution of this Amendment, each of Landlord and Tenant hereby acknowledge and confirm (a) receipt of a copy of a Disclosure Regarding Real Estate Agency Relationship conforming to the requirements of California Civil Code 2079.16, and (b) the agency relationships specified herein, which acknowledgement and confirmation is expressly made for the benefit of Tenant&#8217;s Broker. If there is no Tenant&#8217;s Broker so identified herein, then such acknowledgement and confirmation is expressly made for the benefit of Landlord&#8217;s Broker. By the execution of this Amendment, Landlord and Tenant are executing the confirmation of the agency relationships set forth herein. The warranty and indemnity provisions of Article 18 of the Lease, as amended hereby, will be binding and enforceable in connection with the negotiation of this Amendment.</font></div><div style="padding-left:40.95pt;padding-right:6.8pt"><font><br></font></div><div style="padding-left:41pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">V.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:26.57pt">EXECUTION.</font></div><div><font><br></font></div><div style="padding-left:41pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Landlord and Tenant executed this Amendment on the date as set forth in &#8220;I. PARTIES AND DATE.&#8221;</font></div><div style="padding-left:5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">above.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.950%"><tr><td style="width:1.0%"></td><td style="width:45.931%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.612%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.057%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4.1pt;padding-left:41pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LANDLORD&#58;</font></div><div style="padding-right:2.77pt"><font><br></font></div><div style="padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520 NEWPORT CENTER DRIVE LLC,</font></div><div style="padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a Delaware limited liability company</font></div><div style="margin-top:4.1pt;padding-left:41pt;padding-right:2.77pt"><font><br></font></div><div style="padding-right:2.77pt"><font><br></font></div><div style="padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;&#47;s&#47;Steven M. Case</font></div><div style="padding-right:9.87pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Steven M. Case </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President Office Properties</font></div><div style="padding-right:2.77pt"><font><br></font></div><div style="padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58; &#47;s&#47;Stacy Nishoka</font></div><div style="padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stacy Nishioka</font></div><div style="padding-right:-3.23pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President, Operations Office Properties</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:4.1pt;padding-left:41pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TENANT&#58;</font></div><div style="padding-right:2.77pt"><font><br></font></div><div style="padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EVOLUS, INC.,</font></div><div style="padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a Delaware corporation</font></div><div style="padding-right:2.77pt"><font><br></font></div><div style="padding-right:2.77pt"><font><br></font></div><div style="padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; &#47;s&#47;David Moatazedi</font></div><div style="padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">David Moatazedi </font></div><div style="padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CEO</font></div><div style="padding-right:2.77pt"><font><br></font></div><div style="padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; &#47;s&#47;Sandra Beaver</font></div><div style="padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sandra Beaver </font></div><div style="padding-right:2.77pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CFO</font></div></td></tr></table></div><div><font><br></font></div><div style="height:51.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:5.309%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-top:0.75pt"><font><br></font></div></td></tr></table></div></div></div><div id="i6cc9fc3964ca4126a5d7032fdb942c37_4"></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This exhibit has been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Registrant undertakes to provide such information to the Securities and Exchange Commission upon request</font></div><div style="height:51.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:5.241%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-top:0.75pt"><font><br></font></div></td></tr></table></div></div></div><div id="i6cc9fc3964ca4126a5d7032fdb942c37_7"></div><hr style="page-break-after:always"><div style="min-height:66.96pt;width:100%"><div><font><br></font></div></div><div style="padding-left:111.82pt;padding-right:111.82pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT X</font></div><div style="padding-left:111.77pt;padding-right:111.77pt;text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This exhibit has been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Registrant undertakes to provide such information to the Securities and Exchange Commission upon reques</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">t</font></div><div style="height:51.84pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.498%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6</font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19
<SEQUENCE>4
<FILENAME>ex19.htm
<DESCRIPTION>EX-19
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i96b852c65843430181dfff3e662d63d9_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">EVOLUS, INC.<br>INSIDER TRADING POLICY</font></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center"><font><br></font></div><div style="padding-left:11pt;padding-right:5.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">The United States federal and state securities laws prohibit certain persons who possess material nonpublic information about a company from buying or selling securities of that company or for giving such information (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">tipping</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8221;) to another person who may trade on the basis of that information. Therefore,  Evolus, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8221;), has adopted this Insider Trading Policy (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Trading Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8221;) to promote compliance with these laws and to avoid even the appearance of improper conduct by anyone associated with the Company. All persons subject to this Trading Policy must carefully read this Trading Policy and adhere to its guidelines. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">It is your personal responsibility to comply with this Trading Policy and federal and state securities laws.</font></div><div style="padding-left:11pt;padding-right:5.75pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:47pt;padding-right:6.95pt;text-align:justify;text-indent:-41.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:34.4pt">PERSONS SUBJECT TO THIS TRADING POLICY</font></div><div style="padding-left:5.9pt;text-indent:5.1pt"><font><br></font></div><div style="padding-left:5.9pt;text-align:justify;text-indent:30.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">This Trading Policy applies to (a) all directors, officers and employees of the Company and its subsidiaries and (b) any other persons, such as contractors or consultants, whom the Compliance Officer (as defined hereinafter) has designated as subject to this Trading Policy because such other persons have access to material nonpublic information concerning the Company (such persons referred to in clause (a) and (b) are hereinafter referred to as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Company Personnel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8221;).  The restrictions in this Trading Policy also apply to each such person&#8217;s spouse, family members (and others who live in such person&#8217;s household or whose transactions are directed by such person), business partners, trusts, family partnerships, other entities formed for the benefit of such person or over which such person has the ability to influence, and to any other individual or entity who might reasonably be deemed to have a relationship (legal, personal or otherwise) meriting coverage (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Affiliated Persons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8221;). Company Personnel are responsible for ensuring compliance with this Trading Policy by their Affiliated Persons.  All persons identified in this paragraph are hereinafter referred to in this policy as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Insiders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">.&#8221;</font></div><div style="padding-left:5.9pt;text-align:justify;text-indent:30.1pt"><font><br></font></div><div style="padding-left:46.95pt;text-align:justify;text-indent:-40.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">II.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:29.42pt">DEFINITION OF &#8220;MATERIAL NONPUBLIC INFORMATION&#8221; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:14.8pt">&#8220;Material.&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Information is considered to be &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">material</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8221; under the securities laws and this Trading Policy if (a) there is a substantial likelihood that a reasonable investor would consider the information important in determining whether to trade in a security or (b) the information, if made public, could be expected to affect the market price of a company&#8217;s securities. Both positive and negative information may be material. While it is not possible to identify all information that would be deemed material, the following types of information ordinarily would be considered material&#58;</font></div><div style="padding-left:47pt;padding-right:5.8pt;text-align:justify"><font><br></font></div><div style="padding-left:92pt;padding-right:6pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:23.33pt">Financial performance, especially quarterly and year-end operating results, and significant changes in financial performance or liquidity.</font></div><div style="padding-left:92pt;padding-right:6pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:23.33pt">Company projections and strategic plans.</font></div><div style="padding-left:91.95pt;text-align:justify;text-indent:-26.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:23.28pt">Major discoveries or significant changes or developments in products or product lines, research or technologies, including, without limitation results of clinical trials and the receipt, denial or change in status of regulatory approval and clearance for products.</font></div><div style="padding-left:91.95pt;text-align:justify;text-indent:-26.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:23.28pt">Significant write-downs in assets or increases in resources.</font></div><div style="padding-left:92pt;padding-right:5.9pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:23.33pt">Potential mergers or acquisitions, the sale of Company assets or subsidiaries or major partnering agreements.</font></div><div style="padding-left:92pt;padding-right:5.8pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:23.33pt">New major contracts, orders, suppliers, customers or finance sources or the loss thereof.</font></div><div style="padding-left:91.95pt;text-align:justify;text-indent:-26.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:23.28pt">Changes in earnings estimates or unusual gains or losses in major operations.</font></div><div style="padding-left:91.95pt;text-align:justify;text-indent:-26.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:23.28pt">Significant pricing changes.</font></div><div style="padding-left:91.95pt;text-align:justify;text-indent:-26.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:23.28pt">Significant changes or developments in supplies or inventory, including significant product defects, recalls or product returns.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.724%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">1</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:92pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:23.33pt">Stock splits, public or private securities&#47;debt offerings, or changes in Company dividend policies or amounts.</font></div><div style="padding-left:91.95pt;text-align:justify;text-indent:-26.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:23.28pt">Significant changes in senior management or membership of the Board of Directors.</font></div><div style="padding-left:91.95pt;text-align:justify;text-indent:-26.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:23.28pt">Significant labor disputes or negotiations.</font></div><div style="padding-left:91.95pt;text-align:justify;text-indent:-26.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:23.28pt">Pending regulatory filing.</font></div><div style="padding-left:91.95pt;text-align:justify;text-indent:-26.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:23.28pt">Actual or threatened major litigation or the resolution of such litigation.</font></div><div style="padding-left:92pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:23.33pt">Capital investment plans and changes in such plans.</font></div><div style="padding-left:92pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:23.33pt">A significant cybersecurity incident or other significant disruption in the Company&#8217;s operations due to a breach or unauthorized access of the Company&#8217;s information technology infrastructure.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Material information is not limited to historical facts and could also include future, speculative or contingent events even if it is significant only when considered in combination with publicly available information. With respect to a future event, such as a merger, acquisition or introduction of a new product, the point at which negotiations or product development are determined to be material is determined by balancing the probability that the event will occur against the magnitude of the effect the event would have on a company&#8217;s operations or stock price should it occur. Thus, information concerning an event that would have a large effect on stock price, such as a merger, may be material even if the possibility that the event will occur is relatively small. </font></div><div style="padding-left:11pt;padding-right:5.65pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:11pt;padding-right:5.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">If you are unsure whether information is material, you should either consult the Compliance Officer or assume that the information is material.</font></div><div style="padding-left:11pt;padding-right:5.65pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:11pt;padding-right:5.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:15.38pt">&#8220;Nonpublic.&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Material information is &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">nonpublic</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8221; if it has not been widely disseminated to the general public through a report filed with the SEC or through major newswire services, national news services or financial news services. The fact that information has been disclosed to a few members of the public or because it has been discussed in the press, does not make it public for insider trading purposes. To be &#8220;public&#8221; the information must have been disseminated in a manner designed to reach investors, generally, and the investors must be given the opportunity to absorb the information. For the purpose of this Trading Policy, information will be considered public after the close of trading on the second full trading day following the Company&#8217;s widespread public release of the information. For purposes of this Policy, &#8220;trading day&#8221; means a day on which national stock exchanges, including the Nasdaq Stock Market, are open for trading.</font></div><div style="padding-left:11pt;padding-right:5.7pt;text-align:justify"><font><br></font></div><div style="padding-left:47pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Nonpublic information may include&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:91.95pt;text-align:justify;text-indent:-26.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:23.28pt">Information available to a select group of analysts or brokers or institutional investors.</font></div><div style="padding-left:92pt;padding-right:5.95pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:23.33pt">Undisclosed facts that are the subject of rumors, even if the rumors are widely circulated.</font></div><div style="padding-left:92pt;padding-right:5.8pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:23.33pt">Information that has been entrusted to the Company on a confidential basis.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">If you are unsure whether information is considered &#8220;nonpublic&#8221;, you should either consult with the Compliance Officer or assume that the information is nonpublic and treat it as confidential.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:47pt;padding-right:6.95pt;text-align:justify;text-indent:-41.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">III.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:26.24pt">GENERAL PROHIBITIONS </font></div><div style="padding-left:11pt;padding-right:5.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:17.72pt">Trading</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">. No Insider may purchase or sell, or offer to purchase or sell, any Company security, whether or not issued by the Company, while in possession of material nonpublic information about the Company. (The terms &#8220;material&#8221; and &#8220;nonpublic&#8221; are defined in Part II, Section A and B above.)</font></div><div style="padding-left:47pt;padding-right:5.8pt;text-align:right"><font><br></font></div><div style="padding-left:11pt;padding-right:5.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In addition, no Insider may purchase or sell any security of any other company, whether or not issued by the Company, while in possession of material nonpublic information about that company, or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.724%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">2</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:11pt;padding-right:5.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">while not directly about such other company would reasonably be expected to impact the value of the other company&#8217;s securities, that was obtained in the course of his or her involvement with the Company.  For instance, if you learned that the Company was about to award a major contract to ABC Corporation, it would probably be an insider trading violation to buy ABC securities.  Further, if you learn in the course of your relationship with the Company that ABC Corporation is being acquired and you proceed to purchase shares of DEF Corporation, a competitor of ABC Corporation, based on an expectation that the acquisition of ABC Corporation will be material to DEF Corporation, you may be liable for an insider trading violation.</font></div><div style="padding-left:11pt;padding-right:5.7pt;text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:17.13pt">Tipping</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">. No Insider may communicate or otherwise disclose material nonpublic information to any other person, including Family Members and friends,  who may trade or advise others to trade on the basis of that information.</font></div><div style="padding-left:47pt;padding-right:5.7pt;text-align:right"><font><br></font></div><div style="padding-left:11pt;padding-right:5.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No Insider may make recommendations or express opinions as to trading in a company&#8217;s securities while in possession of material nonpublic information regarding such company, except such person may advise others not to trade in the Company&#8217;s securities if doing so might violate the law or this Trading Policy.</font></div><div style="padding-left:11pt;padding-right:5.7pt;text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;When tipping occurs, both the &#8220;tipper&#8221; and the &#8220;tippee&#8221; may be held liable, and this liability may extend to all those to whom the tippee provides the information.  Besides being considered a form of insider trading, tipping is also a serious breach of corporate confidentiality.  For this reason, you should be careful to avoid discussing sensitive information in any place (for instance, at lunch, on public transportation, in elevators) where such information may be heard by others.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:46.95pt;text-align:justify;text-indent:-37.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">IV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:22.97pt">ADDITIONAL RESTRICTIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:14.8pt">Section 16 Insiders. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">The Company has designated certain persons who are subject to the reporting provisions and trading restrictions of Section 16 of the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8221;), and the underlying rules and regulations promulgated by the Securities and Exchange Commission (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8221;). Each such person is referred to herein as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Section 16 Insider</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">.&#8221; The Company maintains a list of Section 16 Insiders and will amend such list from time to time as necessary to reflect the addition and the resignation or departure of Section 16 Insiders.</font></div><div style="padding-left:47pt;padding-right:5.8pt;text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:15.38pt">Access Persons. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">The Company will maintain a list of other persons who have frequent access to material nonpublic information concerning the Company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Access Persons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8221;). The Company will maintain a list of Access Persons and amend such list from time to time as necessary to reflect the addition and the resignation or departure of Access Persons.</font></div><div style="padding-right:5.9pt;text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:14.8pt">Additional Restrictions. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">All Section 16 Insiders, Access Persons and certain other employees are subject to the additional restrictions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> hereto.</font></div><div style="padding-right:6pt;text-align:justify"><font><br></font></div><div style="padding-left:47pt;padding-right:29.95pt;text-align:justify;text-indent:-35.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">V.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:24.85pt">TRANSACTIONS COVERED BY THIS TRADING POLICY AND CERTAIN EXCEPTIONS</font></div><div style="padding-left:47pt;padding-right:29.95pt;text-align:right"><font><br></font></div><div style="padding-left:11pt;padding-right:5.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:14.8pt">General Rule. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">This Trading Policy applies to all transactions in the Company&#8217;s securities, including common stock, options to purchase common stock and any other securities the Company may issue from time to time, such as preferred stock, convertible notes, warrants and convertible debentures, as well as derivative securities relating to the Company&#8217;s stock, whether or not issued by the Company, such as exchange-traded options or swaps. For purposes of this Trading Policy, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">trade</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8221; includes any transaction in the Company&#8217;s securities, including bona fide gifts (including charitable donations and transfers for estate planning purposes).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.724%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">3</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:47pt;padding-right:5.85pt;text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:15.38pt">Equity Incentive Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">.  The trading prohibitions and restrictions set forth in this Trading Policy do not apply to the exercise of stock options or other equity awards for cash, but do apply to all sales of securities acquired through the exercise of stock options or other equity awards. Thus, this Trading Policy does apply to the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">same-day sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8221; or cashless exercise of Company stock options.</font></div><div style="padding-right:5.85pt;text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:14.8pt">Short Sales. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Short sales of the Company&#8217;s securities evidence an expectation on the part of the seller that the securities will decline in value, and therefore signal to the market that the seller has no confidence in the Company or its short-term prospects. In addition, short sales may reduce the seller&#8217;s incentive to improve the Company&#8217;s performance. For these reasons, short sales of the Company&#8217;s securities are prohibited by this Trading Policy. In addition, Section 16(c) of the Exchange Act expressly prohibits executive officers and directors from engaging in short sales.</font></div><div style="padding-left:45pt;padding-right:5.85pt"><font><br></font></div><div style="padding-left:13.5pt;padding-right:5.85pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:16.8pt">Publicly Traded Options. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">A transaction in options is, in effect, a bet on the short-term movement of the Company&#8217;s stock and therefore creates the appearance that the officer, director or other employee is trading based on inside information. Transactions in options also may focus the officer&#8217;s, director&#8217;s or other employee&#8217;s attention on short-term performance at the expense of the Company&#8217;s long-term objectives. Accordingly, transactions in puts, calls or other derivative securities involving the Company&#8217;s stock, on an exchange or in any other organized market, are </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">prohibited </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">by this Trading Policy. (Option positions arising from certain types of hedging transactions are governed by the section below captioned &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Hedging Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">.&#8221;)</font></div><div style="padding-left:45pt;padding-right:5.85pt"><font><br></font></div><div style="padding-left:13.5pt;padding-right:5.85pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:17.38pt">Hedging Transactions. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Certain forms of hedging or monetization transactions, such as zero- cost collars and forward sale contracts, allow an officer, director or other employee to lock in much of the value of his or her stock holdings, often in exchange for all or part of the potential for upside appreciation in the stock. These transactions allow the officer, director or other employee to continue to own the covered securities, but without the full risks and rewards of ownership. When that occurs, the officer, director or other employee may no longer have the same objectives as the Company&#8217;s other stockholders. Therefore, such transactions involving the Company&#8217;s securities are prohibited by this Trading Policy.</font></div><div style="padding-left:45pt;padding-right:5.85pt"><font><br></font></div><div style="padding-left:13.5pt;padding-right:5.85pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">F.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:17.97pt">Margin Accounts and Pledges. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Securities held in a margin account may be sold by the broker without the customer&#8217;s consent if the customer fails to meet a margin call. Similarly, securities pledged (or hypothecated) as collateral for a loan may be sold in foreclosure if the borrower defaults on the loan. Because a margin sale or foreclosure sale may occur at a time when the pledgor is aware of material nonpublic information or otherwise is not permitted to trade in Company securities, directors and officers are prohibited from holding Company securities in a margin account or pledging Company securities as collateral for a loan.</font></div><div style="padding-left:45pt;padding-right:5.85pt"><font><br></font></div><div style="padding-left:13.5pt;padding-right:5.85pt;text-indent:31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">G.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:16.22pt">Certain Exceptions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">.</font></div><div style="padding-right:5.85pt"><font><br></font></div><div style="padding-left:18pt;padding-right:5.85pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, except as otherwise stated herein and unless otherwise prohibited by the Compliance Officer, the trading restrictions in this Policy do not apply in the case of the following transactions&#58;</font></div><div style="padding-right:5.85pt"><font><br></font></div><div style="padding-left:90pt;padding-right:5.85pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:14.33pt">The exercise of tax withholding rights pursuant to which a participant in any of the Company&#8217;s incentive plans pursuant to such plan elects to have the Company withhold shares to satisfy any tax withholding requirements.</font></div><div style="padding-left:90pt;padding-right:5.85pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:14.33pt">The vesting of restricted stock or restricted stock unit awards.</font></div><div style="padding-left:90pt;padding-right:5.85pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:14.33pt">Exercising, but not selling, Company stock options.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.724%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">4</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:90pt;padding-right:5.85pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:14.33pt">Making scheduled purchases of shares of the Company&#8217;s common stock through the Company&#8217;s employee stock purchase plan.  </font></div><div style="padding-left:90pt;padding-right:5.85pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:14.33pt">Acquisitions of Company securities via a bona fide gift.</font></div><div style="padding-left:90pt;padding-right:5.85pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:14.33pt">Trades in Company securities pursuant to a Rule 10b5-1 Plan (as defined hereinafter). </font></div><div style="padding-left:90pt;padding-right:5.85pt"><font><br></font></div><div style="padding-right:5.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;A disposition of the Company&#8217;s securities by bona fide gift (including charitable donations and transfers for estate planning purposes) could create insider trading concerns under some circumstances if the donor is aware of material nonpublic information. Therefore, unless approved by the Compliance Officer, Insiders are not permitted to gift Company securities when aware of material nonpublic information about the Company or its securities or otherwise subject to a closed trading window (as described in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">).  This approval requirement applies even if you are not otherwise subject to the pre-approval requirements set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> below. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:46.95pt;text-align:justify;text-indent:-35.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">VI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:21.42pt">INSIDER TRADING COMPLIANCE OFFICER </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">The Company has initially designated its General Counsel as its Insider Trading Compliance Officer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Compliance Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="padding-left:11pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:47pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">The duties of the Compliance Officer will include the following&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:101pt;padding-right:5.85pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:14.33pt">Administering this Trading Policy and monitoring and enforcing compliance with all policy provisions and procedures.</font></div><div style="padding-left:100.95pt;text-align:justify;text-indent:-17.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:14.28pt">Responding to all inquiries relating to this Trading Policy and its procedures.</font></div><div style="padding-left:101pt;padding-right:5.9pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:14.33pt">Designating and announcing special trading blackout periods during which no Insiders may trade in Company securities.</font></div><div style="padding-left:100.8pt;padding-right:5.9pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:14.33pt">Providing copies of this Trading Policy and other appropriate materials to all current and new directors, officers and employees, and such other persons as the Compliance Officer determines have access to material nonpublic information concerning the Company.</font></div><div style="padding-left:100.8pt;padding-right:5.85pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:14.33pt">Administering, monitoring and enforcing compliance with federal and state insider trading laws and regulations&#59; and assisting in the preparation and filing of all required SEC reports relating to trading in Company securities, including without limitation Forms 3, 4, 5 and 144 and Schedules 13D and 13G.</font></div><div style="padding-left:101pt;padding-right:5.85pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:14.33pt">Pre-clearing all trading in securities of the Company by Section 16 Insiders and Access Persons in accordance with the procedures set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> hereto.</font></div><div style="padding-left:101pt;padding-right:5.75pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:14.33pt">Selecting designated brokers through which Section 16 Insiders and Access Persons are authorized to trade Company securities.</font></div><div style="padding-left:101pt;padding-right:5.85pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:14.33pt">Providing approval of any Rule 10b5-1 Plans in accordance with the procedures set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> hereto.</font></div><div style="padding-left:101pt;padding-right:5.8pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:14.33pt">Revising the Trading Policy as necessary to reflect changes in federal or state insider trading laws and regulations.</font></div><div style="padding-left:101pt;padding-right:5.75pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:14.33pt">Maintaining as Company records originals or copies of all documents required by the provisions of this Trading Policy or the procedures set forth herein, and copies of all required SEC reports relating to insider trading, including without limitation Forms 3, 4, 5 and 144 and Schedules 13D and 13G.</font></div><div style="padding-left:101pt;padding-right:5.85pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:14.33pt">Maintaining the accuracy of the list of Section 16 Insiders and the list of Access Persons, and updating such lists periodically as necessary to reflect additions or deletions.<br></font></div><div style="padding-left:11pt;padding-right:5.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">The Compliance Officer may designate one or more individuals who may perform the Compliance Officer&#8217;s duties in the event that the Compliance Officer is unable or unavailable to perform such duties. In </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.724%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">5</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:11pt;padding-right:5.7pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">fulfilling his or her duties under this Trading Policy, the Compliance Officer shall be authorized to consult with the Company&#8217;s outside counsel.</font></div><div style="padding-left:11pt;padding-right:5.7pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:47pt;padding-right:5.85pt;text-align:justify;text-indent:-41.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">VII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:23.29pt">EMPLOYEES MAY NOT PARTICIPATE IN CHAT ROOMS AND SOCIAL MEDIA</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Employees are prohibited from participating in chat room discussions, blogs, social media or other Internet forums regarding the Company&#8217;s securities or business.</font></div><div style="padding-left:11pt;padding-right:5.9pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:47pt;padding-right:5.9pt;text-align:justify;text-indent:-40.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">VIII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:17.81pt">ONLY DESIGNATED COMPANY SPOKESPERSONS ARE AUTHORIZED TO DISCLOSE MATERIAL NONPUBLIC INFORMATION</font></div><div style="padding-left:11pt;padding-right:5.9pt;text-align:justify;text-indent:-22.25pt"><font><br></font></div><div style="padding-left:11pt;padding-right:5.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">The Company is required under the federal securities laws to avoid the selective disclosure of material nonpublic information. The Company has established procedures for releasing material information in a manner that is designed to achieve broad dissemination of the information immediately upon its release. Insiders may not, therefore, disclose material information to anyone outside the Company, including Family Members and friends, other than in accordance with those established procedures. Any inquiries from outsiders regarding material nonpublic information about the Company should be forwarded to the Compliance Officer.</font></div><div style="padding-left:11pt;padding-right:5.75pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:47pt;padding-right:5.9pt;text-align:justify;text-indent:-40.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">IX.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:25.97pt">THE COMPANY MAY SUSPEND ALL TRADING ACTIVITIES BY INSIDERS</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">In order to avoid any questions and to protect both Insiders and the Company from any potential liability, from time to time the Company may impose a &#8220;blackout&#8221; period during which some or all of the Insiders may not buy or sell the Company&#8217;s securities. The Compliance Officer will impose such a blackout period if, in his judgment, there exists nonpublic information that would make trades by the Insiders (or certain of the Insiders) inappropriate in light of the risk that such trades could be viewed as violating applicable securities laws.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:47pt;padding-right:6.95pt;text-align:justify;text-indent:-40.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">X.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:30.75pt">VIOLATIONS OF INSIDER TRADING LAWS OR THIS TRADING POLICY CAN RESULT IN SEVERE CONSEQUENCES</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:14.8pt">Civil and Criminal Penalties. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">A person who violates insider trading laws by engaging in transactions in a company&#8217;s securities when he or she has material nonpublic information can be sentenced to a substantial jail term and required to pay a criminal penalty of several times the amount of profits gained or losses avoided. In addition, a person who tips others may also be liable for transactions by the tippees to whom he or she has disclosed material nonpublic information. Tippers can be subject to the same penalties and sanctions as the tippees, and the SEC has imposed large penalties even when the tipper did not profit from the transaction.</font></div><div style="padding-left:47pt;padding-right:5.65pt;text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">The SEC can also seek substantial civil penalties from any person who, at the time of an insider trading violation, &#8220;directly or indirectly controlled the person who committed such violation,&#8221; which would apply to the Company and&#47;or management and supervisory personnel. These control persons may be held liable for up to the greater of $1 million or three times the amount of the profits gained or losses avoided. Even for violations that result in a small or no profit, the SEC can seek penalties from a company and&#47;or its management and supervisory personnel as control persons.</font></div><div style="padding-left:11pt;padding-right:5.8pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:11pt;padding-right:5.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:15.38pt">Company Discipline. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Violation of this Trading Policy or federal or state insider trading laws by any Insider may subject the director to removal proceedings and the officer or employee to disciplinary action by the Company, including termination for cause.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.724%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">6</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:11pt;padding-right:5.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:14.8pt">Reporting Violations. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Any person who violates this Trading Policy or any federal or state laws governing insider trading, or knows of any such violation by any other person, must report the violation immediately to the Compliance Officer or the Audit Committee of the Company&#8217;s Board of Directors. Upon learning of any such violation, the Compliance Officer or Audit Committee, in consultation with the Company&#8217;s legal counsel, will determine whether the Company should release any material nonpublic information or whether the Company should report the violation to the SEC or other appropriate governmental authority.</font></div><div style="padding-right:5.75pt;text-align:justify"><font><br></font></div><div style="padding-left:47.65pt;text-align:justify;text-indent:-42.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">XI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:28.02pt">EVERY INDIVIDUAL IS RESPONSIBLE</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">All Company Personnel and their Affiliated Persons have an individual responsibility to comply with this Trading Policy against illegal insider trading. Company Personnel and their Affiliated Persons may, from time to time, have to forego a proposed transaction in the Company&#8217;s securities even if he or she planned to make the transaction before learning of the material nonpublic information and even though such person believes that he or she may suffer an economic loss or forego anticipated profit by waiting.</font></div><div style="padding-left:11pt;padding-right:5.75pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:47.65pt;padding-right:6.95pt;text-align:justify;text-indent:-40.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">XII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:22.44pt">THIS TRADING POLICY CONTINUES TO APPLY FOLLOWING TERMINATION OF EMPLOYMENT </font></div><div style="padding-left:47.65pt;padding-right:6.95pt;text-align:right"><font><br></font></div><div style="padding-left:11pt;padding-right:5.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">The Trading Policy will apply to Company Personnel and their Affiliated Persons so long as the Company Personnel are associated with the Company and for as long as they are in possession of material nonpublic information. If Company Personnel leave the Company for any reason and remain in possession of material nonpublic information when his or her relationship with the Company terminates, he or she may not trade in the Company&#8217;s securities until that information has become public or is no longer material.</font></div><div style="padding-right:5.8pt;text-align:justify"><font><br></font></div><div style="padding-left:48.4pt;padding-right:5.8pt;text-align:justify;text-indent:-39.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">XIII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:16.96pt">THE COMPLIANCE OFFICER IS AVAILABLE TO ANSWER QUESTIONS ABOUT THIS TRADING POLICY</font></div><div style="padding-left:11pt;padding-right:5.85pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:11pt;padding-right:5.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Please direct all inquiries regarding any of the provisions or procedures of this Trading Policy to the Compliance Officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:47.65pt;text-align:justify;text-indent:-40.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">XIV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:18.89pt">THIS TRADING POLICY IS SUBJECT TO REVISION </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">The Company may change the terms of this Trading Policy from time to time to respond to developments in law and practice. The Nominating and Corporate Governance Committee will be responsible for monitoring and recommending modifications to the Trading Policy, if necessary or advisable, to the Board of Directors for adoption.  The Company will take steps to inform all persons subject to this Trading Policy of any material change to this Trading Policy.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:48.4pt;padding-right:5.9pt;text-align:justify;text-indent:-42.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">XV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:24.47pt">ALL COMPANY PERSONNEL MUST ACKNOWLEDGE THEIR AGREEMENT TO COMPLY WITH THIS TRADING POLICY </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">This Trading Policy is being delivered to all officers, director, employees and any other persons designated as Insiders, and to all new officers, directors, employees and designated Insiders at the start of their employment or relationship with the Company and&#47;or its subsidiaries. Upon first receiving a copy of the Trading Policy or any revised versions, each Insider must sign an acknowledgment that he or she has received a copy and agrees to comply with the Trading Policy&#8217;s terms. This acknowledgment and agreement will constitute consent for the Company to impose sanctions for violation of this Trading Policy and to issue any necessary stop-transfer orders to the Company&#8217;s transfer agent to enforce compliance with this Trading Policy.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:2.724%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.8pt;padding-left:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">7</font></div></td></tr></table></div></div></div><div id="i96b852c65843430181dfff3e662d63d9_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:2.5pt;padding-right:2.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">APPENDIX I</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:2.47pt;padding-right:2.47pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Additional Restrictions on Transactions in Company Securities</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:46.95pt;text-align:justify;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:28.08pt">Overview</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">To minimize the risk of apparent or actual violations of the rules governing insider trading, the Company has adopted these additional restrictions relating to transactions in Company securities by all Section 16 Insiders, Access Persons and certain other employees determined by the Board of Directors, or its designated committee, from time to time (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Restricted Persons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8221;). As with the other provisions of this Trading Policy, Restricted Persons are responsible for ensuring compliance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">, including restrictions on all trading during certain periods, by Family Members and by entities over which they exercise voting or investment control. Restricted Persons should provide each of these persons or entities with a copy of this Trading Policy.</font></div><div style="padding-right:5.65pt;text-align:justify"><font><br></font></div><div style="padding-left:46.95pt;text-align:justify;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:28.08pt">Trading Window</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Any trade by a Restricted Person will be permitted only during an open &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">trading window</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">.&#8221; The trading window generally opens following the close of trading on the second full trading day following the public issuance of the Company&#8217;s earnings release for the most recent fiscal quarter and closes at the close of trading two weeks before the end of the next fiscal quarter. In addition to the times when the trading window is scheduled to be closed, the Company may impose a special blackout period at its discretion due to the existence of material nonpublic information, such as a pending acquisition, that is likely to be widely known among Restricted Persons. Following termination of employment or other service, Restricted Persons will be subject to the trading window for the quarter in which termination occurs, as well as any special blackout period in effect at the time of termination. Even when the trading window is open, Restricted Persons  are still prohibited from trading in the Company&#8217;s securities while in possession of material nonpublic information. The Company&#8217;s Compliance Officer will advise Restricted Persons when the trading window opens and closes.</font></div><div style="padding-left:11pt;padding-right:5.7pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:46.95pt;text-align:justify;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:28.08pt">Hardship Exemptions</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">The Compliance Officer may, on a case by case basis, authorize a transaction in the Company&#8217;s securities outside of the trading window (but in no event during a special blackout period) due to extreme financial or other hardship, provided such Insider is not in possession of material nonpublic information. Any request for a hardship exemption must be in writing and must describe the amount and nature of the proposed transaction and the circumstances of the hardship. (The request may be made as part of a pre-clearance request, so long as it is in writing.) The Restricted Person requesting the hardship exemption must also certify to the Compliance Officer within two business days prior to the date of the proposed trade that he or she is not in possession of material nonpublic information concerning the Company.</font></div><div style="padding-left:11pt;padding-right:5.7pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:11pt;padding-right:6.05pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">The existence of the foregoing procedure does not in any way obligate the Compliance Officer to approve any hardship exemption requested by a Restricted Person.</font></div><div style="padding-left:11pt;padding-right:6.05pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:46.95pt;text-align:justify;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:28.08pt">Individual Account Plan Blackout Periods</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Certain trading restrictions apply during a blackout period applicable to any Company individual account plan in which participants may hold Company stock. For the purpose of such restrictions, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">blackout period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8221; is a period in which the plan participants are temporarily restricted from making trades in Company stock. During any blackout period, Section 16 Insiders are prohibited from trading in shares of the Company&#8217;s stock that were acquired in connection with such Section 16 Insider&#8217;s service or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:0.8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Appendix-I</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:11pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">employment with the Company. Such trading restriction is required by law, and no hardship exemptions are available. The Company will notify Section 16 Insiders in the event of any blackout period.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:46.95pt;text-align:justify;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:28.08pt">Pre-Clearance of Trades</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.65pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">ll transactions in securities of the Company by Section 16 Insiders and Access Persons, even during a trading window under Section 2 above, must be pre-cleared by the Compliance Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">. The intent of this requirement is to prevent inadvertent violations of the Trading Policy, avoid trades involving the appearance of improper insider trading, facilitate timely Form 4 reporting and avoid transactions that are subject to disgorgement under Section 16(b) of the Exchange Act.</font></div><div style="padding-left:11pt;padding-right:5.65pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:11pt;padding-right:5.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Requests for pre-clearance must be submitted to the Compliance Officer at least two business days in advance of each proposed transaction. The request must be submitted either in writing or in an email addressed to the Compliance Officer, or at such other account as may be designated by the Compliance Officer pursuant to which the Compliance Officer and other designated persons have access. If the Section 16 Insider or Access Person submits the request by email and does not receive a response within 24 hours, the Section 16 Insider or Access Person will be responsible for following up to ensure that the message was received. The denial of a trading request should not be communicated to any other person, and may itself be considered under this Trading Policy to be material nonpublic information about the Company.</font></div><div style="padding-left:11pt;padding-right:5.9pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:47pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">A request for pre-clearance should provide the following information&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:82.95pt;text-align:justify;text-indent:-17.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:14.28pt">The nature of the proposed transaction and the expected date of the transaction.</font></div><div style="padding-left:82.95pt;text-align:justify;text-indent:-17.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:14.28pt">The number of shares involved.</font></div><div style="padding-left:83pt;padding-right:6pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:14.33pt">If the transaction involves a stock option exercise, the specific option to be exercised and the manner of exercise (e.g., &#8220;same-day sale&#8221; or &#8220;cashless exercise&#8221;).</font></div><div style="padding-left:82.95pt;text-align:justify;text-indent:-17.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:14.28pt">Contact information for the broker who will execute the transaction.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.75pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Once the proposed transaction is pre-cleared, the Section 16 Insider or Access Person may proceed with it on the approved terms, provided that he or she complies with all other securities law requirements, such as Rule 144 and prohibitions regarding trading on the basis of material nonpublic information, and with any special trading blackout imposed by the Company prior to the completion of the trade. The Section 16 Insider and his or her broker will be responsible for immediately reporting the results of the transaction as further described below. Unless revoked, a grant of permission will normally remain valid until the close of trading two business days following the day on which it was granted. If the transaction does not occur during the two-day period, pre-clearance of the transaction must be re- requested.</font></div><div style="padding-left:11pt;padding-right:5.75pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:11pt;padding-right:5.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">In addition, pre-clearance is required for the establishment of a Rule 10b5-1 Plan. However, pre-clearance will not be required for individual transactions effected pursuant to a pre-cleared Rule 10b5-1 Plan. The results of transactions effected under a Rule 10b5-1 Plan must be reported immediately to the Company since they will be reportable on Form 4 within two business days following the execution of the trade, subject to an extension of not more than two additional business days where the Section 16 Insider is not immediately aware of the execution of the trade.</font></div><div style="padding-left:11pt;padding-right:5.8pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:11pt;padding-right:5.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, any transactions by the Compliance Officer shall be subject to pre-clearance by the Chief Executive Officer.</font></div><div style="padding-left:11pt;padding-right:5.9pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:46.95pt;text-align:justify;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:28.08pt">Designated Brokers</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Each market transaction in the Company&#8217;s stock by a Section 16 Insider, or any person whose trades must be reported on Form 4 (such as a member of the Section 16 Insider&#8217;s immediate family who </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:0.8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Appendix-I</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:11pt;padding-right:5.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">lives in the Section 16 Insider&#8217;s household), must be executed by a broker designated by the Company unless the Section 16 Insider has received authorization from the Compliance Officer to use a different broker.</font></div><div style="padding-left:11pt;padding-right:5.95pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:11pt;padding-right:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">A Section 16 Insider and any broker that handles the Section 16 Insider&#8217;s transactions in the Company&#8217;s stock will be required to enter into an agreement whereby&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:83pt;padding-right:5.7pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:14.33pt">The Section 16 Insider authorizes the broker to immediately report directly to the Company the details of all transactions in Company equity securities executed by the broker in the Section 16 Insider&#8217;s account and the accounts of all others designated by the Section 16 Insider whose transactions may be attributed to the Section 16 Insider.</font></div><div style="padding-left:83pt;padding-right:5.8pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:14.33pt">The broker agrees not to execute any transaction for the Section 16 Insider or any of the foregoing designated persons (other than under a pre-approved Rule 10b5-1 Plan) until the broker has verified with the Company that the transaction has been pre-cleared.</font></div><div style="padding-left:83pt;padding-right:5.8pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:14.33pt">The broker agrees to immediately report the transaction details (including transactions under Rule 10b5-1 Plans) directly to the Company and to the Section 16 Insider by telephone and in writing (by fax or email).</font></div><div style="padding-left:83pt;padding-right:5.8pt;text-align:right"><font><br></font></div><div style="padding-left:11pt;padding-right:5.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Should a Section 16 Insider wish to use a broker other than one of the Company&#8217;s designated brokers, the Section 16 Insider should submit a request to use that broker to the Compliance Officer.</font></div><div style="padding-left:11pt;padding-right:5.95pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:46.95pt;text-align:justify;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:28.08pt">Reporting of Transactions</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">To facilitate timely reporting under Section 16 of the Exchange Act of Section 16 Insider transactions in Company stock, Section 16 Insiders are required to (a) report the details of each transaction immediately after it is executed and (b) arrange with persons whose trades must be reported by the Section 16 Insider under Section 16 (such as immediate family members living in the Section 16 Insider&#8217;s household) to immediately report directly to the Company and to the Section 16 Insider the details of any transactions they have in the Company&#8217;s stock.</font></div><div style="padding-left:47pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Transaction details to be reported include&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:82.95pt;text-align:justify;text-indent:-17.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:14.28pt">Transaction date (trade date).</font></div><div style="padding-left:82.95pt;text-align:justify;text-indent:-17.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:14.28pt">Number of shares involved.</font></div><div style="padding-left:83pt;padding-right:5.75pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:14.33pt">Price per share at which the transaction was executed (before addition or deduction of brokerage commissions and other transaction fees).</font></div><div style="padding-left:82.95pt;text-align:justify;text-indent:-17.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:14.28pt">If the transaction was a stock option exercise, the specific option exercised.</font></div><div style="padding-left:82.95pt;text-align:justify;text-indent:-17.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:14.28pt">Contact information for the broker who executed the transaction.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">The transaction details must be reported to the Compliance Officer, with copies to the Company personnel who will assist the Section 16 Insider in preparing his or her Form 4.</font></div><div style="padding-left:11pt;padding-right:6pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:46.95pt;text-align:justify;text-indent:-35.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:28.08pt">Short-Swing Profit</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Restricted Persons may not engage in any &#8220;opposite way&#8221; (e.g. a sale if the Restricted Person is proposing a purchase, or a purchase if the Restricted Person is proposing a sale) transactions within the previous six months that were not exempt from Section 16(b) of the Exchange Act.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:46.95pt;text-align:justify;text-indent:-31.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:23.58pt">Form 4 Reporting</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.85pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Under Section 16, most trades by Section 16 Insiders are subject to reporting on Form 4 within two business days following the trade date (which in the case of an open market trade is the date when the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:0.8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Appendix-I</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:11pt;padding-right:5.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">broker places the buy or sell order, not the date when the trade is settled). To facilitate timely reporting, all transactions that are subject to Section 16 must be reported to the Company </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">on the same day as the trade date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">, or, with respect to transactions effected pursuant to a Rule 10b5-1 Plan, on the day the Section 16 Insider is advised of the terms of the transaction.</font></div><div style="padding-left:11pt;padding-right:5.85pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:46.95pt;text-align:justify;text-indent:-31.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%;padding-left:18.33pt">Special Guidelines for 10b5-1 Plans</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, a Restricted Person will not be deemed to have violated the Trading Policy if he or she effects a transaction that meets all of the enumerated criteria below.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:14.8pt">The transaction must be made pursuant to a non-discretionary plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Rule 10b5-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8221;) entered into in good faith that complies with all provisions of Rule 10b5-1 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">Rule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8221;), including, without limitation&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:101pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:10.13pt">Each Rule 10b5-1 Plan must be in the form of a written, binding contract that specifies either&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:6.05pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:700;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:17.13pt">the amount of securities to be purchased or sold and the price at which and the date on which the securities are to be purchased or sold,</font></div><div style="padding-left:11pt;padding-right:5.85pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:700;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:17.13pt">a written formula or algorithm, or computer program, for determining the amount of securities to be purchased or sold and the price at which and the date on which the securities are to be purchased or sold, or</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.8pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-style:italic;font-weight:700;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:17.72pt">that a third party retains the discretionary authority to execute purchases and sales thereunder, outside the control of the Restricted Person, so long as such third party does not possess any material nonpublic information about the Company.</font></div><div style="padding-right:5.8pt;text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.75pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:17.13pt">The Rule 10b5-1 Plan must prohibit the Restricted Person and any other person who possesses material nonpublic information from exercising any subsequent influence over how, when, or whether to effect purchases or sales and must state that any person executing Rule 10b5-1 Plan transactions may not deviate from Rule 10b5-1 Plan instructions.</font></div><div style="padding-left:83pt;padding-right:5.75pt;text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:15.38pt">Each Rule 10b5-1 Plan must be approved at least one (1) month prior to the effective time of such Rule 10b5-1 Plan by the Compliance Officer. The Company reserves the right to withhold approval of any Rule 10b5-1 Plan that the Compliance Officer determines, in its sole discretion&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:101pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:10.13pt">fails to comply with the Rule&#59;</font></div><div style="padding-left:101pt;text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:6.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:17.13pt">exposes the Company or the Restricted Person to liability under any other applicable state or federal rule, regulation or law&#59;</font></div><div style="padding-right:6.05pt;text-align:justify"><font><br></font></div><div style="padding-left:101pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:10.13pt">creates any appearance of impropriety&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:101pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:10.13pt">fails to meet the guidelines established by the Company&#59; or</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:17.13pt">otherwise fails to satisfy review by the Compliance Officer for any reason, such failure to be determined in the sole discretion of the Compliance Officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:64.9pt;text-align:justify;text-indent:-17.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:7.7pt">Each Rule 10b5-1 Plan must be established&#58;</font></div><div style="padding-left:64.9pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:0.8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Appendix-I</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:11pt;padding-right:6.05pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:17.13pt">at a time when the Restricted Person is not aware of material nonpublic information about the Company or the securities covered by the Rule 10b5-1 Plan&#59; and</font></div><div style="padding-left:101pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:10.13pt">at a time when the trading window is open&#59;</font></div><div style="padding-left:65pt;text-align:justify"><font><br></font></div><div style="padding-left:101pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:10.13pt">in good faith and not as part of a plan or scheme to evade the insider trading rules&#59;</font></div><div style="padding-left:11pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:9pt;text-indent:74pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:17.13pt">to provide that the first transaction under the Rule 10b5-1 Plan will occur no sooner than the later of ninety (90) days after the date of establishment of the Rule 10b5-1 Plan and two (2) business days following the filing of the Company&#8217;s Form 10-Q or Form 10-K containing financial results for the fiscal quarter in which the Rule 10b5-1 Plan was adopted (subject to a maximum waiting period of 120 days) (such period in which trades may not occur, the &#8220;Cooling-Off Period&#8221;).</font></div><div style="padding-left:47pt;padding-right:5.7pt;text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:14.8pt">Any modifications to the Rule 10b5-1 Plan, deviations from the Rule 10b5-1 Plan or termination of the Rule 10b5-1 Plan without prior approval of the Compliance Officer will result in a failure to comply with the Trading Policy. Any such modification, deviation or termination is subject to the approval of the Compliance Officer in accordance with Section B above. No Rule 10b5-1 Plan may be modified more than once in any 12-month period. Each Rule 10b5-1 Plan must include representations that&#58;</font></div><div style="padding-left:47pt;padding-right:5.7pt;text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:17.13pt">the Restricted Person will only modify the Rule 10b5-1 Plan while not aware of any material nonpublic information about the Company or the securities covered by the Rule 10b5-1 Plan and at a time when the Company&#8217;s trading window is open, and will require that the first transaction following modification of the Rule 10b5-1 Plan will be effected following the Cooling-Off Period running from the date of such modification&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:17.13pt">any termination of the Rule 10b5-1 Plan prior to its fixed termination date or sale of all securities will be made only when the Restricted Person is not aware of material nonpublic information about the Company or the securities covered by the Rule 10b5-1 Plan.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Following the termination of a Rule 10b5-1 Plan, the Restricted Person will not be permitted to establish a new Rule 10b5-1 Plan sooner than the first open trading window occurring after the Cooling-Off Period running from the date of termination.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:64.9pt;text-align:justify;text-indent:-17.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:8.28pt">Each Rule 10b5-1 Plan must either&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:17.13pt">have a fixed termination date that is at least twelve months after the date the first transaction is effectuated under the Rule 10b5-1 Plan&#59; or</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:6pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:17.13pt">continue for an indefinite period and until no more securities covered by the Rule 10b5-1 Plan remain available.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">F.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:15.97pt">Each Rule 10b5-1 Plan must restrict the size of the transactions which are to be effected under the Rule 10b5-1 Plan on any trading day to an amount that does not exceed 10% of the average daily trading volume over the period of four calendar weeks preceding the date of the transaction.</font></div><div style="padding-left:47pt;padding-right:6pt;text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">G.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:14.22pt">Each Rule 10b5-1 Plan must provide appropriate mechanisms to ensure that the Restricted Person complies with all rules and regulations, including Rule 144, Rule 701 and Section 16(b), applicable to securities transactions under the Rule 10b5-1 Plan by the Restricted Person.</font></div><div style="padding-left:11pt;text-indent:36pt"><font><br></font></div><div style="padding-left:11pt;padding-right:5.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">H.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:14.22pt">Each Rule 10b5-1 Plan must provide for automatic suspension or termination of the Rule 10b5-1 Plan in the sole discretion of the Company&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:0.8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Appendix-I</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:11pt;padding-right:5.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:17.13pt">to comply with a lock-up agreement required in connection with a securities issuance transaction in which the Company is a participant&#59; or</font></div><div style="padding-left:83pt;padding-right:5.85pt;text-align:justify"><font><br></font></div><div style="padding-left:101pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:10.13pt">upon the occurrence of an event that would violate the law&#59; or</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:101pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:10.13pt">upon the occurrence of other similar events.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:11pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Further, each Rule 10b5-1 Plan must provide for the suspension of all transactions under such Rule 10b5-1 Plan in the event that the Company, in its sole discretion, deems such suspension necessary and advisable.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:47pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:18.3pt">Each Rule 10b5-1 Plan must not be designed to effect the open-market purchase or sale of securities in a single transaction if such Restricted Person has adopted another Rule 10b5-1 Plan contemplating only a single transaction within the prior 12 months.</font></div><div style="padding-left:47pt;text-align:justify"><font><br></font></div><div style="padding-left:64.95pt;text-align:justify;text-indent:-17.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">J.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:10.08pt">Each Rule 10b5-1 Plan should include the following representations, warranties and covenants of the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Restricted Person&#58;</font></div><div style="padding-left:11pt;text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:17.13pt">As of the date the Rule 10b5-1 Plan is established, the Restricted Person is not aware of any material nonpublic information concerning the Company or the securities covered by the Rule 10b5-1 Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:17.13pt">The Restricted Person is entering into the Rule 10b5-1 Plan in good faith and not as part of a plan or scheme to evade compliance with federal or state securities laws.</font></div><div style="padding-left:83pt;padding-right:5.9pt;text-align:justify"><font><br></font></div><div style="padding-left:9pt;padding-right:5.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:19.13pt">While the Rule 10b5-1 Plan is in effect, the Restricted Person agrees not to enter into or alter any corresponding or hedging transaction or position with respect to the securities covered by the Rule 10b5-1 Plan. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.95pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:17.13pt">The Restricted Person agrees that he or she shall not, directly or indirectly, communicate any information relating to the securities or the Company to any broker, dealer, financial advisor, trustee or any other third party who is involved, directly or indirectly, in executing the Rule 10b5-1 Plan at any time while the Rule 10b5-1 Plan is in effect.</font></div><div style="padding-right:5.95pt;text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:17.13pt">The Restricted Person agrees not to take, and agrees to cause any person or entity with which the Restricted Person would be required to aggregate sales of securities pursuant to paragraph (a)(2) or (e) of Rule 144 not to take, any action that would cause the sales made under the Rule 10b5-1 Plan not to meet all applicable requirements of Rule 144.</font></div><div style="padding-left:83pt;padding-right:5.85pt;text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.95pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:17.13pt">The Restricted Person agrees to timely make all filings required under the Securities Act of 1933, as amended, and the Exchange Act.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:17.13pt">The Restricted Person acknowledges and agrees that the he or she does not have, and shall not attempt to exercise, any influence over how, when or whether to effect purchases or sales of securities pursuant to the Rule 10b5-1 Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:17.13pt">The Restricted Person agrees that any modifications to the Rule 10b5-1 Plan must be made in good faith at a time when the Restricted Person is not aware of any material nonpublic information concerning the Company or the securities covered by the Rule 10b5-1 Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:0.8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Appendix-I</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:11pt;padding-right:5.9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:17.13pt">The Restricted Person agrees that termination of the Rule 10b5-1 Plan prior to its expiration pursuant to the terms of the Rule 10b5-1 Plan will be made in good faith.</font></div><div style="padding-right:5.9pt;text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.85pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:11.88pt">The Restricted Person agrees that the Company is required to publicly disclose each quarter whether directors or certain officers have adopted, modified, or terminated a Rule 10b5-1 Plan during the quarter covered by such periodic report (or the fourth quarter in the case of an annual report on Form 10-K), may, in its sole discretion, make public announcements regarding the Rule 10b5-1 Plan in any press release or filings with the SEC, including, among other things, the name of the director or officer, the date of adoption or termination, the duration, the aggregate number of securities to be purchased or sold, and to the extent required or advisable under applicable law, information as to the timing of the transactions and the amount and price of the securities to be sold.</font></div><div style="padding-right:5.85pt;text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:11.88pt">The Restricted Person agrees to return any securities not sold pursuant to the Rule 10b5-1 Plan to the Company for relegending.</font></div><div style="padding-right:5.9pt;text-align:justify"><font><br></font></div><div style="padding-left:11pt;padding-right:5.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:120%">K.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:14.22pt">None of the Company, the Board of Directors, the Compliance Officer nor any of the Company&#8217;s officers, employees or other representatives shall be deemed, solely by their approval of an Restricted Person&#8217;s Rule 10b5-1 Plan, to have represented that any Rule 10b5-1 Plan complies with the Rule or to have assumed any liability or responsibility to the Insider or any other party if such Rule 10b5-1 Plan fails to comply with the Rule.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:0.8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Appendix-I</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>exhibit21112312410k.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i1194e066cb7f440bbe7966a8bf7f8000_1"></div><div style="min-height:36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:138%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">EVOLUS, INC.</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:138%">LIST OF SUBSIDIARIES</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.194%"><tr><td style="width:1.0%"></td><td style="width:43.013%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Name of Subsidiary</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Jurisdiction of Incorporation or Organization</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Evolus Pharma Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Ireland</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Evolus Pharma BV</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Netherlands</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Evolus International Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">United Kingdom</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Evolus GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Germany</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Evolus Australia Pty Ltd</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Australia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Evolus-Pharma Spain SL</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Spain</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Evolus New Zealand Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">New Zealand</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>exhibit23112312410k.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i99a6715c24894227b558f0fbcab9414c_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;23.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1)</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">Registration Statement (Form S-8 No. 333-223068), pertaining to the Evolus, Inc. 2017 Omnibus Incentive Plan of Evolus, Inc., </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(2)</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">Registration Statement (Form S-8 No. 333-229184), pertaining to the Evolus, Inc. 2017 Omnibus Incentive Plan of Evolus, Inc., </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(3)</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">Registration Statement (Form S-8 No. 333-236620), pertaining to the Evolus, Inc. 2017 Omnibus Incentive Plan of Evolus, Inc., </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(4)</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">Registration Statement (Form S-8 No. 333-254746), pertaining to the Evolus, Inc. 2017 Omnibus Incentive Plan of Evolus, Inc., </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(5)</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">Registration Statement (Form S-8 No. 333-263325), pertaining to (i) the Evolus, Inc. 2017 Omnibus Incentive Plan of Evolus, Inc., (ii) certain Inducement Stock Option awards, and (iii) certain Inducement Restricted Stock Unit awards,</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(6)</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">Registration Statement (Form S-8 No. 333-267359), pertaining to (i) certain Inducement Stock Option awards and (ii) certain Inducement Restricted Stock Unit awards,</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(7)</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">Registration Statement (Form S-8 No. 333-270360) pertaining to the Evolus, Inc. 2017 Omnibus Incentive Plan of Evolus, Inc.,</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(8)</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">Registration Statement (Form S-3 333-270370), </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(9)</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:6.34pt">Registration Statement (Form S-8 No. 333-274906), pertaining to (i) the Evolus, Inc. 2023 Inducement Incentive Plan of Evolus, Inc. (ii) certain Inducement Stock Option awards, and (iii) certain Inducement Restricted Stock Unit awards&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(10)</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:1.34pt">Registration Statement (Form S-8 No. 333-277754), pertaining to the Evolus, Inc. 2017 Omnibus Incentive Plan of Evolus, Inc., and</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(11)</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:1.34pt">Registration Statement (Form S-8 No. 333-283043), pertaining to the Evolus, Inc. 2024 Employee Stock Purchase Plan of Evolus, Inc&#59; </font></div><div><font><br></font></div><div><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of our reports dated March 4, 2025, with respect to the consolidated financial statements of Evolus, Inc. and the effectiveness of internal control over financial reporting of Evolus, Inc. included in this Annual Report (Form 10-K) of Evolus, Inc. for the year ended December 31, 2024.</font></div><div><font><br></font></div><div style="margin-bottom:8pt;margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:24.825%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:72.975%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Ernst &#38; Young LLP</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Irvine, California&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;4, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>exhibit31112312410k.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i63f5c102536b41169c10e198c2322249_1"></div><div style="min-height:45pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, David Moatazedi, certify that&#58;</font></div><div style="margin-bottom:9pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">I have reviewed this Annual Report on Form 10-K of Evolus, Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such&#160;internal control over financial reporting, or caused such&#160;internal control over financial reporting&#160;to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.460%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 4, 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; David Moatazedi</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Moatazedi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>exhibit31212312410k.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i074a4c8b271e4efcb0750af4ee8846a1_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Sandra Beaver, certify that&#58;</font></div><div style="margin-bottom:9pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">I have reviewed this Annual Report on Form 10-K of Evolus, Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:49.5pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:49.5pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such&#160;internal control over financial reporting, or caused such&#160;internal control over financial reporting&#160;to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:49.5pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:49.5pt;text-align:justify;text-indent:-20.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:49.5pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.215%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 4, 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Sandra Beaver</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sandra Beaver</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>exhibit32112312410k.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="iadc7b4534b8f4d0dac65a1f2b7849257_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#167; 1350 AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the undersigned hereby certifies, pursuant to 18 U.S.C. &#167;&#160;1350, as adopted in accordance with Section&#160;906 of the Sarbanes-Oxley Act of 2002, in his or her capacity as an officer of Evolus, Inc., that, to his or her knowledge&#58;</font></div><div style="margin-bottom:10pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) the Annual Report on Form&#160;10-K of Evolus, Inc. for the fiscal year ended December&#160;31, 2024 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934&#59; and </font></div><div style="margin-bottom:10pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Evolus, Inc.</font></div><div style="padding-left:24.75pt;text-indent:-22.5pt"><font><br></font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.274%"><tr><td style="width:1.0%"></td><td style="width:43.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.915%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.513%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 4, 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; David Moatazedi</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Moatazedi</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 4, 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Sandra Beaver</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sandra Beaver</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>eols-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:919f993d-eaea-4622-b01f-fde76d4f5f0d,g:96b2bf92-d476-42b7-9d6e-4ee6308f0735-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:eols="http://www.evolus.com/20241231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.evolus.com/20241231">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af-sub/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eols-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eols-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eols-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eols-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.evolus.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.evolus.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.evolus.com/role/ConsolidatedBalanceSheets">
        <link:definition>9952151 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.evolus.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>9952153 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquityDeficit" roleURI="http://www.evolus.com/role/ConsolidatedStatementsofStockholdersEquityDeficit">
        <link:definition>9952154 - Statement - Consolidated Statements of Stockholders&#8217; Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.evolus.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>9952155 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusiness" roleURI="http://www.evolus.com/role/DescriptionofBusiness">
        <link:definition>9952156 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPolicies" roleURI="http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies">
        <link:definition>9952157 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.evolus.com/role/FairValueMeasurements">
        <link:definition>9952158 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssets">
        <link:definition>9952159 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://www.evolus.com/role/AccruedExpenses">
        <link:definition>9952160 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipment" roleURI="http://www.evolus.com/role/PropertyPlantandEquipment">
        <link:definition>9952161 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TermLoans" roleURI="http://www.evolus.com/role/TermLoans">
        <link:definition>9952162 - Disclosure - Term Loans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeases" roleURI="http://www.evolus.com/role/OperatingLeases">
        <link:definition>9952163 - Disclosure - Operating Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.evolus.com/role/CommitmentsandContingencies">
        <link:definition>9952164 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.evolus.com/role/StockholdersEquity">
        <link:definition>9952165 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedytoxSettlementAgreements" roleURI="http://www.evolus.com/role/MedytoxSettlementAgreements">
        <link:definition>9952166 - Disclosure - Medytox Settlement Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlan" roleURI="http://www.evolus.com/role/EmployeeBenefitPlan">
        <link:definition>9952167 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.evolus.com/role/IncomeTaxes">
        <link:definition>9952168 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://www.evolus.com/role/SegmentReporting">
        <link:definition>9952169 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.evolus.com/role/SubsequentEvents">
        <link:definition>9952170 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9955511 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.evolus.com/role/FairValueMeasurementsTables">
        <link:definition>9955512 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>9955513 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://www.evolus.com/role/AccruedExpensesTables">
        <link:definition>9955514 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentTables" roleURI="http://www.evolus.com/role/PropertyPlantandEquipmentTables">
        <link:definition>9955515 - Disclosure - Property, Plant and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TermLoansTables" roleURI="http://www.evolus.com/role/TermLoansTables">
        <link:definition>9955516 - Disclosure - Term Loans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesTables" roleURI="http://www.evolus.com/role/OperatingLeasesTables">
        <link:definition>9955517 - Disclosure - Operating Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.evolus.com/role/StockholdersEquityTables">
        <link:definition>9955518 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.evolus.com/role/IncomeTaxesTables">
        <link:definition>9955519 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://www.evolus.com/role/SegmentReportingTables">
        <link:definition>9955520 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessDetails" roleURI="http://www.evolus.com/role/DescriptionofBusinessDetails">
        <link:definition>9955521 - Disclosure - Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails">
        <link:definition>9955522 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" roleURI="http://www.evolus.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails">
        <link:definition>9955523 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.evolus.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>9955524 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsReconciliationofFairValueMeasurementofContingentRoyaltyObligationPayableDetails" roleURI="http://www.evolus.com/role/FairValueMeasurementsReconciliationofFairValueMeasurementofContingentRoyaltyObligationPayableDetails">
        <link:definition>9955525 - Disclosure - Fair Value Measurements - Reconciliation of Fair Value Measurement of Contingent Royalty Obligation Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails" roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails">
        <link:definition>9955526 - Disclosure - Goodwill and Intangible Assets - Schedule of Definite and Indefinite-Lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails_1" roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails_1">
        <link:definition>9955526 - Disclosure - Goodwill and Intangible Assets - Schedule of Definite and Indefinite-Lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails" roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails">
        <link:definition>9955527 - Disclosure - Goodwill and Intangible Assets - Estimated Future Amortization Expense of Intangibles (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNarrativeDetails" roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails">
        <link:definition>9955528 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesDetails" roleURI="http://www.evolus.com/role/AccruedExpensesDetails">
        <link:definition>9955529 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" roleURI="http://www.evolus.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails">
        <link:definition>9955530 - Disclosure - Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNarrativeDetails" roleURI="http://www.evolus.com/role/PropertyPlantandEquipmentNarrativeDetails">
        <link:definition>9955531 - Disclosure - Property, Plant and Equipment - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TermLoansNarrativeDetails" roleURI="http://www.evolus.com/role/TermLoansNarrativeDetails">
        <link:definition>9955532 - Disclosure - Term Loans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TermLoansScheduleofLongTermDebtMaturitiesDetails" roleURI="http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails">
        <link:definition>9955533 - Disclosure - Term Loans - Schedule of Long Term Debt Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesNarrativeDetails" roleURI="http://www.evolus.com/role/OperatingLeasesNarrativeDetails">
        <link:definition>9955534 - Disclosure - Operating Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesComponentsofLeaseExpenseandOtherQuantitativeInformationDetails" roleURI="http://www.evolus.com/role/OperatingLeasesComponentsofLeaseExpenseandOtherQuantitativeInformationDetails">
        <link:definition>9955535 - Disclosure - Operating Leases - Components of Lease Expense and Other Quantitative Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesWeightedAverageRemainingLeaseTermandDiscountRateDetails" roleURI="http://www.evolus.com/role/OperatingLeasesWeightedAverageRemainingLeaseTermandDiscountRateDetails">
        <link:definition>9955536 - Disclosure - Operating Leases - Weighted-Average Remaining Lease Term and Discount Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails" roleURI="http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails">
        <link:definition>9955537 - Disclosure - Operating Leases - Maturity of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails_1" roleURI="http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails_1">
        <link:definition>9955537 - Disclosure - Operating Leases - Maturity of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesDetails" roleURI="http://www.evolus.com/role/CommitmentandContingenciesDetails">
        <link:definition>9955538 - Disclosure - Commitment and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.evolus.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>9955539 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofWeightedAverageAssumptionsDetails" roleURI="http://www.evolus.com/role/StockholdersEquityScheduleofWeightedAverageAssumptionsDetails">
        <link:definition>9955540 - Disclosure - Stockholders' Equity - Schedule of Weighted-Average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofStockOptionActivityDetails" roleURI="http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails">
        <link:definition>9955541 - Disclosure - Stockholders' Equity - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofRestrictedStockUnitActivityDetails" roleURI="http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails">
        <link:definition>9955542 - Disclosure - Stockholders' Equity - Schedule of Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityStockbasedCompensationExpenseDetails" roleURI="http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseDetails">
        <link:definition>9955543 - Disclosure - Stockholders' Equity - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedytoxSettlementAgreementsDetails" roleURI="http://www.evolus.com/role/MedytoxSettlementAgreementsDetails">
        <link:definition>9955544 - Disclosure - Medytox Settlement Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlanDetails" roleURI="http://www.evolus.com/role/EmployeeBenefitPlanDetails">
        <link:definition>9955545 - Disclosure - Employee Benefit Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofLossbeforeIncomeTaxesfromUSOperationsandForeignDetails" roleURI="http://www.evolus.com/role/IncomeTaxesScheduleofLossbeforeIncomeTaxesfromUSOperationsandForeignDetails">
        <link:definition>9955546 - Disclosure - Income Taxes - Schedule of Loss before Income Taxes from U.S. Operations and Foreign (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofComponentsofCurrentandDeferredIncomeTaxExpenseDetails" roleURI="http://www.evolus.com/role/IncomeTaxesScheduleofComponentsofCurrentandDeferredIncomeTaxExpenseDetails">
        <link:definition>9955547 - Disclosure - Income Taxes - Schedule of Components of Current and Deferred Income Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.evolus.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>9955548 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>9955549 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofEffectiveIncomeTaxDetails" roleURI="http://www.evolus.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxDetails">
        <link:definition>9955550 - Disclosure - Income Taxes - Schedule of Effective Income Tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" roleURI="http://www.evolus.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails">
        <link:definition>9955551 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingNarrativeDetails" roleURI="http://www.evolus.com/role/SegmentReportingNarrativeDetails">
        <link:definition>9955552 - Disclosure - Segment Reporting - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" roleURI="http://www.evolus.com/role/SegmentReportingReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails">
        <link:definition>9955553 - Disclosure - Segment Reporting - Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingScheduleofRevenuebyCountryDetails" roleURI="http://www.evolus.com/role/SegmentReportingScheduleofRevenuebyCountryDetails">
        <link:definition>9955554 - Disclosure - Segment Reporting - Schedule of Revenue by Country (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="eols_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" abstract="false" name="ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_LicenseSupplyAndDistributionAgreementContingentMilestoneLiabilityNoncurrent" abstract="false" name="LicenseSupplyAndDistributionAgreementContingentMilestoneLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_ResearchAndDevelopmentInProcess1" abstract="false" name="ResearchAndDevelopmentInProcess1" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_StockIssuedDuringPeriodSharesIncentiveEquityPlan" abstract="false" name="StockIssuedDuringPeriodSharesIncentiveEquityPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="eols_StockIssuedDuringPeriodValueIncentiveEquityPlan" abstract="false" name="StockIssuedDuringPeriodValueIncentiveEquityPlan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement" abstract="false" name="StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="eols_StockIssuedDuringPeriodValueIssuedForLicenseSupplyAndDistributionAgreement" abstract="false" name="StockIssuedDuringPeriodValueIssuedForLicenseSupplyAndDistributionAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_NonCashInResearchAndDevelopmentInProcessExpenses" abstract="false" name="NonCashInResearchAndDevelopmentInProcessExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_IncreaseDecreaseInOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_PaymentsOfContingentRoyaltyObligation" abstract="false" name="PaymentsOfContingentRoyaltyObligation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_IntellectualPropertyDisputesJeuveauMember" abstract="true" name="IntellectualPropertyDisputesJeuveauMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="eols_FollowOnOfferingMember" abstract="true" name="FollowOnOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="eols_SymateseEuropeAgreementMember" abstract="true" name="SymateseEuropeAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_SymateseU.S.AgreementMember" abstract="true" name="SymateseU.S.AgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts" abstract="false" name="LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="eols_LicenseSupplyAndDistributionAgreementExpectedRegulatoryApprovalNumberOfProducts" abstract="false" name="LicenseSupplyAndDistributionAgreementExpectedRegulatoryApprovalNumberOfProducts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="eols_SaleOfStockGrantedOptionsExercisablePeriod" abstract="false" name="SaleOfStockGrantedOptionsExercisablePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eols_DistributionRightsEvolysseNasolabialFoldProductMember" abstract="true" name="DistributionRightsEvolysseNasolabialFoldProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_DistributionRightsEvolysseProductsMember" abstract="true" name="DistributionRightsEvolysseProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_EvolusIncMember" abstract="true" name="EvolusIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="eols_SCHAEONLLCMember" abstract="true" name="SCHAEONLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="eols_MilestoneAxis" abstract="true" name="MilestoneAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="eols_MilestoneDomain" abstract="true" name="MilestoneDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_FirstMilestonePaymentMember" abstract="true" name="FirstMilestonePaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_SecondMilestonePaymentMember" abstract="true" name="SecondMilestonePaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_PerformanceRestrictedStockUnitsPRSUMember" abstract="true" name="PerformanceRestrictedStockUnitsPRSUMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="eols_AccountsReceivableCreditCardTransactionConvertedToCashPeriod" abstract="false" name="AccountsReceivableCreditCardTransactionConvertedToCashPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eols_LicenseSupplyAndDistributionAgreementRightToCommercializeAndDistributeNumberOfProductCandidates" abstract="false" name="LicenseSupplyAndDistributionAgreementRightToCommercializeAndDistributeNumberOfProductCandidates" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="eols_LicenseSupplyAndDistributionAgreementMinimumMilestonePayment" abstract="false" name="LicenseSupplyAndDistributionAgreementMinimumMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement" abstract="false" name="LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod" abstract="false" name="LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne" abstract="false" name="LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo" abstract="false" name="LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree" abstract="false" name="LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour" abstract="false" name="LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense" abstract="false" name="LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_LicenseSupplyAndDistributionAgreementInitialTerm" abstract="false" name="LicenseSupplyAndDistributionAgreementInitialTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eols_LicenseSupplyAndDistributionAgreementRenewalTerm" abstract="false" name="LicenseSupplyAndDistributionAgreementRenewalTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eols_LicenseSupplyAndDistributionAgreementNumberOfProductCandidates" abstract="false" name="LicenseSupplyAndDistributionAgreementNumberOfProductCandidates" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="eols_LicenseSupplyAndDistributionAgreementNumberOfCountriesUseAestheticsAndDermatologicalFields" abstract="false" name="LicenseSupplyAndDistributionAgreementNumberOfCountriesUseAestheticsAndDermatologicalFields" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="eols_LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment" abstract="false" name="LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="eols_LicenseSupplyAndDistributionAgreementAnnualRevenue" abstract="false" name="LicenseSupplyAndDistributionAgreementAnnualRevenue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_LicenseSupplyAndDistributionAgreementPendingRegulatoryApprovalNumberOfProducts" abstract="false" name="LicenseSupplyAndDistributionAgreementPendingRegulatoryApprovalNumberOfProducts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="eols_LicenseSupplyAndDistributionAgreementMilestonePaymentPayablePeriod" abstract="false" name="LicenseSupplyAndDistributionAgreementMilestonePaymentPayablePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eols_LicenseSupplyAndDistributionAgreementLiabilityNoncurrent" abstract="false" name="LicenseSupplyAndDistributionAgreementLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_LicenseSupplyAndDistributionAgreementIntangibleAsset" abstract="false" name="LicenseSupplyAndDistributionAgreementIntangibleAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale" abstract="false" name="RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eols_RebatesAndCouponsCreditsAndPayments" abstract="false" name="RebatesAndCouponsCreditsAndPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability" abstract="false" name="PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_AccountsReceivableAllowanceForCreditLossWriteOffRecovery" abstract="false" name="AccountsReceivableAllowanceForCreditLossWriteOffRecovery" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_LossContingencySettlementAgreementPaymentTerms" abstract="false" name="LossContingencySettlementAgreementPaymentTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eols_StockIssuedDuringPeriodSharesLitigationSettlement" abstract="false" name="StockIssuedDuringPeriodSharesLitigationSettlement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="eols_ContingentRoyaltyObligationMember" abstract="true" name="ContingentRoyaltyObligationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="eols_PharmakonTermLoansMember" abstract="true" name="PharmakonTermLoansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="eols_IntangibleAssetsGrossIncludingGoodwill" abstract="false" name="IntangibleAssetsGrossIncludingGoodwill" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_MarketingFixturesMember" abstract="true" name="MarketingFixturesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_PharmakonTermLoansOneMember" abstract="true" name="PharmakonTermLoansOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="eols_PharmakonTermLoansTwoMember" abstract="true" name="PharmakonTermLoansTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="eols_DebtInstrumentPrepaymentTermsAxis" abstract="true" name="DebtInstrumentPrepaymentTermsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="eols_DebtInstrumentPrepaymentTermsDomain" abstract="true" name="DebtInstrumentPrepaymentTermsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="eols_TermOneMember" abstract="true" name="TermOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="eols_TermTwoMember" abstract="true" name="TermTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="eols_TermThreeMember" abstract="true" name="TermThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="eols_LondonInterbankOfferedRateLIBOR1Member" abstract="true" name="LondonInterbankOfferedRateLIBOR1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_SecuredFinancingOfferedRateSOFRMember" abstract="true" name="SecuredFinancingOfferedRateSOFRMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_DebtInstrumentNumberOfTranches" abstract="false" name="DebtInstrumentNumberOfTranches" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="eols_DebtInstrumentNumberOfInstallments" abstract="false" name="DebtInstrumentNumberOfInstallments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="eols_DebtInstrumentPeriodicPaymentOutstandingPrincipalAmountDuePercentage" abstract="false" name="DebtInstrumentPeriodicPaymentOutstandingPrincipalAmountDuePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="eols_DebtInstrumentPeriodicPaymentNumberOfPrincipalPayments" abstract="false" name="DebtInstrumentPeriodicPaymentNumberOfPrincipalPayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="eols_DebtInstrumentPeriodicPaymentInitialPrincipalPaymentDuePeriod" abstract="false" name="DebtInstrumentPeriodicPaymentInitialPrincipalPaymentDuePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eols_DebtInstrumentPrepaymentAmountThreshold" abstract="false" name="DebtInstrumentPrepaymentAmountThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount" abstract="false" name="DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="eols_LesseeOperatingLeaseAbatementPeriod" abstract="false" name="LesseeOperatingLeaseAbatementPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eols_PaymentsForInventory" abstract="false" name="PaymentsForInventory" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_LicenseSupplyAndDistributionAgreementAnnualPaymentTriggeredRegulatoryApprovalNumberOfProducts" abstract="false" name="LicenseSupplyAndDistributionAgreementAnnualPaymentTriggeredRegulatoryApprovalNumberOfProducts" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="eols_LossContingencyNumberDefendantsOfficers" abstract="false" name="LossContingencyNumberDefendantsOfficers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="eols_ATMSalesAgreementMember" abstract="true" name="ATMSalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="eols_A2023InducementIncentivePlanMember" abstract="true" name="A2023InducementIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_TwoThousandAndSeventeenOmnibusIncentivePlanMember" abstract="true" name="TwoThousandAndSeventeenOmnibusIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_A2024EmployeeStockPurchasePlanMember" abstract="true" name="A2024EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_CEOPerformanceRestrictedShareUnitsCPRSUMember" abstract="true" name="CEOPerformanceRestrictedShareUnitsCPRSUMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalShareIncreaseAvailableForIssuance" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalShareIncreaseAvailableForIssuance" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="eols_SaleOfStockMaximumConsiderationReceivable" abstract="false" name="SaleOfStockMaximumConsiderationReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage" abstract="false" name="SaleOfStockCommissionPaymentUponGrossProceedsPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" abstract="false" name="CommonStockAdditionalCapitalSharesReservedforFutureIssuance" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueVested" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueVested" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eols_ShareBasedPaymentArrangementNumberOfConsecutiveDays" abstract="false" name="ShareBasedPaymentArrangementNumberOfConsecutiveDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="eols_ShareBasedCompensationConsecutiveTradingDaysPerShareTarget" abstract="false" name="ShareBasedCompensationConsecutiveTradingDaysPerShareTarget" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsAfterTermination" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsAfterTermination" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract" abstract="true" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="eols_LossContingencySettlementAgreementManufacturingLicensePeriod" abstract="false" name="LossContingencySettlementAgreementManufacturingLicensePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodOne" abstract="false" name="ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodOne" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodTwo" abstract="false" name="ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodTwo" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodThree" abstract="false" name="ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodThree" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="eols_DeferredTaxAssetsOperatingLeaseLiabilities" abstract="false" name="DeferredTaxAssetsOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_DeferredTaxAssetsResearchAndExperimentationCapitalization" abstract="false" name="DeferredTaxAssetsResearchAndExperimentationCapitalization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_DeferredTaxAssetsFixedAssetDepreciation" abstract="false" name="DeferredTaxAssetsFixedAssetDepreciation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation" abstract="false" name="EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation" abstract="false" name="EffectiveIncomeTaxRateReconciliationOfficersCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="eols_ReportableSegmentMember" abstract="true" name="ReportableSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>eols-20241231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:919f993d-eaea-4622-b01f-fde76d4f5f0d,g:96b2bf92-d476-42b7-9d6e-4ee6308f0735-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.evolus.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="eols-20241231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_cf1bd238-960f-43c7-855d-e33d70bbfdda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7cd6a1dc-d126-4149-826c-20bcdcf673fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cf1bd238-960f-43c7-855d-e33d70bbfdda" xlink:to="loc_us-gaap_StockholdersEquity_7cd6a1dc-d126-4149-826c-20bcdcf673fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_a8e32910-d70f-42ec-8c9a-88f57e461f26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cf1bd238-960f-43c7-855d-e33d70bbfdda" xlink:to="loc_us-gaap_CommitmentsAndContingencies_a8e32910-d70f-42ec-8c9a-88f57e461f26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2010aaad-e63b-4b79-8990-6835f56e75c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cf1bd238-960f-43c7-855d-e33d70bbfdda" xlink:to="loc_us-gaap_Liabilities_2010aaad-e63b-4b79-8990-6835f56e75c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4aa33a7c-6b80-4978-98b4-3d780d05ae3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_95e27ee2-cdb5-43d8-916d-f19dd5cad820" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4aa33a7c-6b80-4978-98b4-3d780d05ae3a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_95e27ee2-cdb5-43d8-916d-f19dd5cad820" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_ca196b9e-4496-4c0c-b2db-9aaa387869d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4aa33a7c-6b80-4978-98b4-3d780d05ae3a" xlink:to="loc_us-gaap_InventoryNet_ca196b9e-4496-4c0c-b2db-9aaa387869d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a19a74f4-0e7f-4bb6-bf68-6bbeca622adf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4aa33a7c-6b80-4978-98b4-3d780d05ae3a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a19a74f4-0e7f-4bb6-bf68-6bbeca622adf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_375271ce-d95b-4e0c-8915-7387590e11f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4aa33a7c-6b80-4978-98b4-3d780d05ae3a" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_375271ce-d95b-4e0c-8915-7387590e11f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_20e85f62-cb34-4b33-9d8a-985a5839990b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4aa33a7c-6b80-4978-98b4-3d780d05ae3a" xlink:to="loc_us-gaap_OtherAssetsCurrent_20e85f62-cb34-4b33-9d8a-985a5839990b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a02a8126-a2fe-4f10-b4f5-f3b1d0c226ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_723373eb-6b75-4612-bd00-d9259e8bfc2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a02a8126-a2fe-4f10-b4f5-f3b1d0c226ae" xlink:to="loc_us-gaap_AccountsPayableCurrent_723373eb-6b75-4612-bd00-d9259e8bfc2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_093e47f9-7669-436f-9516-985c432eb2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a02a8126-a2fe-4f10-b4f5-f3b1d0c226ae" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_093e47f9-7669-436f-9516-985c432eb2bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ecfb2772-5ef0-4f69-9d08-f868ddf7fb45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a02a8126-a2fe-4f10-b4f5-f3b1d0c226ae" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ecfb2772-5ef0-4f69-9d08-f868ddf7fb45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_6f0c1bf9-0336-40c5-a5ac-eb77137c102a" xlink:href="eols-20241231.xsd#eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_a02a8126-a2fe-4f10-b4f5-f3b1d0c226ae" xlink:to="loc_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_6f0c1bf9-0336-40c5-a5ac-eb77137c102a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8b60185b-3479-4e1c-ad5c-0ca1bbde7bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_88a51786-4a34-498a-ab4a-b0c27d14f6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8b60185b-3479-4e1c-ad5c-0ca1bbde7bb9" xlink:to="loc_us-gaap_PreferredStockValue_88a51786-4a34-498a-ab4a-b0c27d14f6f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_8fe07b9f-d7ee-4bfc-91c4-b068b71bafc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8b60185b-3479-4e1c-ad5c-0ca1bbde7bb9" xlink:to="loc_us-gaap_CommonStockValue_8fe07b9f-d7ee-4bfc-91c4-b068b71bafc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3a8de733-32e2-435f-ad05-126943aa415d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8b60185b-3479-4e1c-ad5c-0ca1bbde7bb9" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3a8de733-32e2-435f-ad05-126943aa415d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e571389d-551f-40bc-b2c4-ba6293f3e42e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8b60185b-3479-4e1c-ad5c-0ca1bbde7bb9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e571389d-551f-40bc-b2c4-ba6293f3e42e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7e5040d6-e831-4a41-be71-17b6ed9bbca7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_8b60185b-3479-4e1c-ad5c-0ca1bbde7bb9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7e5040d6-e831-4a41-be71-17b6ed9bbca7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_cc743862-9d2a-4d2f-8f77-f1a50f547542" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_62f22e04-cb24-4ae2-8a99-92b0fc516877" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_cc743862-9d2a-4d2f-8f77-f1a50f547542" xlink:to="loc_us-gaap_LiabilitiesCurrent_62f22e04-cb24-4ae2-8a99-92b0fc516877" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_fa24e477-f1ae-4cb5-8ea1-2012ad880352" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_cc743862-9d2a-4d2f-8f77-f1a50f547542" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_fa24e477-f1ae-4cb5-8ea1-2012ad880352" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementContingentMilestoneLiabilityNoncurrent_86595b91-dffc-4b5c-81e2-d4faa99030ba" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementContingentMilestoneLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_cc743862-9d2a-4d2f-8f77-f1a50f547542" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementContingentMilestoneLiabilityNoncurrent_86595b91-dffc-4b5c-81e2-d4faa99030ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_78e2ce47-4946-4d13-8e1e-9117746189e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_cc743862-9d2a-4d2f-8f77-f1a50f547542" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_78e2ce47-4946-4d13-8e1e-9117746189e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_8247af45-2b9e-4d3b-b407-86c65b310f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_cc743862-9d2a-4d2f-8f77-f1a50f547542" xlink:to="loc_us-gaap_ContractualObligation_8247af45-2b9e-4d3b-b407-86c65b310f0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt_f2a07f91-655c-425b-92e9-9160e03ef080" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_cc743862-9d2a-4d2f-8f77-f1a50f547542" xlink:to="loc_us-gaap_SecuredLongTermDebt_f2a07f91-655c-425b-92e9-9160e03ef080" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0f9404c9-46f3-47a0-b7fb-c67589021834" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1838a808-ba0d-470c-b6c9-88456b46fadf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0f9404c9-46f3-47a0-b7fb-c67589021834" xlink:to="loc_us-gaap_AssetsCurrent_1838a808-ba0d-470c-b6c9-88456b46fadf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_16968186-81d8-4835-bafb-bff6f12ae2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0f9404c9-46f3-47a0-b7fb-c67589021834" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_16968186-81d8-4835-bafb-bff6f12ae2d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_20530616-55ff-400e-a220-c6bf1f4dcd08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0f9404c9-46f3-47a0-b7fb-c67589021834" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_20530616-55ff-400e-a220-c6bf1f4dcd08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_24ad51fb-c85a-42a2-a29e-3923821d5193" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0f9404c9-46f3-47a0-b7fb-c67589021834" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_24ad51fb-c85a-42a2-a29e-3923821d5193" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_af89bd6d-e9e9-4599-8f10-fdac85180234" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0f9404c9-46f3-47a0-b7fb-c67589021834" xlink:to="loc_us-gaap_Goodwill_af89bd6d-e9e9-4599-8f10-fdac85180234" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_8706583b-c009-4c15-9cb3-242ebd66ef6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0f9404c9-46f3-47a0-b7fb-c67589021834" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_8706583b-c009-4c15-9cb3-242ebd66ef6e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="eols-20241231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_c8c3be62-f091-4374-87a9-ef3a3042241a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_ae12eda8-487e-4a03-8d94-b0c1282c17a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c8c3be62-f091-4374-87a9-ef3a3042241a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_ae12eda8-487e-4a03-8d94-b0c1282c17a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_03b7f1db-a1cf-42c2-aae1-1bd2fb15cc32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c8c3be62-f091-4374-87a9-ef3a3042241a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_03b7f1db-a1cf-42c2-aae1-1bd2fb15cc32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_b21bd5ea-d7f3-4044-8770-835645cd3cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c8c3be62-f091-4374-87a9-ef3a3042241a" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_b21bd5ea-d7f3-4044-8770-835645cd3cc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6e41456f-0c45-4b84-93fe-777bd9b1d443" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c8c3be62-f091-4374-87a9-ef3a3042241a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6e41456f-0c45-4b84-93fe-777bd9b1d443" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ResearchAndDevelopmentInProcess1_f5675228-073f-4221-96f3-07b1ee1e91c2" xlink:href="eols-20241231.xsd#eols_ResearchAndDevelopmentInProcess1"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_c8c3be62-f091-4374-87a9-ef3a3042241a" xlink:to="loc_eols_ResearchAndDevelopmentInProcess1_f5675228-073f-4221-96f3-07b1ee1e91c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a0f6a848-c194-4fe2-9d2f-df2fd70f09b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_1ffdd1d9-b180-47c0-a20b-6f87047fe818" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a0f6a848-c194-4fe2-9d2f-df2fd70f09b5" xlink:to="loc_us-gaap_CostsAndExpenses_1ffdd1d9-b180-47c0-a20b-6f87047fe818" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_8b8a9106-e9e9-49b7-b58b-fe5cb8341e91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_a0f6a848-c194-4fe2-9d2f-df2fd70f09b5" xlink:to="loc_us-gaap_GrossProfit_8b8a9106-e9e9-49b7-b58b-fe5cb8341e91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_712d7357-68ae-40a0-86e3-f3e664704a47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_81efc61b-fc1a-4339-a9e5-b347867bc35f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_712d7357-68ae-40a0-86e3-f3e664704a47" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_81efc61b-fc1a-4339-a9e5-b347867bc35f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_57a91751-a2c2-44e7-afb1-1647a9b1a342" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_712d7357-68ae-40a0-86e3-f3e664704a47" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_57a91751-a2c2-44e7-afb1-1647a9b1a342" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_5cb5e0bf-164d-4522-839c-d088a161f9e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8fa41edd-61c4-42e1-86dd-959230e7ae56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_5cb5e0bf-164d-4522-839c-d088a161f9e9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8fa41edd-61c4-42e1-86dd-959230e7ae56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_4832458d-27c5-4d1b-8f94-5801e0b568cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_5cb5e0bf-164d-4522-839c-d088a161f9e9" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_4832458d-27c5-4d1b-8f94-5801e0b568cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_ea402444-801b-4855-9468-528d6c838b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4d61efeb-7c74-4570-82b9-46aab800793c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ea402444-801b-4855-9468-528d6c838b7b" xlink:to="loc_us-gaap_NetIncomeLoss_4d61efeb-7c74-4570-82b9-46aab800793c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_31c2700c-6050-4e7e-abb2-1bccdfc9cb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_ea402444-801b-4855-9468-528d6c838b7b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_31c2700c-6050-4e7e-abb2-1bccdfc9cb1d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_190a1d88-645b-4b8b-a390-e50dadf8c59e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a7cc5a2b-c502-48f2-af24-30f4170e9fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_190a1d88-645b-4b8b-a390-e50dadf8c59e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a7cc5a2b-c502-48f2-af24-30f4170e9fd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_9b8b6f68-c131-4505-970b-5af86c3b3ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_190a1d88-645b-4b8b-a390-e50dadf8c59e" xlink:to="loc_us-gaap_InterestExpenseNonoperating_9b8b6f68-c131-4505-970b-5af86c3b3ed0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_c87732ae-75ee-45ca-9641-e43c9874be89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_190a1d88-645b-4b8b-a390-e50dadf8c59e" xlink:to="loc_us-gaap_InvestmentIncomeNet_c87732ae-75ee-45ca-9641-e43c9874be89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_96ebec85-9f42-4123-9ccf-1b361a89a7f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_190a1d88-645b-4b8b-a390-e50dadf8c59e" xlink:to="loc_us-gaap_OperatingIncomeLoss_96ebec85-9f42-4123-9ccf-1b361a89a7f9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="eols-20241231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d1704ea-8063-483b-8c96-4c00059dfada" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_1e715521-7b57-4eea-a979-2fed3019f81e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d1704ea-8063-483b-8c96-4c00059dfada" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_1e715521-7b57-4eea-a979-2fed3019f81e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_1ba616c1-9ee1-4643-b127-d2312017380c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d1704ea-8063-483b-8c96-4c00059dfada" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_1ba616c1-9ee1-4643-b127-d2312017380c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_2095bf52-fd13-4602-948c-5981c01f35aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d1704ea-8063-483b-8c96-4c00059dfada" xlink:to="loc_us-gaap_ShareBasedCompensation_2095bf52-fd13-4602-948c-5981c01f35aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b4cc7113-3cc7-468f-9ae8-3f289a82564d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d1704ea-8063-483b-8c96-4c00059dfada" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b4cc7113-3cc7-468f-9ae8-3f289a82564d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_07e937a7-e4c7-4d06-bf2b-8547f6041887" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d1704ea-8063-483b-8c96-4c00059dfada" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_07e937a7-e4c7-4d06-bf2b-8547f6041887" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9183583e-6adf-4df1-9b5b-650e13e08276" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d1704ea-8063-483b-8c96-4c00059dfada" xlink:to="loc_us-gaap_NetIncomeLoss_9183583e-6adf-4df1-9b5b-650e13e08276" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_ef326e6c-10a4-4a96-adef-32226cf93a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d1704ea-8063-483b-8c96-4c00059dfada" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_ef326e6c-10a4-4a96-adef-32226cf93a0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a06d0184-9b9b-421c-99f0-4d6ca52a3199" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d1704ea-8063-483b-8c96-4c00059dfada" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a06d0184-9b9b-421c-99f0-4d6ca52a3199" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_6c7a48e5-e99e-4a96-8d07-d4700f84b0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d1704ea-8063-483b-8c96-4c00059dfada" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_6c7a48e5-e99e-4a96-8d07-d4700f84b0ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_41d4bb67-d73c-42d4-bf52-0ab0241b24eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d1704ea-8063-483b-8c96-4c00059dfada" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_41d4bb67-d73c-42d4-bf52-0ab0241b24eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_NonCashInResearchAndDevelopmentInProcessExpenses_34d05ff0-d22a-471b-9c4c-1a2e002d7e98" xlink:href="eols-20241231.xsd#eols_NonCashInResearchAndDevelopmentInProcessExpenses"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d1704ea-8063-483b-8c96-4c00059dfada" xlink:to="loc_eols_NonCashInResearchAndDevelopmentInProcessExpenses_34d05ff0-d22a-471b-9c4c-1a2e002d7e98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IncreaseDecreaseInOperatingLeaseLiabilities_16447ff0-fea7-4218-9e6a-a352ea400078" xlink:href="eols-20241231.xsd#eols_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d1704ea-8063-483b-8c96-4c00059dfada" xlink:to="loc_eols_IncreaseDecreaseInOperatingLeaseLiabilities_16447ff0-fea7-4218-9e6a-a352ea400078" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_eb33aac0-083b-4ac8-8449-7fba3f387bab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d1704ea-8063-483b-8c96-4c00059dfada" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_eb33aac0-083b-4ac8-8449-7fba3f387bab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_18f48f43-a7d7-43fb-8ef7-3fc34701b518" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d1704ea-8063-483b-8c96-4c00059dfada" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_18f48f43-a7d7-43fb-8ef7-3fc34701b518" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_e803f5ad-f098-4ee9-8cec-99203148045c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d1704ea-8063-483b-8c96-4c00059dfada" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_e803f5ad-f098-4ee9-8cec-99203148045c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_cf81fd87-d52a-4095-b65e-ac0028827ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d1704ea-8063-483b-8c96-4c00059dfada" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_cf81fd87-d52a-4095-b65e-ac0028827ddd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_4b54af2e-0ed6-4aa7-b647-7302468b729f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d1704ea-8063-483b-8c96-4c00059dfada" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_4b54af2e-0ed6-4aa7-b647-7302468b729f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9ca13efe-875b-438d-8da6-ad4cab4b209e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PaymentsOfContingentRoyaltyObligation_543719d2-106d-4472-b625-b4dccda54544" xlink:href="eols-20241231.xsd#eols_PaymentsOfContingentRoyaltyObligation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9ca13efe-875b-438d-8da6-ad4cab4b209e" xlink:to="loc_eols_PaymentsOfContingentRoyaltyObligation_543719d2-106d-4472-b625-b4dccda54544" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_fa603bb8-2711-49c7-a5fa-716074173ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9ca13efe-875b-438d-8da6-ad4cab4b209e" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_fa603bb8-2711-49c7-a5fa-716074173ef7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0cc9c755-5c0e-4338-a283-72f0504a420b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9ca13efe-875b-438d-8da6-ad4cab4b209e" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0cc9c755-5c0e-4338-a283-72f0504a420b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_77bb6bec-16f4-4a85-9460-60bffddfd21d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9ca13efe-875b-438d-8da6-ad4cab4b209e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_77bb6bec-16f4-4a85-9460-60bffddfd21d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_7df0c086-d4e4-418c-94d3-cc49eeb80be2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9ca13efe-875b-438d-8da6-ad4cab4b209e" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_7df0c086-d4e4-418c-94d3-cc49eeb80be2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_d63ece8e-8ac9-418a-85ed-4052a10900e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9ca13efe-875b-438d-8da6-ad4cab4b209e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_d63ece8e-8ac9-418a-85ed-4052a10900e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_bcfff5c6-2d8e-4f18-be20-509ed8da2dba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9ca13efe-875b-438d-8da6-ad4cab4b209e" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_bcfff5c6-2d8e-4f18-be20-509ed8da2dba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_25653dd6-c91b-475d-bfea-4251953d5ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_43ad0a05-8d1c-4122-aea9-8ad834824893" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_25653dd6-c91b-475d-bfea-4251953d5ee8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_43ad0a05-8d1c-4122-aea9-8ad834824893" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eca4612f-6d19-4ca5-a398-dcd0e6012f82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_25653dd6-c91b-475d-bfea-4251953d5ee8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_eca4612f-6d19-4ca5-a398-dcd0e6012f82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7be4190a-da1a-4900-96b8-3ef3fecf531d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_25653dd6-c91b-475d-bfea-4251953d5ee8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7be4190a-da1a-4900-96b8-3ef3fecf531d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ee9f2db3-11f1-4682-b54c-2341cc993ced" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_25653dd6-c91b-475d-bfea-4251953d5ee8" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ee9f2db3-11f1-4682-b54c-2341cc993ced" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ee44a9df-019f-4533-a270-1eca9c5d1ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0839b32f-8861-4182-b472-6d6009d72f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ee44a9df-019f-4533-a270-1eca9c5d1ecc" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0839b32f-8861-4182-b472-6d6009d72f8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForSoftware_95ac6554-c0ce-49ca-9353-4256a0433efd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForSoftware"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ee44a9df-019f-4533-a270-1eca9c5d1ecc" xlink:to="loc_us-gaap_PaymentsForSoftware_95ac6554-c0ce-49ca-9353-4256a0433efd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_82189655-8558-4121-b907-b505d807a02b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b9634af9-9971-4111-a855-13f6964dcce4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_82189655-8558-4121-b907-b505d807a02b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b9634af9-9971-4111-a855-13f6964dcce4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5afe7231-a345-47bc-99bd-d81dc0456f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_82189655-8558-4121-b907-b505d807a02b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5afe7231-a345-47bc-99bd-d81dc0456f0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_2928cac8-9ada-4660-9b31-16e6d4e21973" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IntangibleAssetsGrossIncludingGoodwill_ea3fe8d1-43a4-4d57-81ce-3d13b1636580" xlink:href="eols-20241231.xsd#eols_IntangibleAssetsGrossIncludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_2928cac8-9ada-4660-9b31-16e6d4e21973" xlink:to="loc_eols_IntangibleAssetsGrossIncludingGoodwill_ea3fe8d1-43a4-4d57-81ce-3d13b1636580" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c012e1af-4e8c-4a84-83b0-e380fa7ac1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_2928cac8-9ada-4660-9b31-16e6d4e21973" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c012e1af-4e8c-4a84-83b0-e380fa7ac1d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IntangibleAssetsGrossIncludingGoodwill_f3807972-078e-4d67-9792-48df8fa290c7" xlink:href="eols-20241231.xsd#eols_IntangibleAssetsGrossIncludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e1413f5c-31cf-47eb-8296-5472ed194f61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_eols_IntangibleAssetsGrossIncludingGoodwill_f3807972-078e-4d67-9792-48df8fa290c7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e1413f5c-31cf-47eb-8296-5472ed194f61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_dbd06190-f745-4caf-9aca-c52fc8d2241c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_eols_IntangibleAssetsGrossIncludingGoodwill_f3807972-078e-4d67-9792-48df8fa290c7" xlink:to="loc_us-gaap_Goodwill_dbd06190-f745-4caf-9aca-c52fc8d2241c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="eols-20241231.xsd#GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_fdfc5902-61e5-42ad-909c-2b46587b9ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6e7e6fbd-e853-46eb-b377-48b576c09616" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_fdfc5902-61e5-42ad-909c-2b46587b9ccf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6e7e6fbd-e853-46eb-b377-48b576c09616" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4ce95e83-ac5d-401e-bf08-b1942c8b87a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_fdfc5902-61e5-42ad-909c-2b46587b9ccf" xlink:to="loc_us-gaap_Goodwill_4ce95e83-ac5d-401e-bf08-b1942c8b87a9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e213dcf1-7fdc-4e34-8dbd-f108b3287d93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_89ceec21-3a3b-4de2-b43e-078d85ce35a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e213dcf1-7fdc-4e34-8dbd-f108b3287d93" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_89ceec21-3a3b-4de2-b43e-078d85ce35a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_30eccf9f-93bf-4d0e-b8dd-2bd87f3ba5d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e213dcf1-7fdc-4e34-8dbd-f108b3287d93" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_30eccf9f-93bf-4d0e-b8dd-2bd87f3ba5d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_48895263-5470-46b1-8a85-a4eda1d62198" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e213dcf1-7fdc-4e34-8dbd-f108b3287d93" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_48895263-5470-46b1-8a85-a4eda1d62198" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2aee1f6d-e03d-4312-a60f-5e3d965739ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e213dcf1-7fdc-4e34-8dbd-f108b3287d93" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2aee1f6d-e03d-4312-a60f-5e3d965739ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_e7527bd8-aca9-4730-aa77-4bd2462fedc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e213dcf1-7fdc-4e34-8dbd-f108b3287d93" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_e7527bd8-aca9-4730-aa77-4bd2462fedc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_f528e026-375a-44f3-8a69-566f6f7a8c13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e213dcf1-7fdc-4e34-8dbd-f108b3287d93" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_f528e026-375a-44f3-8a69-566f6f7a8c13" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#AccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_6ee7c690-3960-495b-8d65-d5c21c0f7e03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5aff4ff5-2c2a-47f1-9400-f54338dbd70f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_6ee7c690-3960-495b-8d65-d5c21c0f7e03" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5aff4ff5-2c2a-47f1-9400-f54338dbd70f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_20eb7947-c1a8-4804-bd7d-6d83f3f693d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_6ee7c690-3960-495b-8d65-d5c21c0f7e03" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_20eb7947-c1a8-4804-bd7d-6d83f3f693d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_86276e19-e2d8-428a-9d89-8b1441ddeaac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_6ee7c690-3960-495b-8d65-d5c21c0f7e03" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_86276e19-e2d8-428a-9d89-8b1441ddeaac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_4e8b1807-05d0-43fc-b2af-bb9ea63ddd56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_6ee7c690-3960-495b-8d65-d5c21c0f7e03" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_4e8b1807-05d0-43fc-b2af-bb9ea63ddd56" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_78d027c6-2118-43a2-97c1-2df2e7db4854" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_617a6233-ac93-40d6-bfd8-eea0c91b151c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_78d027c6-2118-43a2-97c1-2df2e7db4854" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_617a6233-ac93-40d6-bfd8-eea0c91b151c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c6bedd87-6b99-42bd-9b0d-f8fdf9975748" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_78d027c6-2118-43a2-97c1-2df2e7db4854" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c6bedd87-6b99-42bd-9b0d-f8fdf9975748" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#TermLoansScheduleofLongTermDebtMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_32ef49eb-7754-4347-aaa8-b2d6058507d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_97a50fbd-1cb5-4fc2-8a6d-2a0962de6df5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_32ef49eb-7754-4347-aaa8-b2d6058507d9" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_97a50fbd-1cb5-4fc2-8a6d-2a0962de6df5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_cf5c5588-a1f7-438d-bb34-e7789baf06a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_32ef49eb-7754-4347-aaa8-b2d6058507d9" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_cf5c5588-a1f7-438d-bb34-e7789baf06a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_59873d06-086e-4934-bc34-0210e8743ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_e45c8199-99d3-4f36-9aa0-ac50b3b2d29b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_59873d06-086e-4934-bc34-0210e8743ad9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_e45c8199-99d3-4f36-9aa0-ac50b3b2d29b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_0564a2ae-edde-47fb-a9a2-9e7887c73571" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_59873d06-086e-4934-bc34-0210e8743ad9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_0564a2ae-edde-47fb-a9a2-9e7887c73571" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_8e98c493-d94e-4475-870c-c511375e9799" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_59873d06-086e-4934-bc34-0210e8743ad9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_8e98c493-d94e-4475-870c-c511375e9799" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_c527f5f5-7881-4a85-ae19-b79782ba3130" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_59873d06-086e-4934-bc34-0210e8743ad9" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_c527f5f5-7881-4a85-ae19-b79782ba3130" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/OperatingLeasesComponentsofLeaseExpenseandOtherQuantitativeInformationDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#OperatingLeasesComponentsofLeaseExpenseandOtherQuantitativeInformationDetails"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/OperatingLeasesComponentsofLeaseExpenseandOtherQuantitativeInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_f9a796dc-16bb-46fa-9973-2c589f61679f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_8f7d9fc1-d605-495c-b169-b8845c3b3e41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_f9a796dc-16bb-46fa-9973-2c589f61679f" xlink:to="loc_us-gaap_OperatingLeaseCost_8f7d9fc1-d605-495c-b169-b8845c3b3e41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_37c5ecd8-7675-41c6-b9d9-68b3cc3d2741" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_f9a796dc-16bb-46fa-9973-2c589f61679f" xlink:to="loc_us-gaap_VariableLeaseCost_37c5ecd8-7675-41c6-b9d9-68b3cc3d2741" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_31113c29-c064-434a-ba0b-4caed65270de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d89ad8a3-856f-4e54-8884-6a2012a93ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_31113c29-c064-434a-ba0b-4caed65270de" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d89ad8a3-856f-4e54-8884-6a2012a93ac3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_68868af8-de36-4e6d-8c3d-faf0b842c730" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_31113c29-c064-434a-ba0b-4caed65270de" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_68868af8-de36-4e6d-8c3d-faf0b842c730" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_df7b1f3f-2ad3-4a66-9697-1dad943febdc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_31113c29-c064-434a-ba0b-4caed65270de" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_df7b1f3f-2ad3-4a66-9697-1dad943febdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_bef7bb89-7af7-490b-9e4b-328793777f40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_31113c29-c064-434a-ba0b-4caed65270de" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_bef7bb89-7af7-490b-9e4b-328793777f40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7b6159a9-97b6-4333-9b1a-e49c8ac5ef22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_31113c29-c064-434a-ba0b-4caed65270de" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7b6159a9-97b6-4333-9b1a-e49c8ac5ef22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_72409400-0f5f-414b-bdb3-14ec5672b83c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_31113c29-c064-434a-ba0b-4caed65270de" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_72409400-0f5f-414b-bdb3-14ec5672b83c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="eols-20241231.xsd#OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3c1242b9-055a-4153-b898-dfe53a2c70eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_15335510-eaff-4e4c-9dcb-5b55c46ecdfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3c1242b9-055a-4153-b898-dfe53a2c70eb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_15335510-eaff-4e4c-9dcb-5b55c46ecdfa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_7b05c514-8ae2-4fa0-a1c3-1446451016e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3c1242b9-055a-4153-b898-dfe53a2c70eb" xlink:to="loc_us-gaap_OperatingLeaseLiability_7b05c514-8ae2-4fa0-a1c3-1446451016e3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesScheduleofLossbeforeIncomeTaxesfromUSOperationsandForeignDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#IncomeTaxesScheduleofLossbeforeIncomeTaxesfromUSOperationsandForeignDetails"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/IncomeTaxesScheduleofLossbeforeIncomeTaxesfromUSOperationsandForeignDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_eda396db-77c3-4f4a-b56a-5be0fa9b0ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_49cdfaba-092f-44ae-b5b0-197bf7f06e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_eda396db-77c3-4f4a-b56a-5be0fa9b0ca8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_49cdfaba-092f-44ae-b5b0-197bf7f06e2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_64654de6-295a-4ac1-a4ae-a92c77e6381c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_eda396db-77c3-4f4a-b56a-5be0fa9b0ca8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_64654de6-295a-4ac1-a4ae-a92c77e6381c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesScheduleofComponentsofCurrentandDeferredIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#IncomeTaxesScheduleofComponentsofCurrentandDeferredIncomeTaxExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/IncomeTaxesScheduleofComponentsofCurrentandDeferredIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_93769027-16d8-4e8c-827d-b729d2348f97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_13310bd0-eef8-4542-9bbe-8989e5512e79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_93769027-16d8-4e8c-827d-b729d2348f97" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_13310bd0-eef8-4542-9bbe-8989e5512e79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_9483bd5a-8451-4644-acb7-4f4fc9435a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_93769027-16d8-4e8c-827d-b729d2348f97" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_9483bd5a-8451-4644-acb7-4f4fc9435a2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_8cdc8927-4fd5-453e-93aa-3ef2ff6949ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_93769027-16d8-4e8c-827d-b729d2348f97" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_8cdc8927-4fd5-453e-93aa-3ef2ff6949ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_403cbd32-ec97-4e71-97e4-9fcd7aa02a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_097cac01-b02f-410d-88fb-3892aeaaccf8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_403cbd32-ec97-4e71-97e4-9fcd7aa02a8c" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_097cac01-b02f-410d-88fb-3892aeaaccf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_3c014699-6031-42c8-8172-ab92b2445757" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_403cbd32-ec97-4e71-97e4-9fcd7aa02a8c" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_3c014699-6031-42c8-8172-ab92b2445757" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_9a03c2c6-6d84-467d-a007-037771ddffb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_403cbd32-ec97-4e71-97e4-9fcd7aa02a8c" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_9a03c2c6-6d84-467d-a007-037771ddffb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_623d8b6a-d3da-482f-bc99-a06e80f8aa63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_717d0443-7a9d-458b-8312-93bc41e969c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_623d8b6a-d3da-482f-bc99-a06e80f8aa63" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_717d0443-7a9d-458b-8312-93bc41e969c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_bed005b1-5e52-4827-9b54-4d24f00893f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_623d8b6a-d3da-482f-bc99-a06e80f8aa63" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_bed005b1-5e52-4827-9b54-4d24f00893f9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_ccc4c60f-0f36-4fb6-8811-cabd70030464" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_110d4dac-e05f-457d-9418-023aece11a72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_ccc4c60f-0f36-4fb6-8811-cabd70030464" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_110d4dac-e05f-457d-9418-023aece11a72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_207670de-f15b-40f5-a183-1297d1cd6d85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_ccc4c60f-0f36-4fb6-8811-cabd70030464" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_207670de-f15b-40f5-a183-1297d1cd6d85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_33eaa764-6ba1-4d75-bf5a-a656cab9d5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_f94b92ca-a9c7-4fc0-985c-d707ececee0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_33eaa764-6ba1-4d75-bf5a-a656cab9d5ec" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_f94b92ca-a9c7-4fc0-985c-d707ececee0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_fc9d3318-18dd-45f5-b72f-bd70cdb41b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_33eaa764-6ba1-4d75-bf5a-a656cab9d5ec" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_fc9d3318-18dd-45f5-b72f-bd70cdb41b9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_dbb13fa9-b704-4628-881e-eee411536965" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_33eaa764-6ba1-4d75-bf5a-a656cab9d5ec" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_dbb13fa9-b704-4628-881e-eee411536965" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_eea167cd-2bd8-46ed-85eb-51279aa994e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_eeec83bd-3940-401e-b4b9-5a32a2a590a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_eea167cd-2bd8-46ed-85eb-51279aa994e7" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_eeec83bd-3940-401e-b4b9-5a32a2a590a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DeferredTaxAssetsFixedAssetDepreciation_0b703419-9e69-4212-8843-6da97b4c1c99" xlink:href="eols-20241231.xsd#eols_DeferredTaxAssetsFixedAssetDepreciation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_eea167cd-2bd8-46ed-85eb-51279aa994e7" xlink:to="loc_eols_DeferredTaxAssetsFixedAssetDepreciation_0b703419-9e69-4212-8843-6da97b4c1c99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0fc1c75d-6b28-4412-aa5f-b130ab60e821" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_eea167cd-2bd8-46ed-85eb-51279aa994e7" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0fc1c75d-6b28-4412-aa5f-b130ab60e821" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_d7f2a93e-5adf-4c79-8000-198095a6b1f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_eea167cd-2bd8-46ed-85eb-51279aa994e7" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_d7f2a93e-5adf-4c79-8000-198095a6b1f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_a7f26512-a64f-44f4-bf70-77c9ae0f42af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_eea167cd-2bd8-46ed-85eb-51279aa994e7" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_a7f26512-a64f-44f4-bf70-77c9ae0f42af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DeferredTaxAssetsOperatingLeaseLiabilities_b67e1403-c7b7-4361-a3ec-044681d1b98a" xlink:href="eols-20241231.xsd#eols_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_eea167cd-2bd8-46ed-85eb-51279aa994e7" xlink:to="loc_eols_DeferredTaxAssetsOperatingLeaseLiabilities_b67e1403-c7b7-4361-a3ec-044681d1b98a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_23471f39-f09c-4793-8a93-d10a0985522e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_eea167cd-2bd8-46ed-85eb-51279aa994e7" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_23471f39-f09c-4793-8a93-d10a0985522e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5fb35e77-d094-4a81-9cd9-dc4e115b5b96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_eea167cd-2bd8-46ed-85eb-51279aa994e7" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5fb35e77-d094-4a81-9cd9-dc4e115b5b96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements_f07590e0-ee0f-4a5d-b927-2a52c057c1c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_eea167cd-2bd8-46ed-85eb-51279aa994e7" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements_f07590e0-ee0f-4a5d-b927-2a52c057c1c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DeferredTaxAssetsResearchAndExperimentationCapitalization_2a081b16-964d-4c92-a895-1087456bce81" xlink:href="eols-20241231.xsd#eols_DeferredTaxAssetsResearchAndExperimentationCapitalization"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_eea167cd-2bd8-46ed-85eb-51279aa994e7" xlink:to="loc_eols_DeferredTaxAssetsResearchAndExperimentationCapitalization_2a081b16-964d-4c92-a895-1087456bce81" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxDetails"/>
  <link:calculationLink xlink:role="http://www.evolus.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8f125365-8950-46c1-9e00-a01487d44b70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_5300434f-5021-48b7-a9cf-08d7195441b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8f125365-8950-46c1-9e00-a01487d44b70" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_5300434f-5021-48b7-a9cf-08d7195441b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingenciesOther_d1d07892-1512-4c2f-8b60-f7e7b3cbd26b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8f125365-8950-46c1-9e00-a01487d44b70" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingenciesOther_d1d07892-1512-4c2f-8b60-f7e7b3cbd26b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_91be4041-23a8-463d-bf83-adaab99ea59c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8f125365-8950-46c1-9e00-a01487d44b70" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_91be4041-23a8-463d-bf83-adaab99ea59c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_5fc9f757-4bec-4b6d-80ea-11cb5fcb3593" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8f125365-8950-46c1-9e00-a01487d44b70" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_5fc9f757-4bec-4b6d-80ea-11cb5fcb3593" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_8f200cd5-314e-4649-bda1-dab7d00b75a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8f125365-8950-46c1-9e00-a01487d44b70" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_8f200cd5-314e-4649-bda1-dab7d00b75a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c43713c5-68e5-4459-8f6c-c2032bb8d6ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8f125365-8950-46c1-9e00-a01487d44b70" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_c43713c5-68e5-4459-8f6c-c2032bb8d6ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_49a7daa8-4f88-4e75-a55e-a71748caa5e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8f125365-8950-46c1-9e00-a01487d44b70" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_49a7daa8-4f88-4e75-a55e-a71748caa5e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_dc6b7e9b-b0d4-4d13-a4fd-91a3d76bc9d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8f125365-8950-46c1-9e00-a01487d44b70" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_dc6b7e9b-b0d4-4d13-a4fd-91a3d76bc9d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation_41b68d4c-010f-4942-bab6-4a2c484aff64" xlink:href="eols-20241231.xsd#eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8f125365-8950-46c1-9e00-a01487d44b70" xlink:to="loc_eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation_41b68d4c-010f-4942-bab6-4a2c484aff64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_990e3759-3679-4149-b83d-5c68f0bf2252" xlink:href="eols-20241231.xsd#eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_8f125365-8950-46c1-9e00-a01487d44b70" xlink:to="loc_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_990e3759-3679-4149-b83d-5c68f0bf2252" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>eols-20241231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:919f993d-eaea-4622-b01f-fde76d4f5f0d,g:96b2bf92-d476-42b7-9d6e-4ee6308f0735-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="eols-20241231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_71321173-e360-4786-aa23-a136d501e71c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_76ecb48a-6a86-4e7d-aea5-6c6e1b123c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_71321173-e360-4786-aa23-a136d501e71c" xlink:to="loc_us-gaap_StatementTable_76ecb48a-6a86-4e7d-aea5-6c6e1b123c9b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_97190b4d-68d9-4dbd-bab9-d804d5b3e79e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_76ecb48a-6a86-4e7d-aea5-6c6e1b123c9b" xlink:to="loc_srt_ProductOrServiceAxis_97190b4d-68d9-4dbd-bab9-d804d5b3e79e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_97190b4d-68d9-4dbd-bab9-d804d5b3e79e_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_97190b4d-68d9-4dbd-bab9-d804d5b3e79e" xlink:to="loc_srt_ProductsAndServicesDomain_97190b4d-68d9-4dbd-bab9-d804d5b3e79e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_68bd18df-54e7-4456-a388-176418840118" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_97190b4d-68d9-4dbd-bab9-d804d5b3e79e" xlink:to="loc_srt_ProductsAndServicesDomain_68bd18df-54e7-4456-a388-176418840118" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_161e1012-e507-4f08-a183-643999b38e54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_68bd18df-54e7-4456-a388-176418840118" xlink:to="loc_us-gaap_ProductMember_161e1012-e507-4f08-a183-643999b38e54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_d825474a-4b2a-4819-8130-6d599acd8bff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_68bd18df-54e7-4456-a388-176418840118" xlink:to="loc_us-gaap_ServiceMember_d825474a-4b2a-4819-8130-6d599acd8bff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_1b592762-b4cc-4880-9ab4-40b40c42489b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_71321173-e360-4786-aa23-a136d501e71c" xlink:to="loc_us-gaap_RevenuesAbstract_1b592762-b4cc-4880-9ab4-40b40c42489b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3243e8da-d17d-4bee-9c40-e74a6082a067" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_1b592762-b4cc-4880-9ab4-40b40c42489b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3243e8da-d17d-4bee-9c40-e74a6082a067" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_9eb06663-760d-4a7a-bfb6-afa7b503614b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_71321173-e360-4786-aa23-a136d501e71c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_9eb06663-760d-4a7a-bfb6-afa7b503614b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList_757d8b37-2692-4fc3-a4ce-44588784c090" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfCostGoodOrServiceExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_9eb06663-760d-4a7a-bfb6-afa7b503614b" xlink:to="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList_757d8b37-2692-4fc3-a4ce-44588784c090" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_efd2e887-863b-4495-8e86-8c072a811c10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_71321173-e360-4786-aa23-a136d501e71c" xlink:to="loc_us-gaap_GrossProfit_efd2e887-863b-4495-8e86-8c072a811c10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_c5300156-6e6a-44d0-ae4d-7f961034cf57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_71321173-e360-4786-aa23-a136d501e71c" xlink:to="loc_us-gaap_OperatingExpensesAbstract_c5300156-6e6a-44d0-ae4d-7f961034cf57" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6372431c-b53d-4ad5-a44e-d196e0d2b9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c5300156-6e6a-44d0-ae4d-7f961034cf57" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6372431c-b53d-4ad5-a44e-d196e0d2b9f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_71a8f0c0-0463-418f-8561-ea735e4a4141" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c5300156-6e6a-44d0-ae4d-7f961034cf57" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_71a8f0c0-0463-418f-8561-ea735e4a4141" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ResearchAndDevelopmentInProcess1_7e5b89df-c61d-48e6-ba62-7e19d6d825e0" xlink:href="eols-20241231.xsd#eols_ResearchAndDevelopmentInProcess1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c5300156-6e6a-44d0-ae4d-7f961034cf57" xlink:to="loc_eols_ResearchAndDevelopmentInProcess1_7e5b89df-c61d-48e6-ba62-7e19d6d825e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_4d52d47f-5bcf-470b-9f12-3727f697a061" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c5300156-6e6a-44d0-ae4d-7f961034cf57" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_4d52d47f-5bcf-470b-9f12-3727f697a061" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_410de302-e7e8-442f-90f6-021ed0c17653" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c5300156-6e6a-44d0-ae4d-7f961034cf57" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_410de302-e7e8-442f-90f6-021ed0c17653" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_189324af-e93c-44cc-894f-a5a150d29af5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c5300156-6e6a-44d0-ae4d-7f961034cf57" xlink:to="loc_us-gaap_CostsAndExpenses_189324af-e93c-44cc-894f-a5a150d29af5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bea1563a-ebd3-45cf-b2ef-4d27588bbde0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_71321173-e360-4786-aa23-a136d501e71c" xlink:to="loc_us-gaap_OperatingIncomeLoss_bea1563a-ebd3-45cf-b2ef-4d27588bbde0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_729e926d-db3d-4ff8-ba21-e33ad476aeff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_71321173-e360-4786-aa23-a136d501e71c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_729e926d-db3d-4ff8-ba21-e33ad476aeff" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_f93da68f-f5a7-4533-9d03-d25cc8d1793e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_729e926d-db3d-4ff8-ba21-e33ad476aeff" xlink:to="loc_us-gaap_InvestmentIncomeNet_f93da68f-f5a7-4533-9d03-d25cc8d1793e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_7ebe09ce-2a9d-44e9-ab34-eb64292644f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_729e926d-db3d-4ff8-ba21-e33ad476aeff" xlink:to="loc_us-gaap_InterestExpenseNonoperating_7ebe09ce-2a9d-44e9-ab34-eb64292644f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e2828db5-357d-4749-b64f-5ed42086ebcd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_729e926d-db3d-4ff8-ba21-e33ad476aeff" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e2828db5-357d-4749-b64f-5ed42086ebcd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a545e853-6457-4040-9fe8-d69e837591f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_71321173-e360-4786-aa23-a136d501e71c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a545e853-6457-4040-9fe8-d69e837591f1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f80731eb-119d-475a-9ae8-57e398749d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_71321173-e360-4786-aa23-a136d501e71c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f80731eb-119d-475a-9ae8-57e398749d8f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_efbeb735-d1f0-4f32-b3aa-0467eb8d6c43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_71321173-e360-4786-aa23-a136d501e71c" xlink:to="loc_us-gaap_NetIncomeLoss_efbeb735-d1f0-4f32-b3aa-0467eb8d6c43" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_579526af-8aa7-4426-9b0b-7af5e72aaeab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_71321173-e360-4786-aa23-a136d501e71c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_579526af-8aa7-4426-9b0b-7af5e72aaeab" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f55d1235-8350-4d44-9e9a-1b03bf2ea391" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_579526af-8aa7-4426-9b0b-7af5e72aaeab" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f55d1235-8350-4d44-9e9a-1b03bf2ea391" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f3997335-2d48-430a-9d22-74796a4e5677" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_71321173-e360-4786-aa23-a136d501e71c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_f3997335-2d48-430a-9d22-74796a4e5677" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ba184e84-7987-439f-972e-76d33e6073fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_71321173-e360-4786-aa23-a136d501e71c" xlink:to="loc_us-gaap_EarningsPerShareBasic_ba184e84-7987-439f-972e-76d33e6073fc" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_277b2d2d-3a1f-4d05-bea4-f396ce30e61e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_71321173-e360-4786-aa23-a136d501e71c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_277b2d2d-3a1f-4d05-bea4-f396ce30e61e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_16d363e3-2813-49e6-b24f-eb6f61252e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_71321173-e360-4786-aa23-a136d501e71c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_16d363e3-2813-49e6-b24f-eb6f61252e1a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5f4f01b9-c0e0-4d15-8379-588efa503a74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_71321173-e360-4786-aa23-a136d501e71c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5f4f01b9-c0e0-4d15-8379-588efa503a74" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/ConsolidatedStatementsofStockholdersEquityDeficit" xlink:type="simple" xlink:href="eols-20241231.xsd#ConsolidatedStatementsofStockholdersEquityDeficit"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/ConsolidatedStatementsofStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b38d8eb4-367d-4c81-8792-d3040ee9bb10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2ea73308-cabb-4c25-bacc-0b0e4eb2b561" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b38d8eb4-367d-4c81-8792-d3040ee9bb10" xlink:to="loc_us-gaap_StatementTable_2ea73308-cabb-4c25-bacc-0b0e4eb2b561" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b23cb47f-848f-4fde-ad42-4a894e6fc311" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2ea73308-cabb-4c25-bacc-0b0e4eb2b561" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b23cb47f-848f-4fde-ad42-4a894e6fc311" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b23cb47f-848f-4fde-ad42-4a894e6fc311_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b23cb47f-848f-4fde-ad42-4a894e6fc311" xlink:to="loc_us-gaap_EquityComponentDomain_b23cb47f-848f-4fde-ad42-4a894e6fc311_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ce65ad55-637e-4bdb-8039-ff0954b84634" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b23cb47f-848f-4fde-ad42-4a894e6fc311" xlink:to="loc_us-gaap_EquityComponentDomain_ce65ad55-637e-4bdb-8039-ff0954b84634" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8b279777-def5-410a-a42b-d87bd8fe742f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ce65ad55-637e-4bdb-8039-ff0954b84634" xlink:to="loc_us-gaap_CommonStockMember_8b279777-def5-410a-a42b-d87bd8fe742f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9f660b93-ebd6-47db-853f-bbaf6f69e5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ce65ad55-637e-4bdb-8039-ff0954b84634" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9f660b93-ebd6-47db-853f-bbaf6f69e5c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c59f4df3-d082-4cac-950b-fd33251251e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ce65ad55-637e-4bdb-8039-ff0954b84634" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c59f4df3-d082-4cac-950b-fd33251251e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9f9d026b-e7c0-44ff-899d-b7074ab452d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ce65ad55-637e-4bdb-8039-ff0954b84634" xlink:to="loc_us-gaap_RetainedEarningsMember_9f9d026b-e7c0-44ff-899d-b7074ab452d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d436fa3-6708-4c16-acdf-fd3d4dfabea7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b38d8eb4-367d-4c81-8792-d3040ee9bb10" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d436fa3-6708-4c16-acdf-fd3d4dfabea7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_d10014a1-972f-4656-ab41-17b65d116fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d436fa3-6708-4c16-acdf-fd3d4dfabea7" xlink:to="loc_us-gaap_CommonStockSharesIssued_d10014a1-972f-4656-ab41-17b65d116fe1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_95188caa-faca-41a0-a91d-711a931b84df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d436fa3-6708-4c16-acdf-fd3d4dfabea7" xlink:to="loc_us-gaap_StockholdersEquity_95188caa-faca-41a0-a91d-711a931b84df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodSharesIncentiveEquityPlan_95aabf10-3033-41fb-8e6b-f9725ca879e0" xlink:href="eols-20241231.xsd#eols_StockIssuedDuringPeriodSharesIncentiveEquityPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d436fa3-6708-4c16-acdf-fd3d4dfabea7" xlink:to="loc_eols_StockIssuedDuringPeriodSharesIncentiveEquityPlan_95aabf10-3033-41fb-8e6b-f9725ca879e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodValueIncentiveEquityPlan_4d5e7b77-de86-40df-a3ca-ef87b9103316" xlink:href="eols-20241231.xsd#eols_StockIssuedDuringPeriodValueIncentiveEquityPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d436fa3-6708-4c16-acdf-fd3d4dfabea7" xlink:to="loc_eols_StockIssuedDuringPeriodValueIncentiveEquityPlan_4d5e7b77-de86-40df-a3ca-ef87b9103316" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement_0fb5c311-054e-4fd9-8395-e6b383ef7db3" xlink:href="eols-20241231.xsd#eols_StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d436fa3-6708-4c16-acdf-fd3d4dfabea7" xlink:to="loc_eols_StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement_0fb5c311-054e-4fd9-8395-e6b383ef7db3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodValueIssuedForLicenseSupplyAndDistributionAgreement_fe4595b4-4278-4a54-a361-b6e8d3b441c0" xlink:href="eols-20241231.xsd#eols_StockIssuedDuringPeriodValueIssuedForLicenseSupplyAndDistributionAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d436fa3-6708-4c16-acdf-fd3d4dfabea7" xlink:to="loc_eols_StockIssuedDuringPeriodValueIssuedForLicenseSupplyAndDistributionAgreement_fe4595b4-4278-4a54-a361-b6e8d3b441c0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_37f6a53f-f551-4eb4-83ae-e92e81e7c073" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d436fa3-6708-4c16-acdf-fd3d4dfabea7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_37f6a53f-f551-4eb4-83ae-e92e81e7c073" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7c244a7d-7584-4890-9df4-a2e3d2184c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d436fa3-6708-4c16-acdf-fd3d4dfabea7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7c244a7d-7584-4890-9df4-a2e3d2184c1f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fd462b67-0687-4af9-9446-296c84ca656f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d436fa3-6708-4c16-acdf-fd3d4dfabea7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fd462b67-0687-4af9-9446-296c84ca656f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_73c8314e-68d3-4392-b15f-42f3c441aa73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d436fa3-6708-4c16-acdf-fd3d4dfabea7" xlink:to="loc_us-gaap_NetIncomeLoss_73c8314e-68d3-4392-b15f-42f3c441aa73" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3f372bf9-a2e7-4778-be14-23b026b6d5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d436fa3-6708-4c16-acdf-fd3d4dfabea7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3f372bf9-a2e7-4778-be14-23b026b6d5b7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_cd2fc46e-a656-4803-9dac-6c65b77c3691" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_68ade2de-ff86-4b6a-b6d4-c61fafbfdebc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#DescriptionofBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/DescriptionofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_36d5f51b-7af9-44c4-a976-641a6819f426" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_b87c1718-4efc-472d-8636-06c0802d3706" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_36d5f51b-7af9-44c4-a976-641a6819f426" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_b87c1718-4efc-472d-8636-06c0802d3706" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_cc26eba7-8df4-4a86-a377-7da99ab61ba6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_b87c1718-4efc-472d-8636-06c0802d3706" xlink:to="loc_srt_LitigationCaseAxis_cc26eba7-8df4-4a86-a377-7da99ab61ba6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_cc26eba7-8df4-4a86-a377-7da99ab61ba6_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_cc26eba7-8df4-4a86-a377-7da99ab61ba6" xlink:to="loc_srt_LitigationCaseTypeDomain_cc26eba7-8df4-4a86-a377-7da99ab61ba6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_fc299cd6-b030-42fb-a6a0-fe8a80526b65" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_cc26eba7-8df4-4a86-a377-7da99ab61ba6" xlink:to="loc_srt_LitigationCaseTypeDomain_fc299cd6-b030-42fb-a6a0-fe8a80526b65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IntellectualPropertyDisputesJeuveauMember_ebb1b767-0a83-48af-b165-620d29b8cd55" xlink:href="eols-20241231.xsd#eols_IntellectualPropertyDisputesJeuveauMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_fc299cd6-b030-42fb-a6a0-fe8a80526b65" xlink:to="loc_eols_IntellectualPropertyDisputesJeuveauMember_ebb1b767-0a83-48af-b165-620d29b8cd55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_b91361be-6cab-4b28-bd77-a2a813d4051a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_b87c1718-4efc-472d-8636-06c0802d3706" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_b91361be-6cab-4b28-bd77-a2a813d4051a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b91361be-6cab-4b28-bd77-a2a813d4051a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b91361be-6cab-4b28-bd77-a2a813d4051a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b91361be-6cab-4b28-bd77-a2a813d4051a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7f6b1661-454b-4cce-9a3e-cbaa4c1b3498" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b91361be-6cab-4b28-bd77-a2a813d4051a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7f6b1661-454b-4cce-9a3e-cbaa4c1b3498" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_FollowOnOfferingMember_e74f1263-10b5-4f95-9878-58cb1302830b" xlink:href="eols-20241231.xsd#eols_FollowOnOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7f6b1661-454b-4cce-9a3e-cbaa4c1b3498" xlink:to="loc_eols_FollowOnOfferingMember_e74f1263-10b5-4f95-9878-58cb1302830b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_3d93b791-b24c-4559-908b-17bf250d98a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7f6b1661-454b-4cce-9a3e-cbaa4c1b3498" xlink:to="loc_us-gaap_OverAllotmentOptionMember_3d93b791-b24c-4559-908b-17bf250d98a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_84700079-b928-4cf2-a5df-f1075e38d277" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_b87c1718-4efc-472d-8636-06c0802d3706" xlink:to="loc_us-gaap_TypeOfArrangementAxis_84700079-b928-4cf2-a5df-f1075e38d277" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_84700079-b928-4cf2-a5df-f1075e38d277_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_84700079-b928-4cf2-a5df-f1075e38d277" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_84700079-b928-4cf2-a5df-f1075e38d277_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18890ef0-46fc-4f69-8eb2-a2cb2470c69f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_84700079-b928-4cf2-a5df-f1075e38d277" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18890ef0-46fc-4f69-8eb2-a2cb2470c69f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SymateseEuropeAgreementMember_8a79c87e-bea4-417d-a5de-93bbacf3d45c" xlink:href="eols-20241231.xsd#eols_SymateseEuropeAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18890ef0-46fc-4f69-8eb2-a2cb2470c69f" xlink:to="loc_eols_SymateseEuropeAgreementMember_8a79c87e-bea4-417d-a5de-93bbacf3d45c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SymateseU.S.AgreementMember_2a2840da-7d97-4afa-8b68-abe42bebf595" xlink:href="eols-20241231.xsd#eols_SymateseU.S.AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18890ef0-46fc-4f69-8eb2-a2cb2470c69f" xlink:to="loc_eols_SymateseU.S.AgreementMember_2a2840da-7d97-4afa-8b68-abe42bebf595" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts_98619b96-363a-4a86-9b90-abd5c7096243" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_36d5f51b-7af9-44c4-a976-641a6819f426" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts_98619b96-363a-4a86-9b90-abd5c7096243" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementExpectedRegulatoryApprovalNumberOfProducts_6cd57cf2-0678-4a76-a062-67becb96a4bf" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementExpectedRegulatoryApprovalNumberOfProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_36d5f51b-7af9-44c4-a976-641a6819f426" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementExpectedRegulatoryApprovalNumberOfProducts_6cd57cf2-0678-4a76-a062-67becb96a4bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_21d14c4c-11cc-4a27-9321-a047f944bca4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_36d5f51b-7af9-44c4-a976-641a6819f426" xlink:to="loc_us-gaap_OperatingIncomeLoss_21d14c4c-11cc-4a27-9321-a047f944bca4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5b499225-f447-4916-8385-a5ba87bcb183" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_36d5f51b-7af9-44c4-a976-641a6819f426" xlink:to="loc_us-gaap_NetIncomeLoss_5b499225-f447-4916-8385-a5ba87bcb183" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be90926d-9518-458d-be7f-5653a8c856cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_36d5f51b-7af9-44c4-a976-641a6819f426" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be90926d-9518-458d-be7f-5653a8c856cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_59053612-e6bf-4f6e-8c18-d2ea64732d31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_36d5f51b-7af9-44c4-a976-641a6819f426" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_59053612-e6bf-4f6e-8c18-d2ea64732d31" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_81f10394-9886-4a9b-988b-61cdafb684c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_36d5f51b-7af9-44c4-a976-641a6819f426" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_81f10394-9886-4a9b-988b-61cdafb684c5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4e727135-ba1c-4cc8-bd50-e02760c72030" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_36d5f51b-7af9-44c4-a976-641a6819f426" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4e727135-ba1c-4cc8-bd50-e02760c72030" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_4df0d811-6f77-4c60-aef7-c42c0fffd738" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_36d5f51b-7af9-44c4-a976-641a6819f426" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_4df0d811-6f77-4c60-aef7-c42c0fffd738" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2a0f04f4-0863-4fcd-a334-14b37695ae9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_36d5f51b-7af9-44c4-a976-641a6819f426" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2a0f04f4-0863-4fcd-a334-14b37695ae9b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SaleOfStockGrantedOptionsExercisablePeriod_bd920a14-ca23-4970-b38c-da3e1d460117" xlink:href="eols-20241231.xsd#eols_SaleOfStockGrantedOptionsExercisablePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_36d5f51b-7af9-44c4-a976-641a6819f426" xlink:to="loc_eols_SaleOfStockGrantedOptionsExercisablePeriod_bd920a14-ca23-4970-b38c-da3e1d460117" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4b5309ad-c84d-471b-9ba1-2ce47d15f9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4b5309ad-c84d-471b-9ba1-2ce47d15f9bb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cb8f45e6-96a7-4c62-993e-e9acc0a8be3f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4b5309ad-c84d-471b-9ba1-2ce47d15f9bb" xlink:to="loc_srt_RangeAxis_cb8f45e6-96a7-4c62-993e-e9acc0a8be3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cb8f45e6-96a7-4c62-993e-e9acc0a8be3f_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_cb8f45e6-96a7-4c62-993e-e9acc0a8be3f" xlink:to="loc_srt_RangeMember_cb8f45e6-96a7-4c62-993e-e9acc0a8be3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ea2cd741-ad19-439e-a93a-b39044b80b21" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_cb8f45e6-96a7-4c62-993e-e9acc0a8be3f" xlink:to="loc_srt_RangeMember_ea2cd741-ad19-439e-a93a-b39044b80b21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_08f05879-02e2-4b3c-b838-981d6ced1c74" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ea2cd741-ad19-439e-a93a-b39044b80b21" xlink:to="loc_srt_MinimumMember_08f05879-02e2-4b3c-b838-981d6ced1c74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_12344b2e-9b24-4f94-a051-5d852fe295f9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ea2cd741-ad19-439e-a93a-b39044b80b21" xlink:to="loc_srt_MaximumMember_12344b2e-9b24-4f94-a051-5d852fe295f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_223cf32a-461a-44d5-979d-39e36b693f56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4b5309ad-c84d-471b-9ba1-2ce47d15f9bb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_223cf32a-461a-44d5-979d-39e36b693f56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_223cf32a-461a-44d5-979d-39e36b693f56_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_223cf32a-461a-44d5-979d-39e36b693f56" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_223cf32a-461a-44d5-979d-39e36b693f56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5039cac-7bbd-4eb3-98b1-d8358e406b58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_223cf32a-461a-44d5-979d-39e36b693f56" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5039cac-7bbd-4eb3-98b1-d8358e406b58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DistributionRightsEvolysseNasolabialFoldProductMember_82d6ee9b-c4ec-4ef7-a745-737175330ca0" xlink:href="eols-20241231.xsd#eols_DistributionRightsEvolysseNasolabialFoldProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5039cac-7bbd-4eb3-98b1-d8358e406b58" xlink:to="loc_eols_DistributionRightsEvolysseNasolabialFoldProductMember_82d6ee9b-c4ec-4ef7-a745-737175330ca0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DistributionRightsMember_39f960ca-e6fc-4e13-93e0-082c27b9c58e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DistributionRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5039cac-7bbd-4eb3-98b1-d8358e406b58" xlink:to="loc_us-gaap_DistributionRightsMember_39f960ca-e6fc-4e13-93e0-082c27b9c58e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DistributionRightsEvolysseProductsMember_597de75c-96b4-4fd9-9ac3-354ac41bf2b1" xlink:href="eols-20241231.xsd#eols_DistributionRightsEvolysseProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5039cac-7bbd-4eb3-98b1-d8358e406b58" xlink:to="loc_eols_DistributionRightsEvolysseProductsMember_597de75c-96b4-4fd9-9ac3-354ac41bf2b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_fb7ca3d0-4263-4207-ba66-cb477247baed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5039cac-7bbd-4eb3-98b1-d8358e406b58" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_fb7ca3d0-4263-4207-ba66-cb477247baed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5e36ed9c-0797-468e-9a66-0597027b9af8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4b5309ad-c84d-471b-9ba1-2ce47d15f9bb" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5e36ed9c-0797-468e-9a66-0597027b9af8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5e36ed9c-0797-468e-9a66-0597027b9af8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5e36ed9c-0797-468e-9a66-0597027b9af8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5e36ed9c-0797-468e-9a66-0597027b9af8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_31778ac7-7f31-4150-8d79-3b84867250ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5e36ed9c-0797-468e-9a66-0597027b9af8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_31778ac7-7f31-4150-8d79-3b84867250ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_EvolusIncMember_b121f5a2-70b9-4375-8482-d43bfa843297" xlink:href="eols-20241231.xsd#eols_EvolusIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_31778ac7-7f31-4150-8d79-3b84867250ec" xlink:to="loc_eols_EvolusIncMember_b121f5a2-70b9-4375-8482-d43bfa843297" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a1b3fc6a-19c5-430f-97b8-068b84edd990" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4b5309ad-c84d-471b-9ba1-2ce47d15f9bb" xlink:to="loc_dei_LegalEntityAxis_a1b3fc6a-19c5-430f-97b8-068b84edd990" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a1b3fc6a-19c5-430f-97b8-068b84edd990_default" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_a1b3fc6a-19c5-430f-97b8-068b84edd990" xlink:to="loc_dei_EntityDomain_a1b3fc6a-19c5-430f-97b8-068b84edd990_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_df04deb9-ff87-4769-a2d2-8439f5077a14" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_a1b3fc6a-19c5-430f-97b8-068b84edd990" xlink:to="loc_dei_EntityDomain_df04deb9-ff87-4769-a2d2-8439f5077a14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SCHAEONLLCMember_05c5fba0-ad25-4956-bd0d-95e19b846cf0" xlink:href="eols-20241231.xsd#eols_SCHAEONLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_df04deb9-ff87-4769-a2d2-8439f5077a14" xlink:to="loc_eols_SCHAEONLLCMember_05c5fba0-ad25-4956-bd0d-95e19b846cf0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fd7104a0-52d2-4806-9025-e13fd7b8c920" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4b5309ad-c84d-471b-9ba1-2ce47d15f9bb" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fd7104a0-52d2-4806-9025-e13fd7b8c920" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fd7104a0-52d2-4806-9025-e13fd7b8c920_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fd7104a0-52d2-4806-9025-e13fd7b8c920" xlink:to="loc_us-gaap_EquityComponentDomain_fd7104a0-52d2-4806-9025-e13fd7b8c920_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3d896c7a-85fb-41f2-b331-18972560d0d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fd7104a0-52d2-4806-9025-e13fd7b8c920" xlink:to="loc_us-gaap_EquityComponentDomain_3d896c7a-85fb-41f2-b331-18972560d0d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_10e4479c-2f1a-4411-9f9d-c147c2ffeb8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3d896c7a-85fb-41f2-b331-18972560d0d7" xlink:to="loc_us-gaap_CommonStockMember_10e4479c-2f1a-4411-9f9d-c147c2ffeb8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_74b7ba75-6f71-4572-bbaf-f440779708e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4b5309ad-c84d-471b-9ba1-2ce47d15f9bb" xlink:to="loc_us-gaap_TypeOfArrangementAxis_74b7ba75-6f71-4572-bbaf-f440779708e9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_74b7ba75-6f71-4572-bbaf-f440779708e9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_74b7ba75-6f71-4572-bbaf-f440779708e9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_74b7ba75-6f71-4572-bbaf-f440779708e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b2e806f0-8361-47fc-ae56-8e8cd127dbd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_74b7ba75-6f71-4572-bbaf-f440779708e9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b2e806f0-8361-47fc-ae56-8e8cd127dbd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SymateseU.S.AgreementMember_9e3ac528-49ac-4b19-99f3-427efe437b56" xlink:href="eols-20241231.xsd#eols_SymateseU.S.AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b2e806f0-8361-47fc-ae56-8e8cd127dbd2" xlink:to="loc_eols_SymateseU.S.AgreementMember_9e3ac528-49ac-4b19-99f3-427efe437b56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SymateseEuropeAgreementMember_ac09e342-e5f1-40e7-9c4d-25532cfff5d8" xlink:href="eols-20241231.xsd#eols_SymateseEuropeAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b2e806f0-8361-47fc-ae56-8e8cd127dbd2" xlink:to="loc_eols_SymateseEuropeAgreementMember_ac09e342-e5f1-40e7-9c4d-25532cfff5d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_2758001d-6b92-40f1-8028-d4cc9a56bf61" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4b5309ad-c84d-471b-9ba1-2ce47d15f9bb" xlink:to="loc_srt_LitigationCaseAxis_2758001d-6b92-40f1-8028-d4cc9a56bf61" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_2758001d-6b92-40f1-8028-d4cc9a56bf61_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_2758001d-6b92-40f1-8028-d4cc9a56bf61" xlink:to="loc_srt_LitigationCaseTypeDomain_2758001d-6b92-40f1-8028-d4cc9a56bf61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_f10d8d10-06cc-4b9d-8a86-abcb3ed45f7f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_2758001d-6b92-40f1-8028-d4cc9a56bf61" xlink:to="loc_srt_LitigationCaseTypeDomain_f10d8d10-06cc-4b9d-8a86-abcb3ed45f7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IntellectualPropertyDisputesJeuveauMember_23448806-ea80-44a6-ae19-347bedcab39f" xlink:href="eols-20241231.xsd#eols_IntellectualPropertyDisputesJeuveauMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_f10d8d10-06cc-4b9d-8a86-abcb3ed45f7f" xlink:to="loc_eols_IntellectualPropertyDisputesJeuveauMember_23448806-ea80-44a6-ae19-347bedcab39f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ce48b98c-69da-4683-bff7-847c6aa782ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4b5309ad-c84d-471b-9ba1-2ce47d15f9bb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ce48b98c-69da-4683-bff7-847c6aa782ae" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ce48b98c-69da-4683-bff7-847c6aa782ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ce48b98c-69da-4683-bff7-847c6aa782ae" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ce48b98c-69da-4683-bff7-847c6aa782ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_80fd2a4d-4f97-4a9b-9f3d-ea31be4aee1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ce48b98c-69da-4683-bff7-847c6aa782ae" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_80fd2a4d-4f97-4a9b-9f3d-ea31be4aee1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_962eb997-d29d-41f8-9e0f-65003deec6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_80fd2a4d-4f97-4a9b-9f3d-ea31be4aee1b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_962eb997-d29d-41f8-9e0f-65003deec6e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_62a6e5bd-8185-4e48-8de7-c355815e52df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_80fd2a4d-4f97-4a9b-9f3d-ea31be4aee1b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_62a6e5bd-8185-4e48-8de7-c355815e52df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_MilestoneAxis_9e597067-4f50-4457-9c65-d87a8783fe74" xlink:href="eols-20241231.xsd#eols_MilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4b5309ad-c84d-471b-9ba1-2ce47d15f9bb" xlink:to="loc_eols_MilestoneAxis_9e597067-4f50-4457-9c65-d87a8783fe74" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_MilestoneDomain_9e597067-4f50-4457-9c65-d87a8783fe74_default" xlink:href="eols-20241231.xsd#eols_MilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_eols_MilestoneAxis_9e597067-4f50-4457-9c65-d87a8783fe74" xlink:to="loc_eols_MilestoneDomain_9e597067-4f50-4457-9c65-d87a8783fe74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_MilestoneDomain_284d3184-1628-46c9-9c93-bedfef1b67ee" xlink:href="eols-20241231.xsd#eols_MilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_eols_MilestoneAxis_9e597067-4f50-4457-9c65-d87a8783fe74" xlink:to="loc_eols_MilestoneDomain_284d3184-1628-46c9-9c93-bedfef1b67ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_FirstMilestonePaymentMember_c4b37277-f696-4593-a998-0f3b7ea8f03c" xlink:href="eols-20241231.xsd#eols_FirstMilestonePaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_MilestoneDomain_284d3184-1628-46c9-9c93-bedfef1b67ee" xlink:to="loc_eols_FirstMilestonePaymentMember_c4b37277-f696-4593-a998-0f3b7ea8f03c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SecondMilestonePaymentMember_d30f0754-b709-423c-90b0-083cc92ce9ac" xlink:href="eols-20241231.xsd#eols_SecondMilestonePaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_MilestoneDomain_284d3184-1628-46c9-9c93-bedfef1b67ee" xlink:to="loc_eols_SecondMilestonePaymentMember_d30f0754-b709-423c-90b0-083cc92ce9ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4cec4932-ff82-4d0c-b1a8-80a68b4b05fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4b5309ad-c84d-471b-9ba1-2ce47d15f9bb" xlink:to="loc_us-gaap_AwardTypeAxis_4cec4932-ff82-4d0c-b1a8-80a68b4b05fb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4cec4932-ff82-4d0c-b1a8-80a68b4b05fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4cec4932-ff82-4d0c-b1a8-80a68b4b05fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4cec4932-ff82-4d0c-b1a8-80a68b4b05fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e7df0ed3-1e31-40d2-84ea-6c87f86be540" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4cec4932-ff82-4d0c-b1a8-80a68b4b05fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e7df0ed3-1e31-40d2-84ea-6c87f86be540" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PerformanceRestrictedStockUnitsPRSUMember_cf51c542-5477-44a6-a424-917a6cd3b6c7" xlink:href="eols-20241231.xsd#eols_PerformanceRestrictedStockUnitsPRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e7df0ed3-1e31-40d2-84ea-6c87f86be540" xlink:to="loc_eols_PerformanceRestrictedStockUnitsPRSUMember_cf51c542-5477-44a6-a424-917a6cd3b6c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_35aba368-46bb-46c1-bd1d-67c8182d6901" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_us-gaap_NumberOfReportableSegments_35aba368-46bb-46c1-bd1d-67c8182d6901" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_a776c918-5d6c-4732-9c38-259e96db5069" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_us-gaap_NumberOfOperatingSegments_a776c918-5d6c-4732-9c38-259e96db5069" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_AccountsReceivableCreditCardTransactionConvertedToCashPeriod_1c3d4995-ab55-43cc-9bc0-bdfc8116017e" xlink:href="eols-20241231.xsd#eols_AccountsReceivableCreditCardTransactionConvertedToCashPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_AccountsReceivableCreditCardTransactionConvertedToCashPeriod_1c3d4995-ab55-43cc-9bc0-bdfc8116017e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_9ed795e7-bdf4-40ca-98dc-2f08e4a5185b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_9ed795e7-bdf4-40ca-98dc-2f08e4a5185b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_9b0553ed-94da-4cb1-ba36-3503c9e44be5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_us-gaap_NumberOfReportingUnits_9b0553ed-94da-4cb1-ba36-3503c9e44be5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_b71f42bd-d2f0-4cd3-a0ed-fbf92249ca06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_b71f42bd-d2f0-4cd3-a0ed-fbf92249ca06" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ResearchAndDevelopmentInProcess1_02271259-bfb8-449e-9d17-ba151ee5d523" xlink:href="eols-20241231.xsd#eols_ResearchAndDevelopmentInProcess1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_ResearchAndDevelopmentInProcess1_02271259-bfb8-449e-9d17-ba151ee5d523" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementRightToCommercializeAndDistributeNumberOfProductCandidates_fa91bdb3-5d94-450a-ae78-e650aeff97cb" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementRightToCommercializeAndDistributeNumberOfProductCandidates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementRightToCommercializeAndDistributeNumberOfProductCandidates_fa91bdb3-5d94-450a-ae78-e650aeff97cb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementMinimumMilestonePayment_09ed5446-3cb1-4751-816d-71d8f45acf38" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementMinimumMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementMinimumMilestonePayment_09ed5446-3cb1-4751-816d-71d8f45acf38" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement_e0d8296b-2495-4cff-bb80-215e5bd8e5cd" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement_e0d8296b-2495-4cff-bb80-215e5bd8e5cd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod_98015621-d2d0-4ab4-9790-58dd2bc31073" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod_98015621-d2d0-4ab4-9790-58dd2bc31073" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne_e88f090b-86d2-4b44-bd4d-5a4529ba77c2" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne_e88f090b-86d2-4b44-bd4d-5a4529ba77c2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo_5eaa31b8-7b81-41f9-80b5-603d16b0f72e" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo_5eaa31b8-7b81-41f9-80b5-603d16b0f72e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree_30d3ab72-e9ff-4c02-9fd6-7c6d645f5e90" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree_30d3ab72-e9ff-4c02-9fd6-7c6d645f5e90" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour_768907d2-bad7-4bb7-bcd0-e7bb27ba82ef" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour_768907d2-bad7-4bb7-bcd0-e7bb27ba82ef" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense_d67729b5-47e4-4e97-8430-480d9cc0b19e" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense_d67729b5-47e4-4e97-8430-480d9cc0b19e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementInitialTerm_3099f90a-38c6-4916-99a1-84971c407c7f" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementInitialTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementInitialTerm_3099f90a-38c6-4916-99a1-84971c407c7f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementRenewalTerm_fae88a3e-02e6-4cc8-8df9-6c04c6cd19dd" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementRenewalTerm_fae88a3e-02e6-4cc8-8df9-6c04c6cd19dd" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementNumberOfProductCandidates_38823553-b3bf-43e8-bf26-2e847d2aa55c" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementNumberOfProductCandidates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementNumberOfProductCandidates_38823553-b3bf-43e8-bf26-2e847d2aa55c" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementNumberOfCountriesUseAestheticsAndDermatologicalFields_ec6a4b38-27a0-4165-a5bb-1d39fcde46a2" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementNumberOfCountriesUseAestheticsAndDermatologicalFields"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementNumberOfCountriesUseAestheticsAndDermatologicalFields_ec6a4b38-27a0-4165-a5bb-1d39fcde46a2" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement_42a1400f-06a2-4b96-ae5b-7c4bce9511b1" xlink:href="eols-20241231.xsd#eols_StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement_42a1400f-06a2-4b96-ae5b-7c4bce9511b1" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment_498b8c59-bc47-41ea-ad40-784e0aad6c75" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment_498b8c59-bc47-41ea-ad40-784e0aad6c75" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementAnnualRevenue_fe8e3fec-bd4a-43d8-8ddd-74437371414d" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementAnnualRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementAnnualRevenue_fe8e3fec-bd4a-43d8-8ddd-74437371414d" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_NonCashInResearchAndDevelopmentInProcessExpenses_bef84e3c-9eee-4c12-9550-4fadf1a8077d" xlink:href="eols-20241231.xsd#eols_NonCashInResearchAndDevelopmentInProcessExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_NonCashInResearchAndDevelopmentInProcessExpenses_bef84e3c-9eee-4c12-9550-4fadf1a8077d" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_b880adf0-8cb0-4245-ac8e-9b53c38492ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_b880adf0-8cb0-4245-ac8e-9b53c38492ff" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0e4922d9-9597-4794-aebe-ea5f5898bbc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0e4922d9-9597-4794-aebe-ea5f5898bbc6" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementPendingRegulatoryApprovalNumberOfProducts_65dad83f-e22a-4c25-ba96-63fb29164079" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementPendingRegulatoryApprovalNumberOfProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementPendingRegulatoryApprovalNumberOfProducts_65dad83f-e22a-4c25-ba96-63fb29164079" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementMilestonePaymentPayablePeriod_266cc484-403b-4e4d-860c-c5187c97af4e" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementMilestonePaymentPayablePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementMilestonePaymentPayablePeriod_266cc484-403b-4e4d-860c-c5187c97af4e" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts_d9ad7ef0-c60e-40c4-8c42-1f37e1295e0e" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts_d9ad7ef0-c60e-40c4-8c42-1f37e1295e0e" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementLiabilityNoncurrent_be94f518-d89d-4654-9b61-8b1518c19b2c" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementLiabilityNoncurrent_be94f518-d89d-4654-9b61-8b1518c19b2c" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementIntangibleAsset_7dd6d26f-5034-46d2-8845-34b4e077c081" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementIntangibleAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementIntangibleAsset_7dd6d26f-5034-46d2-8845-34b4e077c081" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_bf209dd3-2f57-4560-9f4d-23f467a3a28a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_bf209dd3-2f57-4560-9f4d-23f467a3a28a" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_670e6f83-eeed-414b-89f8-47da6cfd849a" xlink:href="eols-20241231.xsd#eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_670e6f83-eeed-414b-89f8-47da6cfd849a" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_479b008d-0d09-4f33-992a-eb42925d738f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_479b008d-0d09-4f33-992a-eb42925d738f" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_RebatesAndCouponsCreditsAndPayments_28e946cc-34c0-4333-a0bc-3dee5208baf1" xlink:href="eols-20241231.xsd#eols_RebatesAndCouponsCreditsAndPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_RebatesAndCouponsCreditsAndPayments_28e946cc-34c0-4333-a0bc-3dee5208baf1" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability_2290b944-7974-4b51-aefd-9fb097c34d5a" xlink:href="eols-20241231.xsd#eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability_2290b944-7974-4b51-aefd-9fb097c34d5a" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1f0e47c8-9ac7-4401-883e-15b6a1163920" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1f0e47c8-9ac7-4401-883e-15b6a1163920" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_65e4080a-0e68-4534-a7ca-51780a475bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_65e4080a-0e68-4534-a7ca-51780a475bdf" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_be0fba65-fdfc-4d80-9ab3-d91f96ff2721" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_be0fba65-fdfc-4d80-9ab3-d91f96ff2721" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_AccountsReceivableAllowanceForCreditLossWriteOffRecovery_1d986781-08b8-41c4-b529-a5f9d75c826d" xlink:href="eols-20241231.xsd#eols_AccountsReceivableAllowanceForCreditLossWriteOffRecovery"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_AccountsReceivableAllowanceForCreditLossWriteOffRecovery_1d986781-08b8-41c4-b529-a5f9d75c826d" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_95bb53be-3a4e-4c51-9320-3074d485d0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_95bb53be-3a4e-4c51-9320-3074d485d0cd" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LossContingencySettlementAgreementPaymentTerms_d6a1d45a-9f7e-40de-9352-a77166d279e3" xlink:href="eols-20241231.xsd#eols_LossContingencySettlementAgreementPaymentTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LossContingencySettlementAgreementPaymentTerms_d6a1d45a-9f7e-40de-9352-a77166d279e3" xlink:type="arc" order="41"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_7b94ee6d-2b32-4f3e-9905-91fd0c78c1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_7b94ee6d-2b32-4f3e-9905-91fd0c78c1e1" xlink:type="arc" order="42"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_debf845a-27ec-4e91-9db9-4317b29896cf" xlink:href="eols-20241231.xsd#eols_StockIssuedDuringPeriodSharesLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_debf845a-27ec-4e91-9db9-4317b29896cf" xlink:type="arc" order="43"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_4b71327b-29cd-4376-8f48-ef5f8c94deb9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_us-gaap_LitigationReserveCurrent_4b71327b-29cd-4376-8f48-ef5f8c94deb9" xlink:type="arc" order="44"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c95bef60-7bc8-4497-8e9d-9f7cf0b1c133" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c95bef60-7bc8-4497-8e9d-9f7cf0b1c133" xlink:type="arc" order="45"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_5f3aa64e-409c-493f-8404-dea47b7bae6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_us-gaap_AdvertisingExpense_5f3aa64e-409c-493f-8404-dea47b7bae6f" xlink:type="arc" order="46"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c038f05a-da16-4779-922a-0e953e5db3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c038f05a-da16-4779-922a-0e953e5db3d7" xlink:type="arc" order="47"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f6b1b5cf-aab3-4d36-ae57-1d07ef1bf9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_781af877-a3c3-4234-9909-2b2cd3f1986f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f6b1b5cf-aab3-4d36-ae57-1d07ef1bf9eb" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_781af877-a3c3-4234-9909-2b2cd3f1986f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1fd7e858-c50e-4ead-a8e8-63be162d7ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_781af877-a3c3-4234-9909-2b2cd3f1986f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1fd7e858-c50e-4ead-a8e8-63be162d7ed6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1fd7e858-c50e-4ead-a8e8-63be162d7ed6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1fd7e858-c50e-4ead-a8e8-63be162d7ed6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1fd7e858-c50e-4ead-a8e8-63be162d7ed6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7458929b-8783-4c3d-b394-01b656ecb4c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1fd7e858-c50e-4ead-a8e8-63be162d7ed6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7458929b-8783-4c3d-b394-01b656ecb4c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_aa47eb8c-fa23-49e8-bd6c-9ba5d63115a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7458929b-8783-4c3d-b394-01b656ecb4c4" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_aa47eb8c-fa23-49e8-bd6c-9ba5d63115a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a5b476b0-f1c8-4b3e-825d-f90836322a33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_781af877-a3c3-4234-9909-2b2cd3f1986f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a5b476b0-f1c8-4b3e-825d-f90836322a33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a5b476b0-f1c8-4b3e-825d-f90836322a33_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a5b476b0-f1c8-4b3e-825d-f90836322a33" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a5b476b0-f1c8-4b3e-825d-f90836322a33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50b6e7d3-8c85-4f3a-a68e-c447c0be67e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a5b476b0-f1c8-4b3e-825d-f90836322a33" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50b6e7d3-8c85-4f3a-a68e-c447c0be67e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_14e7ba4b-2dc8-4aa6-bf1d-e79600559b71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50b6e7d3-8c85-4f3a-a68e-c447c0be67e3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_14e7ba4b-2dc8-4aa6-bf1d-e79600559b71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5e818d7e-614f-445e-a0cf-2bd876113065" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50b6e7d3-8c85-4f3a-a68e-c447c0be67e3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5e818d7e-614f-445e-a0cf-2bd876113065" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c65d5521-79f2-40f3-9c8a-bdad12d608bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50b6e7d3-8c85-4f3a-a68e-c447c0be67e3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c65d5521-79f2-40f3-9c8a-bdad12d608bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_d06e3678-c6bd-4c23-8cce-28bce603c269" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f6b1b5cf-aab3-4d36-ae57-1d07ef1bf9eb" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_d06e3678-c6bd-4c23-8cce-28bce603c269" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b9453b6-3962-4aea-a67c-068930f9a7d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7b908b44-845d-4934-9ee8-3342938b004e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b9453b6-3962-4aea-a67c-068930f9a7d1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7b908b44-845d-4934-9ee8-3342938b004e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8283f6e8-da69-4bf2-8f81-69142c61e2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7b908b44-845d-4934-9ee8-3342938b004e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8283f6e8-da69-4bf2-8f81-69142c61e2bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8283f6e8-da69-4bf2-8f81-69142c61e2bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8283f6e8-da69-4bf2-8f81-69142c61e2bb" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8283f6e8-da69-4bf2-8f81-69142c61e2bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1538bac9-3960-4431-b4bb-b3cbebacfcc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8283f6e8-da69-4bf2-8f81-69142c61e2bb" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1538bac9-3960-4431-b4bb-b3cbebacfcc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ContingentRoyaltyObligationMember_b071a619-352f-4ca1-95d0-ec4fc7cc28b9" xlink:href="eols-20241231.xsd#eols_ContingentRoyaltyObligationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1538bac9-3960-4431-b4bb-b3cbebacfcc1" xlink:to="loc_eols_ContingentRoyaltyObligationMember_b071a619-352f-4ca1-95d0-ec4fc7cc28b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_0776cf83-508b-4970-9c48-31f845473472" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7b908b44-845d-4934-9ee8-3342938b004e" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_0776cf83-508b-4970-9c48-31f845473472" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_0776cf83-508b-4970-9c48-31f845473472_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_0776cf83-508b-4970-9c48-31f845473472" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_0776cf83-508b-4970-9c48-31f845473472_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_01efbba0-5596-4c03-828d-e54b8e8fbf9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_0776cf83-508b-4970-9c48-31f845473472" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_01efbba0-5596-4c03-828d-e54b8e8fbf9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_a35b96a5-f20f-406b-a82d-440811d13965" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_01efbba0-5596-4c03-828d-e54b8e8fbf9f" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_a35b96a5-f20f-406b-a82d-440811d13965" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ca250c13-9207-4b21-af2a-6859317ab008" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7b908b44-845d-4934-9ee8-3342938b004e" xlink:to="loc_srt_RangeAxis_ca250c13-9207-4b21-af2a-6859317ab008" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ca250c13-9207-4b21-af2a-6859317ab008_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ca250c13-9207-4b21-af2a-6859317ab008" xlink:to="loc_srt_RangeMember_ca250c13-9207-4b21-af2a-6859317ab008_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b13607be-ff36-44c4-a3b1-3ff4b16e6380" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ca250c13-9207-4b21-af2a-6859317ab008" xlink:to="loc_srt_RangeMember_b13607be-ff36-44c4-a3b1-3ff4b16e6380" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c880846b-d80c-401f-965b-3b7fc4a94032" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b13607be-ff36-44c4-a3b1-3ff4b16e6380" xlink:to="loc_srt_MaximumMember_c880846b-d80c-401f-965b-3b7fc4a94032" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_d9a624a9-a4bd-44c3-82e0-df650a580bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7b908b44-845d-4934-9ee8-3342938b004e" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_d9a624a9-a4bd-44c3-82e0-df650a580bc1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_d9a624a9-a4bd-44c3-82e0-df650a580bc1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_d9a624a9-a4bd-44c3-82e0-df650a580bc1" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_d9a624a9-a4bd-44c3-82e0-df650a580bc1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_e62daa8d-e5f8-40c4-b289-92310f587577" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_d9a624a9-a4bd-44c3-82e0-df650a580bc1" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_e62daa8d-e5f8-40c4-b289-92310f587577" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_fe0ff7c8-36e5-4881-a99b-c782b3097b19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_e62daa8d-e5f8-40c4-b289-92310f587577" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_fe0ff7c8-36e5-4881-a99b-c782b3097b19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_479c3ae4-4515-44ab-9a2b-17d48c59247f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_fe0ff7c8-36e5-4881-a99b-c782b3097b19" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_479c3ae4-4515-44ab-9a2b-17d48c59247f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_50219aa5-dfce-4816-a15a-6ff4d2096dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7b908b44-845d-4934-9ee8-3342938b004e" xlink:to="loc_us-gaap_DebtInstrumentAxis_50219aa5-dfce-4816-a15a-6ff4d2096dc7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_50219aa5-dfce-4816-a15a-6ff4d2096dc7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_50219aa5-dfce-4816-a15a-6ff4d2096dc7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_50219aa5-dfce-4816-a15a-6ff4d2096dc7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fc475be8-862f-4b6a-b55d-25252ec58567" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_50219aa5-dfce-4816-a15a-6ff4d2096dc7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fc475be8-862f-4b6a-b55d-25252ec58567" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansMember_0f2ac5ec-d8bf-4504-9d59-7729209dd79c" xlink:href="eols-20241231.xsd#eols_PharmakonTermLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fc475be8-862f-4b6a-b55d-25252ec58567" xlink:to="loc_eols_PharmakonTermLoansMember_0f2ac5ec-d8bf-4504-9d59-7729209dd79c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_9e5fa904-43e0-45ad-96da-c1a1d5066446" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AlternativeInvestmentMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b9453b6-3962-4aea-a67c-068930f9a7d1" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_9e5fa904-43e0-45ad-96da-c1a1d5066446" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2f89b0f9-7e56-4907-ba93-dfb75a10a442" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b9453b6-3962-4aea-a67c-068930f9a7d1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2f89b0f9-7e56-4907-ba93-dfb75a10a442" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_68897cc3-99f7-412d-acf7-b38954a16167" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f271bd5a-995a-44b8-9ae4-28af9eb6b7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_68897cc3-99f7-412d-acf7-b38954a16167" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f271bd5a-995a-44b8-9ae4-28af9eb6b7ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_af495e68-7488-4ad2-ada8-defb6331d065" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f271bd5a-995a-44b8-9ae4-28af9eb6b7ba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_af495e68-7488-4ad2-ada8-defb6331d065" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_af495e68-7488-4ad2-ada8-defb6331d065_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_af495e68-7488-4ad2-ada8-defb6331d065" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_af495e68-7488-4ad2-ada8-defb6331d065_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f0c8c308-808f-47b7-8f85-bbf57f6a5fca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_af495e68-7488-4ad2-ada8-defb6331d065" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f0c8c308-808f-47b7-8f85-bbf57f6a5fca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DistributionRightsMember_e41890e8-b469-44f0-819b-be2f70107ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DistributionRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f0c8c308-808f-47b7-8f85-bbf57f6a5fca" xlink:to="loc_us-gaap_DistributionRightsMember_e41890e8-b469-44f0-819b-be2f70107ca4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_f5ca8fa1-9cd1-41bf-b6f6-ae639545cc61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f0c8c308-808f-47b7-8f85-bbf57f6a5fca" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_f5ca8fa1-9cd1-41bf-b6f6-ae639545cc61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_bf6750e0-1b2e-4301-aec1-c006380c9178" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_68897cc3-99f7-412d-acf7-b38954a16167" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_bf6750e0-1b2e-4301-aec1-c006380c9178" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ed7a5dca-3ab9-4abd-9794-a58a1da29a04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_bf6750e0-1b2e-4301-aec1-c006380c9178" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ed7a5dca-3ab9-4abd-9794-a58a1da29a04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_104d860b-acf3-4bd6-952b-d25cea0a726d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_bf6750e0-1b2e-4301-aec1-c006380c9178" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_104d860b-acf3-4bd6-952b-d25cea0a726d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9318f66f-0068-41b0-a6ac-5551e06f657d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_bf6750e0-1b2e-4301-aec1-c006380c9178" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9318f66f-0068-41b0-a6ac-5551e06f657d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d850726b-eb4c-4c73-8eb6-bbc9c2b1a47a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_bf6750e0-1b2e-4301-aec1-c006380c9178" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d850726b-eb4c-4c73-8eb6-bbc9c2b1a47a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_b3feeb32-dd7b-4ebf-a14e-9c62e84b8dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_68897cc3-99f7-412d-acf7-b38954a16167" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_b3feeb32-dd7b-4ebf-a14e-9c62e84b8dc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5450e4f4-b3f1-40a4-88f9-e02570b6ad1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_b3feeb32-dd7b-4ebf-a14e-9c62e84b8dc3" xlink:to="loc_us-gaap_Goodwill_5450e4f4-b3f1-40a4-88f9-e02570b6ad1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IntangibleAssetsGrossIncludingGoodwill_02ace2fe-a754-466e-a98d-e4091647835f" xlink:href="eols-20241231.xsd#eols_IntangibleAssetsGrossIncludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_68897cc3-99f7-412d-acf7-b38954a16167" xlink:to="loc_eols_IntangibleAssetsGrossIncludingGoodwill_02ace2fe-a754-466e-a98d-e4091647835f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_cce76e5a-86a3-443a-8650-93f2aecee5ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_68897cc3-99f7-412d-acf7-b38954a16167" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_cce76e5a-86a3-443a-8650-93f2aecee5ca" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_5b1e1251-fe25-4802-896f-a75bd0739ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_459cb587-e22c-4a90-b397-6ee68443ad0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5b1e1251-fe25-4802-896f-a75bd0739ec8" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_459cb587-e22c-4a90-b397-6ee68443ad0c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_923bfe7e-753e-4904-ad79-9a022b72006d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_459cb587-e22c-4a90-b397-6ee68443ad0c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_923bfe7e-753e-4904-ad79-9a022b72006d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_923bfe7e-753e-4904-ad79-9a022b72006d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_923bfe7e-753e-4904-ad79-9a022b72006d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_923bfe7e-753e-4904-ad79-9a022b72006d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f5551c6d-bad0-4c52-a88d-9e11fe20d39f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_923bfe7e-753e-4904-ad79-9a022b72006d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f5551c6d-bad0-4c52-a88d-9e11fe20d39f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DistributionRightsEvolysseNasolabialFoldProductMember_eb5d3be2-34fe-4a85-872d-601a48b915bf" xlink:href="eols-20241231.xsd#eols_DistributionRightsEvolysseNasolabialFoldProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f5551c6d-bad0-4c52-a88d-9e11fe20d39f" xlink:to="loc_eols_DistributionRightsEvolysseNasolabialFoldProductMember_eb5d3be2-34fe-4a85-872d-601a48b915bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_eb210266-3417-421b-b5e8-a733ee9bfee8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f5551c6d-bad0-4c52-a88d-9e11fe20d39f" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_eb210266-3417-421b-b5e8-a733ee9bfee8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a1ab02a8-cc84-4f63-a14f-5727068f3b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_459cb587-e22c-4a90-b397-6ee68443ad0c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a1ab02a8-cc84-4f63-a14f-5727068f3b7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a1ab02a8-cc84-4f63-a14f-5727068f3b7e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a1ab02a8-cc84-4f63-a14f-5727068f3b7e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a1ab02a8-cc84-4f63-a14f-5727068f3b7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ac9734d9-7b84-4cd2-8148-d3e83873cfd7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a1ab02a8-cc84-4f63-a14f-5727068f3b7e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ac9734d9-7b84-4cd2-8148-d3e83873cfd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SymateseEuropeAgreementMember_182c65cd-f908-4473-8e20-5dc67d359a6a" xlink:href="eols-20241231.xsd#eols_SymateseEuropeAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ac9734d9-7b84-4cd2-8148-d3e83873cfd7" xlink:to="loc_eols_SymateseEuropeAgreementMember_182c65cd-f908-4473-8e20-5dc67d359a6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_07e62812-3c7f-4819-a30a-9969ec9a7bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5b1e1251-fe25-4802-896f-a75bd0739ec8" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_07e62812-3c7f-4819-a30a-9969ec9a7bfc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8eb9694d-7328-4faa-9c21-8ce028559c67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5b1e1251-fe25-4802-896f-a75bd0739ec8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8eb9694d-7328-4faa-9c21-8ce028559c67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAdditions_fc9fea39-7444-46a2-ad07-57fc1b1c2b79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedComputerSoftwareAdditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5b1e1251-fe25-4802-896f-a75bd0739ec8" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAdditions_fc9fea39-7444-46a2-ad07-57fc1b1c2b79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_7d379a49-2f69-49e7-9863-52e8922c2614" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5b1e1251-fe25-4802-896f-a75bd0739ec8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_7d379a49-2f69-49e7-9863-52e8922c2614" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_23acb1f6-2a9e-42bd-8f0f-ceaf30e53212" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5b1e1251-fe25-4802-896f-a75bd0739ec8" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_23acb1f6-2a9e-42bd-8f0f-ceaf30e53212" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7603d1f1-0a1d-4403-a48c-73fc7e154a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6d82f35e-6fbd-42dc-a025-9c753c15a5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7603d1f1-0a1d-4403-a48c-73fc7e154a0a" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6d82f35e-6fbd-42dc-a025-9c753c15a5c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1b053a80-64ae-411d-86b2-4d0afc12ad84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6d82f35e-6fbd-42dc-a025-9c753c15a5c9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1b053a80-64ae-411d-86b2-4d0afc12ad84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1b053a80-64ae-411d-86b2-4d0afc12ad84_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1b053a80-64ae-411d-86b2-4d0afc12ad84" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1b053a80-64ae-411d-86b2-4d0afc12ad84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9785c9ab-fd8b-498c-87bb-d2e1acba76b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1b053a80-64ae-411d-86b2-4d0afc12ad84" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9785c9ab-fd8b-498c-87bb-d2e1acba76b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_63fc8464-2b09-429e-bdc6-2c7f6d45ef1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9785c9ab-fd8b-498c-87bb-d2e1acba76b5" xlink:to="loc_us-gaap_EquipmentMember_63fc8464-2b09-429e-bdc6-2c7f6d45ef1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_0a53419f-b51f-40b0-85ef-97c85646912c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9785c9ab-fd8b-498c-87bb-d2e1acba76b5" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_0a53419f-b51f-40b0-85ef-97c85646912c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_bb1a902d-7c47-419c-9632-7859643bce38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9785c9ab-fd8b-498c-87bb-d2e1acba76b5" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_bb1a902d-7c47-419c-9632-7859643bce38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_2b306d4f-c9a4-43e3-ba7e-7e95cc20aa87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9785c9ab-fd8b-498c-87bb-d2e1acba76b5" xlink:to="loc_us-gaap_ComputerEquipmentMember_2b306d4f-c9a4-43e3-ba7e-7e95cc20aa87" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_MarketingFixturesMember_1172e908-8bab-483c-9797-117f0e27a0cd" xlink:href="eols-20241231.xsd#eols_MarketingFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9785c9ab-fd8b-498c-87bb-d2e1acba76b5" xlink:to="loc_eols_MarketingFixturesMember_1172e908-8bab-483c-9797-117f0e27a0cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_e0ba0aa7-603d-43cd-878b-a82599edda1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7603d1f1-0a1d-4403-a48c-73fc7e154a0a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_e0ba0aa7-603d-43cd-878b-a82599edda1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_bf8a33a6-4b06-4c1b-b283-5185823c1604" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7603d1f1-0a1d-4403-a48c-73fc7e154a0a" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_bf8a33a6-4b06-4c1b-b283-5185823c1604" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a862d4fd-b0ae-42bd-bde4-774764b9057b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7603d1f1-0a1d-4403-a48c-73fc7e154a0a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a862d4fd-b0ae-42bd-bde4-774764b9057b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/TermLoansNarrativeDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#TermLoansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/TermLoansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_291304e3-e9da-4d87-94e0-77400199977d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9782f76f-b92f-4416-87d9-d5e40b589db5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_291304e3-e9da-4d87-94e0-77400199977d" xlink:to="loc_us-gaap_DebtInstrumentTable_9782f76f-b92f-4416-87d9-d5e40b589db5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0094c72e-5f75-4602-932f-20cf3825bb85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9782f76f-b92f-4416-87d9-d5e40b589db5" xlink:to="loc_us-gaap_DebtInstrumentAxis_0094c72e-5f75-4602-932f-20cf3825bb85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0094c72e-5f75-4602-932f-20cf3825bb85_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_0094c72e-5f75-4602-932f-20cf3825bb85" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0094c72e-5f75-4602-932f-20cf3825bb85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_018dce93-1a37-4904-bb0a-891a3ee22616" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_0094c72e-5f75-4602-932f-20cf3825bb85" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_018dce93-1a37-4904-bb0a-891a3ee22616" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansMember_7cc2301b-4ce5-4549-ae3b-335fda86bbf7" xlink:href="eols-20241231.xsd#eols_PharmakonTermLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_018dce93-1a37-4904-bb0a-891a3ee22616" xlink:to="loc_eols_PharmakonTermLoansMember_7cc2301b-4ce5-4549-ae3b-335fda86bbf7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansOneMember_22181b81-fec2-436c-9d50-7d26bed9a796" xlink:href="eols-20241231.xsd#eols_PharmakonTermLoansOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_018dce93-1a37-4904-bb0a-891a3ee22616" xlink:to="loc_eols_PharmakonTermLoansOneMember_22181b81-fec2-436c-9d50-7d26bed9a796" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansTwoMember_6b7e06f3-1eee-41a7-af5e-20f21b530dd4" xlink:href="eols-20241231.xsd#eols_PharmakonTermLoansTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_018dce93-1a37-4904-bb0a-891a3ee22616" xlink:to="loc_eols_PharmakonTermLoansTwoMember_6b7e06f3-1eee-41a7-af5e-20f21b530dd4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_beb3e3ac-9117-4764-b625-8a125020f4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9782f76f-b92f-4416-87d9-d5e40b589db5" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_beb3e3ac-9117-4764-b625-8a125020f4fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_beb3e3ac-9117-4764-b625-8a125020f4fa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_beb3e3ac-9117-4764-b625-8a125020f4fa" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_beb3e3ac-9117-4764-b625-8a125020f4fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6c30b6a3-383e-4306-b933-69966312f6fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_beb3e3ac-9117-4764-b625-8a125020f4fa" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6c30b6a3-383e-4306-b933-69966312f6fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_72e4be86-d3fd-4c08-b666-620b80f3e36c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6c30b6a3-383e-4306-b933-69966312f6fb" xlink:to="loc_us-gaap_SecuredDebtMember_72e4be86-d3fd-4c08-b666-620b80f3e36c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentTermsAxis_37588a1a-68eb-48c4-ba87-5adf01e2f15c" xlink:href="eols-20241231.xsd#eols_DebtInstrumentPrepaymentTermsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9782f76f-b92f-4416-87d9-d5e40b589db5" xlink:to="loc_eols_DebtInstrumentPrepaymentTermsAxis_37588a1a-68eb-48c4-ba87-5adf01e2f15c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentTermsDomain_37588a1a-68eb-48c4-ba87-5adf01e2f15c_default" xlink:href="eols-20241231.xsd#eols_DebtInstrumentPrepaymentTermsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_eols_DebtInstrumentPrepaymentTermsAxis_37588a1a-68eb-48c4-ba87-5adf01e2f15c" xlink:to="loc_eols_DebtInstrumentPrepaymentTermsDomain_37588a1a-68eb-48c4-ba87-5adf01e2f15c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentTermsDomain_d327f251-8689-4f8f-915a-8c4f4e8ccb9a" xlink:href="eols-20241231.xsd#eols_DebtInstrumentPrepaymentTermsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_eols_DebtInstrumentPrepaymentTermsAxis_37588a1a-68eb-48c4-ba87-5adf01e2f15c" xlink:to="loc_eols_DebtInstrumentPrepaymentTermsDomain_d327f251-8689-4f8f-915a-8c4f4e8ccb9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TermOneMember_1209799c-e379-4745-9a3b-6fb6019ef7a5" xlink:href="eols-20241231.xsd#eols_TermOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_DebtInstrumentPrepaymentTermsDomain_d327f251-8689-4f8f-915a-8c4f4e8ccb9a" xlink:to="loc_eols_TermOneMember_1209799c-e379-4745-9a3b-6fb6019ef7a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TermTwoMember_da94b9b1-c207-4b13-80cf-5dea54f8bdfa" xlink:href="eols-20241231.xsd#eols_TermTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_DebtInstrumentPrepaymentTermsDomain_d327f251-8689-4f8f-915a-8c4f4e8ccb9a" xlink:to="loc_eols_TermTwoMember_da94b9b1-c207-4b13-80cf-5dea54f8bdfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TermThreeMember_9b0291e5-cde9-451b-86e3-e610853ae6eb" xlink:href="eols-20241231.xsd#eols_TermThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_DebtInstrumentPrepaymentTermsDomain_d327f251-8689-4f8f-915a-8c4f4e8ccb9a" xlink:to="loc_eols_TermThreeMember_9b0291e5-cde9-451b-86e3-e610853ae6eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_068f6364-addb-40c4-8255-157b483605ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_9782f76f-b92f-4416-87d9-d5e40b589db5" xlink:to="loc_us-gaap_VariableRateAxis_068f6364-addb-40c4-8255-157b483605ed" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_068f6364-addb-40c4-8255-157b483605ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_068f6364-addb-40c4-8255-157b483605ed" xlink:to="loc_us-gaap_VariableRateDomain_068f6364-addb-40c4-8255-157b483605ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_e95dc5df-e97c-49eb-b14b-e6d3274c7c83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_068f6364-addb-40c4-8255-157b483605ed" xlink:to="loc_us-gaap_VariableRateDomain_e95dc5df-e97c-49eb-b14b-e6d3274c7c83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LondonInterbankOfferedRateLIBOR1Member_9fcacdb3-4e76-4fae-a601-e9fd5f29dece" xlink:href="eols-20241231.xsd#eols_LondonInterbankOfferedRateLIBOR1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_e95dc5df-e97c-49eb-b14b-e6d3274c7c83" xlink:to="loc_eols_LondonInterbankOfferedRateLIBOR1Member_9fcacdb3-4e76-4fae-a601-e9fd5f29dece" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SecuredFinancingOfferedRateSOFRMember_3ea5d566-4ed4-41d6-a4ad-6a618af74b5a" xlink:href="eols-20241231.xsd#eols_SecuredFinancingOfferedRateSOFRMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_e95dc5df-e97c-49eb-b14b-e6d3274c7c83" xlink:to="loc_eols_SecuredFinancingOfferedRateSOFRMember_3ea5d566-4ed4-41d6-a4ad-6a618af74b5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentNumberOfTranches_de099271-911d-4237-8e58-08dfe4e809e7" xlink:href="eols-20241231.xsd#eols_DebtInstrumentNumberOfTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_291304e3-e9da-4d87-94e0-77400199977d" xlink:to="loc_eols_DebtInstrumentNumberOfTranches_de099271-911d-4237-8e58-08dfe4e809e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_96847f5a-bf98-416b-b973-a2fd7e1d75b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_291304e3-e9da-4d87-94e0-77400199977d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_96847f5a-bf98-416b-b973-a2fd7e1d75b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_15ef86e3-900b-4f43-a984-06401b8921de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_291304e3-e9da-4d87-94e0-77400199977d" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_15ef86e3-900b-4f43-a984-06401b8921de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_65bae14b-d1c5-46c2-a260-f0701f60b96e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_291304e3-e9da-4d87-94e0-77400199977d" xlink:to="loc_us-gaap_DebtInstrumentTerm_65bae14b-d1c5-46c2-a260-f0701f60b96e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentNumberOfInstallments_cbbacfdb-8c3c-455b-a943-eceebf9ac686" xlink:href="eols-20241231.xsd#eols_DebtInstrumentNumberOfInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_291304e3-e9da-4d87-94e0-77400199977d" xlink:to="loc_eols_DebtInstrumentNumberOfInstallments_cbbacfdb-8c3c-455b-a943-eceebf9ac686" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_6f2612bd-8931-4c4d-bf27-6793ffeded4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_291304e3-e9da-4d87-94e0-77400199977d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_6f2612bd-8931-4c4d-bf27-6793ffeded4d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPeriodicPaymentOutstandingPrincipalAmountDuePercentage_2f32cff1-d98d-4db1-83db-deb9156cb3d2" xlink:href="eols-20241231.xsd#eols_DebtInstrumentPeriodicPaymentOutstandingPrincipalAmountDuePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_291304e3-e9da-4d87-94e0-77400199977d" xlink:to="loc_eols_DebtInstrumentPeriodicPaymentOutstandingPrincipalAmountDuePercentage_2f32cff1-d98d-4db1-83db-deb9156cb3d2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPeriodicPaymentNumberOfPrincipalPayments_2b6bfd6f-543c-4740-9b68-6c40c3c4137f" xlink:href="eols-20241231.xsd#eols_DebtInstrumentPeriodicPaymentNumberOfPrincipalPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_291304e3-e9da-4d87-94e0-77400199977d" xlink:to="loc_eols_DebtInstrumentPeriodicPaymentNumberOfPrincipalPayments_2b6bfd6f-543c-4740-9b68-6c40c3c4137f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPeriodicPaymentInitialPrincipalPaymentDuePeriod_0f86bc1c-7394-4e85-8671-54ae979694b7" xlink:href="eols-20241231.xsd#eols_DebtInstrumentPeriodicPaymentInitialPrincipalPaymentDuePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_291304e3-e9da-4d87-94e0-77400199977d" xlink:to="loc_eols_DebtInstrumentPeriodicPaymentInitialPrincipalPaymentDuePeriod_0f86bc1c-7394-4e85-8671-54ae979694b7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d61007cb-2678-461c-a6fd-314d109e08b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_291304e3-e9da-4d87-94e0-77400199977d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d61007cb-2678-461c-a6fd-314d109e08b2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_c6d2da64-18eb-4d1f-bcdc-b64cfef19b11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_291304e3-e9da-4d87-94e0-77400199977d" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_c6d2da64-18eb-4d1f-bcdc-b64cfef19b11" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentAmountThreshold_54448677-17db-4cdf-9c3f-d23385c62bd3" xlink:href="eols-20241231.xsd#eols_DebtInstrumentPrepaymentAmountThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_291304e3-e9da-4d87-94e0-77400199977d" xlink:to="loc_eols_DebtInstrumentPrepaymentAmountThreshold_54448677-17db-4cdf-9c3f-d23385c62bd3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount_658ffccd-e81e-4e0f-a5aa-96f093ca355e" xlink:href="eols-20241231.xsd#eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_291304e3-e9da-4d87-94e0-77400199977d" xlink:to="loc_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount_658ffccd-e81e-4e0f-a5aa-96f093ca355e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_eae6e45c-168d-4c06-a3d1-b480fdfe37ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_291304e3-e9da-4d87-94e0-77400199977d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_eae6e45c-168d-4c06-a3d1-b480fdfe37ad" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_3c9edb29-7758-4cf1-b69f-8157c8f715e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_291304e3-e9da-4d87-94e0-77400199977d" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_3c9edb29-7758-4cf1-b69f-8157c8f715e6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_dd0b7215-59e3-4359-826b-d8cc472b2cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_291304e3-e9da-4d87-94e0-77400199977d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_dd0b7215-59e3-4359-826b-d8cc472b2cb3" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentandContingenciesDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#CommitmentandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/CommitmentandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_61bcd30b-3213-433a-a5e9-88a935ca504b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:to="loc_us-gaap_LossContingenciesTable_61bcd30b-3213-433a-a5e9-88a935ca504b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2d7e4321-5f97-464b-a44f-d28810f8a4f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_61bcd30b-3213-433a-a5e9-88a935ca504b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2d7e4321-5f97-464b-a44f-d28810f8a4f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2d7e4321-5f97-464b-a44f-d28810f8a4f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2d7e4321-5f97-464b-a44f-d28810f8a4f9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2d7e4321-5f97-464b-a44f-d28810f8a4f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fd5aea87-b1e2-4873-9203-123e391f38c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2d7e4321-5f97-464b-a44f-d28810f8a4f9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fd5aea87-b1e2-4873-9203-123e391f38c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SymateseU.S.AgreementMember_644ce47c-9f89-4db6-8bf7-f5e79ae9ddb9" xlink:href="eols-20241231.xsd#eols_SymateseU.S.AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fd5aea87-b1e2-4873-9203-123e391f38c7" xlink:to="loc_eols_SymateseU.S.AgreementMember_644ce47c-9f89-4db6-8bf7-f5e79ae9ddb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SymateseEuropeAgreementMember_64a06d54-85fa-4838-875a-1f66c578a9c5" xlink:href="eols-20241231.xsd#eols_SymateseEuropeAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fd5aea87-b1e2-4873-9203-123e391f38c7" xlink:to="loc_eols_SymateseEuropeAgreementMember_64a06d54-85fa-4838-875a-1f66c578a9c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PaymentsForInventory_3ea259f2-410b-4e15-b7c4-e3e364e85119" xlink:href="eols-20241231.xsd#eols_PaymentsForInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:to="loc_eols_PaymentsForInventory_3ea259f2-410b-4e15-b7c4-e3e364e85119" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementMinimumMilestonePayment_6ad5bb29-9c0b-45ee-b6af-3f519ae9e116" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementMinimumMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementMinimumMilestonePayment_6ad5bb29-9c0b-45ee-b6af-3f519ae9e116" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement_d8564846-2470-49f3-b938-a4947146a354" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement_d8564846-2470-49f3-b938-a4947146a354" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod_42022c6d-821d-4b64-a633-16ab48dd79b5" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod_42022c6d-821d-4b64-a633-16ab48dd79b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne_6b257959-36eb-4df5-92fa-978fa54addf9" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne_6b257959-36eb-4df5-92fa-978fa54addf9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo_ad6d0280-d3fe-4d9c-aeb9-d4c7bbd707a4" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo_ad6d0280-d3fe-4d9c-aeb9-d4c7bbd707a4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree_df707c01-0472-4414-b5fe-9c9d8d31798f" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree_df707c01-0472-4414-b5fe-9c9d8d31798f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour_12516ced-91b5-4bab-a3eb-518ae4926620" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour_12516ced-91b5-4bab-a3eb-518ae4926620" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentTriggeredRegulatoryApprovalNumberOfProducts_32df65c7-7e04-4d7d-a649-33d647a93936" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementAnnualPaymentTriggeredRegulatoryApprovalNumberOfProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentTriggeredRegulatoryApprovalNumberOfProducts_32df65c7-7e04-4d7d-a649-33d647a93936" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense_3c084b29-e9d3-4df8-bd07-437c43ce5327" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense_3c084b29-e9d3-4df8-bd07-437c43ce5327" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment_761d8ade-36f3-4fa0-bc80-d90154f8feff" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment_761d8ade-36f3-4fa0-bc80-d90154f8feff" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementAnnualRevenue_cfac64e4-e71e-4240-91e4-24e6e3deb8cf" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementAnnualRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementAnnualRevenue_cfac64e4-e71e-4240-91e4-24e6e3deb8cf" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts_54a95af2-ff7a-4f85-987f-f59837e04fb0" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts_54a95af2-ff7a-4f85-987f-f59837e04fb0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementMilestonePaymentPayablePeriod_a42d01e3-e52b-4e1c-8688-913234933d7c" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementMilestonePaymentPayablePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementMilestonePaymentPayablePeriod_a42d01e3-e52b-4e1c-8688-913234933d7c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_8fdb2b99-74f1-4531-aea2-b78542d195ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_8fdb2b99-74f1-4531-aea2-b78542d195ef" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LossContingencyNumberDefendantsOfficers_f22b6fa4-d345-4639-b460-2555b8b11d7a" xlink:href="eols-20241231.xsd#eols_LossContingencyNumberDefendantsOfficers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:to="loc_eols_LossContingencyNumberDefendantsOfficers_f22b6fa4-d345-4639-b460-2555b8b11d7a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_0789014a-59f3-415d-aa13-2979c2d82124" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_0789014a-59f3-415d-aa13-2979c2d82124" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_8cfbd8ac-b66a-4b90-be13-4a48de99b814" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_8cfbd8ac-b66a-4b90-be13-4a48de99b814" xlink:type="arc" order="17"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_13780bb0-2640-4adb-b2f8-fe0efcf9d0b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_13780bb0-2640-4adb-b2f8-fe0efcf9d0b1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3d3b9758-5235-471b-bdb3-3723b4cb78f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_13780bb0-2640-4adb-b2f8-fe0efcf9d0b1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3d3b9758-5235-471b-bdb3-3723b4cb78f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3d3b9758-5235-471b-bdb3-3723b4cb78f3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3d3b9758-5235-471b-bdb3-3723b4cb78f3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3d3b9758-5235-471b-bdb3-3723b4cb78f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_075438b1-1b58-4a54-b568-65502c00e262" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3d3b9758-5235-471b-bdb3-3723b4cb78f3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_075438b1-1b58-4a54-b568-65502c00e262" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_FollowOnOfferingMember_522fe7ba-841d-4972-ac3d-e2a31c9dba6d" xlink:href="eols-20241231.xsd#eols_FollowOnOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_075438b1-1b58-4a54-b568-65502c00e262" xlink:to="loc_eols_FollowOnOfferingMember_522fe7ba-841d-4972-ac3d-e2a31c9dba6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ATMSalesAgreementMember_1207d9a0-e63d-43ed-8e65-472bd29cabb7" xlink:href="eols-20241231.xsd#eols_ATMSalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_075438b1-1b58-4a54-b568-65502c00e262" xlink:to="loc_eols_ATMSalesAgreementMember_1207d9a0-e63d-43ed-8e65-472bd29cabb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4504b65b-5e50-46ee-9357-d17ac3f6b683" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_13780bb0-2640-4adb-b2f8-fe0efcf9d0b1" xlink:to="loc_us-gaap_PlanNameAxis_4504b65b-5e50-46ee-9357-d17ac3f6b683" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4504b65b-5e50-46ee-9357-d17ac3f6b683_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_4504b65b-5e50-46ee-9357-d17ac3f6b683" xlink:to="loc_us-gaap_PlanNameDomain_4504b65b-5e50-46ee-9357-d17ac3f6b683_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0c503a50-6ba0-4577-945b-196ef9d8ba78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_4504b65b-5e50-46ee-9357-d17ac3f6b683" xlink:to="loc_us-gaap_PlanNameDomain_0c503a50-6ba0-4577-945b-196ef9d8ba78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_A2023InducementIncentivePlanMember_f23be0fb-a987-4002-91f2-bd4148052ce9" xlink:href="eols-20241231.xsd#eols_A2023InducementIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0c503a50-6ba0-4577-945b-196ef9d8ba78" xlink:to="loc_eols_A2023InducementIncentivePlanMember_f23be0fb-a987-4002-91f2-bd4148052ce9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TwoThousandAndSeventeenOmnibusIncentivePlanMember_9db09098-0c1a-49a6-83a4-2fd85622f654" xlink:href="eols-20241231.xsd#eols_TwoThousandAndSeventeenOmnibusIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0c503a50-6ba0-4577-945b-196ef9d8ba78" xlink:to="loc_eols_TwoThousandAndSeventeenOmnibusIncentivePlanMember_9db09098-0c1a-49a6-83a4-2fd85622f654" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_A2024EmployeeStockPurchasePlanMember_b0cff228-51f6-4878-bd66-ccbf712bfaa9" xlink:href="eols-20241231.xsd#eols_A2024EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0c503a50-6ba0-4577-945b-196ef9d8ba78" xlink:to="loc_eols_A2024EmployeeStockPurchasePlanMember_b0cff228-51f6-4878-bd66-ccbf712bfaa9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5d8970b6-f113-41cf-ad15-ffdd95489c0c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_13780bb0-2640-4adb-b2f8-fe0efcf9d0b1" xlink:to="loc_srt_RangeAxis_5d8970b6-f113-41cf-ad15-ffdd95489c0c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5d8970b6-f113-41cf-ad15-ffdd95489c0c_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5d8970b6-f113-41cf-ad15-ffdd95489c0c" xlink:to="loc_srt_RangeMember_5d8970b6-f113-41cf-ad15-ffdd95489c0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6a762eaf-a928-47c4-a8a6-2a4e5f7c0f9d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5d8970b6-f113-41cf-ad15-ffdd95489c0c" xlink:to="loc_srt_RangeMember_6a762eaf-a928-47c4-a8a6-2a4e5f7c0f9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_39f65004-63f6-41d6-8323-3c51f007571f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6a762eaf-a928-47c4-a8a6-2a4e5f7c0f9d" xlink:to="loc_srt_MinimumMember_39f65004-63f6-41d6-8323-3c51f007571f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6a0d4fbc-c434-4d7e-8064-1c84bb3b9b0d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6a762eaf-a928-47c4-a8a6-2a4e5f7c0f9d" xlink:to="loc_srt_MaximumMember_6a0d4fbc-c434-4d7e-8064-1c84bb3b9b0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2d29470e-22f9-43ee-8361-1a2e07ed111a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_13780bb0-2640-4adb-b2f8-fe0efcf9d0b1" xlink:to="loc_us-gaap_AwardTypeAxis_2d29470e-22f9-43ee-8361-1a2e07ed111a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2d29470e-22f9-43ee-8361-1a2e07ed111a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2d29470e-22f9-43ee-8361-1a2e07ed111a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2d29470e-22f9-43ee-8361-1a2e07ed111a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d734191d-16cf-47a1-bafe-c0b9caa9a53a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2d29470e-22f9-43ee-8361-1a2e07ed111a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d734191d-16cf-47a1-bafe-c0b9caa9a53a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_31a5acac-b50f-4492-825d-c9d4104e8835" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d734191d-16cf-47a1-bafe-c0b9caa9a53a" xlink:to="loc_us-gaap_EmployeeStockMember_31a5acac-b50f-4492-825d-c9d4104e8835" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_20df98e7-1c43-458a-baa1-082814d05051" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d734191d-16cf-47a1-bafe-c0b9caa9a53a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_20df98e7-1c43-458a-baa1-082814d05051" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_58e82a9f-2256-4dd0-b0c6-69731848ab1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d734191d-16cf-47a1-bafe-c0b9caa9a53a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_58e82a9f-2256-4dd0-b0c6-69731848ab1c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PerformanceRestrictedStockUnitsPRSUMember_163c78cf-94c8-4af8-be06-ba416d4dadce" xlink:href="eols-20241231.xsd#eols_PerformanceRestrictedStockUnitsPRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d734191d-16cf-47a1-bafe-c0b9caa9a53a" xlink:to="loc_eols_PerformanceRestrictedStockUnitsPRSUMember_163c78cf-94c8-4af8-be06-ba416d4dadce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_CEOPerformanceRestrictedShareUnitsCPRSUMember_2d9bc369-0d12-4f88-9778-3c839a649d88" xlink:href="eols-20241231.xsd#eols_CEOPerformanceRestrictedShareUnitsCPRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d734191d-16cf-47a1-bafe-c0b9caa9a53a" xlink:to="loc_eols_CEOPerformanceRestrictedShareUnitsCPRSUMember_2d9bc369-0d12-4f88-9778-3c839a649d88" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_8d8b1e16-be9b-493f-ab09-96a3d787c31b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_13780bb0-2640-4adb-b2f8-fe0efcf9d0b1" xlink:to="loc_us-gaap_VestingAxis_8d8b1e16-be9b-493f-ab09-96a3d787c31b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_8d8b1e16-be9b-493f-ab09-96a3d787c31b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_8d8b1e16-be9b-493f-ab09-96a3d787c31b" xlink:to="loc_us-gaap_VestingDomain_8d8b1e16-be9b-493f-ab09-96a3d787c31b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_54bddb05-bbbc-4159-81e3-dab5b050181e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_8d8b1e16-be9b-493f-ab09-96a3d787c31b" xlink:to="loc_us-gaap_VestingDomain_54bddb05-bbbc-4159-81e3-dab5b050181e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_61104405-5d0d-4bc8-bb51-39f0a50892d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_54bddb05-bbbc-4159-81e3-dab5b050181e" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_61104405-5d0d-4bc8-bb51-39f0a50892d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_f9b7119c-e257-443e-a188-70606acf1eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_54bddb05-bbbc-4159-81e3-dab5b050181e" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_f9b7119c-e257-443e-a188-70606acf1eaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_66af1d9f-e9bb-47a3-94f4-0483663179b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_66af1d9f-e9bb-47a3-94f4-0483663179b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6f34a4e0-a249-43b6-b0d2-cbd28aa532e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6f34a4e0-a249-43b6-b0d2-cbd28aa532e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_70c7dbfc-8d4a-4674-896d-f8c37237cc89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_70c7dbfc-8d4a-4674-896d-f8c37237cc89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_c6766e52-30b2-4029-a05f-1eb09d2db0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_PreferredStockSharesIssued_c6766e52-30b2-4029-a05f-1eb09d2db0d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_27d2e188-c597-4fc5-bb62-f55e0c1761fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_27d2e188-c597-4fc5-bb62-f55e0c1761fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_39b37c3b-1c8c-45b7-b5f8-1bfe0e22b450" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_39b37c3b-1c8c-45b7-b5f8-1bfe0e22b450" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_1bb9ac8b-8e47-4692-b24d-9ed7ab05718c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_CommonStockSharesIssued_1bb9ac8b-8e47-4692-b24d-9ed7ab05718c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1eebd436-775d-49d3-8e56-7433aebd9230" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1eebd436-775d-49d3-8e56-7433aebd9230" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_e1176e39-66b5-4232-b112-793d09bb727b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_e1176e39-66b5-4232-b112-793d09bb727b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_314948a1-b73a-443b-b8d4-5685c114695e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_314948a1-b73a-443b-b8d4-5685c114695e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_33fa4a33-0527-429a-9363-523e1527d0c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_33fa4a33-0527-429a-9363-523e1527d0c5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_bb28b7bd-5c65-4206-8600-8a7eeaa3490f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_bb28b7bd-5c65-4206-8600-8a7eeaa3490f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalShareIncreaseAvailableForIssuance_ccc6ddb4-c83f-4725-bf76-23f09630046a" xlink:href="eols-20241231.xsd#eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalShareIncreaseAvailableForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalShareIncreaseAvailableForIssuance_ccc6ddb4-c83f-4725-bf76-23f09630046a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_59c4685e-0c8a-42e7-bd69-a33b7b4e4198" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_59c4685e-0c8a-42e7-bd69-a33b7b4e4198" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SaleOfStockMaximumConsiderationReceivable_cfbacdc6-b545-4b49-926f-717312b4119d" xlink:href="eols-20241231.xsd#eols_SaleOfStockMaximumConsiderationReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_eols_SaleOfStockMaximumConsiderationReceivable_cfbacdc6-b545-4b49-926f-717312b4119d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage_843b112d-672d-4607-8d98-7759805c1ccb" xlink:href="eols-20241231.xsd#eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage_843b112d-672d-4607-8d98-7759805c1ccb" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1eb5d626-2955-4fcd-8259-8186e14a7275" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1eb5d626-2955-4fcd-8259-8186e14a7275" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_4fe2a52c-0070-4bc5-8414-01b957168852" xlink:href="eols-20241231.xsd#eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_4fe2a52c-0070-4bc5-8414-01b957168852" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8a3b247e-a873-416e-b717-e922143b5133" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8a3b247e-a873-416e-b717-e922143b5133" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a5421cda-55b4-4bd2-b9d3-3f0034f3ce44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a5421cda-55b4-4bd2-b9d3-3f0034f3ce44" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_702c9727-2f9d-4ceb-a8a4-99f560aec4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_702c9727-2f9d-4ceb-a8a4-99f560aec4e8" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm_1796b901-4c80-48f2-960c-1282f941c3f0" xlink:href="eols-20241231.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm_1796b901-4c80-48f2-960c-1282f941c3f0" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_db266b9c-87cf-4336-8d07-968a316b1862" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_db266b9c-87cf-4336-8d07-968a316b1862" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8bdcf586-32f6-4804-b001-93240d146440" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8bdcf586-32f6-4804-b001-93240d146440" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueVested_e912d0e5-4095-4693-a0eb-83257db8b75c" xlink:href="eols-20241231.xsd#eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueVested_e912d0e5-4095-4693-a0eb-83257db8b75c" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_1b0acfaf-97db-4782-8fbf-1238c146b3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_1b0acfaf-97db-4782-8fbf-1238c146b3d4" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2afbf61e-1f81-4ef6-9454-74346ae1789f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2afbf61e-1f81-4ef6-9454-74346ae1789f" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod_1fb6b0f8-f8f1-42db-90e2-2b02be85dd3e" xlink:href="eols-20241231.xsd#eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod_1fb6b0f8-f8f1-42db-90e2-2b02be85dd3e" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_f1dad7ed-f0b2-4c6f-9b3f-e9464542fe34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_f1dad7ed-f0b2-4c6f-9b3f-e9464542fe34" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ShareBasedPaymentArrangementNumberOfConsecutiveDays_75169d19-076a-4fe1-8283-15e078b8f254" xlink:href="eols-20241231.xsd#eols_ShareBasedPaymentArrangementNumberOfConsecutiveDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_eols_ShareBasedPaymentArrangementNumberOfConsecutiveDays_75169d19-076a-4fe1-8283-15e078b8f254" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ShareBasedCompensationConsecutiveTradingDaysPerShareTarget_2e11381f-f5c1-4771-a0b4-87fe1e0a6eff" xlink:href="eols-20241231.xsd#eols_ShareBasedCompensationConsecutiveTradingDaysPerShareTarget"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_eols_ShareBasedCompensationConsecutiveTradingDaysPerShareTarget_2e11381f-f5c1-4771-a0b4-87fe1e0a6eff" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_5f9e1f4e-ca71-43c5-9a82-ccc4ff786b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_5f9e1f4e-ca71-43c5-9a82-ccc4ff786b5b" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsAfterTermination_844938dc-d844-42dd-9ec8-b55668eee89b" xlink:href="eols-20241231.xsd#eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsAfterTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsAfterTermination_844938dc-d844-42dd-9ec8-b55668eee89b" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_28c58b6d-a6f5-4562-a66f-564b20e1e8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_28c58b6d-a6f5-4562-a66f-564b20e1e8ce" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_15e2c598-2a8d-4aac-bc69-57b09b68e97e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_15e2c598-2a8d-4aac-bc69-57b09b68e97e" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4c8e0925-8de1-4aa8-ab5e-cd629ec11619" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4c8e0925-8de1-4aa8-ab5e-cd629ec11619" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d174a1d5-9022-4658-85aa-fe3b1149cc91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d174a1d5-9022-4658-85aa-fe3b1149cc91" xlink:type="arc" order="36"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityScheduleofWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#StockholdersEquityScheduleofWeightedAverageAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/StockholdersEquityScheduleofWeightedAverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ac5d263-560c-48d8-92fc-5f68a9f24743" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d3c25d2a-354b-4cd0-a4c9-332f1b483408" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ac5d263-560c-48d8-92fc-5f68a9f24743" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d3c25d2a-354b-4cd0-a4c9-332f1b483408" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7595f7b1-1bce-4bbe-9602-0d4a4e94f286" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d3c25d2a-354b-4cd0-a4c9-332f1b483408" xlink:to="loc_us-gaap_AwardTypeAxis_7595f7b1-1bce-4bbe-9602-0d4a4e94f286" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7595f7b1-1bce-4bbe-9602-0d4a4e94f286_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7595f7b1-1bce-4bbe-9602-0d4a4e94f286" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7595f7b1-1bce-4bbe-9602-0d4a4e94f286_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e0589cbb-60bf-437a-9129-cf53ce2eb1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7595f7b1-1bce-4bbe-9602-0d4a4e94f286" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e0589cbb-60bf-437a-9129-cf53ce2eb1ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_13e56730-007c-4330-9b3b-eb8c5215ca24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e0589cbb-60bf-437a-9129-cf53ce2eb1ca" xlink:to="loc_us-gaap_EmployeeStockOptionMember_13e56730-007c-4330-9b3b-eb8c5215ca24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c979fb37-fb0c-4af1-9d66-4b7c07529409" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ac5d263-560c-48d8-92fc-5f68a9f24743" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c979fb37-fb0c-4af1-9d66-4b7c07529409" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_767ea9d6-9e03-450e-9e57-d536ee89b660" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ac5d263-560c-48d8-92fc-5f68a9f24743" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_767ea9d6-9e03-450e-9e57-d536ee89b660" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_31f9e9ef-1fed-40d1-8667-1832e1795b11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ac5d263-560c-48d8-92fc-5f68a9f24743" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_31f9e9ef-1fed-40d1-8667-1832e1795b11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a9be5643-2ecf-42ab-8a31-19ed74a26a10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ac5d263-560c-48d8-92fc-5f68a9f24743" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a9be5643-2ecf-42ab-8a31-19ed74a26a10" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#StockholdersEquityScheduleofStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e51ac523-d43f-4815-b7aa-0a79c67df010" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63db7519-3647-4b61-bdbd-95f1fc38f78b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e51ac523-d43f-4815-b7aa-0a79c67df010" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63db7519-3647-4b61-bdbd-95f1fc38f78b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_dc1dc9d2-2bdc-4ab0-83c8-4882ff193368" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63db7519-3647-4b61-bdbd-95f1fc38f78b" xlink:to="loc_us-gaap_AwardTypeAxis_dc1dc9d2-2bdc-4ab0-83c8-4882ff193368" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dc1dc9d2-2bdc-4ab0-83c8-4882ff193368_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_dc1dc9d2-2bdc-4ab0-83c8-4882ff193368" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dc1dc9d2-2bdc-4ab0-83c8-4882ff193368_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7191aef4-4f22-418c-a208-8fadc0e5f13b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_dc1dc9d2-2bdc-4ab0-83c8-4882ff193368" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7191aef4-4f22-418c-a208-8fadc0e5f13b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_eb5cf3b6-3613-4295-9805-4a8a7aa9ee3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7191aef4-4f22-418c-a208-8fadc0e5f13b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_eb5cf3b6-3613-4295-9805-4a8a7aa9ee3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f814c9ee-308f-43dc-bae7-9b4b56612f81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e51ac523-d43f-4815-b7aa-0a79c67df010" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f814c9ee-308f-43dc-bae7-9b4b56612f81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e40c3f58-d903-4d53-8694-7f48fd459396" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f814c9ee-308f-43dc-bae7-9b4b56612f81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e40c3f58-d903-4d53-8694-7f48fd459396" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_de0a67e5-a52e-414e-9b3b-1584e2aa6623" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f814c9ee-308f-43dc-bae7-9b4b56612f81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_de0a67e5-a52e-414e-9b3b-1584e2aa6623" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a64cd7c2-212d-4b29-b467-37145341651b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f814c9ee-308f-43dc-bae7-9b4b56612f81" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a64cd7c2-212d-4b29-b467-37145341651b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_a7ce2214-5812-493c-938f-b01572258c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f814c9ee-308f-43dc-bae7-9b4b56612f81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_a7ce2214-5812-493c-938f-b01572258c5d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0e2a4cb8-a153-427f-88af-22ec91770458" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_7e62cffd-28b7-45f3-87ec-aa3783fdb4b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e51ac523-d43f-4815-b7aa-0a79c67df010" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_7e62cffd-28b7-45f3-87ec-aa3783fdb4b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a0c865d7-1bcb-4d1c-8d2c-b80a997f630c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e51ac523-d43f-4815-b7aa-0a79c67df010" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a0c865d7-1bcb-4d1c-8d2c-b80a997f630c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cb991e5b-dade-403d-afe8-b392e3940f43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e51ac523-d43f-4815-b7aa-0a79c67df010" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cb991e5b-dade-403d-afe8-b392e3940f43" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_db53c05a-3f12-4929-b110-1d64d49bdf88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cb991e5b-dade-403d-afe8-b392e3940f43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_db53c05a-3f12-4929-b110-1d64d49bdf88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9e4ca009-7f9d-4312-82d4-cd1a1b5a3746" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cb991e5b-dade-403d-afe8-b392e3940f43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9e4ca009-7f9d-4312-82d4-cd1a1b5a3746" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4a995b41-ef96-40c9-a724-0b3e0c4414b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cb991e5b-dade-403d-afe8-b392e3940f43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4a995b41-ef96-40c9-a724-0b3e0c4414b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9a674723-93d3-4498-80ea-0c22a26eafcc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cb991e5b-dade-403d-afe8-b392e3940f43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9a674723-93d3-4498-80ea-0c22a26eafcc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_44da28da-da26-4a61-beb4-914bf409b4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_9d6e5607-1f16-47a1-899d-f6480460f416" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e51ac523-d43f-4815-b7aa-0a79c67df010" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_9d6e5607-1f16-47a1-899d-f6480460f416" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_ee66f11c-403c-4b51-aae1-a4bb3dec2b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e51ac523-d43f-4815-b7aa-0a79c67df010" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_ee66f11c-403c-4b51-aae1-a4bb3dec2b2a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c855b42b-34b2-477a-b0f0-665c23e82537" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e51ac523-d43f-4815-b7aa-0a79c67df010" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c855b42b-34b2-477a-b0f0-665c23e82537" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_be69930a-c597-4e0a-8b4f-d7abe86adbf5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c855b42b-34b2-477a-b0f0-665c23e82537" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_be69930a-c597-4e0a-8b4f-d7abe86adbf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_fda3ec3d-8057-4792-9d45-04148a112cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e51ac523-d43f-4815-b7aa-0a79c67df010" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_fda3ec3d-8057-4792-9d45-04148a112cc1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable_80075d5f-5baf-46eb-b5f0-b634dd43e0ce" xlink:href="eols-20241231.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e51ac523-d43f-4815-b7aa-0a79c67df010" xlink:to="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable_80075d5f-5baf-46eb-b5f0-b634dd43e0ce" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_8e8bb010-684f-4b92-8531-8016d2f145d5" xlink:href="eols-20241231.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e51ac523-d43f-4815-b7aa-0a79c67df010" xlink:to="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_8e8bb010-684f-4b92-8531-8016d2f145d5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1b4a7608-cb70-45ce-bcdf-b4474d8b99bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_8e8bb010-684f-4b92-8531-8016d2f145d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1b4a7608-cb70-45ce-bcdf-b4474d8b99bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_c8713665-0453-4f41-8cc0-36c8a497ae14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e51ac523-d43f-4815-b7aa-0a79c67df010" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_c8713665-0453-4f41-8cc0-36c8a497ae14" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a3b280bd-1da1-41e9-9e57-cf2c8a59083f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e51ac523-d43f-4815-b7aa-0a79c67df010" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a3b280bd-1da1-41e9-9e57-cf2c8a59083f" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cd1d9fd-90a8-407d-bfd9-ecc174e4d2dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ade1714c-81d0-441f-b44c-4d05f613bf25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cd1d9fd-90a8-407d-bfd9-ecc174e4d2dd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ade1714c-81d0-441f-b44c-4d05f613bf25" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9c5fb293-117a-4a37-a391-f3aca64bc259" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ade1714c-81d0-441f-b44c-4d05f613bf25" xlink:to="loc_us-gaap_AwardTypeAxis_9c5fb293-117a-4a37-a391-f3aca64bc259" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9c5fb293-117a-4a37-a391-f3aca64bc259_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9c5fb293-117a-4a37-a391-f3aca64bc259" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9c5fb293-117a-4a37-a391-f3aca64bc259_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_239e8699-d51c-49b0-a818-4c623e4e2f51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9c5fb293-117a-4a37-a391-f3aca64bc259" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_239e8699-d51c-49b0-a818-4c623e4e2f51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_821ab484-f9d1-40ca-9ddf-2b12935054de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_239e8699-d51c-49b0-a818-4c623e4e2f51" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_821ab484-f9d1-40ca-9ddf-2b12935054de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PerformanceRestrictedStockUnitsPRSUMember_223ec174-dcd5-4e75-82c8-8578e736cacb" xlink:href="eols-20241231.xsd#eols_PerformanceRestrictedStockUnitsPRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_239e8699-d51c-49b0-a818-4c623e4e2f51" xlink:to="loc_eols_PerformanceRestrictedStockUnitsPRSUMember_223ec174-dcd5-4e75-82c8-8578e736cacb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8df1c62d-4691-48aa-8a1b-0d03bef1f319" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cd1d9fd-90a8-407d-bfd9-ecc174e4d2dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8df1c62d-4691-48aa-8a1b-0d03bef1f319" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_43ca6e8c-aeae-4560-9d6f-34473d844f07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8df1c62d-4691-48aa-8a1b-0d03bef1f319" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_43ca6e8c-aeae-4560-9d6f-34473d844f07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4f71f6f9-c070-44d6-abc0-c415509f10ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8df1c62d-4691-48aa-8a1b-0d03bef1f319" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4f71f6f9-c070-44d6-abc0-c415509f10ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_759d79ca-d78d-4c85-943e-477dc45c1eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8df1c62d-4691-48aa-8a1b-0d03bef1f319" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_759d79ca-d78d-4c85-943e-477dc45c1eb3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7eb54e2c-6606-4d75-af9a-b035602cee12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8df1c62d-4691-48aa-8a1b-0d03bef1f319" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7eb54e2c-6606-4d75-af9a-b035602cee12" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_697bf477-8679-4b83-87fa-f86808d5de37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3fbb9041-86b6-4334-98e6-00350eec5ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cd1d9fd-90a8-407d-bfd9-ecc174e4d2dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3fbb9041-86b6-4334-98e6-00350eec5ee6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a146a7ec-5d78-49da-b717-3d69f8495189" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3fbb9041-86b6-4334-98e6-00350eec5ee6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a146a7ec-5d78-49da-b717-3d69f8495189" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_23217470-f0b1-4875-80ee-6b8661c30ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3fbb9041-86b6-4334-98e6-00350eec5ee6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_23217470-f0b1-4875-80ee-6b8661c30ab6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e10f4173-7913-4448-bb68-29f26e95e715" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3fbb9041-86b6-4334-98e6-00350eec5ee6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e10f4173-7913-4448-bb68-29f26e95e715" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1302f8d2-cb62-4d9b-bf58-fabdc4bdca4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3fbb9041-86b6-4334-98e6-00350eec5ee6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1302f8d2-cb62-4d9b-bf58-fabdc4bdca4b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f12fac8f-16f0-4fe8-b68d-2f38f355f005" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#StockholdersEquityStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3427cb1c-a3b7-492d-a192-2e5bb2fac69a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f4527ced-a4c9-4e7b-b95d-7548a4ffece5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3427cb1c-a3b7-492d-a192-2e5bb2fac69a" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f4527ced-a4c9-4e7b-b95d-7548a4ffece5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_bfffc2c4-3d21-488b-9bdd-27b751e1f213" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f4527ced-a4c9-4e7b-b95d-7548a4ffece5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_bfffc2c4-3d21-488b-9bdd-27b751e1f213" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_bfffc2c4-3d21-488b-9bdd-27b751e1f213_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bfffc2c4-3d21-488b-9bdd-27b751e1f213" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_bfffc2c4-3d21-488b-9bdd-27b751e1f213_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7e71b08f-4caa-470a-8484-7bf835745f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bfffc2c4-3d21-488b-9bdd-27b751e1f213" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7e71b08f-4caa-470a-8484-7bf835745f4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_eb796d42-52af-4700-8b99-3aa9ba5da11d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7e71b08f-4caa-470a-8484-7bf835745f4e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_eb796d42-52af-4700-8b99-3aa9ba5da11d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_701bc98d-c2d7-4542-92c6-851919926b50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7e71b08f-4caa-470a-8484-7bf835745f4e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_701bc98d-c2d7-4542-92c6-851919926b50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_71af6bb2-7023-48a9-baf5-b6e1ab42f1fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3427cb1c-a3b7-492d-a192-2e5bb2fac69a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_71af6bb2-7023-48a9-baf5-b6e1ab42f1fa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/MedytoxSettlementAgreementsDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#MedytoxSettlementAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/MedytoxSettlementAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_97da0942-107d-4040-a5eb-137a6118166d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_605efa06-caad-40d5-878c-1d4e1573ff48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_97da0942-107d-4040-a5eb-137a6118166d" xlink:to="loc_us-gaap_LossContingenciesTable_605efa06-caad-40d5-878c-1d4e1573ff48" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_28ccd33b-e964-409d-812e-35e968ec3276" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_605efa06-caad-40d5-878c-1d4e1573ff48" xlink:to="loc_srt_LitigationCaseAxis_28ccd33b-e964-409d-812e-35e968ec3276" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_28ccd33b-e964-409d-812e-35e968ec3276_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_28ccd33b-e964-409d-812e-35e968ec3276" xlink:to="loc_srt_LitigationCaseTypeDomain_28ccd33b-e964-409d-812e-35e968ec3276_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_64ec4449-9087-4764-8786-fac76de3e409" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_28ccd33b-e964-409d-812e-35e968ec3276" xlink:to="loc_srt_LitigationCaseTypeDomain_64ec4449-9087-4764-8786-fac76de3e409" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IntellectualPropertyDisputesJeuveauMember_5444ab77-b747-41c1-a44c-98632278de67" xlink:href="eols-20241231.xsd#eols_IntellectualPropertyDisputesJeuveauMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_64ec4449-9087-4764-8786-fac76de3e409" xlink:to="loc_eols_IntellectualPropertyDisputesJeuveauMember_5444ab77-b747-41c1-a44c-98632278de67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c44d51d7-5f6d-4c98-975e-cf594904be7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_605efa06-caad-40d5-878c-1d4e1573ff48" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c44d51d7-5f6d-4c98-975e-cf594904be7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c44d51d7-5f6d-4c98-975e-cf594904be7a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c44d51d7-5f6d-4c98-975e-cf594904be7a" xlink:to="loc_us-gaap_EquityComponentDomain_c44d51d7-5f6d-4c98-975e-cf594904be7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3d89db8f-bdbe-40af-97b7-8ce412c3baaa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c44d51d7-5f6d-4c98-975e-cf594904be7a" xlink:to="loc_us-gaap_EquityComponentDomain_3d89db8f-bdbe-40af-97b7-8ce412c3baaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_388b8c18-7763-4b0c-b15b-613d235c01ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3d89db8f-bdbe-40af-97b7-8ce412c3baaa" xlink:to="loc_us-gaap_CommonStockMember_388b8c18-7763-4b0c-b15b-613d235c01ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LossContingencySettlementAgreementManufacturingLicensePeriod_633d9bf0-d7e5-4c36-b9df-ee99edbbc2a7" xlink:href="eols-20241231.xsd#eols_LossContingencySettlementAgreementManufacturingLicensePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_97da0942-107d-4040-a5eb-137a6118166d" xlink:to="loc_eols_LossContingencySettlementAgreementManufacturingLicensePeriod_633d9bf0-d7e5-4c36-b9df-ee99edbbc2a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_bb610fd1-099f-49d8-b139-b6badbd88052" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_97da0942-107d-4040-a5eb-137a6118166d" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_bb610fd1-099f-49d8-b139-b6badbd88052" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LossContingencySettlementAgreementPaymentTerms_5a1c1609-fb86-4a2e-9748-c732c1225e1c" xlink:href="eols-20241231.xsd#eols_LossContingencySettlementAgreementPaymentTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_97da0942-107d-4040-a5eb-137a6118166d" xlink:to="loc_eols_LossContingencySettlementAgreementPaymentTerms_5a1c1609-fb86-4a2e-9748-c732c1225e1c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_1ad26fa8-6f45-4d25-82c5-a207812d6782" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_97da0942-107d-4040-a5eb-137a6118166d" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_1ad26fa8-6f45-4d25-82c5-a207812d6782" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_b1d75cfc-9b80-44ad-87d5-2d7380193158" xlink:href="eols-20241231.xsd#eols_StockIssuedDuringPeriodSharesLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_97da0942-107d-4040-a5eb-137a6118166d" xlink:to="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_b1d75cfc-9b80-44ad-87d5-2d7380193158" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_bffc178f-d7db-42ae-8a74-0b7074871712" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_97da0942-107d-4040-a5eb-137a6118166d" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_bffc178f-d7db-42ae-8a74-0b7074871712" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodOne_6ba60416-d8b8-4ba1-8a99-29e7794db3f0" xlink:href="eols-20241231.xsd#eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_97da0942-107d-4040-a5eb-137a6118166d" xlink:to="loc_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodOne_6ba60416-d8b8-4ba1-8a99-29e7794db3f0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodTwo_e3212185-2dde-485b-84e2-78d43c60b2e1" xlink:href="eols-20241231.xsd#eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_97da0942-107d-4040-a5eb-137a6118166d" xlink:to="loc_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodTwo_e3212185-2dde-485b-84e2-78d43c60b2e1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodThree_b010b04f-98ef-4ae0-a2d9-83e6db3514ff" xlink:href="eols-20241231.xsd#eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_97da0942-107d-4040-a5eb-137a6118166d" xlink:to="loc_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodThree_b010b04f-98ef-4ae0-a2d9-83e6db3514ff" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_e3a087d8-7c41-4082-84b7-5a5cc088bb7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_97da0942-107d-4040-a5eb-137a6118166d" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_e3a087d8-7c41-4082-84b7-5a5cc088bb7d" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_36a5b968-c4df-4ddc-9082-7e67b0bbde53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_e480e877-1a93-4705-9b97-d962b582e61e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_36a5b968-c4df-4ddc-9082-7e67b0bbde53" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_e480e877-1a93-4705-9b97-d962b582e61e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_4da17f80-a1a9-434c-b0d9-4d3e2f280282" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_e480e877-1a93-4705-9b97-d962b582e61e" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_4da17f80-a1a9-434c-b0d9-4d3e2f280282" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_4da17f80-a1a9-434c-b0d9-4d3e2f280282_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_4da17f80-a1a9-434c-b0d9-4d3e2f280282" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_4da17f80-a1a9-434c-b0d9-4d3e2f280282_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_f7145756-b8bb-4737-b745-81f2e53f4f80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_4da17f80-a1a9-434c-b0d9-4d3e2f280282" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_f7145756-b8bb-4737-b745-81f2e53f4f80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_597a919d-7745-4e90-94c1-299cf7a3ba6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_f7145756-b8bb-4737-b745-81f2e53f4f80" xlink:to="loc_us-gaap_DomesticCountryMember_597a919d-7745-4e90-94c1-299cf7a3ba6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_e44f57f6-9242-4053-8f4b-f37a546fe2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_f7145756-b8bb-4737-b745-81f2e53f4f80" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_e44f57f6-9242-4053-8f4b-f37a546fe2ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_6481a2de-ec72-41b2-a195-9f75d2f24d23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_f7145756-b8bb-4737-b745-81f2e53f4f80" xlink:to="loc_us-gaap_ForeignCountryMember_6481a2de-ec72-41b2-a195-9f75d2f24d23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_583af1d2-61e9-4a3a-a89b-3227b65d64ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_e480e877-1a93-4705-9b97-d962b582e61e" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_583af1d2-61e9-4a3a-a89b-3227b65d64ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_583af1d2-61e9-4a3a-a89b-3227b65d64ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_583af1d2-61e9-4a3a-a89b-3227b65d64ca" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_583af1d2-61e9-4a3a-a89b-3227b65d64ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_b49ec30e-7da6-4f28-8c1b-3764d07d739c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_583af1d2-61e9-4a3a-a89b-3227b65d64ca" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_b49ec30e-7da6-4f28-8c1b-3764d07d739c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_392100cf-c743-48e3-9764-795761a883ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_b49ec30e-7da6-4f28-8c1b-3764d07d739c" xlink:to="loc_us-gaap_ResearchMember_392100cf-c743-48e3-9764-795761a883ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_844a4136-1ca0-422f-af7a-f0cd40e44b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_36a5b968-c4df-4ddc-9082-7e67b0bbde53" xlink:to="loc_us-gaap_OperatingLossCarryforwards_844a4136-1ca0-422f-af7a-f0cd40e44b0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_6aed91d7-1507-4673-8a2e-5f280bf8edff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_36a5b968-c4df-4ddc-9082-7e67b0bbde53" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_6aed91d7-1507-4673-8a2e-5f280bf8edff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_12598b8e-d5fc-43c0-b88e-b8b76062d837" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_36a5b968-c4df-4ddc-9082-7e67b0bbde53" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_12598b8e-d5fc-43c0-b88e-b8b76062d837" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_a5529e5c-9442-4044-9f5e-1e58f6b0c798" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_36a5b968-c4df-4ddc-9082-7e67b0bbde53" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_a5529e5c-9442-4044-9f5e-1e58f6b0c798" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_12b742bf-8c14-4672-9b0d-8177dc6340c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_36a5b968-c4df-4ddc-9082-7e67b0bbde53" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_12b742bf-8c14-4672-9b0d-8177dc6340c9" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/SegmentReportingReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#SegmentReportingReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/SegmentReportingReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_77d967ea-38d6-4db6-860f-8ec2de869589" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_a680a76b-6405-459f-9724-1cb653dab763" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_77d967ea-38d6-4db6-860f-8ec2de869589" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_a680a76b-6405-459f-9724-1cb653dab763" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_279aadda-e2be-43ed-93cf-8aa338ec0dad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_a680a76b-6405-459f-9724-1cb653dab763" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_279aadda-e2be-43ed-93cf-8aa338ec0dad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_279aadda-e2be-43ed-93cf-8aa338ec0dad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_279aadda-e2be-43ed-93cf-8aa338ec0dad" xlink:to="loc_us-gaap_SegmentDomain_279aadda-e2be-43ed-93cf-8aa338ec0dad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ca399280-dd82-42da-a04a-bcb48b0cb38f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_279aadda-e2be-43ed-93cf-8aa338ec0dad" xlink:to="loc_us-gaap_SegmentDomain_ca399280-dd82-42da-a04a-bcb48b0cb38f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ReportableSegmentMember_c268022d-5d38-43d5-82cd-0595d2f17c67" xlink:href="eols-20241231.xsd#eols_ReportableSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_ca399280-dd82-42da-a04a-bcb48b0cb38f" xlink:to="loc_eols_ReportableSegmentMember_c268022d-5d38-43d5-82cd-0595d2f17c67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_83189873-2beb-4b79-80d8-589d5df52736" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_77d967ea-38d6-4db6-860f-8ec2de869589" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_83189873-2beb-4b79-80d8-589d5df52736" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_76593a08-4fe2-46fc-8e76-f4adf2a11588" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_77d967ea-38d6-4db6-860f-8ec2de869589" xlink:to="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_76593a08-4fe2-46fc-8e76-f4adf2a11588" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_cba77d42-1e9c-474c-9416-cdc9420ee0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_76593a08-4fe2-46fc-8e76-f4adf2a11588" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_cba77d42-1e9c-474c-9416-cdc9420ee0e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_67372f18-1182-41e2-8d92-188cab7de495" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_76593a08-4fe2-46fc-8e76-f4adf2a11588" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_67372f18-1182-41e2-8d92-188cab7de495" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_79f7c10a-ee99-4438-b28c-57669f6988e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_76593a08-4fe2-46fc-8e76-f4adf2a11588" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_79f7c10a-ee99-4438-b28c-57669f6988e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0e4a31c6-dcfc-440c-95a9-a5c6387ec903" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_76593a08-4fe2-46fc-8e76-f4adf2a11588" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0e4a31c6-dcfc-440c-95a9-a5c6387ec903" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ResearchAndDevelopmentInProcess1_c41c64ce-fe72-4820-8327-2eb642177c92" xlink:href="eols-20241231.xsd#eols_ResearchAndDevelopmentInProcess1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_76593a08-4fe2-46fc-8e76-f4adf2a11588" xlink:to="loc_eols_ResearchAndDevelopmentInProcess1_c41c64ce-fe72-4820-8327-2eb642177c92" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2a57eab1-fe23-40d0-b20c-15f769c6a711" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_76593a08-4fe2-46fc-8e76-f4adf2a11588" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2a57eab1-fe23-40d0-b20c-15f769c6a711" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1102a0a2-2b82-46cf-b7a5-232b8d2964ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_76593a08-4fe2-46fc-8e76-f4adf2a11588" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1102a0a2-2b82-46cf-b7a5-232b8d2964ea" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_26333593-2291-427c-8d29-771f4d1a4251" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_76593a08-4fe2-46fc-8e76-f4adf2a11588" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_26333593-2291-427c-8d29-771f4d1a4251" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_238c434a-ec84-4c5e-b905-442cf2c76d03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_76593a08-4fe2-46fc-8e76-f4adf2a11588" xlink:to="loc_us-gaap_InvestmentIncomeNet_238c434a-ec84-4c5e-b905-442cf2c76d03" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_5eb59fc8-917a-4867-83d5-827f464dbda3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_76593a08-4fe2-46fc-8e76-f4adf2a11588" xlink:to="loc_us-gaap_InterestExpenseNonoperating_5eb59fc8-917a-4867-83d5-827f464dbda3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9ab479b4-7845-4d74-a614-e00ad2b33456" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_76593a08-4fe2-46fc-8e76-f4adf2a11588" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_9ab479b4-7845-4d74-a614-e00ad2b33456" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e4574e04-79a1-43b5-a91e-aeb79520ca6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_76593a08-4fe2-46fc-8e76-f4adf2a11588" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e4574e04-79a1-43b5-a91e-aeb79520ca6a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_15806b37-10d2-44d6-8701-fa11e5dc0dba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_76593a08-4fe2-46fc-8e76-f4adf2a11588" xlink:to="loc_us-gaap_NetIncomeLoss_15806b37-10d2-44d6-8701-fa11e5dc0dba" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolus.com/role/SegmentReportingScheduleofRevenuebyCountryDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#SegmentReportingScheduleofRevenuebyCountryDetails"/>
  <link:definitionLink xlink:role="http://www.evolus.com/role/SegmentReportingScheduleofRevenuebyCountryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_e02ed1c7-f42c-4d3a-9643-979e55d222bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_6e820135-28ce-47a4-bea1-f0961f4591d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_e02ed1c7-f42c-4d3a-9643-979e55d222bc" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_6e820135-28ce-47a4-bea1-f0961f4591d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_bd8fa659-d086-42dc-b745-507f8636a79c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_6e820135-28ce-47a4-bea1-f0961f4591d6" xlink:to="loc_srt_StatementGeographicalAxis_bd8fa659-d086-42dc-b745-507f8636a79c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_bd8fa659-d086-42dc-b745-507f8636a79c_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_bd8fa659-d086-42dc-b745-507f8636a79c" xlink:to="loc_srt_SegmentGeographicalDomain_bd8fa659-d086-42dc-b745-507f8636a79c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_036d922f-7a23-483c-b9fa-23176efb29ce" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_bd8fa659-d086-42dc-b745-507f8636a79c" xlink:to="loc_srt_SegmentGeographicalDomain_036d922f-7a23-483c-b9fa-23176efb29ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_e70e5c20-c1c8-49bc-a484-219fe13e1d77" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_036d922f-7a23-483c-b9fa-23176efb29ce" xlink:to="loc_country_US_e70e5c20-c1c8-49bc-a484-219fe13e1d77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_fb5371b5-e496-40c9-97a1-362bab8a4425" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_036d922f-7a23-483c-b9fa-23176efb29ce" xlink:to="loc_us-gaap_NonUsMember_fb5371b5-e496-40c9-97a1-362bab8a4425" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8b15e66f-87ec-4011-a561-49b8cb4c73ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_e02ed1c7-f42c-4d3a-9643-979e55d222bc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8b15e66f-87ec-4011-a561-49b8cb4c73ad" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>eols-20241231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:919f993d-eaea-4622-b01f-fde76d4f5f0d,g:96b2bf92-d476-42b7-9d6e-4ee6308f0735-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_5e5431d6-313b-48c3-b7e8-e4a91ad52740_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average remaining contractual term, vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_bf4baef2-1c48-431c-829f-189c56221778_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_f4e4581d-0a10-492d-b680-bc1347c1a75e_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_ae4f094d-a64f-488d-8244-902ddfad9f59_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_888e64fe-51d9-4f74-b29d-91803d7e9a55_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Composition of Lease Expense and Other Quantitative Information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_5129fbc2-940f-4214-b254-daf64de5e79f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax at statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1f2b550d-1a69-4666-9372-12af3d9c88dd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_498b8e8b-26bf-48f1-b84a-8693f2059ed2_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentPeriodicPaymentOutstandingPrincipalAmountDuePercentage_c7543710-c4d1-4aae-9333-603cb514c89c_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPeriodicPaymentOutstandingPrincipalAmountDuePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Periodic payment, percentage of outstanding principal amount</link:label>
    <link:label id="lab_eols_DebtInstrumentPeriodicPaymentOutstandingPrincipalAmountDuePercentage_label_en-US" xlink:label="lab_eols_DebtInstrumentPeriodicPaymentOutstandingPrincipalAmountDuePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment, Outstanding Principal Amount Due, Percentage</link:label>
    <link:label id="lab_eols_DebtInstrumentPeriodicPaymentOutstandingPrincipalAmountDuePercentage_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPeriodicPaymentOutstandingPrincipalAmountDuePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment, Outstanding Principal Amount Due, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPeriodicPaymentOutstandingPrincipalAmountDuePercentage" xlink:href="eols-20241231.xsd#eols_DebtInstrumentPeriodicPaymentOutstandingPrincipalAmountDuePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPeriodicPaymentOutstandingPrincipalAmountDuePercentage" xlink:to="lab_eols_DebtInstrumentPeriodicPaymentOutstandingPrincipalAmountDuePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_RebatesAndCouponsCreditsAndPayments_a75257d0-86a8-45b4-baf9-85b1ecf6e3aa_terseLabel_en-US" xlink:label="lab_eols_RebatesAndCouponsCreditsAndPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rebates and coupons, credits and payments</link:label>
    <link:label id="lab_eols_RebatesAndCouponsCreditsAndPayments_label_en-US" xlink:label="lab_eols_RebatesAndCouponsCreditsAndPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rebates And Coupons, Credits And Payments</link:label>
    <link:label id="lab_eols_RebatesAndCouponsCreditsAndPayments_documentation_en-US" xlink:label="lab_eols_RebatesAndCouponsCreditsAndPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rebates And Coupons, Credits And Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_RebatesAndCouponsCreditsAndPayments" xlink:href="eols-20241231.xsd#eols_RebatesAndCouponsCreditsAndPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_RebatesAndCouponsCreditsAndPayments" xlink:to="lab_eols_RebatesAndCouponsCreditsAndPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_caf8ecb4-6a20-4417-9b1b-e5f394c6bca3_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input, Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_639bad5c-5140-4115-9839-7a914330c7dc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Maturity of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_7648c16c-14b2-4a57-a76a-a5bb660f4bb6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_d097b2af-3789-4032-8b44-3468cd323923_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ebd37340-0eb2-436d-804a-d5082f3541a0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_6a662f0f-db59-40b2-936d-3b0b4945980c_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_2e78af7c-c8cd-4e64-926d-8a976cbb5d5f_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_4c22a905-c305-4b80-9619-0b06d27dc088_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_741ffdca-eccc-4cad-8390-ab8007926a53_terseLabel_en-US" xlink:label="lab_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revaluation of contingent royalty obligation</link:label>
    <link:label id="lab_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_label_en-US" xlink:label="lab_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Revaluation Of Contingent Royalty Obligation</link:label>
    <link:label id="lab_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_documentation_en-US" xlink:label="lab_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Revaluation Of Contingent Royalty Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation" xlink:href="eols-20241231.xsd#eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation" xlink:to="lab_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_16e8fb73-6347-4acc-857c-54c3200337bb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_7d3c2f97-ea55-4433-ba79-1f0d77beca1d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_421e7c96-1c2e-40cc-967b-5956afafb769_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_436a65f6-fc7f-4af7-9985-c6cba724fb51_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total net book value</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_fa83971f-b405-4a0a-ac71-af12c1ad628d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories and cost of goods sold</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_22ce13df-8af9-4c88-91b2-fd4a03aece9f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred provision (benefit):</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_2f28511b-8b28-4094-8733-6d9a000eac5e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_f72a9ef0-d1e0-44fd-83bc-e07ce931374d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0da43f66-b59b-4073-9705-623640024cfe_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_8bdc3352-5d61-412e-a50e-6c8684bd9745_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">R&amp;D</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_a98f85a1-2f6c-4a01-bc76-d05d35a4026e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_ebc5681f-58e9-424d-bb1d-2a325be84d80_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_0859d085-7435-41ee-bc23-8e916bce8e14_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_8a2546f1-2e00-4b14-9537-f3d21b8a9b1f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_4ed6693e-51b0-49ad-a373-16e3c1a8a021_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_617ae558-e51d-4e24-bd09-eb06fb274cb1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_ResearchAndDevelopmentInProcess1_e5189749-77e1-4342-a776-6b1f3ac09d46_terseLabel_en-US" xlink:label="lab_eols_ResearchAndDevelopmentInProcess1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_eols_ResearchAndDevelopmentInProcess1_label_en-US" xlink:label="lab_eols_ResearchAndDevelopmentInProcess1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development In Process 1</link:label>
    <link:label id="lab_eols_ResearchAndDevelopmentInProcess1_documentation_en-US" xlink:label="lab_eols_ResearchAndDevelopmentInProcess1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development In Process 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ResearchAndDevelopmentInProcess1" xlink:href="eols-20241231.xsd#eols_ResearchAndDevelopmentInProcess1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ResearchAndDevelopmentInProcess1" xlink:to="lab_eols_ResearchAndDevelopmentInProcess1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f3bd2de1-1cb6-4b0d-8666-6979bdac63c4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock available for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_9de5c235-3ab6-43cc-aa86-b3280de19a41_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_71d93ebb-5ab2-4367-8572-f82129e3c85d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_0b617439-c374-45b4-8508-32f08abd6f19_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_d338d096-94c3-4556-965f-5d8b296a2dfe_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued revenue contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_c6571628-da0f-4ffd-b115-0897ec14ed85_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementLiabilityNoncurrent_b7640f58-e975-4d07-a8f2-b572d1213c9b_terseLabel_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License, supply and distribution agreement, liability, noncurrent</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementLiabilityNoncurrent_label_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License, Supply And Distribution Agreement, Liability, Noncurrent</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementLiabilityNoncurrent_documentation_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License, Supply And Distribution Agreement, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementLiabilityNoncurrent" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LicenseSupplyAndDistributionAgreementLiabilityNoncurrent" xlink:to="lab_eols_LicenseSupplyAndDistributionAgreementLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_27bc6431-c23a-40d2-8514-679b81a36a9f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering price per share (in dollar per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_4889b55c-e40f-48de-8bc3-15d3334dc53b_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_d89f8938-ca43-4595-8792-2870db559351_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_3ce08816-b4e9-4780-be3f-89e52def38e0_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_2cb96c47-08f1-460a-b5c2-ef57f97860ba_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Original Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_09cbfc79-6b2d-425e-96f3-223679b97744_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_f8073bd0-5043-4b00-87e8-ed9836d166bc_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases to prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_76f1835a-b095-420f-9432-83e0a34678af_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_2d471655-2c99-4b2c-b070-7357355c4b14_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accrued litigation settlement</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_25dc917b-5260-4eb2-a189-c443356eced5_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for legal settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_6df4f082-1176-449b-ab84-eff5545764ab_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f36ad2dc-2db7-4e66-b33d-e11a22894e2a_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentTriggeredRegulatoryApprovalNumberOfProducts_e2fd7e82-b453-4d08-8712-98c759115b2c_terseLabel_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentTriggeredRegulatoryApprovalNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual payment triggered, number of products with regulatory approval</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentTriggeredRegulatoryApprovalNumberOfProducts_label_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentTriggeredRegulatoryApprovalNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License, Supply And Distribution Agreement, Annual Payment Triggered, Regulatory Approval, Number Of Products</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentTriggeredRegulatoryApprovalNumberOfProducts_documentation_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentTriggeredRegulatoryApprovalNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License, Supply And Distribution Agreement, Annual Payment Triggered, Regulatory Approval, Number Of Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentTriggeredRegulatoryApprovalNumberOfProducts" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementAnnualPaymentTriggeredRegulatoryApprovalNumberOfProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentTriggeredRegulatoryApprovalNumberOfProducts" xlink:to="lab_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentTriggeredRegulatoryApprovalNumberOfProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_e9991544-d01c-4492-84f1-5e4a309d6738_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_5db6f49b-1905-4240-90f5-15ff3b208e9d_negatedLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_PharmakonTermLoansOneMember_e99b576b-5de9-495b-8504-7e5903cdd9a6_terseLabel_en-US" xlink:label="lab_eols_PharmakonTermLoansOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche A Loan</link:label>
    <link:label id="lab_eols_PharmakonTermLoansOneMember_label_en-US" xlink:label="lab_eols_PharmakonTermLoansOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pharmakon Term Loans One [Member]</link:label>
    <link:label id="lab_eols_PharmakonTermLoansOneMember_documentation_en-US" xlink:label="lab_eols_PharmakonTermLoansOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pharmakon Term Loans One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansOneMember" xlink:href="eols-20241231.xsd#eols_PharmakonTermLoansOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_PharmakonTermLoansOneMember" xlink:to="lab_eols_PharmakonTermLoansOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_54b9219b-7fbb-4f86-8465-8e2a9c6edd69_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate net proceeds from stock offering</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8fe884d3-8a29-4ada-a1ea-62802a4764d2_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_A2024EmployeeStockPurchasePlanMember_032147bf-c62e-4754-94c3-5abbb4de1e41_terseLabel_en-US" xlink:label="lab_eols_A2024EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_eols_A2024EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_eols_A2024EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2024 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_eols_A2024EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_eols_A2024EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2024 Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_A2024EmployeeStockPurchasePlanMember" xlink:href="eols-20241231.xsd#eols_A2024EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_A2024EmployeeStockPurchasePlanMember" xlink:to="lab_eols_A2024EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_0f68f015-c0eb-4c8f-b15e-bbf6fa84b52e_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Loan</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentPrepaymentAmountThreshold_c32a9c9c-ee01-4b23-b565-0ef0f019ac91_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentAmountThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, prepayment amount threshold</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentAmountThreshold_label_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentAmountThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Amount Threshold</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentAmountThreshold_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentAmountThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Amount Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentAmountThreshold" xlink:href="eols-20241231.xsd#eols_DebtInstrumentPrepaymentAmountThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPrepaymentAmountThreshold" xlink:to="lab_eols_DebtInstrumentPrepaymentAmountThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_9b036cd5-d284-481e-b3f5-c3a0b50ef48b_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_58d18eea-e346-408f-9b09-5b5e4eb59690_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_5676e5a9-a876-4460-bb07-0c10472b4f48_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b763f27c-ec4c-4228-a6fb-3b8824c13e64_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_e67c26d3-c26c-44ca-8456-1fe5d7e35853_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_3844d9fa-d654-462d-b53f-15541cbc2dce_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements_3376b196-d7dc-4493-b190-efce7e0f112c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued legal settlement</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_7a9e311c-b9e8-4910-a447-e64a69c4a3c9_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_c44a2bc6-bbef-4a8c-a6a8-e129e44a882b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_e0bfd401-0881-41d3-87a0-66fe72f28b46_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_b5386fb2-f62c-4a30-a6d9-5ea7ce69634b_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_a591eb24-05b7-4fa9-9f72-3c27222b7e6c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_fbbe3bc6-567a-4a4f-8897-73421d89c482_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_d4d6c821-57ce-4b2b-b522-9878a2e39c40_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_b9bd0e14-ad91-4d29-bb92-b66501dbdc61_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less:</link:label>
    <link:label id="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_label_en-US" xlink:label="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:to="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_3019810b-aa42-4101-8325-5a5b433a1db0_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Smaller Reporting Company</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_9bb6d7b2-3b21-4753-a7a5-f2a9a9c05ca6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_971169c1-3d4f-43d8-ba29-fff8ca76d81a_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment_af72a380-c1e7-440d-8c20-cd8c22260a50_terseLabel_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of milestone payment</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment_label_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License, Supply and Distribution Agreement, Number Of Milestone Payment</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment_documentation_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License, Supply and Distribution Agreement, Number Of Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment" xlink:to="lab_eols_LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_09fbb879-2741-41b5-86b6-0687461e4e19_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments for debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_c9821f4d-30dd-478b-b3c5-ffc1e5ffeb39_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_25df668a-8ffb-4876-9c84-cbc25aa0416a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_0238f900-eb6a-4e69-ac2e-790b204522f2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7fd959a3-22e6-4804-abb2-b698c589603d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_5997b8aa-e23c-4556-b75c-f3b916c934ba_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-live intangible assets capitalized</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementMinimumMilestonePayment_ac2efc56-705c-4809-a4bb-49fe71960817_terseLabel_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementMinimumMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent milestone payment</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementMinimumMilestonePayment_label_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementMinimumMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License, Supply and Distribution Agreement, Minimum Milestone Payment</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementMinimumMilestonePayment_documentation_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementMinimumMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License, Supply and Distribution Agreement, Minimum Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementMinimumMilestonePayment" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementMinimumMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LicenseSupplyAndDistributionAgreementMinimumMilestonePayment" xlink:to="lab_eols_LicenseSupplyAndDistributionAgreementMinimumMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_596425e0-4638-4898-a13c-df9343f8a816_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementNumberOfProductCandidates_4ed58603-d42c-4b42-a94c-ffc14706f271_terseLabel_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementNumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of product candidates</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementNumberOfProductCandidates_label_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementNumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License, Supply And Distribution Agreement, Number Of Product Candidates</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementNumberOfProductCandidates_documentation_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementNumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License, Supply And Distribution Agreement, Number Of Product Candidates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementNumberOfProductCandidates" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementNumberOfProductCandidates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LicenseSupplyAndDistributionAgreementNumberOfProductCandidates" xlink:to="lab_eols_LicenseSupplyAndDistributionAgreementNumberOfProductCandidates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_0bd85c27-e396-4536-aa6c-48241f38514a_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_b19a497e-8a9d-4566-8632-9c3072e0bc11_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_002169c3-7f45-4c5b-b775-82babd7bcf74_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Securities excluded from the computation of diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_61fdc3a0-28d5-45ff-affe-9e6ff62fbe9f_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plan</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_f773187b-6b19-4a69-8043-6f0f9fe1c87c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">20 Consecutive Trading Days with a $30 Share Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_LossContingencyNumberDefendantsOfficers_88051a45-c043-4b24-abe3-3e19375834ef_terseLabel_en-US" xlink:label="lab_eols_LossContingencyNumberDefendantsOfficers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency, number of defendants, officers</link:label>
    <link:label id="lab_eols_LossContingencyNumberDefendantsOfficers_label_en-US" xlink:label="lab_eols_LossContingencyNumberDefendantsOfficers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Number Defendants, Officers</link:label>
    <link:label id="lab_eols_LossContingencyNumberDefendantsOfficers_documentation_en-US" xlink:label="lab_eols_LossContingencyNumberDefendantsOfficers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Number Defendants, Officers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LossContingencyNumberDefendantsOfficers" xlink:href="eols-20241231.xsd#eols_LossContingencyNumberDefendantsOfficers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LossContingencyNumberDefendantsOfficers" xlink:to="lab_eols_LossContingencyNumberDefendantsOfficers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d0b63805-5da0-44d0-a014-2ce4ef355aec_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_537e9f1f-4187-40cf-bd33-916da9ce2156_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_150c9e30-acc2-42fc-a4ee-64fb2566b1fc_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation cost related to nonvested awards not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_59eba684-1be7-4303-8624-b6460a49ce6f_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_43bbfc05-5636-4109-b751-2da6f299b69b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_d7db2022-0c2f-4fd7-a652-54816e719874_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_e0a21ffc-367f-4399-93d1-675bd30e0a0f_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_87c69c6b-6808-4712-ace9-e676b9aa6ef0_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_cad0b39a-35e5-4161-b48e-1b15eab70869_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_e4960dc4-597a-4c55-8657-17e3f5b23b16_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax withholding paid on behalf of employees for net share settlement</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_e0043b71-5dbb-4e72-ac16-fbbfc7e4e67b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement_27f5a28c-e633-4fb0-9830-5f1fd27086f3_verboseLabel_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with Symatese Europe Agreement (in shares)</link:label>
    <link:label id="lab_eols_StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement_987d4fbf-9cc0-4964-944e-3cd8642fa06d_terseLabel_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issued in exchange for license, supply, and distribution agreement (in shares)</link:label>
    <link:label id="lab_eols_StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement_label_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Issued For License, Supply and Distribution Agreement</link:label>
    <link:label id="lab_eols_StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement_documentation_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Issued for License, Supply and Distribution Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement" xlink:href="eols-20241231.xsd#eols_StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement" xlink:to="lab_eols_StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_21048e42-edda-4d9b-8387-d73c7ebf6ace_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_9320f472-775b-45e6-a1bd-ab90c9439e88_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_eb12e158-f709-4ef1-a5a7-f06e594f1c47_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_bcbaddcc-a48b-486a-9669-3926c81b27c1_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_b4cf7ea4-ad47-472a-a14d-03725338a6a5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c909687b-2729-4496-99dc-74503086385b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_642f482d-cd19-4f06-9289-a04a923123a2_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_072fa6b6-b8f1-4cd1-b5eb-038a105a4ba4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_26c81799-3df7-410f-a0e3-83bbc127c8e6_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7e9809b5-92a1-47c3-9fb6-eb20e2634da5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DistributionRightsMember_ac546466-8ef3-4e36-8547-860c192f97f8_terseLabel_en-US" xlink:label="lab_us-gaap_DistributionRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distribution rights</link:label>
    <link:label id="lab_us-gaap_DistributionRightsMember_label_en-US" xlink:label="lab_us-gaap_DistributionRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distribution Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DistributionRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DistributionRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DistributionRightsMember" xlink:to="lab_us-gaap_DistributionRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_ContingentRoyaltyObligationMember_2a2ce905-3fbf-4d85-84eb-2f465081bdd5_terseLabel_en-US" xlink:label="lab_eols_ContingentRoyaltyObligationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Royalty Obligation</link:label>
    <link:label id="lab_eols_ContingentRoyaltyObligationMember_label_en-US" xlink:label="lab_eols_ContingentRoyaltyObligationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Royalty Obligation [Member]</link:label>
    <link:label id="lab_eols_ContingentRoyaltyObligationMember_documentation_en-US" xlink:label="lab_eols_ContingentRoyaltyObligationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Royalty Obligation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ContingentRoyaltyObligationMember" xlink:href="eols-20241231.xsd#eols_ContingentRoyaltyObligationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ContingentRoyaltyObligationMember" xlink:to="lab_eols_ContingentRoyaltyObligationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_7a8c020a-4da3-4d73-9dbd-6ac018e57106_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_e806bd4f-9476-4bd7-bbc2-54d615b4ff73_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementNumberOfCountriesUseAestheticsAndDermatologicalFields_f2635a5a-d844-40ac-abbc-e19f97134feb_terseLabel_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementNumberOfCountriesUseAestheticsAndDermatologicalFields" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of countries use aesthetics and dermatological fields</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementNumberOfCountriesUseAestheticsAndDermatologicalFields_label_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementNumberOfCountriesUseAestheticsAndDermatologicalFields" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License, Supply and Distribution Agreement, Number Of Countries Use Aesthetics and Dermatological Fields</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementNumberOfCountriesUseAestheticsAndDermatologicalFields_documentation_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementNumberOfCountriesUseAestheticsAndDermatologicalFields" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License, Supply and Distribution Agreement, Number Of Countries Use Aesthetics and Dermatological Fields</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementNumberOfCountriesUseAestheticsAndDermatologicalFields" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementNumberOfCountriesUseAestheticsAndDermatologicalFields"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LicenseSupplyAndDistributionAgreementNumberOfCountriesUseAestheticsAndDermatologicalFields" xlink:to="lab_eols_LicenseSupplyAndDistributionAgreementNumberOfCountriesUseAestheticsAndDermatologicalFields" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_7bb4bba7-168a-4f2f-83b7-5c5d5054702a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_StockIssuedDuringPeriodValueIssuedForLicenseSupplyAndDistributionAgreement_aec78ad3-46bc-4cb3-bbe9-392392e56f97_terseLabel_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodValueIssuedForLicenseSupplyAndDistributionAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with Symatese Europe Agreement</link:label>
    <link:label id="lab_eols_StockIssuedDuringPeriodValueIssuedForLicenseSupplyAndDistributionAgreement_label_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodValueIssuedForLicenseSupplyAndDistributionAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Issued for License, Supply and Distribution Agreement</link:label>
    <link:label id="lab_eols_StockIssuedDuringPeriodValueIssuedForLicenseSupplyAndDistributionAgreement_documentation_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodValueIssuedForLicenseSupplyAndDistributionAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Issued for License, Supply and Distribution Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodValueIssuedForLicenseSupplyAndDistributionAgreement" xlink:href="eols-20241231.xsd#eols_StockIssuedDuringPeriodValueIssuedForLicenseSupplyAndDistributionAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_StockIssuedDuringPeriodValueIssuedForLicenseSupplyAndDistributionAgreement" xlink:to="lab_eols_StockIssuedDuringPeriodValueIssuedForLicenseSupplyAndDistributionAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementAnnualRevenue_3639209f-a861-498b-8562-11b02d653b76_terseLabel_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementAnnualRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual revenue (in euro)</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementAnnualRevenue_label_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementAnnualRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License, Supply and Distribution Agreement, Annual revenue</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementAnnualRevenue_documentation_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementAnnualRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License, Supply and Distribution Agreement, Annual revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementAnnualRevenue" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementAnnualRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LicenseSupplyAndDistributionAgreementAnnualRevenue" xlink:to="lab_eols_LicenseSupplyAndDistributionAgreementAnnualRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_01fcba17-d0d4-47ab-a947-628b6a103fc1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Unit</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_da6199d2-6b70-4a08-8cd4-78689d35c4e9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_225e32e4-9a4f-4d5c-a0c6-f92934d540e2_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_7764d64d-fa69-4bfc-933e-1057c4bff10b_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_ee31ee46-557f-4e17-8462-1d00baa732ec_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_PharmakonTermLoansMember_9f07b251-6b4e-436e-9aea-f39bb73d6a23_terseLabel_en-US" xlink:label="lab_eols_PharmakonTermLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pharmakon Term Loans</link:label>
    <link:label id="lab_eols_PharmakonTermLoansMember_label_en-US" xlink:label="lab_eols_PharmakonTermLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pharmakon Term Loans [Member]</link:label>
    <link:label id="lab_eols_PharmakonTermLoansMember_documentation_en-US" xlink:label="lab_eols_PharmakonTermLoansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pharmakon Term Loans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansMember" xlink:href="eols-20241231.xsd#eols_PharmakonTermLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_PharmakonTermLoansMember" xlink:to="lab_eols_PharmakonTermLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_2fb5fa7e-4fc2-460c-afbe-9fb2df44528f_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentNumberOfInstallments_b5fdc9e9-0587-42a3-b4fb-06cfe75c036c_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentNumberOfInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, number of installments</link:label>
    <link:label id="lab_eols_DebtInstrumentNumberOfInstallments_label_en-US" xlink:label="lab_eols_DebtInstrumentNumberOfInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number of Installments</link:label>
    <link:label id="lab_eols_DebtInstrumentNumberOfInstallments_documentation_en-US" xlink:label="lab_eols_DebtInstrumentNumberOfInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number of Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentNumberOfInstallments" xlink:href="eols-20241231.xsd#eols_DebtInstrumentNumberOfInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentNumberOfInstallments" xlink:to="lab_eols_DebtInstrumentNumberOfInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_567f05f7-03e9-4bdf-bf5b-ac46f0237eab_terseLabel_en-US" xlink:label="lab_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of termination of first commercial sale</link:label>
    <link:label id="lab_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_label_en-US" xlink:label="lab_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Period Of Termination Of First Commercial Sale</link:label>
    <link:label id="lab_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_documentation_en-US" xlink:label="lab_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Period Of Termination Of First Commercial Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale" xlink:href="eols-20241231.xsd#eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale" xlink:to="lab_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense_c035766d-77de-4f70-b63f-fc11c5f28325_terseLabel_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License, supply and distribution agreement, upfront payment</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License, Supply and Distribution Agreement, Upfront Payment, In-Process Research and Development Expense</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License, Supply and Distribution Agreement, Upfront Payment, In-Process Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense" xlink:to="lab_eols_LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_efd87ece-030d-4cc4-a9cb-8c14d09451d4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_8ed625c1-7d2b-40b2-84d2-ece2efcec394_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_2236560c-154a-4a95-891c-c3d7f3525329_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a804827e-fd89-45c1-94b1-b237259d4394_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_d2114265-544a-43d6-9a20-3177786e7d1b_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_SaleOfStockMaximumConsiderationReceivable_e8826064-db43-4e0a-af78-144a579c82c2_terseLabel_en-US" xlink:label="lab_eols_SaleOfStockMaximumConsiderationReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum consideration receivable</link:label>
    <link:label id="lab_eols_SaleOfStockMaximumConsiderationReceivable_label_en-US" xlink:label="lab_eols_SaleOfStockMaximumConsiderationReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Maximum Consideration Receivable</link:label>
    <link:label id="lab_eols_SaleOfStockMaximumConsiderationReceivable_documentation_en-US" xlink:label="lab_eols_SaleOfStockMaximumConsiderationReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Maximum Consideration Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SaleOfStockMaximumConsiderationReceivable" xlink:href="eols-20241231.xsd#eols_SaleOfStockMaximumConsiderationReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_SaleOfStockMaximumConsiderationReceivable" xlink:to="lab_eols_SaleOfStockMaximumConsiderationReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0cb4fded-54a0-4b5d-a71a-251388aad356_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_14371527-f4cc-4b66-b440-dfbbb24772a6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_4049e76c-0c76-468e-a41b-70d6f6515ab3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_93671188-9304-4630-8f6e-c7d4c21ffb32_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_10e06acf-249d-4492-b376-a8af001ade56_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_4936929e-55b5-4911-87a6-85d1b5001781_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_PaymentsForInventory_bac7cb2f-9958-4f20-a419-2d2e57af1692_terseLabel_en-US" xlink:label="lab_eols_PaymentsForInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory payments</link:label>
    <link:label id="lab_eols_PaymentsForInventory_label_en-US" xlink:label="lab_eols_PaymentsForInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments For Inventory</link:label>
    <link:label id="lab_eols_PaymentsForInventory_documentation_en-US" xlink:label="lab_eols_PaymentsForInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments For Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PaymentsForInventory" xlink:href="eols-20241231.xsd#eols_PaymentsForInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_PaymentsForInventory" xlink:to="lab_eols_PaymentsForInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_73ec1877-a0ff-4582-b577-8e661c23f51e_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0226b841-c9e2-4979-ac87-f319e762d662_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_FirstMilestonePaymentMember_897f1083-79e4-460d-804c-6bcdadd090c2_terseLabel_en-US" xlink:label="lab_eols_FirstMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">First Milestone Payment</link:label>
    <link:label id="lab_eols_FirstMilestonePaymentMember_label_en-US" xlink:label="lab_eols_FirstMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">First Milestone Payment [Member]</link:label>
    <link:label id="lab_eols_FirstMilestonePaymentMember_documentation_en-US" xlink:label="lab_eols_FirstMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">First Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_FirstMilestonePaymentMember" xlink:href="eols-20241231.xsd#eols_FirstMilestonePaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_FirstMilestonePaymentMember" xlink:to="lab_eols_FirstMilestonePaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_3cea9eb0-b65d-4de1-ae47-f76023bf408a_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computers</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentPeriodicPaymentInitialPrincipalPaymentDuePeriod_3f1e6c62-392f-485d-b0bb-470295fd0795_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPeriodicPaymentInitialPrincipalPaymentDuePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Periodic payment, Initial principal payment, period</link:label>
    <link:label id="lab_eols_DebtInstrumentPeriodicPaymentInitialPrincipalPaymentDuePeriod_label_en-US" xlink:label="lab_eols_DebtInstrumentPeriodicPaymentInitialPrincipalPaymentDuePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment, Initial Principal Payment Due, Period</link:label>
    <link:label id="lab_eols_DebtInstrumentPeriodicPaymentInitialPrincipalPaymentDuePeriod_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPeriodicPaymentInitialPrincipalPaymentDuePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment, Initial Principal Payment Due, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPeriodicPaymentInitialPrincipalPaymentDuePeriod" xlink:href="eols-20241231.xsd#eols_DebtInstrumentPeriodicPaymentInitialPrincipalPaymentDuePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPeriodicPaymentInitialPrincipalPaymentDuePeriod" xlink:to="lab_eols_DebtInstrumentPeriodicPaymentInitialPrincipalPaymentDuePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_9751b267-4bf6-4f67-bf8d-6218644ee9e8_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_014e7ca2-a5da-4397-bf59-c2c44c53cbb9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_8b79dc09-0cf8-47dc-8dc0-2ac2f521fbd5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_10ea7f2a-a858-4789-b6a6-8950f88eb8b8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_AccountsReceivableCreditCardTransactionConvertedToCashPeriod_e6ab0ade-d3aa-4294-b310-2bcea153bb85_terseLabel_en-US" xlink:label="lab_eols_AccountsReceivableCreditCardTransactionConvertedToCashPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, credit card transaction, converted to cash, period</link:label>
    <link:label id="lab_eols_AccountsReceivableCreditCardTransactionConvertedToCashPeriod_label_en-US" xlink:label="lab_eols_AccountsReceivableCreditCardTransactionConvertedToCashPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Credit Card Transaction, Converted To Cash, Period</link:label>
    <link:label id="lab_eols_AccountsReceivableCreditCardTransactionConvertedToCashPeriod_documentation_en-US" xlink:label="lab_eols_AccountsReceivableCreditCardTransactionConvertedToCashPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Credit Card Transaction, Converted To Cash, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_AccountsReceivableCreditCardTransactionConvertedToCashPeriod" xlink:href="eols-20241231.xsd#eols_AccountsReceivableCreditCardTransactionConvertedToCashPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_AccountsReceivableCreditCardTransactionConvertedToCashPeriod" xlink:to="lab_eols_AccountsReceivableCreditCardTransactionConvertedToCashPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredLongTermDebt_0587be2f-9a3c-483f-9f51-2459a1f4a1de_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term loan, net of discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_SecuredLongTermDebt_label_en-US" xlink:label="lab_us-gaap_SecuredLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Long-Term Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredLongTermDebt" xlink:to="lab_us-gaap_SecuredLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_7748a507-394d-4fcb-a9f4-47f36d9aec2f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_a3083d87-4221-4a9f-a716-f4e52dc67143_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6a73749d-6f11-452b-8f21-921570608c61_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_52189eb9-ee9b-486f-8735-80f2d0531dc8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ce0efd6c-c2ce-455f-82d3-3de18decdd53_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a9ff8801-7d44-4662-b994-d111e874f998_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares outstanding used to compute diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_e1d37c76-526e-4561-b6bb-54d62c38151c_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_a3c43eea-7905-4117-b278-909700f44038_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_c00b995f-3efd-441b-95b1-55dee1233901_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_caa5c3ac-e7f4-4f41-9688-66789d1b1f34_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_7808bb40-5764-4297-a366-310021366ede_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_aa4dc86d-1a95-4ca5-9821-c84d92bb97c8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_1663dbef-7e3b-410e-88de-bdf970584ace_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_SaleOfStockGrantedOptionsExercisablePeriod_f0655809-d747-4b59-91e2-469cd28b7ff8_terseLabel_en-US" xlink:label="lab_eols_SaleOfStockGrantedOptionsExercisablePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted options, exercisable period</link:label>
    <link:label id="lab_eols_SaleOfStockGrantedOptionsExercisablePeriod_label_en-US" xlink:label="lab_eols_SaleOfStockGrantedOptionsExercisablePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Granted Options, Exercisable Period</link:label>
    <link:label id="lab_eols_SaleOfStockGrantedOptionsExercisablePeriod_documentation_en-US" xlink:label="lab_eols_SaleOfStockGrantedOptionsExercisablePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Granted Options, Exercisable Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SaleOfStockGrantedOptionsExercisablePeriod" xlink:href="eols-20241231.xsd#eols_SaleOfStockGrantedOptionsExercisablePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_SaleOfStockGrantedOptionsExercisablePeriod" xlink:to="lab_eols_SaleOfStockGrantedOptionsExercisablePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_ea7f1a50-48f5-425d-85c3-2c10bd57e51c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_c6fa048c-4121-4d35-a4ba-06620581e414_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_c56476d1-6efd-495e-9579-a729b781a5d0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_570babeb-2271-4116-8e50-fffd647b5028_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred (benefit) provision</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_ffd9194a-90f1-47e0-bb17-06cd0052207b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_1e40db9a-dae4-48d2-9430-bdcda579c720_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_d9ea45fe-413f-4e8b-8b81-a693c2c38bf7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_f5f6afd9-0071-45d0-b794-732ae3b4e31a_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_3b69ab83-8b75-44e3-828c-c7abf815d7c8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined contributions to 401(k) plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_62dfb350-1647-489f-912a-ab23282430dc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_a52e278e-0308-419f-b3e1-4eff27deea02_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_30519e87-b594-4838-bc17-506917ad8164_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_28155f04-be99-4af7-b455-8070ef964de8_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product revenue, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_21315c92-524c-45b0-90b8-238b9c55116c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum number of shares authorized under the plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_A2023InducementIncentivePlanMember_acadf74d-442f-4d91-babd-b11d99735be8_terseLabel_en-US" xlink:label="lab_eols_A2023InducementIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 Inducement Incentive Plan</link:label>
    <link:label id="lab_eols_A2023InducementIncentivePlanMember_label_en-US" xlink:label="lab_eols_A2023InducementIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2023 Inducement Incentive Plan [Member]</link:label>
    <link:label id="lab_eols_A2023InducementIncentivePlanMember_documentation_en-US" xlink:label="lab_eols_A2023InducementIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2023 Inducement Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_A2023InducementIncentivePlanMember" xlink:href="eols-20241231.xsd#eols_A2023InducementIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_A2023InducementIncentivePlanMember" xlink:to="lab_eols_A2023InducementIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_ef530d87-3d21-4fb6-a2c7-a324c3c9e035_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_66cad6a1-57c4-49db-83e0-cb99f48bd32f_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Long term debt, net of discounts and issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_a630215c-3616-4654-bec3-fb195d3fcbda_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_72ce672d-41e9-422b-b247-bb5f823ea593_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_dcdd6b15-c426-4bda-82d8-1c3ea6aabc72_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued litigation settlement</link:label>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_label_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveCurrent" xlink:to="lab_us-gaap_LitigationReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_ShareBasedCompensationConsecutiveTradingDaysPerShareTarget_3a105903-275b-4ba0-9131-2f1a6de09321_terseLabel_en-US" xlink:label="lab_eols_ShareBasedCompensationConsecutiveTradingDaysPerShareTarget" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consecutive trading amount (in dollars per share)</link:label>
    <link:label id="lab_eols_ShareBasedCompensationConsecutiveTradingDaysPerShareTarget_label_en-US" xlink:label="lab_eols_ShareBasedCompensationConsecutiveTradingDaysPerShareTarget" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation, Consecutive Trading Days, Per Share Target</link:label>
    <link:label id="lab_eols_ShareBasedCompensationConsecutiveTradingDaysPerShareTarget_documentation_en-US" xlink:label="lab_eols_ShareBasedCompensationConsecutiveTradingDaysPerShareTarget" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation, Consecutive Trading Days, Per Share Target</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ShareBasedCompensationConsecutiveTradingDaysPerShareTarget" xlink:href="eols-20241231.xsd#eols_ShareBasedCompensationConsecutiveTradingDaysPerShareTarget"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ShareBasedCompensationConsecutiveTradingDaysPerShareTarget" xlink:to="lab_eols_ShareBasedCompensationConsecutiveTradingDaysPerShareTarget" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingenciesOther_b5230351-fe6e-4dc4-aa38-0d96499394dc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingenciesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingenciesOther_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingenciesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Other, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingenciesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxContingenciesOther" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxContingenciesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_StockIssuedDuringPeriodValueIncentiveEquityPlan_0cf95b22-c2a4-46d2-bd67-350228d90de6_terseLabel_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodValueIncentiveEquityPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with the incentive equity plan</link:label>
    <link:label id="lab_eols_StockIssuedDuringPeriodValueIncentiveEquityPlan_label_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodValueIncentiveEquityPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Incentive Equity Plan</link:label>
    <link:label id="lab_eols_StockIssuedDuringPeriodValueIncentiveEquityPlan_documentation_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodValueIncentiveEquityPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Incentive Equity Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodValueIncentiveEquityPlan" xlink:href="eols-20241231.xsd#eols_StockIssuedDuringPeriodValueIncentiveEquityPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_StockIssuedDuringPeriodValueIncentiveEquityPlan" xlink:to="lab_eols_StockIssuedDuringPeriodValueIncentiveEquityPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_9831928f-8b88-4313-a4c1-ce71e440892e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2b66bce1-5ec3-41ae-8680-90a827c79f2a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options contractual term, outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_be66acd4-778b-410c-82a5-56bc940feea8_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e829fea4-64bd-4e57-af34-035d43030c06_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_2f787b76-da7d-4411-8c2a-52c06f6c0487_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ce9c74e7-493f-4440-b8ad-5d25f46f0fab_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_673765bd-754c-4862-a7e6-709596f55bbe_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate, effective percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_IncreaseDecreaseInOperatingLeaseLiabilities_2094c006-8236-4d09-b1aa-b5bf9b708a40_terseLabel_en-US" xlink:label="lab_eols_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_eols_IncreaseDecreaseInOperatingLeaseLiabilities_label_en-US" xlink:label="lab_eols_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Operating Lease Liabilities</link:label>
    <link:label id="lab_eols_IncreaseDecreaseInOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_eols_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:href="eols-20241231.xsd#eols_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lab_eols_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_76f64b5f-7677-4bc3-9679-e306f86c9cf7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Revenue to Net Loss</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_32447b2c-3e61-4c12-b357-09dedb60add4_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized software</link:label>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_label_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Software, Intangible Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_3bc2aa24-1cc4-4816-90e5-a17c1bf14438_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_AuditInformationAbstract_label_en-US" xlink:label="lab_eols_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_eols_AuditInformationAbstract_documentation_en-US" xlink:label="lab_eols_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_AuditInformationAbstract" xlink:href="eols-20241231.xsd#eols_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_AuditInformationAbstract" xlink:to="lab_eols_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_cb008b02-591b-493f-ae7f-abb10ae0a499_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueVested_d9d60ee1-d876-4554-8aae-994357aaffb1_terseLabel_en-US" xlink:label="lab_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total intrinsic value of options that vested</link:label>
    <link:label id="lab_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueVested_label_en-US" xlink:label="lab_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:label id="lab_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueVested_documentation_en-US" xlink:label="lab_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueVested" xlink:href="eols-20241231.xsd#eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueVested" xlink:to="lab_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueVested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_ef752938-b69d-4323-a3b8-25dee082a6df_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Estimated Future Amortization Expense of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_749c7ab5-5121-4c44-9e8b-2e5a69c71d39_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_a093f83c-d706-4428-8b12-4bc67cf6b73a_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_6856c04e-905a-489b-8aad-7814dd6dbff7_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_a627ac1a-e2c7-4bff-98aa-733be597490e_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization of distribution right</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_42858a54-e39f-4a03-b0e1-ff377b1517bf_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_eb760b21-7112-4df8-84ea-d4507a861693_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Book Value</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_d0914343-7c4b-4957-b8d4-289cdcdeb24c_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_62b9de5b-1648-488c-979f-3bb3389e8cf6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_8f68fa57-4830-49d3-b8c0-4ddcc0b04b44_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_fe228f06-2d24-43ec-be82-ab472f27bcf6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts_92707773-5d28-44b6-a166-435b4543d138_verboseLabel_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Regulatory approval, number of products</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts_label_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License, Supply And Distribution Agreement, Regulatory Approval, Number Of Products</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts_documentation_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License, Supply and Distribution Agreement, Regulatory Approval, Number Of Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts" xlink:to="lab_eols_LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_fbcb5878-3fed-465d-9c0e-230825f13bb6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_adb68b73-e656-4d4f-a59d-48eb171a5299_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_043711a6-7a3c-4981-b83a-b5e2e0ea3789_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Royalty Obligation Payable and Promissory Note Payable to the Evolus Founders</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_4adf8fbd-a5f0-4831-9577-fd8dbf9ee238_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold Improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour_9b75f489-128b-4764-86ca-e73542593133_terseLabel_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License, supply and distribution agreement payment, June 2028 (in euro)</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour_label_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License, Supply and Distribution Agreement, Annual Payment, Year Four</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour_documentation_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License, Supply and Distribution Agreement, Annual Principal Payment, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour" xlink:to="lab_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_65cd7510-19a2-4755-adae-1f6da106c638_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Key Assumptions Used to Determine Fair Value of Options Granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_cfae5294-64bf-4d81-b50b-97b634d6ceeb_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a6ca85bf-2830-4756-9dd6-29efb2919af5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm_be16936e-7d70-4986-8b38-454f11558c79_terseLabel_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value assumptions, weighted average expected term</link:label>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm_label_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Term</link:label>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm_documentation_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm" xlink:href="eols-20241231.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm" xlink:to="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage_48cddd81-7b57-4a5c-b6b0-c5f0cfe5b286_terseLabel_en-US" xlink:label="lab_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, commission payment upon gross proceeds</link:label>
    <link:label id="lab_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage_label_en-US" xlink:label="lab_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Commission Payment Upon Gross Proceeds, Percentage</link:label>
    <link:label id="lab_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage_documentation_en-US" xlink:label="lab_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Commission Payment Upon Gross Proceeds, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage" xlink:href="eols-20241231.xsd#eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage" xlink:to="lab_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_b0082b68-9633-4695-8314-92da190107a0_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Lease, cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_81c05251-9f6f-42d3-992d-6466f9644a59_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6cac32af-1d1b-46e0-b941-92ddaa2b2c3a_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes:</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_90b353d8-baeb-400b-b205-da3319c3c2ea_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes:</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_939bb920-1958-4eee-b8fa-b7682f7bce38_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan shares issued during the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_TermTwoMember_121c4df8-b91a-4e33-b36b-d22975bcc17e_terseLabel_en-US" xlink:label="lab_eols_TermTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">After the 3rd anniversary but prior to the 4th anniversary</link:label>
    <link:label id="lab_eols_TermTwoMember_label_en-US" xlink:label="lab_eols_TermTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Two [Member]</link:label>
    <link:label id="lab_eols_TermTwoMember_documentation_en-US" xlink:label="lab_eols_TermTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TermTwoMember" xlink:href="eols-20241231.xsd#eols_TermTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_TermTwoMember" xlink:to="lab_eols_TermTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_2fb4d055-0916-4700-b474-fec1b1aa4bf4_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a11e60a1-5af7-4bbc-a3a3-4be61f0ea30c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_14c28147-0c29-4c45-9679-39714f19de4e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Fixed asset depreciation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_ea3baaa8-13d2-4438-adad-86bea5024d64_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_a729dfc3-dc73-41e6-8b25-74bf4560ba7f_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable operating lease expense</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_b155ba31-c2ce-49c9-83da-d57436133417_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_8c5ded85-7e33-43d9-b410-5bdda9db79b5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ce3aecc1-a04e-409b-9d6b-0b6416b08d55_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Useful lives of intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_c34e0c53-34d7-41fe-beac-f43aad88ce2c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Life (Years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_4a28e96a-71a8-40dc-9d77-06d1b9720917_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_7992254a-ee87-4d8d-a55f-f88e08a49ad1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_003eeb17-fb6a-4e4d-b3c7-ab78dc70957a_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_0b62dd80-012d-420f-aaec-14e57f29ed31_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_753d8380-3cdc-41c4-9f89-dd80490fd359_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_620e668e-2a96-4561-ada1-a1abebc9a031_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_bb8ad1d1-d238-4221-90b1-d286995cd2ba_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_4bb7e3c1-354a-4f1d-b374-b29a8ab8e2dc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_86ce5249-ec27-45ba-8ab8-3e5668d906ab_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_127c1748-1aa7-4c1b-a082-c4c322b01d44_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_dad171a6-d040-4858-8917-4c3987e8d380_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_SecuredFinancingOfferedRateSOFRMember_40dff8a5-89e7-4605-95e6-ea3a27d63e30_terseLabel_en-US" xlink:label="lab_eols_SecuredFinancingOfferedRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Financing Offered Rate (SOFR)</link:label>
    <link:label id="lab_eols_SecuredFinancingOfferedRateSOFRMember_label_en-US" xlink:label="lab_eols_SecuredFinancingOfferedRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Financing Offered Rate (SOFR) [Member]</link:label>
    <link:label id="lab_eols_SecuredFinancingOfferedRateSOFRMember_documentation_en-US" xlink:label="lab_eols_SecuredFinancingOfferedRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Secured Financing Offered Rate (SOFR)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SecuredFinancingOfferedRateSOFRMember" xlink:href="eols-20241231.xsd#eols_SecuredFinancingOfferedRateSOFRMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_SecuredFinancingOfferedRateSOFRMember" xlink:to="lab_eols_SecuredFinancingOfferedRateSOFRMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_a208976f-3d90-4c8e-815f-03f86b515b85_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current provision</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementContingentMilestoneLiabilityNoncurrent_e99a7b79-67fc-4a6e-8da9-d9ed8c10406d_terseLabel_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementContingentMilestoneLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent milestone payment</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementContingentMilestoneLiabilityNoncurrent_label_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementContingentMilestoneLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License, Supply And Distribution Agreement, Contingent Milestone Liability, Noncurrent</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementContingentMilestoneLiabilityNoncurrent_documentation_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementContingentMilestoneLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License, Supply And Distribution Agreement, Contingent Milestone Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementContingentMilestoneLiabilityNoncurrent" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementContingentMilestoneLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LicenseSupplyAndDistributionAgreementContingentMilestoneLiabilityNoncurrent" xlink:to="lab_eols_LicenseSupplyAndDistributionAgreementContingentMilestoneLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_8a804e9d-12a4-4a2a-b12f-0fb4a90ec0a8_terseLabel_en-US" xlink:label="lab_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional shares reserved for issuance (in shares)</link:label>
    <link:label id="lab_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_label_en-US" xlink:label="lab_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Additional Capital Shares Reserved for Future Issuance</link:label>
    <link:label id="lab_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_documentation_en-US" xlink:label="lab_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Additional Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:href="eols-20241231.xsd#eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:to="lab_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_80bb2fdc-fea7-4115-bffc-823a10049409_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation_7d68d84c-1176-4153-98bf-61007c4aea21_terseLabel_en-US" xlink:label="lab_eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Officers' compensation</link:label>
    <link:label id="lab_eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation_label_en-US" xlink:label="lab_eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Officers' Compensation</link:label>
    <link:label id="lab_eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation_documentation_en-US" xlink:label="lab_eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Officers' Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation" xlink:href="eols-20241231.xsd#eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation" xlink:to="lab_eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentPrepaymentTermsDomain_59d19158-834b-4f32-ab0d-656cc343886d_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentTermsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Terms [Domain]</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentTermsDomain_label_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentTermsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Terms [Domain]</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentTermsDomain_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentTermsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Terms [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentTermsDomain" xlink:href="eols-20241231.xsd#eols_DebtInstrumentPrepaymentTermsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPrepaymentTermsDomain" xlink:to="lab_eols_DebtInstrumentPrepaymentTermsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_660fc282-f9c0-4923-b2b9-84634e8baf3d_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_2882681a-a851-4466-a6e0-5bba16bf109f_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_d59ec118-7539-40ac-b3ea-00e562ac4867_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_5c18d617-4fd9-4729-a672-167bd9eac82c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_db2ebf6f-694f-44a8-87f9-7455148887e7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementRenewalTerm_46dd9949-f3f8-4034-9c3f-6a95d98e2e67_terseLabel_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License, supply and distribution agreement, renewal term</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementRenewalTerm_label_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License, Supply and Distribution Agreement, Renewal Term</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementRenewalTerm_documentation_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License, Supply and Distribution Agreement, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementRenewalTerm" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LicenseSupplyAndDistributionAgreementRenewalTerm" xlink:to="lab_eols_LicenseSupplyAndDistributionAgreementRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_31a75301-c663-4bb4-b291-69038c2b7979_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_6713ade1-36d1-4c16-8c0d-e28699304ff0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_28d7e4d0-ae51-490b-98b3-a462fb033833_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c5997a42-d202-4a79-aced-c188bcc82a48_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units that vested, fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_28d9def2-b527-4830-a40b-ae3e223a6f77_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">20 Consecutive Trading Days with a $50 Share Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodTwo_adac7a3c-1601-41f0-8f77-4d6be97033df_terseLabel_en-US" xlink:label="lab_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share issuance agreement, percentage of share dispose per year, period two</link:label>
    <link:label id="lab_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodTwo_label_en-US" xlink:label="lab_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Issuance Agreement, Percentage of Share Dispose Per Year, Period Two</link:label>
    <link:label id="lab_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodTwo_documentation_en-US" xlink:label="lab_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Issuance Agreement, Percentage of Share Dispose Per Year, Period Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodTwo" xlink:href="eols-20241231.xsd#eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodTwo" xlink:to="lab_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_ca226864-0424-4048-b260-a0f0e90c8a7a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_4d036343-685c-47b3-8d22-aeec2a6855d3_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_a0f4e2e6-c1ef-409c-b451-579838dd51b5_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_90b3e514-9a26-4efc-882f-a0461bd915ed_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate on debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement_ca90740d-4b4f-480e-98d3-4106dce8297b_terseLabel_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License, supply and distribution agreement, initial payment</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement_label_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License, Supply and Distribution Agreement, Initial Payment in Connection with Agreement</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement_documentation_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License, Supply and Distribution Agreement, Initial Payment in Connection with Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement" xlink:to="lab_eols_LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_129f23bc-c5bc-480e-a863-3440a6fc06a8_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_16b7f3c3-1491-41f9-a28c-14d8a08dabbb_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation cost related to nonvested awards not yet recognized, expected weighted-average period for recognition (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodOne_590c9b3d-3da7-4cbd-b335-c09ef9b9c075_terseLabel_en-US" xlink:label="lab_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share issuance agreement, percentage of share dispose per year, initial period</link:label>
    <link:label id="lab_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodOne_label_en-US" xlink:label="lab_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Issuance Agreement, Percentage of Share Dispose Per Year, Period One</link:label>
    <link:label id="lab_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodOne_documentation_en-US" xlink:label="lab_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Issuance Agreement, Percentage of Share Dispose Per Year, Period One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodOne" xlink:href="eols-20241231.xsd#eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodOne" xlink:to="lab_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bb0a9fb8-0793-40af-9514-83efda89b5ac_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ecca969a-836f-4237-8e86-e1f4d866a753_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total net revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_50756e1f-6004-4cea-a460-18735761ba19_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, In-Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_81c18adb-07ff-45ca-a2a0-62707896aecb_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service revenue</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AlternativeInvestmentMeasurementInput_ed82f062-e5bb-438c-babe-56be72a2fa40_terseLabel_en-US" xlink:label="lab_us-gaap_AlternativeInvestmentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement input</link:label>
    <link:label id="lab_us-gaap_AlternativeInvestmentMeasurementInput_label_en-US" xlink:label="lab_us-gaap_AlternativeInvestmentMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alternative Investment, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AlternativeInvestmentMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AlternativeInvestmentMeasurementInput" xlink:to="lab_us-gaap_AlternativeInvestmentMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_StockIssuedDuringPeriodSharesIncentiveEquityPlan_13af31be-c252-469a-832a-ba0e9c4d45d1_terseLabel_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodSharesIncentiveEquityPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with the incentive equity plan (in shares)</link:label>
    <link:label id="lab_eols_StockIssuedDuringPeriodSharesIncentiveEquityPlan_label_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodSharesIncentiveEquityPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Incentive Equity Plan</link:label>
    <link:label id="lab_eols_StockIssuedDuringPeriodSharesIncentiveEquityPlan_documentation_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodSharesIncentiveEquityPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Incentive Equity Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodSharesIncentiveEquityPlan" xlink:href="eols-20241231.xsd#eols_StockIssuedDuringPeriodSharesIncentiveEquityPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_StockIssuedDuringPeriodSharesIncentiveEquityPlan" xlink:to="lab_eols_StockIssuedDuringPeriodSharesIncentiveEquityPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementInitialTerm_f181e59e-4423-4bde-92d9-e54aa8d813cb_terseLabel_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementInitialTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License, supply and distribution agreement, initial term</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementInitialTerm_label_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementInitialTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License, Supply and Distribution Agreement, Initial Term</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementInitialTerm_documentation_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementInitialTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License, Supply and Distribution Agreement, Initial Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementInitialTerm" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementInitialTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LicenseSupplyAndDistributionAgreementInitialTerm" xlink:to="lab_eols_LicenseSupplyAndDistributionAgreementInitialTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_SecondMilestonePaymentMember_e88777e1-115e-4e7e-adfd-8c7d1bd7c6df_terseLabel_en-US" xlink:label="lab_eols_SecondMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Second Milestone Payment</link:label>
    <link:label id="lab_eols_SecondMilestonePaymentMember_label_en-US" xlink:label="lab_eols_SecondMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Second Milestone Payment [Member]</link:label>
    <link:label id="lab_eols_SecondMilestonePaymentMember_documentation_en-US" xlink:label="lab_eols_SecondMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Second Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SecondMilestonePaymentMember" xlink:href="eols-20241231.xsd#eols_SecondMilestonePaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_SecondMilestonePaymentMember" xlink:to="lab_eols_SecondMilestonePaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_53321282-8ff9-41cf-a66e-117fe0f3101b_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_2cdd9b98-b08a-4287-b8b7-9264abf1cfa5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_eeb1a27c-0b7d-4ad6-8aeb-15a48e1ead1d_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_7f3369ac-0854-4c0f-9bda-43ab6f4f1761_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_2c765ccf-30c8-4bf1-b122-26fe5edad2eb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_83e4693c-13bb-4713-96fe-87310f0ab4a8_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_2981dee6-af94-4244-beca-189d679da4cb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_bb662c4a-bb6e-48d6-8e9a-3b159e1b709e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0dd3510d-7ab1-4fda-bdb3-77cf6e806c36_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_f77634cb-0d2b-41b6-baec-452a8570e394_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_12949a5f-2ff4-4cfd-9022-7392af91dfd3_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_b2340bf6-b09b-4a12-9f1b-2f0ee7c47da5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_854bec2c-8ae8-4344-bef3-4761e9251757_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued payroll and related benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_8156440e-ff7f-45c6-a1a4-72b3e830adfe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_afbd2e73-ce08-452f-afc7-9e09feebe9af_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_c3a79738-796a-4952-93ae-28530b54c82d_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7dd97a25-3c25-4e6b-a0d2-4f54b8d0a5ec_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_3f3198fb-3921-4a32-a190-0aeb910c3ff0_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e321cd33-7aa0-4653-b51e-c83034d95517_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod_6c3a7a3a-1b6a-411a-a07d-2832f06f01b8_terseLabel_en-US" xlink:label="lab_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance period</link:label>
    <link:label id="lab_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod_label_en-US" xlink:label="lab_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Performance Period</link:label>
    <link:label id="lab_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod_documentation_en-US" xlink:label="lab_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Performance Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod" xlink:href="eols-20241231.xsd#eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod" xlink:to="lab_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_6c244b84-3031-4490-abf2-16e61d16c0dd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable_6d4ebeaf-bb3e-45de-b762-93d970e3a486_terseLabel_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term, exercisable</link:label>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable_label_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Exercisable</link:label>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable_documentation_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable" xlink:href="eols-20241231.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable" xlink:to="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_47a336a6-0619-4805-a354-302b5bc010c5_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets obtained in exchange for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_79b31d31-2efd-4743-8e31-ba2038662873_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_cca7612a-8c55-4885-b18d-978e50029f2d_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5ab9b3be-9965-41e8-998b-327638542159_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_80b66232-5b32-4a46-855f-3a7ad8f122ee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cancelled/forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_TwoThousandAndSeventeenOmnibusIncentivePlanMember_370aedd6-63a1-4e60-8b8d-e1fcc4337dde_terseLabel_en-US" xlink:label="lab_eols_TwoThousandAndSeventeenOmnibusIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Omnibus Incentive Plan</link:label>
    <link:label id="lab_eols_TwoThousandAndSeventeenOmnibusIncentivePlanMember_label_en-US" xlink:label="lab_eols_TwoThousandAndSeventeenOmnibusIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand And Seventeen Omnibus Incentive Plan [Member]</link:label>
    <link:label id="lab_eols_TwoThousandAndSeventeenOmnibusIncentivePlanMember_documentation_en-US" xlink:label="lab_eols_TwoThousandAndSeventeenOmnibusIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand And Seventeen Omnibus Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TwoThousandAndSeventeenOmnibusIncentivePlanMember" xlink:href="eols-20241231.xsd#eols_TwoThousandAndSeventeenOmnibusIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_TwoThousandAndSeventeenOmnibusIncentivePlanMember" xlink:to="lab_eols_TwoThousandAndSeventeenOmnibusIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_08e534a0-1a91-414e-a007-8ba0fecf38cf_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_03a32b30-22af-490a-996b-a4be5a90d3ea_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_0e3430a8-38c1-4f3e-b37a-104ae0f5530f_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_7c40bf73-8ba1-4fb1-b2cd-1676226ec1ea_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_06fc6242-e584-4e19-8a54-9ef26cee830a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_fefe7c00-da59-41db-905f-81d9e871a385_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_e06db62e-464d-412f-baf3-0582503d80d7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_f5b980d0-ad47-4795-9b87-7d8256ff4af2_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_2266fcfc-ad80-4fc9-9fc0-422122079ad4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_2e2f3a46-93e7-441a-a239-c57ca07c5384_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1e8d6ca6-94eb-43d1-b755-66caa86185bd_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_4bd438a8-b401-4f03-9a22-a00cd107827c_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_EvolusIncMember_11f6aa96-c0ab-4ba9-abbd-dc42c232a142_terseLabel_en-US" xlink:label="lab_eols_EvolusIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Evolus, Inc.</link:label>
    <link:label id="lab_eols_EvolusIncMember_label_en-US" xlink:label="lab_eols_EvolusIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Evolus, Inc [Member]</link:label>
    <link:label id="lab_eols_EvolusIncMember_documentation_en-US" xlink:label="lab_eols_EvolusIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Evolus, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_EvolusIncMember" xlink:href="eols-20241231.xsd#eols_EvolusIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_EvolusIncMember" xlink:to="lab_eols_EvolusIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_914cb1ff-128a-4d5b-b156-7df0cb97cef6_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_aa01bce9-25fd-415b-92e0-dbefa7f4ee24_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f32d864b-4334-4278-b1c9-90e48ff77369_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_680fa5fc-553e-4bcd-af8d-55cc2ae081a9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent royalty obligation payable to Evolus Founders</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_288e2238-8208-48c9-a38a-805fbf726220_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value, beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4c413b34-ef62-4aea-b7e7-ab36658e30ca_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value, end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_96fe938d-71ed-4e34-bd9f-baca064a281a_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software Development</link:label>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember" xlink:to="lab_us-gaap_SoftwareDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_e208aa0f-4dd1-471b-8e64-265cf430416b_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency, new claims filed, number</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f43412ff-3718-487a-a616-0196c84f8ec7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unamortized debt discounts and issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_15ab9991-4bf4-4a57-a4fd-1ddaf0c47e0e_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency, number of plaintiffs</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_faaaac76-3df6-4e1c-93a1-3c44debf3885_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_5c579a35-e98a-4e27-ae9b-69d51dee3c75_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options, vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d575fae5-c4ee-4ecd-a1e2-1d5472b0a18a_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_fde526ec-27ad-4713-85ed-89c2d1113f5e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest and penalties related to income tax matters</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination, Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_PharmakonTermLoansTwoMember_caff1e18-c639-482c-9539-fe1ec84c51da_terseLabel_en-US" xlink:label="lab_eols_PharmakonTermLoansTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche B Loan</link:label>
    <link:label id="lab_eols_PharmakonTermLoansTwoMember_label_en-US" xlink:label="lab_eols_PharmakonTermLoansTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pharmakon Term Loans Two [Member]</link:label>
    <link:label id="lab_eols_PharmakonTermLoansTwoMember_documentation_en-US" xlink:label="lab_eols_PharmakonTermLoansTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pharmakon Term Loans Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansTwoMember" xlink:href="eols-20241231.xsd#eols_PharmakonTermLoansTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_PharmakonTermLoansTwoMember" xlink:to="lab_eols_PharmakonTermLoansTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_df9f2575-4922-4f95-9f04-8d9df865077a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ec62a226-e411-4de8-b9e4-d38004559bb8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f0e09afc-b842-48b0-8973-2fd0f5c22472_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_cdbfe10b-13b9-4865-8a1c-aeaf0496dc98_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_575b1e18-40a8-4baf-8501-e9b1c33ffa01_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f64857da-3f69-4dac-bc97-07f00d350946_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalShareIncreaseAvailableForIssuance_a5e336b1-d637-4899-896f-621aa83281a1_terseLabel_en-US" xlink:label="lab_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalShareIncreaseAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional shares available for issuance (in shares)</link:label>
    <link:label id="lab_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalShareIncreaseAvailableForIssuance_label_en-US" xlink:label="lab_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalShareIncreaseAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Additional Share Increase Available for Issuance</link:label>
    <link:label id="lab_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalShareIncreaseAvailableForIssuance_documentation_en-US" xlink:label="lab_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalShareIncreaseAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Additional Share Increase Available for Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalShareIncreaseAvailableForIssuance" xlink:href="eols-20241231.xsd#eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalShareIncreaseAvailableForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalShareIncreaseAvailableForIssuance" xlink:to="lab_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalShareIncreaseAvailableForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAdditions_bea28e18-c6df-4af1-9359-366ec643e61c_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized computer software</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAdditions_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalized Computer Software, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedComputerSoftwareAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_50e20722-a809-45c5-9f09-4dc9ddcc1b6a_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for bad debts</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo_a317ae6e-bc89-46f5-a4be-51005e163a70_terseLabel_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License, supply and distribution agreement payment, June 2026 (in euro)</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo_label_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License, Supply and Distribution Agreement, Annual Payment, Year Two</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo_documentation_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License, Supply and Distribution Agreement, Annual Payment, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo" xlink:to="lab_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_c92de3e8-4583-473b-99ef-c6fe37ab964c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_MarketingFixturesMember_374c7af4-c007-4a24-8c14-cb8f4e342583_terseLabel_en-US" xlink:label="lab_eols_MarketingFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketing Fixtures</link:label>
    <link:label id="lab_eols_MarketingFixturesMember_label_en-US" xlink:label="lab_eols_MarketingFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketing Fixtures [Member]</link:label>
    <link:label id="lab_eols_MarketingFixturesMember_documentation_en-US" xlink:label="lab_eols_MarketingFixturesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Marketing Fixtures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_MarketingFixturesMember" xlink:href="eols-20241231.xsd#eols_MarketingFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_MarketingFixturesMember" xlink:to="lab_eols_MarketingFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_3c76e929-479e-446f-a729-048b8ba95903_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total principal payments</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_bd6a3004-ed0f-4e8e-be37-11efed1c072f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_29eb90b2-5f76-4bc7-9385-109aeabb87e2_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_b63a6b5c-eae7-4df0-9a5b-414953f4119b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NOL carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_TermThreeMember_a73bf203-15a4-4b5e-a83c-9f20f1b45d38_terseLabel_en-US" xlink:label="lab_eols_TermThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">After the 4th anniversary</link:label>
    <link:label id="lab_eols_TermThreeMember_label_en-US" xlink:label="lab_eols_TermThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Three [Member]</link:label>
    <link:label id="lab_eols_TermThreeMember_documentation_en-US" xlink:label="lab_eols_TermThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TermThreeMember" xlink:href="eols-20241231.xsd#eols_TermThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_TermThreeMember" xlink:to="lab_eols_TermThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_3ac31ab5-eb1d-45e6-9f0d-408a7f72ed00_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_2ad74e8d-7471-4005-a9d6-b9ae091149f5_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_46d0cd79-b9e7-4e56-a69c-c9750d3f432c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_6c6a79e2-7012-489f-aaed-2cbd80f84114_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_813a537e-1373-4d5b-bfea-84944cd9f131_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_57d24fed-4353-473c-af8d-4557c18fcbfc_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability_a6a74757-57f1-4164-a58d-165391cb9696_terseLabel_en-US" xlink:label="lab_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for provisions for accrued volume-based rebate and coupon liability</link:label>
    <link:label id="lab_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability_label_en-US" xlink:label="lab_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments For Provisions For Accrued Volume-Based Rebate And Coupon Liability</link:label>
    <link:label id="lab_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability_documentation_en-US" xlink:label="lab_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments For Provisions For Accrued Volume-Based Rebate, Coupon And Consumer Loyalty Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability" xlink:href="eols-20241231.xsd#eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability" xlink:to="lab_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_d1c1d773-92be-4ed0-91ed-eb27875c87e4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity term of debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_2b822cb1-01df-4694-9b83-04d92ed109c8_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_64cbe538-009c-4a7f-9171-01cc5fab6f79_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_FollowOnOfferingMember_860393fd-b44d-40d6-8b78-4d0108d1e4ed_terseLabel_en-US" xlink:label="lab_eols_FollowOnOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Follow-on Offering</link:label>
    <link:label id="lab_eols_FollowOnOfferingMember_label_en-US" xlink:label="lab_eols_FollowOnOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Follow-On Offering [Member]</link:label>
    <link:label id="lab_eols_FollowOnOfferingMember_documentation_en-US" xlink:label="lab_eols_FollowOnOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Follow-On Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_FollowOnOfferingMember" xlink:href="eols-20241231.xsd#eols_FollowOnOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_FollowOnOfferingMember" xlink:to="lab_eols_FollowOnOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_eb390086-a30e-4dea-b52e-970f19f86313_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_523a8358-6768-4a45-9d1e-e55cbf9f04f1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_e6eb7bda-952c-4e43-b6e1-dcda3ca43326_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_6687904f-1053-4f68-b3ff-ee22e6ce412a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_942d11cf-c080-40e3-99c2-4a1e00d69269_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementExpectedRegulatoryApprovalNumberOfProducts_bdb79180-12cb-4341-842c-cdc02b694bdf_terseLabel_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementExpectedRegulatoryApprovalNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected regulatory approval, number of products</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementExpectedRegulatoryApprovalNumberOfProducts_label_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementExpectedRegulatoryApprovalNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License, Supply And Distribution Agreement, Expected Regulatory Approval, Number Of Products</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementExpectedRegulatoryApprovalNumberOfProducts_documentation_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementExpectedRegulatoryApprovalNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License, Supply And Distribution Agreement, Expected Regulatory Approval, Number Of Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementExpectedRegulatoryApprovalNumberOfProducts" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementExpectedRegulatoryApprovalNumberOfProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LicenseSupplyAndDistributionAgreementExpectedRegulatoryApprovalNumberOfProducts" xlink:to="lab_eols_LicenseSupplyAndDistributionAgreementExpectedRegulatoryApprovalNumberOfProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_dd4e3299-df2b-4871-a298-4bbd49439b17_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_fce5d540-286c-497a-88b4-39043b8b4d17_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_639d53f5-09d7-4711-a00e-270e3b6e63b3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_8d66c822-e80b-4139-8647-e79c793857e8_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_ATMSalesAgreementMember_350bcdab-6c0c-46a4-93e8-e21f109a980c_terseLabel_en-US" xlink:label="lab_eols_ATMSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ATM Sales Agreement</link:label>
    <link:label id="lab_eols_ATMSalesAgreementMember_label_en-US" xlink:label="lab_eols_ATMSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">A T M Sales Agreement [Member]</link:label>
    <link:label id="lab_eols_ATMSalesAgreementMember_documentation_en-US" xlink:label="lab_eols_ATMSalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">A T M Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ATMSalesAgreementMember" xlink:href="eols-20241231.xsd#eols_ATMSalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ATMSalesAgreementMember" xlink:to="lab_eols_ATMSalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodThree_d4c31eb9-e768-44e2-883f-35fbd4306e4f_terseLabel_en-US" xlink:label="lab_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share issuance agreement, percentage of share dispose per year, period three</link:label>
    <link:label id="lab_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodThree_label_en-US" xlink:label="lab_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Issuance Agreement, Percentage of Share Dispose Per Year, Period Three</link:label>
    <link:label id="lab_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodThree_documentation_en-US" xlink:label="lab_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Issuance Agreement, Percentage of Share Dispose Per Year, Period Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodThree" xlink:href="eols-20241231.xsd#eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodThree" xlink:to="lab_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_LossContingencySettlementAgreementManufacturingLicensePeriod_cd0f2163-2791-4aee-b1b1-81e6bf91af1c_terseLabel_en-US" xlink:label="lab_eols_LossContingencySettlementAgreementManufacturingLicensePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlement agreement, manufacturing license period (months)</link:label>
    <link:label id="lab_eols_LossContingencySettlementAgreementManufacturingLicensePeriod_label_en-US" xlink:label="lab_eols_LossContingencySettlementAgreementManufacturingLicensePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Settlement Agreement, Manufacturing License Period</link:label>
    <link:label id="lab_eols_LossContingencySettlementAgreementManufacturingLicensePeriod_documentation_en-US" xlink:label="lab_eols_LossContingencySettlementAgreementManufacturingLicensePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Settlement Agreement, Manufacturing License Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LossContingencySettlementAgreementManufacturingLicensePeriod" xlink:href="eols-20241231.xsd#eols_LossContingencySettlementAgreementManufacturingLicensePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LossContingencySettlementAgreementManufacturingLicensePeriod" xlink:to="lab_eols_LossContingencySettlementAgreementManufacturingLicensePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_3346aa04-e789-4679-9cdb-1e0c8c95ad82_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_bf7c6d98-4912-44f4-b827-6d2d69c28cac_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with Symatese Europe Agreement</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b05698f0-b411-4900-a2d2-3d7ef87e922e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_99238541-51af-4764-8bab-46f976f00572_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_e6a6a1b8-92c8-4b0f-9394-34d561a8511a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards, not subject to expiration</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8fcfb52c-61cc-41dd-95f0-6155f29f0098_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities, current</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_40262308-d78d-490f-990d-60cf1d820764_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost, Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_7f5afb11-8cc5-4ccb-8e46-26d6b3f82a5e_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne_b4738c83-ceb5-4364-84a3-a4f69061308d_terseLabel_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License, supply and distribution agreement payment, June 2025 (in euro)</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne_label_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License, Supply and Distribution Agreement, Annual Payment, Year One</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne_documentation_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License, Supply and Distribution Agreement, Annual Payment, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne" xlink:to="lab_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_bf228b60-1a7e-4207-982e-c8604031902b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_SymateseEuropeAgreementMember_f8fed7c7-b9c5-4161-a4f8-c2264815e323_terseLabel_en-US" xlink:label="lab_eols_SymateseEuropeAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Symatese Europe Agreement</link:label>
    <link:label id="lab_eols_SymateseEuropeAgreementMember_label_en-US" xlink:label="lab_eols_SymateseEuropeAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Symatese Europe Agreement [Member]</link:label>
    <link:label id="lab_eols_SymateseEuropeAgreementMember_documentation_en-US" xlink:label="lab_eols_SymateseEuropeAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Symatese Europe Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SymateseEuropeAgreementMember" xlink:href="eols-20241231.xsd#eols_SymateseEuropeAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_SymateseEuropeAgreementMember" xlink:to="lab_eols_SymateseEuropeAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_8eb96d66-fb18-435a-a57f-864b980e9e06_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementRightToCommercializeAndDistributeNumberOfProductCandidates_95131869-8e53-4049-aeb4-b2c660df86c9_terseLabel_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementRightToCommercializeAndDistributeNumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right to commercialize and distribute, number of product candidates</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementRightToCommercializeAndDistributeNumberOfProductCandidates_label_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementRightToCommercializeAndDistributeNumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License, Supply And Distribution Agreement, Right To Commercialize And Distribute, Number Of Product Candidates</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementRightToCommercializeAndDistributeNumberOfProductCandidates_documentation_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementRightToCommercializeAndDistributeNumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License, Supply And Distribution Agreement, Right To Commercialize And Distribute, Number Of Product Candidates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementRightToCommercializeAndDistributeNumberOfProductCandidates" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementRightToCommercializeAndDistributeNumberOfProductCandidates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LicenseSupplyAndDistributionAgreementRightToCommercializeAndDistributeNumberOfProductCandidates" xlink:to="lab_eols_LicenseSupplyAndDistributionAgreementRightToCommercializeAndDistributeNumberOfProductCandidates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_849e89a6-4f39-4563-a460-81041e93d99e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_01e4e14f-65eb-44ce-a032-fd98a27b1db2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_9216058b-7716-4224-9bfb-3464b84b7bf6_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of RSUs Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ff123007-150f-457a-ab8d-b038bac23517_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_be0e0cc7-7052-435d-b63e-dc628861327a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ef9aaed4-c878-44e0-ab01-83ab5bb9e232_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_f4858594-9136-4cff-a616-5b79e724f657_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_9dffdbd6-e4e1-4340-9c79-693e67f98dcd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_98319c6f-7029-456b-9054-50c0ff702e82_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_df9fc4cb-9c5b-44b3-a40b-13e6f3ebbca7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_39c2ab24-2cfd-48bf-aa49-0dd70624b956_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod_21e07c50-4dda-4ed3-9473-c140ac8e2146_terseLabel_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License, supply and distribution agreement, initial payment due, period</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod_label_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License, Supply and Distribution Agreement, Initial Payment Due, Period</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod_documentation_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License, Supply and Distribution Agreement, Initial Payment Due, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod" xlink:to="lab_eols_LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_98633b5e-ee82-47ac-a6a6-dab5b3395716_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments for offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_01c4e39b-6f5c-4835-926b-ea6f40af673e_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_cf425c89-0ca8-4110-b935-5245f387f18a_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medytox Settlement Agreements</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_46107939-4381-4bff-b681-c9a0709c03cc_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_831f93b5-2fe9-4b51-a28f-1568ea7fd069_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_39a053cd-2564-4d84-b0c3-121cfe004c13_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_939c747d-2edc-4818-b76d-d1a50799a737_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases to current year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_52528859-d844-461e-9d80-4acd33e72cd7_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2f343042-dde0-47ea-a4a9-75473b2cb5bf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6fb6795e-c26d-427e-ba90-464fa2bb3edf_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Fair Value Measurement for Contingent Royalty Obligation Payable</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2bbc01b8-3adc-4cb6-9860-b3965e501721_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon follow-on offering, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_b0587b02-6347-4787-b397-451b16df63a2_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_PaymentsOfContingentRoyaltyObligation_b078c4a0-9247-4800-89e7-2990d74226d8_negatedTerseLabel_en-US" xlink:label="lab_eols_PaymentsOfContingentRoyaltyObligation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of contingent royalty obligation to Evolus Founders</link:label>
    <link:label id="lab_eols_PaymentsOfContingentRoyaltyObligation_label_en-US" xlink:label="lab_eols_PaymentsOfContingentRoyaltyObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Of Contingent Royalty Obligation</link:label>
    <link:label id="lab_eols_PaymentsOfContingentRoyaltyObligation_documentation_en-US" xlink:label="lab_eols_PaymentsOfContingentRoyaltyObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments Of Contingent Royalty Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PaymentsOfContingentRoyaltyObligation" xlink:href="eols-20241231.xsd#eols_PaymentsOfContingentRoyaltyObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_PaymentsOfContingentRoyaltyObligation" xlink:to="lab_eols_PaymentsOfContingentRoyaltyObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_161bfe51-1d9f-447e-88e3-4873ae637c82_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_MilestoneDomain_a675cab2-200f-4981-b20d-82b1b5c35b2d_terseLabel_en-US" xlink:label="lab_eols_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:label id="lab_eols_MilestoneDomain_label_en-US" xlink:label="lab_eols_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:label id="lab_eols_MilestoneDomain_documentation_en-US" xlink:label="lab_eols_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_MilestoneDomain" xlink:href="eols-20241231.xsd#eols_MilestoneDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_MilestoneDomain" xlink:to="lab_eols_MilestoneDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_95a6e3f2-0bc5-421f-b5e8-17a6583f2734_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent royalty obligation payable to Evolus Founders</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentPeriodicPaymentNumberOfPrincipalPayments_c26cfb99-a2be-4eb8-98c2-8a96293f6fb8_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPeriodicPaymentNumberOfPrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Periodic payment, number of quarterly principal payments due</link:label>
    <link:label id="lab_eols_DebtInstrumentPeriodicPaymentNumberOfPrincipalPayments_label_en-US" xlink:label="lab_eols_DebtInstrumentPeriodicPaymentNumberOfPrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment, Number of Principal Payments</link:label>
    <link:label id="lab_eols_DebtInstrumentPeriodicPaymentNumberOfPrincipalPayments_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPeriodicPaymentNumberOfPrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment, Number of Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPeriodicPaymentNumberOfPrincipalPayments" xlink:href="eols-20241231.xsd#eols_DebtInstrumentPeriodicPaymentNumberOfPrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPeriodicPaymentNumberOfPrincipalPayments" xlink:to="lab_eols_DebtInstrumentPeriodicPaymentNumberOfPrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_60207e31-4099-450a-9dad-70d2a1103ea4_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_d5106fb0-939b-482b-bd7d-dd54cc604807_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity CIK</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount_3c9fb312-fce5-4c81-b613-1de56a74ac82_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, percentage of principal amount, prepaid multiplied</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount_label_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Terms, Prepayment Multiple On Principal Amount</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Terms, Prepayment Multiple On Principal Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount" xlink:href="eols-20241231.xsd#eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount" xlink:to="lab_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentPrepaymentTermsAxis_14fc793e-98ce-4f00-8f20-57f61c5171bc_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentTermsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Terms [Axis]</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentTermsAxis_label_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentTermsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Terms [Axis]</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentTermsAxis_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentTermsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentTermsAxis" xlink:href="eols-20241231.xsd#eols_DebtInstrumentPrepaymentTermsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPrepaymentTermsAxis" xlink:to="lab_eols_DebtInstrumentPrepaymentTermsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_fe1ebff1-fbf0-40a5-9e97-eacad10c05ac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_076de094-7f57-4caa-b8e3-d3581b9e7d30_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_26b19c1b-0527-4e18-880d-509ed749ce7a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_46cf9f66-c162-4ca0-8a95-c88e42b8cc80_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_a91eb8d2-d343-47a0-b6c9-9755b4f1b61c_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_eba2f4e8-bb1a-40e7-8afd-8b42f05ac635_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_49da85c4-cc25-4965-9bc0-d918779234f7_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Revaluation of contingent royalty obligation payable to Evolus Founders</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d7126f81-aa59-487d-842f-b67be8d457cc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value recorded in operating expenses</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_b3e37032-34be-4d98-a495-c64b9ecc8219_negatedNetLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xml:lang="en-US">Revaluation of contingent royalty obligation</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_8e9393b9-64b1-4fb3-b504-165f542bfe72_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revaluation of contingent royalty obligation to Evolus Founders</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_eb6983ab-b87b-4f90-ac9d-63535f9e9606_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_25f3e0a1-1245-45c6-8438-788736d142ee_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_f7eec189-43b0-4905-a2cf-d6151c4f51c0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_9c8a838c-910b-4623-bf6d-c833eb0cbebc_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementMilestonePaymentPayablePeriod_56a247a4-c359-4de0-8941-0071fec1a224_terseLabel_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementMilestonePaymentPayablePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment, payable period</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementMilestonePaymentPayablePeriod_label_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementMilestonePaymentPayablePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License, Supply And Distribution Agreement, Milestone Payment, Payable Period</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementMilestonePaymentPayablePeriod_documentation_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementMilestonePaymentPayablePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License, Supply And Distribution Agreement, Milestone Payment, Payable Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementMilestonePaymentPayablePeriod" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementMilestonePaymentPayablePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LicenseSupplyAndDistributionAgreementMilestonePaymentPayablePeriod" xlink:to="lab_eols_LicenseSupplyAndDistributionAgreementMilestonePaymentPayablePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_TermOneMember_c412a594-f25e-4bde-ab35-9b729081dc0d_terseLabel_en-US" xlink:label="lab_eols_TermOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior to the 3rd anniversary</link:label>
    <link:label id="lab_eols_TermOneMember_label_en-US" xlink:label="lab_eols_TermOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term One [Member]</link:label>
    <link:label id="lab_eols_TermOneMember_documentation_en-US" xlink:label="lab_eols_TermOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TermOneMember" xlink:href="eols-20241231.xsd#eols_TermOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_TermOneMember" xlink:to="lab_eols_TermOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_ShareBasedPaymentArrangementNumberOfConsecutiveDays_107286ae-a3ff-4c20-8a70-38f20ad4aa84_terseLabel_en-US" xlink:label="lab_eols_ShareBasedPaymentArrangementNumberOfConsecutiveDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of consecutive days</link:label>
    <link:label id="lab_eols_ShareBasedPaymentArrangementNumberOfConsecutiveDays_label_en-US" xlink:label="lab_eols_ShareBasedPaymentArrangementNumberOfConsecutiveDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Number of Consecutive Days</link:label>
    <link:label id="lab_eols_ShareBasedPaymentArrangementNumberOfConsecutiveDays_documentation_en-US" xlink:label="lab_eols_ShareBasedPaymentArrangementNumberOfConsecutiveDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Number of Consecutive Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ShareBasedPaymentArrangementNumberOfConsecutiveDays" xlink:href="eols-20241231.xsd#eols_ShareBasedPaymentArrangementNumberOfConsecutiveDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ShareBasedPaymentArrangementNumberOfConsecutiveDays" xlink:to="lab_eols_ShareBasedPaymentArrangementNumberOfConsecutiveDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_7063e8bc-3a9f-4278-b019-ae353b0a5662_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0278a42b-19a0-4e27-a8c9-157fa665f7c8_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_c3b3e1d6-0c88-44d1-bf83-c623a58c7e6a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Loss before Income Taxes from U.S. Operations and Foreign</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_eef9412d-5c6b-4810-af34-867abe84beb8_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_1ccfe0cd-cab9-41e2-84db-4415e20baf34_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_LondonInterbankOfferedRateLIBOR1Member_7faae5b6-1f22-4e67-ad51-58c0be2bf012_terseLabel_en-US" xlink:label="lab_eols_LondonInterbankOfferedRateLIBOR1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">London Interbank Offered Rate</link:label>
    <link:label id="lab_eols_LondonInterbankOfferedRateLIBOR1Member_label_en-US" xlink:label="lab_eols_LondonInterbankOfferedRateLIBOR1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">London Interbank Offered Rate (LIBOR) 1 [Member]</link:label>
    <link:label id="lab_eols_LondonInterbankOfferedRateLIBOR1Member_documentation_en-US" xlink:label="lab_eols_LondonInterbankOfferedRateLIBOR1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">London Interbank Offered Rate (LIBOR) 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LondonInterbankOfferedRateLIBOR1Member" xlink:href="eols-20241231.xsd#eols_LondonInterbankOfferedRateLIBOR1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LondonInterbankOfferedRateLIBOR1Member" xlink:to="lab_eols_LondonInterbankOfferedRateLIBOR1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_57e49010-b8ad-491c-b7b2-41fe0183ffd0_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_f5488c6e-1695-4747-b858-308df9b576c9_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_4834e5ce-5c51-4fa2-9819-b259098d9bae_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_1e85c22f-6b53-4ff8-938c-fc1811b20fa2_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_ReportableSegmentMember_5cab461d-115b-461a-b2a3-dbb1ab80cb15_terseLabel_en-US" xlink:label="lab_eols_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:label id="lab_eols_ReportableSegmentMember_label_en-US" xlink:label="lab_eols_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reportable Segment [Member]</link:label>
    <link:label id="lab_eols_ReportableSegmentMember_documentation_en-US" xlink:label="lab_eols_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ReportableSegmentMember" xlink:href="eols-20241231.xsd#eols_ReportableSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ReportableSegmentMember" xlink:to="lab_eols_ReportableSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsAfterTermination_370281a7-ca02-4e9f-96c7-dbc28b4baabf_terseLabel_en-US" xlink:label="lab_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsAfterTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual term after termination</link:label>
    <link:label id="lab_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsAfterTermination_label_en-US" xlink:label="lab_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsAfterTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms, After Termination</link:label>
    <link:label id="lab_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsAfterTermination_documentation_en-US" xlink:label="lab_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsAfterTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms, After Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsAfterTermination" xlink:href="eols-20241231.xsd#eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsAfterTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsAfterTermination" xlink:to="lab_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsAfterTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_fef9b4af-ca8a-42b2-a5c6-e0bd5e22849a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_a12c1ec2-73f0-4d1c-85e1-a91e0fe45b6d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_8b5769b5-37ca-41a2-b298-8fc6a84ba9bc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_a4e271c7-e920-46e8-bcc4-ec70fb5d63e8_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash investing and financing information</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_fc45e5ef-babd-43d4-b234-f843548cd43b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_c3c3a60b-ea6a-4970-8eca-e443ecfc7d21_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_72522d6c-5000-412e-8877-d2f96833f0ea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options, exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_22d621c7-cfe3-4a74-b49f-8a839254624b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_1ebee8a1-2815-4bf5-95c2-527e96ec9cf9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_891c075b-6066-4147-a462-d58c2cf1764b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in state tax rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_f4b342c5-b351-4161-b3dd-ab60d571a790_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6f8090a8-7eae-447b-a414-efc067784105_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value, options (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_f40afd72-c00c-491a-bb37-35d2b98799e1_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed cash payments estimated to be over term of lease</link:label>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_label_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:to="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_d6465e72-57a1-4f21-bcc2-d396cfbbcc48_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_85e9e652-1d90-4421-8708-6607031c31b0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_7d8cc34d-a3ca-4dd7-97e4-d79e5c037751_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_7e3e068b-1532-42d3-864f-1750842a13bc_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_70564c46-1e79-40bf-9e0e-15eb8ce59b0c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_acac555e-51e0-401d-893b-5fbeac55f6c5_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_42b72576-2f37-4be9-a4e3-5cbea2a4bcc8_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_7562dc0c-91db-42e2-bf7c-3561c7b71d83_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_5e8a6dc7-7a94-412f-a232-4634a10cf432_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementPendingRegulatoryApprovalNumberOfProducts_09ead0b0-15b3-4f30-8f7b-52dd78481876_terseLabel_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementPendingRegulatoryApprovalNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pending regulatory approval, number of products</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementPendingRegulatoryApprovalNumberOfProducts_label_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementPendingRegulatoryApprovalNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License, Supply And Distribution Agreement, Pending Regulatory Approval, Number Of Products</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementPendingRegulatoryApprovalNumberOfProducts_documentation_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementPendingRegulatoryApprovalNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License, Supply And Distribution Agreement, Pending Regulatory Approval, Number Of Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementPendingRegulatoryApprovalNumberOfProducts" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementPendingRegulatoryApprovalNumberOfProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LicenseSupplyAndDistributionAgreementPendingRegulatoryApprovalNumberOfProducts" xlink:to="lab_eols_LicenseSupplyAndDistributionAgreementPendingRegulatoryApprovalNumberOfProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_548c1ba0-030a-4b8d-9098-36e0d96dc7b1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0066fc1f-d018-4b4b-95e2-974501567d21_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_40aaf4d7-0913-4995-a3ef-ddf693c611bb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock" xlink:to="lab_us-gaap_DebtPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_700940c9-b3b6-45e1-b7e5-f2a1c9efc986_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_865cd694-4d92-4ab8-956a-a0e24dc53330_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Present value of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_4c4ea2c4-aa0b-46e5-95fc-ddc9b8aa0bc0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_bdfe31e6-c878-4f6e-be8f-2dab19379c00_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_AccountsReceivableAllowanceForCreditLossWriteOffRecovery_843123c0-a8eb-4c69-9cf9-4c4c89a14f21_terseLabel_en-US" xlink:label="lab_eols_AccountsReceivableAllowanceForCreditLossWriteOffRecovery" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Write-off amount</link:label>
    <link:label id="lab_eols_AccountsReceivableAllowanceForCreditLossWriteOffRecovery_label_en-US" xlink:label="lab_eols_AccountsReceivableAllowanceForCreditLossWriteOffRecovery" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Write-off (Recovery)</link:label>
    <link:label id="lab_eols_AccountsReceivableAllowanceForCreditLossWriteOffRecovery_documentation_en-US" xlink:label="lab_eols_AccountsReceivableAllowanceForCreditLossWriteOffRecovery" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Write-off (Recovery)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_AccountsReceivableAllowanceForCreditLossWriteOffRecovery" xlink:href="eols-20241231.xsd#eols_AccountsReceivableAllowanceForCreditLossWriteOffRecovery"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_AccountsReceivableAllowanceForCreditLossWriteOffRecovery" xlink:to="lab_eols_AccountsReceivableAllowanceForCreditLossWriteOffRecovery" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_ddb58b54-b1ba-4df9-8bc8-1c17912fde82_terseLabel_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_label_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:href="eols-20241231.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_639d1526-8a18-4012-aafd-d4594980ef49_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_68b485b9-ac00-469d-9027-ccd602c59388_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_b1fb9477-8feb-4bd3-9b91-3351588ded20_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_b1018f67-5ab5-417f-a12f-498dab0f7729_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_a6aa9789-24ab-49b4-8662-c1342a0e3823_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Rate Differential</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_c680b33a-0e96-4fee-8291-d8bfcf554706_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_a755142a-1535-44cb-9f2d-6174a63b8daa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_2b7e36bf-4a58-4b19-9fab-8140ef8c48eb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_06b243b1-ea85-4ef5-84f9-b4762beb98b0_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, number of shares issued in transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_4fd7cce0-c09e-4b9a-8a75-fce4597e548a_netLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Term Loans</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_4607635c-d259-4125-8f12-4c2340a4768e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining amortization period</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_310666f6-cb01-41ba-b8e5-cab45d2a39b8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_c5067e9c-cac5-4a0a-a670-0f49499e0d8e_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_a8b2cf66-75d7-4f20-a77f-1760727962cc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_bfcae896-52ef-4640-8586-a4857bf5dfab_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon follow-on offering, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_74ba20ef-8ec5-47c2-b258-85c4dead13a3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_bb7f9617-b125-44cd-a672-e82eb7de057c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_24734566-10c1-41b8-a3cc-74cb5c95a568_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_87577551-fd71-4082-9638-c5f6155cbea4_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9bd5af78-52e4-4826-a771-d5fe15795714_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_95ddd10d-5741-495c-9235-9747dddbefec_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e351b21f-ab4b-4843-8a0a-07f75addf0f2_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_6f8a7980-1d0f-4784-a669-3ee42768fb88_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent royalty obligation payable to Evolus Founders</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree_9fab37bb-61a2-49fd-a983-fe291b921a7a_terseLabel_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License, supply and distribution agreement payment, June 2027 (in euro)</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree_label_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License, Supply and Distribution Agreement, Annual Payment, Year Three</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree_documentation_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License, Supply and Distribution Agreement, Annual Payment, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree" xlink:to="lab_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_e8b4e4a3-2639-4a66-b790-f80ac322be50_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_d236a645-78c5-4e9c-8c96-e87c679685e9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, $0.00001 par value; 100,000,000 shares authorized; 63,497,548 and 57,820,621 shares issued and outstanding at December&#160;31, 2024 and 2023, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_5e11478a-5c10-4f62-a20a-ef6b9d637dd8_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_742b93c2-0b83-4bc6-bd61-9a0a9be58ac1_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_CEOPerformanceRestrictedShareUnitsCPRSUMember_c2085735-78a5-4bff-ba3f-b1bf63bdd2c7_terseLabel_en-US" xlink:label="lab_eols_CEOPerformanceRestrictedShareUnitsCPRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CEO Performance Restricted Share Units (CPRSU)</link:label>
    <link:label id="lab_eols_CEOPerformanceRestrictedShareUnitsCPRSUMember_label_en-US" xlink:label="lab_eols_CEOPerformanceRestrictedShareUnitsCPRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CEO Performance Restricted Share Units (CPRSU) [Member]</link:label>
    <link:label id="lab_eols_CEOPerformanceRestrictedShareUnitsCPRSUMember_documentation_en-US" xlink:label="lab_eols_CEOPerformanceRestrictedShareUnitsCPRSUMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CEO Performance Restricted Share Units (CPRSU)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_CEOPerformanceRestrictedShareUnitsCPRSUMember" xlink:href="eols-20241231.xsd#eols_CEOPerformanceRestrictedShareUnitsCPRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_CEOPerformanceRestrictedShareUnitsCPRSUMember" xlink:to="lab_eols_CEOPerformanceRestrictedShareUnitsCPRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_ee91ebfd-a4d5-4468-ba97-46e576970723_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_aef4f8e8-e482-4f69-82e8-3510ed5c6130_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_628354fb-38d9-48ed-8f35-f360d621f4b4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7a0cc508-a80e-45be-a674-5aef72d91e8e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_5e84270e-1711-43eb-a283-2b16ab0fdcdb_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current provision:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_075b9265-8c5d-48dc-a252-5810eb19a67d_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_998cbf6c-a668-46a3-b2c2-26090fc453fb_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, $0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at December&#160;31, 2024 and 2023, respectively</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_6f7d5e6b-f615-4919-a0ce-0586e4f292da_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State income taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_70491045-d4eb-48e0-9629-5b8379b35725_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_4b6b5445-3438-47c7-bf5c-51b5ba2401f8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementIntangibleAsset_81292128-c37d-4f1f-89e0-871ff0d1b689_terseLabel_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementIntangibleAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License, supply and distribution agreement, intangible assets</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementIntangibleAsset_label_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementIntangibleAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License, Supply And Distribution Agreement, Intangible Asset</link:label>
    <link:label id="lab_eols_LicenseSupplyAndDistributionAgreementIntangibleAsset_documentation_en-US" xlink:label="lab_eols_LicenseSupplyAndDistributionAgreementIntangibleAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License, Supply And Distribution Agreement, Intangible Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementIntangibleAsset" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementIntangibleAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LicenseSupplyAndDistributionAgreementIntangibleAsset" xlink:to="lab_eols_LicenseSupplyAndDistributionAgreementIntangibleAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_c45b4995-3e85-4a02-b483-5918bb91b5be_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_5260c935-cfa1-4c9a-9d71-04a929433581_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_769604da-0f6e-4d6f-94c6-2c7f48b07e21_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_5eddea2c-add7-4507-9b17-2cd9cc1f5850_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_e04a8223-544e-4e1a-89ba-7b756b8118b6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_e87603ce-7310-4ef1-a69b-4dcdfbb9b125_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from follow-on offering, net of underwriting fees</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_8fb0550d-13a1-481d-9955-de9b27c3eb45_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligation_f63ee80f-01fc-4641-88b6-e522e71a5a74_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent royalty obligation payable to Evolus Founders</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_label_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="lab_us-gaap_ContractualObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b3d9e88d-1b90-49b8-9251-8f55220c1497_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment award, expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_965c8da3-b6a7-4b41-9a0e-ab572507fce1_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DeferredTaxAssetsResearchAndExperimentationCapitalization_3702c18c-e535-4051-9136-d47ed1c0097e_terseLabel_en-US" xlink:label="lab_eols_DeferredTaxAssetsResearchAndExperimentationCapitalization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">R&amp;E capitalization</link:label>
    <link:label id="lab_eols_DeferredTaxAssetsResearchAndExperimentationCapitalization_label_en-US" xlink:label="lab_eols_DeferredTaxAssetsResearchAndExperimentationCapitalization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Research and Experimentation Capitalization</link:label>
    <link:label id="lab_eols_DeferredTaxAssetsResearchAndExperimentationCapitalization_documentation_en-US" xlink:label="lab_eols_DeferredTaxAssetsResearchAndExperimentationCapitalization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Research and Experimentation Capitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DeferredTaxAssetsResearchAndExperimentationCapitalization" xlink:href="eols-20241231.xsd#eols_DeferredTaxAssetsResearchAndExperimentationCapitalization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DeferredTaxAssetsResearchAndExperimentationCapitalization" xlink:to="lab_eols_DeferredTaxAssetsResearchAndExperimentationCapitalization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_72018b93-0d26-4661-98e9-9171494ba8ec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual term</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_db5287e0-2ed1-44e5-bbad-000d9574d0d7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_d42b062c-7162-47e6-9c57-2e6aedee1607_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Intangible amortization</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_d90a18ad-d43c-46cd-9790-4826266660cf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_5a2b0d08-5822-42a4-bc6d-b3bbeae804d6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Definite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_7258903a-4d82-446e-ad63-4ae542082a2d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_IntangibleAssetsGrossIncludingGoodwill_abb72e86-6137-421a-a138-626a1da29384_totalLabel_en-US" xlink:label="lab_eols_IntangibleAssetsGrossIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, gross (including goodwill)</link:label>
    <link:label id="lab_eols_IntangibleAssetsGrossIncludingGoodwill_label_en-US" xlink:label="lab_eols_IntangibleAssetsGrossIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Including Goodwill)</link:label>
    <link:label id="lab_eols_IntangibleAssetsGrossIncludingGoodwill_documentation_en-US" xlink:label="lab_eols_IntangibleAssetsGrossIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IntangibleAssetsGrossIncludingGoodwill" xlink:href="eols-20241231.xsd#eols_IntangibleAssetsGrossIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_IntangibleAssetsGrossIncludingGoodwill" xlink:to="lab_eols_IntangibleAssetsGrossIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_8def6c70-a5bf-4ad9-a5f4-2f6280e2b4fb_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_ee1cc10e-9bca-46f9-b835-73bfb63628ff_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risks and Uncertainties and Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_339e1fbb-223a-468b-8cf4-ce87b6585d90_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_1e9593a1-7df6-463c-ac32-cd5d70298a42_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_e6752a98-8dc7-4572-bc69-46cfa812a9ff_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising Costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f35105a5-0a63-45d1-b025-d1b49de6a901_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_1178d950-cba1-46bd-997c-fce8d92ee54c_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5c5a2083-42a0-4e50-b5a1-a9239801b9e2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_f169992e-da06-4282-8ff7-b805661740a0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual increase percentage of maximum shares outstanding (equal to)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_NonCashInResearchAndDevelopmentInProcessExpenses_ed0e6183-7aef-44ad-b1b4-83943e1efd32_terseLabel_en-US" xlink:label="lab_eols_NonCashInResearchAndDevelopmentInProcessExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash in-process research and development expense</link:label>
    <link:label id="lab_eols_NonCashInResearchAndDevelopmentInProcessExpenses_label_en-US" xlink:label="lab_eols_NonCashInResearchAndDevelopmentInProcessExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-cash In Research And Development In Process Expenses</link:label>
    <link:label id="lab_eols_NonCashInResearchAndDevelopmentInProcessExpenses_documentation_en-US" xlink:label="lab_eols_NonCashInResearchAndDevelopmentInProcessExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-cash In Research And Development In Process Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_NonCashInResearchAndDevelopmentInProcessExpenses" xlink:href="eols-20241231.xsd#eols_NonCashInResearchAndDevelopmentInProcessExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_NonCashInResearchAndDevelopmentInProcessExpenses" xlink:to="lab_eols_NonCashInResearchAndDevelopmentInProcessExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_b9152210-9c48-4214-95ca-5ab01571578c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 9)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_8b802f8e-84b8-4f89-8f08-9f938d83bbb6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_bda62c69-2ac2-455a-a506-1a5ed4be7ed6_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued royalties under the Medytox Settlement Agreements</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_54034fe7-f173-4843-8aad-55f2307d6c8c_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued royalties under the medytox settlement agreements</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_394251d9-720d-4d50-821c-34d9bbe36639_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_PerformanceRestrictedStockUnitsPRSUMember_518335ff-d3ae-4a0f-808f-6331f1339482_terseLabel_en-US" xlink:label="lab_eols_PerformanceRestrictedStockUnitsPRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Restricted Stock Units (PRSU)</link:label>
    <link:label id="lab_eols_PerformanceRestrictedStockUnitsPRSUMember_label_en-US" xlink:label="lab_eols_PerformanceRestrictedStockUnitsPRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Restricted Stock Units (PRSU) [Member]</link:label>
    <link:label id="lab_eols_PerformanceRestrictedStockUnitsPRSUMember_documentation_en-US" xlink:label="lab_eols_PerformanceRestrictedStockUnitsPRSUMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Restricted Stock Units (PRSU)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PerformanceRestrictedStockUnitsPRSUMember" xlink:href="eols-20241231.xsd#eols_PerformanceRestrictedStockUnitsPRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_PerformanceRestrictedStockUnitsPRSUMember" xlink:to="lab_eols_PerformanceRestrictedStockUnitsPRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4b0f96fa-e529-4b1c-b83c-62f8b84e717e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_876c84d3-a0fa-4be7-9eaa-7cdaa6a78082_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_f28adba8-6355-4230-8a1d-a9025d5681ea_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DistributionRightsEvolysseProductsMember_199b6f58-fd97-4a39-85f6-d42014ade2b5_terseLabel_en-US" xlink:label="lab_eols_DistributionRightsEvolysseProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distribution Rights, Evolysse Products</link:label>
    <link:label id="lab_eols_DistributionRightsEvolysseProductsMember_label_en-US" xlink:label="lab_eols_DistributionRightsEvolysseProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distribution Rights, Evolysse Products [Member]</link:label>
    <link:label id="lab_eols_DistributionRightsEvolysseProductsMember_documentation_en-US" xlink:label="lab_eols_DistributionRightsEvolysseProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Distribution Rights, Evolysse Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DistributionRightsEvolysseProductsMember" xlink:href="eols-20241231.xsd#eols_DistributionRightsEvolysseProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DistributionRightsEvolysseProductsMember" xlink:to="lab_eols_DistributionRightsEvolysseProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_61ac4b7e-84ed-4932-9eff-6ccba909123e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Country</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_0e29bb98-b54a-4a8c-a606-21640ab30b82_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_62a5cc2b-a4ad-426f-b291-b91ddf86166f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of long-term debt, net of discounts</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_43cfeaa2-be9a-4f27-8c22-5dba2cd59b23_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_da4dac13-2e2c-487c-834c-d6153ea3211f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3e6546d4-a6a0-4db8-8596-1c09a9b318a0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Options Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_eeebedaf-3ce0-4ab9-8659-f62accc11803_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_4bd2472d-2577-4b76-b107-738e388803c8_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_923bf934-57a9-4a35-9f78-9e432ae013cc_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_6ae6434c-eb1b-4800-b62e-e921a70b8a5a_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f86baa40-4478-4c84-8c5b-70624d2af006_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_2c48ff8c-41af-4192-8780-06789c658254_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_86ea0b00-31d4-4d05-880a-b8e047337383_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c750d505-ec4f-4f8a-9fb6-29ca3e7219ef_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_9356566f-5c11-4af7-9e8d-ccab95e4a361_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_f4d25c76-8a33-4746-9a2f-02f99ccb9fbc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_c75243d3-c934-40ae-b07a-88e44688d9e6_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Tax Jurisdiction</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_fd3db625-ac8f-4bb7-b7ea-880b2a393018_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_fe29e0e8-8348-49ea-801d-fd5648e0ab3c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_LossContingencySettlementAgreementPaymentTerms_c897bf1f-81bf-40ba-bfc2-b080d1613ff3_terseLabel_en-US" xlink:label="lab_eols_LossContingencySettlementAgreementPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlement agreement, payment terms (in years)</link:label>
    <link:label id="lab_eols_LossContingencySettlementAgreementPaymentTerms_label_en-US" xlink:label="lab_eols_LossContingencySettlementAgreementPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Settlement Agreement, Payment Terms</link:label>
    <link:label id="lab_eols_LossContingencySettlementAgreementPaymentTerms_documentation_en-US" xlink:label="lab_eols_LossContingencySettlementAgreementPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Settlement Agreement, Payment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LossContingencySettlementAgreementPaymentTerms" xlink:href="eols-20241231.xsd#eols_LossContingencySettlementAgreementPaymentTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LossContingencySettlementAgreementPaymentTerms" xlink:to="lab_eols_LossContingencySettlementAgreementPaymentTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_a84607e3-4e7f-46fb-a224-3068f308eb0f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_45603fb0-6596-4c05-8f7a-88ad3c6cfb45_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_58e23c89-8bf8-4f00-9bca-092fa5443078_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_e1a844dc-8cb0-42a1-8087-f06876c1df7b_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_2a0ddb54-6417-4e6b-bf8b-e9f251d94531_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived intangible asset</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_43900a62-ef56-4409-8afb-a31ff22e599d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_15ed3a4f-4502-4288-880e-1cfe4a363484_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rates on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_44791181-c664-4701-8cd2-7080f76de6f1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_7ac7b4fd-9877-4b75-9f69-93fe5a9f4620_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_aba90714-a1dc-4cf0-98d0-3370a06aef25_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_278de8ff-c216-49fe-b682-633ee28cd6e1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DeferredTaxAssetsOperatingLeaseLiabilities_8f703fe1-aa86-481a-8cf4-28feeab2d77e_terseLabel_en-US" xlink:label="lab_eols_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_eols_DeferredTaxAssetsOperatingLeaseLiabilities_label_en-US" xlink:label="lab_eols_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Operating Lease Liabilities</link:label>
    <link:label id="lab_eols_DeferredTaxAssetsOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_eols_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:href="eols-20241231.xsd#eols_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="lab_eols_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_d11aaccf-ad5e-4a6f-85b5-dde70f1257b4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease term (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_SCHAEONLLCMember_53e2e227-0a07-437c-8f98-cab65e79dfc1_terseLabel_en-US" xlink:label="lab_eols_SCHAEONLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SCH</link:label>
    <link:label id="lab_eols_SCHAEONLLCMember_label_en-US" xlink:label="lab_eols_SCHAEONLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SCH-AEON, LLC [Member]</link:label>
    <link:label id="lab_eols_SCHAEONLLCMember_documentation_en-US" xlink:label="lab_eols_SCHAEONLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SCH-AEON, LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SCHAEONLLCMember" xlink:href="eols-20241231.xsd#eols_SCHAEONLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_SCHAEONLLCMember" xlink:to="lab_eols_SCHAEONLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_cef483b8-fe5d-4e3b-96a2-6069faec1cd6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_e18522e3-f7a1-4b67-a1e0-30dc02a9fd37_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_a35ade88-d0e9-4b05-bdd0-9046d4bd30a6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_96f99899-ce94-469f-a777-ae48b6afd5dc_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9fb2be3a-09b9-4f86-856c-d8b558156a30_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_16dacba5-78dc-471e-8e08-0c5dd3ff408e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_ed45bc59-70af-4eab-99f3-8c96a36d3a5b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Meals and entertainment</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Meals and Entertainment, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_a961afc5-ff7c-4c41-a361-f511a41a8b5b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b5c21bbe-3f4b-4e3a-a320-873b9ca86300_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_MilestoneAxis_c15fb5be-4633-4ed4-be94-2fa8c53fe73c_terseLabel_en-US" xlink:label="lab_eols_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:label id="lab_eols_MilestoneAxis_label_en-US" xlink:label="lab_eols_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:label id="lab_eols_MilestoneAxis_documentation_en-US" xlink:label="lab_eols_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_MilestoneAxis" xlink:href="eols-20241231.xsd#eols_MilestoneAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_MilestoneAxis" xlink:to="lab_eols_MilestoneAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DistributionRightsEvolysseNasolabialFoldProductMember_ea6a4bc4-107b-4f99-affc-ce4a078b5c00_terseLabel_en-US" xlink:label="lab_eols_DistributionRightsEvolysseNasolabialFoldProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distribution Rights, Evolysse Nasolabial Fold Product</link:label>
    <link:label id="lab_eols_DistributionRightsEvolysseNasolabialFoldProductMember_label_en-US" xlink:label="lab_eols_DistributionRightsEvolysseNasolabialFoldProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distribution Rights, Evolysse Nasolabial Fold Product [Member]</link:label>
    <link:label id="lab_eols_DistributionRightsEvolysseNasolabialFoldProductMember_documentation_en-US" xlink:label="lab_eols_DistributionRightsEvolysseNasolabialFoldProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Distribution Rights, Evolysse Nasolabial Fold Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DistributionRightsEvolysseNasolabialFoldProductMember" xlink:href="eols-20241231.xsd#eols_DistributionRightsEvolysseNasolabialFoldProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DistributionRightsEvolysseNasolabialFoldProductMember" xlink:to="lab_eols_DistributionRightsEvolysseNasolabialFoldProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_IntellectualPropertyDisputesJeuveauMember_4f28eaf1-6c7c-4bc2-834f-75c80ccff794_terseLabel_en-US" xlink:label="lab_eols_IntellectualPropertyDisputesJeuveauMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intellectual Property Disputes, Jeuveau</link:label>
    <link:label id="lab_eols_IntellectualPropertyDisputesJeuveauMember_label_en-US" xlink:label="lab_eols_IntellectualPropertyDisputesJeuveauMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intellectual Property Disputes, Jeuveau [Member]</link:label>
    <link:label id="lab_eols_IntellectualPropertyDisputesJeuveauMember_documentation_en-US" xlink:label="lab_eols_IntellectualPropertyDisputesJeuveauMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intellectual Property Disputes, Jeuveau</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IntellectualPropertyDisputesJeuveauMember" xlink:href="eols-20241231.xsd#eols_IntellectualPropertyDisputesJeuveauMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_IntellectualPropertyDisputesJeuveauMember" xlink:to="lab_eols_IntellectualPropertyDisputesJeuveauMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_StockIssuedDuringPeriodSharesLitigationSettlement_23bc2909-7ea7-41d2-8719-6a38956b76e1_terseLabel_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodSharesLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with litigation settlement (in shares)</link:label>
    <link:label id="lab_eols_StockIssuedDuringPeriodSharesLitigationSettlement_label_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodSharesLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Shares Litigation Settlement</link:label>
    <link:label id="lab_eols_StockIssuedDuringPeriodSharesLitigationSettlement_documentation_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodSharesLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Shares, Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement" xlink:href="eols-20241231.xsd#eols_StockIssuedDuringPeriodSharesLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement" xlink:to="lab_eols_StockIssuedDuringPeriodSharesLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e295930b-c2e9-49ce-8f60-57d715a213ce_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with customer, liability, revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_LesseeOperatingLeaseAbatementPeriod_d76a8d9e-70d2-427e-b1bb-201871b3b4d3_terseLabel_en-US" xlink:label="lab_eols_LesseeOperatingLeaseAbatementPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, operating lease, abatement period</link:label>
    <link:label id="lab_eols_LesseeOperatingLeaseAbatementPeriod_label_en-US" xlink:label="lab_eols_LesseeOperatingLeaseAbatementPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Abatement Period</link:label>
    <link:label id="lab_eols_LesseeOperatingLeaseAbatementPeriod_documentation_en-US" xlink:label="lab_eols_LesseeOperatingLeaseAbatementPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Abatement Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LesseeOperatingLeaseAbatementPeriod" xlink:href="eols-20241231.xsd#eols_LesseeOperatingLeaseAbatementPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LesseeOperatingLeaseAbatementPeriod" xlink:to="lab_eols_LesseeOperatingLeaseAbatementPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList_15b4e2f7-9ba3-4f25-b184-6d7391e8a21f_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost, Product and Service [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList_label_en-US" xlink:label="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost, Product and Service [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfCostGoodOrServiceExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:to="lab_us-gaap_TypeOfCostGoodOrServiceExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_SymateseU.S.AgreementMember_9dac9512-ee55-4c2f-b7ee-e42ce9022b86_terseLabel_en-US" xlink:label="lab_eols_SymateseU.S.AgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Symatese U.S. Agreement</link:label>
    <link:label id="lab_eols_SymateseU.S.AgreementMember_label_en-US" xlink:label="lab_eols_SymateseU.S.AgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Symatese U.S. Agreement [Member]</link:label>
    <link:label id="lab_eols_SymateseU.S.AgreementMember_documentation_en-US" xlink:label="lab_eols_SymateseU.S.AgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Symatese U.S. Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SymateseU.S.AgreementMember" xlink:href="eols-20241231.xsd#eols_SymateseU.S.AgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_SymateseU.S.AgreementMember" xlink:to="lab_eols_SymateseU.S.AgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_32d14c6c-6e02-4126-a8b4-a7583184710e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_46f39368-1213-4e05-8e69-af3a7e69c8fe_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_65915d3f-1472-4dec-af44-b13bd4622cf1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_8dbbedfe-304c-43b6-835c-bbed75bf0d57_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_d016fb18-e575-41c7-93e9-e4b24d272b08_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d50c3925-d200-473e-a3b0-e892f4ec5c4b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_403b807d-6d10-4fc9-80b0-951d5b315fe5_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_eea3b4a3-f45a-483e-b5a9-ac334032b5dc_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_09543078-1fb2-4b6f-a6ec-399c24289237_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DebtInstrumentNumberOfTranches_f91165dc-f996-4234-bcbc-b90102b666bb_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of tranches</link:label>
    <link:label id="lab_eols_DebtInstrumentNumberOfTranches_label_en-US" xlink:label="lab_eols_DebtInstrumentNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number of Tranches</link:label>
    <link:label id="lab_eols_DebtInstrumentNumberOfTranches_documentation_en-US" xlink:label="lab_eols_DebtInstrumentNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number of Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentNumberOfTranches" xlink:href="eols-20241231.xsd#eols_DebtInstrumentNumberOfTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentNumberOfTranches" xlink:to="lab_eols_DebtInstrumentNumberOfTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0f62af97-f7ec-4162-ba2e-fbd63cd986b1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares outstanding used to compute basic net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForSoftware_3436ef3a-f87d-4abd-a171-5fa45d25f19b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForSoftware" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Additions to capitalized software</link:label>
    <link:label id="lab_us-gaap_PaymentsForSoftware_label_en-US" xlink:label="lab_us-gaap_PaymentsForSoftware" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForSoftware" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForSoftware"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForSoftware" xlink:to="lab_us-gaap_PaymentsForSoftware" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_dee9c5b2-5416-43ba-9a33-589b322e4c86_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_ba0c855d-0dbc-4f91-b7e2-a2af50de3c55_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unvested Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_cb01815d-8607-48d3-b187-5cf37cdd6bd8_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_5a2a0d06-a28a-479c-9857-13f3439bd0d0_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_58267941-7445-445e-acf5-0151d955e3b4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_DeferredTaxAssetsFixedAssetDepreciation_9c995619-d4fb-4d95-be61-a5ea2e661e3e_terseLabel_en-US" xlink:label="lab_eols_DeferredTaxAssetsFixedAssetDepreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed asset depreciation</link:label>
    <link:label id="lab_eols_DeferredTaxAssetsFixedAssetDepreciation_label_en-US" xlink:label="lab_eols_DeferredTaxAssetsFixedAssetDepreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Fixed Asset Depreciation</link:label>
    <link:label id="lab_eols_DeferredTaxAssetsFixedAssetDepreciation_documentation_en-US" xlink:label="lab_eols_DeferredTaxAssetsFixedAssetDepreciation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Fixed Asset Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DeferredTaxAssetsFixedAssetDepreciation" xlink:href="eols-20241231.xsd#eols_DeferredTaxAssetsFixedAssetDepreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DeferredTaxAssetsFixedAssetDepreciation" xlink:to="lab_eols_DeferredTaxAssetsFixedAssetDepreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_86bc3548-cd49-4611-9fda-fd3ae377b372_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cancelled/forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_7c62fa9f-7b8b-4918-9f5a-dda500d9b136_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Current and Deferred Income Tax Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_7217ff51-5c68-41ab-b7e3-c3e5262ba2ac_terseLabel_en-US" xlink:label="lab_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent royalty obligation payable to Evolus Founders</link:label>
    <link:label id="lab_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_label_en-US" xlink:label="lab_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Royalty Obligation Payable to Related Party, Current</link:label>
    <link:label id="lab_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_documentation_en-US" xlink:label="lab_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Royalty Obligation Payable to Related Party, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" xlink:href="eols-20241231.xsd#eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" xlink:to="lab_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_d62554dd-4697-4ccd-ab91-c93a5b8f2707_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_c9e9ce6e-6530-4fc7-987c-c1844c10ebc9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards, subject to expiration</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_fe30a7bd-4096-49e8-99c2-8723630cb91a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_28034e0a-397b-4e7f-9708-243dd8b17ab1_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>eols-20241231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:919f993d-eaea-4622-b01f-fde76d4f5f0d,g:96b2bf92-d476-42b7-9d6e-4ee6308f0735-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.evolus.com/role/Cover" xlink:type="simple" xlink:href="eols-20241231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_3d0ec5d0-c937-4357-8b3d-41eb82984ac3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_5335dded-4c5d-4175-8a60-401b3e8184c0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0ec5d0-c937-4357-8b3d-41eb82984ac3" xlink:to="loc_dei_DocumentType_5335dded-4c5d-4175-8a60-401b3e8184c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_4a46d5c0-bf01-4834-98b3-728d750846b0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0ec5d0-c937-4357-8b3d-41eb82984ac3" xlink:to="loc_dei_DocumentAnnualReport_4a46d5c0-bf01-4834-98b3-728d750846b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_6eb06558-7998-461e-8889-f704b3891038" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0ec5d0-c937-4357-8b3d-41eb82984ac3" xlink:to="loc_dei_DocumentPeriodEndDate_6eb06558-7998-461e-8889-f704b3891038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_f70fa021-66b8-4bf5-95f4-578002186899" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0ec5d0-c937-4357-8b3d-41eb82984ac3" xlink:to="loc_dei_CurrentFiscalYearEndDate_f70fa021-66b8-4bf5-95f4-578002186899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_f766b6d7-5b58-42a8-83d3-db640221bc2b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0ec5d0-c937-4357-8b3d-41eb82984ac3" xlink:to="loc_dei_DocumentTransitionReport_f766b6d7-5b58-42a8-83d3-db640221bc2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_610e1ef7-ebc2-4b06-a759-22c9c28b3212" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0ec5d0-c937-4357-8b3d-41eb82984ac3" xlink:to="loc_dei_EntityFileNumber_610e1ef7-ebc2-4b06-a759-22c9c28b3212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_9ca91bee-877c-4569-ad3b-35c3bc6410e7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0ec5d0-c937-4357-8b3d-41eb82984ac3" xlink:to="loc_dei_EntityRegistrantName_9ca91bee-877c-4569-ad3b-35c3bc6410e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_af807864-7ea6-483b-ab11-a63a605fd10b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0ec5d0-c937-4357-8b3d-41eb82984ac3" xlink:to="loc_dei_EntityIncorporationStateCountryCode_af807864-7ea6-483b-ab11-a63a605fd10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_77d73367-14c7-4a7c-823b-b5f25cc98ff3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0ec5d0-c937-4357-8b3d-41eb82984ac3" xlink:to="loc_dei_EntityTaxIdentificationNumber_77d73367-14c7-4a7c-823b-b5f25cc98ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_759b4cf2-3f60-4a92-a1e5-1c4cac112935" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0ec5d0-c937-4357-8b3d-41eb82984ac3" xlink:to="loc_dei_EntityAddressAddressLine1_759b4cf2-3f60-4a92-a1e5-1c4cac112935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_294fc592-b344-4708-9bfc-b33e61ba5311" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0ec5d0-c937-4357-8b3d-41eb82984ac3" xlink:to="loc_dei_EntityAddressCityOrTown_294fc592-b344-4708-9bfc-b33e61ba5311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_1917b30c-59a9-427a-ae23-c4027312eee0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0ec5d0-c937-4357-8b3d-41eb82984ac3" xlink:to="loc_dei_EntityAddressStateOrProvince_1917b30c-59a9-427a-ae23-c4027312eee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_eecc0a52-9b94-40bd-9074-5fa602f6d07e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0ec5d0-c937-4357-8b3d-41eb82984ac3" xlink:to="loc_dei_EntityAddressPostalZipCode_eecc0a52-9b94-40bd-9074-5fa602f6d07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_4237667d-24f7-4d23-ae29-4eb2476949c6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0ec5d0-c937-4357-8b3d-41eb82984ac3" xlink:to="loc_dei_CityAreaCode_4237667d-24f7-4d23-ae29-4eb2476949c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_b426ca98-e8a8-4732-b223-4e9d3e4e75e5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0ec5d0-c937-4357-8b3d-41eb82984ac3" xlink:to="loc_dei_LocalPhoneNumber_b426ca98-e8a8-4732-b223-4e9d3e4e75e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_1f0f2cc7-da2f-46cd-80bf-d54c571fddf8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0ec5d0-c937-4357-8b3d-41eb82984ac3" xlink:to="loc_dei_Security12bTitle_1f0f2cc7-da2f-46cd-80bf-d54c571fddf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_9295ab40-99a1-4c73-8b3c-8a2ed07bd5e2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0ec5d0-c937-4357-8b3d-41eb82984ac3" xlink:to="loc_dei_TradingSymbol_9295ab40-99a1-4c73-8b3c-8a2ed07bd5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_7f932926-f4f4-4b05-94d2-ededb0f52803" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0ec5d0-c937-4357-8b3d-41eb82984ac3" xlink:to="loc_dei_SecurityExchangeName_7f932926-f4f4-4b05-94d2-ededb0f52803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_e4c552cb-9291-43fe-8f2d-886fdce2c816" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0ec5d0-c937-4357-8b3d-41eb82984ac3" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_e4c552cb-9291-43fe-8f2d-886fdce2c816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_446ec54d-d1f1-4398-b231-dee486bb77dc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0ec5d0-c937-4357-8b3d-41eb82984ac3" xlink:to="loc_dei_EntityVoluntaryFilers_446ec54d-d1f1-4398-b231-dee486bb77dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_130ff88d-9b21-48f2-8f74-93b125df1d0c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0ec5d0-c937-4357-8b3d-41eb82984ac3" xlink:to="loc_dei_EntityCurrentReportingStatus_130ff88d-9b21-48f2-8f74-93b125df1d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_7614bc8c-5aa5-4737-9ed5-5f23295d03c3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0ec5d0-c937-4357-8b3d-41eb82984ac3" xlink:to="loc_dei_EntityInteractiveDataCurrent_7614bc8c-5aa5-4737-9ed5-5f23295d03c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_9a288e13-e562-45ce-a277-4b28f9596462" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0ec5d0-c937-4357-8b3d-41eb82984ac3" xlink:to="loc_dei_EntityFilerCategory_9a288e13-e562-45ce-a277-4b28f9596462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_21966b07-42d5-4358-bfb6-bf0ce8ba8cdc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0ec5d0-c937-4357-8b3d-41eb82984ac3" xlink:to="loc_dei_EntitySmallBusiness_21966b07-42d5-4358-bfb6-bf0ce8ba8cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_0aa327e6-1356-45aa-97a4-8809ad2320e3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0ec5d0-c937-4357-8b3d-41eb82984ac3" xlink:to="loc_dei_EntityEmergingGrowthCompany_0aa327e6-1356-45aa-97a4-8809ad2320e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_fa1ce439-9869-4959-822f-fdf3746f91c7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0ec5d0-c937-4357-8b3d-41eb82984ac3" xlink:to="loc_dei_IcfrAuditorAttestationFlag_fa1ce439-9869-4959-822f-fdf3746f91c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_35bd6e51-7b43-45bf-af1e-d429440b7440" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0ec5d0-c937-4357-8b3d-41eb82984ac3" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_35bd6e51-7b43-45bf-af1e-d429440b7440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_6abcf3d6-a846-4715-8409-bd69d2f72de0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0ec5d0-c937-4357-8b3d-41eb82984ac3" xlink:to="loc_dei_EntityShellCompany_6abcf3d6-a846-4715-8409-bd69d2f72de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_5e7b730e-a436-4922-855a-21cc0d5e0fd0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0ec5d0-c937-4357-8b3d-41eb82984ac3" xlink:to="loc_dei_EntityPublicFloat_5e7b730e-a436-4922-855a-21cc0d5e0fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_afd60b07-52e1-424a-9bbc-c441c3cbdd4a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0ec5d0-c937-4357-8b3d-41eb82984ac3" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_afd60b07-52e1-424a-9bbc-c441c3cbdd4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_753a0d28-9c23-41b2-887a-8c0162b6fdf1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0ec5d0-c937-4357-8b3d-41eb82984ac3" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_753a0d28-9c23-41b2-887a-8c0162b6fdf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_2419ad64-2221-4218-af92-fe338771bae5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0ec5d0-c937-4357-8b3d-41eb82984ac3" xlink:to="loc_dei_AmendmentFlag_2419ad64-2221-4218-af92-fe338771bae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_1997243b-d89f-4a68-912d-70417a5caaec" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0ec5d0-c937-4357-8b3d-41eb82984ac3" xlink:to="loc_dei_DocumentFiscalYearFocus_1997243b-d89f-4a68-912d-70417a5caaec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_39d32007-720f-4cec-979e-09d5e6d18e6e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0ec5d0-c937-4357-8b3d-41eb82984ac3" xlink:to="loc_dei_DocumentFiscalPeriodFocus_39d32007-720f-4cec-979e-09d5e6d18e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_4c1b8822-4d2d-40e1-af79-c665d5550353" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3d0ec5d0-c937-4357-8b3d-41eb82984ac3" xlink:to="loc_dei_EntityCentralIndexKey_4c1b8822-4d2d-40e1-af79-c665d5550353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/AuditInformation" xlink:type="simple" xlink:href="eols-20241231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_eols_AuditInformationAbstract_5d6dc085-51af-4cb1-9b5a-8dd253c650ff" xlink:href="eols-20241231.xsd#eols_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_643691ff-11df-45a3-9692-243627fe64c8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AuditInformationAbstract_5d6dc085-51af-4cb1-9b5a-8dd253c650ff" xlink:to="loc_dei_AuditorFirmId_643691ff-11df-45a3-9692-243627fe64c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_fc073e21-0542-48cc-983d-4596b3813e00" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AuditInformationAbstract_5d6dc085-51af-4cb1-9b5a-8dd253c650ff" xlink:to="loc_dei_AuditorName_fc073e21-0542-48cc-983d-4596b3813e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_9806c4c0-3334-4361-8b53-fd533ae443ed" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_AuditInformationAbstract_5d6dc085-51af-4cb1-9b5a-8dd253c650ff" xlink:to="loc_dei_AuditorLocation_9806c4c0-3334-4361-8b53-fd533ae443ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="eols-20241231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b507296a-d2a3-440a-a853-85055b3e6acb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_b4222c43-72f0-4697-be6e-014389e547a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b507296a-d2a3-440a-a853-85055b3e6acb" xlink:to="loc_us-gaap_AssetsAbstract_b4222c43-72f0-4697-be6e-014389e547a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_f4f48b50-c8ab-4575-94b1-470057fbefde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b4222c43-72f0-4697-be6e-014389e547a1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_f4f48b50-c8ab-4575-94b1-470057fbefde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_08fea606-c54d-481f-bc3c-e85328ee18bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f4f48b50-c8ab-4575-94b1-470057fbefde" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_08fea606-c54d-481f-bc3c-e85328ee18bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2f43d477-eb61-403b-ad00-80d7723d7465" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f4f48b50-c8ab-4575-94b1-470057fbefde" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2f43d477-eb61-403b-ad00-80d7723d7465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d5cf8335-692b-4a3b-b5a5-06b674037743" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f4f48b50-c8ab-4575-94b1-470057fbefde" xlink:to="loc_us-gaap_InventoryNet_d5cf8335-692b-4a3b-b5a5-06b674037743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_d8215a64-2b2b-4c18-bfb6-aa1f3d0375df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f4f48b50-c8ab-4575-94b1-470057fbefde" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_d8215a64-2b2b-4c18-bfb6-aa1f3d0375df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_a6edf711-bc53-4809-995d-33c1d4a81585" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f4f48b50-c8ab-4575-94b1-470057fbefde" xlink:to="loc_us-gaap_OtherAssetsCurrent_a6edf711-bc53-4809-995d-33c1d4a81585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_01fbe38c-41e4-4d4f-9d24-79e5a50525a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_f4f48b50-c8ab-4575-94b1-470057fbefde" xlink:to="loc_us-gaap_AssetsCurrent_01fbe38c-41e4-4d4f-9d24-79e5a50525a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d23b2b95-1352-4aea-97d3-b9dbca8c2c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b4222c43-72f0-4697-be6e-014389e547a1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d23b2b95-1352-4aea-97d3-b9dbca8c2c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6e0ccf70-f02c-4983-a4fc-9fb727f0c1c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b4222c43-72f0-4697-be6e-014389e547a1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6e0ccf70-f02c-4983-a4fc-9fb727f0c1c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5204c0ef-7155-4228-8d2c-8d1e996b075a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b4222c43-72f0-4697-be6e-014389e547a1" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5204c0ef-7155-4228-8d2c-8d1e996b075a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6ef94d98-ead4-49ca-84ea-69a5b8cc0bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b4222c43-72f0-4697-be6e-014389e547a1" xlink:to="loc_us-gaap_Goodwill_6ef94d98-ead4-49ca-84ea-69a5b8cc0bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1c593ada-6228-46a1-ac7c-9e116845a88d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b4222c43-72f0-4697-be6e-014389e547a1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1c593ada-6228-46a1-ac7c-9e116845a88d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ccb0c920-f986-4ccb-9f84-2c9e2536a9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b4222c43-72f0-4697-be6e-014389e547a1" xlink:to="loc_us-gaap_Assets_ccb0c920-f986-4ccb-9f84-2c9e2536a9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2fa4ee16-bc6f-4781-8ebb-41876af6d282" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b507296a-d2a3-440a-a853-85055b3e6acb" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2fa4ee16-bc6f-4781-8ebb-41876af6d282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_92ee2649-0bab-4072-beae-59580e608dde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2fa4ee16-bc6f-4781-8ebb-41876af6d282" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_92ee2649-0bab-4072-beae-59580e608dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_4d22d40d-743c-4948-a9bf-2ad0c9e686d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_92ee2649-0bab-4072-beae-59580e608dde" xlink:to="loc_us-gaap_AccountsPayableCurrent_4d22d40d-743c-4948-a9bf-2ad0c9e686d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_50d631a2-9cf0-4bc7-aa31-454ca6d7a60b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_92ee2649-0bab-4072-beae-59580e608dde" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_50d631a2-9cf0-4bc7-aa31-454ca6d7a60b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_91fa9461-c42b-4e01-9036-5715ff610f86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_92ee2649-0bab-4072-beae-59580e608dde" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_91fa9461-c42b-4e01-9036-5715ff610f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_2292d657-e980-4c19-a298-596da34afd49" xlink:href="eols-20241231.xsd#eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_92ee2649-0bab-4072-beae-59580e608dde" xlink:to="loc_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_2292d657-e980-4c19-a298-596da34afd49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_19338286-5b63-4ea3-bbe8-3b3cf0927e54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_92ee2649-0bab-4072-beae-59580e608dde" xlink:to="loc_us-gaap_LiabilitiesCurrent_19338286-5b63-4ea3-bbe8-3b3cf0927e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0c5c444f-5f04-4b2f-96cf-56ff6b9fda40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2fa4ee16-bc6f-4781-8ebb-41876af6d282" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0c5c444f-5f04-4b2f-96cf-56ff6b9fda40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_a70224c9-691e-4e6e-9f1b-a1b8a8bcd832" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2fa4ee16-bc6f-4781-8ebb-41876af6d282" xlink:to="loc_us-gaap_ContractualObligation_a70224c9-691e-4e6e-9f1b-a1b8a8bcd832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt_51a6c2a0-1422-42fd-8136-fb4e4e7a6f64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2fa4ee16-bc6f-4781-8ebb-41876af6d282" xlink:to="loc_us-gaap_SecuredLongTermDebt_51a6c2a0-1422-42fd-8136-fb4e4e7a6f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementContingentMilestoneLiabilityNoncurrent_9b85e8cc-0d13-46af-9608-ae36f2048a7c" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementContingentMilestoneLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2fa4ee16-bc6f-4781-8ebb-41876af6d282" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementContingentMilestoneLiabilityNoncurrent_9b85e8cc-0d13-46af-9608-ae36f2048a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_9c5bc185-036a-459d-8a4f-aa60c782fc9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2fa4ee16-bc6f-4781-8ebb-41876af6d282" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_9c5bc185-036a-459d-8a4f-aa60c782fc9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2385b926-fab2-4937-9394-c203fe4f394a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2fa4ee16-bc6f-4781-8ebb-41876af6d282" xlink:to="loc_us-gaap_Liabilities_2385b926-fab2-4937-9394-c203fe4f394a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e9a7cec4-d62c-4f38-870a-8a8ee2e12527" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2fa4ee16-bc6f-4781-8ebb-41876af6d282" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e9a7cec4-d62c-4f38-870a-8a8ee2e12527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_d2c529d9-de09-4e85-96bc-e6e4bcad3cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2fa4ee16-bc6f-4781-8ebb-41876af6d282" xlink:to="loc_us-gaap_StockholdersEquityAbstract_d2c529d9-de09-4e85-96bc-e6e4bcad3cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_d878c65d-952b-4cf6-9d1e-72dc855c6fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d2c529d9-de09-4e85-96bc-e6e4bcad3cfc" xlink:to="loc_us-gaap_PreferredStockValue_d878c65d-952b-4cf6-9d1e-72dc855c6fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_02742d6a-7d5c-4b7e-8049-3bd0519ddeec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d2c529d9-de09-4e85-96bc-e6e4bcad3cfc" xlink:to="loc_us-gaap_CommonStockValue_02742d6a-7d5c-4b7e-8049-3bd0519ddeec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_cdaba666-6333-4bb1-8dc6-fd17cf5a1dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d2c529d9-de09-4e85-96bc-e6e4bcad3cfc" xlink:to="loc_us-gaap_AdditionalPaidInCapital_cdaba666-6333-4bb1-8dc6-fd17cf5a1dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2ffc3936-bc66-4a1f-9baf-23ea54b2275b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d2c529d9-de09-4e85-96bc-e6e4bcad3cfc" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2ffc3936-bc66-4a1f-9baf-23ea54b2275b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a7c8897c-0a33-4d79-90cf-12e6e3d44f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d2c529d9-de09-4e85-96bc-e6e4bcad3cfc" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a7c8897c-0a33-4d79-90cf-12e6e3d44f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4a4de8ad-5044-452f-8a05-664b198eaafc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_d2c529d9-de09-4e85-96bc-e6e4bcad3cfc" xlink:to="loc_us-gaap_StockholdersEquity_4a4de8ad-5044-452f-8a05-664b198eaafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_16bf6a2e-da1f-4fdf-b721-9368bec62559" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2fa4ee16-bc6f-4781-8ebb-41876af6d282" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_16bf6a2e-da1f-4fdf-b721-9368bec62559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="eols-20241231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_d61d0c0b-0ea7-4bc4-9278-49c5bca14739" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6ae0758a-00fe-440c-a86a-783b736c452b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d61d0c0b-0ea7-4bc4-9278-49c5bca14739" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6ae0758a-00fe-440c-a86a-783b736c452b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_0ba15e69-d2c9-411b-97b2-9f3768ad0ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d61d0c0b-0ea7-4bc4-9278-49c5bca14739" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_0ba15e69-d2c9-411b-97b2-9f3768ad0ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_acb76953-a52f-4c2a-aca3-6ad55fb11b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d61d0c0b-0ea7-4bc4-9278-49c5bca14739" xlink:to="loc_us-gaap_PreferredStockSharesIssued_acb76953-a52f-4c2a-aca3-6ad55fb11b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_0ff78b2a-fb7f-45f5-be83-ba6d2c680008" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d61d0c0b-0ea7-4bc4-9278-49c5bca14739" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_0ff78b2a-fb7f-45f5-be83-ba6d2c680008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_e2624059-7a8e-41bb-b078-7e2de7c2041c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d61d0c0b-0ea7-4bc4-9278-49c5bca14739" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_e2624059-7a8e-41bb-b078-7e2de7c2041c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_27b1613e-1205-4f5c-b568-067e8a223f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d61d0c0b-0ea7-4bc4-9278-49c5bca14739" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_27b1613e-1205-4f5c-b568-067e8a223f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_eb1542ae-4e8a-4ae4-b057-68c79dc0f192" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d61d0c0b-0ea7-4bc4-9278-49c5bca14739" xlink:to="loc_us-gaap_CommonStockSharesIssued_eb1542ae-4e8a-4ae4-b057-68c79dc0f192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d6399e25-cec0-4131-807d-b2628f4a53d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d61d0c0b-0ea7-4bc4-9278-49c5bca14739" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d6399e25-cec0-4131-807d-b2628f4a53d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="eols-20241231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_8bf4f590-b93a-40e9-85a2-a5138fcb669a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_76ecb48a-6a86-4e7d-aea5-6c6e1b123c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8bf4f590-b93a-40e9-85a2-a5138fcb669a" xlink:to="loc_us-gaap_StatementTable_76ecb48a-6a86-4e7d-aea5-6c6e1b123c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_97190b4d-68d9-4dbd-bab9-d804d5b3e79e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_76ecb48a-6a86-4e7d-aea5-6c6e1b123c9b" xlink:to="loc_srt_ProductOrServiceAxis_97190b4d-68d9-4dbd-bab9-d804d5b3e79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_68bd18df-54e7-4456-a388-176418840118" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_97190b4d-68d9-4dbd-bab9-d804d5b3e79e" xlink:to="loc_srt_ProductsAndServicesDomain_68bd18df-54e7-4456-a388-176418840118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_161e1012-e507-4f08-a183-643999b38e54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_68bd18df-54e7-4456-a388-176418840118" xlink:to="loc_us-gaap_ProductMember_161e1012-e507-4f08-a183-643999b38e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_d825474a-4b2a-4819-8130-6d599acd8bff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_68bd18df-54e7-4456-a388-176418840118" xlink:to="loc_us-gaap_ServiceMember_d825474a-4b2a-4819-8130-6d599acd8bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_71321173-e360-4786-aa23-a136d501e71c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_76ecb48a-6a86-4e7d-aea5-6c6e1b123c9b" xlink:to="loc_us-gaap_StatementLineItems_71321173-e360-4786-aa23-a136d501e71c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_1b592762-b4cc-4880-9ab4-40b40c42489b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_71321173-e360-4786-aa23-a136d501e71c" xlink:to="loc_us-gaap_RevenuesAbstract_1b592762-b4cc-4880-9ab4-40b40c42489b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3243e8da-d17d-4bee-9c40-e74a6082a067" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_1b592762-b4cc-4880-9ab4-40b40c42489b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3243e8da-d17d-4bee-9c40-e74a6082a067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_9eb06663-760d-4a7a-bfb6-afa7b503614b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_71321173-e360-4786-aa23-a136d501e71c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_9eb06663-760d-4a7a-bfb6-afa7b503614b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList_757d8b37-2692-4fc3-a4ce-44588784c090" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfCostGoodOrServiceExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_9eb06663-760d-4a7a-bfb6-afa7b503614b" xlink:to="loc_us-gaap_TypeOfCostGoodOrServiceExtensibleList_757d8b37-2692-4fc3-a4ce-44588784c090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_efd2e887-863b-4495-8e86-8c072a811c10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_71321173-e360-4786-aa23-a136d501e71c" xlink:to="loc_us-gaap_GrossProfit_efd2e887-863b-4495-8e86-8c072a811c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_c5300156-6e6a-44d0-ae4d-7f961034cf57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_71321173-e360-4786-aa23-a136d501e71c" xlink:to="loc_us-gaap_OperatingExpensesAbstract_c5300156-6e6a-44d0-ae4d-7f961034cf57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6372431c-b53d-4ad5-a44e-d196e0d2b9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c5300156-6e6a-44d0-ae4d-7f961034cf57" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6372431c-b53d-4ad5-a44e-d196e0d2b9f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_71a8f0c0-0463-418f-8561-ea735e4a4141" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c5300156-6e6a-44d0-ae4d-7f961034cf57" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_71a8f0c0-0463-418f-8561-ea735e4a4141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ResearchAndDevelopmentInProcess1_7e5b89df-c61d-48e6-ba62-7e19d6d825e0" xlink:href="eols-20241231.xsd#eols_ResearchAndDevelopmentInProcess1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c5300156-6e6a-44d0-ae4d-7f961034cf57" xlink:to="loc_eols_ResearchAndDevelopmentInProcess1_7e5b89df-c61d-48e6-ba62-7e19d6d825e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_4d52d47f-5bcf-470b-9f12-3727f697a061" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c5300156-6e6a-44d0-ae4d-7f961034cf57" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_4d52d47f-5bcf-470b-9f12-3727f697a061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_410de302-e7e8-442f-90f6-021ed0c17653" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c5300156-6e6a-44d0-ae4d-7f961034cf57" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization_410de302-e7e8-442f-90f6-021ed0c17653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_189324af-e93c-44cc-894f-a5a150d29af5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c5300156-6e6a-44d0-ae4d-7f961034cf57" xlink:to="loc_us-gaap_CostsAndExpenses_189324af-e93c-44cc-894f-a5a150d29af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bea1563a-ebd3-45cf-b2ef-4d27588bbde0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_71321173-e360-4786-aa23-a136d501e71c" xlink:to="loc_us-gaap_OperatingIncomeLoss_bea1563a-ebd3-45cf-b2ef-4d27588bbde0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_729e926d-db3d-4ff8-ba21-e33ad476aeff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_71321173-e360-4786-aa23-a136d501e71c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_729e926d-db3d-4ff8-ba21-e33ad476aeff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_f93da68f-f5a7-4533-9d03-d25cc8d1793e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_729e926d-db3d-4ff8-ba21-e33ad476aeff" xlink:to="loc_us-gaap_InvestmentIncomeNet_f93da68f-f5a7-4533-9d03-d25cc8d1793e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_7ebe09ce-2a9d-44e9-ab34-eb64292644f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_729e926d-db3d-4ff8-ba21-e33ad476aeff" xlink:to="loc_us-gaap_InterestExpenseNonoperating_7ebe09ce-2a9d-44e9-ab34-eb64292644f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e2828db5-357d-4749-b64f-5ed42086ebcd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_729e926d-db3d-4ff8-ba21-e33ad476aeff" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e2828db5-357d-4749-b64f-5ed42086ebcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a545e853-6457-4040-9fe8-d69e837591f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_71321173-e360-4786-aa23-a136d501e71c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a545e853-6457-4040-9fe8-d69e837591f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f80731eb-119d-475a-9ae8-57e398749d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_71321173-e360-4786-aa23-a136d501e71c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f80731eb-119d-475a-9ae8-57e398749d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_efbeb735-d1f0-4f32-b3aa-0467eb8d6c43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_71321173-e360-4786-aa23-a136d501e71c" xlink:to="loc_us-gaap_NetIncomeLoss_efbeb735-d1f0-4f32-b3aa-0467eb8d6c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_579526af-8aa7-4426-9b0b-7af5e72aaeab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_71321173-e360-4786-aa23-a136d501e71c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_579526af-8aa7-4426-9b0b-7af5e72aaeab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f55d1235-8350-4d44-9e9a-1b03bf2ea391" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_579526af-8aa7-4426-9b0b-7af5e72aaeab" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f55d1235-8350-4d44-9e9a-1b03bf2ea391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f3997335-2d48-430a-9d22-74796a4e5677" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_71321173-e360-4786-aa23-a136d501e71c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_f3997335-2d48-430a-9d22-74796a4e5677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ba184e84-7987-439f-972e-76d33e6073fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_71321173-e360-4786-aa23-a136d501e71c" xlink:to="loc_us-gaap_EarningsPerShareBasic_ba184e84-7987-439f-972e-76d33e6073fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_277b2d2d-3a1f-4d05-bea4-f396ce30e61e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_71321173-e360-4786-aa23-a136d501e71c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_277b2d2d-3a1f-4d05-bea4-f396ce30e61e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_16d363e3-2813-49e6-b24f-eb6f61252e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_71321173-e360-4786-aa23-a136d501e71c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_16d363e3-2813-49e6-b24f-eb6f61252e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5f4f01b9-c0e0-4d15-8379-588efa503a74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_71321173-e360-4786-aa23-a136d501e71c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5f4f01b9-c0e0-4d15-8379-588efa503a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/ConsolidatedStatementsofStockholdersEquityDeficit" xlink:type="simple" xlink:href="eols-20241231.xsd#ConsolidatedStatementsofStockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/ConsolidatedStatementsofStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_c61c0dac-8563-4f4e-9a26-98257663ed93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2ea73308-cabb-4c25-bacc-0b0e4eb2b561" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_c61c0dac-8563-4f4e-9a26-98257663ed93" xlink:to="loc_us-gaap_StatementTable_2ea73308-cabb-4c25-bacc-0b0e4eb2b561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b23cb47f-848f-4fde-ad42-4a894e6fc311" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2ea73308-cabb-4c25-bacc-0b0e4eb2b561" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b23cb47f-848f-4fde-ad42-4a894e6fc311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ce65ad55-637e-4bdb-8039-ff0954b84634" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b23cb47f-848f-4fde-ad42-4a894e6fc311" xlink:to="loc_us-gaap_EquityComponentDomain_ce65ad55-637e-4bdb-8039-ff0954b84634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8b279777-def5-410a-a42b-d87bd8fe742f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ce65ad55-637e-4bdb-8039-ff0954b84634" xlink:to="loc_us-gaap_CommonStockMember_8b279777-def5-410a-a42b-d87bd8fe742f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9f660b93-ebd6-47db-853f-bbaf6f69e5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ce65ad55-637e-4bdb-8039-ff0954b84634" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9f660b93-ebd6-47db-853f-bbaf6f69e5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c59f4df3-d082-4cac-950b-fd33251251e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ce65ad55-637e-4bdb-8039-ff0954b84634" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c59f4df3-d082-4cac-950b-fd33251251e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9f9d026b-e7c0-44ff-899d-b7074ab452d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ce65ad55-637e-4bdb-8039-ff0954b84634" xlink:to="loc_us-gaap_RetainedEarningsMember_9f9d026b-e7c0-44ff-899d-b7074ab452d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b38d8eb4-367d-4c81-8792-d3040ee9bb10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2ea73308-cabb-4c25-bacc-0b0e4eb2b561" xlink:to="loc_us-gaap_StatementLineItems_b38d8eb4-367d-4c81-8792-d3040ee9bb10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d436fa3-6708-4c16-acdf-fd3d4dfabea7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b38d8eb4-367d-4c81-8792-d3040ee9bb10" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d436fa3-6708-4c16-acdf-fd3d4dfabea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_d10014a1-972f-4656-ab41-17b65d116fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d436fa3-6708-4c16-acdf-fd3d4dfabea7" xlink:to="loc_us-gaap_CommonStockSharesIssued_d10014a1-972f-4656-ab41-17b65d116fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_95188caa-faca-41a0-a91d-711a931b84df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d436fa3-6708-4c16-acdf-fd3d4dfabea7" xlink:to="loc_us-gaap_StockholdersEquity_95188caa-faca-41a0-a91d-711a931b84df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodSharesIncentiveEquityPlan_95aabf10-3033-41fb-8e6b-f9725ca879e0" xlink:href="eols-20241231.xsd#eols_StockIssuedDuringPeriodSharesIncentiveEquityPlan"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d436fa3-6708-4c16-acdf-fd3d4dfabea7" xlink:to="loc_eols_StockIssuedDuringPeriodSharesIncentiveEquityPlan_95aabf10-3033-41fb-8e6b-f9725ca879e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodValueIncentiveEquityPlan_4d5e7b77-de86-40df-a3ca-ef87b9103316" xlink:href="eols-20241231.xsd#eols_StockIssuedDuringPeriodValueIncentiveEquityPlan"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d436fa3-6708-4c16-acdf-fd3d4dfabea7" xlink:to="loc_eols_StockIssuedDuringPeriodValueIncentiveEquityPlan_4d5e7b77-de86-40df-a3ca-ef87b9103316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement_0fb5c311-054e-4fd9-8395-e6b383ef7db3" xlink:href="eols-20241231.xsd#eols_StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d436fa3-6708-4c16-acdf-fd3d4dfabea7" xlink:to="loc_eols_StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement_0fb5c311-054e-4fd9-8395-e6b383ef7db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodValueIssuedForLicenseSupplyAndDistributionAgreement_fe4595b4-4278-4a54-a361-b6e8d3b441c0" xlink:href="eols-20241231.xsd#eols_StockIssuedDuringPeriodValueIssuedForLicenseSupplyAndDistributionAgreement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d436fa3-6708-4c16-acdf-fd3d4dfabea7" xlink:to="loc_eols_StockIssuedDuringPeriodValueIssuedForLicenseSupplyAndDistributionAgreement_fe4595b4-4278-4a54-a361-b6e8d3b441c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_37f6a53f-f551-4eb4-83ae-e92e81e7c073" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d436fa3-6708-4c16-acdf-fd3d4dfabea7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_37f6a53f-f551-4eb4-83ae-e92e81e7c073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7c244a7d-7584-4890-9df4-a2e3d2184c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d436fa3-6708-4c16-acdf-fd3d4dfabea7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7c244a7d-7584-4890-9df4-a2e3d2184c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fd462b67-0687-4af9-9446-296c84ca656f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d436fa3-6708-4c16-acdf-fd3d4dfabea7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fd462b67-0687-4af9-9446-296c84ca656f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_73c8314e-68d3-4392-b15f-42f3c441aa73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d436fa3-6708-4c16-acdf-fd3d4dfabea7" xlink:to="loc_us-gaap_NetIncomeLoss_73c8314e-68d3-4392-b15f-42f3c441aa73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3f372bf9-a2e7-4778-be14-23b026b6d5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d436fa3-6708-4c16-acdf-fd3d4dfabea7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3f372bf9-a2e7-4778-be14-23b026b6d5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_cd2fc46e-a656-4803-9dac-6c65b77c3691" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d436fa3-6708-4c16-acdf-fd3d4dfabea7" xlink:to="loc_us-gaap_CommonStockSharesIssued_cd2fc46e-a656-4803-9dac-6c65b77c3691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_68ade2de-ff86-4b6a-b6d4-c61fafbfdebc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0d436fa3-6708-4c16-acdf-fd3d4dfabea7" xlink:to="loc_us-gaap_StockholdersEquity_68ade2de-ff86-4b6a-b6d4-c61fafbfdebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="eols-20241231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_9d6df759-d524-4fb0-b4f6-c4ee2222c5b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ef05ec5d-d06d-415a-a2c5-6b07d950bdf2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9d6df759-d524-4fb0-b4f6-c4ee2222c5b9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ef05ec5d-d06d-415a-a2c5-6b07d950bdf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_70090546-f977-4454-b628-ca81d63491ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ef05ec5d-d06d-415a-a2c5-6b07d950bdf2" xlink:to="loc_us-gaap_NetIncomeLoss_70090546-f977-4454-b628-ca81d63491ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2b26195c-0ac8-438d-9e5f-41ec5dda1130" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ef05ec5d-d06d-415a-a2c5-6b07d950bdf2" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2b26195c-0ac8-438d-9e5f-41ec5dda1130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4a0b9d80-f202-4a24-ae8a-36529cf97183" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2b26195c-0ac8-438d-9e5f-41ec5dda1130" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4a0b9d80-f202-4a24-ae8a-36529cf97183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_516c2edc-2c0a-45f9-b297-72ca53bb742d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2b26195c-0ac8-438d-9e5f-41ec5dda1130" xlink:to="loc_us-gaap_ShareBasedCompensation_516c2edc-2c0a-45f9-b297-72ca53bb742d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_d6fd3f85-ca74-4545-b4ee-59d1a89d989c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2b26195c-0ac8-438d-9e5f-41ec5dda1130" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_d6fd3f85-ca74-4545-b4ee-59d1a89d989c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_821cf3fe-e6f6-4d94-bbc7-0331a9008cee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2b26195c-0ac8-438d-9e5f-41ec5dda1130" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_821cf3fe-e6f6-4d94-bbc7-0331a9008cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7a054a93-50a5-4ea7-b1d4-84e9e2864957" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2b26195c-0ac8-438d-9e5f-41ec5dda1130" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7a054a93-50a5-4ea7-b1d4-84e9e2864957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7e2c87bb-12e4-40fd-a1ca-7ac20710e5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2b26195c-0ac8-438d-9e5f-41ec5dda1130" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7e2c87bb-12e4-40fd-a1ca-7ac20710e5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_4997f546-c799-46c6-87fc-59fa15d8dfc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2b26195c-0ac8-438d-9e5f-41ec5dda1130" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_4997f546-c799-46c6-87fc-59fa15d8dfc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_NonCashInResearchAndDevelopmentInProcessExpenses_ebb2519a-f87d-4c9e-b45d-6de9265444ae" xlink:href="eols-20241231.xsd#eols_NonCashInResearchAndDevelopmentInProcessExpenses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2b26195c-0ac8-438d-9e5f-41ec5dda1130" xlink:to="loc_eols_NonCashInResearchAndDevelopmentInProcessExpenses_ebb2519a-f87d-4c9e-b45d-6de9265444ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9fb96222-872e-4b4d-8102-7c1affdf5c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2b26195c-0ac8-438d-9e5f-41ec5dda1130" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9fb96222-872e-4b4d-8102-7c1affdf5c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_c3895fad-d7dd-4d2c-a4d8-41fbb5b7fe3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9fb96222-872e-4b4d-8102-7c1affdf5c0f" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_c3895fad-d7dd-4d2c-a4d8-41fbb5b7fe3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e4d42d0f-da3a-4c9e-aac2-353a132f4580" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9fb96222-872e-4b4d-8102-7c1affdf5c0f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e4d42d0f-da3a-4c9e-aac2-353a132f4580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_0fe15b85-5171-4c1d-9e16-7ea82fa0370f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9fb96222-872e-4b4d-8102-7c1affdf5c0f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_0fe15b85-5171-4c1d-9e16-7ea82fa0370f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_8a620157-1616-4372-8f2b-10e69198d41c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9fb96222-872e-4b4d-8102-7c1affdf5c0f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_8a620157-1616-4372-8f2b-10e69198d41c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9a1d663a-dcaa-4245-89c9-e3c8d1f78d29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9fb96222-872e-4b4d-8102-7c1affdf5c0f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9a1d663a-dcaa-4245-89c9-e3c8d1f78d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_8a51e87b-131a-49ea-8213-455bbc801dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9fb96222-872e-4b4d-8102-7c1affdf5c0f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_8a51e87b-131a-49ea-8213-455bbc801dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_b5255835-b8e4-4fc4-b3f0-89c9d111a2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9fb96222-872e-4b4d-8102-7c1affdf5c0f" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_b5255835-b8e4-4fc4-b3f0-89c9d111a2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IncreaseDecreaseInOperatingLeaseLiabilities_6b4c02d0-7813-451c-a961-28d48c5bfcf6" xlink:href="eols-20241231.xsd#eols_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9fb96222-872e-4b4d-8102-7c1affdf5c0f" xlink:to="loc_eols_IncreaseDecreaseInOperatingLeaseLiabilities_6b4c02d0-7813-451c-a961-28d48c5bfcf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c4ba1b3c-a597-40dd-a694-becda2c17198" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ef05ec5d-d06d-415a-a2c5-6b07d950bdf2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c4ba1b3c-a597-40dd-a694-becda2c17198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71e0f701-d172-4bfa-96d8-83dacf0b23c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9d6df759-d524-4fb0-b4f6-c4ee2222c5b9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71e0f701-d172-4bfa-96d8-83dacf0b23c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9e793818-a3b9-4314-a70f-9530fdc55447" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71e0f701-d172-4bfa-96d8-83dacf0b23c2" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9e793818-a3b9-4314-a70f-9530fdc55447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForSoftware_bab24712-77de-4f1d-b8bd-39582999f9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForSoftware"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71e0f701-d172-4bfa-96d8-83dacf0b23c2" xlink:to="loc_us-gaap_PaymentsForSoftware_bab24712-77de-4f1d-b8bd-39582999f9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6e789db0-7b3f-4953-ad4a-61b6019404a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71e0f701-d172-4bfa-96d8-83dacf0b23c2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6e789db0-7b3f-4953-ad4a-61b6019404a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_f0388bd4-ac71-45ca-8b52-e16ffc8e8abb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9d6df759-d524-4fb0-b4f6-c4ee2222c5b9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_f0388bd4-ac71-45ca-8b52-e16ffc8e8abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PaymentsOfContingentRoyaltyObligation_c544ae90-435b-4754-bed3-f45ebebc72a8" xlink:href="eols-20241231.xsd#eols_PaymentsOfContingentRoyaltyObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_f0388bd4-ac71-45ca-8b52-e16ffc8e8abb" xlink:to="loc_eols_PaymentsOfContingentRoyaltyObligation_c544ae90-435b-4754-bed3-f45ebebc72a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e8fa8cdd-6853-427d-a426-fee7b5b2419d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_f0388bd4-ac71-45ca-8b52-e16ffc8e8abb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e8fa8cdd-6853-427d-a426-fee7b5b2419d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_6a96cfd8-8272-413c-99f2-19dcb5b2b29b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_f0388bd4-ac71-45ca-8b52-e16ffc8e8abb" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_6a96cfd8-8272-413c-99f2-19dcb5b2b29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c0e02958-3d0f-4d28-90ca-374739b39c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_f0388bd4-ac71-45ca-8b52-e16ffc8e8abb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c0e02958-3d0f-4d28-90ca-374739b39c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_f9ff4a2c-dc6c-43d7-9310-c4bc9a14a404" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_f0388bd4-ac71-45ca-8b52-e16ffc8e8abb" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_f9ff4a2c-dc6c-43d7-9310-c4bc9a14a404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_b0701e76-71e6-4f40-b39d-59a8731c3cda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_f0388bd4-ac71-45ca-8b52-e16ffc8e8abb" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_b0701e76-71e6-4f40-b39d-59a8731c3cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_16a2a251-cd87-4267-851a-5a3ff1c64653" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_f0388bd4-ac71-45ca-8b52-e16ffc8e8abb" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_16a2a251-cd87-4267-851a-5a3ff1c64653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_819cbb93-0da0-4e00-a85b-cae8284e13d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_f0388bd4-ac71-45ca-8b52-e16ffc8e8abb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_819cbb93-0da0-4e00-a85b-cae8284e13d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7db6cc6e-1522-40ea-aaff-70fd0c37ec53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9d6df759-d524-4fb0-b4f6-c4ee2222c5b9" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7db6cc6e-1522-40ea-aaff-70fd0c37ec53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1ba57515-5ffc-4afc-8584-792c44515e50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9d6df759-d524-4fb0-b4f6-c4ee2222c5b9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1ba57515-5ffc-4afc-8584-792c44515e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2433d7cf-25da-4ae0-83d7-330e295d5106" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9d6df759-d524-4fb0-b4f6-c4ee2222c5b9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2433d7cf-25da-4ae0-83d7-330e295d5106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6869174f-3510-4c47-b400-1c8b41e246bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9d6df759-d524-4fb0-b4f6-c4ee2222c5b9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6869174f-3510-4c47-b400-1c8b41e246bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_a2d397cb-7caa-4e85-b2ee-57c47de2790c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9d6df759-d524-4fb0-b4f6-c4ee2222c5b9" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_a2d397cb-7caa-4e85-b2ee-57c47de2790c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_200ca61f-db9a-4292-96ce-93ebf1a9b995" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_a2d397cb-7caa-4e85-b2ee-57c47de2790c" xlink:to="loc_us-gaap_InterestPaidNet_200ca61f-db9a-4292-96ce-93ebf1a9b995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_eee0573b-c8a7-4d96-b4b9-c57ce187a9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_a2d397cb-7caa-4e85-b2ee-57c47de2790c" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_eee0573b-c8a7-4d96-b4b9-c57ce187a9a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_87decb28-a949-432e-bc78-39896f46f24f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_9d6df759-d524-4fb0-b4f6-c4ee2222c5b9" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_87decb28-a949-432e-bc78-39896f46f24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_392016f5-0058-475f-9c90-ebb16bd0bf44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_87decb28-a949-432e-bc78-39896f46f24f" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_392016f5-0058-475f-9c90-ebb16bd0bf44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_9ff00172-6542-496a-88c6-e228a8297d56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_87decb28-a949-432e-bc78-39896f46f24f" xlink:to="loc_us-gaap_StockIssued1_9ff00172-6542-496a-88c6-e228a8297d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="eols-20241231.xsd#DescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/DescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_09c6a894-5740-402b-b559-ce37cd09e79f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_83a0ac8e-e659-48bd-95ce-ff027f2f5e97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_09c6a894-5740-402b-b559-ce37cd09e79f" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_83a0ac8e-e659-48bd-95ce-ff027f2f5e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="eols-20241231.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_164f96ac-ddc1-4868-a02a-cfac138a09cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_90be6ce2-a01e-4e9e-b240-576d2f9f493d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_164f96ac-ddc1-4868-a02a-cfac138a09cd" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_90be6ce2-a01e-4e9e-b240-576d2f9f493d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="eols-20241231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5e46f405-859a-4bb5-b56c-b386e226c397" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_0558344d-131b-4efd-8530-ac478da721bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5e46f405-859a-4bb5-b56c-b386e226c397" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_0558344d-131b-4efd-8530-ac478da721bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="eols-20241231.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2d8cf1aa-40b8-4339-aac5-11076f445543" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_ee1892cb-5a14-495c-a45c-06094065609d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2d8cf1aa-40b8-4339-aac5-11076f445543" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_ee1892cb-5a14-495c-a45c-06094065609d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/AccruedExpenses" xlink:type="simple" xlink:href="eols-20241231.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_dad0e9af-0bb0-4559-85bc-460c89371589" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_3eb3f177-dd26-430e-9d1c-557cb6a5244b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_dad0e9af-0bb0-4559-85bc-460c89371589" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_3eb3f177-dd26-430e-9d1c-557cb6a5244b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/PropertyPlantandEquipment" xlink:type="simple" xlink:href="eols-20241231.xsd#PropertyPlantandEquipment"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/PropertyPlantandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_73aaa48c-faa9-4ce5-b23d-b821752145b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_71356d64-d325-48af-baf5-1c1a1c0eeb29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_73aaa48c-faa9-4ce5-b23d-b821752145b0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_71356d64-d325-48af-baf5-1c1a1c0eeb29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/TermLoans" xlink:type="simple" xlink:href="eols-20241231.xsd#TermLoans"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/TermLoans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7362a855-9798-46e2-ac4d-9189894a00b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_3fe6c080-033b-4e79-9551-7b9b9dd62d87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7362a855-9798-46e2-ac4d-9189894a00b9" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_3fe6c080-033b-4e79-9551-7b9b9dd62d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/OperatingLeases" xlink:type="simple" xlink:href="eols-20241231.xsd#OperatingLeases"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/OperatingLeases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f80550ec-0374-4e0c-8532-72c1407f2ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_8c15b7cb-e4fa-4665-80e0-194d32e86395" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f80550ec-0374-4e0c-8532-72c1407f2ccb" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_8c15b7cb-e4fa-4665-80e0-194d32e86395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="eols-20241231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c554d030-f63e-477a-a292-0b02b85039d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_95497d8a-fa91-49ee-975e-f94e5666c579" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c554d030-f63e-477a-a292-0b02b85039d9" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_95497d8a-fa91-49ee-975e-f94e5666c579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquity" xlink:type="simple" xlink:href="eols-20241231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5b70995c-3880-42b1-b9cb-aefdac1f9752" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2f0c320b-4cef-4c62-b5d2-b8098d40d078" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5b70995c-3880-42b1-b9cb-aefdac1f9752" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_2f0c320b-4cef-4c62-b5d2-b8098d40d078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/MedytoxSettlementAgreements" xlink:type="simple" xlink:href="eols-20241231.xsd#MedytoxSettlementAgreements"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/MedytoxSettlementAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_febb4fea-9b29-494c-aa1b-7c5dc99342b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ef55eb60-6663-40d0-800d-b1400d2e9920" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_febb4fea-9b29-494c-aa1b-7c5dc99342b9" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ef55eb60-6663-40d0-800d-b1400d2e9920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="eols-20241231.xsd#EmployeeBenefitPlan"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/EmployeeBenefitPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_fa5a2085-892e-4d4b-9db2-3516e3721f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_4e42b75c-ccf7-403b-9f62-8f4670ec98f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_fa5a2085-892e-4d4b-9db2-3516e3721f4a" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_4e42b75c-ccf7-403b-9f62-8f4670ec98f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxes" xlink:type="simple" xlink:href="eols-20241231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b86276f4-2fc6-47a0-8a72-a2bc04106e51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_e827c898-2c75-4f51-ab59-a86a960766d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b86276f4-2fc6-47a0-8a72-a2bc04106e51" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_e827c898-2c75-4f51-ab59-a86a960766d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/SegmentReporting" xlink:type="simple" xlink:href="eols-20241231.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_dd581d55-fdc0-4988-ba1b-9c739cc58cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_5d45a80d-7ce3-42e9-9b49-56376ce8948a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_dd581d55-fdc0-4988-ba1b-9c739cc58cbf" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_5d45a80d-7ce3-42e9-9b49-56376ce8948a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/SubsequentEvents" xlink:type="simple" xlink:href="eols-20241231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0d36e0ff-fbc1-4b2c-a508-5f28e5a40dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_ddbac61e-95f0-49cc-aadb-d5e22b473f50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0d36e0ff-fbc1-4b2c-a508-5f28e5a40dbc" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_ddbac61e-95f0-49cc-aadb-d5e22b473f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="eols-20241231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7268052d-0f4e-4bee-a96d-2b62bb31ab1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_917a7502-76e7-4b04-8efd-de193b7f4406" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7268052d-0f4e-4bee-a96d-2b62bb31ab1c" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_917a7502-76e7-4b04-8efd-de193b7f4406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_0fccf9b1-6f09-4171-b43c-a467a6294432" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7268052d-0f4e-4bee-a96d-2b62bb31ab1c" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_0fccf9b1-6f09-4171-b43c-a467a6294432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_0334e483-4a9a-42aa-a75d-2bb07497df54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7268052d-0f4e-4bee-a96d-2b62bb31ab1c" xlink:to="loc_us-gaap_UseOfEstimates_0334e483-4a9a-42aa-a75d-2bb07497df54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_17ec8d3b-e89f-43a3-89f0-ba30496276a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7268052d-0f4e-4bee-a96d-2b62bb31ab1c" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_17ec8d3b-e89f-43a3-89f0-ba30496276a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_5ee10d29-0712-49f7-892c-61198db3f394" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7268052d-0f4e-4bee-a96d-2b62bb31ab1c" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_5ee10d29-0712-49f7-892c-61198db3f394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_b11d3c51-de14-46d8-b726-c7fa98547877" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7268052d-0f4e-4bee-a96d-2b62bb31ab1c" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_b11d3c51-de14-46d8-b726-c7fa98547877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_31c10c8e-083d-4eb6-9441-e80f556e962b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7268052d-0f4e-4bee-a96d-2b62bb31ab1c" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_31c10c8e-083d-4eb6-9441-e80f556e962b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_19fb464f-afcc-4e63-8c00-e9cb920f3f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7268052d-0f4e-4bee-a96d-2b62bb31ab1c" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_19fb464f-afcc-4e63-8c00-e9cb920f3f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1999ffd1-843f-4440-97b9-e1b456b908e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7268052d-0f4e-4bee-a96d-2b62bb31ab1c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1999ffd1-843f-4440-97b9-e1b456b908e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_63918e9c-48ea-41f5-ba29-ae3eaac1646f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7268052d-0f4e-4bee-a96d-2b62bb31ab1c" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_63918e9c-48ea-41f5-ba29-ae3eaac1646f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_ace0cedf-34bb-4364-9541-a1e69116c58d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7268052d-0f4e-4bee-a96d-2b62bb31ab1c" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_ace0cedf-34bb-4364-9541-a1e69116c58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_30a4aef8-959d-4694-84b5-20b14fa9de94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7268052d-0f4e-4bee-a96d-2b62bb31ab1c" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_30a4aef8-959d-4694-84b5-20b14fa9de94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_9661d490-b78e-4617-b870-2d69767b3718" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7268052d-0f4e-4bee-a96d-2b62bb31ab1c" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_9661d490-b78e-4617-b870-2d69767b3718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_57d80e22-e003-46d0-80e1-8b9996890584" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7268052d-0f4e-4bee-a96d-2b62bb31ab1c" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_57d80e22-e003-46d0-80e1-8b9996890584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtPolicyTextBlock_28be0023-1249-4285-8416-b2c4f456273d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7268052d-0f4e-4bee-a96d-2b62bb31ab1c" xlink:to="loc_us-gaap_DebtPolicyTextBlock_28be0023-1249-4285-8416-b2c4f456273d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_36a56b95-b6d2-41f5-962d-30ce73eb69e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7268052d-0f4e-4bee-a96d-2b62bb31ab1c" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_36a56b95-b6d2-41f5-962d-30ce73eb69e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_e7381f94-5cc8-42de-a9e7-bf9da6381513" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7268052d-0f4e-4bee-a96d-2b62bb31ab1c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_e7381f94-5cc8-42de-a9e7-bf9da6381513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_11b720aa-6dec-400c-a543-0382431867d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7268052d-0f4e-4bee-a96d-2b62bb31ab1c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_11b720aa-6dec-400c-a543-0382431867d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_6c610b64-5254-4717-82af-2136725914ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7268052d-0f4e-4bee-a96d-2b62bb31ab1c" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_6c610b64-5254-4717-82af-2136725914ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_a0d13c5b-dea6-434f-ab84-8dda7fc34f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7268052d-0f4e-4bee-a96d-2b62bb31ab1c" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_a0d13c5b-dea6-434f-ab84-8dda7fc34f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_d717780f-9a20-4ab3-a217-9b36e77848c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7268052d-0f4e-4bee-a96d-2b62bb31ab1c" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_d717780f-9a20-4ab3-a217-9b36e77848c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_49582fb2-5f52-4d30-8494-3c9329afb8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7268052d-0f4e-4bee-a96d-2b62bb31ab1c" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_49582fb2-5f52-4d30-8494-3c9329afb8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f7142f42-e56b-45a5-88b2-45ca5ba1c15f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7268052d-0f4e-4bee-a96d-2b62bb31ab1c" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f7142f42-e56b-45a5-88b2-45ca5ba1c15f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="eols-20241231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d5e05496-ec28-4644-9139-30caadfa4e62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_f6827f2d-e076-44e5-94f5-7436910ed072" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d5e05496-ec28-4644-9139-30caadfa4e62" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_f6827f2d-e076-44e5-94f5-7436910ed072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_99876efe-97d4-465c-8ec5-5a01a7520eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d5e05496-ec28-4644-9139-30caadfa4e62" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_99876efe-97d4-465c-8ec5-5a01a7520eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="eols-20241231.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_930dc828-3bdc-42df-8a28-8cb557633288" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_4e5cbae4-093a-4d30-b37f-d3a366ea96ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_930dc828-3bdc-42df-8a28-8cb557633288" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_4e5cbae4-093a-4d30-b37f-d3a366ea96ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_ff6ea9a7-27c7-4de1-a06e-302e1fc436b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_930dc828-3bdc-42df-8a28-8cb557633288" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_ff6ea9a7-27c7-4de1-a06e-302e1fc436b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="eols-20241231.xsd#AccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_c60c0b51-7fee-422e-a04c-85423271fd8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_ca1ca013-37dc-4f8d-95a8-dbc880f86729" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_c60c0b51-7fee-422e-a04c-85423271fd8c" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_ca1ca013-37dc-4f8d-95a8-dbc880f86729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/PropertyPlantandEquipmentTables" xlink:type="simple" xlink:href="eols-20241231.xsd#PropertyPlantandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/PropertyPlantandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_202d310e-cbd9-419d-a9ca-cdf90b61889d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1db4e33c-aee3-42b2-b25c-b747dfa5a8f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_202d310e-cbd9-419d-a9ca-cdf90b61889d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1db4e33c-aee3-42b2-b25c-b747dfa5a8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/TermLoansTables" xlink:type="simple" xlink:href="eols-20241231.xsd#TermLoansTables"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/TermLoansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_876a1b6f-1dcb-4bb4-aa9b-4f49555302e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_8b224ff8-d42c-42f1-b73a-3415180b263b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_876a1b6f-1dcb-4bb4-aa9b-4f49555302e8" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_8b224ff8-d42c-42f1-b73a-3415180b263b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/OperatingLeasesTables" xlink:type="simple" xlink:href="eols-20241231.xsd#OperatingLeasesTables"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/OperatingLeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_57c198c0-7e2a-423c-ad80-068e738c96d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_38a31135-7d25-4f15-921b-49811b1a78fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_57c198c0-7e2a-423c-ad80-068e738c96d8" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_38a31135-7d25-4f15-921b-49811b1a78fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_e756f5bf-3e82-4c3a-b23d-0096c99a70a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_57c198c0-7e2a-423c-ad80-068e738c96d8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_e756f5bf-3e82-4c3a-b23d-0096c99a70a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="eols-20241231.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_043f18da-d8ee-43cb-8e55-fc0a7f063082" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3fd29bd1-b0e3-41cc-af0d-e6c6cf3780d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_043f18da-d8ee-43cb-8e55-fc0a7f063082" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3fd29bd1-b0e3-41cc-af0d-e6c6cf3780d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_09a6c081-083f-4424-8f56-3005e455c1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_043f18da-d8ee-43cb-8e55-fc0a7f063082" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_09a6c081-083f-4424-8f56-3005e455c1f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_36278a69-b5dc-42b7-9bff-8543eb85ac74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_043f18da-d8ee-43cb-8e55-fc0a7f063082" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_36278a69-b5dc-42b7-9bff-8543eb85ac74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_c4f8f4d9-7b01-4271-9674-50f243ccfa10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_043f18da-d8ee-43cb-8e55-fc0a7f063082" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_c4f8f4d9-7b01-4271-9674-50f243ccfa10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="eols-20241231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d31d4c79-810b-40c5-aa57-d511d02d9a43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_c63d247c-51f9-422e-8858-7c9a06353128" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d31d4c79-810b-40c5-aa57-d511d02d9a43" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_c63d247c-51f9-422e-8858-7c9a06353128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_851381e0-6509-4da5-aa78-37343cb58584" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d31d4c79-810b-40c5-aa57-d511d02d9a43" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_851381e0-6509-4da5-aa78-37343cb58584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_e5dd87ee-cc87-449b-874a-442e3bfcdff6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d31d4c79-810b-40c5-aa57-d511d02d9a43" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_e5dd87ee-cc87-449b-874a-442e3bfcdff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_15624e74-3581-492a-bb23-6155b5601ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d31d4c79-810b-40c5-aa57-d511d02d9a43" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_15624e74-3581-492a-bb23-6155b5601ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_ffd088d6-f273-4ba4-9e3f-cb52c4d0d00e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d31d4c79-810b-40c5-aa57-d511d02d9a43" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_ffd088d6-f273-4ba4-9e3f-cb52c4d0d00e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="eols-20241231.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_5a9137ab-2229-41ea-8e4a-77f2720e7275" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_59cb1d58-a014-45ad-aafe-7b568869a82b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5a9137ab-2229-41ea-8e4a-77f2720e7275" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_59cb1d58-a014-45ad-aafe-7b568869a82b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_a6f998d7-9f78-438c-a537-ea17e012a763" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5a9137ab-2229-41ea-8e4a-77f2720e7275" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_a6f998d7-9f78-438c-a537-ea17e012a763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#DescriptionofBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/DescriptionofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bd108019-4b45-4bd2-9f4f-2b665a0a7b90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_b87c1718-4efc-472d-8636-06c0802d3706" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bd108019-4b45-4bd2-9f4f-2b665a0a7b90" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_b87c1718-4efc-472d-8636-06c0802d3706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_cc26eba7-8df4-4a86-a377-7da99ab61ba6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_b87c1718-4efc-472d-8636-06c0802d3706" xlink:to="loc_srt_LitigationCaseAxis_cc26eba7-8df4-4a86-a377-7da99ab61ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_fc299cd6-b030-42fb-a6a0-fe8a80526b65" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_cc26eba7-8df4-4a86-a377-7da99ab61ba6" xlink:to="loc_srt_LitigationCaseTypeDomain_fc299cd6-b030-42fb-a6a0-fe8a80526b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IntellectualPropertyDisputesJeuveauMember_ebb1b767-0a83-48af-b165-620d29b8cd55" xlink:href="eols-20241231.xsd#eols_IntellectualPropertyDisputesJeuveauMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_fc299cd6-b030-42fb-a6a0-fe8a80526b65" xlink:to="loc_eols_IntellectualPropertyDisputesJeuveauMember_ebb1b767-0a83-48af-b165-620d29b8cd55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_b91361be-6cab-4b28-bd77-a2a813d4051a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_b87c1718-4efc-472d-8636-06c0802d3706" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_b91361be-6cab-4b28-bd77-a2a813d4051a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7f6b1661-454b-4cce-9a3e-cbaa4c1b3498" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b91361be-6cab-4b28-bd77-a2a813d4051a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7f6b1661-454b-4cce-9a3e-cbaa4c1b3498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_FollowOnOfferingMember_e74f1263-10b5-4f95-9878-58cb1302830b" xlink:href="eols-20241231.xsd#eols_FollowOnOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7f6b1661-454b-4cce-9a3e-cbaa4c1b3498" xlink:to="loc_eols_FollowOnOfferingMember_e74f1263-10b5-4f95-9878-58cb1302830b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_3d93b791-b24c-4559-908b-17bf250d98a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7f6b1661-454b-4cce-9a3e-cbaa4c1b3498" xlink:to="loc_us-gaap_OverAllotmentOptionMember_3d93b791-b24c-4559-908b-17bf250d98a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_84700079-b928-4cf2-a5df-f1075e38d277" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_b87c1718-4efc-472d-8636-06c0802d3706" xlink:to="loc_us-gaap_TypeOfArrangementAxis_84700079-b928-4cf2-a5df-f1075e38d277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18890ef0-46fc-4f69-8eb2-a2cb2470c69f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_84700079-b928-4cf2-a5df-f1075e38d277" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18890ef0-46fc-4f69-8eb2-a2cb2470c69f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SymateseEuropeAgreementMember_8a79c87e-bea4-417d-a5de-93bbacf3d45c" xlink:href="eols-20241231.xsd#eols_SymateseEuropeAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18890ef0-46fc-4f69-8eb2-a2cb2470c69f" xlink:to="loc_eols_SymateseEuropeAgreementMember_8a79c87e-bea4-417d-a5de-93bbacf3d45c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SymateseU.S.AgreementMember_2a2840da-7d97-4afa-8b68-abe42bebf595" xlink:href="eols-20241231.xsd#eols_SymateseU.S.AgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_18890ef0-46fc-4f69-8eb2-a2cb2470c69f" xlink:to="loc_eols_SymateseU.S.AgreementMember_2a2840da-7d97-4afa-8b68-abe42bebf595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_36d5f51b-7af9-44c4-a976-641a6819f426" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_b87c1718-4efc-472d-8636-06c0802d3706" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_36d5f51b-7af9-44c4-a976-641a6819f426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts_98619b96-363a-4a86-9b90-abd5c7096243" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_36d5f51b-7af9-44c4-a976-641a6819f426" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts_98619b96-363a-4a86-9b90-abd5c7096243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementExpectedRegulatoryApprovalNumberOfProducts_6cd57cf2-0678-4a76-a062-67becb96a4bf" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementExpectedRegulatoryApprovalNumberOfProducts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_36d5f51b-7af9-44c4-a976-641a6819f426" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementExpectedRegulatoryApprovalNumberOfProducts_6cd57cf2-0678-4a76-a062-67becb96a4bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_21d14c4c-11cc-4a27-9321-a047f944bca4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_36d5f51b-7af9-44c4-a976-641a6819f426" xlink:to="loc_us-gaap_OperatingIncomeLoss_21d14c4c-11cc-4a27-9321-a047f944bca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5b499225-f447-4916-8385-a5ba87bcb183" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_36d5f51b-7af9-44c4-a976-641a6819f426" xlink:to="loc_us-gaap_NetIncomeLoss_5b499225-f447-4916-8385-a5ba87bcb183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be90926d-9518-458d-be7f-5653a8c856cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_36d5f51b-7af9-44c4-a976-641a6819f426" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be90926d-9518-458d-be7f-5653a8c856cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_59053612-e6bf-4f6e-8c18-d2ea64732d31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_36d5f51b-7af9-44c4-a976-641a6819f426" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_59053612-e6bf-4f6e-8c18-d2ea64732d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_81f10394-9886-4a9b-988b-61cdafb684c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_36d5f51b-7af9-44c4-a976-641a6819f426" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_81f10394-9886-4a9b-988b-61cdafb684c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4e727135-ba1c-4cc8-bd50-e02760c72030" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_36d5f51b-7af9-44c4-a976-641a6819f426" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4e727135-ba1c-4cc8-bd50-e02760c72030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_4df0d811-6f77-4c60-aef7-c42c0fffd738" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_36d5f51b-7af9-44c4-a976-641a6819f426" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_4df0d811-6f77-4c60-aef7-c42c0fffd738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2a0f04f4-0863-4fcd-a334-14b37695ae9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_36d5f51b-7af9-44c4-a976-641a6819f426" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2a0f04f4-0863-4fcd-a334-14b37695ae9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SaleOfStockGrantedOptionsExercisablePeriod_bd920a14-ca23-4970-b38c-da3e1d460117" xlink:href="eols-20241231.xsd#eols_SaleOfStockGrantedOptionsExercisablePeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_36d5f51b-7af9-44c4-a976-641a6819f426" xlink:to="loc_eols_SaleOfStockGrantedOptionsExercisablePeriod_bd920a14-ca23-4970-b38c-da3e1d460117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f59ab1ec-5fbb-470c-9fda-a0d1f46e4c11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4b5309ad-c84d-471b-9ba1-2ce47d15f9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f59ab1ec-5fbb-470c-9fda-a0d1f46e4c11" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4b5309ad-c84d-471b-9ba1-2ce47d15f9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cb8f45e6-96a7-4c62-993e-e9acc0a8be3f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4b5309ad-c84d-471b-9ba1-2ce47d15f9bb" xlink:to="loc_srt_RangeAxis_cb8f45e6-96a7-4c62-993e-e9acc0a8be3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ea2cd741-ad19-439e-a93a-b39044b80b21" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_cb8f45e6-96a7-4c62-993e-e9acc0a8be3f" xlink:to="loc_srt_RangeMember_ea2cd741-ad19-439e-a93a-b39044b80b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_08f05879-02e2-4b3c-b838-981d6ced1c74" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ea2cd741-ad19-439e-a93a-b39044b80b21" xlink:to="loc_srt_MinimumMember_08f05879-02e2-4b3c-b838-981d6ced1c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_12344b2e-9b24-4f94-a051-5d852fe295f9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ea2cd741-ad19-439e-a93a-b39044b80b21" xlink:to="loc_srt_MaximumMember_12344b2e-9b24-4f94-a051-5d852fe295f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_223cf32a-461a-44d5-979d-39e36b693f56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4b5309ad-c84d-471b-9ba1-2ce47d15f9bb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_223cf32a-461a-44d5-979d-39e36b693f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5039cac-7bbd-4eb3-98b1-d8358e406b58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_223cf32a-461a-44d5-979d-39e36b693f56" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5039cac-7bbd-4eb3-98b1-d8358e406b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DistributionRightsEvolysseNasolabialFoldProductMember_82d6ee9b-c4ec-4ef7-a745-737175330ca0" xlink:href="eols-20241231.xsd#eols_DistributionRightsEvolysseNasolabialFoldProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5039cac-7bbd-4eb3-98b1-d8358e406b58" xlink:to="loc_eols_DistributionRightsEvolysseNasolabialFoldProductMember_82d6ee9b-c4ec-4ef7-a745-737175330ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DistributionRightsMember_39f960ca-e6fc-4e13-93e0-082c27b9c58e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DistributionRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5039cac-7bbd-4eb3-98b1-d8358e406b58" xlink:to="loc_us-gaap_DistributionRightsMember_39f960ca-e6fc-4e13-93e0-082c27b9c58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DistributionRightsEvolysseProductsMember_597de75c-96b4-4fd9-9ac3-354ac41bf2b1" xlink:href="eols-20241231.xsd#eols_DistributionRightsEvolysseProductsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5039cac-7bbd-4eb3-98b1-d8358e406b58" xlink:to="loc_eols_DistributionRightsEvolysseProductsMember_597de75c-96b4-4fd9-9ac3-354ac41bf2b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_fb7ca3d0-4263-4207-ba66-cb477247baed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5039cac-7bbd-4eb3-98b1-d8358e406b58" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_fb7ca3d0-4263-4207-ba66-cb477247baed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5e36ed9c-0797-468e-9a66-0597027b9af8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4b5309ad-c84d-471b-9ba1-2ce47d15f9bb" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5e36ed9c-0797-468e-9a66-0597027b9af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_31778ac7-7f31-4150-8d79-3b84867250ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5e36ed9c-0797-468e-9a66-0597027b9af8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_31778ac7-7f31-4150-8d79-3b84867250ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_EvolusIncMember_b121f5a2-70b9-4375-8482-d43bfa843297" xlink:href="eols-20241231.xsd#eols_EvolusIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_31778ac7-7f31-4150-8d79-3b84867250ec" xlink:to="loc_eols_EvolusIncMember_b121f5a2-70b9-4375-8482-d43bfa843297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a1b3fc6a-19c5-430f-97b8-068b84edd990" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4b5309ad-c84d-471b-9ba1-2ce47d15f9bb" xlink:to="loc_dei_LegalEntityAxis_a1b3fc6a-19c5-430f-97b8-068b84edd990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_df04deb9-ff87-4769-a2d2-8439f5077a14" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_a1b3fc6a-19c5-430f-97b8-068b84edd990" xlink:to="loc_dei_EntityDomain_df04deb9-ff87-4769-a2d2-8439f5077a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SCHAEONLLCMember_05c5fba0-ad25-4956-bd0d-95e19b846cf0" xlink:href="eols-20241231.xsd#eols_SCHAEONLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_df04deb9-ff87-4769-a2d2-8439f5077a14" xlink:to="loc_eols_SCHAEONLLCMember_05c5fba0-ad25-4956-bd0d-95e19b846cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fd7104a0-52d2-4806-9025-e13fd7b8c920" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4b5309ad-c84d-471b-9ba1-2ce47d15f9bb" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fd7104a0-52d2-4806-9025-e13fd7b8c920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3d896c7a-85fb-41f2-b331-18972560d0d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fd7104a0-52d2-4806-9025-e13fd7b8c920" xlink:to="loc_us-gaap_EquityComponentDomain_3d896c7a-85fb-41f2-b331-18972560d0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_10e4479c-2f1a-4411-9f9d-c147c2ffeb8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3d896c7a-85fb-41f2-b331-18972560d0d7" xlink:to="loc_us-gaap_CommonStockMember_10e4479c-2f1a-4411-9f9d-c147c2ffeb8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_74b7ba75-6f71-4572-bbaf-f440779708e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4b5309ad-c84d-471b-9ba1-2ce47d15f9bb" xlink:to="loc_us-gaap_TypeOfArrangementAxis_74b7ba75-6f71-4572-bbaf-f440779708e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b2e806f0-8361-47fc-ae56-8e8cd127dbd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_74b7ba75-6f71-4572-bbaf-f440779708e9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b2e806f0-8361-47fc-ae56-8e8cd127dbd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SymateseU.S.AgreementMember_9e3ac528-49ac-4b19-99f3-427efe437b56" xlink:href="eols-20241231.xsd#eols_SymateseU.S.AgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b2e806f0-8361-47fc-ae56-8e8cd127dbd2" xlink:to="loc_eols_SymateseU.S.AgreementMember_9e3ac528-49ac-4b19-99f3-427efe437b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SymateseEuropeAgreementMember_ac09e342-e5f1-40e7-9c4d-25532cfff5d8" xlink:href="eols-20241231.xsd#eols_SymateseEuropeAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b2e806f0-8361-47fc-ae56-8e8cd127dbd2" xlink:to="loc_eols_SymateseEuropeAgreementMember_ac09e342-e5f1-40e7-9c4d-25532cfff5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_2758001d-6b92-40f1-8028-d4cc9a56bf61" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4b5309ad-c84d-471b-9ba1-2ce47d15f9bb" xlink:to="loc_srt_LitigationCaseAxis_2758001d-6b92-40f1-8028-d4cc9a56bf61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_f10d8d10-06cc-4b9d-8a86-abcb3ed45f7f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_2758001d-6b92-40f1-8028-d4cc9a56bf61" xlink:to="loc_srt_LitigationCaseTypeDomain_f10d8d10-06cc-4b9d-8a86-abcb3ed45f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IntellectualPropertyDisputesJeuveauMember_23448806-ea80-44a6-ae19-347bedcab39f" xlink:href="eols-20241231.xsd#eols_IntellectualPropertyDisputesJeuveauMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_f10d8d10-06cc-4b9d-8a86-abcb3ed45f7f" xlink:to="loc_eols_IntellectualPropertyDisputesJeuveauMember_23448806-ea80-44a6-ae19-347bedcab39f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ce48b98c-69da-4683-bff7-847c6aa782ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4b5309ad-c84d-471b-9ba1-2ce47d15f9bb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ce48b98c-69da-4683-bff7-847c6aa782ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_80fd2a4d-4f97-4a9b-9f3d-ea31be4aee1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ce48b98c-69da-4683-bff7-847c6aa782ae" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_80fd2a4d-4f97-4a9b-9f3d-ea31be4aee1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_962eb997-d29d-41f8-9e0f-65003deec6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_80fd2a4d-4f97-4a9b-9f3d-ea31be4aee1b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_962eb997-d29d-41f8-9e0f-65003deec6e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_62a6e5bd-8185-4e48-8de7-c355815e52df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_80fd2a4d-4f97-4a9b-9f3d-ea31be4aee1b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_62a6e5bd-8185-4e48-8de7-c355815e52df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_MilestoneAxis_9e597067-4f50-4457-9c65-d87a8783fe74" xlink:href="eols-20241231.xsd#eols_MilestoneAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4b5309ad-c84d-471b-9ba1-2ce47d15f9bb" xlink:to="loc_eols_MilestoneAxis_9e597067-4f50-4457-9c65-d87a8783fe74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_MilestoneDomain_284d3184-1628-46c9-9c93-bedfef1b67ee" xlink:href="eols-20241231.xsd#eols_MilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_MilestoneAxis_9e597067-4f50-4457-9c65-d87a8783fe74" xlink:to="loc_eols_MilestoneDomain_284d3184-1628-46c9-9c93-bedfef1b67ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_FirstMilestonePaymentMember_c4b37277-f696-4593-a998-0f3b7ea8f03c" xlink:href="eols-20241231.xsd#eols_FirstMilestonePaymentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_MilestoneDomain_284d3184-1628-46c9-9c93-bedfef1b67ee" xlink:to="loc_eols_FirstMilestonePaymentMember_c4b37277-f696-4593-a998-0f3b7ea8f03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SecondMilestonePaymentMember_d30f0754-b709-423c-90b0-083cc92ce9ac" xlink:href="eols-20241231.xsd#eols_SecondMilestonePaymentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_MilestoneDomain_284d3184-1628-46c9-9c93-bedfef1b67ee" xlink:to="loc_eols_SecondMilestonePaymentMember_d30f0754-b709-423c-90b0-083cc92ce9ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4cec4932-ff82-4d0c-b1a8-80a68b4b05fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4b5309ad-c84d-471b-9ba1-2ce47d15f9bb" xlink:to="loc_us-gaap_AwardTypeAxis_4cec4932-ff82-4d0c-b1a8-80a68b4b05fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e7df0ed3-1e31-40d2-84ea-6c87f86be540" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4cec4932-ff82-4d0c-b1a8-80a68b4b05fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e7df0ed3-1e31-40d2-84ea-6c87f86be540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PerformanceRestrictedStockUnitsPRSUMember_cf51c542-5477-44a6-a424-917a6cd3b6c7" xlink:href="eols-20241231.xsd#eols_PerformanceRestrictedStockUnitsPRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e7df0ed3-1e31-40d2-84ea-6c87f86be540" xlink:to="loc_eols_PerformanceRestrictedStockUnitsPRSUMember_cf51c542-5477-44a6-a424-917a6cd3b6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4b5309ad-c84d-471b-9ba1-2ce47d15f9bb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_35aba368-46bb-46c1-bd1d-67c8182d6901" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_us-gaap_NumberOfReportableSegments_35aba368-46bb-46c1-bd1d-67c8182d6901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_a776c918-5d6c-4732-9c38-259e96db5069" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_us-gaap_NumberOfOperatingSegments_a776c918-5d6c-4732-9c38-259e96db5069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_AccountsReceivableCreditCardTransactionConvertedToCashPeriod_1c3d4995-ab55-43cc-9bc0-bdfc8116017e" xlink:href="eols-20241231.xsd#eols_AccountsReceivableCreditCardTransactionConvertedToCashPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_AccountsReceivableCreditCardTransactionConvertedToCashPeriod_1c3d4995-ab55-43cc-9bc0-bdfc8116017e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_9ed795e7-bdf4-40ca-98dc-2f08e4a5185b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_9ed795e7-bdf4-40ca-98dc-2f08e4a5185b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_9b0553ed-94da-4cb1-ba36-3503c9e44be5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_us-gaap_NumberOfReportingUnits_9b0553ed-94da-4cb1-ba36-3503c9e44be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_b71f42bd-d2f0-4cd3-a0ed-fbf92249ca06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_b71f42bd-d2f0-4cd3-a0ed-fbf92249ca06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ResearchAndDevelopmentInProcess1_02271259-bfb8-449e-9d17-ba151ee5d523" xlink:href="eols-20241231.xsd#eols_ResearchAndDevelopmentInProcess1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_ResearchAndDevelopmentInProcess1_02271259-bfb8-449e-9d17-ba151ee5d523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementRightToCommercializeAndDistributeNumberOfProductCandidates_fa91bdb3-5d94-450a-ae78-e650aeff97cb" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementRightToCommercializeAndDistributeNumberOfProductCandidates"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementRightToCommercializeAndDistributeNumberOfProductCandidates_fa91bdb3-5d94-450a-ae78-e650aeff97cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementMinimumMilestonePayment_09ed5446-3cb1-4751-816d-71d8f45acf38" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementMinimumMilestonePayment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementMinimumMilestonePayment_09ed5446-3cb1-4751-816d-71d8f45acf38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement_e0d8296b-2495-4cff-bb80-215e5bd8e5cd" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement_e0d8296b-2495-4cff-bb80-215e5bd8e5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod_98015621-d2d0-4ab4-9790-58dd2bc31073" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod_98015621-d2d0-4ab4-9790-58dd2bc31073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne_e88f090b-86d2-4b44-bd4d-5a4529ba77c2" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne_e88f090b-86d2-4b44-bd4d-5a4529ba77c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo_5eaa31b8-7b81-41f9-80b5-603d16b0f72e" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo_5eaa31b8-7b81-41f9-80b5-603d16b0f72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree_30d3ab72-e9ff-4c02-9fd6-7c6d645f5e90" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree_30d3ab72-e9ff-4c02-9fd6-7c6d645f5e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour_768907d2-bad7-4bb7-bcd0-e7bb27ba82ef" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour_768907d2-bad7-4bb7-bcd0-e7bb27ba82ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense_d67729b5-47e4-4e97-8430-480d9cc0b19e" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense_d67729b5-47e4-4e97-8430-480d9cc0b19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementInitialTerm_3099f90a-38c6-4916-99a1-84971c407c7f" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementInitialTerm"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementInitialTerm_3099f90a-38c6-4916-99a1-84971c407c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementRenewalTerm_fae88a3e-02e6-4cc8-8df9-6c04c6cd19dd" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementRenewalTerm"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementRenewalTerm_fae88a3e-02e6-4cc8-8df9-6c04c6cd19dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementNumberOfProductCandidates_38823553-b3bf-43e8-bf26-2e847d2aa55c" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementNumberOfProductCandidates"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementNumberOfProductCandidates_38823553-b3bf-43e8-bf26-2e847d2aa55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementNumberOfCountriesUseAestheticsAndDermatologicalFields_ec6a4b38-27a0-4165-a5bb-1d39fcde46a2" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementNumberOfCountriesUseAestheticsAndDermatologicalFields"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementNumberOfCountriesUseAestheticsAndDermatologicalFields_ec6a4b38-27a0-4165-a5bb-1d39fcde46a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement_42a1400f-06a2-4b96-ae5b-7c4bce9511b1" xlink:href="eols-20241231.xsd#eols_StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement_42a1400f-06a2-4b96-ae5b-7c4bce9511b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment_498b8c59-bc47-41ea-ad40-784e0aad6c75" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment_498b8c59-bc47-41ea-ad40-784e0aad6c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementAnnualRevenue_fe8e3fec-bd4a-43d8-8ddd-74437371414d" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementAnnualRevenue"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementAnnualRevenue_fe8e3fec-bd4a-43d8-8ddd-74437371414d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_NonCashInResearchAndDevelopmentInProcessExpenses_bef84e3c-9eee-4c12-9550-4fadf1a8077d" xlink:href="eols-20241231.xsd#eols_NonCashInResearchAndDevelopmentInProcessExpenses"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_NonCashInResearchAndDevelopmentInProcessExpenses_bef84e3c-9eee-4c12-9550-4fadf1a8077d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_b880adf0-8cb0-4245-ac8e-9b53c38492ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_b880adf0-8cb0-4245-ac8e-9b53c38492ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0e4922d9-9597-4794-aebe-ea5f5898bbc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0e4922d9-9597-4794-aebe-ea5f5898bbc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementPendingRegulatoryApprovalNumberOfProducts_65dad83f-e22a-4c25-ba96-63fb29164079" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementPendingRegulatoryApprovalNumberOfProducts"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementPendingRegulatoryApprovalNumberOfProducts_65dad83f-e22a-4c25-ba96-63fb29164079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementMilestonePaymentPayablePeriod_266cc484-403b-4e4d-860c-c5187c97af4e" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementMilestonePaymentPayablePeriod"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementMilestonePaymentPayablePeriod_266cc484-403b-4e4d-860c-c5187c97af4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts_d9ad7ef0-c60e-40c4-8c42-1f37e1295e0e" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts_d9ad7ef0-c60e-40c4-8c42-1f37e1295e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementLiabilityNoncurrent_be94f518-d89d-4654-9b61-8b1518c19b2c" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementLiabilityNoncurrent"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementLiabilityNoncurrent_be94f518-d89d-4654-9b61-8b1518c19b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementIntangibleAsset_7dd6d26f-5034-46d2-8845-34b4e077c081" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementIntangibleAsset"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementIntangibleAsset_7dd6d26f-5034-46d2-8845-34b4e077c081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_bf209dd3-2f57-4560-9f4d-23f467a3a28a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_bf209dd3-2f57-4560-9f4d-23f467a3a28a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_670e6f83-eeed-414b-89f8-47da6cfd849a" xlink:href="eols-20241231.xsd#eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_670e6f83-eeed-414b-89f8-47da6cfd849a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_479b008d-0d09-4f33-992a-eb42925d738f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_479b008d-0d09-4f33-992a-eb42925d738f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_RebatesAndCouponsCreditsAndPayments_28e946cc-34c0-4333-a0bc-3dee5208baf1" xlink:href="eols-20241231.xsd#eols_RebatesAndCouponsCreditsAndPayments"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_RebatesAndCouponsCreditsAndPayments_28e946cc-34c0-4333-a0bc-3dee5208baf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability_2290b944-7974-4b51-aefd-9fb097c34d5a" xlink:href="eols-20241231.xsd#eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability_2290b944-7974-4b51-aefd-9fb097c34d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1f0e47c8-9ac7-4401-883e-15b6a1163920" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1f0e47c8-9ac7-4401-883e-15b6a1163920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_65e4080a-0e68-4534-a7ca-51780a475bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_65e4080a-0e68-4534-a7ca-51780a475bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_be0fba65-fdfc-4d80-9ab3-d91f96ff2721" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_be0fba65-fdfc-4d80-9ab3-d91f96ff2721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_AccountsReceivableAllowanceForCreditLossWriteOffRecovery_1d986781-08b8-41c4-b529-a5f9d75c826d" xlink:href="eols-20241231.xsd#eols_AccountsReceivableAllowanceForCreditLossWriteOffRecovery"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_AccountsReceivableAllowanceForCreditLossWriteOffRecovery_1d986781-08b8-41c4-b529-a5f9d75c826d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_95bb53be-3a4e-4c51-9320-3074d485d0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_95bb53be-3a4e-4c51-9320-3074d485d0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LossContingencySettlementAgreementPaymentTerms_d6a1d45a-9f7e-40de-9352-a77166d279e3" xlink:href="eols-20241231.xsd#eols_LossContingencySettlementAgreementPaymentTerms"/>
    <link:presentationArc order="42" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_LossContingencySettlementAgreementPaymentTerms_d6a1d45a-9f7e-40de-9352-a77166d279e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_7b94ee6d-2b32-4f3e-9905-91fd0c78c1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="43" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_7b94ee6d-2b32-4f3e-9905-91fd0c78c1e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_debf845a-27ec-4e91-9db9-4317b29896cf" xlink:href="eols-20241231.xsd#eols_StockIssuedDuringPeriodSharesLitigationSettlement"/>
    <link:presentationArc order="44" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_debf845a-27ec-4e91-9db9-4317b29896cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_4b71327b-29cd-4376-8f48-ef5f8c94deb9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="45" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_us-gaap_LitigationReserveCurrent_4b71327b-29cd-4376-8f48-ef5f8c94deb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c95bef60-7bc8-4497-8e9d-9f7cf0b1c133" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="46" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c95bef60-7bc8-4497-8e9d-9f7cf0b1c133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_5f3aa64e-409c-493f-8404-dea47b7bae6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="47" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_us-gaap_AdvertisingExpense_5f3aa64e-409c-493f-8404-dea47b7bae6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c038f05a-da16-4779-922a-0e953e5db3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="48" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_cca0ec21-a8de-4057-9761-4442744ad37d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c038f05a-da16-4779-922a-0e953e5db3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a6beffef-8cc1-4ce5-9b77-f25422ddbf98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_781af877-a3c3-4234-9909-2b2cd3f1986f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a6beffef-8cc1-4ce5-9b77-f25422ddbf98" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_781af877-a3c3-4234-9909-2b2cd3f1986f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1fd7e858-c50e-4ead-a8e8-63be162d7ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_781af877-a3c3-4234-9909-2b2cd3f1986f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1fd7e858-c50e-4ead-a8e8-63be162d7ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7458929b-8783-4c3d-b394-01b656ecb4c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1fd7e858-c50e-4ead-a8e8-63be162d7ed6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7458929b-8783-4c3d-b394-01b656ecb4c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_aa47eb8c-fa23-49e8-bd6c-9ba5d63115a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7458929b-8783-4c3d-b394-01b656ecb4c4" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_aa47eb8c-fa23-49e8-bd6c-9ba5d63115a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a5b476b0-f1c8-4b3e-825d-f90836322a33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_781af877-a3c3-4234-9909-2b2cd3f1986f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a5b476b0-f1c8-4b3e-825d-f90836322a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50b6e7d3-8c85-4f3a-a68e-c447c0be67e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a5b476b0-f1c8-4b3e-825d-f90836322a33" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50b6e7d3-8c85-4f3a-a68e-c447c0be67e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_14e7ba4b-2dc8-4aa6-bf1d-e79600559b71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50b6e7d3-8c85-4f3a-a68e-c447c0be67e3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_14e7ba4b-2dc8-4aa6-bf1d-e79600559b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5e818d7e-614f-445e-a0cf-2bd876113065" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50b6e7d3-8c85-4f3a-a68e-c447c0be67e3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5e818d7e-614f-445e-a0cf-2bd876113065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c65d5521-79f2-40f3-9c8a-bdad12d608bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50b6e7d3-8c85-4f3a-a68e-c447c0be67e3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c65d5521-79f2-40f3-9c8a-bdad12d608bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f6b1b5cf-aab3-4d36-ae57-1d07ef1bf9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_781af877-a3c3-4234-9909-2b2cd3f1986f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f6b1b5cf-aab3-4d36-ae57-1d07ef1bf9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_d06e3678-c6bd-4c23-8cce-28bce603c269" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f6b1b5cf-aab3-4d36-ae57-1d07ef1bf9eb" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_d06e3678-c6bd-4c23-8cce-28bce603c269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_df8e1ac8-2a4a-4f41-a54b-ef852ad28774" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7b908b44-845d-4934-9ee8-3342938b004e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_df8e1ac8-2a4a-4f41-a54b-ef852ad28774" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7b908b44-845d-4934-9ee8-3342938b004e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8283f6e8-da69-4bf2-8f81-69142c61e2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7b908b44-845d-4934-9ee8-3342938b004e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8283f6e8-da69-4bf2-8f81-69142c61e2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1538bac9-3960-4431-b4bb-b3cbebacfcc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8283f6e8-da69-4bf2-8f81-69142c61e2bb" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1538bac9-3960-4431-b4bb-b3cbebacfcc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ContingentRoyaltyObligationMember_b071a619-352f-4ca1-95d0-ec4fc7cc28b9" xlink:href="eols-20241231.xsd#eols_ContingentRoyaltyObligationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1538bac9-3960-4431-b4bb-b3cbebacfcc1" xlink:to="loc_eols_ContingentRoyaltyObligationMember_b071a619-352f-4ca1-95d0-ec4fc7cc28b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_0776cf83-508b-4970-9c48-31f845473472" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7b908b44-845d-4934-9ee8-3342938b004e" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_0776cf83-508b-4970-9c48-31f845473472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_01efbba0-5596-4c03-828d-e54b8e8fbf9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_0776cf83-508b-4970-9c48-31f845473472" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_01efbba0-5596-4c03-828d-e54b8e8fbf9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_a35b96a5-f20f-406b-a82d-440811d13965" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_01efbba0-5596-4c03-828d-e54b8e8fbf9f" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_a35b96a5-f20f-406b-a82d-440811d13965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ca250c13-9207-4b21-af2a-6859317ab008" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7b908b44-845d-4934-9ee8-3342938b004e" xlink:to="loc_srt_RangeAxis_ca250c13-9207-4b21-af2a-6859317ab008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b13607be-ff36-44c4-a3b1-3ff4b16e6380" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ca250c13-9207-4b21-af2a-6859317ab008" xlink:to="loc_srt_RangeMember_b13607be-ff36-44c4-a3b1-3ff4b16e6380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c880846b-d80c-401f-965b-3b7fc4a94032" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b13607be-ff36-44c4-a3b1-3ff4b16e6380" xlink:to="loc_srt_MaximumMember_c880846b-d80c-401f-965b-3b7fc4a94032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_d9a624a9-a4bd-44c3-82e0-df650a580bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7b908b44-845d-4934-9ee8-3342938b004e" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_d9a624a9-a4bd-44c3-82e0-df650a580bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_e62daa8d-e5f8-40c4-b289-92310f587577" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_d9a624a9-a4bd-44c3-82e0-df650a580bc1" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_e62daa8d-e5f8-40c4-b289-92310f587577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_fe0ff7c8-36e5-4881-a99b-c782b3097b19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_e62daa8d-e5f8-40c4-b289-92310f587577" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_fe0ff7c8-36e5-4881-a99b-c782b3097b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_479c3ae4-4515-44ab-9a2b-17d48c59247f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_fe0ff7c8-36e5-4881-a99b-c782b3097b19" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_479c3ae4-4515-44ab-9a2b-17d48c59247f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_50219aa5-dfce-4816-a15a-6ff4d2096dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7b908b44-845d-4934-9ee8-3342938b004e" xlink:to="loc_us-gaap_DebtInstrumentAxis_50219aa5-dfce-4816-a15a-6ff4d2096dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fc475be8-862f-4b6a-b55d-25252ec58567" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_50219aa5-dfce-4816-a15a-6ff4d2096dc7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fc475be8-862f-4b6a-b55d-25252ec58567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansMember_0f2ac5ec-d8bf-4504-9d59-7729209dd79c" xlink:href="eols-20241231.xsd#eols_PharmakonTermLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fc475be8-862f-4b6a-b55d-25252ec58567" xlink:to="loc_eols_PharmakonTermLoansMember_0f2ac5ec-d8bf-4504-9d59-7729209dd79c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b9453b6-3962-4aea-a67c-068930f9a7d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7b908b44-845d-4934-9ee8-3342938b004e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b9453b6-3962-4aea-a67c-068930f9a7d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_9e5fa904-43e0-45ad-96da-c1a1d5066446" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AlternativeInvestmentMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b9453b6-3962-4aea-a67c-068930f9a7d1" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_9e5fa904-43e0-45ad-96da-c1a1d5066446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2f89b0f9-7e56-4907-ba93-dfb75a10a442" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b9453b6-3962-4aea-a67c-068930f9a7d1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2f89b0f9-7e56-4907-ba93-dfb75a10a442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsReconciliationofFairValueMeasurementofContingentRoyaltyObligationPayableDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#FairValueMeasurementsReconciliationofFairValueMeasurementofContingentRoyaltyObligationPayableDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsReconciliationofFairValueMeasurementofContingentRoyaltyObligationPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2713f839-1950-4693-9a0e-652857d40f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b3b2f50d-6aab-4c48-9abb-3f93256b9481" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2713f839-1950-4693-9a0e-652857d40f3b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b3b2f50d-6aab-4c48-9abb-3f93256b9481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_47a596bc-68b8-4236-b5bd-0bf0897fab38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b3b2f50d-6aab-4c48-9abb-3f93256b9481" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_47a596bc-68b8-4236-b5bd-0bf0897fab38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_62646652-2fc6-4344-ae23-72bb33979b89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b3b2f50d-6aab-4c48-9abb-3f93256b9481" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_62646652-2fc6-4344-ae23-72bb33979b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9549c4ab-eeae-4fb5-a594-9deadc9c0669" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b3b2f50d-6aab-4c48-9abb-3f93256b9481" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9549c4ab-eeae-4fb5-a594-9deadc9c0669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_898d8c4d-e9b9-41ae-b81f-dd8e8a93e430" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b3b2f50d-6aab-4c48-9abb-3f93256b9481" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_898d8c4d-e9b9-41ae-b81f-dd8e8a93e430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_aeb0cb7d-eb04-42d7-bee4-db417206ff40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f271bd5a-995a-44b8-9ae4-28af9eb6b7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_aeb0cb7d-eb04-42d7-bee4-db417206ff40" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f271bd5a-995a-44b8-9ae4-28af9eb6b7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_af495e68-7488-4ad2-ada8-defb6331d065" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f271bd5a-995a-44b8-9ae4-28af9eb6b7ba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_af495e68-7488-4ad2-ada8-defb6331d065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f0c8c308-808f-47b7-8f85-bbf57f6a5fca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_af495e68-7488-4ad2-ada8-defb6331d065" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f0c8c308-808f-47b7-8f85-bbf57f6a5fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DistributionRightsMember_e41890e8-b469-44f0-819b-be2f70107ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DistributionRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f0c8c308-808f-47b7-8f85-bbf57f6a5fca" xlink:to="loc_us-gaap_DistributionRightsMember_e41890e8-b469-44f0-819b-be2f70107ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_f5ca8fa1-9cd1-41bf-b6f6-ae639545cc61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f0c8c308-808f-47b7-8f85-bbf57f6a5fca" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_f5ca8fa1-9cd1-41bf-b6f6-ae639545cc61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_68897cc3-99f7-412d-acf7-b38954a16167" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f271bd5a-995a-44b8-9ae4-28af9eb6b7ba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_68897cc3-99f7-412d-acf7-b38954a16167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_bf6750e0-1b2e-4301-aec1-c006380c9178" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_68897cc3-99f7-412d-acf7-b38954a16167" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_bf6750e0-1b2e-4301-aec1-c006380c9178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ed7a5dca-3ab9-4abd-9794-a58a1da29a04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_bf6750e0-1b2e-4301-aec1-c006380c9178" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ed7a5dca-3ab9-4abd-9794-a58a1da29a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_104d860b-acf3-4bd6-952b-d25cea0a726d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_bf6750e0-1b2e-4301-aec1-c006380c9178" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_104d860b-acf3-4bd6-952b-d25cea0a726d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9318f66f-0068-41b0-a6ac-5551e06f657d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_bf6750e0-1b2e-4301-aec1-c006380c9178" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9318f66f-0068-41b0-a6ac-5551e06f657d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d850726b-eb4c-4c73-8eb6-bbc9c2b1a47a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_bf6750e0-1b2e-4301-aec1-c006380c9178" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d850726b-eb4c-4c73-8eb6-bbc9c2b1a47a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_b3feeb32-dd7b-4ebf-a14e-9c62e84b8dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_68897cc3-99f7-412d-acf7-b38954a16167" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_b3feeb32-dd7b-4ebf-a14e-9c62e84b8dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5450e4f4-b3f1-40a4-88f9-e02570b6ad1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_b3feeb32-dd7b-4ebf-a14e-9c62e84b8dc3" xlink:to="loc_us-gaap_Goodwill_5450e4f4-b3f1-40a4-88f9-e02570b6ad1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IntangibleAssetsGrossIncludingGoodwill_02ace2fe-a754-466e-a98d-e4091647835f" xlink:href="eols-20241231.xsd#eols_IntangibleAssetsGrossIncludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_68897cc3-99f7-412d-acf7-b38954a16167" xlink:to="loc_eols_IntangibleAssetsGrossIncludingGoodwill_02ace2fe-a754-466e-a98d-e4091647835f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_cce76e5a-86a3-443a-8650-93f2aecee5ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_68897cc3-99f7-412d-acf7-b38954a16167" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_cce76e5a-86a3-443a-8650-93f2aecee5ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7a23f66d-f23e-4208-b150-b262c844478e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_dc11bbcb-b75f-43d3-b28a-270654e27101" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7a23f66d-f23e-4208-b150-b262c844478e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_dc11bbcb-b75f-43d3-b28a-270654e27101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_6da0d868-f65d-4b98-a395-dc70385a7b90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7a23f66d-f23e-4208-b150-b262c844478e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_6da0d868-f65d-4b98-a395-dc70385a7b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_88c2c719-4983-49d7-aaaf-e076341b436b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7a23f66d-f23e-4208-b150-b262c844478e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_88c2c719-4983-49d7-aaaf-e076341b436b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_aeddbff8-c6cf-41b1-a70b-6f78f4fa6ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7a23f66d-f23e-4208-b150-b262c844478e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_aeddbff8-c6cf-41b1-a70b-6f78f4fa6ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_00073604-432d-4581-bc99-7b3295150158" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7a23f66d-f23e-4208-b150-b262c844478e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_00073604-432d-4581-bc99-7b3295150158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_fd4638af-ad6b-4453-b627-54e1afef1656" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7a23f66d-f23e-4208-b150-b262c844478e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_fd4638af-ad6b-4453-b627-54e1afef1656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e82d874c-159d-4fe2-8b7a-9f3181ae35b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7a23f66d-f23e-4208-b150-b262c844478e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e82d874c-159d-4fe2-8b7a-9f3181ae35b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3a8ec5f3-29cd-4ad8-95ff-ac70bfd3ab5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_459cb587-e22c-4a90-b397-6ee68443ad0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3a8ec5f3-29cd-4ad8-95ff-ac70bfd3ab5c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_459cb587-e22c-4a90-b397-6ee68443ad0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_923bfe7e-753e-4904-ad79-9a022b72006d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_459cb587-e22c-4a90-b397-6ee68443ad0c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_923bfe7e-753e-4904-ad79-9a022b72006d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f5551c6d-bad0-4c52-a88d-9e11fe20d39f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_923bfe7e-753e-4904-ad79-9a022b72006d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f5551c6d-bad0-4c52-a88d-9e11fe20d39f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DistributionRightsEvolysseNasolabialFoldProductMember_eb5d3be2-34fe-4a85-872d-601a48b915bf" xlink:href="eols-20241231.xsd#eols_DistributionRightsEvolysseNasolabialFoldProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f5551c6d-bad0-4c52-a88d-9e11fe20d39f" xlink:to="loc_eols_DistributionRightsEvolysseNasolabialFoldProductMember_eb5d3be2-34fe-4a85-872d-601a48b915bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_eb210266-3417-421b-b5e8-a733ee9bfee8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f5551c6d-bad0-4c52-a88d-9e11fe20d39f" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_eb210266-3417-421b-b5e8-a733ee9bfee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a1ab02a8-cc84-4f63-a14f-5727068f3b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_459cb587-e22c-4a90-b397-6ee68443ad0c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a1ab02a8-cc84-4f63-a14f-5727068f3b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ac9734d9-7b84-4cd2-8148-d3e83873cfd7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a1ab02a8-cc84-4f63-a14f-5727068f3b7e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ac9734d9-7b84-4cd2-8148-d3e83873cfd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SymateseEuropeAgreementMember_182c65cd-f908-4473-8e20-5dc67d359a6a" xlink:href="eols-20241231.xsd#eols_SymateseEuropeAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ac9734d9-7b84-4cd2-8148-d3e83873cfd7" xlink:to="loc_eols_SymateseEuropeAgreementMember_182c65cd-f908-4473-8e20-5dc67d359a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_5b1e1251-fe25-4802-896f-a75bd0739ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_459cb587-e22c-4a90-b397-6ee68443ad0c" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_5b1e1251-fe25-4802-896f-a75bd0739ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_07e62812-3c7f-4819-a30a-9969ec9a7bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5b1e1251-fe25-4802-896f-a75bd0739ec8" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_07e62812-3c7f-4819-a30a-9969ec9a7bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8eb9694d-7328-4faa-9c21-8ce028559c67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5b1e1251-fe25-4802-896f-a75bd0739ec8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8eb9694d-7328-4faa-9c21-8ce028559c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAdditions_fc9fea39-7444-46a2-ad07-57fc1b1c2b79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalizedComputerSoftwareAdditions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5b1e1251-fe25-4802-896f-a75bd0739ec8" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAdditions_fc9fea39-7444-46a2-ad07-57fc1b1c2b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_7d379a49-2f69-49e7-9863-52e8922c2614" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5b1e1251-fe25-4802-896f-a75bd0739ec8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_7d379a49-2f69-49e7-9863-52e8922c2614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_23acb1f6-2a9e-42bd-8f0f-ceaf30e53212" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_5b1e1251-fe25-4802-896f-a75bd0739ec8" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_23acb1f6-2a9e-42bd-8f0f-ceaf30e53212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#AccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_8123b6d9-7a21-43c8-8b0d-4495fcdb7bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_ef0e4a8a-5e72-4d56-a448-027abb058f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8123b6d9-7a21-43c8-8b0d-4495fcdb7bc4" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_ef0e4a8a-5e72-4d56-a448-027abb058f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_559f023e-cc28-43cb-a9b9-b60903ccb1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8123b6d9-7a21-43c8-8b0d-4495fcdb7bc4" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_559f023e-cc28-43cb-a9b9-b60903ccb1e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_30d7dc75-aacf-4dd6-a339-f01c7f196b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8123b6d9-7a21-43c8-8b0d-4495fcdb7bc4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_30d7dc75-aacf-4dd6-a339-f01c7f196b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_35139be6-0ee8-4e14-a7b0-bfd9e90f117c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8123b6d9-7a21-43c8-8b0d-4495fcdb7bc4" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_35139be6-0ee8-4e14-a7b0-bfd9e90f117c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cb2ec32e-a347-453a-b368-f2561964e116" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8123b6d9-7a21-43c8-8b0d-4495fcdb7bc4" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cb2ec32e-a347-453a-b368-f2561964e116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_67f6225c-118f-4eeb-b337-2d48810d75ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6d82f35e-6fbd-42dc-a025-9c753c15a5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_67f6225c-118f-4eeb-b337-2d48810d75ff" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6d82f35e-6fbd-42dc-a025-9c753c15a5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1b053a80-64ae-411d-86b2-4d0afc12ad84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6d82f35e-6fbd-42dc-a025-9c753c15a5c9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1b053a80-64ae-411d-86b2-4d0afc12ad84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9785c9ab-fd8b-498c-87bb-d2e1acba76b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1b053a80-64ae-411d-86b2-4d0afc12ad84" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9785c9ab-fd8b-498c-87bb-d2e1acba76b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_63fc8464-2b09-429e-bdc6-2c7f6d45ef1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9785c9ab-fd8b-498c-87bb-d2e1acba76b5" xlink:to="loc_us-gaap_EquipmentMember_63fc8464-2b09-429e-bdc6-2c7f6d45ef1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_0a53419f-b51f-40b0-85ef-97c85646912c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9785c9ab-fd8b-498c-87bb-d2e1acba76b5" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_0a53419f-b51f-40b0-85ef-97c85646912c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_bb1a902d-7c47-419c-9632-7859643bce38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9785c9ab-fd8b-498c-87bb-d2e1acba76b5" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_bb1a902d-7c47-419c-9632-7859643bce38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_2b306d4f-c9a4-43e3-ba7e-7e95cc20aa87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9785c9ab-fd8b-498c-87bb-d2e1acba76b5" xlink:to="loc_us-gaap_ComputerEquipmentMember_2b306d4f-c9a4-43e3-ba7e-7e95cc20aa87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_MarketingFixturesMember_1172e908-8bab-483c-9797-117f0e27a0cd" xlink:href="eols-20241231.xsd#eols_MarketingFixturesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9785c9ab-fd8b-498c-87bb-d2e1acba76b5" xlink:to="loc_eols_MarketingFixturesMember_1172e908-8bab-483c-9797-117f0e27a0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7603d1f1-0a1d-4403-a48c-73fc7e154a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6d82f35e-6fbd-42dc-a025-9c753c15a5c9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7603d1f1-0a1d-4403-a48c-73fc7e154a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_e0ba0aa7-603d-43cd-878b-a82599edda1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7603d1f1-0a1d-4403-a48c-73fc7e154a0a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_e0ba0aa7-603d-43cd-878b-a82599edda1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_bf8a33a6-4b06-4c1b-b283-5185823c1604" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7603d1f1-0a1d-4403-a48c-73fc7e154a0a" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_bf8a33a6-4b06-4c1b-b283-5185823c1604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a862d4fd-b0ae-42bd-bde4-774764b9057b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7603d1f1-0a1d-4403-a48c-73fc7e154a0a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a862d4fd-b0ae-42bd-bde4-774764b9057b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/PropertyPlantandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#PropertyPlantandEquipmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/PropertyPlantandEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1fa2f73c-03c5-4e00-8f1f-b8b5244465ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_3f574591-d9a1-41cc-b971-a98977906c20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_1fa2f73c-03c5-4e00-8f1f-b8b5244465ff" xlink:to="loc_us-gaap_Depreciation_3f574591-d9a1-41cc-b971-a98977906c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/TermLoansNarrativeDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#TermLoansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/TermLoansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_999cecd5-f2d4-4829-9110-647705069706" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_9782f76f-b92f-4416-87d9-d5e40b589db5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_999cecd5-f2d4-4829-9110-647705069706" xlink:to="loc_us-gaap_DebtInstrumentTable_9782f76f-b92f-4416-87d9-d5e40b589db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_0094c72e-5f75-4602-932f-20cf3825bb85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9782f76f-b92f-4416-87d9-d5e40b589db5" xlink:to="loc_us-gaap_DebtInstrumentAxis_0094c72e-5f75-4602-932f-20cf3825bb85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_018dce93-1a37-4904-bb0a-891a3ee22616" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_0094c72e-5f75-4602-932f-20cf3825bb85" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_018dce93-1a37-4904-bb0a-891a3ee22616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansMember_7cc2301b-4ce5-4549-ae3b-335fda86bbf7" xlink:href="eols-20241231.xsd#eols_PharmakonTermLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_018dce93-1a37-4904-bb0a-891a3ee22616" xlink:to="loc_eols_PharmakonTermLoansMember_7cc2301b-4ce5-4549-ae3b-335fda86bbf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansOneMember_22181b81-fec2-436c-9d50-7d26bed9a796" xlink:href="eols-20241231.xsd#eols_PharmakonTermLoansOneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_018dce93-1a37-4904-bb0a-891a3ee22616" xlink:to="loc_eols_PharmakonTermLoansOneMember_22181b81-fec2-436c-9d50-7d26bed9a796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PharmakonTermLoansTwoMember_6b7e06f3-1eee-41a7-af5e-20f21b530dd4" xlink:href="eols-20241231.xsd#eols_PharmakonTermLoansTwoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_018dce93-1a37-4904-bb0a-891a3ee22616" xlink:to="loc_eols_PharmakonTermLoansTwoMember_6b7e06f3-1eee-41a7-af5e-20f21b530dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_beb3e3ac-9117-4764-b625-8a125020f4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9782f76f-b92f-4416-87d9-d5e40b589db5" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_beb3e3ac-9117-4764-b625-8a125020f4fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6c30b6a3-383e-4306-b933-69966312f6fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_beb3e3ac-9117-4764-b625-8a125020f4fa" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6c30b6a3-383e-4306-b933-69966312f6fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_72e4be86-d3fd-4c08-b666-620b80f3e36c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6c30b6a3-383e-4306-b933-69966312f6fb" xlink:to="loc_us-gaap_SecuredDebtMember_72e4be86-d3fd-4c08-b666-620b80f3e36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentTermsAxis_37588a1a-68eb-48c4-ba87-5adf01e2f15c" xlink:href="eols-20241231.xsd#eols_DebtInstrumentPrepaymentTermsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9782f76f-b92f-4416-87d9-d5e40b589db5" xlink:to="loc_eols_DebtInstrumentPrepaymentTermsAxis_37588a1a-68eb-48c4-ba87-5adf01e2f15c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentTermsDomain_d327f251-8689-4f8f-915a-8c4f4e8ccb9a" xlink:href="eols-20241231.xsd#eols_DebtInstrumentPrepaymentTermsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DebtInstrumentPrepaymentTermsAxis_37588a1a-68eb-48c4-ba87-5adf01e2f15c" xlink:to="loc_eols_DebtInstrumentPrepaymentTermsDomain_d327f251-8689-4f8f-915a-8c4f4e8ccb9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TermOneMember_1209799c-e379-4745-9a3b-6fb6019ef7a5" xlink:href="eols-20241231.xsd#eols_TermOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DebtInstrumentPrepaymentTermsDomain_d327f251-8689-4f8f-915a-8c4f4e8ccb9a" xlink:to="loc_eols_TermOneMember_1209799c-e379-4745-9a3b-6fb6019ef7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TermTwoMember_da94b9b1-c207-4b13-80cf-5dea54f8bdfa" xlink:href="eols-20241231.xsd#eols_TermTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DebtInstrumentPrepaymentTermsDomain_d327f251-8689-4f8f-915a-8c4f4e8ccb9a" xlink:to="loc_eols_TermTwoMember_da94b9b1-c207-4b13-80cf-5dea54f8bdfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TermThreeMember_9b0291e5-cde9-451b-86e3-e610853ae6eb" xlink:href="eols-20241231.xsd#eols_TermThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DebtInstrumentPrepaymentTermsDomain_d327f251-8689-4f8f-915a-8c4f4e8ccb9a" xlink:to="loc_eols_TermThreeMember_9b0291e5-cde9-451b-86e3-e610853ae6eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_068f6364-addb-40c4-8255-157b483605ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9782f76f-b92f-4416-87d9-d5e40b589db5" xlink:to="loc_us-gaap_VariableRateAxis_068f6364-addb-40c4-8255-157b483605ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_e95dc5df-e97c-49eb-b14b-e6d3274c7c83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_068f6364-addb-40c4-8255-157b483605ed" xlink:to="loc_us-gaap_VariableRateDomain_e95dc5df-e97c-49eb-b14b-e6d3274c7c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LondonInterbankOfferedRateLIBOR1Member_9fcacdb3-4e76-4fae-a601-e9fd5f29dece" xlink:href="eols-20241231.xsd#eols_LondonInterbankOfferedRateLIBOR1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_e95dc5df-e97c-49eb-b14b-e6d3274c7c83" xlink:to="loc_eols_LondonInterbankOfferedRateLIBOR1Member_9fcacdb3-4e76-4fae-a601-e9fd5f29dece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SecuredFinancingOfferedRateSOFRMember_3ea5d566-4ed4-41d6-a4ad-6a618af74b5a" xlink:href="eols-20241231.xsd#eols_SecuredFinancingOfferedRateSOFRMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_e95dc5df-e97c-49eb-b14b-e6d3274c7c83" xlink:to="loc_eols_SecuredFinancingOfferedRateSOFRMember_3ea5d566-4ed4-41d6-a4ad-6a618af74b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_291304e3-e9da-4d87-94e0-77400199977d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_9782f76f-b92f-4416-87d9-d5e40b589db5" xlink:to="loc_us-gaap_DebtInstrumentLineItems_291304e3-e9da-4d87-94e0-77400199977d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentNumberOfTranches_de099271-911d-4237-8e58-08dfe4e809e7" xlink:href="eols-20241231.xsd#eols_DebtInstrumentNumberOfTranches"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_291304e3-e9da-4d87-94e0-77400199977d" xlink:to="loc_eols_DebtInstrumentNumberOfTranches_de099271-911d-4237-8e58-08dfe4e809e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_96847f5a-bf98-416b-b973-a2fd7e1d75b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_291304e3-e9da-4d87-94e0-77400199977d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_96847f5a-bf98-416b-b973-a2fd7e1d75b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_15ef86e3-900b-4f43-a984-06401b8921de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_291304e3-e9da-4d87-94e0-77400199977d" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_15ef86e3-900b-4f43-a984-06401b8921de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_65bae14b-d1c5-46c2-a260-f0701f60b96e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_291304e3-e9da-4d87-94e0-77400199977d" xlink:to="loc_us-gaap_DebtInstrumentTerm_65bae14b-d1c5-46c2-a260-f0701f60b96e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentNumberOfInstallments_cbbacfdb-8c3c-455b-a943-eceebf9ac686" xlink:href="eols-20241231.xsd#eols_DebtInstrumentNumberOfInstallments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_291304e3-e9da-4d87-94e0-77400199977d" xlink:to="loc_eols_DebtInstrumentNumberOfInstallments_cbbacfdb-8c3c-455b-a943-eceebf9ac686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_6f2612bd-8931-4c4d-bf27-6793ffeded4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_291304e3-e9da-4d87-94e0-77400199977d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_6f2612bd-8931-4c4d-bf27-6793ffeded4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPeriodicPaymentOutstandingPrincipalAmountDuePercentage_2f32cff1-d98d-4db1-83db-deb9156cb3d2" xlink:href="eols-20241231.xsd#eols_DebtInstrumentPeriodicPaymentOutstandingPrincipalAmountDuePercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_291304e3-e9da-4d87-94e0-77400199977d" xlink:to="loc_eols_DebtInstrumentPeriodicPaymentOutstandingPrincipalAmountDuePercentage_2f32cff1-d98d-4db1-83db-deb9156cb3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPeriodicPaymentNumberOfPrincipalPayments_2b6bfd6f-543c-4740-9b68-6c40c3c4137f" xlink:href="eols-20241231.xsd#eols_DebtInstrumentPeriodicPaymentNumberOfPrincipalPayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_291304e3-e9da-4d87-94e0-77400199977d" xlink:to="loc_eols_DebtInstrumentPeriodicPaymentNumberOfPrincipalPayments_2b6bfd6f-543c-4740-9b68-6c40c3c4137f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPeriodicPaymentInitialPrincipalPaymentDuePeriod_0f86bc1c-7394-4e85-8671-54ae979694b7" xlink:href="eols-20241231.xsd#eols_DebtInstrumentPeriodicPaymentInitialPrincipalPaymentDuePeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_291304e3-e9da-4d87-94e0-77400199977d" xlink:to="loc_eols_DebtInstrumentPeriodicPaymentInitialPrincipalPaymentDuePeriod_0f86bc1c-7394-4e85-8671-54ae979694b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d61007cb-2678-461c-a6fd-314d109e08b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_291304e3-e9da-4d87-94e0-77400199977d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d61007cb-2678-461c-a6fd-314d109e08b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_c6d2da64-18eb-4d1f-bcdc-b64cfef19b11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_291304e3-e9da-4d87-94e0-77400199977d" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_c6d2da64-18eb-4d1f-bcdc-b64cfef19b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentAmountThreshold_54448677-17db-4cdf-9c3f-d23385c62bd3" xlink:href="eols-20241231.xsd#eols_DebtInstrumentPrepaymentAmountThreshold"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_291304e3-e9da-4d87-94e0-77400199977d" xlink:to="loc_eols_DebtInstrumentPrepaymentAmountThreshold_54448677-17db-4cdf-9c3f-d23385c62bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount_658ffccd-e81e-4e0f-a5aa-96f093ca355e" xlink:href="eols-20241231.xsd#eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_291304e3-e9da-4d87-94e0-77400199977d" xlink:to="loc_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount_658ffccd-e81e-4e0f-a5aa-96f093ca355e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_eae6e45c-168d-4c06-a3d1-b480fdfe37ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_291304e3-e9da-4d87-94e0-77400199977d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_eae6e45c-168d-4c06-a3d1-b480fdfe37ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_3c9edb29-7758-4cf1-b69f-8157c8f715e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_291304e3-e9da-4d87-94e0-77400199977d" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_3c9edb29-7758-4cf1-b69f-8157c8f715e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_dd0b7215-59e3-4359-826b-d8cc472b2cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_291304e3-e9da-4d87-94e0-77400199977d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_dd0b7215-59e3-4359-826b-d8cc472b2cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#TermLoansScheduleofLongTermDebtMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_63191c53-0dc9-4b4d-8a47-aa28e28a3813" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_78befba7-f834-42f3-a4f8-366504b7b120" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_63191c53-0dc9-4b4d-8a47-aa28e28a3813" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_78befba7-f834-42f3-a4f8-366504b7b120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_793d1cc5-3faa-4bd5-97cc-6df41b1be370" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_63191c53-0dc9-4b4d-8a47-aa28e28a3813" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_793d1cc5-3faa-4bd5-97cc-6df41b1be370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_e9aa1f93-2011-44bc-9e9b-72b807eeae1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_63191c53-0dc9-4b4d-8a47-aa28e28a3813" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_e9aa1f93-2011-44bc-9e9b-72b807eeae1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_fa171453-0e11-412c-aa54-2c061f0a4543" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_63191c53-0dc9-4b4d-8a47-aa28e28a3813" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_fa171453-0e11-412c-aa54-2c061f0a4543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_7253b85f-4f84-486b-a804-1087048d905e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_63191c53-0dc9-4b4d-8a47-aa28e28a3813" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_7253b85f-4f84-486b-a804-1087048d905e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f27361bd-ab07-4d7f-ae4c-56ea71db6e33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_63191c53-0dc9-4b4d-8a47-aa28e28a3813" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f27361bd-ab07-4d7f-ae4c-56ea71db6e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_a1673983-201b-4434-8d0a-267ea54eb799" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_63191c53-0dc9-4b4d-8a47-aa28e28a3813" xlink:to="loc_us-gaap_LongTermDebt_a1673983-201b-4434-8d0a-267ea54eb799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/OperatingLeasesNarrativeDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#OperatingLeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/OperatingLeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_80015066-471c-4851-b7fd-881649b31955" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_eb9ec6e9-706d-44ff-af84-a6fb544178e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_80015066-471c-4851-b7fd-881649b31955" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_eb9ec6e9-706d-44ff-af84-a6fb544178e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_5fd5833c-f8b0-440b-9efa-d7b27def4ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_80015066-471c-4851-b7fd-881649b31955" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_5fd5833c-f8b0-440b-9efa-d7b27def4ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LesseeOperatingLeaseAbatementPeriod_ea162eba-afbb-4222-b0c1-d34961a37c49" xlink:href="eols-20241231.xsd#eols_LesseeOperatingLeaseAbatementPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_80015066-471c-4851-b7fd-881649b31955" xlink:to="loc_eols_LesseeOperatingLeaseAbatementPeriod_ea162eba-afbb-4222-b0c1-d34961a37c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_6d3f82cb-9772-4b1b-a363-0a31a1df07fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_80015066-471c-4851-b7fd-881649b31955" xlink:to="loc_us-gaap_OperatingLeaseLiability_6d3f82cb-9772-4b1b-a363-0a31a1df07fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_116ead11-eb41-42ea-8bab-0f863e94fa5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_80015066-471c-4851-b7fd-881649b31955" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_116ead11-eb41-42ea-8bab-0f863e94fa5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_6e168d35-e460-42bd-b145-b621cb663558" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_80015066-471c-4851-b7fd-881649b31955" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_6e168d35-e460-42bd-b145-b621cb663558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/OperatingLeasesComponentsofLeaseExpenseandOtherQuantitativeInformationDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#OperatingLeasesComponentsofLeaseExpenseandOtherQuantitativeInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/OperatingLeasesComponentsofLeaseExpenseandOtherQuantitativeInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_28c3bddd-7a17-43e2-8303-7fef77383de0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_850bb090-def8-42f3-9edc-b51b5c17f98a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_28c3bddd-7a17-43e2-8303-7fef77383de0" xlink:to="loc_us-gaap_OperatingLeaseCost_850bb090-def8-42f3-9edc-b51b5c17f98a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_6ab83d72-d56c-4ba8-ac92-fe8afb750b48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_28c3bddd-7a17-43e2-8303-7fef77383de0" xlink:to="loc_us-gaap_VariableLeaseCost_6ab83d72-d56c-4ba8-ac92-fe8afb750b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_6e6009a5-3940-48b3-8a52-c62fbd65ec04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_28c3bddd-7a17-43e2-8303-7fef77383de0" xlink:to="loc_us-gaap_LeaseCost_6e6009a5-3940-48b3-8a52-c62fbd65ec04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/OperatingLeasesWeightedAverageRemainingLeaseTermandDiscountRateDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#OperatingLeasesWeightedAverageRemainingLeaseTermandDiscountRateDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/OperatingLeasesWeightedAverageRemainingLeaseTermandDiscountRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_cd60d042-69c6-42cb-a79b-f5c86c7c4b85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0dec1cfc-50f5-467a-bb16-cb8683790f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cd60d042-69c6-42cb-a79b-f5c86c7c4b85" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0dec1cfc-50f5-467a-bb16-cb8683790f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_08efcac1-18d7-491f-aa1c-cda04900009b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cd60d042-69c6-42cb-a79b-f5c86c7c4b85" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_08efcac1-18d7-491f-aa1c-cda04900009b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_2c07fb30-a3ff-47ac-b96b-009ee639f79a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cd60d042-69c6-42cb-a79b-f5c86c7c4b85" xlink:to="loc_us-gaap_OperatingLeasePayments_2c07fb30-a3ff-47ac-b96b-009ee639f79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_56ac02e3-7a16-4fcc-a626-c4e11e585ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_45e67457-d0c2-4f43-901f-c002e2ab6f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_56ac02e3-7a16-4fcc-a626-c4e11e585ee2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_45e67457-d0c2-4f43-901f-c002e2ab6f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d2b6586f-7d64-4b9b-8ca4-87e388cf9dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_56ac02e3-7a16-4fcc-a626-c4e11e585ee2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d2b6586f-7d64-4b9b-8ca4-87e388cf9dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6dc4b50e-a5da-4585-9063-05c1144b1adf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_56ac02e3-7a16-4fcc-a626-c4e11e585ee2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6dc4b50e-a5da-4585-9063-05c1144b1adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1e773823-5ce2-41f5-a7f0-f5813aab9084" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_56ac02e3-7a16-4fcc-a626-c4e11e585ee2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1e773823-5ce2-41f5-a7f0-f5813aab9084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9ea6302d-aa46-466b-99f5-3678f2516238" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_56ac02e3-7a16-4fcc-a626-c4e11e585ee2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9ea6302d-aa46-466b-99f5-3678f2516238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_edaaa45f-e22f-4114-ba27-f52c5b524b03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_56ac02e3-7a16-4fcc-a626-c4e11e585ee2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_edaaa45f-e22f-4114-ba27-f52c5b524b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4906f5b2-b83f-45d0-897f-a489fd2f6a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_56ac02e3-7a16-4fcc-a626-c4e11e585ee2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4906f5b2-b83f-45d0-897f-a489fd2f6a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8e0c6dfa-c22e-44f8-86ab-e23d83d35df4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_56ac02e3-7a16-4fcc-a626-c4e11e585ee2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8e0c6dfa-c22e-44f8-86ab-e23d83d35df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_131af7de-8d55-4578-867e-a146a7fdc084" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_56ac02e3-7a16-4fcc-a626-c4e11e585ee2" xlink:to="loc_us-gaap_OperatingLeaseLiability_131af7de-8d55-4578-867e-a146a7fdc084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentandContingenciesDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#CommitmentandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/CommitmentandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b46fc58f-6b3f-4eaf-9246-e4f482bb2f34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_61bcd30b-3213-433a-a5e9-88a935ca504b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b46fc58f-6b3f-4eaf-9246-e4f482bb2f34" xlink:to="loc_us-gaap_LossContingenciesTable_61bcd30b-3213-433a-a5e9-88a935ca504b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2d7e4321-5f97-464b-a44f-d28810f8a4f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_61bcd30b-3213-433a-a5e9-88a935ca504b" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2d7e4321-5f97-464b-a44f-d28810f8a4f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fd5aea87-b1e2-4873-9203-123e391f38c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2d7e4321-5f97-464b-a44f-d28810f8a4f9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fd5aea87-b1e2-4873-9203-123e391f38c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SymateseU.S.AgreementMember_644ce47c-9f89-4db6-8bf7-f5e79ae9ddb9" xlink:href="eols-20241231.xsd#eols_SymateseU.S.AgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fd5aea87-b1e2-4873-9203-123e391f38c7" xlink:to="loc_eols_SymateseU.S.AgreementMember_644ce47c-9f89-4db6-8bf7-f5e79ae9ddb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SymateseEuropeAgreementMember_64a06d54-85fa-4838-875a-1f66c578a9c5" xlink:href="eols-20241231.xsd#eols_SymateseEuropeAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fd5aea87-b1e2-4873-9203-123e391f38c7" xlink:to="loc_eols_SymateseEuropeAgreementMember_64a06d54-85fa-4838-875a-1f66c578a9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_61bcd30b-3213-433a-a5e9-88a935ca504b" xlink:to="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PaymentsForInventory_3ea259f2-410b-4e15-b7c4-e3e364e85119" xlink:href="eols-20241231.xsd#eols_PaymentsForInventory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:to="loc_eols_PaymentsForInventory_3ea259f2-410b-4e15-b7c4-e3e364e85119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementMinimumMilestonePayment_6ad5bb29-9c0b-45ee-b6af-3f519ae9e116" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementMinimumMilestonePayment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementMinimumMilestonePayment_6ad5bb29-9c0b-45ee-b6af-3f519ae9e116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement_d8564846-2470-49f3-b938-a4947146a354" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement_d8564846-2470-49f3-b938-a4947146a354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod_42022c6d-821d-4b64-a633-16ab48dd79b5" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod_42022c6d-821d-4b64-a633-16ab48dd79b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne_6b257959-36eb-4df5-92fa-978fa54addf9" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne_6b257959-36eb-4df5-92fa-978fa54addf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo_ad6d0280-d3fe-4d9c-aeb9-d4c7bbd707a4" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo_ad6d0280-d3fe-4d9c-aeb9-d4c7bbd707a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree_df707c01-0472-4414-b5fe-9c9d8d31798f" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree_df707c01-0472-4414-b5fe-9c9d8d31798f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour_12516ced-91b5-4bab-a3eb-518ae4926620" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour_12516ced-91b5-4bab-a3eb-518ae4926620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentTriggeredRegulatoryApprovalNumberOfProducts_32df65c7-7e04-4d7d-a649-33d647a93936" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementAnnualPaymentTriggeredRegulatoryApprovalNumberOfProducts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentTriggeredRegulatoryApprovalNumberOfProducts_32df65c7-7e04-4d7d-a649-33d647a93936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense_3c084b29-e9d3-4df8-bd07-437c43ce5327" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense_3c084b29-e9d3-4df8-bd07-437c43ce5327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment_761d8ade-36f3-4fa0-bc80-d90154f8feff" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment_761d8ade-36f3-4fa0-bc80-d90154f8feff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementAnnualRevenue_cfac64e4-e71e-4240-91e4-24e6e3deb8cf" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementAnnualRevenue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementAnnualRevenue_cfac64e4-e71e-4240-91e4-24e6e3deb8cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts_54a95af2-ff7a-4f85-987f-f59837e04fb0" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts_54a95af2-ff7a-4f85-987f-f59837e04fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LicenseSupplyAndDistributionAgreementMilestonePaymentPayablePeriod_a42d01e3-e52b-4e1c-8688-913234933d7c" xlink:href="eols-20241231.xsd#eols_LicenseSupplyAndDistributionAgreementMilestonePaymentPayablePeriod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:to="loc_eols_LicenseSupplyAndDistributionAgreementMilestonePaymentPayablePeriod_a42d01e3-e52b-4e1c-8688-913234933d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_8fdb2b99-74f1-4531-aea2-b78542d195ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_8fdb2b99-74f1-4531-aea2-b78542d195ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LossContingencyNumberDefendantsOfficers_f22b6fa4-d345-4639-b460-2555b8b11d7a" xlink:href="eols-20241231.xsd#eols_LossContingencyNumberDefendantsOfficers"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:to="loc_eols_LossContingencyNumberDefendantsOfficers_f22b6fa4-d345-4639-b460-2555b8b11d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_0789014a-59f3-415d-aa13-2979c2d82124" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_0789014a-59f3-415d-aa13-2979c2d82124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_8cfbd8ac-b66a-4b90-be13-4a48de99b814" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4c8ede9b-eeea-4202-86dd-235c25113d76" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_8cfbd8ac-b66a-4b90-be13-4a48de99b814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6d73f6d8-bbd7-4eae-b385-60a687a4ef81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_13780bb0-2640-4adb-b2f8-fe0efcf9d0b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6d73f6d8-bbd7-4eae-b385-60a687a4ef81" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_13780bb0-2640-4adb-b2f8-fe0efcf9d0b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3d3b9758-5235-471b-bdb3-3723b4cb78f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_13780bb0-2640-4adb-b2f8-fe0efcf9d0b1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3d3b9758-5235-471b-bdb3-3723b4cb78f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_075438b1-1b58-4a54-b568-65502c00e262" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3d3b9758-5235-471b-bdb3-3723b4cb78f3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_075438b1-1b58-4a54-b568-65502c00e262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_FollowOnOfferingMember_522fe7ba-841d-4972-ac3d-e2a31c9dba6d" xlink:href="eols-20241231.xsd#eols_FollowOnOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_075438b1-1b58-4a54-b568-65502c00e262" xlink:to="loc_eols_FollowOnOfferingMember_522fe7ba-841d-4972-ac3d-e2a31c9dba6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ATMSalesAgreementMember_1207d9a0-e63d-43ed-8e65-472bd29cabb7" xlink:href="eols-20241231.xsd#eols_ATMSalesAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_075438b1-1b58-4a54-b568-65502c00e262" xlink:to="loc_eols_ATMSalesAgreementMember_1207d9a0-e63d-43ed-8e65-472bd29cabb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4504b65b-5e50-46ee-9357-d17ac3f6b683" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_13780bb0-2640-4adb-b2f8-fe0efcf9d0b1" xlink:to="loc_us-gaap_PlanNameAxis_4504b65b-5e50-46ee-9357-d17ac3f6b683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0c503a50-6ba0-4577-945b-196ef9d8ba78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_4504b65b-5e50-46ee-9357-d17ac3f6b683" xlink:to="loc_us-gaap_PlanNameDomain_0c503a50-6ba0-4577-945b-196ef9d8ba78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_A2023InducementIncentivePlanMember_f23be0fb-a987-4002-91f2-bd4148052ce9" xlink:href="eols-20241231.xsd#eols_A2023InducementIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0c503a50-6ba0-4577-945b-196ef9d8ba78" xlink:to="loc_eols_A2023InducementIncentivePlanMember_f23be0fb-a987-4002-91f2-bd4148052ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_TwoThousandAndSeventeenOmnibusIncentivePlanMember_9db09098-0c1a-49a6-83a4-2fd85622f654" xlink:href="eols-20241231.xsd#eols_TwoThousandAndSeventeenOmnibusIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0c503a50-6ba0-4577-945b-196ef9d8ba78" xlink:to="loc_eols_TwoThousandAndSeventeenOmnibusIncentivePlanMember_9db09098-0c1a-49a6-83a4-2fd85622f654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_A2024EmployeeStockPurchasePlanMember_b0cff228-51f6-4878-bd66-ccbf712bfaa9" xlink:href="eols-20241231.xsd#eols_A2024EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0c503a50-6ba0-4577-945b-196ef9d8ba78" xlink:to="loc_eols_A2024EmployeeStockPurchasePlanMember_b0cff228-51f6-4878-bd66-ccbf712bfaa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5d8970b6-f113-41cf-ad15-ffdd95489c0c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_13780bb0-2640-4adb-b2f8-fe0efcf9d0b1" xlink:to="loc_srt_RangeAxis_5d8970b6-f113-41cf-ad15-ffdd95489c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6a762eaf-a928-47c4-a8a6-2a4e5f7c0f9d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5d8970b6-f113-41cf-ad15-ffdd95489c0c" xlink:to="loc_srt_RangeMember_6a762eaf-a928-47c4-a8a6-2a4e5f7c0f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_39f65004-63f6-41d6-8323-3c51f007571f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6a762eaf-a928-47c4-a8a6-2a4e5f7c0f9d" xlink:to="loc_srt_MinimumMember_39f65004-63f6-41d6-8323-3c51f007571f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6a0d4fbc-c434-4d7e-8064-1c84bb3b9b0d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6a762eaf-a928-47c4-a8a6-2a4e5f7c0f9d" xlink:to="loc_srt_MaximumMember_6a0d4fbc-c434-4d7e-8064-1c84bb3b9b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2d29470e-22f9-43ee-8361-1a2e07ed111a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_13780bb0-2640-4adb-b2f8-fe0efcf9d0b1" xlink:to="loc_us-gaap_AwardTypeAxis_2d29470e-22f9-43ee-8361-1a2e07ed111a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d734191d-16cf-47a1-bafe-c0b9caa9a53a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2d29470e-22f9-43ee-8361-1a2e07ed111a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d734191d-16cf-47a1-bafe-c0b9caa9a53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_31a5acac-b50f-4492-825d-c9d4104e8835" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d734191d-16cf-47a1-bafe-c0b9caa9a53a" xlink:to="loc_us-gaap_EmployeeStockMember_31a5acac-b50f-4492-825d-c9d4104e8835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_20df98e7-1c43-458a-baa1-082814d05051" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d734191d-16cf-47a1-bafe-c0b9caa9a53a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_20df98e7-1c43-458a-baa1-082814d05051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_58e82a9f-2256-4dd0-b0c6-69731848ab1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d734191d-16cf-47a1-bafe-c0b9caa9a53a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_58e82a9f-2256-4dd0-b0c6-69731848ab1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PerformanceRestrictedStockUnitsPRSUMember_163c78cf-94c8-4af8-be06-ba416d4dadce" xlink:href="eols-20241231.xsd#eols_PerformanceRestrictedStockUnitsPRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d734191d-16cf-47a1-bafe-c0b9caa9a53a" xlink:to="loc_eols_PerformanceRestrictedStockUnitsPRSUMember_163c78cf-94c8-4af8-be06-ba416d4dadce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_CEOPerformanceRestrictedShareUnitsCPRSUMember_2d9bc369-0d12-4f88-9778-3c839a649d88" xlink:href="eols-20241231.xsd#eols_CEOPerformanceRestrictedShareUnitsCPRSUMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d734191d-16cf-47a1-bafe-c0b9caa9a53a" xlink:to="loc_eols_CEOPerformanceRestrictedShareUnitsCPRSUMember_2d9bc369-0d12-4f88-9778-3c839a649d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_8d8b1e16-be9b-493f-ab09-96a3d787c31b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_13780bb0-2640-4adb-b2f8-fe0efcf9d0b1" xlink:to="loc_us-gaap_VestingAxis_8d8b1e16-be9b-493f-ab09-96a3d787c31b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_54bddb05-bbbc-4159-81e3-dab5b050181e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_8d8b1e16-be9b-493f-ab09-96a3d787c31b" xlink:to="loc_us-gaap_VestingDomain_54bddb05-bbbc-4159-81e3-dab5b050181e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_61104405-5d0d-4bc8-bb51-39f0a50892d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_54bddb05-bbbc-4159-81e3-dab5b050181e" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_61104405-5d0d-4bc8-bb51-39f0a50892d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_f9b7119c-e257-443e-a188-70606acf1eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_54bddb05-bbbc-4159-81e3-dab5b050181e" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_f9b7119c-e257-443e-a188-70606acf1eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_13780bb0-2640-4adb-b2f8-fe0efcf9d0b1" xlink:to="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_66af1d9f-e9bb-47a3-94f4-0483663179b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_66af1d9f-e9bb-47a3-94f4-0483663179b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6f34a4e0-a249-43b6-b0d2-cbd28aa532e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6f34a4e0-a249-43b6-b0d2-cbd28aa532e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_70c7dbfc-8d4a-4674-896d-f8c37237cc89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_70c7dbfc-8d4a-4674-896d-f8c37237cc89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_c6766e52-30b2-4029-a05f-1eb09d2db0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_PreferredStockSharesIssued_c6766e52-30b2-4029-a05f-1eb09d2db0d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_27d2e188-c597-4fc5-bb62-f55e0c1761fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_27d2e188-c597-4fc5-bb62-f55e0c1761fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_39b37c3b-1c8c-45b7-b5f8-1bfe0e22b450" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_39b37c3b-1c8c-45b7-b5f8-1bfe0e22b450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_1bb9ac8b-8e47-4692-b24d-9ed7ab05718c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_CommonStockSharesIssued_1bb9ac8b-8e47-4692-b24d-9ed7ab05718c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1eebd436-775d-49d3-8e56-7433aebd9230" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1eebd436-775d-49d3-8e56-7433aebd9230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_e1176e39-66b5-4232-b112-793d09bb727b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_e1176e39-66b5-4232-b112-793d09bb727b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_314948a1-b73a-443b-b8d4-5685c114695e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_314948a1-b73a-443b-b8d4-5685c114695e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_33fa4a33-0527-429a-9363-523e1527d0c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_33fa4a33-0527-429a-9363-523e1527d0c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_bb28b7bd-5c65-4206-8600-8a7eeaa3490f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_bb28b7bd-5c65-4206-8600-8a7eeaa3490f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalShareIncreaseAvailableForIssuance_ccc6ddb4-c83f-4725-bf76-23f09630046a" xlink:href="eols-20241231.xsd#eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalShareIncreaseAvailableForIssuance"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalShareIncreaseAvailableForIssuance_ccc6ddb4-c83f-4725-bf76-23f09630046a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_59c4685e-0c8a-42e7-bd69-a33b7b4e4198" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_59c4685e-0c8a-42e7-bd69-a33b7b4e4198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SaleOfStockMaximumConsiderationReceivable_cfbacdc6-b545-4b49-926f-717312b4119d" xlink:href="eols-20241231.xsd#eols_SaleOfStockMaximumConsiderationReceivable"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_eols_SaleOfStockMaximumConsiderationReceivable_cfbacdc6-b545-4b49-926f-717312b4119d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage_843b112d-672d-4607-8d98-7759805c1ccb" xlink:href="eols-20241231.xsd#eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage_843b112d-672d-4607-8d98-7759805c1ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1eb5d626-2955-4fcd-8259-8186e14a7275" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1eb5d626-2955-4fcd-8259-8186e14a7275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_4fe2a52c-0070-4bc5-8414-01b957168852" xlink:href="eols-20241231.xsd#eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_4fe2a52c-0070-4bc5-8414-01b957168852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8a3b247e-a873-416e-b717-e922143b5133" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_8a3b247e-a873-416e-b717-e922143b5133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a5421cda-55b4-4bd2-b9d3-3f0034f3ce44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_a5421cda-55b4-4bd2-b9d3-3f0034f3ce44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_702c9727-2f9d-4ceb-a8a4-99f560aec4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_702c9727-2f9d-4ceb-a8a4-99f560aec4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm_1796b901-4c80-48f2-960c-1282f941c3f0" xlink:href="eols-20241231.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm_1796b901-4c80-48f2-960c-1282f941c3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_db266b9c-87cf-4336-8d07-968a316b1862" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_db266b9c-87cf-4336-8d07-968a316b1862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8bdcf586-32f6-4804-b001-93240d146440" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8bdcf586-32f6-4804-b001-93240d146440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueVested_e912d0e5-4095-4693-a0eb-83257db8b75c" xlink:href="eols-20241231.xsd#eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueVested"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueVested_e912d0e5-4095-4693-a0eb-83257db8b75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_1b0acfaf-97db-4782-8fbf-1238c146b3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_1b0acfaf-97db-4782-8fbf-1238c146b3d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2afbf61e-1f81-4ef6-9454-74346ae1789f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2afbf61e-1f81-4ef6-9454-74346ae1789f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod_1fb6b0f8-f8f1-42db-90e2-2b02be85dd3e" xlink:href="eols-20241231.xsd#eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod_1fb6b0f8-f8f1-42db-90e2-2b02be85dd3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_f1dad7ed-f0b2-4c6f-9b3f-e9464542fe34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_f1dad7ed-f0b2-4c6f-9b3f-e9464542fe34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ShareBasedPaymentArrangementNumberOfConsecutiveDays_75169d19-076a-4fe1-8283-15e078b8f254" xlink:href="eols-20241231.xsd#eols_ShareBasedPaymentArrangementNumberOfConsecutiveDays"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_eols_ShareBasedPaymentArrangementNumberOfConsecutiveDays_75169d19-076a-4fe1-8283-15e078b8f254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ShareBasedCompensationConsecutiveTradingDaysPerShareTarget_2e11381f-f5c1-4771-a0b4-87fe1e0a6eff" xlink:href="eols-20241231.xsd#eols_ShareBasedCompensationConsecutiveTradingDaysPerShareTarget"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_eols_ShareBasedCompensationConsecutiveTradingDaysPerShareTarget_2e11381f-f5c1-4771-a0b4-87fe1e0a6eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_5f9e1f4e-ca71-43c5-9a82-ccc4ff786b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_5f9e1f4e-ca71-43c5-9a82-ccc4ff786b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsAfterTermination_844938dc-d844-42dd-9ec8-b55668eee89b" xlink:href="eols-20241231.xsd#eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsAfterTermination"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsAfterTermination_844938dc-d844-42dd-9ec8-b55668eee89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_28c58b6d-a6f5-4562-a66f-564b20e1e8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_28c58b6d-a6f5-4562-a66f-564b20e1e8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_15e2c598-2a8d-4aac-bc69-57b09b68e97e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_15e2c598-2a8d-4aac-bc69-57b09b68e97e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4c8e0925-8de1-4aa8-ab5e-cd629ec11619" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4c8e0925-8de1-4aa8-ab5e-cd629ec11619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d174a1d5-9022-4658-85aa-fe3b1149cc91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_088f338d-31c9-4446-bc38-549a3d5d3176" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d174a1d5-9022-4658-85aa-fe3b1149cc91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityScheduleofWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#StockholdersEquityScheduleofWeightedAverageAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquityScheduleofWeightedAverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6ade0200-14f4-4183-b10f-b206586c4559" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d3c25d2a-354b-4cd0-a4c9-332f1b483408" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6ade0200-14f4-4183-b10f-b206586c4559" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d3c25d2a-354b-4cd0-a4c9-332f1b483408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7595f7b1-1bce-4bbe-9602-0d4a4e94f286" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d3c25d2a-354b-4cd0-a4c9-332f1b483408" xlink:to="loc_us-gaap_AwardTypeAxis_7595f7b1-1bce-4bbe-9602-0d4a4e94f286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e0589cbb-60bf-437a-9129-cf53ce2eb1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7595f7b1-1bce-4bbe-9602-0d4a4e94f286" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e0589cbb-60bf-437a-9129-cf53ce2eb1ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_13e56730-007c-4330-9b3b-eb8c5215ca24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e0589cbb-60bf-437a-9129-cf53ce2eb1ca" xlink:to="loc_us-gaap_EmployeeStockOptionMember_13e56730-007c-4330-9b3b-eb8c5215ca24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ac5d263-560c-48d8-92fc-5f68a9f24743" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d3c25d2a-354b-4cd0-a4c9-332f1b483408" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ac5d263-560c-48d8-92fc-5f68a9f24743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c979fb37-fb0c-4af1-9d66-4b7c07529409" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ac5d263-560c-48d8-92fc-5f68a9f24743" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c979fb37-fb0c-4af1-9d66-4b7c07529409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_767ea9d6-9e03-450e-9e57-d536ee89b660" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ac5d263-560c-48d8-92fc-5f68a9f24743" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_767ea9d6-9e03-450e-9e57-d536ee89b660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_31f9e9ef-1fed-40d1-8667-1832e1795b11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ac5d263-560c-48d8-92fc-5f68a9f24743" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_31f9e9ef-1fed-40d1-8667-1832e1795b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a9be5643-2ecf-42ab-8a31-19ed74a26a10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8ac5d263-560c-48d8-92fc-5f68a9f24743" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a9be5643-2ecf-42ab-8a31-19ed74a26a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#StockholdersEquityScheduleofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d30074a1-1eaf-4a0d-af24-2a0815c6dfea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63db7519-3647-4b61-bdbd-95f1fc38f78b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d30074a1-1eaf-4a0d-af24-2a0815c6dfea" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63db7519-3647-4b61-bdbd-95f1fc38f78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_dc1dc9d2-2bdc-4ab0-83c8-4882ff193368" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63db7519-3647-4b61-bdbd-95f1fc38f78b" xlink:to="loc_us-gaap_AwardTypeAxis_dc1dc9d2-2bdc-4ab0-83c8-4882ff193368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7191aef4-4f22-418c-a208-8fadc0e5f13b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_dc1dc9d2-2bdc-4ab0-83c8-4882ff193368" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7191aef4-4f22-418c-a208-8fadc0e5f13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_eb5cf3b6-3613-4295-9805-4a8a7aa9ee3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7191aef4-4f22-418c-a208-8fadc0e5f13b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_eb5cf3b6-3613-4295-9805-4a8a7aa9ee3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e51ac523-d43f-4815-b7aa-0a79c67df010" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63db7519-3647-4b61-bdbd-95f1fc38f78b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e51ac523-d43f-4815-b7aa-0a79c67df010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f814c9ee-308f-43dc-bae7-9b4b56612f81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e51ac523-d43f-4815-b7aa-0a79c67df010" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f814c9ee-308f-43dc-bae7-9b4b56612f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e40c3f58-d903-4d53-8694-7f48fd459396" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f814c9ee-308f-43dc-bae7-9b4b56612f81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e40c3f58-d903-4d53-8694-7f48fd459396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_de0a67e5-a52e-414e-9b3b-1584e2aa6623" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f814c9ee-308f-43dc-bae7-9b4b56612f81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_de0a67e5-a52e-414e-9b3b-1584e2aa6623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a64cd7c2-212d-4b29-b467-37145341651b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f814c9ee-308f-43dc-bae7-9b4b56612f81" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a64cd7c2-212d-4b29-b467-37145341651b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_a7ce2214-5812-493c-938f-b01572258c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f814c9ee-308f-43dc-bae7-9b4b56612f81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_a7ce2214-5812-493c-938f-b01572258c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0e2a4cb8-a153-427f-88af-22ec91770458" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f814c9ee-308f-43dc-bae7-9b4b56612f81" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0e2a4cb8-a153-427f-88af-22ec91770458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_7e62cffd-28b7-45f3-87ec-aa3783fdb4b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e51ac523-d43f-4815-b7aa-0a79c67df010" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_7e62cffd-28b7-45f3-87ec-aa3783fdb4b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a0c865d7-1bcb-4d1c-8d2c-b80a997f630c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e51ac523-d43f-4815-b7aa-0a79c67df010" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a0c865d7-1bcb-4d1c-8d2c-b80a997f630c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cb991e5b-dade-403d-afe8-b392e3940f43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e51ac523-d43f-4815-b7aa-0a79c67df010" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cb991e5b-dade-403d-afe8-b392e3940f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_db53c05a-3f12-4929-b110-1d64d49bdf88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cb991e5b-dade-403d-afe8-b392e3940f43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_db53c05a-3f12-4929-b110-1d64d49bdf88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9e4ca009-7f9d-4312-82d4-cd1a1b5a3746" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cb991e5b-dade-403d-afe8-b392e3940f43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9e4ca009-7f9d-4312-82d4-cd1a1b5a3746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4a995b41-ef96-40c9-a724-0b3e0c4414b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cb991e5b-dade-403d-afe8-b392e3940f43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4a995b41-ef96-40c9-a724-0b3e0c4414b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9a674723-93d3-4498-80ea-0c22a26eafcc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cb991e5b-dade-403d-afe8-b392e3940f43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_9a674723-93d3-4498-80ea-0c22a26eafcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_44da28da-da26-4a61-beb4-914bf409b4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_cb991e5b-dade-403d-afe8-b392e3940f43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_44da28da-da26-4a61-beb4-914bf409b4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_9d6e5607-1f16-47a1-899d-f6480460f416" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e51ac523-d43f-4815-b7aa-0a79c67df010" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_9d6e5607-1f16-47a1-899d-f6480460f416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_ee66f11c-403c-4b51-aae1-a4bb3dec2b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e51ac523-d43f-4815-b7aa-0a79c67df010" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_ee66f11c-403c-4b51-aae1-a4bb3dec2b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c855b42b-34b2-477a-b0f0-665c23e82537" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e51ac523-d43f-4815-b7aa-0a79c67df010" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c855b42b-34b2-477a-b0f0-665c23e82537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_be69930a-c597-4e0a-8b4f-d7abe86adbf5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c855b42b-34b2-477a-b0f0-665c23e82537" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_be69930a-c597-4e0a-8b4f-d7abe86adbf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_fda3ec3d-8057-4792-9d45-04148a112cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e51ac523-d43f-4815-b7aa-0a79c67df010" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_fda3ec3d-8057-4792-9d45-04148a112cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable_80075d5f-5baf-46eb-b5f0-b634dd43e0ce" xlink:href="eols-20241231.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e51ac523-d43f-4815-b7aa-0a79c67df010" xlink:to="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable_80075d5f-5baf-46eb-b5f0-b634dd43e0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_8e8bb010-684f-4b92-8531-8016d2f145d5" xlink:href="eols-20241231.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e51ac523-d43f-4815-b7aa-0a79c67df010" xlink:to="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_8e8bb010-684f-4b92-8531-8016d2f145d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1b4a7608-cb70-45ce-bcdf-b4474d8b99bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_8e8bb010-684f-4b92-8531-8016d2f145d5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1b4a7608-cb70-45ce-bcdf-b4474d8b99bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_c8713665-0453-4f41-8cc0-36c8a497ae14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e51ac523-d43f-4815-b7aa-0a79c67df010" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_c8713665-0453-4f41-8cc0-36c8a497ae14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a3b280bd-1da1-41e9-9e57-cf2c8a59083f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e51ac523-d43f-4815-b7aa-0a79c67df010" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a3b280bd-1da1-41e9-9e57-cf2c8a59083f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e5fc3b9f-4c4a-4961-93e7-cfb7d9323a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ade1714c-81d0-441f-b44c-4d05f613bf25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e5fc3b9f-4c4a-4961-93e7-cfb7d9323a1e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ade1714c-81d0-441f-b44c-4d05f613bf25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9c5fb293-117a-4a37-a391-f3aca64bc259" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ade1714c-81d0-441f-b44c-4d05f613bf25" xlink:to="loc_us-gaap_AwardTypeAxis_9c5fb293-117a-4a37-a391-f3aca64bc259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_239e8699-d51c-49b0-a818-4c623e4e2f51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9c5fb293-117a-4a37-a391-f3aca64bc259" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_239e8699-d51c-49b0-a818-4c623e4e2f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_821ab484-f9d1-40ca-9ddf-2b12935054de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_239e8699-d51c-49b0-a818-4c623e4e2f51" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_821ab484-f9d1-40ca-9ddf-2b12935054de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_PerformanceRestrictedStockUnitsPRSUMember_223ec174-dcd5-4e75-82c8-8578e736cacb" xlink:href="eols-20241231.xsd#eols_PerformanceRestrictedStockUnitsPRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_239e8699-d51c-49b0-a818-4c623e4e2f51" xlink:to="loc_eols_PerformanceRestrictedStockUnitsPRSUMember_223ec174-dcd5-4e75-82c8-8578e736cacb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cd1d9fd-90a8-407d-bfd9-ecc174e4d2dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ade1714c-81d0-441f-b44c-4d05f613bf25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cd1d9fd-90a8-407d-bfd9-ecc174e4d2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8df1c62d-4691-48aa-8a1b-0d03bef1f319" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cd1d9fd-90a8-407d-bfd9-ecc174e4d2dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8df1c62d-4691-48aa-8a1b-0d03bef1f319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_43ca6e8c-aeae-4560-9d6f-34473d844f07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8df1c62d-4691-48aa-8a1b-0d03bef1f319" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_43ca6e8c-aeae-4560-9d6f-34473d844f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4f71f6f9-c070-44d6-abc0-c415509f10ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8df1c62d-4691-48aa-8a1b-0d03bef1f319" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4f71f6f9-c070-44d6-abc0-c415509f10ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_759d79ca-d78d-4c85-943e-477dc45c1eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8df1c62d-4691-48aa-8a1b-0d03bef1f319" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_759d79ca-d78d-4c85-943e-477dc45c1eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7eb54e2c-6606-4d75-af9a-b035602cee12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8df1c62d-4691-48aa-8a1b-0d03bef1f319" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7eb54e2c-6606-4d75-af9a-b035602cee12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_697bf477-8679-4b83-87fa-f86808d5de37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8df1c62d-4691-48aa-8a1b-0d03bef1f319" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_697bf477-8679-4b83-87fa-f86808d5de37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3fbb9041-86b6-4334-98e6-00350eec5ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1cd1d9fd-90a8-407d-bfd9-ecc174e4d2dd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3fbb9041-86b6-4334-98e6-00350eec5ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a146a7ec-5d78-49da-b717-3d69f8495189" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3fbb9041-86b6-4334-98e6-00350eec5ee6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a146a7ec-5d78-49da-b717-3d69f8495189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_23217470-f0b1-4875-80ee-6b8661c30ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3fbb9041-86b6-4334-98e6-00350eec5ee6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_23217470-f0b1-4875-80ee-6b8661c30ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e10f4173-7913-4448-bb68-29f26e95e715" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3fbb9041-86b6-4334-98e6-00350eec5ee6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e10f4173-7913-4448-bb68-29f26e95e715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1302f8d2-cb62-4d9b-bf58-fabdc4bdca4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3fbb9041-86b6-4334-98e6-00350eec5ee6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1302f8d2-cb62-4d9b-bf58-fabdc4bdca4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f12fac8f-16f0-4fe8-b68d-2f38f355f005" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3fbb9041-86b6-4334-98e6-00350eec5ee6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f12fac8f-16f0-4fe8-b68d-2f38f355f005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#StockholdersEquityStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0af65ce5-094a-4a54-b407-8c31cedc667c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f4527ced-a4c9-4e7b-b95d-7548a4ffece5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0af65ce5-094a-4a54-b407-8c31cedc667c" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f4527ced-a4c9-4e7b-b95d-7548a4ffece5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_bfffc2c4-3d21-488b-9bdd-27b751e1f213" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f4527ced-a4c9-4e7b-b95d-7548a4ffece5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_bfffc2c4-3d21-488b-9bdd-27b751e1f213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7e71b08f-4caa-470a-8484-7bf835745f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bfffc2c4-3d21-488b-9bdd-27b751e1f213" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7e71b08f-4caa-470a-8484-7bf835745f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_eb796d42-52af-4700-8b99-3aa9ba5da11d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7e71b08f-4caa-470a-8484-7bf835745f4e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_eb796d42-52af-4700-8b99-3aa9ba5da11d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_701bc98d-c2d7-4542-92c6-851919926b50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7e71b08f-4caa-470a-8484-7bf835745f4e" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_701bc98d-c2d7-4542-92c6-851919926b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3427cb1c-a3b7-492d-a192-2e5bb2fac69a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f4527ced-a4c9-4e7b-b95d-7548a4ffece5" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3427cb1c-a3b7-492d-a192-2e5bb2fac69a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_71af6bb2-7023-48a9-baf5-b6e1ab42f1fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3427cb1c-a3b7-492d-a192-2e5bb2fac69a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_71af6bb2-7023-48a9-baf5-b6e1ab42f1fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/MedytoxSettlementAgreementsDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#MedytoxSettlementAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/MedytoxSettlementAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7e32333d-46ab-4fd9-9120-60daa5e25c71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_605efa06-caad-40d5-878c-1d4e1573ff48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7e32333d-46ab-4fd9-9120-60daa5e25c71" xlink:to="loc_us-gaap_LossContingenciesTable_605efa06-caad-40d5-878c-1d4e1573ff48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_28ccd33b-e964-409d-812e-35e968ec3276" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_605efa06-caad-40d5-878c-1d4e1573ff48" xlink:to="loc_srt_LitigationCaseAxis_28ccd33b-e964-409d-812e-35e968ec3276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_64ec4449-9087-4764-8786-fac76de3e409" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_28ccd33b-e964-409d-812e-35e968ec3276" xlink:to="loc_srt_LitigationCaseTypeDomain_64ec4449-9087-4764-8786-fac76de3e409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_IntellectualPropertyDisputesJeuveauMember_5444ab77-b747-41c1-a44c-98632278de67" xlink:href="eols-20241231.xsd#eols_IntellectualPropertyDisputesJeuveauMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_64ec4449-9087-4764-8786-fac76de3e409" xlink:to="loc_eols_IntellectualPropertyDisputesJeuveauMember_5444ab77-b747-41c1-a44c-98632278de67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c44d51d7-5f6d-4c98-975e-cf594904be7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_605efa06-caad-40d5-878c-1d4e1573ff48" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c44d51d7-5f6d-4c98-975e-cf594904be7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3d89db8f-bdbe-40af-97b7-8ce412c3baaa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c44d51d7-5f6d-4c98-975e-cf594904be7a" xlink:to="loc_us-gaap_EquityComponentDomain_3d89db8f-bdbe-40af-97b7-8ce412c3baaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_388b8c18-7763-4b0c-b15b-613d235c01ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3d89db8f-bdbe-40af-97b7-8ce412c3baaa" xlink:to="loc_us-gaap_CommonStockMember_388b8c18-7763-4b0c-b15b-613d235c01ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_97da0942-107d-4040-a5eb-137a6118166d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_605efa06-caad-40d5-878c-1d4e1573ff48" xlink:to="loc_us-gaap_LossContingenciesLineItems_97da0942-107d-4040-a5eb-137a6118166d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LossContingencySettlementAgreementManufacturingLicensePeriod_633d9bf0-d7e5-4c36-b9df-ee99edbbc2a7" xlink:href="eols-20241231.xsd#eols_LossContingencySettlementAgreementManufacturingLicensePeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_97da0942-107d-4040-a5eb-137a6118166d" xlink:to="loc_eols_LossContingencySettlementAgreementManufacturingLicensePeriod_633d9bf0-d7e5-4c36-b9df-ee99edbbc2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_bb610fd1-099f-49d8-b139-b6badbd88052" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_97da0942-107d-4040-a5eb-137a6118166d" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_bb610fd1-099f-49d8-b139-b6badbd88052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_LossContingencySettlementAgreementPaymentTerms_5a1c1609-fb86-4a2e-9748-c732c1225e1c" xlink:href="eols-20241231.xsd#eols_LossContingencySettlementAgreementPaymentTerms"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_97da0942-107d-4040-a5eb-137a6118166d" xlink:to="loc_eols_LossContingencySettlementAgreementPaymentTerms_5a1c1609-fb86-4a2e-9748-c732c1225e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_1ad26fa8-6f45-4d25-82c5-a207812d6782" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_97da0942-107d-4040-a5eb-137a6118166d" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_1ad26fa8-6f45-4d25-82c5-a207812d6782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_b1d75cfc-9b80-44ad-87d5-2d7380193158" xlink:href="eols-20241231.xsd#eols_StockIssuedDuringPeriodSharesLitigationSettlement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_97da0942-107d-4040-a5eb-137a6118166d" xlink:to="loc_eols_StockIssuedDuringPeriodSharesLitigationSettlement_b1d75cfc-9b80-44ad-87d5-2d7380193158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_bffc178f-d7db-42ae-8a74-0b7074871712" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_97da0942-107d-4040-a5eb-137a6118166d" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_bffc178f-d7db-42ae-8a74-0b7074871712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodOne_6ba60416-d8b8-4ba1-8a99-29e7794db3f0" xlink:href="eols-20241231.xsd#eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodOne"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_97da0942-107d-4040-a5eb-137a6118166d" xlink:to="loc_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodOne_6ba60416-d8b8-4ba1-8a99-29e7794db3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodTwo_e3212185-2dde-485b-84e2-78d43c60b2e1" xlink:href="eols-20241231.xsd#eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodTwo"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_97da0942-107d-4040-a5eb-137a6118166d" xlink:to="loc_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodTwo_e3212185-2dde-485b-84e2-78d43c60b2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodThree_b010b04f-98ef-4ae0-a2d9-83e6db3514ff" xlink:href="eols-20241231.xsd#eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodThree"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_97da0942-107d-4040-a5eb-137a6118166d" xlink:to="loc_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodThree_b010b04f-98ef-4ae0-a2d9-83e6db3514ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_e3a087d8-7c41-4082-84b7-5a5cc088bb7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_97da0942-107d-4040-a5eb-137a6118166d" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_e3a087d8-7c41-4082-84b7-5a5cc088bb7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/EmployeeBenefitPlanDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#EmployeeBenefitPlanDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/EmployeeBenefitPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3d6d850f-bde0-41a9-b2e6-bc3f33c61130" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_0c342ed6-0857-4d98-a47d-bb20cfffc3cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3d6d850f-bde0-41a9-b2e6-bc3f33c61130" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_0c342ed6-0857-4d98-a47d-bb20cfffc3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesScheduleofLossbeforeIncomeTaxesfromUSOperationsandForeignDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#IncomeTaxesScheduleofLossbeforeIncomeTaxesfromUSOperationsandForeignDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/IncomeTaxesScheduleofLossbeforeIncomeTaxesfromUSOperationsandForeignDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8a7a6451-8bf0-4d4d-af94-9ef27b0520de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_339507a5-c49c-4620-a27e-051820a9b226" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8a7a6451-8bf0-4d4d-af94-9ef27b0520de" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_339507a5-c49c-4620-a27e-051820a9b226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_da957523-668a-46aa-9a80-38a5a02eecf7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8a7a6451-8bf0-4d4d-af94-9ef27b0520de" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_da957523-668a-46aa-9a80-38a5a02eecf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ef8bb4bf-468c-46c8-9cfe-edbdc798ab81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8a7a6451-8bf0-4d4d-af94-9ef27b0520de" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ef8bb4bf-468c-46c8-9cfe-edbdc798ab81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesScheduleofComponentsofCurrentandDeferredIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#IncomeTaxesScheduleofComponentsofCurrentandDeferredIncomeTaxExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/IncomeTaxesScheduleofComponentsofCurrentandDeferredIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_43a801e0-34c9-49db-b40c-e8f3e0a10db9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_0c2b4c97-e794-4ace-8689-2cafb7561c91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_43a801e0-34c9-49db-b40c-e8f3e0a10db9" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_0c2b4c97-e794-4ace-8689-2cafb7561c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_bb6fe06e-52ff-423e-83c4-f228e24ea57c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_0c2b4c97-e794-4ace-8689-2cafb7561c91" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_bb6fe06e-52ff-423e-83c4-f228e24ea57c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_f82ca703-0cc5-44d7-89a7-a797d04b8b83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_0c2b4c97-e794-4ace-8689-2cafb7561c91" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_f82ca703-0cc5-44d7-89a7-a797d04b8b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_6e7fda51-0062-4fc9-8c53-2ff8d18a9edf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_0c2b4c97-e794-4ace-8689-2cafb7561c91" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_6e7fda51-0062-4fc9-8c53-2ff8d18a9edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_340d06c5-d9dc-41ed-9f42-10aee2a43cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_0c2b4c97-e794-4ace-8689-2cafb7561c91" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_340d06c5-d9dc-41ed-9f42-10aee2a43cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_e920bad3-f678-4364-ad05-423afce50ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_43a801e0-34c9-49db-b40c-e8f3e0a10db9" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_e920bad3-f678-4364-ad05-423afce50ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_bd183878-f622-4658-bbe3-aa74f84eb6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_e920bad3-f678-4364-ad05-423afce50ebd" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_bd183878-f622-4658-bbe3-aa74f84eb6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_04d8421c-f027-40ca-a2f9-524171780a33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_e920bad3-f678-4364-ad05-423afce50ebd" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_04d8421c-f027-40ca-a2f9-524171780a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_e3a35d3c-fb7f-41bc-bfff-fb33771b6099" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_e920bad3-f678-4364-ad05-423afce50ebd" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_e3a35d3c-fb7f-41bc-bfff-fb33771b6099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_46de09da-33f8-4469-9ae8-fe342ab8bb31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_e920bad3-f678-4364-ad05-423afce50ebd" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_46de09da-33f8-4469-9ae8-fe342ab8bb31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a8cafd67-59e4-40c8-b2be-885ba73230d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_43a801e0-34c9-49db-b40c-e8f3e0a10db9" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a8cafd67-59e4-40c8-b2be-885ba73230d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5de7dd51-7b6a-43d6-9e1d-9868710a0600" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_e480e877-1a93-4705-9b97-d962b582e61e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5de7dd51-7b6a-43d6-9e1d-9868710a0600" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_e480e877-1a93-4705-9b97-d962b582e61e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_4da17f80-a1a9-434c-b0d9-4d3e2f280282" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_e480e877-1a93-4705-9b97-d962b582e61e" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_4da17f80-a1a9-434c-b0d9-4d3e2f280282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_f7145756-b8bb-4737-b745-81f2e53f4f80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_4da17f80-a1a9-434c-b0d9-4d3e2f280282" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_f7145756-b8bb-4737-b745-81f2e53f4f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_597a919d-7745-4e90-94c1-299cf7a3ba6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_f7145756-b8bb-4737-b745-81f2e53f4f80" xlink:to="loc_us-gaap_DomesticCountryMember_597a919d-7745-4e90-94c1-299cf7a3ba6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_e44f57f6-9242-4053-8f4b-f37a546fe2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_f7145756-b8bb-4737-b745-81f2e53f4f80" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_e44f57f6-9242-4053-8f4b-f37a546fe2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_6481a2de-ec72-41b2-a195-9f75d2f24d23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_f7145756-b8bb-4737-b745-81f2e53f4f80" xlink:to="loc_us-gaap_ForeignCountryMember_6481a2de-ec72-41b2-a195-9f75d2f24d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_583af1d2-61e9-4a3a-a89b-3227b65d64ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_e480e877-1a93-4705-9b97-d962b582e61e" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_583af1d2-61e9-4a3a-a89b-3227b65d64ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_b49ec30e-7da6-4f28-8c1b-3764d07d739c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_583af1d2-61e9-4a3a-a89b-3227b65d64ca" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_b49ec30e-7da6-4f28-8c1b-3764d07d739c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_392100cf-c743-48e3-9764-795761a883ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_b49ec30e-7da6-4f28-8c1b-3764d07d739c" xlink:to="loc_us-gaap_ResearchMember_392100cf-c743-48e3-9764-795761a883ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_36a5b968-c4df-4ddc-9082-7e67b0bbde53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_e480e877-1a93-4705-9b97-d962b582e61e" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_36a5b968-c4df-4ddc-9082-7e67b0bbde53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_844a4136-1ca0-422f-af7a-f0cd40e44b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_36a5b968-c4df-4ddc-9082-7e67b0bbde53" xlink:to="loc_us-gaap_OperatingLossCarryforwards_844a4136-1ca0-422f-af7a-f0cd40e44b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_6aed91d7-1507-4673-8a2e-5f280bf8edff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_36a5b968-c4df-4ddc-9082-7e67b0bbde53" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_6aed91d7-1507-4673-8a2e-5f280bf8edff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_12598b8e-d5fc-43c0-b88e-b8b76062d837" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_36a5b968-c4df-4ddc-9082-7e67b0bbde53" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_12598b8e-d5fc-43c0-b88e-b8b76062d837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_a5529e5c-9442-4044-9f5e-1e58f6b0c798" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_36a5b968-c4df-4ddc-9082-7e67b0bbde53" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_a5529e5c-9442-4044-9f5e-1e58f6b0c798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_12b742bf-8c14-4672-9b0d-8177dc6340c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_36a5b968-c4df-4ddc-9082-7e67b0bbde53" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_12b742bf-8c14-4672-9b0d-8177dc6340c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c6188b92-7e7a-45d5-9fe7-0a2b3fa22121" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_ea54246a-baea-4df6-9132-e42c979a20f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c6188b92-7e7a-45d5-9fe7-0a2b3fa22121" xlink:to="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_ea54246a-baea-4df6-9132-e42c979a20f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_236547af-7bf3-4564-96bd-101de8aa3fef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_ea54246a-baea-4df6-9132-e42c979a20f0" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_236547af-7bf3-4564-96bd-101de8aa3fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1fb089f1-1b3e-4b8f-ac20-dc5fc7e0b925" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_ea54246a-baea-4df6-9132-e42c979a20f0" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1fb089f1-1b3e-4b8f-ac20-dc5fc7e0b925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_27d65136-1c89-48ac-b3b2-1c16b5f19f90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_ea54246a-baea-4df6-9132-e42c979a20f0" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_27d65136-1c89-48ac-b3b2-1c16b5f19f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_ed8a41f5-02b3-4666-bc77-475217e6f833" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_ea54246a-baea-4df6-9132-e42c979a20f0" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_ed8a41f5-02b3-4666-bc77-475217e6f833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DeferredTaxAssetsOperatingLeaseLiabilities_40d66acf-05fb-447e-b1ab-bd7f1731cac6" xlink:href="eols-20241231.xsd#eols_DeferredTaxAssetsOperatingLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_ea54246a-baea-4df6-9132-e42c979a20f0" xlink:to="loc_eols_DeferredTaxAssetsOperatingLeaseLiabilities_40d66acf-05fb-447e-b1ab-bd7f1731cac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements_ac4778f5-3e14-4055-a841-64013a365049" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_ea54246a-baea-4df6-9132-e42c979a20f0" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements_ac4778f5-3e14-4055-a841-64013a365049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DeferredTaxAssetsResearchAndExperimentationCapitalization_ed00274f-a3ca-489e-b640-01451f58784f" xlink:href="eols-20241231.xsd#eols_DeferredTaxAssetsResearchAndExperimentationCapitalization"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_ea54246a-baea-4df6-9132-e42c979a20f0" xlink:to="loc_eols_DeferredTaxAssetsResearchAndExperimentationCapitalization_ed00274f-a3ca-489e-b640-01451f58784f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_DeferredTaxAssetsFixedAssetDepreciation_d738386d-f881-4071-aeaa-be7e9e778f8a" xlink:href="eols-20241231.xsd#eols_DeferredTaxAssetsFixedAssetDepreciation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_ea54246a-baea-4df6-9132-e42c979a20f0" xlink:to="loc_eols_DeferredTaxAssetsFixedAssetDepreciation_d738386d-f881-4071-aeaa-be7e9e778f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_3c80f516-684f-4f21-a6fd-823d798f21bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_ea54246a-baea-4df6-9132-e42c979a20f0" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_3c80f516-684f-4f21-a6fd-823d798f21bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_fb669a71-57c0-4b63-bfd7-15b0f15e3ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_ea54246a-baea-4df6-9132-e42c979a20f0" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_fb669a71-57c0-4b63-bfd7-15b0f15e3ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_240d0536-fe7f-4f9b-9845-c0614672fd8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_ea54246a-baea-4df6-9132-e42c979a20f0" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_240d0536-fe7f-4f9b-9845-c0614672fd8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_c177c539-633a-48c3-a44d-fd37895dd5d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c6188b92-7e7a-45d5-9fe7-0a2b3fa22121" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_c177c539-633a-48c3-a44d-fd37895dd5d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_bd0fc2bf-c952-40b9-a4bc-f308004ad552" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_c177c539-633a-48c3-a44d-fd37895dd5d2" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_bd0fc2bf-c952-40b9-a4bc-f308004ad552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_5e6c9602-6b07-4561-80a8-2faf5658f07c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_c177c539-633a-48c3-a44d-fd37895dd5d2" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_5e6c9602-6b07-4561-80a8-2faf5658f07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_62964bf6-2fc7-4029-9b3e-2d31fcda697c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_c177c539-633a-48c3-a44d-fd37895dd5d2" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_62964bf6-2fc7-4029-9b3e-2d31fcda697c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_44030ec9-2b8c-42af-afbd-a6ac2bb07044" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_c177c539-633a-48c3-a44d-fd37895dd5d2" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_44030ec9-2b8c-42af-afbd-a6ac2bb07044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_95e2fbef-812d-4430-a5b7-a161b48633d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c6188b92-7e7a-45d5-9fe7-0a2b3fa22121" xlink:to="loc_us-gaap_DeferredTaxLiabilities_95e2fbef-812d-4430-a5b7-a161b48633d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#IncomeTaxesScheduleofEffectiveIncomeTaxDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3de69041-8535-46ef-9c81-52329ecd663f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_2ac94d1b-18af-4fe2-810c-15ba2217256b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3de69041-8535-46ef-9c81-52329ecd663f" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_2ac94d1b-18af-4fe2-810c-15ba2217256b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_d8c4337b-87cc-4b58-a352-d9d4e9eefc38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3de69041-8535-46ef-9c81-52329ecd663f" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_d8c4337b-87cc-4b58-a352-d9d4e9eefc38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_32a319ea-9789-48a7-a8f3-81788b1fb11e" xlink:href="eols-20241231.xsd#eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3de69041-8535-46ef-9c81-52329ecd663f" xlink:to="loc_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_32a319ea-9789-48a7-a8f3-81788b1fb11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_dbbda99e-deb4-4fc3-8131-c63b835ac6a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3de69041-8535-46ef-9c81-52329ecd663f" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_dbbda99e-deb4-4fc3-8131-c63b835ac6a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_d19aca14-dfa9-42ed-aa3b-e49c8f2eeb0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3de69041-8535-46ef-9c81-52329ecd663f" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_d19aca14-dfa9-42ed-aa3b-e49c8f2eeb0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation_318e2391-a78f-4fce-b7d2-9639a25f3378" xlink:href="eols-20241231.xsd#eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3de69041-8535-46ef-9c81-52329ecd663f" xlink:to="loc_eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation_318e2391-a78f-4fce-b7d2-9639a25f3378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_9207cf48-7596-4c41-81e2-6f74092c7301" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3de69041-8535-46ef-9c81-52329ecd663f" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_9207cf48-7596-4c41-81e2-6f74092c7301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_4742f021-287e-4afd-be04-85ec62178504" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3de69041-8535-46ef-9c81-52329ecd663f" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_4742f021-287e-4afd-be04-85ec62178504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingenciesOther_21c0c062-2948-4c9c-9a18-e318513c4b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3de69041-8535-46ef-9c81-52329ecd663f" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingenciesOther_21c0c062-2948-4c9c-9a18-e318513c4b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c80b4e0f-8720-4704-b3d6-ab62c6c81f51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3de69041-8535-46ef-9c81-52329ecd663f" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c80b4e0f-8720-4704-b3d6-ab62c6c81f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4f7f8754-4119-4bbb-a83d-f8650c54b14e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3de69041-8535-46ef-9c81-52329ecd663f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4f7f8754-4119-4bbb-a83d-f8650c54b14e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4b9fccc6-f929-4359-82c4-790ec3ed8d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_194360fe-4d83-4b77-a11f-0fd7b69d7eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4b9fccc6-f929-4359-82c4-790ec3ed8d1c" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_194360fe-4d83-4b77-a11f-0fd7b69d7eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_2b628d53-94f8-4235-befa-8ce0ec3104a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_194360fe-4d83-4b77-a11f-0fd7b69d7eb2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_2b628d53-94f8-4235-befa-8ce0ec3104a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_9ed50ec7-741f-43c7-8348-5e1a6dd91214" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_194360fe-4d83-4b77-a11f-0fd7b69d7eb2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_9ed50ec7-741f-43c7-8348-5e1a6dd91214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_e8caceb7-f339-4bdd-8478-73ef46b4f418" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_194360fe-4d83-4b77-a11f-0fd7b69d7eb2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_e8caceb7-f339-4bdd-8478-73ef46b4f418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_c1cd5042-1f8c-4d4e-80e3-f5daab0361c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_194360fe-4d83-4b77-a11f-0fd7b69d7eb2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_c1cd5042-1f8c-4d4e-80e3-f5daab0361c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/SegmentReportingNarrativeDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#SegmentReportingNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/SegmentReportingNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_9523d3a7-3805-4a1b-81b4-4769c364fc49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_2e8a6a5b-2848-4954-b8b6-1a5e2fd18c94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_9523d3a7-3805-4a1b-81b4-4769c364fc49" xlink:to="loc_us-gaap_NumberOfOperatingSegments_2e8a6a5b-2848-4954-b8b6-1a5e2fd18c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/SegmentReportingReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#SegmentReportingReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/SegmentReportingReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_219655d4-d4b3-46dd-bdda-133d132f2ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_a680a76b-6405-459f-9724-1cb653dab763" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_219655d4-d4b3-46dd-bdda-133d132f2ef0" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_a680a76b-6405-459f-9724-1cb653dab763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_279aadda-e2be-43ed-93cf-8aa338ec0dad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_a680a76b-6405-459f-9724-1cb653dab763" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_279aadda-e2be-43ed-93cf-8aa338ec0dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_ca399280-dd82-42da-a04a-bcb48b0cb38f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_279aadda-e2be-43ed-93cf-8aa338ec0dad" xlink:to="loc_us-gaap_SegmentDomain_ca399280-dd82-42da-a04a-bcb48b0cb38f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ReportableSegmentMember_c268022d-5d38-43d5-82cd-0595d2f17c67" xlink:href="eols-20241231.xsd#eols_ReportableSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_ca399280-dd82-42da-a04a-bcb48b0cb38f" xlink:to="loc_eols_ReportableSegmentMember_c268022d-5d38-43d5-82cd-0595d2f17c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_77d967ea-38d6-4db6-860f-8ec2de869589" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_a680a76b-6405-459f-9724-1cb653dab763" xlink:to="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_77d967ea-38d6-4db6-860f-8ec2de869589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_83189873-2beb-4b79-80d8-589d5df52736" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_77d967ea-38d6-4db6-860f-8ec2de869589" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_83189873-2beb-4b79-80d8-589d5df52736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_76593a08-4fe2-46fc-8e76-f4adf2a11588" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_77d967ea-38d6-4db6-860f-8ec2de869589" xlink:to="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_76593a08-4fe2-46fc-8e76-f4adf2a11588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_cba77d42-1e9c-474c-9416-cdc9420ee0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_76593a08-4fe2-46fc-8e76-f4adf2a11588" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_cba77d42-1e9c-474c-9416-cdc9420ee0e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_67372f18-1182-41e2-8d92-188cab7de495" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_76593a08-4fe2-46fc-8e76-f4adf2a11588" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_67372f18-1182-41e2-8d92-188cab7de495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_79f7c10a-ee99-4438-b28c-57669f6988e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_76593a08-4fe2-46fc-8e76-f4adf2a11588" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_79f7c10a-ee99-4438-b28c-57669f6988e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0e4a31c6-dcfc-440c-95a9-a5c6387ec903" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_76593a08-4fe2-46fc-8e76-f4adf2a11588" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0e4a31c6-dcfc-440c-95a9-a5c6387ec903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_eols_ResearchAndDevelopmentInProcess1_c41c64ce-fe72-4820-8327-2eb642177c92" xlink:href="eols-20241231.xsd#eols_ResearchAndDevelopmentInProcess1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_76593a08-4fe2-46fc-8e76-f4adf2a11588" xlink:to="loc_eols_ResearchAndDevelopmentInProcess1_c41c64ce-fe72-4820-8327-2eb642177c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2a57eab1-fe23-40d0-b20c-15f769c6a711" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_76593a08-4fe2-46fc-8e76-f4adf2a11588" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_2a57eab1-fe23-40d0-b20c-15f769c6a711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1102a0a2-2b82-46cf-b7a5-232b8d2964ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_76593a08-4fe2-46fc-8e76-f4adf2a11588" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1102a0a2-2b82-46cf-b7a5-232b8d2964ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_26333593-2291-427c-8d29-771f4d1a4251" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_76593a08-4fe2-46fc-8e76-f4adf2a11588" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_26333593-2291-427c-8d29-771f4d1a4251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_238c434a-ec84-4c5e-b905-442cf2c76d03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_76593a08-4fe2-46fc-8e76-f4adf2a11588" xlink:to="loc_us-gaap_InvestmentIncomeNet_238c434a-ec84-4c5e-b905-442cf2c76d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_5eb59fc8-917a-4867-83d5-827f464dbda3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_76593a08-4fe2-46fc-8e76-f4adf2a11588" xlink:to="loc_us-gaap_InterestExpenseNonoperating_5eb59fc8-917a-4867-83d5-827f464dbda3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9ab479b4-7845-4d74-a614-e00ad2b33456" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_76593a08-4fe2-46fc-8e76-f4adf2a11588" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_9ab479b4-7845-4d74-a614-e00ad2b33456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e4574e04-79a1-43b5-a91e-aeb79520ca6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_76593a08-4fe2-46fc-8e76-f4adf2a11588" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e4574e04-79a1-43b5-a91e-aeb79520ca6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_15806b37-10d2-44d6-8701-fa11e5dc0dba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_76593a08-4fe2-46fc-8e76-f4adf2a11588" xlink:to="loc_us-gaap_NetIncomeLoss_15806b37-10d2-44d6-8701-fa11e5dc0dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolus.com/role/SegmentReportingScheduleofRevenuebyCountryDetails" xlink:type="simple" xlink:href="eols-20241231.xsd#SegmentReportingScheduleofRevenuebyCountryDetails"/>
  <link:presentationLink xlink:role="http://www.evolus.com/role/SegmentReportingScheduleofRevenuebyCountryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_306324fb-c1ac-4e8c-b17b-b3715887ebcc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_6e820135-28ce-47a4-bea1-f0961f4591d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_306324fb-c1ac-4e8c-b17b-b3715887ebcc" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_6e820135-28ce-47a4-bea1-f0961f4591d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_bd8fa659-d086-42dc-b745-507f8636a79c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_6e820135-28ce-47a4-bea1-f0961f4591d6" xlink:to="loc_srt_StatementGeographicalAxis_bd8fa659-d086-42dc-b745-507f8636a79c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_036d922f-7a23-483c-b9fa-23176efb29ce" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_bd8fa659-d086-42dc-b745-507f8636a79c" xlink:to="loc_srt_SegmentGeographicalDomain_036d922f-7a23-483c-b9fa-23176efb29ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_e70e5c20-c1c8-49bc-a484-219fe13e1d77" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_036d922f-7a23-483c-b9fa-23176efb29ce" xlink:to="loc_country_US_e70e5c20-c1c8-49bc-a484-219fe13e1d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_fb5371b5-e496-40c9-97a1-362bab8a4425" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_036d922f-7a23-483c-b9fa-23176efb29ce" xlink:to="loc_us-gaap_NonUsMember_fb5371b5-e496-40c9-97a1-362bab8a4425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_e02ed1c7-f42c-4d3a-9643-979e55d222bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_6e820135-28ce-47a4-bea1-f0961f4591d6" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_e02ed1c7-f42c-4d3a-9643-979e55d222bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8b15e66f-87ec-4011-a561-49b8cb4c73ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_e02ed1c7-f42c-4d3a-9643-979e55d222bc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8b15e66f-87ec-4011-a561-49b8cb4c73ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>eols-20241231_g1.jpg
<TEXT>
begin 644 eols-20241231_g1.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_X0*617AI9@  34T *@    @ ! $[  (
M   ,   !2H=I  0    !   !5IR=  $    8   "=NH<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M36%T="!396%R8WD   'J'  '   !#    6@     '.H    !
M
M
M
M
M
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M:H_X:DU__H&C_O\ I_\ &J\*HH ]U_X:DU__ *!H_P"_Z?\ QJM__A?NO_\
M"N/^$K\@?\A;^S?LNY/^>/F;]_E_AC'OFOFNN^_YMQ_[FO\ ]M* .W_X:DU_
M_H&C_O\ I_\ &J/^&I-?_P"@:/\ O^G_ ,:KPJB@#W7_ (:DU_\ Z!H_[_I_
M\:H_X:DU_P#Z!H_[_I_\:KPJB@#W7_AJ37_^@:/^_P"G_P :H_X:DU__ *!H
M_P"_Z?\ QJO"J* /=?\ AJ37_P#H&C_O^G_QJC_AJ37_ /H&C_O^G_QJO"J*
M /=?^&I-?_Z!H_[_ *?_ !JC_AJ37_\ H&C_ +_I_P#&J\*HH ]U_P"&I-?_
M .@:/^_Z?_&J/^&I-?\ ^@:/^_Z?_&J\*HH ]U_X:DU__H&C_O\ I_\ &J/^
M&I-?_P"@:/\ O^G_ ,:KPJB@#W7_ (:DU_\ Z!H_[_I_\:H_X:DU_P#Z!H_[
M_I_\:KPJB@#W7_AJ37_^@:/^_P"G_P :H_X:DU__ *!H_P"_Z?\ QJO"J* /
M=?\ AJ37_P#H&C_O^G_QJC_AJ37_ /H&C_O^G_QJO"J* /=?^&I-?_Z!H_[_
M *?_ !JK^@_M(:_K?B33=*^Q"#[==Q6WF^8C;-[A=V/+&<9SC(KY[K?\!_\
M)1_#?_86M?\ T<M 'LNO?M(:_HGB34M*^Q"?[#=RVWF^8B[]CE=V/+.,XSC)
MJA_PU)K_ /T#1_W_ $_^-5Y3X\_Y*/XD_P"PM=?^CFK H ]U_P"&I-?_ .@:
M/^_Z?_&J/^&I-?\ ^@:/^_Z?_&J\*HH ]U_X:DU__H&C_O\ I_\ &J/^&I-?
M_P"@:/\ O^G_ ,:KPJB@#W7_ (:DU_\ Z!H_[_I_\:H_X:DU_P#Z!H_[_I_\
M:KPJB@#W7_AJ37_^@:/^_P"G_P :H_X:DU__ *!H_P"_Z?\ QJO"J* /=?\
MAJ37_P#H&C_O^G_QJC_AJ37_ /H&C_O^G_QJO"J* /=?^&I-?_Z!H_[_ *?_
M !JC_AJ37_\ H&C_ +_I_P#&J\*HH ]U_P"&I-?_ .@:/^_Z?_&J/^&I-?\
M^@:/^_Z?_&J\*HH ^E/^%^Z__P *X_X2OR!_R%O[-^R[D_YX^9OW^7^&,>^:
MP/\ AJ37_P#H&C_O^G_QJN(_YMQ_[FO_ -M*X&@#W7_AJ37_ /H&C_O^G_QJ
MC_AJ37_^@:/^_P"G_P :KPJB@#W7_AJ37_\ H&C_ +_I_P#&J/\ AJ37_P#H
M&C_O^G_QJO"J* /=?^&I-?\ ^@:/^_Z?_&J/^&I-?_Z!H_[_ *?_ !JO"J*
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MI-?_ .@:/^_Z?_&J/^&I-?\ ^@:/^_Z?_&J\*HH ]U_X:DU__H&C_O\ I_\
M&J/^&I-?_P"@:/\ O^G_ ,:KPJB@#W7_ (:DU_\ Z!H_[_I_\:H_X:DU_P#Z
M!H_[_I_\:KPJB@#W7_AJ37_^@:/^_P"G_P :H_X:DU__ *!H_P"_Z?\ QJO"
MJ* /=?\ AJ37_P#H&C_O^G_QJC_AJ37_ /H&C_O^G_QJO"J* /=?^&I-?_Z!
MH_[_ *?_ !JC_AJ37_\ H&C_ +_I_P#&J\*HH ]U_P"&I-?_ .@:/^_Z?_&J
M/^&I-?\ ^@:/^_Z?_&J\*HH ]U_X:DU__H&C_O\ I_\ &J/^&I-?_P"@:/\
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M !JC_AJ37_\ H&C_ +_I_P#&J\*HH ]U_P"&I-?_ .@:/^_Z?_&J/^&I-?\
M^@:/^_Z?_&J\*HH ]U_X:DU__H&C_O\ I_\ &J/^&I-?_P"@:/\ O^G_ ,:K
MPJB@#W7_ (:DU_\ Z!H_[_I_\:H_X:DU_P#Z!H_[_I_\:KPJB@#W7_AJ37_^
M@:/^_P"G_P :H_X:DU__ *!H_P"_Z?\ QJO"J* /=?\ AJ37_P#H&C_O^G_Q
MJC_AJ37_ /H&C_O^G_QJO"J* /=?^&I-?_Z!H_[_ *?_ !JC_AJ37_\ H&C_
M +_I_P#&J\*HH ]U_P"&I-?_ .@:/^_Z?_&J/^&I-?\ ^@:/^_Z?_&J\*HH
M]U_X:DU__H&C_O\ I_\ &J/^&I-?_P"@:/\ O^G_ ,:KPJB@#W7_ (:DU_\
MZ!H_[_I_\:H_X:DU_P#Z!H_[_I_\:KPJB@#W7_AJ37_^@:/^_P"G_P :H_X:
MDU__ *!H_P"_Z?\ QJO"J* /=?\ AJ37_P#H&C_O^G_QJC_AJ37_ /H&C_O^
MG_QJO"J* /=?^&I-?_Z!H_[_ *?_ !JC_AJ37_\ H&C_ +_I_P#&J\*HH ]U
M_P"&I-?_ .@:/^_Z?_&J/^&I-?\ ^@:/^_Z?_&J\*HH ]U_X:DU__H&C_O\
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M7A5% 'NO_#4FO_\ 0-'_ '_3_P"-4?\ #4FO_P#0-'_?]/\ XU7A5% 'NO\
MPU)K_P#T#1_W_3_XU1_PU)K_ /T#1_W_ $_^-5X510![K_PU)K__ $#1_P!_
MT_\ C5'_  U)K_\ T#1_W_3_ .-5X510![K_ ,-2:_\ ] T?]_T_^-4?\-2:
M_P#] T?]_P!/_C5>%44 >Z_\-2:__P! T?\ ?]/_ (U1_P -2:__ - T?]_T
M_P#C5>%44 >Z_P##4FO_ /0-'_?]/_C5'_#4FO\ _0-'_?\ 3_XU7A5% 'NO
M_#4FO_\ 0-'_ '_3_P"-4?\ #4FO_P#0-'_?]/\ XU7A5% 'NO\ PU)K_P#T
M#1_W_3_XU1_PU)K_ /T#1_W_ $_^-5X510![K_PU)K__ $#1_P!_T_\ C5'_
M  U)K_\ T#1_W_3_ .-5X510![K_ ,-2:_\ ] T?]_T_^-4?\-2:_P#] T?]
M_P!/_C5>%44 >Z_\-2:__P! T?\ ?]/_ (U1_P -2:__ - T?]_T_P#C5>%4
M4 >Z_P##4FO_ /0-'_?]/_C5'_#4FO\ _0-'_?\ 3_XU7A5% 'NO_#4FO_\
M0-'_ '_3_P"-4?\ #4FO_P#0-'_?]/\ XU7A5% 'NO\ PU)K_P#T#1_W_3_X
MU1_PU)K_ /T#1_W_ $_^-5X510![K_PU)K__ $#1_P!_T_\ C5'_  U)K_\
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MN^_YMQ_[FO\ ]M* .!HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *W_ ?_)1_#?\ V%K7_P!'+6!6_P" _P#DH_AO_L+6O_HY: #Q
MY_R4?Q)_V%KK_P!'-6!6_P"//^2C^)/^PM=?^CFK H **** "BBB@ HHHH *
M*** "BBB@ HHHH **** .^_YMQ_[FO\ ]M*X&N^_YMQ_[FO_ -M*X&@ KHO
MW@G4O'_B9-#T::U@N6B>4/=.RIA>O*JQS^%<[7KG[,__ "62#_KRG_D*J*NR
M)MI77E^9Y[%X6O9O'0\*++;B_.H?V?YA9O*\SS/+SG&=N>^,X[5T#_"#Q/\
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M^&__  K+Q#9Z7_:O]I_:;07/F_9_)VY9EVXW-G[O7/>N'KW']JG_ )*#H_\
MV"5_]&R5X=6,7=?>5-)-6[+\D%=]X1_Y(W\0_P#N&?\ I0U<#7?>$?\ DC?Q
M#_[AG_I0U40<#1110 4444 %%%% !78_#WX9:S\2KF^AT.YL+8V,:R2M>R.B
MD,2!C:K>AKCJ^@OV4@#J/BH,VU3:0Y.,XY>GW^8G_D<)K'P1\0Z;X4N/$6G:
MGH?B#3K7)GDT:],_EJ.I.5 ('?!)'I7G%?2VFZ9I7PZ_9[\1ZIX.U&;Q;%K*
M&"6[CB\B.W4@Q[FB8EEV[^>I)QG YJ[IO@?P_P""_AUX<D6S\#R:CJ4:7-[<
M>+YP/,!569(<J>F['' X)#$T6U?;3[V4M8KOK]R/ERBOI6V\$?#C5_VA["'1
M3INHZ5<:;)=/96$PGMTN$;&&V9"J1SM.!D=.<'0\86]CX6^%.N:EXH\">"])
MUDW#6^EPPV<4GGQLP <8YW!2QR".@) Z5+=HW_K>PU&\N7T_%7/EJN@\">%?
M^$V\<:=X>^V?8OMSLOVCRO,V;49ONY&?NXZCK7I'Q3T+2-.^!WP_O]/TNRM;
MR[@0W%Q!;HDDQ\D'+L!EN>>:]&UK0-'T+X^_#8:)I5EIPGM[AI1:6Z1"0B(\
MMM R>>IH4ES\K[V_"Y#^&Z[7/F[QKX:_X0[QIJ6@&[^V?89?+\_R_+W\ YVY
M..OJ:PJ^DH_#]UJWQN\?7-MX4T761!*F+W7IBMI9G8"=R;6WDCZ8"]1FG_$3
M1-#TSX5:1XT@T/P?/JUC?H)/[$B$FG70W,I1E&-XX&0>001FHA+]W&4NJ7XE
MM7DTO/\  \)\4>!_$7@P61\2Z=]B%_&9+;]]')YBC&3\C''WAUQUK KZF^/&
MJFY/A'PZ-(T>4^((_(^V7%IOFLMSQ#,+9^3[WOT%9WBB[\(_#KXC:!X%L? 6
MAZA93K"MU>7]JLMPYE<KE78'D=><CL,8K3K;SLB+Z7\KGS517T]HOPU\,Z1^
MTW?Z*-*M;K2KC16O8[.ZA6:.%F=5.T,#T(./3.*HZ%XL^'>K?%ZR\*P^ =)L
M[*)[C3_.N+6&0SR#;L<Y7(.8V7)+'YQSS2B^9I+=_H4]+WZ?\.?-]%?2&E_#
MW1_ASHOQ&UWQ+I%E?PV,YM])CO;=95P0&C*[@>298U)']TU\WT)W^Y/[QM6^
M_P#(****9(4444 %%%% '??"K_F=/^Q4OO\ V2N!KOOA5_S.G_8J7W_LE<#0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5WWA'_DC?Q#_P"X9_Z4-7 UWWA'_DC?Q#_[AG_I
M0U ' T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!]B?LV_\DR7_ *Z?U-%'[-O_ "3)?^NG]310!Q?[5WW]'^@_
M]J5\WU](?M7??T?Z#_VI7S?0 4444 %>Q-\$-!T[P?H6O>)_B FCQZU%&T*/
MI+RJK.@?:663L/XB *\=KZP\06?@W4/A-\-K/Q[-J$-I.ELD#VC*J"0P#_6D
M\A,<97D>W6JM[EUO=+[Q7U^3/!/B;\,[_P"&NL6UM=7D.H6=[&9;2\B&T2 8
MW KDX(R.Y&".?3BJ^KO$^C2>)?VD/#>@>)-.MET#3;&2XT^($NMR .C9 Z,J
MY7D87OFK6J_$3P;;ZYK^A^-_&MI?Z6V^U71#X=FC^Q,IQ@2@-OQCKCK@@CI4
M?9OZ_@RMW]WXH^1ZW_!5IX9OO%$$'CC4;K3='9',MQ:H6=6Q\HP%;J?]DU]"
M> !-H'P'T2[\.ZSHWA.\O-19KB_UH(@O8A(_ +=25 P.. <$9S4C>.K7QA^U
M/X;M=%U*._TK3;6=4:)1L\YH9/,*MC+# 0=2.#BM5'W^7U_!7):T;?\ 6O\
M7R/FGQ!#I-MXBOH?#EU-=Z4DS"TGG7:\D>>"1@<_@/H.E9U?47ARRM-&O/BQ
MXXM[*"[UK2]1NULS,F_R=H+;@.V2W)'.%Q6;8ZY=?%;]G/Q3J7C>.WNK[1WD
M:SO1 L; JBN ,  <G;QU!YK"]H7[)-_,TE']XUYM?<?-]%?4/C?Q]JW@'X;_
M  YN/#\=HEU>6$*27$T =Q&D<1,8)Z!MW/?@8Q7#?M0:;9V7Q+LKBTMXX9+S
M3DEG*+CS'WNNX^^ !GVK6I%P=O-K[A1BW&_E?\;'B]%%%22%;_@/_DH_AO\
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M4'%:]VON"BBB@@*W_ ?_ "4?PW_V%K7_ -'+6!6_X#_Y*/X;_P"PM:_^CEH
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MEF^UNC;6&S[NU5P/F/7->8U[]^U!_J?!7_7C+_[2KP&GU?J_S$MEZ+\COO\
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M#43TWWT_%V/CRBOICP!\<KCQ=\5K?1M9TVRL-.O()K&**')'7=&&)Z\*R\
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ML6>X3C&0P< 'Z 9[UA>'_B_XG\/^.-1\6 VNH:IJ,)AG:]C8KMRI& C+C&P
M=L5PM%+K?^M0Z6.N\+?$C6/".D^(-.TVWLI8=?B,5TUQ&Y9!M=<IAA@X<]<]
MJY&BBC=W*<F]_4****"0K?\  ?\ R4?PW_V%K7_T<M8%;_@/_DH_AO\ ["UK
M_P"CEH /'G_)1_$G_86NO_1S5@JQ5@PZ@YK>\>?\E'\2?]A:Z_\ 1S5@4TVG
M= =?\0/B5K/Q(N;"?7+>Q@:QB:*(6<;J""023N9N>/:H? 'Q!U7X<:W/JFAV
M]G///;FW9;Q&90I96R K*<Y4=ZY:BDO=V_J^X;F[X6\9:SX-\3+KN@SK#=C<
M'5EW)(K')1AW!_H.]=7KGQNUS6M)U*RBT/P[I;:JACO;K3]/,<TZGJ&=F;.?
M7K7F]%#U5AW;ES=3T?0?C?XCT7PM;>'[G3M%UNPLV!MEU:S,QAQ]T+A@..Q(
M)'K4,'QH\2P0^)XS;Z;(?$P(O&:!@8QY9CQ'M8 84]P>E>?44/6]^HEI:W0[
MB3XL:[)X/T'PX;73Q9Z%=QW=LXC?S'="2 YWX(^8] *DU/XO:_JOQ*L/&]Q:
MZ<NIV$8CBB2)Q"0 PY!<M_&?XA7!T4=;_,.EOD>C:=\;_$NF>*M?\06]GI;7
M>OHB7*/#(40*NT;!OR./4FJOA'XO^(/"/AN;P_'::7J^D2L6^Q:K;&:-23DX
M 8<$\X.1FN#HH6FB#S/3+3X]>+;/7[W4DMM)>&]MDM9=->T/V41ID* @8'^)
MN_.<'MBOXI^-7B#Q9X/D\,WFFZ-9Z:TB.D=C;-%Y(0@A5&\@+D>AZUYW12:3
M5F&QUWCSXDZQ\0UTL:U;V4 TR%H8?LD;KN!VY+;F;)^4=,5R-%%,#OO^;<?^
MYK_]M*X&N^_YMQ_[FO\ ]M*X&@ HHHH *]1^!/PZTKX@>)KX:^TDEEIMN)6M
M8G*-.S' &1R ,'.,'D<UY=7:?#6U\=1ZM<ZU\.8+B6ZTU%^T^1L8E')PIC8Y
M<':> #TSQQ51M?44KVT-?Q,/!6LJ= \->!-5\.>*6ODM[:&:]:19 S8VR"5A
ML8Y' & >^*Z'XD_L_P!SX6\)V&K^'8;VZ\FU:?6?M-U!MMBJJ?E VDC._INZ
M#\>T\>7%QXK_ &>;O7?B9X?AT77[:0)8,8S'*YW+C"M\RAOF!4GHN?3&3\==
M'U'7/AGX'U'1[*:]LK/3FEN)X$+)"GE1'<Q'0?*>?:H>D7W37XK^KK\BXV<E
MV:?X?UH_S/%=<\">(_#:Z4VM:=]F&L+OL?W\;^</E_NL=OWU^]CK4^J?#CQ9
MHWBBS\.ZAHTJZM?('M[6*1)6D4DC.48@#Y3G)X R>*]U^(_A/6O&>F_"V[\,
MV3W]M% @EFB^[$"L+!F/\(PC<GN,=2!79WT]G!^U/IBWC(LLOAMTMMQ',GG,
M<#WVAOUK1Q2E;S:^XSBVXMOLG][2//?@U\'-5T/7-5/Q$\*6KV\E@3;&[6"Z
M0.&&<8+!6P?8]:X#3H;D_L_:C*O@"QN;=;C#>)VGA$\!\Q/E"$>8?[O!Q\U>
MT?"70/&6D^.O'5WXECNXM/NII#$;ACMGDW$AT!/(V8&1QC [<</H&/\ AC+7
M-W3[=SC_ *[15%^:-_)?BRXJU5+^]^AYMH'P>\>>)]'CU31?#TTUE*,QRR31
M0[QZJ'8$CW Q6;IOP^\5:OXHN/#MAHES)JUMGS[9@$,0'=F8A0.1@DX.1BOJ
M#QY=1?9?"&KZ#X"O/&%M#$DEA/IVIS0+:-A=I*1@@@C^(C P0:Y:T\:>,?\
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MV%T5@VG&=KJVW)ZE?FP,\BL];/O_ ,#\?P)TT[?\-_74\2FBN?\ AGF";_A
M+%+?[3M'B@3P^>Q\X_+LQYG^QR<8%96B_!CX@>(-)BU/2O#<TEI,NZ-Y9XH2
MZ]B%=P2#V.,'M7J)CMK3]D>RCNW6>UAUG;*Z<B1!>-DCV(K9^+OA_P 7Z_\
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M :O\5)-.@;_1M'MTM$4'@-C<Q'_?0'_ :\FI1?,KH&K:'??"K_F=/^Q4OO\
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M ' T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7<>)_BWXC\4_V
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M^&=/AY_T!_\ R:N/_CM>J44 >5_\,Z?#S_H#_P#DU<?_ !VC_AG3X>?] ?\
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M /)JX_\ CM'_  SI\//^@/\ ^35Q_P#':]4HH \K_P"&=/AY_P! ?_R:N/\
MX[1_PSI\//\ H#_^35Q_\=KU2B@#RO\ X9T^'G_0'_\ )JX_^.T?\,Z?#S_H
M#_\ DU<?_':]4HH \K_X9T^'G_0'_P#)JX_^.T?\,Z?#S_H#_P#DU<?_ !VO
M5** /-K'X+^#?#OVC^R]-\K^TH&T^X_?S-OADQN7YG.,X'(P?>JG_#.GP\_Z
M _\ Y-7'_P =KTF__P"7;_KX7^M6Z /*_P#AG3X>?] ?_P FKC_X[1_PSI\/
M/^@/_P"35Q_\=KU2B@#RO_AG3X>?] ?_ ,FKC_X[1_PSI\//^@/_ .35Q_\
M':]4HH \K_X9T^'G_0'_ /)JX_\ CM'_  SI\//^@/\ ^35Q_P#':]4HH \K
M_P"&=/AY_P! ?_R:N/\ X[1_PSI\//\ H#_^35Q_\=KU2B@#RO\ X9T^'G_0
M'_\ )JX_^.T?\,Z?#S_H#_\ DU<?_':]4HH \K_X9T^'G_0'_P#)JX_^.T?\
M,Z?#S_H#_P#DU<?_ !VO5** /*_^&=/AY_T!_P#R:N/_ ([1_P ,Z?#S_H#_
M /DU<?\ QVO5** /*_\ AG3X>?\ 0'_\FKC_ ..T?\,Z?#S_ * __DU<?_':
M]4HH \K_ .&=/AY_T!__ ":N/_CM'_#.GP\_Z __ )-7'_QVO5** /*_^&=/
MAY_T!_\ R:N/_CM'_#.GP\_Z _\ Y-7'_P =KU2B@#RO_AG3X>?] ?\ \FKC
M_P".T?\ #.GP\_Z _P#Y-7'_ ,=KU2B@#RO_ (9T^'G_ $!__)JX_P#CM'_#
M.GP\_P"@/_Y-7'_QVO5** /*_P#AG3X>?] ?_P FKC_X[1_PSI\//^@/_P"3
M5Q_\=KU2B@#RO_AG3X>?] ?_ ,FKC_X[1_PSI\//^@/_ .35Q_\ ':]4HH \
MK_X9T^'G_0'_ /)JX_\ CM'_  SI\//^@/\ ^35Q_P#':]4HH \K_P"&=/AY
M_P! ?_R:N/\ X[5N#X+^#=-T^[T2TTW99:QL^UQ^?,=_E'>G)?(P3V(]\UZ3
M52X_Y"5G_P #_E0!YM_PSI\//^@/_P"35Q_\=H_X9T^'G_0'_P#)JX_^.UZI
M10!Y7_PSI\//^@/_ .35Q_\ ':/^&=/AY_T!_P#R:N/_ ([7JE% 'E?_  SI
M\//^@/\ ^35Q_P#':/\ AG3X>?\ 0'_\FKC_ ..UZI10!Y7_ ,,Z?#S_ * _
M_DU<?_':/^&=/AY_T!__ ":N/_CM>J44 >5_\,Z?#S_H#_\ DU<?_':/^&=/
MAY_T!_\ R:N/_CM>J44 >5_\,Z?#S_H#_P#DU<?_ !VC_AG3X>?] ?\ \FKC
M_P".UZI10!Y7_P ,Z?#S_H#_ /DU<?\ QVC_ (9T^'G_ $!__)JX_P#CM>J4
M4 >5_P##.GP\_P"@/_Y-7'_QVC_AG3X>?] ?_P FKC_X[7JE% 'E?_#.GP\_
MZ __ )-7'_QVC_AG3X>?] ?_ ,FKC_X[7JE% 'E?_#.GP\_Z _\ Y-7'_P =
MH_X9T^'G_0'_ /)JX_\ CM>J44 >5_\ #.GP\_Z _P#Y-7'_ ,=H_P"&=/AY
M_P! ?_R:N/\ X[7JE% 'E?\ PSI\//\ H#_^35Q_\=H_X9T^'G_0'_\ )JX_
M^.UZI10!Y7_PSI\//^@/_P"35Q_\=H_X9T^'G_0'_P#)JX_^.UZI10!Y7_PS
MI\//^@/_ .35Q_\ ':/^&=/AY_T!_P#R:N/_ ([7JE% 'E?_  SI\//^@/\
M^35Q_P#':/\ AG3X>?\ 0'_\FKC_ ..UZI10!Y7_ ,,Z?#S_ * __DU<?_':
M/^&=/AY_T!__ ":N/_CM>J44 >5_\,Z?#S_H#_\ DU<?_':/^&=/AY_T!_\
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M^?2.\_X6[KW_ #Z:=_WZD_\ BZ/^%NZ]_P ^FG?]^I/_ (NN#HH]M4[A_9&
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5+45I_QYP_\ 7-?Y5+0 4444 %%%% !1110 4444 %%%% !1110 54_YC/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !5BQL;G4[Z*TL8FFGE;"HO^>E%C8W.IWT5
MI8Q--/*V%1?\]*]R\'>#K;PO8[FVS7\H_?38Z?[*^W\ZUI4G4?D>1F>9T\!3
M[S>R_5^0>#O!UMX7L=S;9K^4?OIL=/\ 97V_G72T45Z<8J*LC\SKUZF(J.I4
M=VPHHHJC$*J7'_(2L_\ @?\ *K=5+C_D)6?_  /^5 %NBBB@ HHHH XSQ;X
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M)K>07&TPE#YF_IMQSGVQ7DG[/_AR&QT/5->ADFEMM0NW@TQIR=RV43L(P,]
M26./I7KU%"T;?]?U_P 'N#U5OZ_K_@&;XBTZ\U?PY?:?INI/I5U<PF..]C3>
MT)/\0&1SCW%>>^'/A?XV\+:9;Z;H_P 2(;>QA;=Y*^'8,ODY8LQ<DD]V))KU
M2BA:.X/56.-\2^!+O4O$\'B7PSKTF@:U';_99IOLRW$5Q#G<%>-B.0>000:-
M$\!7&C:9KDO]O3W/B36T_P!(UJ2!048(5C*1#A53J%S^/IV5%*VEAWUN>3>'
MOA3XV\+::;'0_B7';PM(TTA/AV%WE=CEG=VD+,Q]22:Z_7O#?B2^U""^\/\
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M#_IZNO\ OY1]@_Z>KK_OY0!;HJI]@_Z>KK_OY1]@_P"GJZ_[^4 6Z*J?8/\
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M=P27=NJM-;K(#)&&^Z67J <'&>N*?<W,%E:RW-Y/';V\*%Y)97"HB@9))/
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M"BX!15#1=;T_Q%I,.IZ/<"YM)MP238R\JQ4@JP!!!!&".U7Z "BBB@ HHHH
M*BN_^/.;_KFW\JEJ*[_X\YO^N;?RH +3_CSA_P"N:_RJ6HK3_CSA_P"N:_RJ
M6@"AKMM+>>'=2M;9-\TUK+'&N0-S%" ,GCJ:\7_X5QXK_P"@5_Y,1?\ Q5>[
MT5C4I1J.[/6P&;5\!%QI)._>_P"C1X1_PKCQ7_T"O_)B+_XJC_A7'BO_ *!7
M_DQ%_P#%5[O16?U6'=GH_P"LV,_EC]S_ ,SPC_A7'BO_ *!7_DQ%_P#%4?\
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MB+_XJO=Z*/JL.[#_ %FQG\L?N?\ F>$?\*X\5_\ 0*_\F(O_ (JC_A7'BO\
MZ!7_ ),1?_%5[O11]5AW8?ZS8S^6/W/_ #/"/^%<>*_^@5_Y,1?_ !5'_"N/
M%?\ T"O_ "8B_P#BJ]WHH^JP[L/]9L9_+'[G_F>$?\*X\5_] K_R8B_^*H_X
M5QXK_P"@5_Y,1?\ Q5>[T4?58=V'^LV,_EC]S_S/"/\ A7'BO_H%?^3$7_Q5
M'_"N/%?_ $"O_)B+_P"*KW>BCZK#NP_UFQG\L?N?^9X1_P *X\5_] K_ ,F(
MO_BJ/^%<>*_^@5_Y,1?_ !5>[T4?58=V'^LV,_EC]S_S/"/^%<>*_P#H%?\
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MG#_US7^52U%:?\></_7-?Y5+0!!?7D>GZ=<WLP9H[>)I7"#)(4$G'OQ7%_\
M"W=!_P"?34?^_4?_ ,773^)_^11U?_KQF_\ 19KYTKEKU90:L?4Y'EF'QM.<
MJR>C[GLG_"W=!_Y]-1_[]1__ !='_"W=!_Y]-1_[]1__ !=>-T5S_6*A[_\
MJ[@.S^\]D_X6[H/_ #Z:C_WZC_\ BZ/^%NZ#_P ^FH_]^H__ (NO&Z*/K%0/
M]7<!V?WGLG_"W=!_Y]-1_P"_4?\ \71_PMW0?^?34?\ OU'_ /%UXW11]8J!
M_J[@.S^\]D_X6[H/_/IJ/_?J/_XNC_A;N@_\^FH_]^H__BZ\;HH^L5 _U=P'
M9_>>R?\ "W=!_P"?34?^_4?_ ,71_P +=T'_ )]-1_[]1_\ Q=>-T4?6*@?Z
MNX#L_O/9/^%NZ#_SZ:C_ -^H_P#XNC_A;N@_\^FH_P#?J/\ ^+KQNBCZQ4#_
M %=P'9_>>N_\+7T/^T//^RZAM\K9CRTSG.?[]3_\+=T'_GTU'_OU'_\ %UXW
M11]8J!_J[@.S^\]D_P"%NZ#_ ,^FH_\ ?J/_ .+H_P"%NZ#_ ,^FH_\ ?J/_
M .+KQNBCZQ4#_5W =G]Y[)_PMW0?^?34?^_4?_Q='_"W=!_Y]-1_[]1__%UX
MW11]8J!_J[@.S^\]D_X6[H/_ #Z:C_WZC_\ BZ/^%NZ#_P ^FH_]^H__ (NO
M&Z*/K%0/]7<!V?WGLG_"W=!_Y]-1_P"_4?\ \71_PMW0?^?34?\ OU'_ /%U
MXW11]8J!_J[@.S^\]D_X6[H/_/IJ/_?J/_XNC_A;N@_\^FH_]^H__BZ\;HH^
ML5 _U=P'9_>>R?\ "W=!_P"?34?^_4?_ ,71_P +=T'_ )]-1_[]1_\ Q=>-
MT4?6*@?ZNX#L_O/9/^%NZ#_SZ:C_ -^H_P#XNC_A;N@_\^FH_P#?J/\ ^+KQ
MNBCZQ4#_ %=P'9_>>R?\+=T'_GTU'_OU'_\ %T?\+=T'_GTU'_OU'_\ %UXW
M11]8J!_J[@.S^\]D_P"%NZ#_ ,^FH_\ ?J/_ .+J"7XKZ&]W!*+74-L>[.8T
MSR/]^O(J*/K%0/\ 5W =G]Y[)_PMW0?^?34?^_4?_P 71_PMW0?^?34?^_4?
M_P 77C=%'UBH'^KN [/[SV3_ (6[H/\ SZ:C_P!^H_\ XNC_ (6[H/\ SZ:C
M_P!^H_\ XNO&Z*/K%0/]7<!V?WGLG_"W=!_Y]-1_[]1__%T?\+=T'_GTU'_O
MU'_\77C=%'UBH'^KN [/[SV3_A;N@_\ /IJ/_?J/_P"+H_X6[H/_ #Z:C_WZ
MC_\ BZ\;HH^L5 _U=P'9_>>R?\+=T'_GTU'_ +]1_P#Q='_"W=!_Y]-1_P"_
M4?\ \77C=%'UBH'^KN [/[SV3_A;N@_\^FH_]^H__BZ/^%NZ#_SZ:C_WZC_^
M+KQNBCZQ4#_5W =G]Y[)_P +=T'_ )]-1_[]1_\ Q='_  MW0?\ GTU'_OU'
M_P#%UXW11]8J!_J[@.S^\]D_X6[H/_/IJ/\ WZC_ /BZ/^%NZ#_SZ:C_ -^H
M_P#XNO&Z*/K%0/\ 5W =G]Y[)_PMW0?^?34?^_4?_P 71_PMW0?^?34?^_4?
M_P 77C=%'UBH'^KN [/[SV3_ (6[H/\ SZ:C_P!^H_\ XNC_ (6[H/\ SZ:C
M_P!^H_\ XNO&Z*/K%0/]7<!V?WGLG_"W=!_Y]-1_[]1__%T?\+=T'_GTU'_O
MU'_\77C=%'UBH'^KN [/[SV3_A;N@_\ /IJ/_?J/_P"+H_X6[H/_ #Z:C_WZ
MC_\ BZ\;HH^L5 _U=P'9_>>R?\+=T'_GTU'_ +]1_P#Q='_"W=!_Y]-1_P"_
M4?\ \77C=%'UBH'^KN [/[SV3_A;N@_\^FH_]^H__BZ/^%NZ#_SZ:C_WZC_^
M+KQNBCZQ4#_5W =G]YZ[<_%?0YO)VVNH#9*KG,:=!_P.I_\ A;N@_P#/IJ/_
M 'ZC_P#BZ\;HH^L5 _U=P'9_>>R?\+=T'_GTU'_OU'_\71_PMW0?^?34?^_4
M?_Q=>-T4?6*@?ZNX#L_O/9/^%NZ#_P ^FH_]^H__ (NC_A;N@_\ /IJ/_?J/
M_P"+KQNBCZQ4#_5W =G]Y[)_PMW0?^?34?\ OU'_ /%T?\+=T'_GTU'_ +]1
M_P#Q=>-T4?6*@?ZNX#L_O/9/^%NZ#_SZ:C_WZC_^+H_X6[H/_/IJ/_?J/_XN
MO&Z*/K%0/]7<!V?WGLG_  MW0?\ GTU'_OU'_P#%T?\ "W=!_P"?34?^_4?_
M ,77C=%'UBH'^KN [/[SV3_A;N@_\^FH_P#?J/\ ^+H_X6[H/_/IJ/\ WZC_
M /BZ\;HH^L5 _P!7<!V?WGLG_"W=!_Y]-1_[]1__ !='_"W=!_Y]-1_[]1__
M !=>-T4?6*@?ZNX#L_O/9/\ A;N@_P#/IJ/_ 'ZC_P#BZ/\ A;N@_P#/IJ/_
M 'ZC_P#BZ\;HH^L5 _U=P'9_>>R?\+=T'_GTU'_OU'_\71_PMW0?^?34?^_4
M?_Q=>-T4?6*@?ZNX#L_O/9/^%NZ#_P ^FH_]^H__ (NC_A;N@_\ /IJ/_?J/
M_P"+KQNBCZQ4#_5W =G]Y[)_PMW0?^?34?\ OU'_ /%T?\+=T'_GTU'_ +]1
M_P#Q=>-T4?6*@?ZNX#L_O/9/^%NZ#_SZ:C_WZC_^+H'Q=T$G_CTU$>_E)_\
M%UXW11]8J!_J[@.S^\^F+&^MM2LHKNRE6:"5=R.O>IZ\&\'>,;GPO>[7W36$
MK?O8<]/]I??^=>Y6-];:E917=E*LT$J[D=>]=E*JJB\SXW,\LJ8"IWB]G^C\
MR>BBBMCR0HHHH *J7'_(2L_^!_RJW52X_P"0E9_\#_E0!;HHHH **** "BLS
MQ#XBTKPKH<^L:_=BSL+?:))2C/C<P4?*H)/)'05:T[4;35M,MM0TZ99[2ZB6
M6&5<X=&&0>>>E %FBBJ]]J%EIEN)]2NX+2$NJ"2XE6-2S'"KDG&2> .] %BB
MLK7?$NE>&HK.36KDVZ7MTEG 1$S[Y7SM7Y0<9P>3Q6K0 45EZUXETKP_-IT6
MK7)@?4[I;.U B=_,E;HOR@XZ=3@5J4 %%%% !15;^T;(:F--^V6_VXQ>>+7S
M5\WR\XW[,YVYXSC&:LT %%%8OBSQ39>#M!;5M3BN);=9HX2MNJLV9'"#@D#&
M3SS0!M445FZ/X@TS7C?#2;G[0=/NWLKG]VR^7,F-R_,!G&1R,CWH TJ*** "
MBBB@ HHHH **Q[+Q-9WWBS4_#T,<XN],AAFF=E'EL)02NTYR3\ISD#\:V* \
M@HJO?ZA9Z582WNIW4-I:PKNDGG<(B#U)/ KCM-^-/P]U;5(]/LO$L!N)6V1^
M;#+$CGI@.ZA3^?-"U=D&RNSN:*RO$7BC1?">EG4/$>HPV%MNVAY2<NW]U5&2
MQX/ !/%4_"OCWPSXVCG;PQJT5\;<@2Q['C=,]"4<!L>^,4+78-MSH:*AN[NW
ML+.6[OIX[>VA0O+-*X544<DDG@"N4T+XL^!_$NMKI&C>((;B^?/EQ-%)'YF/
M[C.H#?@31N[!LKG8T5A^)?&?A_PA% _B'4DM#<,5AB"-))*1UVQH"QQD9('&
M:?H7B_0/$NBR:MHFJ07-E"6$TI)3R2HR0X8 I@<_,!QS1Y@;-%<7I?Q>\!ZS
MKT>C:;XCMYKZ5]D:&.14D;IA9&4(Q/;!.>U:'BSX@^&? [VJ>*-2-DUX&, %
MO++OVXW?<5L8W#K0'D=)16!X5\;^'_&UO<3^&;]KR.V<)*QMY8MI(R!\ZKG\
M*WZ-@W"BBB@ HHHH **** "BBB@# T#_ )&#Q#_U]1_^BUHHT#_D8/$/_7U'
M_P"BUHH >/\ DH)_[!8_]&FMRL,?\E!/_8+'_HTUN4 %%%% !1110 5XK\3_
M /DX?X;_ .])_.O:JX#XF?#BY\97&D:QH.I+I>OZ)-YMG/(FZ-^0=KCTRHYY
M[C!S0M)QEV8]XRCW1RG[3W_(BZ)_V&HO_1<E-^)GAOQ;HWQ2TSXB^%M(3Q##
M9V@@FL#S)&!N!*+UY#<%02#G@BM"]^'/C?QYK6DR?$O5-#CTK2IQ<I8Z+'*?
MM+C^^TF"/3C/!/ SFNG\2VOQ*37I+CP9J/AZ73I8U M-8AE4P,!R5:+EL]?F
MZ4;)=[M_@D&[^5OQN0_"_P"(&A>/K+4+K2M-_LK4XI5_M*T=%$@D(P&+ #>/
ME(R0#\N,"N[K@?AE\.KGP7)K.JZWJ,>HZYKEQ]HO988]D2'+':@[C+,<X';C
MBN^INQ/<****0PHHHH *BN_^/.;_ *YM_*I:BN_^/.;_ *YM_*@ M/\ CSA_
MZYK_ "JIKVNZ=X:T.ZU?6K@6UE:INED()QS@  <DDD  >M6[3_CSA_ZYK_*L
M3QSX2@\<>#KW0;FX>U^T!6CG1=QBD5@RMCN 0,CC([CK2=[:#5KZF?H/Q'M-
M;UBWTZ?0/$&CR7BEK635+#RH[C +$*P9L':"<-@X%=A7FND>,_%/AKQ+I?AG
MXCZ?:R?VDY@L-<TYSY4\@&0LD9Y1R.XXR>!@$C.L-'UCQE\0/&ME=^+=;T_2
M["^B6"VTZZ,3J[0*<^9R50==BX!)).:K?;^MO\R=5O\ UO\ Y'K=%>&:!I?B
M?Q1\,M1UC5_'.M17ND_:H+(V$H@4F L \V!F4L5YR<8]R36K=^,-<\1>%_AY
MIEIJ#Z9>^+$S>ZA;J!)&D<0>3R\C"LQZ'MVI;[>7X[#VW\_PW/7J*\JN[74O
MASX\\,167B/6-6TO7;IK&ZM-6N3=%'V$I)&Y&5Y'(Z'^1IUIJ/Q+\5>)I+WQ
M'K.D:;HVH-IEG::1=FU)9%&^61@-S$DC /  [T;[?UM_F@VW_K?_ "9Z;J%_
M;:5IESJ%_)Y5K:Q---)M)V(H)8X&2< 'I6/K/BZUT_X>W7BW3X_[0M(K WT*
MY,7G)MW+R1E<CU''I7F<LNIZS\-_B%X;UW6;^ZE\,-.L%_%*89;F+R&=$E*X
M#^C#^+C-.@\/QZ1^S'J-XFI:I=M?^&DD:*\O&FC@_<YQ$IX0?-T'8#TJ9/W)
M279-?--EQ7O13[M/Y-(]ATV\_M#2K2]V>7]IA279G.W<H.,]^M6:\2UG2M>\
M'^ =&\8P>+]7N=0MVL_.LWF"V4D4C(AB$ &  &&&^]P3G/3VVM9I)NW=K^OO
M,HMM*_8****@H*J?\QG_ +=__9JMU4_YC/\ V[_^S4 6Z*** "BBB@ HHHH
M**** ,?Q)X9LO%%E;6]\\T+6EW%>6\]NP62*6-L@@D$>H/'0FMBBB@ HHHH
M*0C*D D<=1VI:* ,CPOX:LO">A)I>G/-+&)'EDFN&#2S2.Q9G<@ $DGTK7HH
MH **** "BBB@ J*[_P"/.;_KFW\JEJ*[_P"/.;_KFW\J "T_X\X?^N:_RJ6H
MK3_CSA_ZYK_*I: ,OQ/_ ,BCJ_\ UXS?^BS7SI7T7XG_ .11U?\ Z\9O_19K
MYTK@Q6Z/N^%_X-3U7Y!1117(?7!1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !73>#O&-SX7O=K[IK"5OWL.>G^TOO_ #KF:*<9.+NC&O0IXBFZ
M=573/IBQOK;4K**[LI5F@E7<CKWJ>O!_!OC&Y\,WP1MTUA,W[V$=0?[R^_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ I0"3@#)- !)P!DFO6? '@ 60CU?6XLW)^:"W8?ZK_:8?WO;M]>ETZ;F[
M(X,=CJ6!I>TJ;]%W#P!X %D(]7UN+-R?F@MV'^J_VF'][V[?7IZ+117J0@H*
MR/S#&8RKC*KJU7_P/)!1115G(%5+C_D)6?\ P/\ E5NJEQ_R$K/_ ('_ "H
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MXO\ OL4 2T5%]KM_^>\7_?8H^UV__/>+_OL4 2T5%]KM_P#GO%_WV*/M=O\
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M\G-=][?HSYEHKZ:^UV__ #WB_P"^Q1]KM_\ GO%_WV*Q^J^9Z_\ K5_TY_\
M)O\ [4^9:*^FOM=O_P ]XO\ OL4?:[?_ )[Q?]]BCZKYA_K5_P!.?_)O_M3Y
MEHKZ:^UV_P#SWB_[[%'VNW_Y[Q?]]BCZKYA_K5_TY_\ )O\ [4^9:*^FOM=O
M_P ]XO\ OL4?:[?_ )[Q?]]BCZKYA_K5_P!.?_)O_M3YEHKZ:^UV_P#SWB_[
M[%'VNW_Y[Q?]]BCZKYA_K5_TY_\ )O\ [4^9:*^FOM=O_P ]XO\ OL4?:[?_
M )[Q?]]BCZKYA_K5_P!.?_)O_M3YEHKZ0^T0_P!K;_-CV^1C=N&,[NE6OM=O
M_P ]XO\ OL4?5?,/]:O^G/\ Y-_]J?,M%?37VNW_ .>\7_?8H^UV_P#SWB_[
M[%'U7S#_ %J_Z<_^3?\ VI\RT5]-?:[?_GO%_P!]BC[7;_\ />+_ +[%'U7S
M#_6K_IS_ .3?_:GS+17TU]KM_P#GO%_WV*/M=O\ \]XO^^Q1]5\P_P!:O^G/
M_DW_ -J?,M%?37VNW_Y[Q?\ ?8H^UV__ #WB_P"^Q1]5\P_UJ_Z<_P#DW_VI
M\RT5]-?:[?\ Y[Q?]]BC[7;_ //>+_OL4?5?,/\ 6K_IS_Y-_P#:GS+17TU]
MKM_^>\7_ 'V*/M=O_P ]XO\ OL4?5?,/]:O^G/\ Y-_]J?,M%?37VNW_ .>\
M7_?8H^UV_P#SWB_[[%'U7S#_ %J_Z<_^3?\ VI\RT5]-?:[?_GO%_P!]BC[7
M;_\ />+_ +[%'U7S#_6K_IS_ .3?_:GS+17TU]KM_P#GO%_WV*JSW$)O[5A+
M&57?DAA@<4?5?,/]:O\ IS_Y-_\ :GS?17TU]KM_^>\7_?8H^UV__/>+_OL4
M?5?,/]:O^G/_ )-_]J?,M%?37VNW_P">\7_?8H^UV_\ SWB_[[%'U7S#_6K_
M *<_^3?_ &I\RT5]-?:[?_GO%_WV*/M=O_SWB_[[%'U7S#_6K_IS_P"3?_:G
MS+17TU]KM_\ GO%_WV*/M=O_ ,]XO^^Q1]5\P_UJ_P"G/_DW_P!J?,M%?37V
MNW_Y[Q?]]BC[7;_\]XO^^Q1]5\P_UJ_Z<_\ DW_VI\RT5]-?:[?_ )[Q?]]B
MC[7;_P#/>+_OL4?5?,/]:O\ IS_Y-_\ :GS+17TU]KM_^>\7_?8H^UV__/>+
M_OL4?5?,/]:O^G/_ )-_]J?,M%?37VNW_P">\7_?8H^UV_\ SWB_[[%'U7S#
M_6K_ *<_^3?_ &I\RT5]-?:[?_GO%_WV*/M=O_SWB_[[%'U7S#_6K_IS_P"3
M?_:GS+17TU]KM_\ GO%_WV*/M=O_ ,]XO^^Q1]5\P_UJ_P"G/_DW_P!J?,M%
M?37VNW_Y[Q?]]BC[7;_\]XO^^Q1]5\P_UJ_Z<_\ DW_VI\RT5]-?:[?_ )[Q
M?]]BC[7;_P#/>+_OL4?5?,/]:O\ IS_Y-_\ :GS+17TU]KM_^>\7_?8H^UV_
M_/>+_OL4?5?,/]:O^G/_ )-_]J?,M%?37VNW_P">\7_?8H^UV_\ SWB_[[%'
MU7S#_6K_ *<_^3?_ &I\RT5](7MQ"_V?;+&V)U)PPX'K5K[7;_\ />+_ +[%
M'U7S#_6K_IS_ .3?_:GS+17TU]KM_P#GO%_WV*/M=O\ \]XO^^Q1]5\P_P!:
MO^G/_DW_ -J?,M%?37VNW_Y[Q?\ ?8H^UV__ #WB_P"^Q1]5\P_UJ_Z<_P#D
MW_VI\RT5]-?:[?\ Y[Q?]]BC[7;_ //>+_OL4?5?,/\ 6K_IS_Y-_P#:GS+1
M7TU]KM_^>\7_ 'V*/M=O_P ]XO\ OL4?5?,/]:O^G/\ Y-_]J?,M%?37VNW_
M .>\7_?8H^UV_P#SWB_[[%'U7S#_ %J_Z<_^3?\ VI\RT5]-?:[?_GO%_P!]
MBC[7;_\ />+_ +[%'U7S#_6K_IS_ .3?_:GS+17TU]KM_P#GO%_WV*/M=O\
M\]XO^^Q1]5\P_P!:O^G/_DW_ -J?,M%?37VNW_Y[Q?\ ?8H^UV__ #WB_P"^
MQ1]5\P_UJ_Z<_P#DW_VI\RT5]-?:[?\ Y[Q?]]BC[7;_ //>+_OL4?5?,/\
M6K_IS_Y-_P#:GS+17TU]KM_^>\7_ 'V*/M=O_P ]XO\ OL4?5?,/]:O^G/\
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M+_OL4?:[?_GO%_WV* ):*B^UV_\ SWB_[[%'VNW_ .>\7_?8H EHJ+[7;_\
M/>+_ +[%'VNW_P">\7_?8H EHJ+[7;_\]XO^^Q1]KM_^>\7_ 'V* ):*B^UV
M_P#SWB_[[%'VNW_Y[Q?]]B@"6BHOM=O_ ,]XO^^Q1]KM_P#GO%_WV* ):*B^
MUV__ #WB_P"^Q1]KM_\ GO%_WV* ):*B^UV__/>+_OL4?:[?_GO%_P!]B@"6
MBHOM=O\ \]XO^^Q1]KM_^>\7_?8H EHJ+[7;_P#/>+_OL4?:[?\ Y[Q?]]B@
M"6BHOM=O_P ]XO\ OL4?:[?_ )[Q?]]B@"6BHOM=O_SWB_[[%'VNW_Y[Q?\
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M_A<O_4"_\G/_ +"CV]/N']@YC_S[_&/^9Z5]DM_^>$7_ 'P*/LEO_P \(O\
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MY]_C'_,]*^R6_P#SPB_[X%'V2W_YX1?]\"O-?^%R_P#4"_\ )S_["C_A<O\
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M_P!\"I:* (OLEO\ \\(O^^!1]DM_^>$7_? J6B@"+[);_P#/"+_O@4?9+?\
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MB_[X%'V2W_YX1?\ ? J6B@"+[);_ //"+_O@4?9+?_GA%_WP*EHH B^R6_\
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M2W_YX1?]\"I:* .?\/*J:]XA5%"J+J/  Q_RS6BET#_D8/$/_7U'_P"BUHH
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M'7D9P,UV%.Q-PHHHI#"BN7\ ^)KSQ3H]_=ZA%!');:I=6:"!2 4BD*J3DGG
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M,99592C#JK*P#*?8@=16M0 5%=_\><W_ %S;^52U%=_\><W_ %S;^5 !:?\
M'G#_ -<U_E4M16G_ !YP_P#7-?Y5+0!E^)_^11U?_KQF_P#19KYTKZ+\3_\
M(HZO_P!>,W_HLU\Z5P8K='W?"_\ !J>J_(****Y#ZX**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "NN\
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M<#&/2IC\5V-_#9?U_P .0>!&V_&?XD1S?Z\RV+KGO'Y)VTO@H>9\</B+-!S
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MX^27W)E)VFI=FW][1X]X]DOH]<^&NHOK<&AVJVLJ_P!IWELL\,%PT*%=P9E
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MBCJ__7C-_P"BS7SI7T=XBBDG\+ZI%"C2226<RHB#)8E"  .YKP7_ (1C7O\
MH":C_P" DG^%<.)3;5C[?AFI"%&IS-+5?D9=%:G_  C&O?\ 0$U'_P !)/\
M"C_A&->_Z FH_P#@))_A7)RR['UGUBC_ #K[T9=%:G_",:]_T!-1_P# 23_"
MC_A&->_Z FH_^ DG^%'++L'UBC_.OO1ET5J?\(QKW_0$U'_P$D_PH_X1C7O^
M@)J/_@))_A1RR[!]8H_SK[T9=%:G_",:]_T!-1_\!)/\*/\ A&->_P"@)J/_
M ("2?X4<LNP?6*/\Z^]&716I_P (QKW_ $!-1_\  23_  H_X1C7O^@)J/\
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MNBM3_A&->_Z FH_^ DG^%'_",:]_T!-1_P# 23_"CEEV#ZQ1_G7WHRZ*U/\
MA&->_P"@)J/_ ("2?X4?\(QKW_0$U'_P$D_PHY9=@^L4?YU]Z,NK%C8W.IWT
M5I8Q--/*V%1?\]*OP^%/$$TR1+HM^I=@H+VSJH^I(P!7L?@[P=;>%['<VV:_
ME'[Z;'3_ &5]OYUK3HRFSS,QS:C@Z5XM2D]E_GY!X.\'6WA>QW-MFOY1^^FQ
MT_V5]OYUTM%%>E&*BK(_-:]>IB*CJ5'=L****HQ"BBB@ HHHH J7_P#R[?\
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M+]FN&P@&1'P>*D^W_P#3K=?]^ZFM/^/.'_KFO\JEH J?;_\ IUNO^_='V_\
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M[JW10!4^W_\ 3K=?]^Z/M_\ TZW7_?NK=% %3[?_ -.MU_W[H^W_ /3K=?\
M?NK=% %3[?\ ].MU_P!^Z/M__3K=?]^ZMT4 5/M__3K=?]^Z/M__ $ZW7_?N
MK=% %3[?_P!.MU_W[H^W_P#3K=?]^ZMT4 5/M_\ TZW7_?NJ\UWNO;9_L\XV
M[OE*<G([5IU4N/\ D)6?_ _Y4 'V_P#Z=;K_ +]T?;_^G6Z_[]U;HH J?;_^
MG6Z_[]T?;_\ IUNO^_=6Z* *GV__ *=;K_OW1]O_ .G6Z_[]U;HH J?;_P#I
MUNO^_='V_P#Z=;K_ +]U;HH J?;_ /IUNO\ OW1]O_Z=;K_OW5NB@"I]O_Z=
M;K_OW1]O_P"G6Z_[]U;HH J?;_\ IUNO^_='V_\ Z=;K_OW5NB@"I]O_ .G6
MZ_[]T?;_ /IUNO\ OW5NB@"I]O\ ^G6Z_P"_='V__IUNO^_=6Z* *GV__IUN
MO^_='V__ *=;K_OW5NB@"I]O_P"G6Z_[]T?;_P#IUNO^_=6Z* *GV_\ Z=;K
M_OW1]O\ ^G6Z_P"_=6Z* *GV_P#Z=;K_ +]T?;_^G6Z_[]U;HH J?;_^G6Z_
M[]T?;_\ IUNO^_=6Z* *GV__ *=;K_OW1]O_ .G6Z_[]U;HH J?;_P#IUNO^
M_='V_P#Z=;K_ +]U;HH J?;_ /IUNO\ OW1]O_Z=;K_OW5NB@"I]O_Z=;K_O
MW1]O_P"G6Z_[]U;HH J?;_\ IUNO^_='V_\ Z=;K_OW5NB@"I]O_ .G6Z_[]
MT?;_ /IUNO\ OW5NB@"I]O\ ^G6Z_P"_='V__IUNO^_=6Z* *GV__IUNO^_=
M'V__ *=;K_OW5NB@"I]O_P"G6Z_[]T?;_P#IUNO^_=6Z* *GV_\ Z=;K_OW1
M]O\ ^G6Z_P"_=6Z* .>\./YFN>('VLF;I.&&"/W8HIV@?\C!XA_Z^H__ $6M
M% #Q_P E!/\ V"Q_Z--;E88_Y*"?^P6/_1IK<H **** "BBB@ HHHH ****
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M110 4444 %%%% !1110 4444 %%%% !45W_QYS?]<V_E4M17?_'G-_US;^5
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M_P +E_Z@7_DY_P#84?\ "Y?^H%_Y.?\ V%>7T4>WJ=P_L'+O^??XR_S/4/\
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M4 %%%% !1110 54N/^0E9_\  _Y5;JI<?\A*S_X'_*@"W1110 4444 %%%%
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MX7_@U/5?D%%%%<A]<%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ;7AGQ->>&-2%Q:G?$V!- 3\L@_H?0U[MHVLV>O:
M;'>Z?)OC;@J?O(>ZD=C7S?6[X3\0ZAH&LQOIRM.)F"26PY\[V^OH:Z*-9P=G
ML?/9QE$,9#VM/2:_'U_S/H*BF1.TD*.\;1,R@E&QE3Z''%/KTC\W>@54N/\
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M_1:T4 /'_)03_P!@L?\ HTUN5AC_ )*"?^P6/_1IK<H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "HKO_CSF_ZYM_*I:BN_^/.;_KFW\J "T_X\X?\
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M@#+\3_\ (HZO_P!>,W_HLU\Z5]%^)_\ D4=7_P"O&;_T6:^=*X,5NC[OA?\
M@U/5?D%%%%<A]<%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 444^&&2XF2&!&DD=@JHHR6)["@&[*["&&2XF2&!&DD=@JHH
MR6)["O:/ O@6/P_"M]J*K)J3KP.H@![#W]3^'U/ O@6/P_"M]J*K)J3KP.H@
M![#W]3^'U[2N^C1Y?>EN? YUG3KMX?#OW>K[_P# _/T"BBBNL^4"JEQ_R$K/
M_@?\JMU4N/\ D)6?_ _Y4 6Z*** "BBB@ HHHH **** "BBB@ HHHH ****
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M-_PUS_U)/_E6_P#M- 'TE17S;_PUS_U)/_E6_P#M-'_#7/\ U)/_ )5O_M-
M'TE17S;_ ,-<_P#4D_\ E6_^TT?\-<_]23_Y5O\ [30!])45\V_\-<_]23_Y
M5O\ [31_PUS_ -23_P"5;_[30!])45\V_P##7/\ U)/_ )5O_M-'_#7/_4D_
M^5;_ .TT ?25%?-O_#7/_4D_^5;_ .TT?\-<_P#4D_\ E6_^TT ?25%?-O\
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M5YA_PT7\//\ H,?^2MQ_\:J6U^//@76+R'3+'5?,N;V1;>%/LTXW.YVJ,F,
M<D=30!Z5:?\ 'G#_ -<U_E4M>877QY\"Z/>3:9?:KY=S92-;S)]FG.UT.UAD
M1D'D'H:B_P"&B_AY_P!!C_R5N/\ XU0!Z'XBBDG\+ZI%"C2226<RHB#)8E"
M .YKP7_A&->_Z FH_P#@))_A7;_\-%_#S_H,?^2MQ_\ &J/^&B_AY_T&/_)6
MX_\ C58U**J.[9[66YO/+X2C&*=SB/\ A&->_P"@)J/_ ("2?X4?\(QKW_0$
MU'_P$D_PKM_^&B_AY_T&/_)6X_\ C5'_  T7\//^@Q_Y*W'_ ,:K+ZK'N>I_
MK16_Y]K[V<1_PC&O?] 34?\ P$D_PH_X1C7O^@)J/_@))_A7;_\ #1?P\_Z#
M'_DK<?\ QJC_ (:+^'G_ $&/_)6X_P#C5'U6/</]:*W_ #[7WLXC_A&->_Z
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M ("/_A7JW@7P+'X?A6^U%5DU)UX'40 ]A[^I_#Z\_P#\-%_#S_H,?^2MQ_\
M&J/^&B_AY_T&/_)6X_\ C57##Q@[G#CL]Q&+I>RMRI[VZGJE%>5_\-%_#S_H
M,?\ DK<?_&J/^&B_AY_T&/\ R5N/_C5=!\^>J45Y7_PT7\//^@Q_Y*W'_P :
MH_X:+^'G_08_\E;C_P"-4 >J54N/^0E9_P# _P"5>;?\-%_#S_H,?^2MQ_\
M&JMP?&CP;J6GW>MVFI;[+1]GVN3R)AL\T[$X*9.2.P/OB@#TFBO*_P#AHOX>
M?]!C_P E;C_XU1_PT7\//^@Q_P"2MQ_\:H ]4HKRO_AHOX>?]!C_ ,E;C_XU
M1_PT7\//^@Q_Y*W'_P :H ]4HKRO_AHOX>?]!C_R5N/_ (U1_P -%_#S_H,?
M^2MQ_P#&J /5**\K_P"&B_AY_P!!C_R5N/\ XU1_PT7\//\ H,?^2MQ_\:H
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MB_AY_P!!C_R5N/\ XU1_PT7\//\ H,?^2MQ_\:H ]4HKRO\ X:+^'G_08_\
M)6X_^-4?\-%_#S_H,?\ DK<?_&J /5**\K_X:+^'G_08_P#)6X_^-4?\-%_#
MS_H,?^2MQ_\ &J /5**\K_X:+^'G_08_\E;C_P"-4?\ #1?P\_Z#'_DK<?\
MQJ@#U2BO*_\ AHOX>?\ 08_\E;C_ .-4?\-%_#S_ *#'_DK<?_&J /5**\K_
M .&B_AY_T&/_ "5N/_C5'_#1?P\_Z#'_ )*W'_QJ@#U2BO*_^&B_AY_T&/\
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MC_R5N/\ XU0!ZI17E?\ PT7\//\ H,?^2MQ_\:H_X:+^'G_08_\ )6X_^-4
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M /;2@#@:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHHH **** "BBB@ HHHH **** "BBB@ KOO"/_)&_B'_W#/\ TH:N!KOO"/\
MR1OXA_\ <,_]*&H X&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /L3]FW_ ))DO_73^IHH_9M_Y)DO_73^IHH
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M9[RZF.(X+>,R.YZX"CDT;@045/>V-WIM[+9ZC:S6EU"=LD$\91T/H5/(J"@
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M !1110 4444 ?8G[-O\ R3)?^NG]311^S;_R3)?^NG]310!Q?[5WW]'^@_\
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M/4[ZRDU1[&+8MO-O1C@EE!(&2N\ CZ^E$MY12[V\]-S%:Q4O3Y:G@OB70/\
MA&M9;3O[6TO5MJ*_VG2KGSX3GL&P.1WK)K8\4^%=5\&ZX^D:_"D%ZB*[QI*L
MFT,,CE21FL>DG=%/1A7??\VX_P#<U_\ MI7 UWW_ #;C_P!S7_[:4Q' T444
M %>]_$GPAI;?"'X<_P!BZ5I]EJ6JM;0R74=NL;2L\(YD=1D_,<G.:\$KZ;\;
ML/\ A6OP>Y'_ !^6'_HM:<E>G_V]'\R;V=_)_D<&?V:_%\>IFPGU;P]!<MG[
M/')>N&N@%!8QKY>X@9P<@<CTYKE?#GPE\5>)O&&H>&[2VBMKS3"1>274FV*#
M!P,L 2<]L Y'/2O;?&+?\9C>%<GI:(.O3Y9JUM&O+2\^*GQ4\+QW4=GJNJQ1
MBTD9L%_]&VG'^Z6!XYY/I4Q;:OY/3TL6[7MMMKZF#X?\%WG@O]G7QS;WE]IN
MHQW4;S0W6FW'G0N @4C=@<@J0>*X;QU%XUN?@EX*@U2+19-'E>)--2P64W;,
M8V"B0-\N2,_=ZG%=WH/@W5/ W[.?C?2M?FMQ?R127#6D4XD-NA4*N[!P"VPF
MC6M4L]&^$?PAU'4L&TM=0M)92?X5$;9;\.OX463J-/\ N?FR4VH[?S?H>;3_
M +/OBJTLU-YJ6@6^H-;-<KI4E_BZ9%&3A=N#CU#8]ZJ:%\$==UO2=,OI-;\.
MZ4=54/96VH:ALFG4]"JJK9SZ=?:O0?C%\*/$'C+QY=>*M'O=.DT&XLTF6_GO
M%6*$(@&WC)(.,@@8YYQ74>&O">FV7A#P??> O#'AC58)A'-JNL:L%>2VP%9F
M!/S!L[L8^Z0..].-W=OR_7^O^''+2R6NGZ(\W^&OP91_BQ>>'O'RV#)81;GL
MC>/')=AE)5X=N"RC&3R,9Y':M;PSX,UOP9\=+NW^'6I^%+N>:*[\JVN+N6=;
M.%9%_=R[!O63E0!D]&R:Z[5M0M=/_;&TYKR985FTL0HSG +LKX&??I]:K>"?
M".K^&OVH-4O-7ACBAU>*^N+,K*K%X_-0Y(!R/O#K[T1?-RORE^#?_#A*R4O6
M/XGCNF_#/Q5\0/%_B.2%;"U^QWLYU"]FD,5I%)O8L%."<=2..!C.*@\7?"+Q
M!X1\-P^()+O2]7TB9@OVW2;DSQJ2<#)*C@GC(R,\5Z_X;6+Q?X!^(_@C1KN"
MWUZ;6KJ>.)Y-IN$,JD?@=A4^F1GK63K&GR_#3]F._P##'BRYACUO5[L26^GK
M,LCQ+OC)Z$C "$DCC+ =34[1^2^=]_Z\BXI.6O=KT\SEC^SCXLCDM1=:MX>M
M8[M$-O+<7KHLKMG$2@Q[B^!G &.>":N_"?X;ZAHO[0]MHOB2",3:3&]Z0IW)
M* N$=3W&YE/3MV-==\;V'_"9_"WYN!(AZ_\ 32&NNENXK?\ :[ACE8!KGPYY
M48)ZMYA?'Y*:T3:DFN[7W(Q;3C9]E^)X7K7AW7OB_P#'#Q'%HPAWI<R[IIW*
M10PQGRU+$ GHHZ UFZIX.UCX7:EH?B5=5TC5+<7H:&YTF\\Y!)&P+(3M'/;O
MWKK? $7B_2_C5XM'@_\ LV:]MY[@7&G:A+L^V1^<<JG^UT.20!GG/2KOQX\)
MZ!9:)X?O;31;/0/%6H3!+K2;*974*0><+\O#;1D 9W'KBHIMQA3DM]/O-9VE
M.:EYE']I[1XK7Q]I^M6RJL>KV*NQ ^\Z'!/_ 'R4_*O%:]Y_:DGCCU;PMI>[
M,]II[-(!V#%5'_HLUX-2C;6W=_F$KNS?9?D%;_@/_DH_AO\ ["UK_P"CEK K
M?\!_\E'\-_\ 86M?_1RU1(>//^2C^)/^PM=?^CFK"B ,J \@L,UN^//^2C^)
M/^PM=?\ HYJPXO\ 7)_O#^=:4_C7J)['U;XZ?PUX0\>>$- MOA_X9O+/7"(K
M@MID8F0EU0,K 8XW9.0<XZBO/?&_P1.I?&:_\.^!&M+2-=.74C!=2N$CRVTH
MI"L>N" ?7KTKT'XX_$F_^'^M>'Y=(TC1;N[EM)&2[OK4R30<@8C8,-H.>?6N
M0_9U\0:EXG^,VN:QKETUS>W.ENTDC #I)$  !P  ,8%9TTIOTYOPO9?(=^6/
MW'%ZK\ _&>E^(-'T4K8W5[JT<DB+;S,5@6/;O,C%0 !O'3.>W;,>O_ _Q'HG
MAV^UJWU+1-:MM.8K>+I5X97M\?>W JN,=QU'I76?L^^+;6V^*>KQ^(M0_P!)
MU.)X[>XNY<AI-X)4DGJP ^NT#TKI?$)^(GA;PEXG%QX7\ ^'=)EMI(IKFTB,
M+7JE2H\L)(27^8X#@<FE+2"?=7_';^M2^6U1P?1V_P"">5>'?@KXBU[PQ!K]
MQ?Z/H>GW3A+:35[LP>?G@%<*>IZ9P3VXKTOX8:!>>&/AM\5-%U01_:K.!XY/
M+;<I/V=R"#W&"#4WB[PO??%SX/\ @J3P%);W']F0K!=V7VA4\EO+123D]5*G
MKR0V1FH?ACH<WAGX;_%/1[RYM;B>SMWCDEM9-\9/V=R<-@9QG!XZ@U5315(^
M3_34FGK.D_-?+?0Y?6[+QKJOP+\'V%W_ & NA7=]#!8-$)1="1BZJ921MV\M
MG;STJN?V:_%\>IFPGU;P]!<MG[/')>N&N@%!8QKY>X@9P<@<CTYKM[HC_AG_
M .&'/_,<M/\ T.2KGC%O^,QO"N3TM$'7I\LU.2_>-=Y6_!$IVI)]HW_%G$?!
M[2?'V@:YXOTGP]!HD-[:0K%J,>L"0X +X\LQ]<\]>",5QO@_X2Z_XP\/W&NQ
M7.FZ3I%NVTW^K7)@B8CK@A3TZ9.!GC.<U]">$"!\<OBGD@#[/;_^BJXS2M)F
M^)7[+VG^'?!\L+ZOI=UON; S*C28=SSD@#.\,">,C':HB[PYNME^+96G,ULK
MO\D>=1?!+Q++XFO=(:]T:)+&UCNYM1DO=MJ(I,[&#XS@X/\ #V^F:GB_X2:[
MX/\ #=MX@EO=*U;2;B01K>:3<F:-2<XR2HX.",C(S7IWPL^%NFZ)K/B'3O$U
MIHNO>*+2R2>RTR6<20@LK':P(QNW!0>#M!![UN_%"VO[/]F>:WU?2M'T>]2]
MB,MAHR!8("9,A< D;L$$X/4TIOEC]WXNP1U>O]:'+_M/@"+P5@?\N,O_ +2K
MP*O??VGR#%X*P?\ EQE_]I5X%3ZOU?YDKX5Z+\COO^;<?^YK_P#;2N!KOO\
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M_N&?^E#5P-=]X1_Y(W\0_P#N&?\ I0U ' T444 %%%% !1110 4444 %%%%
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MENHQ!(\9W,%<G:3RG0_P'TJ;72\TOP^(+I-]DW^-K?<?/OQ,^&@^&ZZ+%/K
MOKW4;8W$UN+?R_LW3C.X[LDL,X'W:X2O0/C=XKA\7?%74KNQN([FQM@MK:RQ
ML&5D0<D$<$%BQ!]Z\_J8NZN5)6T.^^%7_,Z?]BI??^R5P-=]\*O^9T_[%2^_
M]DK@:HD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ%^]W/K7!444=;ALK!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3O\ H6?_ "?MO_CE?;5% 'Q+_P ,^?$[_H6?_)^V_P#CE'_#/GQ._P"A9_\
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M_P"&?/B=_P!"S_Y/VW_QROMJB@#XE_X9\^)W_0L_^3]M_P#'*/\ AGSXG?\
M0L_^3]M_\<K[:HH ^)?^&?/B=_T+/_D_;?\ QRC_ (9\^)W_ $+/_D_;?_'*
M^VJ* /B7_AGSXG?]"S_Y/VW_ ,<H_P"&?/B=_P!"S_Y/VW_QROMJB@#XE_X9
M\^)W_0L_^3]M_P#'*/\ AGSXG?\ 0L_^3]M_\<K[:HH ^2?^%1_$/_A5O_"*
M_P#",_Z;_;/]H_\ (0M_]7Y/E_W\=??/M7-_\,^?$[_H6?\ R?MO_CE?9_\
MS&?^W?\ ]FJW0!\2_P##/GQ._P"A9_\ )^V_^.4?\,^?$[_H6?\ R?MO_CE?
M;5% 'Q+_ ,,^?$[_ *%G_P G[;_XY1_PSY\3O^A9_P#)^V_^.5]M44 ?$O\
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MOMJB@#XE_P"&?/B=_P!"S_Y/VW_QRC_AGSXG?]"S_P"3]M_\<K[:HH ^)?\
MAGSXG?\ 0L_^3]M_\<H_X9\^)W_0L_\ D_;?_'*^VJ* /B7_ (9\^)W_ $+/
M_D_;?_'*/^&?/B=_T+/_ )/VW_QROMJB@#XE_P"&?/B=_P!"S_Y/VW_QRC_A
MGSXG?]"S_P"3]M_\<K[:HH ^)?\ AGSXG?\ 0L_^3]M_\<H_X9\^)W_0L_\
MD_;?_'*^VJ* /B7_ (9\^)W_ $+/_D_;?_'*/^&?/B=_T+/_ )/VW_QROMJB
M@#Y)\'?"/XA^&?[>^V^&?^0IHUQIT/\ Q,+?_62;=O1S_=/7 ]ZYO_AGSXG?
M]"S_ .3]M_\ '*^S[_\ Y=O^OA?ZU;H ^)?^&?/B=_T+/_D_;?\ QRC_ (9\
M^)W_ $+/_D_;?_'*^VJ* /B7_AGSXG?]"S_Y/VW_ ,<H_P"&?/B=_P!"S_Y/
MVW_QROMJB@#XE_X9\^)W_0L_^3]M_P#'*/\ AGSXG?\ 0L_^3]M_\<K[:HH
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M/VW_ ,<H_P"&?/B=_P!"S_Y/VW_QROMJB@#XE_X9\^)W_0L_^3]M_P#'*/\
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M^A9_\G[;_P".4?\ #/GQ._Z%G_R?MO\ XY7VU10!\2_\,^?$[_H6?_)^V_\
MCE'_  SY\3O^A9_\G[;_ ..5]M44 ?$O_#/GQ._Z%G_R?MO_ (Y1_P ,^?$[
M_H6?_)^V_P#CE?;5% 'Q+_PSY\3O^A9_\G[;_P".4?\ #/GQ._Z%G_R?MO\
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M110 4444 %%%% !1110 4444 %%%% !45W_QYS?]<V_E4M17?_'G-_US;^5
M!:?\></_ %S7^52U%:?\></_ %S7^52T >8?&7_F#?\ ;?\ ]IUY?7J'QE_Y
M@W_;?_VG7E]>77_B,_3\A_Y%U/Y_^E,****Q/:"BBB@ HHHH **** "BBB@
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MPM.HIP=IO=?KY?J:E%%%=A\D%%%% !52X_Y"5G_P/^56ZJ7'_(2L_P#@?\J
M+=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 8&@?\C!XA_Z^H__ $6M%&@?\C!XA_Z^H_\ T6M% #Q_R4$_]@L?
M^C36Y6&/^2@G_L%C_P!&FMR@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *BN_\ CSF_ZYM_*I:BN_\ CSF_ZYM_*@ M/^/.'_KFO\JEJ*T_X\X?^N:_
MRJ6@ HHHH **** "BBB@ HHHH **** "BBB@ JI_S&?^W?\ ]FJW53_F,_\
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MF'_3K_X]5?\ TS^TO^6'F^3[[<9_G0!IT54_XF'_ $Z_^/4?\3#_ *=?_'J
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MC_\ GZSC_P#A46@_\_>H_P#?V/\ ^(H_X5%H/_/WJ/\ W]C_ /B*[#_B8?\
M3K_X]1_Q,/\ IU_\>H]C3[!_:^/_ .?K./\ ^%1:#_S]ZC_W]C_^(H_X5%H/
M_/WJ/_?V/_XBNP_XF'_3K_X]1_Q,/^G7_P >H]C3[!_:^/\ ^?K./_X5%H/_
M #]ZC_W]C_\ B*/^%1:#_P _>H_]_8__ (BNP_XF'_3K_P"/4?\ $P_Z=?\
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MH_XF'_3K_P"/4>QI]@_M?'_\_6<?_P *BT'_ )^]1_[^Q_\ Q%'_  J+0?\
MG[U'_O['_P#$5V'_ !,/^G7_ ,>H_P")A_TZ_P#CU'L:?8/[7Q__ #]9Q_\
MPJ+0?^?O4?\ O['_ /$4?\*BT'_G[U'_ +^Q_P#Q%=A_Q,/^G7_QZC_B8?\
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M[9;HJI_Q,/\ IU_\>H_XF'_3K_X]3,RW153_ (F'_3K_ ./4?\3#_IU_\>H
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MB@ HHHH **** "BBB@ HHHH *J?\QG_MW_\ 9JMU4_YC/_;O_P"S4 6Z***
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M_J!?^3G_ -A1_P +E_Z@7_DY_P#85/MZ?<V_L',?^??XQ_S/3Z*\P_X7+_U
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MKS#_ (7+_P!0+_R<_P#L*/\ A<O_ % O_)S_ .PH]O3[A_8.8_\ /O\ &/\
MF>GT5YA_PN7_ *@7_DY_]A1_PN7_ *@7_DY_]A1[>GW#^P<Q_P"??XQ_S/3Z
M*\P_X7+_ -0+_P G/_L*/^%R_P#4"_\ )S_["CV]/N']@YC_ ,^_QC_F>GT5
MYA_PN7_J!?\ DY_]A1_PN7_J!?\ DY_]A1[>GW#^P<Q_Y]_C'_,]/HKS#_A<
MO_4"_P#)S_["C_A<O_4"_P#)S_["CV]/N']@YC_S[_&/^9Z?17F'_"Y?^H%_
MY.?_ &%'_"Y?^H%_Y.?_ &%'MZ?</[!S'_GW^,?\ST^BO,/^%R_]0+_R<_\
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MZ@7_ ).?_84>WI]P_L',?^??XQ_S/3Z*\P_X7+_U O\ R<_^PH_X7+_U O\
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M"_\ )S_["CV]/N']@YC_ ,^_QC_F>GT5YA_PN7_J!?\ DY_]A1_PN7_J!?\
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MO_CSF_ZYM_*@ M/^/.'_ *YK_*I:BM/^/.'_ *YK_*I: /,/C+_S!O\ MO\
M^TZ\OKU#XR_\P;_MO_[3KR^O+K_Q&?I^0_\ (NI_/_TIA1116)[04444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M? WX;:%%=S6=IKFHQV=[-#(48PEY&,88<C=@#CW'>I6J5NO+_P"3?Y%/1_\
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M9((HPN,F25^%Z\#!)P:RO!7Q E\2ZUJ>@ZWH<V@:[IBK)-923K.K1M]UTD4
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M -N__LU6ZJ?\QG_MW_\ 9J +=%%<UK_Q#\)^%]:M-(U_6[>ROKO!BB<,>"<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA!&&4'!!4@8((-5_#GPWTCPSXCDUVTNM1NM2FM3;7%Q>W'G-<?,&WN2,[OE
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MTF"TN]OVBWBL8ECFVG(WJ%PV.V:T7T^RDOH;V2T@>[MT9(9VB!DC5L;@K8R
M<#('7%-:-/\ K:PGK&W];K_(X".$I^T%K7V,!)I_#$3$CC<XF95)]\ "O./
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M_@))_A1_PC&O?] 34?\ P$D_PHY9=@^L4?YU]Z,NBM3_ (1C7O\ H":C_P"
MDG^%'_",:]_T!-1_\!)/\*.678/K%'^=?>C+HK4_X1C7O^@)J/\ X"2?X4?\
M(QKW_0$U'_P$D_PHY9=@^L4?YU]Z,NBM3_A&->_Z FH_^ DG^%'_  C&O?\
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MC7O^@)J/_@))_A1_PC&O?] 34?\ P$D_PHY9=@^L4?YU]Z,NBM3_ (1C7O\
MH":C_P" DG^%'_",:]_T!-1_\!)/\*.678/K%'^=?>C+HK4_X1C7O^@)J/\
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M_P !)/\ "C_A&->_Z FH_P#@))_A1RR[!]8H_P Z^]&716I_PC&O?] 34?\
MP$D_PH_X1C7O^@)J/_@))_A1RR[!]8H_SK[T9=%:G_",:]_T!-1_\!)/\*/^
M$8U[_H":C_X"2?X4<LNP?6*/\Z^]&716I_PC&O?] 34?_ 23_"C_ (1C7O\
MH":C_P" DG^%'++L'UBC_.OO1ET5J?\ ",:]_P! 34?_  $D_P */^$8U[_H
M":C_ . DG^%'++L'UBC_ #K[T9=%:G_",:]_T!-1_P# 23_"C_A&->_Z FH_
M^ DG^%'++L'UBC_.OO1ET5J?\(QKW_0$U'_P$D_PH_X1C7O^@)J/_@))_A1R
MR[!]8H_SK[T9=>C^ / 'VPQZOKD6+?[T%NP_UGHS#^[Z#O\ 3J[P+\/))IEU
M+Q%;M'&C?NK25<%R.[ ]![=_IU]6 P,#@5UT:%_>D?)YUG?+?#X9Z]7^B_S
M# P.!1117<?$!1110 4444 %5+C_ )"5G_P/^56ZJ7'_ "$K/_@?\J +=%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 8&@?\C!XA_Z^H_\ T6M%&@?\C!XA_P"OJ/\ ]%K10 \?\E!/_8+'_HTU
MN5AC_DH)_P"P6/\ T::W* "BBN?\;^,].\!>&)==UB*YFMHI$C*6J*SDL<#
M9@/UI-I;C2;.@HK@O#OQ5C\1ZI96EOX+\86<5YRE[>:4([=5*Y#-('. 1T/N
M*@U+XTZ#::Y>Z9IFDZ_K[Z>VR]GT?3S/%;-D@AVW#I@] 1P:>PMST2BO/]<^
M+^FZ+9P7T?AKQ/J>FSV27PU"PTW? D; GYG9EVD 9(/2JNA?&NQ\1PK<:5X.
M\7RVCQRR)=_V:GD-L5B0)!)MR2I4<_>P*._D!Z517'^'?B=X=\2> KOQ=:23
M0:=9B0W*7"J)8B@R054D9(P1@\Y%8UY\<O#MAX T_P 776F:REAJ-TUM;Q>1
M'YSD _-CS,;?E(SG/M0]-_ZOL"U_KL>DT5A>#O%^F>.?#-OKFB&46TQ9=DZA
M9(V4X*L 2 ?H3UKF+3XV>&+[XBCP;:P:E)>FZ>T%T(4^SF1 2P#;]W&,?=Z^
MW-.SYN7J'3FZ'HE%>>:]\9=)T/QK=^%HO#_B+6-3M(UDD32K)9QM95;.-X;
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M>/R-J#'+=LBM6@ HK+UK7#H\VG1KI>HZA]NNEMBUE!Y@M\_\M)3D;4'<UJ4
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M^I/_ (NI^L4SH_U=Q_9?>>QT5XY_PMW7O^?33O\ OU)_\71_PMW7O^?33O\
MOU)_\71]8IA_J[C^R^\]CHKQS_A;NO?\^FG?]^I/_BZ/^%NZ]_SZ:=_WZD_^
M+H^L4P_U=Q_9?>>QT5XY_P +=U[_ )]-._[]2?\ Q='_  MW7O\ GTT[_OU)
M_P#%T?6*8?ZNX_LOO/8Z*\<_X6[KW_/IIW_?J3_XNC_A;NO?\^FG?]^I/_BZ
M/K%,/]7<?V7WGL=%>.?\+=U[_GTT[_OU)_\ %T?\+=U[_GTT[_OU)_\ %T?6
M*8?ZNX_LOO/6/^8S_P!N_P#[-5NO&/\ A:^N?:?/^RZ?NV;,>6^,9S_?J3_A
M;NO?\^FG?]^I/_BZ/K%,/]7<?V7WGL=%>.?\+=U[_GTT[_OU)_\ %T?\+=U[
M_GTT[_OU)_\ %T?6*8?ZNX_LOO/8Z*\<_P"%NZ]_SZ:=_P!^I/\ XNC_ (6[
MKW_/IIW_ 'ZD_P#BZ/K%,/\ 5W']E]Y['17CG_"W=>_Y]-._[]2?_%T?\+=U
M[_GTT[_OU)_\71]8IA_J[C^R^\]CHKQS_A;NO?\ /IIW_?J3_P"+H_X6[KW_
M #Z:=_WZD_\ BZ/K%,/]7<?V7WGL=%>.?\+=U[_GTT[_ +]2?_%T?\+=U[_G
MTT[_ +]2?_%T?6*8?ZNX_LOO/8Z*\<_X6[KW_/IIW_?J3_XNC_A;NO?\^FG?
M]^I/_BZ/K%,/]7<?V7WGL=%>.?\ "W=>_P"?33O^_4G_ ,71_P +=U[_ )]-
M._[]2?\ Q='UBF'^KN/[+[SV.BO'/^%NZ]_SZ:=_WZD_^+H_X6[KW_/IIW_?
MJ3_XNCZQ3#_5W']E]Y['52X_Y"5G_P #_E7D_P#PMW7O^?33O^_4G_Q=1O\
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M_P 71]8IA_J[C^R^\]CHKQS_ (6[KW_/IIW_ 'ZD_P#BZ/\ A;NO?\^FG?\
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M_?J3_P"+H^L4P_U=Q_9?>>QT5XY_PMW7O^?33O\ OU)_\71_PMW7O^?33O\
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M.?+S_$R@,0 ,BN@NO ][J-CX<35?$,M]=Z-J:ZC+=2VR@W) ?Y JD!!\_'7
M'>N5U31-2U?X_P"J/H>O3Z)>VVA6S),D*S1N#+("LD;8##TY!!Y!HZI/N_\
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MZ@;CG@#/0URFC(O_  R*R[1C_A'ISC'?:YS7L%%*2O%KO_P?\P3M)/M_P/\
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MU#XR_P#,&_[;_P#M.O+Z\NO_ !&?I^0_\BZG\_\ TIA1116)[04444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\5I6G_'G#_US7^52T >5_P!D^,?'?C;P[J?B3PQ;^%[+P_<-<Y.H1W<]RQ7
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M_P"N;?RJ6HKO_CSF_P"N;?RH +3_ (\X?^N:_P JEJ*T_P"/.'_KFO\ *I:
M/,/C+_S!O^V__M.O+Z]0^,O_ #!O^V__ +3KR^O+K_Q&?I^0_P#(NI_/_P!*
M84445B>T%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444H!)P!DF@!\
M,LL$Z2V[LDJ,"C(<$'MBOH7PQ<:K<^'[:7785ANV7D \L.Q8=B?3_P#4.0\
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MX\5_] K_ ,F(O_BJ/9S[,/[0P?\ S]C_ .!+_,Y>BNH_X5QXK_Z!7_DQ%_\
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M(O\ XJC_ (5QXK_Z!7_DQ%_\51[.?9A_:&#_ .?L?_ E_F<O174?\*X\5_\
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M51_PKCQ7_P! K_R8B_\ BJ/9S[,/[0P?_/V/_@2_S.7HKJ/^%<>*_P#H%?\
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MZC_A7'BO_H%?^3$7_P 51_PKCQ7_ - K_P F(O\ XJCV<^S#^T,'_P _8_\
M@2_S.7HKJ/\ A7'BO_H%?^3$7_Q5'_"N/%?_ $"O_)B+_P"*H]G/LP_M#!_\
M_8_^!+_,Y>BNH_X5QXK_ .@5_P"3$7_Q5'_"N/%?_0*_\F(O_BJ/9S[,/[0P
M?_/V/_@2_P SEZ*ZC_A7'BO_ *!7_DQ%_P#%4?\ "N/%?_0*_P#)B+_XJCV<
M^S#^T,'_ ,_8_P#@2_S.7HKJ/^%<>*_^@5_Y,1?_ !5'_"N/%?\ T"O_ "8B
M_P#BJ/9S[,/[0P?_ #]C_P"!+_,Y>BNH_P"%<>*_^@5_Y,1?_%4?\*X\5_\
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M\H^P?]/5U_W\JW10!4^P?]/5U_W\J.XLMEM*WVFX;"$X,G!XJ_45W_QYS?\
M7-OY4 5;>RWVT3?:;A<H#@2<#BI/L'_3U=?]_*FM/^/.'_KFO\JEH J?8/\
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MU'_OU'_\71[:GW#^R,?_ ,^F=A]@_P"GJZ_[^4?8/^GJZ_[^5Q__  MW0?\
MGTU'_OU'_P#%T?\ "W=!_P"?34?^_4?_ ,71[:GW#^R,?_SZ9V'V#_IZNO\
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M $]77_?RN/\ ^%NZ#_SZ:C_WZC_^+H_X6[H/_/IJ/_?J/_XNCVU/N']D8_\
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M $]77_?RN/\ ^%NZ#_SZ:C_WZC_^+H_X6[H/_/IJ/_?J/_XNCVU/N']D8_\
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M*T*J7'_(2L_^!_RH MT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#7B6S\3::+FT.R5<": GYHV_J/0ULUZ:::NC\UJTIT9NG45F@HHHIF84444
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M_P!&FMRL,?\ )03_ -@L?^C36Y0 4444 %%%% !1110 4444 %%%% !1110
M4444 %17?_'G-_US;^52U%=_\><W_7-OY4 %I_QYP_\ 7-?Y5+45I_QYP_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[\+_ (4 0_\ "1Z)_P!!C3__  *3_&C_ (2/1/\ H,:?_P"!2?XU-_9&F_\
M0/M?^_"_X4?V1IO_ $#[7_OPO^% $/\ PD>B?]!C3_\ P*3_ !H_X2/1/^@Q
MI_\ X%)_C4W]D:;_ - ^U_[\+_A1_9&F_P#0/M?^_"_X4 0_\)'HG_08T_\
M\"D_QJ.Y\0Z*UI,%U>P)*, !<ISQ]:M?V1IO_0/M?^_"_P"%']D:;_T#[7_O
MPO\ A0!5MO$.BK:0AM7L 0B@@W*<<?6I/^$CT3_H,:?_ .!2?XU-_9&F_P#0
M/M?^_"_X4?V1IO\ T#[7_OPO^% $/_"1Z)_T&-/_ / I/\:/^$CT3_H,:?\
M^!2?XU-_9&F_] ^U_P"_"_X4?V1IO_0/M?\ OPO^% $/_"1Z)_T&-/\ _ I/
M\:/^$CT3_H,:?_X%)_C4W]D:;_T#[7_OPO\ A1_9&F_] ^U_[\+_ (4 0_\
M"1Z)_P!!C3__  *3_&C_ (2/1/\ H,:?_P"!2?XU-_9&F_\ 0/M?^_"_X4?V
M1IO_ $#[7_OPO^% $/\ PD>B?]!C3_\ P*3_ !H_X2/1/^@QI_\ X%)_C4W]
MD:;_ - ^U_[\+_A1_9&F_P#0/M?^_"_X4 0_\)'HG_08T_\ \"D_QH_X2/1/
M^@QI_P#X%)_C4W]D:;_T#[7_ +\+_A1_9&F_] ^U_P"_"_X4 0_\)'HG_08T
M_P#\"D_QH_X2/1/^@QI__@4G^-3?V1IO_0/M?^_"_P"%']D:;_T#[7_OPO\
MA0!#_P )'HG_ $&-/_\  I/\:K?\)!HW]K;_ .U[';Y&-WVE,9W=.M7_ .R-
M-_Z!]K_WX7_"C^R--_Z!]K_WX7_"@"'_ (2/1/\ H,:?_P"!2?XT?\)'HG_0
M8T__ ,"D_P :F_LC3?\ H'VO_?A?\*/[(TW_ *!]K_WX7_"@"'_A(]$_Z#&G
M_P#@4G^-'_"1Z)_T&-/_ / I/\:F_LC3?^@?:_\ ?A?\*/[(TW_H'VO_ 'X7
M_"@"'_A(]$_Z#&G_ /@4G^-'_"1Z)_T&-/\ _ I/\:F_LC3?^@?:_P#?A?\
M"C^R--_Z!]K_ -^%_P * (?^$CT3_H,:?_X%)_C1_P )'HG_ $&-/_\  I/\
M:F_LC3?^@?:_]^%_PH_LC3?^@?:_]^%_PH A_P"$CT3_ *#&G_\ @4G^-'_"
M1Z)_T&-/_P# I/\ &IO[(TW_ *!]K_WX7_"C^R--_P"@?:_]^%_PH A_X2/1
M/^@QI_\ X%)_C1_PD>B?]!C3_P#P*3_&IO[(TW_H'VO_ 'X7_"C^R--_Z!]K
M_P!^%_PH A_X2/1/^@QI_P#X%)_C1_PD>B?]!C3_ /P*3_&IO[(TW_H'VO\
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MO_?A?\*/[(TW_H'VO_?A?\* (?\ A(]$_P"@QI__ (%)_C1_PD>B?]!C3_\
MP*3_ !J;^R--_P"@?:_]^%_PH_LC3?\ H'VO_?A?\* (?^$CT3_H,:?_ .!2
M?XT?\)'HG_08T_\ \"D_QJ;^R--_Z!]K_P!^%_PH_LC3?^@?:_\ ?A?\* (?
M^$CT3_H,:?\ ^!2?XT?\)'HG_08T_P#\"D_QJ;^R--_Z!]K_ -^%_P */[(T
MW_H'VO\ WX7_  H A_X2/1/^@QI__@4G^-'_  D>B?\ 08T__P "D_QJ;^R-
M-_Z!]K_WX7_"C^R--_Z!]K_WX7_"@"'_ (2/1/\ H,:?_P"!2?XT?\)'HG_0
M8T__ ,"D_P :F_LC3?\ H'VO_?A?\*/[(TW_ *!]K_WX7_"@"A_PD&C?VMO_
M +7L=OD8W?:4QG=TZU9_X2/1/^@QI_\ X%)_C4W]D:;_ - ^U_[\+_A1_9&F
M_P#0/M?^_"_X4 0_\)'HG_08T_\ \"D_QH_X2/1/^@QI_P#X%)_C4W]D:;_T
M#[7_ +\+_A1_9&F_] ^U_P"_"_X4 0_\)'HG_08T_P#\"D_QH_X2/1/^@QI_
M_@4G^-3?V1IO_0/M?^_"_P"%']D:;_T#[7_OPO\ A0!#_P )'HG_ $&-/_\
M I/\:/\ A(]$_P"@QI__ (%)_C4W]D:;_P! ^U_[\+_A1_9&F_\ 0/M?^_"_
MX4 0_P#"1Z)_T&-/_P# I/\ &C_A(]$_Z#&G_P#@4G^-3?V1IO\ T#[7_OPO
M^%']D:;_ - ^U_[\+_A0!#_PD>B?]!C3_P#P*3_&C_A(]$_Z#&G_ /@4G^-3
M?V1IO_0/M?\ OPO^%']D:;_T#[7_ +\+_A0!#_PD>B?]!C3_ /P*3_&C_A(]
M$_Z#&G_^!2?XU-_9&F_] ^U_[\+_ (4?V1IO_0/M?^_"_P"% $/_  D>B?\
M08T__P "D_QH_P"$CT3_ *#&G_\ @4G^-3?V1IO_ $#[7_OPO^%']D:;_P!
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M_P"!2?XU-_9&F_\ 0/M?^_"_X4?V1IO_ $#[7_OPO^% $/\ PD>B?]!C3_\
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MU_[\+_A0!#_PD>B?]!C3_P#P*3_&C_A(]$_Z#&G_ /@4G^-3?V1IO_0/M?\
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M_C4W]D:;_P! ^U_[\+_A1_9&F_\ 0/M?^_"_X4 0_P#"1Z)_T&-/_P# I/\
M&C_A(]$_Z#&G_P#@4G^-3?V1IO\ T#[7_OPO^%']D:;_ - ^U_[\+_A0!#_P
MD>B?]!C3_P#P*3_&C_A(]$_Z#&G_ /@4G^-3?V1IO_0/M?\ OPO^%']D:;_T
M#[7_ +\+_A0!#_PD>B?]!C3_ /P*3_&JT_B#1CJ%JPU>Q*KOR1<I@<?6K_\
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M[\+_ (4 0_\ "1Z)_P!!C3__  *3_&C_ (2/1/\ H,:?_P"!2?XU-_9&F_\
M0/M?^_"_X4?V1IO_ $#[7_OPO^% $/\ PD>B?]!C3_\ P*3_ !H_X2/1/^@Q
MI_\ X%)_C4W]D:;_ - ^U_[\+_A1_9&F_P#0/M?^_"_X4 0_\)'HG_08T_\
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M (4?V1IO_0/M?^_"_P"% $/_  D>B?\ 08T__P "D_QH_P"$CT3_ *#&G_\
M@4G^-3?V1IO_ $#[7_OPO^%']D:;_P! ^U_[\+_A0!#_ ,)'HG_08T__ ,"D
M_P :/^$CT3_H,:?_ .!2?XU-_9&F_P#0/M?^_"_X4?V1IO\ T#[7_OPO^% $
M/_"1Z)_T&-/_ / I/\:/^$CT3_H,:?\ ^!2?XU-_9&F_] ^U_P"_"_X4?V1I
MO_0/M?\ OPO^% &1X9N(;K6M?FMI4FB>Z0J\;!E;]V.A%%;T%I;VH86MO%"&
*ZB- N?RHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>eols-20241231_g2.jpg
<TEXT>
begin 644 eols-20241231_g2.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:\LKKQ'H^AV_B'PSKME:?9EUK2)7\IF>'<PCGAF!C;:=K@A@J8*CF?A?\?\
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M%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\
MOI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z
M6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'
M_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=
M7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)
M=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0
MO?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"
M]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#
M8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C
M_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL
M?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_
M .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_
M *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[
MZ6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_
M[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:
M-BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A
M)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$
MEU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%
M"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z
M%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\
MOI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z
M6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'
M_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=
M7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)
M=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0
MO?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"
M]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#
M8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C
M_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL
M?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_
M .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_
M *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[
MZ6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_
M[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:
M-BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A
M)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$
MEU?_ *%"]_[Z6N,^./Q@UKP1X/86&C3V5]?N8;2>9E/E\99P!U('3T)!KSLW
MS3"Y+EE7'8EVA35WW\DO-NR7FSJP6#K8_%PP]+XI.R_S^6YU?BGXI_#WP5/]
ME\3>*[6VFQDP EY /4H@+#\11X6^*?P]\:S_ &7PSXKM;F;&1 24D(]0C@,?
MP%?'5Q<3W<[W5U,\DDC%I))&)9F/)))ZFBWN)[2=+JUF>.6-@T<D;$,K#D$$
M=#7\]_\ $<LV^O<WU2'L;_#>7/;_ !7M?_MP_3/^(>X+ZO;VTN?O9<M_3?\
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MC&KW2O"_ /\ RD$\?_\ 8B:5_P"C&KW2@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\:?$
MKQC?>._&M_XCO)F999V6V0GB.$$A%'IQ^9)/>OLNOBSQOHUOX>\7ZEHMI>17
M$-M>2)#-!(&5DSQR.,XQD=CD5^$^.<\4LMP<8O\ =N4N9=Y)+E^Y<Q^B>'L:
M+Q5=M>\DK>EW?]#*K=^&OC&^\">-;#Q'9S,JQ3JMR@/$D)(#J?7C\B >U85;
MOPU\'7WCOQK8>'+.%F66=6N7 XCA!!=CZ<?F2!WK^?<H^N_VI0^IW]KSQY+;
M\UU;\3]+QOU?ZG4]O\'*^:_:VI]@:=H.BZ3=75]IFE0037LOFW<L40#3/C&6
M/?\ ^N?4U;HHK^]:=*G1CRPBDNR5M]7][U/YRE.4W>3NPHHHJR0HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.\@E
MN;26V@O)+=Y(V5+B$*7B)& RAPRY'49!''((XJ2B@#Y+_8&U'QS%^V-^TUX*
M\8?$[Q!XG@T'Q!H,6E3>(+_SFMX9+:ZE,:*H6.-07QM15' XS7??M'?L<^*O
MVG?B)!KNO?M._$3P/H&DZ:MMI.D?#7Q&=-DN9G;?-<W4AC</_!&D87Y1&6W?
MO"J\%^PY_P G\_M9?]C)X;_]()Z^IO$GB'1_"/AV_P#%?B&]6VT_2[*6[OKE
M_NQ0QH7=S[!5)_"@#Y)_8]_9]U/X8_MR^.M&T#]I'XK>,_#7@?PE8V-]!X_\
M:R:A&=:OB;@A$5(X_P!U:)"?F4D&ZZ\"O.OC1^T7^R_^U/\ M?>(/@Y\4/VX
M_B5\*'\+Z@NA>%M/\'Z^^C6>JR* ;FZGN6@DC9FG8PQAF1=EN&!8RX'TU_P3
M^\.:Q%^S\GQ:\663P:[\3]:O/&>KQ2?>B^W.'MH3W'EV:VL6#T\NNL_:9_9M
M^"W[3_PLU/X=_&SPO8WEA-:2>1J,\2"?3'VG%S#*>8G3[V0<$ ALJ2" ;?P;
M^&-C\&OAII7PUT_QAX@U^+2X60:SXJU9K[4+LL[.7FG8#>V6.,       "NG
MKPS_ ()HR_$"7]A/X:GXF7L]SJBZ"4CNKC.^:S6:06<AW<G=:B @GD@BO<Z
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MQ16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_ -!NR_\
M 8_XT?8O&_\ T&[+_P !C_C0!L45C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_
M  &/^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_
M -!NR_\  8_XT?8O&_\ T&[+_P !C_C0!L45C_8O&_\ T&[+_P !C_C1]B\;
M_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%
M%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C0!L45C_8O&_\ T&[+_P !
MC_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\
M 8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C0!L45C_8O&_\
MT&[+_P !C_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_
M -!NR_\  8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C0!L45
MC_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_  &/
M^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !
MC_C0!L45C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0
M;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\
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MIDL#ZCQ35_#?B#P_>'3];T6ZM)E;!CG@92?ID<_A7VU'''%&L42!54 *JC
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#POP#_RD$\?_P#8B:5_Z,:O
M=*\+\ _\I!/'_P#V(FE?^C&KW2@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HI))$B1I97"JH)9F. !ZFO/+K]I+P0?'EEX*T6.6_6XN/)GO[?F.-CPH
M4 $R#.,D< <C->7F>=95DZA]=K1ASM1C=ZMMVT6_75[+=M(Z\)@,9CG+V$'+
ME5W;HE_7SZ'2?$#XG>$?AKIOV[Q)J $CJ3;V<6&FF/\ LKZ>YP!ZUXOK5AXB
M_:>L[SQ1I?A3[%>:8=EA)D^7=P=3"SM@&56RP(P,.0<<&N]U#]FOP]K_ ,1[
MSQKXGUBYO;2>021:=(YX;NK.3DH#T48P.,X'/HUE96>FVD=AI]K'!!$H6*&%
M JH!V ' %?&8W(N(.+\35HYORT<$G)1IQM*=2UU&HYV]VSM**7I)6W][#YCE
MN24H5,%>I7=FY.ZC'O%1Z]FWZI]OBG5_#?B#P_>'3];T6ZM)E;!CG@92?ID<
M_A77?"WX"^,/B#J44M[IT]AI08&>]N(RA9?2,'[Q/KT'?T/U;17RV \$,IP^
M/57$XJ52FG?DY5&_DY<SNN]DGYH]?$^(&,JX=PI45&;^U>_S2LOQ;(--TZST
MC3H-*TZ 16]M"L4,:]%11@#\A4]%%?MT(1IP48JR6B1\!*3E)MO5A6;XO\-V
MGC#PQ?>&+YML=[;-$7 R4)'##W!P?PK2HJ*]"EB:$J-57C)--=TU9K[BJ=2=
M*HIP=FG=>J/BKQ=X1UWP1KLWA[Q#9-#<0MP<?+(O9U/=3V-9E?:WB3PAX8\8
M6@L?$^A6U[&N2@GC!*'U4]5/T(K$TCX%?"30[P7^G^"+7S5.5,[O, ?4"1F
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MV*X/XE?M">"/AQ=MH\GFZAJ"#Y[2T(Q%[.YX4^PR?:I_B5KOC;P3X%U+Q/\
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M6_KH;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-?2'E&Q16/]B\;_\
M0;LO_ 8_XT?8O&__ $&[+_P&/^- &Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[
M+_P&/^- &Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^- &Q16/]B\;_\
M0;LO_ 8_XT?8O&__ $&[+_P&/^- &Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[
M+_P&/^- &Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^- &Q16/]B\;_\
M0;LO_ 8_XT?8O&__ $&[+_P&/^- &Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[
M+_P&/^- &Q16/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^- &Q16/]B\;_\
M0;LO_ 8_XT?8O&__ $&[+_P&/^- &Q7G/Q \8>$?V?((+G1/ 63J]XS7$]N
MB_>#/N8Y.<$E5Z=<8QBNN^Q>-_\ H-V7_@,?\:Q?'_P\\0_$'PO<>&M7U:R9
M) &A?[,08Y!]U@>WI]"1WKP^(<)C\3EE2>7N,<3%-TY.*=GU2NG;F2Y;_/H>
MAEE;#TL7&.)NZ3:YDFU==]-[;G5Z7J=CK6FP:OIERLUO<Q++!*O1E89!J>O'
M/V=8?BQINGW_ (,U&R>TL]-N'6WN+N#*;]Q#QJ<@L,Y8$9')YY%>E_8O&_\
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M-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\ @,?\:/L7C?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2]4TVWUU/#/A;^RA=VFI1:W\2+B!HX6#IIENV\.1T\QNF/\ 9&<^O8^Y@ #
M& .@%%%?;<.<+Y/PMA'A\!"W-K*3=Y2?2[\NB5DM;+5G@9IF^.SBNJF)E>VR
M6B7HOZ84445]">8%%%% !1110 4444 %?F)_P4-_Y/"\7_\ </\ _3?;5^G=
M?F)_P4-_Y/"\7_\ </\ _3?;5^L^#G_)3UO^O,O_ $NF?D7C1_R2U'_K]'_T
MBH>+4445_29_,A^G?_!/+_DSWPA_W$/_ $X7->TU^?'[//[<7Q>^"7P>T?P/
MI?P-_M?1K#[0;74]MPGG![B65_G"LAPSLO'3;SSFOT#M9)I;6.6XBV2-&"Z
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MTNK+FWDEY)_UH6****^J/'"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.VG*V\5N^!<H.5" ']U'SR/O9SW^:O8["PLM+LHM.TVTC@@A0)%#$@544=
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M K-^*7[1GP!^!]Y::?\ &3XT^%_"MQ?Q-)8P>(-<@M'G12 S()6!8 D D>M
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M>"R^5.>*QT[0A]A/WY-JZ2[+S.GUKX(>#/B1XUL_B=>:G/=64]HDGV%R2DW
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MBQ_PCW]J_P!E?9_] ^U^1YOFW$</W]C[<>9N^Z<XQQG-?,/_  ]]_P"K>?\
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M9W5NY^1]%?:7_#H+_JX;_P M+_[KH_X=!?\ 5PW_ ):7_P!UU_2/_$3."/\
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M]SYC%>(_!F#Q,\/6Q5IP;BUR5'9IV:NH-/7JFUV/M*BOBW_A[[_U;S_Y=O\
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M42BHNS4N2=F^ZM?0^P\+:6;UN(IK+JD825-N3DN9.//"Z79MVU/INO./C/\
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M%CEB\J(&8GOD\UT%% !1110 4444 >%^ ?\ E()X_P#^Q$TK_P!&-7NE>%^
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M6H[7Q;\%[G3; QRM->6FNBZD4K&S(JQF",,6<*F2X W9/3%='^R]^U;^T/\
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M\(/^%]?![6/A/_PD/]E?VK]G_P!/^R>?Y7E7$<WW-Z;L^7M^\,9SSC%?,/\
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M#7O/[(.A:+<VFI^,&O[F35//-O<1O*=@C;#AB,_,2<\G^[QZG\]O^%\_%?\
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M+D[N_17?0^DZ_%NOM+_AJ[_@I#XD_P"0/^SA]B5ON-_PB%ZGZS28-?%M?O\
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M=KHYK_@H_P#M%_"OXZZQX:TCX9:U+J"^'GOUO;P6[)#(9?LVWRRV"X_=."<
M=,9!S7S-7Z ?$;_@EI\+_$/A_1-#^'/B^7P])IOGG4M0N]/-]/J;2"+:7/FQ
MA-FQL*HQ^\/ YSR/_#H+_JX;_P M+_[KK]LX;XXX#R;):6#I8B48PYK*<)N6
MLF[MQBXZWNK/1-)V=T?AO$W G'^=9W5QM7#1E*?+=PG!1TC%62G)2TM9W6K3
M:NK,^+:^R/\ @D?H>BZE>^.M2U'1[6XN;)M*:SN)[=7> M]LR48C*YP,XQG
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M4**** "BBJVLZOI^@:1=:[J]RL-K9V[SW,K=$1%+,?P - XQE.2C%7;/G_\
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M6NHVJS19/*Y'*GW4Y4^X-?G'X@\0:UXJUFX\0^(M2EO+VZ??<7,[99SC'/X
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M>2>N%?BW7[245]WP5QK_ *G_ %C_ &?VOM>3[?+;EYO[LKWYO*UCX'CC@?\
MUS^K_P"T>R]ES_8YK\W+_>C:W+YWN?BW17[245]W_P 1K_Z@/_*O_P!S/@?^
M('_]3#_RE_\ = KYZ_:T_8T\=_'KQW9?$WP+\7O[$U'3=-6TL[.2"1$7#NY<
M31-N4DOS\IZ#TKZ%HK\<RG-\=DF,6*PDDII-:I25GNK--:_>?M&;Y/@,]P3P
MN,BW!M/1N+NMG=-/3[CXF\O_ (*C?L_<J\WC'38?=-4$F/KMNOY5P7[;GQ0^
M(GQ@^%/PV\:_$WP7'H.HR7NNPBRCCE3*1FR7>4E^9"7#C!)X4<\U^BU?%O\
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M4 >;?&?Q7J7PZ_X+/^'-2\-(=^L?L_7RZI OW9Q;W%[/$6'<[X(USZ#%;O\
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MHKOR*?\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\
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MJ#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4SB*?\
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M8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT* *?\
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M?]]4?\)CX8_Z#4'_ 'U5S^SM/_Y\8?\ OT*/[.T__GQA_P"_0H ^4OCC<0?
M?]I/3?C7X-F673M5F,NH00'@N?EN(_\ @:G>"?XB3_#7TW8>/_!VIV,.I6/B
M"WD@N(EDAD!.&5AD'\C7._'_ .$5A\5_A=J/ABUL85OT3[1I<@0 K<("5&>P
M890^SFO.OV%_B+;^(_!]W\+_ !# G]I: Y:W6:,;VMF;H<\Y1\J?0,@[5BO<
MJ6Z,^YQW_"_PM3QJUK86U.?=TW\$OD_=^]L]M_X3'PQ_T&H/^^J/^$Q\,?\
M0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5L?#%/\ X3'PQ_T&H/\ OJK&
MGZWI.JNT>G7\<S(,L$/05)_9VG_\^,/_ 'Z%/BMK: DP6Z(3U*(!F@!]%%%
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MZ2;E>[;>M[[Z7MT"BBBN(R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,EAVKT2M$U)71\YC\%7R[&U,+65I0;3^7Z/=>04444SD"BBB@ HHHH ****
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MJ=T]+K1'3E>;X[)ZSJ8:5K[IZI^J_IGR]I'[*_Q;U"\$&H:;:V$6?FGGO4<
M>PC+$_I7O/PJ^%6A?"K0CIFF.9[F<AKV]=<-,PZ#'91DX'N>N:ZBBO&X9\.^
M'.%<2\3A8RG4V4IM-I/>UE%*_>U[:7LV=V;<3YIG%+V59I0[15D_6[;_ !L%
M%%%?='SP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4DDB
M1(TLCA54$LS'  ]:6N&_:3\8?\(/\$/$6M1R[)GL&M;8@\^9,1$"/<;]W_ :
M3=E<Z<%A:F.QE/#PWG)17JW8\6_9)C?XH_M'>+?C#<H7A@\UK4L/N-/(5C'X
M1(ZU]15XI^P?X/\ ^$?^"Q\0S18EUO499PQ'/E)^Z4?FKG_@5>UU%)6@O,^B
MXUQ5/$<0U:=/X*5J<?)05FOON%%%%:'R@4444 %%%% !1110 4R>""Z@>VN8
M5DCD0K)&ZY#*1@@CN,4^B@$VG='RC\/9YOV4OVI[KP%J$K1^'O$#*EO)(WRB
M)V)MY"3U*/NC)/JQKZNKQ7]MSX2'QW\-/^$STFVW:EX=W3'8/FDM3CS5_P"
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M+#*S?\U1_'+[]%VUMH%%%%:GQP4444 %%%% !1110 5P/[17P3T[XW> I=&
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M*** "BBB@ HHHH **** "BBB@ HHHH ***^8?^&M/^,L/^0G_P 4M_R!OO\
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M1_PDNK_]"A>_]]+6Q10!C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM;%%
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M]E^T_9=WS^3NV[\>F[C/K1":G&YCGV1ULFQ[I1?/3:YH26TH/9_Y^?E8H_\
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M^?F/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL
M44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%
M% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL
M44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%
M% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBB@ HHHH **** "BBB@ HHHH **** /F;]O76+OQ+XK\)?"'2'S/=3>>T?\
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ME]?N5SEO^"?/ABXFTSQ)\2=2S)-?WJ6D<S]3M'F2'WR9$_%:^CZX']F'P?\
M\(3\"_#VER1;9KBS%Y<9'.^8F3!]P&5?^ UWU*FN6"1V\5X]9EQ#B*R^'FY5
MZ1]U?@KA1115GSP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &%X
MZ^&7@+XEZ?\ V;XX\+6FH(%(C>6/$D?^Y(,,GX$5X/XS_8;\1>%=2/BOX!>/
MKFSNHLM%:7=P8I%_V4G3&?3##ZM7TK142A&6Y[N5<29QDWNX>I[CWA+WH/\
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MBBBMCX,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZO\ ]"A>_P#?2T?\)+J__0H7O_?2UL44 8__  DNK_\ 0H7O_?2T?\)+J_\
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MZO\ ]"A>_P#?2T?\)+J__0H7O_?2UL44 8__  DNK_\ 0H7O_?2T?\)+J_\
MT*%[_P!]+6Q10!C_ /"2ZO\ ]"A>_P#?2T?\)+J__0H7O_?2UL44 8__  DN
MK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+6Q10!C_ /"2ZO\ ]"A>_P#?2T?\)+J_
M_0H7O_?2UL44 8__  DNK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+6Q10!C_ /"2
MZO\ ]"A>_P#?2T?\)+J__0H7O_?2UL44 8__  DNK_\ 0H7O_?2T?\)+J_\
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M%"]_[Z6MBB@#'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6MBB@#'_ .$EU?\
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MK8HH Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EK8HH Q_P#A)=7_ .A0O?\
MOI:/^$EU?_H4+W_OI:V** ,?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI:V**
M,?\ X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6MBB@#'_X275_^A0O?^^EH_P"$
MEU?_ *%"]_[Z6MBB@#'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EK8HH Q_^
M$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EK8HH Q_P#A)=7_ .A0O?\ OI:/^$EU
M?_H4+W_OI:V** ,?_A)=7_Z%"]_[Z6K6E:K>ZA(Z76B3VH5<AI2,-[<5>HH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#POP#_ ,I!/'__ &(F
ME?\ HQJ]TKPOP#_RD$\?_P#8B:5_Z,:O=* "BBB@ HHHH **** "OEGX._\
M%C_VS-9^';_NM/UMI8[53PH#C[1!CUP,Q_5C7U-7S-^W9H5]X2\9>%/C7H2;
M9[:=8))!P!+$_G0Y^O[S\%%95=$I=C[/@J<<3BZ^63?NXFG**_QI<T'\FG;U
M/IFBLGP5XV\.?$#P_#XD\+ZE'<V\JKN,;9\MBBML;T8!AD>]:U:IW/D*M*I1
MJ.G434EHT]T%%5]4U;2M#L)-5UK4K>SM85W2W%U,L:(/4LQ %>)_$[]NWX=>
M&&?2_A]82^(;T':LRYBME;I]XC<_/]T8/]ZIE.,=V>AEF2YKG-7DP=)S[OHO
M5O1?-GNA( R3@#J37EWQ1_:\^#WPT66RBUC^VM10$"QTI@X5O1Y/N+SUY+#^
M[7D@\'_M??M/GS?%E^WAS0)N?L\JM;1,A["$?O)?4>8<'L:\_P#VD/A?\/O@
MI>6'P^\.:A<:GK/DBYUC4;A@HC#<)$D:\)D98Y+-C;@X)%8SJRY;I?>?=Y%P
M9DU3,H83&XGVE5W;A2U44M^>>R[-*SOLS@_&GBW5O'GBS4/&.NR[[K4;III<
M'A<GA1[*,*/8"O9_V2?VIM#^%>FR_#[X@M<+I<MSYMC?1(7%HS??5E'.PGYO
MER02>#GCP2GP/%'.DD\/F(K@O'NQN&>1D=,URQG*,KH_9LTR3+\VRSZC7C^[
MTM;1JVUNUMNUM'H?I9H'B+0?%6E1:YX:UBVOK.89BN;68.C>V1W]1U%7:^1-
M)^#/QB^&VD6GQ@_9F\7W6JZ/J%LMP;%<&<+CF.6'[DY4Y4E1N!!PHZUZ!\)O
MVYO"^NSKX;^+FF'P_J2-Y;W85OLS.."&!^:$Y['('=A7;&JMI:'\_8_@[$*$
MZ^5S^L4XM\R6E2#6ZE#>Z\M][)'O=%165]9:G:1ZAIMY%<03(&BG@D#HZGH0
M1P1[BI:U/C&G%V84444""BBB@ HHHH **** .8^-/C > ?A1K_BQ9=DEIILG
MV9L])F&R/_Q]EKRK_@GYX/\ [)^&>I>,)HL2:QJ6R-L?>AA7 /\ WV\@_"C_
M (*!^,/[(^&6F^#X9=LFL:EOD7/WH81N(_[[:,_A7JGP5\'_ /" _"C0/";1
M;)+338_M*XZ3,-\G_C[-67Q5O0^U_P"1=P+_ 'L55^^%/_[<ZBBBBM3XH***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH \+\ _\ *03Q_P#]B)I7_HQJ]TKPOP#_ ,I!/'__ &(F
ME?\ HQJ]TH **** "BBB@ HHHH *\H_;4AT"7]G[53KDRI(EQ;MIQ/4W'F#
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M4 _W8T9?H17U%65+5.7<^TXT?U2MA<L7_,/2BG_CE[TOON@HHHK4^+"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,8RNF>GFOB%F^<Y?/!XBC2Y)]E*ZZIKWWJGY!1116Q\&%%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *Y7XL?%*S^&FD6\=GI<FKZ_J\QM?#7AVVD"S:E=;<[03D1Q(/GDE(VQH
M"QSP#U5>#_'O_@GA\$OVC_B<?BU\1/%_CN/55L5L[5='\7SV<-K;C:3'$D>
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MC_C1]B\;_P#0;LO_  &/^-;%% &/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\
M 8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C6Q10!C_8O&_\
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M'LY_5O9SA=7Y^:Z?1KECL]5KW[F/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\
M 8_XUL45J?&&/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\
M0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[
M+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\
M0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[
M+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\
M0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[
M+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\
M0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[
M+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\
M0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[
M+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\
M0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[
M+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\
M0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[
M+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\
M0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[
M+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\
M0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[
M+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\
M0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[
M+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\
M0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[
M+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\
M0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[
M+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\
M0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[
M+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\
M0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[
M+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\
M0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[
M+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\
M0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[
M+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\
M0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[
M+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XU:TJ#7X9'.L7\$RE?D$46T@U>HH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#POP#_P I!/'_ /V(FE?^
MC&KW2O"_ /\ RD$\?_\ 8B:5_P"C&KW2@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH \+\ _\I!/'_\ V(FE?^C&KW2O"_ /_*03Q_\ ]B)I
M7_HQJ]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M10!\I_\ #GK]F'_HH/Q3_P##B7='_#GK]F'_ **#\4__  XEW7U910!\I_\
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M^'/7[,/_ $4'XI_^'$NZ^K** /E/_ASU^S#_ -%!^*?_ (<2[H_X<]?LP_\
M10?BG_X<2[KZLHH ^4_^'/7[,/\ T4'XI_\ AQ+NC_ASU^S#_P!%!^*?_AQ+
MNOJRB@#Y3_X<]?LP_P#10?BG_P"'$NZ/^'/7[,/_ $4'XI_^'$NZ^K** /E/
M_ASU^S#_ -%!^*?_ (<2[H_X<]?LP_\ 10?BG_X<2[KZLHH ^4_^'/7[,/\
MT4'XI_\ AQ+NC_ASU^S#_P!%!^*?_AQ+NOJRB@#Y3_X<]?LP_P#10?BG_P"'
M$NZ/^'/7[,/_ $4'XI_^'$NZ^K** /@#]D3_ ()D_ ;XL_#/4/$GBKQ[\2%N
M8/%6I648LO'=U$GE0SE$R!U;'4]Z]3_X<]?LP_\ 10?BG_X<2[KVO]FOX,ZG
M\#/ 5[X0U76H+^2Z\0WVHK-;QLJJL\I<)@]P#@UZ#0!\I_\ #GK]F'_HH/Q3
M_P##B7=>E_LT_L1_"7]E;7M2\1?#KQ+XOOI]5M%MKA/$GB>:_C5%;<"BR<*V
M>X[5[#10 4444 %%%% !1110 4444 %%%% !1110 444CJKJ4=05(P01P10!
M@:/\5OAIXA\=ZC\,- \>:5?>(=(MEN-6T:SODEN+*-FVJ944DQY(X#8)]*@^
M+/QH^$WP(\*MXW^,GQ$TGPUI0E$2WNKWJPK)(02(T!.7<@$[5!. 3C@U\Q_L
MS>$/"O@G_@K5\<]'\'>'+'2K-O GA^7['IUHD$0=HUW,$0  G&3QR>:^C_%O
MP#^&?Q!^)-I\2_B'X9LM?N-,THV6B6>L6:7$&G%Y&:>>)'! EE'DHSXR%A4
M@,P(!:^$7QR^#WQ\\--XP^"_Q)T?Q-IJ2^5-=:1>K,(9,9V2 ',;8(.U@#@@
MXP:U/%/C?POX+ETJW\2:I]GDUO5H]-TJ,0O(UQ=.CNL8"*2/DCD8L<*JHQ)
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M""."* ,#1_BM\-/$/CO4?AAH'CS2K[Q#I%LMQJVC6=\DMQ91LVU3*BDF/)'
M;!/I4'Q9^-'PF^!'A5O&_P 9/B)I/AK2A*(EO=7O5A620@D1H"<NY )VJ"<
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M*![G7M,BNOLEE'$L:V<(D5MD.X22LH^\\SDYX ^6_P!BC2(?V5O!O[57Q/\
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M1?"SQ#\3]3MFGBT+2)[P6L?W[AT0E(4'=W;:BCNS 4 4M7_: ^"_AWPAK?Q
M\2_$;3=+T/P[JDVFZQJVJS&VMX+J)@DD0>4*)"'.SY-P+@J,L"!#\%_VD?@+
M^T5IUUJGP.^+6A^)XK%PMZNE7RR26Y.=OF1_?0'!P2 #@XSBN2^'W[)'@Y_
M/@'2?C)I=IXAO?"MC<WE[8W]NDUG<:[>,LUWJ+1N"K2B9[GRR<[1<R$<D$>.
M+\ _"O@[_@K_ .'/%'P!\.6NA01_"^\N_B;:Z-;K!:S)+*T-EYB( @EDE3?C
M +"UW=B2 ?0?QF_:S_9J_9YU*ST7XV?&WP[X;O;]/,M++4]059GCR1YGEC+!
M,@C>0%R",\5VOAGQ/X;\:^'[3Q9X/\066JZ7J$"S6.HZ==)-!<1GHZ.A*LI]
M0:X=?V4O@/J%]XDUSQS\-=$\2ZEXKO99M<U+Q!I4-S-/$1LBMMTBG;#%"$C1
M!@ *6QN9B?%?^"/OP_O?A]^S[XOM=(NKA_!=[\5==G^&R7$K/C0UF6&%T+<[
M'>*5QV.2_._- 'UA1110 4444 %%%% !1110 4444 %%%% !1110!S_BGXK?
M#3P3XDT?P;XM\>:5I^L>(;G[/H>E75\BW-_)@G$41.Y\ ') P.Y%:VMZYHOA
MG1[KQ#XCU>UT_3[&!I[V^O;A8H;>)1EG=V(55 !))(  KY%_;P\&^$]._;G_
M &7_ !AIWAFPM]5OO'FHQWVHP6:)/<J+2+:)' W.!@8W$X[5]-_%GX0^$/C5
MH=CX2^(%FM]HD&K0WNH:-.@>WU,1!FCAG0\/$)?*E*'AFA4,"I((!@_!_P#:
M^_9?^/VOW/A7X,_'7PUXBU.T0O-I^FZDC3; <%U0X+H#C+*"HR.>17=>)?$>
MB>#_  [J'BWQ-J,=GINEV4MYJ%W+G;!!$A>1SCG 523]*^/_ -M?]G#P':?M
M:?LX^(_@+X,T[0/'(^(8DOKC0;)+4S>'K:/S;\S"( ,BH4B!;_GY* _/@^[_
M +5W_%7:%X;^ =O\S?$'Q+!I^I1C_H$P!KS4-W^Q);P-;$_WKI!WH U?BG^U
M;^SG\$/#VD^)_C!\7]&\-6NN0K+I*ZS.;>:Y0J&RL+@2<!EW94;20&P>*ZWP
M7XV\'_$?PM9>-_ 'BBPUK1]1A\VPU/3+I9X)TR1E70D'D$'T((/(K@OCDW[*
MOP:T?Q!\<OVA(_#MM;7UFMMJFI>(X$N&FMTC(6SB20,S(?G801@[GD=MI+$U
MY?\ \$B?"'@+PO\ LC?VI\-/&MEJNC^(O%NIZS9V%A=>:FA13R+Y>FMGE9(H
MUC+J0,.[XW AF /H'5?BM\--#\?:7\*]6\>:5!XEUM)7TK0'OD^V7*1QM([K
M%G=L548EL8XQG/%=!7QU\>/!OA+P]_P5\_9^U[0/#-A97NK>'?%3ZI=6EHD<
MEVRV3E6D90"[#>W+9/S&OJ+XO_$;3_A%\+/$/Q/U.V:>+0M(GO!:Q_?N'1"4
MA0=W=MJ*.[,!0!2U?]H#X+^'?"&M_$#Q+\1M-TO0_#NJ3:;K&K:K,;:W@NHF
M"21!Y0HD(<[/DW N"HRP($/P7_:1^ O[16G76J? [XM:'XGBL7"WJZ5?+));
MDYV^9']] <'!( .#C.*Y+X??LD>#G\ ^ =)^,FEVGB&]\*V-S>7MC?VZ36=Q
MKMXRS7>HM&X*M*)GN?+)SM%S(1R01XXOP#\*^#O^"O\ X<\4? 'PY:Z%!'\+
M[R[^)MKHUNL%K,DLK0V7F(@""625-^, L+7=V)(!]"_&?]J[]FW]G>_LM)^-
MWQJ\/>&KO44WV=GJ>H*DTJ9QYFP98)D$;R N01GBNUT#Q!H/BO1+3Q-X7UJT
MU'3K^W2>QO[&X66&XB895T=2592"""#@UX[^U#J/[&7[/OPX\6?$O]I#2/#[
M6OB.&0ZNNL6Z7%YK16(1I:Q*^7<!=B(BX5,[OERS5E?\$L? .B_#7]A'P%X9
MT#XC6'BFW-E<71U/2[LS6R//<RS/;QL0#B)G,9! .Y&RJD[0 ?0=%%% !111
M0 4444 %%%% !1110 4444 %%%% '/\ BGXK?#3P3XDT?P;XM\>:5I^L>(;G
M[/H>E75\BW-_)@G$41.Y\ ') P.Y%:VMZYHOAG1[KQ#XCU>UT_3[&!I[V^O;
MA8H;>)1EG=V(55 !))(  KY%_;P\&^$]._;G_9?\8:=X9L+?5;[QYJ,=]J,%
MFB3W*BTBVB1P-S@8&-Q..U?3?Q9^$/A#XU:'8^$OB!9K?:)!JT-[J&C3H'M]
M3$09HX9T/#Q"7RI2AX9H5# J2" 8/P?_ &OOV7_C]K]SX5^#/QU\->(M3M$+
MS:?INI(TVP'!=4."Z XRR@J,CGD5W7B7Q'HG@_P[J'BWQ-J,=GINEV4MYJ%W
M+G;!!$A>1SCG 523]*^/_P!M?]G#P':?M:?LX^(_@+X,T[0/'(^(8DOKC0;)
M+4S>'K:/S;\S"( ,BH4B!;_GY* _/@^[_M7?\5=H7AOX!V_S-\0?$L&GZE&/
M^@3 &O-0W?[$EO UL3_>ND'>@#5^*?[5O[.?P0\/:3XG^,'Q?T;PU:ZY"LND
MKK,YMYKE"H;*PN!)P&7=E1M) ;!XKK?!?C;P?\1_"UEXW\ >*+#6M'U&'S;#
M4],NEG@G3)&5="0>00?0@@\BN"^.3?LJ_!K1_$'QR_:$C\.VUM?6:VVJ:EXC
M@2X::W2,A;.)) S,A^=A!&#N>1VVDL37E_\ P2)\(> O"_[(W]J?#3QK9:KH
M_B+Q;J>LV=A877FIH44\B^7IK9Y62*-8RZD##N^-P(9@#Z!U7XK?#30_'VE_
M"O5O'FE0>)=;25]*T![Y/MERD<;2.ZQ9W;%5&);&.,9SQ705\=?'CP;X2\/?
M\%?/V?M>T#PS865[JWAWQ4^J75I:)')=LMDY5I&4 NPWMRV3\QKZB^+_ ,1M
M/^$7PL\0_$_4[9IXM"TB>\%K']^X=$)2%!W=VVHH[LP% %+5_P!H#X+^'?"&
MM_$#Q+\1M-TO0_#NJ3:;K&K:K,;:W@NHF"21!Y0HD(<[/DW N"HRP($/P7_:
M1^ O[16G76J? [XM:'XGBL7"WJZ5?+));DYV^9']] <'!( .#C.*Y+X??LD>
M#G\ ^ =)^,FEVGB&]\*V-S>7MC?VZ36=QKMXRS7>HM&X*M*)GN?+)SM%S(1R
M01XXOP#\*^#O^"O_ (<\4? 'PY:Z%!'\+[R[^)MKHUNL%K,DLK0V7F(@""62
M5-^, L+7=V)(!]BR2)$C2RN%502S,< #U-87PU^)_P /_C%X/M_B!\+O%MEK
MFB7<LT=KJ>GR[X96BE:*3:W?#HRY''%>>?'&\OOCAXME_9A\+W<L6DQ6:7?Q
M-U.VD*F*P<$Q:4CCE9KO!WXY2V#GY6FA:O,O^")/_*-7X?\ _7QK'_IUNZ /
MJZBBB@ HHHH **** "BBB@ HHHH **** /D/X$:YHT__  6'^..G0:K;/.?
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M($DC<=&5E0$'W%3:_P###X:^*]0.K^*/AYH>I790(;J_TF&:0J.@W.I.!Z4
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MOCSX*_L8_#KX8_$X2)KNE>'8TU"WE?<ULSLTBVY/K$KK'QP-F!Q7=^'O@O\
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M8C?(V/4  %F*JK,-K6_A3\+O$NIR:UXC^&V@:A>3;?.N[[1X)97P HRS*2<
M #)Z "K.M> _ WB33[;2/$7@S2;^TLP!:6M[IT4L<  VC8K*0O''':@#Y3^%
MW[>O[$MAXCO?C+XW_:&T#Q!\0_$5O%86FB^'A-=O8VQDS!I%B/+!<M*P+RG;
MYTS;FV1K&D?M?A#/Q&_:N\3>,V&^P\ :)#X:TTGD#4+P17^H$=CB$:6@(Z$2
MCU%=G8_!KX0:7>PZEIOPI\-V]S;RK+;W$&A6Z/$ZG*LK!,J00"".016WIFBZ
M-HOV@:/I-M:?:[E[FZ^S0+'YTSXW2/M W.<#+'DXYH XR\_:._9RN?'.M_!K
M5_C!X677]'@7^V_#]_JL,<T4<D8?YXY"-RE'4G&0 PSC->+_ /!.'X,:+\.?
M&7QI\>_#&P6Q^'7C#QXESX%M((]EM+%%;A;FZMD'RBWDG9UB9?E9(%*Y383[
M_P"(?@Q\'O%WB)/&'BOX4>&M3U:,*(]4U#0K>:Y4+]T"5T+#';GBND5550J@
M  8 ':@#Y#_:7US1K7_@K?\ LX65SJUM',OASQ0&B>90RF2R81@@GC<58#U(
M.*]G_:"_XKOXB?#WX$Q?/#J6NGQ'K\?7_B7:2T<Z@^S7\FG*0>&4R#GD5VFJ
M?"'X3:YJ$VK:U\+_  [>7=P^^>YNM$@DDD;U9F0DGW-; T311K \0C2+47XM
M?LPOOLZ^<(=V[RM^-VS<,[<XSSB@#R[]K7]L?X0_LC>%;._\?^*]+MM8UR?[
M-X=TS4+X0+<2\9EE8!C%;QY#22;6('RJKNR(WG7[-O[77[%=KXE@\$^ OV@-
M/\>_$;Q_K:RZS=:-:2/<:E=>7\SA2-MO:6\"'8A?$<4.,O(27^B/$GP[^'_C
M&ZCO?%_@71]5FBCV13:EID4[(N<[074D#))Q[U#H?PL^&'AC4DUGPU\.-!TZ
M\C!$=W8Z/!#*@(P0&101D$@\]#0!\X_M-?MZ?LM7WQ!U']EKQ%^T;HOAFQM4
M\OQ_J_\ :#+/Y;9#:7:M&"5F< K-*,&%"54^:VZ'UW]FK]HW]G/XXZ;>>&/V
M9]>M=4T+PE;6EFUSI%DT5A;;D81VL3%5#,D<:DJH*JKISDX'4W/P5^#=[<R7
MEY\)?#,LTKEY99=!MV9V)R6)*9))YS6MX<\)>%?!UF^G>$?#.GZ5;R2^9)!I
MME' C/@#<50 $X &>O H T**** "BBB@ HHHH **** "BBB@ HHHH **** /
MD/\ X*%:YHVF_MD_LJP:AJMM _\ PGVH/LEF52%-O$@/)Z%F"@^IQ7T'^T1^
MT7\)_P!EOX87OQ8^,/B:+3M-M2(X(RZ^=>W# [+>%6(WR-CU  !9BJJS#:UO
MX4_"[Q+J<FM>(_AMH&H7DVWSKN^T>"65\ *,LRDG   R>@ JSK7@/P-XDT^V
MTCQ%X,TF_M+, 6EK>Z=%+'  -HV*RD+QQQVH ^4_A=^WK^Q+8>([WXR^-_VA
MM \0?$/Q%;Q6%IHOAX37;V-L9,P:18CRP7+2L"\IV^=,VYMD:QI'[7X0S\1O
MVKO$WC-AOL/ &B0^&M-)Y U"\$5_J!'8XA&EH".A$H]179V/P:^$&EWL.I:;
M\*?#=O<V\JRV]Q!H5NCQ.IRK*P3*D$ @CD$5MZ9HNC:+]H&CZ3;6GVNY>YNO
MLT"Q^=,^-TC[0-SG RQY..: .,O/VCOV<KGQSK?P:U?XP>%EU_1X%_MOP_?Z
MK#'-%')&'^>.0C<I1U)QD ,,XS7B_P#P3A^#&B_#GQE\:?'OPQL%L?AUXP\>
M)<^!;2"/9;2Q16X6YNK9!\HMY)V=8F7Y62!2N4V$^_\ B'X,?![Q=XB3QAXK
M^%'AK4]6C"B/5-0T*WFN5"_= E="PQVYXKI%554*H  & !VH ^0_VE]<T:U_
MX*W_ +.%E<ZM;1S+X<\4!HGF4,IDLF$8()XW%6 ]2#BO9_V@O^*[^(GP]^!,
M7SPZEKI\1Z_'U_XEVDM'.H/LU_)IRD'AE,@YY%=IJGPA^$VN:A-JVM?"_P .
MWEW</OGN;K1()))&]69D))]S6P-$T4:P/$(TBU%^+7[,+[[.OG"'=N\K?C=L
MW#.W.,\XH \N_:U_;'^$/[(WA6SO_'_BO2[;6-<G^S>'=,U"^$"W$O&996 8
MQ6\>0TDFUB!\JJ[LB-YU^S;^UU^Q7:^)8/!/@+]H#3_'OQ&\?ZVLNLW6C6DC
MW&I77E_,X4C;;VEO AV(7Q'%#C+R$E_HCQ)\._A_XQNH[WQ?X%T?59HH]D4V
MI:9%.R+G.T%U) R2<>]0Z'\+/AAX8U)-9\-?#C0=.O(P1'=V.CP0RH",$!D4
M$9!(//0T <O=?M'?LK>,+WQ/\-M9^,/@N[FT%I;/Q9HFJ:K;C[, ")$GBF(!
M0<AB05X(/((KRS_@EQ\%V^#?PE\;G1+"YL?"7B7XIZQK'@#3[J-D,.B.8HK9
M@C_,B.(BZ @$HR,>6->Z7WP7^#NJ>+/^$\U+X3^&;C7-ZO\ VU/H5N]WN4
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MH+J2!DDX]ZAT/X6?##PQJ2:SX:^'&@Z=>1@B.[L='@AE0$8(#(H(R"0>>AH
M^;[']B/]MGP;<:]/\/\ _@I9=:39ZUK=YJUS:M\(=)N9&FG<L=\\SM)(0NV-
M2Q^5(T10JJJCD?\ @A1X-^*>F_L9:!XSU[XS/J7A74DOX]"\%GP_;PKH\J:E
M<B647:_O;CS&#-M?A=V!P!7VX0",$9!ZBJFB:#H?AG3(]%\-Z+::?9PEO*M+
M&V6*),DL<*H &223QU)H MT444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%<G\;_B;:?"/X::EXTF*F>*+R]/B;_EK</PBX[C/S'_ &5-)M)7
M9OA<-6QF)A0I*\IM)+S>AUE%<G\$/B;:?%SX::;XTA*B>6+R]0B7_EE<)PZX
M[#/S#_985UE"::N@Q6&K8/$SH55:4&TUYK0***\]_:K\9_$'X9?L]>,OBG\,
M]5TRWU3PMX8U#6(8M6TU[F"Y-M;/-Y3*DL;*&V8W!N,YP<8IF!Z%17SA^R;\
M0?VO/VF?V;?"GQVN?B]X&T>X\3:6;IM.C^'=S.ENV]TV[CJBEQ\N>@ZUZ[\"
MKSXS7'@F:U^/2Z2_B&SUB]MVO-#L)+:UO+99F^SSI%)+*R;X=A92[8;<,G%
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M%</X7\+?'*P^.?BCQ5XI^*=A?^!+_3[./PMX5BT9([C3+A%Q<2/<#YI0[98
MY W  +M)>Y\-?C1X&^+.N^+=#\$ZBMX?!GB(Z)JUQ$P:/[8MM#/)&I!Y*>>J
M-Z.KKVH ZRBBB@ HKY:_:N_:5_:2^#W[8?P?^ W@'Q!X4.A?%&_O8;B75/#<
M\UUIRVHB=]CI=(LFY9,#*C:1DYSBOJ&U2XBM8X[N<2RK&!+*J;0[8Y(&3C)Y
MQDXH DHHJCXDMO$5YH5U:^$]7M+#4GB(L[R^L&NH87_O-$LD9<>P=?KVH O4
M5\]_\$P?CQ\5OVD?V2M-^*OQHUV#4=?NM=U2"XN+:RCMXPD5W)&B*D:@ *J@
M G+''))YKZ$H **** "BBB@ HHHH ***\P_;*^(?C'X4_LV^(_'W@'6/L&K6
M'V/[)=_9XY?+WWD$;?+(K*<H[#D'KD<X-=> P=7,<=2PE-I2J2C%7VO)I*]K
MNUWKHSCS#&TLMP%7%U4W&G&4W;>T4V[7:5[+2[7J>GT5^8G_  \-_;"_Z*__
M .6_I_\ \CT?\/#?VPO^BO\ _EOZ?_\ (]?IW_$'.)_^?U'_ ,"G_P#*S\N_
MXC1PM_SYK?\ @,/_ )8?IW17PG^QK^V5^TE\5OVDO#G@'Q]\1_M^DW_VS[7:
M?V/9Q>9LLYY%^:.%6&'13P1TP>,BONROA^)>&L=PMCHX3%RC*4HJ7NMM6;:Z
MJ+O>+Z'W7#'$^ XKP$L7A(RC&,G!\Z2=THOI*2M:2Z]] HK/\3V?B2_T2>U\
M(ZY:Z;J#+_H]Y>:>;J*,_P"U$)(RP]@Z_6ODW]C#_@HUXP\??M%>*_V/_P!J
MNPT32_&6F:Y?V_A'6=$LI[73_$4%I/+;S+$L\CL)5>"1AAB& =< QG=\\?1G
MV%17D?[3/CKXU>!/$?P_MOA?XGT&UM?%/CBVT/5(M8T&2Z>*&2WN9VEB9+B+
M#_N H# CYL]L'UBU2XCMHX[N<2RK&!)*J;0[8Y(&3C)[9XH DHHHH **KZK'
MJDVFSQ:)>06]XT3"VGNK9IHXWQ\K-&KH7 /50RD^HZU\^?\ !-?XZ?&3X]?#
M+QUK'QO\46NK:MX?^*VKZ#;3V.F1VD*6UJMNJHD:9.-S.V79V^;!8X% 'T71
M110 445R_P :-1\:Z+\+M<\0?#W6+"RU;3=+N+NTDU/3VN8&:.)W".BR1M@D
M#)# XH ZBBOE+]BCXT_MJ_M??LI:'^T3!\3_ (=:-J&MO>B#1YOA]>3V\9M[
MN:W"O*NJ*Q#>5DL%!7=T..>P_8?_ &R->_:6U#QY\*_B?X'M?#_CWX8Z\-*\
M56>F733V-P6:58[FW=P&".89?E;) "G)W8 ![[17$?![PM\<O#>L>+[GXQ_%
M*P\26>H^)Y[GP?;66C):-I.EL!Y=I(R_ZYEY^=LDXSGG:O;T %%<G\:/C1X'
M^!'@Q?&OCS45A@GU.TTZQA#@275W<S+###&"?F8LV3CHJLQX4UUE !1110 4
M5\U_M7?''X\?"K]KWX$_#[PEXTTVW\(^/O$=[9:WIBZ&K73K!;HX!N)'<;6+
MY^1(V&T?,V37TI0 4444 %%%?-G[?'QQ^._P/\=?!0?#/QIIUAH?C+XOZ)X:
M\163Z&LUU/!<3DR!9Y'941HT9,+$'!;<)!P  ?2=%%% !1110 4444 %%?+'
MQ9_:2_:7\'_\%%? /[)'AWQ)X3'AKQKX?O-6EO[OPS.][9K;I<N859;M4?=Y
M* .5&-Q.#C!^IHPZQJLCAF &Y@,9/KB@!:**YCXTWWC?2OA1X@UCX<ZU8:?K
M-EI%Q<6-UJ>G-=PHZ1LPS&LL9.<8SNP.I#=" =/17BG_  3K^,/Q!^/W[&'@
M;XP?%/6DU#7]<LKF;4;Q+6.!79;R>-<)$JJH"(J\#MDY.2?:Z "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX:2XMKB,,DB_8)^"#^?L1FO7/!'[//BS7/VAT_:I^.5UH[>(=.\--H?AC0=
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MOX]\%^)Y)[>UOIX1B&]@N((Y&AE R"K1.K;Y#P6R #S7]FV?Q5X8_:D^.?\
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MC#QE\6/V4M?TSXF>(]#O/&FN)'K)TO5Y1;Y:RBD\U+5F-NLREY"DAC)!;D,
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M]^$?CC\?QH-E;_#Z.[D\*>%_#U_->QM?W""-[ZXN)H("Q2-=L<2Q81F9B['
M'-^%_P!DWXN_LZ?M$>-OC%^S'K7AN[\/?$BZ74/%'@OQ5<7%JEKJ@+%KRUN(
M(IB/,WN7B:/DGAP H4 \9^"GBC]J:^\ _M2?L0?#7QQJ>K>(OAG.L/PTUW4M
M1+7RV=]'-)!9M<N<^;''%MCE9@0T@^951=NU^R!\:?V5OB[\>_"_AS2OA[JG
MP;^+'A2"[77OAQK%G):_VPKVCI(ZG(6\D0XD6:0><4$AP5)8>M:/^Q[XX\)?
M"KX@S^$?B99V_P 4/B+XBBU[5/%WV!UM;6[BFB>WABAW%C;P1Q[%5F+/EBQ&
M_ 77/V8_B/\ &SX[_#?XU_'73/"&E7?PSFN;FTN/"EW<7-QJ\\L/EA'::"(V
MMNK%I/)W3EFVC>!NW 'GG[.6A/;_ /!3_P#:$^'MYXEUW4-(_P"$.T$P6NJ^
M(+NZ:V6X@W2I%)+(SQ*6=R K +NPNT  <-_P3N\#_"WX+Z!^TM\9M(\$)]J^
M''QD\8+H4,5U,%AL[6W!6W";]I&S<H+ GGKP*]Z^$_[,_P 9?!'[;GC[]J77
M]9\-2Z3X[TJQT]]&M)[C[18):1*D<@D:,+,6VG<N$QOX)V_-4^ /[''Q0^#'
MQ8^*"7OQ'T'4?AM\1_&6I>)KS0FT20ZC)<7T92:U>8R>6MN,@_*A=MB\H"P(
M!XQH7[/?QX_;!_8T\/\ Q.T'1O"L'Q&\4:/::[I?Q5D^)6I0ZE87LA6;"I#I
MQ$$*9:'[*DAC11@$L-Y^TOA-9_$;3OA?X>T[XOZGI][XJM]%MHO$5[I+,;:X
MO5C432Q;D0[&<,P!5<9Z"OE/X,_L*_MW?LQW%Q\&/@%^U]H-M\)Y;Z672TU_
MPZ;S6=#AE<N\5MD>4[98X9VV;B7\L993]=^#O"NE>!O">F^#=#,QM-+L8K6W
M:YF,DKJBA0SN>7<XRS'EB23R: /D+]O;_E)3^R3_ -A?Q#_Z(M:/VL?!FH:K
M_P %2/@5X=T[XD>+-+LO%&@^)#JUMI_B2Y6,>18.,P1L[):NR.R-)"J/SN5E
M<!QV_P"TW^R;\>_C=^U5\,/VA?"_B/PEIUC\+;R[FL-+OY+F674Q<>6LGF.D
M8$/R1J  'VG));I6G\6OV:_CE\0_VQ/AG^U#I6H>%+6S^'FF7]L="N+VY>2^
M:^MC%.?.$($80GY/D;=LR0N[:H!YM^SWX6TC]F7_ (*D>-_@)\-]4U:V\$ZM
M\&X?%ESHE_K-S?)!J$>H);-,C7$DC@LC.6^8DEO0*!=_87T#PI^WU\!-6_:>
M^/%C+JNJ^-/$&I1Z,'NW5_"]A!.T%M;V#*1]DD41^89H]LCN^YF.!CT"P_9G
M^,EO_P % ;O]L.?5O#!T>[\"CPDV@B>X-PMH+M;D77F&+:9-R_ZO&W!V[^-U
M<C^S[^Q=^U#^Q[XK\0^ ?V<OBWX.?X5Z_K$NIV&E^*])NI]0\.2RXWQVPAD1
M)X\ 8$CK]T'&=Y< ^?\ ]EOXQ>,?@?\ \$B_"-GX*UEK75/%?Q;/A9-8>]-N
MUK'=ZO(DTWG!',+>4D@$H5C&7#@$J ?=?$W['?[1^F_'#P!\8?V>_#7@7X=O
MH.KJOC>*S^(&IWB>)=*9D\V&>)M.19I]H<K-(2^Y@2V0"*GPK_X)=:^O[!VL
M?L6?';XJ:9?Q7NIRZEHNJ^'](DCFT>\:<SK)YDDH%P!)V$</RNZYY##J?@-^
MSC^WM!<Z7X1_:N_:A\.^)/".@7$$T,.@:*\>I:X8&5X%O;B0*%C#HC.J!FEV
M[7<JS[@#R7]O'2[K_@G[^T+X<_;E^&<5O?\ A_6H[K0_%'@K5-2F^RVUQ+ Y
MCU.WB&_RU7;B;RT)";L+^]8CZM_96^"?@?X)_"73]/\ !VO_ -N2:K E_J/B
M3[09!JDLH,GFQY9@D'SGRHU.U$( SR3DZ5\"/&7C'Q_XY\6?M!6'AGQ%8Z[H
M[Z+X:TF&2;RK#2G4^?:2"1,%IW"O+,O+;(UVXB2L+]@?]G3X_?LI_#B3X*_$
MOX@Z)XD\-:?<2OX4EM3.+O3+=GW+9NTBXFB7+;7RK+]W!7:$ /?**** "BBB
M@#G?BU\1++X2_#?6/B1J.G2W<&CV9N);:!PKR $# )X'6OB[]IC_ (*)^"_C
MK\$M;^%6D_#K5+"XU7[-Y=W<W4;(GE7,4QR%Y.1&1]37W=>V-EJ5J]CJ-G%<
M02KMDAFC#HX]"#P:\(_;\\$^#-(_9)\6:CI/A'2[6XC^P>7/;V$:.N;^W!PR
MJ",@D?0U]SP/B\CHYMAZ>*PSG6E6AR34W%1]Z*5X[2L]?/8^#X[P>?5LHQ-7
M"8E4Z,:-3G@X*3E:,F[2WC>.GEN?FO1117]9G\AG=_LS_%S3O@5\;=$^*NK:
M1/?V^E?:?,M+9PKOYMM+",%N!@R _05]J?"3_@I3X'^+?Q(T?X;Z=\--6M)]
M8NQ;Q7,]W$R1D@G) Y/2OE/]@/3=.U?]K;PGIVK6$%U;R?;_ #(+B(.C8L+@
MC*L"#@@'ZBOTLLO G@C3;I+[3O!NE6\\3;HYH=.B1T/J"%R*_"_%+&</T,VC
M3QF%E4K.BN6:FXJ-Y32O%*SL[OSO8_>O"G!<15\HE5P>+C3HJL^:#IJ3E:,&
M[2;NKQLO*US5KXI\5_L5Z/\ MA_L\^*XM#U;^P?'OA;XS^+]1\ ^*X&,<NGW
MJ:W<L$+K\PB<JH;'*E5< E #]GZI)J<6GS2:+:03W8C)MX;JX:*-V[!G5'*C
MW"GZ5YC^RW\+OB_\(])\0Z%\3KWP[>QZQXNU;7K:ZT.:=3"U]>/<FW:.5/F"
M-(X$F_)  V=37X.?OQ\R?"#]M/6/VBV^&?P<^.6D_P!@?%_P!\8[*R\;:!.@
MC:XVZ?J""^A4<-&_&[;\JLPQ\CQEO6_CUX6\&ZI^UY97?Q3\02^/;.X\!M;^
M&?@E8Z4+ITNC<YFU>59)%MXUV 0K/<F-5)*JX;@[WQN_86\!_%']J;X=_M=Z
M"\.E^*_!NI?\3698OEUBQ\F1!')C_EK&7!1_[NY#D;"F-XM_90_:(T']M?5O
MVI_@-\6O"]E8^+_#5KH_BC2_%>B7%X]J+<C9-:"&6/<<#.QW5<LQ.[(V@'CO
M['M[^T;X[_8$^/OPS^$FOZG#XK\,_$GQ-X=\!P7^K^9<Z=!%';/'9I<LYPR^
M;*B/OPK,I#  $;'[('QI_96^+OQ[\+^'-*^'NJ?!OXL>%(+M=>^'&L6<EK_;
M"O:.DCJ<A;R1#B19I!YQ02'!4EAU'P>_84_:3^#'@/XL^"_#/[1>DEO&GCRY
M\4^%]2?0R+BUOIKFUE,]VR%4?:MJJB*)$0EY"3AE5.SUS]F/XC_&SX[_  W^
M-?QUTSPAI5W\,YKFYM+CPI=W%S<:O/+#Y81VF@B-K;JQ:3R=TY9MHW@;MP!P
M?[&8\*?M]0_$OX[_ !RTE=>ME\?W_ASPEHE](QM]#TRT2(1M @($5U(9&D>X
M7$F2H5E50*\V_86\(ZY8?\$^_C[X)\,_'EO!%U:?%GQ):K\0-8N2SV$<8M%D
MN992RD.R*P,FX,&?<#D"O6OAM^QC^TK^RU\;?&&N?LI_$_P</ 'C[6GUC4_#
M'C/3;J5]%OY/];+:?9W02J>/D=H_E5%S\N\\CIW_  2Y^,&I?LB_%?\ 9D\:
M_'K17_X6#XUN?$NFWEAH4JM:W374$RB9S*!)&XMT#1K$-C.Q#N !0!S'BG4?
M#?PS_:D_9GUO]GOP/KWAG2=?U>YT35_$%Q;_ &"/QC:-:(1+-:O(9YCNS();
MF-7)<,I;AAZY\.M7TW]L3]L+XO>#OBE$=1\(_"J?3=%T+PG-*WV.XNYX9);J
M^NH0=MQ)N41Q;\JBJQ4!F+5G?$S]CK]M+XSZU\)_B;X\^/O@2#Q5\.?$8O3;
M:=X4N/[->-H@DDI#3"6:=BH.T-!%@X"@C<;7C3]BW]I?X<?M4ZI^T_\ L=_&
MCPUITOC6QM;?X@^'O'.DS3V=]-;H(TO8Q:E#YNW)V Q@,SG=ARH ,G_@G[H4
M?@;]N']I_P"%^C:KJ4FA>'KSPK%H&G7VI37,>G02VM[<-!#YK-Y<0>5MJ#
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MC '/)X[GFOFK]D_]G7X=Z=^V;\:/VE_ TTLFEWNM?V7ID DS:QZFT4$FLW$
MZ9DGC@B=^OF6\Z]  /J"@#XP^/?_ "FT^!7_ &3G6O\ T3?57^+/PZE\3?\
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MO/\ X]7I]%2X1;NT>EALYSC!TE2P^)J0BND9R2^Y.QYA_P ,:?LV_P#1./\
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MM-:D\4>&%E7P]J%KXEO;=;!94V2B.**58QO7(;*G<#@YKTFB@ HHHH ****
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M&T' P*])HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DDCCEC:*5
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=** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064178287040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 28, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EVOLUS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-1385614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">520 Newport Center Dr., Suite 1200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Newport Beach<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">284-4555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.00001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EOLS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Smaller Reporting Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 671.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,586,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Portions of the registrant's definitive proxy statement (the &#8220;Proxy Statement&#8221;) for its 2024 Annual Meeting of Stockholders are incorporated by reference into Part III, Items 10, 11, 12, 13 and 14 of this Annual Report on Form 10-K. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant's fiscal year ended December 31, 2024.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity CIK</a></td>
<td class="text">0001570562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064179136336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Irvine, California<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064177044960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 86,952<span></span>
</td>
<td class="nump">$ 62,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">47,682<span></span>
</td>
<td class="nump">30,529<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">12,158<span></span>
</td>
<td class="nump">10,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">3,349<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">1,201<span></span>
</td>
<td class="nump">2,356<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">151,342<span></span>
</td>
<td class="nump">112,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,222<span></span>
</td>
<td class="nump">2,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">7,185<span></span>
</td>
<td class="nump">5,763<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">48,754<span></span>
</td>
<td class="nump">47,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">21,208<span></span>
</td>
<td class="nump">21,208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">858<span></span>
</td>
<td class="nump">409<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">232,569<span></span>
</td>
<td class="nump">188,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">9,236<span></span>
</td>
<td class="nump">4,271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">40,791<span></span>
</td>
<td class="nump">33,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,718<span></span>
</td>
<td class="nump">1,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">11,215<span></span>
</td>
<td class="nump">8,830<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">62,960<span></span>
</td>
<td class="nump">48,291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">6,755<span></span>
</td>
<td class="nump">4,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">33,550<span></span>
</td>
<td class="nump">36,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecuredLongTermDebt', window );">Term loan, net of discount and issuance costs</a></td>
<td class="nump">121,506<span></span>
</td>
<td class="nump">120,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementContingentMilestoneLiabilityNoncurrent', window );">Contingent milestone payment</a></td>
<td class="nump">2,270<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">227,047<span></span>
</td>
<td class="nump">209,687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, $0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at December&#160;31, 2024 and 2023, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, $0.00001 par value; 100,000,000 shares authorized; 63,497,548 and 57,820,621 shares issued and outstanding at December&#160;31, 2024 and 2023, respectively</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">615,825<span></span>
</td>
<td class="nump">538,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(905)<span></span>
</td>
<td class="num">(427)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(609,399)<span></span>
</td>
<td class="num">(558,979)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit)</a></td>
<td class="nump">5,522<span></span>
</td>
<td class="num">(20,689)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity (deficit)</a></td>
<td class="nump">$ 232,569<span></span>
</td>
<td class="nump">$ 188,998<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Royalty Obligation Payable to Related Party, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LicenseSupplyAndDistributionAgreementContingentMilestoneLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License, Supply And Distribution Agreement, Contingent Milestone Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LicenseSupplyAndDistributionAgreementContingentMilestoneLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064180986016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="nump">63,497,548<span></span>
</td>
<td class="nump">57,820,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (in shares)</a></td>
<td class="nump">63,497,548<span></span>
</td>
<td class="nump">57,820,621<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064176763888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 266,274<span></span>
</td>
<td class="nump">$ 202,085<span></span>
</td>
<td class="nump">$ 148,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">$ 83,970<span></span>
</td>
<td class="nump">$ 64,514<span></span>
</td>
<td class="nump">$ 58,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfCostGoodOrServiceExtensibleList', window );">Cost, Product and Service [Extensible Enumeration]</a></td>
<td class="text">Product revenue, net<span></span>
</td>
<td class="text">Product revenue, net<span></span>
</td>
<td class="text">Product revenue, net<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">$ 182,304<span></span>
</td>
<td class="nump">$ 137,571<span></span>
</td>
<td class="nump">$ 89,774<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">198,025<span></span>
</td>
<td class="nump">164,944<span></span>
</td>
<td class="nump">141,840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">9,172<span></span>
</td>
<td class="nump">6,556<span></span>
</td>
<td class="nump">4,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_ResearchAndDevelopmentInProcess1', window );">In-process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,869<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Revaluation of contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">7,176<span></span>
</td>
<td class="nump">4,257<span></span>
</td>
<td class="nump">5,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,342<span></span>
</td>
<td class="nump">2,178<span></span>
</td>
<td class="nump">767<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">216,715<span></span>
</td>
<td class="nump">186,804<span></span>
</td>
<td class="nump">155,104<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(34,411)<span></span>
</td>
<td class="num">(49,233)<span></span>
</td>
<td class="num">(65,330)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income</a></td>
<td class="nump">3,263<span></span>
</td>
<td class="nump">860<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(18,735)<span></span>
</td>
<td class="num">(13,832)<span></span>
</td>
<td class="num">(9,097)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">127<span></span>
</td>
<td class="nump">696<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes:</a></td>
<td class="num">(49,756)<span></span>
</td>
<td class="num">(61,509)<span></span>
</td>
<td class="num">(74,317)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">664<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(50,420)<span></span>
</td>
<td class="num">(61,685)<span></span>
</td>
<td class="num">(74,412)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss, net of tax</a></td>
<td class="num">(478)<span></span>
</td>
<td class="num">(90)<span></span>
</td>
<td class="num">(337)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (50,898)<span></span>
</td>
<td class="num">$ (61,775)<span></span>
</td>
<td class="num">$ (74,749)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.81)<span></span>
</td>
<td class="num">$ (1.08)<span></span>
</td>
<td class="num">$ (1.33)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.81)<span></span>
</td>
<td class="num">$ (1.08)<span></span>
</td>
<td class="num">$ (1.33)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding used to compute basic net loss per share (in shares)</a></td>
<td class="nump">62,016,853<span></span>
</td>
<td class="nump">56,918,721<span></span>
</td>
<td class="nump">56,065,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding used to compute diluted net loss per share (in shares)</a></td>
<td class="nump">62,016,853<span></span>
</td>
<td class="nump">56,918,721<span></span>
</td>
<td class="nump">56,065,297<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 264,306<span></span>
</td>
<td class="nump">$ 199,721<span></span>
</td>
<td class="nump">$ 146,592<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 1,968<span></span>
</td>
<td class="nump">$ 2,364<span></span>
</td>
<td class="nump">$ 2,024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_ResearchAndDevelopmentInProcess1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development In Process 1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_ResearchAndDevelopmentInProcess1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfCostGoodOrServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of cost from product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfCostGoodOrServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064177706800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders&#8217; Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,576,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 81,876<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 504,757<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (422,882)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_StockIssuedDuringPeriodSharesIncentiveEquityPlan', window );">Issuance of common stock in connection with the incentive equity plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">683,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_StockIssuedDuringPeriodValueIncentiveEquityPlan', window );">Issuance of common stock in connection with the incentive equity plan</a></td>
<td class="nump">539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">10,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(74,412)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(337)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(337)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,260,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">18,499<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">516,129<span></span>
</td>
<td class="num">(337)<span></span>
</td>
<td class="num">(497,294)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_StockIssuedDuringPeriodSharesIncentiveEquityPlan', window );">Issuance of common stock in connection with the incentive equity plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">950,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_StockIssuedDuringPeriodValueIncentiveEquityPlan', window );">Issuance of common stock in connection with the incentive equity plan</a></td>
<td class="nump">224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement', window );">Issuance of common stock in connection with Symatese Europe Agreement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">610,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_StockIssuedDuringPeriodValueIssuedForLicenseSupplyAndDistributionAgreement', window );">Issuance of common stock in connection with Symatese Europe Agreement</a></td>
<td class="nump">5,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">16,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(61,685)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61,685)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">$ (90)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">57,820,621<span></span>
</td>
<td class="nump">57,820,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="num">$ (20,689)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">538,716<span></span>
</td>
<td class="num">(427)<span></span>
</td>
<td class="num">(558,979)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_StockIssuedDuringPeriodSharesIncentiveEquityPlan', window );">Issuance of common stock in connection with the incentive equity plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,804,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_StockIssuedDuringPeriodValueIncentiveEquityPlan', window );">Issuance of common stock in connection with the incentive equity plan</a></td>
<td class="nump">3,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon follow-on offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,872,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon follow-on offering, net of issuance costs</a></td>
<td class="nump">50,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">22,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(50,420)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,420)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">$ (478)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(478)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">63,497,548<span></span>
</td>
<td class="nump">63,497,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="nump">$ 5,522<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 615,825<span></span>
</td>
<td class="num">$ (905)<span></span>
</td>
<td class="num">$ (609,399)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_StockIssuedDuringPeriodSharesIncentiveEquityPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Incentive Equity Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_StockIssuedDuringPeriodSharesIncentiveEquityPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Issued for License, Supply and Distribution Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_StockIssuedDuringPeriodValueIncentiveEquityPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Incentive Equity Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_StockIssuedDuringPeriodValueIncentiveEquityPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_StockIssuedDuringPeriodValueIssuedForLicenseSupplyAndDistributionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Issued for License, Supply and Distribution Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_StockIssuedDuringPeriodValueIssuedForLicenseSupplyAndDistributionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064178030112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (50,420)<span></span>
</td>
<td class="num">$ (61,685)<span></span>
</td>
<td class="num">$ (74,412)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">5,297<span></span>
</td>
<td class="nump">5,133<span></span>
</td>
<td class="nump">3,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">22,254<span></span>
</td>
<td class="nump">16,458<span></span>
</td>
<td class="nump">10,833<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for bad debts</a></td>
<td class="nump">2,449<span></span>
</td>
<td class="nump">1,440<span></span>
</td>
<td class="nump">1,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating lease right-of-use assets</a></td>
<td class="nump">723<span></span>
</td>
<td class="nump">734<span></span>
</td>
<td class="nump">775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance costs</a></td>
<td class="nump">1,147<span></span>
</td>
<td class="nump">1,116<span></span>
</td>
<td class="nump">1,086<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(21)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Revaluation of contingent royalty obligation to Evolus Founders</a></td>
<td class="nump">7,176<span></span>
</td>
<td class="nump">4,257<span></span>
</td>
<td class="nump">5,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_NonCashInResearchAndDevelopmentInProcessExpenses', window );">Non-cash in-process research and development expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,429<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">3,252<span></span>
</td>
<td class="nump">4,193<span></span>
</td>
<td class="num">(10,688)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(19,602)<span></span>
</td>
<td class="num">(9,521)<span></span>
</td>
<td class="num">(9,389)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">2,351<span></span>
</td>
<td class="num">(1,798)<span></span>
</td>
<td class="nump">1,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other assets</a></td>
<td class="nump">706<span></span>
</td>
<td class="num">(864)<span></span>
</td>
<td class="nump">4,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">391<span></span>
</td>
<td class="num">(1,017)<span></span>
</td>
<td class="nump">968<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">7,014<span></span>
</td>
<td class="nump">9,019<span></span>
</td>
<td class="num">(5,199)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Accrued litigation settlement</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="num">(15,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(716)<span></span>
</td>
<td class="num">(907)<span></span>
</td>
<td class="num">(977)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(17,999)<span></span>
</td>
<td class="num">(34,008)<span></span>
</td>
<td class="num">(84,912)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,472)<span></span>
</td>
<td class="num">(473)<span></span>
</td>
<td class="num">(1,618)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForSoftware', window );">Additions to capitalized software</a></td>
<td class="num">(3,351)<span></span>
</td>
<td class="num">(1,154)<span></span>
</td>
<td class="num">(1,321)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(4,823)<span></span>
</td>
<td class="num">(1,627)<span></span>
</td>
<td class="num">(2,939)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_PaymentsOfContingentRoyaltyObligation', window );">Payment of contingent royalty obligation to Evolus Founders</a></td>
<td class="num">(7,441)<span></span>
</td>
<td class="num">(5,537)<span></span>
</td>
<td class="num">(4,185)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt, net of discounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments for debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(46)<span></span>
</td>
<td class="num">(500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from follow-on offering, net of underwriting fees</a></td>
<td class="nump">51,211<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments for offering costs</a></td>
<td class="num">(248)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from exercise of stock options</a></td>
<td class="nump">4,882<span></span>
</td>
<td class="nump">231<span></span>
</td>
<td class="nump">539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax withholding paid on behalf of employees for net share settlement</a></td>
<td class="num">(990)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">47,414<span></span>
</td>
<td class="nump">44,641<span></span>
</td>
<td class="num">(4,146)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rates on cash and cash equivalents</a></td>
<td class="num">(478)<span></span>
</td>
<td class="num">(90)<span></span>
</td>
<td class="num">(337)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Change in cash and cash equivalents</a></td>
<td class="nump">24,114<span></span>
</td>
<td class="nump">8,916<span></span>
</td>
<td class="num">(92,334)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">62,838<span></span>
</td>
<td class="nump">53,922<span></span>
</td>
<td class="nump">146,256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">86,952<span></span>
</td>
<td class="nump">62,838<span></span>
</td>
<td class="nump">53,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">17,545<span></span>
</td>
<td class="nump">12,708<span></span>
</td>
<td class="nump">7,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing and financing information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">3,002<span></span>
</td>
<td class="nump">4,550<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Issuance of common stock in connection with Symatese Europe Agreement</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,476<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_NonCashInResearchAndDevelopmentInProcessExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash In Research And Development In Process Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_NonCashInResearchAndDevelopmentInProcessExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_PaymentsOfContingentRoyaltyObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments Of Contingent Royalty Obligation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_PaymentsOfContingentRoyaltyObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064177910272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of Business</a></td>
<td class="text">Description of Business <div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolus, Inc., (&#8220;Evolus&#8221; or the &#8220;Company&#8221;) is a global performance beauty company focused on delivering products in the cash-pay aesthetic market. The Company received the approval of its first product Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (prabotulinumtoxinA-xvfs) from the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) in February 2019. The product was also approved by Health Canada in August 2018, the European Commission (&#8220;EC&#8221;) in September 2019, the Australian Therapeutics Good Administration (&#8220;TGA&#8221;) in January 2023, and Swissmedic in November 2023. Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a proprietary 900 kDa purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as &#8220;frown lines,&#8221; in adults. The Company commercially launched Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States in May 2019, in Canada through a distribution partner in October 2019, and began its launch in Europe in September 2022. In 2023, the Company entered into an agreement to be the exclusive distributor of Evolysse&#8482;, a collection of hyaluronic acid gels currently in late-stage development in the U.S. and Europe. Regulatory approval has been received for the four Evolysse&#8482; hyaluronic acid gel products in Europe under the brand name Estyme</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company anticipates launching all four approved Evolysse&#8482; products in Europe in the second half of 2025. In February 2025, the Company received approval from the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) for Evolysse&#8482; Form and Evolysse&#8482; Smooth injectable hyaluronic acid gels for wrinkles and folds, such as nasolabial folds. The Company anticipates launching Evolysse&#8482; Form and Evolysse&#8482; Smooth in the United States in the second quarter of 2025. The Company anticipates two additional Evolysse&#8482; products to be approved and launched in the United States in 2026 and 2027. The Company currently generates all of its net revenues from Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company is headquartered in Newport Beach, California.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Financial Condition</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared on a basis that assumes that the Company will continue as a going concern. This basis of accounting contemplates the recovery of the Company&#8217;s assets and the satisfaction of the Company&#8217;s liabilities and commitments in the normal course of business and does not include any adjustments to reflect the possible future effects of the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, the Company has incurred recurring net operating losses and negative cash flows from operating activities; however, management anticipates achieving operating income and positive cash flows based on current projections for at least the next twelve months. The Company recorded loss from operations of $34,411 and a total net loss of $50,420 for the twelve months ended December 31, 2024. The Company used cash of $17,999 from operations during the twelve months ended December 31, 2024. As of December&#160;31, 2024, the Company had $86,952 in cash and cash equivalents and an accumulated deficit of $609,399. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, the Company completed a follow-on offering and issued 3,554,000 shares of its common stock, at a price to the public of $14.07 per share. The Company received net proceeds of $46,794 from the offering, after deducting underwriting discounts and commissions and other offering expenses. In addition, the Company granted the underwriters an option, exercisable for 30 days, to purchase up to 533,100 additional shares of common stock (the &#8220;option shares&#8221;) at the purchase price. In April 2024, the underwriters exercised their option to purchase 318,100 of the allotted option shares. The net proceeds to the Company from the sale of the option shares, after deducting the underwriters&#8217; discounts and commissions, was $4,169.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 8, 2023, the Company entered into an &#8220;at-the-market&#8221; sales agreement (the &#8220;ATM Sales Agreement&#8221;) and filed a shelf registration statement on Form S-3 and corresponding prospectus with the Securities and Exchange Commission (&#8220;SEC&#8221;) to permit sales under the ATM Sales Agreement, which registration statement became effective on June 8, 2023. The Company has not sold any shares under the ATM Sales Agreement. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stockholders&#8217; Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that its current capital resources, which consist of cash and cash equivalents, will be sufficient to fund its operations through at least the next twelve months from the date the accompanying consolidated financial statements are issued based on its expected cash needs. The Company may need to raise additional capital to fund future operations or execute corporate development activities through entering into licensing or collaboration agreements with partners, grants or other sources of financing. Sufficient funds may not be available to the Company at all or on attractive terms when needed from equity or debt financings. If the Company is unable to obtain additional funding from these or other sources when needed, or to the extent needed, it may be necessary to reduce its scope of operations to reduce the current rate of spending through actions such as reductions in staff and delaying, scaling back, or suspending certain research and development, sales and marketing programs and other operational goals.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064271605664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Summary of Significant Accounting Policies <div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s consolidated financial statements include the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries and have been prepared in conformity with GAAP. All intercompany transactions have been eliminated.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is required to make certain estimates and assumptions in order to prepare consolidated financial statements in conformity with GAAP. Such estimates and assumptions affect the reported consolidated financial statements. These estimates include, but are not limited to net revenues, allowance for doubtful accounts, fair value measurements and stock-based compensation, among others. Management bases estimates on historical experience and on assumptions that management believes are reasonable. The Company&#8217;s actual results could differ materially from those estimates.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to an agreement (the &#8220;Daewoong Agreement&#8221;) with Daewoong Pharmaceutical Co. Ltd. (&#8220;Daewoong&#8221;), pursuant to which the Company received an exclusive distribution license to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from Daewoong for aesthetic indications in the United States, European Union, United Kingdom, members of the European Economic Area, Switzerland, Canada, Australia, New Zealand, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;is manufactured by Daewoong in a facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in a territory covered by the Daewoong Agreement. The Company relies on Daewoong, its exclusive and sole supplier, to manufacture Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company&#8217;s commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9. Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company commercially launched Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;starting in the United States in May 2019 and in Canada through its distribution partner in October 2019. The Company also began commercially launching Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Europe in 2022 and Australia in 2024 and, as such, has a limited history of sales in those markets. If any previously granted approval to market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is retracted or the Company is denied approval or approval is delayed by regulators in any other jurisdictions, it may have a material adverse impact on the Company&#8217;s business and its consolidated financial statements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to risks common to companies in the pharmaceutical industry including, but not limited to, dependency on the commercial success of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Evolysse&#8482; the Company&#8217;s approved products, significant competition within the medical aesthetics industry, its ability to maintain regulatory approval of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, third party litigation and challenges to its intellectual property, uncertainty of broad adoption of its product by aesthetic practitioners and patients, its ability to in-license, acquire or develop additional product candidates and to obtain the necessary approvals for those product candidates, and the need to scale manufacturing capabilities over time.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any disruption and volatility in the global capital markets, including caused by other events, such as public health crises, increased inflation and rising interest rates, increased tariffs, and geopolitical conflicts, including the military conflict between Russia and Ukraine and the ongoing conflict in the Middle East, may increase the Company&#8217;s cost of capital and adversely affect its ability to access financing when and on terms that the Company desires. Any of these events could have a material adverse effect on the Company&#8217;s business, financial condition, results of operations and cash flows.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that it operates in a single operating and reportable segment. The Company&#8217;s chief operating decision maker is its Chief Executive Officer who manages operations and reviews the financial information as a single operating segment for the purposes of allocating resources and evaluating its financial performance.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and accounts receivable. Substantially all of the Company&#8217;s cash is held by financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. To date, the Company has not experienced any losses associated with this credit risk and continues to believe that this exposure is not significant. The Company invests, or plans to soon invest, its excess cash, in line with its investment policy, primarily in money market funds and debt instruments of U.S. government agencies. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts receivable is derived from customers located principally in the United States and Europe. Concentrations of credit risk with respect to trade receivables are limited due to the Company&#8217;s credit evaluation process. The Company does not typically require collateral from its customers. The Company continuously monitors customer payments and maintains an allowance for credit losses based on its assessment of various factors including historical experience, age of the receivable balances, and other current economic conditions or other factors that may affect customers&#8217; ability to pay.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash and highly liquid investments with remaining maturities at purchase of three months or less that can be liquidated without prior notice or penalty. Cash and cash equivalents may include deposits, money market funds and debt securities. Amounts receivable from credit card issuers are typically converted to cash within <span style="-sec-ix-hidden:f-398">two</span> to four days of the original sales transaction and are considered to be cash equivalents.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories and cost of goods sold</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of finished goods held for sale and distribution. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost is determined using the first-in, first-out method. Inventory is measured at the lower of cost and net realizable value based on a number of factors including, but not limited to, damage, expiration, or changes in price level.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2024, cost of goods sold, consisted of the inventory cost, amortization of distribution right intangible assets related to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and certain royalties on the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> payable to Medytox and Allergan pursuant to the Medytox Settlement Agreements (as such term is defined in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11. Medytox Settlement Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The prior years Consolidated Statements of Operations and Comprehensive Loss has been adjusted to conform to this presentation.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in an orderly transaction between market participants in a principal market on the measurement date.</span></div><div style="margin-bottom:9pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy defines a three-tiered valuation hierarchy for disclosure of fair value measurement is classified and disclosed by the Company in one of the three categories as follows:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1&#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2&#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets; quoted prices in markets that are not active; or other inputs that are observable, either directly or indirectly, or can be corroborated by observable market data for substantially the full term of the asset or liability; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3&#8212;Prices or valuation techniques that require inputs that are unobservable that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of approximately <span style="-sec-ix-hidden:f-403">three</span> to five years. Leasehold improvements are amortized over the shorter of the estimated useful lives of the improvements or the term of the related lease. </span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. The Company assesses goodwill for impairment annually and whenever events or changes in circumstances indicate that the carrying amount of goodwill may not be recoverable. The Company performs an annual qualitative assessment of its goodwill in the fourth quarter of each calendar year to determine if any events or circumstances exist, such as an adverse change in business climate or a decline in the overall industry demand, that would indicate that it would more likely than not reduce the fair value of a reporting unit below its carrying amount, including goodwill. If events or circumstances do not indicate that the fair value of a reporting unit is below its carrying amount, then goodwill is not considered to be impaired and no further testing is required. For the purpose of impairment testing, the Company has determined that it has one reporting unit. There was no impairment of goodwill for any of the periods presented.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-process Research and Development</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets acquired that are used for research and development, do not yet have regulatory approval for commercialization, and have no future alternative use are expensed as in-process research and development.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Company entered into a License and Research Collaboration Agreement (the &#8220;Collaboration Agreement&#8221;) with a 3D printing company with biomaterial capabilities (the &#8220;Licensor&#8221;). Under the terms of the Collaboration Agreement, the Company was granted a license to the Licensor&#8217;s technology to develop and commercialize any aesthetic product or non-therapeutic product that is created through the use or practice of the Licensor&#8217;s patents. The Company paid $2,000 upon the signing of the Collaboration Agreement and has research funding, ongoing milestone and royalty payment obligations depending on the development plans, the success of such development and approval and commercialization of products. The upfront payment of $2,000 was recorded as in-process research and development expense.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Symatese U.S. Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 9, 2023, the Company and Symatese Aesthetics S.A.S (&#8220;Symatese&#8221;), entered into a License, Supply and Distribution Agreement (the &#8220;Symatese U.S. Agreement&#8221;), pursuant to which Symatese granted to the Company an exclusive right to commercialize and distribute its five hyaluronic acid gel product candidates, including the products referred to as: (i) Form; (ii) Smooth; (iii) Sculpt; (iv) Lips; and (v) Eye (collectively, the &#8220;Products&#8221;) in the United States for use in the aesthetics and dermatological field of use. The Company also has the right of first negotiation to obtain a license from Symatese to commercialize and distribute any new products developed using the same technology as the Evolysse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> collection of hyaluronic acid gels.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As consideration for the rights granted under the Symatese U.S. Agreement, the Company is required to make up to &#8364;16,200 in milestone payments to Symatese, including an initial payment of &#8364;4,100 within 30 days of execution of the Symatese U.S. Agreement, and additional annual payments of &#8364;1,600 in June 2025, &#8364;4,100 in June 2026, &#8364;3,200 in June 2027, and &#8364;3,200 in </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 2028, in each case subject to three of the Products gaining approval prior to that date. In June 2023, the Company paid $4,441 as an upfront payment upon the signing of the Symatese U.S. Agreement and has developmental costs, ongoing milestone and royalty payment obligations. The Symatese U.S. Agreement is also subject to minimum purchase requirements and failure to meet such requirements may result in a reduction or termination of the Company&#8217;s exclusive rights, subject to certain exceptions. Additionally, the Company agreed to a specified cost-sharing agreement with Symatese related to the registration of the Lips and Eye Products with the FDA.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial term of the Symatese U.S. Agreement is fifteen (15) years from the first FDA approval of a Product, with automatic renewals for successive five (5)-year terms subject to the terms of the Symatese U.S. Agreement. The upfront payment of $4,441 was recorded as in-process research and development expense in the twelve months ended December&#160;31, 2023.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Symatese Europe Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 20, 2023, the Company entered into a License, Supply and Distribution Agreement (the &#8220;Symatese Europe Agreement&#8221;), pursuant to which Symatese granted to us an exclusive right to commercialize and distribute four hyaluronic acid gel product candidates, which are referred to as: (i) Form; (ii) Smooth; (iii) Sculpt and (iv) Lips in 50 countries in Europe for use in the aesthetics and dermatological fields. The initial agreement is for a term of fifteen (15) years, with automatic year renewal provisions.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In exchange for the rights granted under the Symatese Europe Agreement, the Company issued 610,000 shares of common stock and is required to pay two milestone payments: (i) &#8364;1,200 on the second anniversary of certain regulatory approvals, and (ii) &#8364;1,900 on the earlier of the third anniversary of certain regulatory approvals or following a year in which the Company achieves &#8364;25,000 in revenue in Europe; provided that the payment shall occur no later than December 2029. The Symatese Europe Agreement is also subject to minimum purchase requirements and failure to meet such requirements may result in a reduction or termination of the Company&#8217;s exclusive rights, subject to certain exceptions. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon signing of the Symatese Europe Agreement and issuance of 610,000 shares, the Company recorded $4,429 in in-process research and development expense and $1,476 in intangible assets in the twelve months ended December&#160;31, 2023 for the stock issuance of 610,000 shares. The intangible assets of $1,476 represents the value of the nasolabial fold product in Europe which was already approved at the time of signing the Symatese Europe Agreement and is amortized over its estimated useful life of 15 years. The remaining value recorded in in-process research and development expense relates to the distribution rights for the three remaining products that did not yet have regulatory approval as of the execution date.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The distribution right intangible asset related to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is amortized over the period the asset is expected to contribute to the future cash flows of the Company. The Company determined the pattern of this intangible asset&#8217;s future cash flows could not be readily determined with a high level of precision. As a result, the distribution right intangible asset is being amortized on a straight-line basis over the estimated useful life of&#160;20 years.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of the Symatese Europe Agreement represents the license and distribution right to Evolysse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Europe. The definite-lived distribution right intangible asset related to the Evolysse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> nasolabial fold product approved in Europe is amortized on a straight-line basis over the estimated useful life of 15 years.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Symatese Europe Agreement, the Company is required to pay two milestone payments: (i) &#8364;1,200 on the second anniversary of certain regulatory approvals, and (ii) &#8364;1,900 on the earlier of the third anniversary of certain regulatory approvals or following a year in which the Company achieves &#8364;25,000 in revenue in Europe, provided that the payment shall occur no later than December 2029.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2024, the Company received European Union Medical Device Regulation (&#8220;MDR&#8221;) approval for the remaining three hyaluronic acid gel products. As a result, the two milestone payments have been triggered. The first milestone payment is payable in October 2026, the two-year anniversary of the approval. For the second milestone payment, the Company determined that it is probable the payment will be made no later than December 2029. As such, the Company recorded $1,035 and $1,200 in long-term liabilities for the first and second milestone payments, and $1,035 and $1,200 in intangible assets for the first and second milestone payments as of December&#160;31, 2024. These amounts reflect the </span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">application of a discount to account for the time value of money, which adjusts the present value of the liabilities and intangible assets based on the timing of future payments. The definite-lived distribution right intangible asset related to the Evolysse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products approved in Europe is amortized on a straight-line basis over the remaining estimated useful life of 14 years and 2 months. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain internal-use software costs associated with the development of its mobile and web-based customer platforms. These costs include personnel expenses and external costs that are directly associated with the software projects. These costs are included as intangible assets in the accompanying consolidated balance sheets. The capitalized internal-use software costs are amortized on a straight-line basis over the estimated useful life of&#160;two years&#160;upon being placed in service.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews long-term and identifiable definite-lived intangible assets or asset groups for impairment when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset or an asset group, further impairment analysis is performed. An impairment loss is measured as the amount by which the carrying amount of the asset or asset groups exceeds the fair value for assets to be held and used or fair value less cost to sell for assets to be disposed of. The Company also reviews the useful lives of its assets periodically to determine whether events and circumstances warrant a revision to the remaining useful life. Changes in the useful life are adjusted prospectively by revising the remaining period over which the asset is amortized. There was no material impairment of long-lived assets for any periods presented.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, upon lease commencement, the Company records a lease liability which represents the Company&#8217;s obligation to make lease payments arising from the lease, and a corresponding right-of-use (&#8220;ROU&#8221;) asset which represents the Company&#8217;s right to use an underlying asset during the lease term. Operating lease assets and liabilities are included in ROU assets, current portion of operating lease liabilities and noncurrent operating lease liabilities in the accompanying consolidated balance sheets.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease ROU assets and lease liabilities are initially recognized based on the present value of the future minimum lease payments over the lease term at commencement date calculated using the Company&#8217;s incremental borrowing rate applicable to the underlying asset unless the implicit rate is readily determinable. The incremental borrowing rate, the ROU asset and the lease liability are reevaluated upon a lease modification. Operating lease ROU assets also include any lease payments made at or before lease commencement and exclude any lease incentives received, if any. The Company determines the lease term as the noncancellable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. The Company&#8217;s leases do not contain any residual value guarantees. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets. For operating leases, the Company recognized rent expense on a straight-line basis over the lease term. There were no significant finance leases as of&#160;December&#160;31, 2024.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Royalty Obligation Payable to Evolus Founders</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was acquired by Strathspey Crown Holdings Group, LLC (&#8220;SCH&#8221;) in 2013 and subsequently by its subsidiary, Alphaeon Corporation (&#8220;Alphaeon&#8221;), by means of a stock purchase agreement (&#8220;Stock Purchase Agreement&#8221;) pursuant to which Alphaeon assumed certain payment obligations related to the acquisition. On December 14, 2017, the Stock Purchase Agreement was amended (&#8220;Amended Stock Purchase Agreement&#8221;), and, as a result, effective upon the closing of the Company&#8217;s initial public offering in February 2018, the Company assumed all of Alphaeon&#8217;s payment obligations under the Amended Stock Purchase Agreement.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment obligations to the Evolus Founders consist of quarterly royalty payments of a low single digit percentage of net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The obligations terminate in the second quarter of 2029, which is the&#160;10-year anniversary of the first commercial sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;in the United States. Under the Amended Stock Purchase Agreement, the Company recorded the fair value of all revised payment obligations owed to the Evolus Founders. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value of the contingent royalty obligation payable at each reporting period end based on Level 3 inputs using a discounted cash flows method. Changes in the fair value of the contingent royalty obligation payable are determined at each reporting period end and recorded in operating expenses in the accompanying consolidated statements of operations and comprehensive loss and as a liability in the accompanying consolidated balance sheets.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Term Debt</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt represents the debt balance with Pharmakon (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7. Term Loans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), net of discount and issuance costs. Debt issuance costs represent legal, lender and consulting costs or fees associated with debt financing. Debt&#160;discounts and issuance costs are amortized into interest expense over the term of the debt.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements of foreign subsidiaries are measured using the local currency as the functional currency. Assets and liabilities are translated into U.S. dollars at current exchange rates as of balance sheet date, and income and expense items are translated into U.S. dollars using the average rates of exchange prevailing during the period. Gains and losses arising from translation are recorded in other comprehensive loss as a separate component of stockholders&#8217; equity. Foreign currency gains or losses on transactions denominated in a currency other than the Company&#8217;s functional currency are recorded in other expenses, net in the accompanying consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when control of the promised goods or services is transferred to its customers, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for the goods or services. In order to achieve that core principle, a five-step approach is applied: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue allocated to each performance obligation when the Company satisfies the performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account for revenue recognition.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates product revenue from the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States, Europe, and Australia, and service revenue from the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through a distribution partner in Canada.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For product revenue, the Company recognizes revenue when control of the promised goods under a contract is transferred to a customer, in an amount that reflects the consideration the Company expects to receive in exchange for those goods as specified in the customer contract. The transfer of control occurs upon receipt of the goods by the customer since that is when the customer has obtained control of the goods&#8217; economic benefits. The Company does not provide any service-type warranties and does not accept product returns except under limited circumstances such as damages in transit or ineffective product. The Company also excludes any amounts related to taxes assessed by governmental authorities from revenue measurement. Shipping and handling costs associated with outbound product freight are accounted for as fulfillment costs </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and are included in selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For service revenue, the Company evaluated the arrangement with the distribution partner in Canada and determined that it acts as an agent in the distribution of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in Canada as it does not control the product before control is transferred to a customer. The indicators of which party exercises control include primary responsibility over performance obligations, inventory risk before the good or service is transferred and discretion in establishing the price. Accordingly, the Company records the sale as service revenue on a net basis. Revenue from services is recognized in the period the service is performed for the amount of consideration expected to be received.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s disaggregation of revenue is consistent with its operating segment as disclosed above.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gross-to-Net Revenue Adjustments</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides customers with discounts, such as trade and volume discounts and prompt pay discounts, that are directly reflected in the invoice price. Revenues are recorded net of sales-related adjustments, wherever applicable, primarily for the volume based rebates, consumer loyalty programs and co-branded marketing programs. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Volume-Based Rebates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Volume-based rebates are contractually offered to certain customers. The rebates payable to each customer are determined based on the contract and quarterly purchase volumes. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Consumer Loyalty Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company&#8217;s consumer loyalty program allows participating customers to earn rewards for qualifying treatments to their patients (i.e. consumers) using Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and redeem the rewards for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the future at no additional cost. The loyalty program represents a customer option that provides a material right and, accordingly, is a performance obligation. At the time Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product is sold to customers, the invoice price is allocated between the product sold and the estimated material right reward (&#8220;Reward&#8221;) that the customer might redeem in the future. The standalone selling price of the Reward is measured based on estimated average selling price of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at the time of redemption and the expected redemption rate by customers based on historical sales data. The portion of invoice price allocated to the Reward is initially recorded as deferred revenue. Subsequently, when customers redeem the Reward and the related product is delivered, the deferred revenue is recognized in net revenues at that time. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Co-Branded Marketing Programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company offers eligible customers with a certain level of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> purchases to receive advertising co-branded with the Company. The co-branded advertising represents a performance obligation. At the time Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product is sold to customers, the invoice price is allocated between the product sold and the advertisement. The standalone selling price of the advertisement is measured based on the estimated market value of similar advertisement adjusted for the customer&#8217;s portion of the advertisement. The portion of invoice price allocated to the advertisement is initially recorded as deferred revenue. Subsequently, when the advertisement airs, the deferred revenue is recognized in net revenues at that time.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Balances</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A contract with a customer states the terms of the sale, including the description, quantity and price of each product purchased. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration becomes unconditional. The Company does not have any significant financing components in customer contracts given the expected time between transfer of the promised products and the payment of the associated consideration is less than one year. As of&#160;December&#160;31, 2024 and 2023, all amounts included in accounts receivable, net on the accompanying consolidated balance sheets are related to contracts with customers.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any contract assets nor unbilled receivables as of&#160;December&#160;31, 2024 or 2023. Sales commissions are included in selling, general and administrative expenses when incurred.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities reflect estimated amounts that the Company is obligated to pay to customers or patients primarily under the rebate and deferred revenue associated with Rewards under the consumer loyalty program and co-branded marketing </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">programs. The Company&#8217;s contract liabilities are included in accounts payable and accrued expenses in the accompanying consolidated balance sheets.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, 2023, and 2022, the accrued revenue contract liabilities, primarily related to volume-based rebates, consumer loyalty program and co-branded marketing programs, were $14,454,  $11,033, and $9,011,respectively, which were recorded in accrued expenses in the accompanying consolidated balance sheets. For the years ended December 31, 2024, 2023, and 2022 provisions for rebate, consumer loyalty programs and co-branded marketing programs were $40,783, $32,511, and $22,759,respectively, which were offset by related payments, redemptions and adjustments of $37,362, $30,489, and $21,682, respectively, which were recorded as adjustments to gross revenues in the accompanying consolidated statement of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the&#160;years ended December 31, 2024, 2023, and 2022, the Company recognized $10,220, $7,868, and $7,566, respectively, of revenue related to amounts included in contract liabilities at the beginning of the period and did not recognize any revenue related to changes in transaction prices regarding its contracts with customers from previous periods.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collectability</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded at the invoiced amount and do not bear interest. At the time of contract inception or new customer account set-up, the Company performs a collectability assessment of the customer&#8217;s creditworthiness. The Company assesses the probability that the Company will collect the entitled consideration in exchange for the goods sold, by considering the customer&#8217;s ability and intention to pay when consideration is due. The Company&#8217;s expected loss allowance methodology for accounts receivable is developed using historical collection experience, current and future economic and market conditions and periodic evaluation of customers&#8217; receivables balances using relevant available information, from internal and external sources, relating to past events, current conditions and forecasts. Historical credit loss experience provides the basis for estimation of expected credit losses and are adjusted as necessary using the relevant information available. The Company writes off accounts receivable balances when it is determined that there is no possibility of collection. As of December 31, 2024, 2023, and 2022, allowance for credit losses was $2,714, $1,490, and $2,050, respectively. For the years ended December 31, 2024, 2023, and 2022, provision for bad debts was $2,449, $1,440, and $1,598, respectively, and the write-off amount was $1,225, $2,000, and $1,933, respectively.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Practical Expedients</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses sales commissions when incurred as the amortization period is one year or less. These costs are recorded within selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss. The Company does not adjust the amount of promised consideration for the effects of the time value of money for contracts in which the anticipated period between when the Company transfers the goods or services to the customer and when the customer pays within one year.</span></div><div style="margin-bottom:10pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses include personnel-related costs, costs associated with pre-clinical and clinical development activities, costs associated with and costs for prototype products that are manufactured prior to market approval for that prototype product, internal and external costs associated with the Company&#8217;s regulatory compliance and quality assurance functions, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs, including allocated facility related expenses.</span></div><div style="margin-bottom:10pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation Settlement</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, upon entering into certain agreements to settle intellectual property disputes relating to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company agreed to pay to Allergan and Medytox </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$35,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in multiple payments over two years, of which $15,000 was paid in the third quarter of 2021, $15,000 was paid in the first quarter of 2022, and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was paid in the first quarter of 2023, and issued 6,762,652 shares of its common stock to Medytox. As of December&#160;31, 2024 and 2023, there were no liabilities recorded in the accompanying consolidated balance sheets related to the litigation settlement with Allergan and Medytox.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, for the period from December 16, 2020 through September 16, 2022 (the &#8220;Restricted Period&#8221;), the Company agreed to pay to Allergan and Medytox a royalty on the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, based on a certain dollar amount per vial sold in the United States and a low-double digit royalty on net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sold in other Evolus territories. Royalties for sales during the Restricted Period ended in the third quarter of 2022. For the period from December 16, 2020 to September 16, 2022, Daewoong agreed to reimburse the Company certain amounts with respect to the royalties payable to Medytox and Allergan. This reimbursement was received quarterly and recorded as an offset to the related royalties to Medytox and Allergan in the cost of goods sold on the accompanying consolidated statements of operations and comprehensive loss. For the period from September 17, 2022 to September 16, 2032, the Company agreed to pay Medytox a mid-single digit royalty percentage on all net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The royalty payments are made quarterly and recorded as cost of goods sold on the accompanying consolidated statements of operations and comprehensive loss in the periods the royalties are incurred.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11. Medytox Settlement Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the details of all litigation settlement agreements.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes stock-based compensation expense for employees, consultants and members of the Board of Directors based on the fair value at the date of grant.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option pricing model to value stock option grants. The Black-Scholes option pricing model requires the input of subjective assumptions, including the expected volatility of the Company&#8217;s common stock, expected risk-free interest rate, and the option&#8217;s expected life. The fair value of the Company&#8217;s restricted stock units (&#8220;RSUs&#8221;) is based on the fair value on the grant date of the Company&#8217;s common stock. The Company also evaluates the impact of modifications made to the original terms of equity awards when they occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a Monte Carlo simulation model to determine the fair value of performance units with market conditions at the grant date. The Monte Carlo simulation model involves the generation of a large number of possible stock price outcomes for the Company&#8217;s stock which is assumed to follow a Geometric Brownian Motion. The use of the Monte Carlo simulation model requires the input of a number of assumptions including expected volatility of the Company&#8217;s stock price, which is based on the historical volatility of its stock; risk-free interest rate, which is based on the treasury zero-coupon yield commensurate with the term of the performance unit as of the grant date; and expected dividends as applicable, which is zero, as the Company has never paid any cash dividends.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options and RSUs with service conditions that are expected to vest is amortized on a straight-line basis over the requisite service period. Stock-based compensation for RSUs with performance or market conditions is recorded over the requisite service period using the accelerated attribution method. Stock-based compensation expense is recognized net of actual forfeitures when they occur, as an increase to additional paid-in capital in the consolidated balance sheets and in the selling, general and administrative or research and development expenses in the consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Costs</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs are expensed as incurred and primarily include costs related to social media ads and co-branded marketing programs. Advertising costs are included in selling, general and administrative expenses. For the years ended December 31, 2024, 2023, and 2022, the Company incurred advertising costs of $8,698, $7,490, and $11,642, respectively.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:9pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined on the basis of differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. </span></div><div style="margin-bottom:9pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is recorded against deferred tax assets to reduce the net carrying value when it is more likely than not that some portion or all of a deferred tax asset will not be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, and ongoing prudent and feasible tax planning strategies in assessing the amount of the valuation </span></div><div style="margin-bottom:9pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allowance. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. Accordingly, the Company establishes reserves for uncertain tax positions. The Company has not recognized interest or penalties in its consolidated statement of operations and comprehensive loss.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to file federal and state income tax returns in the United States and various other state jurisdictions. The preparation of these income tax returns requires the Company to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company. An amount is accrued for the estimate of additional tax liability, including interest and penalties, for any uncertain tax positions taken or expected to be taken in an income tax return. The Company reviews and updates the accrual for uncertain tax positions as more definitive information becomes available. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of the Company&#8217;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than&#160;50%&#160;likely of being realized upon settlement. While the Company believes it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcomes of examinations by tax authorities in determining the adequacy of its provision for income taxes. The Company continually assesses the likelihood and amount of potential revisions and adjusts the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company monitors changes to the tax laws in the states it conducts business and files corporate income tax returns. The Company does not expect changes to state tax laws through December&#160;31, 2024 to materially impact its consolidated financial statements.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period including contingently issuable shares. Diluted earnings per share is based on the treasury stock method and includes the effect from potential issuance of ordinary shares, such as shares issuable pursuant to the exercise of stock options and the vesting of restricted stock units. Because the impact of the options and non-vested RSUs are anti-dilutive during periods of net loss, there was no difference between the weighted-average number of shares used to calculate basic and diluted net loss per common share for the periods presented. Excluded from the dilutive net loss per share computation for the twelve months ended December&#160;31, 2024, 2023, and 2022, were stock options of 6,151,069, 5,753,466, and 4,769,521, respectively, and non-vested RSUs of 3,476,314, 3,281,045, and 2,663,320, respectively. Although these securities were anti-dilutive for these periods, they could be dilutive in future periods.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Pronouncements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting - Improving Reportable Segment Disclosures (Topic 280)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The standard requires disclosures to include significant segment expenses that are regularly provided to the chief operating decision maker (&#8220;CODM&#8221;), a description of other segment items by reportable segment, and any additional measures of a segment's profit or loss used by the CODM when deciding how to allocate resources. The ASU also requires all annual disclosures currently required by Topic 280 to be included in interim periods. ASU 2023-07 is effective for annual reporting periods beginning after December </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15, 2023 and interim reporting periods after December 15, 2024. The Company adopted this guidance on December&#160;31, 2024 and updated its disclosures to conform to this new segment disclosure requirement.</span></div><div style="margin-bottom:9pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements&#160;Issued But Not&#160;Adopted&#160;</span></div><div style="margin-bottom:9pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This update requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income taxes paid. ASU No. 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.</span></div><div style="margin-bottom:9pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU No. 2024-03 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires disaggregated disclosure of certain costs and expenses on an interim and annual basis. ASU No. 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The disclosure updates are required to be applied prospectively with the option for retrospective application. The Company is currently evaluating the impact of adopting ASU No. 2024-03.</span></div><div style="margin-bottom:9pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by management to, have a material impact on the Company&#8217;s present or future financial position, results of operations or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064179135952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements <div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. The fair value of these instruments was as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"></td><td style="width:52.873%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent royalty obligation payable to Evolus Founders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"></td><td style="width:52.873%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent royalty obligation payable to Evolus Founders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not transfer any assets or liabilities measured at fair value on a recurring basis between levels during the&#160;year ended December 31, 2024.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value of the contingent royalty obligation payable to Evolus Founders based on Level 3 inputs using a discounted cash flows method. The significant unobservable input assumptions that can significantly change the fair value include (i) projected amount and timing of U.S. net revenues of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the payment period, which terminates at the end of the second quarter of 2029, (ii) the discount rate, and (iii) the timing of payments. During the years ended December 31, 2024 and 2023, the Company utilized discount rates between 14% and 15%, reflecting changes in the Company&#8217;s risk profile. Net revenue projections are also updated to reflect changes in the timing of expected sales. Significant increases (decreases) in the discount rate and to the projected net revenues would result in a significantly lower (higher) fair value measurement, which could materially impact their fair value reported on the consolidated balance sheet.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a reconciliation of the beginning and ending fair value measurements of the contingent royalty obligation payable:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,030&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,310&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,441)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,537)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,185)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value recorded in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,765&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,030&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,310&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Financial Assets and Liabilities</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist primarily of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses, lease liabilities, and long-term debt. The carrying amount of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of long-term debt and operating lease liabilities using the discounted cash flow analysis based on the interest rates for similar rated debt securities (Level 2). As of December 31, 2024 and 2023, the fair value of long-term debt was $132,078 and $140,241, respectively. The fair value of operating lease liabilities&#160;as of December&#160;31, 2024 and 2023 approximated their carrying value.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064179609936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible Assets <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below shows the weighted-average life, original cost, accumulated amortization and net book value by major intangible asset classification:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.824%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Original Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Book Value</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution rights</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,580)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,770)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,104&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,350)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,754&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Indefinite-lived intangible asset</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total as of December&#160;31, 2024</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,312&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,350)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,962&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.824%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Original Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Book Value</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution right</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,746)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,356&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,246)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,110&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Indefinite-lived intangible asset</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total as of December&#160;31, 2023</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,564&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,246)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,318&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table outlines the estimated future amortization expense related to intangible assets held as of&#160;December&#160;31, 2024 that are subject to amortization:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.142%"><tr><td style="width:1.0%"></td><td style="width:55.931%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.869%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,754&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distribution rights represent the license and associated distribution rights to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Evolysse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For the years ended December 31, 2024 and 2023, the Company capitalized $2,235 and $1,476 related to the license and distribution right to Evolysse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> nasolabial fold product in Europe, which is amortized on a straight-line basis over the estimated useful life of 15 years.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2024 and 2023, the Company capitalized $3,513 and $1,168, respectively, related to costs of computer software developed for internal use. The software is amortized over a two-year period using the straight-line method. For the years ended December 31, 2024, 2023, and 2022, total intangible assets amortization expense of $4,104, $4,072, and $3,350, respectively, was recorded within depreciation and amortization on the accompanying consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064179156368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">Accrued Expenses <div style="margin-bottom:9pt;padding-right:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalties under the Medytox Settlement Agreements</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,743&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,657&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and related benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued revenue contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,791&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,813&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064271605664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text">Property, Plant and Equipment<div style="margin-bottom:9pt;padding-right:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment consisted of the following:</span></div><div style="margin-bottom:9pt;padding-right:15.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold Improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing Fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant, and equipment</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,745&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,487&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,523)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,222&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,087&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;padding-right:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2024, 2023, and 2022, depreciation expense was $1,194, $1,001, and $373, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064177748800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Term Loans</a></td>
<td class="text">Term Loans<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmakon Term Loans</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2021, the Company entered into a loan agreement with Pharmakon. Pursuant to the terms of the agreement, Pharmakon agreed to make term loans to the Company in two tranches (the &#8220;Pharmakon Term Loans&#8221;). The first tranche of $75,000 was funded on December 29, 2021. On December 5, 2022, the Company entered into a Second Amendment to the loan agreement to extend the Company&#8217;s option to draw down the second tranche of $50,000 until December 31, 2023, and paid an amendment fee of $500 to Pharmakon. The Pharmakon Term Loans will mature on the <span style="-sec-ix-hidden:f-623">sixth year</span> anniversary of the closing date of the first tranche (the &#8220;Maturity Date&#8221;). </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 9, 2023, the Company entered into the Third Amendment to the loan agreement. Under the Third Amendment, Pharmakon agreed to advance the second tranche of $50,000 to the Company in two installments: (i) $25,000 advanced on May 31, 2023 and (ii) $25,000 advanced on December 15, 2023. The Third Amendment amended the principal payment terms to seven quarterly payments, each in an amount equal to 1/12</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the outstanding principal amount of the Pharmakon Term Loans following the 51st-month anniversary of the closing date of the first tranche and the remaining principal balance of the Pharmakon Term Loans on the Maturity Date. The Third Amendment replaced the interest rates based on LIBOR with </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interest rates based on the Secured Overnight Financing Rate (&#8220;SOFR&#8221;) throughout the remaining term of the Pharmakon Term Loans.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Initially, the Pharmakon Term Loans accrued interest at a per annum rate equal to the 3-month U.S. Dollar LIBOR rate (subject to a LIBOR rate floor of 1.0%) plus 8.5% per annum. Beginning May 2023, the Pharmakon Term Loans accrue interest at a per annum rate equal to the 3-month SOFR rate (subject to a SOFR rate floor of 1.0%) plus 8.5% per annum.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may elect to prepay all amounts, not less than $20,000, owed prior to the Maturity Date. Prepayments of the first tranche prior to the second anniversary of the closing date of the first tranche and prepayments of the second tranche prior to the second anniversary of the date on which the second tranche is drawn by the Company will be accompanied by a make whole amount equal to the sum of all interest that would have accrued through such second anniversary. Prepayments of the Pharmakon Term Loans will also be accompanied by a prepayment premium equal to the principal amount so prepaid multiplied by 3.0% if made prior to the third anniversary of the closing date of the first tranche, 2.0% if made on or after the third anniversary of the closing date of the first tranche but prior to the fourth anniversary of the closing date of the first tranche, and 1.0% if made on or after the fourth anniversary of the closing date of the first tranche but prior to the Maturity Date. If the Pharmakon Term Loans are accelerated following the occurrence of an event of default, including a material adverse change, the Company is required to immediately pay Pharmakon an amount equal to the sum of all outstanding principal, unpaid interest, and applicable make whole and prepayment premiums.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmakon Term Loans are secured by substantially all of the Company&#8217;s assets. The Pharmakon Term Loans contain customary affirmative and restrictive covenants and representations and warranties. The affirmative covenants include, among others, certain information delivery requirements, obligations to maintain certain insurance, and certain notice requirements. The restrictive covenants include, among others, incurring certain additional indebtedness, consummating certain change in control transactions, or incurring any non- permitted lien or other encumbrance on the Company&#8217;s assets, without Pharmakon&#8217;s prior written consent. The Pharmakon Term Loans do not contain covenants requiring the Company to maintain a minimum cash threshold or minimum revenues or earnings. As of December&#160;31, 2024, the Company was in compliance with its debt covenants.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing date of the first tranche, the Company incurred $3,042 and $3,263 in debt discounts and issuance costs related to the Pharmakon Term Loans, respectively. Debt discounts and issuance costs related to the entire Pharmakon Term Loans have been allocated pro rata between the funded and unfunded portions. Debt discounts and issuance costs allocated to the first tranche of $75,000 have been presented as a deduction to the debt balance and amortized into interest expense using the effective interest method. Debt discounts and issuance costs associated with the unfunded second tranche are deferred as assets until the tranche is drawn and are amortized into interest expense using the straight-line method over the term of the debt. Upon the first draw of the second tranche in May 2023, debt discounts and issuance costs associated with the second tranche were reclassified from assets to debt as a deduction to the debt balance.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the borrowings outstanding under the Pharmakon Term Loans were classified as long-term debt in the accompanying consolidated balance sheets. The overall effective interest rate was approximately 14.52% and 13.21% for the first and second tranche, respectively, as of December&#160;31, 2024.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the principal amounts of long-term debt maturities for each of the next five fiscal years are as follows:</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.476%"><tr><td style="width:1.0%"></td><td style="width:68.218%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.582%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total principal payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discounts and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,494)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term debt, net of discounts and issuance costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,506&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064177718704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Operating Leases</a></td>
<td class="text">Operating Leases<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 15, 2019, the Company entered into a five-year non-cancelable operating lease (the &#8220;Lease Agreement&#8221;), which was set to expire January 31, 2025, for its corporate headquarters in Newport Beach, California. Lease payments increase each year on February 1 based on an annual rent escalation clause. The Company has an option to extend the term of the lease for an additional 60 months, which was not recognized as part of its ROU assets and lease liabilities.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 27, 2023, the Company entered into the First Amendment to the Lease Agreement (the &#8220;First Lease Amendment&#8221;) for its corporate headquarters. The First Lease Amendment includes a lease extension to January 31, 2030 with a three-month rent abatement period and additional office space. On July 27, 2023, the effective date of the First Lease Amendment, the Company recognized additional ROU assets and lease liabilities in the amount of $4,550. On August 1, 2024, the lease commencement date for the additional office space, the Company recognized additional ROU assets and lease liabilities in the amount of $3,002.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 16, 2024, the Company entered into the Second Amendment to the Lease Agreement (the &#8220;Second Lease Amendment&#8221;) to lease additional office space for its corporate headquarters. The lease is expected to commence on or around the second half of 2025 and is set to expire January 31, 2030. Fixed cash payments under this amendment are estimated to be $1,876 over the term of the lease. The Company expects to account for this lease an operating lease.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s lease agreement does not contain any residual value guarantees or material restrictive covenants. The payments associated with the renewal will only be included in the measurement of the lease liability and ROU assets if the exercise of the renewal option is determined to be reasonably certain. The Company considers the timing of the renewal period and other economic factors such as the financial implications of a decision to extend or not to extend a lease&#160;in&#160;determining&#160;if the renewal option is reasonably certain to be exercised.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease expense are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,526&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,164&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable operating lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,676&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,347&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average remaining lease term and discount rate are as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,433</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,320</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,265</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease&#160;expenses were included in the selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the future minimum payments under the operating lease agreements with non-cancelable terms as of December&#160;31, 2024:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.327%"><tr><td style="width:1.0%"></td><td style="width:76.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.452%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,718&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,926&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,453)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,473&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064176169440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Daewoong Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Daewoong Agreement includes certain minimum annual purchases that the Company is required to make in order to maintain the exclusivity of the license. The Company may, however, meet these minimum purchase obligations by achieving certain market share in the licensed territories. These potential minimum purchase obligations are contingent upon the occurrence of future events, including receipt of governmental approvals and the Company&#8217;s future market share in various jurisdictions.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total inventory payments to Daewoong were $62,233, $50,770, and $50,685 for the years ended December 31, 2024, 2023, and 2022, respectively.</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Symatese U.S. Agreement and Symatese Europe Agreement</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Symatese U.S. Agreement and the Symatese Europe Agreement include certain minimum purchase requirements, and failure to meet such requirements may result in a reduction or termination of the Company&#8217;s exclusive rights, subject to certain exceptions. These potential minimum purchase obligations are contingent upon the occurrence of future events, including receipt of governmental approvals and the Company&#8217;s future market share in various jurisdictions.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Symatese U.S. Agreement, the Company is required to make up to &#8364;16,200 in milestone payments to Symatese, including an initial payment of &#8364;4,100 within 30 days of execution of the Symatese U.S. Agreement, and additional annual payments of &#8364;1,600 in June 2025, &#8364;4,100 in June 2026, &#8364;3,200 in June 2027, and &#8364;3,200 in June 2028, in each case subject to three of the Products gaining approval prior to that date. In June 2023, the Company paid $4,441 as an upfront payment upon the signing of the Symatese U.S. Agreement and has developmental costs, ongoing milestone and royalty payment obligations.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Symatese Europe Agreement, the Company is required to pay two milestone payments: (i) &#8364;1,200 on the second anniversary of certain regulatory approvals, and (ii) &#8364;1,900 on the earlier of the third anniversary of certain regulatory approvals or following a year in which the Company achieves &#8364;25,000 in revenue in Europe, provided that the payment shall occur no later than December 2029.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2024, the Company received European Union Medical Device Regulation (&#8220;MDR&#8221;) approval for the remaining three hyaluronic acid gel products. As a result, the two milestone payments have been triggered. The first milestone </span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payment is payable on the two-year anniversary of the approval. For the second milestone payment, the Company determined that it is probable the payment will be made no later than December 2029.</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Class Action Lawsuit</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 16 and 28, 2020, two putative securities class action complaints were filed in the U.S. District Court for the Southern District of New York by Evolus shareholders Armin Malakouti and Clinton Cox, respectively, naming the Company and certain of its officers as defendants. The complaints assert violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, claiming that the defendants made false and materially misleading statements and failed to disclose material adverse facts related to the Company&#8217;s acquisition of the right to sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the complaint against the Company filed by Allergan and Medytox in the U.S. International Trade Commission related to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;ITC Action&#8221;), and risks related to the ITC Action. The complaints assert a putative class period of February 1, 2019 to July 6, 2020. The court consolidated the actions on November 13, 2020, under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Evolus Inc. Securities Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 1:20-cv-08647 (PGG). On September 17, 2021, the court appointed a lead plaintiff and lead counsel. On November 17, 2021, the lead plaintiff filed an amended class action complaint against the Company, three of its officers, and Alphaeon Corporation, the Company&#8217;s former majority shareholder. On January 18, 2022, the Company and the officer defendants served their motion to dismiss the amended complaint. On February 10, 2022, Alphaeon Corporation served its motion to dismiss the amended complaint. Both motions were fully briefed on June 16, 2022.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 26, 2024, the court granted the Company&#8217;s motion to dismiss the amended complaint and on October 18, 2024, the court entered final judgment in favor of the defendants.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shareholder Derivative Lawsuit</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2020 and December 2, 2020, two putative Evolus shareholders filed substantially similar shareholder derivative actions in the U.S. District Court for the Southern District of New York against certain of the Company&#8217;s officers and directors as defendants. The complaints alleged substantially similar facts as those in the Securities Class Action and assert claims for, among other things, breach of fiduciary duty, waste of corporate assets, unjust enrichment, and violations of Section 14(a) of the Exchange Act and for contribution under Sections 10(b) and 21(D) of the Exchange Act. On December 29, 2020, the plaintiffs filed a joint stipulation to consolidate their actions and on February 5, 2021, the court consolidated the action under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Evolus, Inc. Derivative Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 1:20-cv-09986-PPG, and adjourned defendants&#8217; time to move, answer or otherwise respond to the complaints. On September 20, 2021, the court so-ordered the parties&#8217; stipulated stay of the consolidated derivative suit pending the court&#8217;s decision on the defendants&#8217; motion to dismiss the Securities Class Action.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that additional suits will be filed, or additional allegations will be made by stockholders, with respect to these same or similar or other matters and also naming the Company and/or its officers and directors as defendants. The Company believes that the complaints are without merit and intends to vigorously defend against it. However, the outcome of the legal proceeding is uncertain at this point. Based on information available to the Company at present, management cannot reasonably estimate a range of loss with respect to this matter.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Books and Records Demand</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 5, 2021, the Company received a letter from a putative stockholder demanding inspection of specified categories of the Company&#8217;s books and records under Section 220 of the Delaware General Corporations Law. The Company was subsequently informed that the stockholder sold his shares of the Company&#8217;s common stock. On October 13, 2021, the Company received a substantially similar demand to inspect specified categories of the Company&#8217;s books and records under Section 220 of the Delaware General Corporations Law from another putative stockholder. The subject of the demand is substantially similar to the allegations in the putative securities class action and derivative complaints described above. The Company responded to the demand in December 2021. The outcome of this matter is uncertain at this point. Based on information available to the Company at present, management cannot reasonably estimate a range of loss with respect to this matter.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Legal Matters</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is, from time to time, involved in various litigation matters or regulatory encounters arising in the ordinary course of business that could result in unasserted or asserted claims or litigation. These other matters may raise difficult and complex legal issues and are subject to many uncertainties, including, but not limited to, the facts and circumstances of each particular case or claim, the jurisdiction in which each suit or regulatory encounter is brought, and differences in applicable laws and regulations. Except as set forth above, the Company does not believe that these other matters would have a material adverse effect on its accompanying financial position, results of operations or cash flows. However, the resolution of one or more of the other matters in any reporting period could have a material adverse impact on the Company&#8217;s financial results for that period.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company&#8217;s exposure under these agreements is unknown because they involve claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. No amounts were accrued as of December&#160;31, 2024.</span></div> Medytox Settlement Agreements<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">U.S. Settlement Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 18, 2021, the Company, Allergan and Medytox entered into a Settlement and License Agreement (the &#8220;U.S. Settlement Agreement&#8221;), pursuant to which, among other things: (i) Allergan and Medytox agreed to file a petition requesting the remedial orders related to the ITC Action be rescinded with respect to the Company; (ii) Medytox agreed to dismiss substantially similar litigation in California against the Company; (iii) the Company, on the one hand, and Medytox and Allergan, on the other hand, agreed to mutually release certain claims they may have against one another and their respective affiliates; (iv) Allergan and Medytox granted to the Company and its agents a license to manufacture and commercialize certain products identified in the U.S. Settlement Agreement, including Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;Licensed Products&#8221;), in the United States during the 21 month period that, pursuant to the ITC Action, the Company was restricted from, among other things, selling, marketing, or promoting such imported Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States (the &#8220;Restricted Period&#8221;); (v) the Company agreed to pay to Allergan and Medytox $35,000 in multiple payments over two years, of which the Company paid the first cash payment of $15,000 in the third quarter of 2021, the second cash payment of $15,000 in the first quarter of 2022, and the final cash payment of $5,000 in the first quarter of 2023; and (vi) during the Restricted Period, the Company agreed to pay to Allergan and Medytox certain confidential royalties on the sale of Licensed Products, calculated on dollar amount per vial sold of Licensed Products by or on behalf of the Company in the United States. Royalties for sales during the Restricted Period ended on September 16, 2022.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ROW Settlement Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 18, 2021, the Company and Medytox entered into a Settlement and License Agreement (the &#8220;ROW Settlement Agreement&#8221; and, together with the U.S. Settlement Agreement, the &#8220;Medytox/Allergan Settlement Agreements&#8221;), pursuant to which, among other things: (i) the Company and Medytox agreed to mutually release certain claims they may have against one another and their respective affiliates; (ii) Medytox granted to the Company and its agents a license to manufacture and commercialize the Licensed Products, in Canada, the European Union, Switzerland, member countries and cooperating countries of the European Economic Area, certain members of the Commonwealth of Independent States, South Africa, Australia and Japan (the &#8220;ROW Territories&#8221;) during the Restricted Period; (iii) Medytox granted to the Company and its agents a fully paid up license to manufacture and commercialize the Licensed Products in the ROW Territories and the United States from the end of the Restricted Period (the &#8220;Medytox License Period&#8221;); (iv) the Company and Medytox agreed to enter into the Share Issuance Agreement (as defined below) pursuant to which the Company issued 6,762,652 shares (the &#8220;Settlement Shares&#8221;) of the Company&#8217;s common stock, par value $0.00001 per share, to Medytox; (v) the Company and Medytox agreed to enter into the Registration Rights Agreement (as defined below), pursuant to which the Company granted certain registration rights to Medytox with respect to the Settlement Shares; (vi) during the Restricted Period that ended September 16, 2022, the Company agreed to pay Medytox a confidential low-double digit royalty on net sales of the Licensed Products sold by or on behalf of the Company in the ROW Territories; and (vii) during the Medytox License Period from September 17, 2022 to September 16, 2032, the Company agreed to pay Medytox a mid-single digit royalty percentage on net sales of the Licensed Products sold by or on behalf of the Company in the United States and the ROW Territories.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Share Issuance Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the ROW Settlement Agreement, the Company and Medytox entered into a Share Issuance Agreement effective February 18, 2021 (the &#8220;Share Issuance Agreement&#8221;). Pursuant to the Share Issuance Agreement and subject to the terms and conditions set forth therein, among other things, the Company issued to Medytox the Settlement Shares to enter into the ROW Settlement Agreement and in consideration for Medytox&#8217;s representations, warranties, and other agreements set forth in the Share Issuance Agreement. The Settlement Shares are subject to contractual restrictions on transfer that, subject to certain limited exceptions such as transfers to affiliates, prevented Medytox from transferring any shares of common stock prior to February 16, 2022 or more than 25% of the shares it held prior to September 16, 2023 and, thereafter, prohibit Medytox from transferring more than 50% of the shares it holds prior to September 16, 2024 and more than 75% of the shares it holds prior to September 16, 2025, with such contractual restrictions terminating on September 16, 2025.</span></div>As of December&#160;31, 2024 and 2023, the Company accrued $4,743 and $3,657 for royalties under the Medytox Settlement Agreements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064177899488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has 10,000,000 authorized shares of preferred stock with a par value of $0.00001 per share. As of December&#160;31, 2024, no shares of its preferred stock were issued and outstanding.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has 100,000,000 authorized shares of common stock with a par value of $0.00001 per share. As of December&#160;31, 2024, 63,497,548 shares of its common stock were issued and outstanding.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, the Company completed a follow-on offering and issued 3,554,000 shares of its common stock, at a price to the public of $14.07 per share. Refer to Note 1. Description of Business for additional details regarding the follow-on offering.</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2024 Employee Stock Purchase Plan (&#8220;ESPP&#8221;)</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2024, the Company approved the adoption of the 2024 Employee Stock Purchase Plan. The 2024 ESPP provides an opportunity to purchase shares of the Company&#8217;s common stock at a favorable price and upon favorable terms in consideration of the participating employees&#8217; continued services. Eligible employees will be entitled to purchase, by means of payroll deductions, limited amounts of the Company&#8217;s common stock at a discount during periodic offering periods. There were 579,648 shares initially reserved for issuance under the 2024 ESPP, which shall automatically increase on March 5 of each calendar year, by an amount equal to the lesser of (i) 1.0% of the total number of shares of common stock issued and outstanding on March 4 of the year in which such increase is to occur, (ii) 579,648 shares of common stock, or (iii) such number of shares of common stock as may be established by the Board of Directors. There were no shares issued under the 2024 ESPP during the twelve months ended December 31, 2024.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8220;At-the-market&#8221; Offerings of Common Stock</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 8, 2023, the Company entered into the ATM Sales Agreement with Leerink Partners LLC (formerly known as SVB Securities LLC) (the &#8220;Sales Agent&#8221;) pursuant to which shares of the Company&#8217;s common stock can be sold from time to time for aggregate gross proceeds of up to $50,000 (the &#8220;ATM Program&#8221;). Under the ATM Sales Agreement, the Sales Agent is entitled to compensation, at a commission rate equal to 3.0% of the gross proceeds from sales of the Company&#8217;s common shares under the ATM Program. The Company has not sold any shares under the ATM Sales Agreement.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 Omnibus Incentive Plan and Stock-based Compensation Allocation</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 2017 Omnibus Incentive Plan (the &#8220;Plan&#8221;) provides for the grant of incentive options to employees of the Company, and for the grant of non-statutory options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of stock compensation to the Company&#8217;s officers, directors, consultants </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and employees of the Company. The maximum number of shares of common stock that may be issued under the Plan is 4,361,291 shares, plus an annual increase on November 21 of each year equal to 4.0% of the total issued and outstanding shares of the Company&#8217;s common stock as of such anniversary (or such lesser number of shares as may be determined by the Company&#8217;s Board of Directors). On November 21, 2024, 2023, and 2022, an additional 2,535,476, 2,287,649, and 2,249,863, shares, respectively, were reserved under the evergreen provision of the Plan. As of December&#160;31, 2024, the Company had an aggregate of 3,605,334 shares of its common stock available for future issuance under the Plan.</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2023 Inducement Incentive Plan</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, the Company&#8217;s Board of Directors adopted the Company&#8217;s 2023 Inducement Incentive Plan (the &#8220;Inducement Plan&#8221;) in accordance with Nasdaq Listing Rule 5635(c)(4). The Company&#8217;s Inducement Plan provides for the grant of equity awards to selected individuals in connection with their commencing employment with the Company as an inducement material to their accepting such employment. The Board of Directors reserved 1,000,000 shares of common stock for issuance under the Inducement Plan. As of December&#160;31, 2024, the Company had an aggregate of 105,788 shares of its common stock available for future issuance under the Inducement Plan. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inducement Grants</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company has granted equity awards to its newly hired employees, including executives, in accordance with Nasdaq Listing Rule 5635(c)(4) and outside of the Company&#8217;s Plan and Inducement Plan. Such grants were made pursuant to a stand-alone nonstatutory stock option agreement and a stand-alone RSU agreement, which were approved by the Compensation Committee of the Board of Directors. Any shares underlying the inducement grants are not, upon forfeiture, cancellation or expiration, returned to a pool of shares reserved for future issuance. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options to purchase the Company&#8217;s stock are granted at exercise prices based on the Company&#8217;s common stock price on the date of grant. The option grants generally vest over a <span style="-sec-ix-hidden:f-739">one</span>-to four-year period. The options have a contractual term of ten years. The fair value of options is estimated using the Black&#8209;Scholes option pricing model, which has various inputs, including the grant date common share price, exercise price, risk&#8209;free interest rate, volatility, expected life and dividend yield. The change of any of these inputs could significantly impact the determination of the fair value of the Company&#8217;s options as well as significantly impact its results of operations. The Company records stock-based compensation expense net of actual forfeitures when they occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant assumptions used in the Black-Scholes option-pricing are as follows:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Volatility.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The expected volatility of common stock is estimated based on the historical volatility of the Company&#8217;s common stock over the most recent period commensurate with the estimated expected term of the stock options.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Term.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The expected term represents the period of time in which the options granted are expected to be outstanding. The Company estimates the expected term of options with consideration of vesting date, contractual term, and historical experience. The expected term of &#8220;plain vanilla&#8221; options is estimated based on the midpoint between the vesting date and the end of the contractual term under the simplified method permitted by the SEC implementation guidance. The weighted&#8209;average expected term of the Company&#8217;s options is approximately six years.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Risk&#8209;Free Rate.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The risk&#8209;free interest rate is selected based upon the implied yields in effect at the time of the option grant on U.S. Treasury zero&#8209;coupon issues with a term approximately equal to the expected life of the option being valued.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Dividends.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Company does not anticipate paying cash dividends in the foreseeable future. Consequently, the Company uses an expected dividend yield rate of zero.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used in determining the fair value of stock options granted were as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:38.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt 0 5.5pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.7%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.6%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.9%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.19</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity for the year ended December 31, 2024, 2023, and 2022 is presented below:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:41.224%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.764%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contractual</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intrinsic</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Terms (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,753,466&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.69</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,111&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,127,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(537,293)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192,937)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,151,069&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,691&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,151,069&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.16</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,691&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,619,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.64</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,801&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share of stock options granted during the years ended December&#160;31, 2024, 2023, and 2022 was $9.71, $7.73, and $4.76, respectively. The total intrinsic value of stock options that vested during the years ended December&#160;31, 2024, 2023, and 2022 was $3,171, $136, and $55, respectively. The aggregate intrinsic value of outstanding and exercisable options represents the excess of the fair market value of the Company&#8217;s common stock over the exercise price of underlying options as of&#160;December&#160;31, 2024, 2023, and 2022.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSU grants generally vest over a <span style="-sec-ix-hidden:f-786">one</span>- to four-year period. The fair value of RSU grants is determined at the grant date based on the common share price. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU activity for the year ended December 31, 2024, 2023, and 2022, is presented below:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:58.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,281,045&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,571,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,131,101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(342,357)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,378,867&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.80&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of restricted stock units that vested during the years ended December&#160;31, 2024, 2023, and 2022 was $15,740, $7,593, and $6,008, respectively.</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance Restricted Stock Units</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the Company&#8217;s Board of Directors granted 292,349 shares of performance restricted stock units (&#8220;PRSUs&#8221;) to certain executive officers under the Plan. The PRSU awards function in the same manner as restricted stock units except that vesting terms are based on achievement of certain pre-established performance measures. </span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2024, the Company&#8217;s Board of Directors granted 219,485 shares of PRSUs to certain executive officers under the Plan. The PRSU awards are measured on a cumulative two-year period ending in 2025. The performance measure milestones have not been met, and all were outstanding as of December&#160;31, 2024. As of December&#160;31, 2024, the achievement of the performance measure milestones was considered probable.</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2024, the Company&#8217;s Board of Directors granted 79,052 shares of PRSUs to an executive officer under the Plan. The PRSU awards are measured on regulatory approval ending in 2027. The performance measure milestones have not been met and all were outstanding as of December&#160;31, 2024. As of December&#160;31, 2024, one of the three achievement of the performance measure milestones was considered probable. </span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of PRSU activity for the year ended December 31, 2024 and 2023, is presented below:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:58.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Performance</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136,433)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395,984&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.12&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CEO Performance Award</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For RSUs granted to employees that vest based on market conditions, such as the trading price of the Company&#8217;s common stock exceeding certain price targets, the Company uses a Monte Carlo Simulation in estimating the fair value at grant date and recognizes compensation cost over the requisite service period. On May 8, 2023, the Company granted the Company&#8217;s Chief Executive Officer (&#8220;CEO&#8221;) an award of 560,000 PRSUs under the Plan.</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock units subject to the award are subject to both performance- and time-based vesting requirements. 40% of the stock units subject to the award are eligible to vest if the average of the closing prices for a share of the Company&#8217;s common stock over a period of 20 consecutive trading days is $30 or more and an additional 60% of the stock units subject to the award are eligible to vest if the average of the closing prices for a share of the Company&#8217;s common stock over a period of 20 consecutive trading days is $50 or more, in each case within five years after the grant of the award and while the CEO is employed by the Company (or, in certain circumstances, within 20 days following a termination of his employment). Any stock units that become eligible to vest based on stock price will vest, subject to the CEO&#8217;s continued service, over the four-year period after the grant date.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company used a Monte Carlo simulation to determine that the grant date fair value of the awards was $3,774. Compensation expense is recorded if the service condition is met regardless of whether the market condition is satisfied.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock-based compensation expense:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.875%"><tr><td style="width:1.0%"></td><td style="width:36.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.330%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.330%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,172&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,564&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,565&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,188&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,458&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,833&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the amounts recorded in selling, general and administrative and research and development, the Company capitalized $66 of stock-based compensation expense as part of capitalized software during the year ended December 31, 2024. As of December&#160;31, 2024, unrecognized compensation cost totaled $47,092 and will be recognized over a weighted-average period of 2.2 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064275352832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medytox Settlement Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Medytox Settlement Agreements</a></td>
<td class="text">Commitments and Contingencies <div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Daewoong Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Daewoong Agreement includes certain minimum annual purchases that the Company is required to make in order to maintain the exclusivity of the license. The Company may, however, meet these minimum purchase obligations by achieving certain market share in the licensed territories. These potential minimum purchase obligations are contingent upon the occurrence of future events, including receipt of governmental approvals and the Company&#8217;s future market share in various jurisdictions.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total inventory payments to Daewoong were $62,233, $50,770, and $50,685 for the years ended December 31, 2024, 2023, and 2022, respectively.</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Symatese U.S. Agreement and Symatese Europe Agreement</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Symatese U.S. Agreement and the Symatese Europe Agreement include certain minimum purchase requirements, and failure to meet such requirements may result in a reduction or termination of the Company&#8217;s exclusive rights, subject to certain exceptions. These potential minimum purchase obligations are contingent upon the occurrence of future events, including receipt of governmental approvals and the Company&#8217;s future market share in various jurisdictions.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Symatese U.S. Agreement, the Company is required to make up to &#8364;16,200 in milestone payments to Symatese, including an initial payment of &#8364;4,100 within 30 days of execution of the Symatese U.S. Agreement, and additional annual payments of &#8364;1,600 in June 2025, &#8364;4,100 in June 2026, &#8364;3,200 in June 2027, and &#8364;3,200 in June 2028, in each case subject to three of the Products gaining approval prior to that date. In June 2023, the Company paid $4,441 as an upfront payment upon the signing of the Symatese U.S. Agreement and has developmental costs, ongoing milestone and royalty payment obligations.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Symatese Europe Agreement, the Company is required to pay two milestone payments: (i) &#8364;1,200 on the second anniversary of certain regulatory approvals, and (ii) &#8364;1,900 on the earlier of the third anniversary of certain regulatory approvals or following a year in which the Company achieves &#8364;25,000 in revenue in Europe, provided that the payment shall occur no later than December 2029.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2024, the Company received European Union Medical Device Regulation (&#8220;MDR&#8221;) approval for the remaining three hyaluronic acid gel products. As a result, the two milestone payments have been triggered. The first milestone </span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payment is payable on the two-year anniversary of the approval. For the second milestone payment, the Company determined that it is probable the payment will be made no later than December 2029.</span></div><div style="margin-bottom:10pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Class Action Lawsuit</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 16 and 28, 2020, two putative securities class action complaints were filed in the U.S. District Court for the Southern District of New York by Evolus shareholders Armin Malakouti and Clinton Cox, respectively, naming the Company and certain of its officers as defendants. The complaints assert violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, claiming that the defendants made false and materially misleading statements and failed to disclose material adverse facts related to the Company&#8217;s acquisition of the right to sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the complaint against the Company filed by Allergan and Medytox in the U.S. International Trade Commission related to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;ITC Action&#8221;), and risks related to the ITC Action. The complaints assert a putative class period of February 1, 2019 to July 6, 2020. The court consolidated the actions on November 13, 2020, under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Evolus Inc. Securities Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 1:20-cv-08647 (PGG). On September 17, 2021, the court appointed a lead plaintiff and lead counsel. On November 17, 2021, the lead plaintiff filed an amended class action complaint against the Company, three of its officers, and Alphaeon Corporation, the Company&#8217;s former majority shareholder. On January 18, 2022, the Company and the officer defendants served their motion to dismiss the amended complaint. On February 10, 2022, Alphaeon Corporation served its motion to dismiss the amended complaint. Both motions were fully briefed on June 16, 2022.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 26, 2024, the court granted the Company&#8217;s motion to dismiss the amended complaint and on October 18, 2024, the court entered final judgment in favor of the defendants.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shareholder Derivative Lawsuit</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2020 and December 2, 2020, two putative Evolus shareholders filed substantially similar shareholder derivative actions in the U.S. District Court for the Southern District of New York against certain of the Company&#8217;s officers and directors as defendants. The complaints alleged substantially similar facts as those in the Securities Class Action and assert claims for, among other things, breach of fiduciary duty, waste of corporate assets, unjust enrichment, and violations of Section 14(a) of the Exchange Act and for contribution under Sections 10(b) and 21(D) of the Exchange Act. On December 29, 2020, the plaintiffs filed a joint stipulation to consolidate their actions and on February 5, 2021, the court consolidated the action under the caption </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Evolus, Inc. Derivative Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 1:20-cv-09986-PPG, and adjourned defendants&#8217; time to move, answer or otherwise respond to the complaints. On September 20, 2021, the court so-ordered the parties&#8217; stipulated stay of the consolidated derivative suit pending the court&#8217;s decision on the defendants&#8217; motion to dismiss the Securities Class Action.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that additional suits will be filed, or additional allegations will be made by stockholders, with respect to these same or similar or other matters and also naming the Company and/or its officers and directors as defendants. The Company believes that the complaints are without merit and intends to vigorously defend against it. However, the outcome of the legal proceeding is uncertain at this point. Based on information available to the Company at present, management cannot reasonably estimate a range of loss with respect to this matter.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Books and Records Demand</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 5, 2021, the Company received a letter from a putative stockholder demanding inspection of specified categories of the Company&#8217;s books and records under Section 220 of the Delaware General Corporations Law. The Company was subsequently informed that the stockholder sold his shares of the Company&#8217;s common stock. On October 13, 2021, the Company received a substantially similar demand to inspect specified categories of the Company&#8217;s books and records under Section 220 of the Delaware General Corporations Law from another putative stockholder. The subject of the demand is substantially similar to the allegations in the putative securities class action and derivative complaints described above. The Company responded to the demand in December 2021. The outcome of this matter is uncertain at this point. Based on information available to the Company at present, management cannot reasonably estimate a range of loss with respect to this matter.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Legal Matters</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is, from time to time, involved in various litigation matters or regulatory encounters arising in the ordinary course of business that could result in unasserted or asserted claims or litigation. These other matters may raise difficult and complex legal issues and are subject to many uncertainties, including, but not limited to, the facts and circumstances of each particular case or claim, the jurisdiction in which each suit or regulatory encounter is brought, and differences in applicable laws and regulations. Except as set forth above, the Company does not believe that these other matters would have a material adverse effect on its accompanying financial position, results of operations or cash flows. However, the resolution of one or more of the other matters in any reporting period could have a material adverse impact on the Company&#8217;s financial results for that period.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company&#8217;s exposure under these agreements is unknown because they involve claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. No amounts were accrued as of December&#160;31, 2024.</span></div> Medytox Settlement Agreements<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">U.S. Settlement Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 18, 2021, the Company, Allergan and Medytox entered into a Settlement and License Agreement (the &#8220;U.S. Settlement Agreement&#8221;), pursuant to which, among other things: (i) Allergan and Medytox agreed to file a petition requesting the remedial orders related to the ITC Action be rescinded with respect to the Company; (ii) Medytox agreed to dismiss substantially similar litigation in California against the Company; (iii) the Company, on the one hand, and Medytox and Allergan, on the other hand, agreed to mutually release certain claims they may have against one another and their respective affiliates; (iv) Allergan and Medytox granted to the Company and its agents a license to manufacture and commercialize certain products identified in the U.S. Settlement Agreement, including Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;Licensed Products&#8221;), in the United States during the 21 month period that, pursuant to the ITC Action, the Company was restricted from, among other things, selling, marketing, or promoting such imported Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States (the &#8220;Restricted Period&#8221;); (v) the Company agreed to pay to Allergan and Medytox $35,000 in multiple payments over two years, of which the Company paid the first cash payment of $15,000 in the third quarter of 2021, the second cash payment of $15,000 in the first quarter of 2022, and the final cash payment of $5,000 in the first quarter of 2023; and (vi) during the Restricted Period, the Company agreed to pay to Allergan and Medytox certain confidential royalties on the sale of Licensed Products, calculated on dollar amount per vial sold of Licensed Products by or on behalf of the Company in the United States. Royalties for sales during the Restricted Period ended on September 16, 2022.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">ROW Settlement Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 18, 2021, the Company and Medytox entered into a Settlement and License Agreement (the &#8220;ROW Settlement Agreement&#8221; and, together with the U.S. Settlement Agreement, the &#8220;Medytox/Allergan Settlement Agreements&#8221;), pursuant to which, among other things: (i) the Company and Medytox agreed to mutually release certain claims they may have against one another and their respective affiliates; (ii) Medytox granted to the Company and its agents a license to manufacture and commercialize the Licensed Products, in Canada, the European Union, Switzerland, member countries and cooperating countries of the European Economic Area, certain members of the Commonwealth of Independent States, South Africa, Australia and Japan (the &#8220;ROW Territories&#8221;) during the Restricted Period; (iii) Medytox granted to the Company and its agents a fully paid up license to manufacture and commercialize the Licensed Products in the ROW Territories and the United States from the end of the Restricted Period (the &#8220;Medytox License Period&#8221;); (iv) the Company and Medytox agreed to enter into the Share Issuance Agreement (as defined below) pursuant to which the Company issued 6,762,652 shares (the &#8220;Settlement Shares&#8221;) of the Company&#8217;s common stock, par value $0.00001 per share, to Medytox; (v) the Company and Medytox agreed to enter into the Registration Rights Agreement (as defined below), pursuant to which the Company granted certain registration rights to Medytox with respect to the Settlement Shares; (vi) during the Restricted Period that ended September 16, 2022, the Company agreed to pay Medytox a confidential low-double digit royalty on net sales of the Licensed Products sold by or on behalf of the Company in the ROW Territories; and (vii) during the Medytox License Period from September 17, 2022 to September 16, 2032, the Company agreed to pay Medytox a mid-single digit royalty percentage on net sales of the Licensed Products sold by or on behalf of the Company in the United States and the ROW Territories.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Share Issuance Agreement</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the ROW Settlement Agreement, the Company and Medytox entered into a Share Issuance Agreement effective February 18, 2021 (the &#8220;Share Issuance Agreement&#8221;). Pursuant to the Share Issuance Agreement and subject to the terms and conditions set forth therein, among other things, the Company issued to Medytox the Settlement Shares to enter into the ROW Settlement Agreement and in consideration for Medytox&#8217;s representations, warranties, and other agreements set forth in the Share Issuance Agreement. The Settlement Shares are subject to contractual restrictions on transfer that, subject to certain limited exceptions such as transfers to affiliates, prevented Medytox from transferring any shares of common stock prior to February 16, 2022 or more than 25% of the shares it held prior to September 16, 2023 and, thereafter, prohibit Medytox from transferring more than 50% of the shares it holds prior to September 16, 2024 and more than 75% of the shares it holds prior to September 16, 2025, with such contractual restrictions terminating on September 16, 2025.</span></div>As of December&#160;31, 2024 and 2023, the Company accrued $4,743 and $3,657 for royalties under the Medytox Settlement Agreements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064179123360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text">Employee Benefit Plan<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a defined contribution&#160;401(k) plan covering substantially all employees. Matching contributions totaled $2,023, $1,582, and $773&#160;for the years ended December 31, 2024, 2023, and 2022, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064179133072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s loss before income taxes was generated from its U.S. operations and foreign operations as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.096%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.096%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,349&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,004&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,103&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,756&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,509&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,317&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the expense (benefit) for income taxes:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.694%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provision:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current provision</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">685&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred provision (benefit):</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred (benefit) provision</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company has federal net operating loss (&#8220;NOL&#8221;) carryforwards of $315,179, of which $68,301 will begin to expire in 2034. The federal NOLs generated in 2018 and in the subsequent years in the amount of $246,877 have an indefinite carryforward period. As of December&#160;31, 2024,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company has state NOL carryforwards of $231,980, which will begin to expire in 2024. As of December&#160;31, 2024, the Company has foreign NOL carryforwards of $38,922, which can be carried forward indefinitely. As of December&#160;31, 2024, the Company has federal research and development </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;R&amp;D&#8221;) credit carryforwards of $2,929, which will begin to expire in 2034. The Company also has California R&amp;D credit carryforwards of $2,918, which has an indefinite carryforward period. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, if a company experiences a greater than 50 percentage point aggregate change in ownership of certain significant stockholders over a three-year period, utilization of its pre-change NOL carryforwards and R&amp;D credit carryforwards, and interest expense under section 163(j), is subject to an annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and similar state laws. The annual limitation may result in the expiration of the Company&#8217;s tax attribute carryforwards before utilization and may be material. The Company has completed a study to evaluate whether an ownership change, as defined by Section 382 of the Internal Revenue Code, occurred from the Company's formation through December 31, 2023. Based on the findings of this study, the Company has determined that several ownership changes have occurred. Consequently, the Company&#8217;s tax attribute carryforwards allocable to the periods preceding the ownership change are subject to limitation under Section 382. However, it is important to note that the Company&#8217;s tax attribute carryforwards, which include net operating losses (NOLs), research and development (R&amp;D) credits, and interest expense under Section 163(j), are not anticipated to expire unused, solely due to the limitations under Section 382. The Company started but has not completed a study to determine whether its tax attribute carryforwards generated through December 31, 2024, are likely to be limited by Section 382 and 383. The Company&#8217;s net deferred income tax assets have been offset by a valuation allowance. Therefore, any resulting reduction to the Company&#8217;s tax attribute carryforwards once the analysis is completed will be offset by a corresponding reduction of the valuation allowance and there would be no impact on the Company&#8217;s consolidated balance sheet, statement of operations, or cash flows.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of deferred tax assets and liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.694%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,808&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;E capitalization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed asset depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124,895)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116,073)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,695)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,162&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,163&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,343&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,343)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,730)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,525)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,825)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,460)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(495)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed asset depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(345)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,168)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,190)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,365)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the difference between the provision (benefit) for income taxes and income taxes at the statutory U.S. federal income tax rate is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.694%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax at statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,413)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,917)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,607)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(753)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,981)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,673)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation of contingent royalty obligation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,823&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Meals and entertainment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in state tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers' compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,529)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Rate Differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,377)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(449)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(391)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.401%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.401%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to current year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has considered the amounts and probabilities of the outcomes that can be realized upon ultimate settlement with the tax authorities and determined unrecognized tax benefits primarily related to credits should be established as noted in the summary rollforward above. The Company&#8217;s effective income tax rate would not be impacted if the unrecognized tax benefits are recognized. Additional amounts in the summary rollforward could impact the Company&#8217;s effective tax rate if it did not maintain a full valuation allowance on its net deferred tax assets. The Company does not expect its unrecognized tax benefits to change significantly over the next 12&#160;months.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy is to recognize interest expense and penalties related to income tax matters as a component of income tax expense. There were no accrued interest and penalties associated with uncertain tax positions as of December&#160;31, 2024, 2023, and 2022. The Company&#8217;s tax returns for all years since inception are open for audit. The Internal Revenue Service (&#8220;IRS&#8221;) commenced an examination of our U.S. income tax returns for the tax year ended December&#160;31, 2022, in the third quarter of 2024. The exam is still in progress. As of December&#160;31, 2024, the IRS has not proposed any adjustments to our tax positions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064179141536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment Reporting<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducts business as a single operating segment, which is the business of performance beauty focused on delivering products in the cash-pay aesthetic market. The Company&#8217;s chief executive officer, who is the chief operating decision maker (&#8220;CODM&#8221;), reviews financial information on a consolidated basis for allocating and evaluating financial performance. The single operating segment is further based upon the Company&#8217;s organizational and management structure and other factors.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key measure of segment profit and loss that the CODM uses to allocate resources and assess performance is the Company&#8217;s net loss, which is utilized to evaluate the achievement of the Company&#8217;s business operations. The table below </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shows the Company&#8217;s reconciliation of revenue and significant segment items to net loss, regularly provided to and reviewed by the CODM, as computed under U.S. GAAP:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.042%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.741%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt 0 5.5pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product cost of goods sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,015&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of distribution right</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In process research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation of contingent royalty obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(860)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(696)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,420)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61,685)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,412)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets provided to the CODM are consistent with those reported on the Balance Sheets with particular emphasis on the Company&#8217;s available liquidity, including its cash and cash equivalents, and financial instruments owned, reduced by current liabilities. All long-lived assets are maintained in the United States of America.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The product and service revenue attributed to foreign countries from which the Company derives product and service revenue is as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.042%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.741%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue by country, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue by country, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,274&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,085&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,616&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064180634208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 13, 2025, the Company received FDA approval for Evolysse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Form and Evolysse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Smooth injectable hyaluronic acid gels for the treatment and improvement of moderate to severe nasolabial folds facial wrinkles.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064179111440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (50,420)<span></span>
</td>
<td class="num">$ (61,685)<span></span>
</td>
<td class="num">$ (74,412)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064180352096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064271355152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064176747104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity risk management process is designed to identify and manage internal and external cybersecurity threats and vulnerabilities to and within our business and operations. Our cybersecurity program is integrated into our overall risk management systems, business continuity and crisis management programs, third-party risk management program, insurance risk management program, and employee compliance programs. Our cybersecurity program includes systems and processes such as, but not limited to, maintenance and monitoring of information security policies, implementation and maintenance of infrastructure security systems, programs and policies designed to promote employee awareness of cyber policies and practices (including implementing an annual process for employees to complete security awareness training in addition to new employee cybersecurity awareness training), information systems configuration management, use of third-party risk management systems, process to promote identity and information asset protection and cybersecurity threat operations with continuous monitoring. This program also includes processes to oversee and identify material risks from cybersecurity threats associated with our use of third-party service providers.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed an incident response plan designed to coordinate the activities that we and our third-party security service providers take to prepare to respond and recover from cybersecurity incidents, which include processes to triage, assess severity, investigate, escalate, contain, and remediate an incident, as well as to comply with potentially applicable legal obligations and mitigate any reputational damage. Additionally, as part of our overall risk management program, we maintain a global insurance portfolio with cybersecurity coverage.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">Our cybersecurity program is integrated into our overall risk management systems, business continuity and crisis management programs, third-party risk management program, insurance risk management program, and employee compliance programs. Our cybersecurity program includes systems and processes such as, but not limited to, maintenance and monitoring of information security policies, implementation and maintenance of infrastructure security systems, programs and policies designed to promote employee awareness of cyber policies and practices (including implementing an annual process for employees to complete security awareness training in addition to new employee cybersecurity awareness training), information systems configuration management, use of third-party risk management systems, process to promote identity and information asset protection and cybersecurity threat operations with continuous monitoring. This program also includes processes to oversee and identify material risks from cybersecurity threats associated with our use of third-party service providers.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text">Our management, with involvement and input from our Board of Directors, performs annual enterprise-wide cybersecurity assessments to identify and manage key existing and emerging risks for our company.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Our management, with involvement and input from our Board of Directors, performs annual enterprise-wide cybersecurity assessments to identify and manage key existing and emerging risks for our company.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">The Board of Directors receives periodic updates on our cybersecurity risks from our SVP of IT and Operations, which include risk assessments, areas of emerging risks, incidents and industry trends, and other areas of importance. These reports include updates on our progress preparing for, preventing, detecting, responding to and recovering from material cyber incidents, if any. In addition, as needed, management updates the Board of Directors regarding any material cybersecurity incidents.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity team is led by the SVP of IT and Operations, who reports to our Chief Financial Officer. Our SVP of IT and Operations and the cybersecurity team have over 25 years of experience managing and securing technology infrastructure. The cybersecurity team has responsibility for the planning and execution of our processes to manage cybersecurity and other information technology risks. The cybersecurity team also institutes and maintains controls for our systems, applications, and databases. Our management, with involvement and input from our Board of Directors, performs annual enterprise-wide cybersecurity assessments to identify and manage key existing and emerging risks for our company.</span></div>The Board of Directors receives periodic updates on our cybersecurity risks from our SVP of IT and Operations, which include risk assessments, areas of emerging risks, incidents and industry trends, and other areas of importance. These reports include updates on our progress preparing for, preventing, detecting, responding to and recovering from material cyber incidents, if any. In addition, as needed, management updates the Board of Directors regarding any material cybersecurity incidents.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">Our cybersecurity team is led by the SVP of IT and Operations, who reports to our Chief Financial Officer.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">Our SVP of IT and Operations and the cybersecurity team have over 25 years of experience managing and securing technology infrastructure.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text">The cybersecurity team has responsibility for the planning and execution of our processes to manage cybersecurity and other information technology risks. The cybersecurity team also institutes and maintains controls for our systems, applications, and databases. Our management, with involvement and input from our Board of Directors, performs annual enterprise-wide cybersecurity assessments to identify and manage key existing and emerging risks for our company.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064177650384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div>The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s consolidated financial statements include the Company&#8217;s accounts and those of the Company&#8217;s wholly owned subsidiaries and have been prepared in conformity with GAAP. All intercompany transactions have been eliminated.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is required to make certain estimates and assumptions in order to prepare consolidated financial statements in conformity with GAAP. Such estimates and assumptions affect the reported consolidated financial statements. These estimates include, but are not limited to net revenues, allowance for doubtful accounts, fair value measurements and stock-based compensation, among others. Management bases estimates on historical experience and on assumptions that management believes are reasonable. The Company&#8217;s actual results could differ materially from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Risks and Uncertainties and Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to an agreement (the &#8220;Daewoong Agreement&#8221;) with Daewoong Pharmaceutical Co. Ltd. (&#8220;Daewoong&#8221;), pursuant to which the Company received an exclusive distribution license to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from Daewoong for aesthetic indications in the United States, European Union, United Kingdom, members of the European Economic Area, Switzerland, Canada, Australia, New Zealand, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;is manufactured by Daewoong in a facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in a territory covered by the Daewoong Agreement. The Company relies on Daewoong, its exclusive and sole supplier, to manufacture Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company&#8217;s commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9. Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company commercially launched Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;starting in the United States in May 2019 and in Canada through its distribution partner in October 2019. The Company also began commercially launching Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Europe in 2022 and Australia in 2024 and, as such, has a limited history of sales in those markets. If any previously granted approval to market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is retracted or the Company is denied approval or approval is delayed by regulators in any other jurisdictions, it may have a material adverse impact on the Company&#8217;s business and its consolidated financial statements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to risks common to companies in the pharmaceutical industry including, but not limited to, dependency on the commercial success of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Evolysse&#8482; the Company&#8217;s approved products, significant competition within the medical aesthetics industry, its ability to maintain regulatory approval of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, third party litigation and challenges to its intellectual property, uncertainty of broad adoption of its product by aesthetic practitioners and patients, its ability to in-license, acquire or develop additional product candidates and to obtain the necessary approvals for those product candidates, and the need to scale manufacturing capabilities over time.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any disruption and volatility in the global capital markets, including caused by other events, such as public health crises, increased inflation and rising interest rates, increased tariffs, and geopolitical conflicts, including the military conflict between Russia and Ukraine and the ongoing conflict in the Middle East, may increase the Company&#8217;s cost of capital and adversely affect its ability to access financing when and on terms that the Company desires. Any of these events could have a material adverse effect on the Company&#8217;s business, financial condition, results of operations and cash flows.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and accounts receivable. Substantially all of the Company&#8217;s cash is held by financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. To date, the Company has not experienced any losses associated with this credit risk and continues to believe that this exposure is not significant. The Company invests, or plans to soon invest, its excess cash, in line with its investment policy, primarily in money market funds and debt instruments of U.S. government agencies. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts receivable is derived from customers located principally in the United States and Europe. Concentrations of credit risk with respect to trade receivables are limited due to the Company&#8217;s credit evaluation process. The Company does not typically require collateral from its customers. The Company continuously monitors customer payments and maintains an allowance for credit losses based on its assessment of various factors including historical experience, age of the receivable balances, and other current economic conditions or other factors that may affect customers&#8217; ability to pay.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that it operates in a single operating and reportable segment. The Company&#8217;s chief operating decision maker is its Chief Executive Officer who manages operations and reviews the financial information as a single operating segment for the purposes of allocating resources and evaluating its financial performance.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash and highly liquid investments with remaining maturities at purchase of three months or less that can be liquidated without prior notice or penalty. Cash and cash equivalents may include deposits, money market funds and debt securities. Amounts receivable from credit card issuers are typically converted to cash within <span style="-sec-ix-hidden:f-398">two</span> to four days of the original sales transaction and are considered to be cash equivalents.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories and cost of goods sold</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories and cost of goods sold</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of finished goods held for sale and distribution. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost is determined using the first-in, first-out method. Inventory is measured at the lower of cost and net realizable value based on a number of factors including, but not limited to, damage, expiration, or changes in price level.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2024, cost of goods sold, consisted of the inventory cost, amortization of distribution right intangible assets related to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and certain royalties on the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> payable to Medytox and Allergan pursuant to the Medytox Settlement Agreements (as such term is defined in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11. Medytox Settlement Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The prior years Consolidated Statements of Operations and Comprehensive Loss has been adjusted to conform to this presentation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in an orderly transaction between market participants in a principal market on the measurement date.</span></div><div style="margin-bottom:9pt;padding-right:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy defines a three-tiered valuation hierarchy for disclosure of fair value measurement is classified and disclosed by the Company in one of the three categories as follows:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1&#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2&#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets; quoted prices in markets that are not active; or other inputs that are observable, either directly or indirectly, or can be corroborated by observable market data for substantially the full term of the asset or liability; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3&#8212;Prices or valuation techniques that require inputs that are unobservable that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div>Property and equipment are stated at cost. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of approximately <span style="-sec-ix-hidden:f-403">three</span> to five years. Leasehold improvements are amortized over the shorter of the estimated useful lives of the improvements or the term of the related lease.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div>Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. The Company assesses goodwill for impairment annually and whenever events or changes in circumstances indicate that the carrying amount of goodwill may not be recoverable. The Company performs an annual qualitative assessment of its goodwill in the fourth quarter of each calendar year to determine if any events or circumstances exist, such as an adverse change in business climate or a decline in the overall industry demand, that would indicate that it would more likely than not reduce the fair value of a reporting unit below its carrying amount, including goodwill. If events or circumstances do not indicate that the fair value of a reporting unit is below its carrying amount, then goodwill is not considered to be impaired and no further testing is required. For the purpose of impairment testing, the Company has determined that it has one reporting unit.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">In-process Research and Development</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-process Research and Development</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets acquired that are used for research and development, do not yet have regulatory approval for commercialization, and have no future alternative use are expensed as in-process research and development.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The distribution right intangible asset related to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is amortized over the period the asset is expected to contribute to the future cash flows of the Company. The Company determined the pattern of this intangible asset&#8217;s future cash flows could not be readily determined with a high level of precision. As a result, the distribution right intangible asset is being amortized on a straight-line basis over the estimated useful life of&#160;20 years.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of the Symatese Europe Agreement represents the license and distribution right to Evolysse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Europe. The definite-lived distribution right intangible asset related to the Evolysse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> nasolabial fold product approved in Europe is amortized on a straight-line basis over the estimated useful life of 15 years.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Symatese Europe Agreement, the Company is required to pay two milestone payments: (i) &#8364;1,200 on the second anniversary of certain regulatory approvals, and (ii) &#8364;1,900 on the earlier of the third anniversary of certain regulatory approvals or following a year in which the Company achieves &#8364;25,000 in revenue in Europe, provided that the payment shall occur no later than December 2029.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2024, the Company received European Union Medical Device Regulation (&#8220;MDR&#8221;) approval for the remaining three hyaluronic acid gel products. As a result, the two milestone payments have been triggered. The first milestone payment is payable in October 2026, the two-year anniversary of the approval. For the second milestone payment, the Company determined that it is probable the payment will be made no later than December 2029. As such, the Company recorded $1,035 and $1,200 in long-term liabilities for the first and second milestone payments, and $1,035 and $1,200 in intangible assets for the first and second milestone payments as of December&#160;31, 2024. These amounts reflect the </span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">application of a discount to account for the time value of money, which adjusts the present value of the liabilities and intangible assets based on the timing of future payments. The definite-lived distribution right intangible asset related to the Evolysse</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> products approved in Europe is amortized on a straight-line basis over the remaining estimated useful life of 14 years and 2 months. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain internal-use software costs associated with the development of its mobile and web-based customer platforms. These costs include personnel expenses and external costs that are directly associated with the software projects. These costs are included as intangible assets in the accompanying consolidated balance sheets. The capitalized internal-use software costs are amortized on a straight-line basis over the estimated useful life of&#160;two years&#160;upon being placed in service.</span></div>The Company reviews long-term and identifiable definite-lived intangible assets or asset groups for impairment when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset or an asset group, further impairment analysis is performed. An impairment loss is measured as the amount by which the carrying amount of the asset or asset groups exceeds the fair value for assets to be held and used or fair value less cost to sell for assets to be disposed of. The Company also reviews the useful lives of its assets periodically to determine whether events and circumstances warrant a revision to the remaining useful life. Changes in the useful life are adjusted prospectively by revising the remaining period over which the asset is amortized.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, upon lease commencement, the Company records a lease liability which represents the Company&#8217;s obligation to make lease payments arising from the lease, and a corresponding right-of-use (&#8220;ROU&#8221;) asset which represents the Company&#8217;s right to use an underlying asset during the lease term. Operating lease assets and liabilities are included in ROU assets, current portion of operating lease liabilities and noncurrent operating lease liabilities in the accompanying consolidated balance sheets.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease ROU assets and lease liabilities are initially recognized based on the present value of the future minimum lease payments over the lease term at commencement date calculated using the Company&#8217;s incremental borrowing rate applicable to the underlying asset unless the implicit rate is readily determinable. The incremental borrowing rate, the ROU asset and the lease liability are reevaluated upon a lease modification. Operating lease ROU assets also include any lease payments made at or before lease commencement and exclude any lease incentives received, if any. The Company determines the lease term as the noncancellable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. The Company&#8217;s leases do not contain any residual value guarantees. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets. For operating leases, the Company recognized rent expense on a straight-line basis over the lease term. There were no significant finance leases as of&#160;December&#160;31, 2024.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingent Royalty Obligation Payable and Promissory Note Payable to the Evolus Founders</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Royalty Obligation Payable to Evolus Founders</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was acquired by Strathspey Crown Holdings Group, LLC (&#8220;SCH&#8221;) in 2013 and subsequently by its subsidiary, Alphaeon Corporation (&#8220;Alphaeon&#8221;), by means of a stock purchase agreement (&#8220;Stock Purchase Agreement&#8221;) pursuant to which Alphaeon assumed certain payment obligations related to the acquisition. On December 14, 2017, the Stock Purchase Agreement was amended (&#8220;Amended Stock Purchase Agreement&#8221;), and, as a result, effective upon the closing of the Company&#8217;s initial public offering in February 2018, the Company assumed all of Alphaeon&#8217;s payment obligations under the Amended Stock Purchase Agreement.</span></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment obligations to the Evolus Founders consist of quarterly royalty payments of a low single digit percentage of net sales of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The obligations terminate in the second quarter of 2029, which is the&#160;10-year anniversary of the first commercial sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;in the United States. Under the Amended Stock Purchase Agreement, the Company recorded the fair value of all revised payment obligations owed to the Evolus Founders. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value of the contingent royalty obligation payable at each reporting period end based on Level 3 inputs using a discounted cash flows method. Changes in the fair value of the contingent royalty obligation payable are determined at each reporting period end and recorded in operating expenses in the accompanying consolidated statements of operations and comprehensive loss and as a liability in the accompanying consolidated balance sheets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Long-Term Debt</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Term Debt</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt represents the debt balance with Pharmakon (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7. Term Loans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), net of discount and issuance costs. Debt issuance costs represent legal, lender and consulting costs or fees associated with debt financing. Debt&#160;discounts and issuance costs are amortized into interest expense over the term of the debt.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements of foreign subsidiaries are measured using the local currency as the functional currency. Assets and liabilities are translated into U.S. dollars at current exchange rates as of balance sheet date, and income and expense items are translated into U.S. dollars using the average rates of exchange prevailing during the period. Gains and losses arising from translation are recorded in other comprehensive loss as a separate component of stockholders&#8217; equity. Foreign currency gains or losses on transactions denominated in a currency other than the Company&#8217;s functional currency are recorded in other expenses, net in the accompanying consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when control of the promised goods or services is transferred to its customers, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for the goods or services. In order to achieve that core principle, a five-step approach is applied: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue allocated to each performance obligation when the Company satisfies the performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account for revenue recognition.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generates product revenue from the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States, Europe, and Australia, and service revenue from the sale of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through a distribution partner in Canada.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For product revenue, the Company recognizes revenue when control of the promised goods under a contract is transferred to a customer, in an amount that reflects the consideration the Company expects to receive in exchange for those goods as specified in the customer contract. The transfer of control occurs upon receipt of the goods by the customer since that is when the customer has obtained control of the goods&#8217; economic benefits. The Company does not provide any service-type warranties and does not accept product returns except under limited circumstances such as damages in transit or ineffective product. The Company also excludes any amounts related to taxes assessed by governmental authorities from revenue measurement. Shipping and handling costs associated with outbound product freight are accounted for as fulfillment costs </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and are included in selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For service revenue, the Company evaluated the arrangement with the distribution partner in Canada and determined that it acts as an agent in the distribution of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in Canada as it does not control the product before control is transferred to a customer. The indicators of which party exercises control include primary responsibility over performance obligations, inventory risk before the good or service is transferred and discretion in establishing the price. Accordingly, the Company records the sale as service revenue on a net basis. Revenue from services is recognized in the period the service is performed for the amount of consideration expected to be received.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s disaggregation of revenue is consistent with its operating segment as disclosed above.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gross-to-Net Revenue Adjustments</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides customers with discounts, such as trade and volume discounts and prompt pay discounts, that are directly reflected in the invoice price. Revenues are recorded net of sales-related adjustments, wherever applicable, primarily for the volume based rebates, consumer loyalty programs and co-branded marketing programs. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Volume-Based Rebates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Volume-based rebates are contractually offered to certain customers. The rebates payable to each customer are determined based on the contract and quarterly purchase volumes. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Consumer Loyalty Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company&#8217;s consumer loyalty program allows participating customers to earn rewards for qualifying treatments to their patients (i.e. consumers) using Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and redeem the rewards for Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the future at no additional cost. The loyalty program represents a customer option that provides a material right and, accordingly, is a performance obligation. At the time Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product is sold to customers, the invoice price is allocated between the product sold and the estimated material right reward (&#8220;Reward&#8221;) that the customer might redeem in the future. The standalone selling price of the Reward is measured based on estimated average selling price of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> at the time of redemption and the expected redemption rate by customers based on historical sales data. The portion of invoice price allocated to the Reward is initially recorded as deferred revenue. Subsequently, when customers redeem the Reward and the related product is delivered, the deferred revenue is recognized in net revenues at that time. </span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Co-Branded Marketing Programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company offers eligible customers with a certain level of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> purchases to receive advertising co-branded with the Company. The co-branded advertising represents a performance obligation. At the time Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product is sold to customers, the invoice price is allocated between the product sold and the advertisement. The standalone selling price of the advertisement is measured based on the estimated market value of similar advertisement adjusted for the customer&#8217;s portion of the advertisement. The portion of invoice price allocated to the advertisement is initially recorded as deferred revenue. Subsequently, when the advertisement airs, the deferred revenue is recognized in net revenues at that time.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Balances</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A contract with a customer states the terms of the sale, including the description, quantity and price of each product purchased. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration becomes unconditional. The Company does not have any significant financing components in customer contracts given the expected time between transfer of the promised products and the payment of the associated consideration is less than one year. As of&#160;December&#160;31, 2024 and 2023, all amounts included in accounts receivable, net on the accompanying consolidated balance sheets are related to contracts with customers.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any contract assets nor unbilled receivables as of&#160;December&#160;31, 2024 or 2023. Sales commissions are included in selling, general and administrative expenses when incurred.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities reflect estimated amounts that the Company is obligated to pay to customers or patients primarily under the rebate and deferred revenue associated with Rewards under the consumer loyalty program and co-branded marketing </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">programs. The Company&#8217;s contract liabilities are included in accounts payable and accrued expenses in the accompanying consolidated balance sheets.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, 2023, and 2022, the accrued revenue contract liabilities, primarily related to volume-based rebates, consumer loyalty program and co-branded marketing programs, were $14,454,  $11,033, and $9,011,respectively, which were recorded in accrued expenses in the accompanying consolidated balance sheets. For the years ended December 31, 2024, 2023, and 2022 provisions for rebate, consumer loyalty programs and co-branded marketing programs were $40,783, $32,511, and $22,759,respectively, which were offset by related payments, redemptions and adjustments of $37,362, $30,489, and $21,682, respectively, which were recorded as adjustments to gross revenues in the accompanying consolidated statement of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the&#160;years ended December 31, 2024, 2023, and 2022, the Company recognized $10,220, $7,868, and $7,566, respectively, of revenue related to amounts included in contract liabilities at the beginning of the period and did not recognize any revenue related to changes in transaction prices regarding its contracts with customers from previous periods.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collectability</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded at the invoiced amount and do not bear interest. At the time of contract inception or new customer account set-up, the Company performs a collectability assessment of the customer&#8217;s creditworthiness. The Company assesses the probability that the Company will collect the entitled consideration in exchange for the goods sold, by considering the customer&#8217;s ability and intention to pay when consideration is due. The Company&#8217;s expected loss allowance methodology for accounts receivable is developed using historical collection experience, current and future economic and market conditions and periodic evaluation of customers&#8217; receivables balances using relevant available information, from internal and external sources, relating to past events, current conditions and forecasts. Historical credit loss experience provides the basis for estimation of expected credit losses and are adjusted as necessary using the relevant information available. The Company writes off accounts receivable balances when it is determined that there is no possibility of collection. As of December 31, 2024, 2023, and 2022, allowance for credit losses was $2,714, $1,490, and $2,050, respectively. For the years ended December 31, 2024, 2023, and 2022, provision for bad debts was $2,449, $1,440, and $1,598, respectively, and the write-off amount was $1,225, $2,000, and $1,933, respectively.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Practical Expedients</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses sales commissions when incurred as the amortization period is one year or less. These costs are recorded within selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss. The Company does not adjust the amount of promised consideration for the effects of the time value of money for contracts in which the anticipated period between when the Company transfers the goods or services to the customer and when the customer pays within one year.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-bottom:10pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses include personnel-related costs, costs associated with pre-clinical and clinical development activities, costs associated with and costs for prototype products that are manufactured prior to market approval for that prototype product, internal and external costs associated with the Company&#8217;s regulatory compliance and quality assurance functions, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs, including allocated facility related expenses.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes stock-based compensation expense for employees, consultants and members of the Board of Directors based on the fair value at the date of grant.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option pricing model to value stock option grants. The Black-Scholes option pricing model requires the input of subjective assumptions, including the expected volatility of the Company&#8217;s common stock, expected risk-free interest rate, and the option&#8217;s expected life. The fair value of the Company&#8217;s restricted stock units (&#8220;RSUs&#8221;) is based on the fair value on the grant date of the Company&#8217;s common stock. The Company also evaluates the impact of modifications made to the original terms of equity awards when they occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a Monte Carlo simulation model to determine the fair value of performance units with market conditions at the grant date. The Monte Carlo simulation model involves the generation of a large number of possible stock price outcomes for the Company&#8217;s stock which is assumed to follow a Geometric Brownian Motion. The use of the Monte Carlo simulation model requires the input of a number of assumptions including expected volatility of the Company&#8217;s stock price, which is based on the historical volatility of its stock; risk-free interest rate, which is based on the treasury zero-coupon yield commensurate with the term of the performance unit as of the grant date; and expected dividends as applicable, which is zero, as the Company has never paid any cash dividends.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options and RSUs with service conditions that are expected to vest is amortized on a straight-line basis over the requisite service period. Stock-based compensation for RSUs with performance or market conditions is recorded over the requisite service period using the accelerated attribution method. Stock-based compensation expense is recognized net of actual forfeitures when they occur, as an increase to additional paid-in capital in the consolidated balance sheets and in the selling, general and administrative or research and development expenses in the consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Costs</span></div>Advertising costs are expensed as incurred and primarily include costs related to social media ads and co-branded marketing programs. Advertising costs are included in selling, general and administrative expenses.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:9pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined on the basis of differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. </span></div><div style="margin-bottom:9pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is recorded against deferred tax assets to reduce the net carrying value when it is more likely than not that some portion or all of a deferred tax asset will not be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, and ongoing prudent and feasible tax planning strategies in assessing the amount of the valuation </span></div><div style="margin-bottom:9pt;padding-right:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allowance. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. Accordingly, the Company establishes reserves for uncertain tax positions. The Company has not recognized interest or penalties in its consolidated statement of operations and comprehensive loss.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to file federal and state income tax returns in the United States and various other state jurisdictions. The preparation of these income tax returns requires the Company to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company. An amount is accrued for the estimate of additional tax liability, including interest and penalties, for any uncertain tax positions taken or expected to be taken in an income tax return. The Company reviews and updates the accrual for uncertain tax positions as more definitive information becomes available. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of the Company&#8217;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than&#160;50%&#160;likely of being realized upon settlement. While the Company believes it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcomes of examinations by tax authorities in determining the adequacy of its provision for income taxes. The Company continually assesses the likelihood and amount of potential revisions and adjusts the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company monitors changes to the tax laws in the states it conducts business and files corporate income tax returns. The Company does not expect changes to state tax laws through December&#160;31, 2024 to materially impact its consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div>Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period including contingently issuable shares. Diluted earnings per share is based on the treasury stock method and includes the effect from potential issuance of ordinary shares, such as shares issuable pursuant to the exercise of stock options and the vesting of restricted stock units. Because the impact of the options and non-vested RSUs are anti-dilutive during periods of net loss, there was no difference between the weighted-average number of shares used to calculate basic and diluted net loss per common share for the periods presented. Excluded from the dilutive net loss per share computation for the twelve months ended<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Pronouncements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting - Improving Reportable Segment Disclosures (Topic 280)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The standard requires disclosures to include significant segment expenses that are regularly provided to the chief operating decision maker (&#8220;CODM&#8221;), a description of other segment items by reportable segment, and any additional measures of a segment's profit or loss used by the CODM when deciding how to allocate resources. The ASU also requires all annual disclosures currently required by Topic 280 to be included in interim periods. ASU 2023-07 is effective for annual reporting periods beginning after December </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15, 2023 and interim reporting periods after December 15, 2024. The Company adopted this guidance on December&#160;31, 2024 and updated its disclosures to conform to this new segment disclosure requirement.</span></div><div style="margin-bottom:9pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements&#160;Issued But Not&#160;Adopted&#160;</span></div><div style="margin-bottom:9pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU No. 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This update requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income taxes paid. ASU No. 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.</span></div><div style="margin-bottom:9pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU No. 2024-03 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires disaggregated disclosure of certain costs and expenses on an interim and annual basis. ASU No. 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The disclosure updates are required to be applied prospectively with the option for retrospective application. The Company is currently evaluating the impact of adopting ASU No. 2024-03.</span></div><div style="margin-bottom:9pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by management to, have a material impact on the Company&#8217;s present or future financial position, results of operations or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 450<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477850/954-450-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064177184944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. The fair value of these instruments was as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"></td><td style="width:52.873%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent royalty obligation payable to Evolus Founders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"><tr><td style="width:1.0%"></td><td style="width:52.873%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.848%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent royalty obligation payable to Evolus Founders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Reconciliation of Fair Value Measurement for Contingent Royalty Obligation Payable</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a reconciliation of the beginning and ending fair value measurements of the contingent royalty obligation payable:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,030&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,310&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,441)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,537)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,185)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value recorded in operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,755&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,765&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,030&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,310&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064176872816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Intangible Assets and Goodwill</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below shows the weighted-average life, original cost, accumulated amortization and net book value by major intangible asset classification:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.824%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Original Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Book Value</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution rights</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,580)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,770)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,104&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,350)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,754&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Indefinite-lived intangible asset</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total as of December&#160;31, 2024</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,312&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,350)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,962&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.824%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Original Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Book Value</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution right</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,804&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,746)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,356&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,246)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,110&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Indefinite-lived intangible asset</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total as of December&#160;31, 2023</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,564&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,246)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,318&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Estimated Future Amortization Expense of Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table outlines the estimated future amortization expense related to intangible assets held as of&#160;December&#160;31, 2024 that are subject to amortization:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.142%"><tr><td style="width:1.0%"></td><td style="width:55.931%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.869%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,754&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064179244032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued royalties under the Medytox Settlement Agreements</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,743&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,657&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll and related benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued revenue contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,791&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,813&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064264817664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment consisted of the following:</span></div><div style="margin-bottom:9pt;padding-right:15.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold Improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketing Fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant, and equipment</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,745&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,487&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,523)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,400)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,222&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,087&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064271727072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-term Debt</a></td>
<td class="text"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the principal amounts of long-term debt maturities for each of the next five fiscal years are as follows:</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.476%"><tr><td style="width:1.0%"></td><td style="width:68.218%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.582%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total principal payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discounts and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,494)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term debt, net of discounts and issuance costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,506&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064180334464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Composition of Lease Expense and Other Quantitative Information</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease expense are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,526&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,164&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable operating lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,676&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,347&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average remaining lease term and discount rate are as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,433</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,320</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,265</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity of Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the future minimum payments under the operating lease agreements with non-cancelable terms as of December&#160;31, 2024:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.327%"><tr><td style="width:1.0%"></td><td style="width:76.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.452%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fiscal year</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,718&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,926&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,453)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,473&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064271558256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Key Assumptions Used to Determine Fair Value of Options Granted</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used in determining the fair value of stock options granted were as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:38.095%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt 0 5.5pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.7%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.6%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.9%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.21</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.19</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield rate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Options Activity</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity for the year ended December 31, 2024, 2023, and 2022 is presented below:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:41.224%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.764%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contractual</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intrinsic</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Terms (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,753,466&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.69</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,111&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,127,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(537,293)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192,937)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,151,069&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,691&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,151,069&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.16</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,691&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,619,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.64</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,801&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of RSUs Activity</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU activity for the year ended December 31, 2024, 2023, and 2022, is presented below:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:58.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,281,045&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.88&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,571,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,131,101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(342,357)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,378,867&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.80&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of PRSU activity for the year ended December 31, 2024 and 2023, is presented below:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:58.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.721%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Performance</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,880&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136,433)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395,984&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.12&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock-based compensation expense:</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.875%"><tr><td style="width:1.0%"></td><td style="width:36.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.330%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.330%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,172&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,564&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,565&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,188&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,458&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,833&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064178065952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Loss before Income Taxes from U.S. Operations and Foreign</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s loss before income taxes was generated from its U.S. operations and foreign operations as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.096%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.096%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,349&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,004&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,103&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,756&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,509&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,317&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Current and Deferred Income Tax Expense</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the expense (benefit) for income taxes:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.694%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provision:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current provision</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">685&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred provision (benefit):</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred (benefit) provision</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of deferred tax assets and liabilities were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.694%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,808&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal settlement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,283&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,674&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;E capitalization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,415&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed asset depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(124,895)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116,073)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103,695)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,162&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,163&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,343&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,343)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,730)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,525)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,825)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,460)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(495)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed asset depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(345)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,168)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,190)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,365)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the difference between the provision (benefit) for income taxes and income taxes at the statutory U.S. federal income tax rate is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.694%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax at statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,413)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,917)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,607)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(753)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,981)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,673)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation of contingent royalty obligation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,823&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Meals and entertainment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in state tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers' compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,529)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Rate Differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,377)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(449)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(391)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.401%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.401%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to prior year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to current year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064179156880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Reconciliation of Revenue to Net Loss</a></td>
<td class="text">The table below <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shows the Company&#8217;s reconciliation of revenue and significant segment items to net loss, regularly provided to and reviewed by the CODM, as computed under U.S. GAAP:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.042%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.741%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt 0 5.5pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product cost of goods sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,015&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of distribution right</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In process research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation of contingent royalty obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(860)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(696)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,420)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61,685)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,412)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Revenue by Country</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The product and service revenue attributed to foreign countries from which the Company derives product and service revenue is as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.042%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.741%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue by country, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue by country, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,274&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,085&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,616&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064176821744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2024 </div>
<div>product</div>
</th>
<th class="th">
<div>Apr. 30, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>product</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,411<span></span>
</td>
<td class="nump">$ 49,233<span></span>
</td>
<td class="nump">$ 65,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,420<span></span>
</td>
<td class="nump">61,685<span></span>
</td>
<td class="nump">74,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,999<span></span>
</td>
<td class="nump">34,008<span></span>
</td>
<td class="nump">$ 84,912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,952<span></span>
</td>
<td class="nump">62,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 609,399<span></span>
</td>
<td class="nump">$ 558,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eols_SymateseEuropeAgreementMember', window );">Symatese Europe Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts', window );">Regulatory approval, number of products | product</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eols_SymateseU.S.AgreementMember', window );">Symatese U.S. Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementExpectedRegulatoryApprovalNumberOfProducts', window );">Expected regulatory approval, number of products | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=eols_FollowOnOfferingMember', window );">Follow-on Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,554,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per share (in dollar per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate net proceeds from stock offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">318,100<span></span>
</td>
<td class="nump">533,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate net proceeds from stock offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_SaleOfStockGrantedOptionsExercisablePeriod', window );">Granted options, exercisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LicenseSupplyAndDistributionAgreementExpectedRegulatoryApprovalNumberOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License, Supply And Distribution Agreement, Expected Regulatory Approval, Number Of Products</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LicenseSupplyAndDistributionAgreementExpectedRegulatoryApprovalNumberOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License, Supply and Distribution Agreement, Regulatory Approval, Number Of Products</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_SaleOfStockGrantedOptionsExercisablePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Granted Options, Exercisable Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_SaleOfStockGrantedOptionsExercisablePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eols_SymateseEuropeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eols_SymateseEuropeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eols_SymateseU.S.AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eols_SymateseU.S.AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=eols_FollowOnOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=eols_FollowOnOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064167384432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 20, 2023 </div>
<div>EUR (&#8364;) </div>
<div>product </div>
<div>productCandidate </div>
<div>country </div>
<div>milestonePayment </div>
<div>shares</div>
</th>
<th class="th">
<div>May 09, 2023 </div>
<div>EUR (&#8364;) </div>
<div>productCandidate</div>
</th>
<th class="th">
<div>Feb. 18, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Dec. 14, 2017</div></th>
<th class="th">
<div>Oct. 31, 2024 </div>
<div>milestonePayment </div>
<div>product</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>segment </div>
<div>product </div>
<div>reporting_unit </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | reporting_unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_ResearchAndDevelopmentInProcess1', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,869,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_NonCashInResearchAndDevelopmentInProcessExpenses', window );">Non-cash in-process research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,429,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Accrued revenue contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,454,000<span></span>
</td>
<td class="nump">11,033,000<span></span>
</td>
<td class="nump">9,011,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_RebatesAndCouponsCreditsAndPayments', window );">Rebates and coupons, credits and payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,783,000<span></span>
</td>
<td class="nump">32,511,000<span></span>
</td>
<td class="nump">22,759,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability', window );">Payments for provisions for accrued volume-based rebate and coupon liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,362,000<span></span>
</td>
<td class="nump">30,489,000<span></span>
</td>
<td class="nump">21,682,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with customer, liability, revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,220,000<span></span>
</td>
<td class="nump">7,868,000<span></span>
</td>
<td class="nump">7,566,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,714,000<span></span>
</td>
<td class="nump">1,490,000<span></span>
</td>
<td class="nump">2,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for bad debts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,449,000<span></span>
</td>
<td class="nump">1,440,000<span></span>
</td>
<td class="nump">1,598,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_AccountsReceivableAllowanceForCreditLossWriteOffRecovery', window );">Write-off amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,225,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">1,933,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Accrued litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,698,000<span></span>
</td>
<td class="nump">$ 7,490,000<span></span>
</td>
<td class="nump">$ 11,642,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=eols_PerformanceRestrictedStockUnitsPRSUMember', window );">Performance Restricted Stock Units (PRSU)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities excluded from the computation of diluted net loss per share (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,151,069<span></span>
</td>
<td class="nump">5,753,466<span></span>
</td>
<td class="nump">4,769,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities excluded from the computation of diluted net loss per share (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,476,314<span></span>
</td>
<td class="nump">3,281,045<span></span>
</td>
<td class="nump">2,663,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=eols_IntellectualPropertyDisputesJeuveauMember', window );">Intellectual Property Disputes, Jeuveau</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LossContingencySettlementAgreementPaymentTerms', window );">Settlement agreement, payment terms (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eols_SymateseU.S.AgreementMember', window );">Symatese U.S. Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementRightToCommercializeAndDistributeNumberOfProductCandidates', window );">Right to commercialize and distribute, number of product candidates | productCandidate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementMinimumMilestonePayment', window );">Contingent milestone payment | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 16,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement', window );">License, supply and distribution agreement, initial payment | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod', window );">License, supply and distribution agreement, initial payment due, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne', window );">License, supply and distribution agreement payment, June 2025 (in euro) | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo', window );">License, supply and distribution agreement payment, June 2026 (in euro) | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree', window );">License, supply and distribution agreement payment, June 2027 (in euro) | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour', window );">License, supply and distribution agreement payment, June 2028 (in euro) | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense', window );">License, supply and distribution agreement, upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,441,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,441,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementInitialTerm', window );">License, supply and distribution agreement, initial term</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementRenewalTerm', window );">License, supply and distribution agreement, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eols_SymateseEuropeAgreementMember', window );">Symatese Europe Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo', window );">License, supply and distribution agreement payment, June 2026 (in euro) | &#8364;</a></td>
<td class="nump">&#8364; 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree', window );">License, supply and distribution agreement payment, June 2027 (in euro) | &#8364;</a></td>
<td class="nump">&#8364; 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementNumberOfProductCandidates', window );">Number of product candidates | productCandidate</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementNumberOfCountriesUseAestheticsAndDermatologicalFields', window );">Number of countries use aesthetics and dermatological fields | country</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment', window );">Number of milestone payment | milestonePayment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementAnnualRevenue', window );">Annual revenue (in euro) | &#8364;</a></td>
<td class="nump">&#8364; 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementPendingRegulatoryApprovalNumberOfProducts', window );">Pending regulatory approval, number of products | product</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementMilestonePaymentPayablePeriod', window );">Milestone payment, payable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts', window );">Regulatory approval, number of products | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eols_SymateseEuropeAgreementMember', window );">Symatese Europe Agreement | First Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementLiabilityNoncurrent', window );">License, supply and distribution agreement, liability, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,035,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementIntangibleAsset', window );">License, supply and distribution agreement, intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,035,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eols_SymateseEuropeAgreementMember', window );">Symatese Europe Agreement | Second Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementLiabilityNoncurrent', window );">License, supply and distribution agreement, liability, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementIntangibleAsset', window );">License, supply and distribution agreement, intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement', window );">Stock issued in exchange for license, supply, and distribution agreement (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">610,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_StockIssuedDuringPeriodSharesLitigationSettlement', window );">Issuance of common stock in connection with litigation settlement (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,762,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,762,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Symatese Europe Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement', window );">Stock issued in exchange for license, supply, and distribution agreement (in shares) | shares</a></td>
<td class="nump">610,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember', window );">Evolus, Inc. | SCH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale', window );">Period of termination of first commercial sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eols_DistributionRightsEvolysseNasolabialFoldProductMember', window );">Distribution Rights, Evolysse Nasolabial Fold Product | Symatese Europe Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-live intangible assets capitalized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,235,000<span></span>
</td>
<td class="nump">$ 1,476,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful lives of intangible assets</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember', window );">Distribution rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful lives of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eols_DistributionRightsEvolysseProductsMember', window );">Distribution Rights, Evolysse Products | Symatese Europe Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful lives of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years 2 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years 2 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_SoftwareDevelopmentMember', window );">Software Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful lives of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_AccountsReceivableCreditCardTransactionConvertedToCashPeriod', window );">Accounts receivable, credit card transaction, converted to cash, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_AccountsReceivableCreditCardTransactionConvertedToCashPeriod', window );">Accounts receivable, credit card transaction, converted to cash, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_AccountsReceivableAllowanceForCreditLossWriteOffRecovery">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Allowance for Credit Loss, Write-off (Recovery)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_AccountsReceivableAllowanceForCreditLossWriteOffRecovery</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_AccountsReceivableCreditCardTransactionConvertedToCashPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Credit Card Transaction, Converted To Cash, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_AccountsReceivableCreditCardTransactionConvertedToCashPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License, Supply and Distribution Agreement, Annual Principal Payment, Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License, Supply and Distribution Agreement, Annual Payment, Year One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License, Supply and Distribution Agreement, Annual Payment, Year Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License, Supply and Distribution Agreement, Annual Payment, Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LicenseSupplyAndDistributionAgreementAnnualRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License, Supply and Distribution Agreement, Annual revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LicenseSupplyAndDistributionAgreementAnnualRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License, Supply and Distribution Agreement, Initial Payment Due, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License, Supply and Distribution Agreement, Initial Payment in Connection with Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LicenseSupplyAndDistributionAgreementInitialTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License, Supply and Distribution Agreement, Initial Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LicenseSupplyAndDistributionAgreementInitialTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LicenseSupplyAndDistributionAgreementIntangibleAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License, Supply And Distribution Agreement, Intangible Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LicenseSupplyAndDistributionAgreementIntangibleAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LicenseSupplyAndDistributionAgreementLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License, Supply And Distribution Agreement, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LicenseSupplyAndDistributionAgreementLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LicenseSupplyAndDistributionAgreementMilestonePaymentPayablePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License, Supply And Distribution Agreement, Milestone Payment, Payable Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LicenseSupplyAndDistributionAgreementMilestonePaymentPayablePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LicenseSupplyAndDistributionAgreementMinimumMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License, Supply and Distribution Agreement, Minimum Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LicenseSupplyAndDistributionAgreementMinimumMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LicenseSupplyAndDistributionAgreementNumberOfCountriesUseAestheticsAndDermatologicalFields">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License, Supply and Distribution Agreement, Number Of Countries Use Aesthetics and Dermatological Fields</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LicenseSupplyAndDistributionAgreementNumberOfCountriesUseAestheticsAndDermatologicalFields</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License, Supply and Distribution Agreement, Number Of Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LicenseSupplyAndDistributionAgreementNumberOfProductCandidates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License, Supply And Distribution Agreement, Number Of Product Candidates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LicenseSupplyAndDistributionAgreementNumberOfProductCandidates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LicenseSupplyAndDistributionAgreementPendingRegulatoryApprovalNumberOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License, Supply And Distribution Agreement, Pending Regulatory Approval, Number Of Products</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LicenseSupplyAndDistributionAgreementPendingRegulatoryApprovalNumberOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License, Supply and Distribution Agreement, Regulatory Approval, Number Of Products</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LicenseSupplyAndDistributionAgreementRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License, Supply and Distribution Agreement, Renewal Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LicenseSupplyAndDistributionAgreementRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LicenseSupplyAndDistributionAgreementRightToCommercializeAndDistributeNumberOfProductCandidates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License, Supply And Distribution Agreement, Right To Commercialize And Distribute, Number Of Product Candidates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LicenseSupplyAndDistributionAgreementRightToCommercializeAndDistributeNumberOfProductCandidates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License, Supply and Distribution Agreement, Upfront Payment, In-Process Research and Development Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LossContingencySettlementAgreementPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Settlement Agreement, Payment Terms</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LossContingencySettlementAgreementPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_NonCashInResearchAndDevelopmentInProcessExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash In Research And Development In Process Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_NonCashInResearchAndDevelopmentInProcessExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Provisions For Accrued Volume-Based Rebate, Coupon And Consumer Loyalty Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_RebatesAndCouponsCreditsAndPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rebates And Coupons, Credits And Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_RebatesAndCouponsCreditsAndPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Period Of Termination Of First Commercial Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_ResearchAndDevelopmentInProcess1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development In Process 1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_ResearchAndDevelopmentInProcess1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Issued for License, Supply and Distribution Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_StockIssuedDuringPeriodSharesLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares, Litigation Settlement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_StockIssuedDuringPeriodSharesLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483385/720-35-55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=eols_PerformanceRestrictedStockUnitsPRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=eols_PerformanceRestrictedStockUnitsPRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=eols_IntellectualPropertyDisputesJeuveauMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=eols_IntellectualPropertyDisputesJeuveauMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eols_SymateseU.S.AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eols_SymateseU.S.AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eols_SymateseEuropeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eols_SymateseEuropeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_MilestoneAxis=eols_FirstMilestonePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_MilestoneAxis=eols_FirstMilestonePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_MilestoneAxis=eols_SecondMilestonePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_MilestoneAxis=eols_SecondMilestonePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=eols_SCHAEONLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=eols_SCHAEONLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eols_DistributionRightsEvolysseNasolabialFoldProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eols_DistributionRightsEvolysseNasolabialFoldProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eols_DistributionRightsEvolysseProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eols_DistributionRightsEvolysseProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064178276608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - Contingent royalty obligation payable to Evolus Founders - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">$ 44,765<span></span>
</td>
<td class="nump">$ 45,030<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">$ 44,765<span></span>
</td>
<td class="nump">$ 45,030<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064178738848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">$ 44,765<span></span>
</td>
<td class="nump">$ 45,030<span></span>
</td>
<td class="nump">$ 46,310<span></span>
</td>
<td class="nump">$ 44,740<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Pharmakon Term Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">$ 132,078<span></span>
</td>
<td class="nump">$ 140,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=eols_ContingentRoyaltyObligationMember', window );">Contingent Royalty Obligation | Measurement Input, Discount Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.14<span></span>
</td>
<td class="nump">0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestmentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure alternative investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestmentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=eols_ContingentRoyaltyObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=eols_ContingentRoyaltyObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064180380624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Reconciliation of Fair Value Measurement of Contingent Royalty Obligation Payable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, beginning of period</a></td>
<td class="nump">$ 45,030<span></span>
</td>
<td class="nump">$ 46,310<span></span>
</td>
<td class="nump">$ 44,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="num">(7,441)<span></span>
</td>
<td class="num">(5,537)<span></span>
</td>
<td class="num">(4,185)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value recorded in operating expenses</a></td>
<td class="nump">7,176<span></span>
</td>
<td class="nump">4,257<span></span>
</td>
<td class="nump">5,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, end of period</a></td>
<td class="nump">$ 44,765<span></span>
</td>
<td class="nump">$ 45,030<span></span>
</td>
<td class="nump">$ 46,310<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064178342176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of Definite and Indefinite-Lived Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Definite-lived intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Original Cost</a></td>
<td class="nump">$ 76,104<span></span>
</td>
<td class="nump">$ 70,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(27,350)<span></span>
</td>
<td class="num">(23,246)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Book Value</a></td>
<td class="nump">48,754<span></span>
</td>
<td class="nump">47,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-lived intangible asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">21,208<span></span>
</td>
<td class="nump">21,208<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_IntangibleAssetsGrossIncludingGoodwill', window );">Intangible assets, gross (including goodwill)</a></td>
<td class="nump">97,312<span></span>
</td>
<td class="nump">91,564<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Total net book value</a></td>
<td class="nump">$ 69,962<span></span>
</td>
<td class="nump">68,318<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember', window );">Distribution rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Definite-lived intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted-Average Life (Years)</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Original Cost</a></td>
<td class="nump">$ 62,787<span></span>
</td>
<td class="nump">60,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(17,580)<span></span>
</td>
<td class="num">(14,500)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Book Value</a></td>
<td class="nump">45,207<span></span>
</td>
<td class="nump">46,052<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Capitalized software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Definite-lived intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Original Cost</a></td>
<td class="nump">13,317<span></span>
</td>
<td class="nump">9,804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(9,770)<span></span>
</td>
<td class="num">(8,746)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Book Value</a></td>
<td class="nump">$ 3,547<span></span>
</td>
<td class="nump">$ 1,058<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_IntangibleAssetsGrossIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets, Gross (Including Goodwill)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_IntangibleAssetsGrossIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after impairment and amortization, of goodwill, indefinite-lived, and finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064176354000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Estimated Future Amortization Expense of Intangibles (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 4,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2026</a></td>
<td class="nump">4,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2027</a></td>
<td class="nump">3,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2028</a></td>
<td class="nump">3,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2029</a></td>
<td class="nump">3,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">29,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Book Value</a></td>
<td class="nump">$ 48,754<span></span>
</td>
<td class="nump">$ 47,110<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064180903360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 20, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAdditions', window );">Capitalized computer software</a></td>
<td class="nump">$ 3,513<span></span>
</td>
<td class="nump">$ 1,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">4,104<span></span>
</td>
<td class="nump">4,072<span></span>
</td>
<td class="nump">$ 3,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eols_DistributionRightsEvolysseNasolabialFoldProductMember', window );">Distribution Rights, Evolysse Nasolabial Fold Product | Symatese Europe Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-live intangible assets capitalized</a></td>
<td class="nump">$ 2,235<span></span>
</td>
<td class="nump">$ 1,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful lives of intangible assets</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Capitalized software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Remaining amortization period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additions made to capitalized computer software costs during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eols_DistributionRightsEvolysseNasolabialFoldProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=eols_DistributionRightsEvolysseNasolabialFoldProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eols_SymateseEuropeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eols_SymateseEuropeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064178538912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties under the Medytox Settlement Agreements</a></td>
<td class="nump">$ 4,743<span></span>
</td>
<td class="nump">$ 3,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and related benefits</a></td>
<td class="nump">14,127<span></span>
</td>
<td class="nump">13,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Accrued revenue contract liabilities</a></td>
<td class="nump">14,454<span></span>
</td>
<td class="nump">11,033<span></span>
</td>
<td class="nump">$ 9,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">7,467<span></span>
</td>
<td class="nump">5,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities, current</a></td>
<td class="nump">$ 40,791<span></span>
</td>
<td class="nump">$ 33,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064177026320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 6,745<span></span>
</td>
<td class="nump">$ 4,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(3,523)<span></span>
</td>
<td class="num">(2,400)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,222<span></span>
</td>
<td class="nump">2,087<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">452<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">702<span></span>
</td>
<td class="nump">345<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">3,574<span></span>
</td>
<td class="nump">2,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">317<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eols_MarketingFixturesMember', window );">Marketing Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=eols_MarketingFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=eols_MarketingFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064178384064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 1,194<span></span>
</td>
<td class="nump">$ 1,001<span></span>
</td>
<td class="nump">$ 373<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064179392368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loans - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 15, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 09, 2023 </div>
<div>USD ($) </div>
<div>installment </div>
<div>payment</div>
</th>
<th class="th">
<div>Dec. 05, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 14, 2021 </div>
<div>USD ($) </div>
<div>tranche</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments for debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 46,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_DebtInstrumentNumberOfInstallments', window );">Debt instrument, number of installments | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt, net of discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_DebtInstrumentPrepaymentAmountThreshold', window );">Debt instrument, prepayment amount threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansMember', window );">Pharmakon Term Loans | Prior to the 3rd anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt, net of discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansMember', window );">Pharmakon Term Loans | After the 3rd anniversary but prior to the 4th anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt, net of discounts</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansMember', window );">Pharmakon Term Loans | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_DebtInstrumentNumberOfTranches', window );">Number of tranches | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Maturity term of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_DebtInstrumentPeriodicPaymentOutstandingPrincipalAmountDuePercentage', window );">Periodic payment, percentage of outstanding principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_DebtInstrumentPeriodicPaymentNumberOfPrincipalPayments', window );">Periodic payment, number of quarterly principal payments due | payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_DebtInstrumentPeriodicPaymentInitialPrincipalPaymentDuePeriod', window );">Periodic payment, Initial principal payment, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">51 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,042,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,263,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansMember', window );">Pharmakon Term Loans | Term Loan | London Interbank Offered Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansMember', window );">Pharmakon Term Loans | Term Loan | Secured Financing Offered Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansOneMember', window );">Tranche A Loan | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate, effective percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.52%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansOneMember', window );">Tranche A Loan | Term Loan | Prior to the 3rd anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount', window );">Debt instrument, percentage of principal amount, prepaid multiplied</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansOneMember', window );">Tranche A Loan | Term Loan | After the 3rd anniversary but prior to the 4th anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount', window );">Debt instrument, percentage of principal amount, prepaid multiplied</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansOneMember', window );">Tranche A Loan | Term Loan | After the 4th anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount', window );">Debt instrument, percentage of principal amount, prepaid multiplied</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansTwoMember', window );">Tranche B Loan | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments for debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate, effective percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.21%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentNumberOfInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number of Installments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentNumberOfInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number of Tranches</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPeriodicPaymentInitialPrincipalPaymentDuePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Payment, Initial Principal Payment Due, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPeriodicPaymentInitialPrincipalPaymentDuePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPeriodicPaymentNumberOfPrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Payment, Number of Principal Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPeriodicPaymentNumberOfPrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPeriodicPaymentOutstandingPrincipalAmountDuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Payment, Outstanding Principal Amount Due, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPeriodicPaymentOutstandingPrincipalAmountDuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPrepaymentAmountThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Amount Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPrepaymentAmountThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Terms, Prepayment Multiple On Principal Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPrepaymentTermsAxis=eols_TermOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPrepaymentTermsAxis=eols_TermOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPrepaymentTermsAxis=eols_TermTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPrepaymentTermsAxis=eols_TermTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=eols_LondonInterbankOfferedRateLIBOR1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=eols_LondonInterbankOfferedRateLIBOR1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=eols_SecuredFinancingOfferedRateSOFRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=eols_SecuredFinancingOfferedRateSOFRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPrepaymentTermsAxis=eols_TermThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPrepaymentTermsAxis=eols_TermThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_PharmakonTermLoansTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064180627840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Term Loans - Schedule of Long Term Debt Maturities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2026</a></td>
<td class="nump">41,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2027</a></td>
<td class="nump">83,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2028</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal payments</a></td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discounts and issuance costs</a></td>
<td class="num">(3,494)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term debt, net of discounts and issuance costs</a></td>
<td class="nump">$ 121,506<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064176670288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Oct. 16, 2024</div></th>
<th class="th"><div>Aug. 01, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jul. 27, 2023</div></th>
<th class="th"><div>Mar. 15, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LesseeOperatingLeaseAbatementPeriod', window );">Lessee, operating lease, abatement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">$ 8,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 7,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,002<span></span>
</td>
<td class="nump">$ 5,763<span></span>
</td>
<td class="nump">$ 4,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount', window );">Fixed cash payments estimated to be over term of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LesseeOperatingLeaseAbatementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Abatement Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LesseeOperatingLeaseAbatementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecorded obligation to transfer funds in future for fixed or minimum amount or quantity of product and service at fixed or minimum price. Includes, but is not limited to, lease not yet commenced and take-or-pay and throughput contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064178398128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases - Components of Lease Expense and Other Quantitative Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Fixed operating lease expense</a></td>
<td class="nump">$ 1,526<span></span>
</td>
<td class="nump">$ 1,164<span></span>
</td>
<td class="nump">$ 1,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable operating lease expense</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease, cost</a></td>
<td class="nump">$ 1,676<span></span>
</td>
<td class="nump">$ 1,347<span></span>
</td>
<td class="nump">$ 1,175<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064177371088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases - Weighted-Average Remaining Lease Term and Discount Rate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (years)</a></td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">9.70%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">9.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">$ 1,433<span></span>
</td>
<td class="nump">$ 1,320<span></span>
</td>
<td class="nump">$ 1,265<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064179641696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Maturity of Operating Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Aug. 01, 2024</div></th>
<th class="th"><div>Jul. 27, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 1,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">2,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">2,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">2,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">2,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">10,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(2,453)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">$ 8,473<span></span>
</td>
<td class="nump">$ 3,002<span></span>
</td>
<td class="nump">$ 4,550<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064176144896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 09, 2023 </div>
<div>EUR (&#8364;) </div>
<div>product</div>
</th>
<th class="th">
<div>Nov. 17, 2021 </div>
<div>officer</div>
</th>
<th class="th">
<div>Dec. 02, 2020 </div>
<div>plaintiff</div>
</th>
<th class="th">
<div>Oct. 28, 2020 </div>
<div>complaint</div>
</th>
<th class="th">
<div>Oct. 31, 2024 </div>
<div>milestonePayment </div>
<div>product</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>product</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 20, 2023 </div>
<div>EUR (&#8364;) </div>
<div>milestonePayment</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_PaymentsForInventory', window );">Inventory payments | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,233,000<span></span>
</td>
<td class="nump">$ 50,770,000<span></span>
</td>
<td class="nump">$ 50,685,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss contingency, new claims filed, number | complaint</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LossContingencyNumberDefendantsOfficers', window );">Loss contingency, number of defendants, officers | officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Loss contingency, number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eols_SymateseU.S.AgreementMember', window );">Symatese U.S. Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementMinimumMilestonePayment', window );">Contingent milestone payment</a></td>
<td class="nump">&#8364; 16,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement', window );">License, supply and distribution agreement, initial payment</a></td>
<td class="nump">&#8364; 4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod', window );">License, supply and distribution agreement, initial payment due, period</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne', window );">License, supply and distribution agreement payment, June 2025 (in euro)</a></td>
<td class="nump">&#8364; 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo', window );">License, supply and distribution agreement payment, June 2026 (in euro)</a></td>
<td class="nump">4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree', window );">License, supply and distribution agreement payment, June 2027 (in euro)</a></td>
<td class="nump">3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour', window );">License, supply and distribution agreement payment, June 2028 (in euro)</a></td>
<td class="nump">&#8364; 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentTriggeredRegulatoryApprovalNumberOfProducts', window );">Annual payment triggered, number of products with regulatory approval | product</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense', window );">License, supply and distribution agreement, upfront payment | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,441,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,441,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=eols_SymateseEuropeAgreementMember', window );">Symatese Europe Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo', window );">License, supply and distribution agreement payment, June 2026 (in euro)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree', window );">License, supply and distribution agreement payment, June 2027 (in euro)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment', window );">Number of milestone payment | milestonePayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementAnnualRevenue', window );">Annual revenue (in euro)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts', window );">Regulatory approval, number of products | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LicenseSupplyAndDistributionAgreementMilestonePaymentPayablePeriod', window );">Milestone payment, payable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentTriggeredRegulatoryApprovalNumberOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License, Supply And Distribution Agreement, Annual Payment Triggered, Regulatory Approval, Number Of Products</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LicenseSupplyAndDistributionAgreementAnnualPaymentTriggeredRegulatoryApprovalNumberOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License, Supply and Distribution Agreement, Annual Principal Payment, Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License, Supply and Distribution Agreement, Annual Payment, Year One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License, Supply and Distribution Agreement, Annual Payment, Year Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License, Supply and Distribution Agreement, Annual Payment, Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LicenseSupplyAndDistributionAgreementAnnualRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License, Supply and Distribution Agreement, Annual revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LicenseSupplyAndDistributionAgreementAnnualRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License, Supply and Distribution Agreement, Initial Payment Due, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License, Supply and Distribution Agreement, Initial Payment in Connection with Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LicenseSupplyAndDistributionAgreementMilestonePaymentPayablePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License, Supply And Distribution Agreement, Milestone Payment, Payable Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LicenseSupplyAndDistributionAgreementMilestonePaymentPayablePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LicenseSupplyAndDistributionAgreementMinimumMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License, Supply and Distribution Agreement, Minimum Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LicenseSupplyAndDistributionAgreementMinimumMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License, Supply and Distribution Agreement, Number Of Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License, Supply and Distribution Agreement, Regulatory Approval, Number Of Products</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License, Supply and Distribution Agreement, Upfront Payment, In-Process Research and Development Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LossContingencyNumberDefendantsOfficers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Defendants, Officers</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LossContingencyNumberDefendantsOfficers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_PaymentsForInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Inventory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_PaymentsForInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eols_SymateseU.S.AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eols_SymateseU.S.AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=eols_SymateseEuropeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=eols_SymateseEuropeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064171045824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 06, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 08, 2023 </div>
<div>USD ($) </div>
<div>trading_day </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 08, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 21, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 29, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 21, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 21, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 21, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,497,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,497,548<span></span>
</td>
<td class="nump">57,820,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,497,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,497,548<span></span>
</td>
<td class="nump">57,820,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Capital shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,605,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,605,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Annual increase percentage of maximum shares outstanding (equal to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum number of shares authorized under the plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,361,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance', window );">Additional shares reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,535,476<span></span>
</td>
<td class="nump">2,287,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,249,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueVested', window );">Total intrinsic value of options that vested | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,171<span></span>
</td>
<td class="nump">$ 136<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,188<span></span>
</td>
<td class="nump">16,458<span></span>
</td>
<td class="nump">10,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation cost related to nonvested awards not yet recognized | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation cost related to nonvested awards not yet recognized, expected weighted-average period for recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Restricted stock units that vested, fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,740<span></span>
</td>
<td class="nump">$ 7,593<span></span>
</td>
<td class="nump">$ 6,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,571,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based payment award, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm', window );">Fair value assumptions, weighted average expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, options (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.71<span></span>
</td>
<td class="nump">$ 7.73<span></span>
</td>
<td class="nump">$ 4.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=eols_PerformanceRestrictedStockUnitsPRSUMember', window );">Performance Restricted Stock Units (PRSU)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,485<span></span>
</td>
<td class="nump">292,349<span></span>
</td>
<td class="nump">298,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod', window );">Performance period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Unvested Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Unvested Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eols_A2023InducementIncentivePlanMember', window );">2023 Inducement Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Capital shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock available for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eols_TwoThousandAndSeventeenOmnibusIncentivePlanMember', window );">2017 Omnibus Incentive Plan | CEO Performance Restricted Share Units (CPRSU)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsAfterTermination', window );">Contractual term after termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eols_TwoThousandAndSeventeenOmnibusIncentivePlanMember', window );">2017 Omnibus Incentive Plan | CEO Performance Restricted Share Units (CPRSU) | 20 Consecutive Trading Days with a $30 Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_ShareBasedPaymentArrangementNumberOfConsecutiveDays', window );">Number of consecutive days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_ShareBasedCompensationConsecutiveTradingDaysPerShareTarget', window );">Consecutive trading amount (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eols_TwoThousandAndSeventeenOmnibusIncentivePlanMember', window );">2017 Omnibus Incentive Plan | CEO Performance Restricted Share Units (CPRSU) | 20 Consecutive Trading Days with a $50 Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_ShareBasedPaymentArrangementNumberOfConsecutiveDays', window );">Number of consecutive days | trading_day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_ShareBasedCompensationConsecutiveTradingDaysPerShareTarget', window );">Consecutive trading amount (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=eols_A2024EmployeeStockPurchasePlanMember', window );">2024 Employee Stock Purchase Plan | Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Capital shares reserved for future issuance (in shares)</a></td>
<td class="nump">579,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Annual increase percentage of maximum shares outstanding (equal to)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalShareIncreaseAvailableForIssuance', window );">Additional shares available for issuance (in shares)</a></td>
<td class="nump">579,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Employee stock purchase plan shares issued during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=eols_FollowOnOfferingMember', window );">Follow-on Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,554,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price per share (in dollar per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=eols_ATMSalesAgreementMember', window );">ATM Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_SaleOfStockMaximumConsiderationReceivable', window );">Maximum consideration receivable | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage', window );">Sale of stock, commission payment upon gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Additional Capital Shares Reserved for Future Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Commission Payment Upon Gross Proceeds, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_SaleOfStockMaximumConsiderationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Consideration Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_SaleOfStockMaximumConsiderationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalShareIncreaseAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Additional Share Increase Available for Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalShareIncreaseAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsAfterTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms, After Termination</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsAfterTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value, Vested</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Performance Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_ShareBasedCompensationConsecutiveTradingDaysPerShareTarget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation, Consecutive Trading Days, Per Share Target</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_ShareBasedCompensationConsecutiveTradingDaysPerShareTarget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_ShareBasedPaymentArrangementNumberOfConsecutiveDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Payment Arrangement, Number of Consecutive Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_ShareBasedPaymentArrangementNumberOfConsecutiveDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=eols_PerformanceRestrictedStockUnitsPRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=eols_PerformanceRestrictedStockUnitsPRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=eols_A2023InducementIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=eols_A2023InducementIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=eols_TwoThousandAndSeventeenOmnibusIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=eols_TwoThousandAndSeventeenOmnibusIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=eols_CEOPerformanceRestrictedShareUnitsCPRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=eols_CEOPerformanceRestrictedShareUnitsCPRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=eols_A2024EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=eols_A2024EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=eols_FollowOnOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=eols_FollowOnOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=eols_ATMSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=eols_ATMSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064180474080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Weighted-Average Assumptions (Details) - Stock Options<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">83.70%<span></span>
</td>
<td class="nump">83.60%<span></span>
</td>
<td class="nump">78.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">6 years 2 months 15 days<span></span>
</td>
<td class="text">6 years 2 months 15 days<span></span>
</td>
<td class="text">6 years 2 months 8 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064178202512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Stock Option Activity (Details) - Stock Options - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">5,753,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,127,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(537,293)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled/forfeited (in shares)</a></td>
<td class="num">(192,937)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">6,151,069<span></span>
</td>
<td class="nump">5,753,466<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Stock options, vested and expected to vest (in shares)</a></td>
<td class="nump">6,151,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock options, exercisable (in shares)</a></td>
<td class="nump">3,619,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 9.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">13.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">7.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled/forfeited (in dollars per share)</a></td>
<td class="nump">10.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">10.29<span></span>
</td>
<td class="nump">$ 9.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, vested and expected to vest (in dollars per share)</a></td>
<td class="nump">10.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable (in dollars per share)</a></td>
<td class="nump">$ 9.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Stock options contractual term, outstanding</a></td>
<td class="text">6 years 1 month 28 days<span></span>
</td>
<td class="text">6 years 8 months 8 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Average remaining contractual term, vested and expected to vest</a></td>
<td class="text">6 years 1 month 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable', window );">Weighted average remaining contractual term, exercisable</a></td>
<td class="text">4 years 7 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, outstanding</a></td>
<td class="nump">$ 10,691<span></span>
</td>
<td class="nump">$ 11,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, vested and expected to vest</a></td>
<td class="nump">10,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable</a></td>
<td class="nump">$ 7,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Exercisable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064178600800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Restricted Stock Unit Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Unit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,281,045<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,571,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,131,101)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(342,357)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">3,378,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,378,867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">$ 10.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=eols_PerformanceRestrictedStockUnitsPRSUMember', window );">Performance Restricted Stock Units (PRSU)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Unit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">79,052<span></span>
</td>
<td class="nump">219,485<span></span>
</td>
<td class="nump">292,349<span></span>
</td>
<td class="nump">298,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(136,433)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">395,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">395,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">$ 12.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.12<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=eols_PerformanceRestrictedStockUnitsPRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=eols_PerformanceRestrictedStockUnitsPRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064179625296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 22,188<span></span>
</td>
<td class="nump">$ 16,458<span></span>
</td>
<td class="nump">$ 10,833<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">21,172<span></span>
</td>
<td class="nump">15,564<span></span>
</td>
<td class="nump">10,565<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 1,016<span></span>
</td>
<td class="nump">$ 894<span></span>
</td>
<td class="nump">$ 268<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064178724304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medytox Settlement Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 18, 2021</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LossContingencySettlementAgreementManufacturingLicensePeriod', window );">Settlement agreement, manufacturing license period (months)</a></td>
<td class="text">21 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodOne', window );">Share issuance agreement, percentage of share dispose per year, initial period</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodTwo', window );">Share issuance agreement, percentage of share dispose per year, period two</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodThree', window );">Share issuance agreement, percentage of share dispose per year, period three</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties under the medytox settlement agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,743,000<span></span>
</td>
<td class="nump">$ 3,657,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_StockIssuedDuringPeriodSharesLitigationSettlement', window );">Issuance of common stock in connection with litigation settlement (in shares)</a></td>
<td class="nump">6,762,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,762,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=eols_IntellectualPropertyDisputesJeuveauMember', window );">Intellectual Property Disputes, Jeuveau</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_LossContingencySettlementAgreementPaymentTerms', window );">Settlement agreement, payment terms (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LossContingencySettlementAgreementManufacturingLicensePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Settlement Agreement, Manufacturing License Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LossContingencySettlementAgreementManufacturingLicensePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LossContingencySettlementAgreementPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Settlement Agreement, Payment Terms</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LossContingencySettlementAgreementPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Issuance Agreement, Percentage of Share Dispose Per Year, Period One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Issuance Agreement, Percentage of Share Dispose Per Year, Period Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Issuance Agreement, Percentage of Share Dispose Per Year, Period Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_StockIssuedDuringPeriodSharesLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares, Litigation Settlement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_StockIssuedDuringPeriodSharesLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=eols_IntellectualPropertyDisputesJeuveauMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=eols_IntellectualPropertyDisputesJeuveauMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064176245232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contributions to 401(k) plan</a></td>
<td class="nump">$ 2,023<span></span>
</td>
<td class="nump">$ 1,582<span></span>
</td>
<td class="nump">$ 773<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064274667744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Loss before Income Taxes from U.S. Operations and Foreign (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="nump">$ 33,349<span></span>
</td>
<td class="nump">$ 51,004<span></span>
</td>
<td class="nump">$ 66,103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">16,407<span></span>
</td>
<td class="nump">10,505<span></span>
</td>
<td class="nump">8,214<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes:</a></td>
<td class="nump">$ 49,756<span></span>
</td>
<td class="nump">$ 61,509<span></span>
</td>
<td class="nump">$ 74,317<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064177619536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Current and Deferred Income Tax Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current provision:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">279<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">406<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current provision</a></td>
<td class="nump">685<span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred provision (benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(18)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred (benefit) provision</a></td>
<td class="num">(21)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision for income taxes</a></td>
<td class="nump">$ 664<span></span>
</td>
<td class="nump">$ 176<span></span>
</td>
<td class="nump">$ 95<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064176227120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Accrued interest and penalties related to income tax matters</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">315,179,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Operating loss carryforwards, subject to expiration</a></td>
<td class="nump">68,301,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Operating loss carryforwards, not subject to expiration</a></td>
<td class="nump">246,877,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | R&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">2,929,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">231,980,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | R&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">2,918,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">$ 38,922,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064165508368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract', window );"><strong>Deferred income tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 86,277<span></span>
</td>
<td class="nump">$ 83,257<span></span>
</td>
<td class="nump">$ 80,494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">7,808<span></span>
</td>
<td class="nump">5,442<span></span>
</td>
<td class="nump">5,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development credits</a></td>
<td class="nump">2,617<span></span>
</td>
<td class="nump">2,617<span></span>
</td>
<td class="nump">2,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation', window );">Accrued compensation</a></td>
<td class="nump">6,405<span></span>
</td>
<td class="nump">5,955<span></span>
</td>
<td class="nump">4,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">2,152<span></span>
</td>
<td class="nump">1,567<span></span>
</td>
<td class="nump">646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements', window );">Accrued legal settlement</a></td>
<td class="nump">16,283<span></span>
</td>
<td class="nump">17,674<span></span>
</td>
<td class="nump">19,203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_DeferredTaxAssetsResearchAndExperimentationCapitalization', window );">R&amp;E capitalization</a></td>
<td class="nump">4,107<span></span>
</td>
<td class="nump">3,415<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_DeferredTaxAssetsFixedAssetDepreciation', window );">Fixed asset depreciation</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other, net</a></td>
<td class="nump">8,382<span></span>
</td>
<td class="nump">5,126<span></span>
</td>
<td class="nump">2,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(124,895)<span></span>
</td>
<td class="num">(116,073)<span></span>
</td>
<td class="num">(103,695)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred income tax assets</a></td>
<td class="nump">9,162<span></span>
</td>
<td class="nump">9,163<span></span>
</td>
<td class="nump">12,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred income tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible amortization</a></td>
<td class="num">(7,343)<span></span>
</td>
<td class="num">(7,730)<span></span>
</td>
<td class="num">(11,525)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating lease right-of-use assets</a></td>
<td class="num">(1,825)<span></span>
</td>
<td class="num">(1,460)<span></span>
</td>
<td class="num">(495)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed asset depreciation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(345)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred income tax liabilities</a></td>
<td class="num">(9,168)<span></span>
</td>
<td class="num">(9,190)<span></span>
</td>
<td class="num">(12,365)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred income taxes</a></td>
<td class="num">$ (6)<span></span>
</td>
<td class="num">$ (27)<span></span>
</td>
<td class="num">$ (22)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DeferredTaxAssetsFixedAssetDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Fixed Asset Depreciation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DeferredTaxAssetsFixedAssetDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DeferredTaxAssetsResearchAndExperimentationCapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Research and Experimentation Capitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DeferredTaxAssetsResearchAndExperimentationCapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the estimated loss from legal settlements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064178732608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax at statutory rate</a></td>
<td class="num">$ (10,413)<span></span>
</td>
<td class="num">$ (12,917)<span></span>
</td>
<td class="num">$ (15,607)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="num">(753)<span></span>
</td>
<td class="num">(1,981)<span></span>
</td>
<td class="num">(2,673)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation', window );">Revaluation of contingent royalty obligation</a></td>
<td class="nump">1,823<span></span>
</td>
<td class="nump">1,078<span></span>
</td>
<td class="nump">1,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment', window );">Meals and entertainment</a></td>
<td class="nump">713<span></span>
</td>
<td class="nump">385<span></span>
</td>
<td class="nump">358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Change in state tax rate</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation', window );">Officers' compensation</a></td>
<td class="nump">1,231<span></span>
</td>
<td class="nump">793<span></span>
</td>
<td class="num">(1,529)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign Rate Differential</a></td>
<td class="nump">443<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="num">(1,377)<span></span>
</td>
<td class="nump">449<span></span>
</td>
<td class="nump">299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingenciesOther', window );">Other, net</a></td>
<td class="nump">125<span></span>
</td>
<td class="num">(449)<span></span>
</td>
<td class="num">(391)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">8,822<span></span>
</td>
<td class="nump">12,378<span></span>
</td>
<td class="nump">18,169<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision for income taxes</a></td>
<td class="nump">$ 664<span></span>
</td>
<td class="nump">$ 176<span></span>
</td>
<td class="nump">$ 95<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Officers' Compensation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Revaluation Of Contingent Royalty Obligation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible meals and entertainment expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingenciesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in other income tax contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingenciesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064175559952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Unrecognized Tax Benefits [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 2,924<span></span>
</td>
<td class="nump">$ 2,924<span></span>
</td>
<td class="nump">$ 2,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases to prior year tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases to current year tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 2,924<span></span>
</td>
<td class="nump">$ 2,924<span></span>
</td>
<td class="nump">$ 2,924<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064179657440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064177708912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenues</a></td>
<td class="nump">$ 266,274<span></span>
</td>
<td class="nump">$ 202,085<span></span>
</td>
<td class="nump">$ 148,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">83,970<span></span>
</td>
<td class="nump">64,514<span></span>
</td>
<td class="nump">58,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of distribution right</a></td>
<td class="nump">4,104<span></span>
</td>
<td class="nump">4,072<span></span>
</td>
<td class="nump">3,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">198,025<span></span>
</td>
<td class="nump">164,944<span></span>
</td>
<td class="nump">141,840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">9,172<span></span>
</td>
<td class="nump">6,556<span></span>
</td>
<td class="nump">4,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_ResearchAndDevelopmentInProcess1', window );">In-process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,869<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Revaluation of contingent royalty obligation</a></td>
<td class="nump">7,176<span></span>
</td>
<td class="nump">4,257<span></span>
</td>
<td class="nump">5,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">22,188<span></span>
</td>
<td class="nump">16,458<span></span>
</td>
<td class="nump">10,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">5,297<span></span>
</td>
<td class="nump">5,133<span></span>
</td>
<td class="nump">3,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income</a></td>
<td class="num">(3,263)<span></span>
</td>
<td class="num">(860)<span></span>
</td>
<td class="num">(119)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="nump">18,735<span></span>
</td>
<td class="nump">13,832<span></span>
</td>
<td class="nump">9,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(127)<span></span>
</td>
<td class="num">(696)<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">664<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(50,420)<span></span>
</td>
<td class="num">(61,685)<span></span>
</td>
<td class="num">(74,412)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=eols_ReportableSegmentMember', window );">Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenues</a></td>
<td class="nump">266,274<span></span>
</td>
<td class="nump">202,085<span></span>
</td>
<td class="nump">148,616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">81,015<span></span>
</td>
<td class="nump">61,559<span></span>
</td>
<td class="nump">55,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of distribution right</a></td>
<td class="nump">2,955<span></span>
</td>
<td class="nump">2,955<span></span>
</td>
<td class="nump">2,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">176,853<span></span>
</td>
<td class="nump">149,380<span></span>
</td>
<td class="nump">131,275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">8,156<span></span>
</td>
<td class="nump">5,662<span></span>
</td>
<td class="nump">4,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_eols_ResearchAndDevelopmentInProcess1', window );">In-process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,869<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Revaluation of contingent royalty obligation</a></td>
<td class="nump">7,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">22,188<span></span>
</td>
<td class="nump">16,458<span></span>
</td>
<td class="nump">10,833<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,342<span></span>
</td>
<td class="nump">2,178<span></span>
</td>
<td class="nump">767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income</a></td>
<td class="num">(3,263)<span></span>
</td>
<td class="num">(860)<span></span>
</td>
<td class="num">(119)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="nump">18,735<span></span>
</td>
<td class="nump">13,832<span></span>
</td>
<td class="nump">9,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(127)<span></span>
</td>
<td class="num">(696)<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">664<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (50,420)<span></span>
</td>
<td class="num">$ (61,685)<span></span>
</td>
<td class="num">$ (74,412)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_ResearchAndDevelopmentInProcess1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development In Process 1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_ResearchAndDevelopmentInProcess1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=eols_ReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=eols_ReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46064275352880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Schedule of Revenue by Country (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenues</a></td>
<td class="nump">$ 266,274<span></span>
</td>
<td class="nump">$ 202,085<span></span>
</td>
<td class="nump">$ 148,616<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenues</a></td>
<td class="nump">253,159<span></span>
</td>
<td class="nump">195,424<span></span>
</td>
<td class="nump">146,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenues</a></td>
<td class="nump">$ 13,115<span></span>
</td>
<td class="nump">$ 6,661<span></span>
</td>
<td class="nump">$ 2,466<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>88
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M[=3;]UK;&R56[:NA6Z&4*-O+)27:#2.@OU\(3?B[&_.VJ7N[./\74$L#!!0
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M54]??5'U,=5$\:)L!69<Z<:B'&:Z]P-A O3^G'/U,C'=1=--QG\ 4$L#!!0
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M5^W7#<MR)AJ _GW%N3I<- \XG@:Z^R]02P,$%     @ ^H1D6G0(B\@6!P
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MW<3"EM/I(:#""2B:!XKF/UX1D896%L%PND@#)=Q[<C69$U!A!!3-PPII1+X
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M8"];O1</+AHMNU2T<8<.6(:] '+SK=ZI?)#-!(SO6X_J. F)G0^NBN'41@)
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MJ+IME$%"L;&Z6KAOJA5:J9"FN/X@Y4@<@B*N5[?45WOF (J^Q504<HO6 ,;
M")$CM;&YH<N3Q6(\@S4'A7=GV*%1]UJ;>%!:V3<YJ93T)[ #6)5+_*P&?M\#
MGM!&G;1+6NQA76"P(Y2)=5&>;2 C[.&(CMSS6W)^9[O>=QZAVPG;D_&],P_A
MIE)TOU_'/+0^6HYGIPCZ#UW0/QG_P.B0S"O#$58=Q2F^FZ((LQ\,%T-_7'Y^
M+Z[X^67W?.<5Z@QUQ;GEUZJB>K3:=:Q]WT#$R>W>U=$BZ006]0UU(O&M@V]
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MKLK1 CPO,>%W%W1 _]WLXK]02P,$%     @ ^H1D6M?>Y[&J*   IH<  !@
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ML"SWR4L&>"<O*Q0"\!M#\[<&SI(0*'"@:T"B.3I\0Z3.;+INNA(P"&S?NFX
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MI2OAN2)B%Z<$A%A&?("&  .-K#*4OR#H-T8CU>!]XV5A)@A]>N1'.A#P- @
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MI%3F4EB',U55DBGSGIG('XP!E*B_)4UE@D+71QH-2/A4#UEA? U1+@BL^]:
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M ;BSI^<O%T]GI\#IZ&][0>7S#O"8[A*3&=7IE1VE-X/,D 7/9PN4'.SCG9V
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M!G"\!AP_)_U;8O-=@N#<6J2'*#-X(T4BE722/-+29" <]%BYAN =IK4QLES
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M\#3/@K$DMB].K_Q\NM .IUV_;/#G!1@2P.^UUF[[0@YV/UCF?P%02P,$%
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MJIO6HJ;39 1)=@177-^B)1IP43TX. -).(KCS?A%62Z@>9E:^$=N S@(1T2
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M+C8J:71M)6V-6''O;1,Y8VO9^5PH'F#RR;/$*Y6FV"%HFF ;M0E-,NGK> Z
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ME<GX<J,D4C6]@.=K8ZKF%]K _QW3F_\'4$L#!!0    ( /J$9%IO)[]GO!(
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MP/.9<U7\@S9H?M3Z^K\!4$L#!!0    ( /J$9%JGY65$?P(  (@%   9
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M]2>S9.3ZS.Z/41O[Y7*AC%&EO5T+CH1-"_!^J9#AVC_$H/^4??T/4$L#!!0
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M-^!N%[]=B3?!SN5[D;$-P>9R.2.=DN,7\/>)M6%]PPKJ+XC._@M02P,$%
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M)^L^,]!^JP7Q.B5.8"(%[*=E)H)<!=#4=AF^,T4&?VZF""A(#H#,@)V #SD
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MC]&V[)<5<!OX^7;3",MU0Q&%UHZY93=&S+&]74D.@_'B9;6BFAGT8P&SXU
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MEQCX(JE " N\=(LL/6)@9JUMSWVSK-2_@Y\FCODT^^?0 >.3I;EK.!^N.S2
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M.)>&QH$S:YJ_J*P#G5=2FL/"7C!,].PO4$L#!!0    ( /J$9%JC_\@LT (
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MW@A[J]9?<:-GX/ R)4P[PKJS39@'66.LJC;.Q* J93?SYTT>=AQ&X3L.;./
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M?@"Z74"M8U7MAWZN+*T0;Y:TLU&[ +I?*&4WCDO0_0M,_P%02P,$%     @
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M<9QBH86/_31P4A:?@.^Y872 70.('#_T'<_:XKE!JID9F8D3I3X\$,$)6B<
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MZX:7N_/EN7IP49-.[B,@:2XHS0.E^:"T (K6SI?&C=/?RH[30?TX4)H+2O-
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MJA4J#;Y:,/,%LW6<<920E:Q*.Y_8(\2J-2C5CJ#;<@G$/16"IN7FAN"(L**
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M=F2I362]7R?]Z+K4J*M%?KD;6>C<XJBFHYJ!:B:J6:AFHYJ#:BZJ>:CFHUJ
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MSI75\^6IN\[)Z^3XR>E$:AJJZ:AFH)J):A:JV:CFH)J+:MZ!%]I <B&*W(\
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MZTAW>_A)T]UEKJG"CTT3#END]"Y3W$RJNQ]T R/K]L3<2(/G;_M8XI4*E W
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MPXI]]E]>OTAYA[G:1P$2LE%N\"9078*?WDV<%I+MB[_W*R8E2XO+'<$QX=I
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M-/'XVB]A5%17M&KF6@9*2B%9WH@504Z*^H[731XV!+;WBL!I!,Y;!6XC<*M
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M!]QU(VL+O-?Z0/"@!0_V@4==X,$NN&/;6^"]U@>"ARUXN ]\T 4>O@6\U_I
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M    >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;+5876^;2!3]*R.VJEHI#<R
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MWG3Q>J?Z;:=B_]"H[2+L71WQ:958<']D^9N*1U LWJ!;]F3"0#?!7I"3S])
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MI=E1;OL[[TR!USU#<98M;K+W_AE:U$$U"M485.-034 UB=+L4+=-H7>%G7!
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M2 %+VG!S+S>?89O/R/+EDFOW3S;MWB3V2-YH(ZLM&!U43+1/^KQ]#SN *#H
MB+: R/ENA9S+&34T2Y7<$&5W(YL-7*H.C>:8L!]E;A2N,L29[ %41;Y**C0Y
M)W/\Y$7#@<@ESHD5<:LS6!AR2TVCF&&@R>D,#&5<?R GA GR4,I&4U'HU#=H
MR-+Z^5;\NA6/#HC/(+\@@_",1$$T)(_S&3D]^? WC8_Y=$E%75*1XQT<Y$7'
M,Z9S+G6C@/RX6FBCL !^]GELN8;]7/907.J:YC#UL.HUJ#5XV?MW81Q\/.)T
MT#D='&//,/%1GZ<6E3B4/5?K+$C]=8_0L!,:OB44]PFUJ'A':!C&<=(O-NK$
M1F^))7UBHSVQ\0!__6)Q)Q:_)3;N$XOWQ Z\PJ032HX*/4A#.:D5$SFK;41?
ML#N9WKI/]L3#:!0$!QR,.P?CHPX>!:VD,NPW%-AYL,8+K''9H >"!Y PK1LJ
M<B"YU/VVQGNVS@?#R;#?U:1S-3GJRG4*8SN%]71&!%XEV$#^U]MDK^3#*!P%
M\3_F_)U>9Z^-6ZI6#+L7AR4"@XL$BTRUK;@=&%F[]K>0!INI"TN\O4#9#;B^
ME-*\#FQ'[>[#[ ]02P,$%     @ ^H1D6FKX?R"X P  !1,  !D   !X;"]W
M;W)K<VAE971S+W-H965T-3 N>&ULK9A=;]LV&(7_"J$50PLDEJQ/+[4%I+'E
M=NB6(&G7BV$7M/S:)BJ)*DG9R;\?*2F"'<N$#?#&U@?/\Y(Z1Y2H\8ZRGWP#
M(-!SGA5\8FV$*&]LFZ<;R#$?T!(*>69%68Z%W&5KFY<,\+(6Y9GM.DYHYY@4
M5CRNCSVP>$PKD9$"'ACB59YC]O(),KJ;6$/K]< C66^$.F#'XQ*OX0G$]_*!
MR3V[HRQ)#@4GM$ ,5A/K=G@S'ZGV=8-_".SXWC92(UE0^E/M?%E.+$=U"#)(
MA2)@^;>%.\@R!9+=^-4RK:ZD$NYOO]*3>NQR+ O,X8YF/\A2;";6R$)+6.$J
M$X]T]QG:\02*E]*,U[]HU[0-?0NE%1<T;\6R!SDIFG_\W%Z'/<'PE,!M!>ZY
M J\5>.<*_%;@GRL(6D%PKB!L!>&Y@J@51+59S=6MK9EB@>,QHSO$5&M)4QNU
MO[5:.D(*E<0GP>19(G4BOB^!84&*-?H*TE&.KM'?F*E#6T#OIR PR?@'>?3[
MTQ2]?_<!O4.D0-\VM.*X6/*Q+60G%,I.VX*?FH+NB8)32 ?(&UXAUW']'OF=
M7GZ?B@$:AB?E4[W\MEH/D'.Z^NS\SGL]\D0O_[/*!LB-3LKG>OE?F,FQ!TH^
M_.-0;DO;.^_=SGNWYGDG>*WC_]XNN&!R3OBOS\T&X?<CU#QYPTN<PL22$R$'
MM@4K_OVW8>A\[//6)&QJ$C8S"4M,PN:&8 <)\;J$>#IZ_ U8CN@*I;2H$](7
M$"WATH"8A$U-PF8F88E)V%QO88!> #.N"8/?A<'7DAZA@!W.D)"AZ N"7ATZ
M*)<IVO0],NZTTDMM-PF;F80E)F%S0["#* 1=% *MF5^!<X K1+NWATP]2ZX0
M7F !\D55('F&T&5?3K3H2R<,D["I2=C,)"S1V^&=OK7FAKIQ$).PBTFH[=>#
M0LHL;'%6@7J.O,D+R@A>D(P( KUOD@T]JNEJ2;6-1WXD7YRV^PG0=N'2!!Q7
M]!S'/:PX,UDQ.:[H!X%S6'%NJ.*!B5%G8J0U\?Z-9TPM[J[IZKJ2.UC. Z+7
MN^AH7-%P%+SQ3EOY4N^.*_9X=]PHB,(WD4J.&_5X8JCO!YZ,.D]&6D\2\@Q+
ME&*^025^4?,M1\ %D4MS>5Q0M)"WVQ98_:Q6-UYM79]-VCJ73L:CH^LV'$7A
MX76;FJPX,PE+3,+FAF!-/.R]!;[Z0"17@FM2<&GK2N*=021G>=9\=&EV!"WK
M-?^""D'S>G,#> E,-9#G5Y2*UQWU&:'[\A7_#U!+ P04    " #ZA&1:>N[$
M_-@"  !+"   &0   'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6RM5EU/VS 4
M_2M6AB:0&/ELRE@;B3:@(0W1P6 /TQ[<Y+:Q2.S,=MKNW\]VTM"6M&(2+_5'
MSCFYYU['MX,EX\\B Y!H5>14#*U,RO+"MD6208'%&2N!JB<SQ@LLU9+/;5%R
MP*DA%;GM.4YH%YA0*QJ8O0F/!JR2.:$PX4A418'YWQ'D;#FT7&N]<4_FF=0;
M=C0H\1P>0#Z6$ZY6=JN2D@*H((PB#K.A=>E>Q*'&&\ 3@:78F"/M9,K8LU[<
MI$/+T0%!#HG4"E@-"QA#GFLA%<:?1M-J7ZF)F_.U^K7QKKQ,L8 QRW^25&9#
MZ]Q"*<QPE<M[MOP*C9^>UDM8+LPO6C98QT)))20K&K**H""T'O&JR<,&P0WW
M$+R&X.T2@CT$OR'X;R4$#2$PF:FMF#S$6.)HP-D2<8U6:GIBDFG8RCZANNP/
MDJNG1/%D=%<"QY+0.?H&*GT"?4)C5I2, I4"L5F]C:Y6ZIRI$=,4W<D,./I>
M82J)Q+ILZ(;6!U!7\C@&B4DN3I34XT.,CH].T!$B%/W(6"64@!C84D6NWV\G
M392C.DIO3Y2NAVX9E9E 5S2%=%O 5I9;W][:]\@[J!A#<H9\]Q1YCA=T!#1^
M.]WOH,=OIWL'W/AM%7VCY^_1:VKWZW(J)%>?TN^N%-<20;>$OEXN1(D3&%KJ
M_A# %V!%'S^XH?.E*SWO*1:_D]A6ZH(V=<$A]>B:K"!%K/T,<G/>H3[O76FL
MY?I&3E^JB\CM>>' 7FRFIP/DAL$V*.X .><OH"T[O=9.[Z"=)\P)GN;P/XYJ
MQ7#+D;-CJ -S[N_X>8WY[':["5LWX4$WYER?HH0)V15X^#J!87^W%!T@/^CO
MA-X!<ON]G>#MC6NV #XW[4JHZ"HJZYNGW6T[XJ5I!#O[(]4IZ\;V(E.WV5O,
MYX0*5;.9DG3.^BJGO&Y=]4*RTESF4R95:S#33'5[X!J@GL\8D^N%?D'[_R'Z
M!U!+ P04    " #ZA&1:_"89^PL#  #_"   &0   'AL+W=O<FMS:&5E=',O
M<VAE970U,BYX;6RM5MMNVD 0_961&U6)U,0W(&T*E@"W:J5&C7)I'JH^+/:
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M'AM] RU@B1,J[]CV&^0+ZFJ_.:,B_47;/-8RT#P1DH6Y6&40DBB[XN<<Q([
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M.^]D'<GB] 0P8U*=)]+F6IT1@>L -;YD3+YV]*&B.'4&_P%02P,$%     @
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MQ&.Z_YM5 [)SWC*-LN(WVE=M#0TM=YE(XRI8]B .D_*O_[T2XB! <KH#2!5
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M^*$2]9VD[BA>F5/Z+5=XYC?-#.]Q('0 /I]SKC8=_8+V9AC]!E!+ P04
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M85NAT&+F2B5<3^^FK<B'1J1_023VT7=&Y4:@+S2#[)S 58X[V_[!]H,_R)A
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M%W =H)ZO&).'@9Z@.\_%_P-02P,$%     @ ^H1D6L$_X-DK!   R!H  !D
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M"0L(QZF=0]1SB$8YW,#V$E&LVF8PIX\P.]8P"20J(,V9M&Y,9*S#C[&^+Z>
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M0@'@_H)S^7RB/J+T7]EF_P-02P,$%     @ ^H1D6OIFW.L]!   M0X  !D
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M)  6.8/:[A/I!0.V*X;/<LVJ)Q9O:\T(4C&W^3-,C(4%H/Q([]L :JP<O5[
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MN1Y\!GFV?;\LM<.I),NP>^FO"?5-!QD7,J6R"1/ZJZ%AG],,[$@VG<%=%64
MH%)%KALI(]-"D-K#BF$;6G9".;^#;Y"OV8;V(FOM6[WIHFEJ0[9I9$P']-MJ
M1KLM>_DB7:]DCX7Z,-?+$74?JI3>2IJQ1=U?9(T!3#W$U4E9\N5[SJ8BIV;Q
M>P<<]LF*Y\T*R9YT-"B5B1Z@TO<>J51LTA[Y+DEY3Q=J54Z+#/?</4+/?S?/
M4RJH)+QM6M?^(6?YQ8[M*_=?>*Z_5K8=.TU&5X?OT1XQ#MUD? PFCV*[>\=@
M,CE\D]$1>+3'TT,W&1ZDR< >UUIGPHT383/JP<E[X'^!<SQ?!_7&<\85$[8W
M8VE*Q;.#H9979*S_8-W0U_-3FI$Y5_<-./#7[<\T9?,\:6;=0B+LK'7[$RPO
MC)MCOX[%1$H7-!W9KIR.ZZ:G&SJJO8"PC=S4EQO!. 9S(X!A<3 '&,>PL#C_
MTWIZZ'H,AGGK.9$>RNFA',-R(:/Z@\5Q<Q)]N5>:)%$4QUA&1R.G@Q&6MSB&
M'[<:Y@T86!R(]&>YQG<;KY#==8#MZ:X*P5:*5R*V4CS7@+CS!HPD<>\V%@<8
MV"Y@M0/QW7&@IMR<*()=Q;QA3S".) F&0"VZ:S2.D>S$\''O#_:41%&2N!'
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MTZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0
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M+"LAKEW;-^G>&8O])]#[S[<__0102P,$%     @ ^H1D6MMVL'$Q @  B2D
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M_Z>L]\ZM_SA^?):=;?JW?#;^67'Q E!+ 0(4 Q0    ( /J$9%H'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ ^H1D6BK\2G'O    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ ^H1D6IE<G",0!@  G"<  !,
M         ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #Z
MA&1:M+#?J2 (   L,0  &               @($."   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ ^H1D6I(HB%(Z @  N@4  !@
M         ("!9!   'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0
M   ( /J$9%I.\@0[F@8  &D<   8              " @=02  !X;"]W;W)K
M<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " #ZA&1:K/+\WO0"  !9"@
M&               @(&D&0  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L!
M A0#%     @ ^H1D6FDSDKQ)!P  &20  !@              ("!SAP  'AL
M+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( /J$9%IT"(O(%@<
M $ W   8              " @4TD  !X;"]W;W)K<VAE971S+W-H965T-BYX
M;6Q02P$"% ,4    " #ZA&1:P^Y5-H )  "N+0  &               @(&9
M*P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ ^H1D6D2V
MD)SB"@  0QL  !@              ("!3S4  'AL+W=O<FMS:&5E=',O<VAE
M970X+GAM;%!+ 0(4 Q0    ( /J$9%K7WN>QJB@  *:'   8
M  " @6=   !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " #Z
MA&1:31.,"S,&  ! $   &0              @(%':0  >&PO=V]R:W-H965T
M<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( /J$9%J>P3*-(P4  +P,   9
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M970Q-2YX;6Q02P$"% ,4    " #ZA&1:WWUF#K42  #@.@  &0
M    @($VBP  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (
M /J$9%K;P'US+1$  -,T   9              " @2*>  !X;"]W;W)K<VAE
M971S+W-H965T,3<N>&UL4$L! A0#%     @ ^H1D6F\GOV>\$@  X#H  !D
M             ("!AJ\  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"
M% ,4    " #ZA&1:I^5E1'\"  "(!0  &0              @(%YP@  >&PO
M=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( /J$9%JZW*<GE0L
M -8>   9              " @2_%  !X;"]W;W)K<VAE971S+W-H965T,C N
M>&UL4$L! A0#%     @ ^H1D6D6#5 5$!@  E0T  !D              ("!
M^]   'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " #ZA&1:
MJYB2\7D"  !\!0  &0              @(%VUP  >&PO=V]R:W-H965T<R]S
M:&5E=#(R+GAM;%!+ 0(4 Q0    ( /J$9%I,T5BA6P(  '\&   9
M      " @2;:  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%
M  @ ^H1D6BQU:+Y# @  B@8  !D              ("!N-P  'AL+W=O<FMS
M:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " #ZA&1:/*4S.!$"  #=!
M&0              @($RWP  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+
M 0(4 Q0    ( /J$9%HA[&JE/P@  $TD   9              " @7KA  !X
M;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ ^H1D6E\])1V$
M+0  XIL  !D              ("!\.D  'AL+W=O<FMS:&5E=',O<VAE970R
M-RYX;6Q02P$"% ,4    " #ZA&1:[DWH6ZH#  !0"0  &0
M@(&K%P$ >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( /J$
M9%IW\<]7_P,   0*   9              " @8P; 0!X;"]W;W)K<VAE971S
M+W-H965T,CDN>&UL4$L! A0#%     @ ^H1D6C7T&\JP @  W04  !D
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M=#,T+GAM;%!+ 0(4 Q0    ( /J$9%H3%EOKP@8   (2   9
M  " @3(R 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @
M^H1D6DRQR(N>!   _@D  !D              ("!*SD! 'AL+W=O<FMS:&5E
M=',O<VAE970S-BYX;6Q02P$"% ,4    " #ZA&1:W/O &J\&   5-   &0
M            @($ /@$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4
M Q0    ( /J$9%K"\6V?AQL  ![! 0 9              " @>9$ 0!X;"]W
M;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ ^H1D6A$+(508 P
M@@X  !D              ("!I& ! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX
M;6Q02P$"% ,4    " #ZA&1:7F"S(X(#  #K$   &0              @('S
M8P$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( /J$9%H1
M2[0;4P,  + )   9              " @:QG 0!X;"]W;W)K<VAE971S+W-H
M965T-#$N>&UL4$L! A0#%     @ ^H1D6L>8-.TP!   +1(  !D
M     ("!-FL! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /J$9%I45_A#> (  *4&   9              "
M@2]^ 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ ^H1D
M6D]FK /B"@  TXL  !D              ("!WH ! 'AL+W=O<FMS:&5E=',O
M<VAE970T."YX;6Q02P$"% ,4    " #ZA&1:$$%U];8"   ;!P  &0
M        @('WBP$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0
M   ( /J$9%IJ^'\@N ,   43   9              " @>2. 0!X;"]W;W)K
M<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ ^H1D6GKNQ/S8 @  2P@
M !D              ("!TY(! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q0
M2P$"% ,4    " #ZA&1:_"89^PL#  #_"   &0              @('BE0$
M>&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( /J$9%K25*&S
M5P,  ($.   9              " @229 0!X;"]W;W)K<VAE971S+W-H965T
M-3,N>&UL4$L! A0#%     @ ^H1D6CXL^[<8"0  .6P  !D
M ("!LIP! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " #Z
MA&1:V@C VU 8  ##DP$ &0              @($!I@$ >&PO=V]R:W-H965T
M<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( /J$9%H^JK.?(0,  )@)   9
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M970V,"YX;6Q02P$"% ,4    " #ZA&1:P/&D0G\"  "7!@  &0
M    @(%>UP$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    (
M /J$9%KH$T-6Z0(  $X(   9              " @13: 0!X;"]W;W)K<VAE
M971S+W-H965T-C(N>&UL4$L! A0#%     @ ^H1D6K.T)V66 P  VPT  !D
M             ("!--T! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"
M% ,4    " #ZA&1:P3_@V2L$  #(&@  &0              @($!X0$ >&PO
M=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( /J$9%JL>)_/N 0
M '$3   9              " @6/E 0!X;"]W;W)K<VAE971S+W-H965T-C4N
M>&UL4$L! A0#%     @ ^H1D6OIFW.L]!   M0X  !D              ("!
M4NH! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"% ,4    " #ZA&1:
M1YE.R=H"   ,"0  &0              @('&[@$ >&PO=V]R:W-H965T<R]S
M:&5E=#8W+GAM;%!+ 0(4 Q0    ( /J$9%J6/D 3(0(  *8$   9
M      " @=?Q 0!X;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%
M  @ ^H1D6EQ_R!VZ!@  D"(  !D              ("!+_0! 'AL+W=O<FMS
M:&5E=',O<VAE970V.2YX;6Q02P$"% ,4    " #ZA&1:@HG "CH#  !.#0
M&0              @($@^P$ >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+
M 0(4 Q0    ( /J$9%K4B6T*7P,  -(5   -              "  9'^ 0!X
M;"]S='EL97,N>&UL4$L! A0#%     @ ^H1D6I>*NQS     $P(   L
M         ( !&P(" %]R96QS+RYR96QS4$L! A0#%     @ ^H1D6OR;QX:-
M!0  0BX   \              ( !! ," 'AL+W=O<FMB;V]K+GAM;%!+ 0(4
M Q0    ( /J$9%K;=K!Q,0(  (DI   :              "  ;X( @!X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( /J$9%JDR,-W^@$
M +0H   3              "  2<+ @!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%
3!@    !. $X 614  %(- @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>199</ContextCount>
  <ElementCount>440</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>65</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>18</UnitCount>
  <MyReports>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952151 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952153 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952154 - Statement - Consolidated Statements of Stockholders??? Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/ConsolidatedStatementsofStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Stockholders??? Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952155 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/DescriptionofBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/PropertyPlantandEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Term Loans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/TermLoans</Role>
      <ShortName>Term Loans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/OperatingLeases</Role>
      <ShortName>Operating Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Medytox Settlement Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/MedytoxSettlementAgreements</Role>
      <ShortName>Medytox Settlement Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/FairValueMeasurements</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/AccruedExpenses</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Property, Plant and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/PropertyPlantandEquipmentTables</Role>
      <ShortName>Property, Plant and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/PropertyPlantandEquipment</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Term Loans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/TermLoansTables</Role>
      <ShortName>Term Loans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/TermLoans</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Operating Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/OperatingLeasesTables</Role>
      <ShortName>Operating Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/OperatingLeases</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/StockholdersEquity</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/IncomeTaxes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/SegmentReporting</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/DescriptionofBusinessDetails</Role>
      <ShortName>Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/DescriptionofBusiness</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Fair Value Measurements - Reconciliation of Fair Value Measurement of Contingent Royalty Obligation Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/FairValueMeasurementsReconciliationofFairValueMeasurementofContingentRoyaltyObligationPayableDetails</Role>
      <ShortName>Fair Value Measurements - Reconciliation of Fair Value Measurement of Contingent Royalty Obligation Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Goodwill and Intangible Assets - Schedule of Definite and Indefinite-Lived Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of Definite and Indefinite-Lived Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Goodwill and Intangible Assets - Estimated Future Amortization Expense of Intangibles (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Estimated Future Amortization Expense of Intangibles (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/AccruedExpensesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Property, Plant and Equipment - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/PropertyPlantandEquipmentNarrativeDetails</Role>
      <ShortName>Property, Plant and Equipment - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Term Loans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/TermLoansNarrativeDetails</Role>
      <ShortName>Term Loans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Term Loans - Schedule of Long Term Debt Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails</Role>
      <ShortName>Term Loans - Schedule of Long Term Debt Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Operating Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/OperatingLeasesNarrativeDetails</Role>
      <ShortName>Operating Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Operating Leases - Components of Lease Expense and Other Quantitative Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/OperatingLeasesComponentsofLeaseExpenseandOtherQuantitativeInformationDetails</Role>
      <ShortName>Operating Leases - Components of Lease Expense and Other Quantitative Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Operating Leases - Weighted-Average Remaining Lease Term and Discount Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/OperatingLeasesWeightedAverageRemainingLeaseTermandDiscountRateDetails</Role>
      <ShortName>Operating Leases - Weighted-Average Remaining Lease Term and Discount Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Operating Leases - Maturity of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Operating Leases - Maturity of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Commitment and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/CommitmentandContingenciesDetails</Role>
      <ShortName>Commitment and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Stockholders' Equity - Schedule of Weighted-Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquityScheduleofWeightedAverageAssumptionsDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Weighted-Average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Stockholders' Equity - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Stockholders' Equity - Schedule of Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Stockholders' Equity - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stockholders' Equity - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - Medytox Settlement Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/MedytoxSettlementAgreementsDetails</Role>
      <ShortName>Medytox Settlement Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/MedytoxSettlementAgreements</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - Employee Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/EmployeeBenefitPlanDetails</Role>
      <ShortName>Employee Benefit Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - Income Taxes - Schedule of Loss before Income Taxes from U.S. Operations and Foreign (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/IncomeTaxesScheduleofLossbeforeIncomeTaxesfromUSOperationsandForeignDetails</Role>
      <ShortName>Income Taxes - Schedule of Loss before Income Taxes from U.S. Operations and Foreign (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - Income Taxes - Schedule of Components of Current and Deferred Income Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/IncomeTaxesScheduleofComponentsofCurrentandDeferredIncomeTaxExpenseDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of Current and Deferred Income Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - Income Taxes - Schedule of Effective Income Tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9955551 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9955552 - Disclosure - Segment Reporting - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/SegmentReportingNarrativeDetails</Role>
      <ShortName>Segment Reporting - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9955553 - Disclosure - Segment Reporting - Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/SegmentReportingReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails</Role>
      <ShortName>Segment Reporting - Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="eols-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9955554 - Disclosure - Segment Reporting - Schedule of Revenue by Country (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/SegmentReportingScheduleofRevenuebyCountryDetails</Role>
      <ShortName>Segment Reporting - Schedule of Revenue by Country (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="eols-20241231.htm">eols-20241231.htm</File>
    <File>eols-20241231.xsd</File>
    <File>eols-20241231_cal.xml</File>
    <File>eols-20241231_def.xml</File>
    <File>eols-20241231_lab.xml</File>
    <File>eols-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>eols-20241231_g1.jpg</File>
    <File>eols-20241231_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="847">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>95
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "eols-20241231.htm": {
   "nsprefix": "eols",
   "nsuri": "http://www.evolus.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "eols-20241231.htm"
     ]
    },
    "schema": {
     "local": [
      "eols-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "eols-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "eols-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "eols-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "eols-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 369,
   "keyCustom": 71,
   "axisStandard": 26,
   "axisCustom": 2,
   "memberStandard": 36,
   "memberCustom": 27,
   "hidden": {
    "total": 17,
    "http://fasb.org/us-gaap/2024": 11,
    "http://xbrl.sec.gov/dei/2024": 4,
    "http://www.evolus.com/20241231": 2
   },
   "contextCount": 199,
   "entityCount": 1,
   "segmentCount": 65,
   "elementCount": 744,
   "unitCount": 18,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 847,
    "http://xbrl.sec.gov/dei/2024": 38,
    "http://xbrl.sec.gov/cyd/2024": 15,
    "http://xbrl.sec.gov/ecd/2024": 5
   },
   "report": {
    "R1": {
     "role": "http://www.evolus.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.evolus.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.evolus.com/role/ConsolidatedBalanceSheets",
     "longName": "9952151 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.evolus.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "9952152 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R5": {
     "role": "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
     "longName": "9952153 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GrossProfit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.evolus.com/role/ConsolidatedStatementsofStockholdersEquityDeficit",
     "longName": "9952154 - Statement - Consolidated Statements of Stockholders\u2019 Equity (Deficit)",
     "shortName": "Consolidated Statements of Stockholders\u2019 Equity (Deficit)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "9952155 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.evolus.com/role/DescriptionofBusiness",
     "longName": "9952156 - Disclosure - Description of Business",
     "shortName": "Description of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
     "longName": "9952157 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.evolus.com/role/FairValueMeasurements",
     "longName": "9952158 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.evolus.com/role/GoodwillandIntangibleAssets",
     "longName": "9952159 - Disclosure - Goodwill and Intangible Assets",
     "shortName": "Goodwill and Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.evolus.com/role/AccruedExpenses",
     "longName": "9952160 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.evolus.com/role/PropertyPlantandEquipment",
     "longName": "9952161 - Disclosure - Property, Plant and Equipment",
     "shortName": "Property, Plant and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.evolus.com/role/TermLoans",
     "longName": "9952162 - Disclosure - Term Loans",
     "shortName": "Term Loans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.evolus.com/role/OperatingLeases",
     "longName": "9952163 - Disclosure - Operating Leases",
     "shortName": "Operating Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.evolus.com/role/CommitmentsandContingencies",
     "longName": "9952164 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R17": {
     "role": "http://www.evolus.com/role/StockholdersEquity",
     "longName": "9952165 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.evolus.com/role/MedytoxSettlementAgreements",
     "longName": "9952166 - Disclosure - Medytox Settlement Agreements",
     "shortName": "Medytox Settlement Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R19": {
     "role": "http://www.evolus.com/role/EmployeeBenefitPlan",
     "longName": "9952167 - Disclosure - Employee Benefit Plan",
     "shortName": "Employee Benefit Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.evolus.com/role/IncomeTaxes",
     "longName": "9952168 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.evolus.com/role/SegmentReporting",
     "longName": "9952169 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.evolus.com/role/SubsequentEvents",
     "longName": "9952170 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R24": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-199",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-199",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "a",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "a",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9955511 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.evolus.com/role/FairValueMeasurementsTables",
     "longName": "9955512 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.evolus.com/role/GoodwillandIntangibleAssetsTables",
     "longName": "9955513 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.evolus.com/role/AccruedExpensesTables",
     "longName": "9955514 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.evolus.com/role/PropertyPlantandEquipmentTables",
     "longName": "9955515 - Disclosure - Property, Plant and Equipment (Tables)",
     "shortName": "Property, Plant and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.evolus.com/role/TermLoansTables",
     "longName": "9955516 - Disclosure - Term Loans (Tables)",
     "shortName": "Term Loans (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.evolus.com/role/OperatingLeasesTables",
     "longName": "9955517 - Disclosure - Operating Leases (Tables)",
     "shortName": "Operating Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.evolus.com/role/StockholdersEquityTables",
     "longName": "9955518 - Disclosure - Stockholders' Equity (Tables)",
     "shortName": "Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.evolus.com/role/IncomeTaxesTables",
     "longName": "9955519 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.evolus.com/role/SegmentReportingTables",
     "longName": "9955520 - Disclosure - Segment Reporting (Tables)",
     "shortName": "Segment Reporting (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.evolus.com/role/DescriptionofBusinessDetails",
     "longName": "9955521 - Disclosure - Description of Business (Details)",
     "shortName": "Description of Business (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-44",
      "name": "eols:LicenseSupplyAndDistributionAgreementExpectedRegulatoryApprovalNumberOfProducts",
      "unitRef": "product",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
     "longName": "9955522 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Details)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportingUnits",
      "unitRef": "reporting_unit",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportingUnits",
      "unitRef": "reporting_unit",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.evolus.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
     "longName": "9955523 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-86",
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-86",
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.evolus.com/role/FairValueMeasurementsNarrativeDetails",
     "longName": "9955524 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-96",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.evolus.com/role/FairValueMeasurementsReconciliationofFairValueMeasurementofContingentRoyaltyObligationPayableDetails",
     "longName": "9955525 - Disclosure - Fair Value Measurements - Reconciliation of Fair Value Measurement of Contingent Royalty Obligation Payable (Details)",
     "shortName": "Fair Value Measurements - Reconciliation of Fair Value Measurement of Contingent Royalty Obligation Payable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails",
     "longName": "9955526 - Disclosure - Goodwill and Intangible Assets - Schedule of Definite and Indefinite-Lived Intangible Assets (Details)",
     "shortName": "Goodwill and Intangible Assets - Schedule of Definite and Indefinite-Lived Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails",
     "longName": "9955527 - Disclosure - Goodwill and Intangible Assets - Estimated Future Amortization Expense of Intangibles (Details)",
     "shortName": "Goodwill and Intangible Assets - Estimated Future Amortization Expense of Intangibles (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
     "longName": "9955528 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)",
     "shortName": "Goodwill and Intangible Assets - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CapitalizedComputerSoftwareAdditions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CapitalizedComputerSoftwareAdditions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.evolus.com/role/AccruedExpensesDetails",
     "longName": "9955529 - Disclosure - Accrued Expenses (Details)",
     "shortName": "Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AccruedRoyaltiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.evolus.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails",
     "longName": "9955530 - Disclosure - Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details)",
     "shortName": "Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.evolus.com/role/PropertyPlantandEquipmentNarrativeDetails",
     "longName": "9955531 - Disclosure - Property, Plant and Equipment - Narrative (Details)",
     "shortName": "Property, Plant and Equipment - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.evolus.com/role/TermLoansNarrativeDetails",
     "longName": "9955532 - Disclosure - Term Loans - Narrative (Details)",
     "shortName": "Term Loans - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PaymentsOfDebtIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-118",
      "name": "eols:DebtInstrumentNumberOfInstallments",
      "unitRef": "installment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails",
     "longName": "9955533 - Disclosure - Term Loans - Schedule of Long Term Debt Maturities (Details)",
     "shortName": "Term Loans - Schedule of Long Term Debt Maturities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.evolus.com/role/OperatingLeasesNarrativeDetails",
     "longName": "9955534 - Disclosure - Operating Leases - Narrative (Details)",
     "shortName": "Operating Leases - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-132",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-132",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.evolus.com/role/OperatingLeasesComponentsofLeaseExpenseandOtherQuantitativeInformationDetails",
     "longName": "9955535 - Disclosure - Operating Leases - Components of Lease Expense and Other Quantitative Information (Details)",
     "shortName": "Operating Leases - Components of Lease Expense and Other Quantitative Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.evolus.com/role/OperatingLeasesWeightedAverageRemainingLeaseTermandDiscountRateDetails",
     "longName": "9955536 - Disclosure - Operating Leases - Weighted-Average Remaining Lease Term and Discount Rate (Details)",
     "shortName": "Operating Leases - Weighted-Average Remaining Lease Term and Discount Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails",
     "longName": "9955537 - Disclosure - Operating Leases - Maturity of Operating Lease Liabilities (Details)",
     "shortName": "Operating Leases - Maturity of Operating Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.evolus.com/role/CommitmentandContingenciesDetails",
     "longName": "9955538 - Disclosure - Commitment and Contingencies (Details)",
     "shortName": "Commitment and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "eols:PaymentsForInventory",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "eols:PaymentsForInventory",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.evolus.com/role/StockholdersEquityNarrativeDetails",
     "longName": "9955539 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-146",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.evolus.com/role/StockholdersEquityScheduleofWeightedAverageAssumptionsDetails",
     "longName": "9955540 - Disclosure - Stockholders' Equity - Schedule of Weighted-Average Assumptions (Details)",
     "shortName": "Stockholders' Equity - Schedule of Weighted-Average Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-154",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-154",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails",
     "longName": "9955541 - Disclosure - Stockholders' Equity - Schedule of Stock Option Activity (Details)",
     "shortName": "Stockholders' Equity - Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-157",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-154",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails",
     "longName": "9955542 - Disclosure - Stockholders' Equity - Schedule of Restricted Stock Unit Activity (Details)",
     "shortName": "Stockholders' Equity - Schedule of Restricted Stock Unit Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-161",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-161",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseDetails",
     "longName": "9955543 - Disclosure - Stockholders' Equity - Stock-based Compensation Expense (Details)",
     "shortName": "Stockholders' Equity - Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-174",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.evolus.com/role/MedytoxSettlementAgreementsDetails",
     "longName": "9955544 - Disclosure - Medytox Settlement Agreements (Details)",
     "shortName": "Medytox Settlement Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-180",
      "name": "eols:LossContingencySettlementAgreementManufacturingLicensePeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-180",
      "name": "eols:LossContingencySettlementAgreementManufacturingLicensePeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.evolus.com/role/EmployeeBenefitPlanDetails",
     "longName": "9955545 - Disclosure - Employee Benefit Plan (Details)",
     "shortName": "Employee Benefit Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.evolus.com/role/IncomeTaxesScheduleofLossbeforeIncomeTaxesfromUSOperationsandForeignDetails",
     "longName": "9955546 - Disclosure - Income Taxes - Schedule of Loss before Income Taxes from U.S. Operations and Foreign (Details)",
     "shortName": "Income Taxes - Schedule of Loss before Income Taxes from U.S. Operations and Foreign (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.evolus.com/role/IncomeTaxesScheduleofComponentsofCurrentandDeferredIncomeTaxExpenseDetails",
     "longName": "9955547 - Disclosure - Income Taxes - Schedule of Components of Current and Deferred Income Tax Expense (Details)",
     "shortName": "Income Taxes - Schedule of Components of Current and Deferred Income Tax Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.evolus.com/role/IncomeTaxesNarrativeDetails",
     "longName": "9955548 - Disclosure - Income Taxes - Narrative (Details)",
     "shortName": "Income Taxes - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails",
     "longName": "9955549 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.evolus.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxDetails",
     "longName": "9955550 - Disclosure - Income Taxes - Schedule of Effective Income Tax (Details)",
     "shortName": "Income Taxes - Schedule of Effective Income Tax (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.evolus.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails",
     "longName": "9955551 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)",
     "shortName": "Income Taxes - Schedule of Unrecognized Tax Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-18",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.evolus.com/role/SegmentReportingNarrativeDetails",
     "longName": "9955552 - Disclosure - Segment Reporting - Narrative (Details)",
     "shortName": "Segment Reporting - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R69": {
     "role": "http://www.evolus.com/role/SegmentReportingReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
     "longName": "9955553 - Disclosure - Segment Reporting - Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details)",
     "shortName": "Segment Reporting - Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-190",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.evolus.com/role/SegmentReportingScheduleofRevenuebyCountryDetails",
     "longName": "9955554 - Disclosure - Segment Reporting - Schedule of Revenue by Country (Details)",
     "shortName": "Segment Reporting - Schedule of Revenue by Country (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-193",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eols-20241231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "eols_A2023InducementIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "A2023InducementIncentivePlanMember",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Inducement Incentive Plan",
        "label": "2023 Inducement Incentive Plan [Member]",
        "documentation": "2023 Inducement Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "eols_A2024EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "A2024EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Employee Stock Purchase Plan",
        "label": "2024 Employee Stock Purchase Plan [Member]",
        "documentation": "2024 Employee Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "eols_ATMSalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "ATMSalesAgreementMember",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATM Sales Agreement",
        "label": "A T M Sales Agreement [Member]",
        "documentation": "A T M Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/AccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.evolus.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts payable and accrued liabilities, current",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.evolus.com/role/AccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r60",
      "r64",
      "r1125"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r888"
     ]
    },
    "eols_AccountsReceivableAllowanceForCreditLossWriteOffRecovery": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "AccountsReceivableAllowanceForCreditLossWriteOffRecovery",
     "crdr": "debit",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Write-off amount",
        "label": "Accounts Receivable, Allowance for Credit Loss, Write-off (Recovery)",
        "documentation": "Accounts Receivable, Allowance for Credit Loss, Write-off (Recovery)"
       }
      }
     },
     "auth_ref": []
    },
    "eols_AccountsReceivableCreditCardTransactionConvertedToCashPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "AccountsReceivableCreditCardTransactionConvertedToCashPeriod",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, credit card transaction, converted to cash, period",
        "label": "Accounts Receivable, Credit Card Transaction, Converted To Cash, Period",
        "documentation": "Accounts Receivable, Credit Card Transaction, Converted To Cash, Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedRoyaltiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/AccruedExpensesDetails",
      "http://www.evolus.com/role/MedytoxSettlementAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued royalties under the Medytox Settlement Agreements",
        "verboseLabel": "Accrued royalties under the medytox settlement agreements",
        "label": "Accrued Royalties, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r833"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r149",
      "r693"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r76",
      "r157",
      "r689",
      "r729",
      "r730"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r10",
      "r17",
      "r547",
      "r550",
      "r609",
      "r725",
      "r726",
      "r1039",
      "r1040",
      "r1041",
      "r1051",
      "r1052",
      "r1053",
      "r1054"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r888",
      "r1195"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r742",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1136",
      "r1196"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r449"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdvertisingCostsPolicyTextBlock",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advertising Costs",
        "label": "Advertising Cost [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for advertising cost."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_AdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdvertisingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advertising costs",
        "label": "Advertising Expense",
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line."
       }
      }
     },
     "auth_ref": [
      "r489",
      "r872"
     ]
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r937",
      "r948",
      "r958",
      "r991"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r940",
      "r951",
      "r961",
      "r994"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r941",
      "r952",
      "r962",
      "r986",
      "r995",
      "r999",
      "r1007"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.evolus.com/role/SegmentReportingReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails",
      "http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total stock-based compensation expense",
        "verboseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r480",
      "r487"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for doubtful accounts",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r262",
      "r297",
      "r300",
      "r302",
      "r1163"
     ]
    },
    "us-gaap_AlternativeInvestmentMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AlternativeInvestmentMeasurementInput",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement input",
        "label": "Alternative Investment, Measurement Input",
        "documentation": "Value of input used to measure alternative investment."
       }
      }
     },
     "auth_ref": [
      "r879",
      "r1140",
      "r1141",
      "r1142"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt discount and issuance costs",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r858",
      "r859",
      "r1045",
      "r1148"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.evolus.com/role/SegmentReportingReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization expense",
        "verboseLabel": "Amortization of distribution right",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r330",
      "r337",
      "r853"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Securities excluded from the computation of diluted net loss per share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/CommitmentandContingenciesDetails",
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r541"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r126",
      "r153",
      "r188",
      "r216",
      "r223",
      "r248",
      "r252",
      "r294",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r542",
      "r544",
      "r581",
      "r684",
      "r769",
      "r844",
      "r845",
      "r888",
      "r915",
      "r1093",
      "r1094",
      "r1154"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r163",
      "r188",
      "r294",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r542",
      "r544",
      "r581",
      "r888",
      "r1093",
      "r1094",
      "r1154"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "eols_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.evolus.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r920",
      "r921",
      "r944"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.evolus.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r920",
      "r921",
      "r944"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.evolus.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r920",
      "r921",
      "r944"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofWeightedAverageAssumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r452",
      "r453",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1000"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree [Domain]",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r537",
      "r866",
      "r867"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Axis]",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r537",
      "r866",
      "r867"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Line Items]",
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revaluation of contingent royalty obligation to Evolus Founders",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement."
       }
      }
     },
     "auth_ref": [
      "r538",
      "r1044"
     ]
    },
    "eols_CEOPerformanceRestrictedShareUnitsCPRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "CEOPerformanceRestrictedShareUnitsCPRSUMember",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CEO Performance Restricted Share Units (CPRSU)",
        "label": "CEO Performance Restricted Share Units (CPRSU) [Member]",
        "documentation": "CEO Performance Restricted Share Units (CPRSU)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalizedComputerSoftwareAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalizedComputerSoftwareAdditions",
     "crdr": "debit",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized computer software",
        "label": "Capitalized Computer Software, Additions",
        "documentation": "Additions made to capitalized computer software costs during the period."
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheets",
      "http://www.evolus.com/role/DescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r147",
      "r830"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r90",
      "r184"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Change in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r90"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r974"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r972"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r218",
      "r408",
      "r409",
      "r410",
      "r412",
      "r415",
      "r420",
      "r422",
      "r736",
      "r737",
      "r738",
      "r739",
      "r860",
      "r1029",
      "r1046"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 9)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r119",
      "r686",
      "r756"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.evolus.com/role/CommitmentsandContingencies",
      "http://www.evolus.com/role/MedytoxSettlementAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Commitments and Contingencies",
        "terseLabel": "Medytox Settlement Agreements",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r356",
      "r358",
      "r812",
      "r1082",
      "r1087"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Royalty Obligation Payable and Promissory Note Payable to the Evolus Founders",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r813"
     ]
    },
    "eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "CommonStockAdditionalCapitalSharesReservedforFutureIssuance",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional shares reserved for issuance (in shares)",
        "label": "Common Stock, Additional Capital Shares Reserved for Future Issuance",
        "documentation": "Common Stock, Additional Capital Shares Reserved for Future Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital shares reserved for future issuance (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/ConsolidatedStatementsofStockholdersEquityDeficit",
      "http://www.evolus.com/role/MedytoxSettlementAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r905",
      "r906",
      "r907",
      "r909",
      "r910",
      "r911",
      "r912",
      "r1051",
      "r1052",
      "r1054",
      "r1136",
      "r1194",
      "r1196"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.evolus.com/role/MedytoxSettlementAgreementsDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r757"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.evolus.com/role/ConsolidatedStatementsofStockholdersEquityDeficit",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares, issued (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares, outstanding (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r70",
      "r757",
      "r775",
      "r1196",
      "r1197"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock, $0.00001 par value; 100,000,000 shares authorized; 63,497,548 and 57,820,621 shares issued and outstanding at December\u00a031, 2024 and 2023, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r688",
      "r888"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r983"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r982"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r981"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://www.evolus.com/role/EmployeeBenefitPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Benefit Plan",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r109"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Benefits [Abstract]",
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r168",
      "r170",
      "r175",
      "r680",
      "r699",
      "r700"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.evolus.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computers",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized software",
        "label": "Computer Software, Intangible Asset [Member]",
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks."
       }
      }
     },
     "auth_ref": [
      "r825",
      "r829",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1080",
      "r1081"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risks and Uncertainties and Concentration of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r132"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r834"
     ]
    },
    "eols_ContingentRoyaltyObligationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "ContingentRoyaltyObligationMember",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Royalty Obligation",
        "label": "Contingent Royalty Obligation [Member]",
        "documentation": "Contingent Royalty Obligation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "ContingentRoyaltyObligationPayabletoRelatedPartyCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent royalty obligation payable to Evolus Founders",
        "label": "Contingent Royalty Obligation Payable to Related Party, Current",
        "documentation": "Contingent Royalty Obligation Payable to Related Party, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/AccruedExpensesDetails",
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued revenue contract liabilities",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r425",
      "r436"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with customer, liability, revenue recognized",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_ContractualObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractualObligation",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent royalty obligation payable to Evolus Founders",
        "label": "Contractual Obligation",
        "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments."
       }
      }
     },
     "auth_ref": [
      "r1050"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.evolus.com/role/SegmentReportingReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of goods sold",
        "label": "Cost of Goods and Services Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r645"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSoldDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation and amortization",
        "label": "Cost, Depreciation and Amortization",
        "documentation": "Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service."
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesScheduleofComponentsofCurrentandDeferredIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofComponentsofCurrentandDeferredIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1031",
      "r1049",
      "r1135"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesScheduleofComponentsofCurrentandDeferredIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofComponentsofCurrentandDeferredIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1031",
      "r1049"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesScheduleofComponentsofCurrentandDeferredIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofComponentsofCurrentandDeferredIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current provision",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r524",
      "r1049"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofComponentsofCurrentandDeferredIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current provision:",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesScheduleofComponentsofCurrentandDeferredIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofComponentsofCurrentandDeferredIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1031",
      "r1049",
      "r1135"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r929",
      "r1018"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r929",
      "r1018"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r931",
      "r1020"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r931",
      "r1020"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r933",
      "r1022"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r931",
      "r1020"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r924",
      "r1013"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r925",
      "r1014"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r925",
      "r1014"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r923",
      "r1012"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r923",
      "r1012"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r923",
      "r1012"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r926",
      "r1015"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r928",
      "r1017"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r928",
      "r1017"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r929",
      "r1018"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r932",
      "r1021"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r930",
      "r1019"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r927",
      "r1016"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.evolus.com/role/TermLoans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Term Loans",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r186",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r365",
      "r366",
      "r376",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r392",
      "r399",
      "r400",
      "r402",
      "r591"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.evolus.com/role/TermLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r59",
      "r60",
      "r116",
      "r118",
      "r191",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r388",
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r886",
      "r1047",
      "r1083",
      "r1084",
      "r1085",
      "r1147",
      "r1149"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.evolus.com/role/TermLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis spread on variable rate",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total principal payments",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r118",
      "r403"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.evolus.com/role/TermLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, face amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r377",
      "r591",
      "r592",
      "r856",
      "r857",
      "r886"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.evolus.com/role/TermLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate, effective percentage",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r406",
      "r591",
      "r592",
      "r886"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.evolus.com/role/TermLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate on debt",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r378"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.evolus.com/role/TermLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r388",
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r401",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r886",
      "r1047",
      "r1147",
      "r1149"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.evolus.com/role/TermLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r191",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r388",
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r886",
      "r1047",
      "r1083",
      "r1084",
      "r1085",
      "r1147",
      "r1149"
     ]
    },
    "eols_DebtInstrumentNumberOfInstallments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "DebtInstrumentNumberOfInstallments",
     "presentation": [
      "http://www.evolus.com/role/TermLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, number of installments",
        "label": "Debt Instrument, Number of Installments",
        "documentation": "Debt Instrument, Number of Installments"
       }
      }
     },
     "auth_ref": []
    },
    "eols_DebtInstrumentNumberOfTranches": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "DebtInstrumentNumberOfTranches",
     "presentation": [
      "http://www.evolus.com/role/TermLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of tranches",
        "label": "Debt Instrument, Number of Tranches",
        "documentation": "Debt Instrument, Number of Tranches"
       }
      }
     },
     "auth_ref": []
    },
    "eols_DebtInstrumentPeriodicPaymentInitialPrincipalPaymentDuePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "DebtInstrumentPeriodicPaymentInitialPrincipalPaymentDuePeriod",
     "presentation": [
      "http://www.evolus.com/role/TermLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Periodic payment, Initial principal payment, period",
        "label": "Debt Instrument, Periodic Payment, Initial Principal Payment Due, Period",
        "documentation": "Debt Instrument, Periodic Payment, Initial Principal Payment Due, Period"
       }
      }
     },
     "auth_ref": []
    },
    "eols_DebtInstrumentPeriodicPaymentNumberOfPrincipalPayments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "DebtInstrumentPeriodicPaymentNumberOfPrincipalPayments",
     "presentation": [
      "http://www.evolus.com/role/TermLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Periodic payment, number of quarterly principal payments due",
        "label": "Debt Instrument, Periodic Payment, Number of Principal Payments",
        "documentation": "Debt Instrument, Periodic Payment, Number of Principal Payments"
       }
      }
     },
     "auth_ref": []
    },
    "eols_DebtInstrumentPeriodicPaymentOutstandingPrincipalAmountDuePercentage": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "DebtInstrumentPeriodicPaymentOutstandingPrincipalAmountDuePercentage",
     "presentation": [
      "http://www.evolus.com/role/TermLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Periodic payment, percentage of outstanding principal amount",
        "label": "Debt Instrument, Periodic Payment, Outstanding Principal Amount Due, Percentage",
        "documentation": "Debt Instrument, Periodic Payment, Outstanding Principal Amount Due, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "eols_DebtInstrumentPrepaymentAmountThreshold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "DebtInstrumentPrepaymentAmountThreshold",
     "crdr": "credit",
     "presentation": [
      "http://www.evolus.com/role/TermLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, prepayment amount threshold",
        "label": "Debt Instrument, Prepayment Amount Threshold",
        "documentation": "Debt Instrument, Prepayment Amount Threshold"
       }
      }
     },
     "auth_ref": []
    },
    "eols_DebtInstrumentPrepaymentTermsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "DebtInstrumentPrepaymentTermsAxis",
     "presentation": [
      "http://www.evolus.com/role/TermLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Prepayment Terms [Axis]",
        "label": "Debt Instrument, Prepayment Terms [Axis]",
        "documentation": "Debt Instrument, Prepayment Terms"
       }
      }
     },
     "auth_ref": []
    },
    "eols_DebtInstrumentPrepaymentTermsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "DebtInstrumentPrepaymentTermsDomain",
     "presentation": [
      "http://www.evolus.com/role/TermLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Prepayment Terms [Domain]",
        "label": "Debt Instrument, Prepayment Terms [Domain]",
        "documentation": "Debt Instrument, Prepayment Terms [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "eols_DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount",
     "presentation": [
      "http://www.evolus.com/role/TermLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, percentage of principal amount, prepaid multiplied",
        "label": "Debt Instrument, Prepayment Terms, Prepayment Multiple On Principal Amount",
        "documentation": "Debt Instrument, Prepayment Terms, Prepayment Multiple On Principal Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.evolus.com/role/TermLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r44",
      "r47",
      "r55",
      "r103",
      "r104",
      "r191",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r388",
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r401",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r886",
      "r1047",
      "r1147",
      "r1149"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://www.evolus.com/role/TermLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity term of debt",
        "label": "Debt Instrument, Term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://www.evolus.com/role/TermLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt discount",
        "label": "Debt Instrument, Unamortized Discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r1096",
      "r1146",
      "r1147",
      "r1149"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unamortized debt discounts and issuance costs",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r404",
      "r590",
      "r591",
      "r592",
      "r856",
      "r857",
      "r886"
     ]
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt",
        "label": "Debt, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesScheduleofComponentsofCurrentandDeferredIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofComponentsofCurrentandDeferredIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1049",
      "r1134",
      "r1135"
     ]
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.evolus.com/role/TermLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance costs",
        "label": "Debt Issuance Costs, Gross",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r1147",
      "r1149"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesScheduleofComponentsofCurrentandDeferredIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofComponentsofCurrentandDeferredIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1049",
      "r1134"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesScheduleofComponentsofCurrentandDeferredIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.evolus.com/role/IncomeTaxesScheduleofComponentsofCurrentandDeferredIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes",
        "totalLabel": "Total deferred (benefit) provision",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r138",
      "r1049"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofComponentsofCurrentandDeferredIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred provision (benefit):",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred income tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r117",
      "r516"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liability",
        "label": "Deferred Income Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r497",
      "r685"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesScheduleofComponentsofCurrentandDeferredIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofComponentsofCurrentandDeferredIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1049",
      "r1134",
      "r1135"
     ]
    },
    "eols_DeferredTaxAssetsFixedAssetDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "DeferredTaxAssetsFixedAssetDepreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed asset depreciation",
        "label": "Deferred Tax Assets, Fixed Asset Depreciation",
        "documentation": "Deferred Tax Assets, Fixed Asset Depreciation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development credits",
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r1132"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred income tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax assets:",
        "label": "Deferred Tax Assets, Net of Valuation Allowance [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "eols_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Deferred Tax Assets Operating Lease Liabilities",
        "documentation": "Deferred Tax Assets Operating Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating losses",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1132"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards, not subject to expiration",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r1132"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards, subject to expiration",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r1132"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other, net",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1132"
     ]
    },
    "eols_DeferredTaxAssetsResearchAndExperimentationCapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "DeferredTaxAssetsResearchAndExperimentationCapitalization",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;E capitalization",
        "label": "Deferred Tax Assets, Research and Experimentation Capitalization",
        "documentation": "Deferred Tax Assets, Research and Experimentation Capitalization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation."
       }
      }
     },
     "auth_ref": [
      "r1132"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1132"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued legal settlement",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Legal Settlements",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the estimated loss from legal settlements."
       }
      }
     },
     "auth_ref": [
      "r1132"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Net deferred income taxes",
        "label": "Deferred Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax liabilities:",
        "label": "Deferred Tax Liabilities, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Intangible amortization",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill."
       }
      }
     },
     "auth_ref": [
      "r1132"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Operating lease right-of-use assets",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r1132"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Fixed asset depreciation",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r1132"
     ]
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.evolus.com/role/EmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined contributions to 401(k) plan",
        "label": "Defined Contribution Plan, Cost",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.evolus.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r38"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.evolus.com/role/SegmentReportingReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r216",
      "r228",
      "r252",
      "r844",
      "r845"
     ]
    },
    "eols_DistributionRightsEvolysseNasolabialFoldProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "DistributionRightsEvolysseNasolabialFoldProductMember",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Distribution Rights, Evolysse Nasolabial Fold Product",
        "label": "Distribution Rights, Evolysse Nasolabial Fold Product [Member]",
        "documentation": "Distribution Rights, Evolysse Nasolabial Fold Product"
       }
      }
     },
     "auth_ref": []
    },
    "eols_DistributionRightsEvolysseProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "DistributionRightsEvolysseProductsMember",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Distribution Rights, Evolysse Products",
        "label": "Distribution Rights, Evolysse Products [Member]",
        "documentation": "Distribution Rights, Evolysse Products"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DistributionRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DistributionRightsMember",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Distribution rights",
        "label": "Distribution Rights [Member]",
        "documentation": "Legal rights, generally of a limited duration, to distribute a product or products, often within specific geographic areas or supply channels."
       }
      }
     },
     "auth_ref": [
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1080",
      "r1081"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r920",
      "r921",
      "r944"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r920",
      "r921",
      "r944",
      "r987"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r965"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r976"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r206",
      "r208",
      "r210",
      "r211",
      "r212",
      "r215",
      "r535",
      "r540",
      "r555",
      "r556",
      "r681",
      "r701",
      "r836"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r208",
      "r210",
      "r211",
      "r212",
      "r215",
      "r535",
      "r540",
      "r555",
      "r556",
      "r681",
      "r701",
      "r836"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r214"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rates on cash and cash equivalents",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "eols_EffectiveIncomeTaxRateReconciliationOfficersCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationOfficersCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Officers' compensation",
        "label": "Effective Income Tax Rate Reconciliation, Officers' Compensation",
        "documentation": "Effective Income Tax Rate Reconciliation, Officers' Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revaluation of contingent royalty obligation",
        "label": "Effective Income Tax Rate Reconciliation, Revaluation Of Contingent Royalty Obligation",
        "documentation": "Effective Income Tax Rate Reconciliation, Revaluation Of Contingent Royalty Obligation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued payroll and related benefits",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Amount Capitalized",
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation cost related to nonvested awards not yet recognized",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation cost related to nonvested awards not yet recognized, expected weighted-average period for recognition (in years)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofWeightedAverageAssumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity CIK",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Smaller Reporting Company",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r917"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "presentation": [
      "http://www.evolus.com/role/SegmentReportingScheduleofRevenuebyCountryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, Major Customer [Line Items]",
        "label": "Revenue, Major Customer [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r970"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.evolus.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/ConsolidatedStatementsofStockholdersEquityDeficit",
      "http://www.evolus.com/role/MedytoxSettlementAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r141",
      "r172",
      "r173",
      "r174",
      "r192",
      "r193",
      "r194",
      "r196",
      "r201",
      "r203",
      "r205",
      "r217",
      "r295",
      "r296",
      "r344",
      "r423",
      "r525",
      "r526",
      "r532",
      "r533",
      "r534",
      "r536",
      "r539",
      "r540",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r554",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r593",
      "r595",
      "r609",
      "r697",
      "r725",
      "r726",
      "r727",
      "r742",
      "r795"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r980"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r937",
      "r948",
      "r958",
      "r991"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r934",
      "r945",
      "r955",
      "r988"
     ]
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Estimate of Fair Value Measurement [Member]",
        "documentation": "Measured as an estimate of fair value."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r580",
      "r856",
      "r857"
     ]
    },
    "eols_EvolusIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "EvolusIncMember",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Evolus, Inc.",
        "label": "Evolus, Inc [Member]",
        "documentation": "Evolus, Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.evolus.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r559",
      "r571",
      "r875"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.evolus.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r559",
      "r571",
      "r875"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r557",
      "r559",
      "r560",
      "r561",
      "r562",
      "r570",
      "r571",
      "r573",
      "r615",
      "r616",
      "r617",
      "r856",
      "r857",
      "r863",
      "r864",
      "r865",
      "r875",
      "r879"
     ]
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementBasisAxis",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Basis [Axis]",
        "label": "Measurement Basis [Axis]",
        "documentation": "Information by measurement basis."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r856",
      "r857"
     ]
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosureItemAmountsDomain",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement [Domain]",
        "label": "Fair Value Measurement [Domain]",
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r856",
      "r857"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r566",
      "r568",
      "r569",
      "r570",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r678",
      "r875",
      "r880"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r439",
      "r444",
      "r559",
      "r571",
      "r615",
      "r863",
      "r864",
      "r865",
      "r875"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r439",
      "r444",
      "r559",
      "r560",
      "r571",
      "r616",
      "r856",
      "r857",
      "r863",
      "r864",
      "r865",
      "r875"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r559",
      "r560",
      "r561",
      "r562",
      "r571",
      "r617",
      "r856",
      "r857",
      "r863",
      "r864",
      "r865",
      "r875",
      "r879"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsReconciliationofFairValueMeasurementofContingentRoyaltyObligationPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Reconciliation of Fair Value Measurement for Contingent Royalty Obligation Payable",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r567",
      "r572"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.evolus.com/role/FairValueMeasurementsReconciliationofFairValueMeasurementofContingentRoyaltyObligationPayableDetails",
      "http://www.evolus.com/role/SegmentReportingReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Revaluation of contingent royalty obligation payable to Evolus Founders",
        "negatedTerseLabel": "Change in fair value recorded in operating expenses",
        "negatedNetLabel": "Revaluation of contingent royalty obligation",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r564",
      "r572"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "crdr": "debit",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsReconciliationofFairValueMeasurementofContingentRoyaltyObligationPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r565",
      "r572"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.evolus.com/role/FairValueMeasurementsReconciliationofFairValueMeasurementofContingentRoyaltyObligationPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent royalty obligation payable to Evolus Founders",
        "periodStartLabel": "Fair value, beginning of period",
        "periodEndLabel": "Fair value, end of period",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r572"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r557",
      "r559",
      "r560",
      "r561",
      "r562",
      "r570",
      "r571",
      "r573",
      "r615",
      "r616",
      "r617",
      "r856",
      "r857",
      "r863",
      "r864",
      "r865",
      "r875",
      "r879"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.evolus.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r298",
      "r299",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r401",
      "r420",
      "r552",
      "r578",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r698",
      "r851",
      "r875",
      "r877",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r889",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1137",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Useful lives of intangible assets",
        "terseLabel": "Weighted-Average Life (Years)",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r314",
      "r336",
      "r853"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1078",
      "r1202"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r825",
      "r853"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r825",
      "r853"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r825",
      "r853"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r825",
      "r853"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r825",
      "r853"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r331",
      "r332",
      "r333",
      "r335",
      "r336",
      "r339",
      "r340",
      "r646",
      "r647",
      "r825"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails": {
       "parentTag": "eols_IntangibleAssetsGrossIncludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Original Cost",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r336",
      "r647",
      "r853"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r336",
      "r339",
      "r340",
      "r342",
      "r646",
      "r825",
      "r853"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r331",
      "r332",
      "r333",
      "r335",
      "r336",
      "r339",
      "r340",
      "r825"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails_1": {
       "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsEstimatedFutureAmortizationExpenseofIntangiblesDetails",
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Book Value",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r646",
      "r1077"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Definite-lived intangible assets",
        "label": "Finite-Lived Intangible Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining amortization period",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "crdr": "debit",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-live intangible assets capitalized",
        "label": "Finite-Lived Intangible Assets Acquired",
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition."
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "eols_FirstMilestonePaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "FirstMilestonePaymentMember",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Milestone Payment",
        "label": "First Milestone Payment [Member]",
        "documentation": "First Milestone Payment"
       }
      }
     },
     "auth_ref": []
    },
    "eols_FollowOnOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "FollowOnOfferingMember",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Follow-on Offering",
        "label": "Follow-On Offering [Member]",
        "documentation": "Follow-On Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Tax Jurisdiction",
        "label": "Foreign Tax Jurisdiction [Member]",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r501"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Translation",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r582"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r941",
      "r952",
      "r962",
      "r995"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r941",
      "r952",
      "r962",
      "r995"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r941",
      "r952",
      "r962",
      "r995"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r941",
      "r952",
      "r962",
      "r995"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r941",
      "r952",
      "r962",
      "r995"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r975"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.evolus.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails": {
       "parentTag": "eols_IntangibleAssetsGrossIncludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails_1": {
       "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.evolus.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheets",
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "verboseLabel": "Goodwill",
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r316",
      "r679",
      "r845",
      "r852",
      "r876",
      "r888",
      "r1069",
      "r1070"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1068",
      "r1071"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r327",
      "r852"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r341",
      "r343"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of goodwill",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r317",
      "r323",
      "r327",
      "r852",
      "r876"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r81",
      "r125",
      "r188",
      "r294",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r581",
      "r838",
      "r844",
      "r1055",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1093"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r920",
      "r921",
      "r944"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of intangible assets",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r330",
      "r341"
     ]
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In-process Research and Development",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesScheduleofLossbeforeIncomeTaxesfromUSOperationsandForeignDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofLossbeforeIncomeTaxesfromUSOperationsandForeignDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "United States",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r499"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.evolus.com/role/IncomeTaxesScheduleofLossbeforeIncomeTaxesfromUSOperationsandForeignDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.evolus.com/role/IncomeTaxesScheduleofLossbeforeIncomeTaxesfromUSOperationsandForeignDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes:",
        "negatedTotalLabel": "Loss before income taxes:",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r121",
      "r125",
      "r682",
      "r695",
      "r838",
      "r844",
      "r1055",
      "r1057",
      "r1058",
      "r1059",
      "r1060"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesScheduleofLossbeforeIncomeTaxesfromUSOperationsandForeignDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofLossbeforeIncomeTaxesfromUSOperationsandForeignDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Foreign",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r499"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r352",
      "r353",
      "r564",
      "r567",
      "r572",
      "r722",
      "r724",
      "r780",
      "r825",
      "r878",
      "r1165"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r353",
      "r564",
      "r567",
      "r572",
      "r722",
      "r724",
      "r780",
      "r825",
      "r878",
      "r1165"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Axis]",
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r500",
      "r501",
      "r510",
      "r521",
      "r874",
      "r1131"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Domain]",
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r500",
      "r501",
      "r510",
      "r521",
      "r874",
      "r1131"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r491",
      "r500",
      "r507",
      "r508",
      "r509",
      "r514",
      "r519",
      "r527",
      "r529",
      "r530",
      "r531",
      "r741",
      "r874"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest and penalties related to income tax matters",
        "label": "Income Tax Examination, Penalties and Interest Accrued",
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r1129"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.evolus.com/role/IncomeTaxesScheduleofComponentsofCurrentandDeferredIncomeTaxExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.evolus.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.evolus.com/role/IncomeTaxesScheduleofComponentsofCurrentandDeferredIncomeTaxExpenseDetails",
      "http://www.evolus.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxDetails",
      "http://www.evolus.com/role/SegmentReportingReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax expense",
        "totalLabel": "Total provision for income taxes",
        "verboseLabel": "Income tax provision",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r139",
      "r204",
      "r205",
      "r216",
      "r231",
      "r252",
      "r498",
      "r500",
      "r528",
      "r702",
      "r874"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r494",
      "r495",
      "r514",
      "r515",
      "r518",
      "r523",
      "r735"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r874",
      "r1127"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in state tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r500",
      "r505",
      "r874"
     ]
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Rate Differential",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r504",
      "r874",
      "r1127"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax at statutory rate",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r500",
      "r874"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Meals and entertainment",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Meals and Entertainment, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible meals and entertainment expense."
       }
      }
     },
     "auth_ref": [
      "r1127",
      "r1128"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r874",
      "r1127",
      "r1128"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income taxes, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r503",
      "r874",
      "r1127"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxContingenciesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationTaxContingenciesOther",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofEffectiveIncomeTaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other, net",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Other, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in other income tax contingencies."
       }
      }
     },
     "auth_ref": [
      "r1127"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for income taxes",
        "label": "Income Taxes Paid, Net",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r183",
      "r520",
      "r521"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Inventories",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "eols_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) In Operating Lease Liabilities",
        "documentation": "Increase (Decrease) In Operating Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other assets",
        "label": "Increase (Decrease) in Other Current Assets",
        "documentation": "Amount of increase (decrease) in current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepaid expenses",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived intangible asset",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r941",
      "r952",
      "r962",
      "r986",
      "r995",
      "r999",
      "r1007"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r922",
      "r1011"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r922",
      "r1011"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r922",
      "r1011"
     ]
    },
    "eols_IntangibleAssetsGrossIncludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "IntangibleAssetsGrossIncludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Intangible assets, gross (including goodwill)",
        "label": "Intangible Assets, Gross (Including Goodwill)",
        "documentation": "Intangible Assets, Gross (Including Goodwill)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r1077",
      "r1079"
     ]
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total net book value",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "documentation": "Amount, after impairment and amortization, of goodwill, indefinite-lived, and finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1067"
     ]
    },
    "eols_IntellectualPropertyDisputesJeuveauMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "IntellectualPropertyDisputesJeuveauMember",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/MedytoxSettlementAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intellectual Property Disputes, Jeuveau",
        "label": "Intellectual Property Disputes, Jeuveau [Member]",
        "documentation": "Intellectual Property Disputes, Jeuveau"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.evolus.com/role/SegmentReportingReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense",
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r1043"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r181",
      "r182"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r831",
      "r888"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories and cost of goods sold",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r146",
      "r159",
      "r309",
      "r310",
      "r311",
      "r644",
      "r835"
     ]
    },
    "us-gaap_InvestmentIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeNet",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.evolus.com/role/SegmentReportingReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "negatedTerseLabel": "Interest income",
        "label": "Investment Income, Net",
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r85",
      "r86"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/OperatingLeasesComponentsofLeaseExpenseandOtherQuantitativeInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesComponentsofLeaseExpenseandOtherQuantitativeInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Lease, cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r600",
      "r887"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Composition of Lease Expense and Other Quantitative Information",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1152"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.evolus.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold Improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r608"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "eols_LesseeOperatingLeaseAbatementPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "LesseeOperatingLeaseAbatementPeriod",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, abatement period",
        "label": "Lessee, Operating Lease, Abatement Period",
        "documentation": "Lessee, Operating Lease, Abatement Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturity of Operating Lease Liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1153"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Renewal term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1150"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of contract",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1150"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r59",
      "r60",
      "r61",
      "r63",
      "r64",
      "r65",
      "r68",
      "r188",
      "r294",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r543",
      "r544",
      "r545",
      "r581",
      "r755",
      "r837",
      "r915",
      "r1093",
      "r1154",
      "r1155"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity (deficit)",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r120",
      "r691",
      "r888",
      "r1048",
      "r1066",
      "r1145"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r145",
      "r188",
      "r294",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r543",
      "r544",
      "r545",
      "r581",
      "r888",
      "r1093",
      "r1154",
      "r1155"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Liabilities",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent royalty obligation payable to Evolus Founders",
        "label": "Liabilities, Fair Value Disclosure",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r559",
      "r1138"
     ]
    },
    "eols_LicenseSupplyAndDistributionAgreementAnnualPaymentTriggeredRegulatoryApprovalNumberOfProducts": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "LicenseSupplyAndDistributionAgreementAnnualPaymentTriggeredRegulatoryApprovalNumberOfProducts",
     "presentation": [
      "http://www.evolus.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual payment triggered, number of products with regulatory approval",
        "label": "License, Supply And Distribution Agreement, Annual Payment Triggered, Regulatory Approval, Number Of Products",
        "documentation": "License, Supply And Distribution Agreement, Annual Payment Triggered, Regulatory Approval, Number Of Products"
       }
      }
     },
     "auth_ref": []
    },
    "eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour",
     "crdr": "debit",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License, supply and distribution agreement payment, June 2028 (in euro)",
        "label": "License, Supply and Distribution Agreement, Annual Payment, Year Four",
        "documentation": "License, Supply and Distribution Agreement, Annual Principal Payment, Year Four"
       }
      }
     },
     "auth_ref": []
    },
    "eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne",
     "crdr": "debit",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License, supply and distribution agreement payment, June 2025 (in euro)",
        "label": "License, Supply and Distribution Agreement, Annual Payment, Year One",
        "documentation": "License, Supply and Distribution Agreement, Annual Payment, Year One"
       }
      }
     },
     "auth_ref": []
    },
    "eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree",
     "crdr": "debit",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License, supply and distribution agreement payment, June 2027 (in euro)",
        "label": "License, Supply and Distribution Agreement, Annual Payment, Year Three",
        "documentation": "License, Supply and Distribution Agreement, Annual Payment, Year Three"
       }
      }
     },
     "auth_ref": []
    },
    "eols_LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License, supply and distribution agreement payment, June 2026 (in euro)",
        "label": "License, Supply and Distribution Agreement, Annual Payment, Year Two",
        "documentation": "License, Supply and Distribution Agreement, Annual Payment, Year Two"
       }
      }
     },
     "auth_ref": []
    },
    "eols_LicenseSupplyAndDistributionAgreementAnnualRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "LicenseSupplyAndDistributionAgreementAnnualRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual revenue (in euro)",
        "label": "License, Supply and Distribution Agreement, Annual revenue",
        "documentation": "License, Supply and Distribution Agreement, Annual revenue"
       }
      }
     },
     "auth_ref": []
    },
    "eols_LicenseSupplyAndDistributionAgreementContingentMilestoneLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "LicenseSupplyAndDistributionAgreementContingentMilestoneLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent milestone payment",
        "label": "License, Supply And Distribution Agreement, Contingent Milestone Liability, Noncurrent",
        "documentation": "License, Supply And Distribution Agreement, Contingent Milestone Liability, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "eols_LicenseSupplyAndDistributionAgreementExpectedRegulatoryApprovalNumberOfProducts": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "LicenseSupplyAndDistributionAgreementExpectedRegulatoryApprovalNumberOfProducts",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected regulatory approval, number of products",
        "label": "License, Supply And Distribution Agreement, Expected Regulatory Approval, Number Of Products",
        "documentation": "License, Supply And Distribution Agreement, Expected Regulatory Approval, Number Of Products"
       }
      }
     },
     "auth_ref": []
    },
    "eols_LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License, supply and distribution agreement, initial payment due, period",
        "label": "License, Supply and Distribution Agreement, Initial Payment Due, Period",
        "documentation": "License, Supply and Distribution Agreement, Initial Payment Due, Period"
       }
      }
     },
     "auth_ref": []
    },
    "eols_LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License, supply and distribution agreement, initial payment",
        "label": "License, Supply and Distribution Agreement, Initial Payment in Connection with Agreement",
        "documentation": "License, Supply and Distribution Agreement, Initial Payment in Connection with Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "eols_LicenseSupplyAndDistributionAgreementInitialTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "LicenseSupplyAndDistributionAgreementInitialTerm",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License, supply and distribution agreement, initial term",
        "label": "License, Supply and Distribution Agreement, Initial Term",
        "documentation": "License, Supply and Distribution Agreement, Initial Term"
       }
      }
     },
     "auth_ref": []
    },
    "eols_LicenseSupplyAndDistributionAgreementIntangibleAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "LicenseSupplyAndDistributionAgreementIntangibleAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License, supply and distribution agreement, intangible assets",
        "label": "License, Supply And Distribution Agreement, Intangible Asset",
        "documentation": "License, Supply And Distribution Agreement, Intangible Asset"
       }
      }
     },
     "auth_ref": []
    },
    "eols_LicenseSupplyAndDistributionAgreementLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "LicenseSupplyAndDistributionAgreementLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License, supply and distribution agreement, liability, noncurrent",
        "label": "License, Supply And Distribution Agreement, Liability, Noncurrent",
        "documentation": "License, Supply And Distribution Agreement, Liability, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "eols_LicenseSupplyAndDistributionAgreementMilestonePaymentPayablePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "LicenseSupplyAndDistributionAgreementMilestonePaymentPayablePeriod",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment, payable period",
        "label": "License, Supply And Distribution Agreement, Milestone Payment, Payable Period",
        "documentation": "License, Supply And Distribution Agreement, Milestone Payment, Payable Period"
       }
      }
     },
     "auth_ref": []
    },
    "eols_LicenseSupplyAndDistributionAgreementMinimumMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "LicenseSupplyAndDistributionAgreementMinimumMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent milestone payment",
        "label": "License, Supply and Distribution Agreement, Minimum Milestone Payment",
        "documentation": "License, Supply and Distribution Agreement, Minimum Milestone Payment"
       }
      }
     },
     "auth_ref": []
    },
    "eols_LicenseSupplyAndDistributionAgreementNumberOfCountriesUseAestheticsAndDermatologicalFields": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "LicenseSupplyAndDistributionAgreementNumberOfCountriesUseAestheticsAndDermatologicalFields",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of countries use aesthetics and dermatological fields",
        "label": "License, Supply and Distribution Agreement, Number Of Countries Use Aesthetics and Dermatological Fields",
        "documentation": "License, Supply and Distribution Agreement, Number Of Countries Use Aesthetics and Dermatological Fields"
       }
      }
     },
     "auth_ref": []
    },
    "eols_LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of milestone payment",
        "label": "License, Supply and Distribution Agreement, Number Of Milestone Payment",
        "documentation": "License, Supply and Distribution Agreement, Number Of Milestone Payment"
       }
      }
     },
     "auth_ref": []
    },
    "eols_LicenseSupplyAndDistributionAgreementNumberOfProductCandidates": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "LicenseSupplyAndDistributionAgreementNumberOfProductCandidates",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of product candidates",
        "label": "License, Supply And Distribution Agreement, Number Of Product Candidates",
        "documentation": "License, Supply And Distribution Agreement, Number Of Product Candidates"
       }
      }
     },
     "auth_ref": []
    },
    "eols_LicenseSupplyAndDistributionAgreementPendingRegulatoryApprovalNumberOfProducts": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "LicenseSupplyAndDistributionAgreementPendingRegulatoryApprovalNumberOfProducts",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pending regulatory approval, number of products",
        "label": "License, Supply And Distribution Agreement, Pending Regulatory Approval, Number Of Products",
        "documentation": "License, Supply And Distribution Agreement, Pending Regulatory Approval, Number Of Products"
       }
      }
     },
     "auth_ref": []
    },
    "eols_LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/CommitmentandContingenciesDetails",
      "http://www.evolus.com/role/DescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Regulatory approval, number of products",
        "label": "License, Supply And Distribution Agreement, Regulatory Approval, Number Of Products",
        "documentation": "License, Supply and Distribution Agreement, Regulatory Approval, Number Of Products"
       }
      }
     },
     "auth_ref": []
    },
    "eols_LicenseSupplyAndDistributionAgreementRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "LicenseSupplyAndDistributionAgreementRenewalTerm",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License, supply and distribution agreement, renewal term",
        "label": "License, Supply and Distribution Agreement, Renewal Term",
        "documentation": "License, Supply and Distribution Agreement, Renewal Term"
       }
      }
     },
     "auth_ref": []
    },
    "eols_LicenseSupplyAndDistributionAgreementRightToCommercializeAndDistributeNumberOfProductCandidates": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "LicenseSupplyAndDistributionAgreementRightToCommercializeAndDistributeNumberOfProductCandidates",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right to commercialize and distribute, number of product candidates",
        "label": "License, Supply And Distribution Agreement, Right To Commercialize And Distribute, Number Of Product Candidates",
        "documentation": "License, Supply And Distribution Agreement, Right To Commercialize And Distribute, Number Of Product Candidates"
       }
      }
     },
     "auth_ref": []
    },
    "eols_LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License, supply and distribution agreement, upfront payment",
        "label": "License, Supply and Distribution Agreement, Upfront Payment, In-Process Research and Development Expense",
        "documentation": "License, Supply and Distribution Agreement, Upfront Payment, In-Process Research and Development Expense"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/MedytoxSettlementAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Axis]",
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/MedytoxSettlementAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Domain]",
        "label": "Litigation Case [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationReserveCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LitigationReserveCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued litigation settlement",
        "label": "Estimated Litigation Liability, Current",
        "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r1088"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "eols_LondonInterbankOfferedRateLIBOR1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "LondonInterbankOfferedRateLIBOR1Member",
     "presentation": [
      "http://www.evolus.com/role/TermLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "London Interbank Offered Rate",
        "label": "London Interbank Offered Rate (LIBOR) 1 [Member]",
        "documentation": "London Interbank Offered Rate (LIBOR) 1"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Long term debt, net of discounts and issuance costs",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r118",
      "r389",
      "r405",
      "r856",
      "r857",
      "r886",
      "r1162"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r191",
      "r394"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Long-Term Debt, Maturity, Year Four",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r191",
      "r394"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Long-Term Debt, Maturity, Year Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r191",
      "r394"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/TermLoansScheduleofLongTermDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r191",
      "r394"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.evolus.com/role/TermLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r1083",
      "r1084",
      "r1085"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.evolus.com/role/TermLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r41",
      "r1083",
      "r1084",
      "r1085"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.evolus.com/role/CommitmentandContingenciesDetails",
      "http://www.evolus.com/role/MedytoxSettlementAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Line Items]",
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r360",
      "r361",
      "r364",
      "r488",
      "r854",
      "r1089",
      "r1090"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.evolus.com/role/CommitmentandContingenciesDetails",
      "http://www.evolus.com/role/MedytoxSettlementAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Table]",
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r360",
      "r361",
      "r364",
      "r488",
      "r854",
      "r1089",
      "r1090"
     ]
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyAccrualAtCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/CommitmentandContingenciesDetails",
      "http://www.evolus.com/role/MedytoxSettlementAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss contingency accrual",
        "label": "Loss Contingency Accrual",
        "documentation": "Amount of loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r1030"
     ]
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyNewClaimsFiledNumber",
     "presentation": [
      "http://www.evolus.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss contingency, new claims filed, number",
        "label": "Loss Contingency, New Claims Filed, Number",
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period."
       }
      }
     },
     "auth_ref": [
      "r1089",
      "r1090"
     ]
    },
    "eols_LossContingencyNumberDefendantsOfficers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "LossContingencyNumberDefendantsOfficers",
     "presentation": [
      "http://www.evolus.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss contingency, number of defendants, officers",
        "label": "Loss Contingency, Number Defendants, Officers",
        "documentation": "Loss Contingency, Number Defendants, Officers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyNumberOfPlaintiffs",
     "presentation": [
      "http://www.evolus.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss contingency, number of plaintiffs",
        "label": "Loss Contingency, Number of Plaintiffs",
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency."
       }
      }
     },
     "auth_ref": [
      "r1089",
      "r1090"
     ]
    },
    "eols_LossContingencySettlementAgreementManufacturingLicensePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "LossContingencySettlementAgreementManufacturingLicensePeriod",
     "presentation": [
      "http://www.evolus.com/role/MedytoxSettlementAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement agreement, manufacturing license period (months)",
        "label": "Loss Contingency, Settlement Agreement, Manufacturing License Period",
        "documentation": "Loss Contingency, Settlement Agreement, Manufacturing License Period"
       }
      }
     },
     "auth_ref": []
    },
    "eols_LossContingencySettlementAgreementPaymentTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "LossContingencySettlementAgreementPaymentTerms",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/MedytoxSettlementAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement agreement, payment terms (in years)",
        "label": "Loss Contingency, Settlement Agreement, Payment Terms",
        "documentation": "Loss Contingency, Settlement Agreement, Payment Terms"
       }
      }
     },
     "auth_ref": []
    },
    "eols_MarketingFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "MarketingFixturesMember",
     "presentation": [
      "http://www.evolus.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketing Fixtures",
        "label": "Marketing Fixtures [Member]",
        "documentation": "Marketing Fixtures"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r360",
      "r361",
      "r362",
      "r363",
      "r446",
      "r488",
      "r562",
      "r643",
      "r721",
      "r723",
      "r731",
      "r747",
      "r748",
      "r800",
      "r802",
      "r804",
      "r805",
      "r807",
      "r823",
      "r824",
      "r850",
      "r860",
      "r868",
      "r879",
      "r880",
      "r884",
      "r885",
      "r899",
      "r1095",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input, Discount Rate",
        "label": "Measurement Input, Discount Rate [Member]",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r1140",
      "r1141",
      "r1142"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Axis]",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r560",
      "r561",
      "r562",
      "r879"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Domain]",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r560",
      "r561",
      "r562",
      "r879"
     ]
    },
    "eols_MilestoneAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "MilestoneAxis",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone [Axis]",
        "label": "Milestone [Axis]",
        "documentation": "Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "eols_MilestoneDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "MilestoneDomain",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone [Domain]",
        "label": "Milestone [Domain]",
        "documentation": "Milestone [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r360",
      "r361",
      "r362",
      "r363",
      "r446",
      "r488",
      "r562",
      "r643",
      "r721",
      "r723",
      "r731",
      "r747",
      "r748",
      "r800",
      "r802",
      "r804",
      "r805",
      "r807",
      "r823",
      "r824",
      "r850",
      "r860",
      "r868",
      "r879",
      "r880",
      "r884",
      "r899",
      "r1095",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.evolus.com/role/DescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "negatedLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r91",
      "r92"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.evolus.com/role/ConsolidatedStatementsofStockholdersEquityDeficit",
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/SegmentReportingReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "negatedLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r92",
      "r122",
      "r143",
      "r166",
      "r169",
      "r174",
      "r188",
      "r195",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r204",
      "r205",
      "r209",
      "r294",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r535",
      "r540",
      "r556",
      "r581",
      "r696",
      "r777",
      "r793",
      "r794",
      "r913",
      "r1093"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "eols_NonCashInResearchAndDevelopmentInProcessExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "NonCashInResearchAndDevelopmentInProcessExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash in-process research and development expense",
        "label": "Non-cash In Research And Development In Process Expenses",
        "documentation": "Non-cash In Research And Development In Process Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r941",
      "r952",
      "r962",
      "r986",
      "r995"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r969"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r968"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "us-gaap_NonUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonUsMember",
     "presentation": [
      "http://www.evolus.com/role/SegmentReportingScheduleofRevenuebyCountryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "International",
        "label": "Non-US [Member]",
        "documentation": "Countries excluding the United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r1198",
      "r1199",
      "r1200",
      "r1201"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash investing and financing information",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayableOtherPayablesMember",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent royalty obligation payable to Evolus Founders",
        "label": "Notes Payable, Other Payables [Member]",
        "documentation": "A written promise to pay a note to a third party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/SegmentReportingNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r845",
      "r1056"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r839",
      "r849",
      "r1056"
     ]
    },
    "us-gaap_NumberOfReportingUnits": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportingUnits",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reporting units",
        "label": "Number of Reporting Units",
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.evolus.com/role/DescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "negatedLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r838",
      "r1055",
      "r1057",
      "r1058",
      "r1059",
      "r1060"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/OperatingLeasesComponentsofLeaseExpenseandOtherQuantitativeInformationDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesComponentsofLeaseExpenseandOtherQuantitativeInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed operating lease expense",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r601",
      "r887"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesMaturityofOperatingLeaseLiabilitiesDetails",
      "http://www.evolus.com/role/OperatingLeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of operating lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r597"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r597"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r597"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesWeightedAverageRemainingLeaseTermandDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r598",
      "r603"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheets",
      "http://www.evolus.com/role/OperatingLeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1045"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesWeightedAverageRemainingLeaseTermandDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r606",
      "r887"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesWeightedAverageRemainingLeaseTermandDiscountRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term (years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r605",
      "r887"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NOL carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of Business",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r113",
      "r732",
      "r733"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued expenses",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r888"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss:",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r10",
      "r114",
      "r167",
      "r170",
      "r201"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized loss, net of tax",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r165",
      "r293"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.evolus.com/role/SegmentReportingReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense), net",
        "negatedLabel": "Other expense, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Other Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r978"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r939",
      "r950",
      "r960",
      "r993"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r942",
      "r953",
      "r963",
      "r996"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r942",
      "r953",
      "r963",
      "r996"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Over-Allotment Option",
        "label": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payables and Accruals [Abstract]",
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "eols_PaymentsForInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "PaymentsForInventory",
     "crdr": "credit",
     "presentation": [
      "http://www.evolus.com/role/CommitmentandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory payments",
        "label": "Payments For Inventory",
        "documentation": "Payments For Inventory"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForLegalSettlements",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.evolus.com/role/MedytoxSettlementAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accrued litigation settlement",
        "terseLabel": "Payments for legal settlements",
        "label": "Payments for Legal Settlements",
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "eols_PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments for provisions for accrued volume-based rebate and coupon liability",
        "label": "Payments For Provisions For Accrued Volume-Based Rebate And Coupon Liability",
        "documentation": "Payments For Provisions For Accrued Volume-Based Rebate, Coupon And Consumer Loyalty Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForSoftware": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForSoftware",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Additions to capitalized software",
        "label": "Payments for Software",
        "documentation": "The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "eols_PaymentsOfContingentRoyaltyObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "PaymentsOfContingentRoyaltyObligation",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of contingent royalty obligation to Evolus Founders",
        "label": "Payments Of Contingent Royalty Obligation",
        "documentation": "Payments Of Contingent Royalty Obligation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.evolus.com/role/TermLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments for debt issuance costs",
        "terseLabel": "Payments for debt issuance costs",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments for offering costs",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax withholding paid on behalf of employees for net share settlement",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r969"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r986"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r979"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r968"
     ]
    },
    "eols_PerformanceRestrictedStockUnitsPRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "PerformanceRestrictedStockUnitsPRSUMember",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Restricted Stock Units (PRSU)",
        "label": "Performance Restricted Stock Units (PRSU) [Member]",
        "documentation": "Performance Restricted Stock Units (PRSU)"
       }
      }
     },
     "auth_ref": []
    },
    "eols_PharmakonTermLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "PharmakonTermLoansMember",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.evolus.com/role/TermLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pharmakon Term Loans",
        "label": "Pharmakon Term Loans [Member]",
        "documentation": "Pharmakon Term Loans"
       }
      }
     },
     "auth_ref": []
    },
    "eols_PharmakonTermLoansOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "PharmakonTermLoansOneMember",
     "presentation": [
      "http://www.evolus.com/role/TermLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche A Loan",
        "label": "Pharmakon Term Loans One [Member]",
        "documentation": "Pharmakon Term Loans One"
       }
      }
     },
     "auth_ref": []
    },
    "eols_PharmakonTermLoansTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "PharmakonTermLoansTwoMember",
     "presentation": [
      "http://www.evolus.com/role/TermLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche B Loan",
        "label": "Pharmakon Term Loans Two [Member]",
        "documentation": "Pharmakon Term Loans Two"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r970"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r969"
     ]
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Portion at Fair Value Measurement",
        "label": "Portion at Fair Value Measurement [Member]",
        "documentation": "Measured at fair value for financial reporting purposes."
       }
      }
     },
     "auth_ref": [
      "r579"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r408"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r757"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r408"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r757",
      "r775",
      "r1196",
      "r1197"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred Stock, $0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at December\u00a031, 2024 and 2023, respectively",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r687",
      "r888"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r312",
      "r313",
      "r832"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from follow-on offering, net of underwriting fees",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.evolus.com/role/TermLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of long-term debt, net of discounts",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r736"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash proceeds from exercise of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r14"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductMember",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product revenue, net",
        "label": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r256",
      "r645",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r827",
      "r861",
      "r898",
      "r899",
      "r900",
      "r903",
      "r904",
      "r1091",
      "r1092",
      "r1097",
      "r1164",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r256",
      "r645",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r827",
      "r861",
      "r898",
      "r899",
      "r900",
      "r903",
      "r904",
      "r1091",
      "r1092",
      "r1097",
      "r1164",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.evolus.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r608"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.evolus.com/role/PropertyPlantandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r133",
      "r136",
      "r137"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r148",
      "r694"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.evolus.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheets",
      "http://www.evolus.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r608",
      "r683",
      "r694",
      "r888"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r133",
      "r136",
      "r692"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.evolus.com/role/PropertyPlantandEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property, Plant and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.evolus.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r608"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for bad debts",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r301"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r360",
      "r361",
      "r362",
      "r363",
      "r438",
      "r446",
      "r476",
      "r477",
      "r478",
      "r488",
      "r562",
      "r618",
      "r627",
      "r643",
      "r721",
      "r723",
      "r731",
      "r747",
      "r748",
      "r800",
      "r802",
      "r804",
      "r805",
      "r807",
      "r823",
      "r824",
      "r850",
      "r860",
      "r868",
      "r879",
      "r880",
      "r884",
      "r885",
      "r899",
      "r907",
      "r1086",
      "r1095",
      "r1141",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r360",
      "r361",
      "r362",
      "r363",
      "r438",
      "r446",
      "r476",
      "r477",
      "r478",
      "r488",
      "r562",
      "r618",
      "r627",
      "r643",
      "r721",
      "r723",
      "r731",
      "r747",
      "r748",
      "r800",
      "r802",
      "r804",
      "r805",
      "r807",
      "r823",
      "r824",
      "r850",
      "r860",
      "r868",
      "r879",
      "r880",
      "r884",
      "r885",
      "r899",
      "r907",
      "r1086",
      "r1095",
      "r1141",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161"
     ]
    },
    "eols_RebatesAndCouponsCreditsAndPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "RebatesAndCouponsCreditsAndPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rebates and coupons, credits and payments",
        "label": "Rebates And Coupons, Credits And Payments",
        "documentation": "Rebates And Coupons, Credits And Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationFromSegmentTotalsToConsolidatedAbstract",
     "presentation": [
      "http://www.evolus.com/role/SegmentReportingReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less:",
        "label": "Segment Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable",
     "presentation": [
      "http://www.evolus.com/role/SegmentReportingReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized Tax Benefits [Roll Forward]",
        "label": "Unrecognized Tax Benefits [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r934",
      "r945",
      "r955",
      "r988"
     ]
    },
    "eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period of termination of first commercial sale",
        "label": "Related Party Transaction, Period Of Termination Of First Commercial Sale",
        "documentation": "Related Party Transaction, Period Of Termination Of First Commercial Sale"
       }
      }
     },
     "auth_ref": []
    },
    "eols_ReportableSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "ReportableSegmentMember",
     "presentation": [
      "http://www.evolus.com/role/SegmentReportingReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable Segment",
        "label": "Reportable Segment [Member]",
        "documentation": "Reportable Segment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.evolus.com/role/SegmentReportingReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r1126"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expenses",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "eols_ResearchAndDevelopmentInProcess1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "ResearchAndDevelopmentInProcess1",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.evolus.com/role/SegmentReportingReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In-process research and development",
        "label": "Research And Development In Process 1",
        "documentation": "Research And Development In Process 1"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;D",
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r1131"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r935",
      "r946",
      "r956",
      "r989"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r936",
      "r947",
      "r957",
      "r990"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r943",
      "r954",
      "r964",
      "r997"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested Restricted Stock Units",
        "verboseLabel": "RSUs",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheets",
      "http://www.evolus.com/role/DescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r105",
      "r690",
      "r728",
      "r730",
      "r740",
      "r758",
      "r888"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r192",
      "r193",
      "r194",
      "r196",
      "r201",
      "r203",
      "r205",
      "r295",
      "r296",
      "r344",
      "r525",
      "r526",
      "r532",
      "r533",
      "r534",
      "r536",
      "r539",
      "r540",
      "r546",
      "r548",
      "r549",
      "r551",
      "r554",
      "r593",
      "r595",
      "r725",
      "r727",
      "r742",
      "r1196"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.evolus.com/role/SegmentReportingReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://www.evolus.com/role/SegmentReportingScheduleofRevenuebyCountryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenues",
        "terseLabel": "Total net revenues",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r216",
      "r224",
      "r225",
      "r246",
      "r252",
      "r256",
      "r258",
      "r260",
      "r434",
      "r435",
      "r645"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r826"
     ]
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "presentation": [
      "http://www.evolus.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue by Country",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets obtained in exchange for operating lease liabilities",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r604",
      "r887"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "eols_SCHAEONLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "SCHAEONLLCMember",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SCH",
        "label": "SCH-AEON, LLC [Member]",
        "documentation": "SCH-AEON, LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "eols_SaleOfStockCommissionPaymentUponGrossProceedsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "SaleOfStockCommissionPaymentUponGrossProceedsPercentage",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, commission payment upon gross proceeds",
        "label": "Sale of Stock, Commission Payment Upon Gross Proceeds, Percentage",
        "documentation": "Sale of Stock, Commission Payment Upon Gross Proceeds, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate net proceeds from stock offering",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "eols_SaleOfStockGrantedOptionsExercisablePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "SaleOfStockGrantedOptionsExercisablePeriod",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted options, exercisable period",
        "label": "Sale of Stock, Granted Options, Exercisable Period",
        "documentation": "Sale of Stock, Granted Options, Exercisable Period"
       }
      }
     },
     "auth_ref": []
    },
    "eols_SaleOfStockMaximumConsiderationReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "SaleOfStockMaximumConsiderationReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum consideration receivable",
        "label": "Sale Of Stock, Maximum Consideration Receivable",
        "documentation": "Sale Of Stock, Maximum Consideration Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, number of shares issued in transaction",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering price per share (in dollar per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.evolus.com/role/AccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53",
      "r537"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Current and Deferred Income Tax Expense",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1133"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Effective Income Tax",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r874",
      "r1127"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "presentation": [
      "http://www.evolus.com/role/SegmentReportingScheduleofRevenuebyCountryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "documentation": "Disclosure of information about the extent of the entity's reliance on its major customers."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Assets and Liabilities Measured on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1138",
      "r1139"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsScheduleofDefiniteandIndefiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Asset, Finite-Lived [Table]",
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r336",
      "r339",
      "r340",
      "r342",
      "r646",
      "r825",
      "r853"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Loss before Income Taxes from U.S. Operations and Foreign",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Intangible Assets and Goodwill",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class."
       }
      }
     },
     "auth_ref": [
      "r1068",
      "r1071"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.evolus.com/role/TermLoansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturities of Long-term Debt",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/PropertyPlantandEquipmentScheduleofPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r608"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.evolus.com/role/SegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Revenue to Net Loss",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r35"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r450",
      "r451",
      "r452",
      "r453",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of RSUs Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Options Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r110"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Key Assumptions Used to Determine Fair Value of Options Granted",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock, Class of Stock [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r101",
      "r103",
      "r104",
      "r105",
      "r154",
      "r155",
      "r156",
      "r218",
      "r408",
      "r409",
      "r410",
      "r412",
      "r415",
      "r420",
      "r422",
      "r736",
      "r737",
      "r738",
      "r739",
      "r860",
      "r1029",
      "r1046"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Unrecognized Tax Benefits",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r511",
      "r873"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Future Amortization Expense of Intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r853",
      "r1078"
     ]
    },
    "eols_SecondMilestonePaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "SecondMilestonePaymentMember",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second Milestone Payment",
        "label": "Second Milestone Payment [Member]",
        "documentation": "Second Milestone Payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecuredDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecuredDebtMember",
     "presentation": [
      "http://www.evolus.com/role/TermLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Loan",
        "label": "Secured Debt [Member]",
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "eols_SecuredFinancingOfferedRateSOFRMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "SecuredFinancingOfferedRateSOFRMember",
     "presentation": [
      "http://www.evolus.com/role/TermLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Financing Offered Rate (SOFR)",
        "label": "Secured Financing Offered Rate (SOFR) [Member]",
        "documentation": "Secured Financing Offered Rate (SOFR)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecuredLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecuredLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term loan, net of discount and issuance costs",
        "label": "Secured Long-Term Debt, Noncurrent",
        "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.evolus.com/role/SegmentReportingReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r126",
      "r216",
      "r220",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r236",
      "r237",
      "r238",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r254",
      "r260",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r342",
      "r354",
      "r355",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r841",
      "r844",
      "r845",
      "r852",
      "r902",
      "r1164",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.evolus.com/role/SegmentReportingScheduleofRevenuebyCountryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r258",
      "r259",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r744",
      "r745",
      "r746",
      "r801",
      "r803",
      "r806",
      "r808",
      "r811",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r828",
      "r862",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r901",
      "r907",
      "r1097",
      "r1164",
      "r1166",
      "r1167",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.evolus.com/role/SegmentReporting"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r216",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r235",
      "r237",
      "r238",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r256",
      "r257",
      "r260",
      "r839",
      "r842",
      "r843",
      "r844",
      "r846",
      "r848",
      "r849"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r255",
      "r258",
      "r840",
      "r841",
      "r847"
     ]
    },
    "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems",
     "presentation": [
      "http://www.evolus.com/role/SegmentReportingReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.evolus.com/role/SegmentReportingReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ServiceMember",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service revenue",
        "label": "Service [Member]",
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service."
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalShareIncreaseAvailableForIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalShareIncreaseAvailableForIssuance",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional shares available for issuance (in shares)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Additional Share Increase Available for Issuance",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Additional Share Increase Available for Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r464"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Unit",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r464"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsAfterTermination": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsAfterTermination",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual term after termination",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms, After Termination",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms, After Termination"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units that vested, fair value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r478"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r450",
      "r451",
      "r452",
      "r453",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum number of shares authorized under the plan (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock available for future issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Term (Years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueVested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueVested",
     "crdr": "debit",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total intrinsic value of options that vested",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value, Vested",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Aggregate Intrinsic Value, Vested"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options, exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, exercisable (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cancelled/forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average grant date fair value, options (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r456"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r456"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options, vested and expected to vest (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price, vested and expected to vest (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual increase percentage of maximum shares outstanding (equal to)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "eols_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Performance Period",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Performance Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee stock purchase plan shares issued during the period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofRestrictedStockUnitActivityDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails",
      "http://www.evolus.com/role/StockholdersEquityScheduleofWeightedAverageAssumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r452",
      "r453",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancelled/forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "20 Consecutive Trading Days with a $30 Share Price",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "20 Consecutive Trading Days with a $50 Share Price",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "eols_ShareBasedCompensationConsecutiveTradingDaysPerShareTarget": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "ShareBasedCompensationConsecutiveTradingDaysPerShareTarget",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consecutive trading amount (in dollars per share)",
        "label": "Share-Based Compensation, Consecutive Trading Days, Per Share Target",
        "documentation": "Share-Based Compensation, Consecutive Trading Days, Per Share Target"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r447",
      "r454",
      "r473",
      "r474",
      "r475",
      "r476",
      "r479",
      "r483",
      "r484",
      "r485",
      "r486"
     ]
    },
    "eols_ShareBasedPaymentArrangementNumberOfConsecutiveDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "ShareBasedPaymentArrangementNumberOfConsecutiveDays",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of consecutive days",
        "label": "Share-based Payment Arrangement, Number of Consecutive Days",
        "documentation": "Share-based Payment Arrangement, Number of Consecutive Days"
       }
      }
     },
     "auth_ref": []
    },
    "eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodOne": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodOne",
     "presentation": [
      "http://www.evolus.com/role/MedytoxSettlementAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share issuance agreement, percentage of share dispose per year, initial period",
        "label": "Share Issuance Agreement, Percentage of Share Dispose Per Year, Period One",
        "documentation": "Share Issuance Agreement, Percentage of Share Dispose Per Year, Period One"
       }
      }
     },
     "auth_ref": []
    },
    "eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodThree": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodThree",
     "presentation": [
      "http://www.evolus.com/role/MedytoxSettlementAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share issuance agreement, percentage of share dispose per year, period three",
        "label": "Share Issuance Agreement, Percentage of Share Dispose Per Year, Period Three",
        "documentation": "Share Issuance Agreement, Percentage of Share Dispose Per Year, Period Three"
       }
      }
     },
     "auth_ref": []
    },
    "eols_ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodTwo": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodTwo",
     "presentation": [
      "http://www.evolus.com/role/MedytoxSettlementAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share issuance agreement, percentage of share dispose per year, period two",
        "label": "Share Issuance Agreement, Percentage of Share Dispose Per Year, Period Two",
        "documentation": "Share Issuance Agreement, Percentage of Share Dispose Per Year, Period Two"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1099"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment award, expiration period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofWeightedAverageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value, exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options contractual term, outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average remaining contractual term, vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value assumptions, weighted average expected term",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Term",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Term"
       }
      }
     },
     "auth_ref": []
    },
    "eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value [Abstract]",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term, exercisable",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Exercisable",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r185"
     ]
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SoftwareDevelopmentMember",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software Development",
        "label": "Software Development [Member]",
        "documentation": "Internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r500"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.evolus.com/role/SegmentReportingReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r126",
      "r142",
      "r216",
      "r220",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r236",
      "r237",
      "r238",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r254",
      "r260",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r342",
      "r346",
      "r354",
      "r355",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r841",
      "r844",
      "r845",
      "r852",
      "r902",
      "r1164",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/ConsolidatedStatementsofStockholdersEquityDeficit",
      "http://www.evolus.com/role/MedytoxSettlementAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r70",
      "r73",
      "r74",
      "r141",
      "r172",
      "r173",
      "r174",
      "r192",
      "r193",
      "r194",
      "r196",
      "r201",
      "r203",
      "r205",
      "r217",
      "r295",
      "r296",
      "r344",
      "r423",
      "r525",
      "r526",
      "r532",
      "r533",
      "r534",
      "r536",
      "r539",
      "r540",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r554",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r593",
      "r595",
      "r609",
      "r697",
      "r725",
      "r726",
      "r727",
      "r742",
      "r795"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.evolus.com/role/SegmentReportingScheduleofRevenuebyCountryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r258",
      "r259",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r744",
      "r745",
      "r746",
      "r801",
      "r803",
      "r806",
      "r808",
      "r811",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r828",
      "r862",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r901",
      "r907",
      "r1097",
      "r1164",
      "r1166",
      "r1167",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.evolus.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r217",
      "r595",
      "r645",
      "r734",
      "r743",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r757",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r776",
      "r778",
      "r779",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r795",
      "r908"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.evolus.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r217",
      "r261",
      "r595",
      "r645",
      "r734",
      "r743",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r757",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r776",
      "r778",
      "r779",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r795",
      "r908"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r938",
      "r949",
      "r959",
      "r992"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in connection with Symatese Europe Agreement",
        "label": "Stock Issued",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27"
     ]
    },
    "eols_StockIssuedDuringPeriodSharesIncentiveEquityPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesIncentiveEquityPlan",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in connection with the incentive equity plan (in shares)",
        "label": "Stock Issued During Period, Shares, Incentive Equity Plan",
        "documentation": "Stock Issued During Period, Shares, Incentive Equity Plan"
       }
      }
     },
     "auth_ref": []
    },
    "eols_StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock in connection with Symatese Europe Agreement (in shares)",
        "terseLabel": "Stock issued in exchange for license, supply, and distribution agreement (in shares)",
        "label": "Stock Issued During Period, Shares, Issued For License, Supply and Distribution Agreement",
        "documentation": "Stock Issued During Period, Shares, Issued for License, Supply and Distribution Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "eols_StockIssuedDuringPeriodSharesLitigationSettlement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesLitigationSettlement",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/MedytoxSettlementAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in connection with litigation settlement (in shares)",
        "label": "Stock Issued During Period Shares Litigation Settlement",
        "documentation": "Stock Issued During Period Shares, Litigation Settlement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon follow-on offering, net of issuance costs (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r69",
      "r70",
      "r105",
      "r736",
      "r795",
      "r809"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r69",
      "r70",
      "r105",
      "r460"
     ]
    },
    "eols_StockIssuedDuringPeriodValueIncentiveEquityPlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "StockIssuedDuringPeriodValueIncentiveEquityPlan",
     "crdr": "credit",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in connection with the incentive equity plan",
        "label": "Stock Issued During Period, Value, Incentive Equity Plan",
        "documentation": "Stock Issued During Period, Value, Incentive Equity Plan"
       }
      }
     },
     "auth_ref": []
    },
    "eols_StockIssuedDuringPeriodValueIssuedForLicenseSupplyAndDistributionAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "StockIssuedDuringPeriodValueIssuedForLicenseSupplyAndDistributionAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in connection with Symatese Europe Agreement",
        "label": "Stock Issued During Period, Value, Issued for License, Supply and Distribution Agreement",
        "documentation": "Stock Issued During Period, Value, Issued for License, Supply and Distribution Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon follow-on offering, net of issuance costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r69",
      "r70",
      "r105",
      "r742",
      "r795",
      "r809",
      "r914"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.evolus.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheets",
      "http://www.evolus.com/role/ConsolidatedStatementsofStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity (deficit)",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r73",
      "r74",
      "r96",
      "r759",
      "r775",
      "r796",
      "r797",
      "r888",
      "r915",
      "r1048",
      "r1066",
      "r1145",
      "r1196"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 equity (deficit)",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r187",
      "r407",
      "r409",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r421",
      "r423",
      "r553",
      "r798",
      "r799",
      "r810"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events [Abstract]",
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.evolus.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r610",
      "r611"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://www.evolus.com/role/DescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of cash flow information",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "eols_SymateseEuropeAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "SymateseEuropeAgreementMember",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/CommitmentandContingenciesDetails",
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Symatese Europe Agreement",
        "label": "Symatese Europe Agreement [Member]",
        "documentation": "Symatese Europe Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "eols_SymateseU.S.AgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "SymateseU.S.AgreementMember",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/CommitmentandContingenciesDetails",
      "http://www.evolus.com/role/DescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Symatese U.S. Agreement",
        "label": "Symatese U.S. Agreement [Member]",
        "documentation": "Symatese U.S. Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r985"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforwards",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Axis]",
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardLineItems",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Line Items]",
        "label": "Tax Credit Carryforward [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward, Name [Domain]",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardTable",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Table]",
        "label": "Tax Credit Carryforward [Table]",
        "documentation": "Disclosure of information about tax credit carryforward available to reduce future taxable income. Includes, but is not limited to, description, amount, expiration date, limitation on use, and related deferred tax asset and valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r522"
     ]
    },
    "eols_TermOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "TermOneMember",
     "presentation": [
      "http://www.evolus.com/role/TermLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior to the 3rd anniversary",
        "label": "Term One [Member]",
        "documentation": "Term One"
       }
      }
     },
     "auth_ref": []
    },
    "eols_TermThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "TermThreeMember",
     "presentation": [
      "http://www.evolus.com/role/TermLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After the 4th anniversary",
        "label": "Term Three [Member]",
        "documentation": "Term Three"
       }
      }
     },
     "auth_ref": []
    },
    "eols_TermTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "TermTwoMember",
     "presentation": [
      "http://www.evolus.com/role/TermLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After the 3rd anniversary but prior to the 4th anniversary",
        "label": "Term Two [Member]",
        "documentation": "Term Two"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r977"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r984"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.evolus.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.evolus.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.evolus.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r401",
      "r420",
      "r552",
      "r578",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r698",
      "r875",
      "r877",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r889",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1137",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "eols_TwoThousandAndSeventeenOmnibusIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.evolus.com/20241231",
     "localname": "TwoThousandAndSeventeenOmnibusIncentivePlanMember",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2017 Omnibus Incentive Plan",
        "label": "Two Thousand And Seventeen Omnibus Incentive Plan [Member]",
        "documentation": "Two Thousand And Seventeen Omnibus Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.evolus.com/role/CommitmentandContingenciesDetails",
      "http://www.evolus.com/role/DescriptionofBusinessDetails",
      "http://www.evolus.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r541"
     ]
    },
    "us-gaap_TypeOfCostGoodOrServiceExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfCostGoodOrServiceExtensibleList",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost, Product and Service [Extensible Enumeration]",
        "label": "Cost, Product and Service [Extensible Enumeration]",
        "documentation": "Indicates type of cost from product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r1098"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://www.evolus.com/role/SegmentReportingScheduleofRevenuebyCountryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r492",
      "r511",
      "r873"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases to current year tax positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r873"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.evolus.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases to prior year tax positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r873"
     ]
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed cash payments estimated to be over term of lease",
        "label": "Unrecorded Unconditional Purchase Obligation",
        "documentation": "Amount of unrecorded obligation to transfer funds in future for fixed or minimum amount or quantity of product and service at fixed or minimum price. Includes, but is not limited to, lease not yet commenced and take-or-pay and throughput contracts."
       }
      }
     },
     "auth_ref": [
      "r357",
      "r1151"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.evolus.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32",
      "r130",
      "r131",
      "r134",
      "r135"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.evolus.com/role/OperatingLeasesComponentsofLeaseExpenseandOtherQuantitativeInformationDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.evolus.com/role/OperatingLeasesComponentsofLeaseExpenseandOtherQuantitativeInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable operating lease expense",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r602",
      "r887"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://www.evolus.com/role/TermLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Axis]",
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://www.evolus.com/role/TermLoansNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Domain]",
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Axis]",
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.evolus.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Domain]",
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r973"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares outstanding used to compute diluted net loss per share (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r212"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.evolus.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares outstanding used to compute basic net loss per share (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r212"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r971"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/710/tableOfContent"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/712/tableOfContent"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-5"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-15"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483385/720-35-55-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>96
<FILENAME>0001570562-25-000020-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001570562-25-000020-xbrl.zip
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MP=ZAQUVW][^HY&7OB&02P#F-_+ YY/Y@F!P=CI./][Z7#(\Z[?9_;N4?8_$
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M#)P1IE["TMB G"<FFI@) 5P.O]+GQOM]3C9F9'_X);[IHP$O!%C@!8NCP(F
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M8U]XOJJ43X7QKV)^AZ52+T(QEB7T:QKV-C#AQ33LS472UJ&TG79MQ*OZU3U
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M2*?CO2B1@,FE6L]%V#>P.(N#+0_TBW)"P1\Y0:HEH0*-Y6YH:I55Y/EB3&$
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M?BJ[)ZF67.=1Y-&8G^-TX)QX(Y -R8"LFW&=?SYIT$;+5E^Z&KF!)U&:RJJ
M*/E#I[4K9-,F\B(:;@!>H9O)]-IQ I:&[I "4A<^NI(;IKX4'*O481L;;&V&
MEQEAG?49*UT =>[*1;O/J*XJL@C0PH1#%O2SV2H2A:.S?CG_(5TD7!<\R!JN
MQL[55T!A4P82$+H4GY^X7_A# S-G]1'B]?IIR_W*ADHH[D@D4Z%^13HXA<&
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M\CK;)$/O]Z,SU '; IWEQ3&,S&O>-6%V-L71Y6[Q\VZG_>['>^L-[&O95RJ
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M^V+JOM *G7VD\" R$!,WIX=-5TK4@8:!53[RB(BJL<*43HL"5H)] :W\%(!
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MY;59PXE'6%&W'/ELUX@V.U)"Z-<3H\;# 61'/:W!6*+CHV@X$^]R:%JF9IO
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M"CL>U<@3!3LF6F4I"JS@YVU8!A\4YF (*L*3V1:UE*8\;Q2209(-/H!!*!3
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M-5ZV3^DH_2)K;:QRQ6+=5XB?EE?4Y2NTL&;O=LPV+[?E^!6KU'RZUX*]I$%
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MBI)QE)Y_:Q.V=+ %IW$,C_) YN!?!("+F1B"_/KYF_#Z:!2&Z<.DOLVR?)_
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M,.INPR(/D+:)&5@-;Q3<.;%U[=/"KZ1H\5GPD&R$4E4<)7C120F+XB;:4]E
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M&:DN>\$=;'BRSLMGI()(/@&*Y?N0EJ2/$$LY[IZ': ]PQT;+9+!=9'2$CS.
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M:CQD/>>63%:,LQ)!MI*.HK9T[<NSO+UH5.KM832,JH&S]+U'[YJ=14CCD)E
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MQWWWDE L3DK2%:<0DJART+WZ@_0JN.W.21<3O5C7B3L<7"CKVDJR0@KAI)#
MCJW QMELY3;JUB242Y_QVM8^$#8/&B *'IAOS+/%#G$[,-$S'PT_2=8RJ&2:
M^<NDULSR.MEUKDWS- ./L!-.K%]E\3O!#Y@-'*SE4^W<.-7B)[?3I6-NIHAN
M<&4F V/D!XJ/C8"=CO\<O+3,].U\6GKO0K.LT#]VQ):+-AG7%71B]+J*V2J4
M*F0VM:FK#*OG1TAFRQZY3L^T_#$CZ'1'ZIJ>%I:/:Z+P<=VSB%QA$!YJ#%:I
M0LI$/=8-]E]466\29GT02V[H_)CY&H0L:0AG8.HXQB5)=]8/*1[4*T@@/,$9
MI/>+N8BDGS"&<+;1B0G)C4>:4ZCV!NM<5Z)S1P BNL_T]F23^/<E-D-6("V@
M3+2ADK*27L$*3P6>(GHREN02459@JG O7FXT[1NXXFAJ"E@A7N? /4V66S*K
M9Y!I1NG&26J%W)VW,=UR@9>JF6R(UU5"T?>MYR6T;ELNC M><TT$H_TL"I&6
M@U(]6C?W3'*&37=S_UK1+46B7U27F#6IM>;HL4_V()B3=R5")B(FE;9)X9#+
MMCK&T;+OQOE(A<TCGNY?9#MR='&?GM44(IC4F><J^6+WT./F\ ,TY>!W#F=G
MZ= .*6*-/9+(E"CA0+2YW.>_JB]JFW>$]%RA8_FY(J?\:[A$' _W ^YJ&.*1
M"BOR![/K5(,<K#3>#HXA_-C:KP^5R%A_>-?5XWZ+R8Q1W3*=GEI$O.:QXM'4
MPTB3G$@@!S-F2%L=0O<^5O@392#]&%[.7:#K.%;%;^ NE'61T]*ATT:MG,V%
M\7>LN29'RT#E05>?TS<!*[SLVG5-)<I:J$IB: M8A"O4OVV[F[.K[@;I7E)(
MC 3N; + CS00/5(]Z& ["IX?BQ)M?NF?$?JVKU?U;O-1BW?'M2I6)?[(U&$+
MDB<]XZH?Z4:$;70V7)5;)M\JJ[Z[(.*,(:1.U1F9:M3&-QU$)*2T'7:HD7]Y
MZA#'M1#1@[$^?K[XJ6WV=XSKYM5T0@4D)P!A(MRJG6(B2#4VTI*19OP%ICM)
MR^@1G>=/:7(F?:.,"R!=[,O'2'@9*6&'9<,X]E[5Z=TX?.Q,72*@81"K&..L
MQ@^-9^7-:.+PMPL9:9P@Q)$A.Y=68GJOU/BK*<.RX)';R$S_L%X,Q'*B(+S(
M6"#3#>I/9N"R4MH@D1[EK,7MQK^&U]JBIYW\X,QX]=,X\O4>V4>(>^FVJY1S
MRT@6Z]9LL9AXSM@UNNF4Q6;>9P+Y*4^5\CP86+(MM2QD(Q+W?H#4I2NJVV;.
M9"L)&@E'J6O/=/L?<O/S_GT25!UR^"$;+X&PY<2&HPQV?=C*X/FA'(%&OM-0
M(--(NU5>X>BCAJQM+ZVU4;E="%J_$N2IBP+>P]G;BTC!0#'L"*LAJ4[$*:WG
M,ZB.I(6B7DSPO55[.5YY@+G]F%YTBCWF&B(X 9:T10T^BQ+&8$+N7,H"6P=(
M!^GT+5#/B0Q;;+)-D8?OZR!":WIS/@D\B-I*<(%T'<'3W*?O/GNZV999CI*:
MQ\CK-@<>FW\$<@Q5N$.N>Z*8RK 9R=?H]'T"U$Z_<-V;R?I,[B*CO'+!M4M4
M;K6S<C;@;6[]G"2U.>*ER$"]FE]>UUV34HC;U%[XZJ;$D"G(T%B_RFV5R;RQ
M;%I'%>>DR[/B3&9:J2K")AF5 UXY?R'1++3--7= #-]5DM19Y).2ST(-U "W
M]"!D8)IJ=2F$(V$K8@8[R^*3S1L1U^H_W,LT4*Z#4U[8Y[MV[J[G $W+*^IJ
M0-\7KQJG >H]=AAD/P6GO@QO?KZDGN#SF(RP+45(D&>&I66QDAA#SF-E[1NW
MC35^+#+VQKD-X>K^.0"0;1!'FFF<0EM!OL29.MZ]H!=+Y20<PHZ][&A&0ED>
M-41N6=%YS)C\ZS44O<9&VA%=".D*9>'""&:*@J<;_G6WNM1CXMHOL32$PJ"_
M,:(-QG63AYV\2WN3:@G,"'+Q-Q@>N^"TEGE"-=QB>+]X=$(UG% -1Q$#U$A%
M]I*\F %8%3/QUESH>IM_(RNI8]28[;>0(.5/8^,R%R&XF6J$ -+FX!X.<D 6
MA&37HZ1/;+:/(?QZ.(D'NV&HU4N$OL+<NXS\235F%"XK<;&WKV ,*WR)Y,#'
M)T%?1N&:T;:']3BC8&2WP43H,:SY[25,5\+QHQZ'5]#7\GV.EB9@Y1+]O^+#
MU_OV>:T/+;!D@ ="UJ;!=IS'&L9NNTAYV-.@?-?J(%BXV([N#0R<DB3:1BG<
M&#.)Y((;!/*T\;;I%1:S.RJ9P%&E4G<?<9"UL.$,IE9<\E OVHD:5>/7'H)J
MJ%F@R5*\>DBSO(+K*GOFAZS<NE6J$(*U@]F*2%&?G8\<<VOZ=0F+YF>7^-[E
MQ4@QCU-B&(1D',!T=)6V,U+XAUN[[$%AGW0(-0ES"]O#&T"8*ECS85W/JMX?
MV]%^VAJMTZI*J-EYNL;A,RRC]&/0;.*(TBYK 2>I"0W7T^!J^+M0IL?,A&/\
M\-/!9]%_<@*#4J*;TR:^D+Z^ON5.%&TOKQ+SUGIZD_>ISUE)0:LFGN%]3.U<
M*L\L)G'NTN6,,X65&8>.S35;+$<^^O^S]RZ\;2-9VO!?(;+=+WH 66U)OB8S
M#:2=I#>SG4F09+8Q^/#A!2669'8H4L.+'<VO?\^M+KQ(EAS+HAPNL-.Q1)'%
MJE.GSO5YHL@?HQF5(*C)[Z6IYO$WO2"W<6RGP2A\))MNS(?DEQ(<0 UBK-9/
MWO=>4[G%5+N.MHX&%@>.W@QA'Q(;+(H:WL?YVF@7;)$OO6C5Q[7%(;9DC$K5
M?-,\Q@%84\Z9F(8]W_8X/TSO;RF*(C%C4**1B#_S"&RV,%41Z)4BX T-31+,
MKB0B*D=%Z&8Q;AGW6F<?]+BU,42;5-(9X'@+$GMS0/  E%G)H1Y+;ZVD#9HA
M+C"]P(!YYH"G^8MC"7+3>JX@C%FO&G6/+@%LD/:C8X;235HXW(2;F[@RAJ,+
M;#Y>NMD0E\HO7RXJA4\28-%CJ5@$@66SP;-?3Q+<Z0OR-ZZ[DWXK,T*!S\7<
M/$:X.<ZO:1L$?Q7^O%9^RK_'W*FH1FOCI>&\I *2U"M1NA-L*C_(9 MUED?#
M<W/C+ZKLC YQ6*6)0IN;2Z7T8+@R6T-$:8QU*D6&C351!N,*XY04E\1J2O.^
M91PS#1O;^JWQSB&F=S.R!!2/5=%D!1GD&E-!7<ZSSA \@'O'N>*2<AGD!XM@
M3&GO1>$7]%UYJBU\?J:#X!K6<&KR*'(:.'('&M4=%2T &/(3+%P&&<&R,/!H
M%V$N(&8,]+0JI:?5:CD42P:F4]!(N28\)DO*5_*DC5J@ ;#?)'JXUBO+D@FW
ML9$N<=Z09<IN\6K)+K-[<CX,C=N2%6.(-$HXY[E@092^E1QM9&H9<?18]\ !
M;2=-@V62*FALEFTJ4&R#U-\O6%"3#@D.K(P(Z)S_-1EAF%[ =;E-TN@0=O\;
MD"GT]4R^I58(8%K_XQ4)0F32L79%TSS8RE%3/TFE<HY/J],)=^% 967FF95@
M4]IMIJ)SJL'(6.%CDQ'9W<V63&W/;E<,LEY$ZF4A:%K!QM(4.1GU^=(CU]15
MR"00S ]5>:#US8$KYD<2OY042!%E! TK^]@4+;*2-YNX!N\&%_^[H,J:>RA.
M]LQY/8V?5!.5U8N'-C&E66 R0[:R+<^(*=J88SW0RD?%@6TR6L%"X@)-5##M
M\'T+4;P5?)'RS\20-JSE26XKK&Q25%=&."@3$F.]C>T+$>B7KD027&"D&;%E
M44TE]OB.*DUQW-:PU^.I#:%'6'$2<B$'2&(RR,V:IU3K*=&2YAWRN434S7DN
M*8,U"+NE-[)!EXIIMW*C.,)F*FLI'V<9'$ORI^8L+B+9!Q$Y?8>N((?M<-6D
M]TO*M52P?<'679I3ZZZ*T&/%"9>J9,LL5_,2>Y!3U5'R)/7W#D:<<ZGHQ*E_
M(]ZV*VT5-,=UTN *;>GQK,!=J,=:7WDETCY'N*0P=RCIF16P%&"L0I]5!-<@
M-5JTFM(^A/DP%16K?7)+.M='B%;CUQ#.A,T^E"'75BU?G8!P14@$>UY=8UAW
M%TGW*W='<;]#&6;'\F@X\3QG7NX3OZMHA7)<S+DA"A'&<K6LRPC2!$-4#;TY
MC.E6:[HKQ650:6#$2]IE;!Y(J@? 6L[1)K=E3+H?RZ@N1#P.R(!'N!1,[3'8
M46]E)U67O%^7O!]TR?LN>=^*,WFN?,R"3XNH$DYP-6=%4:\]=FTZ71PA$V4W
M<.A.^U[IS'>:KVU!L30EKB*JUDI,FYB)CMH?0O5D#7^_W#!![I5//-<;3KXN
M":Q46@O<%=X%#%GPG!Q.5).L*,'OKB0%;\>LWJOWKEI<;TM)JD7:&F31[;XH
M<VSIKD]3 :_/)>OW2S2T#=.U35T[R,<7-P92(3DH=[ JANVFTO0DKDZ8S1T5
ML6E2L%7NE?IR$UEKZK0I5PZ[<5MW\ML_V7\HFN!JF*TV<63D]7#7EI'8L-_#
MR7NP%*[L,"#GU':^)T)B9)(&Z$9J_$6FF],P F3\EK)Q5% 1H:&-)<G!3<@-
M*V;A*M&4/PS#BD:3XQ>HC38.;!0#[5E0/PS^T<!B8T:G7UR/"($8./K-Z0T3
M_R[UAY=!% GAC:K5RRT9NE^KYLR4Q-'*=L/Z.:2WE0"2/O?T46@,ZRGY^C B
M'AAEF$GKDR?@HL#Z4@\2$A(,VMJE#K,J7)Q?;D0EBD5Q"'MK2[&L.Y 4.5>3
M8>6*T.MP?T+I --QRM0A-EP'CL_I%L(0#4W,JXCU'ZZ.=J?7(-HV:6F7AQ..
M*\[AFN#4J@8Z98!9=32L5RFKCA,^8JM!F)XM:H!O8(O-N18239DB)KQ*#S$_
M2L4[6)112BJXV4ZGQ9KDOMC\A:T<H*1M\:ZK]&DK#[/[%D0V8+^; JF2VC-:
MI3*'W!DB15$D%;<8.V09*V3[V358F<\^/##Y/S2^.TY'>!,&!9*AXX%"TH<;
M(N06!9E(#+3H [V,?8@:JD:/8F*")FZQ>KDL,^L]%PT=$<)#HUVA0QS,S+O5
M(I;&8-!JX IE/E^3;OBC3'NRXFTWO)T<[#$W_2"+'D>A%%->.-&K4F55<T$8
M-[)(+,E%-:I6^SC80108U6'9"FX8.C"KBZ5J*>#5D3VZ%<$@K2]XLD:)61YF
MR2H7<E 5Y34F\3E;3U0!R^8V5<<QNPX-W0'?&!G%*'CX12'F?)IAP4QD.XG!
M#?YBS6?FZ0[AA)666E.=O@[3_&[\&%[_]:R4/;<(Q>5A1M?/$(*!S ?M,:?O
MF=(6B"/;TMKDT-8!CUA<R1 S:$+-@.3I_8#*6S&GZXM@G1GAGB[$F+^[LKT<
MOK?=@Y3$]+GJKZ1I\@I^=AUD3VOZ=<VZ^O$Z/X,:LX@<P790\^4&YA!VLWI@
M9>5UA6A3)H54GQA'-EE)<E(]X.O;>95#;0B),--=PI]R2^YK>/LZ1I954P1W
M26-/S[##CENR^'J6Z]SR@[="AK</ 1G;F5KSV;LA4SKVY^*--+<;"=U0O,*G
M&Q<ATBQBB0,B2<[B4(/H6R0$ ]:9&G!#=]97QNU:,=5WLO"E:A9FG,,E%\[Y
MVYGP)"W-MZ9K<?K%=#82_CD)TTDQOS%;S33+4RZ1:ZM-[7H@#I!3*I#H;GUZ
M=E.=<C4&4ZI8P9VT4E1ZEC5,GS,K9  \K462:Q 9V)2QV'"&OG.-F/2]]YIL
M)2+T;WC9GF-%V5BFA>BHCX P1L4.6/=*:P2\ ?*K]Z1D^$ZR+)INW;2\0I[-
MB8<^ UT,<^!@P;,Q*.+HDO+(2<OT";45-3[JZB?3+QW9=Y[4T^T\Y1/]+EH8
M?=BY-S4\?J6G5]NKIKHGW'TK? S%,%UZC][*\TTS?331>5#'&05BKI6YS[;<
M'_=D_5@MR%U2^]DOHV&7U.Z2VJW0YW=B4C\8TO0*YUWK3Q/56:6[OP,$:6?>
MRP3ICP01[<84W5,F13U$B[\2KC?K-7II!).2(H]IQ@!;RN4UN/O,+,/7;(WZ
M7+96I&^"9EZH'&P%'8N</&TM(K!N#ELEJ/=&"C8SDY1MZLH^:)&-N"'S_&_8
M*L>YRH]J)B&'0ZR.>%^M:["ES&DI,&U["F;VW5/S[NTH#=D$KJSIG7JZ^ZHG
MM"<2N!;V;ON:Z-35&QCLC.#'#&J0ARO@Y+C-XO4_>]Z5'_N!W_->(O4QK)=?
M0B"UE<B@42;A@F(X@O+UYM5+O@TAFKY*BYDDC(5*): (<Y[J\@FX\HK,0]:4
MK\ >QAC3E:"=X6,_\&%FKG_][J4S'.W*R$Q@AX7SG@QQ95S<1A!E;J;#A$>C
M4)6G6-Y1)Z&E;X#GQ-*,- \&JQENP7ZGJ@8I8%T]:&P'+U+CZ49+Z5O&WUL"
M3.<.HK.%^4[7Q_"KFY&MNNL&=W3YVQ(.4<Z+:$:*QYXS;T0&WR1)T",!8*?\
M*LGFE%5[.<EY'3]PL^A_$X"C]XF/+OY:I_A%#! U[!.?1'BXT25S/J-IO3@4
M*ID#VA6(YCRQP=9)BID-]IDTF%W/GF-PBEG4=VU@N97R<*0X@DO%*@(;9R:E
M!^=*K#\%/R[F3EI]4&<J_ _,.QU8$UA#^,<455O/.:DR+'K)J/0!AP=BGTPL
MT -63]Q0.3W"XWR%QV:F8-R@&V!I/FQ(ER[S';FM4I7#?X2!Z2X\ .WX)D%<
M0D?;T7:1Z4#;S49] I!6*4[$E'#*_?/$^[ 1=CW(NL\9/JT'*+:./) P;_![
M*LEWNPHB7Q?H3/T)&MHAK_%-""]?CNT[?!L,>ISI%H8J "ZE=]-Y*<Y#/2"P
M84.*":Q1!0*$)QFW:1AS5X/TDSM3:-^F"N?@[GM;CX_'$-L5K]]]<MI3&Z_F
M4ZMT F$NE+L1:JVP.!_.A>[>TYB#5>WC]IQ$_EAQ\R3GT,.,$<!-FXB8#]S6
MWG/UL#-I,@)BJBUA?0OTYB'L%2XI1;L<3F@4E "F:<GA7'(F:39D[U!- OV@
M2E]B+EA-$\(%JJ8R&A4KMZNLKLS4[@[G<,RF=1Q4[LBA C0X\@L+#6FS/"B'
M/CI+K;#-[]_9+%/=H-)H!LO3Z_#3W,%'TX9)N2.HK1R^'E&"O?*.Z[D[VBAZ
M:4'M2>ZV)SV9U7UN"-)DPI#6E$LT0NH<G3ANM%MCZL#_RP4]2=1R75"@R+4N
M_V@-J5MIMZQT659;E^LLQ-4]R34;73"1K);#.DLNW95.33)=^=BA?PH^?*]&
MA9376!#LF5?=]IG1*=N:F7[IG4$C3"@Y\'Q#R28Q7&#H/YX=16J:/Q^=.9]0
M$((_HHAD2.58SX\&%WO;$6B;#\_VR!I<GJ[!"7(</_N%:,!4V99.-,ZOZ;^L
MDHH)JHS906S0!AIV*4C]6[-!C$G+/&/42VAK''2ARXMNX1]YX0FT3UP8#XRX
MG(SG[!HITPBN"<XOCC)B5EU0G>4ZQ'L!;VM,VAA+P>$KTXM;99ICN"",:>A"
MI6ZQ'WFQQ28'7SB@?C<A.4BLN>Q'QOJ2C<JAX4)?=H-E]),D304>H%(V;NMI
M%U0;B9^#H'0K_<@K75XWI_?%UZ#[6,V2*I,'F% 8';TNX80,M4EUXZ=86*TC
M&*D*YV.$*)N;UBS'4Z;F=^,E@GU68-HDU\TE<!GQ<?A.N,;&8_"2.(FMY]N)
MS2.+#3-!@"=I8FB,WA;.G&)&)ZS6;>P]&6I.'+%;@OTL@3A?X0T#N=JHL]9G
MJQ>F*]5Y]LMHU)7J=*4ZG7YZ>/VDO7!JUXQG"9<?E8+PW9GQR&M"D7EVJ#3
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M9PV<AYE!\!N7M+YV;$IS+BY5&$^C@H<W7G*!C GT9U@/8JK*?.JV62:&*TS
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M:;7#-/412%.[#ODUH=;S<>%'53= (CM65ZP"0GKLU?I#N%0%P@55L'"(T$3
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MKQKO0PK>2LZE$1VN:]#Z00X\[T\\3$'BPX4T7'.PUU@.NAEZXE3#.0?(:?V
M7F%VW&%?]-C <+?O*@/C\O+B[.C#A]_6F!?.;:ZT4 G(8O GC!++N:WT:0IE
MC8$_3VX(&C"[1:P_%\I>UV8[ . LL!7#97A<GY<L.2+()*41!RG1I)^M5T!1
ML_M2KVQI,IU-2[CH"Z%O,L\P??N!F@B;;5SQ%?7SFH^I5699ZW7H6TI8@#-!
M.7%VDIW@'7-.ZV@=R3Y7]MI+2..X.&E4_!IP?6N)):**Z,5(29D_)\0EK:,,
M7K,+0$&5/:5@Q<\Z)+F1EORC$JC,*UHS94)T1,G%/*XN9LF5T '=A+,D38J,
M.+CPMD9IA[E3)$RV9I$3&+@(8A7/@!B]-/:&YPL*%YGF8 ,2)@7!@S@]0V7:
M(/S- I$>XQ+,EJY.=NJML4]A3@K72TG+P9 (K+Z^$-1QA]/=)HEM-EI^39(O
MO-H?,: /Z_.*H/%:-/"5YLH[0B<VNI\4L' PH%.&"V!(#4Q<T6$*81! [H;C
M,!['DBPG-F:O051#9=')S7RE,E^EL]$#/]P0T6K&3LUXX_@T&9J%M)'(-T'[
M@F"]$:B0I563TE&6TQDTZ&%$D!&#RXS+!3GMEQ+$H^;Y:39I!!>1 &18H!]K
M,F2E8M963>O%UIF&&)+[RH!Q/AI?2(Y(5ZUN8*<U'=Q5Y'U:/3F);5A%C\<U
M?F#V>>PE96:4Q!/18>MSHSM58N])9CB=\X[/N38-^D[D/RT\=;2>C%'M\VN6
MN4:6)*DA&)?@MW@;-<#_Q(%V/V0?<"MANB3;C=M [Z9@Z,H1GOUR<O(0L#^C
MDP[VIZMAV%MZ_&1E%>([^('WR9^J?(F!%L&?:U6.?!444.ZT_78Z;*T..WT0
M'7;>Z;#O7(?M0:*;M1IWJKZ];T43PC*T0;6M4=FGJRN:WED>)-L ;\)Q5^PC
MOB9ZGQY<P8$^AXI36\]D)KY%PJ'4^U" ETU8K2 B_%O'=VK3<= \9S(G;ZW_
MU*(AKRNJ=UA+L$F0L $B6%/%H!S(<L2NH4/G0&LII Y.J#M;SL=)I.L$7K__
M_9/N[09#?Z*<3"SE> 87K4J'-J_K?TNN":220U<M&O%*DI!DRAM53SC_)35P
MI^3+7?M!I1=@>,*77=LWYGA+<_"'8(3B@F(/0:(R2L#J-J.QBA76JF,IZ2VR
M5F(?,L:-.9I$T:AK%5$$(V-&$>P/X_B%CXR"D;XW/-P949WN*/-F1 R)(NC'
M'%*P/Y4WT'<0=@X! W/)@;%/&@-'M9$S*EAI^'[SZ#%X/DZ3+XIY4.D*A%HF
M'QF)BV)E0)X;7TX&2W'SVI161VN'(VZY'E&>8H+./)A K0Y"A;X2QB7O X*5
M+5LTWDWXO9#HS<=\5R)<7X(^WL37)7Q2EO#+8L%(1P<%:#7*-M)1;7JW-<12
M&$ELNKW0)2&>D WY(8.FI'$LPHEF[:+JQX)X<BLEY@YY Z-&"4T-)7H8?TIS
MAI4I#5_:IV##(5;$<A2R4I"I7Y\1[9;E[)4N%@4_$E[*Z6)?P:?J$I,A1VDY
M3RXL8SU-5-4$L]. L6/YPLI\(KG_U1"/Z9\+6)3DP47Q:08VOL02 &L*TYX0
M/)5IG70K$*]_?&3ZQP(USJG!/BUD)!HVW?"IF;&[O$R:9&T-CUJ@U-SA4/O\
M(-QR+=KW*VQ_;H8G$?\M]1?7+1KQ*A+3,-,]_#3L&0X;SP^+?81K:;&#A$.=
M64^Y4%K;<B!@<A&EEO7'FD?'^_3Z2IA>TD4B!KTI"+EH9B KU1U4F,RBT *Q
M:EL3-KK<D@L=FMX$#DY=O2(H^5,P.[BKCWHNEUH[P'N05K.6K).UH0+WM#)>
M]16IBC%AS4\>4[,==E)C4LA$TS&;KMFQW<<SAA0_=@MY;_1^P_G,R]+)WYZI
M),J.L*IN,!P-_N]LV/]S,7N&;3Q_>S8\/CU]5@E(C<Y/%E]?E)_14(9,C^2O
M)6IR-A@MOF)\91^2O,HE[<)OZ\)O9UU'8Q=):\])I$^?Y!8A_ZBI/@TSVV$S
M*>::&SY/V)#21,%5_Z]'1H>$)3")COM5>6]A9K_RT>!\_VN8.+!$=(VUE_%I
MC!'%Q<LZL<[ZA;NXAR=LY/ +();@7*.A_@!; .LF!6N4T0CPQD(:SDU'$D:)
MD#=9\T<'OL5BP@%4GB\-Y(-+/#>H8--AR)%J3QD&&H7.EP*B:,PPJ6QPZ-E=
MDT"&QJ\6LN_)K$&P..0O! 2W=$.B)Z;ZBIMMF<SG]E.C>K%N\ @$,O(7F7JN
M__$"K/I%Y"^?AS&)%?WH/N?7Y67_XG2 ZBI/X?\#_6#19'T0TY\;/C_M#TY.
M&K\Z[@^V_'QT>;:G.ZU\O6%_<#;J!M4-ZGL8U.7:6_U,>H%U V@?U&1_>S8R
M]K,H**W"%ECL'(6!AX?GBP46V\2SY\/%5V]0-@$C-:TW^=%-'M^/)7/MBK'5
M?J:#T&CL/%CUXOK=CO'-9 +O?]E]IY$MZ59-Y&#X\VCP,Y[1#S>+3W!ZAL?=
M]*R;GD$W/>NF9]A-S[KI&773LVYZ3DK3<]<1[T^^S-($_/,C&>ADHM1T^D)F
M!KOV#_C@YR:T#>1EY3QL*DC;_/YAYO[8:]<*U,(@M (_5"?_@5[>?6G"*6G5
M6\/_]H^/*P';!YT _&JKB>A$MQ/=3=YZ>-X_&W22VTGNP4GNZ:A_<ME);B>Y
M!R>Y9X/^>:=S.\D]/,F]..N?#CO)[23WX"3W\KB%.G?K:,V4_N^@8C+-)0SW
MBM%4WG[K&,V:WV\SXT]MFS>]8KLW\[WB+<U[9V>G32=L3T783D;]LY-.V%JS
M($]:V,Y/^J.S3MA:LR!/6M@&9_VSTT[86K,@3UK8SL[[H\YF:\^"/&5A&PY.
M^\-M U4/)&SW+<$X0*>^H>_@T(HOGO*^;7K%=N_;;RFD.( P<B=L;7JWP?"T
M?W;/#'(G;)VP;2EL)_V+3MC:LR!/6M@&@_[PO!.VUBS(TQ:VT_[)/8L".F'K
MA&U+81OU+[9-QCR0L)%C_S.U9V\!1/#+7\?ISQ44@P[&HPSC<?X0*+HGHPY%
MM\/^>.1HF(65/5N)!/[_?51,P?C_=V#::]7 Q8.H@;-.#71J8&]JX'PU(8!A
MEC&(TL@+4#"?,_'-QGZTS$("EGMC\!>O-(:AT$P9N,;W!JZQ%=""=,?GB \9
M3C;8[9\)RS.*DEO""K(S@8B1R&;F4/%81KSRA/G.A#'>70VTDAE;7/Z]1L!+
M =M+"H2V1;@A'X$Y9XH (PT"8.D^]F$53G:\,DYR1BY*%9%!,0DK(AV1E%QH
MI,$K]XYVS3^5[_BI6"PB^AM!IE_YN:_!"1W<W\!34:9N\9',30/S\C*.$7CS
MHV)$T]A[DZ1S;W!\]#\"U]LT[],DO?73X"A*DB\5RGE"A(+M'!&%%,SX(O(1
MRU,3(_%PB=QNJD&);Y((L62+N4+..F'3QJ\,:1/"$?;D-?"!B$N,*$U1. \-
MY3:B3%D**2'?H<D<O-2S^1'N[;UA>$^#T&V)R>Z<DI<&IY0DA)! P^F4Z?\(
M*S):"H40C4>FC,=#<+(KIZ[O_2LIM(1-?)A#XE,F09/1?T)$17C\/T!V$'_>
M)Z)?'!_=\W>YIY4-5PC6S$1?KKLWIO]EFS']WX._=A.JVS:HP+M0E1%?V_=F
M43)&6BD'HVRL_")?,F)<O&2%XWNP,V'(B!FFD$QVPKCFB)2&A)^PR>#5:;^@
M89-?P_::72.:;E @L:YL$<16/B*@9=BDUPI<6T%NZWOO266F6:Y_U//^KHH;
M&(N>S >=I[/^Z2:61-W\Q<K[HU&_ 01M[&>*#1XX8\]/7NQDW!NNK_?3(O5!
MR@KXJICGR=<P?GGT]6::_:6'L',6H)HH"#5/<QPRAP0JSYYW!2=:X/<,^?+K
M(H4SRD?E7* (B()]62 U113Z!'U-6-V(':A2TA^1#YKUFE4S*29+CVIO8TAW
MU5=-6A?.Y9#1@XO!IO.F,#L$'TC/(@E&Q&.D [Y!=/U%D6:%Y:_5HPC_XYOC
M=UJD=(ZF:H;PAPF<823)-W G8L6 (V*990KTU,G%\$6/L!.CR"KN,$;<7#(-
MKY=^!),2XVZ8A($W@T./CR4#?S^'CZ?^1/6\V(>Y]L<X*6!J!(A+'2YX"M42
M(>O?6J)'IFUO&"*!'QKF1YD:LS"P@#!&A#F<TGE8V7V55_-0;)[7/L4CJ%?[
M]-,\2?+KAL\G1;1@B,3J5[_#Z]%;&48*PXM@N2OU>\E!)F3A;Y*$B3%>I<7,
M>QF ,T0$*(Q%+#".;UZ][-'+-KU!XXCX)>Y<0;SG+2BS+Y&(N*P7X0G#_%=7
MDH41+(=)N$!"1I9Y%,/M1U;?B/K##('$ ^_?,),YDQK@=/8]>CCM@J81(&XR
M"0//M*H_VI42EJ3*$Z_]:&H>U_J3[3T)/AB (&^""AIFZP\?S?I-N/$96^-S
MA4"<D9T=VM9X!=J.&;$%H)PPKS*H'B1(AM\MDHDYSO21R5P6]JD+Q* G+>AR
M8BQPZE.X$[@L*L[8U)2#U7.W<]_[%=[A)@D-4[>C*,9%&L"OA:YZH@_Q5(7S
M,5)"!O:-4 Z-PH2%,@,\2F(81IS$1_6?>;0-U6Q)^WA"I" >F.!?0X(/7[J#
M]L&J#O]=* \V>,$O*,>IYADP,T1;J,CA%O]1;!I7[YDB)JJ^'HZ1A G?'4MC
MEOKSS&Q2QK#EY?*B!/8YW$BN@C,M.1JG/D' L@S@'.A[]/!?S&:.^/TWQO5!
M"%:VI&D.MN/[<$-;?\)[A-/E?EF4/J=*LT_\T_5^6K_%"1R8[58F5UBZ#AOC
M#&OGE3QNYC[@A8;5O98SE P@-#G "($)"#S0C'[.(L><Z5E:+(0A AZ Y+NL
MC\-X&@EQ!MM*X$@R]S2H9MA&^N,87IB]<-HHZ)R!UPQ>')XF2&B"1DL0TO%V
M#5]&L%U@6\OS9=Q"%T+CZA$#"E)5X#",?,,_I@@_C':&>X'AGF""D%[%U5TB
M$RWH+7,9N(C\'-J/8HT1\P2>1Q%2BS -1H+\[F828'^B]PFF)CQ_D6"LC-U3
ML.)0U<',F*%:VA#4T!FR@N#WJ$L=O6RU+ZP+454*$59F%XP8[YUWF9 [2P:H
MPQ_M78/D\'JP]2:#9J*6U:S*93'B%^$;L!P$SOL+9'8C34ESA ?)2)!G9AHA
M/+><M\(@T\7EU\7E+Q\B+G\Z[.+R75Q^'V=O8\B\%01]*T/FS2]R52,4^!?A
M^K]NPM4?GM#)4P+0W BT?E_FA4T&"&Q^,8?QP4VRU3Q5AE\ SZ<$"9D8S%\%
MS[>P$N43##.=[@&WGXO>C[<%[C\9],]/SQ\*._Q\M!X[?!M \]-N4(\^J)/U
M#[^C*6EMY\UE[;+#@,A%Y=B@&Q\=$/Z^EVVX9FXYVZ@_//VVZL3A:# =[K*"
M[R>PO.&V$:KOOVS2+78?9.(62F,-JOF^K[L9QO53F*^'1_Y^0'QKQZ)H 7<[
M\UX0D5_%*N^F;I.I^]%;.7DMZ.<=T?_M4"E_Q(AKH9YOHJ"VADG;1GGMJC6X
M&]SC#.Z!$.VXS^(,')R&C4-_@Z,'^N+YT4EC6< ^]]('R=JDO*<P(IU_$]3"
M$VLZ.4 TB;.3_JA#+FG->CQE61M<7O:W[=SL9*V3M7OAD)_T#Q=JSOQ^N)UU
MT2AV[5N;T3[0B_;SJC\^"(/5$[(@/V%%\T1I"W*E4[9.\C?M7FZ?. S[APL
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ML":^6;YB>05XI&19K&UN?W#41>;.R;TY>_Z0O/.FV^S/N1*,UI_UO 4='(Q
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MDDXLD$IZ_4W=[W.3%A('L1B^$2;2FJJXXJGT;:8CB)Z7'='D8D)1$)#[&3_
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M"#0%PT%3RN?#N'#@)4+0>9<N9LY^*P;,3S'ZA5:!\S*%9[K1>2-J02A+WW_
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MN((X1K="81MXO?MKK]O^+E3M&)G/E6D%@?\06%->F!.2('4P@8D,PK0>BA3
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MK!JDJ@<07NY+E@T7N0[?_PM*<FPKA@[E) [QZ7>-Q8$/$C]-4.9M=+C" 3!
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MW[O..!N;_.P$T^RI_<JJ9(OWE?QZ?77[BW;S\5+[B_/STO.]WS!;#U:*GBX
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M3J]2&G/]:&:#'-Z69MI'03-*.UZ;\*$2/:I*]/C-]\8RJK/$*UC[J7*>3Y%
MBB=SK"60+BBNK9VS,$]7:Z4]M%M-LS9I=.MR-O*EZM;!V$)!\[J=+\5+J4MO
M_V2$1Z',E+)Z60_TLK:I=WM5)7471LR!-'W%5XJOMLC!*<M7_<;(& RJJ$$Z
M'%_5QAJJ7V>P+S=7O]Q\N?E^\^E.N_KMHW;W_?;ZO_]^^^7CIV]WHHFU]NE_
M?K_Y_B_M[<=/GV^N;[Z_6VDW%0!.!OMMP*_MQQBH*-GV:SNE_;56I_R<&YJ2
M?1&C%=95(]>GLYCJ3/:*[41FU@OV+% -R<ZCXU+!IBA?.55LES[<'S1&0]UL
MU[LN1#4@4^Q0M+?+;NPP;(PZNMFO=XW=X;UN1W%H!C%3+06J.&80D!FU=#O6
M&F!>3TOO#ZNJ4ZF!ETD147'A7 T1&8U1NZT/C#-,OSQ\%T=EPE55)> 6,/+/
M/HQ:JCI BI:7+04+-5?H&RH>?X*$5*H\8%=":B,AM?NJG.O8+0B<I.:LGH7-
MS4R<D\NGE6F??3ZW6UD:)04Z P!=IM#^QH%]F\!:6/21_PWG.C+[JQ5LS9W8
MF\'034.5@9T@?:V0\Z])7]W&:* /VF?8^^SP)H7:; ULL>-JH%21'7:N?6TV
M6&B[NWMZ- !DV*NJ=NOPG90J,MC.E>(VF'*[4UR?JD_-W;W4!Z(X==R=5S+1
MZ_@;S\)\V,[?F"WA*"=J!G"XZ?VN,D5/D):V<SEN3TN4MS#8O<;]^.S.4ZB[
M?%57XUFX_#<-\X2+\3&QY:9^H)(\-VQ1++K;K7=C"14SVLNXRRH("),9>KJY
M^Z2$TXT5U5EJ?V?!5'-]RZ,>4IH_T0 (E(1('5N=,(PM;\Q@^Z%J KBUJ+YC
MH!(Q^XOO/2# /[+[LLK1$&/[IJ%W6SMG.2M5NW[TLT%25T _&-(W6WJ[6^^1
M2$J]WJQ>P\-9&,'64:O&AKU*A=XF6O_%&6-6]5T\F[DO5Y[]T0FCP+F/\:%7
M#P%C"-H4[+]*J.]NZ0X[V"[9[-=;9U)*=^4!_+V1W,3YR>R+/UC@YU!;MS&B
M0E_S0ZWI3>GH*ZCO(YLPP+FM1=;/Q O^HI3Q+95Q"<X;;^Q/V7?K9R;@1JWO
MEQ@(([BUUIJ4UKT/K;L\H> 8A)V39D]7O^;-KOIUD;;KDFO6!!NWCI:?>%N>
MTML_&3E2/(6HK*$P (%B]O56IZI4_%KTO-JA\%TQU[DQ5_%LJ;+,-03F:@WU
M7F5CBTZW\=7Q&4W7_G3J1&A/AQ3)&$NK>@R4HKW]S8^8-MRNT57A&8-<L)4]
M2GZ&SJ7GN']M1$',EF-VR;:N//LZNRE)U[!_>.<B11^D =->0-2M D1&21 I
MO_0*=?DN\L<_'GT74SED.SF<\QB]:&]M-G'&3K13.[E#-XRK5P^P[>0P\!\0
MA^T\R0>+^R_PXLM.,REB=#P;V.;R@CXZU,!0Z>TBRM*U-^MDPU<6W#U: 5NK
M--S\]GEY]J%X"[WDJQ7<!G<1UDW]K^7&+'VJT!E:J> PUPNK50OJ[&U![<:H
MU40-8SG;>^D#;68%VA,^\8.V<A<AOBG<#:*TVO JCA[] '!O%U/-,KOJK %S
M_@++07CG!>+(XI8.8,?_"D">+UJSDC>^"@9NXRB,0/T!9M\8,,ALKO<JT-]R
M<?W2B]L&<C=A&"^2Q?IU#5X%:.77!6:.YV^FT.(T[- 22*OV4Q1J5J1]9&,V
MO6<!-Y_:AJZ9+;-#5\(O;5V#VV<,GO;$W#2  0>3"F-L,04Z2QQT3!2/"1I&
MJ[*@H(IL[$H[1NOU9S_O1#S&<1!/K8VV*I5R<XS_MU]G"A#<+AKYIK..OZ*L
M]FMLJ8YOT@BV7,TKZ>(E8+FKGFN45\1+P';GU9$6OJL:+F15G=2!BO">IRP6
M@&KUZO_2RE;J_@66!P9 KZUWAGV]VUGN=;:,<WC-&ASO6W96;>95A>3RYDKI
ME>V"9!Q1WM<'9DOOF06DZ0&9N!*SZ( $6HE%=A:IG1L+\A+Z%QKUDN9L@ME5
M[[[<9Y'U^_H&5Q':,.I.&[4.<ART43NL%+%EN:#5.S:8;-K8FCF1I29^;]VR
M/0'I5X#HC7?-X5DRQ\,PP4#L&5U0)%2+BH,3T>N+W:JH" S[;GN@]XUZYX'7
MVN%UX$D:\32FSIB:3P/"Q_YT%K!'YH6@^FJN'YY9(XJW.\GJ$)8/O^6,2)!@
MI@'1UUD@\S3Z+P#IWUAT._EN_<SCM$YC-&PMR^JE'!*E'1]:3)>BH"4YO3\*
MPI'C.548-:$@I4,7$-$B<>R\E.>]2.1O+++@3?8G*_  '&$&RA\YD$OK0E@-
MUQKJ[>%R)X'B/*:4Z6.6TGN@JCYHV-V!/NS7EJH.7SIW''VIPUTR@G=I&WSZ
MG8,WM1G*0/X30;PT&PZ #?6N:1YO1<SKMZNN&]T=\F2H@ 2I+$OO#78Y",ZT
M((OVT#&:>5.)EG.)ZG=T9*JN*3JZS5%2L":);_:R#4"S_1A;DTJZ>-T24_'<
M&I285@^?G>3?O@&SGP+O*\_>702V6R "VZ;>[575K*TZI![(2E-<K;CZ<)7E
MU7 UQO<'8.(.=Q[066.NWD'_>1]ABW"9?I3)C)Y:P8/CR7V2>IM9YA@T&A94
M36Z;E6B3RE\9TZPQ!I,L[P73O3P_@J='/M(:P9L<FA/'L[RQ0]8Q?$#%R<WY
M=*O,?L4;NAU8PLP/*8)Y&>!@-^>)?7AV[.A1DGOF+@&>5GJ+=0\KB*/5M]08
ML+W.0C9:YB?N )G*L8V!T>KTNVW3GG1,T[KO6MW.T+8'O2'PX?C^_W DKKCI
M,4@3[1_8Q7W K!\7U@1V>&FYS]9+B'28A0T )HN(XC!<#;')9&\0XXB#7?L!
M]?&^I.[Z>!4LQZK-6K3' (7OGS:CK@]& 8T,\"<:%O$CR_SEO37*(XN5Z&@?
MA**73!RB:#[W0-=NO/%JUJ_O\J^S\NPND6*('C$)!"X@JVTN9J=]R8;6CV>[
M;QU/BQ[]&)YA ]+8SS'#$Q13?6F3L&7Q%T#$>E=PA_1R\1&>RMT5.Z:3,!7L
M=(K#SEUK%K)+^<L'>8HZ'JV?;OHP_\(<,Y_>Q[].A1I6K:!@$SX(\6;Q=1.^
M>K_\><]H]MN#W*]:32/W\U6/,EK-82O_JU6/6OUYI].MWZ+:1J^Z1:U_^09G
MTEH_J-%=NB[''.)T6D;O-]O&Q-P3OQ+E_HM9@?8)SAD[2;?7VH8^IU+O IB,
MW5IT&MYN$*O0_YL/,:Q!*-*9I6 /GW. 5UO!JQ2\S#SV6[!R#%[5NAM+[A0
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MHY[>[=9[1IDBM'VE[+T>H>&();U_+''G<_ *W'@7,XY0+:A263@353N?M1A
M: 5?)?QCS#//Q/G)[(L_6.#G\4VO,:(V]N:'FNC6RF)[#5U@"SHJ((3[C=%
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M5N J RZS +CV*M]JY4O*!]-=/)OQCCY@7N(@0]</XX"4;8K 34";TQR/^S-
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M1 5_7'GVUX"%6+B'?]Y.$BI+B>QC4L_W'5[QBPMF;&J==KD93#T:KB+Q&2Z
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MG*&2<\7EM ?[(("H%!0%49KH[+3[)7\[L-C[XK2W34:ZHR-S' 6C'"9GJ[D
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MAVL@_@P1;48; (&O<<OX.Y(@G]WY'!3;>R>*;?(3U=(J(O&J%87I5QK"S]E
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M^+LIX:N6M*.^I&'\557_:<Z.TX5#)\!3/+094>>V3<BV/DDD9SP[+4$5N\Y
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M6+2D.2FS64(X!31Q@9O"#%NV=YF+\.3U^(N)\33^WOV!@;ZJ(%_A6/@Z05>
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MR(D3<Q IMP0E5S%<S!CVF:EK+FMP?!274N$E[FVRTY: G8BLDJ,(0SW#1Z#
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MQF^Q+7^!)_B5KQEIG"%070KU=O/^+? #INYBF]I8@1&X4Y5J]6AA0 J'X8Z
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M\3$?8K8Q2?R(5L610(MVCR=_H4*\JT'RV.;&Z.QJ/+*[G>)@J@?U-^TXN.9
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M]_3KGW10H75'Q4(P&S1:M!8SU K>QC;UVRR(8NJAF,EE:'@S6#]\&D1PCNO
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M=*Z?T-<RUYJ\6X8#N'R*-HN>,/.W;-&DO 4[Z5><*2P7-%;E5[+W)UUV9<6
MSW&E3GHY@AG_C3M %G#GW0G(VWC8[\T7@U[/F0Z=X>!R/I^,+H%K9M/_V^V
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M@.6E1]LVEARJ?=]*:O[3C9=ODPCV)$(E,YM#):9+"GAPM%+B$[.37SA'[5#
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M[&P4>\D<1S#UW%OY7JJZ<>4^]".B! 5)*A?U:[#BW)G(/(O76;[+BG7"KT&
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M4I<':JWKH3Q <>I.I]CP4.2!4[A2OLSB@)!H1V5-IX5;I0KH?=NU(K]3=:_
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M=Q#U_M8< <Q1+JH?Q>(^A2_!(/B'P7;S7MM*L&84735R46TE6,EED@7G;XO
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MQ::[4:JY)O.:?K7A-:5M'0S<VT1&TN^?Q8)OXX <[ MQ*!T,=M/!&K ICA7
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M\IC%.WYETH3U;P]22*^(DG#),@H0?-9G":D:(=*=;V("/H5)!M(TKAFTTX?
MXRKC0H%"K-'(HF 1IPF!=B))&)@ D#CH1& 6 2+EX(61-S?VSYNY;5G,?8.R
M9-R9 .V($[A)73P;<A]UK3:I2/_\BQ&[X5%"REY]E/J]SF3F17YY(R615)Z!
M3Q!GKL=YVN3+8OXBHR1LVFV_=+?3W;N=KN_V8T+J%5I&];'2.!BVN--@?:NB
M(:-A9_)3XAUC@$2<VBQ%0<RKWCF&^0-QK3=^>V_./0H?X$B$N$8-K3V+.3'S
M1*$35[VPW644Y@1*JG\3;F8##CCJRFNX+U-[ C'_#!@U53O$6U$*TI"E1RHY
MB]G@,F5ND_[NV#,FJCF@[@\?5C9SQ!&+PK'>C"[].0.GDKJX6%&X@/I]8\X\
MK_W&RQ7P:F#<PY:+2LX#M/3>5 #90&&&T:M!^10V-80IJ=FP7J2,UVL+,A?W
MN>M;QAND@X0G2T=@<"I71*8\Y?!34&8C\N!V7O!G8(:%3:*% &L4I#V1"&%O
M\JAZ$Z,J79($(N\A>'.(1\)AL_"--HAOA+"^@AN^N5%&9X,,6="#4S<:J52G
M+0\MI8^-4CJ3CS%]_BLAVNZ)5[T#<&@>(F(EG"-E)R5QT!D&F9/(<U" /9]Z
M*.??WRFN2>+B4PL/.1I#ITE:0@7]"T%$P6B)6R%=0K+F6# E12EC=G.0QZW%
M[^/Q^SN<2-,PF[ D*2+#*T2G+7O(BLPUC8]%5J*6^MG!/+QNRN9)YN13C*1\
ME@*BQD,34A?R?!ZY?D<:@ES0P/@]1H;B<'3?9F35%#<,XPFW(U7_!"GMVF!-
MQ4'0I<I/CK87MD6%.V&_X1/C,C.WQ*2'"JH9::'OO-J8>DH"D/0.K]"Z8.'<
MHPM[,B834_/^XWO4!QQ2#CE8'B+;,I(M\J-GEE"+0%7UC8>2G6_31&#'9.+^
MI$V#!K*O6INF6VS3::<;=-I/H"I1FO)M*K[_5VSGEN\CIB(DHOU47K4S">R?
M&U3>E@<^*P_\EJKKGU!=_P;8U1!6N-62H!K$L?^?<P#RQ9"_!DF6"2.";@1$
M&391"9J89UP>+6-@(P^A9B/?,5XB\E<2QB:+)8"A@>.+,GJB<@!1;IXN<REJ
M>0LG/^64(4LB,Z2D0EJ+]:?$^@_"S@P:@NJ%LH-8)8[R9JF3,R(*50",[>.D
MK#:P6] /&'?YD].P2U%T<1WTO(<9["ZZW4K0,F]O<\+:=J^R(09(WYDC<*@'
MJ4S^Q (G/D1D63L3"S(!0GVM,\'?"C<K^Y1.:Z.A,]'0XS8:NHV&;ES$;1L-
MW=S-G30:NEB9&K_M)[72]BWV:,Z9%5%26WGV,_ILQ'T1RB8NRU+Y1'14K B)
MB73YVH]-==N6N6IC1WI2BB;G0\^YL1(7!+^8K>R^A<V_%=]@VV9] _J&Q*X2
MP8K=O6X 2HZQ#-B;^,-;RPZ6CK%Z8[NT5WKI;7Z^DJ;0-!__64BB\;@[TA44
M1J$/_[?BB86<Z@+L?BE^KXVZO;%>^E.OJY1^OVDH9=0=JN6O;!IJ\_=ZOX&+
MTL:#^A:E;AWJ%SI$?I" *HB6E/D;8Y-A_GCP/9"C-X+N9O2_V)AXTY,4H-!?
M\N\K>C) _)RZ_(E/%O&WT(6<<.WYF3+I5__&!("/A3H*";F&UDZ(Y0 C]22=
M[*Q?-@*8DRN2-SY/8D["C;Z]+,AAF%H.3(=NMQ2AKA)>6@NO2O!2JY!AD7&9
M)F,9QE6R;72,;-STIEK]&OWO-'H([3R]<ES3 ;=@S:;-;\2&VA'BY& YSC-3
M7V3/-K],>G3<,U/B@=$[DY'6+99._/L^S&$7CN_B#2V:%-%$;R2:# A-BEE?
M+9J<"4T&C42386<R''6+.71_/TYTKNG\!XC.->V8WT'0%43^RD;<2IP%!_ "
M\*9XOW:$U-T-MVL@A6<4K'A$>#G[61S01D(88>9S,3'\,':YC\G;HL$S"LZ]
MT8 *C=6E7+5HT##!N"\:Z#VP'W=R@S,8E)<@%3_F C=>4:C2^FW$$;IGT[P/
M6ZG@])D3V_0_#"LKSQK!0TFQ'=M)=%5E/9[LG);"59VVWJC35MO3/NEI#QIU
MVAJ>MC+>>MJM>5=ZSA^*$5ZM:7=-T6RP6HJ[5-2WK<9_+L.O\4BBMTAR=K.P
M\4@RV!=)2-;^0K$TV6#9K&@^.N(J"Y!LQ-4M5@NSP]6&*"M]> E15K<2G-H"
MJP6N!4]AZB]M+RE_Q*LSEC>Y6"_ZQ_MH4\(89D4PQWMZ@4%7?:6KJOUZ0HG4
M[E ?-RWHJEU4A44-=F)"B;R*$1A8&-LC7FQ/*7@)CS7->BV/BXE3$/=07>H%
MTR4A1M-TJN<^RLO8O\BB;3&Y/<G+WOXWMC H/^"E N V+DVY!P!.2WV7 :]\
M][H7ABP?1=FLE[I_S#$4)3=>*@@^ P1L-[#-EE_L!:_U4I(O#%V^,E\B]]A+
M!<!W:C7^ZM_Y6(P7!@1R^M;/,-8?;Y^J]E0+WA:\E_M4"]X6O)?[5 O>%KR7
M^U0+WA:\E_M4"]X6O)?[5 O>%KR7^U0+WA:\E_M4"]YS@G??+"8)_ZMWU\)!
M*3&FF.+2J%CM3,=PT:E[/7QV<R4J=3><]JLPU9-*;A6H1VZC8%6YC^:FYN!'
MQ[6+.[[,X7T1H?75&FCJH\Y$EX>Z)O<'Q?HQO/#V^O'7<^0QT?3V/?*-)%TI
M4_&$^+HU#>X<Z/H_ISFYO4^L840:!=97YA,][:!4]81T6N@*PN-;OF)7N#("
M'7<FXV[_1=!FE?</JEQ8&5G/G5Y<7S+Y3D1,PA(S$4<82:#NSCL>]##O>+ ]
M[_B<O/NEL^\KXN [.#?6-C\9ZTX"T2BX9#]52TNI1.E,%$56E&*IF9IY^>G8
M^='64WDZ*R='Y1+-IU]Y#?>#3*028%RK(72R4@&"2GEG^\^BH_"OOA<$54VA
M@0KT*2OJ4!YIVK$DN@7/3Z%4[9-E_L(P<:NVWS].VP\J86-%C7^@ 1YJW>/%
M1 -Q\'K>/Z4?\3(E88S7A\G"$G!<" =Z5;\PQ(2?S]A T?H0@<;YP/D(L9P@
M6^,A 7EE6=?O3'1M**OCHJ0KA(P?@L+G\AQ<)XHU4LC%R'>PG-,[DV$7^X+4
M8@TU"0NOY_W6X"LDY&&_:L=AUB_ <F?,?GG&WPD$WI'6WR=^$I&?,J/*$G$
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M0]O YJ_?YTQZ$O) ,KA D!XPM5*RP"Z79H;M2X]()=(2+"^R--;[Q ;\!1C
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M6O."UP5!S\-YR_4,-E2O>>YK[>\(KHPGHUHQGS&VTM/E8;_HYZA:S6?0OP*
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M;.1I;B/A(/*#$0"((-1E2YJN<BK@*\\G&,=JK6G[9K3 /0$QR54!?EQAFU-
M^Q8AA9]LEY91"GVBZ!CR_2R5)1 G@IIYCN,]D2>5*E2),1'\\P3&N/+77>D6
M@%LH!SD%97Y1PMD2PX6_P6V+)]MQZ&=YG4<*W5LP,U$_,];\Y=0J>#8ZR<H'
MKDXK^Z&Y#FCN1?[6JD3KR(ZF415E^HRJ<\8BM-8LPB"U".%4+<;QB7$\R6]V
MK=YH0NG! 95!=YE;MX#A)M:O+<>%CS_Q8^4BC>H VQD-AT5'<E?*#@]V-HV/
M' L-7Q\KJ@BQ'QNVB5&/#V&%')\] # <%M#MQM.<(=>@5];= /@&3A3,;&:M
MH5!;.WQ7[7"EK1W>U@YO7'WJMG9X<S=WTMKA>G+ALD&_*6@WYIQ9D</N9A^%
M[_B>BY0-:@^7A/#I;O8M=L):7+MY[P5A\!WF>@?/_$C%W+ C,1!^2X;68L0N
MI<(9JBJI;BNJC%'-,_([DU(J?'=FB;2N4,0LKD.&5SGZ!DQ]YBIG@^YHJ%>M
M<J8-NJHZK*>@V+BK:>4_'5#E;#!JWJ+Z2K^^16V?_)C*.8I^H57%_HW5!S\6
MJ@^>H*30WA>Q#8?8UJBG*MM].?#:7&"BA5<9O-0JY+=O&&*C0X+NF0-?/LC2
M W.9#[HKW6=88.O90>B3J7RR8A37'32UQ_XO-S*JZ*+:T:OE1"XJO'%49&58
M<TC3I<<RMK3WHFAO1T^@$]$>;_2D#VH.-&YIKQDHV-+>7K0W. ?M:9@6W@/:
M.WD-HMKB=8_/8SV&6DZ>L?.-!6#08[0JZ,\6>V2.MT0/<+,25T\.AFJT,SP+
M[6"6M]Q3!@U)=JLAY[1%J@Q2C>I!JB+>J)W):'RTLM-B32.Q9GPJK,$N9X-B
MG\N+3JQMM-Y*G4EW7G^=+PNR%NW_Y-13;ZI@-0!=$5\YBX*#P9"JK(R.YCIM
M!G!+W"UQ;R3N'?W:3T3=F,0[D/MZ2]TM=;?4?3KJULY"W0-R[(U*RCU>(G5O
MR-3/Y M4"3P[7P_?.+LOR7=; *C#;+@[K&KW3;K(#2_W%.:SO$UC224#_@N#
M5TL6V(ZV]411OD]7=TN@*$/E86<R*#K9,'IYEW&&*?]+P^<MXS. "+Q9^$21
MIY$?Y^%OZ^*ZJZ-NY":)^FL+H43]$"W)JO#?<0^^%_R3*A^4HA.019M/VPO"
M+U[X;Q:FIU.9TXPZD_Y0[HU+^BU3,AHF,DV9E(&0R+I\$EE<-W%.9R$-<\_8
MWI/!@F/J)\\77^%SY;E-B#TI2,9@.'750DH3I?/ME7F" ^T.Y%<P7:T125";
MP]NQ8.B&..[!N(=8GN2PW8;QMZ":2K\S:Q5Z/Z5[%H8.[TU]^^"S.!R^ +8]
M&D_SH<LF'!R>>7)"D;$M\^2/[GVW%#:5>DJ?0PQ^G,V825+L$YOZ$;;65GB!
M$B4GNF0)Q ?S'S I'OA(C \4[T>2$KNW9T& 3_T&](^,/P&'] J'%&5+-@(M
M+F8B2\O(#R+,O8/1G^:V.9=12(.,\$1B&<B+X(WTRGY=OCP#AZ0:-3-,PL7<
M\I"+?"QX(6I?\*(M"V9AD@?I3:@".(:H;H,_?_[^7KKE4H*89V#:))LP)Q?_
M7&8S0CG WL*J8%G%E5AVL+ #2K;'#-H09G56F(-H.R#S'%C>0U*=YCV(2.!O
MKFW  (;M!F%A"I@C=TRHSL#?V%9^#J"0\_" SS&@TD<)EN+A9)F+"!-W864
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MAF'UAR<7Z)B"+%/]T36REBLN?D>.Y6E6CRF6LCXJ7EO(U?GHKCRR/7=07.0
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M=951;8%^@W'5*,-G"(FL;U$UAD0.QMOWUX9$MB&1;4AD&Q)Y?GB=)"2RT4:
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M%\8*-=_("6.+G"4F<#RYH$,*"!V^#?"^5C+"T+>GT1IR!D#0:'KD((X+PFE
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MF?K,^'%CS&"Q;PSGR5@%> C9;<(>Q>!CG'U_<&S>_&QVLLWS,P!*\GS"C3>
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M)JK26MJ7@CO/>@6Q/Q8-00A?31781DO?N]G,-ID?_%_8X0(UI;;TZVF=ZS'
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MP[ZJDV34ZTQ&\NAX1W5KU381W8Z+)CP%OBF\J=CQR7XMPC41X0YSHYP2X51
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MKT&?&]V4%MVN&MUV7.P]-[JI34.WE^ (RVD(9N1C*8JZ=(3+36LYEX[PGA_
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M>H=UF7ZS>=75U:^&[?[F!=@R!51OU+@_&CYVIZ]^&:>JG<E05H:M$^$J,;3
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M].C\%XV<.[O'/0-V]NE*3NZ5Q(*VV/FBL;,!#G =2W3T1_) J2MYZ:38N2'
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MN^^!3H7LBMH46\"CUC6A!N[@8ZX1;\I>-^UH_PW%7H ;,O;/:<1%O@2# #]
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M@H8?D4<_2T9FF,B[Z#L3^0J^G<A;Z.0YB\-P5R0X)\GQ#JZ@3.5*UL<F:"D
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M62XSS?<"H5RVQ;IL->'R+!I>EO$YI?NHA<MT'-6Z92<X5,]N .1V#VO'L@*
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M)0D<6!*HEY@RCE(2.!"=-/ZA? /%07>1&J[K*=] (ZC$F>$ RDWR9>@YW2C
M:F-P:/&R^0>7OKLC/F\,HU,I9\YOR5.]D?V5<^+5MJJ<LB6%-!5 %AH@FU.
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M\-TH7/_*7&Y+$ U!RIE<+,MPRS;8 TEUAFXM<+/4OS@OK&B[15F@1OM#\M:
MSQC%$ZMT.://%=J'.9Y3=TPG 8I):0D7EB:]/^N6-HLDO*\4(G/;'*>#CV7[
MDDY-8)1"C,?L(_C@FD2CS8I)^QWTDN9*"A9P;32T&1LB'7GN%G#ZH&-???H^
M@PJX?I3OQK1RS9]J.^%/6+9,\:?R\B<QW%APK:"4"CJ^8::><3EH^?#]J7\U
M;^O<_?CY\O'7K[>=W+.RAY0&A4(=9W]%#F=2;$O+S!8*F4;]Q-Z^9LN"-#D
MN=J.0)+LT2@ 05=(I5R*H_!U$(>Q J&L1>B@T,A 4NZC[(@="1*4#43/G$4H
M:8H.:00")X=9H\#ND4^4]P;_]3>CH5_4Q)6B]0R0DDA]H/X(ZU:*I@2M?7AO
MZUG-TG2]OLYXML[DU=)@"W9B/&NUM%:CD=UXUGBKXCDMY+3B/)B6T3?W='0%
M,MS^]N7^U\X9N?M\O4)1"?D"R!LU<7)W&PZR6Z/$IN7<.WNYFISOL=+7(694
M#:KDAGYS;/+)IR$%GN.\)4SN%9J(N0HR(6A'0!"$#R:3.Z;EVO]2'=-J8'2N
M(PJ/8^S=]<!A_>6J/QGL([G0 %;+0 ]??K_]2KY\))>/CU^^?K[]=^Y%(2DQ
M+/_[."]]$!ODHU[H\T!LHB\W30A+M]] 80L /+R>AGZ)('1"4.!$.SH:^0YL
M_,*!$+]UX!].R16C0*QGXA&CO4$L: V%11+^<#C!ZXK$[RX=]R.7T+B2LQP+
MZ$4HMHV=<$!&2;'G(.K*<0@+)(I,OK IBA=<Z*(7RK=!'O.> C0Y^A$7]RK%
MUYD+,2Q^W*,CVI-"'XISJY="].83)BB;S7W-@47AL540[;.1;)WZJ!@!2GRI
M3SFQXP='X_KC,S(>.+ ^ 86E7+D$0SH1QE7BL1X+ LHG*+Y2^YL3".$-1^=)
M,0[[2"R;*.G"3^A& K%2K&/&ZH1R]W#&/'(9T *?^B#D !<%[(7^L<GT&]?^
M<.@$@=@X6!2@*"\6Q^.AK3/K2L)%HPJ^F)B!Y\RYW2@4O?CPOZXS=&3*P%E,
M-V(24JH.)[@D2/O)AN%*P@1A\%&0>>?F2 _73*X$"O2A?R%^&J/I6#Q!NS&,
MJS])8I7Q2@;QJK2KK]U_:62'7M IB.I&K&'8OL=0H_CF\!!.$G[#[V?1#N;U
MSII6SQV[>DVCVU)UF^EFJ+<)KUO,_\1&)FI9']0=?XS4-8*3+[QV7L(RXH\M
M7&^_3"."=\BGMO N3(EFVYT12S:ON+V[GM9N:ZVZD55/,T&[JM<S*6KKG]=K
MV7I:-ZA:4].M9LX&9;0URVCM*8AC=4#].\F*JS313>; 3G)1P[O4C#I<KD'6
M=7ET0O>0:Y)3<KD!3KJ-*:.^!U/&09JMGI]I;3&_O.WUVVP0;UM.[H_EW^9;
M=>NA8]LNRV<UN:GJ?;9.[T8Y9*V\D9=I?&+#KM3K4%RZ\BE'O8O<)(I8[B=P
MLJ'>\6GFN,7=T/+J(SZEYH/L,_HP2.R^V()[F\8&[O96:V*.T@Q?-2:^!X04
M'2*W\F;D'B+U!"+GS&KO#I Y9"H2^);*R/^SRZMIOKS48!?)X$>_>%DY\L;#
M5!2.O.LCIOAQYOD=#S_^S7GF=$@^P7">%4=!=DP=#KUL(<V7>)4R\]U-AV:W
M?/>@)VK'ITEQW@)SWHXS1,?7E4L]Q7E1D8P9K%H+Q5_7K<N.SXSBKP7FK](P
M]:/CNHJC*.ZJN.L6-+++$Z-X:X%YZR^4TP%YH#SH#6BD#+F*PRH.N\VZ[.'<
M*#Y;8#Y[Q:D](9V0C2D/%6-13%8QV=?79=>'9B,'.GR9E+6Y\C\('_+ZE'^5
MO)^'L1PB>5]%Y:NH?!65_WTPD*M $!65KZ+R#Z]$;4SMSF'8,VI8EVX7!DQ^
MU,CO R=DY.[N3@4\*VTKI]K6L9VP?9ZNMZEEF;2EHU+GJEW?GL#_#,*A^\/_
M U!+ P04    " #ZA&1:G*40)A<5  !"\0  $0   &5O;',M,C R-#$R,S$N
M>'-D[5U;<]LXEG[O7\'55NUFJD:V)=M)V]O.E.)+K[?LR"/;W;-/71 )2JA0
MA!H@9:M__>" I$CQ!MX4TZ'R$HO$N7X'MP,0^.4?KPM+6V'&";4O>H.#HYZ&
M;9T:Q)Y=])Z?;OH_]_[Q^:>??OF/?O]?7R9WVA75W06V'>V28>1@0WLASEQS
MYEC[G;)O9(6T!PLY)F6+?O^S)+NDRS4CL[FC#8^&IT&QX"T[/QN<F6=GQT8?
M(XSZ)Q^'P_[T:&#V30-_^FB<F*?FD?'WV?G9Q^EP:IX-^\;)IX_]D^'T4__,
M^(C[)QA_/#[ZV3SZ='PJF;[R<Z[/\0)IPC2;G[_RB][<<9;GAX<O+R\'+\<'
ME,T.AT='@\-_W=\]RJ(]OZQ%[&];I5^GS K*'Q_"ZRGB."B.J;7-'*^HY?(#
MG2X$P?!D,#P>!&6!$\GA36SN(%O?\#8<UG?62\P'Z43B_2&\!T%'_:-!?SA(
MD*HIA_VCX_ZVDH:S(8MJ>'KHO>QIR'$8F;H.OA$H7V$3N98@<>T_7601DV!#
MA)"%(4BV"D1>.XC-L/,5+3!?(ATK7?CY)TT#7,EB29FCV0E"$_&I5)0S1Y+U
M-"\&[JB.'!G:4)('-B7*'V++X?"K#[\.7KG1.RPNU>7]&4++4I*C-)YT_TD9
M#?+"*$V-5!+XU0_H^O"H/QB*H*BL0UA-RND0T-74(;5F9(&BHI2_>5TU-M6L
MM!H^92DUTJMM02P" @#AM(Q CO6#&5T=ZM2U';8N4AG22((?9:K!-K.UT4=F
MG[O34BJL#5_\AKRR!@8F940'Q>&/RC*Q;I21&12'/U)D(MNFCJ2')_ZSY9+8
M)O4>B$=06\^#*CO!9M"%)/I0O\<=G)V='<JWHK>1Q(CIC%HXO_#ADM$E9@[!
M/-K_2@9SALV+'O3"_:"O^&/)\('0)"B2$+#=[L!K(0%ST5M)>^]"@P(64/4N
M>ES@8&'/16VVW\!F6?L%";')#V&]A:9EK1<DV'KWANO(*FNX(-%=JTK4 _F3
M>*\1XZ)W2<7TH:?!L^?);=983DKTB@:\ FYA^'T^DO\&6C^<9_0U2?7+8;QL
MC(O+L3&V/\N_XQ7:)_:+Y!#&7%*8;KL&I9+Y#P/7Y3ATY!K$N;5A#B4U*>;;
M!)72S<-M-TL&6H1#AUQ^26U.+6+ C/8+LF @_#C'V.%%XSJ+/ >$L[/3X> 4
M8OU1N UO@CUDI?F\-(_9'@^'/R FK)ICAP@]:X*SS4N)U+ X4MJ'+=Y_ZRAR
M&V]Q:HY%9R95X\@V+NE"6#G'-B<K?$=YA6I6@K<2V>,\9$-!&C6U4)0F9&E;
MPC20MH?:?'2H_FU.+0,S?OVG2YSUE1"K$Z<>RMELE0"?% <X*N6__O/GX>#3
M_VB>-.V#+V]?G:EYB?C\QJ(O-6MNR$:)X6EQ#(&K)MEV"*DKS'5&EL"-FE]<
M3FQ<M%U-)U4B\A'&CX3K%N4NP_ CY ,P!)PZ!,(7Q(D(ZX>($:*;>'07"\36
MH@DC,YN(-@39SDB7>2YBSQY$%.MBFE<,JUH2E)!^BD,JQ0&848&RZ_-%RC8S
M%*J%4K5 ;(?POT&$_88L%]]C!!Z435(Q8--)E8C]'$<,^&B2D1;EU"$0?J74
M>"&6&) ;M\((>T:F%AYQ7G@ZE\= "<A9')" FZPU(3_-8]@A7$33P%QL7+\N
MQ7BY:'L7)U+Y_^-1W/\^!RU@T2&//W@YQ/6#"&41=P8,9)?0'!3S?3:Y$H5!
M'(6 U]\UR4U6A@V_#D'RA-GBCB*[8/B'Q94N'\9=#K2:).Z0?_T)NCV[$YU?
MT48F3J3T]7'<UQL.FL>B0QZ_I(L%<>0@0Z9?Y. /V\6'M'D,E$B<Q)&(</-3
M-!%^'8(EF2XIAD8*G1*$TS@(42;_[>=/.N3[>VRL'?KZB!W'VP@UFC%<9C*0
MQT")1F)>[G/30G9:R*]#L%POEA9=8_P%VX*M P.18G"D$2IA2,RE RZ:ST:.
MA#KD_EM;.!0_H=>B'4.40.GNQ$38H]8D>8>\_(AG4*\G&'8-B8ZO8*L?IU+Z
M.S'/]5EH&QY=<KH[Y?A/5QAPO2K>RB>H5$[_E)C<ABPTCT>'G%XG%?K]DJX%
MDZ^GIX/$G+F)Y*OV(?BK2\M6J<G4)S2UBB*>QT )9&(FGI&3U3YX'+N$3$YN
MM0P^:C9*E!)S^/Q$;1?!BB5?RP"43JH$)3&=CV=ONPA#9AZV#" J)DIH$I/\
MW)1N%W':)&O+X!(G4N*0F-Z'>=XN.CV6NRWC^G12)0")B7T\^=M%&))IPS)(
M9%(KP4A,^]-2CUT$))(\*8-$DDP)02(3$,V\=-'U\61*J9J03JL"89C,#,33
M,5U$(G5GVQ5V$+'J[(T+."A124SI,[;(P=Y2R;)+X-3)JI3"L E!2J@3D_YF
MLC<=C(O4W(LW"1?>NR-H2BP"'\;Y[PT!YP3K+F/"==+KI:*C.7'*&$FD'+(2
M0_T@Z0#A$E$A*&5H$$K:1@T_V/;1XCOP*V(P(E_A^I&08*5$.9'#R$9YPWP/
M7> 5$=/4UD6\(Z_/32M$S<VN#F="U\ARUN.I16:2Y &M89Q3'_FF-5$&3B+#
MDATXV[I!3Y)>5GX.L=%0\U740ATU7\E.!F!.%AG.!3)<"U/SRI.(92%?/+X3
M=39!4RKD=B1;&62)])$B[2UF$KXZ$$N!0G[A0*6^U"DM:;Z/JH:0_6/PEG'U
MQV ?6:V.K&OND 5\"W?C.L+[HP5,^O^2^OI+)]0,:1IKJBJ*5<92(L>JC*6-
M)IJGBA;5)5@^@D"+J+,/HFTTJPV;RS!4 I_(YRJ![_88.K;.6@JX#%HE1HF$
M;W*1MH-(9"ZPAMUN9I%2L#4A2(7Q<2*?G+_:N]V7*U:&]\$1 E*MR2W.3@ET
MN2^U.M_>;I;KJP&73:X$*N?[KCTJ@5O#)O".VC-X?(6GSCT2(T*90*T&5E&N
M2@P3"> M#*--* CRWH(H+93527QC.S6JU3T5$R5ZB<1N8N-'U^MAS,5P/!*U
MO:->Y!-_@"BZE+$SQ^R?KNA@B"/]%3EXK@ZJ-44J8R"1HTV)@5 '69/A\68"
M"KVI5$2+:A(]=F\?.)C_CN' >&R,5N+Q#$_P @E9_EMH%84; 058+YV(27^=
MB*DJ2QDJB7Q82J@$PON^=&TCWH\;V05 T 0J:*##/D8P][O$]>;\-_]%9+FT
M3EB48*^,!/6.P7[0PZ\CI\QM@B"Z KQ'O@0T19/F=03LT=\Q^N$7_?'C 4K5
M;S4;)9*)Y&3(,WG60">Q2F[DK396+\!'B5;R"]6TK<%='[(G/1W.=F-#HQ'G
M[D+N72Q7\^J)4.%\DMSZFHYS='J=&'=%!._#((:1?#>6SAGIHJ+(HU<;PC^'
MMQ+X1.JR /"RB.8)U *)>\1CJ$PP=QC1Y6FMHM2S$-HX\@5D*",@D1,M$ &A
M7#\80/(^%&(PP1.X$4*>IXUM'EW2KQL"17@KH4^D4K.@A\=]*4Z+RMMD9+H(
M>,[Y0J7 +<!'"60BJYI[7%$GX4HY?Z@43#GT2G@2"<_48XPZ"4OD6[GH"A'G
M4VQ2AB.O3487SX];]Q3<B!)D5@[')@4J@4^D+[<^ZXNO5G&N>4IL%P,]M.>#
MQX/XS0F^-ONX"6",+EQ<NHQY>8HK;&+QM[$AJ=(%-RA/&36)9%=.U&ROD_A*
M>,EN7XT(=:?[ZPB"U?(I>0R4F.8>K=;Y!$IJ[0H"6#Q.^Y2L?O4M*$");?['
MVXDMVEZMA.J8\8':/@)\@*Y-$^O>*K/_MC[HV3Q5.)\FDF0Y.&_$1)O?/; ^
M",\VPSJ=V>0O6?O\47 #55K!6 EQ(AV6 W%4EH0WD-9)G..'+E1<LU!Q42*8
M3&<E#G'H>F\;=W+\(\W-XND#HR*>86("<Q"?C#LT>F]4+7@;D:P,B62:*R4D
MDE^#AFO(GC;:!]#G;]Y\+%!)<^CV-5K[@+)GT03U"MLNGJXOO1O):T6+FJTR
M%!*)LK10V,YT2TG:=*WYLGYTA'\YW+ZHW/N]=9DY7&6._;0BX _7*/\1OSQW
M-.4.0[K3TY#_UT7/82[NR6O8DU?TAN5M^!!J"I<O>^7AWF5R+FHCH0;H>=$S
M7"\/TM.X*\B(X\*O7QEUEQ<]KSAQ\**G.;*X]P26+.S9K7@.3,*+VA.6J#]'
M=^@$6U#='Q!SUOZL.VJHB2R^L;0R/[4CB,T=!$6]5U/O"M6+GBZF&'!99 GW
M+*@MXIJM"SCHCNB01GATETMK/9);^X1OIU+*)LT<6GU/+"S:;GNS]V?]532U
M"J<U*J.MCIR(-@$Q?0[VB8;&HO(#D5M;=#@ZYGR0Z1TU89E*%+/9P-/=F2S7
MDFXY=T4'[D*%?) J/<Z1:"#%:%L4%N,R;^G)NUT@PP7E&>VJ7?$D5C9='CC1
M@.79?&K$PF[C/Q]#^?R&LD)-0<4X*2FCU2&T4W]5$M':P!.= ]QP>VLK&M+P
MHKT,;Y5GU-:&6;0<#/;*7F'O_UL[<^-NIC=*\6BK(\283$[MQGGG$F6ZH"!U
M:VO&K>U@R\*ZXR(K^(Q5U.ZEZV#^?]A=8>3>X\44LZQQ?0D&C;>FAL/Z\!<?
MG!L4/@(I8/ -M2SZ,K;'IHFAN<NW+JMT*TQY7,/I'1Q?N^#W33N<;Y&":'>&
ME;<+%L%+6I5*T@:;"O6@$SR#J3]EZ]%RR>@*65]=,&$,IQ,8KNYD-\6-\=_1
MD(>(9F*&65.>@OX5]B/NVF-EY+RYYQZ1A<?>]N!?F9C=8L/;M"M&(YCIA(-R
MWN@N>S18@L6.[ V("A@<A6P"N]/Y]8I::\[Q5\2I4(X@2[3@AH]1?A-2D5D;
M&I=LU8/HK&IZG+X-UE[+O+$8>^8;E2C6CC[[\G]'U^.O=W>7B@XM4:X5ZF_R
M;J-7PK-TCQ5J0''#.3>(T(3[[4+%3.]&L2MIKU+_H%@;HOZ&,!ZF/?UIAV+P
MFD?2!IL>81'.*&=4/DT;K!+]HUSE$+.WE \V^,/D\3G?Q!(,6M$H^*>PP^F_
MF*Q G4LY9[U$S'@2HP@N+!0RQ01Y)6:'V'BBD$-1C$3J,7W[L4FQ 3ETMD)S
MNEC \ I9Y"\<+8MCH\Q+9!MRX;GN1*"&W!*+*V\W/[@G-EFXBW@S4<]KF4Q;
MF]TI9-8M+!LCR[?F%JJ4C67E^ITX<W4&N5DA/Y(OKUS5?*L>TW?2RHULV]VH
M__\8L;&-ZWDDG6/U9=^=)IBK6?3T0AOVD>3X8_EH+MXT[26/YP_EIQOJLH;=
MY+%\SUYZ7IJ,VLZF1_)7[M(7]OSUO'I.K":QK>MF9;HN.)*KD3[08_1.^KT)
MMO%+$\9O,7HGQN]HYO+>)R:!_M[N4H+Y,\<C,9V88X?H7#8!L$&26G1&=&3=
M$&P9#;FLI,AWY<YF)WK97-^%4[S.VM_*W$2_OV'5UHV5A6QYP**M@(\0=KMD
M6$+,FZ\8%DQ[;-<"?Q-S$S-;!>MWTM4UOL_Y76UJ+CA\V[KEI.Y8,,:LI=.0
MZ";_2,K:B^ZQ"<,Y8LM(')MRK2;,Q\(Z?,YN\)I\W[Y>3? 4!FTC.%;275*;
M>\E]>!#LJ,LQOP!M:].(@8HWE(F.8$5@21-^^!?"_$8M=X&_P-E+GIT;,S>-
M@G(O8AW6K?5;<CUH!%OS0+0PT0L!^&#O=R;$C$T3/O!;89;MK>H,6SLC%]J&
MYZFN4XZ8\B,$6HB<44Y)-F_?FN3N^;\CCK\--[2DVM<#Z9S>^AN!G'W'^<O,
M!0A;L;S\(#RQ0-^HO;E<1+%\GEF^%>;$+WP3S#EL4[)<F#8$=[?E[+DO1M[2
M,=$]8M\PA-T->84[!Q589A9OQ4:/1*"-;5PV-B,DK0C/I(9/+[2L41&25A@%
M%P+=BG!GKNR^&%Y&>K"\K6P%"-NSO2U7V?PM;X5(6P$E:*2L9K%"K5%<695B
MA=JC.*R*%E ]6JP5RM]1VQ"5RG8PFR+[F_R.1\Q_Q.SG[O;+>#+(MZDH=1MZ
MHT>LBP[2N!%3?UL7#49$V<?QS42YJ[((<1OLW&ZJ@J0JY$'T><[JDHKLK3/[
MZ?K!$V19^0F1(J1OGFJ.]3!2,-']F>38=<"WACP*B(@(7")KM(#IN;?;"3YR
M1[/LC%@SS'?DHZ6H674=%*X=^ 8HLV15V;4[4(*M<#&]U1OM:G)]^QQ'U@C-
MBV3H>#F<Y%[4 =GT;5UGR!VBAC_O7<LA2PN/[5AE+^V9XHR;[CLB YVEUSX5
M&>E@SC'>_@!_!&G>,."S4WY%:'?30Y:H I'\]JV]$G_1G/1N>N'6IK?+[\)[
M8F0VDX.T'2]H5Y?ZUF.J6";;4Q".Y+4-),]L,(7]K' F/)O^S3O-T=,]+.WQ
M@I_+9Q9OQ9QM-#P:'M_:(HC\Y5[_C",XW4AA5P'*-LQAQ!3_:4Y=.(%:U+I'
MV%[C8&R/%[:H?+R$P148M<%^P.DDN!5#KKD\N$R?BUZG&,9JVC98>7D]3O^4
M#Y9VY*=\E^J/ 4LR:8/=4K4O\=N*1DS,M6>RZ)=U6,3O5T8OB!DCPY G6")+
MO@^.%QJM$)%&05_.N0N.R%[!^R["=].S%3\7+#RFX1Z]PD=I<"@M,?S[0L(E
M[2('/:@XM'6Y.V*"O%240_K<1_1Y*25Q+O?88X,72")4YM>*X3^H3&VI?1C)
MEVA)'#^@Y7<&;(4-T9;<N+"8IJQ+M7B^=16!@HDKTR+MP'0=%HFV S>(,'GZ
M7>1^R]B5F\&I,+D[^[^? F^?G*C<Z/JGRXQF8B Z$_/-6]BA+MHA73K@-]';
MX9S#:G8KM;7M7E6S(^,(U3% #8IH4W0&JH:&A!]'B'FP[LJ[!] Z>TI8B=>;
M3P_3\8SH^<00Y,=!78&;+/Z$V"QGIVX=ECL<I"Y]4;NL1]Y9NV'*D(^=.69/
M<V3[#4MDQ2'6<$\PC*'%<T@K@%==[[,N/C(=P2+<N=M\U?P^6K>DME?I=RN[
M(7(V6O.C@6:T>O^P;/?1JML&=B7MK>\J4._-O4>V:T(4 $<_OZO*_M=BVI+0
M"B8>D>^P@AF:F-1!"3B5EDJ]X0-V_VN)G),HZK)MQ;2PAA%Y)U#49;LSWWPG
MU^0>/%&?<1O<D[@NL?SYX&58M'2_<L*$R&D-, MGL&_3NRK'3XR0O_('<#4X
MOA<?W9!7,3R!/Z_PDF&=E/1(%GU+[4_>,0G[YK9O&)O@E1A)^!_E53EHOEDA
M;<UM%+$R6':-CNQJN2V=85M=Y%U=!IKYEYGEKQ]E%O^N*T7R5C&NS\5<Y?-/
M_P902P,$%     @ ^H1D6M%=_/E,)P  XXL! !4   !E;VQS+3(P,C0Q,C,Q
M7V-A;"YX;6S=?5N34TF2YGO_"K;V=;V)^Z6MN\<H*&8QHXI:J.J9?9)Y1'B
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M1'Q&'VBVV,1WYSOWQ7][DCGRVR2K.23,M%JU+9X(S49$E@0H<^O!D-F9XT5
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M>I?;W=VY=/>U;!JFSU?KY6FC\%-<+C^WE@";J<J3Z-&*5L@H<[)@:E8M?UI
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MR5\<<]DYD0AX\$1JSDF@+).<P.@DL\HT_;]G?W$Z\) =)TD:320/AKBD@4@
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M>1_ZWD:F%?4\OVDIS?-&(XC3F1]]FI3VD-/+M\/V8C:%]O^#V3?PLV4V)(3
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M:+-7=?10"GP?]*HDU66G:9E6,B\3 (9B$$ )M3QR$UQ$853>AS9A.4[.5-7
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M=(*7(@%.9**1!.;1SJ)>VR #5;FZ+WT3P%&:0+N+>G,W^!W**.9.OV\AE;
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M&T9<<DDSO8>V+8-?V_6_6@Z![;*6GL:/UUS'8<:.5R%(\\RT^]P9:Z2RCKM
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M.$'[_&3ZQD\FE_C#O_D1VNEHA@=TYDJ_ 8TR" Y].2B9_5Y:E(T+EO5,DO7
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MA[QT3BK9E%."+T.IH?=G^(K<.%<72;&+*J5!"-P&$Q)1L30]XE03JRDEUAL
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M2<6:5V6T(K[A'AS.S[?OO#VC],ZMWE&4O:ES^U^J_/+B/]+YE+[_O_Y],;O
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M2=%[CCI"#IF\-R8SA((.HO0"I5>L#*=2_M%</J^,80%I@'[7CAR/<M0R,1U
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M*YD,BP)YUS B.IX\C/;5Q5T8V:/!B'!!6RGC+#)5:E4P>6T!26@B>W 2#2T
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M1912Z=91POLI>@IX::B3#9!IUSQH3=#W."$U+$:HM%7(:M%AH$-01@W!<X2
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M'5NN3M9OUQ\QS/&__^W_ 5!+ P04    " #ZA&1:^^H>7<Z& 0"H;@( %
M &5O;',M,C R-#$R,S%?9S$N:G!G[+P'7%/=MB^Z:*+25 3IH( @2.\U*A\@
M(""@(%UZ)W1"#8A4*0("2E4Z4B+2:^A50'IOB8+TA!H@)#??V?N<O??W[MEG
MWW/+.^^^/</X,;/FX#_7F&7,\5]S+O S^!7@FKJ*F@I 1$0$O"5\ /PJ<:HR
MQ,$6 #0U 3X  "X#I$1R #$A1PD 1.J1#@ I(4]$^-'/S/K]-\   ,0^FRP
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MB.8J'%.R.1[X:(\'X!MXH*<4?%QQ?@;Z#MU1/VT-49C^0W$Q'HC(G\8#OYA
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MRS+]<O8J78XJ9#9GQCB9H&!17DTL#RMF3.G"''I\&FL7L@N"G2GW^16<S_%
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MLHJGUU\ID0.TRX#M%ZP,^DTW&PO:MA0A+ID>45"J^G-!+8!9N$=%\K5-CS#
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M"+;<?MJ8W?#?V/O.J*B6+>&#2%!4!,E9 5&B2I+8H)<D(J+D)HB(),DYMH"
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MWRYG^< PE#:9#6F=^C;'?@VWT\&6N.OC4*/-]J/GX*33):[B</NOMH#OUO;
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M2!/F>[O>RB_9==W@(AYHB[J2%R%:XM4Z*\ET;?/B%35;9_<=>U.Y@!4W=&I
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M)QJ."ZF2B4@(2H>-#P^DZ^ >*N"!#IWZK[HC.4R16X>?&&'>9PTLN79G"59
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M:6ZH;@:T4)7GE8VJ@M!8N1(,;.K-@*U]U6<1WR<5\S6HQ"_WD3JJ=$+TNR&
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M#"E!CF,C$N"GW)XR'HH?%^Q"<'2C#7+>(CCJQ#:MT;R1IZ?W5--$O5MO7>H
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M!_3AZX,X-8)_3;OSU5CM+\K#'^#^I.45T_?LMG55&;7F8AB>.2B->K=AK?!
M'NA$' ]8><\I^(C^N=[XZ/2!QJ!H)SP0"SG*ZZO4&?Y+RO@CK-X_8/VSP+KJ
MY4"!37M55L7SQ+[-;_,/1?UG C?T6J69\7K3QU_%Y%?@12OLFSI8"3S0 S]]
M.H@AFB=ZP3EZ6%/AZ&LA\ U2B <L@X\;ZWT\/07^W-W2CI+?X.-<=OCPN>9S
M:0DAV";N^6ON6J_[KT4JOU21:,[](JJ%@P[GX# 3?C,=7V43OP[ .#/S+^ .
MQ(>&_05_=4:?5^A74?^%/^GG+/+_HM]ZS?T']']"Z+>=?[\;$=O6!X6Z!T8'
MW*R+.LN"!WI%,U]S_::00]<4]^ <'OBDBP>^YE;?(&;71$*"*J4&RZV-K@Y5
M;J9D8)+JORWZY&5,]EVZ*SUROXOMBHWTG%"HB.E+[LM)?OD*RR'DW6I39?4L
M2Z5\;;(<!NM'<!@7]28;2RU2(']H1"S%^GFU[:KUL[=3 9&UVX9N80W"V>Z]
M\[*$-(7\^,U+1%]T?$/HYR4U58GP3_O_C[WWCHIJ6_:%&Q%1HN1,BX"@)$&"
M9#$01&A <@.MDD% <A.;("!90$"1H$2)3<[09$0$).?4Y-Q-;*#I?NS[OK.W
M^]R][[OGW/N^<]Y[YX\UF'.,U46M6;6J?C575<WJ#L2,VC?*!I!$3<^9PXL:
MGP/@AFUJTVZFHVBI5*9-UH>Q.8)U4);VX$&*D.Y@#RXQU]!D/$"AIC+%+,(4
M_CTSBJ_-%11*[GK*T^H;FS@$?V;,ZG^4!#E_V4+O@=%T,0L")#Y\:AA+5+$:
M=T5"^OK)I]#*#\FU"1>C,IPE3[;V\QV/DO5<$E>.KZ;59IZ*XR H%UED9X<)
MX[!04,('I.R-W:W0"Z1>JYEOSV/#!S1ZK@*VJOT)]"-B?-)$J2!!3E>I-B[8
M=A%2Q"?( ](^&X2C*L-HYII8G; E?/#*NB\H4%3(0?65A*KU]E*IB-P+CY7"
M5_)7*R81U-[T&-L\&\$!8U7??/[(X7&1C]$UDVD=019;RXDS'=OQV+2YZ$S[
MBIX;G5J5@W!753[;#3CFJ#)IGMJ@SCM/'8Q*QP/  ^7YX59B:NJ]WVP[Q^W8
MVEL4!ROO3?B_X7=2(AS22\%"4:]/=@(Y1\OMN@JA;J#*2>7 9=YJP0S<,9GL
MZ$R-4(B[!)"ID8\G\D#:(OPQZJQ P_ >'N R3=<=LQ',?^Y=C=:49MRV$#D'
MGU0?P>I&3X8.4U3;3=C[X=2#^J/EW:2)@ ()O9BV3<HG?%?5C.J'-D6W9.$5
MI).V8#&")*2'#B=@7SJTW;O;6BX>==3IRQ&X(/0:^#1:K]&R:F2Y OQZ0N6T
MKI:,%1ORJD.XJ5,%;:MT9Q5'/"K#G5GU!LN0R>L^:#>>8BA<97UMZ<W$9:[
M"-8#T;CZISL.B5\FCI*V,"?L"UD;$XI5+X^8!?--OR@PM79;OXK-2W/*]#>
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MK6TEDP/'7"8L_T*[.2;YNGJ] $SIF.*/_'C8C_D_].]A@/!_+_);AKP7A/Y
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M7&/@L0J ();85T6&+ DIB@>$UC8@PEVF*3MFR--:<W0MHEH6(9UNL<J28Y.
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M(M&VK2?P@.7 9MP-EZ&@I<I6XH_VNSRIG[&5'.X19FR9$:[(TH,&$E6'0#R
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MSM\1CT:>7C4G 5:7/Y.AX.<$6K\3(,ZXQLX)E'XGP.B=7K6"K?XJIOH+D9$
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M)6B@_*T/U(%T%#+C> $T;P3!%),F*JX_4JW+,;S&\>BK7EZ/K=J59SR>P90
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M_+DA^=ESR9J>F=[;9J;REQ9<E2\[^*I+[K#TI3.XZN0D$ ;%D6586ZA7YT
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M554/ZO,SVXUC-0ILZI@OIX3);&GWBDMO,1HV5GLK)65>U>)F)P$:V*A9#C>
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M(,],M@/N#4Z='P=@5[.;0]*-L^J:*7Z13BZ['X"&3%QT/L8_/+S=3<<6AQ'
MQ[$US>O3]:%/[K?Y@2GX:9M7:VJ/B4'+NW(E*H+X[@Z3<1EA7=N^IO%6B^.
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MKR)FGHZH1<?/)HK* IB=N'V=T]-^Q4ZCG).8%H^A!/EE!A6)1E !8.%"*Q=
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MPX@%O2E^A@^P\M+/W.VO9C=A.]2*K1>(63Z?1VC_2^G-&0]/R*#K(OA>U5B
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M3N%7OD->ZXEM5I_WZ[(BN4_L4U>O205"#TO/IXYA-O%TB@0(DSQEW28!+I$
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MS\_NO7E>OW8 _N-NS=*G&PD +6B&'.-4@'&ZUUL*S3\!'I09+&O+<'QYAL-
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M9%V__@-6Z\<$(Y@8//WVK-/A:= ^B$CWVCE_ VX>^&\.M,^!IV5M 6$TX<A
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MS::KPJ]<(:;L(A(30[OFOGWD&>.!T]@ .'9%PG(>OK8[5W<?W6?!N=NEI:>
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MX_<3%"*6B%H ,KN,=1\[ -U<@^+D67]Z<_PV@+],FO)(_YK%81%Q)2?ESQ&
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M17><SCXEH,KP\57PTSL?\0Z\&BJ2@AK5U63<C;4&[J0$X/2F%G%S1Z(A)03
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M0F6<3B-$AHI*Q7KQ]4A;R.+5,_![T_;=SH5L^LCH2L_+4\ZW>NY504\[AVG
MAOB*J*]>;SI#EWCUN8%0K>G-'JCK'A>GMC 62EP(H(\2(E.X@GT6.91DTS7^
M%FFQEH,8_UUIJ(*>>#X?[\Y[=IT@)VIKI:-M*]UP@6-';8:9N7Y)(B [L!-&
MG>4OQ5'@[*HB=]_MB%N!$J<++(_\Y-?P=USQ3&^$$KD'ES*L'8H@+4Z#(-4&
MY.ANV-EQ=]JDAM5I2WL++83&HWOKUD&6V7'*Z567;]V<>4BMRK*[6D_GIP,E
M7?HRKH!29GYU$E4=]?0)@_=)Z9,B>?*:8S5N< QH0:5".0M'M76#ETJE+F@N
M)G!SOK0RM&/N?FDH=W3PZZ]/:EYH+=W9#(WJQDB"!^OI3>TP&IK(4'B.DIF#
MT*C>LB/4U&]%G)TG(YXUO&3D4C6XJ%>]3 L/JU*90N)HPVBJD/HUF>X4H6T+
M;8_+W;JLF!5F^P;O3=['9MBF6=G2NH:WDZ[J#\O3ZO' "Z@/CP]M'@S"![:*
M EZL4#LOWI=HBYOEU6BZVCJX;D]UO;AZ8NAI@,_;T6"[8+Q(Y'3(T:V>)CCU
M91AR,B==UCW8'LO=M?5YQ?+U!<-'I><&3MS@L#9'5W-9;I1/B.S51'5M7G,L
MQ89Q)"D,C#5"R0P8'$9CFPX:"^?.B*Z^J%B[\%%@ZZ6S>!N%:RN-9I4>7 S:
MB7M]]Y,+-U$U5[_^HXTVR4VB8N_3 MK=9<4':7-^ 7TU0%$=>B@2@-2A0,#Y
M1[V\^0?+Y>^VC7;U,B@#I)C7+M591B$/]$7_M5D(O^?B0^S(#>SHDBM87M\.
MA<7?<7H-FO A (KM:J(#5D'>]Y4$$NDPOG-0:@+P=(( -%5@1<.S7:S1!&!]
MA+4SX(-[#[^IT4N[4 IS4] 9 E"!O^;LTS@UFJB(%E;F0.![:[J[)T4M&3WW
M<I9U-YOXJ9SK6<DQ)NHUJ':$O=P31KZPPT@R2SG6CL07DO7JLMWB[75/G>F'
M^!%9[39W;GVZ$O\\T)D'" K?'QK2[X_I@'A%;:K&?5DOA[Q.&DTZ7V9- GVZ
M#T=$A]BAI\J,.AK>K(_"DG8]G"CK!\?  9AW 03@.=6I?)"XCY(=)V1ZWTH"
M;[1=]#P;0N8)C^/3OM]9@O/^2P*_OT47?ZS/AY(/\Y'B=RHT]U:$59#LO0BN
M#?Y,JZF8PTXFR@ 6S2X$R:(@@?P.01:0L\XL<W<JJF\9U@3B)3-"7O)6/$BF
M^<CL0M_0Y4BSIM(4R)G^GU.=L\J0+G'5WR-W(C_L>$AM##6/ 1U7X*.7ITAN
ML*1^<(!?>.=Y;L*Y6?[5N<.8PQ1+6L1!YBXE;=T^@!>.4Q(;,1/MVW!XJ*ER
M=7US1X?[DW=^#!VJHU$1*/&V6>_2R37+>G;7+"\Y-? :^5\[54&"@B'G:J$S
MJH$,S\)GXIX_ZGC]I14MRX_VB=SFFSTUETGC+9&86K<5*)$UXL' R"AT.^3R
MFF%RR>(-F:B924%D77N@#+]SE'W,ED."I%()O/\JL_JLF&V:3/ IC;%X=)%=
MH7ISTW %G+;<^MPGGA/=>_>]^VX,QGVF#%9B-[KPU2A2V85C=5_2\V)9D'Y2
M[(TK*%T6(=1F4X$AS=93NQQ%!RMG4XY'@/-'*23T'L-2K311/CTU1X4]/D*4
MTP8U\323VCCK$I1GI(LU2RA[[,)*:R>I3L!E@=*VHW,+^\K&H;*KK<IY&)WV
M"M Y$0@U1E"54HHA*O^,E&MI-[W[!Y>C(NU0[3P<_S#JGHKI< 0!Z"O:/^.N
M4UU;@HIYR2<\(;W+G;U[[;-C %?+4QE5E<^WPO0]N,N10\6%YE.F^$ED+8(J
M!M:Q;?VD<KLT?JZ3XT+#ZJKN[I1OK4:1N3[%H,B^L/.FO<YH5IT.1TRGO3%7
MJG1GA$WP(O-J?7J9B@O^-4N!JV?^W^E ;?MGN\TZN3E^7"-\'8[O+^(OXH.C
MZ \\Y0C Y14HZ/":+XW:H\0O_T#[VK^;G:YAV\'BO?K C38M/^<XKE6\*[C*
M6;)-=)*S&#'V!/[:\X!IEP"8><"CG'D?%==7]?.GUA1'I21>[:@F (E1!5R%
M<5M2P3T\66%9" N3 Q#;LBMW+-(IV+)6S:B\HAEZYG!'?!7?AX5R+5OT![^-
MZMU/<*6]OLLL$=CU2Y9GPS]@HGRDT4)&9C@9-3_E)R4R<Z,\X/G:7$VTF8-\
MQ<PG #!ZOK-;8'W<>0AT7@Y*?F!_<#\OHP?M=B@SXR/,'^Q]X46'H@*SC:[(
MJG,*U)37"7\&4Q; @6^MV(:67XFBX4.W3?$J<<A4YFF'^6S@Q)#P=D1FE0<M
M&E8PVF/C=J7VZ665#U&/OE#?'Z3_NF5N;2HNTX.$?M4LDM&<QQ1M2VL'HD;<
MQ4VF0:_ ]6)]\JT]@>Q?Y)1R5"4_?GY,6S\C>33S/$!YU&LUMGJXV9K*#'+J
M*DKO[; :)F),A2%P-75+3BIRC:JR^/F9]F"C"S+EMF6,<!4"P+IU569+:Q4V
M@S>I '.P!A9!9G&3- (ZAW[2]-8M<3I=V^0U O%S5M*EB;O-$"&<'"J).%B:
M &@IGQ3HL,C!N-!(.<^G[/B+=&,^92,1D*^4R),9".(J5K47X5!" %Y9&@=.
M/D9HPDZX/U=I>5-%W^;,8Y:-, .!&D&#9/A5BTX4;*E'GZ@:SO"S4NPBG;GS
MS"_ZC&R*M)O!P(+N%!C+%'DGD83,JNQV$S=A01JC4RX7VB[8BAE02K>[1N5J
MK1)UO4AHN"J1E1*5SJPOQZ;//:H_BU*)"<8)6!8NV^C*6]CJ7M;E!#,RI7P\
M%IKK-B02TV1]PLQQKP+- (HT\[#^JJ<=%$"N <@=[7@4TA!6-QRIJ]K(?\)L
M"IEM-"2LXYPO)>]AX6)>_>Y8":O(X'VA4+(BZYFTM"T"X$W7ZYK8K[FY65!6
M)S&+QS_U'D*(1IM!4B\'1T"/Z,LB]^Y^P5V93>"XCQ+SY;.'GE=A"J#+M]*>
MI5!I2A)XY17VN9FW?,!(RK$P:R[8B=J=%G6A;*+V9O 8M))=G0!@EH2S-MJ6
M+E:EIW805:YSM>!\[1"-9E8*ZW(*:MEZQIJ0NXQFSU0W>7A.7=QEVA+0@_K@
M]+*(NM5R[O(MT^'/IL^\9T0[K;D.ER;<SAZ:;WB)%+3[[8R6;67VKE\VO6L_
M^L&(U=<Y7GM^*& Z*<CS(G+N;4BYOX[2G!2I)+72^24=<?2F)K]#AS2\BW_@
M0>T Q!%.0P ^[G6T]DII/"VR8!A*,&%:%@VQK1BFX'J9WRKW](42&VDE;3?&
M8D;QU8Y/UDJ%5G]%9KA?S .L;L9&9U&W<>>39I,;;,N!7_'T&)(FI+L\ZA5J
MZ0-/M6C>A?YNG4,F%]EZ?8_[+JE#D:JIA^#]P+W "'R921F8'W6Z93B1&ID]
ML+.4'&WD8GEB="!JC#TWV/GB(KE-C_:T%.ET =6LDU^AE-J<\Y6!79W53E^*
M*RU!:!HELG0U7X-S@$FHK4O7D\D5!K]RK%B91&B*=$MT]9KC]17*QO0(X1I-
M)3&GBS9):#/>OM6L<00!$,Q(A8IL*Q'EMAUFVCD64:1G#!*]V:Q_"9E3!1N<
M'UI?Y\N,6%%B?1"J+I=?$S!^7RAQHD;+LXYY,[B>VSFV1P/I,!ST7-CH>%U!
MZDHXHMFR7OKS//VPG0#'PB)@U!>"WL;QXDU%IPZF<&%.J;6:]IMGS5B/N-L8
MS4K+S*E6A')'9HQ-Z&<,A.M<:'S4F2=Z*]XK,AYL@MQN< 7YKUDZC,BW=L.@
M1A=J!_CXF"<M&W48E1!  P!<!V@.X#%ST"V.U'T\'0$0,FJ50.>E-EO%DOH5
MEF/'O,<, XV].9OFKBI!?%<;&CE.E-32HHY"J%>U$WT*ENQ,&3;>Y;$/J=\O
MS5.8<NB3!ZXO)TJ&EO<Z^[=(6/N6289 =*ITW)0=.@6^%J_E2A9+ =RAR!.^
MN;HK!XNA#MAGQ0/E@X_6>9(VM;63#Q%PK&7CD[$P&PTWHDRF#QDV3.P\V&4$
MM4P8HE44%AOQY$EZ??:CB:<VZ\??T.M1;1X3>'/OI>M78R2W,6;)G.54/TYN
M1H5A3U\B_+2UQ:E''16,,A8"8Q?4,Y06XRGM'D&.)(I@^#-));6O\6EYM$<]
MD8R,+4(:/2CKK3_5GK,"/F66V2X]OLJ31?9FO\<'[SHH'-7OI@-9A=]<S7(L
MV", ,;,6SCJS(AM9<Z?<N6?A%"HS729K4Q;>;(XQ CUT+^Z$WZ0GE7)C*$>Q
MS9)#J';N;$0TEBLO=[K07>./UCNK_''^PXO<-/;I79(Z(V>^MNW62<DJ3$C.
MF)*)\?/6T !+P?4W8QOC_95KNCNL$R Y?9<\G!PRZW49 6"TB$TLMXH-Z4ZR
MR3"MH&1T?W"<S>D>:=0^^HC\[3CE[F$"P!_7CUJ[D0'ESCCTY(";:F>AI_SM
MU\&?MF0F+)C;HVH<NU88Z1NZA89I/:M8?1$+<87N8KU)2C7*&66E?D.V[P_'
M\Z@WY!+G+E>O#*7>M62[(3H;1\:9FOS7O%K_]UJ*(::F:4A&&%FPX)7[2<HQ
MQNMVF%6CKJ5!\S%OB>PU"_- %8[*?K,)%H<4'#,,>=CE,^H\UF9I;;C4^U@I
MC\1*\\YE02]@M.VZ0*LI!C;SS&=VW9S"7&F7F>.1ER-?1OKX_KFHKP;Q9USG
M;G3?Z.8N2XT;4)8+0T*;>4\W5H=TYUA<06?D3?!]*I>^/]WS8K6]LP8XTK D
M^$*HKX;L;_'L*777F$D M;$PU'[9];6S<$P6"*FH/B.KI3'B?83U;M\/%O5=
M*'Z_M5K-M 30@X@%6FJ>8E4S23D>0?X)AR=?@OO<*"2%?$H&<7K(O=;8\_XX
MM1S96>GSC]XA'J^< '%MG#HZKW7SALV8DWYZ8COH#E(T; X4P"(#H<[?JWAA
M?N;UVKV--_X6]I]]'P977#\B+0G627;GZ2O3<Z5XAM4:EI*%FJ=KJQ1 &,-*
MK2X8^@!'%6TIK,U8Z$M['1),-,HCG.(>)W!4/KY J_7PY-'IHR=(;5UR=]<(
M@ @!.*;'4PN'8$A#G(T:)$Q>UU.OP/!L50,BREW7)\>6^W7UZI]'GS!(?'0,
ML$V.D.7(D@W\4C6X2T6#T9AQ#,B9TE6TF!4F  'IO1UJ&UJ<<BY/V]E<5D/K
MRY>K%7WL#\\W[573Y@_S6[CN4;%]7-&E#Z)K)"-E#+V!6PEI;U8YL=EP8.W'
M1S&FLRPKT^I8^KS*ZXM["7?VA2<[[>57W"P.IYJAJT5JRQZ@.LSZGB<I:P[&
MXA[&&L78N#G]+KT_=8B?I1O?=.U]:F58YT?;8%5.EW%ITR\XD0QW%10T: -G
M?7I%.6,E+'-DI%,HW['X<EB"YAW&^/@-*12BAH)TICLAS2(@?](\MKXN1XX^
M='(17'V.\:G5!86CN85N\2:3J4/U]&;5F7"; C-$17DR9");ITK8K?AD=4-3
MC'K^*9(4@$':86H>M@^JU8^U/"  #=@P*7\5[[V9J98B\A7]9UF9SE8NW6_W
MU.D9*#Z<?T@1G\2#%.J_D??&6>?V%_@S:<4'?<)+!5:[( IV6$2FG9"+^*=/
MNT;]0W5B\DBKH&2,N259QVAL]^)G,06STY]L^\@E/RY&/]N <K7VU],M(YQ>
M$;\D ):K,:Y6*99H^<"5=6,L.^3Z&-4G7^Q$XY(TEW%<<(Q]_4X^?BL2K%H*
MM3,KJIQV5YE.$&N:HMB!7C"SG80V*9FB!9GOZ\2X7*%<"@X^U=95$))L<"1,
M%UM@8)%(U4^4PT\JSG1^LE+O%CA)=8XS<N]>?FT46RXY:K4/MOI8> SF=$#?
M*AR%)6[[!P\TO_G#:JU\TTU_<0'7'8*CJ)H\SP\5"(= =6 E]36-@1SDSAQ
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M;.[A -\YM:&"Y^5*]X81FN6HT+Z9L4TA3L9ZJ^GKI/U,FE,8+6T2G$PITIT
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M0.$>!&,E,A482Q7<G6V ;W_=C@:5;FS7$P#)/0HX],M.%DX9XRQSV>Q +V>
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M:+YI6?/CY'1]:/AT_(*MA YF.P^5?!(ZI\WDGEDC.F95MAYR9?VB@;4MU;M
MMUT7GP/K[A*D/V.7A?>YLH$M@Q"(%O;\Z=[24V?KOU1?X0TAOW&4PJ=3/MJT
MO#[LY/CP J/[0)A9[?NN5?BJH&V46BC'N.KA(R^N&*XP4W!2))QUP$7CD9.D
M:%P5Y;*!1W9".%GN89[JQZY<$*RVCMLJ3&Y8@9J6]F:$?#W(MH_)E[J_O\QJ
M'J?)!$U:NHN+?P=U1T.8FC(M"J^_Q L?"1'H_A1?KGK^\,=K'$>GN$X-5\-.
M0YGN]-48F*,A--!7)8(:E(I%T>V1H_F%,6,A^8K'[)PZN^,+H)1WDINHT<(G
MH)'J%/<J?#AJ!<UB+XVEF5M:M#(_3*ZAU>#3[3)"[ UFY]G7(E4)V7364V&G
M<$XH^: UN]3^^PO:&>ZRL]5F#RLBI6Z_BZ4B7P]N2<*;=^=ZJF,TTE/P4OY[
M$&9K]_C:L>R1%&2".M47,V,3;7EG?XZ0;&9FJ27C!$^&*[F3M:K7L/Z53@6)
MRG3B'_TE9>K(CUBD4SX_=&:LDT?\RR+HN/.*T_4P%2QM6 $"#C?F+E'HZ>8X
M(<G15EI\<?B2%)F\R)' 3"S/'.A;!=6G6,S( '9D55:Q9@I%L3?!!AL<\B "
M1>#T@3<?,9U->QKP_%&H.?KL@DM50?J5E.V6FX%>8>>F[<U;)P^-9-]65?%$
MZA!NPF@[-TT(YR<&0?37L\>AL8U=;=M: NX\_N=A)1)?KK\=%Q<L#S\<F3[3
M*?[%TOMB?X'<81P:W%L**9G? 5\I [M6^F]QZBA"+@73<8Q>E[4NZ?5F7PI#
M\VX=4#939UEU#RH]SE$;MG'*[.^(/"(@4];*\US)QKV=I(7]PRV-&;",?N\6
M!Z[6Z!]\Z1G5Y#ORVBWGW6CH\<^1-, <,SHSN_7"-&%_ 4<MWLXTBQ2$G>)'
MR\%S!O&GW]<5(:O*:EQZ=@QOBG(%/(WP;R-+<G1:BI,Q8'R?[_FX>Y.%]N3$
MPEFOYB"Q 6MS[C,?HI5:$UYX7YL(]@D7B4-X8&!&?342]JE+[/)55>_?0T,2
M5+,S'AP;9* /'XH]<4E**_G-<P678IQ!!^Z5)3JYS';_2N*%L"%/1&V5@M=^
M<?.5*6:\M9(Y_VXYSA(77I!NSX4$K4L)GS"VDF/ )@=YRKKE09:NVB6:T&1:
M[+UHMG[90#%QQJF-*IL]^NY'=M9^3W.4EWSS642(^+ZMYAUY*V6!@N?Z-ZI#
M!_'!# ^#R9(TX2[]XZ>495SSH(&JJ7Q6NG>&Q7.##AUY7#F6Y%2=12YB.!N%
M&6AD9P\10]+B5F?;&KH^&_,S]J C+<+?FYSM:.$P3:#/"'PSH;I&!(X28O8#
MA,H()1#X%Q?,P<3+.FEHP;BL(Q%0*3*@9*PX^_3YQ2Q)K_3V9BVE]L0*GE O
M5P+CN)65ITK*XG!T<XZ8K [<MF U_FDGG8(SS41C@ZO^>$^-X$'R5*UU8[+-
MAGRIX IJ7SXZC/\SE6BUS)QK2K-T%ZJ3$E8OGP]]3@16DBT(PW5,'C+P.@W.
M>R,)B1.N4E.(VYQ929IKR%U#Q[Z)=MB"_*P92>]]C"5P12GWU<CF*&0O5;%V
MBK^.I5OS5U\JG7HB=>@9:ZB255L7X<*B5EUY!K3AEI%$X]DK"7L^H>.0RY2?
M[H'&%=U](D*R(Y(J/['1!LE(P9=$]4=Q]DVQQNQ5Y;HWR\:$'D;?]]VXA6=D
M1A5'1"WI$<[@7)ZVW[W3[ZF5WXY6-[]3ML\Z('HM7+$0UBD6 KWCL>ZT.V-M
M%IL\,8.C65Q "E>1@JBYR.MHT$FKI-.:=/IC>,78QIZF[1S& 8WP!;^7GYO?
M'^7MFB)SY=KJM%IS#KFKCX4%XZ51FN43.!>61)9]R-U]%C>)HT7OSM$HWJ5.
MF$IP )>L!;!S?UT!JWR5XQC3F]=B*]2OBZ<J_LCNC>YHP1S)/5_J>7=2I11^
M5ZV_1-W1B\6HA]/B4=TZHW,,=_-TI.BSH6;W8'IUW61A'.U6^:@&4A['OXD<
M?P MWX>@YIY/%79YWLP9'UNZ6L+(&!N7_QRM*BR&"D633P*28PFG[LGH9%HE
M4PF6=-)9&@L,;(DS8?0G]!8'_&>E7V;89KR+6)?D.@EF?U.0MH3:ZJ]%L=2"
MFN4XJ_H*S!/MSM7ZCPFJIV>=8(YV"J8;C72TRH?0.,,UM7HRL2W!7 /+FT/]
ML^,=LG+2.FZQTL;:&;'-3CX^R9]?KB&<=RRSYW9\1S0ZUP8@G]K[;+9(-M2F
M]ZDD7O6=I?NM_["A:EHD&TIFXC0SAPM\U@B(ZFQ"Z!;'3W;)G=<S6I0X^PE3
MOF;#@X1=-@,'?+D7@1/TG4 L&/65^]5U8FGVF^1MQK9KY?B%B]WN#[T?*K?K
ME!H+-BG7S[.=-'C<)V,@>] R#/=4X]2#U]0F:>?+:;$4.45T/!'1,O_4/=ZY
M5I?L<WMTQ\/(6Y_ $XWKK->OQQ^KP;+-!6]55^_7RDG'+[G-TNO?YN)KHC\O
MPG[Y$I@BS!-<,3^Q?KB0"" LB, FG;&]$P:FC\2\KF-$8K>FA\]?>UA2SBB2
MG@):;"PB__*NQC/=[HEH"\/"M@L1,'W_?(3T@UL\S$4D@<J<(2MIJ\RE'*U8
M!>G<E+%JQ(UZFF%W\!Q+J/4ZV]AA6-G9!T[3GM4R[[<ZO-Y-O-!\%;9"Z48$
MCK_I5B ">$[KXGVNSX_6"5W-GAVNYG)C_+5?:RX<!$V!Z*TG;#>0Y>P4ZZ2'
M42F:O;,VJEK6G<KC:Q+]"/8RA,FK7,XL1FRMR,U(A/M@?P-G @I1>SJS201&
M;'=#]3=@1EK3WI<'3 S4[76Z/(VFO.[>?>_V5NAIGNO9QWFI7+=0X#8^<C(1
MP:2,[0*D46VL-E:^/F@IV&U 6U4L7I%\MH1K"BO.@F?O0V,.2":@9()U= AJ
M-_]%N^DI;OA^X]L+5(W365.1EXZSFH*U)'SP2PB*]H/4,)SB=>9U^:FY2[N0
M\5U9CSV/+C;&.@A&27"L6I5PJ-X >N,B$;!DT](H+4A1Y^-?;LE5SHB2.NB2
M1;-%97K(.L403JW+<8U#BU>J0SKBV0*&//-MAV=VUCJE.D3"FJNN,H:K#FS
M4I**['O6K_\/C.1#<""QB"!/)ZR$-B:@87_?EKY-@;E7W,TV!O7E[<=;BKON
MTTX'W8Y73[F:RL6:([H,$?YPO"9JR4BAQA6M+J]3Y*>K[$Q;+)B>]DPMR2HL
MG'?WR?6M]CL]=6*>LGVEK[N7/=7M=ASE8WS0D6)F"\^64S4\G#JMK@Y19@Z-
M=AG?1!O9ZY0?Y'I>S/B8:]22-6H9NJ&7L7PNHJQSX[+Y$7Q>*YL?Z)AS^UTM
M7!26>^1>[^HJ/-_Y4DR7H49'S-*LVJ5G";SUH10IJ5:()9PTC6HL!J]IG%9A
MX2V*ETDV/*MFS%MB7<P30]-"Q[@=:]>P-18XAE4*D9&=K&9>Q6N^:WAX.L#F
MX4?S\-!JK>MFS8I/)-O9A(3*)'@1 EA$"QN9*LZ>YZ4,9^[0(I-CV[2>DAA]
MM!O916=GEMOAP9I?P#+.[UR1=&+V[)X,5<B 9GJ<W>*X-&2%?Y_%('CH2Y.*
M AG5AX0"G3"VA:?>NGC%F/%O_"O$ZOJAY($%]]B7,K?"S&S/'\\Q?,Z^O$P!
MU;A?3!L/G.J/K4?2>W).6;^RQ8O"&SQD5"M3>;$JY;W\.5Q/IZF<[O7#A5Y,
MW!KJU3*4)0+-$, 29L5$X/1G*JFR5DF[=-M4#[P&^+A> HT#B%IG?:'R+%R0
MLN^]+N'SM4459T(MPBC>LZ?X?J2(4+$J\-]T>;SX=XQ>C'AS/N81P[56+LQ1
MI>_*B#[C=3"$/'28?UQ95$KAOLU\)J=PH1I#@YA'M1T0VI $S1@+[ZY^7YZ)
MB[_>O\KEJ]"_N7+#PM\TM'M52H]"XT:D@A4X!L>CAV'/14NS".,4[]:/"_2@
M[?GJ9[\8W&9Z2/W^]2$^$Q=9_V6:TB>X\F9C'BQ-L?4DOQ$-"S7C])"Z<][;
M-Z.CO$>CCT"'F22YYLJ.WEVGKUO>M.(/C&^J:D>$>5Y$[2])2VK 31QD%]/%
M_"^:Z$AKK9./1O7!^(K_:H^A37M[:0(3$>!8F[%OGIBULQA>340,MSMD&'JE
M\0IQE46475Z)O#*\M''HZ\["@C[#U%G:5W8U((QY4]S6"RUU!_."\2*NS[?+
M[)XG/+L^K^G>WR_C,)5,J6""P,4K=Z5A5MJ_/!DU,&CG--83>''4Q6G]RO%I
MWFV*V@OPFI6=$I\%&!C'GJX K:NH$[4?OD*7/FJA*O)U^DK6XIFW1Y$)EUGY
MGYN.C3XP*?40\\"7;MR._3!Z[X%Y':]^D_S2$_?;$_T-O[P=_TM-VM9MO7?K
M6/"/:K!F<-LG!-8!@?//%[>/Z6L]%E,Z8<C+==$8M^B5UV^1_LYZ;UXN1'XI
MM\D21H\7GQ*O+<;4-G6D<);$J-AI=]SSEZ$Z*K1(/I4$=-XTS H.(I(BR+82
M$P+=0H?(A'7"0*'6[=M8:R0>M'%DA6L?]H&DJNKQY@\P^G@I+/76-CQKONRJ
MI?_&G6[%Q\67;\0;AL#]I&]'E>\&CN%@EB@C</-:_KR<$);IU9JM3=+H*,2S
M'\MY.3&^49G2//R0+"W#XJ:.A,L$8HH(T*B7J/9@Y*PQGRWJSG298=9"2#H*
M0;U8UO,ETK)_CDX-SDG'=;/5$>73>232:<4('%@C\A#DY\T"]5"K[!-<-NU]
M<:==1,2H&7$DX]2'X0;92R*AT2OWM,?T=KV/2N19=V)EIE!VF=S^17B9 <&5
MY2U;1MG^E<-'0@F]R3'.[)6H@)W*58?Y32WULBV/*-.R/UL(^%\;Y_O[0I7>
M'\?JKB\1 ;KD[&GY=:'L#5*@_:VX^=7*7QQ,_2^T:/TM!6=54EQ";SWXO/CD
M7BBZ-OU#W=6PQI/PT+0V]HR@C_,\9!4[6Z"PGJ:+F/8+-:UB-%V?@L\8:9R(
M&-5]O7C5;GY#E+4J1BY6H"1R:)L(//.24G#P/HKM]>;PLW%FO+_%94Q[79*M
M!9F#]T[,=(^(C*N2O]R(>H>RJM+1B2.=3,[LGS(W?DLXSOLM_^P:X_RO>242
MC54\8>*V&F88(A"TC)<W.1M6W,+^IOSR;8?6B Q)K81GIY_B\^*[O/FMR"9M
M=X*<XY4?]V[N<I7P,]YR%:4X%BQ[2$ T[&:P=EVP2Q\[7,&-&YGC>0U#$V"-
M;K=O+-NK37"Z):[.:]E5'][">93[(M/<!4I XE127=\@+ODV-K38XRS.O'$[
M"51X_^89Q:3RNZW<&HJL?O>:Q]]*M8L(:KP+W+ 'H W&?9X2Z#QU[_OF?3)2
MSK)OD<\OY3[14J$M3Y%B]6G1X.?Y ,&\Q26K=6WIR0E<%S548&CO>,L>96%T
M;[+D<< 7Z>#)LXP%X\DO91GK8#Y+F_\::=:(Y!KJ?#V\.&YARHB_^51+E@*\
M<[N:ORVJZ"*31^%N)]GYFYUJN6S6\V?3W\V[:U0?_@A?<-%_K>PJX!JSP)>[
M=<@GU9(?'Y >QD_(=Y-H1IY:&!?$*:$I-<D7"ZT0V:4UY43@(4Q<EW[Z8&M7
M<ZSUHR0PQ_ 9KX5E\MU:\ZD#=7D*.YB[Y58/9X:$Y(*3R$?\CU+P>3CU)FUM
M<L>G6\:)IY9VBXVH4CHZ/BSU>70#-G;GJ$XA)C9 +&_#*Q,'4RVJEFIOJGWM
M\,EI8/8.K5A^J1&+YBIE+<@:4;-.K2^%(CD^9 RHL2=Q='H:3K%TH^;)<*<]
MAMJ#$4\77V4ECTINYUO!C]^X1:V2L:D8!NYQ&[&H)H,#=.+52Z*T?*@<C&5.
MF(6X[>I@*VC?8&B=EA1B0C(78L'@JR[QEI:R4[NQES\>3M<8XG$*O]P2U;HE
M-K/&79V-JW[N4HJLQH$$YO>\X]$@WS)][U*LJVKW9D7 FSVQN%OD'FX,KZ9H
M+C@EX#\\]BGH:8K4Q[EN^V%D)X*$;LY_73C/XK&46G;N<@#+B,S%UAN:-KDK
M<=L.DT2 FAJ\KP9U56':QW>6'OC+2[CNE*]T>&V Q64YU?M7Y-KR%[:K_.HF
MQ]5'*?E,78<_!/<Y26\([> %]Z)L!?8-L)4S2$9Q>UI<T&1L\&-,=%/B;JBR
M]Y#X2ZH"M/*K"[T//UV3:OW O&*X$U0*%]4YB. ,4.L5+)@I[MG$%9CXZ[CX
M-"A>J:#@@\J ;N](RX+4>C9[LN];]L>4<9VT3?71ODRK54)RG](P,/\'/3P]
M#S"K40PA;>1)?0*/Z&XKW?C$="38E8':8L##^VBN7O8P$7B%8N>.H99N1%*4
M:M(#,M(TB2=*(@L>!=H+*@L.PMI$-^\NZ._%I&;ALK<S,>T3SU<%UP@MIBNY
MQGJ2T.V''ZB6PC68:7$G09JV%20Q:1>P+'=WSM@^=(-2[X'N2][Y*W3!M&IW
MQ>"4RE\?0I_*\K6IO^J84Y5^ZG=_+SS%#!$_CHR'N3'NV(Y=V&$7Q)@U=T\U
M$X'364G#9TP)79&"J\\2@S?L#)-:R#CKCEH2VI8UZ_.BN<*K,CXJI0Q&+S'J
M"\5FJ3L+Q6<-#:M "8_;/AYN-K?S-N?P_),L5!F'95G$9(TH],#%]ET<9_F5
M&;D$W!-XR61HK$Q6#UJ]&F(0<XXS"JXD;\\)-G#E6P'YK]?W 'U82X+\5CLL
MV@P7,V5<VO6%P%A4@JP-5>#N7S0Y&2./UO$.''^!U?\N&X4BFA0ZXEI:O*]@
M5K/1FE0&...VAAUJIZ@<)5?9-H8/"B+!?--.227[E+1GH&2-<AQA-S"-WIS=
MSD$[O2F1LHK2YN61UR32\[;.L#)TLA4]D54,O#*R-X(/MT=N(7>+.SS!Z3CX
M5N=Q7(-JMR"B5%;H8EI==^0R]\S;>Q*QG"B-;NDI<9#_TS F(\\'E5CP*S$/
MKRL=7J?U;[)*J(K>NC7R7(H-<D9*J^0PN0IY+5^@M=(.01XSN049N-DHHY5J
M90PZ2/(TM\\S.$BRW)):-3%:W$^/7-!CF>')6>DOW3H0;4F2[LFO$81#O7O4
M"IDNM>4L8B'Y$:-*+.2-6EY; M?VQT2"DTH7KLX&9$.C%"JZG?-@)8.CSRX$
M>7!/'N.,Y@B]-F^%.73OT%>J$UK=X[K?.HA[D61P+DFPVU,IVU.]&V^$@E,[
M#_:HQVI4E#*]LEN(I2F@Q"A"99>^I@MT78QPD0**?!- :CO96C>Z[FN"G_R2
M;O);B@^\[]<.2=<8EWB:V#F+,+'^JUOP.[>WM]\=5SXM%DE_XUT.EVGD-3)Q
MN+$Z%M+D?@$1ZGDA!>JK%=BF&3BY.  _)WE>X.6=9S2N*E%$ ,CL$R(% ]/B
M?4D!*'OZ02BRX8K[;-0LI4&)0![?L_GK''F \I&3UZ?[2]UH/ZZ=MNC&M375
MG?WJ? SQ=(T485A9KIV1/"XDTPM,'3(,E1^&=_K%16^GHV!TJCG&HT8J-)6P
MT_8R^3-T!C-W5"9I&E*R>3+QB%U+7.#P2,=$\KP[ P,J)HF_/^4@P5,J1Q5N
M=/U**HPMDX#@\E>Q3?$( $=YF!\! ),>^=NEJ%HY,=R4_<,TZ 1D8#//2V!<
MDS6N;;3I]$C]NTH*2ZJ,Q.RD S[XFN/NR"J8(@VY51MFF58#OO%U:XW94HZ_
MM@9;4&U6=K5V\ZKG%;"B")T2%Y-]S=+7(Y_N4) E!.]2! H3CF<W&B#.6K7"
MKYN5/_EH@^97SW$H19'1,P*1!I63@(B6<]N7?9Z=T/$=OM6!48\^AFDD78VY
MMSDF)LQBKZGD[$Q-K&N1A>ZL0:>@EK(RYKAAS$P !RT<1+,E:P8"J689-$T=
MQTO+!JG/0>.ZKVWOG/A@JV=HFG=Q/R.!KL4]3WID ,.].+")U]3/7S&'],C(
M4I=4-74.=:\N2BMK--NN5]8C/M.(+D(1[)AF/S2( 7\%.2#LZ8#XZ&PKN+;M
MKC_VIEM>"-P2W]OV>8KJ"1-PJ#\/.F..#6N0#TCBZ"VEQ FM.5,>RU)5C0F\
MW*%A>DR2YM@GNW09;?V1&=SK/L0&GM8CK6:CJ6Q;CA$3DYPYAFN!%/E;I_F@
M(PI**='7SW-YY4]%2FF%DU\6-5Q[9E^P!3J[1& X&Q9T2B7^ML%+DI2J11B/
M?.K0"G:4Z&!B]1T,Y=6O%EY2?35?0 3@-NY908B%I/-%,6N*E?MJ=)H7JBL4
M#94#J"H>7&4_N)C$UM_Y4BS"<]@X/3-99&I?+I,B6OBS0[6=)D6.[-*7NB.X
M1])>0ALZ9\O><RJ\,[XF:%KG4OZ -60%=.-@Q[E37*.G^>I6\D>#XX+B9PS
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M)]1 0O+S?O>?F>]]YI:Y=^Z==M^=9^7)/BLKV6OOL]=>]1"GB O %35E566
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MN.BK;Q;DK>2WTN+Y77A&1I1= NU8Y$+FP,+*NANZ3K\B]J'E\QVIL&N^HT2
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M77-T[.:C _,XYY^M2_8UK.W,SQ;\W.7/#B-4@%C_N@O_IZ!I=!&Z36N*GEG
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MV;#?0>AU+$C$FCQ:B(*GD&RIUEA40Z"T :N_H+[+4ANU6T5A.?;,JL4LYWU
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MS9"% -&0G*G+%Y\K,<U2**?IO"E)[.78T=#8WF#45'H1$,;_Y<+_(-#]=QY
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M4 @M2FOUUU@A/+U'2/S Y&$G*Z@Y+]6YB8UK42]_E\0T(!/\V\@X/[+A$NM
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M(H%*@0A0;RY>CD9G$ACGCR!'\!G0Z/E$W-K'P^_.J;:L3H^Z>C>WNIO*KK+
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M%*KF&.]MSO5E<_@S_\A2B1.#NB^4"%H^4 @X]76US.;DOKWO\+4,1Z<!Y85
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ME7F]6W!"_'3&%ER7Z$[2V(T_.&BD WY4_RVGEG8V6) &<X?CI;[0 6$"#^B
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M'=F71&OGKO9901-@!.J92)*IK\9@J;* 9>0/J\L->L?.SUV[%GY?+^7(G=^
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M'@C'E^/544UD5V\Q?^?FE]GRJ@K7*RM,"GV>9Z4F5HSXE%2>N_@U_+K!"=G
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MX-/-'<T4<G(='.9P25U!M;U!G7.V6V%+1]/2NJC&>W]C1;GYF87FVW9P<I6
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MZ[KA:1+$<.0:'&=+<"8ZGZY6[XP) _ ]H_D<&D9^*.6DH5N,/T<6[D7D!_3
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M)62J/9[]-6N-3J[Q"9*<*=M3%8[ 4"+Y,7NZ$'9++_.0,%-'9DJWI%[*/NC
MS9G$L]]J%1\J5X0^T<GC+.L\E'E;$>32>:*Y#(![_3INLMV3#C@/=\D.@9^D
M75M%GVFZXE_LO'^8C)SF#!#LXURS=CF5 2^:O??X_:N+*1(G![-@+?#S,O85
M8^K,_I\:0--R/_4<SG0NFZ*KG9H*KPX 9]23YRAP:D(3&VW8/%8A1NX>I*@X
M2*H*!SPWVQGW.NZF1/QFK>*E9I-^.SW5G&IYU>'!J<I-C-NS^4';GX%-Q4N+
M4(1*%\2L9<F%+8_'8P5U_7-=A;7"99ER/[5K/<1!X\KH1R.EV*Q3N>QG\%V7
MA(QE+SU8"%&)2D%)PUVVI@:Q?AL3?KFD>^U-,CQ-KU53O?S=+%8>OPWERB:G
MB'9[?XBVOT+H;NY\-[%V  _[\'"$F<^<]Z8Q0F6[RF ?!"D>KW,IR:W[#1/X
M0&J.[O%,:'E:/L'SKD;6Q_7YSV#Q1OEAM)GC*#4O!\6YCI/YZP()F-7'P _K
M$\SZU&L&NWLWR>K6.[HWT9G3$TV=^2TT"7CQ1QQ?_1IL<-H[:'XD;;8LJ?H7
MJ+&D;GYEVI2!E0]A=?^;CZ< ?\C^S]DTAW[_5S\<#,W>-AFG Y"R=,#/U>SW
M_L,,5UXE<$@5H%[[C!TUTH3K9/=%#H$K)G!,!!.,:.C+[Q1YLMR]TAFKXIP1
MV]2'#?!;M[HV>M8_[$O>$EFZ= 2PQ@H+AZH0V!!8=.0A5]1>R0U+.Y= M9*Y
MN0^#F\()PK[QRRM+U[55"7:V=,"Q;3H@40T?26T#[F*\[4; 73;VUL(! Q)Q
M[$RG+YA]_3X@-9^7D;DD7',KL&8N>Q)Z+K2_\%FMRV3QB_6[ILY>=W6LTI;T
MM61\$X:ENW; T]'$=S]1SV68)DDS9OB^Z7*[M=6GU>/[UT1LA_5$*.^\F%-C
MX%4XL!3M)PIOQ Z ^I(X2J%2(ZI'&,N@#C'5\'$E1?2M:M&7 I4W2DOV5Q[[
M7&M:08W(S9F?<_WJC+?I8+OO=TZR--A#TU\&1\7O_. !;>1B&[T?XF_'NP8Q
M3T+3N^2Z$BQV@MT0D/"NG@0V]KN:@7Q<L9CI@+CS<8*GQ$$^3URB<G44Y'O]
MK:;5R!DV[J^QNA_=9*MYN;B'3!']^B/ZE9\.2E3FMZU]@0H,X40K 288/J+&
M- F0#+'Q."E,/!-I48^KSG8VU=#'Z:?L6VB13OXCW7>>C5R"JC%Q>X>I>4X,
MHMGMDM-G>5A37E$5H^WJ##G=R?= 6>+K*P"1XR#]OXUZR]]''>T-1OA0,(N7
M P??B U[0:,2?)M2O=/<9FSSDBGOJ5(+C:<E(R'C1C:;1:#JZD>ANN2IVW/U
MU7\H_SZL[1_#U@AL-^U<;>*BL,]RAI,@E]BS<OI-KO#;7<"%.S^]?.]7@I)I
M P*5#HA.ECFX09IP2! +,=$PFMOYN@6&.V[C9"N\H6HM*5=8^*7OLI*OC$1[
M+^O;^.N+$*29ST'X1:.'F/^IROY>0FI(@RB!I355_3RA^K5KX6J-<W60WI=]
MR<!S<Q8^9VYH_#H+,8ZJ\Y$P3LO@U7=)&T;,R4J8(*S2P^]GV,6JF=BFJ?.1
MYL@2T ?4&*$Q.L ).+6(+9[VC78X]MQ:";]3F((5,S]A;L)'6+;]4=LU-90A
M'P"DJ"H06^B '!0=D$++I@.Z]HBI?W; '^[_]QWP\"K84]!N=B0= ,+.)E@4
MS\<JCSU1."X^$IH8%<-3#P&_78/+^D?NQ9T=M _K7A_]K.MAQG?5V$7"P,2@
M6TTN:HB83?)WQX73 9IP.D"*REC []='Z ![\(PD,8%40M;Q]_ZAKDZ*)U)%
M&!B5#:FD=59$]TTYJD;O:)_^UIJ3=7(UM$,3&F\W\I\CP([!"AYHMB',K(.N
MO[)1DK.I\U</??D3(_J2!5E]![1+6#=!9)N_A)EGE<,ELX(T'Y$1 V>YD>0T
MR,O!D3JQ'%1"_/K"OZXU7FG0(8 QJ+ __?-%VYKDOE6.[16V*3_/O+XXD#G@
MN1UG>OX&]\*%5VP/.$HDY(MZ4Y)L,M/+]7]7N1N\=>DK N5&1LI;BA7E^_X$
M!0HCS7=M!Q-1"TC4CB%P4XH.J#8CN/Z1]L<9TCZ-(>T]W:GER&C(844K@YAO
M9.]?H ,,^FBZA'LTO0PPM94Q$X].D_5HIX[3 ?+L- R0',2P%=-@_ .9@R_P
M_5,,?I]6?4@') AR_:WEP.X&$V->#Z0]_O9)^@\/X=@5'!,^<<&0Z$PJPJ(V
M\L?2S,J\'>6:^X+\5GJT)&/7NW\L5\@!I[>(]@0V] 8=$*=^67_N^.:GZL[M
M=%<GRA-JEOI9:%!4CTQ4TP7:B+)3Z@:;#"*L==D5'2\^H339Z/VS(=N&(6!L
M87UUI0;9HF]V6P)9U,PLV,E4WHF=<4N]$,CCG+(QR9;JAH&;H1&;XV#.\<;#
M^<[=Y\[6<6*+!?B+7PPB,KX:9SB6-Z);&W%N*=^WLO@)D6$-MBRS_H;MRKZ%
M//9!JQ/# UQJLH\R')FWD1T]5/T_K7*?H9AIO26E=$"+.%;MGA'/HO5!Y*/[
M<V<C^WX<!S"K.P]>#H=9@M;5+_SL_6WO+?;XJW)2:EEEVI*[;FK=JJ//"H3!
M(/6@&\C7O:)Q!85CL&F"\;*>E6_%NH_C4M"?(NB*[+<"E4E&^COV.ZK9-_UP
M<Q6JBQ,<%!$XE"TG"DN3^;/5SOSG>:TCO&62 /]34Y-)9">ESAHN'U@KT &%
ML<3%/H/: ?\!5O>(%FQ9U1B?*M\R,<;$=<IV2K+F&?*W-[;,WX:5&7S!^$;(
MO+&+N.V4;;VP[\\]%5W)=A0&@RK;HC(<,Z5FCYVFG?NGE/./_OM;+><?_?>G
MIF+,[8_ZXT&3)."4M[_@)5!&E&GLPO$O@ >"TTZE,AAF'#L^:'&"&$^1@#.B
MY,_3E0"@.QWP-KB-'Y2.<CS\/>(+K5G-L,]X!G*VTQ)EB6H&O?0\ZY$V+ZLO
M[^/S<F-L!/5Y'>/I;^-S',QJ?"MTVLA%9VIJJ@CQ/&V/ 6+?E/_/=/\BE\..
M1 Q5UA5B.R:U48S+E?'T\9/MY--5KKAU%K OWPL; IY7U<%'8_@K"%PM36=Y
MEL93W81OBWASGWK'<^^5CBES -.Q<-6H YD'I%/DI[!9Y0QU"=(*5JGA%B;T
M2L)XAQ//S9J:]\[O=)JQ.@8>7BQLDFM>ZGSY'Y_DQW8\?7*/G<M19$MD(S/W
M>)$O?"GHUM*M3>&BE*?VKYN?(,#GY'TNEEPL'5M2R '9P7SKE) D,0;V<.&1
MBZ5EF!)!3$J5]*<F_J"]Q@;.C7==#N3;Z.O5+/%SBJ* EQT:_=!^\">!<ZB%
ME&P6RCT,]<(]DC?V *HFDKZ2J?>H?J1_]S#]P;5IFX.RL*FR;U]ODEM_K*C&
M_W5+'3FCZ!ZGR"[2[?QX]:DP=VM:CT=Z2KD;KD-:>7YM\/Y/7S]M3(/^CPQX
MIJ./9Y7'<!*BU^]4L_:#=DOQ;CT]RSF7$9>U/E)U4Q=CM6G_#I3.#UHLT3,:
MQKE)OTC7A:B\Q8W-'T6_Z-82E,PXLWCI1Q$8_UOFL-:=4HDBES8BB!K4=W!,
M$L,U7Z4#HB.IC=1&HN%!&#6U:UMUZQ B@IOWJ[Z]/\C'Y]X)O9GNT21X*J1M
MQRQ5*E5*,\A :@V;TKU)B;_WVI\YRBM.HA5+F'2S>K12OU* \]>1NI@^5Y*2
MGC7"<'P[W50>#E(-N#+LE:P!8$T?*OH5JCY&4Z$-'V9'0B6Q2%Q\U1J[U'+M
M"TIMSINSEUNV7G0T7(.B;U\\\[P)'>J_0GU()+:2P9!NXH%K;S]URHXR;UZV
MN)QUP8AP5V>\DVK,;3%@8)#X)2U59G\AU\T.5_^[TK%K%_1;@:(222N2H5FC
MJ,,V6VW(23J@$WA4[@%-PO]"I^%7&Z=]%L\;H?K;0M6:*_T"#<$+ @UJL@9:
MD,WLV+'S];VH[1HZP%O=('(8&7'3)U<K\CQ"R?DB/C'*/<=UO+Q>_4=.K<S4
M^F)*/*&S6:>H?:GYZ_3Q>%"9":WTH<<:NPKOL7@#[4>01F2KB3%(>W5REE-4
MNGV0]4W\=>S&Q-[P9K;9%R/-BP./_DXR)<5KA[#7>;:0NL:>5HBCV\YLS]RY
M<WHW*0 YMK^?.CG(H&4W])N:BNE5(%/#S3IKW%/_Y<8(P1U9]YDS8+RX4B>9
M9=VN&P_'S*6V(".5P:]QMRNFK4-]).+W*FKZ!:DL%^(U7D\WP:@?Y6+O+:)Q
M3"70(()417"B0495C)<7ISGO$XW) \^8;&)UUMZ>O(/AO)OCC.?]W*0%CX/+
M"B7R@Z"!O!0T<>.EG>&?EE*CI#_MDYB6D-.1]T9I3!3_8903^^F9<ZYP#]9=
MYY;*GML]D4-ZG/"SRTUI0S[]M]JFA1%O*B'OY?/WR@U=Q6A"#L<$NB94"*V8
M3&0[*B(P.V39[$(OUT=$#WI[ *,4L_)-= FX4884HX8UB=C:_*Z+;XX_?TL;
M_KEG>ZI=X<Q5F;>"G5\?P+=%5,SU9@O=8L@9(,HS/LDSNN/5YX=2_70H[+2Y
MP$#;BC[X_YAL9_Z!;,_\KR);LFZ4&/+7XN'O?]Q.S&VHB^KX:3TUKO7 WM$G
M@O-]%Y.HRY7KG<-WA'8!:8"$J&WPU"+Q!UX!)TR0Q+*WNI_TUV[C>48'L"&+
M-_8LH1H(ZOM2X8R'K<\>0ML?71VP$5?I[&$6M5]4P)W#H,.RA/'HUFBITSMM
M_#<(X6W#_MZMRO8="0/O"@X8!D;+-.)DZO',N(#37S?N#C%_-K(+QOL1PX9@
M$OZ(-OB9/;436ZWS-_ QWY!O5!6^Z/'%\YF(D*2?),@:^PO9X#Q#3I?7Y9X!
MR1?#)LU3T[:B-V#G*<(34 @"JOX]R)U[;5JMO=*9==3SK4A%E>4S$S_O\V=M
MN9R.)S-QJ=QAKC"R )^A"?N++G*]DHN/$F"3_UVEQFY3IM=X^Y#OM= +E=">
M;TIG\HX6G[QR5M-MZ+]T2"RH!5X-PB63=:#BU+P&[04! $6;?"+Q"1%8;@6W
MG^I=VJH(T3K("_^P-!<OM/=C\6A#ZS\U0J J',$8GGNNR&-1Y^,L-AKS#"D^
M_U.G:)K5;M#6\L#W"1;-YE![6*M;^?6[2=(G'+<5P57%+L>W[N=JH #BY9^D
MD7^2T?N.&Q ">P>0 _4<S>9/[ISNG-F#, (QN'1K@]"^_*(A2_[ WLPH3)/O
MR(AH1MJV?^HK[SC.'YU<T84&1DE)P1,BFR/!]AP0S3TU&#>!603; /WV0=='
M4*R]?^=+_C-LG8'!?L(JVF3D=TX4*73S/QH%BI]YPW??QNW*N^^_7L=DC\)>
M'EFB ZHF<,<]R4I0P5I"2NIG_> OLSU2<NC96QIG^MB$/D:>SN4[$])Y6N7]
M-FH#1Q:&6I-2%X. 470 EQP97>G_*E-+[2[5CR,V[B%N]6K79"3W,;XC(>IO
MJ#FP*[8DLCGX==:I:NN.[Q_M1_&?4[29U4&JKC9N]C/<&Y#)!JF"M31@Y(O=
M?G<0A%PK-28M/75'5L'[!T7-?R5M!T]Q#!\LS_!C=?B6*=^7"S['66*LL/^-
M$-0N[V/4:5Y:6HKLC\+PU+[88LEZSB$H?[)&*Q1\[- \54<><0VB[>C*+CJ&
MLK<]&E0A$KUH7>^D0P>8>3I5G,/5RL(EUF@\M$&[DR1OW[HVF-OG+U>H<W.3
MW&\.<]@NDC.R [?$D$Q,/VRNIBR:R["'17W)'&E(,ZS3KRVHLY1\J9YXKBU@
M7I)]0V+"3688/):7?O M)TIR??"L9#3U,^TLO.60I%8,92BNL$BR)!G$T,NK
M#!WZIS\45JEI>7<N6\9]GGL@H$.R,J>F!0M9*'O49N2;P9-D%]>O@G!\N3%A
MRP:UXXQ083%AM;6[$!V3\G5-M]_6L@@Q/$NJ^<=R_>'__. 9)R&) V)%/%%4
MQJ\M*8,IKPE PAE%7MIKX'8^F/;P(/K_QB-[,63:@'??R)N;>N?B"P?EOIM4
MFK^M@6@*U\,<1WY]9S-IG;1\4GX(?>?EY;*=4B(<U%U3;ON"8: #1$O_H2<C
M!E@#;D>2[D.9N%I+1%9<B:CL2IQJIQ-B^=#]A4PMN]UB<)!SP93^%_3L]1O6
M;3\-)3,DKL6DB X!]&&!4'=2NA_!&VN7OZ@3?5(XM7<$ZW[@X)9Q;;&LLP\^
M;6\QD7U=:I;*U-H0308I6T1%[?Z>-AP .P0?4AJZFMBA1F--[/Z'@YW*^JAL
M8G"WMY/#I/35)Q$QU6PJ9ST\[B@J(O/DX"2QR-8#O#P=< 3"F;='%BHS8*;N
M&C<]0!;![5E!&#J@W?#(()[<R7]V>.^R]CVEUUN5O_,#7"THB.MY";')Q..2
M63$(F.G@B.+Z]6Y8(34_NE4Y[G:T9V*TD;OVU%13(_ER03S9#3:85G!\XJW,
M]5.X@ )=N$5KU-HN?)IY(:[Q-0)J,BR+]A%%/;"@G>>03RZ&=:,KYFL2O?'C
MXYQJ/ ,!CSLQO*\/09+%L!_9Q_;.5*=_@:2P4J[QCOH(&%V["<Q\23OP=?PU
M/_C*D]>@473YL_#_P=Y[AS7YK6FCKQ4+&D%ZBPH*B( @32D1%1 0D"XU(M(%
MI(,$8@.4JE0%) HB'41Z2^A(D4B73A**E$!""8&T$_><F9][SZYGSIQOOG-]
M?[S7M0AYL]9ZUE/N>[6'[!JL]J[0Y4JK;6A"OI6-Z#9^P1R<FF F,1^C13\\
M*5B/<B54M>7-^,W+^'R:90#3+J<ZYNY,29)/4O1A H3)M:A"NLJ33XO?>1T-
MBVQ.G_+=JV#T,>'QP2"1(ZH?AXE2B&,$DD)F..A25.*[^'>7VR972HIZTTA=
MM ];GGO(9=<( 4_7*B==1@R7'F4,8S[# _;9EQWK:?E>%%SUM-[J(WFC^1$\
MVO=R@.620H&<A4JQUOF0P3F#:OF=#BSHA)OM^6$/E>M821VK[O&<:2\?98=T
MG  = +TO^8BZ"XZ"$BF$8/,:^M9\7#VSZ3\B?L[ D6[G_:SSE;?4ZB*KSR1#
MFQ-SU&VSCSF.C!F1$;1:$IX?86"HP3D8JO!WIRNK_LIDQXIY*R0BXSBY:&89
M#9 I6I30!/@<K7@ SZXQ_^#U?6BJ@AF/KW&3X,7 KR47_W)*'64](Z362;82
MS7O>-I GKI.54ILYE'ZOMDMJ.^IGJ"H6%#&*YER0(P;J).)X!F[#5K4G=3P_
MBA2Y2#5L0F0D1E$SB(L:/A0H6>VR^BG5#589@:*PEN,9,UY3R*&_K*L2*13:
MCBKS;$;PC)(IC9#C:DT%=X(0]^OH/^I3NJ?Y-:<O),BF9WV>%:H1F!D9<%*3
M()#L$K 7R_-,C?+TO?3:N?0-76P'/$8>C5Z:EX4>5HJ3ZGWXH[;"N7H@[[!<
MMG(%[SG\(Q?;;MWR1R'WR?8=H4>)!;9:&##'#U>#G$G5BEV+R0LQGK(R9EK
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MDS\UVV/B=H\QH7L(DTD=C@N'_)1GH6V90\K*F<2*&$&G'?FMN'JY"_X?%9O
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M@ 'X:W+++VD2J1Z<E+._Z2PTIH*B^AL"Q*C),X >%EH; YAP6LM@8?[10L?
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MOLI6U<6V[H;U&@L[9R2"SC7&K2Q6ET:+\4=<N+()V6O^,?3KU+%:\A/*=7)
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M96SF5!+OQ),>)U3*46&E(^VBL<:]3%8U4".S_;JA$,&-%$)%2JV>+FL8.,T
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MWZVM^-'U3G_.PCU++;]>#@%-"IX+@Y5BX2?=,F2)!Z8C8;JYJD-;F^U6;R<
MB[C/,\!%0   !([,%YE:)8%+"-P'[!<=3_1X;>X(<P:V4?5M^&W8API&I\8$
M$8UPEB4X/]4KDRHQHJ(K8JD:I><MF?' _59XTCWP- STOMN_+60A>_%1Z,M/
MXS]W]=+]296?"\T(-ZKO]&GN??(3*/FV]@^V-Q@WV4KVPX(PJI#V*P)U17[\
MIJD7,LR%D]26O',F^"[B+;:%VZP59#/.A)DP@(<#7W0Z]>HZ49<E/6>_Z8AE
MUAI\_3.&EXEL*!]X\&G0<Y6+1Q+K(IK4R\FFJ7OR)W N^Y]G$>+:H];X[L^?
MVW%YW],'A<\E)*9J2Q55?8I:^T%>P,%;QU%1"/8M:;Y;=]0O(&T1)^'=$KX8
M;L%8-7OZ )_:(9A>'5F+**U'_'@VFDUW;HE-FEI1%2KH-8&;!^/%BN/H/ .D
M> :0R:3>25$0NJH6528'?Y8!W& &<0DN./51]657']L>>@J]#R.],IT;XIKR
M96ZVJCRBQ2U@):3//M@ES^)Z[@_K"]^M;WQ1/R]0D,4:SO+]Z3%=6S?*A9_3
MG"KBA'[( :HI8=G"(+O+?F#.[:OCACOZ?$W,^('CYNFP.J_O(]GF,)LA]'QT
MQU%6KBO9A_3T9=S%-3ZE_ARP=$7BF1+]Y/7[_*4 HIT)*"L1A^A\KK9R;_(R
MQ.H;U,XQ@.0J4+.4<C2U@Y8DO[,8$AR09_LM=WI";F!"Y]>YR+(Z@631P7B]
MT$B8!ME@!AS%9386$+>I@'K:;RS"=G3T@ZFW3/6+=P$"#R^EW\?E%1O\DHS[
MOTL&35>]8YIS)4XO;D!).DKV.&^3GEF.D:GCEI=A17*GK<NVI][T:T)##'XJ
M+?AXEMW#[VC/\YW[<Q]^7?+F =^^*K_+_0_QF0^"T(XH\Z2=C*,6VL*)2\MJ
M@C!1 J@Y6.*=<B,?_QWU +'XP)B5 0DEGHG]Q>/Z2DKM#R]]-]1)7VSP/RZ'
M[7GV\O-M$Y?!F#NJ HGN3K7^:2&I W[SOKZ&&AZACO_9YFU/4K3<&$ 5O8C(
M#CH:VF$+)@>X?'39=>TL6D:PA_V,75K2[&IRK:RQGVO?IYSTX]:'ZQY:P+[)
MW)(4B",D"E$UE4VQ6&*&4[C+>$F8HJ5'Q$RUWSO-9<S6I_??]H\H'N,LJNOT
M[>)\:U?]ZG'$G,:L1Y%T-(*; 3Q8>\&T/C]$!/CS5!;AK;L*S^<Q\I<%K&#;
MANZY#Q?<%!,\DNU>W,0&!M3-<*<YSRLTLO3+F5\B>(.BN::/^>8BU5R%A&J(
M\/@.JY3FS]^$$//<]PH.I;\]\GSL\ -V=27K&=_!?SV% :R"HBD!XZ(5JB@3
M_0'[LL$>(ULE'A:/4]7[Z*.RB +SP0HL4UH&3U 8,;(L3,/S^'+,0:*4+(N:
M+GU5?7/G=1PEZ9W)A%0MV+PIL#80MLOAR@".?_'-7I1G!O:$.R0_!P?6PD/"
MIYX-)U>#1^.8V/:SVJ&?EJT#GC55%11!C*AH3\1LY[;#D6G"^;7\@=J:C1\K
M9V\=5/C$E]-V6 F5\/G$H29>EMP25G(V1<S&UM5H&7%L]93)VZC.3_KC>T^.
M='O\NKL')]004=,'A;3"I!.\]-GLB 245&F\?R+4"J*6-ZDJ5:ZE;YZ&^_*H
M]Q.?&7)Q"9%/?[M.>DV1H%H-2N_G"T]SL^,*=5EHT *"#W6?W#6OIYXGFWZ
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MRWSIH.["X>\%;E$^]MOO)SZ[!V<7/"0KGN(>DH]'>'BKM?\U7]O2KKWT.>W
M&[#QS$,RWG Z*KO "3_1F&)CQR@8F#CET,W,]_F('^OW[QG7S\V(=BQ=Z;J4
MD!/>,?(&H:.O%]#_]>"ER.K_BR??0DRF:@(%Q.;0>*0<P23,C!)PUT DX_SL
M#7"BRQ6;3P=.AUN#W<),>F;C^<B[%KW=MHCH),N8O(CH>V^$AQ(GZR8I#M]_
M3@.Z_R[IOFDM\_UN@]K %PSQ/!E,W<VA@P(/0&""VCC%=+#I/-*0D(UF PH)
M8^4XW9?=>;WC+_H7I]*-/ 6K685*+__RGL\HO949.2N5>)^Z=Z%+]V+72$?O
M>5F7-<UERPVGZI]^Z[^]O.A_1"W\GXK41Y@C_*LAQ7:__%&%*Q9]Y,/(^G:?
MJ>B0ZUI55*JO](T7IEDG/G*4G=*1+DXK?''M4".Z(8S8'4H'.5<!W79$[#,$
MI]K16?:$6^8!NFTTN2%9M8\E-\J4+TR;HU9O)0H*A0C"^9\$@GGW8Y_BL+"*
MYD[72,A[GX@FT14KN<%MR-$I()@0V_RNIXDRV_NM_]#D+3JHL_P^)>^:6K7H
M^?),4SHH2$"B"$/2+V7KY%Q[[55\W^H<GY3DE U^;VT*<1TE#ESUQ#N[F@-1
M\_ 3&B7(]@XZR,[2R22H;_6+.,<1#C/SZY:?[F@MWFJ1KZ_H%Y,7;@$KD6I6
MF\D)>/&F*Z2\U3YB,_M]P*G;;+2KS%'QXY(\8$Q;X'9Y7!TK:KQ^NE=<VQ1_
MHEIST3"081%'NBG1D$#Q D+R+\ >U@/#)7K9.(+2HI3Z@8&Q0Z+36DLKG,+V
M4YM 2$&*%7#N+?4XX"74/)'"71!M8<%A6_?Z54/%1ZW#LYJVE_%VC" &R\[_
MGIT!AY2N/Z6#IO:ZRR>7XV=X2-"7K#<UK\U2MZSZ_R+Y_.W?2O+\!Z;!F3]!
M:O23B_C55,E6[3=JRSX,ET#[)/KP6S@EKN[;EP[>_ #6'?@1E&X=.?GY]@:W
M ^UD';**[?*2H6 !J#Q("^\!8PVF!)&4J=*(X+J=T--A >T3"F..S&?LFY&!
M ;?6=B^67MU_1O4\>"[FMB@<\W1_G?,1H,@I_2:7S?@!D-C2PDM)K(_^A([5
M4,^[::BD#K 9=![LB=P#8X8W$QN'_:^T/.S_S*T71TH9$J/_44[>7_Q*]=F_
M2>9KQSPIG83\<3))CADIN^<\EN8EDE>PYB+(O..FI'IA^M-5UO%ZI%1G'1RK
M)ID'=-](]BK)<JS02.C]YI$WHW]O+_A.[IL42["38)SU>WXK",3(/['45<H9
M0Y8QB8/\[74R)?Z]Q/ _2:JS:LMDS;/($7*2I@08$FZ:/28?]68IWCFTE_?"
M1<U/,Q+#A3 >[\,P8*DR U.2'0A.Q$Y2G<$'?U.P:*Q,!G5^>HXDT%M2H%5+
M></[1.*)OBT=M"CR,H4.$FK\NK]C-WCAQVY,Y3E7YF#90;$[^9'W#H,>,,#_
MBM)3!96IGOBGF(W_(F.W?-9<\3@LAO]G#$R+E-Q>GY7E,/A:^>HJVY*%\N'W
MG]FYW;+$ZOW&8P^,_"G:(&Y;[V!96O9<:5<0OH/W>Z-MI*H#%HV(/*X)-J16
MPO>A;V%>4DW%S0&.<W&D&.QJQI[N<LW[%24(6/94^JQ1/(NA0?6QV+Q3S[94
M@AA*RU#GB'."EDC'+@PW\M#Z^%TGF[VG+-)/"L_R/>$6?Y"N=?5H26YDON$]
MBMKGT\1/&*[K;]SOX=_(V7&+_YQQDLR=^=NLVR^_K/\.\ROP(AWT-S7'6<8_
M1_XY\L^1?X[\&R,=QQ+?S:YPJEC:)TR&6(2^C%:NX?;[]['VOQ62:)#[5R<)
M_K*(ERF@2@?QP"B?QM#"S>N5^\XYL:-P5D9LI3K6XECW3VN$H<FGN1K;D ""
M'#_2<-[J>:I===J#>/46S@[:TRN[M"V2@:G1X#EOZ$!0GI"^;).I\CK1H5>*
MZN"I3DWQ_@E]G5F.XIYW94==(U&AXJ2F'.'^AG?UT<XXF4BI)ZZ:#*%:C4[&
M!=._6"O?&>0OC^CIV _/'.9&W!NM+&9OTS,Q&RE>77MH.31M>;LL$WSWTS5N
M(H:KV64NS(K/;H@&N:]+%/SB7=3WJCBQ+H"H#(/-\,%F"U[."T]\MWDMZ_1F
M]%OKD.?ZKISQ-D+)/T/T6$*@2H*5)5F+T@!<)0W:E$?=ITV.W.&0?IK+SMTH
M O_0\//;>]J:KR@)LQ:P!\<I=R:O$?H/N: 'SE=5W@Y[_QR]B3!8%!+I:J"#
M*"\ !&D/G[,0UK[![L@KD%[Q+2K-VN##@\P+T^(Z J37_-;Q_3$?+HL;RQ?*
MFN?LX'SBW&SU#"^%<@E&4!(MIT)D[MV=2_>7[9=27?T,[DJ7&6WP)?;?Z%)9
MK5^O$LQ-L1#AE0P1Z;V0]965@IF0I.1^H7$OEU.A0- X6TZ?Y^+7N9LAG5G*
M<\8&G]O0KLGBG,@K\ZWG2&H&G^/AX%>1^ ;_L@]V<7'#BGW\O9?J8+;]EVXW
M*_5!LZQ@]4-C@X7.+F-3595^D)P4YO!*"+>#@5.ZP)A,:=$B?^3BV(/OLQ/"
M^UH&)D[?]"3Q UURH9,:>5W@B=3.';,2;+ZY3&N9!7_;_*N%L'7]>PLZ!A\X
MW+**_9C;7*=2VW97?Q":HU(>DFC9,0N-7XWWY"_C0YD7GR^5?13^:O+$L3@G
M@[J/Q:]>?_YCP7.W\W+-IZ1$T;&5.[,_^@)6XS:>WC,V&3-+R_8+3?7E[N 2
MM<\+NO9]Q8]#B\D_,JD*>C&/]W=J\M!?A!&P,= +(@R 02E09C,AD9LJ.9%Z
M]<S#<A@U(*FAD,;R"T\'K>)"_9*CST1Q.@DD?9R"^/&9'+PK<ZZBU+,'8/\9
MT+XG1DA*Q0,V4V?*"ESC/'<RGKN(T?;L!PA6!223WY&I0.K9+VIG!I_$#^MA
MUZ1B$R[,2=*@_:8HHT9P%1T4YW.(#O+G-MD(@=&F5_Y><O+_6?G?#Y+^EDWL
MU%WA0XB)/2.5;[WQ$IWU#AT_E44>M$#NS>&>I(^N_"2/KXV3G6B<&Q -T@^=
MVAGKMW9KJG!.R_>_FNIYV59UQXRRL_1PEBV_;,7DB;>@_1.&CAX!+RWI(%Z;
MK7/HKF:12NQSFE@S:2=&$5YAG_+RC+5\X:56=[Z/E^_ /]5:'=%AL0J9QTV5
MT$'F(S "#P#&FZ=I;MZ]*UA?[^UM_4.(94LY7UJK;KS7:P>W6C+'K@A[GN(:
MCF(D1,DH+C[7*,BI]'UA(<DN_-FT]E<H$6W,'<*OKYNH"LEQ[[*,6S"B@ZJE
M"&D.>OE3*5_NZFI).4[I.J=55?W<O"I'L=A_VW1EKILHAT6KI+1]K=XN]^'L
MS=I_]2(\XR,UP+BQAH!=728E$RYET_A)'1Y6;Y<,FSO&F79#Q5CH(!"KU(?,
M.C']B^,%OZSL.DV[['2_7CG_M,XPM];:9<R<.G4PO970)W_$8,* BCTUU 6@
MFU&'&,!Q U-SPK'Z?BPAX))[F,BGH]N=/B=_5V!^2KCXJN&PE_EQ99:2@@DZ
MR$JKEW>.C0YR*)W0W-1S(N26G6DD_/38,M?BTD[U?RVS>0MB$KTM%#?4*(G?
M62L@31$AB=G(JN3VR<*'WI9]J0[F^Z^1;-LHOT-.$X6?T!?0O1 VM,RONH3[
MF,>.&PG[>7E=)^O]/N*\X:7'::,V/6=1X&\!00.;J%\>=D]K'3$#*XY#=%#-
M?&7#Y'CY5453RQM9AXY^%"5I>,*.0V60<&(>I9EZ>N? ?)7]U*K B0OOH5<+
M:>V>P7,.I4E4)^4UL;TS#D. "H:GVRO#L7K+?'F+!=5YNX0EXOY&R,B%RQ!9
M.-E$<>\<]6$4 =S)Y^+E/R"E-<JU6I=Q98I/\MQO3G4=;KWBWIZ3SIDBO\J&
MJU[E*$TYL*GQH(H^[TY\\R6G[#J)DKS9D\:N80W6!#F>5@J.#8F#CV1UZ=Z?
M%7\;X)T0.502O'7KY<K=U.AAO:=^OU-MHF<S4Q4&S=MVN#Z>$+O[>15YYXKX
M%Q:E@63T53OBTEH<82YTD+8Y?DMIV0MR1TM9'NV^A@".!^@@9&G=;GUD^?F=
MJ*:+LYIF"EO'F\@[ L3K=\ [UIJ(#.Z?W#:Z]Q:F]_05,/>*0_IXJ>U#D9CY
MY$:YIN]_Z*/W_P0ZXC]8R!@LKKRZ<.\.4*<K%P'C;C#*1,KK5\9>E6^G@<<%
MX<[7E\N'9BS[^&97:F/$HD[=RX[U<;5\*S*H@7I&!S%MTT$AG20,Y370M\>/
M+"2Z5,PC6)#'')1G><:HZAYVC>6QNSPO3?O.+;S_T(('GWM]/6Q2;6I>:XUW
M3XXV0@=5[81#V5%W]C_0)%!G,6PK;!E(<S@)W;2KF%YX.M#%):_67CSF=9[U
ML8>O>6T^/+C?%\BP>T+#$W*$QO>5*@ XY* 4AZD/B<?1,K(\ZD5 H;'3VO75
MBHKD%&]&?YO8"Z#?'];E[__'RO8?*P-%MMQ9#=G37S&I<%2F@1SR/B1FIYN,
M/>E3+>MYA%K/CG=:CY2Z,FRD#,T+0U9 VB\4",E<5E:U[-%I5#+3<6B^09#[
MORG:9/A'T:;EQ7^@:--_%U.TXJ"B*R<2?H=$"RO%V,Q8359>=#PTUW_!A4^:
MU^,;_HW'!3?_1T'+7?(%?+T6!54^)>E^3GE)>1US57F=I8 9CD<64U'BL^P'
M?;*]EG=^#[XA =E0<O-_5^P;$G"5#F(GT$'O^NB@I TZZ*G!7WTW.59@E%"O
MM:UOV87B2GK@0#A+#/@JGEQKN $HNYHLNL,.8(&MI?(\(LB\$\H.Q,@F%SOL
MG)&:NK)6<[[FGM=3&QMCA'7O^S7+9*H49JJ>X-I/P/$WU;I";EIJR&K.Z25?
MN[ K1SBP9BW@"1-C $SLH:K;D6_L71];'VGWS4L3[.7T?.D\Z_F@@*+&([QE
MU6W>EEQ?$DVE@Z#SCKA)SUB1>^3+/D5&M_P1R)4L&9$!2VE4(V0MF;Q$^!&%
MB<(<:=*X+"_H4/1Z?^?"4]<6!LOD$(PK)MCL\]>&&W;OOF]"FK;,63(AFM%)
ML)V/I2[QEQ=NG,SGO_\P,52=NPLHI/@"DO-7^TM12D.36GO#9JT47Y:?<CQ#
M&"ZC/H,GM*UNVCCAF,_>[*%[N*V[N 5^__Q: B*:#F*A.OUF_K+=JHNCK1XB
MWS6D@YY,'=\U":/-X 2KA 4VVPFNSW\ZR"S=4S:K? _E.W*WK$/[Y]U/6G5&
MV*BY,E@KC@V WR5782-_6HH(LIFDW'R1TX%BY[YQ^)%.6W2S>.0OO6_QQG-B
M29<9I3W<+G,GFB48+-A-NMD=<UN7%ZD0DC"]%W+UBB2;F9Z#3T7Y6(^KW0]*
MWJHDX?(VY-ERZ26LLOF([0>9N4<0"9.M&"R5M?%WX:M M RF>Z-US6II;SP%
MND4'81Y!LI[1?I7F%3KJJ3AVMY"K>7E#B"AXS>S=17@#HGU'YJKA'U;XWG]D
MAN6?0:02@3+RK0%";IRK<'KRF=+2E2U!Q'&D]^2U"D<3<\]*KC@A;:BOA-@3
M>S8A$MC("DS>H+$02+H4+/ &+8.Z2<;$SH\:=SY9,]$BHRANDU,QV=V<6H&1
MGS*F]OI[OE]@^$IE &[DH3B'7;/))N'%BF !Y)1)L@E9_]U%_A'76R#K9WSK
M/*2;!2=U>N[/,U$_=?3MW:;U-Q]N=CC0Z2FX]N:8=-ZRAO<I0W Q@W1QKF5L
M)7&1'WY1)6 U.(CA>**XB#7%<S\8>@3]R>IR Q"#EQK@<A3H7$QZ.N]+=#W1
MGZ^@U']:>QF2@K[6+\ 56W_8#G7EP&_P1IT$G%U]"3.P;@B'%X3-RE)'%8#<
M)U=]VE79<.[G#Q;M.0'S.\<_N.D3VO.1Z<"+T.-'B^KNL5 585QR=K6CO.KG
MA$>[?/IM*[2EOZG6JA;?9.+J83*I'7X8*HB\.SLK$:MP)S_\ RLS"*3"ZO7_
MY7(R1W/WFQO\ZC2F[WP@01-K<[!N8OYDJWZ*G" =],7E0#<Q8('QN']=S!_[
M%ST&_^+;'W'>/]O_4]LW\]:&R;J6(<5H<)HM_S,6WW<R#?[NX[TQS=N78-.*
M6U[H= .+K;=+4M/[RJ)DUE#UQ'9F769_Q[G*&GG_>@^81F&Y#B1E]CC9M@R/
MX+Z/;%;']=4/KQO;PZUCWP6H\S/Y<2'0@%R'B"AY[OGV[]IW5J(5_GJ:H[91
M2MU2<;WI?L&)4/RXJ8:EB@O.L)/X62JC4^0SQICB&3+ZZU<)3K/6NF+4::[V
M[_\/[@)R*.QK@RL=I%XO1ST"F]?Z7[_\D3#\L_7/UC];_VS]L_7_[5;CRGQ%
MX+%G$:+U4N(O)@-GT=&5_Z XXI_R[Y?:_E>IH%(V$IB:S=5-!U%..R!V+Q;.
M_&='</YK2(E<-Z;2KJ4Y%/J;AVYR,'_<"LY2=^YS^D<Y%;8<+Y*=NFOZD7CT
M:Q#C1R,=)L;6DD+ST>*GP@(;%HT#"39.XEO./ZI.ENT?1B7304PQ833>L%4L
M$1&#.2G]<*0*'F5U<4RNX=:X5(/%=8M)F;(!:IGV_-F"'2,=T+$OS.-Q/4*#
M15\^EL2^+3SW471;=+AP 0R(^73@3@#C%.UZDES$3]/27,!KWEFWS7L\&5RG
M(^/<4"#*M,,B](./#K*]H&HRNOV_7QCU3_F[PN&8XIQ;D6NQS$M>#UIA#K5A
MYM>\FXV^.=[]V^N#G;"'E4NNML[# S%"U!O.60BJ,%DI;_^=:\[]3Y./2UR*
M2^>98@9OB[L]][*1&GG4U%WDC"$,M,]Q.WE#)<A:SQ2<=0V&!;U3\Q'+[GI7
M,SY[GHS-R;JRM' Z$.IWX(AJH3C)N-;FB5->B/ 4Z4G;VOEFKCG@'1UTN_9Z
M^61 ?F9'+/A4](6.3GW6Y%90, +^+^$S7[LUB3U1ZMG] NE5F291JQ^33U-0
M:^<M 3O3 *AO>;UWGSCJX]NGABWBXPF8]O1F6\CN6=C)@W]$M!P??7F'N1=#
M6BJ="*-%@CMAU,O)7@LX" ;_&L;0P$*6)X2%;L-$J-I*LV?(]Y+,XFK),\,?
MPJ]9^#[>[_JX(K6QN[41C3GB!8MHNDIBCEKURI>Q)OF$(PQJ0^V_5K6]BGQR
M5T7HS=8UD7-T$+O?_BO,][=40SJH/<)'BWKE!^4A'9093(8?M$G,!)AJ@%!Y
M?W;[+]S-RI2\0V-)( FVX+B@?$C7&^2-CF!GHBNWCDV!($YX1C7\^>'N)/CT
MD]C,)CJH% ITD^P,@=3Y.1"RJ=LL: S&C SY*?C*-B;*XEQX;J=81L^  @,1
M]Q>[\^D_L(/_[///T\>KA3:"(^DB)G8(R:N_B,T0I&OW'.<D':0[E.)OX#,_
M56 MS:_U*6^#W<]DQJ@;_05Q;*/I$I67S-NV+V\8V3MO/IPR*57PI5Q3AUF<
M79L8"'4E*5,Y52F.8U2NK!_*S1S0LRPEVX6^"R>HU^N,ILF%0NSMDCF.!QOR
M+Y]M.)US,(>T%*(P (9?^D@10"EMG#[&?$Z@0.PKL?(LXP(,\!Q?;:>#-)B)
M.)J0;AV,,("H .^?A$1B '?9'RN]?_;Y3^N#QSC" 8G2U3U2'P5%1F ;E.<W
M(IPQ.<MZ5_/KR6LC94G'LA8-=\*N2JV_FV^VEPOUF>-'LP%1!/3K@DX;]^+E
M?F?ND>^F8N+!\<SB[M<@RH @C45X3]$)S3+X,W4N''*2:=S/J&$SG';*\OPZ
M<C26^6'"4!7F+Y]L>8#%?@CP;$NQ"\M[_=C_.%30)^X(X\N8>W&K[F8G&39Q
M?ZTD(7_Y(ORT^;/3/VDG$O-JQ &([P&.D^T(Z1E$.#=RAWA]NI58?*OWHLU\
M?7Y";ZA'Q N5:I7TGRM_I=_6,!6(UC0XWBZP%'7JW8\[B!XOHN":AFU-3**1
MW<L/MT7P0@+; J!?<)K0S[T+!V!<'3@PG&&<Z]B_VN2[Y9%_]OJG[P4P4FX>
M8/7'U"- !6G@#EDRLL&??,KE =DXQX:OG#PSHK-PX\K-C\+FPG"_GW^MQRC-
M$Z7XSWDD^1:3)HY1KWRY;W7DXY3,"O.NWG<5O19GP&[LQ_V._UO(*GE/@=:!
M8<'8./O?)?.VEW("3;L!QH/.)5P=Z9(I-$4-YY;,GK9J_]C1586_=\@W]MV*
MP0BW&-.)UI,,S[*HQH #$2*\ CNF !9Q,)D]-223-&\\6+01;QYU=J*Z(/%D
M@H@V7HEE.Q\J3;4']$AB;<7SF&C<"07<<8?K!IRS*SN%K#VGF,*_<"5[,*C>
MXPK4OZRX!5GM)X!9 4D:ZRAY0(OD$R;]M%"))!FVL">29O_BIG"6Y:<3(-";
MQ^2>Q28LV;4%%HKA0(M/HG2!,$*J#'K^]E!,4H1=D6E.AX"[+W]>NKC;M22#
M;UG02SS<H,!/1P^7/D<(-8%1*-(PLAW?W)$&Z9ATU%W0\\JV*FKCOY@6#_(4
M?!!<%7A9=/Y(E9KA/(8-D+4\/]>1DC?Q;>RG_?;,^8ML'\=Y]6-_\!W-QL9?
MX2MK>Y?%>8UIO!=3$=9"!X&IR@<+7(PR'D,?^?[E.^T8/,SOJ97,T/;7#F/K
M#OG/%3<Y%=NDHNXY\)W]I=<C#I;'/1G!$.=IXRGH%&B *J$T-/5.ZEZ>\4A4
MZQ'85.1GP0;L^ES&QC4>E/.>';H7=IPFUDV*ZL950D(4<)PZIT\-N7J%#VFG
MD<L>]W3<]CC*?N^%5GZI'M.)%T[S$.!<&FX53FJGW!O%V-%!?!9(+1TR<Y3E
M:=*68V2QCTB&PKQ*<<>[XDO/'VWVN4U_8*]]- 4?F6-5D\C\CCA,5<3?KP(:
MM/), :O/K5XZKVWU[IZLUJ8N7K%Q/QW3'7_4)4^!P;H-P]TD@-SH2!E_KL8U
MWR]E,D*]3#[3:)<[)SZ0UU!/$:]G^;K4AWFYJ;3)S%U E..PG^4B[>]$-FCE
M:SGD+2=YS,S-Z*:];Q?@];F\>I(3G;B)H'+-MT.%29BUUCUCP+\M13@W]2%S
M1(/:@_*RFON9V("T]NJ1.X<67F,9"Q37$%6Q*'-",YC*5*.*(T(B1(=^,D&V
M6<,59[/J!ZW&9G51VS,>P1^8&*O&:5)491*V_2>0-R_'_]4^7<3I\GIL8?$G
MZ7GMF1NR=)"J@Z8H-C'P"3F:;"Z@5):+#-.N'-\V[ZBM:*J.)0X1Y3?[N/)M
M'JZJ,Y-+W]!!^!+H<5)R.!WT0"Z\KJF9D,K6URAUG7,YV<?8?G,2-GE*(M.;
MJ4M_,"W;CGO687<IDGIQCTV="#]D7EFWB".]=GEJ'Z?,6X^]#69]-IW,>G$V
M4%GMQIX!>@!ZDJP*J';@^!2D5 '7^*X%N\9#4DYY77V^-G20R<G^Q Z7WFX/
MO(?\['CWW'M*(JEO'D/EY.QKGZRLWAE3Z0[^B4092J^*W$ /62A^&DI(6/+-
M[FML>I+XP$]@%8./AYQ$69+]:2P[I+U.].7&E V#H*$?^OX]7RL&N(NGQ\@7
M)9.@%O;9Z3IWX6:@W>M_\P+H<\)&(UGYYS6/B@6=9634 HI)PQU0U1$TG[V(
MVE!IPXUL<YFNXBS3.?$:'H,*9\/SY\ZHQ;4\X5J^@S(%!DFI>*T0\RXZB!]Z
MV@$J,/0\4Z)Q=,.8._XZRXFWDK+?#GGG2X+>N#DMPB92VT2X27 J=^%\.A:_
MP7Y_V=@9#P?W4:ZJ#(J&JVK6OSH-8KC<,Y_0'P AS@5BCM%$J3J50#(9W*YD
MMM_U.D=0AG/@?H5NN )Q4QZNIHU_)IW5HXEZ+'V>@>$5!QOB:-,5E CPBY!+
M#FO%1*C (BI'DGM3?F@WFCZ_9*TJ#EI4:F5V KFI=QUW1.9UT7A)%G5&S1&*
M\(J>XI7!Y;I[CWCC2F33A,<NG-"!B'M<M XQTA0/9"E]20?9@9_1(( K'738
M#"@NHAX?S!BD\N'8M[\WF.<LEX47=8?;I=F&BSL]-^')'[I@L)D:KRUB!YW(
MIX,ZN_=+%?854+L^[8CC2AG*._K%!;Q!QS UW&^4?2$SS3=F Z6!*<KG_9=H
M0:H6EL"+A=G#6!V@XO$W;V3/_CB1':<Z_Z@G(?S5-PZA E&L@57*43'1\2X8
MR5 5]A5'"%LM>$<;H%WX0(I-(()YZC0(BZ/<9NM7KSMT>9E'&)G9'.U<2"+4
MN@E[=%;C"II.(G4UOC2Q 4XM94YD)%:_@M28%K22<.E32O:Y)W&_/GGT$C4$
ML>(<,_KVA[J?TZ10"N2Y",72HTC)[A3CT@+ G:CG-Z#7I(.#^_JLZGASE0TD
MT4'GOCE_8Y<R[+ 2'6R0).QM<".Q=V*'X</2"_7-=<FJ#T,59-?=OYX5WY?Z
MU@Q(=H>B5/%TT%0PI9BT$Z*@JJ?4!N9"(EMMK%W*-$3V5,.<\]\>[I,78;[K
M--GL) 34M*,A (N+#ZP#QJF>LW(4]IV;PZE1RR>SL;@AZ==RW0*SV]$CN XZ
M:+*/X@J<(\R(=4)XT1?M9P6KQIW' DXIONYOV+E8'CK]_C(GB=_'1G/HVA,1
MJ2*29 >8$65 *LZ+10LAF_7&GSIMR]D5+"M'J'$&NKE]U_XH&J02=/3RZ=I4
M[$0>?K9FOM&?J!6KQIP-8(W'D\Z*+%D-GZ[;DWCI+NUD=S3._+'J\_AR;,/6
ME2MX\,&</(HY#9DP;VVN,CEXLC E6U@8%$(V+O3'%\MY"MHDPRL32U%QZ8^V
MC!XR"6&RXG!)@=!"LMS:*1*DE7;1%03@B%T1-H7=TA<MS.!^6:M#MZ^%G'&M
M9]/6/EK.+1=7*12Y5OA-#I"<:YL"1V(._.IRU'7&NR/HL\LIZWG$F>O+-W0P
M7OY7VUY/[[CSA3-.]5E8'ZIK!L23NTJY4#[[0:@3Q&8!1\Y9QS&.:0?EFH0K
M=F_,/I-OKL*EN[BC/$5T'Z=7,FPG_LT0Z5V5P@*M._>B.;28[APY@B6;$_+"
M43[YU M?U'QS$ ?:MMH\QERSHDG'13K+=C+WWMW;OF*!7R6'W@(5Y"R"<@N6
MM2:&=@EU<PBEF,-R4]>_<+9(2OPYI]@U?<N/3&MW]!DNX\<_82J4GZM)X7&
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M<:+I%QBO69L%IX,.AP'S>>KOIM266E18CQK;2)N*Z<WS?S;Q^.8]+6^5O(=
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M=% [.+1):H2]E(@-2Q')\;YSJJYYZ&'*]:RWTROZS#D@)&:U9L\0W;%TIQR
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MZZ)!E(X1I+>H@*" *%U:1*2)B(H4:1&0+DU  L3$1F\" @H"(DVI"H1N0D=
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M[$0*$/U,<)GGY8?P>A=ML17 SV#'.-:#.$9^\/V(,_E8-=0[C^_@O4"3-+<
MK(@MD3GA-@Z1L6H*(?#<F]89S]U-3YTP.14_/:KF)&Y$OS*\D^-KB9[Y.HB?
M?&_'6,T7+WKRWC_X6:;NN^ K$N[+9$GZ94=@V0%0+V?<I]3\_JO+O=] I._;
MB"S%7Y8&;_>>%G]=^$GK&TMT4#85!<B!VY.$B;A$C!JP2TQZ/L'0IL:D\"^W
MU;\RJ9FR^]# '1SZ\,4OH:V;0U]4&!6OSCF6=#PY '5!V?3!\)8NLP6P($.>
M,EY:;BQ@4N8C)MB*/R^\\4RAP"5YANITIJPLZM8AKCM^.(00LG*5USB68G,
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MB]2E=(;PX[_2(RO5F2CB1^2E_6HR='J<KII?N_]<*?\&>?8OOI(A\,^39&;
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M^>.]G0?,T6L13P3W_MDAY]W_C%VI/@#]PI8>@+;T(!0*89J;&7\(.1S^H@Y
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M(TJ2/JQH&O+M,8,5CV^_X+OS*>[=-[M:YBK;#TPD,1\XBR=;%#)[],_N1P5
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MI&GNAUZA"$Z8E^M\8F533[E92?&'"#FN9/T='-PR^&CR4;;V1E*03#*W].6
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M_3>LT\)^Y(GKND-WL-[,C=0TSC[6]!&,U?[3G5D=V_W*5KE2G_$33@Y]AX%
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MB:^C'6L2%F?=>Z8$>7\7F926V7Y05\WBJ]J\?N6/A%<+@3B*4I]!#_L>1%G
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MBI %/DEQ1GRC),8Q8E-G +2DNY/^*U"WU*] N:$/?LB+_O/3-V;,(=1;^*Z
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M[$B"#4VK/6\<+TT'W14*9HO6& !S?UU',%>^^RBM>?UX';$/?'JME^P6]3I
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M-(:$< $13BG$,4XA]X.,R[^E:6"4$SL1GQ/OCEOTNFH/?18!W6)Z2!9\C;R
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M7QC%)R;C=&+_8B<JJ&I @HIW+;V:$A0#OP"W#,L/&O#"U3,#>V9*=KKYU%/
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MH_R+F8IS +V>LIL74#.UUV&YP]Q0ZNP'Q=^/5T"RJ'88I1>GB/RZ0\>1_G/
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M4QY5!@,6\"C!PI=+6;\ [Q$*$^\':SI#&0^CTKO'$-$XG+M43K.E.%!3O9'
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ME9DO<XR*>GAQ8_QQ\\/\+_B1,^G]T563/_,;(7(JUX/%[<NS TV\)EOZ8,T
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M)$,P"0/,0X)XZ!OU.=8C.[$"ZYFX O<=&^W6CG<8,:V9J06FWC)V#Y'A2<2
MSB];Z.SR,+A,+DMLF@CMK.JF%M&9"W&: '%8F]/H;>N(4UZH.@]%ERBINMS(
M;]"[LFZ^<EK>%VT1@)#$&29I*+?R)()(:@J8!BF%-,%$I'[$#+. M*A.'WU2
M/*A"ZVLF:I4CBCS_A[__V+:G,0ZG:&"I'51QBY!Q:*4%9YM^ZSJIPMVU0]/
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M5R'D^1[G3/.HV1POB2+8*]$!>UW+ SJ!P%HB\/A.9URW3<<[F_ES.G:\IR_
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M[&E(L!^3W/<RK7[B&K2=9X:M28-UGW;P;4U;%Z]<0Z-JB]Z1GO3,@*&*]/-
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M#%CD9=7<H\Q('.*81!1RS!.(6.[!#$<$(A]E49@CW\^(&6#2/BG'IO'+W6=
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MN7P9>=0DOZW4VX W+[B^>/]TIY.B5BIOKT8"Z"UWP;OE??2 :<-\LG+J'?.
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MRV/"L]!> <5$J4['"RF Q8J: .K=1MJ'!>;A-8H$G&0VP>R>I&[@;7*;8$#
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MR%\*6#?A$5F.'<%&ILKOZ%?'M?B9/&,LVGY4?RA-@"YA##_MZ+$-5(#7<C8
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M(CWG/@LOQ;CIF-GNEWR=:W&WK-F7>G7%ZZ>6$Q_(V:L]H&/'TNOAK0L@-EE
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M4KIL\4%T_[VIKAAKG4'?;FDNY,XY"T-Y3L98KN(B("C+*4$I3>.$9H$\/"?
M;)YQB8YG\5K:NA,:.$OG#%YZ,]8J"K#9NQ;MO5L+_YO*(][@<G<&%Y,4&SU;
M[275G)$W=1J-GOE'$F<T'S1.E6%"\.:35%GE9"J*R-MB0.D_%UF:^!$3*(T4
MX;XH D22G,J]/.,%I7(%!R?*C$MTGR;3RO?46_(*N6+7/U!=>751B*5TK9M,
MOK8CXH]EJ1HI>H6 AL_.(ZOG):SB!?,2NU"MA7>=Y+?=-:RFR^B9:B]9YHR\
MJ5-E],P_DBBC^:"9D^CK-ZN'S\H%]9>WS3PKJ!_'/D=!I,)L6<!1GL<QXB*G
M8<HB03'(,QP7X]@=M)3R3Z3DTA4L/=(=@E3\?/',N^*:U7?A/0Z.M/+KOVC7
M3N/(^@D\]?S!Y2C!G,!&GM<*G*V31RS&T<=-LC393PB9=(:/&[H_K<]\&E["
M>,7_>5_?B5IE:'RJ[L6?J_<+M1!I5BB>>-SU7IW_\[E9M3/OOO;N/M[N9#DI
M9IIZ5=4KW0Z8(S",SS]+", FGZ[QWA]*&:_5QE)9WQE;C:KV3HTY65'>&:.&
M-7?G/FHP_51&T_WCPZ_54ZEB;_ )>&H UU-0R?7NRT>U"OSZY>[&VX8. =/N
MI/D:$\^&Y<"I-V*TB^EVSD*S"7=RU.FFW#G#=B;=V0^;=I6L6MZ19[*XI8OR
MH4N**I)(B,POD!\4#.$$!RC+:()$'(8B#4A,4A#'Z5$IKO>O+<O*@UHAEO4K
M6:Q>O7HC>QW?\E:U]_&E7CPW<L5HS[709E)'\=/;L%Z,"FS>#L1Y6WDV>SZ.
MF&.M\>,Q&1-W?QPQ\[ %Y-B'+ZC-H.<3BND!&]N?3V5'-W0GEF7-YS3BN<@R
M>4ZEN8]P3C.4A[&<ZT4L)[K/ IQK=7VRKIECU]!E_+=:*$?0[B))E_$O-IJH
MNRJIBD&!AI5WH^="W@1QF-NQ0<6Y?2EWXR_%K.C")H VZRRLZ#5]:85-.(]6
M4U@58.:$[\F?UTO!RZYA7]$59=RW=UQY$K.,*_J/A*0(4]QVW12(4%4ZZZ<%
M$Z#,GM.B'+M)E27:2?:&HN4>7PD'YO., *;GZNS  /-=I@B W=!YXRSYE1%!
MDSJ*\P;OSWR-)PPB#P\/J[NJJ:[X/YMO+^RZ6<&XR4X][SKN\/"P;#/BY7I8
M->UBNHF'-=XWL7PIF9"K;:-;3#,&A480P@(*P!B$-@"6.;W.F6H6C#@UZ'2Q
MB#-F[80BSGW6H"3QH)W+5]$(.83JD:O(4Y?EIDSJFCR5*[(H_[L[:D>I'[(@
M8TC$48RP+X\O>1 EB.-4\(#Y?IYJ=3ZX3 W'\_WK_R*/3__^T6,[0@&%<N;X
MGIG]DZ$&\P]'.S.MU>H8+G85\ZZGAQ90B#@)Q&;5B,Z@AE4D7HS0:%FB^>C3
MU29>C,!.@>+EH_UL#74&A?1[O0:^"I7:+7\_"-?=B^5C,T]#/\AH'B&?APG"
M22)7ETSD<HE) YQC2C+!?HZ^.@;631" 7\>;Y>.//TL['9/O 2 :][/H_'-'
M]/2:ZPS,/M)<9V.Z-_RJM<;_!*PL+M_I6Y.Y.+'MK\$!X_*U3M=WYQ(E+5,/
MWM6+DKUN<QXXC<,L%3X*Y?D-82QB1"GAR/=]GL<IYCX'74KI"G:\&J[5V*77
MLT0XN(^AWG+E AG82G*&>K#3P_NC_Z_5U!)3$%S3$>Z+_3DX"4^ H4U,>.IY
M>,16><*KUBLM7N](R7_O?%M?6@O.'-,<SOE6>;B+ZM7QE#[>2_-O_=:HUTD_
MHJL+U?D KP.48(X" I"#'#2@_49!8%T9D\6$@48/0\301R\C--JE35EWM)'N
M9[_KS?Z_YQR'U$]"AM(@"1%.18)R%J=RZY$0P84($C_=L![I;SDN5DQK(NU1
M(QFTR!K0V#W6RQ4H]FGO)>AM5J;!U#*MTD$[+?L42Q?C89F'R5R?-R%KNAB^
M4XQ.EP]L&#]EWP5_7HC;HBUP>_]ZO2!-TR5:\-PG02;/4AQ'*JU7+D%YJC+_
MLC )$_D_/BM T<S3LEQG\'4]4UIYJNZLITHR24P9 TPS[&<'!F 0S@@!>/CK
MO&VV@E$CDJ8-#9TW^2!0H_&((9=4694K\;E\$0>.XXM8;3L4$[F1X7Z&XBR4
M&YF08$19PA&-*!5$9#[F(!X*/;&.)[ETI:T::*'TN+2'IR:2>E/>/CZPV=_)
M1ZT"A[N,F:?8>%ST%H;9;8ME2D_HM#Q3(" .F*9@3YNYCL'VH^]'/$_#.,O]
MB"#,,^DF<"(0X4F$,!$Q#OTL)"&?K_3I70]%@%R"*9LKZSMN&]>9'X%&;]Y?
M9C!LCN^<)'II]F;R:4LLS=HC B:=H:<-W)^-(Y^$QR=_;U;5PX?5T9Z4<O<O
M_[QI30E+-04/['AU_ETT+?G!!Y6%J=..507W?^_ZK.YU9M4/:<+1/1_<= HL
M;,I;Q-1RWJLQ2$:Q4+BTR:*BQD ,XZ/F@QCDUN[O,%JN[YMJOVL]H30-19:@
M)(A2>80("")!E*$D3$C 29A'&=;9&P!D.MXLW.P?&&;>@])#,5*N>]H_G.UI
M;PSH&<_C!B:8OSER<OBE0VBCA/>+.X0 ";#VD3++=K6#&"RU%6;[:!ZKYE#3
M):W";-O)4 4^:G:(ZN\H,BZ*A*4^(C$MY'&)Y_*G J.P2,+,%R'%!84<G.!7
M$L:')9-8">AFQO7UBNV;$R?7'V]QAS%^$6'E-N%:::+RP)23_%HV_]65X*F?
MYD($C 6^0#EE!.&DR!'-HABE$2UH$LF)48!N$T9D.3[**!%-NY?^3:JP7)&R
M4H?!]C<[6K4,CUT]J'H&3!5R$DN]F68)(=CTVP5 R9H-,9@F2TO#<GL,(R<E
M3<TS<L[D(VPC9Q^Q?@UQ-4@=4(4A52.^R*_ _0^Q>!&_UM7J>S./HEP$!:4H
M#%7P,<DHRIA</IG(4IK$6<QS$,']9>HX]B;R*Q5;NYK00??B*PO+F%F\RFBY
M/P1KL_X'2LZZ$,=M99&(VPX^[J\\=)3Y6:Y" , !KD@@HYIN>YK5;:&.$,U5
MQ?MR\N9;O>#S0.1QKFA]4UZHBK"((<*B$#$>\]0/\XS@$+;K.27*L9MJB^/E
M?D9%0!JOD0*AVYF3&.GN9FQ8#MW,=$:W4MO]W5JN]VT, 8,-RSGCK.U73@J:
M>+MRSN##W<K9)PS/[/Q%;N++IBUB:5;-?G6$2-(X)'F&,LY4NYTT5,D2N4J(
M*D@6R#_!#BYGY#F>QP/I+>$%]*A_!BS-&( ]"(#!@3WKW1Y#-,VT%5,X(VW:
M8(.>Z0=1",W'?K9B\?:"K;E9L_$541SX,8F13U2Z1,P#1.4V'_& XIR+A.0^
MB--K*L4=^Y[U-:1J\=6V]6J ?;TF>X%Z;NQG?"TP?SA=;79GD;IV=L+)..%;
M^.FKJ??4_A]2*'W\94Q7 WU"OF$G&+G,72T6=<M U@GH$U""(,UX'ON(4=4,
M)J&J&4S*4,&$_'TH1(Q!%"(G)3GV]4HNV@CN_0"PO<M)D/3<LQ738?[TJ-4.
M>C*?-<U6LY>3<J;M]W+.W(.6+V<?,*0EZ)O'W-=73#J,I3A9PCR/64Q"/XM4
M>KWJ]R:G-(WEE"9Y&.69']!<A ;%@OH::'W++ZX*O).__RZ=:5M5\C1D+1"&
MK 7Z$.NY <N(F3$7]#JH!@*]%MX>F\%,D^H!3ED MM\6:8&^X&EI"\" '! 7
MP$>8^,0J=RGJ;H\\B-MBP-[2=:TG?Y:/SX_S(DCR7&XI$"=^(MU4%J*L*%)$
M,S].DB#%/@%=L[E4UG54K*H4&52Y;N?ZM-%(N;7'3H?^S.K56Q6]=]++*<*R
M>JJ3K,Z+=7QZM?RZ)C^QWNV\W($%?55D;\-/<$(%(/W6IU(=5?\:)U$ Z-9.
MGQ"9\"*33Q+#NA)?!5,9_Z\?GL5]_7M9+UKM;HO_J!_%M>K7N7S]3'Y</:YT
M:TR@XSIVXKTZWEH?CS^W'9LV*JGIKI3R>JT\J=9,90H\ZVY2C= <=\>N@02F
M5SC!$%0[8@J&4>D(6-ADE2.F, P+1XS',*@;^:*8?9OO-]6 ^?>#>!&+NMT(
MWU1M=^6FZ5,PFKG@OD@">4!.B2@0QH0C&E",LBC'D0A$P2.MU @CZ8Y=D50'
M,=41N:S04R?96PY)KOE6-]5$2ND$*)@ 8WW&!;E&$.:#-N#=5%MF<*F--U!'
M_:U7R%MKY!) 0.V)2R#-JE"L PHK2#$%9+0T!3SH=$4JIO;NE*L8#V*:PO;X
M6';]4*2@33-,5LKO/LV#. P#'^4,9ZK4#Z,\9@3%A/I!G,K_S4!7$B.RG">Q
M;22W7I@-97OOOJ@.T#GP)#^&G-Y!W!(>,">[#\6.6)N);6=MLY;9=EK2Q*EM
M9TT^S&T[_XC- &)W(]*RBZEC9_DB5."RS[:99S3SPR(3*,-4SO<BRU%6^!G*
MBSS*>!912D'L0 8Z./8#[;GZ2!#)1@QO'-M+0G/6$#./N&TB:8-@F],4N@N0
M<!H1&]?@)PAT:4&D%[_2&\HP^9:QY;/@7]N6VP-^'<I)$JHLVY"P$.$X)HC$
M?H("$@N.J4@%C*'LA!S7UPJ=U+ZCN-ICM$W#O=5WX?TJ^.NJ_M/[)E:K13>3
MKAZ6HOT)FI1[ L08^Q$N1(J*((T0SG"$,B*/V7%<A)&?\H3)C=N+6-)Z0AB'
M\JP ^=@#V6R!)):!U//:%L"!>>8U*AN)#HB?SAAE*W?YA)1I<Y;'33W(53[S
M\4L)63\6A6#*VTJW6S^*>_+G5[)J8WER8[@H6]?<<D9NL^^C'(=QP'.4ACY'
MF,<^RL* H0CSG%(1)4F4FS&VPI5QO87K56O)CM;*>9UVBEG9E-75 '7-/=U$
M6 (W=V=@])1JWJYN/6VLHPV?!9BL4\P:J/)&'+3FH)TFJ;U@3(-[A#NQ+.KE
M(Y&&?Q7-:EFJ<M[VP/9;5:Z:NZ_??NNS0.,@BZ*X*!"/B$"8^ 7*_*Q 210%
M11!)9YCI7R!HBW7LUP9Z>%M%^LR$5A7OG5(&PJ^D#ZG&/8$3H&!.2QNC\YFW
MEX %N!-P IK99<#E7S!8]!]L^FC87W^TZ>+]8 MW OWPI^$)(/=+?K5<JKYL
M9=5^6Q1CI&Z6Q]&''7O!@;26W5(_.^.XJ6?\F@TK82[L?DG:C+-A($W;:% Z
MQ:AA1CD3QT><+#%BU*!A]L/X!PV9;4BY;$E6>VZ)B@_H@/N&1?RVDILC>1J4
M+UA^X$M=+=?_?$^:LOE<5N)F)1Z;.:9^D2<%02(.<X2I/*K1+&(H"8N,9EBD
M@5XW>B?:N<[6VO#5SGINQ/8>:J#PND,7]Q23U%K)]E-#K;U6;>\/I;C7:@YL
MZ6'WG>J=!M_L3<'<U)N\)#@7CPLP;5'S6-5M6J8>%[ >$/<X$6+8 D%('<3M
MDU"4:-7#9U4*L-;F=5WS\>%9*#:I^Q_U/$L3EF$>(7GT)$C=2J!<$()2Q@E)
M2"I/HR!R'Z!\QPY:?I438)\$('YZKM(A*C!GV"DR\S:J>*TNLXT[?)VI5%DJ
MVDZ3/>F8U,AB%P8S*&RU: !*G[9_@QDT!\T=#(<Q=#AU]:#VIQ\$7?U*5L_+
MUNM]%4^]H-OB3CHY5CZ1Q4UU0.17A!GAE&0HB>(8X3#R448"CDCNAS'_O]5=
M2Y/;.)*^[Z_@;=T1PBP?X&L/$U$NEV>]8;L<KNJ=V/!!@6=9/2K)*U+5KOGU
M"Y"41)4D$@F"+,]AIMUN$IGY44@D@,POXR0+! &YGR':C.^,@"R)P[ U=$U3
M(09T5$HMI/7RM&(SKU'M>0P>1"<0N')0@W29UEVY@.W$>3D9U.+,_MU"'US1
M;4TD^_"]+&Z>ULMGY4J_;-9\R\IBQVZ1YS21<88DSU.$292C+)8)XCCT TRX
M"&EL?&1O*G5DU]16PZOUF'D[3;R=*H 3:&,T#4[KQ\ (YHS,X+$YJ3?&"7!0
M/P9>=N?T W]6L$-ZJ-F=9_3&@TUW1 ^U[^B$'ORR73#X53R)U5:\5YK?_%1^
M:$66U]NB7#\JE_3V^6]B_; A/[XOV)4N47^1@I $A&&:ZI1=P1'.HU#M1*5$
M"6-4A8.Y^D"@@\0!NDR8]]%HJ<N]FS(V6(@X!'&S '$B'&$>>0>;GB/>3BUO
MKY>&\Z"95ZDV:LJ' Y <!9!#-)DT?'0 V<O@T<60,,?'Q6)^LRK5QN2*<_5[
M+:[5'V\W]^L_5W-?A#FE>89HC(D*%#.&2.(G* P2[!,:^=3L:*U#QLB.JI;J
M-6)GGA:L8/&T:#,WU85/M_MQ9#7,K5@9;.PL#$SJN,Q4;]?S7_WA,.V[QIQD
M.AL8M9NF)H]:<IKI0D+!"SWS/Q3%5F<BW,KV7G*>A"1F+*2(Z"IM'"82T3 /
M$,T#SF66!$D"HL#N%SEVEE6C0+T&+AH5=$RQU&<GI3X[X=79R4I4#/!\43 =
M8@ 3R@VP-0LDW"(&F]C'8'UH@75\T.20LLS86E=49?T"IZ4H,P;@A)K,_,TA
MEV35P?@)^SN.F!2$A(B*7*W:,DQ1QL(0Q9R2D/$XIV$$OQ [*VMD!U'+M+G^
M.H\,Y*IKL+UVUUJUV''+^0P,='I9=5[2*UQ,=9I\_A*J^Q6[R:OG_X'C^.KG
MHIAS@CEA081"$3*$LY2A+,(,\22((T&B, A :_NIB+'/7Y7 %OVX]TW+!*8
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MPL/;?BN.CVD-GA]*UGJ[J=DE/HGR^YI_J'DD1(MM\NWSZ<.[Q^YU7[%Y%/(
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M%!'+*I<:UJG #$4S_^4,&^#YF!M8;%(Y^\UUE[C9(6OJ-,U^L\\D91J\9.<
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M@VBE [C=G&U]N6E\9L)$0%L'(:A"+H#W&:)E5H6HM,CMF]W=1<FXE;KM@=1
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MI! %_5_2T3??E??3T\"GKY_Y8;GX-B7)_7;ZYZJ.[KAL;/XBK:??SKK,7$@
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M6SO3-[K1&@13=YBL8336I\':*NO?QU!M__,&!NI>:AH9ILO/OP,TT1E1D\=
ME&1 V4"'3[ "@HB)*<X,:MYX]SU 3K-&&7>>LT[8Y+P#D:P&532'$+6'X.J8
M!6:-:=X']B%ZQC4LK3!Q;\.,0S70I^'XA$?5^G[$KXME]>KVN@JZ^1DM+H(>
MI*N1';FYR%4N6-:.9ZVAY$3!OW<.ZMQC\,E*GY)V*;:NT;V/EH.OAFY\[ETP
MUEGIX,A#MPGK+"#T%"4H#]I(:Q(ZKUQKYVT'LD;NXM0"&[<NAAHKHU.;<A)7
M^)\G]$&OO^U[#W3K,UK8E ?I:F53;BQR52>=I4%6"I18RP*CJ$/4F0-=A$,=
M*$QN7MMT'RV'=QB\_KE7X,TYAF0X@M>E;HY4;QERA*Q1B*BL+,W[%]]+S-A=
MX!K@X'8'P1:"[]-J'%((/E8!?"^%\&,5Q%MA'-,B RN*(O2(".3W9A#1B!@E
M#Y&WMFG#%<1O%/"^W%C@].R_6T_ W :KF0!KT!+/3(&K-9(9N9?1%J6:MZ/>
MC;)N"^(?@Y*;%F\ I730E.M:KY.;O+"24O&1@RG,@^*60U2RUJL9&XSP2LG6
MK]$/T3-NTZZ!8-5, 1V Z<\5OB^O5^OI<5CC:L*D5*@<A0YATPHV!*"M4<42
MF:W9*T6W[C9XG8)Q!Z .!)@#A-P!1 CNB61W-N;HXW3U'R^)ANFZ?C7A%I/+
M,@*%E@64#!+H"T9!K63*UXNST/K"] %RQIVD,YRU:2+^#I!T\P;C[N-8(W*6
MA0=F>>U[6&Q]PTE@./<N1UFD;VV#=B)LW.DS Z&KO4HZP-GY8(:;DW)N,!4Y
MSS)I7OT\!<ID!Y%$"<F6X)U6UMG6A3\[$3;N")BAK%ASE72 L]H-=DZ_<FN_
M2)XXJYT$F9,9%$8#Y/AQ,M.L:&V03'/KNIC[:!EW,,M :&HB^ X =-E+::M'
MY=LY">CD^&I[3+@O41E5(%!L04P9.N438X ^12]8D<5C8S3M1-BXDU8&@E9[
ME72 LWM+MF_N'^Z]+R5S<$J20ZD4 V^C!^11:1,]<]C:G]^5MG&''@R$MD$4
MTP'@'FBP=/&C\YUDI.>.M@THAQ0,\Z(I>B%/,Z#$$!(WRK1^+=^9N-TN1=DS
MP]PPNND =&_GFV'UJSJB#8F2ZG"^PF\X6VQMJ4E(R!+F E+%2#&S4> UN0B!
MH_&<FZ1=ZR9L.Q&V&]B>VQ5\>YUT +0'=M#-OY\S*%E0 8LCMCSYI<8K,N11
M$U0B5Q3;9&Q^I_%H(G<#X'.[K!]65QV \:R2_JR _M;+EC$\*\\HBJ:82!EN
M(3K+0&3CK;%16MZZ8.\!<G8#V'.[W&\E_PZ@]$"ISJT;09L=0R$ B8YZ4U/+
M=)#<TTB.JG&>:=?:H.U.W6Y >WX/ 8-HIP/<U3Y!-UD0+A+Q0@(7=8R2J)4<
MBAN((JE"(8^PS4<'W$'&;DAZ;I?^A\J[ \B\62QQ>C1_>4)KSXF/99BO2"RD
MF+HY-G^=;?1T:V]($VK 3*&,R>(LJ/&&Y"C) [42H_'8O"?^OL3N!K_G]A;P
M-+KK *0?*="9G^ ;$FPUUU5P?Y^NO[P\6:T7Q[B\R1VQX'BIPY!2<K0%<Y4I
MDLM0? Z&?J9YZY*<QU&X&QR?VV/"@%KJ H-WQ=WG+;<O;K-YM(*% "9C L58
MS2I6$IAT0DGNC,W-9XS^G*S=T/;<WA=:ZZ,#B'WZ0@+]C>*?O%TX^_[K>?GL
MVTW^RO0;;@IG+ZX6D^$L&MI%0BM0EB(C)T(!P:6Q0GNNL'G5T./)W V"S^W1
M86A]=0#)%_D;+M?3%8GNY6)U.]$@L,QETA$RAMH[O;[D1:? Y1QL2?1WUOI)
M]2<D[98I^]S>&EKJH0-87=;SWN0CTX:PCA7P03!0(4H(@O:(C](@_42Y-%@U
M]5Y >G[O" TDWP&"7H?EG&2S^H#+C1F^R8[RVHD2!>BB*<+)DE$83LZF3%X*
M'TITI?6Y^!.2=L/3<WL6:*F'#F#U!W[?$M1R,:<O$VYEK-SDKUBN1%$"D )J
M4#IH<([853H%'0-/7+=^=G\LC;L![[D]%PRJJ3Z+,^\<AOEY,TOG.N$'#.T\
M_[BA1G?>1>U3#/#,&IE6W@ F4;OO*P6>2U\OO$+()2@TK<NYAAS@^2E]P7PR
MJ[EU%ZN</;U2V+$U[>A<\OG]_".FD^62=LJFE&^CA:V=85R=RYT!F27G4:$&
MKXH&JZ3QG&%FMK5PFC+0\8#0Q^#N5G@YFI([.(@O6=Z!TS_GB[C"Y;?*\-OY
MUY,U_7@Q3_2O-B#8>D;VSAKB![S--2U>)W"8-.C >+!:, RM#^LA^!BW&'0P
MO(^N\EY[A3\PFW;_T__G'SKL5-T!/8''S3_UDN7D"*TRYE3?(0JX0']U*6IM
MC93"M<[M>=+9NE?'R,VU:/D+2FX<%G0ZI!A0 ?,RG$5M4=H"609I#)*3GIK?
M*C^>S.<T9?<Q*+O?$1A&@QT<]Q<L+FJQR'1-1\ WO"76-R?K*M+C6F'Y7QL]
MGS_WW'1U2F4P6! V6>(=.01FD XA@;PD<GABZTO$EO2/>[P_/:R?7.=]1O<W
MACCO?[+?_4'MQTP/>((_-"(X&998K%/N"B)!3B!I6M6164I(87G)KG6[HP&'
M35_9]EW&%]\ ?0H\D1\K0=JZ^XK+X'5PD&-RCA5G;//AK8?0V^_8Z<=@ZO[3
M>6 -]FFV[IWHO+\!^]E'#CF'>DBC]M-IPB2%+#E#2#'7GD<^0_ I0,K%LVBX
M<[YUKNYXTZBW:C)S5"AK;R?<-%N- J*@0#U:97/M/^]*ZV9N/Z>J]\G3C\'*
MSM6R^^FD3\-T.>5Y?T-T\R-:SIX>T-#<,X'8U2Y&T13@.450,2H(P=-717FM
M=?646U]T##.!^NK$_3U0=+ Y5]^7=XOY495N7?/&*>NB$*H4.E:5J%%*X81C
M"HNEXIH[%H61K=N(/);&+F=6/P8Q][M% RBI3XMS<PKOWG;G[@]J/]IZ0!MT
M8\2QMHE[EQA8%+557SU8<AU<;ES- T_>Y/8%E&T'7-.GU=2[&ZB5+DC.I0:;
M11T^P35XP6-M2<]YY,&VSS.ZAY2N1EH_1M^W"T$/%W4'5YIW3>:^" 1/SVWB
MZ0T6T6I3="P@T0E0B<Q?%#(#8]XD[X-EH77G]CW('/>"LBG2AE51G\?4[<&H
M^Y]4]W[6(&.(!SRO;@R>94H6[G* [.J%D"3WQV$=-Y)8L(49R5SGPX@OW:^K
M*H4/X7030GX/R[P1[EFIPJH^NI]MW]7JY/CL>S=M;\G"QTPN&:OA(*^3#0K+
M@":95*1U++?N9]66@Z[&&C\&7??[U4^NV X.U;NXWRZ^V>;^15I/O]TVX,P'
MDYCCM;5A[0 F%+BB#4C&-"JM$V]^VW0XU>,>N0/#=T %/@/(?D02ZS2M\6SK
M_CF?KE>;G7P/^]((ZX+Q=49YC9-CK=$HI;Y52(Q.AV2;MW5NR\*XO>F?$,Q#
MJK9ALEH+;%_,=OV$RV_3A'?+X\5L\Y&U2++4A+VC^?2_Z/3"Y721-V5M6P]C
MJKBBL@<;&2=16 [>6 6:%4%*2B7PYC.LAF)FW';Z@^!]3'7W&55MC=O=/YRZ
M_2%M!P$/&$ ]-/HU2YY5LAX<9Q$42QI"T!:RYCPSD7U03S C=XB$RKK(;U@6
M2[Q:D/Y8K:?IQ3R?-VBY^>9O9!;*)M"\^+-D ^>T YM\H/VG)1>M[T(/)+G?
MH<*/0=9#:95#Z[$K/[3:Z,6\EF-=L$[LGF=UG<]FO_DVH[ET'!D878<QY5#%
M;!U(*^L)HEW[+G4'D#MNL#0\7(?57U=0?75. #%X5^W3S;M9G;.SY-:DY"Q%
MAIY\&ZM"C1%1QI)R&3"T?Q2IXX9 PT-T.+UU!<_7I6 -Y:Y.C8]AC3=JD:[S
MRK41"LFUE=J1I^M%@!B%!,.UCMHP'N)P&'T\O>/&+L,#=6 -=H76/^?+RRB,
M&#T_*E8?%[,9>3CU7N)64GUFSF4#15@)*@8%'F4!.C%$4IEEUKR[S_[4CCM6
M;'BD#JJ]/F/JFT/5#GBGO/N36KQ2[D!CJZGV-Y:Z>@,/GDL;(@@A:BXH!G!(
MYZ>UI'K!T JK6^_3>VAI>%M^8X6W<PK/CC?Z^>WT_(=;G9I]BCQ3]!58G7BF
M0Z8]5A L663GC ^N^:2P/4D=-YAN@J$'[L$'4UH')^E6@]/7M*.7\S"[:&ZZ
M^NWT;[@X6H:O7Z;IQ1+#31<WF.*]RQ9\H;A+25=;44H+&+A%QD6P9L">M(\E
M=]P(>A",/I7R^CQ)7^$J+:>;9]5%^>UD-9WC:O4*UV$ZV^L\??#S&IRJN]/;
MZ&Q]OSP*\_,*TVMSR2EP_;#%Q-8TNT_TG;.N1I< C9DSQSAA,RI-_\F"(*-*
M;6AE=&#!1M_ZU:H)X0>?VB=Q-<W3L#Q]OSQ[;_H=UU\6N<Z77*T1/X7-X5 ?
M0>D8N/7+%[^VV7:3Z&SBEM-&PY) 69'!&6F U5?_6O5B6?,(N2']XY[O3X_C
M6\[ 6%@8T4-8+=>3=]/U].A,[F&%+WY,5Y.4A,$8++A<R+\)SD"0UH+-P?L0
M#8]A)R33QV^AF/YVA>"[5Q[9QQP- 8MFZN@*3)_I7[Q:'(?I?%*2\#Y14!^9
M9+5*)D(P@4%!%VHO11/-3J'>HR!UM?XXP&JASWNAL:=P1P1(=<<F;^=KG,TP
MK4_"[**>\]5T]?5DC:O_@2??,)S\CL<1EQ.,D4=K++#@)"@7"D1N-!A11]%'
ME[+6/_/W'K=D+RC95[6+P>7<031[97BW[/%F7T6*LFCS()@4:MF?<! S[:L@
M@N,R*Z9Y\^Y/]Q$S<B0Z]DG65ED]H.Z*_#_",7VY-;7H?*O:8FC?& Y**^(H
M)00?9"UT#T$E'J7RS?-C?DI5+Q[50>J_":JVNAC[1'RSF,T6W]]3:$-K3^='
M%V;9JL*%D<!9K&6#7H-WUH%V*7+)A),L[G3\W?WY(P.CL0H7;>79@<%Y_PV7
M-1%U,_#QK+#@G!&9O8S6<XA"D3W6VH-G+@*WL0C-LG>A=8W7O<2,?,P-@Z*V
M*N@ 2]6??%]>+$DZ1YL;DXT)=LHRQJR'Z&O/VU0$!)T+%,ZL1NFRL*T'(=Y)
MR+@Y1=VX2H<KJ0.D;9%?4Z?^6,S#U7>V!SV>;Z3:[H=AH<C&5($5X\%A)!Y%
MHJUE63*^=6?K1Y(X[CG9 !0W)S(-J*&Q/:E/I\>!PEM\?5(#WA='2]QP=<Z)
M"]8G9Q$B!@6*VURE1N>!C#&D0DZG3CLY5 \N,RY>!M7N8A!1]P*:/__ZZ:\W
M^1!!.,5R )N]!15* !>- _H()2+&HOUN5U /+#*N"_7D@#E4S!T<<G=&M>^F
M<WR[QN/51)JLB^81;*CU%2HI"-X:,(H'X[@O2@SW#G@71>/FPG;C8#54V]@V
MZ]TTU:*)3R=?O\Y.ZR39:2W8C2<;G5YLKH]X=#*KGW+ZXNO7Y>);F/UQ4K?;
M^_)AN<@G:;V:>&>XC]Z -+7;>GV)H+\RVGA9)\N\$3<+W.ZQ;XT(ZO"V:D^
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M<VC.JOVB*TJC 6_"Q@\5X+U$0!]28L%%E#NE./ZD\O%RP9'?T ?1Y>)0P?:
MAHLZA"!2MHI#R+5077HD5Z%.XY&>*17KQ+B=;.HN>!B[K'%/9=U4]QZ2&UGA
MOT_GT^.3XW/"F2M,.^N!"11 KG^"Z*0#[W@V"3/?<?3!3U1^;=&1E;Z/RA8M
MY#>VXL./+<+)!24N!9)I$ZK6'%%8P#0'G9T6!84G,]="\=N+CI./TDSQ>\NO
M@SN<-X3:-;ZKUP!OZWCNHVD=I[[I(_O;Z>_A_RR6+V=AM=H81"%D*K*.?C.\
M=HS-&KSU&4A2TD3C9=&MLT0?0=[(24U#.A%#*ZMO'%XQ5BOFSHODHF;2IY#
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MA[+/U[LA[B23);TK8P1!]?7 @??E[DO!9J4+^<>7TPDFL0CF<Y8@"DE1:</
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M^\*8L+"O\N:M)3D".]*VPE=$K[2,IN;*!:B M>?")F#&><F*#S;W]JAQM/:
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M8@)O72';E;9A.\8&0-Q.RAA!7^R3?/TQR]M7;LR__I7HKV[+Z!RR9'()D(3
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M@I!8](F<X*!E:YSUP<? TU[WA]7=E-W0.AX!SF_%;I>7. \ZI%J>I1FQH+P
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M[>=G]S8.[P@0VE?V(\#1S1D8V[&1-X_%V]F-F1@3Y"05E!Z,J;N0A*0SPKD
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M.64-"JT&1T$<.&T=6FE22/&YT&:W3XZ\X?A8L.M13R.PA W>/GC*//N2P;-
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M@HHL0>0Z@N$R"ZD3XW=7=C8)'F\1,88*C(,4.V\IY1' Y)X%OG[R\C8'YI4
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M!!1:T1(;J1B-W;IY/-69VM13-.O8=>G$4&80:BSK4@(S[Q[FWA^>SS>\+0>
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M85UT7C:+-:EQ[OO[?R63Z_^1.!^0W_06??T7X3]*SNU__\?_ 5!+ P04
M" #ZA&1:_L=QN>X?  "*]   "@   &5X,3 S."YH=&WM7>M3&T>V_W[_BKY.
M-H$J,='HB6S'53+(&[(87$"<O9^V6C,MU/%H1CL/L/+7WW-.=\]+(R0P:&2;
MK:P!:::?Y]V_<_KU-)YY;UY/!7??_,_K_STX8,>!D\R$'S,G%#P6+DLBZ5^S
M/UT1?6('!_JIHV"^".7U-&:M9JO+_@S"3_*&J^]C&7OBC6GG]2_J[]>_4">O
MQX&[>//:E3=,NK^^D#W'&4R<]J#7<7C';O5XU^TWVZV).QYT6DZ[_Q_[!;P*
MCZMWHGCAB5]?S*1_,!78_\M>SQKTYO&K6^G&TY=VL_F/%X5'8_$Y/N">O/9?
MTH#AVTG@QS"0$!I6OZKVEWJ9<]>%N1]X8A*_M&W;.FQ!1^93:BW[.->/ ],6
MH>[(-.8$7A"^_*%)_WN%WQQ,^$QZBY<_#T/)O9\;$?>C@TB$<J*^CN3? B8$
M;=.?MVJ^?7C;D[XP\[=;S7^HSEWA!"&/9>"_3'Q7A/C4BS>7HZ/SLV,V?#\Z
M.X;_7[&K<W8Z&EZ.BI.G?U8LS*HEZ=AFWA+Z\^.7!VW8B2W.^\6;$\L,=6MK
M75B"=M/JT)P_#"^N3D:7; AK?3R\&EGW6MZG&7ZG<LFNIC)BET KOLN&P*$N
M<7L<L%/!(\'V?OKAL-5JOMKVNKYXDP[F*;NN7A.:L_UJG[DD\LZ=.!B+D-F]
M!LJW3H.-%XS#>HU%?"N$S[:_.-U6DYV-_OQP?G'%CH"-1Q?L^.+DXXB=GAYM
M?[T:C+-CX?%;'@KFR9G$5?,D'TM/Q@OF!+,Y]Q<UTM(I[!:T[]9'2@TBF.W/
M?/3Q_/2/RP8[.3MZ4MFX 6& .IIKC50C*5P)G]<I4^ZG"796T=:M:5M]JS?
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M01+&X(#$4S;Q A! \!)^_C85$K6*Y-%G,/LC-/<N<2:U&M\NTHY:'!Y)AUW
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M+.PFT(C';_6^BO_"(!86._?O.NO.H'5J(CG26L,NM$@<7M:#PP?Q(_6G$T1
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M=W\)_\LX<!?P8QK/O#?_#U!+ P04    " #ZA&1:@D#T*MI$   H"@( "
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M! %&U%*'6#@K,8_@(@?Q*@3#MHTL.QQCQ7L8.ZX /P:V9<H4_,3^<G3KC$2
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MY.8JH5O57J77/:)(_O#\>G@VN#)5SZ<7GR\_#?OGIP/GXN/'X2E\]?Q,>.U
MOJ]&Y^:'/D(CL.%H3NR&$E]7$9]&69A(*E'%CS7IK$[-US0V:@\!6W5PK2CJ
MN*/^\C&;Z16WE,1=Z65L7HP;#""N$%"UM<7\RO,WG.SM/[3.Y:4<K?H3T%Y'
MJ^_-0/8D:(Y2>J^&)P L^5D48@, _!3_E&BKNJKV7^\/:DR N*\Y_Z[$,DE]
M!SRLMU_UV.WOKZ:!$>NRR5QZ&Q>7NXM>27#R5.*6RPS]$(W.*J5!_;*CIGG
MNCV0XFY[1.N/Z)DF#5.G#_QG, ;H^&&U%/7,T)4-@7"_HN\X1U)L#SR^C ZM
M:LL<Y<YKWCJ@-L:RQAFM S%L5_O!JWU)?.DL6^=&$]>?3T:"DD<YCWV,GNC
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MJ@J:UQ6QKA^[V0R)!=R\ZY4>1M?9P=758U0E]C.T24&IS%7N4E"#>NJI13M
M7=ZQD:T^:=C\';J[))RK1JWZL3::FB:$:!'0@X6C<$<I%GJ-N*7 ^-$$IFB9
M87M2GZN%J7J86-NKDT7$?H6DYL-6^I$-"U]47]0\[;B[W_H(:=DD)-9+*IW
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M>.Y)($,[JK/=>"W9>/7RLA+M53)RQVHA:HL<WDWE[9/L-@I>Q4/:L*=1W,E
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M4_)69V]1C@]H.FHJ/7):VI+6JK!Z),8!T"F0L3[&" \8OA9$RMFQ2K;OI[M
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MJ\EN.LAVRV+5". ZW<LG"V[=WR[//PU^$&2S_0EZH?=HRO,SHOW B/:,:37
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M5M9O%>BK:]I(SJJ4!C'US+KP5=W]_P502P,$%     @ ^H1D6J/))I/0!
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M_A.A1:F$)I!*DX!F$6.;2#O"!$TN0F<@Z<UAFHHPS3&Z16PP773#VX=F\[5
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MUN==^ !9J;!/=]GZOF?YZ2^E'KC+L/\#4$L#!!0    ( /J$9%JFGMEK(0@
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M,#(T,3(S,5]P<F4N>&UL4$L! A0#%     @ ^H1D6O['<;GN'P  BO0   H
M             ( !C%0( &5X,3 S."YH=&U02P$"% ,4    " #ZA&1:@D#T
M*MI$   H"@( "               @ &B= @ 97@Q.2YH=&U02P$"% ,4
M" #ZA&1:'GMYB]@?  !MXP  #P              @ &BN0@ 97AH:6)I=#$P
M,3<N:'1M4$L! A0#%     @ ^H1D6FVS>/$W P  !!@  !<
M ( !I]D( &5X:&EB:70R,3$Q,C,Q,C0Q,&LN:'1M4$L! A0#%     @ ^H1D
M6J/))I/0!   -"   !<              ( !$]T( &5X:&EB:70R,S$Q,C,Q
M,C0Q,&LN:'1M4$L! A0#%     @ ^H1D6GWE[#10"   $RL  !<
M     ( !&.(( &5X:&EB:70S,3$Q,C,Q,C0Q,&LN:'1M4$L! A0#%     @
M^H1D6J:>V6LA"   PB@  !<              ( !G>H( &5X:&EB:70S,3(Q
M,C,Q,C0Q,&LN:'1M4$L! A0#%     @ ^H1D6D,KVJ\P!0  R!P  !<
M         ( !\_(( &5X:&EB:70S,C$Q,C,Q,C0Q,&LN:'1M4$L%!@     0
- !  $@0  %CX"     $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>eols-20241231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:eols="http://www.evolus.com/20241231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="eols-20241231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseEuropeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseU.S.AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseU.S.AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-09</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseU.S.AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-09</startDate>
            <endDate>2023-05-09</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseU.S.AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseU.S.AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseEuropeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-20</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseU.S.AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-20</startDate>
            <endDate>2023-12-20</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseEuropeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-20</startDate>
            <endDate>2023-12-20</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eols:DistributionRightsEvolysseNasolabialFoldProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseEuropeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eols:DistributionRightsEvolysseNasolabialFoldProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseEuropeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-20</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseEuropeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-20</startDate>
            <endDate>2023-12-20</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eols:DistributionRightsEvolysseNasolabialFoldProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseEuropeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseEuropeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseEuropeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseEuropeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseEuropeAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="eols:MilestoneAxis">eols:FirstMilestonePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseEuropeAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="eols:MilestoneAxis">eols:SecondMilestonePaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:SCHAEONLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-14</startDate>
            <endDate>2017-12-14</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eols:PerformanceRestrictedStockUnitsPRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eols:DistributionRightsEvolysseProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseEuropeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eols:ContingentRoyaltyObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eols:ContingentRoyaltyObligationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">eols:DistributionRightsEvolysseNasolabialFoldProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">eols:SymateseEuropeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eols:MarketingFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">eols:MarketingFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-14</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-14</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-05</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-05</startDate>
            <endDate>2022-12-05</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-05</startDate>
            <endDate>2022-12-05</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-09</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <startDate>2023-05-09</startDate>
            <endDate>2023-05-09</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="eols:DebtInstrumentPrepaymentTermsAxis">eols:TermOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-31</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="eols:DebtInstrumentPrepaymentTermsAxis">eols:TermTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-15</startDate>
            <endDate>2023-12-15</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-09</startDate>
            <endDate>2023-05-09</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-05</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">eols:LondonInterbankOfferedRateLIBOR1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-05</startDate>
            <endDate>2022-12-05</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">eols:SecuredFinancingOfferedRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-09</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">eols:SecuredFinancingOfferedRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-09</startDate>
            <endDate>2023-05-09</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-09</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="eols:DebtInstrumentPrepaymentTermsAxis">eols:TermOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-09</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="eols:DebtInstrumentPrepaymentTermsAxis">eols:TermTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-09</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="eols:DebtInstrumentPrepaymentTermsAxis">eols:TermThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-09</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:PharmakonTermLoansTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <instant>2019-03-15</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <instant>2023-07-27</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <instant>2024-08-01</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <instant>2024-10-16</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <startDate>2020-10-16</startDate>
            <endDate>2020-10-28</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <startDate>2021-11-17</startDate>
            <endDate>2021-11-17</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <startDate>2020-11-27</startDate>
            <endDate>2020-12-02</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eols:A2024EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-06</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eols:A2024EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-06</startDate>
            <endDate>2024-06-06</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eols:A2024EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-08</startDate>
            <endDate>2023-03-08</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-08</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:ATMSalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <instant>2017-11-21</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <startDate>2017-11-21</startDate>
            <endDate>2017-11-21</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <instant>2024-11-21</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <instant>2023-11-21</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <instant>2022-11-21</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eols:A2023InducementIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eols:A2023InducementIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eols:PerformanceRestrictedStockUnitsPRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eols:PerformanceRestrictedStockUnitsPRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eols:PerformanceRestrictedStockUnitsPRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eols:PerformanceRestrictedStockUnitsPRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eols:PerformanceRestrictedStockUnitsPRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eols:CEOPerformanceRestrictedShareUnitsCPRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eols:TwoThousandAndSeventeenOmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-08</startDate>
            <endDate>2023-05-08</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eols:CEOPerformanceRestrictedShareUnitsCPRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eols:TwoThousandAndSeventeenOmnibusIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-08</startDate>
            <endDate>2023-05-08</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eols:CEOPerformanceRestrictedShareUnitsCPRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">eols:TwoThousandAndSeventeenOmnibusIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-08</startDate>
            <endDate>2023-05-08</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <startDate>2021-02-18</startDate>
            <endDate>2021-02-18</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-18</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">eols:IntellectualPropertyDisputesJeuveauMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-18</startDate>
            <endDate>2021-02-18</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-18</startDate>
            <endDate>2021-02-18</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <instant>2021-02-18</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">eols:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">eols:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">eols:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001570562</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="product">
        <measure>eols:product</measure>
    </unit>
    <unit id="reporting_unit">
        <measure>eols:reporting_unit</measure>
    </unit>
    <unit id="productcandidate">
        <measure>eols:productCandidate</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="country">
        <measure>eols:country</measure>
    </unit>
    <unit id="milestonepayment">
        <measure>eols:milestonePayment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>eols:segment</measure>
    </unit>
    <unit id="tranche">
        <measure>eols:tranche</measure>
    </unit>
    <unit id="installment">
        <measure>eols:installment</measure>
    </unit>
    <unit id="payment">
        <measure>eols:payment</measure>
    </unit>
    <unit id="complaint">
        <measure>eols:complaint</measure>
    </unit>
    <unit id="officer">
        <measure>eols:officer</measure>
    </unit>
    <unit id="plaintiff">
        <measure>eols:plaintiff</measure>
    </unit>
    <unit id="trading_day">
        <measure>eols:trading_day</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-32">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-33">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-34">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-35">0001570562</dei:EntityCentralIndexKey>
    <us-gaap:TypeOfCostGoodOrServiceExtensibleList contextRef="c-12" id="f-141">http://fasb.org/us-gaap/2024#ProductMember</us-gaap:TypeOfCostGoodOrServiceExtensibleList>
    <us-gaap:TypeOfCostGoodOrServiceExtensibleList contextRef="c-13" id="f-142">http://fasb.org/us-gaap/2024#ProductMember</us-gaap:TypeOfCostGoodOrServiceExtensibleList>
    <us-gaap:TypeOfCostGoodOrServiceExtensibleList contextRef="c-1" id="f-143">http://fasb.org/us-gaap/2024#ProductMember</us-gaap:TypeOfCostGoodOrServiceExtensibleList>
    <eols:AccountsReceivableCreditCardTransactionConvertedToCashPeriod contextRef="c-49" id="f-398">P2D</eols:AccountsReceivableCreditCardTransactionConvertedToCashPeriod>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-51" id="f-403">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:NumberOfReportableSegments contextRef="c-1" decimals="0" id="f-508" unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments contextRef="c-1" decimals="0" id="f-509" unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-85" id="f-510">P14Y2M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:DebtInstrumentTerm contextRef="c-116" id="f-623">P6Y</us-gaap:DebtInstrumentTerm>
    <eols:DebtInstrumentPeriodicPaymentOutstandingPrincipalAmountDuePercentage contextRef="c-121" decimals="4" id="f-651" unitRef="number">0.0833</eols:DebtInstrumentPeriodicPaymentOutstandingPrincipalAmountDuePercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-152" id="f-739">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-159" id="f-786">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-1056"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-38381</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">EVOLUS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">46-1385614</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">520 Newport Center Dr., Suite 1200</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Newport Beach</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">92660</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">949</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">284-4555</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, $0.00001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">EOLS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-19">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-20">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-23">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-24">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-25">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-26">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-27">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-28">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="-5" id="f-29" unitRef="usd">671400000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-30" unitRef="shares">63586753</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-31">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Portions of the registrant's definitive proxy statement (the &#x201c;Proxy Statement&#x201d;) for its 2024 Annual Meeting of Stockholders are incorporated by reference into Part III, Items 10, 11, 12, 13 and 14 of this Annual Report on Form 10-K. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant's fiscal year ended December 31, 2024.&lt;/span&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c-1" id="f-36">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cybersecurity risk management process is designed to identify and manage internal and external cybersecurity threats and vulnerabilities to and within our business and operations. Our cybersecurity program is integrated into our overall risk management systems, business continuity and crisis management programs, third-party risk management program, insurance risk management program, and employee compliance programs. Our cybersecurity program includes systems and processes such as, but not limited to, maintenance and monitoring of information security policies, implementation and maintenance of infrastructure security systems, programs and policies designed to promote employee awareness of cyber policies and practices (including implementing an annual process for employees to complete security awareness training in addition to new employee cybersecurity awareness training), information systems configuration management, use of third-party risk management systems, process to promote identity and information asset protection and cybersecurity threat operations with continuous monitoring. This program also includes processes to oversee and identify material risks from cybersecurity threats associated with our use of third-party service providers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have developed an incident response plan designed to coordinate the activities that we and our third-party security service providers take to prepare to respond and recover from cybersecurity incidents, which include processes to triage, assess severity, investigate, escalate, contain, and remediate an incident, as well as to comply with potentially applicable legal obligations and mitigate any reputational damage. Additionally, as part of our overall risk management program, we maintain a global insurance portfolio with cybersecurity coverage.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="c-1" id="f-37">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="c-1" id="f-38">Our cybersecurity program is integrated into our overall risk management systems, business continuity and crisis management programs, third-party risk management program, insurance risk management program, and employee compliance programs. Our cybersecurity program includes systems and processes such as, but not limited to, maintenance and monitoring of information security policies, implementation and maintenance of infrastructure security systems, programs and policies designed to promote employee awareness of cyber policies and practices (including implementing an annual process for employees to complete security awareness training in addition to new employee cybersecurity awareness training), information systems configuration management, use of third-party risk management systems, process to promote identity and information asset protection and cybersecurity threat operations with continuous monitoring. This program also includes processes to oversee and identify material risks from cybersecurity threats associated with our use of third-party service providers.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="c-1" id="f-39">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="c-1" id="f-40">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c-1" id="f-41">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="c-1" id="f-43">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cybersecurity team is led by the SVP of IT and Operations, who reports to our Chief Financial Officer. Our SVP of IT and Operations and the cybersecurity team have over 25 years of experience managing and securing technology infrastructure. The cybersecurity team has responsibility for the planning and execution of our processes to manage cybersecurity and other information technology risks. The cybersecurity team also institutes and maintains controls for our systems, applications, and databases. Our management, with involvement and input from our Board of Directors, performs annual enterprise-wide cybersecurity assessments to identify and manage key existing and emerging risks for our company.&lt;/span&gt;&lt;/div&gt;The Board of Directors receives periodic updates on our cybersecurity risks from our SVP of IT and Operations, which include risk assessments, areas of emerging risks, incidents and industry trends, and other areas of importance. These reports include updates on our progress preparing for, preventing, detecting, responding to and recovering from material cyber incidents, if any. In addition, as needed, management updates the Board of Directors regarding any material cybersecurity incidents.</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-42">Our cybersecurity team is led by the SVP of IT and Operations, who reports to our Chief Financial Officer.</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="c-1" id="f-44">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="c-1" id="f-45">Our SVP of IT and Operations and the cybersecurity team have over 25 years of experience managing and securing technology infrastructure.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-46">The cybersecurity team has responsibility for the planning and execution of our processes to manage cybersecurity and other information technology risks. The cybersecurity team also institutes and maintains controls for our systems, applications, and databases. Our management, with involvement and input from our Board of Directors, performs annual enterprise-wide cybersecurity assessments to identify and manage key existing and emerging risks for our company.</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-48">Our management, with involvement and input from our Board of Directors, performs annual enterprise-wide cybersecurity assessments to identify and manage key existing and emerging risks for our company.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c-1" id="f-47">Our management, with involvement and input from our Board of Directors, performs annual enterprise-wide cybersecurity assessments to identify and manage key existing and emerging risks for our company.</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-49">The Board of Directors receives periodic updates on our cybersecurity risks from our SVP of IT and Operations, which include risk assessments, areas of emerging risks, incidents and industry trends, and other areas of importance. These reports include updates on our progress preparing for, preventing, detecting, responding to and recovering from material cyber incidents, if any. In addition, as needed, management updates the Board of Directors regarding any material cybersecurity incidents.</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="c-1" id="f-50">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <dei:AuditorFirmId contextRef="c-1" id="f-51">42</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-52">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-53">Irvine, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-54" unitRef="usd">86952000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-3" id="f-55" unitRef="usd">62838000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-3" id="f-56" unitRef="usd">47682000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-5" decimals="-3" id="f-57" unitRef="usd">30529000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-4" decimals="-3" id="f-58" unitRef="usd">12158000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-5" decimals="-3" id="f-59" unitRef="usd">10998000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-4" decimals="-3" id="f-60" unitRef="usd">3349000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-5" decimals="-3" id="f-61" unitRef="usd">5700000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-62" unitRef="usd">1201000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-63" unitRef="usd">2356000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-64" unitRef="usd">151342000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-5" decimals="-3" id="f-65" unitRef="usd">112421000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-66" unitRef="usd">3222000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-67" unitRef="usd">2087000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-68" unitRef="usd">7185000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-69" unitRef="usd">5763000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-4" decimals="-3" id="f-70" unitRef="usd">48754000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-5" decimals="-3" id="f-71" unitRef="usd">47110000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill contextRef="c-4" decimals="-3" id="f-72" unitRef="usd">21208000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-5" decimals="-3" id="f-73" unitRef="usd">21208000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-74" unitRef="usd">858000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-5" decimals="-3" id="f-75" unitRef="usd">409000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-76" unitRef="usd">232569000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-5" decimals="-3" id="f-77" unitRef="usd">188998000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-78" unitRef="usd">9236000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-5" decimals="-3" id="f-79" unitRef="usd">4271000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-80" unitRef="usd">40791000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-81" unitRef="usd">33813000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-82" unitRef="usd">1718000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-83" unitRef="usd">1377000</us-gaap:OperatingLeaseLiabilityCurrent>
    <eols:ContingentRoyaltyObligationPayabletoRelatedPartyCurrent contextRef="c-4" decimals="-3" id="f-84" unitRef="usd">11215000</eols:ContingentRoyaltyObligationPayabletoRelatedPartyCurrent>
    <eols:ContingentRoyaltyObligationPayabletoRelatedPartyCurrent contextRef="c-5" decimals="-3" id="f-85" unitRef="usd">8830000</eols:ContingentRoyaltyObligationPayabletoRelatedPartyCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-86" unitRef="usd">62960000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-87" unitRef="usd">48291000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-88" unitRef="usd">6755000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-89" unitRef="usd">4810000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractualObligation contextRef="c-4" decimals="-3" id="f-90" unitRef="usd">33550000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation contextRef="c-5" decimals="-3" id="f-91" unitRef="usd">36200000</us-gaap:ContractualObligation>
    <us-gaap:SecuredLongTermDebt contextRef="c-4" decimals="-3" id="f-92" unitRef="usd">121506000</us-gaap:SecuredLongTermDebt>
    <us-gaap:SecuredLongTermDebt contextRef="c-5" decimals="-3" id="f-93" unitRef="usd">120359000</us-gaap:SecuredLongTermDebt>
    <eols:LicenseSupplyAndDistributionAgreementContingentMilestoneLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-94" unitRef="usd">2270000</eols:LicenseSupplyAndDistributionAgreementContingentMilestoneLiabilityNoncurrent>
    <eols:LicenseSupplyAndDistributionAgreementContingentMilestoneLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-95" unitRef="usd">0</eols:LicenseSupplyAndDistributionAgreementContingentMilestoneLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-4" decimals="-3" id="f-96" unitRef="usd">6000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-5" decimals="-3" id="f-97" unitRef="usd">27000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-98" unitRef="usd">227047000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-5" decimals="-3" id="f-99" unitRef="usd">209687000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-100" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-5" id="f-101" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-102"
      unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-103"
      unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-104" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-105" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-106" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-107" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-5" decimals="INF" id="f-108" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="INF" id="f-109" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-3" id="f-110" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-5" decimals="-3" id="f-111" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-112"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-113"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-114" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-115" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-116" unitRef="shares">63497548</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-117" unitRef="shares">63497548</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-5" decimals="INF" id="f-118" unitRef="shares">57820621</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-5" decimals="INF" id="f-119" unitRef="shares">57820621</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-120" unitRef="usd">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-5" decimals="-3" id="f-121" unitRef="usd">1000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-3" id="f-122" unitRef="usd">615825000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-5" decimals="-3" id="f-123" unitRef="usd">538716000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-124" unitRef="usd">-905000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="-3" id="f-125" unitRef="usd">-427000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-126" unitRef="usd">-609399000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-3" id="f-127" unitRef="usd">-558979000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-128" unitRef="usd">5522000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-129" unitRef="usd">-20689000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-130" unitRef="usd">232569000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-5" decimals="-3" id="f-131" unitRef="usd">188998000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-132" unitRef="usd">264306000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-3" id="f-133" unitRef="usd">199721000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-8" decimals="-3" id="f-134" unitRef="usd">146592000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-9" decimals="-3" id="f-135" unitRef="usd">1968000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-10" decimals="-3" id="f-136" unitRef="usd">2364000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-11" decimals="-3" id="f-137" unitRef="usd">2024000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-138" unitRef="usd">266274000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-12" decimals="-3" id="f-139" unitRef="usd">202085000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-13" decimals="-3" id="f-140" unitRef="usd">148616000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-3" id="f-144" unitRef="usd">83970000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-12" decimals="-3" id="f-145" unitRef="usd">64514000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-13" decimals="-3" id="f-146" unitRef="usd">58842000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c-1" decimals="-3" id="f-147" unitRef="usd">182304000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-12" decimals="-3" id="f-148" unitRef="usd">137571000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-13" decimals="-3" id="f-149" unitRef="usd">89774000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-150" unitRef="usd">198025000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-12" decimals="-3" id="f-151" unitRef="usd">164944000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-13" decimals="-3" id="f-152" unitRef="usd">141840000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-1" decimals="-3" id="f-153" unitRef="usd">9172000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-12" decimals="-3" id="f-154" unitRef="usd">6556000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-13" decimals="-3" id="f-155" unitRef="usd">4742000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <eols:ResearchAndDevelopmentInProcess1 contextRef="c-1" decimals="-3" id="f-156" unitRef="usd">0</eols:ResearchAndDevelopmentInProcess1>
    <eols:ResearchAndDevelopmentInProcess1 contextRef="c-12" decimals="-3" id="f-157" unitRef="usd">8869000</eols:ResearchAndDevelopmentInProcess1>
    <eols:ResearchAndDevelopmentInProcess1 contextRef="c-13" decimals="-3" id="f-158" unitRef="usd">2000000</eols:ResearchAndDevelopmentInProcess1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-1" decimals="-3" id="f-159" unitRef="usd">-7176000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-12" decimals="-3" id="f-160" unitRef="usd">-4257000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-13" decimals="-3" id="f-161" unitRef="usd">-5755000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization contextRef="c-1" decimals="-3" id="f-162" unitRef="usd">2342000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization contextRef="c-12" decimals="-3" id="f-163" unitRef="usd">2178000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization contextRef="c-13" decimals="-3" id="f-164" unitRef="usd">767000</us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization>
    <us-gaap:CostsAndExpenses contextRef="c-1" decimals="-3" id="f-165" unitRef="usd">216715000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-12" decimals="-3" id="f-166" unitRef="usd">186804000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-13" decimals="-3" id="f-167" unitRef="usd">155104000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-168" unitRef="usd">-34411000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-12" decimals="-3" id="f-169" unitRef="usd">-49233000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-13" decimals="-3" id="f-170" unitRef="usd">-65330000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet contextRef="c-1" decimals="-3" id="f-171" unitRef="usd">3263000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-12" decimals="-3" id="f-172" unitRef="usd">860000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-13" decimals="-3" id="f-173" unitRef="usd">119000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="-3" id="f-174" unitRef="usd">18735000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-12" decimals="-3" id="f-175" unitRef="usd">13832000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-13" decimals="-3" id="f-176" unitRef="usd">9097000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-177" unitRef="usd">127000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-12" decimals="-3" id="f-178" unitRef="usd">696000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-13" decimals="-3" id="f-179" unitRef="usd">-9000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-180" unitRef="usd">-49756000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-12" decimals="-3" id="f-181" unitRef="usd">-61509000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-13" decimals="-3" id="f-182" unitRef="usd">-74317000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-183" unitRef="usd">664000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-184" unitRef="usd">176000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-185" unitRef="usd">95000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-186" unitRef="usd">-50420000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-3" id="f-187" unitRef="usd">-61685000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-188" unitRef="usd">-74412000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-3" id="f-189" unitRef="usd">-478000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-12" decimals="-3" id="f-190" unitRef="usd">-90000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-13" decimals="-3" id="f-191" unitRef="usd">-337000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-192" unitRef="usd">-50898000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-12" decimals="-3" id="f-193" unitRef="usd">-61775000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-13" decimals="-3" id="f-194" unitRef="usd">-74749000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-195"
      unitRef="usdPerShare">-0.81</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-196"
      unitRef="usdPerShare">-0.81</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-12"
      decimals="2"
      id="f-197"
      unitRef="usdPerShare">-1.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-12"
      decimals="2"
      id="f-198"
      unitRef="usdPerShare">-1.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-13"
      decimals="2"
      id="f-199"
      unitRef="usdPerShare">-1.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-13"
      decimals="2"
      id="f-200"
      unitRef="usdPerShare">-1.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-201" unitRef="shares">62016853</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-202" unitRef="shares">62016853</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-12" decimals="0" id="f-203" unitRef="shares">56918721</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-12" decimals="0" id="f-204" unitRef="shares">56918721</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-13" decimals="0" id="f-205" unitRef="shares">56065297</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-13" decimals="0" id="f-206" unitRef="shares">56065297</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-14"
      decimals="INF"
      id="f-207"
      unitRef="shares">55576988</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-14" decimals="-3" id="f-208" unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-15" decimals="-3" id="f-209" unitRef="usd">504757000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-3" id="f-210" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-211" unitRef="usd">-422882000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-212" unitRef="usd">81876000</us-gaap:StockholdersEquity>
    <eols:StockIssuedDuringPeriodSharesIncentiveEquityPlan
      contextRef="c-19"
      decimals="INF"
      id="f-213"
      unitRef="shares">683582</eols:StockIssuedDuringPeriodSharesIncentiveEquityPlan>
    <eols:StockIssuedDuringPeriodValueIncentiveEquityPlan contextRef="c-20" decimals="-3" id="f-214" unitRef="usd">539000</eols:StockIssuedDuringPeriodValueIncentiveEquityPlan>
    <eols:StockIssuedDuringPeriodValueIncentiveEquityPlan contextRef="c-13" decimals="-3" id="f-215" unitRef="usd">539000</eols:StockIssuedDuringPeriodValueIncentiveEquityPlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-20" decimals="-3" id="f-216" unitRef="usd">10833000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-13" decimals="-3" id="f-217" unitRef="usd">10833000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-218" unitRef="usd">-74412000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-219" unitRef="usd">-74412000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-21" decimals="-3" id="f-220" unitRef="usd">-337000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-13" decimals="-3" id="f-221" unitRef="usd">-337000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-22"
      decimals="INF"
      id="f-222"
      unitRef="shares">56260570</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-223" unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-224" unitRef="usd">516129000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-225" unitRef="usd">-337000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-226" unitRef="usd">-497294000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-227" unitRef="usd">18499000</us-gaap:StockholdersEquity>
    <eols:StockIssuedDuringPeriodSharesIncentiveEquityPlan
      contextRef="c-27"
      decimals="INF"
      id="f-228"
      unitRef="shares">950051</eols:StockIssuedDuringPeriodSharesIncentiveEquityPlan>
    <eols:StockIssuedDuringPeriodValueIncentiveEquityPlan contextRef="c-28" decimals="-3" id="f-229" unitRef="usd">224000</eols:StockIssuedDuringPeriodValueIncentiveEquityPlan>
    <eols:StockIssuedDuringPeriodValueIncentiveEquityPlan contextRef="c-12" decimals="-3" id="f-230" unitRef="usd">224000</eols:StockIssuedDuringPeriodValueIncentiveEquityPlan>
    <eols:StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement
      contextRef="c-27"
      decimals="INF"
      id="f-231"
      unitRef="shares">610000</eols:StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement>
    <eols:StockIssuedDuringPeriodValueIssuedForLicenseSupplyAndDistributionAgreement contextRef="c-28" decimals="-3" id="f-232" unitRef="usd">5905000</eols:StockIssuedDuringPeriodValueIssuedForLicenseSupplyAndDistributionAgreement>
    <eols:StockIssuedDuringPeriodValueIssuedForLicenseSupplyAndDistributionAgreement contextRef="c-12" decimals="-3" id="f-233" unitRef="usd">5905000</eols:StockIssuedDuringPeriodValueIssuedForLicenseSupplyAndDistributionAgreement>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-28" decimals="-3" id="f-234" unitRef="usd">16458000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-12" decimals="-3" id="f-235" unitRef="usd">16458000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-29" decimals="-3" id="f-236" unitRef="usd">-61685000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-3" id="f-237" unitRef="usd">-61685000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-30" decimals="-3" id="f-238" unitRef="usd">-90000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-12" decimals="-3" id="f-239" unitRef="usd">-90000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-31"
      decimals="INF"
      id="f-240"
      unitRef="shares">57820621</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-241" unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-3" id="f-242" unitRef="usd">538716000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-3" id="f-243" unitRef="usd">-427000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-3" id="f-244" unitRef="usd">-558979000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-245" unitRef="usd">-20689000</us-gaap:StockholdersEquity>
    <eols:StockIssuedDuringPeriodSharesIncentiveEquityPlan
      contextRef="c-35"
      decimals="INF"
      id="f-246"
      unitRef="shares">1804827</eols:StockIssuedDuringPeriodSharesIncentiveEquityPlan>
    <eols:StockIssuedDuringPeriodValueIncentiveEquityPlan contextRef="c-36" decimals="-3" id="f-247" unitRef="usd">3892000</eols:StockIssuedDuringPeriodValueIncentiveEquityPlan>
    <eols:StockIssuedDuringPeriodValueIncentiveEquityPlan contextRef="c-1" decimals="-3" id="f-248" unitRef="usd">3892000</eols:StockIssuedDuringPeriodValueIncentiveEquityPlan>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-35"
      decimals="INF"
      id="f-249"
      unitRef="shares">3872100</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-36" decimals="-3" id="f-250" unitRef="usd">50963000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-1" decimals="-3" id="f-251" unitRef="usd">50963000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-36" decimals="-3" id="f-252" unitRef="usd">22254000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-253" unitRef="usd">22254000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-37" decimals="-3" id="f-254" unitRef="usd">-50420000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-255" unitRef="usd">-50420000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-38" decimals="-3" id="f-256" unitRef="usd">-478000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-257" unitRef="usd">-478000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-39"
      decimals="INF"
      id="f-258"
      unitRef="shares">63497548</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-39" decimals="-3" id="f-259" unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-40" decimals="-3" id="f-260" unitRef="usd">615825000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-41" decimals="-3" id="f-261" unitRef="usd">-905000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-42" decimals="-3" id="f-262" unitRef="usd">-609399000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-263" unitRef="usd">5522000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-264" unitRef="usd">-50420000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-3" id="f-265" unitRef="usd">-61685000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-266" unitRef="usd">-74412000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-267" unitRef="usd">5297000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-12" decimals="-3" id="f-268" unitRef="usd">5133000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-13" decimals="-3" id="f-269" unitRef="usd">3722000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-270" unitRef="usd">22254000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-12" decimals="-3" id="f-271" unitRef="usd">16458000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-13" decimals="-3" id="f-272" unitRef="usd">10833000</us-gaap:ShareBasedCompensation>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-1" decimals="-3" id="f-273" unitRef="usd">2449000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-12" decimals="-3" id="f-274" unitRef="usd">1440000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-13" decimals="-3" id="f-275" unitRef="usd">1598000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-3" id="f-276" unitRef="usd">723000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-12" decimals="-3" id="f-277" unitRef="usd">734000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-13" decimals="-3" id="f-278" unitRef="usd">775000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-1" decimals="-3" id="f-279" unitRef="usd">1147000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-12" decimals="-3" id="f-280" unitRef="usd">1116000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-13" decimals="-3" id="f-281" unitRef="usd">1086000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-282" unitRef="usd">-21000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-283" unitRef="usd">5000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-284" unitRef="usd">-18000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-1" decimals="-3" id="f-285" unitRef="usd">7176000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-12" decimals="-3" id="f-286" unitRef="usd">4257000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-13" decimals="-3" id="f-287" unitRef="usd">5755000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <eols:NonCashInResearchAndDevelopmentInProcessExpenses contextRef="c-1" decimals="-3" id="f-288" unitRef="usd">0</eols:NonCashInResearchAndDevelopmentInProcessExpenses>
    <eols:NonCashInResearchAndDevelopmentInProcessExpenses contextRef="c-12" decimals="-3" id="f-289" unitRef="usd">4429000</eols:NonCashInResearchAndDevelopmentInProcessExpenses>
    <eols:NonCashInResearchAndDevelopmentInProcessExpenses contextRef="c-13" decimals="-3" id="f-290" unitRef="usd">0</eols:NonCashInResearchAndDevelopmentInProcessExpenses>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-3" id="f-291" unitRef="usd">-3252000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-12" decimals="-3" id="f-292" unitRef="usd">-4193000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-13" decimals="-3" id="f-293" unitRef="usd">10688000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-294" unitRef="usd">19602000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-12" decimals="-3" id="f-295" unitRef="usd">9521000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-13" decimals="-3" id="f-296" unitRef="usd">9389000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-1" decimals="-3" id="f-297" unitRef="usd">-2351000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-12" decimals="-3" id="f-298" unitRef="usd">1798000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-13" decimals="-3" id="f-299" unitRef="usd">-1180000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c-1" decimals="-3" id="f-300" unitRef="usd">-706000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c-12" decimals="-3" id="f-301" unitRef="usd">864000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="c-13" decimals="-3" id="f-302" unitRef="usd">-4854000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-303" unitRef="usd">391000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-12" decimals="-3" id="f-304" unitRef="usd">-1017000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-13" decimals="-3" id="f-305" unitRef="usd">968000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-306" unitRef="usd">7014000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-12" decimals="-3" id="f-307" unitRef="usd">9019000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-13" decimals="-3" id="f-308" unitRef="usd">-5199000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:PaymentsForLegalSettlements contextRef="c-1" decimals="-3" id="f-309" unitRef="usd">0</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:PaymentsForLegalSettlements contextRef="c-12" decimals="-3" id="f-310" unitRef="usd">5000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:PaymentsForLegalSettlements contextRef="c-13" decimals="-3" id="f-311" unitRef="usd">15000000</us-gaap:PaymentsForLegalSettlements>
    <eols:IncreaseDecreaseInOperatingLeaseLiabilities contextRef="c-1" decimals="-3" id="f-312" unitRef="usd">-716000</eols:IncreaseDecreaseInOperatingLeaseLiabilities>
    <eols:IncreaseDecreaseInOperatingLeaseLiabilities contextRef="c-12" decimals="-3" id="f-313" unitRef="usd">-907000</eols:IncreaseDecreaseInOperatingLeaseLiabilities>
    <eols:IncreaseDecreaseInOperatingLeaseLiabilities contextRef="c-13" decimals="-3" id="f-314" unitRef="usd">-977000</eols:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-315" unitRef="usd">-17999000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-12" decimals="-3" id="f-316" unitRef="usd">-34008000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-13" decimals="-3" id="f-317" unitRef="usd">-84912000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-318" unitRef="usd">1472000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-12" decimals="-3" id="f-319" unitRef="usd">473000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-13" decimals="-3" id="f-320" unitRef="usd">1618000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForSoftware contextRef="c-1" decimals="-3" id="f-321" unitRef="usd">3351000</us-gaap:PaymentsForSoftware>
    <us-gaap:PaymentsForSoftware contextRef="c-12" decimals="-3" id="f-322" unitRef="usd">1154000</us-gaap:PaymentsForSoftware>
    <us-gaap:PaymentsForSoftware contextRef="c-13" decimals="-3" id="f-323" unitRef="usd">1321000</us-gaap:PaymentsForSoftware>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-324" unitRef="usd">-4823000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-12" decimals="-3" id="f-325" unitRef="usd">-1627000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-13" decimals="-3" id="f-326" unitRef="usd">-2939000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <eols:PaymentsOfContingentRoyaltyObligation contextRef="c-1" decimals="-3" id="f-327" unitRef="usd">7441000</eols:PaymentsOfContingentRoyaltyObligation>
    <eols:PaymentsOfContingentRoyaltyObligation contextRef="c-12" decimals="-3" id="f-328" unitRef="usd">5537000</eols:PaymentsOfContingentRoyaltyObligation>
    <eols:PaymentsOfContingentRoyaltyObligation contextRef="c-13" decimals="-3" id="f-329" unitRef="usd">4185000</eols:PaymentsOfContingentRoyaltyObligation>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-1" decimals="-3" id="f-330" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-12" decimals="-3" id="f-331" unitRef="usd">50000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-13" decimals="-3" id="f-332" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-1" decimals="-3" id="f-333" unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-12" decimals="-3" id="f-334" unitRef="usd">46000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-13" decimals="-3" id="f-335" unitRef="usd">500000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-336" unitRef="usd">51211000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-12" decimals="-3" id="f-337" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-13" decimals="-3" id="f-338" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-1" decimals="-3" id="f-339" unitRef="usd">248000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-12" decimals="-3" id="f-340" unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-13" decimals="-3" id="f-341" unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-342" unitRef="usd">4882000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-12" decimals="-3" id="f-343" unitRef="usd">231000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-13" decimals="-3" id="f-344" unitRef="usd">539000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-345" unitRef="usd">990000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-12" decimals="-3" id="f-346" unitRef="usd">7000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-13" decimals="-3" id="f-347" unitRef="usd">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-348" unitRef="usd">47414000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-12" decimals="-3" id="f-349" unitRef="usd">44641000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-13" decimals="-3" id="f-350" unitRef="usd">-4146000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-3" id="f-351" unitRef="usd">-478000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-12" decimals="-3" id="f-352" unitRef="usd">-90000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-13" decimals="-3" id="f-353" unitRef="usd">-337000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-354" unitRef="usd">24114000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-12" decimals="-3" id="f-355" unitRef="usd">8916000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-13" decimals="-3" id="f-356" unitRef="usd">-92334000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-357" unitRef="usd">62838000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-26" decimals="-3" id="f-358" unitRef="usd">53922000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-18" decimals="-3" id="f-359" unitRef="usd">146256000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-360" unitRef="usd">86952000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-361" unitRef="usd">62838000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-26" decimals="-3" id="f-362" unitRef="usd">53922000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-363" unitRef="usd">17545000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-12" decimals="-3" id="f-364" unitRef="usd">12708000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-13" decimals="-3" id="f-365" unitRef="usd">7999000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="-3" id="f-366" unitRef="usd">235000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-12" decimals="-3" id="f-367" unitRef="usd">117000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-13" decimals="-3" id="f-368" unitRef="usd">76000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-369" unitRef="usd">3002000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-12" decimals="-3" id="f-370" unitRef="usd">4550000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-13" decimals="-3" id="f-371" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:StockIssued1 contextRef="c-1" decimals="-3" id="f-372" unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="c-12" decimals="-3" id="f-373" unitRef="usd">1476000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="c-13" decimals="-3" id="f-374" unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-375">Description of Business &lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Evolus, Inc., (&#x201c;Evolus&#x201d; or the &#x201c;Company&#x201d;) is a global performance beauty company focused on delivering products in the cash-pay aesthetic market. The Company received the approval of its first product Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (prabotulinumtoxinA-xvfs) from the U.S. Food and Drug Administration (the &#x201c;FDA&#x201d;) in February 2019. The product was also approved by Health Canada in August 2018, the European Commission (&#x201c;EC&#x201d;) in September 2019, the Australian Therapeutics Good Administration (&#x201c;TGA&#x201d;) in January 2023, and Swissmedic in November 2023. Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is a proprietary 900 kDa purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as &#x201c;frown lines,&#x201d; in adults. The Company commercially launched Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States in May 2019, in Canada through a distribution partner in October 2019, and began its launch in Europe in September 2022. In 2023, the Company entered into an agreement to be the exclusive distributor of Evolysse&#x2122;, a collection of hyaluronic acid gels currently in late-stage development in the U.S. and Europe. Regulatory approval has been received for the four Evolysse&#x2122; hyaluronic acid gel products in Europe under the brand name Estyme&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company anticipates launching all four approved Evolysse&#x2122; products in Europe in the second half of 2025. In February 2025, the Company received approval from the U.S. Food and Drug Administration (the &#x201c;FDA&#x201d;) for Evolysse&#x2122; Form and Evolysse&#x2122; Smooth injectable hyaluronic acid gels for wrinkles and folds, such as nasolabial folds. The Company anticipates launching Evolysse&#x2122; Form and Evolysse&#x2122; Smooth in the United States in the second quarter of 2025. The Company anticipates two additional Evolysse&#x2122; products to be approved and launched in the United States in 2026 and 2027. The Company currently generates all of its net revenues from Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company is headquartered in Newport Beach, California.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity and Financial Condition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared on a basis that assumes that the Company will continue as a going concern. This basis of accounting contemplates the recovery of the Company&#x2019;s assets and the satisfaction of the Company&#x2019;s liabilities and commitments in the normal course of business and does not include any adjustments to reflect the possible future effects of the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since inception, the Company has incurred recurring net operating losses and negative cash flows from operating activities; however, management anticipates achieving operating income and positive cash flows based on current projections for at least the next twelve months. The Company recorded loss from operations of $34,411 and a total net loss of $50,420 for the twelve months ended December 31, 2024. The Company used cash of $17,999 from operations during the twelve months ended December 31, 2024. As of December&#160;31, 2024, the Company had $86,952 in cash and cash equivalents and an accumulated deficit of $609,399. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2024, the Company completed a follow-on offering and issued 3,554,000 shares of its common stock, at a price to the public of $14.07 per share. The Company received net proceeds of $46,794 from the offering, after deducting underwriting discounts and commissions and other offering expenses. In addition, the Company granted the underwriters an option, exercisable for 30 days, to purchase up to 533,100 additional shares of common stock (the &#x201c;option shares&#x201d;) at the purchase price. In April 2024, the underwriters exercised their option to purchase 318,100 of the allotted option shares. The net proceeds to the Company from the sale of the option shares, after deducting the underwriters&#x2019; discounts and commissions, was $4,169.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 8, 2023, the Company entered into an &#x201c;at-the-market&#x201d; sales agreement (the &#x201c;ATM Sales Agreement&#x201d;) and filed a shelf registration statement on Form S-3 and corresponding prospectus with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) to permit sales under the ATM Sales Agreement, which registration statement became effective on June 8, 2023. The Company has not sold any shares under the ATM Sales Agreement. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 10.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that its current capital resources, which consist of cash and cash equivalents, will be sufficient to fund its operations through at least the next twelve months from the date the accompanying consolidated financial statements are issued based on its expected cash needs. The Company may need to raise additional capital to fund future operations or execute corporate development activities through entering into licensing or collaboration agreements with partners, grants or other sources of financing. Sufficient funds may not be available to the Company at all or on attractive terms when needed from equity or debt financings. If the Company is unable to obtain additional funding from these or other sources when needed, or to the extent needed, it may be necessary to reduce its scope of operations to reduce the current rate of spending through actions such as reductions in staff and delaying, scaling back, or suspending certain research and development, sales and marketing programs and other operational goals.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <eols:LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts
      contextRef="c-43"
      decimals="INF"
      id="f-376"
      unitRef="product">4</eols:LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts>
    <eols:LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts
      contextRef="c-43"
      decimals="INF"
      id="f-377"
      unitRef="product">4</eols:LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts>
    <eols:LicenseSupplyAndDistributionAgreementExpectedRegulatoryApprovalNumberOfProducts contextRef="c-44" decimals="0" id="f-378" unitRef="product">2</eols:LicenseSupplyAndDistributionAgreementExpectedRegulatoryApprovalNumberOfProducts>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-379" unitRef="usd">-34411000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-380" unitRef="usd">-50420000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-381" unitRef="usd">-17999000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-382" unitRef="usd">86952000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-383" unitRef="usd">-609399000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-45"
      decimals="INF"
      id="f-384"
      unitRef="shares">3554000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-46"
      decimals="2"
      id="f-385"
      unitRef="usdPerShare">14.07</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-45" decimals="-3" id="f-386" unitRef="usd">46794000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <eols:SaleOfStockGrantedOptionsExercisablePeriod contextRef="c-47" id="f-387">P30D</eols:SaleOfStockGrantedOptionsExercisablePeriod>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-47"
      decimals="INF"
      id="f-388"
      unitRef="shares">533100</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-48"
      decimals="INF"
      id="f-389"
      unitRef="shares">318100</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-48" decimals="-3" id="f-390" unitRef="usd">4169000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-391">Basis of Presentation and Summary of Significant Accounting Policies &lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s consolidated financial statements include the Company&#x2019;s accounts and those of the Company&#x2019;s wholly owned subsidiaries and have been prepared in conformity with GAAP. All intercompany transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management is required to make certain estimates and assumptions in order to prepare consolidated financial statements in conformity with GAAP. Such estimates and assumptions affect the reported consolidated financial statements. These estimates include, but are not limited to net revenues, allowance for doubtful accounts, fair value measurements and stock-based compensation, among others. Management bases estimates on historical experience and on assumptions that management believes are reasonable. The Company&#x2019;s actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is party to an agreement (the &#x201c;Daewoong Agreement&#x201d;) with Daewoong Pharmaceutical Co. Ltd. (&#x201c;Daewoong&#x201d;), pursuant to which the Company received an exclusive distribution license to Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; from Daewoong for aesthetic indications in the United States, European Union, United Kingdom, members of the European Economic Area, Switzerland, Canada, Australia, New Zealand, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;is manufactured by Daewoong in a facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) in a territory covered by the Daewoong Agreement. The Company relies on Daewoong, its exclusive and sole supplier, to manufacture Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company&#x2019;s commercialization of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 9. Commitments and Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company commercially launched Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;starting in the United States in May 2019 and in Canada through its distribution partner in October 2019. The Company also began commercially launching Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in Europe in 2022 and Australia in 2024 and, as such, has a limited history of sales in those markets. If any previously granted approval to market and sell Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is retracted or the Company is denied approval or approval is delayed by regulators in any other jurisdictions, it may have a material adverse impact on the Company&#x2019;s business and its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also subject to risks common to companies in the pharmaceutical industry including, but not limited to, dependency on the commercial success of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and Evolysse&#x2122; the Company&#x2019;s approved products, significant competition within the medical aesthetics industry, its ability to maintain regulatory approval of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, third party litigation and challenges to its intellectual property, uncertainty of broad adoption of its product by aesthetic practitioners and patients, its ability to in-license, acquire or develop additional product candidates and to obtain the necessary approvals for those product candidates, and the need to scale manufacturing capabilities over time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Any disruption and volatility in the global capital markets, including caused by other events, such as public health crises, increased inflation and rising interest rates, increased tariffs, and geopolitical conflicts, including the military conflict between Russia and Ukraine and the ongoing conflict in the Middle East, may increase the Company&#x2019;s cost of capital and adversely affect its ability to access financing when and on terms that the Company desires. Any of these events could have a material adverse effect on the Company&#x2019;s business, financial condition, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has determined that it operates in a single operating and reportable segment. The Company&#x2019;s chief operating decision maker is its Chief Executive Officer who manages operations and reviews the financial information as a single operating segment for the purposes of allocating resources and evaluating its financial performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and accounts receivable. Substantially all of the Company&#x2019;s cash is held by financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. To date, the Company has not experienced any losses associated with this credit risk and continues to believe that this exposure is not significant. The Company invests, or plans to soon invest, its excess cash, in line with its investment policy, primarily in money market funds and debt instruments of U.S. government agencies. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounts receivable is derived from customers located principally in the United States and Europe. Concentrations of credit risk with respect to trade receivables are limited due to the Company&#x2019;s credit evaluation process. The Company does not typically require collateral from its customers. The Company continuously monitors customer payments and maintains an allowance for credit losses based on its assessment of various factors including historical experience, age of the receivable balances, and other current economic conditions or other factors that may affect customers&#x2019; ability to pay.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of cash and highly liquid investments with remaining maturities at purchase of three months or less that can be liquidated without prior notice or penalty. Cash and cash equivalents may include deposits, money market funds and debt securities. Amounts receivable from credit card issuers are typically converted to cash within &lt;span style="-sec-ix-hidden:f-398"&gt;two&lt;/span&gt; to four days of the original sales transaction and are considered to be cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories and cost of goods sold&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consist of finished goods held for sale and distribution. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost is determined using the first-in, first-out method. Inventory is measured at the lower of cost and net realizable value based on a number of factors including, but not limited to, damage, expiration, or changes in price level.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December 31, 2024, cost of goods sold, consisted of the inventory cost, amortization of distribution right intangible assets related to Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and certain royalties on the sale of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; payable to Medytox and Allergan pursuant to the Medytox Settlement Agreements (as such term is defined in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 11. Medytox Settlement Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). The prior years Consolidated Statements of Operations and Comprehensive Loss has been adjusted to conform to this presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in an orderly transaction between market participants in a principal market on the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy defines a three-tiered valuation hierarchy for disclosure of fair value measurement is classified and disclosed by the Company in one of the three categories as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1&#x2014;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2&#x2014;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets; quoted prices in markets that are not active; or other inputs that are observable, either directly or indirectly, or can be corroborated by observable market data for substantially the full term of the asset or liability; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3&#x2014;Prices or valuation techniques that require inputs that are unobservable that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of approximately &lt;span style="-sec-ix-hidden:f-403"&gt;three&lt;/span&gt; to five years. Leasehold improvements are amortized over the shorter of the estimated useful lives of the improvements or the term of the related lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. The Company assesses goodwill for impairment annually and whenever events or changes in circumstances indicate that the carrying amount of goodwill may not be recoverable. The Company performs an annual qualitative assessment of its goodwill in the fourth quarter of each calendar year to determine if any events or circumstances exist, such as an adverse change in business climate or a decline in the overall industry demand, that would indicate that it would more likely than not reduce the fair value of a reporting unit below its carrying amount, including goodwill. If events or circumstances do not indicate that the fair value of a reporting unit is below its carrying amount, then goodwill is not considered to be impaired and no further testing is required. For the purpose of impairment testing, the Company has determined that it has one reporting unit. There was no impairment of goodwill for any of the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;In-process Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets acquired that are used for research and development, do not yet have regulatory approval for commercialization, and have no future alternative use are expensed as in-process research and development.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, the Company entered into a License and Research Collaboration Agreement (the &#x201c;Collaboration Agreement&#x201d;) with a 3D printing company with biomaterial capabilities (the &#x201c;Licensor&#x201d;). Under the terms of the Collaboration Agreement, the Company was granted a license to the Licensor&#x2019;s technology to develop and commercialize any aesthetic product or non-therapeutic product that is created through the use or practice of the Licensor&#x2019;s patents. The Company paid $2,000 upon the signing of the Collaboration Agreement and has research funding, ongoing milestone and royalty payment obligations depending on the development plans, the success of such development and approval and commercialization of products. The upfront payment of $2,000 was recorded as in-process research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Symatese U.S. Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 9, 2023, the Company and Symatese Aesthetics S.A.S (&#x201c;Symatese&#x201d;), entered into a License, Supply and Distribution Agreement (the &#x201c;Symatese U.S. Agreement&#x201d;), pursuant to which Symatese granted to the Company an exclusive right to commercialize and distribute its five hyaluronic acid gel product candidates, including the products referred to as: (i) Form; (ii) Smooth; (iii) Sculpt; (iv) Lips; and (v) Eye (collectively, the &#x201c;Products&#x201d;) in the United States for use in the aesthetics and dermatological field of use. The Company also has the right of first negotiation to obtain a license from Symatese to commercialize and distribute any new products developed using the same technology as the Evolysse&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#x2122;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; collection of hyaluronic acid gels.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As consideration for the rights granted under the Symatese U.S. Agreement, the Company is required to make up to &#x20ac;16,200 in milestone payments to Symatese, including an initial payment of &#x20ac;4,100 within 30 days of execution of the Symatese U.S. Agreement, and additional annual payments of &#x20ac;1,600 in June 2025, &#x20ac;4,100 in June 2026, &#x20ac;3,200 in June 2027, and &#x20ac;3,200 in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June 2028, in each case subject to three of the Products gaining approval prior to that date. In June 2023, the Company paid $4,441 as an upfront payment upon the signing of the Symatese U.S. Agreement and has developmental costs, ongoing milestone and royalty payment obligations. The Symatese U.S. Agreement is also subject to minimum purchase requirements and failure to meet such requirements may result in a reduction or termination of the Company&#x2019;s exclusive rights, subject to certain exceptions. Additionally, the Company agreed to a specified cost-sharing agreement with Symatese related to the registration of the Lips and Eye Products with the FDA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The initial term of the Symatese U.S. Agreement is fifteen (15) years from the first FDA approval of a Product, with automatic renewals for successive five (5)-year terms subject to the terms of the Symatese U.S. Agreement. The upfront payment of $4,441 was recorded as in-process research and development expense in the twelve months ended December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Symatese Europe Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 20, 2023, the Company entered into a License, Supply and Distribution Agreement (the &#x201c;Symatese Europe Agreement&#x201d;), pursuant to which Symatese granted to us an exclusive right to commercialize and distribute four hyaluronic acid gel product candidates, which are referred to as: (i) Form; (ii) Smooth; (iii) Sculpt and (iv) Lips in 50 countries in Europe for use in the aesthetics and dermatological fields. The initial agreement is for a term of fifteen (15) years, with automatic year renewal provisions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In exchange for the rights granted under the Symatese Europe Agreement, the Company issued 610,000 shares of common stock and is required to pay two milestone payments: (i) &#x20ac;1,200 on the second anniversary of certain regulatory approvals, and (ii) &#x20ac;1,900 on the earlier of the third anniversary of certain regulatory approvals or following a year in which the Company achieves &#x20ac;25,000 in revenue in Europe; provided that the payment shall occur no later than December 2029. The Symatese Europe Agreement is also subject to minimum purchase requirements and failure to meet such requirements may result in a reduction or termination of the Company&#x2019;s exclusive rights, subject to certain exceptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon signing of the Symatese Europe Agreement and issuance of 610,000 shares, the Company recorded $4,429 in in-process research and development expense and $1,476 in intangible assets in the twelve months ended December&#160;31, 2023 for the stock issuance of 610,000 shares. The intangible assets of $1,476 represents the value of the nasolabial fold product in Europe which was already approved at the time of signing the Symatese Europe Agreement and is amortized over its estimated useful life of 15 years. The remaining value recorded in in-process research and development expense relates to the distribution rights for the three remaining products that did not yet have regulatory approval as of the execution date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The distribution right intangible asset related to Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is amortized over the period the asset is expected to contribute to the future cash flows of the Company. The Company determined the pattern of this intangible asset&#x2019;s future cash flows could not be readily determined with a high level of precision. As a result, the distribution right intangible asset is being amortized on a straight-line basis over the estimated useful life of&#160;20 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A portion of the Symatese Europe Agreement represents the license and distribution right to Evolysse&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in Europe. The definite-lived distribution right intangible asset related to the Evolysse&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; nasolabial fold product approved in Europe is amortized on a straight-line basis over the estimated useful life of 15 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Symatese Europe Agreement, the Company is required to pay two milestone payments: (i) &#x20ac;1,200 on the second anniversary of certain regulatory approvals, and (ii) &#x20ac;1,900 on the earlier of the third anniversary of certain regulatory approvals or following a year in which the Company achieves &#x20ac;25,000 in revenue in Europe, provided that the payment shall occur no later than December 2029.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2024, the Company received European Union Medical Device Regulation (&#x201c;MDR&#x201d;) approval for the remaining three hyaluronic acid gel products. As a result, the two milestone payments have been triggered. The first milestone payment is payable in October 2026, the two-year anniversary of the approval. For the second milestone payment, the Company determined that it is probable the payment will be made no later than December 2029. As such, the Company recorded $1,035 and $1,200 in long-term liabilities for the first and second milestone payments, and $1,035 and $1,200 in intangible assets for the first and second milestone payments as of December&#160;31, 2024. These amounts reflect the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;application of a discount to account for the time value of money, which adjusts the present value of the liabilities and intangible assets based on the timing of future payments. The definite-lived distribution right intangible asset related to the Evolysse&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; products approved in Europe is amortized on a straight-line basis over the remaining estimated useful life of 14 years and 2 months. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes certain internal-use software costs associated with the development of its mobile and web-based customer platforms. These costs include personnel expenses and external costs that are directly associated with the software projects. These costs are included as intangible assets in the accompanying consolidated balance sheets. The capitalized internal-use software costs are amortized on a straight-line basis over the estimated useful life of&#160;two years&#160;upon being placed in service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews long-term and identifiable definite-lived intangible assets or asset groups for impairment when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset or an asset group, further impairment analysis is performed. An impairment loss is measured as the amount by which the carrying amount of the asset or asset groups exceeds the fair value for assets to be held and used or fair value less cost to sell for assets to be disposed of. The Company also reviews the useful lives of its assets periodically to determine whether events and circumstances warrant a revision to the remaining useful life. Changes in the useful life are adjusted prospectively by revising the remaining period over which the asset is amortized. There was no material impairment of long-lived assets for any periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, upon lease commencement, the Company records a lease liability which represents the Company&#x2019;s obligation to make lease payments arising from the lease, and a corresponding right-of-use (&#x201c;ROU&#x201d;) asset which represents the Company&#x2019;s right to use an underlying asset during the lease term. Operating lease assets and liabilities are included in ROU assets, current portion of operating lease liabilities and noncurrent operating lease liabilities in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease ROU assets and lease liabilities are initially recognized based on the present value of the future minimum lease payments over the lease term at commencement date calculated using the Company&#x2019;s incremental borrowing rate applicable to the underlying asset unless the implicit rate is readily determinable. The incremental borrowing rate, the ROU asset and the lease liability are reevaluated upon a lease modification. Operating lease ROU assets also include any lease payments made at or before lease commencement and exclude any lease incentives received, if any. The Company determines the lease term as the noncancellable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. The Company&#x2019;s leases do not contain any residual value guarantees. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets. For operating leases, the Company recognized rent expense on a straight-line basis over the lease term. There were no significant finance leases as of&#160;December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Royalty Obligation Payable to Evolus Founders&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company was acquired by Strathspey Crown Holdings Group, LLC (&#x201c;SCH&#x201d;) in 2013 and subsequently by its subsidiary, Alphaeon Corporation (&#x201c;Alphaeon&#x201d;), by means of a stock purchase agreement (&#x201c;Stock Purchase Agreement&#x201d;) pursuant to which Alphaeon assumed certain payment obligations related to the acquisition. On December 14, 2017, the Stock Purchase Agreement was amended (&#x201c;Amended Stock Purchase Agreement&#x201d;), and, as a result, effective upon the closing of the Company&#x2019;s initial public offering in February 2018, the Company assumed all of Alphaeon&#x2019;s payment obligations under the Amended Stock Purchase Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payment obligations to the Evolus Founders consist of quarterly royalty payments of a low single digit percentage of net sales of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The obligations terminate in the second quarter of 2029, which is the&#160;10-year anniversary of the first commercial sale of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;in the United States. Under the Amended Stock Purchase Agreement, the Company recorded the fair value of all revised payment obligations owed to the Evolus Founders. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the fair value of the contingent royalty obligation payable at each reporting period end based on Level 3 inputs using a discounted cash flows method. Changes in the fair value of the contingent royalty obligation payable are determined at each reporting period end and recorded in operating expenses in the accompanying consolidated statements of operations and comprehensive loss and as a liability in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-Term Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt represents the debt balance with Pharmakon (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7. Term Loans&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), net of discount and issuance costs. Debt issuance costs represent legal, lender and consulting costs or fees associated with debt financing. Debt&#160;discounts and issuance costs are amortized into interest expense over the term of the debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial statements of foreign subsidiaries are measured using the local currency as the functional currency. Assets and liabilities are translated into U.S. dollars at current exchange rates as of balance sheet date, and income and expense items are translated into U.S. dollars using the average rates of exchange prevailing during the period. Gains and losses arising from translation are recorded in other comprehensive loss as a separate component of stockholders&#x2019; equity. Foreign currency gains or losses on transactions denominated in a currency other than the Company&#x2019;s functional currency are recorded in other expenses, net in the accompanying consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when control of the promised goods or services is transferred to its customers, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for the goods or services. In order to achieve that core principle, a five-step approach is applied: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue allocated to each performance obligation when the Company satisfies the performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account for revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;General&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generates product revenue from the sale of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States, Europe, and Australia, and service revenue from the sale of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; through a distribution partner in Canada.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For product revenue, the Company recognizes revenue when control of the promised goods under a contract is transferred to a customer, in an amount that reflects the consideration the Company expects to receive in exchange for those goods as specified in the customer contract. The transfer of control occurs upon receipt of the goods by the customer since that is when the customer has obtained control of the goods&#x2019; economic benefits. The Company does not provide any service-type warranties and does not accept product returns except under limited circumstances such as damages in transit or ineffective product. The Company also excludes any amounts related to taxes assessed by governmental authorities from revenue measurement. Shipping and handling costs associated with outbound product freight are accounted for as fulfillment costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and are included in selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For service revenue, the Company evaluated the arrangement with the distribution partner in Canada and determined that it acts as an agent in the distribution of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in Canada as it does not control the product before control is transferred to a customer. The indicators of which party exercises control include primary responsibility over performance obligations, inventory risk before the good or service is transferred and discretion in establishing the price. Accordingly, the Company records the sale as service revenue on a net basis. Revenue from services is recognized in the period the service is performed for the amount of consideration expected to be received.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s disaggregation of revenue is consistent with its operating segment as disclosed above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gross-to-Net Revenue Adjustments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides customers with discounts, such as trade and volume discounts and prompt pay discounts, that are directly reflected in the invoice price. Revenues are recorded net of sales-related adjustments, wherever applicable, primarily for the volume based rebates, consumer loyalty programs and co-branded marketing programs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Volume-Based Rebates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Volume-based rebates are contractually offered to certain customers. The rebates payable to each customer are determined based on the contract and quarterly purchase volumes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Consumer Loyalty Program&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; The Company&#x2019;s consumer loyalty program allows participating customers to earn rewards for qualifying treatments to their patients (i.e. consumers) using Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and redeem the rewards for Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the future at no additional cost. The loyalty program represents a customer option that provides a material right and, accordingly, is a performance obligation. At the time Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; product is sold to customers, the invoice price is allocated between the product sold and the estimated material right reward (&#x201c;Reward&#x201d;) that the customer might redeem in the future. The standalone selling price of the Reward is measured based on estimated average selling price of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; at the time of redemption and the expected redemption rate by customers based on historical sales data. The portion of invoice price allocated to the Reward is initially recorded as deferred revenue. Subsequently, when customers redeem the Reward and the related product is delivered, the deferred revenue is recognized in net revenues at that time. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Co-Branded Marketing Programs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; The Company offers eligible customers with a certain level of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; purchases to receive advertising co-branded with the Company. The co-branded advertising represents a performance obligation. At the time Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; product is sold to customers, the invoice price is allocated between the product sold and the advertisement. The standalone selling price of the advertisement is measured based on the estimated market value of similar advertisement adjusted for the customer&#x2019;s portion of the advertisement. The portion of invoice price allocated to the advertisement is initially recorded as deferred revenue. Subsequently, when the advertisement airs, the deferred revenue is recognized in net revenues at that time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Balances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A contract with a customer states the terms of the sale, including the description, quantity and price of each product purchased. Amounts are recorded as accounts receivable when the Company&#x2019;s right to consideration becomes unconditional. The Company does not have any significant financing components in customer contracts given the expected time between transfer of the promised products and the payment of the associated consideration is less than one year. As of&#160;December&#160;31, 2024 and 2023, all amounts included in accounts receivable, net on the accompanying consolidated balance sheets are related to contracts with customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not have any contract assets nor unbilled receivables as of&#160;December&#160;31, 2024 or 2023. Sales commissions are included in selling, general and administrative expenses when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities reflect estimated amounts that the Company is obligated to pay to customers or patients primarily under the rebate and deferred revenue associated with Rewards under the consumer loyalty program and co-branded marketing &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;programs. The Company&#x2019;s contract liabilities are included in accounts payable and accrued expenses in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, 2023, and 2022, the accrued revenue contract liabilities, primarily related to volume-based rebates, consumer loyalty program and co-branded marketing programs, were $14,454,  $11,033, and $9,011,respectively, which were recorded in accrued expenses in the accompanying consolidated balance sheets. For the years ended December 31, 2024, 2023, and 2022 provisions for rebate, consumer loyalty programs and co-branded marketing programs were $40,783, $32,511, and $22,759,respectively, which were offset by related payments, redemptions and adjustments of $37,362, $30,489, and $21,682, respectively, which were recorded as adjustments to gross revenues in the accompanying consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the&#160;years ended December 31, 2024, 2023, and 2022, the Company recognized $10,220, $7,868, and $7,566, respectively, of revenue related to amounts included in contract liabilities at the beginning of the period and did not recognize any revenue related to changes in transaction prices regarding its contracts with customers from previous periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collectability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable are recorded at the invoiced amount and do not bear interest. At the time of contract inception or new customer account set-up, the Company performs a collectability assessment of the customer&#x2019;s creditworthiness. The Company assesses the probability that the Company will collect the entitled consideration in exchange for the goods sold, by considering the customer&#x2019;s ability and intention to pay when consideration is due. The Company&#x2019;s expected loss allowance methodology for accounts receivable is developed using historical collection experience, current and future economic and market conditions and periodic evaluation of customers&#x2019; receivables balances using relevant available information, from internal and external sources, relating to past events, current conditions and forecasts. Historical credit loss experience provides the basis for estimation of expected credit losses and are adjusted as necessary using the relevant information available. The Company writes off accounts receivable balances when it is determined that there is no possibility of collection. As of December 31, 2024, 2023, and 2022, allowance for credit losses was $2,714, $1,490, and $2,050, respectively. For the years ended December 31, 2024, 2023, and 2022, provision for bad debts was $2,449, $1,440, and $1,598, respectively, and the write-off amount was $1,225, $2,000, and $1,933, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Practical Expedients&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses sales commissions when incurred as the amortization period is one year or less. These costs are recorded within selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss. The Company does not adjust the amount of promised consideration for the effects of the time value of money for contracts in which the anticipated period between when the Company transfers the goods or services to the customer and when the customer pays within one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development expenses include personnel-related costs, costs associated with pre-clinical and clinical development activities, costs associated with and costs for prototype products that are manufactured prior to market approval for that prototype product, internal and external costs associated with the Company&#x2019;s regulatory compliance and quality assurance functions, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs, including allocated facility related expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation Settlement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, upon entering into certain agreements to settle intellectual property disputes relating to Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company agreed to pay to Allergan and Medytox &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$35,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in multiple payments over two years, of which $15,000 was paid in the third quarter of 2021, $15,000 was paid in the first quarter of 2022, and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$5,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was paid in the first quarter of 2023, and issued 6,762,652 shares of its common stock to Medytox. As of December&#160;31, 2024 and 2023, there were no liabilities recorded in the accompanying consolidated balance sheets related to the litigation settlement with Allergan and Medytox.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, for the period from December 16, 2020 through September 16, 2022 (the &#x201c;Restricted Period&#x201d;), the Company agreed to pay to Allergan and Medytox a royalty on the sale of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, based on a certain dollar amount per vial sold in the United States and a low-double digit royalty on net sales of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;sold in other Evolus territories. Royalties for sales during the Restricted Period ended in the third quarter of 2022. For the period from December 16, 2020 to September 16, 2022, Daewoong agreed to reimburse the Company certain amounts with respect to the royalties payable to Medytox and Allergan. This reimbursement was received quarterly and recorded as an offset to the related royalties to Medytox and Allergan in the cost of goods sold on the accompanying consolidated statements of operations and comprehensive loss. For the period from September 17, 2022 to September 16, 2032, the Company agreed to pay Medytox a mid-single digit royalty percentage on all net sales of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The royalty payments are made quarterly and recorded as cost of goods sold on the accompanying consolidated statements of operations and comprehensive loss in the periods the royalties are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 11. Medytox Settlement Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the details of all litigation settlement agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes stock-based compensation expense for employees, consultants and members of the Board of Directors based on the fair value at the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the Black-Scholes option pricing model to value stock option grants. The Black-Scholes option pricing model requires the input of subjective assumptions, including the expected volatility of the Company&#x2019;s common stock, expected risk-free interest rate, and the option&#x2019;s expected life. The fair value of the Company&#x2019;s restricted stock units (&#x201c;RSUs&#x201d;) is based on the fair value on the grant date of the Company&#x2019;s common stock. The Company also evaluates the impact of modifications made to the original terms of equity awards when they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses a Monte Carlo simulation model to determine the fair value of performance units with market conditions at the grant date. The Monte Carlo simulation model involves the generation of a large number of possible stock price outcomes for the Company&#x2019;s stock which is assumed to follow a Geometric Brownian Motion. The use of the Monte Carlo simulation model requires the input of a number of assumptions including expected volatility of the Company&#x2019;s stock price, which is based on the historical volatility of its stock; risk-free interest rate, which is based on the treasury zero-coupon yield commensurate with the term of the performance unit as of the grant date; and expected dividends as applicable, which is zero, as the Company has never paid any cash dividends.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options and RSUs with service conditions that are expected to vest is amortized on a straight-line basis over the requisite service period. Stock-based compensation for RSUs with performance or market conditions is recorded over the requisite service period using the accelerated attribution method. Stock-based compensation expense is recognized net of actual forfeitures when they occur, as an increase to additional paid-in capital in the consolidated balance sheets and in the selling, general and administrative or research and development expenses in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advertising costs are expensed as incurred and primarily include costs related to social media ads and co-branded marketing programs. Advertising costs are included in selling, general and administrative expenses. For the years ended December 31, 2024, 2023, and 2022, the Company incurred advertising costs of $8,698, $7,490, and $11,642, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined on the basis of differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A valuation allowance is recorded against deferred tax assets to reduce the net carrying value when it is more likely than not that some portion or all of a deferred tax asset will not be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, and ongoing prudent and feasible tax planning strategies in assessing the amount of the valuation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;allowance. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. Accordingly, the Company establishes reserves for uncertain tax positions. The Company has not recognized interest or penalties in its consolidated statement of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to file federal and state income tax returns in the United States and various other state jurisdictions. The preparation of these income tax returns requires the Company to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company. An amount is accrued for the estimate of additional tax liability, including interest and penalties, for any uncertain tax positions taken or expected to be taken in an income tax return. The Company reviews and updates the accrual for uncertain tax positions as more definitive information becomes available. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of the Company&#x2019;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than&#160;50%&#160;likely of being realized upon settlement. While the Company believes it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcomes of examinations by tax authorities in determining the adequacy of its provision for income taxes. The Company continually assesses the likelihood and amount of potential revisions and adjusts the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company monitors changes to the tax laws in the states it conducts business and files corporate income tax returns. The Company does not expect changes to state tax laws through December&#160;31, 2024 to materially impact its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period including contingently issuable shares. Diluted earnings per share is based on the treasury stock method and includes the effect from potential issuance of ordinary shares, such as shares issuable pursuant to the exercise of stock options and the vesting of restricted stock units. Because the impact of the options and non-vested RSUs are anti-dilutive during periods of net loss, there was no difference between the weighted-average number of shares used to calculate basic and diluted net loss per common share for the periods presented. Excluded from the dilutive net loss per share computation for the twelve months ended December&#160;31, 2024, 2023, and 2022, were stock options of 6,151,069, 5,753,466, and 4,769,521, respectively, and non-vested RSUs of 3,476,314, 3,281,045, and 2,663,320, respectively. Although these securities were anti-dilutive for these periods, they could be dilutive in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting - Improving Reportable Segment Disclosures (Topic 280)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The standard requires disclosures to include significant segment expenses that are regularly provided to the chief operating decision maker (&#x201c;CODM&#x201d;), a description of other segment items by reportable segment, and any additional measures of a segment's profit or loss used by the CODM when deciding how to allocate resources. The ASU also requires all annual disclosures currently required by Topic 280 to be included in interim periods. ASU 2023-07 is effective for annual reporting periods beginning after December &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15, 2023 and interim reporting periods after December 15, 2024. The Company adopted this guidance on December&#160;31, 2024 and updated its disclosures to conform to this new segment disclosure requirement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements&#160;Issued But Not&#160;Adopted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU No. 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This update requires disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as information on income taxes paid. ASU No. 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU No. 2024-03 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires disaggregated disclosure of certain costs and expenses on an interim and annual basis. ASU No. 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The disclosure updates are required to be applied prospectively with the option for retrospective application. The Company is currently evaluating the impact of adopting ASU No. 2024-03.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by management to, have a material impact on the Company&#x2019;s present or future financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-392">&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;).</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-393">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s consolidated financial statements include the Company&#x2019;s accounts and those of the Company&#x2019;s wholly owned subsidiaries and have been prepared in conformity with GAAP. All intercompany transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-394">&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management is required to make certain estimates and assumptions in order to prepare consolidated financial statements in conformity with GAAP. Such estimates and assumptions affect the reported consolidated financial statements. These estimates include, but are not limited to net revenues, allowance for doubtful accounts, fair value measurements and stock-based compensation, among others. Management bases estimates on historical experience and on assumptions that management believes are reasonable. The Company&#x2019;s actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-395">&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is party to an agreement (the &#x201c;Daewoong Agreement&#x201d;) with Daewoong Pharmaceutical Co. Ltd. (&#x201c;Daewoong&#x201d;), pursuant to which the Company received an exclusive distribution license to Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; from Daewoong for aesthetic indications in the United States, European Union, United Kingdom, members of the European Economic Area, Switzerland, Canada, Australia, New Zealand, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;is manufactured by Daewoong in a facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) in a territory covered by the Daewoong Agreement. The Company relies on Daewoong, its exclusive and sole supplier, to manufacture Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company&#x2019;s commercialization of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 9. Commitments and Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company commercially launched Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;starting in the United States in May 2019 and in Canada through its distribution partner in October 2019. The Company also began commercially launching Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in Europe in 2022 and Australia in 2024 and, as such, has a limited history of sales in those markets. If any previously granted approval to market and sell Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is retracted or the Company is denied approval or approval is delayed by regulators in any other jurisdictions, it may have a material adverse impact on the Company&#x2019;s business and its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also subject to risks common to companies in the pharmaceutical industry including, but not limited to, dependency on the commercial success of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and Evolysse&#x2122; the Company&#x2019;s approved products, significant competition within the medical aesthetics industry, its ability to maintain regulatory approval of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, third party litigation and challenges to its intellectual property, uncertainty of broad adoption of its product by aesthetic practitioners and patients, its ability to in-license, acquire or develop additional product candidates and to obtain the necessary approvals for those product candidates, and the need to scale manufacturing capabilities over time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Any disruption and volatility in the global capital markets, including caused by other events, such as public health crises, increased inflation and rising interest rates, increased tariffs, and geopolitical conflicts, including the military conflict between Russia and Ukraine and the ongoing conflict in the Middle East, may increase the Company&#x2019;s cost of capital and adversely affect its ability to access financing when and on terms that the Company desires. Any of these events could have a material adverse effect on the Company&#x2019;s business, financial condition, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and accounts receivable. Substantially all of the Company&#x2019;s cash is held by financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. To date, the Company has not experienced any losses associated with this credit risk and continues to believe that this exposure is not significant. The Company invests, or plans to soon invest, its excess cash, in line with its investment policy, primarily in money market funds and debt instruments of U.S. government agencies. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounts receivable is derived from customers located principally in the United States and Europe. Concentrations of credit risk with respect to trade receivables are limited due to the Company&#x2019;s credit evaluation process. The Company does not typically require collateral from its customers. The Company continuously monitors customer payments and maintains an allowance for credit losses based on its assessment of various factors including historical experience, age of the receivable balances, and other current economic conditions or other factors that may affect customers&#x2019; ability to pay.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-396">&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has determined that it operates in a single operating and reportable segment. The Company&#x2019;s chief operating decision maker is its Chief Executive Officer who manages operations and reviews the financial information as a single operating segment for the purposes of allocating resources and evaluating its financial performance.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-397">&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of cash and highly liquid investments with remaining maturities at purchase of three months or less that can be liquidated without prior notice or penalty. Cash and cash equivalents may include deposits, money market funds and debt securities. Amounts receivable from credit card issuers are typically converted to cash within &lt;span style="-sec-ix-hidden:f-398"&gt;two&lt;/span&gt; to four days of the original sales transaction and are considered to be cash equivalents.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <eols:AccountsReceivableCreditCardTransactionConvertedToCashPeriod contextRef="c-50" id="f-399">P4D</eols:AccountsReceivableCreditCardTransactionConvertedToCashPeriod>
    <us-gaap:InventoryPolicyTextBlock contextRef="c-1" id="f-400">&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories and cost of goods sold&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consist of finished goods held for sale and distribution. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost is determined using the first-in, first-out method. Inventory is measured at the lower of cost and net realizable value based on a number of factors including, but not limited to, damage, expiration, or changes in price level.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December 31, 2024, cost of goods sold, consisted of the inventory cost, amortization of distribution right intangible assets related to Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and certain royalties on the sale of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; payable to Medytox and Allergan pursuant to the Medytox Settlement Agreements (as such term is defined in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 11. Medytox Settlement Agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;). The prior years Consolidated Statements of Operations and Comprehensive Loss has been adjusted to conform to this presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c-1" id="f-401">&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in an orderly transaction between market participants in a principal market on the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy defines a three-tiered valuation hierarchy for disclosure of fair value measurement is classified and disclosed by the Company in one of the three categories as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1&#x2014;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2&#x2014;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets; quoted prices in markets that are not active; or other inputs that are observable, either directly or indirectly, or can be corroborated by observable market data for substantially the full term of the asset or liability; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3&#x2014;Prices or valuation techniques that require inputs that are unobservable that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-402">&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;Property and equipment are stated at cost. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of approximately &lt;span style="-sec-ix-hidden:f-403"&gt;three&lt;/span&gt; to five years. Leasehold improvements are amortized over the shorter of the estimated useful lives of the improvements or the term of the related lease.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-52" id="f-404">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="c-1" id="f-405">&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. The Company assesses goodwill for impairment annually and whenever events or changes in circumstances indicate that the carrying amount of goodwill may not be recoverable. The Company performs an annual qualitative assessment of its goodwill in the fourth quarter of each calendar year to determine if any events or circumstances exist, such as an adverse change in business climate or a decline in the overall industry demand, that would indicate that it would more likely than not reduce the fair value of a reporting unit below its carrying amount, including goodwill. If events or circumstances do not indicate that the fair value of a reporting unit is below its carrying amount, then goodwill is not considered to be impaired and no further testing is required. For the purpose of impairment testing, the Company has determined that it has one reporting unit.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:NumberOfReportingUnits
      contextRef="c-1"
      decimals="INF"
      id="f-406"
      unitRef="reporting_unit">1</us-gaap:NumberOfReportingUnits>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="INF" id="f-407" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-12" decimals="INF" id="f-408" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:InProcessResearchAndDevelopmentPolicy contextRef="c-1" id="f-409">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;In-process Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets acquired that are used for research and development, do not yet have regulatory approval for commercialization, and have no future alternative use are expensed as in-process research and development.&lt;/span&gt;&lt;/div&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <eols:ResearchAndDevelopmentInProcess1 contextRef="c-13" decimals="-3" id="f-410" unitRef="usd">2000000</eols:ResearchAndDevelopmentInProcess1>
    <eols:ResearchAndDevelopmentInProcess1 contextRef="c-13" decimals="-3" id="f-411" unitRef="usd">2000000</eols:ResearchAndDevelopmentInProcess1>
    <eols:LicenseSupplyAndDistributionAgreementRightToCommercializeAndDistributeNumberOfProductCandidates
      contextRef="c-53"
      decimals="0"
      id="f-412"
      unitRef="productcandidate">5</eols:LicenseSupplyAndDistributionAgreementRightToCommercializeAndDistributeNumberOfProductCandidates>
    <eols:LicenseSupplyAndDistributionAgreementMinimumMilestonePayment contextRef="c-54" decimals="-3" id="f-413" unitRef="eur">16200000</eols:LicenseSupplyAndDistributionAgreementMinimumMilestonePayment>
    <eols:LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement contextRef="c-54" decimals="-3" id="f-414" unitRef="eur">4100000</eols:LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement>
    <eols:LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod contextRef="c-54" id="f-415">P30D</eols:LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod>
    <eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne contextRef="c-53" decimals="-3" id="f-416" unitRef="eur">1600000</eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne>
    <eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo contextRef="c-53" decimals="-3" id="f-417" unitRef="eur">4100000</eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo>
    <eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree contextRef="c-53" decimals="-3" id="f-418" unitRef="eur">3200000</eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree>
    <eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour contextRef="c-53" decimals="-3" id="f-419" unitRef="eur">3200000</eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour>
    <eols:LicenseSupplyAndDistributionAgreementAnnualPaymentTriggeredRegulatoryApprovalNumberOfProducts contextRef="c-53" decimals="0" id="f-420" unitRef="product">3</eols:LicenseSupplyAndDistributionAgreementAnnualPaymentTriggeredRegulatoryApprovalNumberOfProducts>
    <eols:LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense contextRef="c-55" decimals="-3" id="f-421" unitRef="usd">4441000</eols:LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense>
    <eols:LicenseSupplyAndDistributionAgreementInitialTerm contextRef="c-54" id="f-422">P15Y</eols:LicenseSupplyAndDistributionAgreementInitialTerm>
    <eols:LicenseSupplyAndDistributionAgreementRenewalTerm contextRef="c-54" id="f-423">P5Y</eols:LicenseSupplyAndDistributionAgreementRenewalTerm>
    <eols:LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense contextRef="c-56" decimals="-3" id="f-424" unitRef="usd">4441000</eols:LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense>
    <eols:LicenseSupplyAndDistributionAgreementNumberOfProductCandidates
      contextRef="c-57"
      decimals="INF"
      id="f-425"
      unitRef="productcandidate">4</eols:LicenseSupplyAndDistributionAgreementNumberOfProductCandidates>
    <eols:LicenseSupplyAndDistributionAgreementNumberOfCountriesUseAestheticsAndDermatologicalFields
      contextRef="c-57"
      decimals="INF"
      id="f-426"
      unitRef="country">50</eols:LicenseSupplyAndDistributionAgreementNumberOfCountriesUseAestheticsAndDermatologicalFields>
    <eols:LicenseSupplyAndDistributionAgreementInitialTerm contextRef="c-58" id="f-427">P15Y</eols:LicenseSupplyAndDistributionAgreementInitialTerm>
    <eols:StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement
      contextRef="c-59"
      decimals="INF"
      id="f-428"
      unitRef="shares">610000</eols:StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement>
    <eols:LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment
      contextRef="c-57"
      decimals="INF"
      id="f-429"
      unitRef="milestonepayment">2</eols:LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment>
    <eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo contextRef="c-57" decimals="-3" id="f-430" unitRef="eur">1200000</eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo>
    <eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree contextRef="c-57" decimals="-3" id="f-431" unitRef="eur">1900000</eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree>
    <eols:LicenseSupplyAndDistributionAgreementAnnualRevenue contextRef="c-57" decimals="-3" id="f-432" unitRef="eur">25000000</eols:LicenseSupplyAndDistributionAgreementAnnualRevenue>
    <eols:StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement
      contextRef="c-59"
      decimals="INF"
      id="f-433"
      unitRef="shares">610000</eols:StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement>
    <eols:NonCashInResearchAndDevelopmentInProcessExpenses contextRef="c-12" decimals="-3" id="f-434" unitRef="usd">4429000</eols:NonCashInResearchAndDevelopmentInProcessExpenses>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c-60" decimals="-3" id="f-435" unitRef="usd">1476000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <eols:StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement
      contextRef="c-59"
      decimals="INF"
      id="f-436"
      unitRef="shares">610000</eols:StockIssuedDuringPeriodSharesIssuedForLicenseSupplyAndDistributionAgreement>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c-60" decimals="-3" id="f-437" unitRef="usd">1476000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-61" id="f-438">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <eols:LicenseSupplyAndDistributionAgreementPendingRegulatoryApprovalNumberOfProducts contextRef="c-62" decimals="0" id="f-439" unitRef="product">3</eols:LicenseSupplyAndDistributionAgreementPendingRegulatoryApprovalNumberOfProducts>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="c-1" id="f-440">&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The distribution right intangible asset related to Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is amortized over the period the asset is expected to contribute to the future cash flows of the Company. The Company determined the pattern of this intangible asset&#x2019;s future cash flows could not be readily determined with a high level of precision. As a result, the distribution right intangible asset is being amortized on a straight-line basis over the estimated useful life of&#160;20 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A portion of the Symatese Europe Agreement represents the license and distribution right to Evolysse&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in Europe. The definite-lived distribution right intangible asset related to the Evolysse&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; nasolabial fold product approved in Europe is amortized on a straight-line basis over the estimated useful life of 15 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Symatese Europe Agreement, the Company is required to pay two milestone payments: (i) &#x20ac;1,200 on the second anniversary of certain regulatory approvals, and (ii) &#x20ac;1,900 on the earlier of the third anniversary of certain regulatory approvals or following a year in which the Company achieves &#x20ac;25,000 in revenue in Europe, provided that the payment shall occur no later than December 2029.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2024, the Company received European Union Medical Device Regulation (&#x201c;MDR&#x201d;) approval for the remaining three hyaluronic acid gel products. As a result, the two milestone payments have been triggered. The first milestone payment is payable in October 2026, the two-year anniversary of the approval. For the second milestone payment, the Company determined that it is probable the payment will be made no later than December 2029. As such, the Company recorded $1,035 and $1,200 in long-term liabilities for the first and second milestone payments, and $1,035 and $1,200 in intangible assets for the first and second milestone payments as of December&#160;31, 2024. These amounts reflect the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;application of a discount to account for the time value of money, which adjusts the present value of the liabilities and intangible assets based on the timing of future payments. The definite-lived distribution right intangible asset related to the Evolysse&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; products approved in Europe is amortized on a straight-line basis over the remaining estimated useful life of 14 years and 2 months. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes certain internal-use software costs associated with the development of its mobile and web-based customer platforms. These costs include personnel expenses and external costs that are directly associated with the software projects. These costs are included as intangible assets in the accompanying consolidated balance sheets. The capitalized internal-use software costs are amortized on a straight-line basis over the estimated useful life of&#160;two years&#160;upon being placed in service.&lt;/span&gt;&lt;/div&gt;The Company reviews long-term and identifiable definite-lived intangible assets or asset groups for impairment when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset or an asset group, further impairment analysis is performed. An impairment loss is measured as the amount by which the carrying amount of the asset or asset groups exceeds the fair value for assets to be held and used or fair value less cost to sell for assets to be disposed of. The Company also reviews the useful lives of its assets periodically to determine whether events and circumstances warrant a revision to the remaining useful life. Changes in the useful life are adjusted prospectively by revising the remaining period over which the asset is amortized.</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-63" id="f-441">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-64" id="f-442">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <eols:LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment
      contextRef="c-57"
      decimals="INF"
      id="f-443"
      unitRef="milestonepayment">2</eols:LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment>
    <eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo contextRef="c-57" decimals="-3" id="f-444" unitRef="eur">1200000</eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo>
    <eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree contextRef="c-57" decimals="-3" id="f-445" unitRef="eur">1900000</eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree>
    <eols:LicenseSupplyAndDistributionAgreementAnnualRevenue contextRef="c-65" decimals="-3" id="f-446" unitRef="eur">25000000</eols:LicenseSupplyAndDistributionAgreementAnnualRevenue>
    <eols:LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts
      contextRef="c-66"
      decimals="INF"
      id="f-447"
      unitRef="product">3</eols:LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts>
    <eols:LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment
      contextRef="c-67"
      decimals="INF"
      id="f-448"
      unitRef="milestonepayment">2</eols:LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment>
    <eols:LicenseSupplyAndDistributionAgreementMilestonePaymentPayablePeriod contextRef="c-66" id="f-449">P2Y</eols:LicenseSupplyAndDistributionAgreementMilestonePaymentPayablePeriod>
    <eols:LicenseSupplyAndDistributionAgreementLiabilityNoncurrent contextRef="c-68" decimals="-3" id="f-450" unitRef="usd">1035000</eols:LicenseSupplyAndDistributionAgreementLiabilityNoncurrent>
    <eols:LicenseSupplyAndDistributionAgreementLiabilityNoncurrent contextRef="c-69" decimals="-3" id="f-451" unitRef="usd">1200000</eols:LicenseSupplyAndDistributionAgreementLiabilityNoncurrent>
    <eols:LicenseSupplyAndDistributionAgreementIntangibleAsset contextRef="c-68" decimals="-3" id="f-452" unitRef="usd">1035000</eols:LicenseSupplyAndDistributionAgreementIntangibleAsset>
    <eols:LicenseSupplyAndDistributionAgreementIntangibleAsset contextRef="c-69" decimals="-3" id="f-453" unitRef="usd">1200000</eols:LicenseSupplyAndDistributionAgreementIntangibleAsset>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-70" id="f-454">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-1" decimals="-3" id="f-455" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-12" decimals="-3" id="f-456" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-457">&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, upon lease commencement, the Company records a lease liability which represents the Company&#x2019;s obligation to make lease payments arising from the lease, and a corresponding right-of-use (&#x201c;ROU&#x201d;) asset which represents the Company&#x2019;s right to use an underlying asset during the lease term. Operating lease assets and liabilities are included in ROU assets, current portion of operating lease liabilities and noncurrent operating lease liabilities in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease ROU assets and lease liabilities are initially recognized based on the present value of the future minimum lease payments over the lease term at commencement date calculated using the Company&#x2019;s incremental borrowing rate applicable to the underlying asset unless the implicit rate is readily determinable. The incremental borrowing rate, the ROU asset and the lease liability are reevaluated upon a lease modification. Operating lease ROU assets also include any lease payments made at or before lease commencement and exclude any lease incentives received, if any. The Company determines the lease term as the noncancellable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. The Company&#x2019;s leases do not contain any residual value guarantees. Leases with a term of 12 months or less are not recognized on the consolidated balance sheets. For operating leases, the Company recognized rent expense on a straight-line basis over the lease term. There were no significant finance leases as of&#160;December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="c-1" id="f-458">&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Royalty Obligation Payable to Evolus Founders&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company was acquired by Strathspey Crown Holdings Group, LLC (&#x201c;SCH&#x201d;) in 2013 and subsequently by its subsidiary, Alphaeon Corporation (&#x201c;Alphaeon&#x201d;), by means of a stock purchase agreement (&#x201c;Stock Purchase Agreement&#x201d;) pursuant to which Alphaeon assumed certain payment obligations related to the acquisition. On December 14, 2017, the Stock Purchase Agreement was amended (&#x201c;Amended Stock Purchase Agreement&#x201d;), and, as a result, effective upon the closing of the Company&#x2019;s initial public offering in February 2018, the Company assumed all of Alphaeon&#x2019;s payment obligations under the Amended Stock Purchase Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payment obligations to the Evolus Founders consist of quarterly royalty payments of a low single digit percentage of net sales of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The obligations terminate in the second quarter of 2029, which is the&#160;10-year anniversary of the first commercial sale of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;in the United States. Under the Amended Stock Purchase Agreement, the Company recorded the fair value of all revised payment obligations owed to the Evolus Founders. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the fair value of the contingent royalty obligation payable at each reporting period end based on Level 3 inputs using a discounted cash flows method. Changes in the fair value of the contingent royalty obligation payable are determined at each reporting period end and recorded in operating expenses in the accompanying consolidated statements of operations and comprehensive loss and as a liability in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <eols:RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale contextRef="c-71" id="f-459">P10Y</eols:RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale>
    <us-gaap:DebtPolicyTextBlock contextRef="c-1" id="f-460">&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-Term Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt represents the debt balance with Pharmakon (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7. Term Loans&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), net of discount and issuance costs. Debt issuance costs represent legal, lender and consulting costs or fees associated with debt financing. Debt&#160;discounts and issuance costs are amortized into interest expense over the term of the debt.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c-1" id="f-461">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial statements of foreign subsidiaries are measured using the local currency as the functional currency. Assets and liabilities are translated into U.S. dollars at current exchange rates as of balance sheet date, and income and expense items are translated into U.S. dollars using the average rates of exchange prevailing during the period. Gains and losses arising from translation are recorded in other comprehensive loss as a separate component of stockholders&#x2019; equity. Foreign currency gains or losses on transactions denominated in a currency other than the Company&#x2019;s functional currency are recorded in other expenses, net in the accompanying consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-462">&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when control of the promised goods or services is transferred to its customers, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for the goods or services. In order to achieve that core principle, a five-step approach is applied: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue allocated to each performance obligation when the Company satisfies the performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account for revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;General&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generates product revenue from the sale of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the United States, Europe, and Australia, and service revenue from the sale of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; through a distribution partner in Canada.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For product revenue, the Company recognizes revenue when control of the promised goods under a contract is transferred to a customer, in an amount that reflects the consideration the Company expects to receive in exchange for those goods as specified in the customer contract. The transfer of control occurs upon receipt of the goods by the customer since that is when the customer has obtained control of the goods&#x2019; economic benefits. The Company does not provide any service-type warranties and does not accept product returns except under limited circumstances such as damages in transit or ineffective product. The Company also excludes any amounts related to taxes assessed by governmental authorities from revenue measurement. Shipping and handling costs associated with outbound product freight are accounted for as fulfillment costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and are included in selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For service revenue, the Company evaluated the arrangement with the distribution partner in Canada and determined that it acts as an agent in the distribution of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in Canada as it does not control the product before control is transferred to a customer. The indicators of which party exercises control include primary responsibility over performance obligations, inventory risk before the good or service is transferred and discretion in establishing the price. Accordingly, the Company records the sale as service revenue on a net basis. Revenue from services is recognized in the period the service is performed for the amount of consideration expected to be received.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s disaggregation of revenue is consistent with its operating segment as disclosed above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gross-to-Net Revenue Adjustments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides customers with discounts, such as trade and volume discounts and prompt pay discounts, that are directly reflected in the invoice price. Revenues are recorded net of sales-related adjustments, wherever applicable, primarily for the volume based rebates, consumer loyalty programs and co-branded marketing programs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Volume-Based Rebates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Volume-based rebates are contractually offered to certain customers. The rebates payable to each customer are determined based on the contract and quarterly purchase volumes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Consumer Loyalty Program&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; The Company&#x2019;s consumer loyalty program allows participating customers to earn rewards for qualifying treatments to their patients (i.e. consumers) using Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and redeem the rewards for Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the future at no additional cost. The loyalty program represents a customer option that provides a material right and, accordingly, is a performance obligation. At the time Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; product is sold to customers, the invoice price is allocated between the product sold and the estimated material right reward (&#x201c;Reward&#x201d;) that the customer might redeem in the future. The standalone selling price of the Reward is measured based on estimated average selling price of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; at the time of redemption and the expected redemption rate by customers based on historical sales data. The portion of invoice price allocated to the Reward is initially recorded as deferred revenue. Subsequently, when customers redeem the Reward and the related product is delivered, the deferred revenue is recognized in net revenues at that time. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Co-Branded Marketing Programs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; The Company offers eligible customers with a certain level of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; purchases to receive advertising co-branded with the Company. The co-branded advertising represents a performance obligation. At the time Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; product is sold to customers, the invoice price is allocated between the product sold and the advertisement. The standalone selling price of the advertisement is measured based on the estimated market value of similar advertisement adjusted for the customer&#x2019;s portion of the advertisement. The portion of invoice price allocated to the advertisement is initially recorded as deferred revenue. Subsequently, when the advertisement airs, the deferred revenue is recognized in net revenues at that time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Balances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A contract with a customer states the terms of the sale, including the description, quantity and price of each product purchased. Amounts are recorded as accounts receivable when the Company&#x2019;s right to consideration becomes unconditional. The Company does not have any significant financing components in customer contracts given the expected time between transfer of the promised products and the payment of the associated consideration is less than one year. As of&#160;December&#160;31, 2024 and 2023, all amounts included in accounts receivable, net on the accompanying consolidated balance sheets are related to contracts with customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not have any contract assets nor unbilled receivables as of&#160;December&#160;31, 2024 or 2023. Sales commissions are included in selling, general and administrative expenses when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities reflect estimated amounts that the Company is obligated to pay to customers or patients primarily under the rebate and deferred revenue associated with Rewards under the consumer loyalty program and co-branded marketing &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;programs. The Company&#x2019;s contract liabilities are included in accounts payable and accrued expenses in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, 2023, and 2022, the accrued revenue contract liabilities, primarily related to volume-based rebates, consumer loyalty program and co-branded marketing programs, were $14,454,  $11,033, and $9,011,respectively, which were recorded in accrued expenses in the accompanying consolidated balance sheets. For the years ended December 31, 2024, 2023, and 2022 provisions for rebate, consumer loyalty programs and co-branded marketing programs were $40,783, $32,511, and $22,759,respectively, which were offset by related payments, redemptions and adjustments of $37,362, $30,489, and $21,682, respectively, which were recorded as adjustments to gross revenues in the accompanying consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the&#160;years ended December 31, 2024, 2023, and 2022, the Company recognized $10,220, $7,868, and $7,566, respectively, of revenue related to amounts included in contract liabilities at the beginning of the period and did not recognize any revenue related to changes in transaction prices regarding its contracts with customers from previous periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collectability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable are recorded at the invoiced amount and do not bear interest. At the time of contract inception or new customer account set-up, the Company performs a collectability assessment of the customer&#x2019;s creditworthiness. The Company assesses the probability that the Company will collect the entitled consideration in exchange for the goods sold, by considering the customer&#x2019;s ability and intention to pay when consideration is due. The Company&#x2019;s expected loss allowance methodology for accounts receivable is developed using historical collection experience, current and future economic and market conditions and periodic evaluation of customers&#x2019; receivables balances using relevant available information, from internal and external sources, relating to past events, current conditions and forecasts. Historical credit loss experience provides the basis for estimation of expected credit losses and are adjusted as necessary using the relevant information available. The Company writes off accounts receivable balances when it is determined that there is no possibility of collection. As of December 31, 2024, 2023, and 2022, allowance for credit losses was $2,714, $1,490, and $2,050, respectively. For the years ended December 31, 2024, 2023, and 2022, provision for bad debts was $2,449, $1,440, and $1,598, respectively, and the write-off amount was $1,225, $2,000, and $1,933, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Practical Expedients&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses sales commissions when incurred as the amortization period is one year or less. These costs are recorded within selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss. The Company does not adjust the amount of promised consideration for the effects of the time value of money for contracts in which the anticipated period between when the Company transfers the goods or services to the customer and when the customer pays within one year.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-4" decimals="-3" id="f-463" unitRef="usd">14454000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-5" decimals="-3" id="f-464" unitRef="usd">11033000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-26" decimals="-3" id="f-465" unitRef="usd">9011000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <eols:RebatesAndCouponsCreditsAndPayments contextRef="c-1" decimals="-3" id="f-466" unitRef="usd">40783000</eols:RebatesAndCouponsCreditsAndPayments>
    <eols:RebatesAndCouponsCreditsAndPayments contextRef="c-12" decimals="-3" id="f-467" unitRef="usd">32511000</eols:RebatesAndCouponsCreditsAndPayments>
    <eols:RebatesAndCouponsCreditsAndPayments contextRef="c-13" decimals="-3" id="f-468" unitRef="usd">22759000</eols:RebatesAndCouponsCreditsAndPayments>
    <eols:PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability contextRef="c-1" decimals="-3" id="f-469" unitRef="usd">37362000</eols:PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability>
    <eols:PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability contextRef="c-12" decimals="-3" id="f-470" unitRef="usd">30489000</eols:PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability>
    <eols:PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability contextRef="c-13" decimals="-3" id="f-471" unitRef="usd">21682000</eols:PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-1" decimals="-3" id="f-472" unitRef="usd">10220000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-12" decimals="-3" id="f-473" unitRef="usd">7868000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-13" decimals="-3" id="f-474" unitRef="usd">7566000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-4" decimals="-3" id="f-475" unitRef="usd">2714000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-5" decimals="-3" id="f-476" unitRef="usd">1490000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="c-26" decimals="-3" id="f-477" unitRef="usd">2050000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-1" decimals="-3" id="f-478" unitRef="usd">2449000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-12" decimals="-3" id="f-479" unitRef="usd">1440000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-13" decimals="-3" id="f-480" unitRef="usd">1598000</us-gaap:ProvisionForDoubtfulAccounts>
    <eols:AccountsReceivableAllowanceForCreditLossWriteOffRecovery contextRef="c-1" decimals="-3" id="f-481" unitRef="usd">1225000</eols:AccountsReceivableAllowanceForCreditLossWriteOffRecovery>
    <eols:AccountsReceivableAllowanceForCreditLossWriteOffRecovery contextRef="c-12" decimals="-3" id="f-482" unitRef="usd">2000000</eols:AccountsReceivableAllowanceForCreditLossWriteOffRecovery>
    <eols:AccountsReceivableAllowanceForCreditLossWriteOffRecovery contextRef="c-13" decimals="-3" id="f-483" unitRef="usd">1933000</eols:AccountsReceivableAllowanceForCreditLossWriteOffRecovery>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-484">&lt;div style="margin-bottom:10pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development expenses include personnel-related costs, costs associated with pre-clinical and clinical development activities, costs associated with and costs for prototype products that are manufactured prior to market approval for that prototype product, internal and external costs associated with the Company&#x2019;s regulatory compliance and quality assurance functions, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs, including allocated facility related expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="c-72" decimals="-3" id="f-485" unitRef="usd">35000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <eols:LossContingencySettlementAgreementPaymentTerms contextRef="c-73" id="f-486">P2Y</eols:LossContingencySettlementAgreementPaymentTerms>
    <us-gaap:PaymentsForLegalSettlements contextRef="c-74" decimals="-3" id="f-487" unitRef="usd">15000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:PaymentsForLegalSettlements contextRef="c-75" decimals="-3" id="f-488" unitRef="usd">15000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:PaymentsForLegalSettlements contextRef="c-76" decimals="-3" id="f-489" unitRef="usd">5000000</us-gaap:PaymentsForLegalSettlements>
    <eols:StockIssuedDuringPeriodSharesLitigationSettlement
      contextRef="c-77"
      decimals="INF"
      id="f-490"
      unitRef="shares">6762652</eols:StockIssuedDuringPeriodSharesLitigationSettlement>
    <us-gaap:LitigationReserveCurrent contextRef="c-5" decimals="-3" id="f-491" unitRef="usd">0</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationReserveCurrent contextRef="c-4" decimals="-3" id="f-492" unitRef="usd">0</us-gaap:LitigationReserveCurrent>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-493">&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes stock-based compensation expense for employees, consultants and members of the Board of Directors based on the fair value at the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the Black-Scholes option pricing model to value stock option grants. The Black-Scholes option pricing model requires the input of subjective assumptions, including the expected volatility of the Company&#x2019;s common stock, expected risk-free interest rate, and the option&#x2019;s expected life. The fair value of the Company&#x2019;s restricted stock units (&#x201c;RSUs&#x201d;) is based on the fair value on the grant date of the Company&#x2019;s common stock. The Company also evaluates the impact of modifications made to the original terms of equity awards when they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses a Monte Carlo simulation model to determine the fair value of performance units with market conditions at the grant date. The Monte Carlo simulation model involves the generation of a large number of possible stock price outcomes for the Company&#x2019;s stock which is assumed to follow a Geometric Brownian Motion. The use of the Monte Carlo simulation model requires the input of a number of assumptions including expected volatility of the Company&#x2019;s stock price, which is based on the historical volatility of its stock; risk-free interest rate, which is based on the treasury zero-coupon yield commensurate with the term of the performance unit as of the grant date; and expected dividends as applicable, which is zero, as the Company has never paid any cash dividends.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options and RSUs with service conditions that are expected to vest is amortized on a straight-line basis over the requisite service period. Stock-based compensation for RSUs with performance or market conditions is recorded over the requisite service period using the accelerated attribution method. Stock-based compensation expense is recognized net of actual forfeitures when they occur, as an increase to additional paid-in capital in the consolidated balance sheets and in the selling, general and administrative or research and development expenses in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-78" decimals="3" id="f-494" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="c-1" id="f-495">&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising Costs&lt;/span&gt;&lt;/div&gt;Advertising costs are expensed as incurred and primarily include costs related to social media ads and co-branded marketing programs. Advertising costs are included in selling, general and administrative expenses.</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense contextRef="c-1" decimals="-3" id="f-496" unitRef="usd">8698000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="c-12" decimals="-3" id="f-497" unitRef="usd">7490000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="c-13" decimals="-3" id="f-498" unitRef="usd">11642000</us-gaap:AdvertisingExpense>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-499">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined on the basis of differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A valuation allowance is recorded against deferred tax assets to reduce the net carrying value when it is more likely than not that some portion or all of a deferred tax asset will not be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, and ongoing prudent and feasible tax planning strategies in assessing the amount of the valuation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;allowance. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the consolidated financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. Accordingly, the Company establishes reserves for uncertain tax positions. The Company has not recognized interest or penalties in its consolidated statement of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to file federal and state income tax returns in the United States and various other state jurisdictions. The preparation of these income tax returns requires the Company to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company. An amount is accrued for the estimate of additional tax liability, including interest and penalties, for any uncertain tax positions taken or expected to be taken in an income tax return. The Company reviews and updates the accrual for uncertain tax positions as more definitive information becomes available. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of the Company&#x2019;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than&#160;50%&#160;likely of being realized upon settlement. While the Company believes it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcomes of examinations by tax authorities in determining the adequacy of its provision for income taxes. The Company continually assesses the likelihood and amount of potential revisions and adjusts the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company monitors changes to the tax laws in the states it conducts business and files corporate income tax returns. The Company does not expect changes to state tax laws through December&#160;31, 2024 to materially impact its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-500">&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period including contingently issuable shares. Diluted earnings per share is based on the treasury stock method and includes the effect from potential issuance of ordinary shares, such as shares issuable pursuant to the exercise of stock options and the vesting of restricted stock units. Because the impact of the options and non-vested RSUs are anti-dilutive during periods of net loss, there was no difference between the weighted-average number of shares used to calculate basic and diluted net loss per common share for the periods presented. Excluded from the dilutive net loss per share computation for the twelve months ended</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-79" decimals="0" id="f-501" unitRef="shares">6151069</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-80" decimals="0" id="f-502" unitRef="shares">5753466</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-81" decimals="0" id="f-503" unitRef="shares">4769521</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-82" decimals="0" id="f-504" unitRef="shares">3476314</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-83" decimals="0" id="f-505" unitRef="shares">3281045</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-84" decimals="0" id="f-506" unitRef="shares">2663320</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-507">&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting - Improving Reportable Segment Disclosures (Topic 280)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The standard requires disclosures to include significant segment expenses that are regularly provided to the chief operating decision maker (&#x201c;CODM&#x201d;), a description of other segment items by reportable segment, and any additional measures of a segment's profit or loss used by the CODM when deciding how to allocate resources. The ASU also requires all annual disclosures currently required by Topic 280 to be included in interim periods. ASU 2023-07 is effective for annual reporting periods beginning after December &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15, 2023 and interim reporting periods after December 15, 2024. The Company adopted this guidance on December&#160;31, 2024 and updated its disclosures to conform to this new segment disclosure requirement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements&#160;Issued But Not&#160;Adopted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU No. 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This update requires disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as information on income taxes paid. ASU No. 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU No. 2024-03 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires disaggregated disclosure of certain costs and expenses on an interim and annual basis. ASU No. 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The disclosure updates are required to be applied prospectively with the option for retrospective application. The Company is currently evaluating the impact of adopting ASU No. 2024-03.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by management to, have a material impact on the Company&#x2019;s present or future financial position, results of operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-511">Fair Value Measurements &lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. The fair value of these instruments was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.873%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent royalty obligation payable to Evolus Founders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.873%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent royalty obligation payable to Evolus Founders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not transfer any assets or liabilities measured at fair value on a recurring basis between levels during the&#160;year ended December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the fair value of the contingent royalty obligation payable to Evolus Founders based on Level 3 inputs using a discounted cash flows method. The significant unobservable input assumptions that can significantly change the fair value include (i) projected amount and timing of U.S. net revenues of Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; during the payment period, which terminates at the end of the second quarter of 2029, (ii) the discount rate, and (iii) the timing of payments. During the years ended December 31, 2024 and 2023, the Company utilized discount rates between 14% and 15%, reflecting changes in the Company&#x2019;s risk profile. Net revenue projections are also updated to reflect changes in the timing of expected sales. Significant increases (decreases) in the discount rate and to the projected net revenues would result in a significantly lower (higher) fair value measurement, which could materially impact their fair value reported on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows a reconciliation of the beginning and ending fair value measurements of the contingent royalty obligation payable:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.588%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.520%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.588%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.376%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.592%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,441)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,537)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,185)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value recorded in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Financial Assets and Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments consist primarily of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses, lease liabilities, and long-term debt. The carrying amount of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of long-term debt and operating lease liabilities using the discounted cash flow analysis based on the interest rates for similar rated debt securities (Level 2). As of December 31, 2024 and 2023, the fair value of long-term debt was $132,078 and $140,241, respectively. The fair value of operating lease liabilities&#160;as of December&#160;31, 2024 and 2023 approximated their carrying value.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-512">&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. The fair value of these instruments was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.873%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent royalty obligation payable to Evolus Founders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.255%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.873%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent royalty obligation payable to Evolus Founders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-86" decimals="-3" id="f-513" unitRef="usd">44765000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-87" decimals="-3" id="f-514" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-88" decimals="-3" id="f-515" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-89" decimals="-3" id="f-516" unitRef="usd">44765000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-90" decimals="-3" id="f-517" unitRef="usd">45030000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-91" decimals="-3" id="f-518" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-92" decimals="-3" id="f-519" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-93" decimals="-3" id="f-520" unitRef="usd">45030000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="c-94"
      decimals="INF"
      id="f-521"
      unitRef="number">0.14</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="c-95"
      decimals="INF"
      id="f-522"
      unitRef="number">0.15</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-523">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows a reconciliation of the beginning and ending fair value measurements of the contingent royalty obligation payable:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.588%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.520%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.588%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.376%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.592%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,441)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,537)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,185)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value recorded in operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-5" decimals="-3" id="f-524" unitRef="usd">45030000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-26" decimals="-3" id="f-525" unitRef="usd">46310000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-18" decimals="-3" id="f-526" unitRef="usd">44740000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="c-1" decimals="-3" id="f-527" unitRef="usd">7441000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="c-12" decimals="-3" id="f-528" unitRef="usd">5537000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="c-13" decimals="-3" id="f-529" unitRef="usd">4185000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-1" decimals="-3" id="f-530" unitRef="usd">-7176000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-12" decimals="-3" id="f-531" unitRef="usd">-4257000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-13" decimals="-3" id="f-532" unitRef="usd">-5755000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-4" decimals="-3" id="f-533" unitRef="usd">44765000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-5" decimals="-3" id="f-534" unitRef="usd">45030000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-26" decimals="-3" id="f-535" unitRef="usd">46310000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-96" decimals="-3" id="f-536" unitRef="usd">132078000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-97" decimals="-3" id="f-537" unitRef="usd">140241000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-538">Goodwill and Intangible Assets &lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below shows the weighted-average life, original cost, accumulated amortization and net book value by major intangible asset classification:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.824%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Original Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Book Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Definite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distribution rights&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,580)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,770)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total as of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.824%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Original Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Book Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Definite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distribution right&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,746)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total as of December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table outlines the estimated future amortization expense related to intangible assets held as of&#160;December&#160;31, 2024 that are subject to amortization:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.142%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.931%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Distribution rights represent the license and associated distribution rights to Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Evolysse&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. For the years ended December 31, 2024 and 2023, the Company capitalized $2,235 and $1,476 related to the license and distribution right to Evolysse&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; nasolabial fold product in Europe, which is amortized on a straight-line basis over the estimated useful life of 15 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December 31, 2024 and 2023, the Company capitalized $3,513 and $1,168, respectively, related to costs of computer software developed for internal use. The software is amortized over a two-year period using the straight-line method. For the years ended December 31, 2024, 2023, and 2022, total intangible assets amortization expense of $4,104, $4,072, and $3,350, respectively, was recorded within depreciation and amortization on the accompanying consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="c-1" id="f-539">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below shows the weighted-average life, original cost, accumulated amortization and net book value by major intangible asset classification:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.824%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Original Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Book Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Definite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distribution rights&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,580)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,770)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total as of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.824%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Original Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Book Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Definite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Distribution right&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,746)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total as of December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-63" decimals="-3" id="f-540" unitRef="usd">62787000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-63" decimals="-3" id="f-541" unitRef="usd">17580000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-63" decimals="-3" id="f-542" unitRef="usd">45207000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-98" decimals="-3" id="f-543" unitRef="usd">13317000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-98" decimals="-3" id="f-544" unitRef="usd">9770000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-98" decimals="-3" id="f-545" unitRef="usd">3547000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-4" decimals="-3" id="f-546" unitRef="usd">76104000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-4" decimals="-3" id="f-547" unitRef="usd">27350000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-4" decimals="-3" id="f-548" unitRef="usd">48754000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill contextRef="c-4" decimals="-3" id="f-549" unitRef="usd">21208000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-4" decimals="-3" id="f-550" unitRef="usd">21208000</us-gaap:Goodwill>
    <eols:IntangibleAssetsGrossIncludingGoodwill contextRef="c-4" decimals="-3" id="f-551" unitRef="usd">97312000</eols:IntangibleAssetsGrossIncludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-4" decimals="-3" id="f-552" unitRef="usd">27350000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill contextRef="c-4" decimals="-3" id="f-553" unitRef="usd">69962000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-99" decimals="-3" id="f-554" unitRef="usd">60552000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-99" decimals="-3" id="f-555" unitRef="usd">14500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-99" decimals="-3" id="f-556" unitRef="usd">46052000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-100" decimals="-3" id="f-557" unitRef="usd">9804000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-100" decimals="-3" id="f-558" unitRef="usd">8746000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-100" decimals="-3" id="f-559" unitRef="usd">1058000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-5" decimals="-3" id="f-560" unitRef="usd">70356000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-5" decimals="-3" id="f-561" unitRef="usd">23246000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-5" decimals="-3" id="f-562" unitRef="usd">47110000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Goodwill contextRef="c-5" decimals="-3" id="f-563" unitRef="usd">21208000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-5" decimals="-3" id="f-564" unitRef="usd">21208000</us-gaap:Goodwill>
    <eols:IntangibleAssetsGrossIncludingGoodwill contextRef="c-5" decimals="-3" id="f-565" unitRef="usd">91564000</eols:IntangibleAssetsGrossIncludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-5" decimals="-3" id="f-566" unitRef="usd">23246000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill contextRef="c-5" decimals="-3" id="f-567" unitRef="usd">68318000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c-1" id="f-568">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table outlines the estimated future amortization expense related to intangible assets held as of&#160;December&#160;31, 2024 that are subject to amortization:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:57.142%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.931%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-4" decimals="-3" id="f-569" unitRef="usd">4946000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-4" decimals="-3" id="f-570" unitRef="usd">4855000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-4" decimals="-3" id="f-571" unitRef="usd">3380000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-4" decimals="-3" id="f-572" unitRef="usd">3211000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-4" decimals="-3" id="f-573" unitRef="usd">3211000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="c-4" decimals="-3" id="f-574" unitRef="usd">29151000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-4" decimals="-3" id="f-575" unitRef="usd">48754000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c-101" decimals="-3" id="f-576" unitRef="usd">2235000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c-60" decimals="-3" id="f-577" unitRef="usd">1476000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-64" id="f-578">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:CapitalizedComputerSoftwareAdditions contextRef="c-1" decimals="-3" id="f-579" unitRef="usd">3513000</us-gaap:CapitalizedComputerSoftwareAdditions>
    <us-gaap:CapitalizedComputerSoftwareAdditions contextRef="c-12" decimals="-3" id="f-580" unitRef="usd">1168000</us-gaap:CapitalizedComputerSoftwareAdditions>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="c-98" id="f-581">P2Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-3" id="f-582" unitRef="usd">4104000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-12" decimals="-3" id="f-583" unitRef="usd">4072000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-13" decimals="-3" id="f-584" unitRef="usd">3350000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c-1" id="f-585">Accrued Expenses &lt;div style="margin-bottom:9pt;padding-right:15.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.721%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.693%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued royalties under the Medytox Settlement Agreements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll and related benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued revenue contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-586">&lt;div style="margin-bottom:9pt;padding-right:15.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.721%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.693%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued royalties under the Medytox Settlement Agreements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll and related benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued revenue contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="c-4" decimals="-3" id="f-587" unitRef="usd">4743000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="c-5" decimals="-3" id="f-588" unitRef="usd">3657000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-589" unitRef="usd">14127000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-590" unitRef="usd">13433000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-4" decimals="-3" id="f-591" unitRef="usd">14454000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-5" decimals="-3" id="f-592" unitRef="usd">11033000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-593" unitRef="usd">7467000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-594" unitRef="usd">5690000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-595" unitRef="usd">40791000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-596" unitRef="usd">33813000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-597">Property, Plant and Equipment&lt;div style="margin-bottom:9pt;padding-right:15.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:15.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.721%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.693%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold Improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketing Fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property, plant, and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,523)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:15.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December 31, 2024, 2023, and 2022, depreciation expense was $1,194, $1,001, and $373, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-598">&lt;div style="margin-bottom:9pt;padding-right:15.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:15.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.721%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.693%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold Improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketing Fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property, plant, and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,523)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-102" decimals="-3" id="f-599" unitRef="usd">452000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-103" decimals="-3" id="f-600" unitRef="usd">81000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-104" decimals="-3" id="f-601" unitRef="usd">702000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-105" decimals="-3" id="f-602" unitRef="usd">345000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-106" decimals="-3" id="f-603" unitRef="usd">3574000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-107" decimals="-3" id="f-604" unitRef="usd">2212000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-108" decimals="-3" id="f-605" unitRef="usd">317000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-109" decimals="-3" id="f-606" unitRef="usd">149000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-110" decimals="-3" id="f-607" unitRef="usd">1700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-111" decimals="-3" id="f-608" unitRef="usd">1700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-3" id="f-609" unitRef="usd">6745000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-5" decimals="-3" id="f-610" unitRef="usd">4487000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-611" unitRef="usd">3523000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-612" unitRef="usd">2400000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-613" unitRef="usd">3222000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-614" unitRef="usd">2087000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-615" unitRef="usd">1194000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-12" decimals="-3" id="f-616" unitRef="usd">1001000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-13" decimals="-3" id="f-617" unitRef="usd">373000</us-gaap:Depreciation>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-618">Term Loans&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pharmakon Term Loans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 14, 2021, the Company entered into a loan agreement with Pharmakon. Pursuant to the terms of the agreement, Pharmakon agreed to make term loans to the Company in two tranches (the &#x201c;Pharmakon Term Loans&#x201d;). The first tranche of $75,000 was funded on December 29, 2021. On December 5, 2022, the Company entered into a Second Amendment to the loan agreement to extend the Company&#x2019;s option to draw down the second tranche of $50,000 until December 31, 2023, and paid an amendment fee of $500 to Pharmakon. The Pharmakon Term Loans will mature on the &lt;span style="-sec-ix-hidden:f-623"&gt;sixth year&lt;/span&gt; anniversary of the closing date of the first tranche (the &#x201c;Maturity Date&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 9, 2023, the Company entered into the Third Amendment to the loan agreement. Under the Third Amendment, Pharmakon agreed to advance the second tranche of $50,000 to the Company in two installments: (i) $25,000 advanced on May 31, 2023 and (ii) $25,000 advanced on December 15, 2023. The Third Amendment amended the principal payment terms to seven quarterly payments, each in an amount equal to 1/12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;th&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of the outstanding principal amount of the Pharmakon Term Loans following the 51st-month anniversary of the closing date of the first tranche and the remaining principal balance of the Pharmakon Term Loans on the Maturity Date. The Third Amendment replaced the interest rates based on LIBOR with &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;interest rates based on the Secured Overnight Financing Rate (&#x201c;SOFR&#x201d;) throughout the remaining term of the Pharmakon Term Loans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Initially, the Pharmakon Term Loans accrued interest at a per annum rate equal to the 3-month U.S. Dollar LIBOR rate (subject to a LIBOR rate floor of 1.0%) plus 8.5% per annum. Beginning May 2023, the Pharmakon Term Loans accrue interest at a per annum rate equal to the 3-month SOFR rate (subject to a SOFR rate floor of 1.0%) plus 8.5% per annum.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may elect to prepay all amounts, not less than $20,000, owed prior to the Maturity Date. Prepayments of the first tranche prior to the second anniversary of the closing date of the first tranche and prepayments of the second tranche prior to the second anniversary of the date on which the second tranche is drawn by the Company will be accompanied by a make whole amount equal to the sum of all interest that would have accrued through such second anniversary. Prepayments of the Pharmakon Term Loans will also be accompanied by a prepayment premium equal to the principal amount so prepaid multiplied by 3.0% if made prior to the third anniversary of the closing date of the first tranche, 2.0% if made on or after the third anniversary of the closing date of the first tranche but prior to the fourth anniversary of the closing date of the first tranche, and 1.0% if made on or after the fourth anniversary of the closing date of the first tranche but prior to the Maturity Date. If the Pharmakon Term Loans are accelerated following the occurrence of an event of default, including a material adverse change, the Company is required to immediately pay Pharmakon an amount equal to the sum of all outstanding principal, unpaid interest, and applicable make whole and prepayment premiums.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Pharmakon Term Loans are secured by substantially all of the Company&#x2019;s assets. The Pharmakon Term Loans contain customary affirmative and restrictive covenants and representations and warranties. The affirmative covenants include, among others, certain information delivery requirements, obligations to maintain certain insurance, and certain notice requirements. The restrictive covenants include, among others, incurring certain additional indebtedness, consummating certain change in control transactions, or incurring any non- permitted lien or other encumbrance on the Company&#x2019;s assets, without Pharmakon&#x2019;s prior written consent. The Pharmakon Term Loans do not contain covenants requiring the Company to maintain a minimum cash threshold or minimum revenues or earnings. As of December&#160;31, 2024, the Company was in compliance with its debt covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the closing date of the first tranche, the Company incurred $3,042 and $3,263 in debt discounts and issuance costs related to the Pharmakon Term Loans, respectively. Debt discounts and issuance costs related to the entire Pharmakon Term Loans have been allocated pro rata between the funded and unfunded portions. Debt discounts and issuance costs allocated to the first tranche of $75,000 have been presented as a deduction to the debt balance and amortized into interest expense using the effective interest method. Debt discounts and issuance costs associated with the unfunded second tranche are deferred as assets until the tranche is drawn and are amortized into interest expense using the straight-line method over the term of the debt. Upon the first draw of the second tranche in May 2023, debt discounts and issuance costs associated with the second tranche were reclassified from assets to debt as a deduction to the debt balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the borrowings outstanding under the Pharmakon Term Loans were classified as long-term debt in the accompanying consolidated balance sheets. The overall effective interest rate was approximately 14.52% and 13.21% for the first and second tranche, respectively, as of December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the principal amounts of long-term debt maturities for each of the next five fiscal years are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.476%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.218%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total principal payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discounts and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,494)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long term debt, net of discounts and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <eols:DebtInstrumentNumberOfTranches
      contextRef="c-112"
      decimals="INF"
      id="f-619"
      unitRef="tranche">2</eols:DebtInstrumentNumberOfTranches>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-113" decimals="INF" id="f-620" unitRef="usd">75000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-114" decimals="INF" id="f-621" unitRef="usd">50000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-115" decimals="-3" id="f-622" unitRef="usd">500000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-117" decimals="-3" id="f-624" unitRef="usd">50000000</us-gaap:DebtInstrumentFaceAmount>
    <eols:DebtInstrumentNumberOfInstallments
      contextRef="c-118"
      decimals="INF"
      id="f-625"
      unitRef="installment">2</eols:DebtInstrumentNumberOfInstallments>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-119" decimals="-3" id="f-626" unitRef="usd">25000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-120" decimals="-3" id="f-627" unitRef="usd">25000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <eols:DebtInstrumentPeriodicPaymentNumberOfPrincipalPayments
      contextRef="c-121"
      decimals="INF"
      id="f-628"
      unitRef="payment">7</eols:DebtInstrumentPeriodicPaymentNumberOfPrincipalPayments>
    <eols:DebtInstrumentPeriodicPaymentInitialPrincipalPaymentDuePeriod contextRef="c-121" id="f-629">P51M</eols:DebtInstrumentPeriodicPaymentInitialPrincipalPaymentDuePeriod>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-122"
      decimals="INF"
      id="f-630"
      unitRef="number">0.010</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-123"
      decimals="INF"
      id="f-631"
      unitRef="number">0.085</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-124"
      decimals="INF"
      id="f-632"
      unitRef="number">0.010</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-125"
      decimals="INF"
      id="f-633"
      unitRef="number">0.085</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <eols:DebtInstrumentPrepaymentAmountThreshold contextRef="c-126" decimals="-3" id="f-634" unitRef="usd">20000000</eols:DebtInstrumentPrepaymentAmountThreshold>
    <eols:DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount
      contextRef="c-127"
      decimals="INF"
      id="f-635"
      unitRef="number">0.030</eols:DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount>
    <eols:DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount
      contextRef="c-128"
      decimals="INF"
      id="f-636"
      unitRef="number">0.020</eols:DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount>
    <eols:DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount
      contextRef="c-129"
      decimals="INF"
      id="f-637"
      unitRef="number">0.010</eols:DebtInstrumentPrepaymentTermsPrepaymentMultipleOnPrincipalAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="c-112" decimals="-3" id="f-638" unitRef="usd">3042000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsGross contextRef="c-112" decimals="-3" id="f-639" unitRef="usd">3263000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-113" decimals="INF" id="f-640" unitRef="usd">75000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-130" decimals="4" id="f-641" unitRef="number">0.1452</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-131" decimals="4" id="f-642" unitRef="number">0.1321</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="c-1" id="f-643">&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the principal amounts of long-term debt maturities for each of the next five fiscal years are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.476%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.218%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total principal payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discounts and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,494)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long term debt, net of discounts and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c-4" decimals="-3" id="f-644" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c-4" decimals="-3" id="f-645" unitRef="usd">41667000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c-4" decimals="-3" id="f-646" unitRef="usd">83333000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="c-4" decimals="-3" id="f-647" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-4" decimals="-3" id="f-648" unitRef="usd">125000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="c-4" decimals="-3" id="f-649" unitRef="usd">3494000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt contextRef="c-4" decimals="-3" id="f-650" unitRef="usd">121506000</us-gaap:LongTermDebt>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-652">Operating Leases&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 15, 2019, the Company entered into a five-year non-cancelable operating lease (the &#x201c;Lease Agreement&#x201d;), which was set to expire January 31, 2025, for its corporate headquarters in Newport Beach, California. Lease payments increase each year on February 1 based on an annual rent escalation clause. The Company has an option to extend the term of the lease for an additional 60 months, which was not recognized as part of its ROU assets and lease liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 27, 2023, the Company entered into the First Amendment to the Lease Agreement (the &#x201c;First Lease Amendment&#x201d;) for its corporate headquarters. The First Lease Amendment includes a lease extension to January 31, 2030 with a three-month rent abatement period and additional office space. On July 27, 2023, the effective date of the First Lease Amendment, the Company recognized additional ROU assets and lease liabilities in the amount of $4,550. On August 1, 2024, the lease commencement date for the additional office space, the Company recognized additional ROU assets and lease liabilities in the amount of $3,002.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 16, 2024, the Company entered into the Second Amendment to the Lease Agreement (the &#x201c;Second Lease Amendment&#x201d;) to lease additional office space for its corporate headquarters. The lease is expected to commence on or around the second half of 2025 and is set to expire January 31, 2030. Fixed cash payments under this amendment are estimated to be $1,876 over the term of the lease. The Company expects to account for this lease an operating lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s lease agreement does not contain any residual value guarantees or material restrictive covenants. The payments associated with the renewal will only be included in the measurement of the lease liability and ROU assets if the exercise of the renewal option is determined to be reasonably certain. The Company considers the timing of the renewal period and other economic factors such as the financial implications of a decision to extend or not to extend a lease&#160;in&#160;determining&#160;if the renewal option is reasonably certain to be exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of operating lease expense are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.560%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average remaining lease term and discount rate are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.560%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1,433&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1,320&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1,265&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease&#160;expenses were included in the selling, general and administrative expenses in the accompanying consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the future minimum payments under the operating lease agreements with non-cancelable terms as of December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.348%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.452%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,453)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-132" id="f-653">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-4" id="f-654">P60M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <eols:LesseeOperatingLeaseAbatementPeriod contextRef="c-133" id="f-655">P3M</eols:LesseeOperatingLeaseAbatementPeriod>
    <us-gaap:OperatingLeaseLiability contextRef="c-133" decimals="-3" id="f-656" unitRef="usd">4550000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-133" decimals="-3" id="f-657" unitRef="usd">4550000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability contextRef="c-134" decimals="-3" id="f-658" unitRef="usd">3002000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-134" decimals="-3" id="f-659" unitRef="usd">3002000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount contextRef="c-135" decimals="-3" id="f-660" unitRef="usd">1876000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-661">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of operating lease expense are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.560%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average remaining lease term and discount rate are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.560%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.7%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1,433&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1,320&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1,265&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-3" id="f-662" unitRef="usd">1526000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-12" decimals="-3" id="f-663" unitRef="usd">1164000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-13" decimals="-3" id="f-664" unitRef="usd">1084000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-1" decimals="-3" id="f-665" unitRef="usd">150000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-12" decimals="-3" id="f-666" unitRef="usd">183000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-13" decimals="-3" id="f-667" unitRef="usd">91000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-3" id="f-668" unitRef="usd">1676000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-12" decimals="-3" id="f-669" unitRef="usd">1347000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-13" decimals="-3" id="f-670" unitRef="usd">1175000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-4" id="f-671">P5Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-5" id="f-672">P6Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-26" id="f-673">P2Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-4" decimals="3" id="f-674" unitRef="number">0.097</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-5" decimals="3" id="f-675" unitRef="number">0.110</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-26" decimals="3" id="f-676" unitRef="number">0.094</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-677" unitRef="usd">1433000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-12" decimals="-3" id="f-678" unitRef="usd">1320000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-13" decimals="-3" id="f-679" unitRef="usd">1265000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-680">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the future minimum payments under the operating lease agreements with non-cancelable terms as of December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.327%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.348%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.452%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fiscal year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,453)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-4" decimals="-3" id="f-681" unitRef="usd">1718000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-4" decimals="-3" id="f-682" unitRef="usd">2138000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-4" decimals="-3" id="f-683" unitRef="usd">2212000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-4" decimals="-3" id="f-684" unitRef="usd">2290000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-4" decimals="-3" id="f-685" unitRef="usd">2370000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-4" decimals="-3" id="f-686" unitRef="usd">198000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-4" decimals="-3" id="f-687" unitRef="usd">10926000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-4" decimals="-3" id="f-688" unitRef="usd">2453000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-4" decimals="-3" id="f-689" unitRef="usd">8473000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-690">Commitments and Contingencies &lt;div style="margin-bottom:10pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Daewoong Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Daewoong Agreement includes certain minimum annual purchases that the Company is required to make in order to maintain the exclusivity of the license. The Company may, however, meet these minimum purchase obligations by achieving certain market share in the licensed territories. These potential minimum purchase obligations are contingent upon the occurrence of future events, including receipt of governmental approvals and the Company&#x2019;s future market share in various jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total inventory payments to Daewoong were $62,233, $50,770, and $50,685 for the years ended December 31, 2024, 2023, and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Symatese U.S. Agreement and Symatese Europe Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Symatese U.S. Agreement and the Symatese Europe Agreement include certain minimum purchase requirements, and failure to meet such requirements may result in a reduction or termination of the Company&#x2019;s exclusive rights, subject to certain exceptions. These potential minimum purchase obligations are contingent upon the occurrence of future events, including receipt of governmental approvals and the Company&#x2019;s future market share in various jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Symatese U.S. Agreement, the Company is required to make up to &#x20ac;16,200 in milestone payments to Symatese, including an initial payment of &#x20ac;4,100 within 30 days of execution of the Symatese U.S. Agreement, and additional annual payments of &#x20ac;1,600 in June 2025, &#x20ac;4,100 in June 2026, &#x20ac;3,200 in June 2027, and &#x20ac;3,200 in June 2028, in each case subject to three of the Products gaining approval prior to that date. In June 2023, the Company paid $4,441 as an upfront payment upon the signing of the Symatese U.S. Agreement and has developmental costs, ongoing milestone and royalty payment obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Symatese Europe Agreement, the Company is required to pay two milestone payments: (i) &#x20ac;1,200 on the second anniversary of certain regulatory approvals, and (ii) &#x20ac;1,900 on the earlier of the third anniversary of certain regulatory approvals or following a year in which the Company achieves &#x20ac;25,000 in revenue in Europe, provided that the payment shall occur no later than December 2029.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2024, the Company received European Union Medical Device Regulation (&#x201c;MDR&#x201d;) approval for the remaining three hyaluronic acid gel products. As a result, the two milestone payments have been triggered. The first milestone &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;payment is payable on the two-year anniversary of the approval. For the second milestone payment, the Company determined that it is probable the payment will be made no later than December 2029.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Securities Class Action Lawsuit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 16 and 28, 2020, two putative securities class action complaints were filed in the U.S. District Court for the Southern District of New York by Evolus shareholders Armin Malakouti and Clinton Cox, respectively, naming the Company and certain of its officers as defendants. The complaints assert violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, claiming that the defendants made false and materially misleading statements and failed to disclose material adverse facts related to the Company&#x2019;s acquisition of the right to sell Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the complaint against the Company filed by Allergan and Medytox in the U.S. International Trade Commission related to Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (the &#x201c;ITC Action&#x201d;), and risks related to the ITC Action. The complaints assert a putative class period of February 1, 2019 to July 6, 2020. The court consolidated the actions on November 13, 2020, under the caption &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Evolus Inc. Securities Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, No. 1:20-cv-08647 (PGG). On September 17, 2021, the court appointed a lead plaintiff and lead counsel. On November 17, 2021, the lead plaintiff filed an amended class action complaint against the Company, three of its officers, and Alphaeon Corporation, the Company&#x2019;s former majority shareholder. On January 18, 2022, the Company and the officer defendants served their motion to dismiss the amended complaint. On February 10, 2022, Alphaeon Corporation served its motion to dismiss the amended complaint. Both motions were fully briefed on June 16, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 26, 2024, the court granted the Company&#x2019;s motion to dismiss the amended complaint and on October 18, 2024, the court entered final judgment in favor of the defendants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shareholder Derivative Lawsuit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 27, 2020 and December 2, 2020, two putative Evolus shareholders filed substantially similar shareholder derivative actions in the U.S. District Court for the Southern District of New York against certain of the Company&#x2019;s officers and directors as defendants. The complaints alleged substantially similar facts as those in the Securities Class Action and assert claims for, among other things, breach of fiduciary duty, waste of corporate assets, unjust enrichment, and violations of Section 14(a) of the Exchange Act and for contribution under Sections 10(b) and 21(D) of the Exchange Act. On December 29, 2020, the plaintiffs filed a joint stipulation to consolidate their actions and on February 5, 2021, the court consolidated the action under the caption &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Evolus, Inc. Derivative Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, No. 1:20-cv-09986-PPG, and adjourned defendants&#x2019; time to move, answer or otherwise respond to the complaints. On September 20, 2021, the court so-ordered the parties&#x2019; stipulated stay of the consolidated derivative suit pending the court&#x2019;s decision on the defendants&#x2019; motion to dismiss the Securities Class Action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is possible that additional suits will be filed, or additional allegations will be made by stockholders, with respect to these same or similar or other matters and also naming the Company and/or its officers and directors as defendants. The Company believes that the complaints are without merit and intends to vigorously defend against it. However, the outcome of the legal proceeding is uncertain at this point. Based on information available to the Company at present, management cannot reasonably estimate a range of loss with respect to this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Books and Records Demand&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 5, 2021, the Company received a letter from a putative stockholder demanding inspection of specified categories of the Company&#x2019;s books and records under Section 220 of the Delaware General Corporations Law. The Company was subsequently informed that the stockholder sold his shares of the Company&#x2019;s common stock. On October 13, 2021, the Company received a substantially similar demand to inspect specified categories of the Company&#x2019;s books and records under Section 220 of the Delaware General Corporations Law from another putative stockholder. The subject of the demand is substantially similar to the allegations in the putative securities class action and derivative complaints described above. The Company responded to the demand in December 2021. The outcome of this matter is uncertain at this point. Based on information available to the Company at present, management cannot reasonably estimate a range of loss with respect to this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Legal Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is, from time to time, involved in various litigation matters or regulatory encounters arising in the ordinary course of business that could result in unasserted or asserted claims or litigation. These other matters may raise difficult and complex legal issues and are subject to many uncertainties, including, but not limited to, the facts and circumstances of each particular case or claim, the jurisdiction in which each suit or regulatory encounter is brought, and differences in applicable laws and regulations. Except as set forth above, the Company does not believe that these other matters would have a material adverse effect on its accompanying financial position, results of operations or cash flows. However, the resolution of one or more of the other matters in any reporting period could have a material adverse impact on the Company&#x2019;s financial results for that period.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company&#x2019;s exposure under these agreements is unknown because they involve claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. No amounts were accrued as of December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt; Medytox Settlement Agreements&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;U.S. Settlement Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective February 18, 2021, the Company, Allergan and Medytox entered into a Settlement and License Agreement (the &#x201c;U.S. Settlement Agreement&#x201d;), pursuant to which, among other things: (i) Allergan and Medytox agreed to file a petition requesting the remedial orders related to the ITC Action be rescinded with respect to the Company; (ii) Medytox agreed to dismiss substantially similar litigation in California against the Company; (iii) the Company, on the one hand, and Medytox and Allergan, on the other hand, agreed to mutually release certain claims they may have against one another and their respective affiliates; (iv) Allergan and Medytox granted to the Company and its agents a license to manufacture and commercialize certain products identified in the U.S. Settlement Agreement, including Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (the &#x201c;Licensed Products&#x201d;), in the United States during the 21 month period that, pursuant to the ITC Action, the Company was restricted from, among other things, selling, marketing, or promoting such imported Jeuveau&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the United States (the &#x201c;Restricted Period&#x201d;); (v) the Company agreed to pay to Allergan and Medytox $35,000 in multiple payments over two years, of which the Company paid the first cash payment of $15,000 in the third quarter of 2021, the second cash payment of $15,000 in the first quarter of 2022, and the final cash payment of $5,000 in the first quarter of 2023; and (vi) during the Restricted Period, the Company agreed to pay to Allergan and Medytox certain confidential royalties on the sale of Licensed Products, calculated on dollar amount per vial sold of Licensed Products by or on behalf of the Company in the United States. Royalties for sales during the Restricted Period ended on September 16, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;ROW Settlement Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective February 18, 2021, the Company and Medytox entered into a Settlement and License Agreement (the &#x201c;ROW Settlement Agreement&#x201d; and, together with the U.S. Settlement Agreement, the &#x201c;Medytox/Allergan Settlement Agreements&#x201d;), pursuant to which, among other things: (i) the Company and Medytox agreed to mutually release certain claims they may have against one another and their respective affiliates; (ii) Medytox granted to the Company and its agents a license to manufacture and commercialize the Licensed Products, in Canada, the European Union, Switzerland, member countries and cooperating countries of the European Economic Area, certain members of the Commonwealth of Independent States, South Africa, Australia and Japan (the &#x201c;ROW Territories&#x201d;) during the Restricted Period; (iii) Medytox granted to the Company and its agents a fully paid up license to manufacture and commercialize the Licensed Products in the ROW Territories and the United States from the end of the Restricted Period (the &#x201c;Medytox License Period&#x201d;); (iv) the Company and Medytox agreed to enter into the Share Issuance Agreement (as defined below) pursuant to which the Company issued 6,762,652 shares (the &#x201c;Settlement Shares&#x201d;) of the Company&#x2019;s common stock, par value $0.00001 per share, to Medytox; (v) the Company and Medytox agreed to enter into the Registration Rights Agreement (as defined below), pursuant to which the Company granted certain registration rights to Medytox with respect to the Settlement Shares; (vi) during the Restricted Period that ended September 16, 2022, the Company agreed to pay Medytox a confidential low-double digit royalty on net sales of the Licensed Products sold by or on behalf of the Company in the ROW Territories; and (vii) during the Medytox License Period from September 17, 2022 to September 16, 2032, the Company agreed to pay Medytox a mid-single digit royalty percentage on net sales of the Licensed Products sold by or on behalf of the Company in the United States and the ROW Territories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Share Issuance Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the execution of the ROW Settlement Agreement, the Company and Medytox entered into a Share Issuance Agreement effective February 18, 2021 (the &#x201c;Share Issuance Agreement&#x201d;). Pursuant to the Share Issuance Agreement and subject to the terms and conditions set forth therein, among other things, the Company issued to Medytox the Settlement Shares to enter into the ROW Settlement Agreement and in consideration for Medytox&#x2019;s representations, warranties, and other agreements set forth in the Share Issuance Agreement. The Settlement Shares are subject to contractual restrictions on transfer that, subject to certain limited exceptions such as transfers to affiliates, prevented Medytox from transferring any shares of common stock prior to February 16, 2022 or more than 25% of the shares it held prior to September 16, 2023 and, thereafter, prohibit Medytox from transferring more than 50% of the shares it holds prior to September 16, 2024 and more than 75% of the shares it holds prior to September 16, 2025, with such contractual restrictions terminating on September 16, 2025.&lt;/span&gt;&lt;/div&gt;As of December&#160;31, 2024 and 2023, the Company accrued $4,743 and $3,657 for royalties under the Medytox Settlement Agreements.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <eols:PaymentsForInventory contextRef="c-1" decimals="-3" id="f-691" unitRef="usd">62233000</eols:PaymentsForInventory>
    <eols:PaymentsForInventory contextRef="c-12" decimals="-3" id="f-692" unitRef="usd">50770000</eols:PaymentsForInventory>
    <eols:PaymentsForInventory contextRef="c-13" decimals="-3" id="f-693" unitRef="usd">50685000</eols:PaymentsForInventory>
    <eols:LicenseSupplyAndDistributionAgreementMinimumMilestonePayment contextRef="c-54" decimals="-3" id="f-694" unitRef="eur">16200000</eols:LicenseSupplyAndDistributionAgreementMinimumMilestonePayment>
    <eols:LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement contextRef="c-54" decimals="-3" id="f-695" unitRef="eur">4100000</eols:LicenseSupplyAndDistributionAgreementInitialPaymentInConnectionWithAgreement>
    <eols:LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod contextRef="c-54" id="f-696">P30D</eols:LicenseSupplyAndDistributionAgreementInitialPaymentDuePeriod>
    <eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne contextRef="c-53" decimals="-3" id="f-697" unitRef="eur">1600000</eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearOne>
    <eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo contextRef="c-53" decimals="-3" id="f-698" unitRef="eur">4100000</eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo>
    <eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree contextRef="c-53" decimals="-3" id="f-699" unitRef="eur">3200000</eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree>
    <eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour contextRef="c-53" decimals="-3" id="f-700" unitRef="eur">3200000</eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearFour>
    <eols:LicenseSupplyAndDistributionAgreementAnnualPaymentTriggeredRegulatoryApprovalNumberOfProducts
      contextRef="c-53"
      decimals="INF"
      id="f-701"
      unitRef="product">3</eols:LicenseSupplyAndDistributionAgreementAnnualPaymentTriggeredRegulatoryApprovalNumberOfProducts>
    <eols:LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense contextRef="c-55" decimals="-3" id="f-702" unitRef="usd">4441000</eols:LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense>
    <eols:LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment
      contextRef="c-57"
      decimals="INF"
      id="f-703"
      unitRef="milestonepayment">2</eols:LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment>
    <eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo contextRef="c-57" decimals="-3" id="f-704" unitRef="eur">1200000</eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearTwo>
    <eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree contextRef="c-57" decimals="-3" id="f-705" unitRef="eur">1900000</eols:LicenseSupplyAndDistributionAgreementAnnualPaymentYearThree>
    <eols:LicenseSupplyAndDistributionAgreementAnnualRevenue contextRef="c-65" decimals="-3" id="f-706" unitRef="eur">25000000</eols:LicenseSupplyAndDistributionAgreementAnnualRevenue>
    <eols:LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts
      contextRef="c-66"
      decimals="INF"
      id="f-707"
      unitRef="product">3</eols:LicenseSupplyAndDistributionAgreementRegulatoryApprovalNumberOfProducts>
    <eols:LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment
      contextRef="c-67"
      decimals="INF"
      id="f-708"
      unitRef="milestonepayment">2</eols:LicenseSupplyAndDistributionAgreementNumberOfMilestonePayment>
    <eols:LicenseSupplyAndDistributionAgreementMilestonePaymentPayablePeriod contextRef="c-66" id="f-709">P2Y</eols:LicenseSupplyAndDistributionAgreementMilestonePaymentPayablePeriod>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="c-136"
      decimals="INF"
      id="f-710"
      unitRef="complaint">2</us-gaap:LossContingencyNewClaimsFiledNumber>
    <eols:LossContingencyNumberDefendantsOfficers
      contextRef="c-137"
      decimals="INF"
      id="f-711"
      unitRef="officer">3</eols:LossContingencyNumberDefendantsOfficers>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="c-138"
      decimals="INF"
      id="f-712"
      unitRef="plaintiff">2</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="c-4" decimals="INF" id="f-713" unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-714">Stockholders&#x2019; Equity &lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has 10,000,000 authorized shares of preferred stock with a par value of $0.00001 per share. As of December&#160;31, 2024, no shares of its preferred stock were issued and outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has 100,000,000 authorized shares of common stock with a par value of $0.00001 per share. As of December&#160;31, 2024, 63,497,548 shares of its common stock were issued and outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2024, the Company completed a follow-on offering and issued 3,554,000 shares of its common stock, at a price to the public of $14.07 per share. Refer to Note 1. Description of Business for additional details regarding the follow-on offering.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2024 Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 6, 2024, the Company approved the adoption of the 2024 Employee Stock Purchase Plan. The 2024 ESPP provides an opportunity to purchase shares of the Company&#x2019;s common stock at a favorable price and upon favorable terms in consideration of the participating employees&#x2019; continued services. Eligible employees will be entitled to purchase, by means of payroll deductions, limited amounts of the Company&#x2019;s common stock at a discount during periodic offering periods. There were 579,648 shares initially reserved for issuance under the 2024 ESPP, which shall automatically increase on March 5 of each calendar year, by an amount equal to the lesser of (i) 1.0% of the total number of shares of common stock issued and outstanding on March 4 of the year in which such increase is to occur, (ii) 579,648 shares of common stock, or (iii) such number of shares of common stock as may be established by the Board of Directors. There were no shares issued under the 2024 ESPP during the twelve months ended December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#x201c;At-the-market&#x201d; Offerings of Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 8, 2023, the Company entered into the ATM Sales Agreement with Leerink Partners LLC (formerly known as SVB Securities LLC) (the &#x201c;Sales Agent&#x201d;) pursuant to which shares of the Company&#x2019;s common stock can be sold from time to time for aggregate gross proceeds of up to $50,000 (the &#x201c;ATM Program&#x201d;). Under the ATM Sales Agreement, the Sales Agent is entitled to compensation, at a commission rate equal to 3.0% of the gross proceeds from sales of the Company&#x2019;s common shares under the ATM Program. The Company has not sold any shares under the ATM Sales Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2017 Omnibus Incentive Plan and Stock-based Compensation Allocation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s 2017 Omnibus Incentive Plan (the &#x201c;Plan&#x201d;) provides for the grant of incentive options to employees of the Company, and for the grant of non-statutory options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of stock compensation to the Company&#x2019;s officers, directors, consultants &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and employees of the Company. The maximum number of shares of common stock that may be issued under the Plan is 4,361,291 shares, plus an annual increase on November 21 of each year equal to 4.0% of the total issued and outstanding shares of the Company&#x2019;s common stock as of such anniversary (or such lesser number of shares as may be determined by the Company&#x2019;s Board of Directors). On November 21, 2024, 2023, and 2022, an additional 2,535,476, 2,287,649, and 2,249,863, shares, respectively, were reserved under the evergreen provision of the Plan. As of December&#160;31, 2024, the Company had an aggregate of 3,605,334 shares of its common stock available for future issuance under the Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2023 Inducement Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2023, the Company&#x2019;s Board of Directors adopted the Company&#x2019;s 2023 Inducement Incentive Plan (the &#x201c;Inducement Plan&#x201d;) in accordance with Nasdaq Listing Rule 5635(c)(4). The Company&#x2019;s Inducement Plan provides for the grant of equity awards to selected individuals in connection with their commencing employment with the Company as an inducement material to their accepting such employment. The Board of Directors reserved 1,000,000 shares of common stock for issuance under the Inducement Plan. As of December&#160;31, 2024, the Company had an aggregate of 105,788 shares of its common stock available for future issuance under the Inducement Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inducement Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company has granted equity awards to its newly hired employees, including executives, in accordance with Nasdaq Listing Rule 5635(c)(4) and outside of the Company&#x2019;s Plan and Inducement Plan. Such grants were made pursuant to a stand-alone nonstatutory stock option agreement and a stand-alone RSU agreement, which were approved by the Compensation Committee of the Board of Directors. Any shares underlying the inducement grants are not, upon forfeiture, cancellation or expiration, returned to a pool of shares reserved for future issuance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options to purchase the Company&#x2019;s stock are granted at exercise prices based on the Company&#x2019;s common stock price on the date of grant. The option grants generally vest over a &lt;span style="-sec-ix-hidden:f-739"&gt;one&lt;/span&gt;-to four-year period. The options have a contractual term of ten years. The fair value of options is estimated using the Black&#x2011;Scholes option pricing model, which has various inputs, including the grant date common share price, exercise price, risk&#x2011;free interest rate, volatility, expected life and dividend yield. The change of any of these inputs could significantly impact the determination of the fair value of the Company&#x2019;s options as well as significantly impact its results of operations. The Company records stock-based compensation expense net of actual forfeitures when they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant assumptions used in the Black-Scholes option-pricing are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Expected Volatility.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;The expected volatility of common stock is estimated based on the historical volatility of the Company&#x2019;s common stock over the most recent period commensurate with the estimated expected term of the stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Expected Term.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;The expected term represents the period of time in which the options granted are expected to be outstanding. The Company estimates the expected term of options with consideration of vesting date, contractual term, and historical experience. The expected term of &#x201c;plain vanilla&#x201d; options is estimated based on the midpoint between the vesting date and the end of the contractual term under the simplified method permitted by the SEC implementation guidance. The weighted&#x2011;average expected term of the Company&#x2019;s options is approximately six years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Risk&#x2011;Free Rate.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;The risk&#x2011;free interest rate is selected based upon the implied yields in effect at the time of the option grant on U.S. Treasury zero&#x2011;coupon issues with a term approximately equal to the expected life of the option being valued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Dividends.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;The Company does not anticipate paying cash dividends in the foreseeable future. Consequently, the Company uses an expected dividend yield rate of zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumptions used in determining the fair value of stock options granted were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.095%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.721%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.721%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.722%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt 0 5.5pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.7%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.9%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.19&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of stock option activity for the year ended December 31, 2024, 2023, and 2022 is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.224%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.759%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.759%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.759%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contractual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Terms (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,753,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,127,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(537,293)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192,937)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,151,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,151,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,619,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value per share of stock options granted during the years ended December&#160;31, 2024, 2023, and 2022 was $9.71, $7.73, and $4.76, respectively. The total intrinsic value of stock options that vested during the years ended December&#160;31, 2024, 2023, and 2022 was $3,171, $136, and $55, respectively. The aggregate intrinsic value of outstanding and exercisable options represents the excess of the fair market value of the Company&#x2019;s common stock over the exercise price of underlying options as of&#160;December&#160;31, 2024, 2023, and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSU grants generally vest over a &lt;span style="-sec-ix-hidden:f-786"&gt;one&lt;/span&gt;- to four-year period. The fair value of RSU grants is determined at the grant date based on the common share price. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of RSU activity for the year ended December 31, 2024, 2023, and 2022, is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.512%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.721%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.722%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Restricted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Grant Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,281,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,571,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,131,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(342,357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,378,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total fair value of restricted stock units that vested during the years ended December&#160;31, 2024, 2023, and 2022 was $15,740, $7,593, and $6,008, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Performance Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2023, the Company&#x2019;s Board of Directors granted 292,349 shares of performance restricted stock units (&#x201c;PRSUs&#x201d;) to certain executive officers under the Plan. The PRSU awards function in the same manner as restricted stock units except that vesting terms are based on achievement of certain pre-established performance measures. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2024, the Company&#x2019;s Board of Directors granted 219,485 shares of PRSUs to certain executive officers under the Plan. The PRSU awards are measured on a cumulative two-year period ending in 2025. The performance measure milestones have not been met, and all were outstanding as of December&#160;31, 2024. As of December&#160;31, 2024, the achievement of the performance measure milestones was considered probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2024, the Company&#x2019;s Board of Directors granted 79,052 shares of PRSUs to an executive officer under the Plan. The PRSU awards are measured on regulatory approval ending in 2027. The performance measure milestones have not been met and all were outstanding as of December&#160;31, 2024. As of December&#160;31, 2024, one of the three achievement of the performance measure milestones was considered probable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of PRSU activity for the year ended December 31, 2024 and 2023, is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.512%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.721%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.722%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Performance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Restricted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Grant Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;CEO Performance Award&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For RSUs granted to employees that vest based on market conditions, such as the trading price of the Company&#x2019;s common stock exceeding certain price targets, the Company uses a Monte Carlo Simulation in estimating the fair value at grant date and recognizes compensation cost over the requisite service period. On May 8, 2023, the Company granted the Company&#x2019;s Chief Executive Officer (&#x201c;CEO&#x201d;) an award of 560,000 PRSUs under the Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The stock units subject to the award are subject to both performance- and time-based vesting requirements. 40% of the stock units subject to the award are eligible to vest if the average of the closing prices for a share of the Company&#x2019;s common stock over a period of 20 consecutive trading days is $30 or more and an additional 60% of the stock units subject to the award are eligible to vest if the average of the closing prices for a share of the Company&#x2019;s common stock over a period of 20 consecutive trading days is $50 or more, in each case within five years after the grant of the award and while the CEO is employed by the Company (or, in certain circumstances, within 20 days following a termination of his employment). Any stock units that become eligible to vest based on stock price will vest, subject to the CEO&#x2019;s continued service, over the four-year period after the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company used a Monte Carlo simulation to determine that the grant date fair value of the awards was $3,774. Compensation expense is recorded if the service condition is met regardless of whether the market condition is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock-based compensation expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.875%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.227%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.330%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.330%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.414%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.331%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the amounts recorded in selling, general and administrative and research and development, the Company capitalized $66 of stock-based compensation expense as part of capitalized software during the year ended December 31, 2024. As of December&#160;31, 2024, unrecognized compensation cost totaled $47,092 and will be recognized over a weighted-average period of 2.2 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-715" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-716"
      unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-717" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="INF" id="f-718" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-719" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-720"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-39"
      decimals="INF"
      id="f-721"
      unitRef="shares">63497548</us-gaap:CommonStockSharesIssued>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-45"
      decimals="INF"
      id="f-722"
      unitRef="shares">3554000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-46"
      decimals="2"
      id="f-723"
      unitRef="usdPerShare">14.07</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-139"
      decimals="INF"
      id="f-724"
      unitRef="shares">579648</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="c-140"
      decimals="INF"
      id="f-725"
      unitRef="number">0.010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <eols:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalShareIncreaseAvailableForIssuance
      contextRef="c-139"
      decimals="INF"
      id="f-726"
      unitRef="shares">579648</eols:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalShareIncreaseAvailableForIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c-141"
      decimals="INF"
      id="f-727"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <eols:SaleOfStockMaximumConsiderationReceivable contextRef="c-142" decimals="-3" id="f-728" unitRef="usd">50000000</eols:SaleOfStockMaximumConsiderationReceivable>
    <eols:SaleOfStockCommissionPaymentUponGrossProceedsPercentage contextRef="c-143" decimals="3" id="f-729" unitRef="number">0.030</eols:SaleOfStockCommissionPaymentUponGrossProceedsPercentage>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-144"
      decimals="INF"
      id="f-730"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-145"
      decimals="INF"
      id="f-731"
      unitRef="shares">4361291</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="c-146"
      decimals="INF"
      id="f-732"
      unitRef="number">0.040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <eols:CommonStockAdditionalCapitalSharesReservedforFutureIssuance
      contextRef="c-147"
      decimals="INF"
      id="f-733"
      unitRef="shares">2535476</eols:CommonStockAdditionalCapitalSharesReservedforFutureIssuance>
    <eols:CommonStockAdditionalCapitalSharesReservedforFutureIssuance
      contextRef="c-148"
      decimals="INF"
      id="f-734"
      unitRef="shares">2287649</eols:CommonStockAdditionalCapitalSharesReservedforFutureIssuance>
    <eols:CommonStockAdditionalCapitalSharesReservedforFutureIssuance
      contextRef="c-149"
      decimals="INF"
      id="f-735"
      unitRef="shares">2249863</eols:CommonStockAdditionalCapitalSharesReservedforFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-4" decimals="INF" id="f-736" unitRef="shares">3605334</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-150"
      decimals="INF"
      id="f-737"
      unitRef="shares">1000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-151"
      decimals="INF"
      id="f-738"
      unitRef="shares">105788</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-153" id="f-740">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-154" id="f-741">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <eols:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm contextRef="c-154" id="f-742">P6Y</eols:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-154"
      decimals="INF"
      id="f-743"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-744">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumptions used in determining the fair value of stock options granted were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.095%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.721%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.721%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.396%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.722%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt 0 5.5pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.7%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.9%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.19&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-154" decimals="3" id="f-745" unitRef="number">0.837</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-155" decimals="3" id="f-746" unitRef="number">0.836</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-156" decimals="3" id="f-747" unitRef="number">0.789</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-154" decimals="3" id="f-748" unitRef="number">0.041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-155" decimals="3" id="f-749" unitRef="number">0.037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-156" decimals="3" id="f-750" unitRef="number">0.021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-154" id="f-751">P6Y2M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-155" id="f-752">P6Y2M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-156" id="f-753">P6Y2M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-154"
      decimals="INF"
      id="f-754"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-155"
      decimals="INF"
      id="f-755"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-156"
      decimals="INF"
      id="f-756"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-757">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of stock option activity for the year ended December 31, 2024, 2023, and 2022 is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.224%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.759%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.759%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.759%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.764%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Contractual&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Terms (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,753,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,127,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(537,293)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192,937)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,151,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,151,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,619,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-157"
      decimals="INF"
      id="f-758"
      unitRef="shares">5753466</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-157"
      decimals="2"
      id="f-759"
      unitRef="usdPerShare">9.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-155" id="f-760">P6Y8M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-157" decimals="-3" id="f-761" unitRef="usd">11111000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-154"
      decimals="INF"
      id="f-762"
      unitRef="shares">1127833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-154"
      decimals="2"
      id="f-763"
      unitRef="usdPerShare">13.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-154"
      decimals="INF"
      id="f-764"
      unitRef="shares">537293</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-154"
      decimals="2"
      id="f-765"
      unitRef="usdPerShare">7.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-154"
      decimals="INF"
      id="f-766"
      unitRef="shares">192937</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-154"
      decimals="2"
      id="f-767"
      unitRef="usdPerShare">10.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-158"
      decimals="INF"
      id="f-768"
      unitRef="shares">6151069</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-158"
      decimals="2"
      id="f-769"
      unitRef="usdPerShare">10.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-154" id="f-770">P6Y1M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-158" decimals="-3" id="f-771" unitRef="usd">10691000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c-158"
      decimals="INF"
      id="f-772"
      unitRef="shares">6151069</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-158"
      decimals="2"
      id="f-773"
      unitRef="usdPerShare">10.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-154" id="f-774">P6Y1M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-158" decimals="-3" id="f-775" unitRef="usd">10691000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-158"
      decimals="INF"
      id="f-776"
      unitRef="shares">3619512</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-158"
      decimals="2"
      id="f-777"
      unitRef="usdPerShare">9.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <eols:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable contextRef="c-154" id="f-778">P4Y7M20D</eols:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermExercisable>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-158" decimals="-3" id="f-779" unitRef="usd">7801000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-154"
      decimals="2"
      id="f-780"
      unitRef="usdPerShare">9.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-155"
      decimals="2"
      id="f-781"
      unitRef="usdPerShare">7.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-156"
      decimals="2"
      id="f-782"
      unitRef="usdPerShare">4.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <eols:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueVested contextRef="c-1" decimals="-3" id="f-783" unitRef="usd">3171000</eols:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueVested>
    <eols:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueVested contextRef="c-12" decimals="-3" id="f-784" unitRef="usd">136000</eols:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueVested>
    <eols:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueVested contextRef="c-13" decimals="-3" id="f-785" unitRef="usd">55000</eols:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-160" id="f-787">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c-1" id="f-788">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of RSU activity for the year ended December 31, 2024, 2023, and 2022, is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.512%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.721%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.722%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Restricted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Grant Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,281,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,571,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,131,101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(342,357)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,378,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of PRSU activity for the year ended December 31, 2024 and 2023, is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.512%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.721%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.545%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.722%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Performance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Restricted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Grant Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136,433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-161"
      decimals="INF"
      id="f-789"
      unitRef="shares">3281045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-161"
      decimals="2"
      id="f-790"
      unitRef="usdPerShare">8.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-162"
      decimals="INF"
      id="f-791"
      unitRef="shares">1571280</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-162"
      decimals="2"
      id="f-792"
      unitRef="usdPerShare">13.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-162"
      decimals="INF"
      id="f-793"
      unitRef="shares">1131101</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-162"
      decimals="2"
      id="f-794"
      unitRef="usdPerShare">8.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-162"
      decimals="INF"
      id="f-795"
      unitRef="shares">342357</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-162"
      decimals="2"
      id="f-796"
      unitRef="usdPerShare">9.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-163"
      decimals="INF"
      id="f-797"
      unitRef="shares">3378867</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-163"
      decimals="2"
      id="f-798"
      unitRef="usdPerShare">10.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-162" decimals="-3" id="f-799" unitRef="usd">15740000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-164" decimals="-3" id="f-800" unitRef="usd">7593000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-165" decimals="-3" id="f-801" unitRef="usd">6008000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-166"
      decimals="INF"
      id="f-802"
      unitRef="shares">292349</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-167"
      decimals="INF"
      id="f-803"
      unitRef="shares">219485</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <eols:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod contextRef="c-167" id="f-804">P2Y</eols:ShareBasedCompensationArrangementByShareBasedPaymentAwardPerformancePeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-168"
      decimals="INF"
      id="f-805"
      unitRef="shares">79052</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-169"
      decimals="INF"
      id="f-806"
      unitRef="shares">233880</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-169"
      decimals="2"
      id="f-807"
      unitRef="usdPerShare">10.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-78"
      decimals="INF"
      id="f-808"
      unitRef="shares">298537</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-78"
      decimals="2"
      id="f-809"
      unitRef="usdPerShare">12.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-78"
      decimals="INF"
      id="f-810"
      unitRef="shares">136433</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-78"
      decimals="2"
      id="f-811"
      unitRef="usdPerShare">10.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-78"
      decimals="INF"
      id="f-812"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-78"
      decimals="2"
      id="f-813"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-170"
      decimals="INF"
      id="f-814"
      unitRef="shares">395984</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-170"
      decimals="2"
      id="f-815"
      unitRef="usdPerShare">12.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-171"
      decimals="-3"
      id="f-816"
      unitRef="shares">560000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-172" decimals="2" id="f-817" unitRef="number">0.40</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <eols:ShareBasedPaymentArrangementNumberOfConsecutiveDays
      contextRef="c-172"
      decimals="INF"
      id="f-818"
      unitRef="trading_day">20</eols:ShareBasedPaymentArrangementNumberOfConsecutiveDays>
    <eols:ShareBasedCompensationConsecutiveTradingDaysPerShareTarget
      contextRef="c-172"
      decimals="INF"
      id="f-819"
      unitRef="usdPerShare">30</eols:ShareBasedCompensationConsecutiveTradingDaysPerShareTarget>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-173" decimals="2" id="f-820" unitRef="number">0.60</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <eols:ShareBasedPaymentArrangementNumberOfConsecutiveDays
      contextRef="c-173"
      decimals="INF"
      id="f-821"
      unitRef="trading_day">20</eols:ShareBasedPaymentArrangementNumberOfConsecutiveDays>
    <eols:ShareBasedCompensationConsecutiveTradingDaysPerShareTarget
      contextRef="c-173"
      decimals="INF"
      id="f-822"
      unitRef="usdPerShare">50</eols:ShareBasedCompensationConsecutiveTradingDaysPerShareTarget>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c-171" id="f-823">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <eols:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsAfterTermination contextRef="c-171" id="f-824">P20D</eols:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTermsAfterTermination>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-171" id="f-825">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-171" decimals="-3" id="f-826" unitRef="usd">3774000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-827">&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock-based compensation expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.875%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.227%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.330%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.330%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.414%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.331%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-174" decimals="-3" id="f-828" unitRef="usd">21172000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-175" decimals="-3" id="f-829" unitRef="usd">15564000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-176" decimals="-3" id="f-830" unitRef="usd">10565000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-177" decimals="-3" id="f-831" unitRef="usd">1016000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-178" decimals="-3" id="f-832" unitRef="usd">894000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-179" decimals="-3" id="f-833" unitRef="usd">268000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-834" unitRef="usd">22188000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-12" decimals="-3" id="f-835" unitRef="usd">16458000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-13" decimals="-3" id="f-836" unitRef="usd">10833000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-1" decimals="-3" id="f-837" unitRef="usd">66000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-4" decimals="-3" id="f-838" unitRef="usd">47092000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-1" id="f-839">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <eols:LossContingencySettlementAgreementManufacturingLicensePeriod contextRef="c-180" id="f-840">P21M</eols:LossContingencySettlementAgreementManufacturingLicensePeriod>
    <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="c-181" decimals="-3" id="f-841" unitRef="usd">35000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <eols:LossContingencySettlementAgreementPaymentTerms contextRef="c-182" id="f-842">P2Y</eols:LossContingencySettlementAgreementPaymentTerms>
    <us-gaap:PaymentsForLegalSettlements contextRef="c-74" decimals="-3" id="f-843" unitRef="usd">15000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:PaymentsForLegalSettlements contextRef="c-75" decimals="-3" id="f-844" unitRef="usd">15000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:PaymentsForLegalSettlements contextRef="c-76" decimals="-3" id="f-845" unitRef="usd">5000000</us-gaap:PaymentsForLegalSettlements>
    <eols:StockIssuedDuringPeriodSharesLitigationSettlement
      contextRef="c-183"
      decimals="INF"
      id="f-846"
      unitRef="shares">6762652</eols:StockIssuedDuringPeriodSharesLitigationSettlement>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-181"
      decimals="INF"
      id="f-847"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <eols:ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodOne contextRef="c-184" decimals="2" id="f-848" unitRef="number">0.25</eols:ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodOne>
    <eols:ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodTwo contextRef="c-184" decimals="2" id="f-849" unitRef="number">0.50</eols:ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodTwo>
    <eols:ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodThree contextRef="c-184" decimals="2" id="f-850" unitRef="number">0.75</eols:ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodThree>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="c-4" decimals="-3" id="f-851" unitRef="usd">4743000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="c-5" decimals="-3" id="f-852" unitRef="usd">3657000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="c-1" id="f-853">Employee Benefit Plan&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a defined contribution&#160;401(k) plan covering substantially all employees. Matching contributions totaled $2,023, $1,582, and $773&#160;for the years ended December 31, 2024, 2023, and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-1" decimals="-3" id="f-854" unitRef="usd">2023000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-12" decimals="-3" id="f-855" unitRef="usd">1582000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-13" decimals="-3" id="f-856" unitRef="usd">773000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-857">Income Taxes &lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s loss before income taxes was generated from its U.S. operations and foreign operations as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.971%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.096%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.096%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the expense (benefit) for income taxes:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.694%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current provision:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred provision (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred (benefit) provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the Company has federal net operating loss (&#x201c;NOL&#x201d;) carryforwards of $315,179, of which $68,301 will begin to expire in 2034. The federal NOLs generated in 2018 and in the subsequent years in the amount of $246,877 have an indefinite carryforward period. As of December&#160;31, 2024,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Company has state NOL carryforwards of $231,980, which will begin to expire in 2024. As of December&#160;31, 2024, the Company has foreign NOL carryforwards of $38,922, which can be carried forward indefinitely. As of December&#160;31, 2024, the Company has federal research and development &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;R&amp;amp;D&#x201d;) credit carryforwards of $2,929, which will begin to expire in 2034. The Company also has California R&amp;amp;D credit carryforwards of $2,918, which has an indefinite carryforward period. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In general, if a company experiences a greater than 50 percentage point aggregate change in ownership of certain significant stockholders over a three-year period, utilization of its pre-change NOL carryforwards and R&amp;amp;D credit carryforwards, and interest expense under section 163(j), is subject to an annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and similar state laws. The annual limitation may result in the expiration of the Company&#x2019;s tax attribute carryforwards before utilization and may be material. The Company has completed a study to evaluate whether an ownership change, as defined by Section 382 of the Internal Revenue Code, occurred from the Company's formation through December 31, 2023. Based on the findings of this study, the Company has determined that several ownership changes have occurred. Consequently, the Company&#x2019;s tax attribute carryforwards allocable to the periods preceding the ownership change are subject to limitation under Section 382. However, it is important to note that the Company&#x2019;s tax attribute carryforwards, which include net operating losses (NOLs), research and development (R&amp;amp;D) credits, and interest expense under Section 163(j), are not anticipated to expire unused, solely due to the limitations under Section 382. The Company started but has not completed a study to determine whether its tax attribute carryforwards generated through December 31, 2024, are likely to be limited by Section 382 and 383. The Company&#x2019;s net deferred income tax assets have been offset by a valuation allowance. Therefore, any resulting reduction to the Company&#x2019;s tax attribute carryforwards once the analysis is completed will be offset by a corresponding reduction of the valuation allowance and there would be no impact on the Company&#x2019;s consolidated balance sheet, statement of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of deferred tax assets and liabilities were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.334%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.694%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued legal settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;E capitalization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed asset depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124,895)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(116,073)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103,695)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,343)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,525)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,825)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(495)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed asset depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,190)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,365)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the difference between the provision (benefit) for income taxes and income taxes at the statutory U.S. federal income tax rate is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.334%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.694%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,413)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,917)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,607)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(753)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,981)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,673)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revaluation of contingent royalty obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Meals and entertainment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in state tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Officers' compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,529)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign Rate Differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,377)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.636%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.826%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases to prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has considered the amounts and probabilities of the outcomes that can be realized upon ultimate settlement with the tax authorities and determined unrecognized tax benefits primarily related to credits should be established as noted in the summary rollforward above. The Company&#x2019;s effective income tax rate would not be impacted if the unrecognized tax benefits are recognized. Additional amounts in the summary rollforward could impact the Company&#x2019;s effective tax rate if it did not maintain a full valuation allowance on its net deferred tax assets. The Company does not expect its unrecognized tax benefits to change significantly over the next 12&#160;months.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s policy is to recognize interest expense and penalties related to income tax matters as a component of income tax expense. There were no accrued interest and penalties associated with uncertain tax positions as of December&#160;31, 2024, 2023, and 2022. The Company&#x2019;s tax returns for all years since inception are open for audit. The Internal Revenue Service (&#x201c;IRS&#x201d;) commenced an examination of our U.S. income tax returns for the tax year ended December&#160;31, 2022, in the third quarter of 2024. The exam is still in progress. As of December&#160;31, 2024, the IRS has not proposed any adjustments to our tax positions.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c-1" id="f-858">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s loss before income taxes was generated from its U.S. operations and foreign operations as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.971%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.096%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.096%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-1" decimals="-3" id="f-859" unitRef="usd">-33349000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-12" decimals="-3" id="f-860" unitRef="usd">-51004000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-13" decimals="-3" id="f-861" unitRef="usd">-66103000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-1" decimals="-3" id="f-862" unitRef="usd">-16407000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-12" decimals="-3" id="f-863" unitRef="usd">-10505000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-13" decimals="-3" id="f-864" unitRef="usd">-8214000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-865" unitRef="usd">-49756000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-12" decimals="-3" id="f-866" unitRef="usd">-61509000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-13" decimals="-3" id="f-867" unitRef="usd">-74317000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-868">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the expense (benefit) for income taxes:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.694%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current provision:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred provision (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred (benefit) provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-869" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-870" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-871" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-872" unitRef="usd">279000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-873" unitRef="usd">138000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-874" unitRef="usd">113000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-875" unitRef="usd">406000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-876" unitRef="usd">33000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-877" unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-878" unitRef="usd">685000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-879" unitRef="usd">171000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-880" unitRef="usd">113000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-881" unitRef="usd">-18000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-882" unitRef="usd">1000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-883" unitRef="usd">-8000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-884" unitRef="usd">-3000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-885" unitRef="usd">4000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-886" unitRef="usd">-10000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-887" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-888" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-889" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-890" unitRef="usd">-21000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-891" unitRef="usd">5000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-892" unitRef="usd">-18000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-893" unitRef="usd">664000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-894" unitRef="usd">176000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-895" unitRef="usd">95000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:OperatingLossCarryforwards contextRef="c-185" decimals="-3" id="f-896" unitRef="usd">315179000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c-185" decimals="-3" id="f-897" unitRef="usd">68301000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration contextRef="c-185" decimals="-3" id="f-898" unitRef="usd">246877000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:OperatingLossCarryforwards contextRef="c-186" decimals="-3" id="f-899" unitRef="usd">231980000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-187" decimals="-3" id="f-900" unitRef="usd">38922000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-188" decimals="-3" id="f-901" unitRef="usd">2929000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-189" decimals="-3" id="f-902" unitRef="usd">2918000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-903">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of deferred tax assets and liabilities were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.334%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.694%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued legal settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;E capitalization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed asset depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(124,895)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(116,073)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103,695)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred income tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,343)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,525)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,825)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(495)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed asset depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,190)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,365)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-4" decimals="-3" id="f-904" unitRef="usd">86277000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-5" decimals="-3" id="f-905" unitRef="usd">83257000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-26" decimals="-3" id="f-906" unitRef="usd">80494000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-4" decimals="-3" id="f-907" unitRef="usd">7808000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-5" decimals="-3" id="f-908" unitRef="usd">5442000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-26" decimals="-3" id="f-909" unitRef="usd">5168000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-4" decimals="-3" id="f-910" unitRef="usd">2617000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-5" decimals="-3" id="f-911" unitRef="usd">2617000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-26" decimals="-3" id="f-912" unitRef="usd">2617000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation contextRef="c-4" decimals="-3" id="f-913" unitRef="usd">6405000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation contextRef="c-5" decimals="-3" id="f-914" unitRef="usd">5955000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation contextRef="c-26" decimals="-3" id="f-915" unitRef="usd">4675000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <eols:DeferredTaxAssetsOperatingLeaseLiabilities contextRef="c-4" decimals="-3" id="f-916" unitRef="usd">2152000</eols:DeferredTaxAssetsOperatingLeaseLiabilities>
    <eols:DeferredTaxAssetsOperatingLeaseLiabilities contextRef="c-5" decimals="-3" id="f-917" unitRef="usd">1567000</eols:DeferredTaxAssetsOperatingLeaseLiabilities>
    <eols:DeferredTaxAssetsOperatingLeaseLiabilities contextRef="c-26" decimals="-3" id="f-918" unitRef="usd">646000</eols:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements contextRef="c-4" decimals="-3" id="f-919" unitRef="usd">16283000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements contextRef="c-5" decimals="-3" id="f-920" unitRef="usd">17674000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements contextRef="c-26" decimals="-3" id="f-921" unitRef="usd">19203000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements>
    <eols:DeferredTaxAssetsResearchAndExperimentationCapitalization contextRef="c-4" decimals="-3" id="f-922" unitRef="usd">4107000</eols:DeferredTaxAssetsResearchAndExperimentationCapitalization>
    <eols:DeferredTaxAssetsResearchAndExperimentationCapitalization contextRef="c-5" decimals="-3" id="f-923" unitRef="usd">3415000</eols:DeferredTaxAssetsResearchAndExperimentationCapitalization>
    <eols:DeferredTaxAssetsResearchAndExperimentationCapitalization contextRef="c-26" decimals="-3" id="f-924" unitRef="usd">1100000</eols:DeferredTaxAssetsResearchAndExperimentationCapitalization>
    <eols:DeferredTaxAssetsFixedAssetDepreciation contextRef="c-4" decimals="-3" id="f-925" unitRef="usd">26000</eols:DeferredTaxAssetsFixedAssetDepreciation>
    <eols:DeferredTaxAssetsFixedAssetDepreciation contextRef="c-5" decimals="-3" id="f-926" unitRef="usd">183000</eols:DeferredTaxAssetsFixedAssetDepreciation>
    <eols:DeferredTaxAssetsFixedAssetDepreciation contextRef="c-26" decimals="-3" id="f-927" unitRef="usd">0</eols:DeferredTaxAssetsFixedAssetDepreciation>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-4" decimals="-3" id="f-928" unitRef="usd">8382000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-5" decimals="-3" id="f-929" unitRef="usd">5126000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-26" decimals="-3" id="f-930" unitRef="usd">2135000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-4" decimals="-3" id="f-931" unitRef="usd">124895000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-3" id="f-932" unitRef="usd">116073000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-26" decimals="-3" id="f-933" unitRef="usd">103695000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-4" decimals="-3" id="f-934" unitRef="usd">9162000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-5" decimals="-3" id="f-935" unitRef="usd">9163000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-26" decimals="-3" id="f-936" unitRef="usd">12343000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-4" decimals="-3" id="f-937" unitRef="usd">7343000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-5" decimals="-3" id="f-938" unitRef="usd">7730000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="c-26" decimals="-3" id="f-939" unitRef="usd">11525000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-4" decimals="-3" id="f-940" unitRef="usd">1825000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-5" decimals="-3" id="f-941" unitRef="usd">1460000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-26" decimals="-3" id="f-942" unitRef="usd">495000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-943" unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-944" unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-26" decimals="-3" id="f-945" unitRef="usd">345000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-4" decimals="-3" id="f-946" unitRef="usd">9168000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-5" decimals="-3" id="f-947" unitRef="usd">9190000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-26" decimals="-3" id="f-948" unitRef="usd">12365000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-4" decimals="-3" id="f-949" unitRef="usd">6000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-5" decimals="-3" id="f-950" unitRef="usd">27000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-26" decimals="-3" id="f-951" unitRef="usd">22000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-952">&lt;div style="margin-bottom:9pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the difference between the provision (benefit) for income taxes and income taxes at the statutory U.S. federal income tax rate is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.334%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.691%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.694%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,413)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,917)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,607)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(753)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,981)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,673)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revaluation of contingent royalty obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Meals and entertainment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in state tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Officers' compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,529)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign Rate Differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,377)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="-3" id="f-953" unitRef="usd">-10413000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-12" decimals="-3" id="f-954" unitRef="usd">-12917000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-13" decimals="-3" id="f-955" unitRef="usd">-15607000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="-3" id="f-956" unitRef="usd">-753000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-12" decimals="-3" id="f-957" unitRef="usd">-1981000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-13" decimals="-3" id="f-958" unitRef="usd">-2673000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <eols:EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation contextRef="c-1" decimals="-3" id="f-959" unitRef="usd">1823000</eols:EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation>
    <eols:EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation contextRef="c-12" decimals="-3" id="f-960" unitRef="usd">1078000</eols:EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation>
    <eols:EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation contextRef="c-13" decimals="-3" id="f-961" unitRef="usd">1462000</eols:EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment contextRef="c-1" decimals="-3" id="f-962" unitRef="usd">713000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment contextRef="c-12" decimals="-3" id="f-963" unitRef="usd">385000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment contextRef="c-13" decimals="-3" id="f-964" unitRef="usd">358000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c-1" decimals="-3" id="f-965" unitRef="usd">50000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c-12" decimals="-3" id="f-966" unitRef="usd">218000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c-13" decimals="-3" id="f-967" unitRef="usd">-3000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <eols:EffectiveIncomeTaxRateReconciliationOfficersCompensation contextRef="c-1" decimals="-3" id="f-968" unitRef="usd">1231000</eols:EffectiveIncomeTaxRateReconciliationOfficersCompensation>
    <eols:EffectiveIncomeTaxRateReconciliationOfficersCompensation contextRef="c-12" decimals="-3" id="f-969" unitRef="usd">793000</eols:EffectiveIncomeTaxRateReconciliationOfficersCompensation>
    <eols:EffectiveIncomeTaxRateReconciliationOfficersCompensation contextRef="c-13" decimals="-3" id="f-970" unitRef="usd">-1529000</eols:EffectiveIncomeTaxRateReconciliationOfficersCompensation>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-1" decimals="-3" id="f-971" unitRef="usd">443000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-12" decimals="-3" id="f-972" unitRef="usd">222000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-13" decimals="-3" id="f-973" unitRef="usd">10000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="-3" id="f-974" unitRef="usd">-1377000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-12" decimals="-3" id="f-975" unitRef="usd">449000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-13" decimals="-3" id="f-976" unitRef="usd">299000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationTaxContingenciesOther contextRef="c-1" decimals="-3" id="f-977" unitRef="usd">125000</us-gaap:IncomeTaxReconciliationTaxContingenciesOther>
    <us-gaap:IncomeTaxReconciliationTaxContingenciesOther contextRef="c-12" decimals="-3" id="f-978" unitRef="usd">-449000</us-gaap:IncomeTaxReconciliationTaxContingenciesOther>
    <us-gaap:IncomeTaxReconciliationTaxContingenciesOther contextRef="c-13" decimals="-3" id="f-979" unitRef="usd">-391000</us-gaap:IncomeTaxReconciliationTaxContingenciesOther>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="-3" id="f-980" unitRef="usd">8822000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-12" decimals="-3" id="f-981" unitRef="usd">12378000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-13" decimals="-3" id="f-982" unitRef="usd">18169000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-983" unitRef="usd">664000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-984" unitRef="usd">176000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-985" unitRef="usd">95000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="c-1" id="f-986">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.636%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.401%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.826%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases to prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="-3" id="f-987" unitRef="usd">2924000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-26" decimals="-3" id="f-988" unitRef="usd">2924000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-18" decimals="-3" id="f-989" unitRef="usd">2924000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-990" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-12" decimals="-3" id="f-991" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-13" decimals="-3" id="f-992" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-993" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-12" decimals="-3" id="f-994" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-13" decimals="-3" id="f-995" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-4" decimals="-3" id="f-996" unitRef="usd">2924000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="-3" id="f-997" unitRef="usd">2924000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-26" decimals="-3" id="f-998" unitRef="usd">2924000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued contextRef="c-26" decimals="INF" id="f-999" unitRef="usd">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued contextRef="c-4" decimals="INF" id="f-1000" unitRef="usd">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued contextRef="c-5" decimals="INF" id="f-1001" unitRef="usd">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-1002">Segment Reporting&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company conducts business as a single operating segment, which is the business of performance beauty focused on delivering products in the cash-pay aesthetic market. The Company&#x2019;s chief executive officer, who is the chief operating decision maker (&#x201c;CODM&#x201d;), reviews financial information on a consolidated basis for allocating and evaluating financial performance. The single operating segment is further based upon the Company&#x2019;s organizational and management structure and other factors.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The key measure of segment profit and loss that the CODM uses to allocate resources and assess performance is the Company&#x2019;s net loss, which is utilized to evaluate the achievement of the Company&#x2019;s business operations. The table below &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;shows the Company&#x2019;s reconciliation of revenue and significant segment items to net loss, regularly provided to and reviewed by the CODM, as computed under U.S. GAAP:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.741%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt 0 5.5pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of distribution right&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;In process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revaluation of contingent royalty obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(860)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(696)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50,420)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61,685)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74,412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets provided to the CODM are consistent with those reported on the Balance Sheets with particular emphasis on the Company&#x2019;s available liquidity, including its cash and cash equivalents, and financial instruments owned, reduced by current liabilities. All long-lived assets are maintained in the United States of America.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The product and service revenue attributed to foreign countries from which the Company derives product and service revenue is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.741%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue by country, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue by country, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-1003">The table below &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;shows the Company&#x2019;s reconciliation of revenue and significant segment items to net loss, regularly provided to and reviewed by the CODM, as computed under U.S. GAAP:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.741%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt 0 5.5pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product cost of goods sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of distribution right&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;In process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revaluation of contingent royalty obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(860)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(696)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50,420)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61,685)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74,412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-190" decimals="-3" id="f-1004" unitRef="usd">266274000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-191" decimals="-3" id="f-1005" unitRef="usd">202085000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-192" decimals="-3" id="f-1006" unitRef="usd">148616000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-190" decimals="-3" id="f-1007" unitRef="usd">81015000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-191" decimals="-3" id="f-1008" unitRef="usd">61559000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-192" decimals="-3" id="f-1009" unitRef="usd">55887000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-190" decimals="-3" id="f-1010" unitRef="usd">2955000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-191" decimals="-3" id="f-1011" unitRef="usd">2955000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-192" decimals="-3" id="f-1012" unitRef="usd">2955000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-190" decimals="-3" id="f-1013" unitRef="usd">176853000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-191" decimals="-3" id="f-1014" unitRef="usd">149380000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-192" decimals="-3" id="f-1015" unitRef="usd">131275000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-190" decimals="-3" id="f-1016" unitRef="usd">8156000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-191" decimals="-3" id="f-1017" unitRef="usd">5662000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-192" decimals="-3" id="f-1018" unitRef="usd">4474000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <eols:ResearchAndDevelopmentInProcess1 contextRef="c-190" decimals="-3" id="f-1019" unitRef="usd">0</eols:ResearchAndDevelopmentInProcess1>
    <eols:ResearchAndDevelopmentInProcess1 contextRef="c-191" decimals="-3" id="f-1020" unitRef="usd">8869000</eols:ResearchAndDevelopmentInProcess1>
    <eols:ResearchAndDevelopmentInProcess1 contextRef="c-192" decimals="-3" id="f-1021" unitRef="usd">2000000</eols:ResearchAndDevelopmentInProcess1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-190" decimals="-3" id="f-1022" unitRef="usd">-7176000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-12" decimals="-3" id="f-1023" unitRef="usd">-4257000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-13" decimals="-3" id="f-1024" unitRef="usd">-5755000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-190" decimals="-3" id="f-1025" unitRef="usd">22188000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-191" decimals="-3" id="f-1026" unitRef="usd">16458000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-192" decimals="-3" id="f-1027" unitRef="usd">10833000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-190" decimals="-3" id="f-1028" unitRef="usd">2342000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-191" decimals="-3" id="f-1029" unitRef="usd">2178000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-192" decimals="-3" id="f-1030" unitRef="usd">767000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:InvestmentIncomeNet contextRef="c-190" decimals="-3" id="f-1031" unitRef="usd">3263000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-191" decimals="-3" id="f-1032" unitRef="usd">860000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-192" decimals="-3" id="f-1033" unitRef="usd">119000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InterestExpenseNonoperating contextRef="c-190" decimals="-3" id="f-1034" unitRef="usd">18735000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-191" decimals="-3" id="f-1035" unitRef="usd">13832000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-192" decimals="-3" id="f-1036" unitRef="usd">9097000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-190" decimals="-3" id="f-1037" unitRef="usd">127000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-191" decimals="-3" id="f-1038" unitRef="usd">696000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-192" decimals="-3" id="f-1039" unitRef="usd">-9000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-190" decimals="-3" id="f-1040" unitRef="usd">664000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-191" decimals="-3" id="f-1041" unitRef="usd">176000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-192" decimals="-3" id="f-1042" unitRef="usd">95000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-190" decimals="-3" id="f-1043" unitRef="usd">-50420000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-191" decimals="-3" id="f-1044" unitRef="usd">-61685000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-192" decimals="-3" id="f-1045" unitRef="usd">-74412000</us-gaap:NetIncomeLoss>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="c-1" id="f-1046">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The product and service revenue attributed to foreign countries from which the Company derives product and service revenue is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.544%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.741%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue by country, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;text-indent:-4.5pt;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue by country, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-193" decimals="-3" id="f-1047" unitRef="usd">253159000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-194" decimals="-3" id="f-1048" unitRef="usd">195424000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-195" decimals="-3" id="f-1049" unitRef="usd">146150000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-196" decimals="-3" id="f-1050" unitRef="usd">13115000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-197" decimals="-3" id="f-1051" unitRef="usd">6661000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-198" decimals="-3" id="f-1052" unitRef="usd">2466000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-1053" unitRef="usd">266274000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-12" decimals="-3" id="f-1054" unitRef="usd">202085000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-13" decimals="-3" id="f-1055" unitRef="usd">148616000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-1057">Subsequent Events&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 13, 2025, the Company received FDA approval for Evolysse&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Form and Evolysse&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Smooth injectable hyaluronic acid gels for the treatment and improvement of moderate to severe nasolabial folds facial wrinkles.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-199" id="f-1058">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-199" id="f-1059">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-199" id="f-1060">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-199" id="f-1061">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c-1" id="f-1062">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
